<DOC>
<DOCNO>WT08-B13-1</DOCNO>
<DOCOLDNO>IA019-000201-B023-151</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/rxlist.cgi??drug=ANALGIN 206.86.175.201 19970106234000 text/html 35331
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:33:46 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE>www.rxlist.com - Neil Sandow, Pharm.D. 
copyright 1995</title></head> <body bgcolor="#ffffff">
<center><a href="http://www.rxlist.com"><img src="rx.gif" 
height=75 width=75 border=0><img src="count.gif" border=0></a></center> 
Searching for: <b></b> <br>scroll down for results 
<hr><hr>
<h1>Enter Brand or Generic Name or Category*</h1>
<h3> Narrow Your Search with <font size=5>*</font>(examples: 
ampi*, *mycin, antibiotic*)</h3>
<form method=get>
<action=>
<input size=30 maxlength=30 name=drug>
<input type=submit>
<input type=reset>
</form>
<HR>
<H3>Your RxList Search Results:</h3>
1<br><b>Brand Name: </b>DIASTAT<br><b>Generic Name: </b>DIAZEPAM RECTAL GEL<br><b>Category: </b>TREATMENT OF SEVERE EPILEPSY
<p>2<br><b>Brand Name: </b>EDEX<br><b>Generic Name: </b>ALPROSTADIL<br><b>Category: </b>TREATMENT OF ERECTILE DYSFUNCTION
<p>3<br><b>Brand Name: </b>GABITRIL<br><b>Generic Name: </b>TIAGABINE<br><b>Category: </b>ANTICONVULSANTS
<p>4<br><b>Brand Name: </b>URSO<br><b>Generic Name: </b>URSODEOXYCHOLIC ACID<br><b>Category: </b>TREATMENT OF PRIMARY BILIARY CIRRHOSIS
<p>5<br><b>Brand Name: </b>LIPITOR<br><b>Generic Name: </b>ATORVASTATIN<br><b>Category: </b>ANTILIPEMIC AGENTS
<p>6<br><b>Brand Name: </b>ZYFLO<br><b>Generic Name: </b>ZILEUTON<br><b>Category: </b>LEUKOTRIENE RECEPTOR ANTAGONIST (LTRA) FOR TREATMENT OF ASTHMA
<p>7<br><b>Brand Name: </b>FEMPATCH<br><b>Generic Name: </b>17-BETA ESTRADIOL (TRANSDERMAL)<br><b>Category: </b>ESTROGENS
<p>8<br><b>Brand Name: </b>DOSTINEX<br><b>Generic Name: </b>CABERGOLINE<br><b>Category: </b>TREATMENT OF HYPERPROLACTINEMIC DISORDERS
<p>9<br><b>Brand Name: </b>THERDERM EMTDS<br><b>Generic Name: </b>ESTRADIOL (TRANSDERMAL)<br><b>Category: </b>ESTROGENS
<p>10<br><b>Brand Name: </b>ELEQUIN<br><b>Generic Name: </b>LEVOFLOXACIN (INJ)<br><b>Category: </b>QUINOLINE ANTIBIOTICS
<p>11<br><b>Brand Name: </b>COPAXONE<br><b>Generic Name: </b>COPOLYMER-1 (INJ)<br><b>Category: </b>TREATMENT OF MULTIPLE SCLEROSIS
<p>12<br><b>Brand Name: </b>MONUROL<br><b>Generic Name: </b>FOSFOMYCIN TROMETHANE<br><b>Category: </b>TREATMENT OF UTI'S
<p>13<br><b>Brand Name: </b>OPATANOL<br><b>Generic Name: </b>OLOPATADINE HCL<br><b>Category: </b>TREATMENT OF ALLERGIC CONJUNCTIVITIS
<p>14<br><b>Brand Name: </b>GLYSET<br><b>Generic Name: </b>MIGLITOL<br><b>Category: </b>ANTIDIABETIC AGENTS
<p>15<br><b>Brand Name: </b>ZAGAM<br><b>Generic Name: </b>SPARFLOXACIN<br><b>Category: </b>QUINOLINE ANTIBIOTICS
<p>16<br><b>Brand Name: </b>ALORA<br><b>Generic Name: </b>ESTRADIOL TRANSDERMAL<br><b>Category: </b>ESTROGENS
<p>17<br><b>Brand Name: </b>LEVAQUIN<br><b>Generic Name: </b>LEVOFLOXACIN<br><b>Category: </b>QUINOLINE ANTIBIOTICS
<p>18<br><b>Brand Name: </b>APHTHASOL<br><b>Generic Name: </b>AMLEXANOX<br><b>Category: </b>TREATMENT OF APHTHOUS ULCERS
<p>19<br><b>Brand Name: </b>LOTREL<br><b>Generic Name: </b>AMLODIPINE/BENAZEPRIL HCL<br><b>Category: </b>SEE AMLODIPINE AND/OR BENAZEPRIL
<p>20<br><b>Brand Name: </b>ERGOMAR<br><b>Generic Name: </b>ERGOTAMINE TARTRATE<br><b>Category: </b>SYMPATHOLYTIC AGENTS
<p>21<br><b>Brand Name: </b>ERGOSTAT<br><b>Generic Name: </b>ERGOTAMINE TARTRATE<br><b>Category: </b>SYMPATHOLYTIC AGENTS
<p>22<br><b>Brand Name: </b>REZULIN<br><b>Generic Name: </b>TROGLITAZONE<br><b>Category: </b>ANTIDIABETIC AGENTS
<p>23<br><b>Brand Name: </b>MERIDIA<br><b>Generic Name: </b>SIBUTRAMINE HCL<br><b>Category: </b>ANTIDEPRESSANT/ANTIOBESITY
<p>24<br><b>Brand Name: </b>NORMIFLO<br><b>Generic Name: </b>ARDEPARIN SODIUM<br><b>Category: </b>ANTICOAGULANT
<p>25<br><b>Brand Name: </b>FERRISELTZ<br><b>Generic Name: </b>FERRIC AMMONIUM CITRATE<br><b>Category: </b>BOWEL CONTRAST AGENT FOR MRI
<p>26<br><b>Brand Name: </b>LEXXEL<br><b>Generic Name: </b>ENALAPRIL MALEATE/FELODIPINE<br><b>Category: </b>ANTIHYPERTENSIVES
<p>27<br><b>Brand Name: </b>ARICEPT<br><b>Generic Name: </b>DONEPEXIL HCL<br><b>Category: </b>TREATMENT OF ALZHEIMER'S DISEASE
<p>28<br><b>Brand Name: </b>E2020<br><b>Generic Name: </b>DONEPEXIL HCL<br><b>Category: </b>TREATMENT OF ALZHEIMER'S DISEASE
<p>29<br><b>Brand Name: </b>AMPHOTEC<br><b>Generic Name: </b>AMPHOTERICIN B CHOLESTERYL SULFATE COMPLEX<br><b>Category: </b>ANTIFUNGALS
<p>30<br><b>Brand Name: </b>MUSE<br><b>Generic Name: </b>ALPROSTADIL<br><b>Category: </b>TREATMENT OF IMPOTENCE
<p>31<br><b>Brand Name: </b>MECTIZAN<br><b>Generic Name: </b>IVERMECTIN<br><b>Category: </b>TREATMENT OF STRONGYLOIDES/ONCHOCERCIASIS
<p>32<br><b>Brand Name: </b>NASCOBAL<br><b>Generic Name: </b>CYANOCOBALAMIN<br><b>Category: </b>VITAMIN B COMPLEX
<p>33<br><b>Brand Name: </b>NIX<br><b>Generic Name: </b>PERMETHRIN<br><b>Category: </b>ERADICATION/PROPHYLAXIS OF HEAD LICE
<p>34<br><b>Brand Name: </b>SR-2599DC<br><b>Generic Name: </b>CLOPIDOGREL<br><b>Category: </b>ORAL ANTITHROMBIC AGENT (INVESTIGATIONAL)
<p>35<br><b>Brand Name: </b>GUAIFENESIN<br><b>Generic Name: </b>GUAIFENESIN<br><b>Category: </b>SEE <a href="http://www.rxlist.com/cgi/generic/guaicod.htm">GUAIFENESIN & CODEINE</a>
<p>36<br><b>Brand Name: </b>GUAIFENESIN<br><b>Generic Name: </b>GUAIFENESIN<br><b>Category: </b>SEE <a href="http://www.rxlist.com/cgi/generic/guaiphen.htm">GUAIFENESIN & PHENYLPROPANOLAMINE</a>
<p>37<br><b>Brand Name: </b>SYNERCID (RP 59500)<br><b>Generic Name: </b>QUINUPRISTIN/DALFOPRISTIN<br><b>Category: </b>ANTIBIOTICS (INVESTIGATIONAL)
<p>38<br><b>Brand Name: </b>DENAVIR<br><b>Generic Name: </b>PENCICLOVIR<br><b>Category: </b>ANTIVIRALS
<p>39<br><b>Brand Name: </b>FERTINEX<br><b>Generic Name: </b>FOLLICLE STIMULATING HORMONE (FSH)<br><b>Category: </b>HORMONES
<p>40<br><b>Brand Name: </b>FERTINEX<br><b>Generic Name: </b>FSH<br><b>Category: </b>HORMONES
<p>41<br><b>Brand Name: </b>COPAXONE<br><b>Generic Name: </b>COPOLYMER 1<br><b>Category: </b>TREATMENT OF M.S.
<p>42<br><b>Brand Name: </b>VIRACEPT<br><b>Generic Name: </b>NELFINAVIR<br><b>Category: </b>ANTIVIRALS
<p>43<br><b>Brand Name: </b>ERGOSET<br><b>Generic Name: </b>BROMOCRIPTINE<br><b>Category: </b>UNCLASSIFIED THERAPEUTIC AGENTS
<p>44<br><b>Brand Name: </b>SORIATANE<br><b>Generic Name: </b>ACITRETIN<br><b>Category: </b>TREATMENT OF PSORIASIS
<p>45<br><b>Brand Name: </b>ASTELIN<br><b>Generic Name: </b>AZELASTINE<br><b>Category: </b>ANTIHISTAMINES
<p>46<br><b>Brand Name: </b>RETAVASE<br><b>Generic Name: </b>RETEPLASE<br><b>Category: </b>THROMBOLYTICS
<p>47<br><b>Brand Name: </b>SAIZEN<br><b>Generic Name: </b>SOMATROPIN<br><b>Category: </b>PITUITARY
<p>48<br><b>Brand Name: </b>ESTROSTEP<br><b>Generic Name: </b>ETHINYL ESTRADIOL/NORETHINDRONE<br><b>Category: </b>CONTRACEPTIVES
<p>49<br><b>Brand Name: </b>LODINE XL<br><b>Generic Name: </b>ETODOLAC<br><b>Category: </b>NONSTEROIDAL ANTIINFLAMMATORY AGENTS
<p>50<br><b>Brand Name: </b>CYSTADANE<br><b>Generic Name: </b>BETAINE<br><b>Category: </b>TREATMENT OF HOMOCYSTINUREAL
<p>51<br><b>Brand Name: </b>COMBIVENT<br><b>Generic Name: </b>ALBUTEROL/IPRATROPIUM<br><b>Category: </b>BRONCHODILATORS
<p>52<br><b>Brand Name: </b>TARKA<br><b>Generic Name: </b>TRANDOLAPRIL/VERAPAMIL<br><b>Category: </b>ANTIHYPERTENSIVES
<p>53<br><b>Brand Name: </b>MENTAX<br><b>Generic Name: </b>BUTENAFINE HCL<br><b>Category: </b>ANTIFUNGALS
<p>54<br><b>Brand Name: </b>TIAMATE<br><b>Generic Name: </b>DILTIAZEM<br><b>Category: </b>ANTIHYPERTENSIVES
<p>55<br><b>Brand Name: </b>DURACLON<br><b>Generic Name: </b>CLONIDINE HCL<br><b>Category: </b>EPIDURAL ADJUNCT TO OPIATE THERAPY
<p>56<br><b>Brand Name: </b><a href="http://www.lec.org/DrugSearch/Documents/Rohypnol.html">ROHYPNOL</a><br><b>Generic Name: </b>FLUNITRAZEPAM<br><b>Category: </b>MISC. SEDATIVES/HYPNOTICS (NOTE: NOT MARKETED IN THE US)
<p>57<br><b>Brand Name: </b>KADIAN<br><b>Generic Name: </b>MORPHINE SULFATE SA<br><b>Category: </b>OPIATE AGONISTS
<p>58<br><b>Brand Name: </b>COCAINE<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/cocaine.htm">COCAINE HCL</a><br><b>Category: </b>ANTIPRURITICS AND LOCAL ANESTHETICS
<p>59<br><b>Brand Name: </b>TECZEM<br><b>Generic Name: </b>ENALAPRIL MALEATE & DILTIAZEM MALEATE<br><b>Category: </b>ANTIHYPERTENSIVES
<p>60<br><b>Brand Name: </b>TICLID<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/ticlop.htm">TICLOPIDINE HCL</a><br><b>Category: </b>PLATELET AGGREGATION INHIBITORS
<p>61<br><b>Brand Name: </b>PARACETAMOL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">SEE ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>62<br><b>Brand Name: </b>DHEA<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/dhea.htm">DEHYDROEPIANDROSTERONE</a><br><b>Category: </b>UNAPPROVED
<p>63<br><b>Brand Name: </b>ANTIBIOTIC<br><b>Generic Name: </b>TYPE ANTIBIOT*<br><b>Category: </b>USE * TO SORT ON CATEGORY
<p>64<br><b>Brand Name: </b>NILANDRON<br><b>Generic Name: </b>NILUTAMIDE<br><b>Category: </b>ANTIANDROGENS
<p>65<br><b>Brand Name: </b>PONDIMIN<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/fenflur.htm">FENFLURAMINE HCL</a><br><b>Category: </b>APPETITE SUPPRESSANT
<p>66<br><b>Brand Name: </b>ALPHAGAN<br><b>Generic Name: </b>BRIMONIDINE TARTRATE<br><b>Category: </b>MISCELLANEOUS EENT AGENTS (GLAUCOMA)
<p>67<br><b>Brand Name: </b>FERTINEX<br><b>Generic Name: </b>UROFOLLITROPIN<br><b>Category: </b>FOLLICLE STIMULATING HORMONE
<p>68<br><b>Brand Name: </b>IVY BLOCK<br><b>Generic Name: </b>URUSHIOL<br><b>Category: </b>MISCEL.SKIN AND MUCUS MEMBRANE AGENTS
<p>69<br><b>Brand Name: </b>ZENTATE<br><b>Generic Name: </b>VITAMINS PRENATAL<br><b>Category: </b>MULTIVITAMIN PREPARATIONS
<p>70<br><b>Brand Name: </b>ETOPOPHOS<br><b>Generic Name: </b>ETOPOSIDE PHOSPHATE<br><b>Category: </b>ANTINEOPLASTICS
<p>71<br><b>Brand Name: </b>SEROSTIM<br><b>Generic Name: </b>SOMATOTROPIN<br><b>Category: </b>PITUITARY
<p>72<br><b>Brand Name: </b>ZYPREXA<br><b>Generic Name: </b>OLANZAPINE<br><b>Category: </b>ANTIPSYCHOTICS
<p>73<br><b>Brand Name: </b>HURRICAINE<br><b>Generic Name: </b>BENZOCAINE<br><b>Category: </b>LOCAL ANESTHETICS
<p>74<br><b>Brand Name: </b>HURRICAINE<br><b>Generic Name: </b>BENZOCAINE<br><b>Category: </b>ANTIPRURITICS AND LOCAL ANESTHETICS
<p>75<br><b>Brand Name: </b>MERREM I.V.<br><b>Generic Name: </b>MEROPENEM<br><b>Category: </b>MISCELLANEOUS ANTIBIOTICS
<p>76<br><b>Brand Name: </b>PROAMATINE<br><b>Generic Name: </b>MIDODRINE<br><b>Category: </b>TREATMENT OF ORTHOSTATIC HYPERTENSION
<p>77<br><b>Brand Name: </b>RU-486<br><b>Generic Name: </b>MIFEPRISTONE<br><b>Category: </b>TERMINATION OF PREGNANCY
<p>78<br><b>Brand Name: </b>ALBENZA<br><b>Generic Name: </b>ALBENDAZOLE<br><b>Category: </b>ANTHELMINTICS
<p>79<br><b>Brand Name: </b>DIFFERIN<br><b>Generic Name: </b>ADAPALENE<br><b>Category: </b>MISCEL.SKIN AND MUCUS MEMBRANE AGENTS
<p>80<br><b>Brand Name: </b>CARBEX<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/seleg.htm">SELEGILINE HCL</a><br><b>Category: </b>FOR PARKINSON'S DISEASE
<p>81<br><b>Brand Name: </b>HELIDAC<br><b>Generic Name: </b>BISMUTH SUBSAL. METRONIDAZOLE & TETRACYCLINE<br><b>Category: </b>FOR PEPTIC ULCER DISEASE
<p>82<br><b>Brand Name: </b>TRITEC<br><b>Generic Name: </b>RANITIDINE BISMUTH CITRATE<br><b>Category: </b>MISCELLANEOUS GI DRUGS
<p>83<br><b>Brand Name: </b>CEREBYX<br><b>Generic Name: </b>FOSPHENYTOIN SODIUM<br><b>Category: </b>HYDANTOINS
<p>84<br><b>Brand Name: </b>ALLEGRA<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/fexofen.htm">FEXOFENADINE</a><br><b>Category: </b>ANTIHISTAMINES
<p>85<br><b>Brand Name: </b>CAMPTOSAR<br><b>Generic Name: </b>IRINOTECAN HCL<br><b>Category: </b>ANTINEOPLASTICS
<p>86<br><b>Brand Name: </b>XALATAN<br><b>Generic Name: </b>LATANOPROST<br><b>Category: </b>GLAUCOMA THERAPY
<p>87<br><b>Brand Name: </b>REMERON<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/mirtaz.htm">MIRTAZAPINE</a><br><b>Category: </b>ANTIDEPRESSANTS
<p>88<br><b>Brand Name: </b>VIRAMUNE<br><b>Generic Name: </b>NEVIRAPINE<br><b>Category: </b>ANIVIRALS
<p>89<br><b>Brand Name: </b>MYOTROPHIN<br><b>Generic Name: </b>SOMATOMEDIN C<br><b>Category: </b>FOR AMYOTROPHIC LATERAL SCLEROSIS
<p>90<br><b>Brand Name: </b>HUMULIN N<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/humnph.htm">HUMAN INSULIN NPH</a> <br><b>Category: </b>INSULINS
<p>91<br><b>Brand Name: </b>HUMULIN R<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/huminsr.htm">HUMAN INSULIN REGULAR</a><br><b>Category: </b>INSULINS
<p>92<br><b>Brand Name: </b>HUMULIN L<br><b>Generic Name: </b>HUMAN INSULIN LENTE<br><b>Category: </b>INSULINS
<p>93<br><b>Brand Name: </b>HUMULIN 70/30<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/hum7030.htm">HUMAN INSULIN NPH/REG 70/30</a><br><b>Category: </b>INULINS
<p>94<br><b>Brand Name: </b>ORTHO-NOVUM 7/7/7<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/norestoc.htm">NORETHINDRONE/ETHINYL ESTRADIOL</a> <br><b>Category: </b>CONTRACEPTIVES
<p>95<br><b>Brand Name: </b>ORTHO-CEPT<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/desest.htm">DESOGESTREL/ETHINYLESTRADIOL</A><br><b>Category: </b>CONTRACEPTIVES
<p>96<br><b>Brand Name: </b>ACCUPRIL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/quinap.htm">QUINAPRIL HCL</a><br><b>Category: </b>HYPOTENSIVE AGENTS
<p>97<br><b>Brand Name: </b>ACTHREL<br><b>Generic Name: </b>CORTICORELIN OVINE TRIFLUTATE<br><b>Category: </b>DIAGNOSTIC AGENTS
<p>98<br><b>Brand Name: </b>BUPHENYL<br><b>Generic Name: </b>SODIUM PHENYLBUTYRATE<br><b>Category: </b>FOR UREA CYCLE DISORDERS
<p>99<br><b>Brand Name: </b>VISIPAQUE<br><b>Generic Name: </b>IODIXANOL<br><b>Category: </b>ROENTGENOGRAPHY
<p>100<br><b>Brand Name: </b>NAPRELAN<br><b>Generic Name: </b>NAPROXEN SODIUM<br><b>Category: </b>NONSTEROIDAL ANTIINFLAMMATORY AGENTS
<p>101<br><b>Brand Name: </b>OXILAN<br><b>Generic Name: </b>IOXILAN<br><b>Category: </b>ROENTGENOGRAPHY
<p>102<br><b>Brand Name: </b>IONTOCAINE<br><b>Generic Name: </b>LIDOCAINE/EPINEPHRINE<br><b>Category: </b>LOCAL ANESTHETICS
<p>103<br><b>Brand Name: </b>PENTACEF<br><b>Generic Name: </b>CEFTAZIDINE<br><b>Category: </b>ANTIBIOTICS: CEPHALOSPORINS
<p>104<br><b>Brand Name: </b>METROCREAM<br><b>Generic Name: </b>METRONIDAZOLE<br><b>Category: </b>MISCELLANEOUS ANTI-INFECTIVES
<p>105<br><b>Brand Name: </b>GENOTROPIN<br><b>Generic Name: </b>SOMATROPIN<br><b>Category: </b>PITUITARY
<p>106<br><b>Brand Name: </b>SEVORANE<br><b>Generic Name: </b>SEVOFLURANE<br><b>Category: </b>GENERAL ANESTHETICS
<p>107<br><b>Brand Name: </b>BIOTROPIN<br><b>Generic Name: </b>SOMATROPIN<br><b>Category: </b>PITUITARY
<p>108<br><b>Brand Name: </b>ULTRAVIST<br><b>Generic Name: </b>IOPROMIDE<br><b>Category: </b>ROENTGENOGRAPHY
<p>109<br><b>Brand Name: </b>NORDITROPIN<br><b>Generic Name: </b>SOMATROPIN<br><b>Category: </b>PITUITARY
<p>110<br><b>Brand Name: </b>PROVEL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/ibup.htm">IBUPROFEN</A><br><b>Category: </b>NONSTEROIDAL ANTIINFLAMMATORY AGENTS
<p>111<br><b>Brand Name: </b>NISOCOR<br><b>Generic Name: </b>NISOLDIPINE<br><b>Category: </b>CARDIAC DRUGS
<p>112<br><b>Brand Name: </b>APTHASOL<br><b>Generic Name: </b>AMLEXANOX<br><b>Category: </b>TREATMENT OF CANKER SORES
<p>113<br><b>Brand Name: </b>ALPHANATE<br><b>Generic Name: </b>ANTIHEMOPHILIC FACTOR<br><b>Category: </b>HEMOSTATICS
<p>114<br><b>Brand Name: </b>OXYCONTIN<br><b>Generic Name: </b>OXYCODONE HCL<br><b>Category: </b>OPIATE AGONISTS
<p>115<br><b>Brand Name: </b>HYCAMTIN<br><b>Generic Name: </b>TOPOTECAN<br><b>Category: </b>ANTINEOPLASTICS
<p>116<br><b>Brand Name: </b>OXANDRIN<br><b>Generic Name: </b>OXANDROLONE<br><b>Category: </b>ANDROGENS
<p>117<br><b>Brand Name: </b>WINRHO SD<br><b>Generic Name: </b>RHO(D)IMMUNE GLOBULIN<br><b>Category: </b>SERUMS
<p>118<br><b>Brand Name: </b>AVONEX<br><b>Generic Name: </b>INTERFERON BETA-1A<br><b>Category: </b>TREATMENT OF MULTIPLE SCLEROSIS
<p>119<br><b>Brand Name: </b>GEMZAR<br><b>Generic Name: </b>GEMCITABINE HCL<br><b>Category: </b>ANTINEOPLASTICS
<p>120<br><b>Brand Name: </b>DEXFERRUM<br><b>Generic Name: </b>IRON DEXTRAN<br><b>Category: </b>IRON PRODUCTS
<p>121<br><b>Brand Name: </b>CORMAX<br><b>Generic Name: </b>CLOBETASOL PROPIONATE<br><b>Category: </b>ANTI-INFLAMMATORY AGENTS
<p>122<br><b>Brand Name: </b>VITRASERT<br><b>Generic Name: </b>GANCICLOVIR<br><b>Category: </b>ANTIVIRALS
<p>123<br><b>Brand Name: </b>CYTOVENE<br><b>Generic Name: </b>GANCICLOVIR<br><b>Category: </b>ANTIVIRALS
<p>124<br><b>Brand Name: </b>HUMALOG<br><b>Generic Name: </b>INSULIN LISPRO<br><b>Category: </b>INSULINS
<p>125<br><b>Brand Name: </b>DAUNOXOME<br><b>Generic Name: </b>DAUNORUBICIN CITRATE (LIPOSOME)<br><b>Category: </b>ANTINEOPLASTICS
<p>126<br><b>Brand Name: </b>ESTRING<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/estrad.htm">ESTRADIOL</A><br><b>Category: </b>ESTROGENS
<p>127<br><b>Brand Name: </b>ARIMEDEX<br><b>Generic Name: </b>ANASTROZOLE<br><b>Category: </b>ANTINEOPLASTICS
<p>128<br><b>Brand Name: </b>VISTIDE<br><b>Generic Name: </b>CIDOFOVIR<br><b>Category: </b>ANTIVIRALS
<p>129<br><b>Brand Name: </b>NICOTROL NS<br><b>Generic Name: </b>NICOTINE(NASAL)<br><b>Category: </b>MISCELLANEOUS AUTONOMIC DRUGS 
<p>130<br><b>Brand Name: </b>VIQUIN FORTE<br><b>Generic Name: </b>HYDROQUINONE<br><b>Category: </b>DEPIGMENTING AGENTS
<p>131<br><b>Brand Name: </b>REDUX<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/dexfen.htm">DEXFENFLURAMINE</a><br><b>Category: </b>ANTI-OBESITY AGENTS
<p>132<br><b>Brand Name: </b>ZANAFLEX<br><b>Generic Name: </b>TIZANIDINE HCL<br><b>Category: </b>SKELETAL MUSCLE RELAXANTS
<p>133<br><b>Brand Name: </b>PREVALITE<br><b>Generic Name: </b>CHOLESTYRAMINE<br><b>Category: </b>ANTILIPEMIC AGENTS
<p>134<br><b>Brand Name: </b>FERIDEX<br><b>Generic Name: </b>FERUMOXIDE<br><b>Category: </b>MAGNETIC RESONANCE IMAGING
<p>135<br><b>Brand Name: </b>MAVIK<br><b>Generic Name: </b>TRANDOLAPRIL<br><b>Category: </b><a href="http://www.rxlist.com/cardiova.htm">HYPOTENSIVE AGENTS</a> 
<p>136<br><b>Brand Name: </b>NAROPIN<br><b>Generic Name: </b>ROPIVACAINE<br><b>Category: </b>LOCAL ANESTHETICS
<p>137<br><b>Brand Name: </b>SCLEROSOL<br><b>Generic Name: </b>TALC<br><b>Category: </b>SCLEROSING AGENTS
<p>138<br><b>Brand Name: </b>TOPAMAX<br><b>Generic Name: </b>TOPIRAMATE<br><b>Category: </b>MISCELLANEOUS ANTICONVULSANTS
<p>139<br><b>Brand Name: </b>VAQTA<br><b>Generic Name: </b>HEPATITIS A VACCINE<br><b>Category: </b>VACCINES
<p>140<br><b>Brand Name: </b>MYOVIEW<br><b>Generic Name: </b>TETROPHOSMIN<br><b>Category: </b>RADIOPHARMACEUTICALS
<p>141<br><b>Brand Name: </b>OCUHIST<br><b>Generic Name: </b>PHENIRAMINE MALEATE<br><b>Category: </b>ANTIHISTAMINE DRUGS
<p>142<br><b>Brand Name: </b>COVERA-HS<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/verapsr.htm">VERAPAMIL</A> HCL<br><b>Category: </b><a href="http://www.rxlist.com/cardiova.htm">CARDIAC DRUGS</a> 
<p>143<br><b>Brand Name: </b>SYNOVIR<br><b>Generic Name: </b>THALIDOMIDE<br><b>Category: </b>AIDS-CACHEXIA
<p>144<br><b>Brand Name: </b>VESANOID<br><b>Generic Name: </b>TRETINOIN<br><b>Category: </b>ANTINEOPLASTIC AGENTS
<p>145<br><b>Brand Name: </b>TEICHOMYCIN<br><b>Generic Name: </b>TEICOPLANIN<br><b>Category: </b>MISCELLANEOUS ANTIBIOTICS
<p>146<br><b>Brand Name: </b>NORVIR<br><b>Generic Name: </b>RITONAVIR<br><b>Category: </b>ANTIVIRALS
<p>147<br><b>Brand Name: </b>NIMBEX<br><b>Generic Name: </b>CISATRACURIUM BESYLATE<br><b>Category: </b>SKELETAL MUSCLE RELAXANTS
<p>148<br><b>Brand Name: </b>MAXIPIME<br><b>Generic Name: </b>CEFEPIME<br><b>Category: </b>ANTIBIOTICS: CEPHALOSPORINS
<p>149<br><b>Brand Name: </b>PENNSAID<br><b>Generic Name: </b>DIMETHAID-D<br><b>Category: </b><a href="http://www.rxlist.com/nsaid.htm">NONSTEROIDAL ANTI-INFLAMMATORY AGENTS</a> 
<p>150<br><b>Brand Name: </b>ADDERALL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/amphet.htm">AMPHETAMINE MIXED SALTS</a><br><b>Category: </b>RESPIRATORY AND CEREBRAL STIMULANTS
<p>151<br><b>Brand Name: </b>CANDIN<br><b>Generic Name: </b>CANDIDA ALBICANS<br><b>Category: </b>FUNGI
<p>152<br><b>Brand Name: </b>ACTRON<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/ketoprof.htm">KETOPROFEN</a><br><b>Category: </b><a href="http://www.rxlist.com/nsaid.htm">NONSTEROIDAL ANTIINFLAMMATORY AGENTS</a> 
<p>153<br><b>Brand Name: </b>CEDAX<br><b>Generic Name: </b>CEFTIBUTEN<br><b>Category: </b>ANTIBIOTICS:CEPHALOSPORINS
<p>154<br><b>Brand Name: </b>RENOVA<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/tretinoin.htm">TRETINOIN</a><br><b>Category: </b>MISCEL.SKIN AND MUCUS MEMBRANE AGENTS
<p>155<br><b>Brand Name: </b>PHOTOFRIN<br><b>Generic Name: </b>PORFIMER SODIUM<br><b>Category: </b>ANTINEOPLASTIC AGENTS (PHOTODYNAMIC)
<p>156<br><b>Brand Name: </b>AMARYL<br><b>Generic Name: </b>GLIMEPIRIDE<br><b>Category: </b>ANTIDIABETIC AGENTS
<p>157<br><b>Brand Name: </b>FLOLAN<br><b>Generic Name: </b>EPOPROSTENOL SODIUM<br><b>Category: </b>VASODILATING AGENTS
<p>158<br><b>Brand Name: </b>RESPIGAM<br><b>Generic Name: </b>RSV-IGIV<br><b>Category: </b>SERUMS
<p>159<br><b>Brand Name: </b>CRIXIVAN<br><b>Generic Name: </b>INDINAVIR SULFATE<br><b>Category: </b>ANTIVIRALS
<p>160<br><b>Brand Name: </b>TRIPEDIA<br><b>Generic Name: </b>WHOOPING COUGH VACCINE<br><b>Category: </b>VACCINES
<p>161<br><b>Brand Name: </b>PROCANABID<br><b>Generic Name: </b>PROCAINAMIDE HCL<br><b>Category: </b>CARDIAC DRUGS
<p>162<br><b>Brand Name: </b>ZYRTEC<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/cetiriz.htm">CETIRIZINE HCL</a><br><b>Category: </b>ANTIHISTAMINE DRUGS
<p>163<br><b>Brand Name: </b>VIVELLE<br><b>Generic Name: </b>ESTRADIOL (TRANSDERMAL SYSTEM)<br><b>Category: </b>ESTROGEN
<p>164<br><b>Brand Name: </b>AZELEX<br><b>Generic Name: </b>ACELAIC ACID<br><b>Category: </b>SKIN AND MUCUS MEMBRANE AGENTS
<p>165<br><b>Brand Name: </b>ETHYOL<br><b>Generic Name: </b>AMIFOSTINE<br><b>Category: </b>UNCLASSIFIED THERAPEUTIC AGENTS
<p>166<br><b>Brand Name: </b>DOXIL<br><b>Generic Name: </b> DOXORUBICIN HCL (LIPOSOME INJECTION)<br><b>Category: </b>ANTIONEOPLASTIC AGENTS
<p>167<br><b>Brand Name: </b>ABELCET<br><b>Generic Name: </b>ABCL(AMPHOTERICIN B LIPID COMPLEX LIPOSOME INJ)<br><b>Category: </b>ANTIFUNGALS
<p>168<br><b>Brand Name: </b>PRECOSE<br><b>Generic Name: </b>ACARBOSE<br><b>Category: </b>ANTIDIABETIC AGENTS
<p>169<br><b>Brand Name: </b>RILUTEK<br><b>Generic Name: </b>RILUZOLE<br><b>Category: </b>FOR AMYOTROPHIC LATERAL SCLEROSIS
<p>170<br><b>Brand Name: </b>VALTREX<br><b>Generic Name: </b>VALACYCLOVIR<br><b>Category: </b>ANIVIRALS
<p>171<br><b>Brand Name: </b>FLOVENT<br><b>Generic Name: </b>FLUTICASONE PROPRIONATE<br><b>Category: </b>ANTIINFLAMMATORY AGENTS
<p>172<br><b>Brand Name: </b>DYNABAC<br><b>Generic Name: </b>DIRITHROMYCIN<br><b>Category: </b>ANTIBIOTICS:ERYTHROMYCINS
<p>173<br><b>Brand Name: </b>CORVERT<br><b>Generic Name: </b>IBUTILIDE<br><b>Category: </b>CARDIAC DRUGS
<p>174<br><b>Brand Name: </b>FARESTON<br><b>Generic Name: </b>TOREMIFENE CITRATE<br><b>Category: </b>ANTINEOPLASTIC AGENTS
<p>175<br><b>Brand Name: </b>COREG<br><b>Generic Name: </b>CARDEDILOL<br><b>Category: </b>CARDIAC DRUGS
<p>176<br><b>Brand Name: </b>TAXOTERE<br><b>Generic Name: </b>DOCETAXEL<br><b>Category: </b>ANTINEOPLASTIC AGENTS
<p>177<br><b>Brand Name: </b>BUTOX<br><b>Generic Name: </b>BOTULINUM TOXIN TYPE A<br><b>Category: </b>TOXOIDS
<p>178<br><b>Brand Name: </b>SULAR<br><b>Generic Name: </b>NISOLDIPINE<br><b>Category: </b>CARDIAC DRUGS
<p>179<br><b>Brand Name: </b>BLEO<br><b>Generic Name: </b>BLEOMYCIN<br><b>Category: </b>ANTINEOPLASTIC AGENTS
<p>180<br><b>Brand Name: </b>BLEOCIN<br><b>Generic Name: </b>BLEOMYCIN<br><b>Category: </b>ANTINEOPLASTIC AGENTS
<p>181<br><b>Brand Name: </b>BLENOXANE<br><b>Generic Name: </b>BLEOMYCIN<br><b>Category: </b>ANTINEOPLASTIC AGENTS
<p>182<br><b>Brand Name: </b>INVIRASE<br><b>Generic Name: </b>SAQUINAVIR<br><b>Category: </b>ANTIVIRALS
<p>183<br><b>Brand Name: </b>EPIVIR<br><b>Generic Name: </b>LAMIVUDINE<br><b>Category: </b>ANTIVIRALS
<p>184<br><b>Brand Name: </b>3TC<br><b>Generic Name: </b>LAMIVUDINE<br><b>Category: </b>ANTIVIRALS
<p>185<br><b>Brand Name: </b>AZT<br><b>Generic Name: </b>ZIDOVUDINE<br><b>Category: </b>ANTIVIRALS
<p>186<br><b>Brand Name: </b>NIZORAL<br><b>Generic Name: </b>KETOCONAZOLE<br><b>Category: </b>ANTIFUNGALS
<p>187<br><b>Brand Name: </b>NIZORAL TOPICAL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/ketocon.htm">KETOCONAZOLE TOPICAL</A><br><b>Category: </b>ANTIFUNGALS
<p>188<br><b>Brand Name: </b>METHERGINE<br><b>Generic Name: </b>METHYLERGONOVINE MALEATE<br><b>Category: </b>OXYTOCICS
<p>189<br><b>Brand Name: </b>LOTREL<br><b>Generic Name: </b>AMLODIPINE/BENAZEPRIL HCL<br><b>Category: </b><a href="http://www.rxlist.com/cardiova.htm">HYPOTENSIVE AGENTS</a> 
<p>190<br><b>Brand Name: </b>VEXOL<br><b>Generic Name: </b>RIMEXOLONE<br><b>Category: </b>OPTHALMIC CORTICOSTEROID
<p>191<br><b>Brand Name: </b>DR-3355<br><b>Generic Name: </b>LEVOFLOXACIN<br><b>Category: </b>INVESTIGATIONAL:ANTIBIOTICS:QUINOLINES
<p>192<br><b>Brand Name: </b>ORG-10172<br><b>Generic Name: </b>DANAPAROID<br><b>Category: </b>INVESTIGATIONAL:ANTICOAGULANTS
<p>193<br><b>Brand Name: </b>RU 44570<br><b>Generic Name: </b>TRANDOLAPRIL<br><b>Category: </b> <a href="http://www.rxlist.com/cardiova.htm">HYPOTENSIVE AGENTS</a> 
<p>194<br><b>Brand Name: </b>ACCOLATE<br><b>Generic Name: </b>ZAFIRLUKAST<br><b>Category: </b>RESPIRATORY:LEUKOTRIENE ANTAGONIST
<p>195<br><b>Brand Name: </b>TIAZAC<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/diltiaz.htm">DILTIAZEM HCL</a> <br><b>Category: </b><a href="http://www.rxlist.com/cardiova.htm">CARDIAC DRUGS</a> 
<p>196<br><b>Brand Name: </b>FOSAMAX<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/alendron.htm">ALENDRONATE SODIUM</a><br><b>Category: </b>MISCELLANEOUS:OSTEOPOROSIS
<p>197<br><b>Brand Name: </b>REOPRO<br><b>Generic Name: </b>ABCIXIMAB<br><b>Category: </b>UNCLASSIFIED THERAPEUTIC AGENTS
<p>198<br><b>Brand Name: </b>SECTRAL<br><b>Generic Name: </b>ACEBUTOLOL HCL<br><b>Category: </b><a href="http://www.rxlist.com/cardiova.htm">CARDIAC DRUGS</a> 
<p>199<br><b>Brand Name: </b>ACI-JEL W/APP<br><b>Generic Name: </b>ACET AC/RICINOLEIC/OXY<br><b>Category: </b>ANTI-INFECTIVES
<p>200<br><b>Brand Name: </b>ACEPHEN<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>201<br><b>Brand Name: </b>ACETAMIN<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>202<br><b>Brand Name: </b>ANACIN AF<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>203<br><b>Brand Name: </b>APAP<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>204<br><b>Brand Name: </b>BL INFANT N/A<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>205<br><b>Brand Name: </b>BL NON-ASPIRN<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>206<br><b>Brand Name: </b>FEVERALL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>207<br><b>Brand Name: </b>GENAPAP X/S<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>208<br><b>Brand Name: </b>GENEBS X/S<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>209<br><b>Brand Name: </b>GNP NON-ASPRN<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>210<br><b>Brand Name: </b>GNP NON-ASPRN<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>211<br><b>Brand Name: </b>GNP XS PAIN<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>212<br><b>Brand Name: </b>INFANTAIRE<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>213<br><b>Brand Name: </b>INFANTOL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>214<br><b>Brand Name: </b>MAPAP ACETAM<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>215<br><b>Brand Name: </b>PAIN &amp; FEVER<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>216<br><b>Brand Name: </b>PANADOL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>217<br><b>Brand Name: </b>PEDIAPAP<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>218<br><b>Brand Name: </b>TEMPRA 1<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>219<br><b>Brand Name: </b>TEMPRA 2<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>220<br><b>Brand Name: </b>TYLENOL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>221<br><b>Brand Name: </b>TYLENOL INFNT<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>222<br><b>Brand Name: </b>TYLENOL X/S<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>223<br><b>Brand Name: </b>BROMO SELTZER<br><b>Generic Name: </b>ACETAMINOPHEN BUFFERED<br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>224<br><b>Brand Name: </b>GENAPAP CHILD<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN CHEW</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>225<br><b>Brand Name: </b>ST JOS CHL/AF<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN CHEW</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>226<br><b>Brand Name: </b>TEMPRA 3 CHEW<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN CHEW</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>227<br><b>Brand Name: </b>TYLENOL CHILD<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN CHEW</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>228<br><b>Brand Name: </b>TYLENOL CHILD<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN CHEW</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>229<br><b>Brand Name: </b>TYLENOL X/RLF<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN SA</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>230<br><b>Brand Name: </b>PROMINOL<br><b>Generic Name: </b>ACETAMINOPHEN/BUTALBITAL<br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>231<br><b>Brand Name: </b>APAP/COD<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/acetcod.htm">ACETAMINOPHEN/CODEINE</a> <br><b>Category: </b><a href="opiate.htm">OPIATE AGONISTS</a> 
<p>232<br><b>Brand Name: </b>CAPITAL W/COD<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/acetcod.htm">ACETAMINOPHEN/CODEINE</a> <br><b>Category: </b><a href="opiate.htm">OPIATE AGONISTS</a> 
<p>233<br><b>Brand Name: </b>PHENAPHEN/COD<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/acetcod.htm">ACETAMINOPHEN/CODEINE</a> <br><b>Category: </b><a href="opiate.htm">OPIATE AGONISTS</a> 
<p>234<br><b>Brand Name: </b>TYLENOL/COD<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/acetcod.htm">ACETAMINOPHEN/CODEINE</a> <br><b>Category: </b><a href="opiate.htm">OPIATE AGONISTS</a> 
<p>235<br><b>Brand Name: </b>ACETAZOLAMIDE<br><b>Generic Name: </b>ACETAZOLAMIDE<br><b>Category: </b>CARBONIC ANHYDRASE INHIBITORS
<p>236<br><b>Brand Name: </b>DIAMOX<br><b>Generic Name: </b>ACETAZOLAMIDE<br><b>Category: </b>CARBONIC ANHYDRASE INHIBITORS
<p>237<br><b>Brand Name: </b>ACETASOL PLN<br><b>Generic Name: </b>ACETIC ACID OTIC<br><b>Category: </b>ANTI-INFECTIVES
<p>238<br><b>Brand Name: </b>DOMEBORO OTIC<br><b>Generic Name: </b>ACETIC ACID OTIC<br><b>Category: </b>ANTI-INFECTIVES
<p>239<br><b>Brand Name: </b>VOSOL OTIC<br><b>Generic Name: </b>ACETIC ACID OTIC<br><b>Category: </b>ANTI-INFECTIVES
<p>240<br><b>Brand Name: </b>ACETASOL HC<br><b>Generic Name: </b>ACETIC ACID/HYDROCORT OTI<br><b>Category: </b>ANTI-INFECTIVES
<p>241<br><b>Brand Name: </b>HYDRO/ACETIC<br><b>Generic Name: </b>ACETIC ACID/HYDROCORT OTI<br><b>Category: </b>ANTI-INFECTIVES
<p>242<br><b>Brand Name: </b>VASOTATE HC<br><b>Generic Name: </b>ACETIC ACID/HYDROCORT OTI<br><b>Category: </b>ANTI-INFECTIVES
<p>243<br><b>Brand Name: </b>VOSOL HC OTIC<br><b>Generic Name: </b>ACETIC ACID/HYDROCORT OTI<br><b>Category: </b>ANTI-INFECTIVES
<p>244<br><b>Brand Name: </b>DYMELOR<br><b>Generic Name: </b>ACETOHEXAMIDE<br><b>Category: </b>SULFONYLUREAS
<p>245<br><b>Brand Name: </b>LITHOSTAT<br><b>Generic Name: </b>ACETOHYDROXAMIC ACID<br><b>Category: </b>AMMONIA DETOXICANTS
<p>246<br><b>Brand Name: </b>SEBA-NIL<br><b>Generic Name: </b>ACETONE/ALCOHOL/POLYSORB<br><b>Category: </b>MISCEL.SKIN AND MUCUS MEMBRANE AGENTS
<p>247<br><b>Brand Name: </b>MIOCHOL E W/<br><b>Generic Name: </b>ACETYLCHOLINE CHL<br><b>Category: </b>MIOTICS
<p>248<br><b>Brand Name: </b>ACETYLCYSTEIN<br><b>Generic Name: </b>ACETYLCYSTEINE<br><b>Category: </b>MUCOLYTIC AGENTS
<p>249<br><b>Brand Name: </b>MUCOMYST<br><b>Generic Name: </b>ACETYLCYSTEINE<br><b>Category: </b>MUCOLYTIC AGENTS
<p>250<br><b>Brand Name: </b>MUCOSIL<br><b>Generic Name: </b>ACETYLCYSTEINE<br><b>Category: </b>MUCOLYTIC AGENTS
<p></body></html>
<P><hr><a href="http://www.rxlist.com"><b>RxList Home Page</ul>
<hr>
</DOC>
<DOC>
<DOCNO>WT08-B13-2</DOCNO>
<DOCOLDNO>IA018-000200-B038-68</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/tercon.htm 206.86.175.201 19970106225903 text/html 10149
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:52:48 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 9967
Last-modified: Sat, 13 Jul 1996 18:58:33 GMT
</DOCHDR>
<html>
<head>
   <title>Terconazole - RxList Generic Information</title>
   <meta name="Author" content="">
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Terconazole</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<p><a name="DESCRIPTION"></a><b>DESCRIPTION </b></p>

<p>Terconazole Vaginal Cream is a white to off-white, water washable cream
for intravaginal administration containing 0.4% of the antifungal agent
terconazole Cis-1-(4-(( 2-(2,4- dichlorophenyl)-2-(1H-1, 2, 4-triazol-1-ylmethyl)-1,3-
dioxolan-4-yl) methoxy)phenyl)-4- (1-methylethyl) piperazine.</p>

<p> Terconazole, a triazole derivative, is a white to almost white powder
with a molecular weight of 532.47. It is insoluble in water; sparingly
soluble in ethanol; and soluble in butanol. </p>

<p><a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY
</b></p>

<p>MICROBIOLOGY: Terconazole exhibits fungicidal activity In Vitro against
Candida Albicans. Antifungal activity also has been demonstrated against
other fungi. The MIC values for terconazole against most species of lactic
acid bacteria typically found in the human vagina were &gt;/= 128 mcg/ml,
therefore these beneficial bacteria are not affected by drug treatment.
</p>

<p>The exact pharmacologic mode of action of terconazole is uncertain;
however, it may exert its antifungal activity by the disruption of normal
fungal cell membrane permeability. No resistance to terconazole has developed
during successive passages of C. Albicans. </p>

<p>HUMAN PHARMACOLOGY: Following intravaginal administration of terconazole
in humans, absorption ranged from 5-8% in three hysterectomized subjects
and 12 16% in two non-hysterectomized subjects with tubal ligations. </p>

<p>Following oral (30 mg) administration of 14C-labelled terconazole, the
half life of elimination from the blood for the parent terconazole was
6.9 hours (range 4.0-11.3). Terconazole is extensively metabolized; the
plasma AUC for terconazole compared to the AUC for total radioactivity
was 0.6%. Total radioactivity was eliminated from the blood with a half-life
of 52.2 hours (range 44-60). Excretion of radioactivity was both by renal
(32-56%) and fecal (47-52%) routes. </p>

<p>Photosensitivity reactions were observed in some normal volunteers following
repeated dermal application of terconazole, 2.0% and 0.8% creams under
conditions of filtered artificial ultraviolet light. Photosensitivity reactions
have not been observed in U.S. and foreign clinical trials in patients
who were treated with terconazole 0.4% vaginal cream. </p>

<p><a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE </b></p>

<p>Terconazole Vaginal Cream is indicated for the local treatment of vulvovaginal
candidiasis (moniliasis). As Terconazole Vaginal Cream is effective only
for vulvovaginitis caused by the genus Candida, the diagnosis should be
confirmed by KOH smears and/or cultures. </p>

<p><a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS </b></p>

<p>Patients known to be hypersensitive to terconazole or to any of the
components of the cream. </p>

<p><a name="WARNINGS"></a><b>WARNINGS </b></p>

<p>None. </p>

<p><a name="PRECAUTIONS"></a><b>PRECAUTIONS </b></p>

<p>GENERAL: Discontinue use and do not retreat with terconazole if sensitization,
irritation, fever, chills or flu-like symptoms are reported during use.
If there is lack of response to Terconazole Vaginal Cream, appropriate
microbiological studies (standard KOH smear and/or cultures) should be
repeated to confirm the diagnosis and rule out other pathogens. </p>

<p>DRUG INTERACTIONS: The therapeutic effect of Terconazole Vaginal Cream
is not affected by oral contraceptive usage. </p>

<p>CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY: </p>

<p>CARCINOGENESIS: Studies to determine the carcinogenic potential of terconazole
have not been performed. </p>

<p>MUTAGENICITY: Terconazole was not mutagenic when tested In Vitro for
induction of microbial point mutations (Ames test) or for inducing cellular
transformation, or In Vivo for chromosome breaks (micronucleus test) or
dominant lethal mutations in mouse germ cells. </p>

<p>IMPAIRMENT OF FERTILITY: No impairment of fertility occurred when female
rats were administered terconazole orally up to 40 mg/kg/day. </p>

<p>PREGNANCY: Pregnancy Category C. </p>

<p>There was no evidence of teratogenicity when terconazole was administered
orally up to 40 mg/kg/day (100 times the recommended intravaginal human
dose) in rats, or 20 mg/kg/day in rabbits, or subcutaneously in rats up
to 20 mg/kg/day. </p>

<p>Dosages at or below 10 mg/kg/day produced no embryotoxicity; however,
there was a delay in fetal ossification at 10 mg/kg/day in rats. There
was some evidence of embryotoxicity in rabbits and rats at 20-40 mg/kg.
In rats this was reflected as a decrease in litter size and number of viable
young and reduced fetal weight. There was also delay in ossification and
increased incidence of skeletal variants. </p>

<p>The no-effect oral dose of 10 mg/kg/day resulted in a mean peak plasma
level of terconazole in pregnant rats of 0.176 mcg/ml which exceeds by
44 times the mean peak plasma levels (0.004 mcg/ml) seen in normal subjects
after intravaginal administration of terconazole. This safety assessment
does not account for possible exposure of the fetus through direct transfer
of terconazole from the irritated vagina to the fetus by diffusion across
amniotic membranes. </p>

<p>Since terconazole is absorbed from the human vagina, it should not be
used in the first trimester of pregnancy unless the physician considers
it essential to the welfare of the patient. </p>

<p>NURSING MOTHERS: It is not known whether this drug is excreted in human
milk. Animal studies have shown that rat offspring exposed via the milk
of treated (40 mg/kg/orally) dams showed decreased survival during the
first few post- partum days, but overall pup weight and weight gain were
comparable to or greater than controls throughout lactation. Because many
drugs are excreted in human milk, and because of the potential for adverse
reaction in nursing infants from terconazole, a decision should be made
whether to discontinue nursing or to discontinue the drug, taking into
account the importance of the drug to the mother. </p>

<p>PEDIATRIC USE: Safety and efficacy in children have not been established.
</p>

<p><a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS </b></p>

<p>The therapeutic effect of Terconazole Vaginal Cream is not affected
by oral contraceptive usage. </p>

<p>(See Also PRECAUTIONS) </p>

<p><a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS </b></p>

<p>During controlled clinical studies conducted in the United States, 521
patients with vulvovaginal candidiasis were treated with terconazole 0.4%
vaginal cream. Based on comparative analyses with placebo, the adverse
experiences considered most likely related to terconazole 0.4% vaginal
cream were headaches (26% Vs 17% with placebo) and body pain (2.1% Vs 0%
with placebo). Vulvovaginal burning (5.2%), itching (2.3%) or irritation
(3.1%) occurred less frequently with terconazole 0.4% vaginal cream than
with the vehicle placebo. Fever (1.7% Vs 0.5% with placebo) and chills
(0.4% Vs 0.0% with placebo) have also been reported. The therapy-related
dropout rate was 1.9%. The adverse drug experience on terconazole most
frequently causing discontinuation was vulvovaginal itching (0.6%), which
was lower than the incidence for placebo (0.9%). </p>

<p><a name="OVERDOSAGE"></a><b>OVERDOSAGE </b></p>

<p>Overdose of terconazole in humans has not been reported to date. In
the rat, the oral LD 50 values were found to be 1741 and 849 mg/kg for
the male and female, respectively. The oral LD 50 values for the male and
female dog were approximately or equal 1280 and &gt;/= 640 mg/kg, respectively.
</p>

<p><a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION
</b></p>

<p>One full applicator (5 g) of Terconazole Vaginal Cream (20 mg terconazole)
is administered intravaginally once daily at bedtime for seven consecutive
days. Before prescribing another course of therapy, the diagnosis should
be reconfirmed by smears and/or cultures and other pathogens commonly associated
with vulvovaginitis ruled out. The therapeutic effect of Terconazole Vaginal
Cream is not affected by menstruation. </p>

<h2 align=center>
<hr width="100%" ></h2>

<h2 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-3</DOCNO>
<DOCOLDNO>IA018-000200-B045-56</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/isomono2.htm 206.86.175.201 19970106232447 text/html 22806
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:18:30 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 22623
Last-modified: Thu, 31 Oct 1996 23:57:25 GMT
</DOCHDR>
<html>
<head>
   <title>Isosorbide Mononitrate - RxList Generic Information</title>
   <meta name="keywords" content="Imdur, Ismo, Monoket">
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Isosorbide Mononitrate</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<p><a name="DESCRIPTION"></a><b>DESCRIPTION </b></p>

<p>Isosorbide mononitrate (ISMN) is 1,4:3,6-dianhydro-D-glucitol,5-nitrate,
an organic nitrate and whose molecular weight is 191.14. The organic nitrates
are vasodilators, active on both arteries and veins. </p>

<p><a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY
</b></p>

<p>Isosorbide mononitrate is the major active metabolite of isosorbide
dinitrate (ISDN), and most of the clinical activity of the dinitrate is
attributable to the mononitrate. </p>

<p>The principal pharmacological action of isosorbide mononitrate is relaxation
of vascular smooth muscle and consequent dilatation of peripheral arteries
and veins, especially the latter. Dilation of the veins promotes peripheral
pooling of blood and decreases venous return to the heart, thereby reducing
left ventricular end-diastolic pressure and pulmonary capillary wedge pressure
(preload). Arteriolar relaxation reduces systemic vascular resistance,
systolic arterial pressure, and mean arterial pressure (afterload). Dilatation
of the coronary arteries also occurs. The relative importance of preload
reduction, afterload reduction, and coronary dilatation remains undefined.
</p>

<p>PHARMACODYNAMICS </p>

<p>Dosing regimens for most chronically used drugs are designed to provide
plasma concentrations that are continuously greater than a minimally effective
concentration. This strategy is inappropriate for organic nitrates. Several
well-controlled clinical trials have used exercise testing to assess the
antianginal efficacy of continuously-delivered nitrates. In the large majority
of these trials, active agents were indistinguishable from placebo after
24 hours (or less) of continuous therapy. Attempts to overcome tolerance
by dose escalation, even to doses far in excess of those used acutely,
have consistently failed. Only after nitrates have been absent from the
body for several hours has their antianginal efficacy been restored. </p>

<p>The drug-free interval sufficient to avoid tolerance to isosorbide mononitrate
has not been completely defined. In the only regimen of twice-daily isosorbide
mononitrate that has been shown to avoid development of tolerance, the
two doses of ISMN tablets are given 7 hours apart, so there is a gap of
17 hours between the second dose of each day and the first dose of the
next day. Taking account of the relatively long half-life of isosorbide
mononitrate this result is consistent with those obtained for other organic
nitrates. </p>

<p>The same twice-daily regimen of ISMN tablets successfully avoided significant
rebound/withdrawal effects. The incidence and magnitude of such phenomena
have appeared, in studies of other nitrates, to be highly dependent upon
the schedule of nitrate administration. </p>

<p>PHARMACOKINETICS </p>

<p>In humans, isosorbide mononitrate is not subject to first pass metabolism
in the liver. The absolute bioavailability of isosorbide mononitrate from
ISMN tablets is nearly 100%. Maximum serum concentrations of isosorbide
mononitrate are achieved 30 to 60 minutes after ingestion of ISMN. The
volume of distribution of isosorbide mononitrate is approximately 0.6 L/Kg,
and less than 4% is bound to plasma proteins. It is cleared from the serum
by denitration to isosorbide; glucuronidation to the mononitrate glucuronide;
and denitration/hydration to sorbitol. None of these metabolites is vasoactive.
Less than 1% of administered isosorbide mononitrate is eliminated in the
urine. </p>

<p>The overall elimination half-life of isosorbide mononitrate is about
5 hours; the rate of clearance is the same in healthy young adults, in
patients with various degrees of renal, hepatic, or cardiac dysfunction,
and in the elderly. In a single-dose study, the pharmacokinetics of isosorbide
mononitrate were dose-proportional up to at least 60 mg. </p>

<p>CLINICAL TRIALS </p>

<p>Controlled trials of single doses of ISMN tablets have demonstrated
that antianginal activity is present about 1 hour after dosing, with peak
effect seen from 1-4 hours after dosing. </p>

<p>In placebo-controlled trials lasting 2-3 weeks, ISMN tablets were administered
twice daily, in asymmetric regimens (with interdosing intervals of 7 and
17 hours) designed to avoid tolerance. One trial tested doses of 10 mg
and 20 mg; one trial tested doses of 20 mg, 40 mg, and 60 mg; and three
trials tested only doses of 20 mg. In each trial, the subjects were persons
with known chronic stable angina, and the primary measure of efficacy was
exercise tolerance on a standardized treadmill test. After initial dosing
and for at least three weeks, exercise tolerance in patients treated with
ISMN 20 mg tablets was significantly greater than that seen in patients
treated with placebo, although there was some attenuation of effect with
time. Treatment with ISMN tablets was superior to placebo for at least
12 hours after the first dose (i.e., 5 hours after the second dose) of
each day. Significant tolerance and rebound phenomena were not observed.
</p>

<p>The 10-mg dose was not unequivocally superior to placebo, while the
effect of the 40-mg dose was similar to that of the 20-mg dose. The 60-mg
dose appeared to be less effective, and it was associated with a rebound
phenomenon (early-morning worsening). </p>

<p><a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE </b></p>

<p>ISMN tablets are indicated for the prevention of angina pectoris due
to coronary artery disease. The onset of action of oral isosorbide mononitrate
is not sufficiently rapid for this product to be useful in aborting an
acute anginal episode. </p>

<p><a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS </b></p>

<p>Allergic reactions to organic nitrates are extremely rare, but they
do occur. Isosorbide mononitrate is contraindicated in patients who are
allergic to it. </p>

<p><a name="WARNINGS"></a><b>WARNINGS </b></p>

<p>The benefits of isosorbide mononitrate in patients with acute myocardial
infarction or congestive heart failure have not been established. Because
the effects of isosorbide mononitrate are difficult to terminate rapidly,
this drug is not recommended in these settings. </p>

<p>If isosorbide mononitrate is used in these conditions, careful clinical
or hemodynamic monitoring must be used to avoid the hazards of hypotension
and tachycardia. </p>

<p><a name="PRECAUTIONS"></a><b>PRECAUTIONS </b></p>

<p>GENERAL Severe hypotension, particularly with upright posture, may occur
with even small doses of isosorbide mononitrate. This drug should therefore
be used with caution in patients who may be volume depleted or who, for
whatever reason, are already hypotensive. Hypotension induced by isosorbide
mononitrate may be accompanied by paradoxical bradycardia and increased
angina pectoris. </p>

<p>Nitrate therapy may aggravate the angina caused by hypertrophic cardiomyopathy.
</p>

<p>In industrial workers who have had long-term exposure to unknown (presumably
high) doses of organic nitrates, tolerance clearly occurs. Chest pain,
acute myocardial infarction, and even sudden death have occurred during
temporary withdrawal of nitrates from these workers, demonstrating the
existence of true physical dependence. The importance of these observations
to the routine, clinical use of oral isosorbide mononitrate is not known.
</p>

<p>INFORMATION FOR PATIENTS </p>

<p>Patients should be told that the antianginal efficacy of ISMN tablets
can be maintained by carefully following the prescribed schedule of dosing
(two doses taken seven hours apart). For most patients, this can be accomplished
by taking the first dose on awakening and the second dose 7 hours later.
</p>

<p>As with other nitrates, daily headaches sometimes accompany treatment
with isosorbide mononitrate. In patients who get these headaches, the headaches
are a marker of the activity of the drug. Patients should resist the temptation
to avoid headaches by altering the schedule of their treatment with isosorbide
mononitrate, since loss of headache may be associated with simultaneous
loss of antianginal efficacy. Aspirin and/or acetaminophen, on the other
hand, often successfully relieve isosorbide mononitrate-induced headaches
with no deleterious effect on isosorbide mononitrate's antianginal efficacy.
</p>

<p>Treatment with isosorbide mononitrate may be associated with light-
headedness on standing, especially just after rising from a recumbent or
seated position. This effect may be more frequent in patients who have
also consumed alcohol. </p>

<p>CARCINOGENESIS, MUTAGENESIS, AND IMPAIRMENT OF FERTILITY 
<br>No carcinogenic effects were observed in mice exposed to oral isosorbide
mononitrate for 104 weeks at doses of up to 900 mg/kg/day (102 X the human
exposure comparing body surface area). Rats treated with 900 mg/kg/day
for 26 weeks (225 X the human exposure comparing body surface area) and
500 mg/kg/day for the remaining 95-111 weeks (males and females, respectively)
showed no evidence of tumors. </p>

<p>No mutagenic activity was seen in a variety of in vitro and in vivo
assays. </p>

<p>No adverse effects on fertility were observed when isosorbide mononitrate
was administered to male and female rats at doses of up to 500 mg/kg/day
(125 X the human exposure comparing body surface area). </p>

<p>PREGNANCY CATEGORY C </p>

<p>Isosorbide mononitrate has been shown to be associated with stillbirths
and neonatal death in rats receiving 500 mg/kg/day of isosorbide mononitrate
(125 X the human exposure comparing body surface area). At 250 mg/kg/day,
no adverse effects on reproduction and development were reported. </p>

<p>In rats and rabbits receiving isosorbide mononitrate at up to 250 mg/kg/day,
no developmental abnormalities, fetal abnormalities, or other effects upon
reproductive performance were detected; these doses are larger than the
maximum recommended human dose by factors between 70 (body-surface-area
basis in rabbits) and 310 (body-weight basis, either species). In rats
receiving 500 mg/kg/day, there were small but statistically significant
increases in the rates of prolonged gestation, prolonged parturition, stillbirth,
and neonatal death; and there were small but statistically significant
decreases in birth weight, live litter size, and pup survival. </p>

<p>There are no adequate and well-controlled studies in pregnant women.
Isosorbide mononitrate should be used during pregnancy only if the potential
benefit justifies the potential risk to the fetus. </p>

<p>NURSING MOTHERS </p>

<p>It is not known whether isosorbide mononitrate is excreted in human
milk. Because many drugs are excreted in human milk, caution should be
exercised when isosorbide mononitrate is administered to a nursing woman.
</p>

<p>PEDIATRIC USE </p>

<p>Safety and effectiveness of isosorbide mononitrate in children have
not been established. </p>

<p><a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS </b></p>

<p>The vasodilating effects of isosorbide mononitrate may be additive with
those of other vasodilators. Alcohol, in particular, has been found to
exhibit additive effects of this variety. </p>

<p>Marked symptomatic orthostatic hypotension has been reported when calcium
channel blockers and organic nitrates were used in combination. Dose adjustments
of either class of agents may be necessary. </p>

<p><a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS </b></p>

<p>The table below shows the frequencies of the adverse reactions observed
in more than 1% of the subjects (a) in 6 placebo-controlled domestic studies
in which patients in the active-treatment arm received 20 mg of isosorbide
mononitrate twice daily, and (b) in all studies in which patients received
isosorbide mononitrate in a variety of regimens. In parentheses, the same
table shows the frequencies with which these adverse reactions led to discontinuation
of treatment. Overall, eleven percent of the patients who received isosorbide
mononitrate in the six controlled U.S. studies discontinued treatment because
of adverse reactions. Most of these discontinued because of headache. &quot;Dizziness&quot;
and nausea were also frequently associated with withdrawal from these studies
(TABLE 1): </p>

<pre> 
                              TABLE 1 
           Frequency of Adverse Reactions (Discontinuations)* 
----------------------------------------------------------------------- 
                             6 Controlled                 92 Clinical 
                               Studies                      Studies 
----------------------------------------------------------------------- 
Dose                    Placebo          20 mg              (varied) 
----------------------------------------------------------------------- 
Patients                  204             219                 3344 
----------------------------------------------------------------------- 
Headache                9%  (0%)       38%  (9%)           19%  (4.3%) 
----------------------------------------------------------------------- 
Dizziness               1%  (0%)        5%  (1%)            3%  (0.2%) 
----------------------------------------------------------------------- 
Nausea, Vomiting       &lt;1%  (0%)        4%  (3%)            2%  (0.2%) 
----------------------------------------------------------------------- 
*Some individuals discontinued for multiple reasons. </pre>

<p>Other adverse reactions, each reported by fewer than 1% of exposed patients,
and in many cases of uncertain relation to drug treatment, were: </p>

<p>Cardiovascular: angina pectoris, arrhythmias, atrial fibrillation, hypotension,
palpitations, postural hypotension, premature ventricular contractions,
supraventricular tachycardia, syncope. </p>

<p>Dermatologic: pruritus, rash. </p>

<p>Gastrointestinal: abdominal pain, diarrhea, dyspepsia, tenesmus, tooth
disorder, vomiting. </p>

<p>Genitourinary: dysuria, impotence, urinary frequency. </p>

<p>Miscellaneous: asthenia, blurred vision, cold sweat, diplopia, edema,
malaise, neck stiffness, rigors. </p>

<p>Musculoskeletal: arthralgia. </p>

<p>Neurologic: agitation, anxiety, confusion, dyscoordination, hypoesthesia,
hypokinesia, increased appetite, insomnia, nervousness, nightmares. </p>

<p>Respiratory: bronchitis, pneumonia, upper respiratory tract infection.
</p>

<p>Extremely rarely, ordinary doses of organic nitrates have caused methemoglobinemia
in normal-seeming patients; for further discussion of its diagnosis and
treatment see under Overdosage. </p>

<p><a name="OVERDOSAGE"></a><b>OVERDOSAGE </b></p>

<p>HEMODYNAMIC EFFECTS </p>

<p>The ill effects of isosorbide mononitrate overdose are generally the
results of isosorbide mononitrate's capacity to induce vasodilatation,
venous pooling, reduced cardiac output, and hypotension. These hemodynamic
changes may have protean manifestations, including increased intracranial
pressure, with any or all of persistent throbbing headache, confusion,
and moderate fever; vertigo; palpitations; visual disturbances; nausea
and vomiting (possibly with colic and even bloody diarrhea); syncope (especially
in the upright posture); air hunger and dyspnea, later followed by reduced
ventilatory effort; diaphoresis, with the skin either flushed or cold and
clammy; heart block and bradycardia; paralysis; coma; seizures and death.
</p>

<p>Laboratory determinations of serum levels of isosorbide mononitrate
and its metabolites are not widely available, and such determinations have,
in any event, no established role in the management of isosorbide mononitrate
overdose. </p>

<p>There are no data suggesting what dose of isosorbide mononitrate is
likely to be life-threatening in humans. In rats and mice, there is significant
lethality at doses of 2000 mg/kg and 3000 mg/kg, respectively. </p>

<p>No data are available to suggest physiological maneuvers (e.g., maneuvers
to change the pH of the urine) that might accelerate elimination of isosorbide
mononitrate. In particular, dialysis is known to be ineffective in removing
isosorbide mononitrate from the body. </p>

<p>No specific antagonist to the vasodilator effects of isosorbide mononitrate
is known, and no intervention has been subject to controlled study as a
therapy of isosorbide mononitrate overdose. Because the hypotension associated
with isosorbide mononitrate overdose is the result of venodilatation and
arterial hypovolemia, prudent therapy in this situation should be directed
toward an increase in central fluid volume. Passive elevation of the patient's
legs may be sufficient, but intravenous infusion of normal saline or similar
fluid may also be necessary. </p>

<p>The use of epinephrine or other arterial vasoconstrictors in this setting
is likely to do more harm than good. </p>

<p>In patients with renal disease or congestive heart failure, therapy
resulting in central volume expansion is not without hazard. Treatment
of isosorbide mononitrate overdose in these patients may be subtle and
difficult, and invasive monitoring may be required. </p>

<p>METHEMOGLOBINEMIA </p>

<p>Methemoglobinemia has been reported in patients receiving other organic
nitrates, and it probably could also occur as a side effect of isosorbide
mononitrate. Certainly nitrate ions liberated during metabolism of isosorbide
mononitrate can oxidize hemoglobin into methemoglobin. Even in patients
totally without cytochrome b5 reductase activity, however, and even assuming
that the nitrate moiety of isosorbide mononitrate is quantitatively applied
to oxidation of hemoglobin, about 2 mg/kg of isosorbide mononitrate should
be required before any of these patients manifests clinically significant
(&amp;62 10%) methemoglobinemia. </p>

<p>In patients with normal reductase function, significant production of
methemoglobin should require even larger doses of isosorbide mononitrate.
In one study in which 36 patients received 2-4 weeks of continuous nitroglycerin
therapy at 3.1 to 4.4 mg/hr (equivalent, in total administered dose of
nitrate ions, to 7.8-11.1 mg of isosorbide mononitrate per hour), the average
methemoglobin level measured was 0.2%; this was comparable to that observed
in parallel patients who received placebo. </p>

<p>Notwithstanding these observations, there are case reports of significant
methemoglobinemia in association with moderate overdoses of organic nitrates.
None of the affected patients had been thought to be unusually susceptible.
</p>

<p>Methemoglobin levels are available from most clinical laboratories.
The diagnosis should be suspected in patients who exhibit signs of impaired
oxygen delivery despite adequate cardiac output and adequate arterial pO2.
Classically, methemoglobinemic blood is described as chocolate brown, without
color change on exposure to air. </p>

<p>When methemoglobinemia is diagnosed, the treatment of choice is methylene
blue, 1-2 mg/kg intravenously. </p>

<p><a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION
</b></p>

<p>The recommended regimen of ISMN tablets is 20 mg (one tablet) twice
daily, with the two doses given seven hours apart. For most patients, this
can be accomplished by taking the first dose on awakening and the second
dose 7 hours later. Dosage adjustments are not necessary for elderly patients
or patients with altered renal or hepatic function. As noted above (Clinical
Pharmacology), multiple studies of organic nitrates have shown that maintenance
of continuous 24-hour plasma levels results in refractory tolerance. The
dosing regimen for ISMN tablets provides a daily nitrate-free interval
to avoid the development of this tolerance. </p>

<p>As also noted under Clinical Pharmacology, well-controlled studies have
shown that tolerance to ISMN tablets is avoided when using the twice-daily
regimen in which the two doses are given seven hours apart. This regimen
has been shown to have antianginal efficacy beginning one hour after the
first dose and lasting at least five hours after the second dose. The duration
(if any) of antianginal activity beyond twelve hours has not been studied;
large controlled studies with other nitrates suggest that no dosing regimen
should be expected to provide more than about twelve hours of continuous
antianginal efficacy per day. </p>

<p>In clinical trials, ISMN tablets have been administered in a variety
of regimens. Single doses less than 20 mg have not been adequately studied,
while single doses greater than 20 mg have demonstrated no greater efficacy
than doses of 20 mg. </p>

<p>
<hr width="100%" ></p>

<h2 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-4</DOCNO>
<DOCOLDNO>IA019-000201-B023-164</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/rxlist.cgi?drug=antibiotic 206.86.175.201 19970106234015 text/html 2401
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:33:55 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE>www.rxlist.com - Neil Sandow, Pharm.D. 
copyright 1995</title></head> <body bgcolor="#ffffff">
<center><a href="http://www.rxlist.com"><img src="rx.gif" 
height=75 width=75 border=0><img src="count.gif" border=0></a></center> 
Searching for: <b>ANTIBIOTIC</b> <br>scroll down for results 
<hr><hr>
<h1>Enter Brand or Generic Name or Category*</h1>
<h3> Narrow Your Search with <font size=5>*</font>(examples: 
ampi*, *mycin, antibiotic*)</h3>
<form method=get>
<action=>
<input size=30 maxlength=30 name=drug>
<input type=submit>
<input type=reset>
</form>
<HR>
<H3>Your RxList Search Results:</h3>
1<br><b>Brand Name: </b>ANTIBIOTIC<br><b>Generic Name: </b>TYPE ANTIBIOT*<br><b>Category: </b>USE * TO SORT ON CATEGORY
<p>2<br><b>Brand Name: </b>ALLERGEN EAR<br><b>Generic Name: </b>ANTIPYRINE/BENZOCAINE<br><b>Category: </b>LOCAL ANESTHETICS
<p>3<br><b>Brand Name: </b>AURALGAN<br><b>Generic Name: </b>ANTIPYRINE/BENZOCAINE<br><b>Category: </b>LOCAL ANESTHETICS
<p>4<br><b>Brand Name: </b>AUROTO EAR<br><b>Generic Name: </b>ANTIPYRINE/BENZOCAINE<br><b>Category: </b>LOCAL ANESTHETICS
<p>5<br><b>Brand Name: </b>A/B OTIC<br><b>Generic Name: </b>ANTIPYRINE/BENZOCAINE<br><b>Category: </b>LOCAL ANESTHETICS
<p>6<br><b>Brand Name: </b>ANTIVENIN<br><b>Generic Name: </b>ANTIVENIN-LATRODECTUS MAC<br><b>Category: </b>SERUMS
<p>7<br><b>Brand Name: </b>ANTIVENIN SER<br><b>Generic Name: </b>ANTIVENIN-POLYVALENT CROT<br><b>Category: </b>SERUMS
<p>8<br><b>Brand Name: </b>ANTABUSE<br><b>Generic Name: </b>DISULFIRAM<br><b>Category: </b>UNCLASSIFIED THERAPEUTIC AGENTS
<p>9<br><b>Brand Name: </b>ANTIVERT<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/mecliz.htm">MECLIZINE HCL</a><br><b>Category: </b>ANTIEMETICS
<p>10<br><b>Brand Name: </b>A-METHAPRED<br><b>Generic Name: </b>METHYLPRED NA SUCC<br><b>Category: </b>ADRENALS
<p>11<br><b>Brand Name: </b>ANTIFUNGAL<br><b>Generic Name: </b>MICONAZOLE NITRATE<br><b>Category: </b>ANTIFUNGALS
<p>12<br><b>Brand Name: </b>ANTIBIOTC EAR<br><b>Generic Name: </b>NEOMYCIN/POLYMYXIN B/HC<br><b>Category: </b>ANTIBIOTICS
<p>13<br><b>Brand Name: </b>ANTIFUNGAL<br><b>Generic Name: </b>TOLNAFTATE<br><b>Category: </b>ANTIFUNGALS
<p></body></html>
<P><hr><a href="http://www.rxlist.com"><b>RxList Home Page</ul>
<hr>
</DOC>
<DOC>
<DOCNO>WT08-B13-5</DOCNO>
<DOCOLDNO>IA018-000200-B035-150</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/nizat.htm 206.86.175.201 19970106224820 text/html 29357
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:42:01 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 29174
Last-modified: Thu, 11 Jul 1996 06:08:40 GMT
</DOCHDR>
<html>
<head>
   <title>Nizatidine - RxList Generic Information</title>
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Nizatidine</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[warn!] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<p><a name="DESCRIPTION"></a><b>DESCRIPTION </b></p>

<p>Nizatidine is a histamine H2-receptor antagonist. Chemically, it is
N-(2-(((2-((dimethylamino)methyl)-4-thiazolyl)methyl)thio) ethyl)-N'-methyl-
2-nitro-1,1-ethenediamine. </p>

<p>Nizatidine has the empirical formula C12H21N5O2S2 representing a molecular
weight of 331.45. It is an off-white to buff crystalline solid that is
soluble in water. Nizatidine has a bitter taste and mild sulfur-like odor.
</p>

<p><a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY
</b></p>

<p>Nizatidine is a competitive, reversible inhibitor of histamine at the
histamine H2-receptors, particularly those in the gastric parietal cells.
</p>

<p>Antisecretory Activity</p>

<p>1. EFFECTS ON ACID SECRETION: Nizatidine significantly inhibited nocturnal
gastric acid secretion for up to 12 hours. Nizatidine also significantly
inhibited gastric acid secretion stimulated by food, caffeine, betazole,
and pentagastrin (Table 1). </p>

<pre>                     Table 1                                                    
  Effect of Oral Nizatidine on Gastric Acid Secretion                                 
-------------------------------------------------                               
                             % Inhibition of                                    
             Time After        Gastric Acid                                     
             Dose (h)      OUTPUT BY DOSE (MG)                                  
                        20-50  75  100  150  300                                
-------------------------------------------------                               
Nocturnal    Up to 10     57        73        90                                
Betazole     Up to 3           93       100   99                                
Pentagastrin Up to 6           25        64   67                                
Meal         Up to 4      41   64        98   97                                
Caffeine     Up to 3           73        85   96                                
-------------------------------------------------                               </pre>

<p>2. EFFECTS ON OTHER GASTROINTESTINAL SECRETIONS--PEPSIN: Oral administration
of 75 to 300 mg of Nizatidine did not affect pepsin activity in gastric
secretions. Total pepsin output was reduced in proportion to the reduced
volume of gastric secretions. </p>

<p>INTRINSIC FACTOR: Oral administration of 75 to 300 mg of Nizatidine
increased betazole-stimulated secretion of intrinsic factor. </p>

<p>SERUM GASTRIN: Nizatidine had no effect on basal serum gastrin. No rebound
of gastrin secretion was observed when food was ingested 12 hours after
administration of Nizatidine. </p>

<p>3. OTHER PHARMACOLOGIC ACTIONS-- </p>

<p>a. HORMONES: Nizatidine was not shown to affect the serum concentrations
of gonadotropins, prolactin, growth hormone, antidiuretic hormone, cortisol,
triiodothyronine, thyroxin, testosterone, 5alpha-dihydrotestosterone, androstenedione,
or estradiol. </p>

<p>b. Nizatidine had no demonstrable antiandrogenic action. </p>

<p>4. PHARMACOKINETICS--The absolute oral bioavailability of nizatidine
exceeds 70%. Peak plasma concentrations (700 to 1,800 mcgm/L for a 150-mg
dose and 1 400 to 3,600 mcgm/L for a 300-mg dose) occur from 0.5 to 3 hours
following the dose. A concentration of 1,000 mcgm/L is equivalent to 3
micromol/L; a dose of 300 mg is equivalent to 905 micromoles. Plasma concentrations
12 hours after administration are less than 10 mcgm/L. The elimination
half-life is 1 to 2 hours, plasma clearance is 40 to 60 L/h, and the volume
of distribution is 0.8 to 1.5 L/kg. </p>

<p>Because of the short half-life and rapid clearance of nizatidine, accumulation
of the drug would not be expected in individuals with normal renal function
who take either 300 mg once daily at bedtime or 150 mg twice daily. Nizatidine
exhibits dose proportionality over the recommended dose range. </p>

<p>The oral bioavailability of nizatidine is unaffected by concomitant
ingestion of propantheline. Antacids consisting of aluminum and magnesium
hydroxides with simethicone decrease the absorption of nizatidine by about
10%. With food, the AUC and Cmax increase by approximately 10%. </p>

<p>In humans, less than 7% of an oral dose is metabolized as N2 monodesmethylnizatidine,
an H2-receptor antagonist, which is the principal metabolite excreted in
the urine. Other likely metabolites are the N2-oxide (less than 5% of the
dose) and the S-oxide (less than 6% of the dose). </p>

<p>More than 90% of an oral dose of nizatidine is excreted in the urine
within 12 hours. About 60% of an oral dose is excreted as unchanged drug.
Renal clearance is about 500 mL/min, which indicates excretion by active
tubular secretion. Less than 6% of an administered dose is eliminated in
the feces. </p>

<p>Moderate to severe renal impairment significantly prolongs the half-life
and decreases the clearance of nizatidine. In individuals who are functionally
anephric, the half-life is 3.5 to 11 hours, and the plasma clearance is
7 to 14 L/h. To avoid accumulation of the drug in individuals with clinically
significant renal impairment, the amount and/or frequency of doses of Nizatidine
should be reduced in proportion to the severity of dysfunction (See Dosage
and Administration). </p>

<p>Approximately 35% of nizatidine is bound to plasma protein, mainly to
alpha1- acid glycoprotein. Warfarin, diazepam, acetaminophen, propantheline,
phenobarbital, and propranolol did not affect plasma protein binding of
nizatidine in vitro. </p>

<p>Clinical Trials</p>

<p>1. ACTIVE DUODENAL ULCER: In multicenter, double-blind, placebo-controlled
studies in the United States, endoscopically diagnosed duodenal ulcers
healed more rapidly following administration of Nizatidine, 300 mg h.s.
or 150 mg b.i.d., than with placebo (Table 2). Lower doses, such as 100
mg h.s., had slightly lower effectiveness. </p>

<pre>------------------------------------------------------------------------        
                              Table 2                                           
                 Healing Response of Ulcers to Nizatidine              
                          Nizatidine                           PLACEBO                
------------------------------------------------------------------------        
             300 mg h.s.          150 mg b.i.d.      Number   Healed/           
         Number   Healed/      Number   Healed/     Entered  Evaluable          
        Entered  Evaluable    Entered  Evaluable                                
STUDY 1                                                                         
 Week 2                        276    93/265 (35%)*   279   55/260 (21%)        
 Week 4                              198/259 (76%)*         95/243 (39%)        
STUDY 2                                                                         
 Week 2   108  24/103 (23%)*   106    27/101 (27%)*   101    9/93  (10%)        
 Week 4        65/97  (67%)*          66/97  (68%)*         24/84  (29%)        
STUDY 3                                                                         
 Week 2    92  22/90  (24%)**                          98   13/92  (14%)        
 Week 4        52/85  (61%)*                                29/88  (33%)        
 Week 8        68/83  (82%)*                                39/79  (49%)        
------------------------------------------------------------------------        </pre>

<p>* P &lt;0.01 as compared with placebo. ** P &lt;0.05 as compared with
placebo. ------------------------------------------------------------------------</p>

<p>2. MAINTENANCE OF HEALED DUODENAL ULCER: </p>

<p>Treatment with a reduced dose of Nizatidine has been shown to be effective
as maintenance therapy following healing of active duodenal ulcers. In
multicenter double-blind, placebo-controlled studies conducted in the United
States, 150 mg of Nizatidine taken at bedtime resulted in a significantly
lower incidence of duodenal ulcer recurrence in patients treated for up
to 1 year (Table 3). </p>

<pre>                     Table 3                                                    
  Percentage of Ulcers Recurring by 3, 6, and 12                                
                    Months in                                                   
   Double-Blind Studies Conducted in the United                                 
                      States                                                    
MONTH       Nizatidine, 150 MG H.S.         PLACEBO                                   
   3          13% (28/208)*        40% (82/204)                                 
   6          24% (45/188)*        57% (106/187)                                
  12          34% (57/166)*        64% (112/175)                                
-------------------------------------------------                               </pre>

<p>* P &lt;0.001 as compared with placebo. </p>

<p>3. GASTROESOPHAGEAL REFLUX DISEASE (GERD): </p>

<p>In 2 multicenter, double-blind, placebo-controlled clinical trials performed
in the United States and Canada, Nizatidine was more effective than placebo
in improving endoscopically diagnosed esophagitis and in healing erosive
and ulcerative esophagitis. </p>

<p>In patients with erosive or ulcerative esophagitis, 150 mg b.i.d. of
Nizatidine given to 88 patients compared with placebo in 98 patients in
Study 1 yielded a higher healing rate at 3 weeks (16% vs 7%) and at 6 weeks
(32% vs 16%, P&lt;0.05). Of 99 patients on Nizatidine and 94 patients on
placebo, Study 2 at the same dosage yielded similar results at 6 weeks
(21% vs 11%, P&lt;0.05) and at 12 weeks (29% vs 13%, P&lt;0.01). </p>

<p>In addition, relief of associated heartburn was greater in patients
treated with Nizatidine. Patients treated with Nizatidine consumed fewer
antacids than did patients treated with placebo. </p>

<p><a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE </b></p>

<p>Nizatidine is indicated for up to 8 weeks for the treatment of active
duodenal ulcer. In most patients, the ulcer will heal within 4 weeks. </p>

<p>Nizatidine is indicated for maintenance therapy for duodenal ulcer patients,
at a reduced dosage of 150 mg h.s. after healing of an active duodenal
ulcer. The consequences of continuous therapy with Nizatidine for longer
than 1 year are not known. </p>

<p>Nizatidine is indicated for up to 12 weeks for the treatment of endoscopically
diagnosed esophagitis, including erosive and ulcerative esophagitis, and
associated heartburn due to GERD. </p>

<p><a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS </b></p>

<p>Nizatidine is contraindicated in patients with known hypersensitivity
to the drug. Because cross sensitivity in this class of compounds has been
observed, H2-receptor antagonists, including Nizatidine, should not be
administered to patients with a history of hypersensitivity to other H2-receptor
antagonists. </p>

<p><a name="PRECAUTIONS"></a><b>PRECAUTIONS </b></p>

<p>General</p>

<p>1. Symptomatic response to nizatidine therapy does not preclude the
presence of gastric malignancy. </p>

<p>2. Because nizatidine is excreted primarily by the kidney, dosage should
be reduced in patients with moderate to severe renal insufficiency (See
Dosage and Administration). </p>

<p>3. Pharmacokinetic studies in patients with hepatorenal syndrome have
not been done. Part of the dose of nizatidine is metabolized in the liver.
In patients with normal renal function and uncomplicated hepatic dysfunction,
the disposition of nizatidine is similar to that in normal subjects.</p>

<p>Laboratory Tests--False-positive tests for urobilinogen with Multistix
may occur during therapy with nizatidine. </p>

<p>Drug Interactions--No interactions have been observed between Nizatidine
and theophylline, chlordiazepoxide, lorazepam, lidocaine, phenytoin, and
warfarin. Nizatidine does not inhibit the cytochrome P-450-linked drug
metabolizing enzyme system; therefore, drug interactions mediated by inhibition
of hepatic metabolism are not expected to occur. In patients given very
high doses (3,900 mg) of aspirin daily, increases in serum salicylate levels
were seen when nizatidine, 150 mg b.i.d., was administered concurrently.
</p>

<p>Carcinogenesis, Mutagenesis, Impairment Of Fertility--A 2-year oral
carcinogenicity study in rats with doses as high as 500 mg/kg/day (about
80 times the recommended daily therapeutic dose) showed no evidence of
a carcinogenic effect. There was a dose-related increase in the density
of enterochromaffin-like (ECL) cells in the gastric oxyntic mucosa. In
a 2-year study in mice, there was no evidence of a carcinogenic effect
in male mice, although hyperplastic nodules of the liver were increased
in the high-dose males as compared with placebo. Female mice given the
high dose of Nizatidine (2,000 mg/kg/day, about 330 times the human dose)
showed marginally statistically significant increases in hepatic carcinoma
and hepatic nodular hyperplasia with no numerical increase seen in any
of the other dose groups. The rate of hepatic carcinoma in the high-dose
animals was within the historical control limits seen for the strain of
mice used. The female mice were given a dose larger than the maximum tolerated
dose, as indicated by excessive (30%) weight decrement as compared with
concurrent controls and evidence of mild liver injury (transaminase elevations).
The occurrence of a marginal finding at high dose only in animals given
an excessive and somewhat hepatotoxic dose, with no evidence of a carcinogenic
effect in rats, male mice, and female mice (given up to 360 mg/kg/day,
about 60 times the human dose), and a negative mutagenicity battery are
not considered evidence of a carcinogenic potential for Nizatidine. </p>

<p>Nizatidine was not mutagenic in a battery of tests performed to evaluate
its potential genetic toxicity, including bacterial mutation tests, unscheduled
DNA synthesis, sister chromatid exchange, the mouse lymphoma assay, chromosome
aberration tests, and a micronucleus test. </p>

<p>In a 2-generation, perinatal and postnatal fertility study in rats,
doses of nizatidine up to 650 mg/kg/day produced no adverse effects on
the reproductive performance of parental animals or their progeny. </p>

<p>Pregnancy--Teratogenic Effects--Pregnancy Category C--Oral reproduction
studies in rats at doses up to 300 times the human dose and in Dutch Belted
rabbits at doses up to 55 times the human dose revealed no evidence of
impaired fertility or teratogenic effect; but, at a dose equivalent to
300 times the human dose, treated rabbits had abortions, decreased number
of live fetuses, and depressed fetal weights. On intravenous administration
to pregnant New Zealand White rabbits, nizatidine at 20 mg/kg produced
cardiac enlargement, coarctation of the aortic arch, and cutaneous edema
in 1 fetus, and at 50 mg/kg, it produced ventricular anomaly, distended
abdomen, spina bifida, hydrocephaly, and enlarged heart in 1 fetus. There
are, however, no adequate and well-controlled studies in pregnant women.
It is also not known whether nizatidine can cause fetal harm when administered
to a pregnant woman or can affect reproduction capacity. Nizatidine should
be used during pregnancy only if the potential benefit justifies the potential
risk to the fetus. </p>

<p>Nursing Mothers--Studies conducted in lactating women have shown that
0.1% of the administered oral dose of nizatidine is secreted in human milk
in proportion to plasma concentrations. Because of the growth depression
in pups reared by lactating rats treated with nizatidine, a decision should
be made whether to discontinue nursing or discontinue the drug, taking
into account the importance of the drug to the mother. </p>

<p>Pediatric Use--Safety and effectiveness in children have not been established.
</p>

<p>Use In Elderly Patients--Ulcer healing rates in elderly patients are
similar to those in younger age groups. The incidence rates of adverse
events and laboratory test abnormalities are also similar to those seen
in other age groups. Age alone may not be an important factor in the disposition
of nizatidine. Elderly patients may have reduced renal function (See Dosage
and Administration). </p>

<p><a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS </b></p>

<p>No interactions have been observed between Nizatidine and theophylline,
chlordiazepoxide, lorazepam, lidocaine, phenytoin, and warfarin. Nizatidine
does not inhibit the cytochrome P-450-linked drug-metabolizing enzyme system;
therefore, drug interactions mediated by inhibition of hepatic metabolism
are not expected to occur. In patients given very high doses (3,900 mg)
of aspirin daily, increases in serum salicylate levels were seen when nizatidine,
150 mg b.i.d., was administered concurrently. </p>

<p>(See Also PRECAUTIONS and ACTIONS/CLINICAL PHARMACOLOGY) </p>

<p><a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS </b></p>

<p>Worldwide, controlled clinical trials of nizatidine included over 6,000
patients given nizatidine in studies of varying durations. Placebo-controlled
trials in the United States and Canada included over 2,600 patients given
nizatidine and over 1,700 given placebo. Among the adverse events in these
placebo-controlled trials, anemia (0.2% vs 0%) and urticaria (0.5% vs 0.1%)
were significantly more common in the nizatidine group. </p>

<p>Incidence In Placebo-Controlled Clinical Trials In The United States
And Canada -Table 4 lists adverse events that occurred at a frequency of
1% or more among nizatidine-treated patients who participated in placebo-controlled
trials. The cited figures provide some basis for estimating the relative
contribution of drug and nondrug factors to the side effect incidence rate
in the population studied. </p>

<pre>                Table 4                                                         
                               
  INCIDENCE OF TREATMENT-EMERGENT                                               
ADVERSE EVENTS IN PLACEBO-CONTROLLED                                            
         CLINICAL TRIALS                                                        
  IN THE UNITED STATES AND CANADA                                               
------------------------------------------------------------------------------- 
                            PERCENTAGE OF PATIENTS                              
                              REPORTING EVENT                                   
BODY SYSTEM/ADVERSE EVENT*  NIZATIDINE    PLACEBO                               
                            (N = 2,694)  (N = 1,729)                            
BODY AS A WHOLE                                                                 
 Headache                     16.6          15.6                                
 Abdominal pain                7.5          12.5                                
 Pain                          4.2           3.8                                
 Asthenia                      3.1           2.9                                
 Back pain                     2.4           2.6                                
 Chest pain                    2.3           2.1                                
 Infection                     1.7           1.1                                
 Fever                         1.6           2.3                                
 Surgical procedure            1.4           1.5                                
 Injury, accident              1.2           0.9                                
DIGESTIVE                                                                       
 Diarrhea                      7.2           6.9                                
 Nausea                        5.4           7.4                                
 Flatulence                    4.9           5.4                                
 Vomiting                      3.6           5.6                                
 Dyspepsia                     3.6           4.4                                
 Constipation                  2.5           3.8                                
 Dry mouth                     1.4           1.3                                
 Nausea and vomiting           1.2           1.9                                
 Anorexia                      1.2           1.6                                
 Gastrointestinal disorder     1.1           1.2                                
 Tooth disorder                1.0           0.8                                
MUSCULOSKELETAL                                                                 
 Myalgia                       1.7           1.5                                
NERVOUS                                                                         
 Dizziness                     4.6           3.8                                
 Insomnia                      2.7           3.4                                
 Abnormal dreams               1.9           1.9                                
 Somnolence                    1.9           1.6                                
 Anxiety                       1.6           1.4                                
 Nervousness                   1.1           0.8                                
RESPIRATORY                                                                     
 Rhinitis                      9.8           9.6                                
 Pharyngitis                   3.3           3.1                                
 Sinusitis                     2.4           2.1                                
 Cough, increased              2.0           2.0                                
SKIN AND APPENDAGES                                                             
 Rash                          1.9           2.1                                
 Pruritus                      1.7           1.3                                
SPECIAL SENSES                                                                  
 Amblyopia                     1.0           0.9                                
------------------------------------------------------------------------------- </pre>

<p>*Events reported by at least 1% of nizatidine-treated patients are included.
-------------------------------------------------------------------------------
</p>

<p>A variety of less common events were also reported; it was not possible
to determine whether these were caused by nizatidine. </p>

<p>Hepatic--Hepatocellular injury, evidenced by elevated liver enzyme tests
(SGOT (AST), SGPT (ALT), or alkaline phosphatase), occurred in some patients
and was possibly or probably related to nizatidine. In some cases there
was marked elevation of SGOT/SGPT enzymes (greater than 500 IU/L) and,
in a single instance, SGPT was greater than 2,000 IU/L. The overall rate
of occurrences of elevated liver enzymes and elevations to 3 times the
upper limit of normal, however, did not significantly differ from the rate
of liver enzyme abnormalities in placebo-treated patients. All abnormalities
were reversible after discontinuation of Nizatidine . Since market introduction,
hepatitis and jaundice have been reported. Rare cases of cholestatic or
mixed hepatocellular and cholestatic injury with jaundice have been reported
with reversal of the abnormalities after discontinuation of Nizatidine.
</p>

<p>Cardiovascular--In clinical pharmacology studies, short episodes of
asymptomatic ventricular tachycardia occurred in 2 individuals administered
Nizatidine and in 3 untreated subjects. </p>

<p>CNS--Rare cases of reversible mental confusion have been reported. </p>

<p>Endocrine--Clinical pharmacology studies and controlled clinical trials
showed no evidence of antiandrogenic activity due to Nizatidine. Impotence
and decreased libido were reported with similar frequency by patients who
received Nizatidine and by those given placebo. Rare reports of gynecomastia
occurred. </p>

<p>Hematologic--Anemia was reported significantly more frequently in nizatidine-
than in placebo-treated patients. Fatal thrombocytopenia was reported in
a patient who was treated with Nizatidine and another H2-receptor antagonist.
On previous occasions, this patient had experienced thrombocytopenia while
taking other drugs. Rare cases of thrombocytopenic purpura have been reported.
</p>

<p>Integumental--Sweating and urticaria were reported significantly more
frequently in nizatidine- than in placebo-treated patients. Rash and exfoliative
dermatitis were also reported. </p>

<p>Hypersensitivity--As with other H2-receptor antagonists, rare cases
of anaphylaxis following administration of nizatidine have been reported.
Rare episodes of hypersensitivity reactions (eg, bronchospasm, laryngeal
edema, rash and eosinophilia) have been reported. </p>

<p>Other--Hyperuricemia unassociated with gout or nephrolithiasis was reported.
Eosinophilia, fever, and nausea related to nizatidine administration have
been reported. </p>

<p><a name="OVERDOSAGE"></a><b>OVERDOSAGE </b></p>

<p>Overdoses of Nizatidine have been reported rarely. The following is
provided to serve as a guide should such an overdose be encountered. </p>

<p>Signs And Symptoms--There is little clinical experience with overdosage
of Nizatidine in humans. Test animals that received large doses of nizatidine
have exhibited cholinergic-type effects, including lacrimation, salivation,
emesis, miosis, and diarrhea. Single oral doses of 800 mg/kg in dogs and
of 1,200 mg/kg in monkeys were not lethal. Intravenous median lethal doses
in the rat and mouse were 301 mg/kg and 232 mg/kg respectively. </p>

<p>Treatment--To obtain up-to-date information about the treatment of overdose,
a good resource is your certified Regional Poison Control Center. Telephone
numbers of certified poison control centers are listed in the Physicians'
Desk Reference (). In managing overdosage, consider the possibility of
multiple drug overdoses, interaction among drugs, and unusual drug kinetics
in your patient. </p>

<p>If overdosage occurs, use of activated charcoal, emesis, or lavage should
be considered along with clinical monitoring and supportive therapy. The
ability of hemodialysis to remove nizatidine from the body has not been
conclusively demonstrated; however, due to its large volume of distribution,
nizatidine is not expected to be efficiently removed from the body by this
method. </p>

<p><a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION
</b></p>

<p>Active Duodenal Ulcer--The recommended oral dosage for adults is 300
mg once daily at bedtime. An alternative dosage regimen is 150 mg twice
daily. </p>

<p>Maintenance Of Healed Duodenal Ulcer--The recommended oral dosage for
adults is 150 mg once daily at bedtime. </p>

<p>Gastroesophageal Reflux Disease--The recommended oral dosage in adults
for the treatment of erosions, ulcerations, and associated heartburn is
150 mg twice daily. </p>

<p>Dosage Adjustment For Patients With Moderate To Severe Renal Insufficiency--The
dose for patients with renal dysfunction should be reduced as follows:
</p>

<p>ACTIVE DUODENAL ULCER OR GERD CCR DOSE 20-50 mL/min 150 mg daily &lt;20
mL/min 150 mg every other day MAINTENANCE THERAPY CCR DOSE 20-50 mL/min
150 mg every other day &lt;20 mL/min 150 mg every 3 days </p>

<p>Some elderly patients may have creatinine clearances of less than 50
mL/min, and, based on pharmacokinetic data in patients with renal impairment,
the dose for such patients should be reduced accordingly. The clinical
effects of this dosage reduction in patients with renal failure have not
been evaluated. </p>

<h2 align=center>
<hr width="100%" ><a href="http://www.rxlist.com/top200.htm">Top 200&nbsp;&nbsp;
<a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;Rxlist
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-6</DOCNO>
<DOCOLDNO>IA019-000201-B023-182</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/rxlist.cgi?drug=lithium 206.86.175.201 19970106234028 text/html 1047
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:34:12 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE>www.rxlist.com - Neil Sandow, Pharm.D. 
copyright 1995</title></head> <body bgcolor="#ffffff">
<center><a href="http://www.rxlist.com"><img src="rx.gif" 
height=75 width=75 border=0><img src="count.gif" border=0></a></center> 
Searching for: <b>LITHIUM</b> <br>scroll down for results 
<hr><hr>
<h1>Enter Brand or Generic Name or Category*</h1>
<h3> Narrow Your Search with <font size=5>*</font>(examples: 
ampi*, *mycin, antibiotic*)</h3>
<form method=get>
<action=>
<input size=30 maxlength=30 name=drug>
<input type=submit>
<input type=reset>
</form>
<HR>
<H3>Your RxList Search Results:</h3>
1<br><b>Brand Name: </b>LODINE<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/etodolac.htm">ETODOLAC</A><br><b>Category: </b><a href="http://www.rxlist.com/nsaid.htm">NONSTEROIDAL ANTIINFLAMMATORY AGENTS</a> 
<p></body></html>
<P><hr><a href="http://www.rxlist.com"><b>RxList Home Page</ul>
<hr>
</DOC>
<DOC>
<DOCNO>WT08-B13-7</DOCNO>
<DOCOLDNO>IA018-000200-B038-167</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/astem.htm 206.86.175.201 19970106230038 text/html 23111
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:54:13 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 22928
Last-modified: Wed, 13 Nov 1996 00:09:12 GMT
</DOCHDR>
<html>
<head>
   <title>Astemizole - RxList Generic Information</title>
<meta name="keywords" content="Hismanal">
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Astemizole</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<p><a name="DESCRIPTION"></a><b>DESCRIPTION </b></p>

<p>Astemizole is a histamine H1-receptor antagonist available in scored
white tablets for oral use.. Astemizole is chemically designated as 1-
((4-fluorophenyl)-methyl)-N-(1-(2-(4-methoxyphenyl)ethyl)-4-piperidinyl)-1H-
benzimidazol-2-amine, with a molecular weight of 458.58. The empirical
formula is C28H31FN4O. </p>

<p>Astemizole is a white to slightly off-white powder; it is insoluble
in water, slightly soluble in ethanol and soluble in chloroform and methanol.
</p>

<p><a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY
</b></p>

<p>Astemizole is a long-acting, selective histamine H1-receptor antagonist.
Receptor binding studies in animals demonstrated that at pharmacological
doses, Astemizole occupies peripheral H1-receptors but does not reach H1-receptors
in the brain. Whole body autoradiographic studies in rats, radiolabel tissue
distribution studies in dogs and radioligand binding studies of guinea
pig brain H1 receptors have shown that Astemizole does not readily cross
the blood-brain barrier. Screening studies in rats at effective antihistaminic
doses showed no anticholinergic effects. Studies in humans using the recommended
dosage regimens have not been performed to determine whether Astemizole
is associated with a different frequency of anticholinergic effects than
therapeutic doses of other antihistamines. </p>

<p>The absorption of Astemizole is reduced by 60% when taken with meals.
In single oral dose studies, Astemizole was rapidly absorbed from the gastrointestinal
tract; peak plasma concentrations of unchanged Astemizole were reached
within one hour. Due to extensive first pass metabolism and significant
tissue distribution, plasma concentrations of unchanged drug were low.
Elimination of unchanged Astemizole occurred with a half-life of approximately
one day. Elimination of Astemizole plus hydroxylated metabolites, considered
together to represent the pharmacologically active fraction in plasma,
was biphasic with half-lives of 20 hours for the distribution phase and
7-11 days for the elimination phase. The pharmacokinetics of Astemizole
plus hydroxylated metabolites are dose proportional following single doses
of 10 to 30 mg. </p>

<p>Following chronic administration, steady state plasma concentrations
of Astemizole plus hydroxylated metabolites (mainly desmethylastemizole)
were reached within four to eight weeks; concentrations of the metabolites
are substantially higher than those of unchanged Astemizole. Astemizole
plus hydroxylated metabolites decayed biphasically with an initial half-life
of 7-9 days, with plasma concentrations being reduced by 75% within this
phase, and with a terminal half-life of about 19 days. The initial phase
(t1/2 = 7-9 days) appears to determine the time to reach steady state plasma
concentrations of Astemizole plus hydroxylated metabolites. Steady state
plasma concentrations of unchanged Astemizole were reached by 6 days (with
a range of 6-9 days); unchanged Astemizole was eliminated from plasma with
a half-life of approximately 2 days (with a range of 1-2.5 days). </p>

<p>Excretion and metabolism studies with 14C-labeled Astemizole in volunteers
demonstrated that the drug is almost completely metabolized in the liver
and primarily excreted in the feces. </p>

<p>Interpatient variability in pharmacokinetic parameters may be greater
in patients with liver disease as compared to normal subjects. Systematic
evaluation of the pharmacokinetics in patients with hepatic or renal dysfunction
has not been performed. </p>

<p>The in-vitro plasma protein binding of unchanged Astemizole (100 ng/mL)
was 96.7% with 2.3% being found as free drug in the plasma water. In human
blood with an astemizole concentration of 100 ng/mL, 61.5% of astemizole
was bound to the plasma proteins, with 36.2% being distributed to the blood
cell fraction. The concentration of astemizole found in the blood was the
same as that found in the plasma fraction of the blood. Binding studies
for the astemizole metabolite(s) which achieve much higher concentrations
than astemizole under chronic dosing conditions have not been conducted.
</p>

<p><a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE </b></p>

<p>Astemizole tablets are indicated for the relief of symptoms associated
with seasonal allergic rhinitis and chronic idiopathic urticaria. Astemizole
should not be used as a p r n product for immediate relief of symptoms.
Patients should be advised not to increase the dose in an attempt to accelerate
the onset of action. </p>

<p>Clinical studies have not been conducted to evaluate the effectiveness
of Astemizole in the common cold. </p>

<p><a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS </b></p>

<p>CONCOMITANT ADMINISTRATION OF ASTEMIZOLE WITH ERYTHROMYCIN IS CONTRAINDICATED
BECAUSE ERYTHROMYCIN IS KNOWN TO IMPAIR THE CYTOCHROME P450 ENZYME SYSTEM
WHICH ALSO INFLUENCES ASTEMIZOLE METABOLISM. THERE HAVE BEEN TWO REPORTS
TO DATE OF SYNCOPE WITH TORSADES DE POINTES, REQUIRING HOSPITALIZATION,
IN PATIENTS TAKING COMBINATIONS OF Astemizole 10 MG DAILY WITH ERYTHROMYCIN.
IN EACH CASE THE QT INTERVALS WERE PROLONGED BEYOND 650 MILLISECONDS AT
THE TIME OF THE EVENT; ONE PATIENT ALSO RECEIVED KETOCONAZOLE AND THE OTHER
PATIENT ALSO HAD HYPOKALEMIA. </p>

<p>CONCOMITANT ADMINISTRATION OF ASTEMIZOLE WITH KETOCONAZOLE TABLETS IS
CONTRAINDICATED BECAUSE AVAILABLE HUMAN PHARMACOKINETIC DATA INDICATE THAT
ORAL KETOCONAZOLE SIGNIFICANTLY INHIBITS THE METABOLISM OF ASTEMIZOLE,
RESULTING IN ELEVATED PLASMA LEVELS OF ASTEMIZOLE AND DESMETHYLASTEMIZOLE.
DATA SUGGEST THAT CARDIOVASCULAR EVENTS ARE ASSOCIATED WITH ELEVATION OF
ASTEMIZOLE AND/OR ASTEMIZOLE METABOLITE LEVELS, RESULTING IN ELECTROCARDIOGRAPHIC
QT PROLONGATION. </p>

<p>CONCOMITANT ADMINISTRATION OF ASTEMIZOLE WITH ITRACONAZOLE IS ALSO CONTRAINDICATED
BASED ON THE CHEMICAL RESEMBLANCE OF ITRACONAZOLE AND </p>

<p>KETOCONAZOLE. IN-VITRO DATA SUGGEST THAT ITRACONAZOLE HAS A LESS PRONOUNCED
EFFECT ON THE BIOTRANSFORMATION SYSTEM RESPONSIBLE FOR THE METABOLISM OF
ASTEMIZOLE COMPARED TO KETOCONAZOLE. </p>

<p>(See WARNINGS and PRECAUTIONS: Drug Interactions.) </p>

<p>Astemizole is contraindicated in patients with known hypersensitivity
to astemizole or any of the inactive ingredients. </p>

<p><a name="WARNINGS"></a><b>WARNINGS </b></p>

<p>QT PROLONGATION/VENTRICULAR ARRHYTHMIAS </p>

<p>RARE CASES OF SERIOUS CARDIOVASCULAR ADVERSE EVENTS INCLUDING DEATH,
CARDIAC ARREST, QT PROLONGATION, TORSADES DE POINTES, AND OTHER VENTRICULAR
ARRHYTHMIAS HAVE BEEN OBSERVED IN PATIENTS EXCEEDING RECOMMENDED DOSES
OF ASTEMIZOLE. WHILE THE MAJORITY OF SUCH EVENTS HAVE OCCURRED FOLLOWING
SUBSTANTIAL OVERDOSES OF ASTEMIZOLE, TORSADES DE POINTES (ARRHYTHMIAS)
HAVE VERY RARELY OCCURRED AT REPORTED DOSES AS LOW AS 20-30 MG DAILY (2-3
TIMES THE RECOMMENDED DAILY DOSE). DATA SUGGEST THAT THESE EVENTS ARE ASSOCIATED
WITH ELEVATION OF ASTEMIZOLE AND/OR ASTEMIZOLE METABOLITE LEVELS, RESULTING
IN ELECTROCARDIOGRAPHIC QT PROLONGATION. </p>

<p>THESE EVENTS HAVE ALSO OCCURRED AT 10 MG DAILY IN A FEW PATIENTS WITH
POSSIBLE AUGMENTING CIRCUMSTANCES (SEE CONTRAINDICATIONS, AND WARNING PARAGRAPHS
BELOW WARNINGS ). IN VIEW OF THE POTENTIAL FOR CARDIAC ARRHYTHMIAS, ADHERENCE
TO THE RECOMMENDED DOSE SHOULD BE EMPHASIZED. </p>

<p>DO NOT EXCEED THE RECOMMENDED DOSE OF 10 MG (ONE TABLET) DAILY. </p>

<p>SOME PATIENTS APPEAR TO INCREASE THE DOSE OF Astemizole IN AN ATTEMPT
TO ACCELERATE THE ONSET OF ACTION. PATIENTS SHOULD BE ADVISED NOT TO DO
THIS AND NOT TO USE Astemizole AS A P R N PRODUCT FOR IMMEDIATE RELIEF
OF SYMPTOMS. </p>

<p>CONCOMITANT ADMINISTRATION OF ASTEMIZOLE WITH KETOCONAZOLE TABLETS,
ITRACONAZOLE, OR ERYTHROMYCIN IS CONTRAINDICATED. (SEE CONTRAINDICATIONS
AND PRECAUTIONS: DRUG INTERACTIONS.) </p>

<p>SINCE ASTEMIZOLE IS EXTENSIVELY METABOLIZED BY THE LIVER, THE USE OF
ASTEMIZOLE IN PATIENTS WITH SIGNIFICANT HEPATIC DYSFUNCTION SHOULD GENERALLY
BE AVOIDED. </p>

<p>IN SOME CASES, SEVERE ARRHYTHMIAS HAVE BEEN PRECEDED BY EPISODES OF
SYNCOPE. SYNCOPE IN PATIENTS RECEIVING ASTEMIZOLE SHOULD LEAD TO IMMEDIATE
DISCONTINUATION OF TREATMENT AND APPROPRIATE CLINICAL EVALUATION, INCLUDING
ELECTROCARDIOGRAPHIC TESTING (LOOKING FOR QT PROLONGATION AND VENTRICULAR
ARRHYTHMIA). </p>

<p>(SEE ACTIONS/CLINICAL PHARMACOLOGY, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS,
AND DOSAGE AND ADMINISTRATION.) </p>

<p>Patients known to have conditions leading to QT prolongation may experience
QT prolongation and/or ventricular arrhythmia with astemizole at recommended
doses. The effect of astemizole in patients who are receiving agents which
alter the QT interval is unknown. However, in view of astemizole's known
potential for QT prolongation, it is advisable to avoid its use in patients
with QT prolongation syndrome or who are taking medications which are reported
to prolong QT intervals (including probucol, certain antiarrhythmics, certain
tricyclic antidepressants, certain phenothiazines, certain calcium channel
blockers such as bepridil, and terfenadine), patients with electrolyte
abnormalities such as hypokalemia or hypomagnesemia, or those taking diuretics
with potential for inducing electrolyte abnormalities. </p>

<p>Rare cases of cardiovascular events have been observed in patients with
hepatic dysfunction. Systematic evaluation of the pharmacokinetics of astemizole
in patients with hepatic dysfunction has not been performed. Since astemizole
is extensively metabolized by the liver, the use of Astemizole in patients
with significant hepatic dysfunction should generally be avoided. </p>

<p><a name="PRECAUTIONS"></a><b>PRECAUTIONS </b></p>

<p>GENERAL: </p>

<p>Caution should be given to potential anticholinergic (drying effects)
in patients with lower airway diseases. </p>

<p>Caution should be used in patients with cirrhosis or other liver diseases.
(See ACTIONS/CLINICAL PHARMACOLOGY section.) </p>

<p>Astemizole does not appear to be dialyzable. </p>

<p>Caution should also be used when treating patients with renal impairment.
</p>

<p>DRUG INTERACTIONS: </p>

<p>See CONTRAINDICATIONS and WARNINGS sections for discussion of information
regarding potential drug interactions. </p>

<p>KETOCONAZOLE/ITRACONAZOLE </p>

<p>CONCOMITANT ADMINISTRATION OF KETOCONAZOLE TABLETS OR ITRACONAZOLE WITH
ASTEMIZOLE IS CONTRAINDICATED. (SEE CONTRAINDICATIONS AND WARNINGS .) </p>

<p>Due to the chemical similarity of fluconazole, metronidazole, and miconazole
i.v. to ketoconazole, concomitant use of these products with astemizole
is not recommended. </p>

<p>MACROLIDES (INCLUDING ERYTHROMYCIN) </p>

<p>CONCOMITANT ADMINISTRATION OF ERYTHROMYCIN WITH ASTEMIZOLE IS CONTRAINDICATED.
(SEE CONTRAINDICATIONS AND WARNINGS ) Concomitant administration of astemizole
with other macrolide antibiotics, including troleandomycin, azithromycin,
and clarithromycin, is not recommended. </p>

<p>INFORMATION FOR PATIENTS: </p>

<p>Patients taking Astemizole should receive the following information
and instructions. Antihistamines are prescribed to reduce allergic symptoms.
Patients taking Astemizole should be advised 1) to adhere to the recommended
dose and 2) that the use of excessive doses may lead to serious cardiovascular
events. Some patients appear to increase the dose of Astemizole in an attempt
to accelerate the onset of action. PATIENTS SHOULD BE ADVISED NOT TO DO
THIS and not to use Astemizole as a p r n product for immediate relief
of symptoms. Patients should be questioned about use of any other prescription
or over-the- counter medication, and should be cautioned regarding the
potential for life- threatening arrhythmias with concurrent use of ketoconazole,
itraconazole, or erythromycin. Patients should be advised to consult the
physician before concurrent use of other medications with astemizole. Patients
should be questioned about pregnancy or lactation before starting Astemizole
therapy, since the drug should be used in pregnancy or lactation only if
the potential benefit justifies the potential risk to fetus or baby. (See
Pregnancy subsection.) In addition, patients should be instructed to take
Astemizole on an empty stomach, e.g., at least 2 hours after a meal. No
additional food should be taken for at least 1 hour after-dosing. Patients
should also be instructed to store this medication in a tightly closed
container in a cool, dry place, away from heat or direct sunlight, and
away from children. </p>

<p>CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY: </p>

<p>Carcinogenic potential has not been revealed in rats given 260X the
recommended human dose of astemizole for 24 months, or in mice given 400X
the recommended human dose for 18 months. Micronucleus, dominant lethal,
sister chromatid exchange and Ames tests of astemizole have not revealed
mutagenic activity. </p>

<p>Impairment of fertility was not observed in male or female rats given
200X the recommended human dose. </p>

<p>PREGNANCY: PREGNANCY CATEGORY C: </p>

<p>Teratogenic effects were not observed in rats administered 200X the
recommended human dose or in rabbits given 200X the recommended human dose.
Maternal toxicity was seen in rabbits administered 200X the recommended
human dose. Embryocidal effects accompanied by maternal toxicity were observed
at 100X the recommended human dose in rats. Embryotoxicity or maternal
toxicity was not observed in rats or rabbits administered 50X the recommended
human dose. There are no adequate and well controlled studies in pregnant
women. Astemizole should be used during pregnancy only if the potential
benefit justifies the potential risk to the fetus. Metabolites may remain
in the body for as long as 4 months after the end of dosing, calculated
on the basis of 6 times the terminal half- life. (See ACTIONS/CLINICAL
PHARMACOLOGY section.) </p>

<p>NURSING MOTHERS: </p>

<p>It is not known whether this drug is excreted in human milk. </p>

<p>Because certain drugs are known to be excreted in human milk, caution
should be exercised when Astemizole is administered to a nursing woman.
Astemizole is excreted in the milk of dogs. </p>

<p>PEDIATRIC USE: </p>

<p>Safety and efficacy in children under 12 years of age has not been demonstrated.
</p>

<p><a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS </b></p>

<p>See CONTRAINDICATIONS and WARNINGS sections for discussion of information
regarding potential drug interactions. </p>

<p>KETOCONAZOLE/ITRACONAZOLE </p>

<p>CONCOMITANT ADMINISTRATION OF KETOCONAZOLE TABLETS OR ITRACONAZOLE WITH
ASTEMIZOLE IS CONTRAINDICATED. (SEE CONTRAINDICATIONS AND WARNINGS .) </p>

<p>Due to the chemical similarity of fluconazole, metronidazole, and miconazole
i.v. to ketoconazole, concomitant use of these products with astemizole
is not recommended. </p>

<p>MACROLIDES (INCLUDING ERYTHROMYCIN) </p>

<p>CONCOMITANT ADMINISTRATION OF ERYTHROMYCIN WITH ASTEMIZOLE IS CONTRAINDICATED.
(SEE CONTRAINDICATIONS AND WARNINGS .) Concomitant administration of astemizole
with other macrolide antibiotics, including troleandomycin, azithromycin,
and clarithromycin, is not recommended. </p>

<p>(See Also PRECAUTIONS) </p>

<p><a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS </b></p>

<p>For information regarding cardiovascular adverse events (e.g. cardiac
arrest, ventricular arrhythmias), please see CONTRAINDICATIONS and WARNINGS
. In some cases, recognition of severe arrhythmias has been preceded by
episodes of syncope. Similarly, rare cases of hypotension, palpitations,
and dizziness have also been reported with Astemizole use, which may reflect
undetected ventricular arrhythmia. </p>

<p>The reported incidences of adverse reactions listed in the following
table are derived from controlled clinical studies in adults. In these
studies the usual maintenance dose of Astemizole was 10 mg once daily.
</p>

<pre>                                       PERCENT OF PATIENTS REPORTING            
                              -----------------------------------------------   
                                            CONTROLLED STUDIES*                 
----------------------------------------------------------------------------    
                               Astemizole           PLACEBO         CLASSICAL**   
                               (N=1630)           (N=1109)          (N=304)     
ADVERSE EVENT                     %                  %                 %        
----------------------------------------------------------------------------    
CENTRAL NERVOUS SYSTEM                                                          
   Drowsiness                    7.1                6.4               22.0      
   Headache                      6.7                9.2                3.3      
   Fatigue                       4.2                1.6               11.8      
   Appetite increase             3.9                1.4                0.0      
   Weight increase               3.6                0.7                1.0      
   Nervousness                   2.1                1.2                0.3      
   Dizzy                         2.0                1.8                1.0      
GASTROINTESTINAL SYSTEM                                                         
   Nausea                        2.5                2.9                1.3      
   Diarrhea                      1.8                2.0                0.7      
   Abdominal pain                1.4                1.2                0.7      
EYE, EAR, NOSE, AND THROAT                                                      
   Mouth dry                     5.2                3.8                7.9      
   Pharyngitis                   1.7                2.3                0.3      
   Conjunctivitis                1.2                1.2                0.7      
OTHER                                                                           
   Arthralgia                    1.2                1.6                0.0      
----------------------------------------------------------------------------    
 * Duration of treatment in Controlled Studies ranged from 7 to 182 Days        
** Classical Drugs: Clemastine (N=137); Chlorpheniramine (N=100); Pheniramine   
    Maleate (N=47); d-Chlorpheniramine (N=20)  </pre>

<p>Adverse reaction information has been obtained from more than 7500 patients
in all clinical trials. Weight gain has been reported in 3.6% of astemizole
treated patients involved in controlled studies, with an average treatment
duration of 53 days. In 46 of the 59 patients for whom actual weight gain
data was available, the average weight gain was 3.2 kg. </p>

<p>Less frequently occurring adverse experiences reported in clinical trials
or spontaneously from marketing experience with Astemizole include: angioedema,
asymptomatic liver enzyme elevations, bronchospasm, depression, edema,
epistaxis, hepatitis, myalgia, palpitation, paresthesia, photosensitivity,
pruritus, and rash. </p>

<p>Marketing experiences include isolated cases of convulsions. A causal
relationship with Astemizole has not been established. </p>

<p><a name="OVERDOSAGE"></a><b>OVERDOSAGE </b></p>

<p>In the event of overdosage, supportive measures including gastric lavage
and emesis should be employed. Substantial overdoses of Astemizole can
cause death, cardiac arrest, QT prolongation, torsades de pointes, and
other ventricular arrhythmias. These events can also occur, although rarely,
at doses (20-30 mg) close to the recommended dose (10 mg/daily). (See WARNINGS
and DOSAGE AND ADMINISTRATION.) </p>

<p>Seizures and syncope have also been reported with overdose and may be
associated with a cardiac event. </p>

<p>Overdose patients should be carefully monitored as long as the QT interval
is prolonged or arrhythmias are present. In some cases, this has been up
to six days. In overdose cases in which ventricular arrhythmias are associated
with significant QT prolongation, treatment with antiarrhythmics known
to prolong QT intervals is not recommended. Astemizole does not appear
to be dialyzable. </p>

<p>Oral LD50 values for Astemizole were 2052 mg/kg in mice and 3154 mg/kg
in rats. In neonatal rats, the oral LD50 was 905 mg/kg in males and 1235
mg/kg in females. </p>

<p><a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION
</b></p>

<p>The recommended dosage for adults and children 12 years of age and older
is 10 mg (1 tablet) once daily. </p>

<p>DO NOT EXCEED THE RECOMMENDED DOSE. Patients should be advised not to
increase the dose of Astemizole in an attempt to accelerate the onset of
action. (See WARNINGS ) USE OF Astemizole IN PATIENTS TAKING KETOCONAZOLE,
ITRACONAZOLE, OR ERYTHROMYCIN IS CONTRAINDICATED. (See CONTRAINDICATIONS,
WARNINGS, and PRECAUTIONS: Drug Interactions.) </p>

<p>Studies evaluating the need for dosage adjustments for patients with
hepatic or renal dysfunction have not been performed. Since astemizole
is extensively metabolized by the liver, use of Astemizole in patients
with significant hepatic dysfunction should generally be avoided. </p>

<p>Astemizole should be taken on an empty stomach, e.g., at least two hours
after a meal. There should be no additional food intake for at least one
hour post- dosing. </p>

<h2 align=center>
<hr width="100%" ></h2>

<h2 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-8</DOCNO>
<DOCOLDNO>IA018-000200-B041-81</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/olsal.htm 206.86.175.201 19970106230836 text/html 19586
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:02:22 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 19403
Last-modified: Sat, 19 Oct 1996 06:27:45 GMT
</DOCHDR>
<html>
<head>
   <title>Olsalazine - RxList Generic Information</title>
   <meta name="keywords" content="Dipentum">
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Olsalazine</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[warn!] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<p><a name="DESCRIPTION"></a><b>DESCRIPTION </b></p>

<p>Olsalazine is a sodium salt of a salicylate, disodium 3, 3'-azobis (6-hydroxybenzoate)
a compound that is effectively bioconverted to 5-aminosalicylic acid (5-ASA),
which has anti-inflammatory activity in ulcerative colitis. Its empirical
formula is C14H8N2Na2O6 with a molecular weight of 346.21. Olsalazine sodium
is a yellow crystalline powder which melts with decomposition at 240oC.
It is the sodium salt of a weak acid, soluble in water and DMSO, and practically
insoluble in ethanol, chloroform and ether. Olsalazine sodium has acceptable
stability under acidic or basic conditions. </p>

<p><a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY
</b></p>

<p>After oral administration, olsalazine has limited systemic bioavailability.
Based on oral and intravenous dosing studies, approximately 2.4% of a single
1.0 g oral dose is absorbed. Less than 1% of olsalazine is recovered in
the urine. The remaining 98- 99% of an oral dose will reach the colon where
each molecule is rapidly converted into two molecules of 5-aminosalicylic
acid (5- ASA) by colonic bacteria and the low prevailing redox potential
found in this environment. The liberated 5-ASA is absorbed slowly resulting
in very high local concentrations in the colon. </p>

<p>The conversion of olsalazine to mesalamine (5-ASA) in the colon is similar
to that of sulfasalazine, which is converted into sulfapyridine and mesalamine.
It is thought that the mesalamine component is therapeutically active in
ulcerative colitis (A.K. Azad-Kahn et al, LANCET, 2: 892-895, 1977). The
usual dose of sulfasalazine for maintenance of remission in patients with
ulcerative colitis is 2 grams daily, which would provide approximately
0.8 gram of mesalamine to the colon. More than 0.9 gram of mesalamine would
usually be made available in the colon from 1 gram of olsalazine. </p>

<p>The mechanism of action of mesalamine (and sulfasalazine) is unknown,
but appears to be topical rather than systemic. Mucosal production of arachidonic
acid (AA) metabolites, both through the cyclooxygenase pathways, i.e.,
prostanoids, and through the lipoxygenase pathways, i.e., leukotrienes
(LTs) and hydroxyeicosatetraenoic acids (HETEs) is increased in patients
with chronic inflammatory bowel disease, and it is possible that mesalamine
diminishes inflammation by blocking cyclooxygenase and inhibiting prostaglandin
(PG) production in the colon. </p>

<p>Pharmacokinetics The pharmacokinetics of olsalazine are similar in both
healthy volunteers and in patients with ulcerative colitis. Maximum serum
concentrations of olsalazine appear after approximately 1 hour, and even
after a 1.0 g single dose are low, e.g., 1.6 - 6.2 umol/l. Olsalazine,
has a very short serum half-life, approximately 0.9 hours. Olsalazine is
more than 99% bound to plasma proteins. It does not interfere with protein
binding of warfarin. The urinary recovery of olsalazine is below 1%. Total
recovery of oral 14C-labeled olsalazine in animals and humans ranges from
90 to 97%. </p>

<p>Approximately 0.1% of an oral dose of olsalazine is metabolized in the
liver to olsalazine-O-sulfate (olsalazine-S). Olsalazine-S, in contrast
to olsalazine has a half-life of 7 days. Olsalazine-S accumulates to steady
state within 2-3 weeks. Patients on daily doses of 1.0 g olsalazine for
2-4 years show a stable plasma concentration of olsalazine-S (3.3-12.4
umol/l). Olsalazine-S, is more than 99% bound to plasma proteins. Its long
half-life is mainly due to slow dissociation from the protein binding site.
Less than 1% of both olsalazine and olsalazine-S appears undissociated
in plasma. 5-aminosalicylic acid (5-ASA): Serum concentration of 5-ASA
are detected after 4-8 hours. The peak levels of 5-ASA after an oral dose
of 1.0 g olsalazine are low, i.e., 0-4.3 umol/l. Of the total 5-ASA found
in the urine, more than 90% is in the form of N-acetyl- 5-ASA (Ac-5-ASA).
Only small amounts of 5-ASA are detected. </p>

<p>N-acetyl-5-ASA (Ac-5-ASA), the major metabolite of 5-ASA found in plasma
and urine, is acetylated (deactivated) in at least two sites, the colonic
epithelium and the liver. Ac-5-ASA is found in the serum, with peak values
of 1.7-8.7 &amp;181mol/l after a single 1.0 g dose. Approximately 20% of
the total 5-ASA is recovered in the urine, where it is found almost exclusively
as Ac-5-ASA. The remaining 5-ASA is partially acetylated and is excreted
in the feces. From fecal dialysis, the concentration of 5-ASA in the colon
following olsalazine has been calculated to be 18-49 mmol/l. No accumulation
of 5-ASA or Ac-5-ASA in plasma has been detected. 5-ASA and Ac-5-ASA are
74 and 81%, respectively, bound to plasma proteins. </p>

<p>ANIMAL TOXICOLOGY Preclinical subacute and chronic toxicity studies
in rats have shown the kidney to be the major target organ of olsalazine
toxicity. At an oral daily dose of 400 mg/kg or higher, olsalazine treatment
produced nephritis and tubular necrosis in a 4-week study; interstitial
nephritis and tubular calcinosis in a 6-month study, and renal fibrosis,
mineralization and transitional cell hyperplasia in a 1 year study. </p>

<p>CLINICAL STUDIES Two controlled studies have demonstrated the efficacy
of olsalazine as maintenance therapy in patients with ulcerative colitis.
In the first, ulcerative colitis patients in remission were randomized
to olsalazine 500 mg B.I.D. or placebo, and relapse rates for a six month
period of time were compared. For the 52 patients randomized to olsalazine,
12 relapses occurred, while for the 49 placebo patients, 22 relapses occurred.
This difference in relapse rates was significant (p&lt;.02). </p>

<p>In the second study, 164 ulcerative colitis patients in remission were
randomized to olsalazine 500 mg B.I.D. or sulfasalazine 1 gram B.I.D.,
and relapse rates were compared after six months. The relapse rate for
olsalazine was 19.5% while that for sulfasalazine was 12.2%, a non-significant
difference. </p>

<p><a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE </b></p>

<p>Olsalazine is indicated for the maintenance of remission of ulcerative
colitis in patients who are intolerant of sulfasalazine. </p>

<p><a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS </b></p>

<p>Hypersensitivity to salicylates. </p>

<p><a name="PRECAUTIONS"></a><b>PRECAUTIONS </b></p>

<p>General Overall, approximately 17% of subjects receiving olsalazine
in clinical studies reported diarrhea sometime during therapy. This diarrhea
resulted in withdrawal of treatment in 6% of patients. This diarrhea appears
to be dose related, although it may be difficult to distinguish from the
underlying symptoms of the disease. Exacerbation of the symptoms of colitis
thought to have been caused by mesalamine or sulfasalazine has been noted.
</p>

<p>Although renal abnormalities were not reported in clinical trials with
olsalazine, there have been rare reports from post-marketing experience
(see under ADVERSE REACTIONS). Therefore, the possibility of renal tubular
damage due to absorbed mesalamine or its n-acetylated metabolite, as noted
in the ANIMAL TOXICOLOGY section must be kept in mind, particularly for
patients with pre-existing renal disease. In these patients, monitoring
with urinalysis, BUN and creatinine determinations is advised. </p>

<p>Information for Patients: Patients should be instructed to take olsalazine
with food. The drug should be taken in evenly divided doses. Patients should
be informed that about 17% of subjects receiving olsalazine during clinical
studies reported diarrhea some time during therapy. If diarrhea occurs,
patients should contact their physician. </p>

<p>Drug/laboratory test interactions. None known. </p>

<p>Carcinogenesis, Mutagenesis, Impairment of Fertility In a two year oral
rat carcinogenicity study, olsalazine was tested in male and female Wistar
rats at daily doses of 200, 400 and 800 mg/kg/day (approximately 10 to
40 times the human maintenance dose, based on a patient weight of 50 kg
and a human dose of 1 g). Urinary bladder transitional cell carcinomas
were found in three male rats (6%, p=0.022, exact trend test) receiving
40 times the human dose and were not found in untreated male controls.
In the same study, urinary bladder transitional cell carcinoma and papilloma
occurred in 2 untreated control female rats (2%). No such tumors were found
in any of the female rats treated at doses up to 40 times the human dose.
</p>

<p>In an eighteen month oral mouse carcinogenicity study, olsalazine was
tested in male and female CD-1 mice at daily doses of 500, 1000 and 2000
mg/kg/day (approximately 25 to 100 times the human maintenance dose). Liver
hemangiosarcomata were found in two male mice (4%) receiving olsalazine
at 100 times the human dose, while no such tumor occurred in the other
treated male mice groups or any of the treated female mice. The observed
incidence of this tumor is within the 4% incidence in historical controls.
</p>

<p>Olsalazine was not mutagenic in in vitro Ames tests, mouse lymphoma
cell mutation assays, human lymphocyte chromosomal aberration tests and
the in vivo rat bone marrow cell chromosomal aberration test. </p>

<p>Olsalazine in a dose range of 100 to 400 mg/kg/day (approximately 5
to 20 times the human maintenance dose) did not influence the fertility
of male or female rats. The oligospermia and infertility in men associated
with sulfasalazine have not been reported with olsalazine. </p>

<p>Pregnancy: Teratogenic effects. Pregnancy Category C. </p>

<p>Olsalazine has been shown to produce fetal developmental toxicity as
indicated by reduced fetal weights, retarded ossifications and immaturity
of the fetal visceral organs when given during organogenesis to pregnant
rats in doses 5 to 20 times the human dose (100 to 400 mg/kg). There are
no adequate and well-controlled studies in pregnant women. Olsalazine should
be used during pregnancy only if the potential benefit justifies the potential
risk to the fetus. </p>

<p>Nursing Mothers Oral administration of olsalazine to lactating rats
in doses 5 to 20 times the human dose produced growth retardation in their
pups. It is not known whether this drug is excreted in human milk. Because
many drugs are excreted in human milk, caution should be exercised when
olsalazine is administered to a nursing woman. </p>

<p>Pediatric Use Safety and effectiveness in a pediatric population have
not been established. </p>

<p><a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS </b></p>

<p>Increased prothrombin time in patients taking concomitant warfarin has
been reported. </p>

<p><a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS </b></p>

<p>Olsalazine has been evaluated in ulcerative colitis patients in remission
as well as those with acute disease. Both sulfasalazine- tolerant and intolerant
patients have been studied in controlled clinical trials. Overall, 10.4%
of patients discontinued olsalazine because of an adverse experience compared
with 6.7% of placebo patients. The most commonly reported adverse reactions
leading to treatment withdrawal were diarrhea or loose stools (olsalazine
5.9%; placebo 4.8%), abdominal pain and rash or itching (slightly more
than 1% of patients receiving olsalazine). Other adverse reactions to olsalazine
leading to withdrawal occurred in fewer than 1% of patients (TABLE 1).
</p>

<pre> 
 
TABLE 1 - Olsalazine Sodium, Adverse Reactions 
Adverse Reactions Resulting in Withdrawal From Controlled Studies 
 
                                            Total 
                           Olsalazine                  Placebo 
                            (N=441)                    (N=208) 
Diarrhea/Loose Stools         26 (5.9%)                  10 (4.8%) 
Nausea                         3                          2 
Abdominal Pain                 5 (1.1%)                   0 
Rash/Itching                   5 (1.1%)                   0 
Headache                       3                          0 
Heartburn                      2                          0 
Rectal Bleeding                1                          0 
Insomnia                       1                          0 
Dizziness                      1                          0 
Anorexia                       1                          0 
Light Headedness               1                          0 
Depression                     1                          0 
Miscellaneous                  4 (0.9%)                   3 (1.4%) 
Total Number of 
Patients Withdrawn            46 (10.4%)                 14 (6.7%) 
 
 
For those controlled studies, the comparative incidences of adverse
reactions reported in 1% or more patients treated with olsalazine or
placebo are provided in TABLE 2. 
 
 
TABLE 2 - Olsalazine Sodium, Adverse Reactions 
COMPARATIVE INCIDENCE (%) OF ADVERSE EFFECTS REPORTED BY ONE 
PERCENT OR MORE OF ULCERATIVE COLITIS PATIENTS TREATED WITH 
OLSALAZINE OR PLACEBO IN DOUBLE BLIND CONTROLLED STUDIES 
 
                             OLSALAZINE                PLACEBO 
                             (N = 441)                 (N = 208) 
ADVERSE EVENT                   %                         % 
Digestive System 
 Diarrhea                      11.1                       6.7 
 Abdominal Pain/Cramps         10.1                       7.2 
 Nausea                         5.0                       3.9 
 Dyspepsia                      4.0                       4.3 
 Bloating                       1.5                       1.4 
 Anorexia                       1.3                       1.9 
 Vomiting                       1.0                        - 
 Stomatitis                     1.0                        - 
 Increased Blood in Stool        -                        3.4 
CNS/Psychiatric 
 Headache                       5.0                       4.8 
 Fatigue/Drowsiness/Lethargy    1.8                       2.9 
 Depression                     1.5                        - 
 Vertigo/Dizziness              1.0                        - 
 Insomnia                        -                        2.4 
Skin 
 Rash                           2.3                       1.4 
 Itching                        1.3                        - 
Musculoskeletal 
 Arthralgia/Joint Pain          4.0                       2.9 
Miscellaneous 
 Upper Respiratory Infection    1.5                        - 
 </pre>

<p>Over 2,500 patients have been treated with olsalazine in various controlled
and uncontrolled clinical studies. In these as well as in the post- marketing
experience, olsalazine was administered mainly to patients intolerant to
sulfasalazine. There have been rare reports of the following adverse effects
in patients receiving olsalazine. These were often difficult to distinguish
from possible symptoms of the underlying disease or from the effects of
prior and/or concomitant therapy. A casual relationship to the drug has
not been demonstrated for some of these reactions. </p>

<p>Digestive: Pancreatis, diarrhea with dehydration, increased blood in
stool, rectal bleeding, flare in symptoms, rectal discomfort, epigastric
discomfort, flatulence. </p>

<p>Rare cases of granulomatous hepatitis and nonspecific, reactive hepatitis
have been reported in patients receiving olsalazine. Additionally, a patient
developed mild cholestatic hepatitis during treatment with sulfasalazine
and experienced the same symptoms two weeks later after the treatment was
changed to olsalazine. Withdrawal of olsalazine led to complete recovery
in these cases. </p>

<p>Neurologic: Paresthesia, tremors, insomnia, mood swings, irritability,
fever, chills, rigors. </p>

<p>Dermatologic: Erythema nodosum, photosensitivity, erythema, hot flashes,
alopecia. </p>

<p>Musculoskeletal: Muscle cramps. </p>

<p>Cardiovascular/Pulmonary: Pericarditis, second degree heart block, interstitial
pulmonary disease, hypertension, orthostatic hypotension, peripheral edema,
chest pains, tachycardia, palpitations, bronchospasm, shortness of breath.
</p>

<p>A patient who developed thyroid disease 9 days after starting Olsalazine
was given propranolol and radioactive iodine and subsequently developed
shortness of breath and nausea. The patient died 5 days later with signs
and symptoms of acute diffuse myocarditis. </p>

<p>Genitourinary: Frequency, dysuria, hematuria, proteinuria, nephrotic
syndrome, interstitial nephritis, impotence, menorrhagia. </p>

<p>Hematologic: Leukopenia, neutropenia, lymphopenia, eosinophilia, thrombocytopenia,
anemia, hemolytic anemia, reticulocytosis. </p>

<p>Laboratory: ALT (SGPT) or AST (SGOT) elevated beyond the normal range.
</p>

<p>Special senses: Tinnitus, dry mouth, dry eyes, watery eyes, blurred
vision. </p>

<p>DRUG ABUSE AND DEPENDENCE </p>

<p>Abuse: None reported. </p>

<p>Dependence: Drug dependence has not been reported with chronic administration
of olsalazine. </p>

<p><a name="OVERDOSAGE"></a><b>OVERDOSAGE </b></p>

<p>No overdosage has been reported in humans. Maximum single oral doses
of 5 g/kg in mice and rats and 2 g/kg in dogs were not lethal. Symptoms
of acute toxicity were decreased motor activity and diarrhea in all species
tested and in addition, vomiting in dogs. </p>

<p><a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION
</b></p>

<p>The usual dosage in adults for maintenance of remission is 1.0 g/day
in two divided doses. </p>

<h2 align=center>
<hr width="100%" ></h2>

<h2 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-9</DOCNO>
<DOCOLDNO>IA019-000201-B023-196</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/rxlist.cgi?drug=levsin 206.86.175.201 19970106234039 text/html 1994
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:34:25 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE>www.rxlist.com - Neil Sandow, Pharm.D. 
copyright 1995</title></head> <body bgcolor="#ffffff">
<center><a href="http://www.rxlist.com"><img src="rx.gif" 
height=75 width=75 border=0><img src="count.gif" border=0></a></center> 
Searching for: <b>LEVSIN</b> <br>scroll down for results 
<hr><hr>
<h1>Enter Brand or Generic Name or Category*</h1>
<h3> Narrow Your Search with <font size=5>*</font>(examples: 
ampi*, *mycin, antibiotic*)</h3>
<form method=get>
<action=>
<input size=30 maxlength=30 name=drug>
<input type=submit>
<input type=reset>
</form>
<HR>
<H3>Your RxList Search Results:</h3>
1<br><b>Brand Name: </b>LEVAQUIN<br><b>Generic Name: </b>LEVOFLOXACIN<br><b>Category: </b>QUINOLINE ANTIBIOTICS
<p>2<br><b>Brand Name: </b>LIPOSYN II<br><b>Generic Name: </b>FAT EMULSION<br><b>Category: </b>CALORIC AGENTS
<p>3<br><b>Brand Name: </b>LIPOSYN III<br><b>Generic Name: </b>FAT EMULSION<br><b>Category: </b>CALORIC AGENTS
<p>4<br><b>Brand Name: </b>LEVSIN<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/hyoscy.htm">HYOSCYAMINE SULFATE</a><br><b>Category: </b>ANTIMUSCARINICS/ANTISPASMODICS
<p>5<br><b>Brand Name: </b>LEVSINEX TIME<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/hyoscy.htm">HYOSCYAMINE SULFATE SA</a><br><b>Category: </b>ANTIMUSCARINICS/ANTISPASMODICS
<p>6<br><b>Brand Name: </b>LEVSIN/SL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/hyoscy.htm">HYOSCYAMINE SULFATE SUBL</a><br><b>Category: </b>ANTIMUSCARINICS/ANTISPASMODICS
<p>7<br><b>Brand Name: </b>LEVSIN W/PB<br><b>Generic Name: </b>HYOSCYAMINE SULF/PHENOBAR<br><b>Category: </b>ANTIMUSCARINICS/ANTISPASMODICS
<p>8<br><b>Brand Name: </b>LIPOGEN<br><b>Generic Name: </b>LIPOTROPICS/B-COMP/VIT C<br><b>Category: </b>LIPOTROPIC AGENTS
<p></body></html>
<P><hr><a href="http://www.rxlist.com"><b>RxList Home Page</ul>
<hr>
</DOC>
<DOC>
<DOCNO>WT08-B13-10</DOCNO>
<DOCOLDNO>IA019-000201-B023-216</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/rxlist.cgi?drug=pegaspar 206.86.175.201 19970106234049 text/html 931
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:34:32 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE>www.rxlist.com - Neil Sandow, Pharm.D. 
copyright 1995</title></head> <body bgcolor="#ffffff">
<center><a href="http://www.rxlist.com"><img src="rx.gif" 
height=75 width=75 border=0><img src="count.gif" border=0></a></center> 
Searching for: <b>PEGASPAR</b> <br>scroll down for results 
<hr><hr>
<h1>Enter Brand or Generic Name or Category*</h1>
<h3> Narrow Your Search with <font size=5>*</font>(examples: 
ampi*, *mycin, antibiotic*)</h3>
<form method=get>
<action=>
<input size=30 maxlength=30 name=drug>
<input type=submit>
<input type=reset>
</form>
<HR>
<H3>Your RxList Search Results:</h3>
1<br><b>Brand Name: </b>ONCASPAR<br><b>Generic Name: </b>PEGASPARGASE<br><b>Category: </b>ANTINEOPLASTIC AGENTS
<p></body></html>
<P><hr><a href="http://www.rxlist.com"><b>RxList Home Page</ul>
<hr>
</DOC>
<DOC>
<DOCNO>WT08-B13-11</DOCNO>
<DOCOLDNO>IA019-000201-B023-226</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/rxlist.cgi?drug=muse 206.86.175.201 19970106234058 text/html 1057
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:34:41 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE>www.rxlist.com - Neil Sandow, Pharm.D. 
copyright 1995</title></head> <body bgcolor="#ffffff">
<center><a href="http://www.rxlist.com"><img src="rx.gif" 
height=75 width=75 border=0><img src="count.gif" border=0></a></center> 
Searching for: <b>MUSE</b> <br>scroll down for results 
<hr><hr>
<h1>Enter Brand or Generic Name or Category*</h1>
<h3> Narrow Your Search with <font size=5>*</font>(examples: 
ampi*, *mycin, antibiotic*)</h3>
<form method=get>
<action=>
<input size=30 maxlength=30 name=drug>
<input type=submit>
<input type=reset>
</form>
<HR>
<H3>Your RxList Search Results:</h3>
1<br><b>Brand Name: </b>MUSE<br><b>Generic Name: </b>ALPROSTADIL<br><b>Category: </b>TREATMENT OF IMPOTENCE
<p>2<br><b>Brand Name: </b>MASSE<br><b>Generic Name: </b>GLYCERIN/LANOLIN<br><b>Category: </b>EMOLLIENTS- DEMULCENTS- AND PROTECTANTS
<p></body></html>
<P><hr><a href="http://www.rxlist.com"><b>RxList Home Page</ul>
<hr>
</DOC>
<DOC>
<DOCNO>WT08-B13-12</DOCNO>
<DOCOLDNO>IA019-000201-B023-244</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/rxlist.cgi?drug=emla 206.86.175.201 19970106234108 text/html 945
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:34:50 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE>www.rxlist.com - Neil Sandow, Pharm.D. 
copyright 1995</title></head> <body bgcolor="#ffffff">
<center><a href="http://www.rxlist.com"><img src="rx.gif" 
height=75 width=75 border=0><img src="count.gif" border=0></a></center> 
Searching for: <b>EMLA</b> <br>scroll down for results 
<hr><hr>
<h1>Enter Brand or Generic Name or Category*</h1>
<h3> Narrow Your Search with <font size=5>*</font>(examples: 
ampi*, *mycin, antibiotic*)</h3>
<form method=get>
<action=>
<input size=30 maxlength=30 name=drug>
<input type=submit>
<input type=reset>
</form>
<HR>
<H3>Your RxList Search Results:</h3>
1<br><b>Brand Name: </b>EMLA<br><b>Generic Name: </b>LIDOCAINE/PRILOCAINE<br><b>Category: </b>ANTIPRURITICS AND LOCAL ANESTHETICS
<p></body></html>
<P><hr><a href="http://www.rxlist.com"><b>RxList Home Page</ul>
<hr>
</DOC>
<DOC>
<DOCNO>WT08-B13-13</DOCNO>
<DOCOLDNO>IA018-000200-B036-302</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/norgeth.htm 206.86.175.201 19970106225359 text/html 41177
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:47:36 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 40994
Last-modified: Tue, 23 Jul 1996 07:05:12 GMT
</DOCHDR>
<html>
<head>
   <title>Norgestrel and Ethinyl Estradiol - RxList Generic Information</title>
   <meta name="Author" content="">
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Norgestrel and Ethinyl Estradiol</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<p><a name="DESCRIPTION"></a><b>DESCRIPTION </b></p>

<p>PATIENTS SHOULD BE COUNSELED THAT THIS PRODUCT DOES NOT PROTECT AGAINST
HIV INFECTION (AIDS) AND OTHER SEXUALLY TRANSMITTED DISEASES. </p>

<p>Each Norgestrel/ethinyl estradiol tablet contains norgestrel (Dl-13-beta-ethyl-17-alpha-ethinyl-17-beta-hydroxygon-4-en-3-one),
a totally synthetic progestogen, and ethinyl estradiol (19-nor-17alpha-pregna-1,3,5
(10)-trien-20-yne- 3 17-diol).</p>

<p><a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY
</b></p>

<p>Combination oral contraceptives act by suppression of gonadotropins.
Although the primary mechanism of this action is inhibition of ovulation,
other alterations include changes in the cervical mucus (which increase
the difficulty of sperm entry into the uterus) and the endometrium (which
reduce the likelihood of implantation). </p>

<p><a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE </b></p>

<p>Oral contraceptives are indicated for the prevention of pregnancy in
women who elect to use this product as a method of contraception. </p>

<p>Oral contraceptives are highly effective. Table I lists the typical
accidental pregnancy rates for users of combination oral contraceptives
and other methods of contraception. The efficacy of these contraceptive
methods, except sterilization and the IUD, depends upon the reliability
with which they are used. Correct and consistent use of methods can result
in lower failure rates. </p>

<pre>TABLE I: LOWEST EXPECTED AND TYPICAL FAILURE                                    
RATES DURING THE FIRST YEAR OF CONTINUOUS                                       
USE OF A METHOD                                                                 
% of Women Experiencing an Accidental Pregnancy                                 
in the First Year of Continuous Use                                             
-------------------------------------------------                               
Method                        Lowest   Typical**                                
                            Expected*                                           
-------------------------------------------------                               
(No Contraception)             (89)       (89)                                  
Oral contraceptives                        3                                    
combined                         0.1      N/A*/*                                
progestin only                   0.5      N/A*/*                                
Diaphragm with spermicidal       3         18                                   
cream or jelly                                                                  
Spermicides alone (foam,         3         21                                   
creams, jellies and                                                             
vaginal suppositories)                                                          
Vaginal Sponge                                                                  
nulliparous                      5         18                                   
multiparous                     &gt;8        &gt;28                                   
IUD (medicated)                  1          6#                                  
Condom without spermicides       2         12                                   
Periodic abstinence                                                             
(all methods)                   2-10       20                                   
Female sterilization             0.2        0.4                                 
Male sterilization               0.1        0.15                                
-------------------------------------------------                               
Adapted from J. Trussell and K. Kost,                                
Studies in Family Planning, 18(5), Sept.-Oct.1987.                              
-------------------------------------------------                               
*   The authors' best guess of the percentage of                                
    women expected to experience an accidental                                  
    pregnancy among couples who initiate a method                               
    (not necessarily for the first time) and who                                
    use it consistently and correctly during the                                
    first year if they do not stop for any other                                
    reason.                                                                     
**  This term represents &quot;typical&quot; couples who                                  
    initiate use of a method (not necessarily for                               
    the first time), who experience an accidental                               
    pregnancy during the first year if they do                                  
    not stop use for any other reason.                                          
*/* N/A--Data not available.                                                    
#   Combined typical rate for both medicated and                                
    nonmedicated IUD. The rate for medicated IUD                                
    alone is not available.                                                     
-------------------------------------------------                               
</pre>

<p>NONCONTRACEPTIVE HEALTH BENEFITS </p>

<p>The following noncontraceptive health benefits related to the use of
oral contraceptives are supported by epidemiological studies which largely
utilized oral contraceptive formulations containing doses exceeding 0.035
mg of ethinyl estradiol or 0.05 mg of mestranol. </p>

<p>Effects on menses: </p>

<p>Increased menstrual cycle regularity. </p>

<p>Decreased blood loss and decreased incidence of iron-deficiency anemia.
</p>

<p>Decreased incidence of dysmenorrhea. </p>

<p>Effects related to inhibition of ovulation: </p>

<p>Decreased incidence of functional ovarian cysts. </p>

<p>Decreased incidence of ectopic pregnancies. </p>

<p>Effects from long-term use: </p>

<p>Decreased incidence of fibroadenomas and fibrocystic disease of the
breast.</p>

<p>Decreased incidence of acute pelvic inflammatory disease.</p>

<p>Decreased incidence of endometrial cancer. </p>

<p>Decreased incidence of ovarian cancer.</p>

<p><a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS </b></p>

<p>Oral contraceptives should not be used in women with any of the following
conditions: </p>

<p>Thrombophlebitis or thromboembolic disorders </p>

<p>A past history of deep-vein thrombophlebitis or thromboembolic disorders
</p>

<p>Cerebral-vascular or coronary-artery disease </p>

<p>Known or suspected carcinoma of the breast Carcinoma of the endometrium
or other known or suspected estrogen-dependent neoplasia </p>

<p>Undiagnosed abnormal genital bleeding </p>

<p>Cholestatic jaundice of pregnancy or jaundice with prior pill use </p>

<p>Hepatic adenomas or carcinomas </p>

<p>Known or suspected pregnancy </p>

<p><a name="WARNINGS"></a><b>WARNINGS </b></p>

<p>CIGARETTE SMOKING INCREASES THE RISK OF SERIOUS CARDIOVASCULAR SIDE
EFFECTS FROM ORAL-CONTRACEPTIVE USE. THIS RISK INCREASES WITH AGE AND WITH
HEAVY SMOKING (15 OR MORE CIGARETTES PER DAY) AND IS QUITE MARKED IN WOMEN
OVER 35 YEARS OF AGE. WOMEN WHO USE ORAL CONTRACEPTIVES SHOULD BE STRONGLY
ADVISED NOT TO SMOKE. </p>

<p>The use of oral contraceptives is associated with increased risks of
several serious conditions including myocardial infarction, thromboembolism,
stroke, hepatic neoplasia, gallbladder disease, and hypertension, although
the risk of serious morbidity or mortality is very small in healthy women
without underlying factors. The risk of morbidity and mortality increases
significantly in the presence of other underlying risk factors such as
hypertension, hyperlipidemias, obesity, and diabetes. </p>

<p>Practitioners prescribing oral contraceptives should be familiar with
the following information relating to these risks. </p>

<p>The information contained in this package insert is based principally
on studies carried out in patients who used oral contraceptives with higher
formulations of estrogens and progestogens than those in common use today.
The effect of long-term use of the oral contraceptives with lower formulations
of both estrogens and progestogens remains to be determined. </p>

<p>Throughout this labeling, epidemiological studies reported are of two
types: retrospective or case control studies and prospective or cohort
studies. Case control studies provide a measure of the relative risk of
disease, namely, a ratio of the incidence of a disease among oral-contraceptive
users to that among nonusers. The relative risk does not provide information
on the actual clinical occurrence of a disease. Cohort studies provide
a measure of attributable risk, which is the difference in the incidence
of disease between oral-contraceptive users and nonusers. The attributable
risk does provide information about the actual occurrence of a disease
in the population. For further information, the reader is referred to a
text on epidemiological methods. </p>

<p>1. THROMBOEMBOLIC DISORDERS AND OTHER VASCULAR PROBLEMS </p>

<p>a. Myocardial Infarction </p>

<p>An increased risk of myocardial infarction has been attributed to oral
contraceptive use. This risk is primarily in smokers or women with other
underlying risk factors for coronary-artery disease such as hypertension,
hypercholesterolemia, morbid obesity, and diabetes. The relative risk of
heart attack for current oral-contraceptive users has been estimated to
be two to six. The risk is very low under the age of 30. </p>

<p>Smoking in combination with oral-contraceptive use has been shown to
contribute substantially to the incidence of myocardial infarctions in
women in their mid thirties or older with smoking accounting for the majority
of excess cases. Mortality rates associated with circulatory disease have
been shown to increase substantially in smokers over the age of 35 and
nonsmokers over the age of 40 among women who use oral contraceptives.
</p>

<p>Oral contraceptives may compound the effects of well-known risk factors,
such as hypertension, diabetes, hyperlipidemias, age, and obesity. In particular,
some progestogens are known to decrease HDL cholesterol and cause glucose
intolerance, while estrogens may create a state of hyperinsulinism. Oral
contraceptives have been shown to increase blood pressure among users (see
section 9 in &quot;Warnings&quot;). Similar effects on risk factors have
been associated with an increased risk of heart disease. Oral contraceptives
must be used with caution in women with cardiovascular disease risk factors.
</p>

<p>b. Thromboembolism </p>

<p>An increased risk of thromboembolic and thrombotic disease associated
with the use of oral contraceptives is well established. Case control studies
have found the relative risk of users compared to nonusers to be 3 for
the first episode of superficial venous thrombosis, 4 to 11 for deep vein
thrombosis or pulmonary embolism, and 1.5 to 6 for women with predisposing
conditions for venous thromboembolic disease. Cohort studies have shown
the relative risk to be somewhat lower, about 3 for new cases and about
4.5 for new cases requiring hospitalization. The risk of thromboembolic
disease due to oral contraceptives is not related to length of use and
disappears after pill use is stopped. </p>

<p>A two- to four-fold increase in relative risk of postoperative thromboembolic
complications has been reported with the use of oral contraceptives. The
relative risk of venous thrombosis in women who have predisposing conditions
is twice that of women without such medical conditions. If feasible, oral
contraceptives should be discontinued at least four weeks prior to and
for two weeks after elective surgery of a type associated with an increase
in risk of thromboembolism and during and following prolonged immobilization.
Since the immediate postpartum period is also associated with an increased
risk of thromboembolism, oral contraceptives should be started no earlier
than four to six weeks after delivery in women who elect not to breast-feed,
or a midtrimester pregnancy termination. </p>

<p>c. Cerebrovascular Diseases </p>

<p>Oral contraceptives have been shown to increase both the relative and
attributable risks of cerebrovascular events (thrombotic and hemorrhagic
strokes), although, in general, the risk is greatest among older (&gt;35
years), hypertensive women who also smoke. Hypertension was found to be
a risk factor for both users and nonusers, for both types of strokes, while
smoking interacted to increase the risk for hemorrhagic strokes. </p>

<p>In a large study, the relative risk of thrombotic strokes has been shown
to range from 3 for normotensive users to 14 for users with severe hypertension.
The relative risk of hemorrhagic stroke is reported to be 1.2 for nonsmokers
who used oral contraceptives, 2.6 for smokers who did not use oral contraceptives,
7.6 for smokers who used oral contraceptives, 1.8 for normotensive users,
and 25.7 for users with severe hypertension. The attributable risk is also
greater in older women. </p>

<p>d. Dose-Related Risk Of Vascular Disease From Oral Contraceptives </p>

<p>A positive association has been observed between the amount of estrogen
and progestogen in oral contraceptives and the risk of vascular disease.
A decline in serum high-density lipoproteins (HDL) has been reported with
many progestational agents. A decline in serum high-density lipoproteins
has been associated with an increased incidence of ischemic heart disease.
Because estrogens increase HDL cholesterol, the net effect of an oral contraceptive
depends on a balance achieved between doses of estrogen and progestogen
and the nature and absolute amount of progestogen used in the contraceptive.
The amount of both hormones should be considered in the choice of an oral
contraceptive. </p>

<p>Minimizing exposure to estrogen and progestogen is in keeping with good
principles of therapeutics. For any particular estrogen/progestogen combination
the dosage regimen prescribed should be one which contains the least amount
of estrogen and progestogen that is compatible with a low failure rate
and the needs of the individual patient. New acceptors of oral-contraceptive
agents should be started on preparations containing less than 50 mcg of
estrogen. </p>

<p>e. Persistence Of Risk Of Vascular Disease </p>

<p>There are two studies which have shown persistence of risk of vascular
disease for ever-users of oral contraceptives. In a study in the United
States, the risk of developing myocardial infarction after discontinuing
oral contraceptives persists for at least 9 years for women 40 to 49 years
who had used oral contraceptives for five or more years, but this increased
risk was not demonstrated in other age groups. In another study in Great
Britain, the risk of developing cerebrovascular disease persisted for at
least 6 years after discontinuation of oral contraceptives, although excess
risk was very small. However, both studies were performed with oral-contraceptive
formulations containing 50 micrograms or higher of estrogens. </p>

<p>2. ESTIMATES OF MORTALITY FROM CONTRACEPTIVE USE </p>

<p>One study gathered data from a variety of sources which have estimated
the mortality rate associated with different methods of contraception at
different ages (Table III). These estimates include the combined risk of
death associated with contraceptive methods plus the risk attributable
to pregnancy in the event of method failure. Each method of contraception
has its specific benefits and risks. The study concluded that with the
exception of oral-contraceptive users 35 and older who smoke and 40 and
older who do not smoke, mortality associated with all methods of birth
control is less than that associated with childbirth. The observation of
a possible increase in risk of mortality with age for oral contraceptive
users is based on data gathered in the 1970's--but not reported until 1983.
However, current clinical practice involves the use of lower estrogen dose
formulations combined with careful restriction of oral contraceptive use
to women who do not have the various risk factors listed in this labeling.
</p>

<p>Because of these changes in practice and, also, because of some limited
new data which suggest that the risk of cardiovascular disease with the
use of oral contraceptives may now be less than previously observed, the
Fertility and Maternal Health Drugs Advisory Committee was asked to review
the topic in 1989. The Committee concluded that although cardiovascular
disease risks may be increased with oral-contraceptive use after age 40
in healthy nonsmoking women (even with the newer low-dose formulations),
there are greater potential health risks associated with pregnancy in older
women and with the alternative surgical and medical procedures which may
be necessary if such women do not have access to effective and acceptable
means of contraception. </p>

<p>Therefore, the Committee recommended that the benefits of oral-contraceptive
use by healthy nonsmoking women over 40 may outweigh the possible risks.
Of course, older women, as all women who take oral contraceptives, should
take the lowest possible dose formulation that is effective. </p>

<pre>TABLE III--ANNUAL NUMBER OF BIRTH-RELATED OR METHOD-RELATED DEATHS ASSOCIATED   
WITH CONTROL OF FERTILITY PER 100,000 NONSTERILE WOMEN, BY FERTILITY-CONTROL    
METHOD ACCORDING TO AGE                                                         
------------------------------------------------------------------------------  
Method of control          15-19    20-24    25-29     30-34    35-39    40-44  
and outcome                                                                     
------------------------------------------------------------------------------  
No fertility-               7.0      7.4      9.1       14.8     25.7     28.2  
control methods*                                                                
Oral contraceptives         0.3      0.5      0.9        1.9     13.8     31.6  
non-smoker**                                                                    
Oral contraceptives         2.2      3.4      6.6       13.5     51.1    117.2  
smoker**                                                                        
IUD**                       0.8      0.8      1.0        1.0      1.4      1.4  
Condom*                     1.1      1.6      0.7        0.2      0.3      0.4  
Diaphragm/                  1.9      1.2      1.2        1.3      2.2      2.8  
spermicide*                                                                     
Periodic abstinence*        2.5      1.6      1.6        1.7      2.9      3.6  
---------------------------                                                     
*   Deaths are birth related                                                    
**  Deaths are method related                                                   
------------------------------------------------------------------------------  
Adapted from H.W. Ory, Family Planning Perspectives, 15:57-63, 1983. </pre>

<p>3. CARCINOMA OF THE REPRODUCTIVE ORGANS </p>

<p>Numerous epidemiological studies have been performed on the incidence
of breast endometrial, ovarian, and cervical cancer in women using oral
contraceptives. The overwhelming evidence in the literature suggests that
use of oral contraceptives is not associated with an increase in the risk
of developing breast cancer, regardless of the age and parity of first
use or with most of the marketed brands and doses. The Cancer amd Steroid
Hormone (CASH) study also showed no latent effect on the risk of breast
cancer for at least a decade following long-term use. A few studies have
shown a slightly increased relative risk of developing breast cancer, although
the methodology of these studies, which included differences in examination
of users and nonusers and differences in age at start of use, has been
questioned. </p>

<p>Some studies suggest that oral-contraceptive use has been associated
with an increase in the risk of cervical intraepithelial neoplasia in some
populations of women. However, there continues to be controversy about
the extent to which such findings may be due to differences in sexual behavior
and other factors. </p>

<p>In spite of many studies of the relationship between oral-contraceptive
use and breast and cervical cancers, a cause-and-effect relationship has
not been established. </p>

<p>4. HEPATIC NEOPLASIA </p>

<p>Benign hepatic adenomas are associated with oral-contraceptive use,
although the incidence of benign tumors is rare in the United States. Indirect
calculations have estimated the attributable risk to be in the range of
3.3 cases/100,000 for users, a risk that increases after four or more years
of use. Rupture of rare, benign, hepatic adenomas may cause death through
intra abdominal hemorrhage. </p>

<p>Studies from Britain have shown an increased risk of developing hepatocellular
carcinoma in long-term (&gt;8 years) oral-contraceptive users. However,
these cancers are extremely rare in the U.S., and the attributable risk
(the excess incidence) of liver cancers in oral contraceptive users approaches
less than one per million users. </p>

<p>5. OCULAR LESIONS </p>

<p>There have been clinical case reports of retinal thrombosis associated
with the use of oral contraceptives. Oral contraceptives should be discontinued
if there is unexplained partial or complete loss of vision; onset of proptosis
or diplopia; papilledema; or retinal vascular lesions. Appropriate diagnostic
and therapeutic measures should be undertaken immediately. </p>

<p>6. ORAL-CONTRACEPTIVE USE BEFORE OR DURING EARLY PREGNANCY </p>

<p>Extensive epidemiological studies have revealed no increased risk of
birth defects in women who have used oral contraceptives prior to pregnancy.
Studies also do not suggest a teratogenic effect, particularly insofar
as cardiac anomalies and limb reduction defects are concerned, when taken
inadvertently during early pregnancy. </p>

<p>The administration of oral contraceptives to induce withdrawal bleeding
should not be used as a test for pregnancy. Oral contraceptives should
not be used during pregnancy to treat threatened or habitual abortion.
</p>

<p>It is recommended that for any patient who has missed two consecutive
periods, pregnancy should be ruled out before continuing oral contraceptive
use. If the patient has not adhered to the prescribed schedule, the possibility
of pregnancy should be considered at the time of the first missed period.
Oral contraceptive use should be discontinued if pregnancy is confirmed.
</p>

<p>7. GALLBLADDER DISEASE </p>

<p>Earlier studies have reported an increased lifetime relative risk of
gallbladder surgery in users of oral contraceptives and estrogens. More
recent studies, however, have shown that the relative risk of developing
gallbladder disease among oral-contraceptive users may be minimal. The
recent findings of minimal risk may be related to the use of oral-contraceptive
formulations containing lower hormonal doses of estrogens and progestogens.</p>

<p>8. CARBOHYDRATE AND LIPID METABOLIC EFFECTS </p>

<p>Oral contraceptives have been shown to cause glucose intolerance in
a significant percentage of users. Oral contraceptives containing greater
than 75 micrograms of estrogens cause hyperinsulinism, while lower doses
of estrogen cause less glucose intolerance. Progestogens increase insulin
secretion and create insulin resistance, this effect varying with different
progestational agents. However, in the nondiabetic woman, oral contraceptives
appear to have no effect on fasting blood glucose. Because of these demonstrated
effects, prediabetic and diabetic women should be carefully observed while
taking oral contraceptives. </p>

<p>A small proportion of women will have persistent hypertriglyceridemia
while on the pill. As discussed earlier (see Warnings, 1a and 1d), changes
in serum triglycerides and lipoprotein levels have been reported in oral-contraceptive
users. </p>

<p>9. ELEVATED BLOOD PRESSURE </p>

<p>An increase in blood pressure has been reported in women taking oral
contraceptives, and this increase is more likely in older oral-contraceptive
users and with continued use. Data from the Royal College of General Practitioners
and subsequent randomized trials have shown that the incidence of hypertension
increases with increasing quantities of progestogens. </p>

<p>Women with a history of hypertension or hypertension-related diseases,
or renal disease, should be encouraged to use another method of contraception.
If women with hypertension elect to use oral contraceptives, they should
be monitored closely, and if significant elevation of blood pressure occurs,
oral contraceptives should be discontinued. For most women, elevated blood
pressure will return to normal after stopping oral contraceptives, and
there is no difference in the occurrence of hypertension among ever- and
never-users. </p>

<p>10. HEADACHE </p>

<p>The onset or exacerbation of migraine or development of headache with
a new pattern that is recurrent, persistent, or severe requires discontinuation
of oral contraceptives and evaluation of the cause. </p>

<p>11. BLEEDING IRREGULARITIES </p>

<p>Breakthrough bleeding and spotting are sometimes encountered in patients
on oral contraceptives, especially during the first three months of use.
The type and dose of progestogen may be important. Non-hormonal causes
should be considered and adequate diagnostic measures taken to rule out
malignancy or pregnancy in the event of breakthrough bleeding, as in the
case of any abnormal vaginal bleeding. If pathology has been excluded,
time or a change to another formulation may solve the problem. In the event
of amenorrhea, pregnancy should be ruled out. </p>

<p>Some women may encounter post-pill amenorrhea or oligomenorrhea, especially
when such a condition was preexistent. </p>

<p><a name="PRECAUTIONS"></a><b>PRECAUTIONS </b></p>

<p>PATIENTS SHOULD BE COUNSELED THAT THIS PRODUCT DOES NOT PROTECT AGAINST
HIV INFECTION (AIDS) AND OTHER SEXUALLY TRANSMITTED DISEASES. </p>

<p>1. PHYSICAL EXAMINATION AND FOLLOW-UP </p>

<p>A complete medical history and physical examination should be taken
prior to the initiation or reinstitution of oral contraceptives and at
least annually during use of oral contraceptives. These physical examinations
should include special reference to blood pressure, breasts, abdomen and
pelvic organs, including cervical cytology, and relevant laboratory tests.
In case of undiagnosed, persistent or recurrent abnormal vaginal bleeding,
appropriate diagnostic measures should be conducted to rule out malignancy.
Women with a strong family history of breast cancer or who have breast
nodules should be monitored with particular care. </p>

<p>2. LIPID DISORDERS </p>

<p>Women who are being treated for hyperlipidemias should be followed closely
if they elect to use oral contraceptives. Some progestogens may elevate
LDL levels and may render the control of hyperlipidemias more difficult.
(See Warnings, 1d.). </p>

<p>3. LIVER FUNCTION </p>

<p>If jaundice develops in any woman receiving such drugs, the medication
should be discontinued. Steroid hormones may be poorly metabolized in patients
with impaired liver function. </p>

<p>4. FLUID RETENTION </p>

<p>Oral contraceptives may cause some degree of fluid retention. They should
be prescribed with caution, and only with careful monitoring, in patients
with conditions which might be aggravated by fluid retention. </p>

<p>5. EMOTIONAL DISORDERS </p>

<p>Patients becoming significantly depressed while taking oral contraceptives
should stop the medication and use an alternate method of contraception
in an attempt to determine whether the symptom is drug related. Women with
a history of depression should be carefully observed and the drug discontinued
if depression recurs to a serious degree. </p>

<p>6. CONTACT LENSES </p>

<p>Contact lens wearers who develop visual changes or changes in lens tolerance
should be assessed by an ophthalmologist. </p>

<p>7. DRUG INTERACTIONS </p>

<p>Reduced efficacy and increased incidence of breakthrough bleeding and
menstrual irregularities have been associated with concomitant use of rifampin.
A similar association, though less marked, has been suggested with barbiturates,
phenylbutazone, phenytoin sodium, and possibly with griseofulvin, ampicillin,
and tetracyclines. </p>

<p>8. INTERACTIONS WITH LABORATORY TESTS </p>

<p>Certain endocrine- and liver-function tests and blood components may
be affected by oral contraceptives: </p>

<p>a. Increased prothrombin and factors VII, VIII, IX, and X; decreased
antithrombin 3; increased norepinephrine-induced platelet aggregability.
</p>

<p>b. Increased thyroid-binding globulin (TBG) leading to increased circulating
total thyroid hormone, as measured by protein-bound iodine (PBI), T4 by
column or by radioimmunoassay. Free T3 resin uptake is decreased, reflecting
the elevated TBG; free T4 concentration is unaltered. </p>

<p>c. Other binding proteins may be elevated in serum. </p>

<p>d. Sex-binding globulins are increased and result in elevated levels
of total circulating sex steroids and corticoids; however, free or biologically
active levels remain unchanged. </p>

<p>e. Triglycerides may be increased. </p>

<p>f. Glucose tolerance may be decreased. </p>

<p>g. Serum folate levels may be depressed by oral-contraceptive therapy.
This may be of clinical significance if a woman becomes pregnant shortly
after discontinuing oral contraceptives. </p>

<p>9. CARCINOGENESIS </p>

<p>See&quot;Warnings&quot; section. </p>

<p>10. PREGNANCY </p>

<p>Pregnancy Category X. See &quot;Contraindications&quot; and &quot;Warnings&quot;
sections.</p>

<p>11. NURSING MOTHERS </p>

<p>Small amounts of oral-contraceptive steroids have been identified in
the milk of nursing mothers, and a few adverse effects on the child have
been reported, including jaundice and breast enlargement. In addition,
oral contraceptives given in the postpartum period may interfere with lactation
by decreasing the quantity and quality of breast milk. If possible, the
nursing mother should be advised not to use oral contraceptives but to
use other forms of contraception until she has completely weaned her child.
</p>

<p><a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS </b></p>

<p>Reduced efficacy and increased incidence of breakthrough bleeding and
menstrual irregularities have been associated with concomitant use of rifampin.
A similar association, though less marked, has been suggested with barbiturates,
phenylbutazone, phenytoin sodium, and possibly with griseofulvin, ampicillin,
and tetracyclines. </p>

<p>(See Also PRECAUTIONS) </p>

<p><a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS </b></p>

<p>An increased risk of the following serious adverse reactions has been
associated with the use of oral contraceptives (see &quot;Warnings&quot;
section): </p>

<p>Thrombophlebitis. </p>

<p>Arterial thromboembolism. </p>

<p>Pulmonary embolism. </p>

<p>Myocardial infarction. </p>

<p>Cerebral hemorrhage. </p>

<p>Cerebral thrombosis. </p>

<p>Hypertension. </p>

<p>Gallbladder disease. </p>

<p>Hepatic adenomas or benign liver tumors. </p>

<p>There is evidence of an association between the following conditions
and the use of oral contraceptives, although additional confirmatory studies
are needed: </p>

<p>Mesenteric thrombosis. </p>

<p>Retinal thrombosis. </p>

<p>The following adverse reactions have been reported in patients receiving
oral contraceptives and are believed to be drug related: </p>

<p>Nausea. </p>

<p>Vomiting. </p>

<p>Gastrointestinal symptoms (such as abdominal cramps and bloating). </p>

<p>Breakthrough bleeding. </p>

<p>Spotting. </p>

<p>Change in menstrual flow. </p>

<p>Amenorrhea. </p>

<p>Temporary infertility after discontinuation of treatment. </p>

<p>Edema. </p>

<p>Melasma which may persist. </p>

<p>Breast changes: tenderness, enlargement, secretion. </p>

<p>Change in weight (increase or decrease). </p>

<p>Change in cervical erosion and secretion. </p>

<p>Diminution in lactation when given immediately postpartum. </p>

<p>Cholestatic jaundice. </p>

<p>Migraine. </p>

<p>Rash (allergic). </p>

<p>Mental depression. </p>

<p>Reduced tolerance to carbohydrates. </p>

<p>Vaginal candidiasis. </p>

<p>Change in corneal curvature (steepening). </p>

<p>Intolerance to contact lenses. </p>

<p>The following adverse reactions have been reported in users of oral
contraceptives, and the association has been neither confirmed nor refuted:
</p>

<p>Congenital anomalies. </p>

<p>Premenstrual syndrome. </p>

<p>Cataracts. </p>

<p>Optic neuritis. </p>

<p>Changes in appetite. </p>

<p>Cystitis-like syndrome. </p>

<p>Headache. </p>

<p>Nervousness. </p>

<p>Dizziness. </p>

<p>Hirsutism. </p>

<p>Loss of scalp hair. </p>

<p>Erythema multiforme.</p>

<p>Erythema nodosum. </p>

<p>Hemorrhagic eruption. </p>

<p>Vaginitis. </p>

<p>Porphyria. </p>

<p>Impaired renal function. </p>

<p>Hemolytic uremic syndrome. </p>

<p>Budd-Chiari syndrome. </p>

<p>Acne. </p>

<p>Changes in libido. </p>

<p>Colitis. </p>

<p>Sickle cell disease. </p>

<p>Cerebral-vascular disease with mitral valve prolapse. </p>

<p>Lupus-like syndromes.</p>

<p><a name="OVERDOSAGE"></a><b>OVERDOSAGE </b></p>

<p>Serious ill effects have not been reported following acute ingestion
of large doses of oral contraceptives by young children. Overdosage may
cause nausea, and withdrawal bleeding may occur in females. </p>

<p><a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION
</b></p>

<p>To achieve maximum contraceptive effectiveness, Norgestrel/ethinyl estradiol
must be taken exactly as directed and at intervals not exceeding 24 hours.
</p>

<p>The dosage of Norgestrel/ethinyl estradiol is one tablet daily for 21
consecutive days per menstrual cycle according to prescribed schedule.
Tablets are then discontinued for 7 days (three weeks on, one week off).
</p>

<p>It is recommended that Norgestrel/ethinyl estradiol tablets be taken
at the same time each day, preferably after the evening meal or at bedtime.
</p>

<p>During the first cycle of medication, the patient is instructed to take
one Norgestrel/ethinyl estradiol tablet daily for twenty-one consecutive
days, beginning on day five of her menstrual cycle. (The first day of menstruation
is day one.) The tablets are then discontinued for one week (7 days). Withdrawal
bleeding should usually occur within 3 days following discontinuation of
Norgestrel/ethinyl estradiol. (If Norgestrel/ethinyl estradiol is first
taken later than the fifth day of the first menstrual cycle of medication
or postpartum, contraceptive reliance should not be placed on Norgestrel/ethinyl
estradiol until after the first seven consecutive days of administration.
The possibility of ovulation and conception prior to initiation of medication
should be considered.) The patient begins her next and all subsequent 21-day
courses of Norgestrel/ethinyl estradiol tablets on the same day of the
week that she began her first course, following the same schedule: 21 days
on--7 days off. She begins taking her tablets on the 8th day after discontinuance,
regardless of whether or not a menstrual period has occurred or is still
in progress. Any time a new cycle of Norgestrel/ethinyl estradiol is started
later than the 8th day, the patient should be protected by another means
of contraception until she has taken a tablet daily for seven consecutive
days. </p>

<p>If spotting or breakthrough bleeding occurs, the patient is instructed
to continue on the same regimen. This type of bleeding is usually transient
and without significance; however, if the bleeding is persistent or prolonged,
the patient is advised to consult her physician. Although the occurrence
of pregnancy is highly unlikely if Norgestrel/ethinyl estradiol is taken
according to directions, if withdrawal bleeding does not occur, the possibility
of pregnancy must be considered. If the patient has not adhered to the
prescribed schedule (missed one or more tablets or started taking them
on a day later than she should have) the probability of pregnancy should
be considered at the time of the first missed period and appropriate diagnostic
measures taken before the medication is resumed. If the patient has adhered
to the prescribed regimen and misses two consecutive periods, pregnancy
should be ruled out before continuing the contraceptive regimen. </p>

<p>The patient should be instructed to take a missed tablet as soon as
it is remembered. If two consecutive tablets are missed, they should both
be taken as soon as remembered. The next tablet should be taken at the
usual time. </p>

<p>Any time the patient misses one or two tablets, she should also use
another method of contraception until she has taken a tablet daily for
seven consecutive days. If breakthrough bleeding occurs following missed
tablets, it will usually be transient and of no consequence. While there
is little likelihood of ovulation occurring if only one or two tablets
are missed, the possibility of ovulation increases with each successive
day that scheduled tablets are missed. If three consecutive tablets are
missed, all medication should be discontinued and the remainder of the
package discarded. A new tablet cycle should be started on the 8th day
after the last tablet was taken, and an alternate means of contraception
should be prescribed during the seven days without tablets and until the
patient has taken a tablet daily for seven consecutive days. </p>

<p>In the nonlactating mother, Norgestrel/ethinyl estradiol may be initiated
postpartum, for contraception. When the tablets are administered in the
postpartum period, the increased risk of thromboembolic disease associated
with the postpartum period must be considered (see &quot;Contraindications&quot;,
&quot;Warnings&quot; and &quot;Precautions&quot; concerning thromboembolic
disease). It is to be noted that early resumption of ovulation may occur
if bromocriptine mesylate has been used for the prevention of lactation.
</p>

<h2 align=center>
<hr width="100%" ></h2>

<h2 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-14</DOCNO>
<DOCOLDNO>IA018-000200-B043-336</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/index.shtml 206.86.175.201 19970106232008 text/html 3181
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:13:54 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
</DOCHDR>
 <html>
<head>
<title>
RxList - The Internet Drug Index
</title>

</head>



<BODY Bgcolor="#ffffff">



<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi">
<img src="rx.gif" alt="click to search RxList" vspace=2 border=0
height=125 width=125 align=left>
</a><a href="http://www.reutershealth.com/ihw/reviews/rxint.html">                  
<img src="hi_rec.gif" height=38 width=25 align=right
border=0 alt="Reuter's review"></a>
</p></center>
<center>
<p><b><font SIZE=+3>RxList
<br>The Internet Drug Index </font></center></b></p>

<pre>
</pre><center>
<form method=post action="http://www.rxlist.com/cgi/rxlist.cgi">



<input name=drug size=25>

<input type=submit value="Search for Drug Name">

</dl></form><a href="http://www.pointcom.com">
<img src="5per.gif" alt="top 5%" vspace=1 border=0 height=65 width=65
align=left alt="Top5%">
</a>

<a href="http://www.arachnid.co.uk/award/health.html"><img src="med60.gif"        
align=right border=0 alt="Gold Medal"></a>
<h2><a href="http://www.rxlist.com/top200.htm">The Top 200
</a></h2>
<h5>[ <a href="http://www.rxlist.com/interact.htm"> Actions/Interactions ]</a>
| <a href="http://www.rxlist.com/rxlinks.htm">[ Links ]</a> | 
<a href="http://www.rxlist.com/about.htm">[ FAQ ]</a><br>[ <a href="http://www.rxlist.com/tempstat.htm">WWW Stats ]</a>  
[<a href="http://www.rxlist.com/stats.htm"> Stats ]</a> [<a href="#mini"> Mini-Survey ]</a><br>
<hr width=40%>
<a href="http://www.netmedicine.com"><img src="nm.gif"></a>
<hr></center>
<h2 align=center>
 
<a name="mini"></a><a href="http://www.rxlist.com/stats.htm#Results">RxList Wants to Know!</a></h2>
<form method="POST" action="formmail.cgi">
<input type=hidden name="recipient" value="survey@rxlist.com"><input type=hidden name="subject" value="Survey">
<input type=hidden name="redirect" value="http://www.rxlist.com">
<pre><ul><font size=4>
<b>Prescriber (i.e. MD, DDS,etc.)</b> <input name="pro" type="radio"
value="md"></pre>
</font><font size=4>

<pre><b>Pharmacist</b>                     <input name="pro" type="radio"
value="ph"></pre>
</font><font size=4>

<pre><b>Nurse</b>                          <input name="pro" type="radio"
value="rn"></pre>
</font><font size=4>

<pre><b>Other Health Professional</b>      <input name="pro" type="radio"
value="hp"></pre>
</font><font size=4>
<pre><b>Not a Health Professional</b>      <input name="pro" type="radio"
value="con"></pre></font>
</ul>
<center>
<p><b>Sex: <select NAME="Sex"><option>Male   <option>Female</select>   Age: <select NAME="Age"><option>Under 20<option>20-29<option>30-39<option>40-49<option>50-59<option>Over
60</select> </b><input type="submit" value="Submit Mini-Survey">
<hr><hr><a href="mailto:rx@rxlist.com">
<img src="mbox.gif" height=45 width=45 border=0 alt="e-mail"></a><br> <a 
href="mailto:rx@rxlist.com"><h4> E-mail Comments, 
Suggestions, & Corrections to </a><br>
 rx@rxlist.com </h4>
<h4>(707)746-8754 - Advertising, Press</h4>
<hr>
<hr>
<p>
<h5>
copyright 1996 - Neil Sandow, Pharm.D.
</h5></center>
<font COLOR="#FFFFFF">
 UNKNOWN </font>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-15</DOCNO>
<DOCOLDNO>IA019-000201-B023-257</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/rxlist.cgi?drug=feverfew 206.86.175.201 19970106234117 text/html 947
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:35:00 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE>www.rxlist.com - Neil Sandow, Pharm.D. 
copyright 1995</title></head> <body bgcolor="#ffffff">
<center><a href="http://www.rxlist.com"><img src="rx.gif" 
height=75 width=75 border=0><img src="count.gif" border=0></a></center> 
Searching for: <b>FEVERFEW</b> <br>scroll down for results 
<hr><hr>
<h1>Enter Brand or Generic Name or Category*</h1>
<h3> Narrow Your Search with <font size=5>*</font>(examples: 
ampi*, *mycin, antibiotic*)</h3>
<form method=get>
<action=>
<input size=30 maxlength=30 name=drug>
<input type=submit>
<input type=reset>
</form>
<HR>
<H3>Your RxList Search Results:</h3>
1<br><b>Brand Name: </b>GERITOL<br><b>Generic Name: </b>FE PYROPHOS/VIT B COMP/VI<br><b>Category: </b>MULTIVITAMIN PREPARATIONS
<p></body></html>
<P><hr><a href="http://www.rxlist.com"><b>RxList Home Page</ul>
<hr>
</DOC>
<DOC>
<DOCNO>WT08-B13-16</DOCNO>
<DOCOLDNO>IA019-000201-B023-269</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/rxlist.cgi??drug=fastin?drug=vistaril 206.86.175.201 19970106234127 text/html 35331
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:35:10 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE>www.rxlist.com - Neil Sandow, Pharm.D. 
copyright 1995</title></head> <body bgcolor="#ffffff">
<center><a href="http://www.rxlist.com"><img src="rx.gif" 
height=75 width=75 border=0><img src="count.gif" border=0></a></center> 
Searching for: <b></b> <br>scroll down for results 
<hr><hr>
<h1>Enter Brand or Generic Name or Category*</h1>
<h3> Narrow Your Search with <font size=5>*</font>(examples: 
ampi*, *mycin, antibiotic*)</h3>
<form method=get>
<action=>
<input size=30 maxlength=30 name=drug>
<input type=submit>
<input type=reset>
</form>
<HR>
<H3>Your RxList Search Results:</h3>
1<br><b>Brand Name: </b>DIASTAT<br><b>Generic Name: </b>DIAZEPAM RECTAL GEL<br><b>Category: </b>TREATMENT OF SEVERE EPILEPSY
<p>2<br><b>Brand Name: </b>EDEX<br><b>Generic Name: </b>ALPROSTADIL<br><b>Category: </b>TREATMENT OF ERECTILE DYSFUNCTION
<p>3<br><b>Brand Name: </b>GABITRIL<br><b>Generic Name: </b>TIAGABINE<br><b>Category: </b>ANTICONVULSANTS
<p>4<br><b>Brand Name: </b>URSO<br><b>Generic Name: </b>URSODEOXYCHOLIC ACID<br><b>Category: </b>TREATMENT OF PRIMARY BILIARY CIRRHOSIS
<p>5<br><b>Brand Name: </b>LIPITOR<br><b>Generic Name: </b>ATORVASTATIN<br><b>Category: </b>ANTILIPEMIC AGENTS
<p>6<br><b>Brand Name: </b>ZYFLO<br><b>Generic Name: </b>ZILEUTON<br><b>Category: </b>LEUKOTRIENE RECEPTOR ANTAGONIST (LTRA) FOR TREATMENT OF ASTHMA
<p>7<br><b>Brand Name: </b>FEMPATCH<br><b>Generic Name: </b>17-BETA ESTRADIOL (TRANSDERMAL)<br><b>Category: </b>ESTROGENS
<p>8<br><b>Brand Name: </b>DOSTINEX<br><b>Generic Name: </b>CABERGOLINE<br><b>Category: </b>TREATMENT OF HYPERPROLACTINEMIC DISORDERS
<p>9<br><b>Brand Name: </b>THERDERM EMTDS<br><b>Generic Name: </b>ESTRADIOL (TRANSDERMAL)<br><b>Category: </b>ESTROGENS
<p>10<br><b>Brand Name: </b>ELEQUIN<br><b>Generic Name: </b>LEVOFLOXACIN (INJ)<br><b>Category: </b>QUINOLINE ANTIBIOTICS
<p>11<br><b>Brand Name: </b>COPAXONE<br><b>Generic Name: </b>COPOLYMER-1 (INJ)<br><b>Category: </b>TREATMENT OF MULTIPLE SCLEROSIS
<p>12<br><b>Brand Name: </b>MONUROL<br><b>Generic Name: </b>FOSFOMYCIN TROMETHANE<br><b>Category: </b>TREATMENT OF UTI'S
<p>13<br><b>Brand Name: </b>OPATANOL<br><b>Generic Name: </b>OLOPATADINE HCL<br><b>Category: </b>TREATMENT OF ALLERGIC CONJUNCTIVITIS
<p>14<br><b>Brand Name: </b>GLYSET<br><b>Generic Name: </b>MIGLITOL<br><b>Category: </b>ANTIDIABETIC AGENTS
<p>15<br><b>Brand Name: </b>ZAGAM<br><b>Generic Name: </b>SPARFLOXACIN<br><b>Category: </b>QUINOLINE ANTIBIOTICS
<p>16<br><b>Brand Name: </b>ALORA<br><b>Generic Name: </b>ESTRADIOL TRANSDERMAL<br><b>Category: </b>ESTROGENS
<p>17<br><b>Brand Name: </b>LEVAQUIN<br><b>Generic Name: </b>LEVOFLOXACIN<br><b>Category: </b>QUINOLINE ANTIBIOTICS
<p>18<br><b>Brand Name: </b>APHTHASOL<br><b>Generic Name: </b>AMLEXANOX<br><b>Category: </b>TREATMENT OF APHTHOUS ULCERS
<p>19<br><b>Brand Name: </b>LOTREL<br><b>Generic Name: </b>AMLODIPINE/BENAZEPRIL HCL<br><b>Category: </b>SEE AMLODIPINE AND/OR BENAZEPRIL
<p>20<br><b>Brand Name: </b>ERGOMAR<br><b>Generic Name: </b>ERGOTAMINE TARTRATE<br><b>Category: </b>SYMPATHOLYTIC AGENTS
<p>21<br><b>Brand Name: </b>ERGOSTAT<br><b>Generic Name: </b>ERGOTAMINE TARTRATE<br><b>Category: </b>SYMPATHOLYTIC AGENTS
<p>22<br><b>Brand Name: </b>REZULIN<br><b>Generic Name: </b>TROGLITAZONE<br><b>Category: </b>ANTIDIABETIC AGENTS
<p>23<br><b>Brand Name: </b>MERIDIA<br><b>Generic Name: </b>SIBUTRAMINE HCL<br><b>Category: </b>ANTIDEPRESSANT/ANTIOBESITY
<p>24<br><b>Brand Name: </b>NORMIFLO<br><b>Generic Name: </b>ARDEPARIN SODIUM<br><b>Category: </b>ANTICOAGULANT
<p>25<br><b>Brand Name: </b>FERRISELTZ<br><b>Generic Name: </b>FERRIC AMMONIUM CITRATE<br><b>Category: </b>BOWEL CONTRAST AGENT FOR MRI
<p>26<br><b>Brand Name: </b>LEXXEL<br><b>Generic Name: </b>ENALAPRIL MALEATE/FELODIPINE<br><b>Category: </b>ANTIHYPERTENSIVES
<p>27<br><b>Brand Name: </b>ARICEPT<br><b>Generic Name: </b>DONEPEXIL HCL<br><b>Category: </b>TREATMENT OF ALZHEIMER'S DISEASE
<p>28<br><b>Brand Name: </b>E2020<br><b>Generic Name: </b>DONEPEXIL HCL<br><b>Category: </b>TREATMENT OF ALZHEIMER'S DISEASE
<p>29<br><b>Brand Name: </b>AMPHOTEC<br><b>Generic Name: </b>AMPHOTERICIN B CHOLESTERYL SULFATE COMPLEX<br><b>Category: </b>ANTIFUNGALS
<p>30<br><b>Brand Name: </b>MUSE<br><b>Generic Name: </b>ALPROSTADIL<br><b>Category: </b>TREATMENT OF IMPOTENCE
<p>31<br><b>Brand Name: </b>MECTIZAN<br><b>Generic Name: </b>IVERMECTIN<br><b>Category: </b>TREATMENT OF STRONGYLOIDES/ONCHOCERCIASIS
<p>32<br><b>Brand Name: </b>NASCOBAL<br><b>Generic Name: </b>CYANOCOBALAMIN<br><b>Category: </b>VITAMIN B COMPLEX
<p>33<br><b>Brand Name: </b>NIX<br><b>Generic Name: </b>PERMETHRIN<br><b>Category: </b>ERADICATION/PROPHYLAXIS OF HEAD LICE
<p>34<br><b>Brand Name: </b>SR-2599DC<br><b>Generic Name: </b>CLOPIDOGREL<br><b>Category: </b>ORAL ANTITHROMBIC AGENT (INVESTIGATIONAL)
<p>35<br><b>Brand Name: </b>GUAIFENESIN<br><b>Generic Name: </b>GUAIFENESIN<br><b>Category: </b>SEE <a href="http://www.rxlist.com/cgi/generic/guaicod.htm">GUAIFENESIN & CODEINE</a>
<p>36<br><b>Brand Name: </b>GUAIFENESIN<br><b>Generic Name: </b>GUAIFENESIN<br><b>Category: </b>SEE <a href="http://www.rxlist.com/cgi/generic/guaiphen.htm">GUAIFENESIN & PHENYLPROPANOLAMINE</a>
<p>37<br><b>Brand Name: </b>SYNERCID (RP 59500)<br><b>Generic Name: </b>QUINUPRISTIN/DALFOPRISTIN<br><b>Category: </b>ANTIBIOTICS (INVESTIGATIONAL)
<p>38<br><b>Brand Name: </b>DENAVIR<br><b>Generic Name: </b>PENCICLOVIR<br><b>Category: </b>ANTIVIRALS
<p>39<br><b>Brand Name: </b>FERTINEX<br><b>Generic Name: </b>FOLLICLE STIMULATING HORMONE (FSH)<br><b>Category: </b>HORMONES
<p>40<br><b>Brand Name: </b>FERTINEX<br><b>Generic Name: </b>FSH<br><b>Category: </b>HORMONES
<p>41<br><b>Brand Name: </b>COPAXONE<br><b>Generic Name: </b>COPOLYMER 1<br><b>Category: </b>TREATMENT OF M.S.
<p>42<br><b>Brand Name: </b>VIRACEPT<br><b>Generic Name: </b>NELFINAVIR<br><b>Category: </b>ANTIVIRALS
<p>43<br><b>Brand Name: </b>ERGOSET<br><b>Generic Name: </b>BROMOCRIPTINE<br><b>Category: </b>UNCLASSIFIED THERAPEUTIC AGENTS
<p>44<br><b>Brand Name: </b>SORIATANE<br><b>Generic Name: </b>ACITRETIN<br><b>Category: </b>TREATMENT OF PSORIASIS
<p>45<br><b>Brand Name: </b>ASTELIN<br><b>Generic Name: </b>AZELASTINE<br><b>Category: </b>ANTIHISTAMINES
<p>46<br><b>Brand Name: </b>RETAVASE<br><b>Generic Name: </b>RETEPLASE<br><b>Category: </b>THROMBOLYTICS
<p>47<br><b>Brand Name: </b>SAIZEN<br><b>Generic Name: </b>SOMATROPIN<br><b>Category: </b>PITUITARY
<p>48<br><b>Brand Name: </b>ESTROSTEP<br><b>Generic Name: </b>ETHINYL ESTRADIOL/NORETHINDRONE<br><b>Category: </b>CONTRACEPTIVES
<p>49<br><b>Brand Name: </b>LODINE XL<br><b>Generic Name: </b>ETODOLAC<br><b>Category: </b>NONSTEROIDAL ANTIINFLAMMATORY AGENTS
<p>50<br><b>Brand Name: </b>CYSTADANE<br><b>Generic Name: </b>BETAINE<br><b>Category: </b>TREATMENT OF HOMOCYSTINUREAL
<p>51<br><b>Brand Name: </b>COMBIVENT<br><b>Generic Name: </b>ALBUTEROL/IPRATROPIUM<br><b>Category: </b>BRONCHODILATORS
<p>52<br><b>Brand Name: </b>TARKA<br><b>Generic Name: </b>TRANDOLAPRIL/VERAPAMIL<br><b>Category: </b>ANTIHYPERTENSIVES
<p>53<br><b>Brand Name: </b>MENTAX<br><b>Generic Name: </b>BUTENAFINE HCL<br><b>Category: </b>ANTIFUNGALS
<p>54<br><b>Brand Name: </b>TIAMATE<br><b>Generic Name: </b>DILTIAZEM<br><b>Category: </b>ANTIHYPERTENSIVES
<p>55<br><b>Brand Name: </b>DURACLON<br><b>Generic Name: </b>CLONIDINE HCL<br><b>Category: </b>EPIDURAL ADJUNCT TO OPIATE THERAPY
<p>56<br><b>Brand Name: </b><a href="http://www.lec.org/DrugSearch/Documents/Rohypnol.html">ROHYPNOL</a><br><b>Generic Name: </b>FLUNITRAZEPAM<br><b>Category: </b>MISC. SEDATIVES/HYPNOTICS (NOTE: NOT MARKETED IN THE US)
<p>57<br><b>Brand Name: </b>KADIAN<br><b>Generic Name: </b>MORPHINE SULFATE SA<br><b>Category: </b>OPIATE AGONISTS
<p>58<br><b>Brand Name: </b>COCAINE<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/cocaine.htm">COCAINE HCL</a><br><b>Category: </b>ANTIPRURITICS AND LOCAL ANESTHETICS
<p>59<br><b>Brand Name: </b>TECZEM<br><b>Generic Name: </b>ENALAPRIL MALEATE & DILTIAZEM MALEATE<br><b>Category: </b>ANTIHYPERTENSIVES
<p>60<br><b>Brand Name: </b>TICLID<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/ticlop.htm">TICLOPIDINE HCL</a><br><b>Category: </b>PLATELET AGGREGATION INHIBITORS
<p>61<br><b>Brand Name: </b>PARACETAMOL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">SEE ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>62<br><b>Brand Name: </b>DHEA<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/dhea.htm">DEHYDROEPIANDROSTERONE</a><br><b>Category: </b>UNAPPROVED
<p>63<br><b>Brand Name: </b>ANTIBIOTIC<br><b>Generic Name: </b>TYPE ANTIBIOT*<br><b>Category: </b>USE * TO SORT ON CATEGORY
<p>64<br><b>Brand Name: </b>NILANDRON<br><b>Generic Name: </b>NILUTAMIDE<br><b>Category: </b>ANTIANDROGENS
<p>65<br><b>Brand Name: </b>PONDIMIN<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/fenflur.htm">FENFLURAMINE HCL</a><br><b>Category: </b>APPETITE SUPPRESSANT
<p>66<br><b>Brand Name: </b>ALPHAGAN<br><b>Generic Name: </b>BRIMONIDINE TARTRATE<br><b>Category: </b>MISCELLANEOUS EENT AGENTS (GLAUCOMA)
<p>67<br><b>Brand Name: </b>FERTINEX<br><b>Generic Name: </b>UROFOLLITROPIN<br><b>Category: </b>FOLLICLE STIMULATING HORMONE
<p>68<br><b>Brand Name: </b>IVY BLOCK<br><b>Generic Name: </b>URUSHIOL<br><b>Category: </b>MISCEL.SKIN AND MUCUS MEMBRANE AGENTS
<p>69<br><b>Brand Name: </b>ZENTATE<br><b>Generic Name: </b>VITAMINS PRENATAL<br><b>Category: </b>MULTIVITAMIN PREPARATIONS
<p>70<br><b>Brand Name: </b>ETOPOPHOS<br><b>Generic Name: </b>ETOPOSIDE PHOSPHATE<br><b>Category: </b>ANTINEOPLASTICS
<p>71<br><b>Brand Name: </b>SEROSTIM<br><b>Generic Name: </b>SOMATOTROPIN<br><b>Category: </b>PITUITARY
<p>72<br><b>Brand Name: </b>ZYPREXA<br><b>Generic Name: </b>OLANZAPINE<br><b>Category: </b>ANTIPSYCHOTICS
<p>73<br><b>Brand Name: </b>HURRICAINE<br><b>Generic Name: </b>BENZOCAINE<br><b>Category: </b>LOCAL ANESTHETICS
<p>74<br><b>Brand Name: </b>HURRICAINE<br><b>Generic Name: </b>BENZOCAINE<br><b>Category: </b>ANTIPRURITICS AND LOCAL ANESTHETICS
<p>75<br><b>Brand Name: </b>MERREM I.V.<br><b>Generic Name: </b>MEROPENEM<br><b>Category: </b>MISCELLANEOUS ANTIBIOTICS
<p>76<br><b>Brand Name: </b>PROAMATINE<br><b>Generic Name: </b>MIDODRINE<br><b>Category: </b>TREATMENT OF ORTHOSTATIC HYPERTENSION
<p>77<br><b>Brand Name: </b>RU-486<br><b>Generic Name: </b>MIFEPRISTONE<br><b>Category: </b>TERMINATION OF PREGNANCY
<p>78<br><b>Brand Name: </b>ALBENZA<br><b>Generic Name: </b>ALBENDAZOLE<br><b>Category: </b>ANTHELMINTICS
<p>79<br><b>Brand Name: </b>DIFFERIN<br><b>Generic Name: </b>ADAPALENE<br><b>Category: </b>MISCEL.SKIN AND MUCUS MEMBRANE AGENTS
<p>80<br><b>Brand Name: </b>CARBEX<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/seleg.htm">SELEGILINE HCL</a><br><b>Category: </b>FOR PARKINSON'S DISEASE
<p>81<br><b>Brand Name: </b>HELIDAC<br><b>Generic Name: </b>BISMUTH SUBSAL. METRONIDAZOLE & TETRACYCLINE<br><b>Category: </b>FOR PEPTIC ULCER DISEASE
<p>82<br><b>Brand Name: </b>TRITEC<br><b>Generic Name: </b>RANITIDINE BISMUTH CITRATE<br><b>Category: </b>MISCELLANEOUS GI DRUGS
<p>83<br><b>Brand Name: </b>CEREBYX<br><b>Generic Name: </b>FOSPHENYTOIN SODIUM<br><b>Category: </b>HYDANTOINS
<p>84<br><b>Brand Name: </b>ALLEGRA<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/fexofen.htm">FEXOFENADINE</a><br><b>Category: </b>ANTIHISTAMINES
<p>85<br><b>Brand Name: </b>CAMPTOSAR<br><b>Generic Name: </b>IRINOTECAN HCL<br><b>Category: </b>ANTINEOPLASTICS
<p>86<br><b>Brand Name: </b>XALATAN<br><b>Generic Name: </b>LATANOPROST<br><b>Category: </b>GLAUCOMA THERAPY
<p>87<br><b>Brand Name: </b>REMERON<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/mirtaz.htm">MIRTAZAPINE</a><br><b>Category: </b>ANTIDEPRESSANTS
<p>88<br><b>Brand Name: </b>VIRAMUNE<br><b>Generic Name: </b>NEVIRAPINE<br><b>Category: </b>ANIVIRALS
<p>89<br><b>Brand Name: </b>MYOTROPHIN<br><b>Generic Name: </b>SOMATOMEDIN C<br><b>Category: </b>FOR AMYOTROPHIC LATERAL SCLEROSIS
<p>90<br><b>Brand Name: </b>HUMULIN N<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/humnph.htm">HUMAN INSULIN NPH</a> <br><b>Category: </b>INSULINS
<p>91<br><b>Brand Name: </b>HUMULIN R<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/huminsr.htm">HUMAN INSULIN REGULAR</a><br><b>Category: </b>INSULINS
<p>92<br><b>Brand Name: </b>HUMULIN L<br><b>Generic Name: </b>HUMAN INSULIN LENTE<br><b>Category: </b>INSULINS
<p>93<br><b>Brand Name: </b>HUMULIN 70/30<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/hum7030.htm">HUMAN INSULIN NPH/REG 70/30</a><br><b>Category: </b>INULINS
<p>94<br><b>Brand Name: </b>ORTHO-NOVUM 7/7/7<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/norestoc.htm">NORETHINDRONE/ETHINYL ESTRADIOL</a> <br><b>Category: </b>CONTRACEPTIVES
<p>95<br><b>Brand Name: </b>ORTHO-CEPT<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/desest.htm">DESOGESTREL/ETHINYLESTRADIOL</A><br><b>Category: </b>CONTRACEPTIVES
<p>96<br><b>Brand Name: </b>ACCUPRIL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/quinap.htm">QUINAPRIL HCL</a><br><b>Category: </b>HYPOTENSIVE AGENTS
<p>97<br><b>Brand Name: </b>ACTHREL<br><b>Generic Name: </b>CORTICORELIN OVINE TRIFLUTATE<br><b>Category: </b>DIAGNOSTIC AGENTS
<p>98<br><b>Brand Name: </b>BUPHENYL<br><b>Generic Name: </b>SODIUM PHENYLBUTYRATE<br><b>Category: </b>FOR UREA CYCLE DISORDERS
<p>99<br><b>Brand Name: </b>VISIPAQUE<br><b>Generic Name: </b>IODIXANOL<br><b>Category: </b>ROENTGENOGRAPHY
<p>100<br><b>Brand Name: </b>NAPRELAN<br><b>Generic Name: </b>NAPROXEN SODIUM<br><b>Category: </b>NONSTEROIDAL ANTIINFLAMMATORY AGENTS
<p>101<br><b>Brand Name: </b>OXILAN<br><b>Generic Name: </b>IOXILAN<br><b>Category: </b>ROENTGENOGRAPHY
<p>102<br><b>Brand Name: </b>IONTOCAINE<br><b>Generic Name: </b>LIDOCAINE/EPINEPHRINE<br><b>Category: </b>LOCAL ANESTHETICS
<p>103<br><b>Brand Name: </b>PENTACEF<br><b>Generic Name: </b>CEFTAZIDINE<br><b>Category: </b>ANTIBIOTICS: CEPHALOSPORINS
<p>104<br><b>Brand Name: </b>METROCREAM<br><b>Generic Name: </b>METRONIDAZOLE<br><b>Category: </b>MISCELLANEOUS ANTI-INFECTIVES
<p>105<br><b>Brand Name: </b>GENOTROPIN<br><b>Generic Name: </b>SOMATROPIN<br><b>Category: </b>PITUITARY
<p>106<br><b>Brand Name: </b>SEVORANE<br><b>Generic Name: </b>SEVOFLURANE<br><b>Category: </b>GENERAL ANESTHETICS
<p>107<br><b>Brand Name: </b>BIOTROPIN<br><b>Generic Name: </b>SOMATROPIN<br><b>Category: </b>PITUITARY
<p>108<br><b>Brand Name: </b>ULTRAVIST<br><b>Generic Name: </b>IOPROMIDE<br><b>Category: </b>ROENTGENOGRAPHY
<p>109<br><b>Brand Name: </b>NORDITROPIN<br><b>Generic Name: </b>SOMATROPIN<br><b>Category: </b>PITUITARY
<p>110<br><b>Brand Name: </b>PROVEL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/ibup.htm">IBUPROFEN</A><br><b>Category: </b>NONSTEROIDAL ANTIINFLAMMATORY AGENTS
<p>111<br><b>Brand Name: </b>NISOCOR<br><b>Generic Name: </b>NISOLDIPINE<br><b>Category: </b>CARDIAC DRUGS
<p>112<br><b>Brand Name: </b>APTHASOL<br><b>Generic Name: </b>AMLEXANOX<br><b>Category: </b>TREATMENT OF CANKER SORES
<p>113<br><b>Brand Name: </b>ALPHANATE<br><b>Generic Name: </b>ANTIHEMOPHILIC FACTOR<br><b>Category: </b>HEMOSTATICS
<p>114<br><b>Brand Name: </b>OXYCONTIN<br><b>Generic Name: </b>OXYCODONE HCL<br><b>Category: </b>OPIATE AGONISTS
<p>115<br><b>Brand Name: </b>HYCAMTIN<br><b>Generic Name: </b>TOPOTECAN<br><b>Category: </b>ANTINEOPLASTICS
<p>116<br><b>Brand Name: </b>OXANDRIN<br><b>Generic Name: </b>OXANDROLONE<br><b>Category: </b>ANDROGENS
<p>117<br><b>Brand Name: </b>WINRHO SD<br><b>Generic Name: </b>RHO(D)IMMUNE GLOBULIN<br><b>Category: </b>SERUMS
<p>118<br><b>Brand Name: </b>AVONEX<br><b>Generic Name: </b>INTERFERON BETA-1A<br><b>Category: </b>TREATMENT OF MULTIPLE SCLEROSIS
<p>119<br><b>Brand Name: </b>GEMZAR<br><b>Generic Name: </b>GEMCITABINE HCL<br><b>Category: </b>ANTINEOPLASTICS
<p>120<br><b>Brand Name: </b>DEXFERRUM<br><b>Generic Name: </b>IRON DEXTRAN<br><b>Category: </b>IRON PRODUCTS
<p>121<br><b>Brand Name: </b>CORMAX<br><b>Generic Name: </b>CLOBETASOL PROPIONATE<br><b>Category: </b>ANTI-INFLAMMATORY AGENTS
<p>122<br><b>Brand Name: </b>VITRASERT<br><b>Generic Name: </b>GANCICLOVIR<br><b>Category: </b>ANTIVIRALS
<p>123<br><b>Brand Name: </b>CYTOVENE<br><b>Generic Name: </b>GANCICLOVIR<br><b>Category: </b>ANTIVIRALS
<p>124<br><b>Brand Name: </b>HUMALOG<br><b>Generic Name: </b>INSULIN LISPRO<br><b>Category: </b>INSULINS
<p>125<br><b>Brand Name: </b>DAUNOXOME<br><b>Generic Name: </b>DAUNORUBICIN CITRATE (LIPOSOME)<br><b>Category: </b>ANTINEOPLASTICS
<p>126<br><b>Brand Name: </b>ESTRING<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/estrad.htm">ESTRADIOL</A><br><b>Category: </b>ESTROGENS
<p>127<br><b>Brand Name: </b>ARIMEDEX<br><b>Generic Name: </b>ANASTROZOLE<br><b>Category: </b>ANTINEOPLASTICS
<p>128<br><b>Brand Name: </b>VISTIDE<br><b>Generic Name: </b>CIDOFOVIR<br><b>Category: </b>ANTIVIRALS
<p>129<br><b>Brand Name: </b>NICOTROL NS<br><b>Generic Name: </b>NICOTINE(NASAL)<br><b>Category: </b>MISCELLANEOUS AUTONOMIC DRUGS 
<p>130<br><b>Brand Name: </b>VIQUIN FORTE<br><b>Generic Name: </b>HYDROQUINONE<br><b>Category: </b>DEPIGMENTING AGENTS
<p>131<br><b>Brand Name: </b>REDUX<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/dexfen.htm">DEXFENFLURAMINE</a><br><b>Category: </b>ANTI-OBESITY AGENTS
<p>132<br><b>Brand Name: </b>ZANAFLEX<br><b>Generic Name: </b>TIZANIDINE HCL<br><b>Category: </b>SKELETAL MUSCLE RELAXANTS
<p>133<br><b>Brand Name: </b>PREVALITE<br><b>Generic Name: </b>CHOLESTYRAMINE<br><b>Category: </b>ANTILIPEMIC AGENTS
<p>134<br><b>Brand Name: </b>FERIDEX<br><b>Generic Name: </b>FERUMOXIDE<br><b>Category: </b>MAGNETIC RESONANCE IMAGING
<p>135<br><b>Brand Name: </b>MAVIK<br><b>Generic Name: </b>TRANDOLAPRIL<br><b>Category: </b><a href="http://www.rxlist.com/cardiova.htm">HYPOTENSIVE AGENTS</a> 
<p>136<br><b>Brand Name: </b>NAROPIN<br><b>Generic Name: </b>ROPIVACAINE<br><b>Category: </b>LOCAL ANESTHETICS
<p>137<br><b>Brand Name: </b>SCLEROSOL<br><b>Generic Name: </b>TALC<br><b>Category: </b>SCLEROSING AGENTS
<p>138<br><b>Brand Name: </b>TOPAMAX<br><b>Generic Name: </b>TOPIRAMATE<br><b>Category: </b>MISCELLANEOUS ANTICONVULSANTS
<p>139<br><b>Brand Name: </b>VAQTA<br><b>Generic Name: </b>HEPATITIS A VACCINE<br><b>Category: </b>VACCINES
<p>140<br><b>Brand Name: </b>MYOVIEW<br><b>Generic Name: </b>TETROPHOSMIN<br><b>Category: </b>RADIOPHARMACEUTICALS
<p>141<br><b>Brand Name: </b>OCUHIST<br><b>Generic Name: </b>PHENIRAMINE MALEATE<br><b>Category: </b>ANTIHISTAMINE DRUGS
<p>142<br><b>Brand Name: </b>COVERA-HS<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/verapsr.htm">VERAPAMIL</A> HCL<br><b>Category: </b><a href="http://www.rxlist.com/cardiova.htm">CARDIAC DRUGS</a> 
<p>143<br><b>Brand Name: </b>SYNOVIR<br><b>Generic Name: </b>THALIDOMIDE<br><b>Category: </b>AIDS-CACHEXIA
<p>144<br><b>Brand Name: </b>VESANOID<br><b>Generic Name: </b>TRETINOIN<br><b>Category: </b>ANTINEOPLASTIC AGENTS
<p>145<br><b>Brand Name: </b>TEICHOMYCIN<br><b>Generic Name: </b>TEICOPLANIN<br><b>Category: </b>MISCELLANEOUS ANTIBIOTICS
<p>146<br><b>Brand Name: </b>NORVIR<br><b>Generic Name: </b>RITONAVIR<br><b>Category: </b>ANTIVIRALS
<p>147<br><b>Brand Name: </b>NIMBEX<br><b>Generic Name: </b>CISATRACURIUM BESYLATE<br><b>Category: </b>SKELETAL MUSCLE RELAXANTS
<p>148<br><b>Brand Name: </b>MAXIPIME<br><b>Generic Name: </b>CEFEPIME<br><b>Category: </b>ANTIBIOTICS: CEPHALOSPORINS
<p>149<br><b>Brand Name: </b>PENNSAID<br><b>Generic Name: </b>DIMETHAID-D<br><b>Category: </b><a href="http://www.rxlist.com/nsaid.htm">NONSTEROIDAL ANTI-INFLAMMATORY AGENTS</a> 
<p>150<br><b>Brand Name: </b>ADDERALL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/amphet.htm">AMPHETAMINE MIXED SALTS</a><br><b>Category: </b>RESPIRATORY AND CEREBRAL STIMULANTS
<p>151<br><b>Brand Name: </b>CANDIN<br><b>Generic Name: </b>CANDIDA ALBICANS<br><b>Category: </b>FUNGI
<p>152<br><b>Brand Name: </b>ACTRON<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/ketoprof.htm">KETOPROFEN</a><br><b>Category: </b><a href="http://www.rxlist.com/nsaid.htm">NONSTEROIDAL ANTIINFLAMMATORY AGENTS</a> 
<p>153<br><b>Brand Name: </b>CEDAX<br><b>Generic Name: </b>CEFTIBUTEN<br><b>Category: </b>ANTIBIOTICS:CEPHALOSPORINS
<p>154<br><b>Brand Name: </b>RENOVA<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/tretinoin.htm">TRETINOIN</a><br><b>Category: </b>MISCEL.SKIN AND MUCUS MEMBRANE AGENTS
<p>155<br><b>Brand Name: </b>PHOTOFRIN<br><b>Generic Name: </b>PORFIMER SODIUM<br><b>Category: </b>ANTINEOPLASTIC AGENTS (PHOTODYNAMIC)
<p>156<br><b>Brand Name: </b>AMARYL<br><b>Generic Name: </b>GLIMEPIRIDE<br><b>Category: </b>ANTIDIABETIC AGENTS
<p>157<br><b>Brand Name: </b>FLOLAN<br><b>Generic Name: </b>EPOPROSTENOL SODIUM<br><b>Category: </b>VASODILATING AGENTS
<p>158<br><b>Brand Name: </b>RESPIGAM<br><b>Generic Name: </b>RSV-IGIV<br><b>Category: </b>SERUMS
<p>159<br><b>Brand Name: </b>CRIXIVAN<br><b>Generic Name: </b>INDINAVIR SULFATE<br><b>Category: </b>ANTIVIRALS
<p>160<br><b>Brand Name: </b>TRIPEDIA<br><b>Generic Name: </b>WHOOPING COUGH VACCINE<br><b>Category: </b>VACCINES
<p>161<br><b>Brand Name: </b>PROCANABID<br><b>Generic Name: </b>PROCAINAMIDE HCL<br><b>Category: </b>CARDIAC DRUGS
<p>162<br><b>Brand Name: </b>ZYRTEC<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/cetiriz.htm">CETIRIZINE HCL</a><br><b>Category: </b>ANTIHISTAMINE DRUGS
<p>163<br><b>Brand Name: </b>VIVELLE<br><b>Generic Name: </b>ESTRADIOL (TRANSDERMAL SYSTEM)<br><b>Category: </b>ESTROGEN
<p>164<br><b>Brand Name: </b>AZELEX<br><b>Generic Name: </b>ACELAIC ACID<br><b>Category: </b>SKIN AND MUCUS MEMBRANE AGENTS
<p>165<br><b>Brand Name: </b>ETHYOL<br><b>Generic Name: </b>AMIFOSTINE<br><b>Category: </b>UNCLASSIFIED THERAPEUTIC AGENTS
<p>166<br><b>Brand Name: </b>DOXIL<br><b>Generic Name: </b> DOXORUBICIN HCL (LIPOSOME INJECTION)<br><b>Category: </b>ANTIONEOPLASTIC AGENTS
<p>167<br><b>Brand Name: </b>ABELCET<br><b>Generic Name: </b>ABCL(AMPHOTERICIN B LIPID COMPLEX LIPOSOME INJ)<br><b>Category: </b>ANTIFUNGALS
<p>168<br><b>Brand Name: </b>PRECOSE<br><b>Generic Name: </b>ACARBOSE<br><b>Category: </b>ANTIDIABETIC AGENTS
<p>169<br><b>Brand Name: </b>RILUTEK<br><b>Generic Name: </b>RILUZOLE<br><b>Category: </b>FOR AMYOTROPHIC LATERAL SCLEROSIS
<p>170<br><b>Brand Name: </b>VALTREX<br><b>Generic Name: </b>VALACYCLOVIR<br><b>Category: </b>ANIVIRALS
<p>171<br><b>Brand Name: </b>FLOVENT<br><b>Generic Name: </b>FLUTICASONE PROPRIONATE<br><b>Category: </b>ANTIINFLAMMATORY AGENTS
<p>172<br><b>Brand Name: </b>DYNABAC<br><b>Generic Name: </b>DIRITHROMYCIN<br><b>Category: </b>ANTIBIOTICS:ERYTHROMYCINS
<p>173<br><b>Brand Name: </b>CORVERT<br><b>Generic Name: </b>IBUTILIDE<br><b>Category: </b>CARDIAC DRUGS
<p>174<br><b>Brand Name: </b>FARESTON<br><b>Generic Name: </b>TOREMIFENE CITRATE<br><b>Category: </b>ANTINEOPLASTIC AGENTS
<p>175<br><b>Brand Name: </b>COREG<br><b>Generic Name: </b>CARDEDILOL<br><b>Category: </b>CARDIAC DRUGS
<p>176<br><b>Brand Name: </b>TAXOTERE<br><b>Generic Name: </b>DOCETAXEL<br><b>Category: </b>ANTINEOPLASTIC AGENTS
<p>177<br><b>Brand Name: </b>BUTOX<br><b>Generic Name: </b>BOTULINUM TOXIN TYPE A<br><b>Category: </b>TOXOIDS
<p>178<br><b>Brand Name: </b>SULAR<br><b>Generic Name: </b>NISOLDIPINE<br><b>Category: </b>CARDIAC DRUGS
<p>179<br><b>Brand Name: </b>BLEO<br><b>Generic Name: </b>BLEOMYCIN<br><b>Category: </b>ANTINEOPLASTIC AGENTS
<p>180<br><b>Brand Name: </b>BLEOCIN<br><b>Generic Name: </b>BLEOMYCIN<br><b>Category: </b>ANTINEOPLASTIC AGENTS
<p>181<br><b>Brand Name: </b>BLENOXANE<br><b>Generic Name: </b>BLEOMYCIN<br><b>Category: </b>ANTINEOPLASTIC AGENTS
<p>182<br><b>Brand Name: </b>INVIRASE<br><b>Generic Name: </b>SAQUINAVIR<br><b>Category: </b>ANTIVIRALS
<p>183<br><b>Brand Name: </b>EPIVIR<br><b>Generic Name: </b>LAMIVUDINE<br><b>Category: </b>ANTIVIRALS
<p>184<br><b>Brand Name: </b>3TC<br><b>Generic Name: </b>LAMIVUDINE<br><b>Category: </b>ANTIVIRALS
<p>185<br><b>Brand Name: </b>AZT<br><b>Generic Name: </b>ZIDOVUDINE<br><b>Category: </b>ANTIVIRALS
<p>186<br><b>Brand Name: </b>NIZORAL<br><b>Generic Name: </b>KETOCONAZOLE<br><b>Category: </b>ANTIFUNGALS
<p>187<br><b>Brand Name: </b>NIZORAL TOPICAL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/ketocon.htm">KETOCONAZOLE TOPICAL</A><br><b>Category: </b>ANTIFUNGALS
<p>188<br><b>Brand Name: </b>METHERGINE<br><b>Generic Name: </b>METHYLERGONOVINE MALEATE<br><b>Category: </b>OXYTOCICS
<p>189<br><b>Brand Name: </b>LOTREL<br><b>Generic Name: </b>AMLODIPINE/BENAZEPRIL HCL<br><b>Category: </b><a href="http://www.rxlist.com/cardiova.htm">HYPOTENSIVE AGENTS</a> 
<p>190<br><b>Brand Name: </b>VEXOL<br><b>Generic Name: </b>RIMEXOLONE<br><b>Category: </b>OPTHALMIC CORTICOSTEROID
<p>191<br><b>Brand Name: </b>DR-3355<br><b>Generic Name: </b>LEVOFLOXACIN<br><b>Category: </b>INVESTIGATIONAL:ANTIBIOTICS:QUINOLINES
<p>192<br><b>Brand Name: </b>ORG-10172<br><b>Generic Name: </b>DANAPAROID<br><b>Category: </b>INVESTIGATIONAL:ANTICOAGULANTS
<p>193<br><b>Brand Name: </b>RU 44570<br><b>Generic Name: </b>TRANDOLAPRIL<br><b>Category: </b> <a href="http://www.rxlist.com/cardiova.htm">HYPOTENSIVE AGENTS</a> 
<p>194<br><b>Brand Name: </b>ACCOLATE<br><b>Generic Name: </b>ZAFIRLUKAST<br><b>Category: </b>RESPIRATORY:LEUKOTRIENE ANTAGONIST
<p>195<br><b>Brand Name: </b>TIAZAC<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/diltiaz.htm">DILTIAZEM HCL</a> <br><b>Category: </b><a href="http://www.rxlist.com/cardiova.htm">CARDIAC DRUGS</a> 
<p>196<br><b>Brand Name: </b>FOSAMAX<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/alendron.htm">ALENDRONATE SODIUM</a><br><b>Category: </b>MISCELLANEOUS:OSTEOPOROSIS
<p>197<br><b>Brand Name: </b>REOPRO<br><b>Generic Name: </b>ABCIXIMAB<br><b>Category: </b>UNCLASSIFIED THERAPEUTIC AGENTS
<p>198<br><b>Brand Name: </b>SECTRAL<br><b>Generic Name: </b>ACEBUTOLOL HCL<br><b>Category: </b><a href="http://www.rxlist.com/cardiova.htm">CARDIAC DRUGS</a> 
<p>199<br><b>Brand Name: </b>ACI-JEL W/APP<br><b>Generic Name: </b>ACET AC/RICINOLEIC/OXY<br><b>Category: </b>ANTI-INFECTIVES
<p>200<br><b>Brand Name: </b>ACEPHEN<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>201<br><b>Brand Name: </b>ACETAMIN<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>202<br><b>Brand Name: </b>ANACIN AF<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>203<br><b>Brand Name: </b>APAP<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>204<br><b>Brand Name: </b>BL INFANT N/A<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>205<br><b>Brand Name: </b>BL NON-ASPIRN<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>206<br><b>Brand Name: </b>FEVERALL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>207<br><b>Brand Name: </b>GENAPAP X/S<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>208<br><b>Brand Name: </b>GENEBS X/S<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>209<br><b>Brand Name: </b>GNP NON-ASPRN<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>210<br><b>Brand Name: </b>GNP NON-ASPRN<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>211<br><b>Brand Name: </b>GNP XS PAIN<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>212<br><b>Brand Name: </b>INFANTAIRE<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>213<br><b>Brand Name: </b>INFANTOL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>214<br><b>Brand Name: </b>MAPAP ACETAM<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>215<br><b>Brand Name: </b>PAIN &amp; FEVER<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>216<br><b>Brand Name: </b>PANADOL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>217<br><b>Brand Name: </b>PEDIAPAP<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>218<br><b>Brand Name: </b>TEMPRA 1<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>219<br><b>Brand Name: </b>TEMPRA 2<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>220<br><b>Brand Name: </b>TYLENOL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>221<br><b>Brand Name: </b>TYLENOL INFNT<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>222<br><b>Brand Name: </b>TYLENOL X/S<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>223<br><b>Brand Name: </b>BROMO SELTZER<br><b>Generic Name: </b>ACETAMINOPHEN BUFFERED<br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>224<br><b>Brand Name: </b>GENAPAP CHILD<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN CHEW</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>225<br><b>Brand Name: </b>ST JOS CHL/AF<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN CHEW</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>226<br><b>Brand Name: </b>TEMPRA 3 CHEW<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN CHEW</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>227<br><b>Brand Name: </b>TYLENOL CHILD<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN CHEW</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>228<br><b>Brand Name: </b>TYLENOL CHILD<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN CHEW</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>229<br><b>Brand Name: </b>TYLENOL X/RLF<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN SA</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>230<br><b>Brand Name: </b>PROMINOL<br><b>Generic Name: </b>ACETAMINOPHEN/BUTALBITAL<br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>231<br><b>Brand Name: </b>APAP/COD<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/acetcod.htm">ACETAMINOPHEN/CODEINE</a> <br><b>Category: </b><a href="opiate.htm">OPIATE AGONISTS</a> 
<p>232<br><b>Brand Name: </b>CAPITAL W/COD<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/acetcod.htm">ACETAMINOPHEN/CODEINE</a> <br><b>Category: </b><a href="opiate.htm">OPIATE AGONISTS</a> 
<p>233<br><b>Brand Name: </b>PHENAPHEN/COD<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/acetcod.htm">ACETAMINOPHEN/CODEINE</a> <br><b>Category: </b><a href="opiate.htm">OPIATE AGONISTS</a> 
<p>234<br><b>Brand Name: </b>TYLENOL/COD<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/acetcod.htm">ACETAMINOPHEN/CODEINE</a> <br><b>Category: </b><a href="opiate.htm">OPIATE AGONISTS</a> 
<p>235<br><b>Brand Name: </b>ACETAZOLAMIDE<br><b>Generic Name: </b>ACETAZOLAMIDE<br><b>Category: </b>CARBONIC ANHYDRASE INHIBITORS
<p>236<br><b>Brand Name: </b>DIAMOX<br><b>Generic Name: </b>ACETAZOLAMIDE<br><b>Category: </b>CARBONIC ANHYDRASE INHIBITORS
<p>237<br><b>Brand Name: </b>ACETASOL PLN<br><b>Generic Name: </b>ACETIC ACID OTIC<br><b>Category: </b>ANTI-INFECTIVES
<p>238<br><b>Brand Name: </b>DOMEBORO OTIC<br><b>Generic Name: </b>ACETIC ACID OTIC<br><b>Category: </b>ANTI-INFECTIVES
<p>239<br><b>Brand Name: </b>VOSOL OTIC<br><b>Generic Name: </b>ACETIC ACID OTIC<br><b>Category: </b>ANTI-INFECTIVES
<p>240<br><b>Brand Name: </b>ACETASOL HC<br><b>Generic Name: </b>ACETIC ACID/HYDROCORT OTI<br><b>Category: </b>ANTI-INFECTIVES
<p>241<br><b>Brand Name: </b>HYDRO/ACETIC<br><b>Generic Name: </b>ACETIC ACID/HYDROCORT OTI<br><b>Category: </b>ANTI-INFECTIVES
<p>242<br><b>Brand Name: </b>VASOTATE HC<br><b>Generic Name: </b>ACETIC ACID/HYDROCORT OTI<br><b>Category: </b>ANTI-INFECTIVES
<p>243<br><b>Brand Name: </b>VOSOL HC OTIC<br><b>Generic Name: </b>ACETIC ACID/HYDROCORT OTI<br><b>Category: </b>ANTI-INFECTIVES
<p>244<br><b>Brand Name: </b>DYMELOR<br><b>Generic Name: </b>ACETOHEXAMIDE<br><b>Category: </b>SULFONYLUREAS
<p>245<br><b>Brand Name: </b>LITHOSTAT<br><b>Generic Name: </b>ACETOHYDROXAMIC ACID<br><b>Category: </b>AMMONIA DETOXICANTS
<p>246<br><b>Brand Name: </b>SEBA-NIL<br><b>Generic Name: </b>ACETONE/ALCOHOL/POLYSORB<br><b>Category: </b>MISCEL.SKIN AND MUCUS MEMBRANE AGENTS
<p>247<br><b>Brand Name: </b>MIOCHOL E W/<br><b>Generic Name: </b>ACETYLCHOLINE CHL<br><b>Category: </b>MIOTICS
<p>248<br><b>Brand Name: </b>ACETYLCYSTEIN<br><b>Generic Name: </b>ACETYLCYSTEINE<br><b>Category: </b>MUCOLYTIC AGENTS
<p>249<br><b>Brand Name: </b>MUCOMYST<br><b>Generic Name: </b>ACETYLCYSTEINE<br><b>Category: </b>MUCOLYTIC AGENTS
<p>250<br><b>Brand Name: </b>MUCOSIL<br><b>Generic Name: </b>ACETYLCYSTEINE<br><b>Category: </b>MUCOLYTIC AGENTS
<p></body></html>
<P><hr><a href="http://www.rxlist.com"><b>RxList Home Page</ul>
<hr>
</DOC>
<DOC>
<DOCNO>WT08-B13-17</DOCNO>
<DOCOLDNO>IA018-000200-B044-38</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/rxlink2.htm 206.86.175.201 19970106232114 text/html 26620
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:14:58 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 26437
Last-modified: Wed, 01 Jan 1997 22:59:43 GMT
</DOCHDR>
<html>                                                                          
<head>
<title>
www.rxlist.com - Neil Sandow, Pharm.D.
</title>
</head>
<body bgcolor="#ffffff">
<a href="http://www.rxlist.com"><img
src="rx.gif" height=50 width=50 align=left><img
src="rx.gif" height=50 width=50 align=right></a><center> <h2>Known 
Links To RxList</h2><p> <hr>
<hr>
</center><b><font size=4>
<li><a href="http://www.achoo.com/achoo/human/diseases/">Achoo</a>
<li><a href="http://www.dmu.ac.uk/ln/CyberRx">CyberRx</a>
<li><a href="http://www.hon.ch">Health on the Net Foundation</a>
<li><a href="http://www.healthseek.com">HealthSeek</a>
<li><a href="http://www-sci.lib.uci.edu:80/~martindale/Pharmacy.html">Martindale's Health Science Guide</a>
<li><a href="http://www.slackinc.com/matrix/">Medical Matrix </a>
<li><a href="http://pharminfo.com">Pharmaceutical Information Network</a>
<li><a href="http://www.pharmweb.net/">PharmWeb - Department of Pharmacy - University of Manchester</a>
<li><a href="http://www.cpb.uokhsc.edu/pharmacy/pharmint.html">Virtual Library Pharmacy Page - Univ. of Oklahoma</a>
<li><a href="http://community.net/~neils/new.html">World Wide Drugs</a>
<hr>
<li><a href="http://wizard.pharm.wayne.edu/items.html">American Chemical Society - Wayne State Universiy</a>
<li><a href="http://nrc.med.auth.gr/drugs.html">Aristotle University of Thessaloniki - GREECE </a>
<li><a href="http://diogenes.baylor.edu/Library/BeyondLib/nursing.html">Baylor University Libraries - Selected Nursing Resources</a>
<li><a href="http://med-amsa.bu.edu/Pharmacology/links.html">Boston University - School of Medicine - Biomolecular Pharmacology</a>
<li><a href="http://http2.brunel.ac.uk:8080/~hssrsdn/">Brunel University - UK - CSHSD</a>
<li><a href="http://www.cato.com/interweb/cato/biotech/bio-info.html">Cato Research - WWW Virtual Library</a>
<li><a href="http://www.cdc.gov/nchswww/sites/sites.htm">CDC - National Center for Health Statistics</a>
<li><a href="http://telemachus.creighton.edu">Creighton U. Pharmacocybernetics Center - School of Pharmacy</a>
<li><a href="http://www.hitchcock.org/">Dartmouth-Hitchcock Medical Center</a>
<li><a href="http://www.uni-kassel.de/fb16/ipm/mt/java/javae.html">Department of Engineering - Universitt Gesamthochschule Kassel</a>
<li><a href="http://wizard.pharm.wayne.edu/drh/drhhome1.htm">Detroit Receiving Hospital and University</a>
<li><a href="http://152.3.86.75/druginfo/adr.htm#Section8">Duke Univertisy - Pharmacy 74 Internet Module</a> 
<li><a href="http://www.humed.com">Hackensack University Medical Center</a>
<li><a href="http://www.hamline.edu/HyperNews/get.cgi/lupus/73/1.html">Hamiline University - Conferencing System</a>
<li><a href="http://www.med.harvard.edu/webref/hsciref.html">Harvard University - Countway Library of Medicine</a>
<li><a href="http://dem0nmac.mgh.harvard.edu/hospitalweb.html">Hospital Web - Massachusetts General Hospital </a>
<li><a href="http://www.drugs.indiana.edu/druginfo/other_drug.html">Indiana Prevention Resource Center - Indiana University</a>
<li><a href="http://www.med.jhu.edu/peds/neonatology/poi.html">John Hokins Hospital - Pediatric Points of Interest</a>
<li><a href="http://maple.lemoyne.edu/%7Ehevern/psychref3.html">Le Moyne College - Psych Refs</a>
<li><a href="http://www.lij.edu/links/medical_reference.html">Long Island Jewish Medical Center - Medical References</a>
<li><a href="http://nimrod.mit.edu/common/reference/tools.html">M.I.T. - Virtual Reference Collection</a>
<li><a href="http://www2.pitt.edu/~martint/">Medical, Clinical & Occupational Toxicology Resources</a>
<li><a href="http://www.intmed.mcw.edu/drug.html">Medical College of Wisconsin - Doyne & FMLH Drug Formulary </a>
<li><a href="http://rzstud1.rz.uni-karlsruhe.de/~ukpq/medical.html">Medical Informations -  University of Karlsruhe, Germany </a>
<li><a href="http://www.musc.edu/pharmacy/linx/linx.html">Medical University of South Carolina </a>
<li><a href="http://golgi.harvard.edu:80/biopages/medicine.html">Medicine (Biosciences) - Harvard University</a>
<li><a href="http://www.meds.com">Medicine On Line</a>
<li><a href="http://www.medfarm.unito.it/">MedPharm - University of Torino Medical School, Italy</a>
<li><a href="http://web.cc.emory.edu/WHSCL/medweb.pharmacy.html">MedWeb Pharmacy and Pharmacology - Emory University</a>
<li><a href="http://www.mercy.org/~bchrist/bill1.html">Mercy Medical Center, Redding, CA</a>
<li><a href="http://www.nihs.go.jp/">National Institute of Health Sciences - Japan</a>
<li><a href="http://www.pharm.nwu.edu">Northwestern University Medical School - Molecular Pharmacology</a>
<li><a href="http://www.ntu.ac.uk/lis/health.htm">Nottingham Trent University - Electronic Library Resources</a>
<li><a href="http://"http://www.med.nyu.edu/biomedinfo.html">NYU Medical Center - Biomedical Information Resources</a>
<li><a href="http://www.onu.edu/Pharmacy/links.html">Ohio Northern University - Rudolph H. Raabe College of Pharmacy</a>
<li><a href="http://solar.rtd.utk.edu/~esmith/rxtra.html">Rxtra Info - University of Tennessee Medical Center</a>
<li><a href="http://www.tcom.ohiou.edu/oucom/medsite.htm">Ohio University College of Osteopathic Medicine</a>
<li><a href="http://www.qut.edu.au/hlth/sph/phlinks_us.html">Queensland University of Technology - Brisbane, Australia</a>
<li><a href="http://wn.apc.org/health/health.html">SangoNet Health - South Africa</a>
<li><a href="http://www.sendit.nodak.edu/sendit/health.html">Sendit - North Dakota's Educational Network</a>  
<li><a href="http://www.estyle.com/thl/">Stanford University - The Health Library</a>
<li><a href="http://www.stlcop.edu/library/library.html">St.Louis College of Pharmacy</a>
<li><a href="http://tmc.edu.tw/">Taipei Medical College</a>
<li><a href="http://www.ashp.com/pub/ashp">The American Society of Health System Pharmacists</a>
<li><a href="http://biosci.cbs.umn.edu/biophys/biophys.html">The Biophysical Society</a>
<li><a href="http://falcon.cc.ukans.edu/~nsween/bscience.html">The Interactive Medical Student Lounge</a>
<li><a href="http://ipl.sils.umich.edu/ref/RR/HEA/medication-rr.html">The Internet Public Library</a>
<li><a href="http://www.rutgers.edu/NB-Pharmacy/resrce.html">The Rutgers College of Pharmacy Information Resource Area</a>
<li><a href="http://www.vicnet.net.au/~shpa/shpa1.htm">The Society of Hospital Pharmacy - Australia</a>
<li><a href="http://midget.towson.edu/~cooklib/bibliographies/drugs96.htm">Towson State University</a>
<li><a href="http://www.toyama-mpu.ac.jp/">Toyama Medical and Pharmaceutical University</a>
<li><a href="http://www.md.ucl.ac.be/">Universite Catholique de Louvain - Faculte de medecin</a>
<li><a href="http://www.physiol.ox.ac.uk/">University Laboratory of Physiology - Oxford University
<li><a href="http://www.ualberta.ca/PHARMACE/">University of Alberta - Continuing Pharmacy Education</a>
<li><a href="http://aloe.ahsl.arizona.edu/pharm.htm#Reference">University of Arizona - Health Services Library</a>
<li><a href="http://www.ub.es/farcli/wp0.htm">University of Barcelona - Department of Pharmacy</a>
<li><a href="http://www.bath.ac.uk/">University of Bath - School of Pharmacy</a>
<li><a href="http://unixg.ubc.ca:880/chweiz/links.html">University of British Columbia</a>
<li><a href="http://www-informatics.ucdmc.ucdavis.edu/weboff.htm">Univ. of  California - Davis - Medical Informatics</a>
<li><a href="http://health.ucsd.edu/">University of California - San Diego</a>
<li><a href="http://galen.library.ucsf.edu/kr/subs/pharm/rxlist.html">University of California - SF - Galen Digital Library</a>
<li><a href="http://www.phar.cam.ac.uk/">University of Cambridge - Department of Pharmacology</a>
<li><a href="http://www.phm.ed.ac.uk/links/links.htm">University of Edinburgh - Department of Pharmacology</a>
<li><a href="http://nervm.nerdc.ufl.edu/~cop28/index.html">University of Florida - College of Pharmacy</a>
<li><a href="http://calvin.mri.uky.edu/pcc">University of Kentucky - Primary Care Information Network</a>
<li><a href="http://www.med.miami.edu/catalog/subject/pharmacology_and_toxicology.html">University of Miami School of Medicine</a>
<li><a href="http://www3.umdnj.edu/~libcwis/univlibs.html">Univ. of Medicine and Dentistry of New Jersey</a>
<li><a href="http://molbio.cbs.umn.edu/biophys/RelatedSites.html">University of Minnesota - Biophysics Related Resources</a>
<li><a href="http://www.pitt.edu/~rxschool/">University of Pittsburgh - School of Pharmacy</a>
<li><a href="http://www.usc.edu/hsc/resources/pharmacy.html/">University of Southern California</a>
<li><a href="http://utmgopher.utmem.edu/psweb/cool.html">University of Tennessee-Memphis - Cool Pharmacy Links</a>
<li><a href="http://www.utmb.edu/">University of Texas Medical Branch at Galveston</a>
<li><a href="http://www.utoronto.ca/pharmacy/resource.htm">University of Toronto - Faculty of Pharmacy</a>
<li><a href="http://merian.pch.univie.ac.at/pch/others.html">University of Vienna, Austria - Institute of Pharmaceutical Chemistry</a>
<li><a href="http://www.hslib.washington.edu/your_health/">University of Washington - Healthlinks</a>
<li><a href="http://maddog.fammed.wisc.edu/hmid/hmid10_2_95.html">University of Wisconsin - Schools of Medicine and Nursing</a>
<li><a href="http://www.au.af.mil/au.html">US Air Force - Air University</a>
<li><a href="http://www.vichosp.london.on.ca">Victoria Hospital, London, Ontario, Canada</a>
<li><a href="http://library.uwaterloo.ca/discipline/Disability_Issues/otherinfo.html">Waterloo University Library - Disability Issues</a>
<hr>
<li><a href="http://www.aos-jax.com/rxlist.htm">Advanced Otolaryngology Services, P.A.</a>
<li><a href="http://www.ailments.com">Ailments.com</a>
<li><a href="http://www.alpha1.org">Alpha 1 National Association - Antitrypsin Deficiency</a>
<li><a href="http://www.psych.org/index.html">American Psychiatric Association</a>
<li><a href="http://www.ritcom.com/amerisource/">Amerisource</a>
<li><a href="http://207.51.37.199:8888/DSM/cafe/links.html">Apollonia Cafe</a>
<li><a href="http://www.arraydev.com/commerce/news-1.html">Array Development</a>
<li><a href="http://www.ascrs.org/links.html">ASCRS-ASOA</a>
<li><a href="http://www.gis.net/~rogeryoung">Ask A Pharmacist - Roger Young</a>
<li><a href="http://www.Tyler.Net/Bear/">Bears' Den</a>
<li><a href="http://www.ci.berkeley.ca.us/bpl/bkmk/health.html">Berkeley Public Library - Health Index</a>
<li><a href="http://www.bhglive.com/guidpags/hlthguid.html">Better Homes and Gardens</a>
<li><a href="http://werple.mira.net.au/~lions/medical.htm">Beyond the Black Stump - Medical & Health</a>
<li><a href="http://biotechlaw.ari.net/page6.html">Biotechnology Law Web Server</a>
<li><a href="http://www.bcbsmd.com">Blue Cross - Blue Shield of Maryland</a>
<li><a href="http://www.erols.com/owl/planet/homepage.html">Blue Planet</a>
<li><a href="http://www.afn.org/~afn05660/health.html">Brues' News:Health</a>
<li><a href="http://www.ceoexpress.com/">CEO Express</a>
<li><a href="http://WWW.BLUECRAB.ORG/">Chesapeake Free-Net</a>
<li><a href="http://www.motility.org/">Children's Motility Disorder Foundation</a>
<li><a href="http://www.Tracknet.com/radio.html">CKNW Radio 98 8/12/96 Internet Update with Margot Sinclair</a>
<li><a href="http://www.cmic.co.jp:443/">Clinical Medicine Information Center Co. - Tokyo, Japan</a>
<li><a href="http://cnn.com">CNN Interactive</a>
<li><a href="http://cnn.com/HEALTH/9612/09/preventing.strokes.ap/index.html">CNN Health Story Page</a>
<li><a href="http://www.zdnet.com/clifeuk/">Computer Life</a>
<li><a href="http://www.consumerworld.org/edgar/pages/resource.htm">Consumer World</a>
<li><a href="http://www.coolcentral.com">Cool Central - Cool Site of the Hour</a>
<li><a href="http://www.odyssee.net/~fnord/nurselink.html">Cool Nursing Site of the Week (8/1/96)</a>
<li><a href="http://www.cwmars.org/">C/W Mars Web Page</a>
<li><a href="http://ch.nus.sg/">Cyberspace Hospital - Singapore</a>
<li><a href="http://www.telemedical.com">Cyberspace Telemedical Office</a>
<li><a href="http://www.interface.co.nz:8001/">David Merritt HomePages</a>
<li><a href="http://dentalxchange.com/chkitout/test/faileduc.htm">Dental X Change</a>
<li><a href="http://DentalGlobe.com/edu.html">Dental Globe</a>
<li><a href="http://www.mediware.com/digi.html">Digimedics - My Hospital Pharmacy Information System Vendor</a>
<li><a href="http://www.divanet.com/search/">Divanet Search Page</a>
<li><a href="http://www.iosphere.net/~dixonr">Dixon's Doorway </a>
<li><a href="http://uhs.bsd.uchicago.edu/~bhsiung/mental.html">Doctor Bob's Mental Health Links</a>
<li><a href="http://www.pslgroup.com/dg/6e06.htm">Doctor's Guide</a>
<li><a href="http://www.psycom.net/depression.central.html">Dr. Ivan's Depression Central</a>
<li><a href="http://www.valley-bbs.com.br/sergio/index.htm">Dr. Sergio dos Passos Ramos - Brazil</a>
<li><a href="http://www.dotpharmacy.co.uk/hotlink1.html">Dot Pharmacy - UK</a> 
<li><a href="http://community.net/~neils">Earl's Urls</a>
<li><a href="http://www.easysearcher.com/ez2.html">Easy Searcher II</a>
<li><a href="http://www.li.net/~edhayes/ed.html">Edmund Hayes - Links to the Medical Professions</a>
<li><a href="http://www.pjbpubs.co.uk/a/emedhome.html">e-med News</a>
<li><a href="http://www.clandjop.com/~aclark/">Emergency Minded</a>
<li><a href="http://www.ezconnect.com//home.htm">EZ Connect</a>
<li><a href="http://www.fastsearch.com/">Fast Search</a>
<li><a href="http://users.icanect.net/~visionx/">Florida School Psychologist Network</a>
<li><a href="http://www.bcl.net/~jtreese/medical.html">Gem's Medical Links</a>
<li><a href="http://www.gate.net/~gmatt/">Glen Matthews - North Broward Hospital District </a>
<li><a href="http://members.aol.com/poison5249/GrierPharm/ghpharm.html">Grier's Pharmacy Page</a>
<li><a href="http://www.gte.net/start/educ&ref/ed-sci.html">GTE Net - Educational Resources - Science</a>
<li><a href="http://www.healthbiz.com">Healthbiz Notes</a>
<li><a href="http://www.zamnet.zm/zamnet/health.html">Health in Zambia</a>
<li><a href="http://www.healthnetconnect.net/drug.html">Healthnet  Connection - Drug Formulary</a>
<li><a href="http://www.heartinfo.org/SD_STATM.htm#-1010341423">Heart Information Network</a>
<li><a href="http://www.hollyberry.com/hot.htm#health">Hollyberry - Hotsites</a>
<li><a href="http://www.eskimo.com/~pageless">Home Pages for the Page Homeless</a>
<li><a href="http://hcn.cleaf.com/">Hood County News</a>
<li><a href="http://www.doctorbbs.com/inter.htm">Hot Sites Internacionais</a>
<li><a href="http://www2.inetconcepts.net/hotsites/search.html">Hotsites.net</a>
<li><a href="http://www.bighug.com/">H.U.G. - Healthcare Users Group</a>
<li><a href="http://he.net/~sagent/resource.html">Internet Resource Center</a>
<li><a href="http://www.cam.org/~ismael/">Ismael's Home Page</a>
<li><a href="http://www.acsu.buffalo.edu/~ivanlau/links.html">Ivan Lau's Pharmacy Links</a>
<li><a href="http://ccnet4.ccnet.com/~jbond/toolkit.html">James Bond - Investigator's Internet Resources</a>
<li><a href="http://logic.csc.cuhk.hk/~s945755/">Jeffrey's Home Page</a>
<li><a href="http://www.jsusco.com">John Susco Healthcare Promotions</a>
<li><a href="http://ivory.lm.com/~kholt/WebSampler/medical.html">Ken's Web Sampler - Medical/Health</a>
<li><a href="http://www.achiever.com/freehmpg/kynurses/">Kentucky Coalition of Nurse Practitioners/Midwives</a>
<li><a href="http://www.eden.com/%7Ekevinaus/">Kevin and Franny Austin</a>
<li><a href="http://www.tricky.com/lfm/awards.htm">Leading Learning Fountain - Award</a>
<li><a href="http://sashimi.wwa.com/~jayhawk/sitejour.html">Librarians' Site Du Jour</a>
<li><a href="http://www.lifestyle.co.uk/">Lifestyle.UK</a>
<li><a href="http://www.lisco.com/lisco/health.htm">Lisco</a>
<li><a href="http://www.looksmart.com/r?l3,f&e65241">LookSmart - Reader's Digest</a>
<li><a href="http://www.lpage.com">LPage - Developer of My Fuzzy Search Engine!</a>
<li><a href="http://www.texas.net/users/pusher/index5.htm">Lynn Ray's Medical Informatics Links</a>
<li><a href="http://www.mindspring.com/~mconti/medical.htm">Maggie's Medical Links</a>
<li><a href="http://www.access.digex.net/~jamba/index.html">Marcia's Bookmarks</a>
<li><a href="http://www.unm.edu/~vuksan/mario/clinic10.html">Mario's Cyberspace Station</a>
<li><a href="http://www.tv.cbc.ca/market/files/health/index.html">Market Place - Your Health and Safety</a>
<li><a href="http://www.marriagebuilders.com">Marriage Builders</a>
<li><a href="http://www.MSHP.org/MSHP/MSHPlink.htm">Maryland Society of Hospital Pharmacists</a>
<li><a href="http://www.mastercard.com/health/index.htm">MasterCard Healthcare</a> 
<li><a href="http://www.mckesson.com/Links.html">McKesson Pharmaceutical Management Solutions</a>
<li><a href="http://www.cris.com/~chenrybu/index.htm">MCP-Logics</a>
<li><a href="http://www.medexcard.com/save.htm">MedEx Prescription Drug Card</a>
<li><a href="http://www.cyber.nl/medibyte/">Medibyte</a>
<li><a href="http://www.pipeline.com/~emu/mt.htm">Medical Information Desk</a>
<li><a href="http://medsource.com/">Medical Source</a>
<li><a href="www.MedicapRx.com">Medicap Pharmacies, Inc.</a>
<li><a href="http://www.medicinenet.com">Medicine Net</a>
<li><a href="http://www.medimall.com/">MediMall</a>
<li><a href="http://www.medlinks.com/links.htm">Medlinks</a>
<li><a href="http://192.115.75.10/web/medline/GenMed/DrugIndex.htm">MedSite Israel</a>
<li><a href="http://www.medsupport.com/headache/t_meds.htm">MedSupport</a>
<li><a href="http://www.medsurf.com/Health_Tips/">MedSurf</a>
<li><a href="http://www.mhsource.com/">Mental Health Infosource</a>
<li><a href="http://www.cmhc.com/guide/pro12.htm">Mental Health Net</a>
<li><a href="http://www.msms.org/siteindx.html">Michigan State Medical Society Site of the Week</a>
<li><a href="http://www.alumni.caltech.edu/~mike/lymphoma.html">Mike's Lymphoma Resource Pages</a>
<li><a href="http://www.netcom.com/~mdponce/favsites.html">Mitzi Ponce's Favorite Sites</a>
<li><a href="http://lamp0.arl.army.mil:8080/~morris/scripts/morris_hotlist_chrono.shtml">Morris Berman's Hotlist</a>
<li><a href="http://www.angelfire.com/mt/links.html">MT Daily - Medical Links</a>
<li><a href="http://www.pipeline.com/~emu/msearch.htm">MT Medical Information</a>
<li><a href="http://www.nashville.com/~health/health_2.htm">Nashville Health Page</a>
<li><a href="http://www.tricky.com/liz/">NBNSOFT Content Awards - May'96</a>
<li><a href="http://www.nctc.net/">Nebraska Central Telephone Company</a>
<li><a href="http://www.teleport.com/~iexportc/ng-helth.htm">Netgiver Award - November '96</a>
<li><a href="http://www.netmedicine.com">NetMedicine</a>
<li><a href="http://www.wazoo.com/~netnerd/">NetNerd's Medical Home Page</a>
<li><a href="http://netvet.wustl.edu/dec95.htm">Net Vet & The Electric Zoo</a>
<li><a href="http://www.novagate.com/novasurf/healthandhappiness.html">Novagate - Health and Happiness</a>
<li><a href="http://www.nurseweek.com/alana.html">NurseWeek - Hotlinks</a>
<li><a href="http://www.healthweek.com/hotlink/allied.html">Nursing and Allied Healthweek</a>
<li><a href="http://www.obgyn.net/english/drugs/drugs.htm">OB-Gyn.net - Clinical Collection</a>
<li><a href="http://www.opma.org/">Ohio Podiatric Medical Association</a>
<li><a href="http://www.ihr.com/topics.html">Online Health Topics - Internet Health Resources Co.</a>
<li><a href="http://www.yellow.net.au/medical/">Oz Medicine Online - A Healthy Idea</a>
<li><a href="http://www.pachealth.com/">Pacific Health Links</a>
<li><a href="http://www.iaehv.nl/users/paul/potd-12.html">Page of the Day - December 13 1995</a>
<li><a href="http://www.pmrinc.com/">Patient Medical Records, Inc.</a>
<li><a href="http://www.pcpro.co.uk/hot24.htm">PC Pro On the Web</a>
<li><a href="http://prep.net/training-sites.html">Pennsylvania PrepNet</a>
<li><a href="http://acs.oakton.edu/~kkalata/index.htm">Pharmacology for Allied Health Professionals</a>
<li><a href="http://www.pharsight.com/links.htm">Pharsight Corporation</a>
<li><a href="http://emporium.turnpike.net/C/CAPNET/medicine.htm">Pharmacy and Pharmaceutical Companies Meta-List</a>
<li><a href="http://members.aol.com/bertrx/phamedmc.htm">Pharmacy, Medicine and Managed Care Springboard</a>
<li><a href="http://www.tassie.net.au/pharmacy/">Pharmacy Web Australia</a>
<li><a href="http://php2.silverplatter.com/physicians/library/pharmco.htm">Physician's Home Page</a>
<li><a href="http://www.newscientist.com">Planet Science - Site of the Day</a>
<li><a href="http://pw2.netcom.com/~kpearl/practical.html">Practical Uses For the Internet</a>
<li><a href="http://www.cybergate.net/~cjmele">Preferred Rx - Online Pharmacy</a>
<li><a href="http://www.yle.fi/prisma/linkit.htm">Prisma</a>
<li><a href="http://www.awod.com/gallery/rwav/dorietz/cancer.html">Prostate Cancer Sucks</a>
<li><a href="http://www.puppynet.com/">Puppynet</a>
<li><a href="http://minf.vub.ac.be/~fquestie/">Questier Frederik - Pharmacy Related Servers</a>
<li><a href="https://wwws.quick-reilly.com/info/links.htm">Quick & Reilly's Internet Trading Site</a>
<li><a href="http://www.iinet.net.au/~raymondo/index.html">Ray's Retreat</a>
<li><a href="http://www.rexallshowcaseintl.com/health.htm">Rexall Showcase International</a>
<li><a href="http://www.rimentalhealth.com/">Rhode Island Mental Health Network</a>
<li><a href="http://www.digisys.net/users/ntstalkr/medical.htm">Sandy's EMS and Medical Room</a>
<li><a href="http://www.sciweb.com/">SciWeb - The LIfe Science Home Page</a>
<li><a href="http://www.infinet.com/~sstickle/">Scott Stickle's Home Page</a>
<li><a href="http://bbs.ci.seaside.ca.us/sealib/referenc.htm">Seaside Community Library</a>
<li><a href="http://208.128.16.30/">Search Engines</a>
<li><a href="http://www.scn.org/test/">Seattle Community Network</a>
<li><a href="http://www.swtexas.net/coolsite.htm">Southwest Texas Telnet Coolsites</a>
<li><a href="http://www.springnet.com/">SpringNet - Nursing '96</a>
<li><a href="http://www.thecodex.com/search.html">Spyking</a>
<li><a href="http://www.win.org/library/intres/irr/health.htm">St. Charles City-County Library District - (SCCCLD)
<li><a href="http://www.starkscripts.com/">Stark Scripts</a>
<li><a href="http://www.synthon.nl/">Synthon BV - Netherlands</a>
<li><a href="http://www.tampatrib.com/tribcar/medical.htm">Tampa Tribune</a>
<li><a href="http://www.ability.org.uk/">The Ability Web Site</a>
<li><a href="http://execpc.com/~edi/aaaai.html">The American Academy of Allergy Asthma & Immunology</a>
<li><a href="http://aimc.com/aimc/Health.html">The American Individual Magazine</a>
<li><a href="http://www.edenia.com/medical">The Complete Online Medical Directory of Costa Rica</a>
<li><a href="http://users.aol.com/cducrx/">The Crohn's and Colitis Website</a>
<li><a href="http://members.aol.com/DrsPage/medlinks.htm">The Doctors' Page - Medical Websites</a>
<li><a href="http://www.dogpatch.org/health.html">The Dogpatch</a>
<li><a href="http://www.itai.com">The Institute of Transcendent Analysis International</a>
<li><a href="http://www.loop.com/~bkrentzman/">The Science of Obesity and Weight Control - B. Krentzman, MD</a>
<li><a href="http://www.isleuth.com/heal.html">The Internet Sleuth</a>
<li><a href="http://member.gnn.com/PeterC/medeng.htm">The Med Engine </a>
<li><a href="http://www.tracknet.com/hotlists/aug12.html">Tracknet - August 12th Hotlist</a>
<li><a href="http://www.io.com/~tradew/vet/drug.html">TW Medical Veterinary Division</a>
<li><a href="http://http://www.usit.net/public/rscarp/medical.htm">U.S. Internet - Medical Links</a>
<li><a href="http://www.volition.com/health.html">Volition Health Links</a>
<li><a href="http://www.wanet.com/">Wanet Internet Services</a>
<li><a href="http://www.wplwloo.org/">Waterloo Public Library</a>
<li><a href="http://www.gretmar.com/WebDoctorHome.html">WebDoctor - Internet Resources for Primary Care Physicians</a>
<li><a href="http://www.stayhealthy.com/index.html">Wellness Interactive Network</a>
<li><a href="http://www.weslaco.lib.tx.us/ENGINES.HTM">Weslaco Public Library</a>
<li><a href="http://www.ivf.com/womhtml.html">Women's Health - Atlanta Reproductive Health Center WWW</a>
<li><a href="http://www.women.com/web/otw/health.html">Women On the Web</a>
<li><a href="http://women.com/web/otw/health.html">Women's Wire - On the Web</a>
<li><a href="http://www.woodtech.com/explore.html">Woodtech Information Systems</a>
<li><a href="http://www.dreamscape.com/frankvad/reference-health.html">WWW Virtual Reference Sites</a>
<li><a href="http://www.physiol.ox.ac.uk/~xl/">Xuguang Liu - Oxford University Lab of Physiology</a>
<li><a href="http://www.xplore.com/xplore500/medium/reference.html">Xplore Reference</a>
<li><a href="http://indigo.ie/~comdiet/eyeathot.htm">Yeats Country Dietitians Office - Ireland</a>
<li><a href="http://www.yona.com/fitness/phenfen.shtml">Yona Health and Fitness Page</a>
<li><a href="http://www.ypn.com:80/">Your Personal Net</a>
<li><a href="http://www.pi.net/~neutel/home.html">Zeestraat Apotheek Homepage</a> 
<hr>
<li><a href="http://altavista.digital.com">Alta Vista Digital</a>
<li><a href="http://www.excite.com">Excite</a>
<li><a href="http://www.infoseek.com">Infoseek</a>
<li><a href="http://lycos.cs.cmu.edu/">Lycos</a>
<li><a href="http://www.opentext.com:8080/omw/f-omw.html">Open Text</a>
<li><a href="http://www.pointcom.com">Point - Top 5% of the Web!</a>
<li><a href="http://webcrawler.com">Webcrawler</a>
<li><a href="http://www.wellweb.com/THYROID/OVERVIEW.HTM">Wellness Web</a>
<li><a href="http://www.yahoo.com/Health/Pharmacology/Drugs/">Yahoo:Health:Pharmacology:Drugs</a>
 <p>
<FORM method=GET action="http://altavista.digital.com/cgi-bin/query">           
<INPUT TYPE=hidden NAME=pg VALUE=q>
<B>Search <SELECT NAME=what>
<OPTION VALUE=web SELECTED>the Web
<OPTION VALUE=news>Usenet
</SELECT>
and Display the Results <SELECT NAME=fmt>
<OPTION VALUE="" SELECTED>in Standard Form
<OPTION VALUE=c>in Compact Form
<OPTION VALUE=d>in Detailed Form
</SELECT></B><BR>
<INPUT NAME=q size=55 maxlength=200 VALUE="+link:http://www.rxlist.com/
 -url:http://www.rxlist.com/">
<INPUT TYPE=submit VALUE=Submit>
</FORM>
<hr><hr><center>
<a href="http://www.rxlist.com">RETURN TO RXLIST</A><hr><hr><p>

<img src="mbox.gif" height=45 width=45><a
href="mailto:missing-links@rxlist.com"><h4>E-mail 'Missing Links' to </a><br>
 missing-links@rxlist.com </h4>
<pre>




</pre>
<h5>
copyright 1996 - Neil Sandow, Pharm.D.
</h5></center>
</body>        
</DOC>
<DOC>
<DOCNO>WT08-B13-18</DOCNO>
<DOCOLDNO>IA019-000201-B023-286</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/rxlist.cgi??drug=oxycontin 206.86.175.201 19970106234141 text/html 35331
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:35:21 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE>www.rxlist.com - Neil Sandow, Pharm.D. 
copyright 1995</title></head> <body bgcolor="#ffffff">
<center><a href="http://www.rxlist.com"><img src="rx.gif" 
height=75 width=75 border=0><img src="count.gif" border=0></a></center> 
Searching for: <b></b> <br>scroll down for results 
<hr><hr>
<h1>Enter Brand or Generic Name or Category*</h1>
<h3> Narrow Your Search with <font size=5>*</font>(examples: 
ampi*, *mycin, antibiotic*)</h3>
<form method=get>
<action=>
<input size=30 maxlength=30 name=drug>
<input type=submit>
<input type=reset>
</form>
<HR>
<H3>Your RxList Search Results:</h3>
1<br><b>Brand Name: </b>DIASTAT<br><b>Generic Name: </b>DIAZEPAM RECTAL GEL<br><b>Category: </b>TREATMENT OF SEVERE EPILEPSY
<p>2<br><b>Brand Name: </b>EDEX<br><b>Generic Name: </b>ALPROSTADIL<br><b>Category: </b>TREATMENT OF ERECTILE DYSFUNCTION
<p>3<br><b>Brand Name: </b>GABITRIL<br><b>Generic Name: </b>TIAGABINE<br><b>Category: </b>ANTICONVULSANTS
<p>4<br><b>Brand Name: </b>URSO<br><b>Generic Name: </b>URSODEOXYCHOLIC ACID<br><b>Category: </b>TREATMENT OF PRIMARY BILIARY CIRRHOSIS
<p>5<br><b>Brand Name: </b>LIPITOR<br><b>Generic Name: </b>ATORVASTATIN<br><b>Category: </b>ANTILIPEMIC AGENTS
<p>6<br><b>Brand Name: </b>ZYFLO<br><b>Generic Name: </b>ZILEUTON<br><b>Category: </b>LEUKOTRIENE RECEPTOR ANTAGONIST (LTRA) FOR TREATMENT OF ASTHMA
<p>7<br><b>Brand Name: </b>FEMPATCH<br><b>Generic Name: </b>17-BETA ESTRADIOL (TRANSDERMAL)<br><b>Category: </b>ESTROGENS
<p>8<br><b>Brand Name: </b>DOSTINEX<br><b>Generic Name: </b>CABERGOLINE<br><b>Category: </b>TREATMENT OF HYPERPROLACTINEMIC DISORDERS
<p>9<br><b>Brand Name: </b>THERDERM EMTDS<br><b>Generic Name: </b>ESTRADIOL (TRANSDERMAL)<br><b>Category: </b>ESTROGENS
<p>10<br><b>Brand Name: </b>ELEQUIN<br><b>Generic Name: </b>LEVOFLOXACIN (INJ)<br><b>Category: </b>QUINOLINE ANTIBIOTICS
<p>11<br><b>Brand Name: </b>COPAXONE<br><b>Generic Name: </b>COPOLYMER-1 (INJ)<br><b>Category: </b>TREATMENT OF MULTIPLE SCLEROSIS
<p>12<br><b>Brand Name: </b>MONUROL<br><b>Generic Name: </b>FOSFOMYCIN TROMETHANE<br><b>Category: </b>TREATMENT OF UTI'S
<p>13<br><b>Brand Name: </b>OPATANOL<br><b>Generic Name: </b>OLOPATADINE HCL<br><b>Category: </b>TREATMENT OF ALLERGIC CONJUNCTIVITIS
<p>14<br><b>Brand Name: </b>GLYSET<br><b>Generic Name: </b>MIGLITOL<br><b>Category: </b>ANTIDIABETIC AGENTS
<p>15<br><b>Brand Name: </b>ZAGAM<br><b>Generic Name: </b>SPARFLOXACIN<br><b>Category: </b>QUINOLINE ANTIBIOTICS
<p>16<br><b>Brand Name: </b>ALORA<br><b>Generic Name: </b>ESTRADIOL TRANSDERMAL<br><b>Category: </b>ESTROGENS
<p>17<br><b>Brand Name: </b>LEVAQUIN<br><b>Generic Name: </b>LEVOFLOXACIN<br><b>Category: </b>QUINOLINE ANTIBIOTICS
<p>18<br><b>Brand Name: </b>APHTHASOL<br><b>Generic Name: </b>AMLEXANOX<br><b>Category: </b>TREATMENT OF APHTHOUS ULCERS
<p>19<br><b>Brand Name: </b>LOTREL<br><b>Generic Name: </b>AMLODIPINE/BENAZEPRIL HCL<br><b>Category: </b>SEE AMLODIPINE AND/OR BENAZEPRIL
<p>20<br><b>Brand Name: </b>ERGOMAR<br><b>Generic Name: </b>ERGOTAMINE TARTRATE<br><b>Category: </b>SYMPATHOLYTIC AGENTS
<p>21<br><b>Brand Name: </b>ERGOSTAT<br><b>Generic Name: </b>ERGOTAMINE TARTRATE<br><b>Category: </b>SYMPATHOLYTIC AGENTS
<p>22<br><b>Brand Name: </b>REZULIN<br><b>Generic Name: </b>TROGLITAZONE<br><b>Category: </b>ANTIDIABETIC AGENTS
<p>23<br><b>Brand Name: </b>MERIDIA<br><b>Generic Name: </b>SIBUTRAMINE HCL<br><b>Category: </b>ANTIDEPRESSANT/ANTIOBESITY
<p>24<br><b>Brand Name: </b>NORMIFLO<br><b>Generic Name: </b>ARDEPARIN SODIUM<br><b>Category: </b>ANTICOAGULANT
<p>25<br><b>Brand Name: </b>FERRISELTZ<br><b>Generic Name: </b>FERRIC AMMONIUM CITRATE<br><b>Category: </b>BOWEL CONTRAST AGENT FOR MRI
<p>26<br><b>Brand Name: </b>LEXXEL<br><b>Generic Name: </b>ENALAPRIL MALEATE/FELODIPINE<br><b>Category: </b>ANTIHYPERTENSIVES
<p>27<br><b>Brand Name: </b>ARICEPT<br><b>Generic Name: </b>DONEPEXIL HCL<br><b>Category: </b>TREATMENT OF ALZHEIMER'S DISEASE
<p>28<br><b>Brand Name: </b>E2020<br><b>Generic Name: </b>DONEPEXIL HCL<br><b>Category: </b>TREATMENT OF ALZHEIMER'S DISEASE
<p>29<br><b>Brand Name: </b>AMPHOTEC<br><b>Generic Name: </b>AMPHOTERICIN B CHOLESTERYL SULFATE COMPLEX<br><b>Category: </b>ANTIFUNGALS
<p>30<br><b>Brand Name: </b>MUSE<br><b>Generic Name: </b>ALPROSTADIL<br><b>Category: </b>TREATMENT OF IMPOTENCE
<p>31<br><b>Brand Name: </b>MECTIZAN<br><b>Generic Name: </b>IVERMECTIN<br><b>Category: </b>TREATMENT OF STRONGYLOIDES/ONCHOCERCIASIS
<p>32<br><b>Brand Name: </b>NASCOBAL<br><b>Generic Name: </b>CYANOCOBALAMIN<br><b>Category: </b>VITAMIN B COMPLEX
<p>33<br><b>Brand Name: </b>NIX<br><b>Generic Name: </b>PERMETHRIN<br><b>Category: </b>ERADICATION/PROPHYLAXIS OF HEAD LICE
<p>34<br><b>Brand Name: </b>SR-2599DC<br><b>Generic Name: </b>CLOPIDOGREL<br><b>Category: </b>ORAL ANTITHROMBIC AGENT (INVESTIGATIONAL)
<p>35<br><b>Brand Name: </b>GUAIFENESIN<br><b>Generic Name: </b>GUAIFENESIN<br><b>Category: </b>SEE <a href="http://www.rxlist.com/cgi/generic/guaicod.htm">GUAIFENESIN & CODEINE</a>
<p>36<br><b>Brand Name: </b>GUAIFENESIN<br><b>Generic Name: </b>GUAIFENESIN<br><b>Category: </b>SEE <a href="http://www.rxlist.com/cgi/generic/guaiphen.htm">GUAIFENESIN & PHENYLPROPANOLAMINE</a>
<p>37<br><b>Brand Name: </b>SYNERCID (RP 59500)<br><b>Generic Name: </b>QUINUPRISTIN/DALFOPRISTIN<br><b>Category: </b>ANTIBIOTICS (INVESTIGATIONAL)
<p>38<br><b>Brand Name: </b>DENAVIR<br><b>Generic Name: </b>PENCICLOVIR<br><b>Category: </b>ANTIVIRALS
<p>39<br><b>Brand Name: </b>FERTINEX<br><b>Generic Name: </b>FOLLICLE STIMULATING HORMONE (FSH)<br><b>Category: </b>HORMONES
<p>40<br><b>Brand Name: </b>FERTINEX<br><b>Generic Name: </b>FSH<br><b>Category: </b>HORMONES
<p>41<br><b>Brand Name: </b>COPAXONE<br><b>Generic Name: </b>COPOLYMER 1<br><b>Category: </b>TREATMENT OF M.S.
<p>42<br><b>Brand Name: </b>VIRACEPT<br><b>Generic Name: </b>NELFINAVIR<br><b>Category: </b>ANTIVIRALS
<p>43<br><b>Brand Name: </b>ERGOSET<br><b>Generic Name: </b>BROMOCRIPTINE<br><b>Category: </b>UNCLASSIFIED THERAPEUTIC AGENTS
<p>44<br><b>Brand Name: </b>SORIATANE<br><b>Generic Name: </b>ACITRETIN<br><b>Category: </b>TREATMENT OF PSORIASIS
<p>45<br><b>Brand Name: </b>ASTELIN<br><b>Generic Name: </b>AZELASTINE<br><b>Category: </b>ANTIHISTAMINES
<p>46<br><b>Brand Name: </b>RETAVASE<br><b>Generic Name: </b>RETEPLASE<br><b>Category: </b>THROMBOLYTICS
<p>47<br><b>Brand Name: </b>SAIZEN<br><b>Generic Name: </b>SOMATROPIN<br><b>Category: </b>PITUITARY
<p>48<br><b>Brand Name: </b>ESTROSTEP<br><b>Generic Name: </b>ETHINYL ESTRADIOL/NORETHINDRONE<br><b>Category: </b>CONTRACEPTIVES
<p>49<br><b>Brand Name: </b>LODINE XL<br><b>Generic Name: </b>ETODOLAC<br><b>Category: </b>NONSTEROIDAL ANTIINFLAMMATORY AGENTS
<p>50<br><b>Brand Name: </b>CYSTADANE<br><b>Generic Name: </b>BETAINE<br><b>Category: </b>TREATMENT OF HOMOCYSTINUREAL
<p>51<br><b>Brand Name: </b>COMBIVENT<br><b>Generic Name: </b>ALBUTEROL/IPRATROPIUM<br><b>Category: </b>BRONCHODILATORS
<p>52<br><b>Brand Name: </b>TARKA<br><b>Generic Name: </b>TRANDOLAPRIL/VERAPAMIL<br><b>Category: </b>ANTIHYPERTENSIVES
<p>53<br><b>Brand Name: </b>MENTAX<br><b>Generic Name: </b>BUTENAFINE HCL<br><b>Category: </b>ANTIFUNGALS
<p>54<br><b>Brand Name: </b>TIAMATE<br><b>Generic Name: </b>DILTIAZEM<br><b>Category: </b>ANTIHYPERTENSIVES
<p>55<br><b>Brand Name: </b>DURACLON<br><b>Generic Name: </b>CLONIDINE HCL<br><b>Category: </b>EPIDURAL ADJUNCT TO OPIATE THERAPY
<p>56<br><b>Brand Name: </b><a href="http://www.lec.org/DrugSearch/Documents/Rohypnol.html">ROHYPNOL</a><br><b>Generic Name: </b>FLUNITRAZEPAM<br><b>Category: </b>MISC. SEDATIVES/HYPNOTICS (NOTE: NOT MARKETED IN THE US)
<p>57<br><b>Brand Name: </b>KADIAN<br><b>Generic Name: </b>MORPHINE SULFATE SA<br><b>Category: </b>OPIATE AGONISTS
<p>58<br><b>Brand Name: </b>COCAINE<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/cocaine.htm">COCAINE HCL</a><br><b>Category: </b>ANTIPRURITICS AND LOCAL ANESTHETICS
<p>59<br><b>Brand Name: </b>TECZEM<br><b>Generic Name: </b>ENALAPRIL MALEATE & DILTIAZEM MALEATE<br><b>Category: </b>ANTIHYPERTENSIVES
<p>60<br><b>Brand Name: </b>TICLID<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/ticlop.htm">TICLOPIDINE HCL</a><br><b>Category: </b>PLATELET AGGREGATION INHIBITORS
<p>61<br><b>Brand Name: </b>PARACETAMOL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">SEE ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>62<br><b>Brand Name: </b>DHEA<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/dhea.htm">DEHYDROEPIANDROSTERONE</a><br><b>Category: </b>UNAPPROVED
<p>63<br><b>Brand Name: </b>ANTIBIOTIC<br><b>Generic Name: </b>TYPE ANTIBIOT*<br><b>Category: </b>USE * TO SORT ON CATEGORY
<p>64<br><b>Brand Name: </b>NILANDRON<br><b>Generic Name: </b>NILUTAMIDE<br><b>Category: </b>ANTIANDROGENS
<p>65<br><b>Brand Name: </b>PONDIMIN<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/fenflur.htm">FENFLURAMINE HCL</a><br><b>Category: </b>APPETITE SUPPRESSANT
<p>66<br><b>Brand Name: </b>ALPHAGAN<br><b>Generic Name: </b>BRIMONIDINE TARTRATE<br><b>Category: </b>MISCELLANEOUS EENT AGENTS (GLAUCOMA)
<p>67<br><b>Brand Name: </b>FERTINEX<br><b>Generic Name: </b>UROFOLLITROPIN<br><b>Category: </b>FOLLICLE STIMULATING HORMONE
<p>68<br><b>Brand Name: </b>IVY BLOCK<br><b>Generic Name: </b>URUSHIOL<br><b>Category: </b>MISCEL.SKIN AND MUCUS MEMBRANE AGENTS
<p>69<br><b>Brand Name: </b>ZENTATE<br><b>Generic Name: </b>VITAMINS PRENATAL<br><b>Category: </b>MULTIVITAMIN PREPARATIONS
<p>70<br><b>Brand Name: </b>ETOPOPHOS<br><b>Generic Name: </b>ETOPOSIDE PHOSPHATE<br><b>Category: </b>ANTINEOPLASTICS
<p>71<br><b>Brand Name: </b>SEROSTIM<br><b>Generic Name: </b>SOMATOTROPIN<br><b>Category: </b>PITUITARY
<p>72<br><b>Brand Name: </b>ZYPREXA<br><b>Generic Name: </b>OLANZAPINE<br><b>Category: </b>ANTIPSYCHOTICS
<p>73<br><b>Brand Name: </b>HURRICAINE<br><b>Generic Name: </b>BENZOCAINE<br><b>Category: </b>LOCAL ANESTHETICS
<p>74<br><b>Brand Name: </b>HURRICAINE<br><b>Generic Name: </b>BENZOCAINE<br><b>Category: </b>ANTIPRURITICS AND LOCAL ANESTHETICS
<p>75<br><b>Brand Name: </b>MERREM I.V.<br><b>Generic Name: </b>MEROPENEM<br><b>Category: </b>MISCELLANEOUS ANTIBIOTICS
<p>76<br><b>Brand Name: </b>PROAMATINE<br><b>Generic Name: </b>MIDODRINE<br><b>Category: </b>TREATMENT OF ORTHOSTATIC HYPERTENSION
<p>77<br><b>Brand Name: </b>RU-486<br><b>Generic Name: </b>MIFEPRISTONE<br><b>Category: </b>TERMINATION OF PREGNANCY
<p>78<br><b>Brand Name: </b>ALBENZA<br><b>Generic Name: </b>ALBENDAZOLE<br><b>Category: </b>ANTHELMINTICS
<p>79<br><b>Brand Name: </b>DIFFERIN<br><b>Generic Name: </b>ADAPALENE<br><b>Category: </b>MISCEL.SKIN AND MUCUS MEMBRANE AGENTS
<p>80<br><b>Brand Name: </b>CARBEX<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/seleg.htm">SELEGILINE HCL</a><br><b>Category: </b>FOR PARKINSON'S DISEASE
<p>81<br><b>Brand Name: </b>HELIDAC<br><b>Generic Name: </b>BISMUTH SUBSAL. METRONIDAZOLE & TETRACYCLINE<br><b>Category: </b>FOR PEPTIC ULCER DISEASE
<p>82<br><b>Brand Name: </b>TRITEC<br><b>Generic Name: </b>RANITIDINE BISMUTH CITRATE<br><b>Category: </b>MISCELLANEOUS GI DRUGS
<p>83<br><b>Brand Name: </b>CEREBYX<br><b>Generic Name: </b>FOSPHENYTOIN SODIUM<br><b>Category: </b>HYDANTOINS
<p>84<br><b>Brand Name: </b>ALLEGRA<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/fexofen.htm">FEXOFENADINE</a><br><b>Category: </b>ANTIHISTAMINES
<p>85<br><b>Brand Name: </b>CAMPTOSAR<br><b>Generic Name: </b>IRINOTECAN HCL<br><b>Category: </b>ANTINEOPLASTICS
<p>86<br><b>Brand Name: </b>XALATAN<br><b>Generic Name: </b>LATANOPROST<br><b>Category: </b>GLAUCOMA THERAPY
<p>87<br><b>Brand Name: </b>REMERON<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/mirtaz.htm">MIRTAZAPINE</a><br><b>Category: </b>ANTIDEPRESSANTS
<p>88<br><b>Brand Name: </b>VIRAMUNE<br><b>Generic Name: </b>NEVIRAPINE<br><b>Category: </b>ANIVIRALS
<p>89<br><b>Brand Name: </b>MYOTROPHIN<br><b>Generic Name: </b>SOMATOMEDIN C<br><b>Category: </b>FOR AMYOTROPHIC LATERAL SCLEROSIS
<p>90<br><b>Brand Name: </b>HUMULIN N<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/humnph.htm">HUMAN INSULIN NPH</a> <br><b>Category: </b>INSULINS
<p>91<br><b>Brand Name: </b>HUMULIN R<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/huminsr.htm">HUMAN INSULIN REGULAR</a><br><b>Category: </b>INSULINS
<p>92<br><b>Brand Name: </b>HUMULIN L<br><b>Generic Name: </b>HUMAN INSULIN LENTE<br><b>Category: </b>INSULINS
<p>93<br><b>Brand Name: </b>HUMULIN 70/30<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/hum7030.htm">HUMAN INSULIN NPH/REG 70/30</a><br><b>Category: </b>INULINS
<p>94<br><b>Brand Name: </b>ORTHO-NOVUM 7/7/7<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/norestoc.htm">NORETHINDRONE/ETHINYL ESTRADIOL</a> <br><b>Category: </b>CONTRACEPTIVES
<p>95<br><b>Brand Name: </b>ORTHO-CEPT<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/desest.htm">DESOGESTREL/ETHINYLESTRADIOL</A><br><b>Category: </b>CONTRACEPTIVES
<p>96<br><b>Brand Name: </b>ACCUPRIL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/quinap.htm">QUINAPRIL HCL</a><br><b>Category: </b>HYPOTENSIVE AGENTS
<p>97<br><b>Brand Name: </b>ACTHREL<br><b>Generic Name: </b>CORTICORELIN OVINE TRIFLUTATE<br><b>Category: </b>DIAGNOSTIC AGENTS
<p>98<br><b>Brand Name: </b>BUPHENYL<br><b>Generic Name: </b>SODIUM PHENYLBUTYRATE<br><b>Category: </b>FOR UREA CYCLE DISORDERS
<p>99<br><b>Brand Name: </b>VISIPAQUE<br><b>Generic Name: </b>IODIXANOL<br><b>Category: </b>ROENTGENOGRAPHY
<p>100<br><b>Brand Name: </b>NAPRELAN<br><b>Generic Name: </b>NAPROXEN SODIUM<br><b>Category: </b>NONSTEROIDAL ANTIINFLAMMATORY AGENTS
<p>101<br><b>Brand Name: </b>OXILAN<br><b>Generic Name: </b>IOXILAN<br><b>Category: </b>ROENTGENOGRAPHY
<p>102<br><b>Brand Name: </b>IONTOCAINE<br><b>Generic Name: </b>LIDOCAINE/EPINEPHRINE<br><b>Category: </b>LOCAL ANESTHETICS
<p>103<br><b>Brand Name: </b>PENTACEF<br><b>Generic Name: </b>CEFTAZIDINE<br><b>Category: </b>ANTIBIOTICS: CEPHALOSPORINS
<p>104<br><b>Brand Name: </b>METROCREAM<br><b>Generic Name: </b>METRONIDAZOLE<br><b>Category: </b>MISCELLANEOUS ANTI-INFECTIVES
<p>105<br><b>Brand Name: </b>GENOTROPIN<br><b>Generic Name: </b>SOMATROPIN<br><b>Category: </b>PITUITARY
<p>106<br><b>Brand Name: </b>SEVORANE<br><b>Generic Name: </b>SEVOFLURANE<br><b>Category: </b>GENERAL ANESTHETICS
<p>107<br><b>Brand Name: </b>BIOTROPIN<br><b>Generic Name: </b>SOMATROPIN<br><b>Category: </b>PITUITARY
<p>108<br><b>Brand Name: </b>ULTRAVIST<br><b>Generic Name: </b>IOPROMIDE<br><b>Category: </b>ROENTGENOGRAPHY
<p>109<br><b>Brand Name: </b>NORDITROPIN<br><b>Generic Name: </b>SOMATROPIN<br><b>Category: </b>PITUITARY
<p>110<br><b>Brand Name: </b>PROVEL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/ibup.htm">IBUPROFEN</A><br><b>Category: </b>NONSTEROIDAL ANTIINFLAMMATORY AGENTS
<p>111<br><b>Brand Name: </b>NISOCOR<br><b>Generic Name: </b>NISOLDIPINE<br><b>Category: </b>CARDIAC DRUGS
<p>112<br><b>Brand Name: </b>APTHASOL<br><b>Generic Name: </b>AMLEXANOX<br><b>Category: </b>TREATMENT OF CANKER SORES
<p>113<br><b>Brand Name: </b>ALPHANATE<br><b>Generic Name: </b>ANTIHEMOPHILIC FACTOR<br><b>Category: </b>HEMOSTATICS
<p>114<br><b>Brand Name: </b>OXYCONTIN<br><b>Generic Name: </b>OXYCODONE HCL<br><b>Category: </b>OPIATE AGONISTS
<p>115<br><b>Brand Name: </b>HYCAMTIN<br><b>Generic Name: </b>TOPOTECAN<br><b>Category: </b>ANTINEOPLASTICS
<p>116<br><b>Brand Name: </b>OXANDRIN<br><b>Generic Name: </b>OXANDROLONE<br><b>Category: </b>ANDROGENS
<p>117<br><b>Brand Name: </b>WINRHO SD<br><b>Generic Name: </b>RHO(D)IMMUNE GLOBULIN<br><b>Category: </b>SERUMS
<p>118<br><b>Brand Name: </b>AVONEX<br><b>Generic Name: </b>INTERFERON BETA-1A<br><b>Category: </b>TREATMENT OF MULTIPLE SCLEROSIS
<p>119<br><b>Brand Name: </b>GEMZAR<br><b>Generic Name: </b>GEMCITABINE HCL<br><b>Category: </b>ANTINEOPLASTICS
<p>120<br><b>Brand Name: </b>DEXFERRUM<br><b>Generic Name: </b>IRON DEXTRAN<br><b>Category: </b>IRON PRODUCTS
<p>121<br><b>Brand Name: </b>CORMAX<br><b>Generic Name: </b>CLOBETASOL PROPIONATE<br><b>Category: </b>ANTI-INFLAMMATORY AGENTS
<p>122<br><b>Brand Name: </b>VITRASERT<br><b>Generic Name: </b>GANCICLOVIR<br><b>Category: </b>ANTIVIRALS
<p>123<br><b>Brand Name: </b>CYTOVENE<br><b>Generic Name: </b>GANCICLOVIR<br><b>Category: </b>ANTIVIRALS
<p>124<br><b>Brand Name: </b>HUMALOG<br><b>Generic Name: </b>INSULIN LISPRO<br><b>Category: </b>INSULINS
<p>125<br><b>Brand Name: </b>DAUNOXOME<br><b>Generic Name: </b>DAUNORUBICIN CITRATE (LIPOSOME)<br><b>Category: </b>ANTINEOPLASTICS
<p>126<br><b>Brand Name: </b>ESTRING<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/estrad.htm">ESTRADIOL</A><br><b>Category: </b>ESTROGENS
<p>127<br><b>Brand Name: </b>ARIMEDEX<br><b>Generic Name: </b>ANASTROZOLE<br><b>Category: </b>ANTINEOPLASTICS
<p>128<br><b>Brand Name: </b>VISTIDE<br><b>Generic Name: </b>CIDOFOVIR<br><b>Category: </b>ANTIVIRALS
<p>129<br><b>Brand Name: </b>NICOTROL NS<br><b>Generic Name: </b>NICOTINE(NASAL)<br><b>Category: </b>MISCELLANEOUS AUTONOMIC DRUGS 
<p>130<br><b>Brand Name: </b>VIQUIN FORTE<br><b>Generic Name: </b>HYDROQUINONE<br><b>Category: </b>DEPIGMENTING AGENTS
<p>131<br><b>Brand Name: </b>REDUX<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/dexfen.htm">DEXFENFLURAMINE</a><br><b>Category: </b>ANTI-OBESITY AGENTS
<p>132<br><b>Brand Name: </b>ZANAFLEX<br><b>Generic Name: </b>TIZANIDINE HCL<br><b>Category: </b>SKELETAL MUSCLE RELAXANTS
<p>133<br><b>Brand Name: </b>PREVALITE<br><b>Generic Name: </b>CHOLESTYRAMINE<br><b>Category: </b>ANTILIPEMIC AGENTS
<p>134<br><b>Brand Name: </b>FERIDEX<br><b>Generic Name: </b>FERUMOXIDE<br><b>Category: </b>MAGNETIC RESONANCE IMAGING
<p>135<br><b>Brand Name: </b>MAVIK<br><b>Generic Name: </b>TRANDOLAPRIL<br><b>Category: </b><a href="http://www.rxlist.com/cardiova.htm">HYPOTENSIVE AGENTS</a> 
<p>136<br><b>Brand Name: </b>NAROPIN<br><b>Generic Name: </b>ROPIVACAINE<br><b>Category: </b>LOCAL ANESTHETICS
<p>137<br><b>Brand Name: </b>SCLEROSOL<br><b>Generic Name: </b>TALC<br><b>Category: </b>SCLEROSING AGENTS
<p>138<br><b>Brand Name: </b>TOPAMAX<br><b>Generic Name: </b>TOPIRAMATE<br><b>Category: </b>MISCELLANEOUS ANTICONVULSANTS
<p>139<br><b>Brand Name: </b>VAQTA<br><b>Generic Name: </b>HEPATITIS A VACCINE<br><b>Category: </b>VACCINES
<p>140<br><b>Brand Name: </b>MYOVIEW<br><b>Generic Name: </b>TETROPHOSMIN<br><b>Category: </b>RADIOPHARMACEUTICALS
<p>141<br><b>Brand Name: </b>OCUHIST<br><b>Generic Name: </b>PHENIRAMINE MALEATE<br><b>Category: </b>ANTIHISTAMINE DRUGS
<p>142<br><b>Brand Name: </b>COVERA-HS<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/verapsr.htm">VERAPAMIL</A> HCL<br><b>Category: </b><a href="http://www.rxlist.com/cardiova.htm">CARDIAC DRUGS</a> 
<p>143<br><b>Brand Name: </b>SYNOVIR<br><b>Generic Name: </b>THALIDOMIDE<br><b>Category: </b>AIDS-CACHEXIA
<p>144<br><b>Brand Name: </b>VESANOID<br><b>Generic Name: </b>TRETINOIN<br><b>Category: </b>ANTINEOPLASTIC AGENTS
<p>145<br><b>Brand Name: </b>TEICHOMYCIN<br><b>Generic Name: </b>TEICOPLANIN<br><b>Category: </b>MISCELLANEOUS ANTIBIOTICS
<p>146<br><b>Brand Name: </b>NORVIR<br><b>Generic Name: </b>RITONAVIR<br><b>Category: </b>ANTIVIRALS
<p>147<br><b>Brand Name: </b>NIMBEX<br><b>Generic Name: </b>CISATRACURIUM BESYLATE<br><b>Category: </b>SKELETAL MUSCLE RELAXANTS
<p>148<br><b>Brand Name: </b>MAXIPIME<br><b>Generic Name: </b>CEFEPIME<br><b>Category: </b>ANTIBIOTICS: CEPHALOSPORINS
<p>149<br><b>Brand Name: </b>PENNSAID<br><b>Generic Name: </b>DIMETHAID-D<br><b>Category: </b><a href="http://www.rxlist.com/nsaid.htm">NONSTEROIDAL ANTI-INFLAMMATORY AGENTS</a> 
<p>150<br><b>Brand Name: </b>ADDERALL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/amphet.htm">AMPHETAMINE MIXED SALTS</a><br><b>Category: </b>RESPIRATORY AND CEREBRAL STIMULANTS
<p>151<br><b>Brand Name: </b>CANDIN<br><b>Generic Name: </b>CANDIDA ALBICANS<br><b>Category: </b>FUNGI
<p>152<br><b>Brand Name: </b>ACTRON<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/ketoprof.htm">KETOPROFEN</a><br><b>Category: </b><a href="http://www.rxlist.com/nsaid.htm">NONSTEROIDAL ANTIINFLAMMATORY AGENTS</a> 
<p>153<br><b>Brand Name: </b>CEDAX<br><b>Generic Name: </b>CEFTIBUTEN<br><b>Category: </b>ANTIBIOTICS:CEPHALOSPORINS
<p>154<br><b>Brand Name: </b>RENOVA<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/tretinoin.htm">TRETINOIN</a><br><b>Category: </b>MISCEL.SKIN AND MUCUS MEMBRANE AGENTS
<p>155<br><b>Brand Name: </b>PHOTOFRIN<br><b>Generic Name: </b>PORFIMER SODIUM<br><b>Category: </b>ANTINEOPLASTIC AGENTS (PHOTODYNAMIC)
<p>156<br><b>Brand Name: </b>AMARYL<br><b>Generic Name: </b>GLIMEPIRIDE<br><b>Category: </b>ANTIDIABETIC AGENTS
<p>157<br><b>Brand Name: </b>FLOLAN<br><b>Generic Name: </b>EPOPROSTENOL SODIUM<br><b>Category: </b>VASODILATING AGENTS
<p>158<br><b>Brand Name: </b>RESPIGAM<br><b>Generic Name: </b>RSV-IGIV<br><b>Category: </b>SERUMS
<p>159<br><b>Brand Name: </b>CRIXIVAN<br><b>Generic Name: </b>INDINAVIR SULFATE<br><b>Category: </b>ANTIVIRALS
<p>160<br><b>Brand Name: </b>TRIPEDIA<br><b>Generic Name: </b>WHOOPING COUGH VACCINE<br><b>Category: </b>VACCINES
<p>161<br><b>Brand Name: </b>PROCANABID<br><b>Generic Name: </b>PROCAINAMIDE HCL<br><b>Category: </b>CARDIAC DRUGS
<p>162<br><b>Brand Name: </b>ZYRTEC<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/cetiriz.htm">CETIRIZINE HCL</a><br><b>Category: </b>ANTIHISTAMINE DRUGS
<p>163<br><b>Brand Name: </b>VIVELLE<br><b>Generic Name: </b>ESTRADIOL (TRANSDERMAL SYSTEM)<br><b>Category: </b>ESTROGEN
<p>164<br><b>Brand Name: </b>AZELEX<br><b>Generic Name: </b>ACELAIC ACID<br><b>Category: </b>SKIN AND MUCUS MEMBRANE AGENTS
<p>165<br><b>Brand Name: </b>ETHYOL<br><b>Generic Name: </b>AMIFOSTINE<br><b>Category: </b>UNCLASSIFIED THERAPEUTIC AGENTS
<p>166<br><b>Brand Name: </b>DOXIL<br><b>Generic Name: </b> DOXORUBICIN HCL (LIPOSOME INJECTION)<br><b>Category: </b>ANTIONEOPLASTIC AGENTS
<p>167<br><b>Brand Name: </b>ABELCET<br><b>Generic Name: </b>ABCL(AMPHOTERICIN B LIPID COMPLEX LIPOSOME INJ)<br><b>Category: </b>ANTIFUNGALS
<p>168<br><b>Brand Name: </b>PRECOSE<br><b>Generic Name: </b>ACARBOSE<br><b>Category: </b>ANTIDIABETIC AGENTS
<p>169<br><b>Brand Name: </b>RILUTEK<br><b>Generic Name: </b>RILUZOLE<br><b>Category: </b>FOR AMYOTROPHIC LATERAL SCLEROSIS
<p>170<br><b>Brand Name: </b>VALTREX<br><b>Generic Name: </b>VALACYCLOVIR<br><b>Category: </b>ANIVIRALS
<p>171<br><b>Brand Name: </b>FLOVENT<br><b>Generic Name: </b>FLUTICASONE PROPRIONATE<br><b>Category: </b>ANTIINFLAMMATORY AGENTS
<p>172<br><b>Brand Name: </b>DYNABAC<br><b>Generic Name: </b>DIRITHROMYCIN<br><b>Category: </b>ANTIBIOTICS:ERYTHROMYCINS
<p>173<br><b>Brand Name: </b>CORVERT<br><b>Generic Name: </b>IBUTILIDE<br><b>Category: </b>CARDIAC DRUGS
<p>174<br><b>Brand Name: </b>FARESTON<br><b>Generic Name: </b>TOREMIFENE CITRATE<br><b>Category: </b>ANTINEOPLASTIC AGENTS
<p>175<br><b>Brand Name: </b>COREG<br><b>Generic Name: </b>CARDEDILOL<br><b>Category: </b>CARDIAC DRUGS
<p>176<br><b>Brand Name: </b>TAXOTERE<br><b>Generic Name: </b>DOCETAXEL<br><b>Category: </b>ANTINEOPLASTIC AGENTS
<p>177<br><b>Brand Name: </b>BUTOX<br><b>Generic Name: </b>BOTULINUM TOXIN TYPE A<br><b>Category: </b>TOXOIDS
<p>178<br><b>Brand Name: </b>SULAR<br><b>Generic Name: </b>NISOLDIPINE<br><b>Category: </b>CARDIAC DRUGS
<p>179<br><b>Brand Name: </b>BLEO<br><b>Generic Name: </b>BLEOMYCIN<br><b>Category: </b>ANTINEOPLASTIC AGENTS
<p>180<br><b>Brand Name: </b>BLEOCIN<br><b>Generic Name: </b>BLEOMYCIN<br><b>Category: </b>ANTINEOPLASTIC AGENTS
<p>181<br><b>Brand Name: </b>BLENOXANE<br><b>Generic Name: </b>BLEOMYCIN<br><b>Category: </b>ANTINEOPLASTIC AGENTS
<p>182<br><b>Brand Name: </b>INVIRASE<br><b>Generic Name: </b>SAQUINAVIR<br><b>Category: </b>ANTIVIRALS
<p>183<br><b>Brand Name: </b>EPIVIR<br><b>Generic Name: </b>LAMIVUDINE<br><b>Category: </b>ANTIVIRALS
<p>184<br><b>Brand Name: </b>3TC<br><b>Generic Name: </b>LAMIVUDINE<br><b>Category: </b>ANTIVIRALS
<p>185<br><b>Brand Name: </b>AZT<br><b>Generic Name: </b>ZIDOVUDINE<br><b>Category: </b>ANTIVIRALS
<p>186<br><b>Brand Name: </b>NIZORAL<br><b>Generic Name: </b>KETOCONAZOLE<br><b>Category: </b>ANTIFUNGALS
<p>187<br><b>Brand Name: </b>NIZORAL TOPICAL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/ketocon.htm">KETOCONAZOLE TOPICAL</A><br><b>Category: </b>ANTIFUNGALS
<p>188<br><b>Brand Name: </b>METHERGINE<br><b>Generic Name: </b>METHYLERGONOVINE MALEATE<br><b>Category: </b>OXYTOCICS
<p>189<br><b>Brand Name: </b>LOTREL<br><b>Generic Name: </b>AMLODIPINE/BENAZEPRIL HCL<br><b>Category: </b><a href="http://www.rxlist.com/cardiova.htm">HYPOTENSIVE AGENTS</a> 
<p>190<br><b>Brand Name: </b>VEXOL<br><b>Generic Name: </b>RIMEXOLONE<br><b>Category: </b>OPTHALMIC CORTICOSTEROID
<p>191<br><b>Brand Name: </b>DR-3355<br><b>Generic Name: </b>LEVOFLOXACIN<br><b>Category: </b>INVESTIGATIONAL:ANTIBIOTICS:QUINOLINES
<p>192<br><b>Brand Name: </b>ORG-10172<br><b>Generic Name: </b>DANAPAROID<br><b>Category: </b>INVESTIGATIONAL:ANTICOAGULANTS
<p>193<br><b>Brand Name: </b>RU 44570<br><b>Generic Name: </b>TRANDOLAPRIL<br><b>Category: </b> <a href="http://www.rxlist.com/cardiova.htm">HYPOTENSIVE AGENTS</a> 
<p>194<br><b>Brand Name: </b>ACCOLATE<br><b>Generic Name: </b>ZAFIRLUKAST<br><b>Category: </b>RESPIRATORY:LEUKOTRIENE ANTAGONIST
<p>195<br><b>Brand Name: </b>TIAZAC<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/diltiaz.htm">DILTIAZEM HCL</a> <br><b>Category: </b><a href="http://www.rxlist.com/cardiova.htm">CARDIAC DRUGS</a> 
<p>196<br><b>Brand Name: </b>FOSAMAX<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/alendron.htm">ALENDRONATE SODIUM</a><br><b>Category: </b>MISCELLANEOUS:OSTEOPOROSIS
<p>197<br><b>Brand Name: </b>REOPRO<br><b>Generic Name: </b>ABCIXIMAB<br><b>Category: </b>UNCLASSIFIED THERAPEUTIC AGENTS
<p>198<br><b>Brand Name: </b>SECTRAL<br><b>Generic Name: </b>ACEBUTOLOL HCL<br><b>Category: </b><a href="http://www.rxlist.com/cardiova.htm">CARDIAC DRUGS</a> 
<p>199<br><b>Brand Name: </b>ACI-JEL W/APP<br><b>Generic Name: </b>ACET AC/RICINOLEIC/OXY<br><b>Category: </b>ANTI-INFECTIVES
<p>200<br><b>Brand Name: </b>ACEPHEN<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>201<br><b>Brand Name: </b>ACETAMIN<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>202<br><b>Brand Name: </b>ANACIN AF<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>203<br><b>Brand Name: </b>APAP<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>204<br><b>Brand Name: </b>BL INFANT N/A<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>205<br><b>Brand Name: </b>BL NON-ASPIRN<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>206<br><b>Brand Name: </b>FEVERALL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>207<br><b>Brand Name: </b>GENAPAP X/S<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>208<br><b>Brand Name: </b>GENEBS X/S<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>209<br><b>Brand Name: </b>GNP NON-ASPRN<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>210<br><b>Brand Name: </b>GNP NON-ASPRN<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>211<br><b>Brand Name: </b>GNP XS PAIN<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>212<br><b>Brand Name: </b>INFANTAIRE<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>213<br><b>Brand Name: </b>INFANTOL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>214<br><b>Brand Name: </b>MAPAP ACETAM<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>215<br><b>Brand Name: </b>PAIN &amp; FEVER<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>216<br><b>Brand Name: </b>PANADOL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>217<br><b>Brand Name: </b>PEDIAPAP<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>218<br><b>Brand Name: </b>TEMPRA 1<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>219<br><b>Brand Name: </b>TEMPRA 2<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>220<br><b>Brand Name: </b>TYLENOL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>221<br><b>Brand Name: </b>TYLENOL INFNT<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>222<br><b>Brand Name: </b>TYLENOL X/S<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>223<br><b>Brand Name: </b>BROMO SELTZER<br><b>Generic Name: </b>ACETAMINOPHEN BUFFERED<br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>224<br><b>Brand Name: </b>GENAPAP CHILD<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN CHEW</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>225<br><b>Brand Name: </b>ST JOS CHL/AF<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN CHEW</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>226<br><b>Brand Name: </b>TEMPRA 3 CHEW<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN CHEW</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>227<br><b>Brand Name: </b>TYLENOL CHILD<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN CHEW</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>228<br><b>Brand Name: </b>TYLENOL CHILD<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN CHEW</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>229<br><b>Brand Name: </b>TYLENOL X/RLF<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN SA</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>230<br><b>Brand Name: </b>PROMINOL<br><b>Generic Name: </b>ACETAMINOPHEN/BUTALBITAL<br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>231<br><b>Brand Name: </b>APAP/COD<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/acetcod.htm">ACETAMINOPHEN/CODEINE</a> <br><b>Category: </b><a href="opiate.htm">OPIATE AGONISTS</a> 
<p>232<br><b>Brand Name: </b>CAPITAL W/COD<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/acetcod.htm">ACETAMINOPHEN/CODEINE</a> <br><b>Category: </b><a href="opiate.htm">OPIATE AGONISTS</a> 
<p>233<br><b>Brand Name: </b>PHENAPHEN/COD<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/acetcod.htm">ACETAMINOPHEN/CODEINE</a> <br><b>Category: </b><a href="opiate.htm">OPIATE AGONISTS</a> 
<p>234<br><b>Brand Name: </b>TYLENOL/COD<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/acetcod.htm">ACETAMINOPHEN/CODEINE</a> <br><b>Category: </b><a href="opiate.htm">OPIATE AGONISTS</a> 
<p>235<br><b>Brand Name: </b>ACETAZOLAMIDE<br><b>Generic Name: </b>ACETAZOLAMIDE<br><b>Category: </b>CARBONIC ANHYDRASE INHIBITORS
<p>236<br><b>Brand Name: </b>DIAMOX<br><b>Generic Name: </b>ACETAZOLAMIDE<br><b>Category: </b>CARBONIC ANHYDRASE INHIBITORS
<p>237<br><b>Brand Name: </b>ACETASOL PLN<br><b>Generic Name: </b>ACETIC ACID OTIC<br><b>Category: </b>ANTI-INFECTIVES
<p>238<br><b>Brand Name: </b>DOMEBORO OTIC<br><b>Generic Name: </b>ACETIC ACID OTIC<br><b>Category: </b>ANTI-INFECTIVES
<p>239<br><b>Brand Name: </b>VOSOL OTIC<br><b>Generic Name: </b>ACETIC ACID OTIC<br><b>Category: </b>ANTI-INFECTIVES
<p>240<br><b>Brand Name: </b>ACETASOL HC<br><b>Generic Name: </b>ACETIC ACID/HYDROCORT OTI<br><b>Category: </b>ANTI-INFECTIVES
<p>241<br><b>Brand Name: </b>HYDRO/ACETIC<br><b>Generic Name: </b>ACETIC ACID/HYDROCORT OTI<br><b>Category: </b>ANTI-INFECTIVES
<p>242<br><b>Brand Name: </b>VASOTATE HC<br><b>Generic Name: </b>ACETIC ACID/HYDROCORT OTI<br><b>Category: </b>ANTI-INFECTIVES
<p>243<br><b>Brand Name: </b>VOSOL HC OTIC<br><b>Generic Name: </b>ACETIC ACID/HYDROCORT OTI<br><b>Category: </b>ANTI-INFECTIVES
<p>244<br><b>Brand Name: </b>DYMELOR<br><b>Generic Name: </b>ACETOHEXAMIDE<br><b>Category: </b>SULFONYLUREAS
<p>245<br><b>Brand Name: </b>LITHOSTAT<br><b>Generic Name: </b>ACETOHYDROXAMIC ACID<br><b>Category: </b>AMMONIA DETOXICANTS
<p>246<br><b>Brand Name: </b>SEBA-NIL<br><b>Generic Name: </b>ACETONE/ALCOHOL/POLYSORB<br><b>Category: </b>MISCEL.SKIN AND MUCUS MEMBRANE AGENTS
<p>247<br><b>Brand Name: </b>MIOCHOL E W/<br><b>Generic Name: </b>ACETYLCHOLINE CHL<br><b>Category: </b>MIOTICS
<p>248<br><b>Brand Name: </b>ACETYLCYSTEIN<br><b>Generic Name: </b>ACETYLCYSTEINE<br><b>Category: </b>MUCOLYTIC AGENTS
<p>249<br><b>Brand Name: </b>MUCOMYST<br><b>Generic Name: </b>ACETYLCYSTEINE<br><b>Category: </b>MUCOLYTIC AGENTS
<p>250<br><b>Brand Name: </b>MUCOSIL<br><b>Generic Name: </b>ACETYLCYSTEINE<br><b>Category: </b>MUCOLYTIC AGENTS
<p></body></html>
<P><hr><a href="http://www.rxlist.com"><b>RxList Home Page</ul>
<hr>
</DOC>
<DOC>
<DOCNO>WT08-B13-19</DOCNO>
<DOCOLDNO>IA019-000201-B023-303</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/rxlist.cgi??drug=fiorcet 206.86.175.201 19970106234152 text/html 35331
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:35:34 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE>www.rxlist.com - Neil Sandow, Pharm.D. 
copyright 1995</title></head> <body bgcolor="#ffffff">
<center><a href="http://www.rxlist.com"><img src="rx.gif" 
height=75 width=75 border=0><img src="count.gif" border=0></a></center> 
Searching for: <b></b> <br>scroll down for results 
<hr><hr>
<h1>Enter Brand or Generic Name or Category*</h1>
<h3> Narrow Your Search with <font size=5>*</font>(examples: 
ampi*, *mycin, antibiotic*)</h3>
<form method=get>
<action=>
<input size=30 maxlength=30 name=drug>
<input type=submit>
<input type=reset>
</form>
<HR>
<H3>Your RxList Search Results:</h3>
1<br><b>Brand Name: </b>DIASTAT<br><b>Generic Name: </b>DIAZEPAM RECTAL GEL<br><b>Category: </b>TREATMENT OF SEVERE EPILEPSY
<p>2<br><b>Brand Name: </b>EDEX<br><b>Generic Name: </b>ALPROSTADIL<br><b>Category: </b>TREATMENT OF ERECTILE DYSFUNCTION
<p>3<br><b>Brand Name: </b>GABITRIL<br><b>Generic Name: </b>TIAGABINE<br><b>Category: </b>ANTICONVULSANTS
<p>4<br><b>Brand Name: </b>URSO<br><b>Generic Name: </b>URSODEOXYCHOLIC ACID<br><b>Category: </b>TREATMENT OF PRIMARY BILIARY CIRRHOSIS
<p>5<br><b>Brand Name: </b>LIPITOR<br><b>Generic Name: </b>ATORVASTATIN<br><b>Category: </b>ANTILIPEMIC AGENTS
<p>6<br><b>Brand Name: </b>ZYFLO<br><b>Generic Name: </b>ZILEUTON<br><b>Category: </b>LEUKOTRIENE RECEPTOR ANTAGONIST (LTRA) FOR TREATMENT OF ASTHMA
<p>7<br><b>Brand Name: </b>FEMPATCH<br><b>Generic Name: </b>17-BETA ESTRADIOL (TRANSDERMAL)<br><b>Category: </b>ESTROGENS
<p>8<br><b>Brand Name: </b>DOSTINEX<br><b>Generic Name: </b>CABERGOLINE<br><b>Category: </b>TREATMENT OF HYPERPROLACTINEMIC DISORDERS
<p>9<br><b>Brand Name: </b>THERDERM EMTDS<br><b>Generic Name: </b>ESTRADIOL (TRANSDERMAL)<br><b>Category: </b>ESTROGENS
<p>10<br><b>Brand Name: </b>ELEQUIN<br><b>Generic Name: </b>LEVOFLOXACIN (INJ)<br><b>Category: </b>QUINOLINE ANTIBIOTICS
<p>11<br><b>Brand Name: </b>COPAXONE<br><b>Generic Name: </b>COPOLYMER-1 (INJ)<br><b>Category: </b>TREATMENT OF MULTIPLE SCLEROSIS
<p>12<br><b>Brand Name: </b>MONUROL<br><b>Generic Name: </b>FOSFOMYCIN TROMETHANE<br><b>Category: </b>TREATMENT OF UTI'S
<p>13<br><b>Brand Name: </b>OPATANOL<br><b>Generic Name: </b>OLOPATADINE HCL<br><b>Category: </b>TREATMENT OF ALLERGIC CONJUNCTIVITIS
<p>14<br><b>Brand Name: </b>GLYSET<br><b>Generic Name: </b>MIGLITOL<br><b>Category: </b>ANTIDIABETIC AGENTS
<p>15<br><b>Brand Name: </b>ZAGAM<br><b>Generic Name: </b>SPARFLOXACIN<br><b>Category: </b>QUINOLINE ANTIBIOTICS
<p>16<br><b>Brand Name: </b>ALORA<br><b>Generic Name: </b>ESTRADIOL TRANSDERMAL<br><b>Category: </b>ESTROGENS
<p>17<br><b>Brand Name: </b>LEVAQUIN<br><b>Generic Name: </b>LEVOFLOXACIN<br><b>Category: </b>QUINOLINE ANTIBIOTICS
<p>18<br><b>Brand Name: </b>APHTHASOL<br><b>Generic Name: </b>AMLEXANOX<br><b>Category: </b>TREATMENT OF APHTHOUS ULCERS
<p>19<br><b>Brand Name: </b>LOTREL<br><b>Generic Name: </b>AMLODIPINE/BENAZEPRIL HCL<br><b>Category: </b>SEE AMLODIPINE AND/OR BENAZEPRIL
<p>20<br><b>Brand Name: </b>ERGOMAR<br><b>Generic Name: </b>ERGOTAMINE TARTRATE<br><b>Category: </b>SYMPATHOLYTIC AGENTS
<p>21<br><b>Brand Name: </b>ERGOSTAT<br><b>Generic Name: </b>ERGOTAMINE TARTRATE<br><b>Category: </b>SYMPATHOLYTIC AGENTS
<p>22<br><b>Brand Name: </b>REZULIN<br><b>Generic Name: </b>TROGLITAZONE<br><b>Category: </b>ANTIDIABETIC AGENTS
<p>23<br><b>Brand Name: </b>MERIDIA<br><b>Generic Name: </b>SIBUTRAMINE HCL<br><b>Category: </b>ANTIDEPRESSANT/ANTIOBESITY
<p>24<br><b>Brand Name: </b>NORMIFLO<br><b>Generic Name: </b>ARDEPARIN SODIUM<br><b>Category: </b>ANTICOAGULANT
<p>25<br><b>Brand Name: </b>FERRISELTZ<br><b>Generic Name: </b>FERRIC AMMONIUM CITRATE<br><b>Category: </b>BOWEL CONTRAST AGENT FOR MRI
<p>26<br><b>Brand Name: </b>LEXXEL<br><b>Generic Name: </b>ENALAPRIL MALEATE/FELODIPINE<br><b>Category: </b>ANTIHYPERTENSIVES
<p>27<br><b>Brand Name: </b>ARICEPT<br><b>Generic Name: </b>DONEPEXIL HCL<br><b>Category: </b>TREATMENT OF ALZHEIMER'S DISEASE
<p>28<br><b>Brand Name: </b>E2020<br><b>Generic Name: </b>DONEPEXIL HCL<br><b>Category: </b>TREATMENT OF ALZHEIMER'S DISEASE
<p>29<br><b>Brand Name: </b>AMPHOTEC<br><b>Generic Name: </b>AMPHOTERICIN B CHOLESTERYL SULFATE COMPLEX<br><b>Category: </b>ANTIFUNGALS
<p>30<br><b>Brand Name: </b>MUSE<br><b>Generic Name: </b>ALPROSTADIL<br><b>Category: </b>TREATMENT OF IMPOTENCE
<p>31<br><b>Brand Name: </b>MECTIZAN<br><b>Generic Name: </b>IVERMECTIN<br><b>Category: </b>TREATMENT OF STRONGYLOIDES/ONCHOCERCIASIS
<p>32<br><b>Brand Name: </b>NASCOBAL<br><b>Generic Name: </b>CYANOCOBALAMIN<br><b>Category: </b>VITAMIN B COMPLEX
<p>33<br><b>Brand Name: </b>NIX<br><b>Generic Name: </b>PERMETHRIN<br><b>Category: </b>ERADICATION/PROPHYLAXIS OF HEAD LICE
<p>34<br><b>Brand Name: </b>SR-2599DC<br><b>Generic Name: </b>CLOPIDOGREL<br><b>Category: </b>ORAL ANTITHROMBIC AGENT (INVESTIGATIONAL)
<p>35<br><b>Brand Name: </b>GUAIFENESIN<br><b>Generic Name: </b>GUAIFENESIN<br><b>Category: </b>SEE <a href="http://www.rxlist.com/cgi/generic/guaicod.htm">GUAIFENESIN & CODEINE</a>
<p>36<br><b>Brand Name: </b>GUAIFENESIN<br><b>Generic Name: </b>GUAIFENESIN<br><b>Category: </b>SEE <a href="http://www.rxlist.com/cgi/generic/guaiphen.htm">GUAIFENESIN & PHENYLPROPANOLAMINE</a>
<p>37<br><b>Brand Name: </b>SYNERCID (RP 59500)<br><b>Generic Name: </b>QUINUPRISTIN/DALFOPRISTIN<br><b>Category: </b>ANTIBIOTICS (INVESTIGATIONAL)
<p>38<br><b>Brand Name: </b>DENAVIR<br><b>Generic Name: </b>PENCICLOVIR<br><b>Category: </b>ANTIVIRALS
<p>39<br><b>Brand Name: </b>FERTINEX<br><b>Generic Name: </b>FOLLICLE STIMULATING HORMONE (FSH)<br><b>Category: </b>HORMONES
<p>40<br><b>Brand Name: </b>FERTINEX<br><b>Generic Name: </b>FSH<br><b>Category: </b>HORMONES
<p>41<br><b>Brand Name: </b>COPAXONE<br><b>Generic Name: </b>COPOLYMER 1<br><b>Category: </b>TREATMENT OF M.S.
<p>42<br><b>Brand Name: </b>VIRACEPT<br><b>Generic Name: </b>NELFINAVIR<br><b>Category: </b>ANTIVIRALS
<p>43<br><b>Brand Name: </b>ERGOSET<br><b>Generic Name: </b>BROMOCRIPTINE<br><b>Category: </b>UNCLASSIFIED THERAPEUTIC AGENTS
<p>44<br><b>Brand Name: </b>SORIATANE<br><b>Generic Name: </b>ACITRETIN<br><b>Category: </b>TREATMENT OF PSORIASIS
<p>45<br><b>Brand Name: </b>ASTELIN<br><b>Generic Name: </b>AZELASTINE<br><b>Category: </b>ANTIHISTAMINES
<p>46<br><b>Brand Name: </b>RETAVASE<br><b>Generic Name: </b>RETEPLASE<br><b>Category: </b>THROMBOLYTICS
<p>47<br><b>Brand Name: </b>SAIZEN<br><b>Generic Name: </b>SOMATROPIN<br><b>Category: </b>PITUITARY
<p>48<br><b>Brand Name: </b>ESTROSTEP<br><b>Generic Name: </b>ETHINYL ESTRADIOL/NORETHINDRONE<br><b>Category: </b>CONTRACEPTIVES
<p>49<br><b>Brand Name: </b>LODINE XL<br><b>Generic Name: </b>ETODOLAC<br><b>Category: </b>NONSTEROIDAL ANTIINFLAMMATORY AGENTS
<p>50<br><b>Brand Name: </b>CYSTADANE<br><b>Generic Name: </b>BETAINE<br><b>Category: </b>TREATMENT OF HOMOCYSTINUREAL
<p>51<br><b>Brand Name: </b>COMBIVENT<br><b>Generic Name: </b>ALBUTEROL/IPRATROPIUM<br><b>Category: </b>BRONCHODILATORS
<p>52<br><b>Brand Name: </b>TARKA<br><b>Generic Name: </b>TRANDOLAPRIL/VERAPAMIL<br><b>Category: </b>ANTIHYPERTENSIVES
<p>53<br><b>Brand Name: </b>MENTAX<br><b>Generic Name: </b>BUTENAFINE HCL<br><b>Category: </b>ANTIFUNGALS
<p>54<br><b>Brand Name: </b>TIAMATE<br><b>Generic Name: </b>DILTIAZEM<br><b>Category: </b>ANTIHYPERTENSIVES
<p>55<br><b>Brand Name: </b>DURACLON<br><b>Generic Name: </b>CLONIDINE HCL<br><b>Category: </b>EPIDURAL ADJUNCT TO OPIATE THERAPY
<p>56<br><b>Brand Name: </b><a href="http://www.lec.org/DrugSearch/Documents/Rohypnol.html">ROHYPNOL</a><br><b>Generic Name: </b>FLUNITRAZEPAM<br><b>Category: </b>MISC. SEDATIVES/HYPNOTICS (NOTE: NOT MARKETED IN THE US)
<p>57<br><b>Brand Name: </b>KADIAN<br><b>Generic Name: </b>MORPHINE SULFATE SA<br><b>Category: </b>OPIATE AGONISTS
<p>58<br><b>Brand Name: </b>COCAINE<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/cocaine.htm">COCAINE HCL</a><br><b>Category: </b>ANTIPRURITICS AND LOCAL ANESTHETICS
<p>59<br><b>Brand Name: </b>TECZEM<br><b>Generic Name: </b>ENALAPRIL MALEATE & DILTIAZEM MALEATE<br><b>Category: </b>ANTIHYPERTENSIVES
<p>60<br><b>Brand Name: </b>TICLID<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/ticlop.htm">TICLOPIDINE HCL</a><br><b>Category: </b>PLATELET AGGREGATION INHIBITORS
<p>61<br><b>Brand Name: </b>PARACETAMOL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">SEE ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>62<br><b>Brand Name: </b>DHEA<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/dhea.htm">DEHYDROEPIANDROSTERONE</a><br><b>Category: </b>UNAPPROVED
<p>63<br><b>Brand Name: </b>ANTIBIOTIC<br><b>Generic Name: </b>TYPE ANTIBIOT*<br><b>Category: </b>USE * TO SORT ON CATEGORY
<p>64<br><b>Brand Name: </b>NILANDRON<br><b>Generic Name: </b>NILUTAMIDE<br><b>Category: </b>ANTIANDROGENS
<p>65<br><b>Brand Name: </b>PONDIMIN<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/fenflur.htm">FENFLURAMINE HCL</a><br><b>Category: </b>APPETITE SUPPRESSANT
<p>66<br><b>Brand Name: </b>ALPHAGAN<br><b>Generic Name: </b>BRIMONIDINE TARTRATE<br><b>Category: </b>MISCELLANEOUS EENT AGENTS (GLAUCOMA)
<p>67<br><b>Brand Name: </b>FERTINEX<br><b>Generic Name: </b>UROFOLLITROPIN<br><b>Category: </b>FOLLICLE STIMULATING HORMONE
<p>68<br><b>Brand Name: </b>IVY BLOCK<br><b>Generic Name: </b>URUSHIOL<br><b>Category: </b>MISCEL.SKIN AND MUCUS MEMBRANE AGENTS
<p>69<br><b>Brand Name: </b>ZENTATE<br><b>Generic Name: </b>VITAMINS PRENATAL<br><b>Category: </b>MULTIVITAMIN PREPARATIONS
<p>70<br><b>Brand Name: </b>ETOPOPHOS<br><b>Generic Name: </b>ETOPOSIDE PHOSPHATE<br><b>Category: </b>ANTINEOPLASTICS
<p>71<br><b>Brand Name: </b>SEROSTIM<br><b>Generic Name: </b>SOMATOTROPIN<br><b>Category: </b>PITUITARY
<p>72<br><b>Brand Name: </b>ZYPREXA<br><b>Generic Name: </b>OLANZAPINE<br><b>Category: </b>ANTIPSYCHOTICS
<p>73<br><b>Brand Name: </b>HURRICAINE<br><b>Generic Name: </b>BENZOCAINE<br><b>Category: </b>LOCAL ANESTHETICS
<p>74<br><b>Brand Name: </b>HURRICAINE<br><b>Generic Name: </b>BENZOCAINE<br><b>Category: </b>ANTIPRURITICS AND LOCAL ANESTHETICS
<p>75<br><b>Brand Name: </b>MERREM I.V.<br><b>Generic Name: </b>MEROPENEM<br><b>Category: </b>MISCELLANEOUS ANTIBIOTICS
<p>76<br><b>Brand Name: </b>PROAMATINE<br><b>Generic Name: </b>MIDODRINE<br><b>Category: </b>TREATMENT OF ORTHOSTATIC HYPERTENSION
<p>77<br><b>Brand Name: </b>RU-486<br><b>Generic Name: </b>MIFEPRISTONE<br><b>Category: </b>TERMINATION OF PREGNANCY
<p>78<br><b>Brand Name: </b>ALBENZA<br><b>Generic Name: </b>ALBENDAZOLE<br><b>Category: </b>ANTHELMINTICS
<p>79<br><b>Brand Name: </b>DIFFERIN<br><b>Generic Name: </b>ADAPALENE<br><b>Category: </b>MISCEL.SKIN AND MUCUS MEMBRANE AGENTS
<p>80<br><b>Brand Name: </b>CARBEX<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/seleg.htm">SELEGILINE HCL</a><br><b>Category: </b>FOR PARKINSON'S DISEASE
<p>81<br><b>Brand Name: </b>HELIDAC<br><b>Generic Name: </b>BISMUTH SUBSAL. METRONIDAZOLE & TETRACYCLINE<br><b>Category: </b>FOR PEPTIC ULCER DISEASE
<p>82<br><b>Brand Name: </b>TRITEC<br><b>Generic Name: </b>RANITIDINE BISMUTH CITRATE<br><b>Category: </b>MISCELLANEOUS GI DRUGS
<p>83<br><b>Brand Name: </b>CEREBYX<br><b>Generic Name: </b>FOSPHENYTOIN SODIUM<br><b>Category: </b>HYDANTOINS
<p>84<br><b>Brand Name: </b>ALLEGRA<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/fexofen.htm">FEXOFENADINE</a><br><b>Category: </b>ANTIHISTAMINES
<p>85<br><b>Brand Name: </b>CAMPTOSAR<br><b>Generic Name: </b>IRINOTECAN HCL<br><b>Category: </b>ANTINEOPLASTICS
<p>86<br><b>Brand Name: </b>XALATAN<br><b>Generic Name: </b>LATANOPROST<br><b>Category: </b>GLAUCOMA THERAPY
<p>87<br><b>Brand Name: </b>REMERON<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/mirtaz.htm">MIRTAZAPINE</a><br><b>Category: </b>ANTIDEPRESSANTS
<p>88<br><b>Brand Name: </b>VIRAMUNE<br><b>Generic Name: </b>NEVIRAPINE<br><b>Category: </b>ANIVIRALS
<p>89<br><b>Brand Name: </b>MYOTROPHIN<br><b>Generic Name: </b>SOMATOMEDIN C<br><b>Category: </b>FOR AMYOTROPHIC LATERAL SCLEROSIS
<p>90<br><b>Brand Name: </b>HUMULIN N<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/humnph.htm">HUMAN INSULIN NPH</a> <br><b>Category: </b>INSULINS
<p>91<br><b>Brand Name: </b>HUMULIN R<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/huminsr.htm">HUMAN INSULIN REGULAR</a><br><b>Category: </b>INSULINS
<p>92<br><b>Brand Name: </b>HUMULIN L<br><b>Generic Name: </b>HUMAN INSULIN LENTE<br><b>Category: </b>INSULINS
<p>93<br><b>Brand Name: </b>HUMULIN 70/30<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/hum7030.htm">HUMAN INSULIN NPH/REG 70/30</a><br><b>Category: </b>INULINS
<p>94<br><b>Brand Name: </b>ORTHO-NOVUM 7/7/7<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/norestoc.htm">NORETHINDRONE/ETHINYL ESTRADIOL</a> <br><b>Category: </b>CONTRACEPTIVES
<p>95<br><b>Brand Name: </b>ORTHO-CEPT<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/desest.htm">DESOGESTREL/ETHINYLESTRADIOL</A><br><b>Category: </b>CONTRACEPTIVES
<p>96<br><b>Brand Name: </b>ACCUPRIL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/quinap.htm">QUINAPRIL HCL</a><br><b>Category: </b>HYPOTENSIVE AGENTS
<p>97<br><b>Brand Name: </b>ACTHREL<br><b>Generic Name: </b>CORTICORELIN OVINE TRIFLUTATE<br><b>Category: </b>DIAGNOSTIC AGENTS
<p>98<br><b>Brand Name: </b>BUPHENYL<br><b>Generic Name: </b>SODIUM PHENYLBUTYRATE<br><b>Category: </b>FOR UREA CYCLE DISORDERS
<p>99<br><b>Brand Name: </b>VISIPAQUE<br><b>Generic Name: </b>IODIXANOL<br><b>Category: </b>ROENTGENOGRAPHY
<p>100<br><b>Brand Name: </b>NAPRELAN<br><b>Generic Name: </b>NAPROXEN SODIUM<br><b>Category: </b>NONSTEROIDAL ANTIINFLAMMATORY AGENTS
<p>101<br><b>Brand Name: </b>OXILAN<br><b>Generic Name: </b>IOXILAN<br><b>Category: </b>ROENTGENOGRAPHY
<p>102<br><b>Brand Name: </b>IONTOCAINE<br><b>Generic Name: </b>LIDOCAINE/EPINEPHRINE<br><b>Category: </b>LOCAL ANESTHETICS
<p>103<br><b>Brand Name: </b>PENTACEF<br><b>Generic Name: </b>CEFTAZIDINE<br><b>Category: </b>ANTIBIOTICS: CEPHALOSPORINS
<p>104<br><b>Brand Name: </b>METROCREAM<br><b>Generic Name: </b>METRONIDAZOLE<br><b>Category: </b>MISCELLANEOUS ANTI-INFECTIVES
<p>105<br><b>Brand Name: </b>GENOTROPIN<br><b>Generic Name: </b>SOMATROPIN<br><b>Category: </b>PITUITARY
<p>106<br><b>Brand Name: </b>SEVORANE<br><b>Generic Name: </b>SEVOFLURANE<br><b>Category: </b>GENERAL ANESTHETICS
<p>107<br><b>Brand Name: </b>BIOTROPIN<br><b>Generic Name: </b>SOMATROPIN<br><b>Category: </b>PITUITARY
<p>108<br><b>Brand Name: </b>ULTRAVIST<br><b>Generic Name: </b>IOPROMIDE<br><b>Category: </b>ROENTGENOGRAPHY
<p>109<br><b>Brand Name: </b>NORDITROPIN<br><b>Generic Name: </b>SOMATROPIN<br><b>Category: </b>PITUITARY
<p>110<br><b>Brand Name: </b>PROVEL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/ibup.htm">IBUPROFEN</A><br><b>Category: </b>NONSTEROIDAL ANTIINFLAMMATORY AGENTS
<p>111<br><b>Brand Name: </b>NISOCOR<br><b>Generic Name: </b>NISOLDIPINE<br><b>Category: </b>CARDIAC DRUGS
<p>112<br><b>Brand Name: </b>APTHASOL<br><b>Generic Name: </b>AMLEXANOX<br><b>Category: </b>TREATMENT OF CANKER SORES
<p>113<br><b>Brand Name: </b>ALPHANATE<br><b>Generic Name: </b>ANTIHEMOPHILIC FACTOR<br><b>Category: </b>HEMOSTATICS
<p>114<br><b>Brand Name: </b>OXYCONTIN<br><b>Generic Name: </b>OXYCODONE HCL<br><b>Category: </b>OPIATE AGONISTS
<p>115<br><b>Brand Name: </b>HYCAMTIN<br><b>Generic Name: </b>TOPOTECAN<br><b>Category: </b>ANTINEOPLASTICS
<p>116<br><b>Brand Name: </b>OXANDRIN<br><b>Generic Name: </b>OXANDROLONE<br><b>Category: </b>ANDROGENS
<p>117<br><b>Brand Name: </b>WINRHO SD<br><b>Generic Name: </b>RHO(D)IMMUNE GLOBULIN<br><b>Category: </b>SERUMS
<p>118<br><b>Brand Name: </b>AVONEX<br><b>Generic Name: </b>INTERFERON BETA-1A<br><b>Category: </b>TREATMENT OF MULTIPLE SCLEROSIS
<p>119<br><b>Brand Name: </b>GEMZAR<br><b>Generic Name: </b>GEMCITABINE HCL<br><b>Category: </b>ANTINEOPLASTICS
<p>120<br><b>Brand Name: </b>DEXFERRUM<br><b>Generic Name: </b>IRON DEXTRAN<br><b>Category: </b>IRON PRODUCTS
<p>121<br><b>Brand Name: </b>CORMAX<br><b>Generic Name: </b>CLOBETASOL PROPIONATE<br><b>Category: </b>ANTI-INFLAMMATORY AGENTS
<p>122<br><b>Brand Name: </b>VITRASERT<br><b>Generic Name: </b>GANCICLOVIR<br><b>Category: </b>ANTIVIRALS
<p>123<br><b>Brand Name: </b>CYTOVENE<br><b>Generic Name: </b>GANCICLOVIR<br><b>Category: </b>ANTIVIRALS
<p>124<br><b>Brand Name: </b>HUMALOG<br><b>Generic Name: </b>INSULIN LISPRO<br><b>Category: </b>INSULINS
<p>125<br><b>Brand Name: </b>DAUNOXOME<br><b>Generic Name: </b>DAUNORUBICIN CITRATE (LIPOSOME)<br><b>Category: </b>ANTINEOPLASTICS
<p>126<br><b>Brand Name: </b>ESTRING<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/estrad.htm">ESTRADIOL</A><br><b>Category: </b>ESTROGENS
<p>127<br><b>Brand Name: </b>ARIMEDEX<br><b>Generic Name: </b>ANASTROZOLE<br><b>Category: </b>ANTINEOPLASTICS
<p>128<br><b>Brand Name: </b>VISTIDE<br><b>Generic Name: </b>CIDOFOVIR<br><b>Category: </b>ANTIVIRALS
<p>129<br><b>Brand Name: </b>NICOTROL NS<br><b>Generic Name: </b>NICOTINE(NASAL)<br><b>Category: </b>MISCELLANEOUS AUTONOMIC DRUGS 
<p>130<br><b>Brand Name: </b>VIQUIN FORTE<br><b>Generic Name: </b>HYDROQUINONE<br><b>Category: </b>DEPIGMENTING AGENTS
<p>131<br><b>Brand Name: </b>REDUX<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/dexfen.htm">DEXFENFLURAMINE</a><br><b>Category: </b>ANTI-OBESITY AGENTS
<p>132<br><b>Brand Name: </b>ZANAFLEX<br><b>Generic Name: </b>TIZANIDINE HCL<br><b>Category: </b>SKELETAL MUSCLE RELAXANTS
<p>133<br><b>Brand Name: </b>PREVALITE<br><b>Generic Name: </b>CHOLESTYRAMINE<br><b>Category: </b>ANTILIPEMIC AGENTS
<p>134<br><b>Brand Name: </b>FERIDEX<br><b>Generic Name: </b>FERUMOXIDE<br><b>Category: </b>MAGNETIC RESONANCE IMAGING
<p>135<br><b>Brand Name: </b>MAVIK<br><b>Generic Name: </b>TRANDOLAPRIL<br><b>Category: </b><a href="http://www.rxlist.com/cardiova.htm">HYPOTENSIVE AGENTS</a> 
<p>136<br><b>Brand Name: </b>NAROPIN<br><b>Generic Name: </b>ROPIVACAINE<br><b>Category: </b>LOCAL ANESTHETICS
<p>137<br><b>Brand Name: </b>SCLEROSOL<br><b>Generic Name: </b>TALC<br><b>Category: </b>SCLEROSING AGENTS
<p>138<br><b>Brand Name: </b>TOPAMAX<br><b>Generic Name: </b>TOPIRAMATE<br><b>Category: </b>MISCELLANEOUS ANTICONVULSANTS
<p>139<br><b>Brand Name: </b>VAQTA<br><b>Generic Name: </b>HEPATITIS A VACCINE<br><b>Category: </b>VACCINES
<p>140<br><b>Brand Name: </b>MYOVIEW<br><b>Generic Name: </b>TETROPHOSMIN<br><b>Category: </b>RADIOPHARMACEUTICALS
<p>141<br><b>Brand Name: </b>OCUHIST<br><b>Generic Name: </b>PHENIRAMINE MALEATE<br><b>Category: </b>ANTIHISTAMINE DRUGS
<p>142<br><b>Brand Name: </b>COVERA-HS<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/verapsr.htm">VERAPAMIL</A> HCL<br><b>Category: </b><a href="http://www.rxlist.com/cardiova.htm">CARDIAC DRUGS</a> 
<p>143<br><b>Brand Name: </b>SYNOVIR<br><b>Generic Name: </b>THALIDOMIDE<br><b>Category: </b>AIDS-CACHEXIA
<p>144<br><b>Brand Name: </b>VESANOID<br><b>Generic Name: </b>TRETINOIN<br><b>Category: </b>ANTINEOPLASTIC AGENTS
<p>145<br><b>Brand Name: </b>TEICHOMYCIN<br><b>Generic Name: </b>TEICOPLANIN<br><b>Category: </b>MISCELLANEOUS ANTIBIOTICS
<p>146<br><b>Brand Name: </b>NORVIR<br><b>Generic Name: </b>RITONAVIR<br><b>Category: </b>ANTIVIRALS
<p>147<br><b>Brand Name: </b>NIMBEX<br><b>Generic Name: </b>CISATRACURIUM BESYLATE<br><b>Category: </b>SKELETAL MUSCLE RELAXANTS
<p>148<br><b>Brand Name: </b>MAXIPIME<br><b>Generic Name: </b>CEFEPIME<br><b>Category: </b>ANTIBIOTICS: CEPHALOSPORINS
<p>149<br><b>Brand Name: </b>PENNSAID<br><b>Generic Name: </b>DIMETHAID-D<br><b>Category: </b><a href="http://www.rxlist.com/nsaid.htm">NONSTEROIDAL ANTI-INFLAMMATORY AGENTS</a> 
<p>150<br><b>Brand Name: </b>ADDERALL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/amphet.htm">AMPHETAMINE MIXED SALTS</a><br><b>Category: </b>RESPIRATORY AND CEREBRAL STIMULANTS
<p>151<br><b>Brand Name: </b>CANDIN<br><b>Generic Name: </b>CANDIDA ALBICANS<br><b>Category: </b>FUNGI
<p>152<br><b>Brand Name: </b>ACTRON<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/ketoprof.htm">KETOPROFEN</a><br><b>Category: </b><a href="http://www.rxlist.com/nsaid.htm">NONSTEROIDAL ANTIINFLAMMATORY AGENTS</a> 
<p>153<br><b>Brand Name: </b>CEDAX<br><b>Generic Name: </b>CEFTIBUTEN<br><b>Category: </b>ANTIBIOTICS:CEPHALOSPORINS
<p>154<br><b>Brand Name: </b>RENOVA<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/tretinoin.htm">TRETINOIN</a><br><b>Category: </b>MISCEL.SKIN AND MUCUS MEMBRANE AGENTS
<p>155<br><b>Brand Name: </b>PHOTOFRIN<br><b>Generic Name: </b>PORFIMER SODIUM<br><b>Category: </b>ANTINEOPLASTIC AGENTS (PHOTODYNAMIC)
<p>156<br><b>Brand Name: </b>AMARYL<br><b>Generic Name: </b>GLIMEPIRIDE<br><b>Category: </b>ANTIDIABETIC AGENTS
<p>157<br><b>Brand Name: </b>FLOLAN<br><b>Generic Name: </b>EPOPROSTENOL SODIUM<br><b>Category: </b>VASODILATING AGENTS
<p>158<br><b>Brand Name: </b>RESPIGAM<br><b>Generic Name: </b>RSV-IGIV<br><b>Category: </b>SERUMS
<p>159<br><b>Brand Name: </b>CRIXIVAN<br><b>Generic Name: </b>INDINAVIR SULFATE<br><b>Category: </b>ANTIVIRALS
<p>160<br><b>Brand Name: </b>TRIPEDIA<br><b>Generic Name: </b>WHOOPING COUGH VACCINE<br><b>Category: </b>VACCINES
<p>161<br><b>Brand Name: </b>PROCANABID<br><b>Generic Name: </b>PROCAINAMIDE HCL<br><b>Category: </b>CARDIAC DRUGS
<p>162<br><b>Brand Name: </b>ZYRTEC<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/cetiriz.htm">CETIRIZINE HCL</a><br><b>Category: </b>ANTIHISTAMINE DRUGS
<p>163<br><b>Brand Name: </b>VIVELLE<br><b>Generic Name: </b>ESTRADIOL (TRANSDERMAL SYSTEM)<br><b>Category: </b>ESTROGEN
<p>164<br><b>Brand Name: </b>AZELEX<br><b>Generic Name: </b>ACELAIC ACID<br><b>Category: </b>SKIN AND MUCUS MEMBRANE AGENTS
<p>165<br><b>Brand Name: </b>ETHYOL<br><b>Generic Name: </b>AMIFOSTINE<br><b>Category: </b>UNCLASSIFIED THERAPEUTIC AGENTS
<p>166<br><b>Brand Name: </b>DOXIL<br><b>Generic Name: </b> DOXORUBICIN HCL (LIPOSOME INJECTION)<br><b>Category: </b>ANTIONEOPLASTIC AGENTS
<p>167<br><b>Brand Name: </b>ABELCET<br><b>Generic Name: </b>ABCL(AMPHOTERICIN B LIPID COMPLEX LIPOSOME INJ)<br><b>Category: </b>ANTIFUNGALS
<p>168<br><b>Brand Name: </b>PRECOSE<br><b>Generic Name: </b>ACARBOSE<br><b>Category: </b>ANTIDIABETIC AGENTS
<p>169<br><b>Brand Name: </b>RILUTEK<br><b>Generic Name: </b>RILUZOLE<br><b>Category: </b>FOR AMYOTROPHIC LATERAL SCLEROSIS
<p>170<br><b>Brand Name: </b>VALTREX<br><b>Generic Name: </b>VALACYCLOVIR<br><b>Category: </b>ANIVIRALS
<p>171<br><b>Brand Name: </b>FLOVENT<br><b>Generic Name: </b>FLUTICASONE PROPRIONATE<br><b>Category: </b>ANTIINFLAMMATORY AGENTS
<p>172<br><b>Brand Name: </b>DYNABAC<br><b>Generic Name: </b>DIRITHROMYCIN<br><b>Category: </b>ANTIBIOTICS:ERYTHROMYCINS
<p>173<br><b>Brand Name: </b>CORVERT<br><b>Generic Name: </b>IBUTILIDE<br><b>Category: </b>CARDIAC DRUGS
<p>174<br><b>Brand Name: </b>FARESTON<br><b>Generic Name: </b>TOREMIFENE CITRATE<br><b>Category: </b>ANTINEOPLASTIC AGENTS
<p>175<br><b>Brand Name: </b>COREG<br><b>Generic Name: </b>CARDEDILOL<br><b>Category: </b>CARDIAC DRUGS
<p>176<br><b>Brand Name: </b>TAXOTERE<br><b>Generic Name: </b>DOCETAXEL<br><b>Category: </b>ANTINEOPLASTIC AGENTS
<p>177<br><b>Brand Name: </b>BUTOX<br><b>Generic Name: </b>BOTULINUM TOXIN TYPE A<br><b>Category: </b>TOXOIDS
<p>178<br><b>Brand Name: </b>SULAR<br><b>Generic Name: </b>NISOLDIPINE<br><b>Category: </b>CARDIAC DRUGS
<p>179<br><b>Brand Name: </b>BLEO<br><b>Generic Name: </b>BLEOMYCIN<br><b>Category: </b>ANTINEOPLASTIC AGENTS
<p>180<br><b>Brand Name: </b>BLEOCIN<br><b>Generic Name: </b>BLEOMYCIN<br><b>Category: </b>ANTINEOPLASTIC AGENTS
<p>181<br><b>Brand Name: </b>BLENOXANE<br><b>Generic Name: </b>BLEOMYCIN<br><b>Category: </b>ANTINEOPLASTIC AGENTS
<p>182<br><b>Brand Name: </b>INVIRASE<br><b>Generic Name: </b>SAQUINAVIR<br><b>Category: </b>ANTIVIRALS
<p>183<br><b>Brand Name: </b>EPIVIR<br><b>Generic Name: </b>LAMIVUDINE<br><b>Category: </b>ANTIVIRALS
<p>184<br><b>Brand Name: </b>3TC<br><b>Generic Name: </b>LAMIVUDINE<br><b>Category: </b>ANTIVIRALS
<p>185<br><b>Brand Name: </b>AZT<br><b>Generic Name: </b>ZIDOVUDINE<br><b>Category: </b>ANTIVIRALS
<p>186<br><b>Brand Name: </b>NIZORAL<br><b>Generic Name: </b>KETOCONAZOLE<br><b>Category: </b>ANTIFUNGALS
<p>187<br><b>Brand Name: </b>NIZORAL TOPICAL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/ketocon.htm">KETOCONAZOLE TOPICAL</A><br><b>Category: </b>ANTIFUNGALS
<p>188<br><b>Brand Name: </b>METHERGINE<br><b>Generic Name: </b>METHYLERGONOVINE MALEATE<br><b>Category: </b>OXYTOCICS
<p>189<br><b>Brand Name: </b>LOTREL<br><b>Generic Name: </b>AMLODIPINE/BENAZEPRIL HCL<br><b>Category: </b><a href="http://www.rxlist.com/cardiova.htm">HYPOTENSIVE AGENTS</a> 
<p>190<br><b>Brand Name: </b>VEXOL<br><b>Generic Name: </b>RIMEXOLONE<br><b>Category: </b>OPTHALMIC CORTICOSTEROID
<p>191<br><b>Brand Name: </b>DR-3355<br><b>Generic Name: </b>LEVOFLOXACIN<br><b>Category: </b>INVESTIGATIONAL:ANTIBIOTICS:QUINOLINES
<p>192<br><b>Brand Name: </b>ORG-10172<br><b>Generic Name: </b>DANAPAROID<br><b>Category: </b>INVESTIGATIONAL:ANTICOAGULANTS
<p>193<br><b>Brand Name: </b>RU 44570<br><b>Generic Name: </b>TRANDOLAPRIL<br><b>Category: </b> <a href="http://www.rxlist.com/cardiova.htm">HYPOTENSIVE AGENTS</a> 
<p>194<br><b>Brand Name: </b>ACCOLATE<br><b>Generic Name: </b>ZAFIRLUKAST<br><b>Category: </b>RESPIRATORY:LEUKOTRIENE ANTAGONIST
<p>195<br><b>Brand Name: </b>TIAZAC<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/diltiaz.htm">DILTIAZEM HCL</a> <br><b>Category: </b><a href="http://www.rxlist.com/cardiova.htm">CARDIAC DRUGS</a> 
<p>196<br><b>Brand Name: </b>FOSAMAX<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/alendron.htm">ALENDRONATE SODIUM</a><br><b>Category: </b>MISCELLANEOUS:OSTEOPOROSIS
<p>197<br><b>Brand Name: </b>REOPRO<br><b>Generic Name: </b>ABCIXIMAB<br><b>Category: </b>UNCLASSIFIED THERAPEUTIC AGENTS
<p>198<br><b>Brand Name: </b>SECTRAL<br><b>Generic Name: </b>ACEBUTOLOL HCL<br><b>Category: </b><a href="http://www.rxlist.com/cardiova.htm">CARDIAC DRUGS</a> 
<p>199<br><b>Brand Name: </b>ACI-JEL W/APP<br><b>Generic Name: </b>ACET AC/RICINOLEIC/OXY<br><b>Category: </b>ANTI-INFECTIVES
<p>200<br><b>Brand Name: </b>ACEPHEN<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>201<br><b>Brand Name: </b>ACETAMIN<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>202<br><b>Brand Name: </b>ANACIN AF<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>203<br><b>Brand Name: </b>APAP<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>204<br><b>Brand Name: </b>BL INFANT N/A<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>205<br><b>Brand Name: </b>BL NON-ASPIRN<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>206<br><b>Brand Name: </b>FEVERALL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>207<br><b>Brand Name: </b>GENAPAP X/S<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>208<br><b>Brand Name: </b>GENEBS X/S<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>209<br><b>Brand Name: </b>GNP NON-ASPRN<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>210<br><b>Brand Name: </b>GNP NON-ASPRN<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>211<br><b>Brand Name: </b>GNP XS PAIN<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>212<br><b>Brand Name: </b>INFANTAIRE<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>213<br><b>Brand Name: </b>INFANTOL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>214<br><b>Brand Name: </b>MAPAP ACETAM<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>215<br><b>Brand Name: </b>PAIN &amp; FEVER<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>216<br><b>Brand Name: </b>PANADOL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>217<br><b>Brand Name: </b>PEDIAPAP<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>218<br><b>Brand Name: </b>TEMPRA 1<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>219<br><b>Brand Name: </b>TEMPRA 2<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>220<br><b>Brand Name: </b>TYLENOL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>221<br><b>Brand Name: </b>TYLENOL INFNT<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>222<br><b>Brand Name: </b>TYLENOL X/S<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>223<br><b>Brand Name: </b>BROMO SELTZER<br><b>Generic Name: </b>ACETAMINOPHEN BUFFERED<br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>224<br><b>Brand Name: </b>GENAPAP CHILD<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN CHEW</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>225<br><b>Brand Name: </b>ST JOS CHL/AF<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN CHEW</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>226<br><b>Brand Name: </b>TEMPRA 3 CHEW<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN CHEW</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>227<br><b>Brand Name: </b>TYLENOL CHILD<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN CHEW</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>228<br><b>Brand Name: </b>TYLENOL CHILD<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN CHEW</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>229<br><b>Brand Name: </b>TYLENOL X/RLF<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN SA</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>230<br><b>Brand Name: </b>PROMINOL<br><b>Generic Name: </b>ACETAMINOPHEN/BUTALBITAL<br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>231<br><b>Brand Name: </b>APAP/COD<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/acetcod.htm">ACETAMINOPHEN/CODEINE</a> <br><b>Category: </b><a href="opiate.htm">OPIATE AGONISTS</a> 
<p>232<br><b>Brand Name: </b>CAPITAL W/COD<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/acetcod.htm">ACETAMINOPHEN/CODEINE</a> <br><b>Category: </b><a href="opiate.htm">OPIATE AGONISTS</a> 
<p>233<br><b>Brand Name: </b>PHENAPHEN/COD<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/acetcod.htm">ACETAMINOPHEN/CODEINE</a> <br><b>Category: </b><a href="opiate.htm">OPIATE AGONISTS</a> 
<p>234<br><b>Brand Name: </b>TYLENOL/COD<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/acetcod.htm">ACETAMINOPHEN/CODEINE</a> <br><b>Category: </b><a href="opiate.htm">OPIATE AGONISTS</a> 
<p>235<br><b>Brand Name: </b>ACETAZOLAMIDE<br><b>Generic Name: </b>ACETAZOLAMIDE<br><b>Category: </b>CARBONIC ANHYDRASE INHIBITORS
<p>236<br><b>Brand Name: </b>DIAMOX<br><b>Generic Name: </b>ACETAZOLAMIDE<br><b>Category: </b>CARBONIC ANHYDRASE INHIBITORS
<p>237<br><b>Brand Name: </b>ACETASOL PLN<br><b>Generic Name: </b>ACETIC ACID OTIC<br><b>Category: </b>ANTI-INFECTIVES
<p>238<br><b>Brand Name: </b>DOMEBORO OTIC<br><b>Generic Name: </b>ACETIC ACID OTIC<br><b>Category: </b>ANTI-INFECTIVES
<p>239<br><b>Brand Name: </b>VOSOL OTIC<br><b>Generic Name: </b>ACETIC ACID OTIC<br><b>Category: </b>ANTI-INFECTIVES
<p>240<br><b>Brand Name: </b>ACETASOL HC<br><b>Generic Name: </b>ACETIC ACID/HYDROCORT OTI<br><b>Category: </b>ANTI-INFECTIVES
<p>241<br><b>Brand Name: </b>HYDRO/ACETIC<br><b>Generic Name: </b>ACETIC ACID/HYDROCORT OTI<br><b>Category: </b>ANTI-INFECTIVES
<p>242<br><b>Brand Name: </b>VASOTATE HC<br><b>Generic Name: </b>ACETIC ACID/HYDROCORT OTI<br><b>Category: </b>ANTI-INFECTIVES
<p>243<br><b>Brand Name: </b>VOSOL HC OTIC<br><b>Generic Name: </b>ACETIC ACID/HYDROCORT OTI<br><b>Category: </b>ANTI-INFECTIVES
<p>244<br><b>Brand Name: </b>DYMELOR<br><b>Generic Name: </b>ACETOHEXAMIDE<br><b>Category: </b>SULFONYLUREAS
<p>245<br><b>Brand Name: </b>LITHOSTAT<br><b>Generic Name: </b>ACETOHYDROXAMIC ACID<br><b>Category: </b>AMMONIA DETOXICANTS
<p>246<br><b>Brand Name: </b>SEBA-NIL<br><b>Generic Name: </b>ACETONE/ALCOHOL/POLYSORB<br><b>Category: </b>MISCEL.SKIN AND MUCUS MEMBRANE AGENTS
<p>247<br><b>Brand Name: </b>MIOCHOL E W/<br><b>Generic Name: </b>ACETYLCHOLINE CHL<br><b>Category: </b>MIOTICS
<p>248<br><b>Brand Name: </b>ACETYLCYSTEIN<br><b>Generic Name: </b>ACETYLCYSTEINE<br><b>Category: </b>MUCOLYTIC AGENTS
<p>249<br><b>Brand Name: </b>MUCOMYST<br><b>Generic Name: </b>ACETYLCYSTEINE<br><b>Category: </b>MUCOLYTIC AGENTS
<p>250<br><b>Brand Name: </b>MUCOSIL<br><b>Generic Name: </b>ACETYLCYSTEINE<br><b>Category: </b>MUCOLYTIC AGENTS
<p></body></html>
<P><hr><a href="http://www.rxlist.com"><b>RxList Home Page</ul>
<hr>
</DOC>
<DOC>
<DOCNO>WT08-B13-20</DOCNO>
<DOCOLDNO>IA019-000201-B023-320</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/rxlist.cgi?drug=piroxicam 206.86.175.201 19970106234204 text/html 3106
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:35:48 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE>www.rxlist.com - Neil Sandow, Pharm.D. 
copyright 1995</title></head> <body bgcolor="#ffffff">
<center><a href="http://www.rxlist.com"><img src="rx.gif" 
height=75 width=75 border=0><img src="count.gif" border=0></a></center> 
Searching for: <b>PIROXICAM</b> <br>scroll down for results 
<hr><hr>
<h1>Enter Brand or Generic Name or Category*</h1>
<h3> Narrow Your Search with <font size=5>*</font>(examples: 
ampi*, *mycin, antibiotic*)</h3>
<form method=get>
<action=>
<input size=30 maxlength=30 name=drug>
<input type=submit>
<input type=reset>
</form>
<HR>
<H3>Your RxList Search Results:</h3>
1<br><b>Brand Name: </b>PRECOSE<br><b>Generic Name: </b>ACARBOSE<br><b>Category: </b>ANTIDIABETIC AGENTS
<p>2<br><b>Brand Name: </b>PROXIGEL<br><b>Generic Name: </b>CARBAMIDE PEROXIDE<br><b>Category: </b>MISCELLANEOUS LOCAL ANTI-INFECTIVES
<p>3<br><b>Brand Name: </b>PROZAC<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/fluoxetine.htm">FLUOXETINE HCL</a> <br><b>Category: </b><a href="http://www.rxlist.com/antidepr.htm">ANTIDEPRESSANTS</a> 
<p>4<br><b>Brand Name: </b>PROXACOL<br><b>Generic Name: </b>HYDROGEN PEROXIDE 10 VOL<br><b>Category: </b>MISCELLANEOUS LOCAL ANTI-INFECTIVES
<p>5<br><b>Brand Name: </b>PREGESTIMIL<br><b>Generic Name: </b>INFANT FORMULA CASEIN BAS<br><b>Category: </b>CALORIC AGENTS
<p>6<br><b>Brand Name: </b>PERCOCET<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/oxyapap.htm">OXYCODONE/ACETAMINOPHEN</a><br><b>Category: </b><a href="http://www.rxlist.com/opiate.htm">OPIATE AGONISTS</a> 
<p>7<br><b>Brand Name: </b>PERCOGESIC<br><b>Generic Name: </b>PHENYLTOLOXAMINE/APAP<br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>8<br><b>Brand Name: </b>FELDENE<br><b>Generic Name: </b>PIROXICAM<br><b>Category: </b><a href="http://www.rxlist.com/nsaid.htm">NONSTEROIDAL ANTIINFLAMMATORY AGENTS</a> 
<p>9<br><b>Brand Name: </b>PIROXICAM<br><b>Generic Name: </b>PIROXICAM<br><b>Category: </b><a href="http://www.rxlist.com/nsaid.htm">NONSTEROIDAL ANTIINFLAMMATORY AGENTS</a> 
<p>10<br><b>Brand Name: </b>MINIPRESS<br><b>Generic Name: </b>PRAZOSIN HCL<br><b>Category: </b><a href="http://www.rxlist.com/cardiova.htm">HYPOTENSIVE AGENTS</a> 
<p>11<br><b>Brand Name: </b>PRAZOSIN<br><b>Generic Name: </b>PRAZOSIN HCL<br><b>Category: </b><a href="http://www.rxlist.com/cardiova.htm">HYPOTENSIVE AGENTS</a> 
<p>12<br><b>Brand Name: </b>MINIZIDE<br><b>Generic Name: </b>PRAZOSIN/POLYTHIAZIDE<br><b>Category: </b><a href="http://www.rxlist.com/cardiova.htm">HYPOTENSIVE AGENTS</a> 
<p>13<br><b>Brand Name: </b>KEMADRIN<br><b>Generic Name: </b>PROCYCLIDINE HCL<br><b>Category: </b>ANTIPARKINSONNIAN AGENTS
<p>14<br><b>Brand Name: </b>GESTEROL<br><b>Generic Name: </b>PROGESTERONE<br><b>Category: </b>PROGESTINS
<p>15<br><b>Brand Name: </b>PROGESTERONE<br><b>Generic Name: </b>PROGESTERONE<br><b>Category: </b>PROGESTINS
<p></body></html>
<P><hr><a href="http://www.rxlist.com"><b>RxList Home Page</ul>
<hr>
</DOC>
<DOC>
<DOCNO>WT08-B13-21</DOCNO>
<DOCOLDNO>IA018-000200-B037-171</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/nitro25m.htm 206.86.175.201 19970106225633 text/html 26439
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:50:17 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 26256
Last-modified: Thu, 11 Jul 1996 07:09:35 GMT
</DOCHDR>
<html>
<head>
   <title>Nitrofurantoin (25% Macrocrystalline) - RxList Generic Information</title>
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Nitrofurantoin (25% Macrocrystalline)</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<p><a name="DESCRIPTION"></a><b>DESCRIPTION </b></p>

<p>Nitrofurantoin is an antibacterial agent specific for urinary tract
infections. </p>

<p>The chemical name of nitrofurantoin macrocrystals is 1-(((5-nitro-2-
furanyl)methylene)amino)-2,4-imidazolidinedione. </p>

<p>Molecular Weight: 238.16 </p>

<p>The chemical name of nitrofurantoin monohydrate is 1-(((5-nitro-2- furanyl)methylene)amino)-2,4-imidazolidinedione
monohydrate. </p>

<p>Molecular Weight: 256.17 </p>

<p><a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY
</b></p>

<p>Each Nitrofurantoin(25% macrocrystalline) capsule contains two forms
of nitrofurantoin. Twenty-five percent is macrocrystalline nitrofurantoin,
which has slower dissolution and absorption than nitrofurantoin monohydrate.
The remaining 75% is nitrofurantoin monohydrate contained in a powder blend
which, upon exposure to gastric and intestinal fluids, forms a gel matrix
that releases nitrofurantoin over time. Based on urinary pharmacokinetic
data, the extent and rate of urinary excretion of nitrofurantoin from the
100-mg Nitrofurantoin(25% macrocrystalline) capsule are similar to those
of the 50- mg or 100-mg Nitrofurantoin (100% macrocrystalline) capsule.
Approximately 20-25% of a single dose of nitrofurantoin is recovered from
the urine unchanged over 24 hours. </p>

<p>Plasma nitrofurantoin concentrations after a single oral dose of the
100-mg Nitrofurantoin(25% macrocrystalline) capsule are low, with peak
levels usually less than 1 mcg/mL. Nitrofurantoin is highly soluble in
urine, to which it may impart a brown color. When Nitrofurantoin(25% macrocrystalline)
is administered with food, the bioavailability of nitrofurantoin is increased
by approximately 40%. </p>

<p>MICROBIOLOGY: Nitrofurantoin is bactericidal in urine at therapeutic
doses. The mechanism of the antimicrobial action of nitrofurantoin is unusual
among antibacterials. Nitrofurantoin is reduced by bacterial flavoproteins
to reactive intermediates which inactivate or alter bacterial ribosomal
proteins and other macromolecules. As a result of such inactivations, the
vital biochemical processes of protein synthesis, aerobic energy metabolism,
DNA synthesis, RNA synthesis, and cell wall synthesis are inhibited. The
broad based nature of this mode of action may explain the lack of acquired
bacterial resistance to nitrofurantoin, as the necessary multiple and simultaneous
mutations of the target macromolecules would likely be lethal to the bacteria.
Development of resistance to nitrofurantoin has not been a significant
problem since its introduction in 1953. Cross-resistance with antibiotics
and sulfonamides has not been observed, and transferable resistance is,
at most, a very rare phenomenon. </p>

<p>Nitrofurantoin, in the form of Nitrofurantoin(25% macrocrystalline),
has been shown to be active against most strains of the following bacteria
both In Vitro and in clinical infections: (See INDICATIONS AND USAGE.)
</p>

<p>GRAM-POSITIVE AEROBES </p>

<p>Staphylococcus Saprophyticus </p>

<p>GRAM-NEGATIVE AEROBES </p>

<p>Escherichia Coli </p>

<p>Nitrofurantoin also demonstrates In Vitro activity against the following
microorganisms, although the clinical significance of these data with respect
to treatment with Nitrofurantoin(25% macrocrystalline) is unknown: </p>

<p>GRAM-POSITIVE AEROBES </p>

<p>Coagulase-negative staphylococci </p>

<p>(including Staphylococcus Epidermidis) </p>

<p>Enterococcus Faecalis </p>

<p>Staphylococcus Aureus </p>

<p>Streptococcus Agalactiae </p>

<p>Group D streptococci </p>

<p>Viridans group streptococci </p>

<p>GRAM-NEGATIVE AEROBES </p>

<p>Citrobacter Amalonaticus </p>

<p>Citrobacter Diversus </p>

<p>Citrobacter Freundii </p>

<p>Klebsiella Oxytoca </p>

<p>Klebsiella Ozaenae </p>

<p>Nitrofurantoin is not active against most strains of Proteus species
or Serratia species. It has no activity against Pseudomonas species. </p>

<p>Antagonism has been demonstrated In Vitro between nitrofurantoin and
quinolone antimicrobials. The clinical significance of this finding is
unknown. </p>

<p>SUSCEPTIBILITY TESTS: </p>

<p>DIFFUSION TECHNIQUES: </p>

<p>Quantitative methods that require measurement of zone diameters give
the most precise estimate of the susceptibility of bacteria to antimicrobial
agents. One such standard procedure, (REF. 1) which has been recommended
for use with disks to test susceptibility of organisms to nitrofurantoin,
uses the 300-mcg nitrofurantoin disk. Interpretation involves the correlation
of the diameter obtained in the disk test with the minimum inhibitory concentration
(MIC) for nitrofurantoin. </p>

<p>Reports from the laboratory giving results of the standard single-disk
susceptibility test with a 300-mcg nitrofurantoin disk should be interpreted
according to the following criteria: </p>

<pre>      Zone Diameter (mm)                                Interpretation         
             &gt;/=17                                       Susceptible            
             15-16                                       Intermediate           
             &lt; or =14                                       Resistant  </pre>

<p>A report of &quot;susceptible&quot; indicates that the pathogen is likely
to be inhibited by generally achievable urinary levels. A report of &quot;intermediate&quot;
indicates that the result be considered equivocal and, if the organism
is not fully susceptible to alternative clinically feasible drugs, the
test should be repeated. This category provides a buffer zone which prevents
small uncontrolled technical factors from causing major discrepancies in
interpretations. A report of &quot;resistant&quot; indicates that achievable
concentrations are unlikely to be inhibitory, and other therapy should
be selected. </p>

<p>Standardized procedures require the use of laboratory control organisms.
The 300-mcg nitrofurantoin disk should give the following zone diameters:
</p>

<pre>             Organism                                   Zone Diameter (mm)      
        E. Coli ATCC 25922                                    20-25             
       S. Aureus ATCC 25923                                   18-22             </pre>

<p>DILUTION TECHNIQUES: </p>

<p>Use a standardized dilution method (REF. 2) (broth, agar, microdilution)
or equivalent with nitrofurantoin powder. The MIC values obtained should
be interpreted according to the following criteria: </p>

<pre>         MIC (mcg/mL)                                   Interpretation         



             &lt; or =32                                       Susceptible            
               64                                        Intermediate           
             &gt;/=128                                      Resistant     </pre>

<p>As with standard diffusion techniques, dilution methods require the
use of laboratory control organisms. Standard nitrofurantoin powder should
provide the following MIC values: </p>

<pre>    Organism                                                MIC (mcg/mL)        
    E. Coli ATCC 25922                                          4-16            
    S. Aureus ATCC 29213                                        8-32            
    E. Faecalis ATCC 29212                                      4-16            </pre>

<p><a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE </b></p>

<p>Nitrofurantoin(25% macrocrystalline) is indicated only for the treatment
of acute uncomplicated urinary tract infections (acute cystitis) caused
by susceptible strains of Escherichia Coli or Staphylococcus Saprophyticus.
</p>

<p>Nitrofurantoin is not indicated for the treatment of pyelonephritis
or perinephric abscesses. </p>

<p>Nitrofurantoins lack the broader tissue distribution of other therapeutic
agents approved for urinary tract infections. Consequently, many patients
who are treated with Nitrofurantoin(25% macrocrystalline) are predisposed
to persistence or reappearance of bacteriuria. (See CLINICAL STUDIES.)
Urine specimens for culture and susceptibility testing should be obtained
before and after completion of therapy. If persistence or reappearance
of bacteriuria occurs after treatment with Nitrofurantoin(25% macrocrystalline),
other therapeutic agents with broader tissue distribution should be selected.
In considering the use of Nitrofurantoin(25% macrocrystalline), lower eradication
rates should be balanced against the increased potential for systemic toxicity
and for the development of antimicrobial resistance when agents with broader
tissue distribution are utilized. </p>

<p><a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS </b></p>

<p>Anuria, oliguria, or significant impairment of renal function (creatinine
clearance under 60 mL per minute or clinically significant elevated serum
creatinine) are contraindications. Treatment of this type of patient carries
an increased risk of toxicity because of impaired excretion of the drug.
</p>

<p>Because of the possibility of hemolytic anemia due to immature erythrocyte
enzyme systems (glutathione instability), the drug is contraindicated in
pregnant patients at term (38-42 weeks gestation), during labor and delivery,
or when the onset of labor is imminent. For the same reason, the drug is
contraindicated in neonates under one month of age. </p>

<p>Nitrofurantoin(25% macrocrystalline) is also contraindicated in those
patients with known hypersensitivity to nitrofurantoin. </p>

<p><a name="WARNINGS"></a><b>WARNINGS </b></p>

<p>ACUTE, SUBACUTE, OR CHRONIC PULMONARY REACTIONS HAVE BEEN OBSERVED IN
PATIENTS TREATED WITH NITROFURANTOIN. IF THESE REACTIONS OCCUR, Nitrofurantoin(25%
macrocrystalline) SHOULD BE DISCONTINUED AND APPROPRIATE MEASURES TAKEN.
REPORTS HAVE CITED PULMONARY REACTIONS AS A CONTRIBUTING CAUSE OF DEATH.
</p>

<p>CHRONIC PULMONARY REACTIONS (DIFFUSE INTERSTITIAL PNEUMONITIS OR PULMONARY
FIBROSIS, OR BOTH) CAN DEVELOP INSIDIOUSLY. THESE REACTIONS OCCUR RARELY
AND GENERALLY IN PATIENTS RECEIVING THERAPY FOR SIX MONTHS OR LONGER. CLOSE
MONITORING OF THE PULMONARY CONDITION OF PATIENTS RECEIVING LONG-TERM THERAPY
IS WARRANTED AND REQUIRES THAT THE BENEFITS OF THERAPY BE WEIGHED AGAINST
POTENTIAL RISKS. (SEE RESPIRATORY REACTIONS.) </p>

<p>Hepatic reactions, including hepatitis, cholestatic jaundice, and chronic
active hepatitis, and hepatic necrosis, occur rarely. Fatalities have been
reported. The onset of chronic active hepatitis may be insidious, and patients
should be monitored periodically for changes in liver function. If hepatitis
occurs, the drug should be withdrawn immediately and appropriate measures
should be taken. </p>

<p>Peripheral neuropathy (including optic neuritis), which may become severe
or irreversible, has occurred. Fatalities have been reported. Conditions
such as renal impairment (creatinine clearance under 60 mL per minute or
clinically significant elevated serum creatinine), anemia, diabetes mellitus,
electrolyte imbalance, vitamin B deficiency, and debilitating disease may
enhance the occurrence of peripheral neuropathy. Patients receiving long-term
therapy should be monitored periodically for changes in renal function.
</p>

<p>Cases of hemolytic anemia of the primaquine-sensitivity type have been
induced by nitrofurantoin. Hemolysis appears to be linked to a glucose-6-phosphate
dehydrogenase deficiency in the red blood cells of the affected patients.
This deficiency is found in 10 percent of Blacks and a small percentage
of ethnic groups of Mediterranean and Near-Eastern origin. Hemolysis is
an indication for discontinuing Nitrofurantoin(25% macrocrystalline); hemolysis
ceases when the drug is withdrawn. </p>

<p><a name="PRECAUTIONS"></a><b>PRECAUTIONS </b></p>

<p>INFORMATION FOR PATIENTS: Patients should be advised to take Nitrofurantoin(25%
macrocrystalline) with food (ideally breakfast and dinner) to further enhance
tolerance and improve drug absorption. Patients should be instructed to
complete the full course of therapy; however, they should be advised to
contact their physician if any unusual symptoms occur during therapy. </p>

<p>Patients should be advised not to use antacid preparations containing
magnesium trisilicate while taking Nitrofurantoin(25% macrocrystalline).
</p>

<p>DRUG INTERACTIONS: Antacids containing magnesium trisilicate, when administered
concomitantly with nitrofurantoin, reduce both the rate and extent of absorption.
The mechanism for this interaction probably is adsorption of nitrofurantoin
onto the surface of magnesium trisilicate. </p>

<p>Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit
renal tubular secretion of nitrofurantoin. The resulting increase in nitrofurantoin
serum levels may increase toxicity, and the decreased urinary levels could
lessen its efficacy as a urinary tract antibacterial. </p>

<p>DRUG/LABORATORY TEST INTERACTIONS: As a result of the presence of nitrofurantoin,
a false-positive reaction for glucose in the urine may occur. This has
been observed with Benedict's and Fehling's solutions but not with the
glucose enzymatic test. </p>

<p>CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY: Nitrofurantoin
was not carcinogenic when fed to female Holtzman rats for 44.5 weeks or
to female Sprague-Dawley rats for 75 weeks. Two chronic rodent bioassays
utilizing male and female Sprague-Dawley rats and two chronic bioassays
in Swiss mice and in BDF1 mice revealed no evidence of carcinogenicity.
</p>

<p>Nitrofurantoin presented evidence of carcinogenic activity in female
B6C3F1 mice as shown by increased incidences of tubular adenomas, benign
mixed tumors, and granulosa cell tumors of the ovary. In male F344/N rats,
there were increased incidences of uncommon kidney tubular cell neoplasms,
osteosarcomas of the bone, and neoplasms of the subcutaneous tissue. In
one study involving subcutaneous administration of 75 mg/kg nitrofurantoin
to pregnant female mice, lung papillary adenomas of unknown significance
were observed in the F1 generation. </p>

<p>Nitrofurantoin has been shown to induce point mutations in certain strains
of Salmonella Typhimurium and forward mutations in L5178Y mouse lymphoma
cells. Nitrofurantoin induced increased numbers of sister chromatid exchanges
and chromosomal aberrations in Chinese hamster ovary cells but not in human
cells in culture. Results of the sex-linked recessive lethal assay in Drosophila
were negative after administration of nitrofurantoin by feeding or by injection.
Nitrofurantoin did not induce heritable mutation in the rodent models examined.
</p>

<p>The significance of the carcinogenicity and mutagenicity findings relative
to the therapeutic use of nitrofurantoin in humans is unknown. </p>

<p>The administration of high doses of nitrofurantoin to rats causes temporary
spermatogenic arrest; this is reversible on discontinuing the drug. Doses
of 10 mg/kg/day or greater in healthy human males may, in certain unpredictable
instances, produce a slight to moderate spermatogenic arrest with a decrease
in sperm count. </p>

<p>PREGNANCY: </p>

<p>TERATOGENIC EFFECTS: Pregnancy Category B. Several reproduction studies
have been performed in rabbits and rats at doses up to six times the human
dose and have revealed no evidence of impaired fertility or harm to the
fetus due to nitrofurantoin. In a single published study conducted in mice
at 68 times the human dose (based on mg/kg administered to the dam), growth
retardation and a low incidence of minor and common malformations were
observed. However, at 25 times the human dose, fetal malformations were
not observed; the relevance of these findings to humans is uncertain. There
are, however, no adequate and well controlled studies in pregnant women.
Because animal reproduction studies are not always predictive of human
response, this drug should be used during pregnancy only if clearly needed.
</p>

<p>NON-TERATOGENIC EFFECTS: Nitrofurantoin has been shown in one published
transplacental carcinogenicity study to induce lung papillary adenomas
in the F1 generation mice at doses 19 times the human dose on a mg/kg basis.
The relationship of this finding to potential human carcinogenesis is presently
unknown. Because of the uncertainty regarding the human implications of
these animal data, this drug should be used during pregnancy only if clearly
needed. </p>

<p>LABOR AND DELIVERY: See CONTRAINDICATIONS. </p>

<p>NURSING MOTHERS: Nitrofurantoin has been detected in human breast milk
in trace amounts. Because of the potential for serious adverse reactions
from nitrofurantoin in nursing infants under one month of age, a decision
should be made whether to discontinue nursing or to discontinue the drug,
taking into account the importance of the drug to the mother. (See CONTRAINDICATIONS.)
</p>

<p>PEDIATRIC USE: Nitrofurantoin(25% macrocrystalline) is contraindicated
in infants below the age of one month. (See CONTRAINDICATIONS.) Safety
and effectiveness in children below the age of twelve years have not been
established. </p>

<p><a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS </b></p>

<p>Antacids containing magnesium trisilicate, when administered concomitantly
with nitrofurantoin, reduce both the rate and extent of absorption. The
mechanism for this interaction probably is adsorption of nitrofurantoin
onto the surface of magnesium trisilicate. </p>

<p>Uricosuric drugs, such as probenecid and sulfinpyrazone, can inhibit
renal tubular secretion of nitrofurantoin. The resulting increase in nitrofurantoin
serum levels may increase toxicity, and the decreased urinary levels could
lessen its efficacy as a urinary tract antibacterial. </p>

<p>(See Also PRECAUTIONS) </p>

<p><a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS </b></p>

<p>In clinical trials of Nitrofurantoin(25% macrocrystalline), the most
frequent clinical adverse events that were reported as possibly or probably
drug-related were nausea (8%), headache (6%), and flatulence (1.5%). Additional
clinical adverse events reported as possibly or probably drug-related occurred
in less than 1% of patients studied and are listed below within each body
system in order of decreasing frequency: </p>

<p>GASTROINTESTINAL: Diarrhea, dyspepsia, abdominal pain, constipation,
emesis </p>

<p>NEUROLOGIC: Dizziness, drowsiness, amblyopia </p>

<p>RESPIRATORY: Acute pulmonary hypersensitivity reaction (see WARNINGS)
</p>

<p>ALLERGIC: Pruritus, urticaria </p>

<p>DERMATOLOGIC: Alopecia </p>

<p>MISCELLANEOUS: Fever, chills, malaise </p>

<p>The following additional clinical adverse events have been reported
with the use of nitrofurantoin: </p>

<p>GASTROINTESTINAL: Sialadenitis, pancreatitis </p>

<p>NEUROLOGIC: Peripheral neuropathy (including optic neuritis), which
may become severe or irreversible, has occurred. Fatalities have been reported.
Conditions such as renal impairment (creatinine clearance under 60 mL per
minute or clinically significant elevated serum creatinine), anemia, diabetes
mellitus, electrolyte imbalance, vitamin B deficiency, and debilitating
diseases may increase the possibility of peripheral neuropathy. (See WARNINGS.)
</p>

<p>Asthenia, vertigo, and nystagmus also have been reported with the use
of nitrofurantoin. </p>

<p>Benign intracranial hypertension has seldom been reported. </p>

<p>Confusion, depression, euphoria, and psychotic reactions have been reported
rarely. </p>

<p>RESPIRATORY: </p>

<p>CHRONIC, SUBACUTE, OR ACUTE PULMONARY HYPERSENSITIVITY REACTIONS MAY
OCCUR WITH THE USE OF NITROFURANTOIN. </p>

<p>CHRONIC PULMONARY REACTIONS GENERALLY OCCUR IN PATIENTS WHO HAVE RECEIVED
CONTINUOUS TREATMENT FOR SIX MONTHS OR LONGER. MALAISE, DYSPNEA ON EXERTION,
COUGH, AND ALTERED PULMONARY FUNCTION ARE COMMON MANIFESTATIONS WHICH CAN
OCCUR INSIDIOUSLY. RADIOLOGIC AND HISTOLOGIC FINDINGS OF DIFFUSE INTERSTITIAL
PNEUMONITIS OR FIBROSIS, OR BOTH, ARE ALSO COMMON MANIFESTATIONS OF THE
CHRONIC PULMONARY REACTION. FEVER IS RARELY PROMINENT. </p>

<p>THE SEVERITY OF CHRONIC PULMONARY REACTIONS AND THEIR DEGREE OF RESOLUTION
APPEAR TO BE RELATED TO THE DURATION OF THERAPY AFTER THE FIRST CLINICAL
SIGNS APPEAR. PULMONARY FUNCTION MAY BE IMPAIRED PERMANENTLY, EVEN AFTER
CESSATION OF THERAPY. THE RISK IS GREATER WHEN CHRONIC PULMONARY REACTIONS
ARE NOT RECOGNIZED EARLY. </p>

<p>In subacute pulmonary reactions, fever and eosinophilia occur less than
in the acute form. Upon cessation of therapy, recovery may require several
months. If the symptoms are not recognized as being drug-related and nitrofurantoin
therapy is not stopped, the symptoms may become more severe. </p>

<p>Acute pulmonary reactions are commonly manifested by fever, chills,
cough, chest pain, dyspnea, pulmonary infiltration with consolidation or
pleural effusion on x-ray, and eosinophilia. Acute reactions usually occur
within the first week of treatment and are reversible with cessation of
therapy. Resolution often is dramatic. (See WARNINGS.) </p>

<p>Changes in EKG may occur associated with pulmonary reactions. </p>

<p>Collapse and cyanosis have seldom been reported. </p>

<p>HEPATIC: Hepatic reactions, including hepatitis, cholestatic jaundice,
chronic active hepatitis, and hepatic necrosis, occur rarely. (See WARNINGS.)
</p>

<p>ALLERGIC: Lupus-like syndrome associated with pulmonary reaction to
nitrofurantoin has been reported. Also, angioedema; maculopapular, erythematous
or eczematous eruptions; anaphylaxis; arthralgia; myalgia; drug fever;
and chills have been reported. </p>

<p>DERMATOLOGIC: Exfoliative dermatitis and erythema multiforme (including
Stevens-Johnson Syndrome) have been reported rarely. </p>

<p>MISCELLANEOUS: As with other antimicrobial agents, superinfections with
resistant organisms, E.g., Pseudomonas species or Candida species, may
occur with the use of nitrofurantoin. Superinfections have been limited
to the genitourinary tract. </p>

<p>In clinical trials of Nitrofurantoin(25% macrocrystalline), the most
frequent laboratory adverse events (1- 5%), without regard to drug relationship,
were as follows: eosinophilia, increased AST (SGOT), increased ALT (SGPT),
decreased hemoglobin, increased serum phosphorus. The following laboratory
adverse events also have been reported with the use of nitrofurantoin:
glucose-6-phosphate dehydrogenase deficiency anemia (see WARNINGS), agranulocytosis,
leukopenia, granulocytopenia hemolytic anemia, thrombocytopenia, megaloblastic
anemia. In most cases, these hematologic abnormalities resolved following
cessation of therapy. Aplastic anemia has been reported rarely. </p>

<p><a name="OVERDOSAGE"></a><b>OVERDOSAGE </b></p>

<p>Occasional incidents of acute overdosage of nitrofurantoin have not
resulted in any specific symptoms other than vomiting. Induction of emesis
is recommended. There is no specific antidote, but a high fluid intake
should be maintained to promote urinary excretion of the drug. Nitrofurantoin
is dialyzable. </p>

<p><a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION
</b></p>

<p>Nitrofurantoin(25% macrocrystalline) capsules should be taken with food.
</p>

<p>ADULTS AND CHILDREN OVER 12 YEARS: One 100-mg capsule every 12 hours
for seven days. </p>

<p>CLINICAL STUDIES </p>

<p>Controlled clinical trials comparing Nitrofurantoin(25% macrocrystalline)
100 mg p.o. q12h and Nitrofurantoin (100% macrocrystalline) 50 mg p.o.
q6h in the treatment of acute uncomplicated urinary tract infections demonstrated
approximately 75% microbiologic eradication of susceptible pathogens in
each treatment group. </p>

<p>REFERENCES </p>

<p>1. National Committee for Clinical Laboratory Standards. Performance
Standards for Antimicrobial Disk Susceptibility Tests--Fourth Edition.
Approved Standard NCCLS Document M2-A4, Vol. 10, No. 7, NCCLS, Villanova,
PA, 1990. </p>

<p>2. National Committee for Clinical Laboratory Standards. Methods for
Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically--Second
Edition. Approved Standard NCCLS Document M7-A2, Vol. 10, No. 8, NCCLS,
Villanova, PA, 1990. </p>

<p>
<hr width="100%" ></p>

<h2 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-22</DOCNO>
<DOCOLDNO>IA019-000201-B023-336</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/rxlist.cgi??drug=dexadrine 206.86.175.201 19970106234217 text/html 35331
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:35:58 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE>www.rxlist.com - Neil Sandow, Pharm.D. 
copyright 1995</title></head> <body bgcolor="#ffffff">
<center><a href="http://www.rxlist.com"><img src="rx.gif" 
height=75 width=75 border=0><img src="count.gif" border=0></a></center> 
Searching for: <b></b> <br>scroll down for results 
<hr><hr>
<h1>Enter Brand or Generic Name or Category*</h1>
<h3> Narrow Your Search with <font size=5>*</font>(examples: 
ampi*, *mycin, antibiotic*)</h3>
<form method=get>
<action=>
<input size=30 maxlength=30 name=drug>
<input type=submit>
<input type=reset>
</form>
<HR>
<H3>Your RxList Search Results:</h3>
1<br><b>Brand Name: </b>DIASTAT<br><b>Generic Name: </b>DIAZEPAM RECTAL GEL<br><b>Category: </b>TREATMENT OF SEVERE EPILEPSY
<p>2<br><b>Brand Name: </b>EDEX<br><b>Generic Name: </b>ALPROSTADIL<br><b>Category: </b>TREATMENT OF ERECTILE DYSFUNCTION
<p>3<br><b>Brand Name: </b>GABITRIL<br><b>Generic Name: </b>TIAGABINE<br><b>Category: </b>ANTICONVULSANTS
<p>4<br><b>Brand Name: </b>URSO<br><b>Generic Name: </b>URSODEOXYCHOLIC ACID<br><b>Category: </b>TREATMENT OF PRIMARY BILIARY CIRRHOSIS
<p>5<br><b>Brand Name: </b>LIPITOR<br><b>Generic Name: </b>ATORVASTATIN<br><b>Category: </b>ANTILIPEMIC AGENTS
<p>6<br><b>Brand Name: </b>ZYFLO<br><b>Generic Name: </b>ZILEUTON<br><b>Category: </b>LEUKOTRIENE RECEPTOR ANTAGONIST (LTRA) FOR TREATMENT OF ASTHMA
<p>7<br><b>Brand Name: </b>FEMPATCH<br><b>Generic Name: </b>17-BETA ESTRADIOL (TRANSDERMAL)<br><b>Category: </b>ESTROGENS
<p>8<br><b>Brand Name: </b>DOSTINEX<br><b>Generic Name: </b>CABERGOLINE<br><b>Category: </b>TREATMENT OF HYPERPROLACTINEMIC DISORDERS
<p>9<br><b>Brand Name: </b>THERDERM EMTDS<br><b>Generic Name: </b>ESTRADIOL (TRANSDERMAL)<br><b>Category: </b>ESTROGENS
<p>10<br><b>Brand Name: </b>ELEQUIN<br><b>Generic Name: </b>LEVOFLOXACIN (INJ)<br><b>Category: </b>QUINOLINE ANTIBIOTICS
<p>11<br><b>Brand Name: </b>COPAXONE<br><b>Generic Name: </b>COPOLYMER-1 (INJ)<br><b>Category: </b>TREATMENT OF MULTIPLE SCLEROSIS
<p>12<br><b>Brand Name: </b>MONUROL<br><b>Generic Name: </b>FOSFOMYCIN TROMETHANE<br><b>Category: </b>TREATMENT OF UTI'S
<p>13<br><b>Brand Name: </b>OPATANOL<br><b>Generic Name: </b>OLOPATADINE HCL<br><b>Category: </b>TREATMENT OF ALLERGIC CONJUNCTIVITIS
<p>14<br><b>Brand Name: </b>GLYSET<br><b>Generic Name: </b>MIGLITOL<br><b>Category: </b>ANTIDIABETIC AGENTS
<p>15<br><b>Brand Name: </b>ZAGAM<br><b>Generic Name: </b>SPARFLOXACIN<br><b>Category: </b>QUINOLINE ANTIBIOTICS
<p>16<br><b>Brand Name: </b>ALORA<br><b>Generic Name: </b>ESTRADIOL TRANSDERMAL<br><b>Category: </b>ESTROGENS
<p>17<br><b>Brand Name: </b>LEVAQUIN<br><b>Generic Name: </b>LEVOFLOXACIN<br><b>Category: </b>QUINOLINE ANTIBIOTICS
<p>18<br><b>Brand Name: </b>APHTHASOL<br><b>Generic Name: </b>AMLEXANOX<br><b>Category: </b>TREATMENT OF APHTHOUS ULCERS
<p>19<br><b>Brand Name: </b>LOTREL<br><b>Generic Name: </b>AMLODIPINE/BENAZEPRIL HCL<br><b>Category: </b>SEE AMLODIPINE AND/OR BENAZEPRIL
<p>20<br><b>Brand Name: </b>ERGOMAR<br><b>Generic Name: </b>ERGOTAMINE TARTRATE<br><b>Category: </b>SYMPATHOLYTIC AGENTS
<p>21<br><b>Brand Name: </b>ERGOSTAT<br><b>Generic Name: </b>ERGOTAMINE TARTRATE<br><b>Category: </b>SYMPATHOLYTIC AGENTS
<p>22<br><b>Brand Name: </b>REZULIN<br><b>Generic Name: </b>TROGLITAZONE<br><b>Category: </b>ANTIDIABETIC AGENTS
<p>23<br><b>Brand Name: </b>MERIDIA<br><b>Generic Name: </b>SIBUTRAMINE HCL<br><b>Category: </b>ANTIDEPRESSANT/ANTIOBESITY
<p>24<br><b>Brand Name: </b>NORMIFLO<br><b>Generic Name: </b>ARDEPARIN SODIUM<br><b>Category: </b>ANTICOAGULANT
<p>25<br><b>Brand Name: </b>FERRISELTZ<br><b>Generic Name: </b>FERRIC AMMONIUM CITRATE<br><b>Category: </b>BOWEL CONTRAST AGENT FOR MRI
<p>26<br><b>Brand Name: </b>LEXXEL<br><b>Generic Name: </b>ENALAPRIL MALEATE/FELODIPINE<br><b>Category: </b>ANTIHYPERTENSIVES
<p>27<br><b>Brand Name: </b>ARICEPT<br><b>Generic Name: </b>DONEPEXIL HCL<br><b>Category: </b>TREATMENT OF ALZHEIMER'S DISEASE
<p>28<br><b>Brand Name: </b>E2020<br><b>Generic Name: </b>DONEPEXIL HCL<br><b>Category: </b>TREATMENT OF ALZHEIMER'S DISEASE
<p>29<br><b>Brand Name: </b>AMPHOTEC<br><b>Generic Name: </b>AMPHOTERICIN B CHOLESTERYL SULFATE COMPLEX<br><b>Category: </b>ANTIFUNGALS
<p>30<br><b>Brand Name: </b>MUSE<br><b>Generic Name: </b>ALPROSTADIL<br><b>Category: </b>TREATMENT OF IMPOTENCE
<p>31<br><b>Brand Name: </b>MECTIZAN<br><b>Generic Name: </b>IVERMECTIN<br><b>Category: </b>TREATMENT OF STRONGYLOIDES/ONCHOCERCIASIS
<p>32<br><b>Brand Name: </b>NASCOBAL<br><b>Generic Name: </b>CYANOCOBALAMIN<br><b>Category: </b>VITAMIN B COMPLEX
<p>33<br><b>Brand Name: </b>NIX<br><b>Generic Name: </b>PERMETHRIN<br><b>Category: </b>ERADICATION/PROPHYLAXIS OF HEAD LICE
<p>34<br><b>Brand Name: </b>SR-2599DC<br><b>Generic Name: </b>CLOPIDOGREL<br><b>Category: </b>ORAL ANTITHROMBIC AGENT (INVESTIGATIONAL)
<p>35<br><b>Brand Name: </b>GUAIFENESIN<br><b>Generic Name: </b>GUAIFENESIN<br><b>Category: </b>SEE <a href="http://www.rxlist.com/cgi/generic/guaicod.htm">GUAIFENESIN & CODEINE</a>
<p>36<br><b>Brand Name: </b>GUAIFENESIN<br><b>Generic Name: </b>GUAIFENESIN<br><b>Category: </b>SEE <a href="http://www.rxlist.com/cgi/generic/guaiphen.htm">GUAIFENESIN & PHENYLPROPANOLAMINE</a>
<p>37<br><b>Brand Name: </b>SYNERCID (RP 59500)<br><b>Generic Name: </b>QUINUPRISTIN/DALFOPRISTIN<br><b>Category: </b>ANTIBIOTICS (INVESTIGATIONAL)
<p>38<br><b>Brand Name: </b>DENAVIR<br><b>Generic Name: </b>PENCICLOVIR<br><b>Category: </b>ANTIVIRALS
<p>39<br><b>Brand Name: </b>FERTINEX<br><b>Generic Name: </b>FOLLICLE STIMULATING HORMONE (FSH)<br><b>Category: </b>HORMONES
<p>40<br><b>Brand Name: </b>FERTINEX<br><b>Generic Name: </b>FSH<br><b>Category: </b>HORMONES
<p>41<br><b>Brand Name: </b>COPAXONE<br><b>Generic Name: </b>COPOLYMER 1<br><b>Category: </b>TREATMENT OF M.S.
<p>42<br><b>Brand Name: </b>VIRACEPT<br><b>Generic Name: </b>NELFINAVIR<br><b>Category: </b>ANTIVIRALS
<p>43<br><b>Brand Name: </b>ERGOSET<br><b>Generic Name: </b>BROMOCRIPTINE<br><b>Category: </b>UNCLASSIFIED THERAPEUTIC AGENTS
<p>44<br><b>Brand Name: </b>SORIATANE<br><b>Generic Name: </b>ACITRETIN<br><b>Category: </b>TREATMENT OF PSORIASIS
<p>45<br><b>Brand Name: </b>ASTELIN<br><b>Generic Name: </b>AZELASTINE<br><b>Category: </b>ANTIHISTAMINES
<p>46<br><b>Brand Name: </b>RETAVASE<br><b>Generic Name: </b>RETEPLASE<br><b>Category: </b>THROMBOLYTICS
<p>47<br><b>Brand Name: </b>SAIZEN<br><b>Generic Name: </b>SOMATROPIN<br><b>Category: </b>PITUITARY
<p>48<br><b>Brand Name: </b>ESTROSTEP<br><b>Generic Name: </b>ETHINYL ESTRADIOL/NORETHINDRONE<br><b>Category: </b>CONTRACEPTIVES
<p>49<br><b>Brand Name: </b>LODINE XL<br><b>Generic Name: </b>ETODOLAC<br><b>Category: </b>NONSTEROIDAL ANTIINFLAMMATORY AGENTS
<p>50<br><b>Brand Name: </b>CYSTADANE<br><b>Generic Name: </b>BETAINE<br><b>Category: </b>TREATMENT OF HOMOCYSTINUREAL
<p>51<br><b>Brand Name: </b>COMBIVENT<br><b>Generic Name: </b>ALBUTEROL/IPRATROPIUM<br><b>Category: </b>BRONCHODILATORS
<p>52<br><b>Brand Name: </b>TARKA<br><b>Generic Name: </b>TRANDOLAPRIL/VERAPAMIL<br><b>Category: </b>ANTIHYPERTENSIVES
<p>53<br><b>Brand Name: </b>MENTAX<br><b>Generic Name: </b>BUTENAFINE HCL<br><b>Category: </b>ANTIFUNGALS
<p>54<br><b>Brand Name: </b>TIAMATE<br><b>Generic Name: </b>DILTIAZEM<br><b>Category: </b>ANTIHYPERTENSIVES
<p>55<br><b>Brand Name: </b>DURACLON<br><b>Generic Name: </b>CLONIDINE HCL<br><b>Category: </b>EPIDURAL ADJUNCT TO OPIATE THERAPY
<p>56<br><b>Brand Name: </b><a href="http://www.lec.org/DrugSearch/Documents/Rohypnol.html">ROHYPNOL</a><br><b>Generic Name: </b>FLUNITRAZEPAM<br><b>Category: </b>MISC. SEDATIVES/HYPNOTICS (NOTE: NOT MARKETED IN THE US)
<p>57<br><b>Brand Name: </b>KADIAN<br><b>Generic Name: </b>MORPHINE SULFATE SA<br><b>Category: </b>OPIATE AGONISTS
<p>58<br><b>Brand Name: </b>COCAINE<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/cocaine.htm">COCAINE HCL</a><br><b>Category: </b>ANTIPRURITICS AND LOCAL ANESTHETICS
<p>59<br><b>Brand Name: </b>TECZEM<br><b>Generic Name: </b>ENALAPRIL MALEATE & DILTIAZEM MALEATE<br><b>Category: </b>ANTIHYPERTENSIVES
<p>60<br><b>Brand Name: </b>TICLID<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/ticlop.htm">TICLOPIDINE HCL</a><br><b>Category: </b>PLATELET AGGREGATION INHIBITORS
<p>61<br><b>Brand Name: </b>PARACETAMOL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">SEE ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>62<br><b>Brand Name: </b>DHEA<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/dhea.htm">DEHYDROEPIANDROSTERONE</a><br><b>Category: </b>UNAPPROVED
<p>63<br><b>Brand Name: </b>ANTIBIOTIC<br><b>Generic Name: </b>TYPE ANTIBIOT*<br><b>Category: </b>USE * TO SORT ON CATEGORY
<p>64<br><b>Brand Name: </b>NILANDRON<br><b>Generic Name: </b>NILUTAMIDE<br><b>Category: </b>ANTIANDROGENS
<p>65<br><b>Brand Name: </b>PONDIMIN<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/fenflur.htm">FENFLURAMINE HCL</a><br><b>Category: </b>APPETITE SUPPRESSANT
<p>66<br><b>Brand Name: </b>ALPHAGAN<br><b>Generic Name: </b>BRIMONIDINE TARTRATE<br><b>Category: </b>MISCELLANEOUS EENT AGENTS (GLAUCOMA)
<p>67<br><b>Brand Name: </b>FERTINEX<br><b>Generic Name: </b>UROFOLLITROPIN<br><b>Category: </b>FOLLICLE STIMULATING HORMONE
<p>68<br><b>Brand Name: </b>IVY BLOCK<br><b>Generic Name: </b>URUSHIOL<br><b>Category: </b>MISCEL.SKIN AND MUCUS MEMBRANE AGENTS
<p>69<br><b>Brand Name: </b>ZENTATE<br><b>Generic Name: </b>VITAMINS PRENATAL<br><b>Category: </b>MULTIVITAMIN PREPARATIONS
<p>70<br><b>Brand Name: </b>ETOPOPHOS<br><b>Generic Name: </b>ETOPOSIDE PHOSPHATE<br><b>Category: </b>ANTINEOPLASTICS
<p>71<br><b>Brand Name: </b>SEROSTIM<br><b>Generic Name: </b>SOMATOTROPIN<br><b>Category: </b>PITUITARY
<p>72<br><b>Brand Name: </b>ZYPREXA<br><b>Generic Name: </b>OLANZAPINE<br><b>Category: </b>ANTIPSYCHOTICS
<p>73<br><b>Brand Name: </b>HURRICAINE<br><b>Generic Name: </b>BENZOCAINE<br><b>Category: </b>LOCAL ANESTHETICS
<p>74<br><b>Brand Name: </b>HURRICAINE<br><b>Generic Name: </b>BENZOCAINE<br><b>Category: </b>ANTIPRURITICS AND LOCAL ANESTHETICS
<p>75<br><b>Brand Name: </b>MERREM I.V.<br><b>Generic Name: </b>MEROPENEM<br><b>Category: </b>MISCELLANEOUS ANTIBIOTICS
<p>76<br><b>Brand Name: </b>PROAMATINE<br><b>Generic Name: </b>MIDODRINE<br><b>Category: </b>TREATMENT OF ORTHOSTATIC HYPERTENSION
<p>77<br><b>Brand Name: </b>RU-486<br><b>Generic Name: </b>MIFEPRISTONE<br><b>Category: </b>TERMINATION OF PREGNANCY
<p>78<br><b>Brand Name: </b>ALBENZA<br><b>Generic Name: </b>ALBENDAZOLE<br><b>Category: </b>ANTHELMINTICS
<p>79<br><b>Brand Name: </b>DIFFERIN<br><b>Generic Name: </b>ADAPALENE<br><b>Category: </b>MISCEL.SKIN AND MUCUS MEMBRANE AGENTS
<p>80<br><b>Brand Name: </b>CARBEX<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/seleg.htm">SELEGILINE HCL</a><br><b>Category: </b>FOR PARKINSON'S DISEASE
<p>81<br><b>Brand Name: </b>HELIDAC<br><b>Generic Name: </b>BISMUTH SUBSAL. METRONIDAZOLE & TETRACYCLINE<br><b>Category: </b>FOR PEPTIC ULCER DISEASE
<p>82<br><b>Brand Name: </b>TRITEC<br><b>Generic Name: </b>RANITIDINE BISMUTH CITRATE<br><b>Category: </b>MISCELLANEOUS GI DRUGS
<p>83<br><b>Brand Name: </b>CEREBYX<br><b>Generic Name: </b>FOSPHENYTOIN SODIUM<br><b>Category: </b>HYDANTOINS
<p>84<br><b>Brand Name: </b>ALLEGRA<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/fexofen.htm">FEXOFENADINE</a><br><b>Category: </b>ANTIHISTAMINES
<p>85<br><b>Brand Name: </b>CAMPTOSAR<br><b>Generic Name: </b>IRINOTECAN HCL<br><b>Category: </b>ANTINEOPLASTICS
<p>86<br><b>Brand Name: </b>XALATAN<br><b>Generic Name: </b>LATANOPROST<br><b>Category: </b>GLAUCOMA THERAPY
<p>87<br><b>Brand Name: </b>REMERON<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/mirtaz.htm">MIRTAZAPINE</a><br><b>Category: </b>ANTIDEPRESSANTS
<p>88<br><b>Brand Name: </b>VIRAMUNE<br><b>Generic Name: </b>NEVIRAPINE<br><b>Category: </b>ANIVIRALS
<p>89<br><b>Brand Name: </b>MYOTROPHIN<br><b>Generic Name: </b>SOMATOMEDIN C<br><b>Category: </b>FOR AMYOTROPHIC LATERAL SCLEROSIS
<p>90<br><b>Brand Name: </b>HUMULIN N<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/humnph.htm">HUMAN INSULIN NPH</a> <br><b>Category: </b>INSULINS
<p>91<br><b>Brand Name: </b>HUMULIN R<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/huminsr.htm">HUMAN INSULIN REGULAR</a><br><b>Category: </b>INSULINS
<p>92<br><b>Brand Name: </b>HUMULIN L<br><b>Generic Name: </b>HUMAN INSULIN LENTE<br><b>Category: </b>INSULINS
<p>93<br><b>Brand Name: </b>HUMULIN 70/30<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/hum7030.htm">HUMAN INSULIN NPH/REG 70/30</a><br><b>Category: </b>INULINS
<p>94<br><b>Brand Name: </b>ORTHO-NOVUM 7/7/7<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/norestoc.htm">NORETHINDRONE/ETHINYL ESTRADIOL</a> <br><b>Category: </b>CONTRACEPTIVES
<p>95<br><b>Brand Name: </b>ORTHO-CEPT<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/desest.htm">DESOGESTREL/ETHINYLESTRADIOL</A><br><b>Category: </b>CONTRACEPTIVES
<p>96<br><b>Brand Name: </b>ACCUPRIL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/quinap.htm">QUINAPRIL HCL</a><br><b>Category: </b>HYPOTENSIVE AGENTS
<p>97<br><b>Brand Name: </b>ACTHREL<br><b>Generic Name: </b>CORTICORELIN OVINE TRIFLUTATE<br><b>Category: </b>DIAGNOSTIC AGENTS
<p>98<br><b>Brand Name: </b>BUPHENYL<br><b>Generic Name: </b>SODIUM PHENYLBUTYRATE<br><b>Category: </b>FOR UREA CYCLE DISORDERS
<p>99<br><b>Brand Name: </b>VISIPAQUE<br><b>Generic Name: </b>IODIXANOL<br><b>Category: </b>ROENTGENOGRAPHY
<p>100<br><b>Brand Name: </b>NAPRELAN<br><b>Generic Name: </b>NAPROXEN SODIUM<br><b>Category: </b>NONSTEROIDAL ANTIINFLAMMATORY AGENTS
<p>101<br><b>Brand Name: </b>OXILAN<br><b>Generic Name: </b>IOXILAN<br><b>Category: </b>ROENTGENOGRAPHY
<p>102<br><b>Brand Name: </b>IONTOCAINE<br><b>Generic Name: </b>LIDOCAINE/EPINEPHRINE<br><b>Category: </b>LOCAL ANESTHETICS
<p>103<br><b>Brand Name: </b>PENTACEF<br><b>Generic Name: </b>CEFTAZIDINE<br><b>Category: </b>ANTIBIOTICS: CEPHALOSPORINS
<p>104<br><b>Brand Name: </b>METROCREAM<br><b>Generic Name: </b>METRONIDAZOLE<br><b>Category: </b>MISCELLANEOUS ANTI-INFECTIVES
<p>105<br><b>Brand Name: </b>GENOTROPIN<br><b>Generic Name: </b>SOMATROPIN<br><b>Category: </b>PITUITARY
<p>106<br><b>Brand Name: </b>SEVORANE<br><b>Generic Name: </b>SEVOFLURANE<br><b>Category: </b>GENERAL ANESTHETICS
<p>107<br><b>Brand Name: </b>BIOTROPIN<br><b>Generic Name: </b>SOMATROPIN<br><b>Category: </b>PITUITARY
<p>108<br><b>Brand Name: </b>ULTRAVIST<br><b>Generic Name: </b>IOPROMIDE<br><b>Category: </b>ROENTGENOGRAPHY
<p>109<br><b>Brand Name: </b>NORDITROPIN<br><b>Generic Name: </b>SOMATROPIN<br><b>Category: </b>PITUITARY
<p>110<br><b>Brand Name: </b>PROVEL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/ibup.htm">IBUPROFEN</A><br><b>Category: </b>NONSTEROIDAL ANTIINFLAMMATORY AGENTS
<p>111<br><b>Brand Name: </b>NISOCOR<br><b>Generic Name: </b>NISOLDIPINE<br><b>Category: </b>CARDIAC DRUGS
<p>112<br><b>Brand Name: </b>APTHASOL<br><b>Generic Name: </b>AMLEXANOX<br><b>Category: </b>TREATMENT OF CANKER SORES
<p>113<br><b>Brand Name: </b>ALPHANATE<br><b>Generic Name: </b>ANTIHEMOPHILIC FACTOR<br><b>Category: </b>HEMOSTATICS
<p>114<br><b>Brand Name: </b>OXYCONTIN<br><b>Generic Name: </b>OXYCODONE HCL<br><b>Category: </b>OPIATE AGONISTS
<p>115<br><b>Brand Name: </b>HYCAMTIN<br><b>Generic Name: </b>TOPOTECAN<br><b>Category: </b>ANTINEOPLASTICS
<p>116<br><b>Brand Name: </b>OXANDRIN<br><b>Generic Name: </b>OXANDROLONE<br><b>Category: </b>ANDROGENS
<p>117<br><b>Brand Name: </b>WINRHO SD<br><b>Generic Name: </b>RHO(D)IMMUNE GLOBULIN<br><b>Category: </b>SERUMS
<p>118<br><b>Brand Name: </b>AVONEX<br><b>Generic Name: </b>INTERFERON BETA-1A<br><b>Category: </b>TREATMENT OF MULTIPLE SCLEROSIS
<p>119<br><b>Brand Name: </b>GEMZAR<br><b>Generic Name: </b>GEMCITABINE HCL<br><b>Category: </b>ANTINEOPLASTICS
<p>120<br><b>Brand Name: </b>DEXFERRUM<br><b>Generic Name: </b>IRON DEXTRAN<br><b>Category: </b>IRON PRODUCTS
<p>121<br><b>Brand Name: </b>CORMAX<br><b>Generic Name: </b>CLOBETASOL PROPIONATE<br><b>Category: </b>ANTI-INFLAMMATORY AGENTS
<p>122<br><b>Brand Name: </b>VITRASERT<br><b>Generic Name: </b>GANCICLOVIR<br><b>Category: </b>ANTIVIRALS
<p>123<br><b>Brand Name: </b>CYTOVENE<br><b>Generic Name: </b>GANCICLOVIR<br><b>Category: </b>ANTIVIRALS
<p>124<br><b>Brand Name: </b>HUMALOG<br><b>Generic Name: </b>INSULIN LISPRO<br><b>Category: </b>INSULINS
<p>125<br><b>Brand Name: </b>DAUNOXOME<br><b>Generic Name: </b>DAUNORUBICIN CITRATE (LIPOSOME)<br><b>Category: </b>ANTINEOPLASTICS
<p>126<br><b>Brand Name: </b>ESTRING<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/estrad.htm">ESTRADIOL</A><br><b>Category: </b>ESTROGENS
<p>127<br><b>Brand Name: </b>ARIMEDEX<br><b>Generic Name: </b>ANASTROZOLE<br><b>Category: </b>ANTINEOPLASTICS
<p>128<br><b>Brand Name: </b>VISTIDE<br><b>Generic Name: </b>CIDOFOVIR<br><b>Category: </b>ANTIVIRALS
<p>129<br><b>Brand Name: </b>NICOTROL NS<br><b>Generic Name: </b>NICOTINE(NASAL)<br><b>Category: </b>MISCELLANEOUS AUTONOMIC DRUGS 
<p>130<br><b>Brand Name: </b>VIQUIN FORTE<br><b>Generic Name: </b>HYDROQUINONE<br><b>Category: </b>DEPIGMENTING AGENTS
<p>131<br><b>Brand Name: </b>REDUX<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/dexfen.htm">DEXFENFLURAMINE</a><br><b>Category: </b>ANTI-OBESITY AGENTS
<p>132<br><b>Brand Name: </b>ZANAFLEX<br><b>Generic Name: </b>TIZANIDINE HCL<br><b>Category: </b>SKELETAL MUSCLE RELAXANTS
<p>133<br><b>Brand Name: </b>PREVALITE<br><b>Generic Name: </b>CHOLESTYRAMINE<br><b>Category: </b>ANTILIPEMIC AGENTS
<p>134<br><b>Brand Name: </b>FERIDEX<br><b>Generic Name: </b>FERUMOXIDE<br><b>Category: </b>MAGNETIC RESONANCE IMAGING
<p>135<br><b>Brand Name: </b>MAVIK<br><b>Generic Name: </b>TRANDOLAPRIL<br><b>Category: </b><a href="http://www.rxlist.com/cardiova.htm">HYPOTENSIVE AGENTS</a> 
<p>136<br><b>Brand Name: </b>NAROPIN<br><b>Generic Name: </b>ROPIVACAINE<br><b>Category: </b>LOCAL ANESTHETICS
<p>137<br><b>Brand Name: </b>SCLEROSOL<br><b>Generic Name: </b>TALC<br><b>Category: </b>SCLEROSING AGENTS
<p>138<br><b>Brand Name: </b>TOPAMAX<br><b>Generic Name: </b>TOPIRAMATE<br><b>Category: </b>MISCELLANEOUS ANTICONVULSANTS
<p>139<br><b>Brand Name: </b>VAQTA<br><b>Generic Name: </b>HEPATITIS A VACCINE<br><b>Category: </b>VACCINES
<p>140<br><b>Brand Name: </b>MYOVIEW<br><b>Generic Name: </b>TETROPHOSMIN<br><b>Category: </b>RADIOPHARMACEUTICALS
<p>141<br><b>Brand Name: </b>OCUHIST<br><b>Generic Name: </b>PHENIRAMINE MALEATE<br><b>Category: </b>ANTIHISTAMINE DRUGS
<p>142<br><b>Brand Name: </b>COVERA-HS<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/verapsr.htm">VERAPAMIL</A> HCL<br><b>Category: </b><a href="http://www.rxlist.com/cardiova.htm">CARDIAC DRUGS</a> 
<p>143<br><b>Brand Name: </b>SYNOVIR<br><b>Generic Name: </b>THALIDOMIDE<br><b>Category: </b>AIDS-CACHEXIA
<p>144<br><b>Brand Name: </b>VESANOID<br><b>Generic Name: </b>TRETINOIN<br><b>Category: </b>ANTINEOPLASTIC AGENTS
<p>145<br><b>Brand Name: </b>TEICHOMYCIN<br><b>Generic Name: </b>TEICOPLANIN<br><b>Category: </b>MISCELLANEOUS ANTIBIOTICS
<p>146<br><b>Brand Name: </b>NORVIR<br><b>Generic Name: </b>RITONAVIR<br><b>Category: </b>ANTIVIRALS
<p>147<br><b>Brand Name: </b>NIMBEX<br><b>Generic Name: </b>CISATRACURIUM BESYLATE<br><b>Category: </b>SKELETAL MUSCLE RELAXANTS
<p>148<br><b>Brand Name: </b>MAXIPIME<br><b>Generic Name: </b>CEFEPIME<br><b>Category: </b>ANTIBIOTICS: CEPHALOSPORINS
<p>149<br><b>Brand Name: </b>PENNSAID<br><b>Generic Name: </b>DIMETHAID-D<br><b>Category: </b><a href="http://www.rxlist.com/nsaid.htm">NONSTEROIDAL ANTI-INFLAMMATORY AGENTS</a> 
<p>150<br><b>Brand Name: </b>ADDERALL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/amphet.htm">AMPHETAMINE MIXED SALTS</a><br><b>Category: </b>RESPIRATORY AND CEREBRAL STIMULANTS
<p>151<br><b>Brand Name: </b>CANDIN<br><b>Generic Name: </b>CANDIDA ALBICANS<br><b>Category: </b>FUNGI
<p>152<br><b>Brand Name: </b>ACTRON<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/ketoprof.htm">KETOPROFEN</a><br><b>Category: </b><a href="http://www.rxlist.com/nsaid.htm">NONSTEROIDAL ANTIINFLAMMATORY AGENTS</a> 
<p>153<br><b>Brand Name: </b>CEDAX<br><b>Generic Name: </b>CEFTIBUTEN<br><b>Category: </b>ANTIBIOTICS:CEPHALOSPORINS
<p>154<br><b>Brand Name: </b>RENOVA<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/tretinoin.htm">TRETINOIN</a><br><b>Category: </b>MISCEL.SKIN AND MUCUS MEMBRANE AGENTS
<p>155<br><b>Brand Name: </b>PHOTOFRIN<br><b>Generic Name: </b>PORFIMER SODIUM<br><b>Category: </b>ANTINEOPLASTIC AGENTS (PHOTODYNAMIC)
<p>156<br><b>Brand Name: </b>AMARYL<br><b>Generic Name: </b>GLIMEPIRIDE<br><b>Category: </b>ANTIDIABETIC AGENTS
<p>157<br><b>Brand Name: </b>FLOLAN<br><b>Generic Name: </b>EPOPROSTENOL SODIUM<br><b>Category: </b>VASODILATING AGENTS
<p>158<br><b>Brand Name: </b>RESPIGAM<br><b>Generic Name: </b>RSV-IGIV<br><b>Category: </b>SERUMS
<p>159<br><b>Brand Name: </b>CRIXIVAN<br><b>Generic Name: </b>INDINAVIR SULFATE<br><b>Category: </b>ANTIVIRALS
<p>160<br><b>Brand Name: </b>TRIPEDIA<br><b>Generic Name: </b>WHOOPING COUGH VACCINE<br><b>Category: </b>VACCINES
<p>161<br><b>Brand Name: </b>PROCANABID<br><b>Generic Name: </b>PROCAINAMIDE HCL<br><b>Category: </b>CARDIAC DRUGS
<p>162<br><b>Brand Name: </b>ZYRTEC<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/cetiriz.htm">CETIRIZINE HCL</a><br><b>Category: </b>ANTIHISTAMINE DRUGS
<p>163<br><b>Brand Name: </b>VIVELLE<br><b>Generic Name: </b>ESTRADIOL (TRANSDERMAL SYSTEM)<br><b>Category: </b>ESTROGEN
<p>164<br><b>Brand Name: </b>AZELEX<br><b>Generic Name: </b>ACELAIC ACID<br><b>Category: </b>SKIN AND MUCUS MEMBRANE AGENTS
<p>165<br><b>Brand Name: </b>ETHYOL<br><b>Generic Name: </b>AMIFOSTINE<br><b>Category: </b>UNCLASSIFIED THERAPEUTIC AGENTS
<p>166<br><b>Brand Name: </b>DOXIL<br><b>Generic Name: </b> DOXORUBICIN HCL (LIPOSOME INJECTION)<br><b>Category: </b>ANTIONEOPLASTIC AGENTS
<p>167<br><b>Brand Name: </b>ABELCET<br><b>Generic Name: </b>ABCL(AMPHOTERICIN B LIPID COMPLEX LIPOSOME INJ)<br><b>Category: </b>ANTIFUNGALS
<p>168<br><b>Brand Name: </b>PRECOSE<br><b>Generic Name: </b>ACARBOSE<br><b>Category: </b>ANTIDIABETIC AGENTS
<p>169<br><b>Brand Name: </b>RILUTEK<br><b>Generic Name: </b>RILUZOLE<br><b>Category: </b>FOR AMYOTROPHIC LATERAL SCLEROSIS
<p>170<br><b>Brand Name: </b>VALTREX<br><b>Generic Name: </b>VALACYCLOVIR<br><b>Category: </b>ANIVIRALS
<p>171<br><b>Brand Name: </b>FLOVENT<br><b>Generic Name: </b>FLUTICASONE PROPRIONATE<br><b>Category: </b>ANTIINFLAMMATORY AGENTS
<p>172<br><b>Brand Name: </b>DYNABAC<br><b>Generic Name: </b>DIRITHROMYCIN<br><b>Category: </b>ANTIBIOTICS:ERYTHROMYCINS
<p>173<br><b>Brand Name: </b>CORVERT<br><b>Generic Name: </b>IBUTILIDE<br><b>Category: </b>CARDIAC DRUGS
<p>174<br><b>Brand Name: </b>FARESTON<br><b>Generic Name: </b>TOREMIFENE CITRATE<br><b>Category: </b>ANTINEOPLASTIC AGENTS
<p>175<br><b>Brand Name: </b>COREG<br><b>Generic Name: </b>CARDEDILOL<br><b>Category: </b>CARDIAC DRUGS
<p>176<br><b>Brand Name: </b>TAXOTERE<br><b>Generic Name: </b>DOCETAXEL<br><b>Category: </b>ANTINEOPLASTIC AGENTS
<p>177<br><b>Brand Name: </b>BUTOX<br><b>Generic Name: </b>BOTULINUM TOXIN TYPE A<br><b>Category: </b>TOXOIDS
<p>178<br><b>Brand Name: </b>SULAR<br><b>Generic Name: </b>NISOLDIPINE<br><b>Category: </b>CARDIAC DRUGS
<p>179<br><b>Brand Name: </b>BLEO<br><b>Generic Name: </b>BLEOMYCIN<br><b>Category: </b>ANTINEOPLASTIC AGENTS
<p>180<br><b>Brand Name: </b>BLEOCIN<br><b>Generic Name: </b>BLEOMYCIN<br><b>Category: </b>ANTINEOPLASTIC AGENTS
<p>181<br><b>Brand Name: </b>BLENOXANE<br><b>Generic Name: </b>BLEOMYCIN<br><b>Category: </b>ANTINEOPLASTIC AGENTS
<p>182<br><b>Brand Name: </b>INVIRASE<br><b>Generic Name: </b>SAQUINAVIR<br><b>Category: </b>ANTIVIRALS
<p>183<br><b>Brand Name: </b>EPIVIR<br><b>Generic Name: </b>LAMIVUDINE<br><b>Category: </b>ANTIVIRALS
<p>184<br><b>Brand Name: </b>3TC<br><b>Generic Name: </b>LAMIVUDINE<br><b>Category: </b>ANTIVIRALS
<p>185<br><b>Brand Name: </b>AZT<br><b>Generic Name: </b>ZIDOVUDINE<br><b>Category: </b>ANTIVIRALS
<p>186<br><b>Brand Name: </b>NIZORAL<br><b>Generic Name: </b>KETOCONAZOLE<br><b>Category: </b>ANTIFUNGALS
<p>187<br><b>Brand Name: </b>NIZORAL TOPICAL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/ketocon.htm">KETOCONAZOLE TOPICAL</A><br><b>Category: </b>ANTIFUNGALS
<p>188<br><b>Brand Name: </b>METHERGINE<br><b>Generic Name: </b>METHYLERGONOVINE MALEATE<br><b>Category: </b>OXYTOCICS
<p>189<br><b>Brand Name: </b>LOTREL<br><b>Generic Name: </b>AMLODIPINE/BENAZEPRIL HCL<br><b>Category: </b><a href="http://www.rxlist.com/cardiova.htm">HYPOTENSIVE AGENTS</a> 
<p>190<br><b>Brand Name: </b>VEXOL<br><b>Generic Name: </b>RIMEXOLONE<br><b>Category: </b>OPTHALMIC CORTICOSTEROID
<p>191<br><b>Brand Name: </b>DR-3355<br><b>Generic Name: </b>LEVOFLOXACIN<br><b>Category: </b>INVESTIGATIONAL:ANTIBIOTICS:QUINOLINES
<p>192<br><b>Brand Name: </b>ORG-10172<br><b>Generic Name: </b>DANAPAROID<br><b>Category: </b>INVESTIGATIONAL:ANTICOAGULANTS
<p>193<br><b>Brand Name: </b>RU 44570<br><b>Generic Name: </b>TRANDOLAPRIL<br><b>Category: </b> <a href="http://www.rxlist.com/cardiova.htm">HYPOTENSIVE AGENTS</a> 
<p>194<br><b>Brand Name: </b>ACCOLATE<br><b>Generic Name: </b>ZAFIRLUKAST<br><b>Category: </b>RESPIRATORY:LEUKOTRIENE ANTAGONIST
<p>195<br><b>Brand Name: </b>TIAZAC<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/diltiaz.htm">DILTIAZEM HCL</a> <br><b>Category: </b><a href="http://www.rxlist.com/cardiova.htm">CARDIAC DRUGS</a> 
<p>196<br><b>Brand Name: </b>FOSAMAX<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/alendron.htm">ALENDRONATE SODIUM</a><br><b>Category: </b>MISCELLANEOUS:OSTEOPOROSIS
<p>197<br><b>Brand Name: </b>REOPRO<br><b>Generic Name: </b>ABCIXIMAB<br><b>Category: </b>UNCLASSIFIED THERAPEUTIC AGENTS
<p>198<br><b>Brand Name: </b>SECTRAL<br><b>Generic Name: </b>ACEBUTOLOL HCL<br><b>Category: </b><a href="http://www.rxlist.com/cardiova.htm">CARDIAC DRUGS</a> 
<p>199<br><b>Brand Name: </b>ACI-JEL W/APP<br><b>Generic Name: </b>ACET AC/RICINOLEIC/OXY<br><b>Category: </b>ANTI-INFECTIVES
<p>200<br><b>Brand Name: </b>ACEPHEN<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>201<br><b>Brand Name: </b>ACETAMIN<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>202<br><b>Brand Name: </b>ANACIN AF<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>203<br><b>Brand Name: </b>APAP<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>204<br><b>Brand Name: </b>BL INFANT N/A<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>205<br><b>Brand Name: </b>BL NON-ASPIRN<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>206<br><b>Brand Name: </b>FEVERALL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>207<br><b>Brand Name: </b>GENAPAP X/S<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>208<br><b>Brand Name: </b>GENEBS X/S<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>209<br><b>Brand Name: </b>GNP NON-ASPRN<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>210<br><b>Brand Name: </b>GNP NON-ASPRN<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>211<br><b>Brand Name: </b>GNP XS PAIN<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>212<br><b>Brand Name: </b>INFANTAIRE<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>213<br><b>Brand Name: </b>INFANTOL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>214<br><b>Brand Name: </b>MAPAP ACETAM<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>215<br><b>Brand Name: </b>PAIN &amp; FEVER<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>216<br><b>Brand Name: </b>PANADOL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>217<br><b>Brand Name: </b>PEDIAPAP<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>218<br><b>Brand Name: </b>TEMPRA 1<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>219<br><b>Brand Name: </b>TEMPRA 2<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>220<br><b>Brand Name: </b>TYLENOL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>221<br><b>Brand Name: </b>TYLENOL INFNT<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>222<br><b>Brand Name: </b>TYLENOL X/S<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>223<br><b>Brand Name: </b>BROMO SELTZER<br><b>Generic Name: </b>ACETAMINOPHEN BUFFERED<br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>224<br><b>Brand Name: </b>GENAPAP CHILD<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN CHEW</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>225<br><b>Brand Name: </b>ST JOS CHL/AF<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN CHEW</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>226<br><b>Brand Name: </b>TEMPRA 3 CHEW<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN CHEW</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>227<br><b>Brand Name: </b>TYLENOL CHILD<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN CHEW</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>228<br><b>Brand Name: </b>TYLENOL CHILD<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN CHEW</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>229<br><b>Brand Name: </b>TYLENOL X/RLF<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN SA</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>230<br><b>Brand Name: </b>PROMINOL<br><b>Generic Name: </b>ACETAMINOPHEN/BUTALBITAL<br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>231<br><b>Brand Name: </b>APAP/COD<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/acetcod.htm">ACETAMINOPHEN/CODEINE</a> <br><b>Category: </b><a href="opiate.htm">OPIATE AGONISTS</a> 
<p>232<br><b>Brand Name: </b>CAPITAL W/COD<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/acetcod.htm">ACETAMINOPHEN/CODEINE</a> <br><b>Category: </b><a href="opiate.htm">OPIATE AGONISTS</a> 
<p>233<br><b>Brand Name: </b>PHENAPHEN/COD<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/acetcod.htm">ACETAMINOPHEN/CODEINE</a> <br><b>Category: </b><a href="opiate.htm">OPIATE AGONISTS</a> 
<p>234<br><b>Brand Name: </b>TYLENOL/COD<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/acetcod.htm">ACETAMINOPHEN/CODEINE</a> <br><b>Category: </b><a href="opiate.htm">OPIATE AGONISTS</a> 
<p>235<br><b>Brand Name: </b>ACETAZOLAMIDE<br><b>Generic Name: </b>ACETAZOLAMIDE<br><b>Category: </b>CARBONIC ANHYDRASE INHIBITORS
<p>236<br><b>Brand Name: </b>DIAMOX<br><b>Generic Name: </b>ACETAZOLAMIDE<br><b>Category: </b>CARBONIC ANHYDRASE INHIBITORS
<p>237<br><b>Brand Name: </b>ACETASOL PLN<br><b>Generic Name: </b>ACETIC ACID OTIC<br><b>Category: </b>ANTI-INFECTIVES
<p>238<br><b>Brand Name: </b>DOMEBORO OTIC<br><b>Generic Name: </b>ACETIC ACID OTIC<br><b>Category: </b>ANTI-INFECTIVES
<p>239<br><b>Brand Name: </b>VOSOL OTIC<br><b>Generic Name: </b>ACETIC ACID OTIC<br><b>Category: </b>ANTI-INFECTIVES
<p>240<br><b>Brand Name: </b>ACETASOL HC<br><b>Generic Name: </b>ACETIC ACID/HYDROCORT OTI<br><b>Category: </b>ANTI-INFECTIVES
<p>241<br><b>Brand Name: </b>HYDRO/ACETIC<br><b>Generic Name: </b>ACETIC ACID/HYDROCORT OTI<br><b>Category: </b>ANTI-INFECTIVES
<p>242<br><b>Brand Name: </b>VASOTATE HC<br><b>Generic Name: </b>ACETIC ACID/HYDROCORT OTI<br><b>Category: </b>ANTI-INFECTIVES
<p>243<br><b>Brand Name: </b>VOSOL HC OTIC<br><b>Generic Name: </b>ACETIC ACID/HYDROCORT OTI<br><b>Category: </b>ANTI-INFECTIVES
<p>244<br><b>Brand Name: </b>DYMELOR<br><b>Generic Name: </b>ACETOHEXAMIDE<br><b>Category: </b>SULFONYLUREAS
<p>245<br><b>Brand Name: </b>LITHOSTAT<br><b>Generic Name: </b>ACETOHYDROXAMIC ACID<br><b>Category: </b>AMMONIA DETOXICANTS
<p>246<br><b>Brand Name: </b>SEBA-NIL<br><b>Generic Name: </b>ACETONE/ALCOHOL/POLYSORB<br><b>Category: </b>MISCEL.SKIN AND MUCUS MEMBRANE AGENTS
<p>247<br><b>Brand Name: </b>MIOCHOL E W/<br><b>Generic Name: </b>ACETYLCHOLINE CHL<br><b>Category: </b>MIOTICS
<p>248<br><b>Brand Name: </b>ACETYLCYSTEIN<br><b>Generic Name: </b>ACETYLCYSTEINE<br><b>Category: </b>MUCOLYTIC AGENTS
<p>249<br><b>Brand Name: </b>MUCOMYST<br><b>Generic Name: </b>ACETYLCYSTEINE<br><b>Category: </b>MUCOLYTIC AGENTS
<p>250<br><b>Brand Name: </b>MUCOSIL<br><b>Generic Name: </b>ACETYLCYSTEINE<br><b>Category: </b>MUCOLYTIC AGENTS
<p></body></html>
<P><hr><a href="http://www.rxlist.com"><b>RxList Home Page</ul>
<hr>
</DOC>
<DOC>
<DOCNO>WT08-B13-23</DOCNO>
<DOCOLDNO>IA018-000200-B040-149</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/cromnas.htm 206.86.175.201 19970106230634 text/html 9621
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:00:19 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 9439
Last-modified: Mon, 14 Oct 1996 03:48:45 GMT
</DOCHDR>
<html>
<head>
   <title>Cromolyn - RxList Generic Information</title>
   <meta name="keywords" content="Colimune, Cromoglicic Acid, Cromogloz, Cromunal, Fintal,
Fivent, Frenal, Gastrocrom, Ifiral, Inostral, Intal, Lomudal, Lomupren, Lomusol, Nalcrom,
Nasalcrom, Opticrom, Rynacrom, Vistacrom">
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Cromolyn Sodium (Nasal)</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[warn!] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [toxicity] [<a href="#DOSAGE AND ADMINISTRATION">dosing</a>]
</font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<p><a name="DESCRIPTION"></a><b>DESCRIPTION </b></p>

<p>Chemically, cromolyn sodium is the disodium salt of 1,3-bis (2- carboxychromon-5-yloxy)-2-hydroxypropane.
The empirical formula is C23H14Na2O11. Pharmacologic Category: Mast cell
stabilizer/antiallergic. </p>

<p>Therapeutic Category: Antiallergic. </p>

<p><a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY
</b></p>

<p>In Vitro and In Vivo animal studies have shown that cromolyn sodium
inhibits the degranulation of sensitized mast cells which occurs after
exposure to specific antigens. Cromolyn sodium inhibits the release of
histamine and SRS-A (the slow- reacting substance of anaphylaxis). Rhinitis
induced by the inhalation of specific antigens can be inhibited to varying
degrees by pretreatment with Cromolyn sodium. </p>

<p>Another activity demonstrated In Vitro is the capacity of cromolyn sodium
to inhibit the degranulation of non-sensitized rat mast cells by phospholipase
A and the subsequent release of chemical mediators. An additional In Vitro
study showed that cromolyn sodium did not inhibit the enzymatic activity
of released phospholipase A on its specific substrate. </p>

<p>Cromolyn sodium has no intrinsic bronchodilator, antihistaminic or anti-
inflammatory activity. </p>

<p>Cromolyn sodium is poorly absorbed from the gastrointestinal tract.
After instillation of Cromolyn sodium, less than 7% of the total dose administered
is absorbed and is rapidly excreted unchanged in the bile and urine. The
remainder of the dose is expelled from the nose, or swallowed and excreted
via the alimentary tract. </p>

<p><a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE </b></p>

<p>Cromolyn sodium is indicated for the prevention and treatment of the
symptoms of allergic rhinitis. </p>

<p><a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS </b></p>

<p>Cromolyn sodium is contraindicated in those patients who have shown
hypersensitivity to any of the ingredients. </p>

<p><a name="PRECAUTIONS"></a><b>PRECAUTIONS </b></p>

<p>GENERAL: Some patients may experience transient nasal stinging and/or
sneezing immediately following instillation of Cromolyn sodium. Except
in rare occurrences, these experiences have not caused discontinuation
of therapy. In view of the biliary and renal routes of excretion for cromolyn
sodium, consideration should be given to decreasing the dosage or discontinuing
the administration of the drug in patients with impaired renal or hepatic
function. </p>

<p>CARCINOGENESIS, MUTAGENESIS, AND IMPAIRMENT OF FERTILITY: Long term
studies in mice (12 months intraperitoneal treatment followed by 6 months
observation), hamsters (12 months intraperitoneal treatment followed by
12 months observation), and rats (18 months subcutaneous treatment) showed
no neoplastic effect of cromolyn sodium. </p>

<p>No evidence of chromosomal damage or cytotoxicity was obtained in various
mutagenesis studies. </p>

<p>No evidence of impaired fertility was shown in laboratory animal reproduction
studies. </p>

<p>PREGNANCY: Pregnancy Category B. Reproduction studies with cromolyn
sodium administered parenterally to pregnant mice, rats, and rabbits in
doses up to 338 times the human clinical dose produced no evidence of fetal
malformations. Adverse fetal effects (increased resorptions and decreased
fetal weight) were noted only at the very high parenteral doses that produced
maternal toxicity. There are, however, no adequate and well-controlled
studies in pregnant women. Because animal reproduction studies are not
always predictive of human response, this drug should be used during pregnancy
only if clearly needed. </p>

<p>DRUG INTERACTION DURING PREGNANCY: Cromolyn sodium and isoproterenol
were studied following subcutaneous injections in pregnant mice. Cromolyn
sodium alone in doses of 60 to 540 mg/kg (38 to 338 times the human dose)
did not cause significant increases in resorptions or major malformations.
Isoproterenol alone at a dose of 2.7 mg/kg (90 times the human dose) increased
both resorptions and malformations. The addition of cromolyn sodium (338
times the human dose) to isoproterenol (90 times the human dose) appears
to have increased the incidence of both resorptions and malformations.
</p>

<p>NURSING MOTHERS: It is not known whether this drug is excreted in human
milk. Because many drugs are excreted in human milk, caution should be
exercised when Cromolyn sodium is administered to a nursing woman. </p>

<p>PEDIATRIC USE: Safety and effectiveness in children below the age of
6 years have not been established. </p>

<p><a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS </b></p>

<p>DRUG INTERACTION DURING PREGNANCY: Cromolyn sodium and isoproterenol
were studied following subcutaneous injections in pregnant mice. Cromolyn
sodium alone in doses of 60 to 540 mg/kg (38 to 338 times the human dose)
did not cause significant increases in resorptions or major malformations.
Isoproterenol alone at a dose of 2.7 mg/kg (90 times the human dose) increased
both resorptions and malformations. The addition of cromolyn sodium (338
times the human dose) to isoproterenol (90 times the human dose) appears
to have increased the incidence of both resorptions and malformations.
(See Also PRECAUTIONS) </p>

<p><a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS </b></p>

<p>The most frequent adverse reactions occurring in the 430 patients included
in the clinical trials with Cromolyn sodium were sneezing (1 in 10 patients),
nasal stinging (1 in 20), nasal burning (1 in 25), and nasal irritation
(1 in 40). Headaches and bad taste were reported in about 1 in 50 patients.
Epistaxis, postnasal drip, and rash were reported in less than one percent
of the patients. One patient in the clinical trials developed anaphylaxis.
</p>

<p>Adverse reactions which have occurred in the use of other cromolyn sodium
formulations for inhalation include angioedema, joint pain and swelling,
urticaria, cough, and wheezing. Other reactions reported rarely are serum
sickness, periarteritic vasculitis, polymyositis, pericarditis, photodermatitis,
exfoliative dermatitis, peripheral neuritis, and nephrosis. </p>

<p><a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION
</b></p>

<p>The dose for adults and children 6 years and older is ONE SPRAY IN EACH
NOSTRIL 3-4 times daily at regular intervals. If needed, this dose may
be increased to one spray to each nostril 6 times daily. The patient should
be instructed to clear the nasal passages before administering the spray
and should inhale through the nose during administration. </p>

<p>In the management of seasonal (pollenotic) rhinitis, and for prevention
of rhinitis caused by exposure to other types of specific inhalant allergens,
treatment with Cromolyn sodium will be more effective if started prior
to expected contact with the offending allergen. Treatment should be continued
throughout the period of exposure, i.e., until the pollen season is over
or until exposure to the offending allergen is terminated. </p>

<p>In the management of perennial allergic rhinitis, the effects of treatment
with Cromolyn sodium may become apparent only after two to four weeks of
treatment. The concomitant use of antihistamines and/or nasal decongestants
may be necessary during the initial phase of treatment, but the need for
this type of medication should diminish and may be eliminated when the
full benefit of Cromolyn sodium is achieved. </p>

<h2 align=center>
<hr width="100%" ></h2>

<h2 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-24</DOCNO>
<DOCOLDNO>IA018-000200-B038-25</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/theosr.htm 206.86.175.201 19970106225822 text/html 33354
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:51:58 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 33171
Last-modified: Fri, 12 Jul 1996 05:07:55 GMT
</DOCHDR>
<html>
<head>
   <title>Theophylline (Extended Release) - RxList Generic Information</title>
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Theophylline (Extended Release)</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<p><a name="DESCRIPTION"></a><b>DESCRIPTION </b></p>

<p>Theophylline (extended release) tablets contain anhydrous theophylline,
a bronchodilator structurally classified as a xanthine derivative. 1H-Purine-2,6-dione,3,7-dihydro-1,3-dimethyl
Anhydrous theophylline is a white, odorless, crystalline powder having
a bitter taste. </p>

<p><a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY
</b></p>

<p>Theophylline directly relaxes the smooth muscle of the bronchial airways
and pulmonary blood vessels, thus acting mainly as a bronchodilator and
smooth muscle relaxant. It has also been demonstrated that aminophylline
has a potent effect on diaphragmatic contractility in normal persons and
may then be capable of reducing fatigability and thereby improve contractility
in patients with chronic obstructive airways disease. The exact mode of
action remains unsettled. Although theophylline does cause inhibition of
phosphodiesterase with a resultant increase in intracellular cyclic AMP,
other agents similarly inhibit the enzyme producing a rise of cyclic AMP
but are unassociated with any demonstrable bronchodilation. Other mechanisms
proposed include an effect on translocation of intracellular calcium; prostaglandin
antagonism; stimulation of catecholamines endogenously; inhibition of cyclic
guanosine monophosphate metabolism and adenosine receptor antagonism. None
of these mechanisms has been proved, however. </p>

<p>In Vitro, theophylline has been shown to act synergistically with beta
agonists and there are now available data which demonstrate an additive
effect In Vivo with combined use. </p>

<p>PHARMACOKINETICS: The half-life of theophylline is influenced by a number
of known variables. It may be prolonged in chronic alcoholics, particularly
those with liver disease (cirrhosis or alcoholic liver disease) or in patients
with congestive heart failure and in patients taking certain other drugs
(see PRECAUTIONS, DRUG INTERACTIONS). </p>

<p>Newborns and neonates have extremely slow clearance rates compared to
older infants and children (i.e. those over 1 year of age). Older children
have rapid clearance rates while most non-smoking adults have clearance
rates between these two extremes. In premature neonates the decreased clearance
is related to metabolic pathways that have yet to be established. </p>

<pre>            THEOPHYLLINE ELIMINATION                                           
                 CHARACTERISTICS                                                
                                  RANGE     MEAN                                
Children                           1-9      3.7                                 
Adults                             3-15     7.7   </pre>

<p>In cigarette smokers (1-2 packs/day) the mean half-life is 4-5 hours,
much shorter than in non-smokers. The increase in clearance associated
with smoking is presumably due to stimulation of the hepatic metabolic
pathway by components of cigarette smoke. The duration of this effect after
cessation of smoking is unknown but may require 6 months to 2 years before
the rate approaches that of the non-smokers. </p>

<p>Theophylline (extended release) (100, 200, 300 AND 450 MG) TABLETS:
In single dose studies with 18 normal fasting subjects, Theophylline (extended
release) at 8 mg/kg body weight (300 700 mg/dose) produced mean peak theophylline
plasma levels of 7.5 +/- 1.9 mcg/mL at 9.2 +/- 1.9 hours following administration.
In multiple dose, steady state, 3 and 5 day studies with 12 normal subjects,
Theophylline (extended release) administered at 8 mg/kg (300-600 mg/dose)
twice daily, achieved an average peak-trough difference of 4 mcg/mL. The
Cmax and Cmin were 13.9 +/- 6.9 and 9.9 +/- 6.0, respectively. The mean
% fluctuation +/- S.D. of the plasma concentration at steady state (% fluctuation
= 100 (Cmax-Cmin)/Cmin) was 54.2 +/- 45.7%. These pharmacokinetic parameters
were measured under fasting conditions. </p>

<p>Theophylline (extended release) (200, 300 AND 450 MG) TABLETS: In a
multiple dose (300-500 mg BID) steady-state, 5 day study involving 14 normal,
nonfasting subjects with theophylline half-lives between 5.8 and 12.3 hours
(mean 8.0 +/- 1.8 hours), Theophylline (extended release), dosed twice
daily, produced mean Cmax and Cmin levels of 12.2 +/- 2.0 and 10.2 +/-
1.6 mcg/mL, respectively, over the a.m. dosing interval and Cmax and Cmin
of 11.6 +/- 1.6 and 8.7 +/- 1.8 mcg/mL, respectively over the p.m. dosing
interval. The mean % fluctuation +/- S.D. over the a.m. dosing interval
was 30.4 +/- 12.9% and 33.7 +/- 13.1% over the p.m. dosing interval. In
the same subjects, Theophylline (extended release) given once daily, in
the morning, in doses ranging from 600-1000 mg (same daily dose as for
BID, above) produced a mean Cmax and Cmin of 14.4 +/- 2.2 and 5.5 +/- 2.0,
respectively and a mean % fluctuation +/- S.D. of 195.8 +/- 106.0%. Average
peak-trough differences over 24 hours were 8.9 +/- 1.3 and 3.7 +/- 1.2
mcg/mL when Theophylline (extended release) was given once or twice daily,
respectively. In both the twice daily and once daily dosing regimens, Theophylline
(extended release) exhibited complete bioavailability when compared to
an immediate release product. </p>

<p>Theophylline (extended release) (200, 300 AND 450 MG) TABLETS: In a
single-dose bioavailability study in eleven subjects, 1000 mg of Theophylline
(extended release) was administered under fasting conditions and immediately
following a high fat content (62 g) breakfast of approximately 1100 kcal.
The rate and extent of absorption of theophylline from Theophylline (extended
release) administered in fasting and fed conditions were similar. </p>

<p><a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE </b></p>

<p>For relief and/or prevention of symptoms from asthma and reversible
bronchospasm associated with chronic bronchitis and emphysema. </p>

<p><a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS </b></p>

<p>This product is contraindicated in individuals who have shown hypersensitivity
to its components. It is also contraindicated in patients with active peptic
ulcer disease, and in individuals with underlying seizure disorders (unless
receiving appropriate anticonvulsant medication). </p>

<p><a name="WARNINGS"></a><b>WARNINGS </b></p>

<p>Serum levels above 20 mcg/mL are rarely found after appropriate administration
of recommended doses. However, in individuals in whom theophylline plasma
clearance is reduced For Any Reason, even conventional doses may result
in increased serum levels and potential toxicity. Reduced theophylline
clearance has been documented in the following readily identifiable groups:
1) patients with impaired liver function; 2) patients over 55 years of
age, particularly males and those with chronic lung disease; 3) those with
cardiac failure from any cause; 4) patients with sustained high fever;
5) neonates and infants under 1 year of age; 6) those patients taking certain
drugs (see PRECAUTIONS, DRUG INTERACTIONS). Frequently, such patients have
markedly prolonged theophylline serum levels following discontinuation
of the drug. </p>

<p>Reduction of dosage and laboratory monitoring is especially appropriate
in the above individuals. </p>

<p>Serious side effects such as ventricular arrhythmias, convulsions or
even death may appear as the first sign of toxicity without any previous
warning. Less serious signs of theophylline toxicity (i.e. nausea and restlessness)
may occur frequently when initiating therapy, but are usually transient;
when signs are persistent during maintenance therapy, they are often associated
with serum concentrations above 20 mcg/mL. Stated differently: Serious
Toxicity Is Not Reliably Preceded By Less Severe Side Effects. Serum concentration
measurements may contribute significant information towards predicting
potential life- threatening toxicity. </p>

<p>Many patients who require theophylline may exhibit tachycardia due to
their underlying disease process so that the cause/effect relationship
to elevated serum theophylline concentrations may not be appreciated. </p>

<p>Theophylline products may cause or worsen arrhythmias and any pre-existing
arrhythmias, and any significant change in rate and/or rhythm warrants
monitoring and further investigation. </p>

<p>Studies in laboratory animals (minipigs, rodents, and dogs) recorded
the occurrence of cardiac arrhythmias and sudden death (with histologic
evidence of myocardial necrosis) when beta-agonists and methylxanthines
were administered concurrently. The significance of these findings when
applied to humans is currently unknown. </p>

<p><a name="PRECAUTIONS"></a><b>PRECAUTIONS </b></p>

<p>Theophylline (extended release) TABLETS SHOULD NOT BE CHEWED OR CRUSHED.
</p>

<p>GENERAL: On the average, theophylline half-life is shorter in cigarette
and marijuana smokers than in non-smokers, but smokers can have half-lives
as long as non-smokers. Theophylline should not be administered concurrently
with other xanthines medication. Use with caution in patients with hypoxemia,
hypertension or those with a history of peptic ulcer. Theophylline may
occasionally act as a local irritant to the G.I. tract although gastrointestinal
symptoms are more commonly centrally mediated and associated with serum
drug concentrations over 20 mcg/mL. </p>

<p>INFORMATION FOR PATIENTS: This information is intended to aid in the
safe and effective use of this medication. It is not a disclosure of all
possible adverse or intended effects. </p>

<p>The physician should reinforce the importance of taking only the prescribed
dose and time interval between doses. Theophylline (extended release) Tablets
should not be chewed or crushed. When dosing Theophylline (extended release)
Tablets on a once daily (q24h) basis, tablets should be taken whole and
not split. As with any controlled-release theophylline product, the patient
should alert the physician if symptoms occur repeatedly, especially near
the end of the dosing interval. </p>

<p>LABORATORY TESTS: Serum theophylline levels should be monitored periodically
to assure achievement of optimal levels for safety and efficacy. For such
measurements, the serum sample should be obtained at the time of peak concentration,
4 to 8 hours when medication is taken every 12 hours or 8 hours when taken
once daily. It is important that the patient has not missed or taken additional
doses during the previous 48 hours and that dosing intervals were reasonably
equally spaced. DOSAGE ADJUSTMENT BASED ON SERUM THEOPHYLLINE MEASUREMENTS
WHEN THESE INSTRUCTIONS HAVE NOT BEEN FOLLOWED MAY RESULT IN RECOMMENDATIONS
THAT PRESENT RISK OF TOXICITY TO THE PATIENT. </p>

<p>DRUG INTERACTIONS: Toxic synergism with ephedrine has been documented
and may occur with some other sympathomimetic bronchodilators. In addition,
the following drug interactions have been demonstrated: </p>

<pre>Theophylline with:  
Allopurinol          Increased serum theophylline                               
 (high dose)         levels                                                     
Cimetidine           Increased serum theophylline                               
                     levels                                                     
Ciprofloxacin        Increased serum theophylline                               
                     levels                                                     
Erythromycin,        Increased serum theophylline                               
 Troleandomycin      levels                                                     
Lithium carbonate    Increased renal excretion                                  
                     of lithium                                                 
Oral contraceptives  Increased serum theophylline                               
                     levels                                                     
Phenytoin            Decreased theophylline and                                 
                     phenytoin serum levels                                     
Propranolol          Increased serum theophylline                               
                     levels                                                     
Rifampin             Decreased serum theophylline                               
                     levels          </pre>

<p>DRUG-FOOD INTERACTIONS: Theophylline (extended release) 100 Mg Tablets
have not been adequately studied to determine whether their bioavailability
is altered when given with food. Available data suggest that drug administration
at the time of food ingestion may influence the absorption characteristics
of theophylline controlled-release products resulting in serum values different
from those found after administration in the fasting state. </p>

<p>A drug-food effect, if any, would likely have its greatest clinical
significance when high theophylline serum levels are being maintained and/or
when large single doses (greater than 13 mg/kg or 900 mg) of a controlled
release theophylline product are given. </p>

<p>Theophylline (extended release) (200, 300 And 450 Mg) Tablets: The rate
and extent of absorption of theophylline from Theophylline (extended release)
200 mg, 300 mg, and 450 mg tablets are similar when administered fasting
or immediately after a high fat content breakfast such as 8 oz. whole milk,
egg/cheese/bacon on muffin, 1 blueberry muffin with margarine, and 1 serving
of hash brown potatoes (about 1100 kcal, including approximately 62 g of
fat). (See ACTIONS/CLINICAL PHARMACOLOGY, PHARMACOKINETICS.) </p>

<p>DRUG-LABORATORY TEST INTERACTIONS: Currently available analytical methods,
including high pressure liquid chromatography and immunoassay techniques,
for measuring serum theophylline levels are specific. Metabolites and other
drugs generally do not affect the results. Other new analytic methods are
also now in use. The physician should be aware of the laboratory method
used and whether other drugs will interfere with the assay for theophylline.
</p>

<p>CARCINOGENESIS, MUTAGENESIS, AND IMPAIRMENT OF FERTILITY: Long-term
carcinogenicity studies have not been performed with theophylline. </p>

<p>Chromosome-breaking activity was detected in human cell cultures at
concentrations of theophylline up to 50 times the therapeutic serum concentration
in humans. Theophylline was not mutagenic in the dominant lethal assay
in male mice given theophylline intraperitoneally in doses up to 30 times
the maximum daily human oral dose. </p>

<p>Studies to determine the effects on fertility have not been performed
with theophylline. </p>

<p>PREGNANCY: Category C Animal reproduction studies have not been conducted
with theophylline. It is not known whether theophylline can cause fetal
harm when administered to a pregnant woman or can affect reproduction capacity.
Xanthines should be given to a pregnant woman only if clearly needed. </p>

<p>NURSING MOTHERS: Theophylline is distributed into breast milk and may
cause irritability or other signs of toxicity in nursing infants. Because
of the potential for serious adverse reactions in nursing infants from
theophylline, a decision should be made whether to discontinue nursing
or to discontinue the drug, taking into account the importance of the drug
to the mother. </p>

<p>PEDIATRIC USE: Safety and effectiveness of Theophylline (extended release)
Tablets administered: </p>

<p>1. Every 24 hours in children under 12 years of age, have not been established.
</p>

<p>2. Every 12 hours in children under 6 years of age, have not been established.
</p>

<p><a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS </b></p>

<p>Toxic synergism with ephedrine has been documented and may occur with
some other sympathomimetic bronchodilators. In addition, the following
drug interactions have been demonstrated: </p>

<p>Theophylline with: </p>

<pre>Allopurinol          Increased serum theophylline                               
 (high dose)         levels                                                     
Cimetidine           Increased serum theophylline                               
                     levels                                                     
Ciprofloxacin        Increased serum theophylline                               
                     levels                                                     
Erythromycin,        Increased serum theophylline                               
 Troleandomycin      levels                                                     
Lithium carbonate    Increased renal excretion                                  
                     of lithium                                                 
Oral contraceptives  Increased serum theophylline                               
                     levels                                                     
Phenytoin            Decreased theophylline and                                 
                     phenytoin serum levels                                     
Propranolol          Increased serum theophylline                               
                     levels                                                     
Rifampin             Decreased serum theophylline                               
                     levels          </pre>

<p>(See Also PRECAUTIONS) </p>

<p><a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS </b></p>

<p>The following adverse reactions have been observed, but there has not
been enough systemic collection of data to support an estimate of their
frequency. </p>

<p>1. Gastrointestinal: nausea, vomiting, epigastric pain, hematemesis,
diarrhea. </p>

<p>2. Central Nervous System: headaches, irritability, restlessness, insomnia,
reflex hyperexcitability, muscle twitching, clonic and tonic generalized
convulsions. </p>

<p>3. Cardiovascular: palpitation, tachycardia, extrasystole, flushing,
hypotension, circulatory failure, ventricular arrhythmia. </p>

<p>4. Respiratory: tachypnea. </p>

<p>5. Renal: potentiation of diuresis. </p>

<p>6. Others: alopecia, hyperglycemia, inappropriate ADH syndrome, rash.
</p>

<p><a name="OVERDOSAGE"></a><b>OVERDOSAGE </b></p>

<p>MANAGEMENT: It is suggested that the management principles (consistent
with the clinical status of the patient when first seen) outlined below
be instituted and that simultaneous contact with a Regional Poison Control
Center be established. In this way both updated information and individualization
regarding the required therapy may be provided. </p>

<p>1. When potential oral overdose is established and seizure has not occurred:
</p>

<p>a) If patient is alert and seen within the early hours after ingestion,
induction of emesis may be of value. Gastric lavage has been demonstrated
to be of no value in influencing outcome in patients who present more than
1 hour after ingestion. </p>

<p>b) Administer a cathartic. Sorbitol solution is reported to be of value.
</p>

<p>c) Administer repeated doses of activated charcoal and monitor theophylline
serum levels. </p>

<p>d) Prophylactic administration of phenobarbital has been shown to elevate
the seizure threshold in laboratory animals, and administration of this
drug can be considered. </p>

<p>2. If patient presents with a seizure: </p>

<p>a) Establish an airway. </p>

<p>b) Administer oxygen. </p>

<p>c) Treat the seizure with intravenous diazepam, 0.1 to 0.3 mg/kg up
to 10 mg. If seizures cannot be controlled, the use of general anesthesia
should be considered. </p>

<p>d) Monitor vital signs, maintain blood pressure and provide adequate
hydration. </p>

<p>3. If post-seizure coma is present: </p>

<p>a) Maintain airway and oxygenation. </p>

<p>b) If result of oral medication, follow above recommendations to prevent
absorption of the drug, but intubation and lavage will have to be performed
instead of inducing emesis, and the cathartic and charcoal will need to
be introduced via a large bore gastric lavage tube. </p>

<p>c) Continue to provide full supportive care and adequate hydration until
the drug is metabolized. In general drug metabolism is sufficiently rapid
so as not to warrant dialysis. If repeated oral activated charcoal is ineffective
(as noted by stable or rising serum levels) charcoal hemoperfusion may
be indicated. </p>

<p><a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION
</b></p>

<p>Theophylline (extended release) (200, 300 And 450 Mg) Tablets: The rate
and extent of absorption of theophylline from Theophylline (extended release)
200, 300 and 450 mg tablets when administered fasting or immediately after
a high fat content breakfast are similar (see ACTIONS/CLINICAL PHARMACOLOGY,
PHARMACOKINETICS). </p>

<p>Theophylline (extended release) 100 Mg Tablets have not been adequately
studied for their bioavailability when administered with food (see PRECAUTIONS,
DRUG-FOOD INTERACTIONS). </p>

<p>Effective use of theophylline (i.e., the concentration of drug in the
serum associated with optimal benefit and minimal risk of toxicity) is
considered to occur when the theophylline concentration is maintained from
10 to 20 mcg/mL. The early studies from which these levels were derived
were carried out in patients immediately or shortly after recovery from
acute exacerbations of their disease (some hospitalized with status asthmaticus).
</p>

<p>Although the 20 mcg/mL remains appropriate as a critical value (above
which toxicity is more likely to occur) for safety purposes, additional
data are now available which indicate that the serum theophylline concentrations
required to produce maximum physiologic benefit may, in fact, fluctuate
with the degree of bronchospasm present and are variable. Therefore, the
physician should individualize the range appropriate to the patient's requirements,
based on both symptomatic response and improvement in pulmonary function.
It should be stressed that serum theophylline concentrations maintained
at the upper level of the 10 to 20 mcg/mL range may be associated with
potential toxicity when factors known to reduce theophylline clearance
are operative (see WARNINGS). If it is not possible to obtain serum level
determinations, restriction of the daily dose (in otherwise healthy adults)
to not greater than 13 mg/kg/day, to a maximum of 900 mg of theophylline
will result in relatively few patients exceeding serum levels of 20 mcg/mL
and the resultant greater risk of toxicity. </p>

<p>Caution should be exercised for younger children who cannot complain
of minor side effects. Older adults, particularly those with cor pulmonale,
congestive heart failure, and/or liver disease may have unusually low dosage
requirements and thus may experience toxicity at the maximal dosage recommended
below. </p>

<p>Theophylline does not distribute into fatty tissue. Dosage should be
calculated on the basis of lean (ideal) body weight where mg/kg doses are
presented.</p>

<p> Frequency of Dosing: When immediate release products with rapid absorption
are used, dosing to maintain serum levels generally requires administration
every 6 hours. This is particularly true in children, but dosing intervals
up to 8 hours may be satisfactory in adults since they eliminate the drug
at a slower rate. Some children, and adults requiring higher than average
doses (those having rapid rates of clearance, e.g. half-lives of under
6 hours) may benefit and be more effectively controlled during chronic
therapy when given products with characteristics since these provide longer
dosing intervals and/or less fluctuation in serum concentration between
dosing.</p>

<p> Dosage guidelines are approximations only and the wide range of theophylline
clearance between individuals (particularly those with concomitant disease)
makes indiscriminate usage hazardous. </p>

<p>DOSAGE GUIDELINES </p>

<p>WARNING: DO NOT ATTEMPT TO MAINTAIN ANY DOSE THAT IS NOT TOLERATED.
</p>

<p>It is recommended that dosing be considered in two stages: initiation
of therapy with Theophylline (extended release), and titration, adjustment,
and chronic maintenance. </p>

<p>Initiation of Therapy: </p>

<p>It is recommended that the appropriate dosage be established using an
immediate release preparation. Slow clinical titration is generally preferred
to help assure acceptance and safety of the medication, and to allow the
patient to develop tolerance to the transient caffeine-like side effects.
Then, if the total 24 hour dose can be given by use of the available strengths
of this product, the patient can usually be switched to Theophylline (extended
release) giving one-half of the daily dose at 12 hour intervals. However,
certain patients, such as the young, smokers and some non-smoking adults
are likely to metabolize theophylline rapidly and require dosing at 8 hour
intervals. Such patients can generally be identified as having trough serum
concentrations lower than desired or repeatedly exhibiting symptoms near
the end of a dosing interval. </p>

<p>Alternatively, therapy can be initiated with Theophylline (extended
release) since it is available in dosage forms/strengths which permit titration
and adjustment in dosage as outlined in the following dosing guidelines.
It is recommended that for children under 25 kg, proper dosage be established
with a liquid preparation to permit titration in small increments. </p>

<p>THE AVERAGE INITIAL ADULT AND CHILDREN'S (over 25 kg) DOSE IS ONE Theophylline
(extended release) 200 mg TABLET q12h. </p>

<p>Titration and Adjustment and Chronic Maintenance: </p>

<p>If the desired response is not achieved with the above AVERAGE INITIAL
DOSE recommendations, there are no adverse reactions and the serum theophylline
level cannot be measured, dosage adjustment should proceed by increasing
the dose in approximately 25% increments at three day intervals. Following
each adjustment, the clinical response should be assessed. If the clinical
response is satisfactory, then that dosage level should be maintained.
Dosage increases may be made in this manner up to the following: </p>

<pre>-------------------------------------------------                               
    MAXIMUM DOSE WITHOUT MEASUREMENT OF SERUM                                   
                  CONCENTRATION                                                 
-------------------------------------------------                               
                             Dose Per Interval                                  
   Children                                                                     
  (25-35 kg)                    250 mg q12h                                     
  Adults and                                                                    
   Children                                                                     
  (35-70 kg)                    300 mg q12h                                     
 Adults (over                                                                   
    70 kg)                      450 mg q12h                                     
-------------------------------------------------   </pre>

<p>It is important that no patient be maintained on any dosage that is
not tolerated. In instructing patients to increase dosage according to
the schedule above, they should be instructed not to take a subsequent
dose if apparent side effects occur and to resume therapy at a lower dose
once adverse effects have disappeared. </p>

<p>If an increased dose is not tolerated because of headaches or stomach
upset (nausea, vomiting, diarrhea, etc.), decrease dose to previous tolerated
level. Do not exceed the above recommended doses unless serum theophylline
levels can be measured. </p>

<p>If serum theophylline levels can be measured and the concentration is
between 10 and 20 mcg/ml, maintain dose if tolerated. CHECK SERUM CONCENTRATION
AT APPROXIMATELY 8 HOURS AFTER A DOSE WHEN NONE HAVE BEEN MISSED OR ADDED
FOR AT LEAST 3 DAYS. RECHECK SERUM THEOPHYLLINE CONCENTRATION AT 6 TO 12
MONTH INTERVALS. This interval may need to be more frequent in some individuals.
Take the following action if the measured serum theophylline concentration
is too high. </p>

<p>20 to 25 mcg/mL--Decrease dose by about 10% and serum theophylline levels
should be rechecked after 3 days*. </p>

<p>25 to 30 mcg/mL--Skip next dose and decrease subsequent doses by 25%
and serum theophylline levels should be rechecked after 3 days. </p>

<p>Over 30 mcg/mL--Skip next 2 doses and decrease subsequent doses by 50%
and serum theophylline levels should be rechecked after 3 days. </p>

<p>Take the following action if the measured serum theophylline concentration
is too low. </p>

<p>7.5 to 10 mcg/mL--Increase dose by 25%**. </p>

<p>5 to 7.5 mcg/mL--Increase dose by 25%. </p>

<p>RECHECK SERUM THEOPHYLLINE FOR GUIDANCE IN FURTHER DOSAGE ADJUSTMENT.
</p>

<p>*Finer adjustments in dosage may be needed for some patients. </p>

<p>**Dividing the daily dosage into 3 doses administered at 8 hour intervals
may be indicated if symptoms occur repeatedly at the end of a dosing interval.
</p>

<p>DOSAGE ADJUSTMENT BASED ON SERUM THEOPHYLLINE CONCENTRATION MEASUREMENTS
WHEN THESE INSTRUCTIONS HAVE NOT BEEN FOLLOWED MAY RESULT IN RECOMMENDATIONS
THAT PRESENT RISK OF TOXICITY TO THE PATIENT. </p>

<p>Once-Daily Dosing: </p>

<p>The slow absorption rate of this preparation may allow once-daily administration
in adult non-smokers with appropriate total body clearance and other patients
with low dosage requirements. Once-daily dosing should be considered only
after the patient has been gradually and satisfactorily titrated to therapeutic
levels with q12h dosing. Once-daily dosing should be based on twice the
q12h dose and should be initiated at the end of the last q12h dosing interval.
The trough concentration (Cmin) obtained following conversion to once-daily
dosing may be lower (especially in high clearance patients) and the peak
concentration (Cmax) may be higher (especially in low clearance patients)
than that obtained with q12h dosing. If symptoms recur, or signs of toxicity
appear during the once-daily dosing interval, dosing on the q12h basis
should be reinstituted. </p>

<p>It is essential that serum theophylline concentrations be monitored
before and after transfer to once-daily dosing. </p>

<p>Food and posture, along with changes associated with circadian rhythm,
may influence the rate of absorption and/or clearance rates of theophylline
from controlled-release dosage forms administered at night. The exact relationship
of these and other factors to nighttime serum concentrations and the clinical
significance of such findings require additional study. Therefore, it is
not recommended that Theophylline (extended release), when used as a once-a-day
product, be administered at night. Theophylline (extended release), when
used as a once-a-day product, must be taken whole and not broken. </p>

<p>
<hr width="100%" ></p>

<h2 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-25</DOCNO>
<DOCOLDNO>IA018-000200-B038-152</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/sucral.htm 206.86.175.201 19970106230014 text/html 15699
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:53:59 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 15516
Last-modified: Thu, 11 Jul 1996 19:05:51 GMT
</DOCHDR>
<html>
<head>
   <title>Sucralfate - RxList Generic Information</title>
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Sucralfate</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[warn!] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<p><a name="DESCRIPTION"></a><b>DESCRIPTION </b></p>

<p>Sucralfate is an alpha-D-glucopyranoside, beta-D-fructofuranosyl- octakis-(hydrogen
sulfate), aluminum complex. </p>

<p>R=SO3(AL2(OH)5.(H2O)2) </p>

<p>Therapeutic category: antiulcer. </p>

<p><a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY
</b></p>

<p>Sucralfate is only minimally absorbed from the gastrointestinal tract.
The small amounts of the sulfated disaccharide that are absorbed are excreted
primarily in the urine. </p>

<p>Although the mechanism of sucralfate's ability to accelerate healing
of duodenal ulcers remains to be fully defined, it is known that it exerts
its effect through a local, rather than systemic, action. The following
observations also appear pertinent: </p>

<p>1. Studies in human subjects and with animal models of ulcer disease
have shown that sucralfate forms an ulcer-adherent complex with proteinaceous
exudate at the ulcer site. </p>

<p>2. In vitro, a sucralfate-albumin film provides a barrier to diffusion
of hydrogen ions. </p>

<p>3. In human subjects, sucralfate given in doses recommended for ulcer
therapy inhibits pepsin activity in gastric juice by 32%. </p>

<p>4. In vitro, sucralfate adsorbs bile salts. </p>

<p>These observations suggest that sucralfate's antiulcer activity is the
result of formation of an ulcer-adherent complex that covers the ulcer
site and protects it against further attack by acid, pepsin, and bile salts.
There are approximately 14-16 mEq of acid-neutralizing capacity per 1-gm
dose of sucralfate. </p>

<p>CLINICAL TRIALS </p>

<p>ACUTE DUODENAL ULCER </p>

<p>Over 600 patients have participated in well-controlled clinical trials
worldwide. Multicenter trials conducted in the United States, both of them
placebo-controlled studies with endoscopic evaluation at 2 and 4 weeks,
showed: </p>

<pre>STUDY 1                                                                         
TREATMENT                                                                       
GROUPS                                  ULCER HEALING/NO. PATIENTS              
                          2 WK                           4 WK (OVERALL)         
Sucralfate                37/105 (35.2%)                 82/109 (75.2%)         
Placebo                   26/106 (24.5%)                 68/107 (63.6%)         
STUDY 2                                                                         
TREATMENT                                                                       
GROUPS                                  ULCER HEALING/NO. PATIENTS              
                          2 WK                           4 WK (OVERALL)         
Sucralfate                8/24 (33%)                     22/24 (92%)            
Placebo                   4/31 (13%)                     18/31 (58%)    </pre>

<p>The sucralfate-placebo differences were statistically significant in
both studies at 4 weeks but not at 2 weeks. The poorer result in the first
study may have occurred because sucralfate was given 2 hours after meals
and at bedtime rather than 1 hour before meals and at bedtime, the regimen
used in international studies and in the second United States study. In
addition, in the first study liquid antacid was utilized as needed, whereas
in the second study antacid tablets were used. </p>

<p>MAINTENANCE THERAPY AFTER HEALING OF DUODENAL ULCER </p>

<p>Two double-blind randomized placebo-controlled U.S. multicenter trials
have demonstrated that sucralfate (1 gm bid) is effective as maintenance
therapy following healing of duodenal ulcers. </p>

<p>In one study, endoscopies were performed monthly for 4 months. Of the
254 patients who enrolled, 239 were analyzed in the intention-to-treat
life table analysis presented below. </p>

<pre><font SIZE=-1>-----------------------------------------------------------------------------   
                        Duodenal Ulcer Recurrence Rate (%)                      
-----------------------------------------------------------------------------   
                                        Months of Therapy                       
-----------------------------------------------------------------------------   
Drug                    N           1           2            3            4     
-----------------------------------------------------------------------------   
Sucralfate               122         20*         30*          38**         42**   
Placebo                117         33          46           55           63     
-----------------------------------------------------------------------------   
*p&lt;0.05, **p&lt;0.01                                                               
Prn antacids were not permitted in this study.                                  
In the other study, scheduled endoscopies were performed at 6 and 12 months,
but for cause endoscopies were permitted as symptoms dictated. Median symptom
scores between the sucralfate and placebo groups were not significantly
different. A life table intention-to-treat analysis for the 94 patients
enrolled in the trial had the following results:  
 
-----------------------------------------------------------------------------   
                        Duodenal Ulcer Recurrence Rate (%)                      
-----------------------------------------------------------------------------   
Drug                       N               6 months              12 months      
-----------------------------------------------------------------------------   
Sucralfate                   48                19*                    27*         
Placebo                    46                54                     65          
-----------------------------------------------------------------------------   
*p&lt;0.002                                                                        
Prn antacids were permitted in this study.   </font></pre>

<p>
<br>Data from placebo-controlled studies longer than 1 year are not available.</p>

<p><a name="INDICATIONS AND USAGE"></a><b> INDICATIONS AND USAGE </b></p>

<p>Sucralfate is indicated in: </p>

<p>--Short-term treatment (up to 8 weeks) of active duodenal ulcer. While
healing with sucralfate may occur during the first week or two, treatment
should be continued for 4 to 8 weeks unless healing has been demonstrated
by x-ray or endoscopic examination. </p>

<p>--Maintenance therapy for duodenal ulcer patients at reduced dosage
after healing of acute ulcers. </p>

<p><a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS </b></p>

<p>There are no known contraindications to the use of sucralfate. </p>

<p><a name="PRECAUTIONS"></a><b>PRECAUTIONS </b></p>

<p>Duodenal ulcer is a chronic, recurrent disease. While short-term treatment
with sucralfate can result in complete healing of the ulcer, a successful
course of treatment with sucralfate should not be expected to alter the
posthealing frequency or severity of duodenal ulceration. </p>

<p>SPECIAL POPULATIONS: CHRONIC RENAL FAILURE AND DIALYSIS PATIENTS: </p>

<p>When sucralfate is administered orally, small amounts of aluminum are
absorbed from the gastrointestinal tract. Concomitant use of sucralfate
with other products that contain aluminum, such as aluminum-containing
antacids, may increase the total body burden of aluminum. Patients with
normal renal function receiving the recommended doses of sucralfate and
aluminum-containing products adequately excrete aluminum in the urine.
Patients with chronic renal failure or those receiving dialysis have impaired
excretion of absorbed aluminum. In addition, aluminum does not cross dialysis
membranes because it is bound to albumin and transferrin plasma proteins.
Aluminum accumulation and toxicity (aluminum osteodystrophy, osteomalacia,
encephalopathy) have been described in patients with renal impairment.
Sucralfate should be used with caution in patients with chronic renal failure.
</p>

<p>DRUG INTERACTIONS </p>

<p>Some studies have shown that simultaneous sucralfate administration
in healthy volunteers reduced the extent of absorption (bioavailability)
of single doses of the following drugs: cimetidine, ciprofloxacin, digoxin,
ketoconazole, norfloxacin, phenytoin, ranitidine, tetracycline, and theophylline.
Subtherapeutic prothrombin times with concomitant warfarin and sucralfate
therapy have been reported in spontaneous and published case reports. However,
two clinical studies have demonstrated no change in either serum warfarin
concentration or prothrombin time with the addition of sucralfate to chronic
warfarin therapy </p>

<p>The mechanism of these interactions appears to be nonsystemic in nature,
presumably resulting from sucralfate binding to the concomitant agent in
the gastrointestinal tract. In all cases studied to date (cimetidine, ciprofloxacin
digoxin, ranitidine, and warfarin), dosing the concomitant medication 2
hours before sucralfate eliminated the interaction. Because of the potential
of Sucralfate to alter the absorption of some drugs, Sucralfate should
be administered separately from other drugs when alterations in bioavailability
are felt to be critical. In these cases, patients should be monitored appropriately.
</p>

<p>CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY </p>

<p>Chronic oral toxicity studies of 24 months' duration were conducted
in mice and rats at doses up to 1 gm/kg (12 times the human dose). There
was no evidence of drug-related tumorigenicity. A reproduction study in
rats at doses up to 38 times the human dose did not reveal any indication
of fertility impairment. Mutagenicity studies were not conducted. </p>

<p>PREGNANCY </p>

<p>TERATOGENIC EFFECTS. PREGNANCY CATEGORY B. Teratogenicity studies have
been performed in mice, rats, and rabbits at doses up to 50 times the human
dose and have revealed no evidence of harm to the fetus due to sucralfate.
There are, however, no adequate and well-controlled studies in pregnant
women. Because animal reproduction studies are not always predictive of
human response, this drug should be used during pregnancy only if clearly
needed. </p>

<p>NURSING MOTHERS </p>

<p>It is not known whether this drug is excreted in human milk. Because
many drugs are excreted in human milk, caution should be exercised when
sucralfate is administered to a nursing woman. </p>

<p>PEDIATRIC USE </p>

<p>Safety and effectiveness in children have not been established. </p>

<p><a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS </b></p>

<p>Some studies have shown that simultaneous sucralfate administration
in healthy volunteers reduced the extent of absorption (bioavailability)
of single doses of the following drugs: cimetidine, ciprofloxacin, digoxin,
ketoconazole, norfloxacin, phenytoin, ranitidine, tetracycline, and theophylline.
</p>

<p>Subtherapeutic prothrombin times with concomitant warfarin and sucralfate
therapy have been reported in spontaneous and published case reports. However,
two clinical studies have demonstrated no change in either serum warfarin
concentration or prothrombin time with the addition of sucralfate to chronic
warfarin therapy </p>

<p>The mechanism of these interactions appears to be nonsystemic in nature,
presumably resulting from sucralfate binding to the concomitant agent in
the gastrointestinal tract. In all cases studied to date (cimetidine, ciprofloxacin
digoxin, ranitidine, and warfarin), dosing the concomitant medication 2
hours before sucralfate eliminated the interaction. Because of the potential
of Sucralfate to alter the absorption of some drugs, Sucralfate should
be administered separately from other drugs when alterations in bioavailability
are felt to be critical. In these cases, patients should be monitored appropriately.
</p>

<p>(See Also PRECAUTIONS) </p>

<p><a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS </b></p>

<p>Adverse reactions to sucralfate in clinical trials were minor and only
rarely led to discontinuation of the drug. In studies involving over 2700
patients treated with sucralfate tablets, adverse effects were reported
in 129 (4.7%). </p>

<p>Constipation was the most frequent complaint (2%). Other adverse effects
reported in less than 0.5% of the patients are listed below by body system:
</p>

<p>GASTROINTESTINAL: diarrhea, nausea, vomiting, gastric discomfort, indigestion,
flatulence, dry mouth </p>

<p>DERMATOLOGICAL: pruritus, rash </p>

<p>NERVOUS SYSTEM: dizziness, insomnia, sleepiness, vertigo </p>

<p>OTHER: back pain, headache </p>

<p>Postmarketing reports of hypersensitivity reactions, including urticaria
(hives), angioedema, respiratory difficulty, and rhinitis have been received.
However, a causal relationship has not been established. </p>

<p><a name="OVERDOSAGE"></a><b>OVERDOSAGE </b></p>

<p>There is no experience in humans with overdosage. Acute oral toxicity
studies in animals, however, using doses up to 12 gm/kg body weight, could
not find a lethal dose. Risks associated with overdosage should, therefore,
be minimal. </p>

<p><a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION
</b></p>

<p>ACTIVE DUODENAL ULCER: The recommended adult oral dosage for duodenal
ulcer is 1 gm four times a day on an empty stomach. </p>

<p>Antacids may be prescribed as needed for relief of pain but should not
be taken within one-half hour before or after sucralfate. </p>

<p>While healing with sucralfate may occur during the first week or two,
treatment should be continued for 4 to 8 weeks unless healing has been
demonstrated by x ray or endoscopic examination. </p>

<p>MAINTENANCE THERAPY: The recommended adult oral dosage is 1 gm twice
a day. </p>

<p>
<hr width="100%" ></p>

<h2 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-26</DOCNO>
<DOCOLDNO>IA019-000201-B023-351</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/rxlist.cgi?drug=sleep 206.86.175.201 19970106234225 text/html 1046
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:36:08 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE>www.rxlist.com - Neil Sandow, Pharm.D. 
copyright 1995</title></head> <body bgcolor="#ffffff">
<center><a href="http://www.rxlist.com"><img src="rx.gif" 
height=75 width=75 border=0><img src="count.gif" border=0></a></center> 
Searching for: <b>SLEEP</b> <br>scroll down for results 
<hr><hr>
<h1>Enter Brand or Generic Name or Category*</h1>
<h3> Narrow Your Search with <font size=5>*</font>(examples: 
ampi*, *mycin, antibiotic*)</h3>
<form method=get>
<action=>
<input size=30 maxlength=30 name=drug>
<input type=submit>
<input type=reset>
</form>
<HR>
<H3>Your RxList Search Results:</h3>
1<br><b>Brand Name: </b>SLOW FE<br><b>Generic Name: </b>FERROUS SUL EXSICCATED<br><b>Category: </b>IRON PREPARATIONS
<p>2<br><b>Brand Name: </b>SULF<br><b>Generic Name: </b>SULFACETAMIDE SOD OPHTH<br><b>Category: </b>SULFONAMIDES
<p></body></html>
<P><hr><a href="http://www.rxlist.com"><b>RxList Home Page</ul>
<hr>
</DOC>
<DOC>
<DOCNO>WT08-B13-27</DOCNO>
<DOCOLDNO>IA019-000201-B024-8</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/rxlist.cgi??drug=watson349 206.86.175.201 19970106234238 text/html 35331
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:36:20 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE>www.rxlist.com - Neil Sandow, Pharm.D. 
copyright 1995</title></head> <body bgcolor="#ffffff">
<center><a href="http://www.rxlist.com"><img src="rx.gif" 
height=75 width=75 border=0><img src="count.gif" border=0></a></center> 
Searching for: <b></b> <br>scroll down for results 
<hr><hr>
<h1>Enter Brand or Generic Name or Category*</h1>
<h3> Narrow Your Search with <font size=5>*</font>(examples: 
ampi*, *mycin, antibiotic*)</h3>
<form method=get>
<action=>
<input size=30 maxlength=30 name=drug>
<input type=submit>
<input type=reset>
</form>
<HR>
<H3>Your RxList Search Results:</h3>
1<br><b>Brand Name: </b>DIASTAT<br><b>Generic Name: </b>DIAZEPAM RECTAL GEL<br><b>Category: </b>TREATMENT OF SEVERE EPILEPSY
<p>2<br><b>Brand Name: </b>EDEX<br><b>Generic Name: </b>ALPROSTADIL<br><b>Category: </b>TREATMENT OF ERECTILE DYSFUNCTION
<p>3<br><b>Brand Name: </b>GABITRIL<br><b>Generic Name: </b>TIAGABINE<br><b>Category: </b>ANTICONVULSANTS
<p>4<br><b>Brand Name: </b>URSO<br><b>Generic Name: </b>URSODEOXYCHOLIC ACID<br><b>Category: </b>TREATMENT OF PRIMARY BILIARY CIRRHOSIS
<p>5<br><b>Brand Name: </b>LIPITOR<br><b>Generic Name: </b>ATORVASTATIN<br><b>Category: </b>ANTILIPEMIC AGENTS
<p>6<br><b>Brand Name: </b>ZYFLO<br><b>Generic Name: </b>ZILEUTON<br><b>Category: </b>LEUKOTRIENE RECEPTOR ANTAGONIST (LTRA) FOR TREATMENT OF ASTHMA
<p>7<br><b>Brand Name: </b>FEMPATCH<br><b>Generic Name: </b>17-BETA ESTRADIOL (TRANSDERMAL)<br><b>Category: </b>ESTROGENS
<p>8<br><b>Brand Name: </b>DOSTINEX<br><b>Generic Name: </b>CABERGOLINE<br><b>Category: </b>TREATMENT OF HYPERPROLACTINEMIC DISORDERS
<p>9<br><b>Brand Name: </b>THERDERM EMTDS<br><b>Generic Name: </b>ESTRADIOL (TRANSDERMAL)<br><b>Category: </b>ESTROGENS
<p>10<br><b>Brand Name: </b>ELEQUIN<br><b>Generic Name: </b>LEVOFLOXACIN (INJ)<br><b>Category: </b>QUINOLINE ANTIBIOTICS
<p>11<br><b>Brand Name: </b>COPAXONE<br><b>Generic Name: </b>COPOLYMER-1 (INJ)<br><b>Category: </b>TREATMENT OF MULTIPLE SCLEROSIS
<p>12<br><b>Brand Name: </b>MONUROL<br><b>Generic Name: </b>FOSFOMYCIN TROMETHANE<br><b>Category: </b>TREATMENT OF UTI'S
<p>13<br><b>Brand Name: </b>OPATANOL<br><b>Generic Name: </b>OLOPATADINE HCL<br><b>Category: </b>TREATMENT OF ALLERGIC CONJUNCTIVITIS
<p>14<br><b>Brand Name: </b>GLYSET<br><b>Generic Name: </b>MIGLITOL<br><b>Category: </b>ANTIDIABETIC AGENTS
<p>15<br><b>Brand Name: </b>ZAGAM<br><b>Generic Name: </b>SPARFLOXACIN<br><b>Category: </b>QUINOLINE ANTIBIOTICS
<p>16<br><b>Brand Name: </b>ALORA<br><b>Generic Name: </b>ESTRADIOL TRANSDERMAL<br><b>Category: </b>ESTROGENS
<p>17<br><b>Brand Name: </b>LEVAQUIN<br><b>Generic Name: </b>LEVOFLOXACIN<br><b>Category: </b>QUINOLINE ANTIBIOTICS
<p>18<br><b>Brand Name: </b>APHTHASOL<br><b>Generic Name: </b>AMLEXANOX<br><b>Category: </b>TREATMENT OF APHTHOUS ULCERS
<p>19<br><b>Brand Name: </b>LOTREL<br><b>Generic Name: </b>AMLODIPINE/BENAZEPRIL HCL<br><b>Category: </b>SEE AMLODIPINE AND/OR BENAZEPRIL
<p>20<br><b>Brand Name: </b>ERGOMAR<br><b>Generic Name: </b>ERGOTAMINE TARTRATE<br><b>Category: </b>SYMPATHOLYTIC AGENTS
<p>21<br><b>Brand Name: </b>ERGOSTAT<br><b>Generic Name: </b>ERGOTAMINE TARTRATE<br><b>Category: </b>SYMPATHOLYTIC AGENTS
<p>22<br><b>Brand Name: </b>REZULIN<br><b>Generic Name: </b>TROGLITAZONE<br><b>Category: </b>ANTIDIABETIC AGENTS
<p>23<br><b>Brand Name: </b>MERIDIA<br><b>Generic Name: </b>SIBUTRAMINE HCL<br><b>Category: </b>ANTIDEPRESSANT/ANTIOBESITY
<p>24<br><b>Brand Name: </b>NORMIFLO<br><b>Generic Name: </b>ARDEPARIN SODIUM<br><b>Category: </b>ANTICOAGULANT
<p>25<br><b>Brand Name: </b>FERRISELTZ<br><b>Generic Name: </b>FERRIC AMMONIUM CITRATE<br><b>Category: </b>BOWEL CONTRAST AGENT FOR MRI
<p>26<br><b>Brand Name: </b>LEXXEL<br><b>Generic Name: </b>ENALAPRIL MALEATE/FELODIPINE<br><b>Category: </b>ANTIHYPERTENSIVES
<p>27<br><b>Brand Name: </b>ARICEPT<br><b>Generic Name: </b>DONEPEXIL HCL<br><b>Category: </b>TREATMENT OF ALZHEIMER'S DISEASE
<p>28<br><b>Brand Name: </b>E2020<br><b>Generic Name: </b>DONEPEXIL HCL<br><b>Category: </b>TREATMENT OF ALZHEIMER'S DISEASE
<p>29<br><b>Brand Name: </b>AMPHOTEC<br><b>Generic Name: </b>AMPHOTERICIN B CHOLESTERYL SULFATE COMPLEX<br><b>Category: </b>ANTIFUNGALS
<p>30<br><b>Brand Name: </b>MUSE<br><b>Generic Name: </b>ALPROSTADIL<br><b>Category: </b>TREATMENT OF IMPOTENCE
<p>31<br><b>Brand Name: </b>MECTIZAN<br><b>Generic Name: </b>IVERMECTIN<br><b>Category: </b>TREATMENT OF STRONGYLOIDES/ONCHOCERCIASIS
<p>32<br><b>Brand Name: </b>NASCOBAL<br><b>Generic Name: </b>CYANOCOBALAMIN<br><b>Category: </b>VITAMIN B COMPLEX
<p>33<br><b>Brand Name: </b>NIX<br><b>Generic Name: </b>PERMETHRIN<br><b>Category: </b>ERADICATION/PROPHYLAXIS OF HEAD LICE
<p>34<br><b>Brand Name: </b>SR-2599DC<br><b>Generic Name: </b>CLOPIDOGREL<br><b>Category: </b>ORAL ANTITHROMBIC AGENT (INVESTIGATIONAL)
<p>35<br><b>Brand Name: </b>GUAIFENESIN<br><b>Generic Name: </b>GUAIFENESIN<br><b>Category: </b>SEE <a href="http://www.rxlist.com/cgi/generic/guaicod.htm">GUAIFENESIN & CODEINE</a>
<p>36<br><b>Brand Name: </b>GUAIFENESIN<br><b>Generic Name: </b>GUAIFENESIN<br><b>Category: </b>SEE <a href="http://www.rxlist.com/cgi/generic/guaiphen.htm">GUAIFENESIN & PHENYLPROPANOLAMINE</a>
<p>37<br><b>Brand Name: </b>SYNERCID (RP 59500)<br><b>Generic Name: </b>QUINUPRISTIN/DALFOPRISTIN<br><b>Category: </b>ANTIBIOTICS (INVESTIGATIONAL)
<p>38<br><b>Brand Name: </b>DENAVIR<br><b>Generic Name: </b>PENCICLOVIR<br><b>Category: </b>ANTIVIRALS
<p>39<br><b>Brand Name: </b>FERTINEX<br><b>Generic Name: </b>FOLLICLE STIMULATING HORMONE (FSH)<br><b>Category: </b>HORMONES
<p>40<br><b>Brand Name: </b>FERTINEX<br><b>Generic Name: </b>FSH<br><b>Category: </b>HORMONES
<p>41<br><b>Brand Name: </b>COPAXONE<br><b>Generic Name: </b>COPOLYMER 1<br><b>Category: </b>TREATMENT OF M.S.
<p>42<br><b>Brand Name: </b>VIRACEPT<br><b>Generic Name: </b>NELFINAVIR<br><b>Category: </b>ANTIVIRALS
<p>43<br><b>Brand Name: </b>ERGOSET<br><b>Generic Name: </b>BROMOCRIPTINE<br><b>Category: </b>UNCLASSIFIED THERAPEUTIC AGENTS
<p>44<br><b>Brand Name: </b>SORIATANE<br><b>Generic Name: </b>ACITRETIN<br><b>Category: </b>TREATMENT OF PSORIASIS
<p>45<br><b>Brand Name: </b>ASTELIN<br><b>Generic Name: </b>AZELASTINE<br><b>Category: </b>ANTIHISTAMINES
<p>46<br><b>Brand Name: </b>RETAVASE<br><b>Generic Name: </b>RETEPLASE<br><b>Category: </b>THROMBOLYTICS
<p>47<br><b>Brand Name: </b>SAIZEN<br><b>Generic Name: </b>SOMATROPIN<br><b>Category: </b>PITUITARY
<p>48<br><b>Brand Name: </b>ESTROSTEP<br><b>Generic Name: </b>ETHINYL ESTRADIOL/NORETHINDRONE<br><b>Category: </b>CONTRACEPTIVES
<p>49<br><b>Brand Name: </b>LODINE XL<br><b>Generic Name: </b>ETODOLAC<br><b>Category: </b>NONSTEROIDAL ANTIINFLAMMATORY AGENTS
<p>50<br><b>Brand Name: </b>CYSTADANE<br><b>Generic Name: </b>BETAINE<br><b>Category: </b>TREATMENT OF HOMOCYSTINUREAL
<p>51<br><b>Brand Name: </b>COMBIVENT<br><b>Generic Name: </b>ALBUTEROL/IPRATROPIUM<br><b>Category: </b>BRONCHODILATORS
<p>52<br><b>Brand Name: </b>TARKA<br><b>Generic Name: </b>TRANDOLAPRIL/VERAPAMIL<br><b>Category: </b>ANTIHYPERTENSIVES
<p>53<br><b>Brand Name: </b>MENTAX<br><b>Generic Name: </b>BUTENAFINE HCL<br><b>Category: </b>ANTIFUNGALS
<p>54<br><b>Brand Name: </b>TIAMATE<br><b>Generic Name: </b>DILTIAZEM<br><b>Category: </b>ANTIHYPERTENSIVES
<p>55<br><b>Brand Name: </b>DURACLON<br><b>Generic Name: </b>CLONIDINE HCL<br><b>Category: </b>EPIDURAL ADJUNCT TO OPIATE THERAPY
<p>56<br><b>Brand Name: </b><a href="http://www.lec.org/DrugSearch/Documents/Rohypnol.html">ROHYPNOL</a><br><b>Generic Name: </b>FLUNITRAZEPAM<br><b>Category: </b>MISC. SEDATIVES/HYPNOTICS (NOTE: NOT MARKETED IN THE US)
<p>57<br><b>Brand Name: </b>KADIAN<br><b>Generic Name: </b>MORPHINE SULFATE SA<br><b>Category: </b>OPIATE AGONISTS
<p>58<br><b>Brand Name: </b>COCAINE<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/cocaine.htm">COCAINE HCL</a><br><b>Category: </b>ANTIPRURITICS AND LOCAL ANESTHETICS
<p>59<br><b>Brand Name: </b>TECZEM<br><b>Generic Name: </b>ENALAPRIL MALEATE & DILTIAZEM MALEATE<br><b>Category: </b>ANTIHYPERTENSIVES
<p>60<br><b>Brand Name: </b>TICLID<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/ticlop.htm">TICLOPIDINE HCL</a><br><b>Category: </b>PLATELET AGGREGATION INHIBITORS
<p>61<br><b>Brand Name: </b>PARACETAMOL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">SEE ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>62<br><b>Brand Name: </b>DHEA<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/dhea.htm">DEHYDROEPIANDROSTERONE</a><br><b>Category: </b>UNAPPROVED
<p>63<br><b>Brand Name: </b>ANTIBIOTIC<br><b>Generic Name: </b>TYPE ANTIBIOT*<br><b>Category: </b>USE * TO SORT ON CATEGORY
<p>64<br><b>Brand Name: </b>NILANDRON<br><b>Generic Name: </b>NILUTAMIDE<br><b>Category: </b>ANTIANDROGENS
<p>65<br><b>Brand Name: </b>PONDIMIN<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/fenflur.htm">FENFLURAMINE HCL</a><br><b>Category: </b>APPETITE SUPPRESSANT
<p>66<br><b>Brand Name: </b>ALPHAGAN<br><b>Generic Name: </b>BRIMONIDINE TARTRATE<br><b>Category: </b>MISCELLANEOUS EENT AGENTS (GLAUCOMA)
<p>67<br><b>Brand Name: </b>FERTINEX<br><b>Generic Name: </b>UROFOLLITROPIN<br><b>Category: </b>FOLLICLE STIMULATING HORMONE
<p>68<br><b>Brand Name: </b>IVY BLOCK<br><b>Generic Name: </b>URUSHIOL<br><b>Category: </b>MISCEL.SKIN AND MUCUS MEMBRANE AGENTS
<p>69<br><b>Brand Name: </b>ZENTATE<br><b>Generic Name: </b>VITAMINS PRENATAL<br><b>Category: </b>MULTIVITAMIN PREPARATIONS
<p>70<br><b>Brand Name: </b>ETOPOPHOS<br><b>Generic Name: </b>ETOPOSIDE PHOSPHATE<br><b>Category: </b>ANTINEOPLASTICS
<p>71<br><b>Brand Name: </b>SEROSTIM<br><b>Generic Name: </b>SOMATOTROPIN<br><b>Category: </b>PITUITARY
<p>72<br><b>Brand Name: </b>ZYPREXA<br><b>Generic Name: </b>OLANZAPINE<br><b>Category: </b>ANTIPSYCHOTICS
<p>73<br><b>Brand Name: </b>HURRICAINE<br><b>Generic Name: </b>BENZOCAINE<br><b>Category: </b>LOCAL ANESTHETICS
<p>74<br><b>Brand Name: </b>HURRICAINE<br><b>Generic Name: </b>BENZOCAINE<br><b>Category: </b>ANTIPRURITICS AND LOCAL ANESTHETICS
<p>75<br><b>Brand Name: </b>MERREM I.V.<br><b>Generic Name: </b>MEROPENEM<br><b>Category: </b>MISCELLANEOUS ANTIBIOTICS
<p>76<br><b>Brand Name: </b>PROAMATINE<br><b>Generic Name: </b>MIDODRINE<br><b>Category: </b>TREATMENT OF ORTHOSTATIC HYPERTENSION
<p>77<br><b>Brand Name: </b>RU-486<br><b>Generic Name: </b>MIFEPRISTONE<br><b>Category: </b>TERMINATION OF PREGNANCY
<p>78<br><b>Brand Name: </b>ALBENZA<br><b>Generic Name: </b>ALBENDAZOLE<br><b>Category: </b>ANTHELMINTICS
<p>79<br><b>Brand Name: </b>DIFFERIN<br><b>Generic Name: </b>ADAPALENE<br><b>Category: </b>MISCEL.SKIN AND MUCUS MEMBRANE AGENTS
<p>80<br><b>Brand Name: </b>CARBEX<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/seleg.htm">SELEGILINE HCL</a><br><b>Category: </b>FOR PARKINSON'S DISEASE
<p>81<br><b>Brand Name: </b>HELIDAC<br><b>Generic Name: </b>BISMUTH SUBSAL. METRONIDAZOLE & TETRACYCLINE<br><b>Category: </b>FOR PEPTIC ULCER DISEASE
<p>82<br><b>Brand Name: </b>TRITEC<br><b>Generic Name: </b>RANITIDINE BISMUTH CITRATE<br><b>Category: </b>MISCELLANEOUS GI DRUGS
<p>83<br><b>Brand Name: </b>CEREBYX<br><b>Generic Name: </b>FOSPHENYTOIN SODIUM<br><b>Category: </b>HYDANTOINS
<p>84<br><b>Brand Name: </b>ALLEGRA<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/fexofen.htm">FEXOFENADINE</a><br><b>Category: </b>ANTIHISTAMINES
<p>85<br><b>Brand Name: </b>CAMPTOSAR<br><b>Generic Name: </b>IRINOTECAN HCL<br><b>Category: </b>ANTINEOPLASTICS
<p>86<br><b>Brand Name: </b>XALATAN<br><b>Generic Name: </b>LATANOPROST<br><b>Category: </b>GLAUCOMA THERAPY
<p>87<br><b>Brand Name: </b>REMERON<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/mirtaz.htm">MIRTAZAPINE</a><br><b>Category: </b>ANTIDEPRESSANTS
<p>88<br><b>Brand Name: </b>VIRAMUNE<br><b>Generic Name: </b>NEVIRAPINE<br><b>Category: </b>ANIVIRALS
<p>89<br><b>Brand Name: </b>MYOTROPHIN<br><b>Generic Name: </b>SOMATOMEDIN C<br><b>Category: </b>FOR AMYOTROPHIC LATERAL SCLEROSIS
<p>90<br><b>Brand Name: </b>HUMULIN N<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/humnph.htm">HUMAN INSULIN NPH</a> <br><b>Category: </b>INSULINS
<p>91<br><b>Brand Name: </b>HUMULIN R<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/huminsr.htm">HUMAN INSULIN REGULAR</a><br><b>Category: </b>INSULINS
<p>92<br><b>Brand Name: </b>HUMULIN L<br><b>Generic Name: </b>HUMAN INSULIN LENTE<br><b>Category: </b>INSULINS
<p>93<br><b>Brand Name: </b>HUMULIN 70/30<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/hum7030.htm">HUMAN INSULIN NPH/REG 70/30</a><br><b>Category: </b>INULINS
<p>94<br><b>Brand Name: </b>ORTHO-NOVUM 7/7/7<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/norestoc.htm">NORETHINDRONE/ETHINYL ESTRADIOL</a> <br><b>Category: </b>CONTRACEPTIVES
<p>95<br><b>Brand Name: </b>ORTHO-CEPT<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/desest.htm">DESOGESTREL/ETHINYLESTRADIOL</A><br><b>Category: </b>CONTRACEPTIVES
<p>96<br><b>Brand Name: </b>ACCUPRIL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/quinap.htm">QUINAPRIL HCL</a><br><b>Category: </b>HYPOTENSIVE AGENTS
<p>97<br><b>Brand Name: </b>ACTHREL<br><b>Generic Name: </b>CORTICORELIN OVINE TRIFLUTATE<br><b>Category: </b>DIAGNOSTIC AGENTS
<p>98<br><b>Brand Name: </b>BUPHENYL<br><b>Generic Name: </b>SODIUM PHENYLBUTYRATE<br><b>Category: </b>FOR UREA CYCLE DISORDERS
<p>99<br><b>Brand Name: </b>VISIPAQUE<br><b>Generic Name: </b>IODIXANOL<br><b>Category: </b>ROENTGENOGRAPHY
<p>100<br><b>Brand Name: </b>NAPRELAN<br><b>Generic Name: </b>NAPROXEN SODIUM<br><b>Category: </b>NONSTEROIDAL ANTIINFLAMMATORY AGENTS
<p>101<br><b>Brand Name: </b>OXILAN<br><b>Generic Name: </b>IOXILAN<br><b>Category: </b>ROENTGENOGRAPHY
<p>102<br><b>Brand Name: </b>IONTOCAINE<br><b>Generic Name: </b>LIDOCAINE/EPINEPHRINE<br><b>Category: </b>LOCAL ANESTHETICS
<p>103<br><b>Brand Name: </b>PENTACEF<br><b>Generic Name: </b>CEFTAZIDINE<br><b>Category: </b>ANTIBIOTICS: CEPHALOSPORINS
<p>104<br><b>Brand Name: </b>METROCREAM<br><b>Generic Name: </b>METRONIDAZOLE<br><b>Category: </b>MISCELLANEOUS ANTI-INFECTIVES
<p>105<br><b>Brand Name: </b>GENOTROPIN<br><b>Generic Name: </b>SOMATROPIN<br><b>Category: </b>PITUITARY
<p>106<br><b>Brand Name: </b>SEVORANE<br><b>Generic Name: </b>SEVOFLURANE<br><b>Category: </b>GENERAL ANESTHETICS
<p>107<br><b>Brand Name: </b>BIOTROPIN<br><b>Generic Name: </b>SOMATROPIN<br><b>Category: </b>PITUITARY
<p>108<br><b>Brand Name: </b>ULTRAVIST<br><b>Generic Name: </b>IOPROMIDE<br><b>Category: </b>ROENTGENOGRAPHY
<p>109<br><b>Brand Name: </b>NORDITROPIN<br><b>Generic Name: </b>SOMATROPIN<br><b>Category: </b>PITUITARY
<p>110<br><b>Brand Name: </b>PROVEL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/ibup.htm">IBUPROFEN</A><br><b>Category: </b>NONSTEROIDAL ANTIINFLAMMATORY AGENTS
<p>111<br><b>Brand Name: </b>NISOCOR<br><b>Generic Name: </b>NISOLDIPINE<br><b>Category: </b>CARDIAC DRUGS
<p>112<br><b>Brand Name: </b>APTHASOL<br><b>Generic Name: </b>AMLEXANOX<br><b>Category: </b>TREATMENT OF CANKER SORES
<p>113<br><b>Brand Name: </b>ALPHANATE<br><b>Generic Name: </b>ANTIHEMOPHILIC FACTOR<br><b>Category: </b>HEMOSTATICS
<p>114<br><b>Brand Name: </b>OXYCONTIN<br><b>Generic Name: </b>OXYCODONE HCL<br><b>Category: </b>OPIATE AGONISTS
<p>115<br><b>Brand Name: </b>HYCAMTIN<br><b>Generic Name: </b>TOPOTECAN<br><b>Category: </b>ANTINEOPLASTICS
<p>116<br><b>Brand Name: </b>OXANDRIN<br><b>Generic Name: </b>OXANDROLONE<br><b>Category: </b>ANDROGENS
<p>117<br><b>Brand Name: </b>WINRHO SD<br><b>Generic Name: </b>RHO(D)IMMUNE GLOBULIN<br><b>Category: </b>SERUMS
<p>118<br><b>Brand Name: </b>AVONEX<br><b>Generic Name: </b>INTERFERON BETA-1A<br><b>Category: </b>TREATMENT OF MULTIPLE SCLEROSIS
<p>119<br><b>Brand Name: </b>GEMZAR<br><b>Generic Name: </b>GEMCITABINE HCL<br><b>Category: </b>ANTINEOPLASTICS
<p>120<br><b>Brand Name: </b>DEXFERRUM<br><b>Generic Name: </b>IRON DEXTRAN<br><b>Category: </b>IRON PRODUCTS
<p>121<br><b>Brand Name: </b>CORMAX<br><b>Generic Name: </b>CLOBETASOL PROPIONATE<br><b>Category: </b>ANTI-INFLAMMATORY AGENTS
<p>122<br><b>Brand Name: </b>VITRASERT<br><b>Generic Name: </b>GANCICLOVIR<br><b>Category: </b>ANTIVIRALS
<p>123<br><b>Brand Name: </b>CYTOVENE<br><b>Generic Name: </b>GANCICLOVIR<br><b>Category: </b>ANTIVIRALS
<p>124<br><b>Brand Name: </b>HUMALOG<br><b>Generic Name: </b>INSULIN LISPRO<br><b>Category: </b>INSULINS
<p>125<br><b>Brand Name: </b>DAUNOXOME<br><b>Generic Name: </b>DAUNORUBICIN CITRATE (LIPOSOME)<br><b>Category: </b>ANTINEOPLASTICS
<p>126<br><b>Brand Name: </b>ESTRING<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/estrad.htm">ESTRADIOL</A><br><b>Category: </b>ESTROGENS
<p>127<br><b>Brand Name: </b>ARIMEDEX<br><b>Generic Name: </b>ANASTROZOLE<br><b>Category: </b>ANTINEOPLASTICS
<p>128<br><b>Brand Name: </b>VISTIDE<br><b>Generic Name: </b>CIDOFOVIR<br><b>Category: </b>ANTIVIRALS
<p>129<br><b>Brand Name: </b>NICOTROL NS<br><b>Generic Name: </b>NICOTINE(NASAL)<br><b>Category: </b>MISCELLANEOUS AUTONOMIC DRUGS 
<p>130<br><b>Brand Name: </b>VIQUIN FORTE<br><b>Generic Name: </b>HYDROQUINONE<br><b>Category: </b>DEPIGMENTING AGENTS
<p>131<br><b>Brand Name: </b>REDUX<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/dexfen.htm">DEXFENFLURAMINE</a><br><b>Category: </b>ANTI-OBESITY AGENTS
<p>132<br><b>Brand Name: </b>ZANAFLEX<br><b>Generic Name: </b>TIZANIDINE HCL<br><b>Category: </b>SKELETAL MUSCLE RELAXANTS
<p>133<br><b>Brand Name: </b>PREVALITE<br><b>Generic Name: </b>CHOLESTYRAMINE<br><b>Category: </b>ANTILIPEMIC AGENTS
<p>134<br><b>Brand Name: </b>FERIDEX<br><b>Generic Name: </b>FERUMOXIDE<br><b>Category: </b>MAGNETIC RESONANCE IMAGING
<p>135<br><b>Brand Name: </b>MAVIK<br><b>Generic Name: </b>TRANDOLAPRIL<br><b>Category: </b><a href="http://www.rxlist.com/cardiova.htm">HYPOTENSIVE AGENTS</a> 
<p>136<br><b>Brand Name: </b>NAROPIN<br><b>Generic Name: </b>ROPIVACAINE<br><b>Category: </b>LOCAL ANESTHETICS
<p>137<br><b>Brand Name: </b>SCLEROSOL<br><b>Generic Name: </b>TALC<br><b>Category: </b>SCLEROSING AGENTS
<p>138<br><b>Brand Name: </b>TOPAMAX<br><b>Generic Name: </b>TOPIRAMATE<br><b>Category: </b>MISCELLANEOUS ANTICONVULSANTS
<p>139<br><b>Brand Name: </b>VAQTA<br><b>Generic Name: </b>HEPATITIS A VACCINE<br><b>Category: </b>VACCINES
<p>140<br><b>Brand Name: </b>MYOVIEW<br><b>Generic Name: </b>TETROPHOSMIN<br><b>Category: </b>RADIOPHARMACEUTICALS
<p>141<br><b>Brand Name: </b>OCUHIST<br><b>Generic Name: </b>PHENIRAMINE MALEATE<br><b>Category: </b>ANTIHISTAMINE DRUGS
<p>142<br><b>Brand Name: </b>COVERA-HS<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/verapsr.htm">VERAPAMIL</A> HCL<br><b>Category: </b><a href="http://www.rxlist.com/cardiova.htm">CARDIAC DRUGS</a> 
<p>143<br><b>Brand Name: </b>SYNOVIR<br><b>Generic Name: </b>THALIDOMIDE<br><b>Category: </b>AIDS-CACHEXIA
<p>144<br><b>Brand Name: </b>VESANOID<br><b>Generic Name: </b>TRETINOIN<br><b>Category: </b>ANTINEOPLASTIC AGENTS
<p>145<br><b>Brand Name: </b>TEICHOMYCIN<br><b>Generic Name: </b>TEICOPLANIN<br><b>Category: </b>MISCELLANEOUS ANTIBIOTICS
<p>146<br><b>Brand Name: </b>NORVIR<br><b>Generic Name: </b>RITONAVIR<br><b>Category: </b>ANTIVIRALS
<p>147<br><b>Brand Name: </b>NIMBEX<br><b>Generic Name: </b>CISATRACURIUM BESYLATE<br><b>Category: </b>SKELETAL MUSCLE RELAXANTS
<p>148<br><b>Brand Name: </b>MAXIPIME<br><b>Generic Name: </b>CEFEPIME<br><b>Category: </b>ANTIBIOTICS: CEPHALOSPORINS
<p>149<br><b>Brand Name: </b>PENNSAID<br><b>Generic Name: </b>DIMETHAID-D<br><b>Category: </b><a href="http://www.rxlist.com/nsaid.htm">NONSTEROIDAL ANTI-INFLAMMATORY AGENTS</a> 
<p>150<br><b>Brand Name: </b>ADDERALL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/amphet.htm">AMPHETAMINE MIXED SALTS</a><br><b>Category: </b>RESPIRATORY AND CEREBRAL STIMULANTS
<p>151<br><b>Brand Name: </b>CANDIN<br><b>Generic Name: </b>CANDIDA ALBICANS<br><b>Category: </b>FUNGI
<p>152<br><b>Brand Name: </b>ACTRON<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/ketoprof.htm">KETOPROFEN</a><br><b>Category: </b><a href="http://www.rxlist.com/nsaid.htm">NONSTEROIDAL ANTIINFLAMMATORY AGENTS</a> 
<p>153<br><b>Brand Name: </b>CEDAX<br><b>Generic Name: </b>CEFTIBUTEN<br><b>Category: </b>ANTIBIOTICS:CEPHALOSPORINS
<p>154<br><b>Brand Name: </b>RENOVA<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/tretinoin.htm">TRETINOIN</a><br><b>Category: </b>MISCEL.SKIN AND MUCUS MEMBRANE AGENTS
<p>155<br><b>Brand Name: </b>PHOTOFRIN<br><b>Generic Name: </b>PORFIMER SODIUM<br><b>Category: </b>ANTINEOPLASTIC AGENTS (PHOTODYNAMIC)
<p>156<br><b>Brand Name: </b>AMARYL<br><b>Generic Name: </b>GLIMEPIRIDE<br><b>Category: </b>ANTIDIABETIC AGENTS
<p>157<br><b>Brand Name: </b>FLOLAN<br><b>Generic Name: </b>EPOPROSTENOL SODIUM<br><b>Category: </b>VASODILATING AGENTS
<p>158<br><b>Brand Name: </b>RESPIGAM<br><b>Generic Name: </b>RSV-IGIV<br><b>Category: </b>SERUMS
<p>159<br><b>Brand Name: </b>CRIXIVAN<br><b>Generic Name: </b>INDINAVIR SULFATE<br><b>Category: </b>ANTIVIRALS
<p>160<br><b>Brand Name: </b>TRIPEDIA<br><b>Generic Name: </b>WHOOPING COUGH VACCINE<br><b>Category: </b>VACCINES
<p>161<br><b>Brand Name: </b>PROCANABID<br><b>Generic Name: </b>PROCAINAMIDE HCL<br><b>Category: </b>CARDIAC DRUGS
<p>162<br><b>Brand Name: </b>ZYRTEC<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/cetiriz.htm">CETIRIZINE HCL</a><br><b>Category: </b>ANTIHISTAMINE DRUGS
<p>163<br><b>Brand Name: </b>VIVELLE<br><b>Generic Name: </b>ESTRADIOL (TRANSDERMAL SYSTEM)<br><b>Category: </b>ESTROGEN
<p>164<br><b>Brand Name: </b>AZELEX<br><b>Generic Name: </b>ACELAIC ACID<br><b>Category: </b>SKIN AND MUCUS MEMBRANE AGENTS
<p>165<br><b>Brand Name: </b>ETHYOL<br><b>Generic Name: </b>AMIFOSTINE<br><b>Category: </b>UNCLASSIFIED THERAPEUTIC AGENTS
<p>166<br><b>Brand Name: </b>DOXIL<br><b>Generic Name: </b> DOXORUBICIN HCL (LIPOSOME INJECTION)<br><b>Category: </b>ANTIONEOPLASTIC AGENTS
<p>167<br><b>Brand Name: </b>ABELCET<br><b>Generic Name: </b>ABCL(AMPHOTERICIN B LIPID COMPLEX LIPOSOME INJ)<br><b>Category: </b>ANTIFUNGALS
<p>168<br><b>Brand Name: </b>PRECOSE<br><b>Generic Name: </b>ACARBOSE<br><b>Category: </b>ANTIDIABETIC AGENTS
<p>169<br><b>Brand Name: </b>RILUTEK<br><b>Generic Name: </b>RILUZOLE<br><b>Category: </b>FOR AMYOTROPHIC LATERAL SCLEROSIS
<p>170<br><b>Brand Name: </b>VALTREX<br><b>Generic Name: </b>VALACYCLOVIR<br><b>Category: </b>ANIVIRALS
<p>171<br><b>Brand Name: </b>FLOVENT<br><b>Generic Name: </b>FLUTICASONE PROPRIONATE<br><b>Category: </b>ANTIINFLAMMATORY AGENTS
<p>172<br><b>Brand Name: </b>DYNABAC<br><b>Generic Name: </b>DIRITHROMYCIN<br><b>Category: </b>ANTIBIOTICS:ERYTHROMYCINS
<p>173<br><b>Brand Name: </b>CORVERT<br><b>Generic Name: </b>IBUTILIDE<br><b>Category: </b>CARDIAC DRUGS
<p>174<br><b>Brand Name: </b>FARESTON<br><b>Generic Name: </b>TOREMIFENE CITRATE<br><b>Category: </b>ANTINEOPLASTIC AGENTS
<p>175<br><b>Brand Name: </b>COREG<br><b>Generic Name: </b>CARDEDILOL<br><b>Category: </b>CARDIAC DRUGS
<p>176<br><b>Brand Name: </b>TAXOTERE<br><b>Generic Name: </b>DOCETAXEL<br><b>Category: </b>ANTINEOPLASTIC AGENTS
<p>177<br><b>Brand Name: </b>BUTOX<br><b>Generic Name: </b>BOTULINUM TOXIN TYPE A<br><b>Category: </b>TOXOIDS
<p>178<br><b>Brand Name: </b>SULAR<br><b>Generic Name: </b>NISOLDIPINE<br><b>Category: </b>CARDIAC DRUGS
<p>179<br><b>Brand Name: </b>BLEO<br><b>Generic Name: </b>BLEOMYCIN<br><b>Category: </b>ANTINEOPLASTIC AGENTS
<p>180<br><b>Brand Name: </b>BLEOCIN<br><b>Generic Name: </b>BLEOMYCIN<br><b>Category: </b>ANTINEOPLASTIC AGENTS
<p>181<br><b>Brand Name: </b>BLENOXANE<br><b>Generic Name: </b>BLEOMYCIN<br><b>Category: </b>ANTINEOPLASTIC AGENTS
<p>182<br><b>Brand Name: </b>INVIRASE<br><b>Generic Name: </b>SAQUINAVIR<br><b>Category: </b>ANTIVIRALS
<p>183<br><b>Brand Name: </b>EPIVIR<br><b>Generic Name: </b>LAMIVUDINE<br><b>Category: </b>ANTIVIRALS
<p>184<br><b>Brand Name: </b>3TC<br><b>Generic Name: </b>LAMIVUDINE<br><b>Category: </b>ANTIVIRALS
<p>185<br><b>Brand Name: </b>AZT<br><b>Generic Name: </b>ZIDOVUDINE<br><b>Category: </b>ANTIVIRALS
<p>186<br><b>Brand Name: </b>NIZORAL<br><b>Generic Name: </b>KETOCONAZOLE<br><b>Category: </b>ANTIFUNGALS
<p>187<br><b>Brand Name: </b>NIZORAL TOPICAL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/ketocon.htm">KETOCONAZOLE TOPICAL</A><br><b>Category: </b>ANTIFUNGALS
<p>188<br><b>Brand Name: </b>METHERGINE<br><b>Generic Name: </b>METHYLERGONOVINE MALEATE<br><b>Category: </b>OXYTOCICS
<p>189<br><b>Brand Name: </b>LOTREL<br><b>Generic Name: </b>AMLODIPINE/BENAZEPRIL HCL<br><b>Category: </b><a href="http://www.rxlist.com/cardiova.htm">HYPOTENSIVE AGENTS</a> 
<p>190<br><b>Brand Name: </b>VEXOL<br><b>Generic Name: </b>RIMEXOLONE<br><b>Category: </b>OPTHALMIC CORTICOSTEROID
<p>191<br><b>Brand Name: </b>DR-3355<br><b>Generic Name: </b>LEVOFLOXACIN<br><b>Category: </b>INVESTIGATIONAL:ANTIBIOTICS:QUINOLINES
<p>192<br><b>Brand Name: </b>ORG-10172<br><b>Generic Name: </b>DANAPAROID<br><b>Category: </b>INVESTIGATIONAL:ANTICOAGULANTS
<p>193<br><b>Brand Name: </b>RU 44570<br><b>Generic Name: </b>TRANDOLAPRIL<br><b>Category: </b> <a href="http://www.rxlist.com/cardiova.htm">HYPOTENSIVE AGENTS</a> 
<p>194<br><b>Brand Name: </b>ACCOLATE<br><b>Generic Name: </b>ZAFIRLUKAST<br><b>Category: </b>RESPIRATORY:LEUKOTRIENE ANTAGONIST
<p>195<br><b>Brand Name: </b>TIAZAC<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/diltiaz.htm">DILTIAZEM HCL</a> <br><b>Category: </b><a href="http://www.rxlist.com/cardiova.htm">CARDIAC DRUGS</a> 
<p>196<br><b>Brand Name: </b>FOSAMAX<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/alendron.htm">ALENDRONATE SODIUM</a><br><b>Category: </b>MISCELLANEOUS:OSTEOPOROSIS
<p>197<br><b>Brand Name: </b>REOPRO<br><b>Generic Name: </b>ABCIXIMAB<br><b>Category: </b>UNCLASSIFIED THERAPEUTIC AGENTS
<p>198<br><b>Brand Name: </b>SECTRAL<br><b>Generic Name: </b>ACEBUTOLOL HCL<br><b>Category: </b><a href="http://www.rxlist.com/cardiova.htm">CARDIAC DRUGS</a> 
<p>199<br><b>Brand Name: </b>ACI-JEL W/APP<br><b>Generic Name: </b>ACET AC/RICINOLEIC/OXY<br><b>Category: </b>ANTI-INFECTIVES
<p>200<br><b>Brand Name: </b>ACEPHEN<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>201<br><b>Brand Name: </b>ACETAMIN<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>202<br><b>Brand Name: </b>ANACIN AF<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>203<br><b>Brand Name: </b>APAP<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>204<br><b>Brand Name: </b>BL INFANT N/A<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>205<br><b>Brand Name: </b>BL NON-ASPIRN<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>206<br><b>Brand Name: </b>FEVERALL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>207<br><b>Brand Name: </b>GENAPAP X/S<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>208<br><b>Brand Name: </b>GENEBS X/S<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>209<br><b>Brand Name: </b>GNP NON-ASPRN<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>210<br><b>Brand Name: </b>GNP NON-ASPRN<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>211<br><b>Brand Name: </b>GNP XS PAIN<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>212<br><b>Brand Name: </b>INFANTAIRE<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>213<br><b>Brand Name: </b>INFANTOL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>214<br><b>Brand Name: </b>MAPAP ACETAM<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>215<br><b>Brand Name: </b>PAIN &amp; FEVER<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>216<br><b>Brand Name: </b>PANADOL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>217<br><b>Brand Name: </b>PEDIAPAP<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>218<br><b>Brand Name: </b>TEMPRA 1<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>219<br><b>Brand Name: </b>TEMPRA 2<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>220<br><b>Brand Name: </b>TYLENOL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>221<br><b>Brand Name: </b>TYLENOL INFNT<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>222<br><b>Brand Name: </b>TYLENOL X/S<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>223<br><b>Brand Name: </b>BROMO SELTZER<br><b>Generic Name: </b>ACETAMINOPHEN BUFFERED<br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>224<br><b>Brand Name: </b>GENAPAP CHILD<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN CHEW</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>225<br><b>Brand Name: </b>ST JOS CHL/AF<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN CHEW</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>226<br><b>Brand Name: </b>TEMPRA 3 CHEW<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN CHEW</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>227<br><b>Brand Name: </b>TYLENOL CHILD<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN CHEW</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>228<br><b>Brand Name: </b>TYLENOL CHILD<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN CHEW</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>229<br><b>Brand Name: </b>TYLENOL X/RLF<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN SA</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>230<br><b>Brand Name: </b>PROMINOL<br><b>Generic Name: </b>ACETAMINOPHEN/BUTALBITAL<br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>231<br><b>Brand Name: </b>APAP/COD<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/acetcod.htm">ACETAMINOPHEN/CODEINE</a> <br><b>Category: </b><a href="opiate.htm">OPIATE AGONISTS</a> 
<p>232<br><b>Brand Name: </b>CAPITAL W/COD<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/acetcod.htm">ACETAMINOPHEN/CODEINE</a> <br><b>Category: </b><a href="opiate.htm">OPIATE AGONISTS</a> 
<p>233<br><b>Brand Name: </b>PHENAPHEN/COD<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/acetcod.htm">ACETAMINOPHEN/CODEINE</a> <br><b>Category: </b><a href="opiate.htm">OPIATE AGONISTS</a> 
<p>234<br><b>Brand Name: </b>TYLENOL/COD<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/acetcod.htm">ACETAMINOPHEN/CODEINE</a> <br><b>Category: </b><a href="opiate.htm">OPIATE AGONISTS</a> 
<p>235<br><b>Brand Name: </b>ACETAZOLAMIDE<br><b>Generic Name: </b>ACETAZOLAMIDE<br><b>Category: </b>CARBONIC ANHYDRASE INHIBITORS
<p>236<br><b>Brand Name: </b>DIAMOX<br><b>Generic Name: </b>ACETAZOLAMIDE<br><b>Category: </b>CARBONIC ANHYDRASE INHIBITORS
<p>237<br><b>Brand Name: </b>ACETASOL PLN<br><b>Generic Name: </b>ACETIC ACID OTIC<br><b>Category: </b>ANTI-INFECTIVES
<p>238<br><b>Brand Name: </b>DOMEBORO OTIC<br><b>Generic Name: </b>ACETIC ACID OTIC<br><b>Category: </b>ANTI-INFECTIVES
<p>239<br><b>Brand Name: </b>VOSOL OTIC<br><b>Generic Name: </b>ACETIC ACID OTIC<br><b>Category: </b>ANTI-INFECTIVES
<p>240<br><b>Brand Name: </b>ACETASOL HC<br><b>Generic Name: </b>ACETIC ACID/HYDROCORT OTI<br><b>Category: </b>ANTI-INFECTIVES
<p>241<br><b>Brand Name: </b>HYDRO/ACETIC<br><b>Generic Name: </b>ACETIC ACID/HYDROCORT OTI<br><b>Category: </b>ANTI-INFECTIVES
<p>242<br><b>Brand Name: </b>VASOTATE HC<br><b>Generic Name: </b>ACETIC ACID/HYDROCORT OTI<br><b>Category: </b>ANTI-INFECTIVES
<p>243<br><b>Brand Name: </b>VOSOL HC OTIC<br><b>Generic Name: </b>ACETIC ACID/HYDROCORT OTI<br><b>Category: </b>ANTI-INFECTIVES
<p>244<br><b>Brand Name: </b>DYMELOR<br><b>Generic Name: </b>ACETOHEXAMIDE<br><b>Category: </b>SULFONYLUREAS
<p>245<br><b>Brand Name: </b>LITHOSTAT<br><b>Generic Name: </b>ACETOHYDROXAMIC ACID<br><b>Category: </b>AMMONIA DETOXICANTS
<p>246<br><b>Brand Name: </b>SEBA-NIL<br><b>Generic Name: </b>ACETONE/ALCOHOL/POLYSORB<br><b>Category: </b>MISCEL.SKIN AND MUCUS MEMBRANE AGENTS
<p>247<br><b>Brand Name: </b>MIOCHOL E W/<br><b>Generic Name: </b>ACETYLCHOLINE CHL<br><b>Category: </b>MIOTICS
<p>248<br><b>Brand Name: </b>ACETYLCYSTEIN<br><b>Generic Name: </b>ACETYLCYSTEINE<br><b>Category: </b>MUCOLYTIC AGENTS
<p>249<br><b>Brand Name: </b>MUCOMYST<br><b>Generic Name: </b>ACETYLCYSTEINE<br><b>Category: </b>MUCOLYTIC AGENTS
<p>250<br><b>Brand Name: </b>MUCOSIL<br><b>Generic Name: </b>ACETYLCYSTEINE<br><b>Category: </b>MUCOLYTIC AGENTS
<p></body></html>
<P><hr><a href="http://www.rxlist.com"><b>RxList Home Page</ul>
<hr>
</DOC>
<DOC>
<DOCNO>WT08-B13-28</DOCNO>
<DOCOLDNO>IA019-000201-B024-23</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/rxlist.cgi?drug=PONDIMIN 206.86.175.201 19970106234248 text/html 2486
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:36:32 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE>www.rxlist.com - Neil Sandow, Pharm.D. 
copyright 1995</title></head> <body bgcolor="#ffffff">
<center><a href="http://www.rxlist.com"><img src="rx.gif" 
height=75 width=75 border=0><img src="count.gif" border=0></a></center> 
Searching for: <b>PONDIMIN</b> <br>scroll down for results 
<hr><hr>
<h1>Enter Brand or Generic Name or Category*</h1>
<h3> Narrow Your Search with <font size=5>*</font>(examples: 
ampi*, *mycin, antibiotic*)</h3>
<form method=get>
<action=>
<input size=30 maxlength=30 name=drug>
<input type=submit>
<input type=reset>
</form>
<HR>
<H3>Your RxList Search Results:</h3>
1<br><b>Brand Name: </b>PONDIMIN<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/fenflur.htm">FENFLURAMINE HCL</a><br><b>Category: </b>APPETITE SUPPRESSANT
<p>2<br><b>Brand Name: </b>NEBUPENT<br><b>Generic Name: </b>PENTAMIDINE ISETHIONATE<br><b>Category: </b>MISCELLANEOUS ANTI-INFECTIVES
<p>3<br><b>Brand Name: </b>PENTAM LYOPHZ<br><b>Generic Name: </b>PENTAMIDINE ISETHIONATE<br><b>Category: </b>MISCELLANEOUS ANTI-INFECTIVES
<p>4<br><b>Brand Name: </b>BONTRIL PDM<br><b>Generic Name: </b>PHENDIMETRAZINE TARTRATE<br><b>Category: </b>RESPIRATORY AND CEREBRAL STIMULANTS
<p>5<br><b>Brand Name: </b>MELFIAT<br><b>Generic Name: </b>PHENDIMETRAZINE TARTRATE<br><b>Category: </b>RESPIRATORY AND CEREBRAL STIMULANTS
<p>6<br><b>Brand Name: </b>PHENDIMETRAZI<br><b>Generic Name: </b>PHENDIMETRAZINE TARTRATE<br><b>Category: </b>RESPIRATORY AND CEREBRAL STIMULANTS
<p>7<br><b>Brand Name: </b>PLEGINE<br><b>Generic Name: </b>PHENDIMETRAZINE TARTRATE<br><b>Category: </b>RESPIRATORY AND CEREBRAL STIMULANTS
<p>8<br><b>Brand Name: </b>PRELU-2<br><b>Generic Name: </b>PHENDIMETRAZINE TARTRATE<br><b>Category: </b>RESPIRATORY AND CEREBRAL STIMULANTS
<p>9<br><b>Brand Name: </b>PHENYTOIN<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/phenyt.htm">PHENYTOIN</a> <br><b>Category: </b>HYDANTOINS
<p>10<br><b>Brand Name: </b>DILANTIN<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/phenyt.htm">PHENYTOIN SODIUM</a> <br><b>Category: </b>HYDANTOINS
<p>11<br><b>Brand Name: </b>DILANTIN<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/phenyt.htm">PHENYTOIN SODIUM EXTENDED</a> <br><b>Category: </b>HYDANTOINS
<p></body></html>
<P><hr><a href="http://www.rxlist.com"><b>RxList Home Page</ul>
<hr>
</DOC>
<DOC>
<DOCNO>WT08-B13-29</DOCNO>
<DOCOLDNO>IA019-000201-B024-34</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/rxlist.cgi?drug=Chlorhexidine 206.86.175.201 19970106234257 text/html 3360
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:36:41 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE>www.rxlist.com - Neil Sandow, Pharm.D. 
copyright 1995</title></head> <body bgcolor="#ffffff">
<center><a href="http://www.rxlist.com"><img src="rx.gif" 
height=75 width=75 border=0><img src="count.gif" border=0></a></center> 
Searching for: <b>CHLORHEXIDINE</b> <br>scroll down for results 
<hr><hr>
<h1>Enter Brand or Generic Name or Category*</h1>
<h3> Narrow Your Search with <font size=5>*</font>(examples: 
ampi*, *mycin, antibiotic*)</h3>
<form method=get>
<action=>
<input size=30 maxlength=30 name=drug>
<input type=submit>
<input type=reset>
</form>
<HR>
<H3>Your RxList Search Results:</h3>
1<br><b>Brand Name: </b>BETASEPT SURG<br><b>Generic Name: </b>CHLORHEXIDINE GLUCONATE<br><b>Category: </b>MISCELLANEOUS LOCAL ANTI-INFECTIVES
<p>2<br><b>Brand Name: </b>CHLOROSTAT 4<br><b>Generic Name: </b>CHLORHEXIDINE GLUCONATE<br><b>Category: </b>MISCELLANEOUS LOCAL ANTI-INFECTIVES
<p>3<br><b>Brand Name: </b>DYNA-HEX<br><b>Generic Name: </b>CHLORHEXIDINE GLUCONATE<br><b>Category: </b>MISCELLANEOUS LOCAL ANTI-INFECTIVES
<p>4<br><b>Brand Name: </b>HIBICLENS<br><b>Generic Name: </b>CHLORHEXIDINE GLUCONATE<br><b>Category: </b>MISCELLANEOUS LOCAL ANTI-INFECTIVES
<p>5<br><b>Brand Name: </b>HIBICLENS HND<br><b>Generic Name: </b>CHLORHEXIDINE GLUCONATE<br><b>Category: </b>MISCELLANEOUS LOCAL ANTI-INFECTIVES
<p>6<br><b>Brand Name: </b>HIBISTAT<br><b>Generic Name: </b>CHLORHEXIDINE GLUCONATE<br><b>Category: </b>MISCELLANEOUS LOCAL ANTI-INFECTIVES
<p>7<br><b>Brand Name: </b>PERIDEX<br><b>Generic Name: </b>CHLORHEXIDINE GLUCONATE<br><b>Category: </b>DENTAL AGENTS
<p>8<br><b>Brand Name: </b>PERIOGARD<br><b>Generic Name: </b>CHLORHEXIDINE GLUCONATE<br><b>Category: </b>DENTAL AGENTS
<p>9<br><b>Brand Name: </b>CHLORESIUM<br><b>Generic Name: </b>CHLOROPHYLLIN<br><b>Category: </b>MISCEL.SKIN AND MUCUS MEMBRANE AGENTS
<p>10<br><b>Brand Name: </b>ARALEN<br><b>Generic Name: </b>CHLOROQUINE PHOSPHATE<br><b>Category: </b>ANTIMALARIAL AGENTS
<p>11<br><b>Brand Name: </b>CAPITROL LOT<br><b>Generic Name: </b>CHLOROXINE SHAMPOO<br><b>Category: </b>MISCELLANEOUS LOCAL ANTI-INFECTIVES
<p>12<br><b>Brand Name: </b>PARAFLEX<br><b>Generic Name: </b>CHLORZOXAZONE<br><b>Category: </b>SKELETAL MUSCLE RELAXANTS
<p>13<br><b>Brand Name: </b>PARAFON FORTE<br><b>Generic Name: </b>CHLORZOXAZONE<br><b>Category: </b>SKELETAL MUSCLE RELAXANTS
<p>14<br><b>Brand Name: </b>TRANXENE SD<br><b>Generic Name: </b>CLORAZEPATE DIPOTASSIUM<br><b>Category: </b>BENZODIAZEPINES
<p>15<br><b>Brand Name: </b>TRANXENE T<br><b>Generic Name: </b>CLORAZEPATE DIPOTASSIUM<br><b>Category: </b>BENZODIAZEPINES
<p>16<br><b>Brand Name: </b>CALLERGY<br><b>Generic Name: </b>DIPHENHYDRAMINE HCL/CALA/<br><b>Category: </b>ANTIPRURITICS AND LOCAL ANESTHETICS
<p>17<br><b>Brand Name: </b>CLEAR EYES<br><b>Generic Name: </b>NAPHAZOLINE HCL OPHTH<br><b>Category: </b>VASOCONSTRICTORS
<p>18<br><b>Brand Name: </b>CHLORASEPTIC<br><b>Generic Name: </b>PHENOL/MENTHOL<br><b>Category: </b>MISCEL.SKIN AND MUCUS MEMBRANE AGENTS
<p>19<br><b>Brand Name: </b>COLREX CMPD<br><b>Generic Name: </b>PHENYLEPHRINE/CPM/COD/APA<br><b>Category: </b>ANTITUSSIVES-EXPECTS. &amp; MUCYOLYTIC AGENTS
<p></body></html>
<P><hr><a href="http://www.rxlist.com"><b>RxList Home Page</ul>
<hr>
</DOC>
<DOC>
<DOCNO>WT08-B13-30</DOCNO>
<DOCOLDNO>IA018-000200-B037-193</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/mupi.htm 206.86.175.201 19970106225647 text/html 6553
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:50:32 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 6371
Last-modified: Wed, 10 Jul 1996 22:22:20 GMT
</DOCHDR>
<html>
<head>
   <title>Mupirocin - RxList Generic Information</title>
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Mupirocin</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [drug-drug]
[<a href="#ADVERSE REACTIONS">side effects</a>] [toxicity] [<a href="#DOSAGE AND ADMINISTRATION">dosing</a>]
</font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<p><a name="DESCRIPTION"></a><b>DESCRIPTION </b></p>

<p>Each gram of Mupirocin Ointment 2% contains 20 mg mupirocin in a bland
water miscible ointment base (polyethylene glycol ointment, N.F.) consisting
of polyethylene glycol 400 and polyethylene glycol 3350. Mupirocin is a
naturally occurring antibiotic. The chemical name is (E)-2S,3R,4R,5S)-5-((2S,3S,4S,5S)-
2 3-Epoxy-5-hydroxy-4-methylhexyl)tetrahydro-3-4-dihydroxy-Beta-methyl-2H-pyran-
2-crotonic acid, ester with 9-hydroxynonanoic acid. </p>

<p><a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY
</b></p>

<p>Mupirocin is produced by fermentation of the organism Pseudomonas Fluorescens.
Mupirocin inhibits bacterial protein synthesis by reversibly and specifically
binding to bacterial isoleucyl transfer-RNA synthetase. Due to this mode
of action, mupirocin shows no cross resistance with chloramphenicol, erythromycin,
fusidic acid, gentamicin, lincomycin, methicillin, neomycin, novobiocin,
penicillin, streptomycin, and tetracycline. </p>

<p>Application of 14C-labeled mupirocin ointment to the lower arm of normal
male subjects followed by occlusion for 24 hours showed no measurable systemic
absorption, (&lt;1.1 nanogram mupirocin per milliliter of whole blood).
Measurable radioactivity was present in the stratum corneum of these subjects
72 hours after application. </p>

<p>MICROBIOLOGY: The following bacteria are susceptible to the action of
mupirocin In Vitro: the aerobic isolates of Staphylococcus Aureus (including
methicillin- resistant and beta-lactamase producing strains), Staphylococcus
Epidermidis, Staphylococcus Saprophyticus, and Streptococcus Pyogenes.
</p>

<p>Only the organisms listed in the INDICATIONS AND USAGE section have
been shown to be clinically susceptible to mupirocin. </p>

<p><a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE </b></p>

<p>Mupirocin (mupirocin) Ointment is indicated for the topical treatment
of impetigo due to: Staphylococcus Aureus, beta hemolytic Streptococcus*,
and Streptococcus Pyogenes. </p>

<p>* Efficacy for this organism in this organ system was studied in fewer
than ten infections. </p>

<p><a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS </b></p>

<p>This drug is contraindicated in individuals with a history of sensitivity
reactions to any of its components. </p>

<p><a name="WARNINGS"></a><b>WARNINGS </b></p>

<p>Mupirocin Ointment is not for ophthalmic use. </p>

<p><a name="PRECAUTIONS"></a><b>PRECAUTIONS </b></p>

<p>If a reaction suggesting sensitivity or chemical irritation should occur
with the use of Mupirocin Ointment, treatment should be discontinued and
appropriate alternative therapy for the infection instituted. </p>

<p>As with other antibacterial products prolonged use may result in overgrowth
of nonsusceptible organisms, including fungi. </p>

<p>Mupirocin is not formulated for use on mucosal surfaces. Intranasal
use has been associated with isolated reports of stinging and drying. </p>

<p>Polyethylene glycol can be absorbed from open wounds and damaged skin
and is excreted by the kidneys. In common with other polyethylene glycol-based
ointments, Mupirocin should not be used in conditions where absorption
of large quantities of polyethylene glycol is possible, especially if there
is evidence of moderate or severe renal impairment. </p>

<p>PREGNANCY CATEGORY B: Reproduction studies have been performed in rats
and rabbits at systemic doses, i.e., orally, subcutaneously, and intramuscularly,
up to 100 times the human topical dose and have revealed no evidence of
impaired fertility or harm to the fetus due to mupirocin. There are, however,
no adequate and well-controlled studies in pregnant women. Because animal
studies are not always predictive of human response, this drug should be
used during pregnancy only if clearly needed. </p>

<p>NURSING MOTHERS: It is not known whether Mupirocin is present in breast
milk. Nursing should be temporarily discontinued while using Mupirocin.
</p>

<p><a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS </b></p>

<p>The following local adverse reactions have been reported in connection
with the use of Mupirocin Ointment: burning, stinging, or pain in 1.5%
of patients; itching in 1% of patients; rash, nausea, erythema, dry skin,
tenderness, swelling, contact dermatitis, and increased exudate in less
than 1% of patients. </p>

<p><a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION
</b></p>

<p>A small amount of Mupirocin Ointment should be applied to the affected
area three times daily. The area treated may be covered with a gauze dressing
if desired. Patients not showing a clinical response within 3 to 5 days
should be re-evaluated. </p>

<p>
<hr width="100%" ></p>

<h2 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-31</DOCNO>
<DOCOLDNO>IA019-000201-B024-46</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/rxlist.cgi?drug=oxycontin 206.86.175.201 19970106234307 text/html 1309
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:36:49 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE>www.rxlist.com - Neil Sandow, Pharm.D. 
copyright 1995</title></head> <body bgcolor="#ffffff">
<center><a href="http://www.rxlist.com"><img src="rx.gif" 
height=75 width=75 border=0><img src="count.gif" border=0></a></center> 
Searching for: <b>OXYCONTIN</b> <br>scroll down for results 
<hr><hr>
<h1>Enter Brand or Generic Name or Category*</h1>
<h3> Narrow Your Search with <font size=5>*</font>(examples: 
ampi*, *mycin, antibiotic*)</h3>
<form method=get>
<action=>
<input size=30 maxlength=30 name=drug>
<input type=submit>
<input type=reset>
</form>
<HR>
<H3>Your RxList Search Results:</h3>
1<br><b>Brand Name: </b>OXYCONTIN<br><b>Generic Name: </b>OXYCODONE HCL<br><b>Category: </b>OPIATE AGONISTS
<p>2<br><b>Brand Name: </b>OXISTAT<br><b>Generic Name: </b>OXICONAZOLE NITRATE<br><b>Category: </b>ANTIFUNGALS
<p>3<br><b>Brand Name: </b>BAG BALM<br><b>Generic Name: </b>OXYQUIN SULF/PETROL/LAN<br><b>Category: </b>MISCELLANEOUS LOCAL ANTI-INFECTIVES
<p>4<br><b>Brand Name: </b>OXYCHINOL<br><b>Generic Name: </b>OXYQUINOLINE<br><b>Category: </b>MISCELLANEOUS LOCAL ANTI-INFECTIVES
<p></body></html>
<P><hr><a href="http://www.rxlist.com"><b>RxList Home Page</ul>
<hr>
</DOC>
<DOC>
<DOCNO>WT08-B13-32</DOCNO>
<DOCOLDNO>IA018-000200-B036-226</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/pentox.htm 206.86.175.201 19970106225308 text/html 17873
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:46:54 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 17690
Last-modified: Mon, 08 Jul 1996 22:34:17 GMT
</DOCHDR>
<html>
<head>
   <title>Pentoxifylline - RxList Generic Information</title>
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Pentoxifylline</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[warn!] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<p><a name="DESCRIPTION"></a><b>DESCRIPTION </b></p>

<p>Pentoxifylline is a tri-substituted xanthine derivative designated chemically
as 1-(5-oxohexyl)-3, 7-dimethylxanthine that, unlike theophylline, is a
hemorheologic agent, i.e. an agent that affects blood viscosity. Pentoxifylline
is soluble in water and ethanol, and sparingly soluble in toluene. </p>

<p><a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY
</b></p>

<p>MODE OF ACTION </p>

<p>Pentoxifylline and its metabolites improve the flow properties of blood
by decreasing its viscosity. In patients with chronic peripheral arterial
disease, this increases blood flow to the affected microcirculation and
enhances tissue oxygenation. The precise mode of action of pentoxifylline
and the sequence of events leading to clinical improvement are still to
be defined. Pentoxifylline administration has been shown to produce dose
related hemorheologic effects, lowering blood viscosity, and improving
erythrocyte flexibility. Leukocyte properties of hemorheologic importance
have been modified in animal and in vitro human studies. Pentoxifylline
has been shown to increase leukocyte deformability and to inhibit neutrophil
adhesion and activation. Tissue oxygen levels have been shown to be significantly
increased by therapeutic doses of pentoxifylline in patients with peripheral
arterial disease. </p>

<p>PHARMACOKINETICS AND METABOLISM </p>

<p>After oral administration in aqueous solution pentoxifylline is almost
completely absorbed. It undergoes a first-pass effect and the various metabolites
appear in plasma very soon after dosing. Peak plasma levels of the parent
compound and its metabolites are reached within 1 hour. The major metabolites
are Metabolite I (1-(5-hydroxyhexyl)-3,7-dimethylxanthine) and Metabolite
V (1-(3-carboxypropyl)-3, 7-dimethylxanthine), and plasma levels of these
metabolites are 5 and 8 times greater, respectively, than pentoxifylline.
</p>

<p>Following oral administration of aqueous solutions containing 100 to
400 mg of pentoxifylline, the pharmacokinetics of the parent compound and
Metabolite I are dose-related and not proportional (non-linear), with half-life
and area under the blood-level time curve (AUC) increasing with dose. The
elimination kinetics of Metabolite V are not dose-dependent. The apparent
plasma half-life of pentoxifylline varies from 0.4 to 0.8 hours and the
apparent plasma half lives of its metabolites vary from 1 to 1.6 hours.
There is no evidence of accumulation or enzyme induction (Cytochrome P450)
following multiple oral doses. </p>

<p>Excretion is almost totally urinary; the main biotransformation product
is Metabolite V. Essentially no parent drug is found in the urine. Despite
large variations in plasma levels of parent compound and its metabolites,
the urinary recovery of Metabolite V is consistent and shows dose proportionality.
Less than 4% of the administered dose is recovered in feces. Food intake
shortly before dosing delays absorption of an immediate release dosage
form but does not affect total absorption. The pharmacokinetics and metabolism
of Pentoxifylline have not been studied in patients with renal and/or hepatic
dysfunction, but AUC was increased and elimination rate decreased in an
older population (60-68 years) compared to younger individuals (22-30 years).
</p>

<p>After administration of the 400 mg controlled-release Pentoxifylline
tablet, plasma levels of the parent compound and its metabolites reach
their maximum within 2 to 4 hours and remain constant over an extended
period of time. The controlled release of pentoxifylline from the tablet
eliminates peaks and troughs in plasma levels for improved gastrointestinal
tolerance. </p>

<p><a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE </b></p>

<p>Pentoxifylline is indicated for the treatment of patients with intermittent
claudication on the basis of chronic occlusive arterial disease of the
limbs. Pentoxifylline can improve function and symptoms but is not intended
to replace more definitive therapy, such as surgical bypass, or removal
of arterial obstructions when treating peripheral vascular disease. </p>

<p><a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS </b></p>

<p>Pentoxifylline should not be used in patients with recent cerebral and/or
retinal hemorrhage or in patients who have previously exhibited intolerance
to this product or methylxanthines such as caffeine, theophylline, and
theobromine. </p>

<p><a name="PRECAUTIONS"></a><b>PRECAUTIONS </b></p>

<p>GENERAL: Patients with chronic occlusive arterial disease of the limbs
frequently show other manifestations of arteriosclerotic disease. Pentoxifylline
has been used safely for treatment of peripheral arterial disease in patients
with concurrent coronary artery and cerebrovascular diseases, but there
have been occasional reports of angina, hypotension, and arrhythmia. Controlled
trials do not show that Pentoxifylline causes such adverse effects more
often than placebo, but, as it is a methylxanthine derivative, it is possible
some individuals will experience such responses. Patients on Warfarin should
have more frequent monitoring of prothrombin times, while patients with
other risk factors complicated by hemorrhage (e.g. recent surgery, peptic
ulceration, cerebral and/or retinal bleeding) should have periodic examinations
for bleeding including hematocrit and/or hemoglobin. </p>

<p>DRUG INTERACTIONS: Although a causal relationship has not been established,
there have been reports of bleeding and/or prolonged prothrombin time in
patients treated with Pentoxifylline with and without anticoagulants or
platelet aggregation inhibitors. Patients on Warfarin should have more
frequent monitoring of prothrombin times, while patients with other risk
factors complicated by hemorrhage (e.g., recent surgery, peptic ulceration)
should have periodic examinations for bleeding including hematocrit and/or
hemoglobin. Pentoxifylline has been used concurrently with antihypertensive
drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics,
without observed problems. Small decreases in blood pressure have been
observed in some patients treated with Pentoxifylline ; periodic systemic
blood pressure monitoring is recommended for patients receiving concomitant
antihypertensive therapy. If indicated, dosage of the antihypertensive
agents should be reduced. </p>

<p>CARCINOGENESIS, MUTAGENESIS AND IMPAIRMENT OF FERTILITY: Long-term studies
of the carcinogenic potential of pentoxifylline were conducted in mice
and rats by dietary administration of the drug at doses up to approximately
24 times (570 mg/kg) the maximum recommended human daily dose (MRHD) of
24 mg/kg for 18 months in mice and 18 months in rats with an additional
6 months without drug exposure in the latter. No carcinogenic potential
for pentoxifylline was noted in the mouse study. In the rat study, there
was a statistically significant increase in benign mammary fibroadenomas
in females in the high dose group (24 X MRHD). The relevance of this finding
to human use is uncertain since this was only a marginal statistically
significant increase for a tumor that is common in aged rats. Pentoxifylline
was devoid of mutagenic activity in various strains of Salmonella (Ames
test) when tested in the presence and absence of metabolic activation.
</p>

<p>PREGNANCY: Category C. Teratogenic studies have been performed in rats
and rabbits at oral doses up to about 25 and 10 times the maximum recommended
human daily dose (MRHD) of 24 mg/kg, respectively. No evidence of fetal
malformation was observed. Increased resorption was seen in rats at 25
times MRHD. There are however, no adequate and well controlled studies
in pregnant women. Because animal reproduction studies are not always predictive
of human response. Pentoxifylline should be used during pregnancy only
if clearly needed. </p>

<p>NURSING MOTHERS: Pentoxifylline and its metabolites are excreted in
human milk. Because of the potential for tumorigenicity shown for pentoxifylline
in rats, a decision should be made whether to discontinue nursing or discontinue
the drug, taking into account the importance of the drug to the mother.
</p>

<p>PEDIATRIC USE: Safety and effectiveness in children below the age of
18 years have not been established. </p>

<p><a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS </b></p>

<p>Although a causal relationship has not been established, there have
been reports of bleeding and/or prolonged prothrombin time in patients
treated with Pentoxifylline with and without anticoagulants or platelet
aggregation inhibitors. Patients on Warfarin should have more frequent
monitoring of prothrombin times, while patients with other risk factors
complicated by hemorrhage (e.g., recent surgery, peptic ulceration) should
have periodic examinations for bleeding including hematocrit and/or hemoglobin.
Pentoxifylline has been used concurrently with antihypertensive drugs,
beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics,
without observed problems. Small decreases in blood pressure have been
observed in some patients treated with Pentoxifylline ; periodic systemic
blood pressure monitoring is recommended for patients receiving concomitant
antihypertensive therapy. If indicated, dosage of the antihypertensive
agents should be reduced. </p>

<p>(See Also PRECAUTIONS) </p>

<p><a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS </b></p>

<p>Clinical trials were conducted using either controlled-release Pentoxifylline
tablets for up to 60 weeks or immediate-release Pentoxifylline capsules
for up to 24 weeks. Dosage ranges in the tablet studies were 400 mg bid
to tid and in the capsule studies, 200-400 mg tid. The table summarizes
the incidence (in percent) of adverse reactions considered drug related,
as well as the numbers of patients who received controlled release Pentoxifylline
tablets, immediate-release Pentoxifylline capsules, or the corresponding
placebos. The incidence of adverse reactions was higher in the capsule
studies (where dose related increases were seen in digestive and nervous
system side effects) than in the tablet studies. Studies with the capsule
include domestic experience, whereas studies with the controlled-release
tablets were conducted outside the U.S. The table indicates that in the
tablet studies few patients discontinued because of adverse effects. </p>

<pre><font SIZE=-1>                          INCIDENCE (%) OF SIDE EFFECTS                         
                                Controlled-Release     Immediate-Release        
                                     TABLETS                CAPSULES            
                                   Commercially          Used only for          
                                    Available         Controlled Clinical       
                                                             Trials             
                           Pentoxifylline    Placebo      Pentoxifylline  Placebo       
(Numbers of Patients at      (321)        (128)         (177)      (138)        
 Risk)                                                                          
Discontinued for Side Effect  3.1           0           9.6         7.2         
CARDIOVASCULAR SYSTEM                                                           
   Angina/Chest pain          0.3           --          1.1         2.2         
   Arrhythmia/Palpitation     --            --          1.7         0.7         
   Flushing                   --            --          2.3         0.7         
DIGESTIVE SYSTEM                                                                
   Abdominal Discomfort       --            --          4.0         1.4         
   Belching/Flatus/Bloating   0.6           --          9.0         3.6         
   Diarrhea                   --            --          3.4         2.9         
   Dyspepsia                  2.8           4.7         9.6         2.9         
   Nausea                     2.2           0.8        28.8         8.7         
   Vomiting                   1.2           --          4.5         0.7         
NERVOUS SYSTEM                                                                  
   Agitation/Nervousness      --            --          1.7         0.7         
   Dizziness                  1.9           3.1        11.9         4.3         
   Drowsiness                 --            --          1.1         5.8         
   Headache                   1.2           1.6         6.2         5.8         
   Insomnia                   --            --          2.3         2.2         
   Tremor                     0.3           0.8          --         --          
   Blurred Vision             --            --          2.3         1.4    </font></pre>

<p>Pentoxifylline has been marketed in Europe and elsewhere since 1972.
In addition to the above symptoms, the following have been reported spontaneously
since marketing or occurred in other clinical trials with an incidence
of less than 1%; the causal relationship was uncertain: </p>

<p>Cardiovascular--dyspnea, edema, hypotension. </p>

<p>Digestive--anorexia, cholecystitis, constipation, dry mouth/thirst.
</p>

<p>Nervous--anxiety, confusion, depression, seizure. </p>

<p>Respiratory--epistaxis, flu-like symptoms, laryngitis, nasal congestion.
</p>

<p>Skin and Appendages--brittle fingernails, pruritus, rash, urticaria,
angioedema. </p>

<p>Special Senses--blurred vision, conjunctivitis, earache, scotoma. </p>

<p>Miscellaneous--bad taste, excessive salivation, leukopenia, malaise,
sore throat/swollen neck glands, weight change. </p>

<p>A few rare events have been reported spontaneously worldwide since marketing
in 1972. Although they occurred under circumstances in which a causal relationship
with pentoxifylline could not be established, they are listed to serve
as information for physicians: &quot;Cardiovascular--angina, arrhythmia,
tachycardia anaphylactoid reactions.&quot; Digestive--hepatitis, jaundice,
increased liver enzymes; and Hemic and Lymphatic--decreased serum fibrinogen,
pancytopenia, aplastic anemia, leukemia, purpura, thrombocytopenia. </p>

<p><a name="OVERDOSAGE"></a><b>OVERDOSAGE </b></p>

<p>Overdosage with Pentoxifylline has been reported in children and adults.
Symptoms appear to be dose related. A report from a poison control center
on 44 patients taking overdoses of enteric-coated pentoxifylline tablets
noted that symptoms usually occurred 4-5 hours after ingestion and lasted
about 12 hours. The highest amount ingested was 80 mg/kg; flushing, hypotension,
convulsions, somnolence, loss of consciousness, fever, and agitation occurred.
All patients recovered. </p>

<p>In addition to symptomatic treatment and gastric lavage, special attention
must be given to supporting respiration, maintaining systemic blood pressure,
and controlling convulsions. Activated charcoal has been used to absorb
pentoxifylline in patients who have overdosed. </p>

<p><a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION
</b></p>

<p>The usual dosage of Pentoxifylline in controlled-release tablet form
is one tablet (400 mg) three times a day with meals. </p>

<p>While the effect of Pentoxifylline may be seen within 2 to 4 weeks it
is recommended that treatment be continued for at least 8 weeks. Efficacy
has been demonstrated in double-blind clinical studies of 6 months duration.
</p>

<p>Digestive and central nervous system side effects are dose related.
If patients develop these side effects it is recommended that the dosage
be lowered to one tablet twice a day (800 mg/day). If side effects persist
at this lower dosage, the administration of Pentoxifylline should be discontinued.
</p>

<p>
<hr width="100%" ></p>

<h2 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-33</DOCNO>
<DOCOLDNO>IA018-000200-B037-34</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/flucon.htm 206.86.175.201 19970106225443 text/html 32609
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:48:27 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 32426
Last-modified: Wed, 10 Jul 1996 04:45:32 GMT
</DOCHDR>
<html>
<head>
   <title>Fluconazole - RxList Generic Information</title>
   <meta name="Author" content="">
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Fluconazole</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<p><a name="DESCRIPTION"></a><b>DESCRIPTION </b></p>

<p>Fluconazole is designated chemically as 2,4-difluoro-alpha,alpha1-bis(1H-1,2,4-
triazol-1-ylmethyl)benzyl alcohol with an empirical formula of C13H12F2N6O
and molecular weight 306.3. </p>

<p>Fluconazole is a white crystalline solid which is slightly soluble in
water and saline. </p>

<p><a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY
</b></p>

<p>MODE OF ACTION </p>

<p>Fluconazole is a highly selective inhibitor of fungal cytochrome P-450
sterol C 14 alpha-demethylation. Mammalian cell demethylation is much less
sensitive to fluconazole inhibition. The subsequent loss of normal sterols
correlates with the accumulation of 14 alpha-methyl sterols in fungi and
may be responsible for the fungistatic activity of fluconazole. </p>

<p>PHARMACOKINETICS AND METABOLISM </p>

<p>The pharmacokinetic properties of fluconazole are similar following
administration by the intravenous or oral routes. In normal volunteers,
the bioavailability of orally administered fluconazole is over 90% compared
with intravenous administration. </p>

<p>Peak plasma concentrations (Cmax) in fasted normal volunteers occur
between 1 and 2 hours with a terminal plasma elimination half-life of approximately
30 hours (range 20-50 hours) after oral administration. </p>

<p>In fasted normal volunteers, administration of a single oral 400 mg
dose of Fluconazole leads to a mean Cmax of 6.72 mcgm/mL (range: 4.12 to
8.08 mcgm/mL) and after single oral doses of 50-400 mg, fluconazole plasma
concentrations and AUC (area under the plasma concentration-time curve)
are dose proportional. </p>

<p>Steady-state concentrations are reached within 5-10 days following oral
doses of 50-400 mg given once daily. Administration of a loading dose (on
Day 1) of twice the usual daily dose results in plasma concentrations close
to steady state by the second day. The apparent volume of distribution
of fluconazole approximates that of total body water. Plasma protein binding
is low (11-12%). Following either single- or multiple-oral doses for up
to 14 days, fluconazole penetrates into all body fluids studied (see table
below). In normal volunteers saliva concentrations of fluconazole were
equal to or slightly greater than plasma concentrations regardless of dose,
route, or duration of dosing. In patients with bronchiectasis, sputum concentrations
of fluconazole following a single 150 mg oral dose were equal to plasma
concentrations at both 4 and 24 hours post dose. In patients with fungal
meningitis, fluconazole concentrations in the CSF are approximately 80%
of the corresponding plasma concentrations. </p>

<pre> 
                            RATIO OF FLUCONAZOLE                                
                           TISSUE (FLUID)/PLASMA                                
TISSUE OR FLUID                CONCENTRATION*                                   
-------------------------------------------------                               
Cerebrospinal fluid**               .5-.9                                       
Saliva                                 1                                        
Sputum                                 1                                        
Blister fluid                          1                                        
Urine                                 10                                        
Normal skin                           10                                        
Nails                                  1                                        
Blister skin                           2                                        
-------------------------------------------------                               
*  Relative to concurrent concentrations in plasma                              
   in subjects with normal renal function.                                      
** Independent of degree of meningeal inflammation.                             
-------------------------------------------------                               </pre>

<p>In normal volunteers, fluconazole is cleared primarily by renal excretion,
with approximately 80% of the administered dose appearing in the urine
as unchanged drug. About 11% of the dose is excreted in the urine as metabolites.
</p>

<p>The pharmacokinetics of fluconazole are markedly affected by reduction
in renal function. There is an inverse relationship between the elimination
half-life and creatinine clearance. The dose of Fluconazole may need to
be reduced in patients with impaired renal function (see Dosage and Administration).
A 3-hour hemodialysis session decreases plasma concentrations by approximately
50%. </p>

<p>In normal volunteers, Fluconazole administration (doses ranging from
200 mg to 400 mg once daily for up to 14 days) was associated with small
and inconsistent effects on testosterone concentrations, endogenous corticosteroid
concentrations, and the ACTH-stimulated cortisol response. </p>

<p>DRUG INTERACTION STUDIES </p>

<p>Oral Contraceptives: Single and multiple 50 mg oral doses of Fluconazole
were administered to healthy women taking oral contraceptives. The AUC
for ethinyl estradiol was decreased by 16%, but no changes were observed
in levonorgestrel pharmacokinetics. </p>

<p>Gastrointestinal Drugs: In fasted normal volunteers, absorption of orally
administered Fluconazole does not appear to be affected by agents that
increase gastric pH. Single dose administration of Fluconazole (100 mg)
with cimetidine (400 mg) resulted in a 13% reduction in AUC (range 4% to
32%) and 21% reduction in Cmax (range 20% to 40%) of fluconazole. Administration
of MAALOX (20 mL) immediately prior to a single dose of Fluconazole (100
mg) had no effect on the absorption or elimination of fluconazole. </p>

<p>Hydrochlorothiazide: Concomitant oral administration of 100 mg Fluconazole
and 50 mg hydrochlorothiazide for 10 days in normal volunteers resulted
in an increase of 41% in Cmax and an increase of 43% in AUC of fluconazole,
compared to Fluconazole given alone. Overall, the plasma concentrations
of fluconazole were approximately 1-2 mcgm/mL higher with concomitant diuretic.
These changes are attributable to a mean net reduction of approximately
20% in the renal clearance of fluconazole. </p>

<p>Rifampin: Administration of a single oral 200 mg dose of Fluconazole
after chronic rifampin administration resulted in a 25% decrease in AUC
and a 20% shorter half-life of fluconazole in normal volunteers. (See Precautions.)
</p>

<p>Warfarin: A single dose of warfarin (15 mg) given to normal volunteers,
following 14 days of orally administered Fluconazole (200 mg) resulted
in a 12% increase in the prothrombin time response (area under the prothrombin
time-time curve). One of 13 subjects experienced a 2-fold increase in his
prothrombin time response. (See Precautions.) </p>

<p>Oral Hypoglycemic Agents: The effects of fluconazole on the pharmacokinetics
of the sulfonylurea oral hypoglycemic agents tolbutamide, glipizide and
glyburide were examined in three placebo-controlled crossover studies in
normal volunteers. All subjects received the sulfonylurea alone and following
treatment with 100 mg of Fluconazole as a single daily oral dose for 7
days. Fluconazole administration resulted in significant increases in Cmax
and AUC of the sulfonylurea. Several subjects in these three studies experienced
symptoms consistent with hypoglycemia. In the glyburide study, several
volunteers required oral glucose treatment. (See Precautions.) </p>

<p>Phenytoin: Concomitant administration of oral Fluconazole (200 mg) at
steady state with phenytoin at steady state resulted in an average increase
of 75% of phenytoin AUC values in normal volunteers. (See Precautions.)
</p>

<p>Cyclosporine: Stable bone marrow transplant patients receiving twice
daily doses of cyclosporine, who were administered Fluconazole (100 mg)
as a single oral dose for 14 days, demonstrated slight increases in cyclosporine
Cmax, Cmin (minimum plasma concentration) and AUC values which did not
achieve statistical significance. There have been several literature reports
associating concomitant administration of high doses of Fluconazole with
an increase in cyclosporine plasma concentrations in renal transplant patients
with or without impaired renal function. (See Precautions.) </p>

<p>Zidovudine And Pentamidine: Formal interaction studies have not been
completed for Fluconazole and concomitant zidovudine and aerosolized pentamidine
isethionate. </p>

<p>MICROBIOLOGY </p>

<p>Fluconazole exhibits In Vitro activity against Cryptococcus Neoformans
and Candida Spp. Fungistatic activity has also been demonstrated in normal
and immunocompromised animal models for systemic and intracranial fungal
infections due to Cryptococcus Neoformans and for systemic infections due
to Candida Albicans. Development of resistance to fluconazole has not been
studied. </p>

<p>In common with other azole antifungal agents, most fungi show a higher
apparent sensitivity to fluconazole In Vivo than In Vitro. Fluconazole
administered orally and/or intravenously was active in a variety of animal
models of fungal infection using standard laboratory strains of fungi.
Activity has been demonstrated against fungal infections caused by Aspergillus
Flavus and Aspergillus Fumigatus in normal mice. Fluconazole has also been
shown to be active in animal models of endemic mycoses, including one model
of Blastomyces Dermatitidis pulmonary infections in normal mice; one model
of Coccidioides Immitis intracranial infections in normal mice; and several
models of Histoplasma Capsulatum pulmonary infection in normal and immunosuppressed
mice. The clinical significance of results obtained in these studies is
unknown. </p>

<p>Concurrent administration of fluconazole and amphotericin B in infected
normal and immunosuppressed mice showed the following results: a small
additive antifungal effect in systemic infection with C. Albicans, no interaction
in intracranial infection with Cr. Neoformans, and antagonism of the two
drugs in systemic infection with Asp. Fumigatus. The clinical significance
of results obtained in these studies is unknown. </p>

<p><a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE </b></p>

<p>Fluconazole is indicated for the treatment of: </p>

<p>1. Oropharyngeal and esophageal candidiasis. Fluconazole is also effective
for the treatment of serious systemic candidal infections, including urinary
tract infection, peritonitis, and pneumonia. </p>

<p>2. Cryptococcal meningitis. </p>

<p>Specimens for fungal culture and other relevant laboratory studies (serology,
histopathology) should be obtained prior to therapy to isolate and identify
causative organisms. Therapy may be instituted before the results of the
cultures and other laboratory studies are known; however, once these results
become available, anti-infective therapy should be adjusted accordingly.
</p>

<p><a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS </b></p>

<p>Fluconazole is contraindicated in patients who have shown hypersensitivity
to fluconazole or to any of its excipients. There is no information regarding
cross hypersensitivity between fluconazole and other azole antifungal agents.
Caution should be used in prescribing Fluconazole to patients with hypersensitivity
to other azoles. </p>

<p><a name="WARNINGS"></a><b>WARNINGS </b></p>

<p>In rare cases, anaphylaxis has been reported. </p>

<p>Patients who develop abnormal liver function tests during Fluconazole
therapy should be monitored for the development of more severe hepatic
injury. Although serious hepatic reactions have been rare and the causal
association with Fluconazole uncertain, if clinical signs and symptoms
consistent with liver disease develop that may be attributable to fluconazole,
Fluconazole should be discontinued. (See Adverse Reactions.) </p>

<p>Immunocompromised patients who develop rashes during treatment with
Fluconazole should be monitored closely and the drug discontinued if lesions
progress. (See Adverse Reactions.) </p>

<p><a name="PRECAUTIONS"></a><b>PRECAUTIONS </b></p>

<p>DRUG INTERACTIONS (See Actions/Clinical Pharmacology) </p>

<p>Fluconazole increased the prothrombin time after warfarin administration.
Careful monitoring of prothrombin time in patients receiving Fluconazole
and coumarin-type anticoagulants is recommended. </p>

<p>Fluconazole increased the plasma concentrations of phenytoin. Careful
monitoring of phenytoin concentrations in patients receiving Fluconazole
and phenytoin is recommended. </p>

<p>Fluconazole has been infrequently associated with an increase in cyclosporine
concentrations in renal transplant patients with or without impaired renal
function. Careful monitoring of cyclosporine concentrations in patients
receiving Fluconazole and cyclosporine is recommended. </p>

<p>Fluconazole increased the plasma concentrations and reduced the metabolism
of tolbutamide, glyburide and glipizide. When Fluconazole is used concomitantly
with these or other sulfonylurea oral hypoglycemic agents, blood glucose
concentrations should be carefully monitored, and the dose of the sulfonylurea
should be adjusted as necessary. </p>

<p>Rifampin enhances the metabolism of concurrently administered Fluconazole.
Depending on clinical circumstances, consideration should be given to increasing
the dose of Fluconazole when it is administered with rifampin. </p>

<p>Physicians should be aware that drug-drug interaction studies with other
medications have not been conducted, but such interactions may occur. </p>

<p>CARCINOGENESIS, MUTAGENESIS AND IMPAIRMENT OF FERTILITY </p>

<p>Fluconazole showed no evidence of carcinogenic potential in mice and
rats treated orally for 24 months at doses of 2.5, 5 or 10 mg/kg/day (approximately
2-7X the recommended human dose). Male rats treated with 5 and 10 mg/kg/day
had an increased incidence of hepatocellular adenomas. </p>

<p>Fluconazole, with or without metabolic activation, was negative in tests
for mutagenicity in 4 strains of S. Typhimurium, and in the mouse lymphoma
L5178Y system. Cytogenetic studies In Vivo (murine bone marrow cells, following
oral administration of fluconazole) and In Vitro (human lymphocytes exposed
to fluconazole at 1000 mcgm/mL) showed no evidence of chromosomal mutations.
</p>

<p>Fluconazole did not affect the fertility of male or female rats treated
orally with daily doses of 5, 10 or 20 mg/kg or with parenteral doses of
5, 25 or 75 mg/kg, although the onset of parturition was slightly delayed
at 20 mg/kg p.o. In an intravenous perinatal study in rats at 5, 20 and
40 mg/kg, dystocia and prolongation of parturition were observed in a few
dams at 20 mg/kg (approximately 5-15X the recommended human dose) and 40
mg/kg, but not at 5 mg/kg. The disturbances in parturition were reflected
by a slight increase in the number of still-born pups and decrease of neonatal
survival at these dose levels. The effects on parturition in rats are consistent
with the species specific estrogen-lowering property produced by high doses
of fluconazole. Such a hormone change has not been observed in women treated
with fluconazole. (See Actions/Clinical Pharmacology.) </p>

<p>PREGNANCY </p>

<p>TERATOGENIC EFFECTS. PREGNANCY CATEGORY C: Fluconazole was administered
orally to pregnant rabbits during organogenesis in two studies, at 5, 10
and 20 mg/kg and at 5, 25, and 75 mg/kg respectively. Maternal weight gain
was impaired at all dose levels, and abortions occurred at 75 mg/kg (approximately
20-60X the recommended human dose); no adverse fetal effects were detected.
In several studies in which pregnant rats were treated orally with fluconazole
during organogenesis, maternal weight gain was impaired and placental weights
were increased at 25 mg/kg. There were no fetal effects at 5 or 10 mg/kg;
increases in fetal anatomical variants (supernumerary ribs, renal pelvis
dilation) and delays in ossification were observed at 25 and 50 mg/kg and
higher doses. At doses ranging from 80 mg/kg (approximately 20-60X the
recommended human dose) to 320 mg/kg, embryolethality in rats was increased
and fetal abnormalities included wavy ribs, cleft palate and abnormal cranio-facial
ossification. These effects are consistent with the inhibition of estrogen
synthesis in rats and may be a result of known effects of lowered estrogen
on pregnancy, organogenesis and parturition. </p>

<p>There are no adequate and well controlled studies in pregnant women.
Fluconazole should be used in pregnancy only if the potential benefit justifies
the possible risk to the fetus. </p>

<p>NURSING MOTHERS </p>

<p>Fluconazole is secreted in human milk at concentrations similar to plasma.
Therefore, the use of Fluconazole in nursing mothers is not recommended.
</p>

<p>PEDIATRIC USE </p>

<p>Efficacy of Fluconazole has not been established in children. A small
number of patients from age 3 to 13 years have been treated safely with
Fluconazole using doses of 3-6 mg/kg daily. </p>

<p>DRUG INTERACTIONS </p>

<p>DRUG INTERACTION STUDIES </p>

<p>Oral Contraceptives: Single and multiple 50 mg oral doses of Fluconazole
were administered to healthy women taking oral contraceptives. The AUC
for ethinyl estradiol was decreased by 16%, but no changes were observed
in levonorgestrel pharmacokinetics. </p>

<p>Gastrointestinal Drugs: In fasted normal volunteers, absorption of orally
administered Fluconazole does not appear to be affected by agents that
increase gastric pH. Single dose administration of Fluconazole (100 mg)
with cimetidine (400 mg) resulted in a 13% reduction in AUC (range 4% to
32%) and 21% reduction in Cmax (range 20% to 40%) of fluconazole. Administration
of MAALOX (20 mL) immediately prior to a single dose of Fluconazole (100
mg) had no effect on the absorption or elimination of fluconazole. </p>

<p>Hydrochlorothiazide: Concomitant oral administration of 100 mg Fluconazole
and 50 mg hydrochlorothiazide for 10 days in normal volunteers resulted
in an increase of 41% in Cmax and an increase of 43% in AUC of fluconazole,
compared to Fluconazole given alone. Overall, the plasma concentrations
of fluconazole were approximately 1-2 mcgm/mL higher with concomitant diuretic.
These changes are attributable to a mean net reduction of approximately
20% in the renal clearance of fluconazole. </p>

<p>Rifampin: Administration of a single oral 200 mg dose of Fluconazole
after chronic rifampin administration resulted in a 25% decrease in AUC
and a 20% shorter half-life of fluconazole in normal volunteers. (See Precautions.)
</p>

<p>Warfarin: A single dose of warfarin (15 mg) given to normal volunteers,
following 14 days of orally administered Fluconazole (200 mg) resulted
in a 12% increase in the prothrombin time response (area under the prothrombin
time-time curve). One of 13 subjects experienced a 2-fold increase in his
prothrombin time response. (See Precautions.) </p>

<p>Oral Hypoglycemic Agents: The effects of fluconazole on the pharmacokinetics
of the sulfonylurea oral hypoglycemic agents tolbutamide, glipizide and
glyburide were examined in three placebo-controlled crossover studies in
normal volunteers. All subjects received the sulfonylurea alone and following
treatment with 100 mg of Fluconazole as a single daily oral dose for 7
days. Fluconazole administration resulted in significant increases in Cmax
and AUC of the sulfonylurea. Several subjects in these three studies experienced
symptoms consistent with hypoglycemia. In the glyburide study, several
volunteers required oral glucose treatment. (See Precautions.) </p>

<p>Phenytoin: Concomitant administration of oral Fluconazole (200 mg) at
steady state with phenytoin at steady state resulted in an average increase
of 75% of phenytoin AUC values in normal volunteers. (See Precautions.)
</p>

<p>Cyclosporine: Stable bone marrow transplant patients receiving twice
daily doses of cyclosporine, who were administered Fluconazole (100 mg)
as a single oral dose for 14 days, demonstrated slight increases in cyclosporine
Cmax, Cmin (minimum plasma concentration) and AUC values which did not
achieve statistical significance. There have been several literature reports
associating concomitant administration of high doses of Fluconazole with
an increase in cyclosporine plasma concentrations in renal transplant patients
with or without impaired renal function. (See Precautions.) </p>

<p>Zidovudine And Pentamidine: Formal interaction studies have not been
completed for Fluconazole and concomitant zidovudine and aerosolized pentamidine
isethionate. </p>

<p><a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS </b></p>

<p>Fluconazole increased the prothrombin time after warfarin administration.
Careful monitoring of prothrombin time in patients receiving Fluconazole
and coumarin-type anticoagulants is recommended. </p>

<p>Fluconazole increased the plasma concentrations of phenytoin. Careful
monitoring of phenytoin concentrations in patients receiving Fluconazole
and phenytoin is recommended. </p>

<p>Fluconazole has been infrequently associated with an increase in cyclosporine
concentrations in renal transplant patients with or without impaired renal
function. Careful monitoring of cyclosporine concentrations in patients
receiving Fluconazole and cyclosporine is recommended. </p>

<p>Fluconazole increased the plasma concentrations and reduced the metabolism
of tolbutamide, glyburide and glipizide. When Fluconazole is used concomitantly
with these or other sulfonylurea oral hypoglycemic agents, blood glucose
concentrations should be carefully monitored, and the dose of the sulfonylurea
should be adjusted as necessary. </p>

<p>Rifampin enhances the metabolism of concurrently administered Fluconazole.
Depending on clinical circumstances, consideration should be given to increasing
the dose of Fluconazole when it is administered with rifampin. </p>

<p>Physicians should be aware that drug-drug interaction studies with other
medications have not been conducted, but such interactions may occur. </p>

<p>(See Also ACTIONS/CLINICAL PHARMACOLOGY And PRECAUTIONS)</p>

<p><a name="ADVERSE REACTIONS"></a><b> ADVERSE REACTIONS </b></p>

<p>Sixteen percent of over 4000 patients treated with Fluconazole in clinical
trials of 7 days or more experienced adverse events. Treatment was discontinued
in 1.5% of patients due to adverse clinical events and in 1.3% of patients
due to laboratory test abnormalities. </p>

<p>In combined clinical trials and foreign marketing experience prior to
U.S. marketing, patients with serious underlying disease (predominantly
AIDS or malignancy) rarely have developed serious hepatic reactions or
exfoliative skin disorders during treatment with Fluconazole (See Warnings).
Two of these hepatic reactions and one exfoliative skin disorder (Stevens-Johnson
syndrome) were associated with a fatal outcome. Because most of these patients
were receiving multiple concomitant medications, including many known to
be hepatotoxic or associated with exfoliative skin disorders, the causal
association of these reactions with Fluconazole therapy is uncertain. </p>

<p>Clinical adverse events were reported more frequently in HIV infected
patients (21%) than in non-HIV infected patients (13%); however, the patterns
in HIV infected and non-HIV infected patients were similar. The proportions
of patients discontinuing therapy due to clinical adverse events were similar
in the two groups (1.5%). </p>

<p>The following treatment-related clinical adverse events occurred at
an incidence of 1% or greater in 4048 patients receiving Fluconazole for
7 or more days in clinical trials: nausea 3.7%, headache 1.9%, skin rash
1.8%, vomiting 1.7%, abdominal pain 1.7%, and diarrhea 1.5%. </p>

<p>In two comparative trials evaluating the efficacy of Fluconazole for
the suppression of relapse of cryptococcal meningitis, a statistically
significant increase was observed in median AST (SGOT) levels from a baseline
value of 30 IU/L to 41 IU/L in one trial and 34 IU/L to 66 IU/L in the
other. The overall rate of serum transaminase elevations of more than 8
times the upper limit of normal was approximately 1% in fluconazole-treated
patients in clinical trials. These elevations occurred in patients with
severe underlying disease, predominantly AIDS or malignancies, most of
whom were receiving multiple concomitant medications, including many known
to be hepatotoxic. The incidence of abnormally elevated serum transaminases
was greater in patients taking Fluconazole concomitantly with one or more
of the following medications: rifampin, phenytoin, isoniazid, valproic
acid, or oral sulfonylurea hypoglycemic agents. </p>

<p>In rare cases, anaphylaxis has been reported. </p>

<p>The following adverse experiences occurred under conditions (e.g. open
trials, marketing experience) where a causal association is uncertain.
</p>

<p>Central Nervous System: seizures </p>

<p>Hematopoietic And Lymphatic: leukopenia, thrombocytopenia. </p>

<p><a name="OVERDOSAGE"></a><b>OVERDOSAGE </b></p>

<p>There has been one reported case of overdosage with Fluconazole. A 42-year
old patient infected with human immunodeficiency virus developed hallucinations
and exhibited paranoid behavior after reportedly ingesting 8,200 mg of
Fluconazole. The patient was admitted to the hospital, and his condition
resolved within 48 hours. </p>

<p>In the event of overdose, symptomatic treatment (with supportive measures
and gastric lavage if clinically indicated) should be instituted. </p>

<p>Fluconazole is largely excreted in urine. A three hour hemodialysis
session decreases plasma levels by approximately 50%. </p>

<p>In mice and rats receiving very high doses of fluconazole, clinical
effects, in both species, included decreased motility and respiration,
ptosis, lacrimation, salivation, urinary incontinence, loss of righting
reflex and cyanosis; death was sometimes preceded by clonic convulsions.
</p>

<p><a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION
</b></p>

<p>SINCE ORAL ABSORPTION IS RAPID AND ALMOST COMPLETE, THE DAILY DOSE OF
Fluconazole IS THE SAME FOR ORAL AND INTRAVENOUS ADMINISTRATION. </p>

<p>The daily dose of Fluconazole should be based on the infecting organism
and the patient's response to therapy. Treatment should be continued until
clinical parameters or laboratory tests indicate that active fungal infection
has subsided. An inadequate period of treatment may lead to recurrence
of active infection. Patients with AIDS and cryptococcal meningitis or
recurrent oropharyngeal candidiasis usually require maintenance therapy
to prevent relapse. </p>

<p>The recommended dosage of Fluconazole for oropharyngeal candidiasis
is 200 mg on the first day, followed by 100 mg once daily. Clinical evidence
of oropharyngeal candidiasis generally resolves within several days, but
treatment should be continued for at least 2 weeks to decrease the likelihood
of relapse. </p>

<p>The recommended dosage of Fluconazole for esophageal candidiasis is
200 mg on the first day, followed by 100 mg once daily. Doses up to 400
mg/day may be used, based on medical judgment of the patient's response
to therapy. Patients with esophageal candidiasis should be treated for
a minimum of three weeks and for at least two weeks following resolution
of symptoms. </p>

<p>For systemic candidiasis, the recommended dosage of Fluconazole is 400
mg on the first day, followed by 200 mg once daily. These patients should
be treated for a minimum of 4 weeks and for at least 2 weeks following
resolution of symptoms. </p>

<p>For cryptococcal meningitis, the recommended dosage of Fluconazole is
400 mg on the first day, followed by 200 mg once daily. A dosage of 400
mg once daily may be used, based on medical judgment of the patient's response
to therapy. The recommended duration of treatment for initial therapy of
cryptococcal meningitis is 10-12 weeks after the cerebrospinal fluid becomes
culture negative. The recommended dosage of Fluconazole for suppression
of relapse of cryptococcal meningitis in patients with AIDS is 200 mg once
daily. </p>

<p>DOSAGE IN PATIENTS WITH IMPAIRED RENAL FUNCTION </p>

<p>Fluconazole is cleared primarily by renal excretion as unchanged drug.
In patients with impaired renal function, an initial loading dose of 50
to 400 mg should be given. After the loading dose, the daily dose (according
to indication) should be based on the following table: </p>

<pre>                       Fluconazole                                                 
                                     PERCENT OF                                 
CREATININE CLEARANCE (ML/MIN)     RECOMMENDED DOSE                              
            &gt;50                         100%                                    
           21-50                         50%                                    
           11-20                         25%                                    
     Patients receiving         one recommended dose                            
    regular hemodialysis        after each dialysis                             
These are suggested dose adjustments based on pharmacokinetics following
administration of single doses. Further adjustment may be needed depending upon 
clinical condition.  
 
When serum creatinine is the only measure of renal function available, the
following formula (based on sex, weight, and age of the patient) should be used 
to estimate the creatinine clearance.  
 
  Males:          Weight (kg) X (140-age)                                       
              --------------------------------                                  
              72 X serum creatinine (mg/100mL)                                  
  Females:      0.85 X above value   </pre>

<p>Fluconazole may be administered either orally or by intravenous infusion.
Fluconazole injection has been used safely for up to fourteen days of intravenous
therapy. The intravenous infusion of Fluconazole should be administered
at a maximum rate of approximately 200 mg/hour, given as a continuous infusion.
</p>

<h2 align=center>
<hr width="100%" ></h2>

<h2 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-34</DOCNO>
<DOCOLDNO>IA019-000201-B024-60</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/rxlist.cgi?drug=hydrocodone 206.86.175.201 19970106234315 text/html 13491
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:36:59 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE>www.rxlist.com - Neil Sandow, Pharm.D. 
copyright 1995</title></head> <body bgcolor="#ffffff">
<center><a href="http://www.rxlist.com"><img src="rx.gif" 
height=75 width=75 border=0><img src="count.gif" border=0></a></center> 
Searching for: <b>HYDROCODONE</b> <br>scroll down for results 
<hr><hr>
<h1>Enter Brand or Generic Name or Category*</h1>
<h3> Narrow Your Search with <font size=5>*</font>(examples: 
ampi*, *mycin, antibiotic*)</h3>
<form method=get>
<action=>
<input size=30 maxlength=30 name=drug>
<input type=submit>
<input type=reset>
</form>
<HR>
<H3>Your RxList Search Results:</h3>
1<br><b>Brand Name: </b>VIQUIN FORTE<br><b>Generic Name: </b>HYDROQUINONE<br><b>Category: </b>DEPIGMENTING AGENTS
<p>2<br><b>Brand Name: </b>HYDRO/ACETIC<br><b>Generic Name: </b>ACETIC ACID/HYDROCORT OTI<br><b>Category: </b>ANTI-INFECTIVES
<p>3<br><b>Brand Name: </b>HYDERGINE LC<br><b>Generic Name: </b>ERGOLOID MESYLATES<br><b>Category: </b>SYMPATHOLYTIC ADRENERGIC BLOCKING AGENTS
<p>4<br><b>Brand Name: </b>HYDERGINE ORA<br><b>Generic Name: </b>ERGOLOID MESYLATES ORAL<br><b>Category: </b>SYMPATHOLYTIC ADRENERGIC BLOCKING AGENTS
<p>5<br><b>Brand Name: </b>HYDROCHL/RES<br><b>Generic Name: </b>HCTZ/RESERPINE<br><b>Category: </b><a href="http://www.rxlist.com/cardiova.htm">HYPOTENSIVE AGENTS</a> 
<p>6<br><b>Brand Name: </b>MURIATIC ACID<br><b>Generic Name: </b>HYDROCHLORIC ACID<br><b>Category: </b>DIGESTANTS
<p>7<br><b>Brand Name: </b>ANEXSIA<br><b>Generic Name: </b>HYDROCODONE/ACETAMINOPHEN<br><b>Category: </b><a href="http://www.rxlist.com/opiate.htm">OPIATE AGONISTS</a> 
<p>8<br><b>Brand Name: </b>BANCAP HC<br><b>Generic Name: </b>HYDROCODONE/ACETAMINOPHEN<br><b>Category: </b><a href="http://www.rxlist.com/opiate.htm">OPIATE AGONISTS</a> 
<p>9<br><b>Brand Name: </b>LORCET<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/hydrocod.htm">HYDROCODONE/ACETAMINOPHEN</a> <br><b>Category: </b><a href="http://www.rxlist.com/opiate.htm">OPIATE AGONISTS</a> 
<p>10<br><b>Brand Name: </b>LORCET PLUS<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/hydrocod.htm">HYDROCODONE/ACETAMINOPHEN</a> <br><b>Category: </b><a href="http://www.rxlist.com/opiate.htm">OPIATE AGONISTS</a> 
<p>11<br><b>Brand Name: </b>LORTAB<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/hydrocod.htm">HYDROCODONE/ACETAMINOPHEN</a> <br><b>Category: </b><a href="http://www.rxlist.com/opiate.htm">OPIATE AGONISTS</a> 
<p>12<br><b>Brand Name: </b>VICODIN<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/hydrocod.htm">HYDROCODONE/ACETAMINOPHEN</a> <br><b>Category: </b><a href="http://www.rxlist.com/opiate.htm">OPIATE AGONISTS</a> 
<p>13<br><b>Brand Name: </b>VICODIN ES<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/hydrocod.htm">HYDROCODONE/ACETAMINOPHEN</a> <br><b>Category: </b><a href="http://www.rxlist.com/opiate.htm">OPIATE AGONISTS</a> 
<p>14<br><b>Brand Name: </b>ZYDONE<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/hydrocod.htm">HYDROCODONE/ACETAMINOPHEN</a> <br><b>Category: </b><a href="http://www.rxlist.com/opiate.htm">OPIATE AGONISTS</a> 
<p>15<br><b>Brand Name: </b>LORTAB/ASA<br><b>Generic Name: </b>HYDROCODONE/ASPIRIN<br><b>Category: </b><a href="http://www.rxlist.com/opiate.htm">OPIATE AGONISTS</a> 
<p>16<br><b>Brand Name: </b>DAMASON-P<br><b>Generic Name: </b>HYDROCODONE/ASPIRIN/CAFF<br><b>Category: </b><a href="http://www.rxlist.com/opiate.htm">OPIATE AGONISTS</a> 
<p>17<br><b>Brand Name: </b>CODICLEAR DH<br><b>Generic Name: </b>HYDROCODONE/GUAIACOLSULF<br><b>Category: </b>EXPECTORANTS
<p>18<br><b>Brand Name: </b>CO TUSSIN<br><b>Generic Name: </b>HYDROCODONE/GUAIFENESIN<br><b>Category: </b>EXPECTORANTS
<p>19<br><b>Brand Name: </b>HYCOSIN<br><b>Generic Name: </b>HYDROCODONE/GUAIFENESIN<br><b>Category: </b>EXPECTORANTS
<p>20<br><b>Brand Name: </b>HYCOTUSS<br><b>Generic Name: </b>HYDROCODONE/GUAIFENESIN<br><b>Category: </b>EXPECTORANTS
<p>21<br><b>Brand Name: </b>KWELCOF<br><b>Generic Name: </b>HYDROCODONE/GUAIFENESIN<br><b>Category: </b>EXPECTORANTS
<p>22<br><b>Brand Name: </b>VICODIN TUSS<br><b>Generic Name: </b>HYDROCODONE/GUAIFENESIN<br><b>Category: </b>EXPECTORANTS
<p>23<br><b>Brand Name: </b>HYCODAN<br><b>Generic Name: </b>HYDROCODONE/HOMATROPINE<br><b>Category: </b>ANTITUSSIVES-EXPECTS. &amp; MUCYOLYTIC AGENTS
<p>24<br><b>Brand Name: </b>HYDROMET<br><b>Generic Name: </b>HYDROCODONE/HOMATROPINE<br><b>Category: </b><a href="http://www.rxlist.com/opiate.htm">OPIATE AGONISTS</a> 
<p>25<br><b>Brand Name: </b>HYDROTROPINE<br><b>Generic Name: </b>HYDROCODONE/HOMATROPINE<br><b>Category: </b><a href="http://www.rxlist.com/opiate.htm">OPIATE AGONISTS</a> 
<p>26<br><b>Brand Name: </b>TUSSIONEX<br><b>Generic Name: </b>HYDROCODONE/PHENYTOLOX<br><b>Category: </b>ANTITUSSIVES-EXPECTS. &amp; MUCYOLYTIC AGENTS
<p>27<br><b>Brand Name: </b>AEROSEB-HC<br><b>Generic Name: </b>HYDROCORTISONE<br><b>Category: </b>ANTI-INFLAMMATORY AGENTS
<p>28<br><b>Brand Name: </b>AQUANIL HC<br><b>Generic Name: </b>HYDROCORTISONE<br><b>Category: </b>ANTI-INFLAMMATORY AGENTS
<p>29<br><b>Brand Name: </b>CALDECORT<br><b>Generic Name: </b>HYDROCORTISONE<br><b>Category: </b>ANTI-INFLAMMATORY AGENTS
<p>30<br><b>Brand Name: </b>CETACORT<br><b>Generic Name: </b>HYDROCORTISONE<br><b>Category: </b>ANTI-INFLAMMATORY AGENTS
<p>31<br><b>Brand Name: </b>CORTAID<br><b>Generic Name: </b>HYDROCORTISONE<br><b>Category: </b>ANTI-INFLAMMATORY AGENTS
<p>32<br><b>Brand Name: </b>CORTAID FAST<br><b>Generic Name: </b>HYDROCORTISONE<br><b>Category: </b>ANTI-INFLAMMATORY AGENTS
<p>33<br><b>Brand Name: </b>CORTAID MX/ST<br><b>Generic Name: </b>HYDROCORTISONE<br><b>Category: </b>ANTI-INFLAMMATORY AGENTS
<p>34<br><b>Brand Name: </b>CORTAID/ALOE<br><b>Generic Name: </b>HYDROCORTISONE<br><b>Category: </b>ANTI-INFLAMMATORY AGENTS
<p>35<br><b>Brand Name: </b>CORTIZONE<br><b>Generic Name: </b>HYDROCORTISONE<br><b>Category: </b>ANTI-INFLAMMATORY AGENTS
<p>36<br><b>Brand Name: </b>CORTIZONE-10<br><b>Generic Name: </b>HYDROCORTISONE<br><b>Category: </b>ANTI-INFLAMMATORY AGENTS
<p>37<br><b>Brand Name: </b>CORTIZONE-5<br><b>Generic Name: </b>HYDROCORTISONE<br><b>Category: </b>ANTI-INFLAMMATORY AGENTS
<p>38<br><b>Brand Name: </b>GYNECORT-10<br><b>Generic Name: </b>HYDROCORTISONE<br><b>Category: </b>ANTI-INFLAMMATORY AGENTS
<p>39<br><b>Brand Name: </b>HYDRO-SKIN<br><b>Generic Name: </b>HYDROCORTISONE<br><b>Category: </b>ANTI-INFLAMMATORY AGENTS
<p>40<br><b>Brand Name: </b>HYTONE<br><b>Generic Name: </b>HYDROCORTISONE<br><b>Category: </b>ANTI-INFLAMMATORY AGENTS
<p>41<br><b>Brand Name: </b>KERICORT-10<br><b>Generic Name: </b>HYDROCORTISONE<br><b>Category: </b>ANTI-INFLAMMATORY AGENTS
<p>42<br><b>Brand Name: </b>LACTICARE HC<br><b>Generic Name: </b>HYDROCORTISONE<br><b>Category: </b>ANTI-INFLAMMATORY AGENTS
<p>43<br><b>Brand Name: </b>LANACORT-10<br><b>Generic Name: </b>HYDROCORTISONE<br><b>Category: </b>ANTI-INFLAMMATORY AGENTS
<p>44<br><b>Brand Name: </b>NUTRACORT<br><b>Generic Name: </b>HYDROCORTISONE<br><b>Category: </b>ANTI-INFLAMMATORY AGENTS
<p>45<br><b>Brand Name: </b>PROCTOCORT<br><b>Generic Name: </b>HYDROCORTISONE<br><b>Category: </b>ANTI-INFLAMMATORY AGENTS
<p>46<br><b>Brand Name: </b>TEXACORT TOPC<br><b>Generic Name: </b>HYDROCORTISONE<br><b>Category: </b>ANTI-INFLAMMATORY AGENTS
<p>47<br><b>Brand Name: </b>ANUCORT HC<br><b>Generic Name: </b>HYDROCORTISONE ACETATE<br><b>Category: </b>ANTI-INFLAMMATORY AGENTS
<p>48<br><b>Brand Name: </b>ANUSOL HC<br><b>Generic Name: </b>HYDROCORTISONE ACETATE<br><b>Category: </b>ANTI-INFLAMMATORY AGENTS
<p>49<br><b>Brand Name: </b>ANU-MED HC<br><b>Generic Name: </b>HYDROCORTISONE ACETATE<br><b>Category: </b>ANTI-INFLAMMATORY AGENTS
<p>50<br><b>Brand Name: </b>CORTICAINE<br><b>Generic Name: </b>HYDROCORTISONE ACETATE<br><b>Category: </b>ANTI-INFLAMMATORY AGENTS
<p>51<br><b>Brand Name: </b>CORTIFOAM<br><b>Generic Name: </b>HYDROCORTISONE ACETATE<br><b>Category: </b>ANTI-INFLAMMATORY AGENTS
<p>52<br><b>Brand Name: </b>HEMRIL HC<br><b>Generic Name: </b>HYDROCORTISONE ACETATE<br><b>Category: </b>ANTI-INFLAMMATORY AGENTS
<p>53<br><b>Brand Name: </b>PROCTOSOL-HC<br><b>Generic Name: </b>HYDROCORTISONE ACETATE<br><b>Category: </b>ANTI-INFLAMMATORY AGENTS
<p>54<br><b>Brand Name: </b>CORTAID W/ALO<br><b>Generic Name: </b>HYDROCORTISONE ACET/ALOE<br><b>Category: </b>ANTI-INFLAMMATORY AGENTS
<p>55<br><b>Brand Name: </b>LANACORT HC<br><b>Generic Name: </b>HYDROCORTISONE ACET/ALOE<br><b>Category: </b>ANTI-INFLAMMATORY AGENTS
<p>56<br><b>Brand Name: </b>LOCOID<br><b>Generic Name: </b>HYDROCORTISONE BUTYRATE<br><b>Category: </b>ANTI-INFLAMMATORY AGENTS
<p>57<br><b>Brand Name: </b>CORTEF<br><b>Generic Name: </b>HYDROCORTISONE CYPIONATE<br><b>Category: </b>ADRENALS
<p>58<br><b>Brand Name: </b>CORTENEMA<br><b>Generic Name: </b>HYDROCORTISONE ENEMA<br><b>Category: </b>ANTI-INFLAMMATORY AGENTS
<p>59<br><b>Brand Name: </b>A-HYDROCORT<br><b>Generic Name: </b>HYDROCORTISONE SOD SUCCIN<br><b>Category: </b>ADRENALS
<p>60<br><b>Brand Name: </b>A-HYDROCORT<br><b>Generic Name: </b>HYDROCORTISONE SOD SUCCIN<br><b>Category: </b>ADRENALS
<p>61<br><b>Brand Name: </b>SOLU CORTEF<br><b>Generic Name: </b>HYDROCORTISONE SOD SUCCIN<br><b>Category: </b>ADRENALS
<p>62<br><b>Brand Name: </b>WESTCORT<br><b>Generic Name: </b>HYDROCORTISONE VALERATE<br><b>Category: </b>ANTI-INFLAMMATORY AGENTS
<p>63<br><b>Brand Name: </b>OTOBIOTIC<br><b>Generic Name: </b>HYDROCORTISONE/POLYMYXIN<br><b>Category: </b>ANTIBIOTICS
<p>64<br><b>Brand Name: </b>ANALPRAM HC<br><b>Generic Name: </b>HYDROCORTISONE/PRAMOXINE<br><b>Category: </b>ANTIPRURITICS AND LOCAL ANESTHETICS
<p>65<br><b>Brand Name: </b>PROCTOCRM HC<br><b>Generic Name: </b>HYDROCORTISONE/PRAMOXINE<br><b>Category: </b>ANTIPRURITICS AND LOCAL ANESTHETICS
<p>66<br><b>Brand Name: </b>CARMOL HC<br><b>Generic Name: </b>HYDROCORTISONE/UREA<br><b>Category: </b>ANTI-INFLAMMATORY AGENTS
<p>67<br><b>Brand Name: </b>MANTADIL<br><b>Generic Name: </b>HYDROCORT/CHLORCYCLIZINE<br><b>Category: </b>ANTIPRURITICS AND LOCAL ANESTHETICS
<p>68<br><b>Brand Name: </b>PEROXYL MOUTH<br><b>Generic Name: </b>HYDROGEN PEROXIDE<br><b>Category: </b>MOUTHWASHES AND GARGLES
<p>69<br><b>Brand Name: </b>HYDROG PEROX<br><b>Generic Name: </b>HYDROGEN PEROXIDE 10 VOL<br><b>Category: </b>MISCELLANEOUS LOCAL ANTI-INFECTIVES
<p>70<br><b>Brand Name: </b>PROXACOL<br><b>Generic Name: </b>HYDROGEN PEROXIDE 10 VOL<br><b>Category: </b>MISCELLANEOUS LOCAL ANTI-INFECTIVES
<p>71<br><b>Brand Name: </b>BLACK/WHITE<br><b>Generic Name: </b>HYDROQUINONE<br><b>Category: </b>DEPIGMENTING AGENTS
<p>72<br><b>Brand Name: </b>ELDOPAQUE FOR<br><b>Generic Name: </b>HYDROQUINONE<br><b>Category: </b>DEPIGMENTING AGENTS
<p>73<br><b>Brand Name: </b>ELDOQUIN<br><b>Generic Name: </b>HYDROQUINONE<br><b>Category: </b>DEPIGMENTING AGENTS
<p>74<br><b>Brand Name: </b>ESOTERICA REG<br><b>Generic Name: </b>HYDROQUINONE<br><b>Category: </b>DEPIGMENTING AGENTS
<p>75<br><b>Brand Name: </b>MELANEX TOPIC<br><b>Generic Name: </b>HYDROQUINONE<br><b>Category: </b>DEPIGMENTING AGENTS
<p>76<br><b>Brand Name: </b>MELQUIN 3<br><b>Generic Name: </b>HYDROQUINONE<br><b>Category: </b>DEPIGMENTING AGENTS
<p>77<br><b>Brand Name: </b>NUQUIN HP<br><b>Generic Name: </b>HYDROQUINONE<br><b>Category: </b>DEPIGMENTING AGENTS
<p>78<br><b>Brand Name: </b>NUQUIN HP<br><b>Generic Name: </b>HYDROQUINONE/PABA/DIOXYBE<br><b>Category: </b>DEPIGMENTING AGENTS
<p>79<br><b>Brand Name: </b>ESOTERICA FAC<br><b>Generic Name: </b>HYDROQUINONE/PADIM O/OXYB<br><b>Category: </b>DEPIGMENTING AGENTS
<p>80<br><b>Brand Name: </b>ESOTERICA SEN<br><b>Generic Name: </b>HYDROQUINONE/PADIM O/OXYB<br><b>Category: </b>DEPIGMENTING AGENTS
<p>81<br><b>Brand Name: </b>ESOTERICA SUN<br><b>Generic Name: </b>HYDROQUINONE/PADIM O/OXYB<br><b>Category: </b>DEPIGMENTING AGENTS
<p>82<br><b>Brand Name: </b>SOLAQUIN<br><b>Generic Name: </b>HYDROQUIN/PABA/DIOXY/OXYB<br><b>Category: </b>KERATOLYTIC AGENTS
<p>83<br><b>Brand Name: </b>PAREMYD<br><b>Generic Name: </b>HYDROXYAMPHET/TROPICAMIDE<br><b>Category: </b>MYDRIATICS
<p>84<br><b>Brand Name: </b>PLAQUENIL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/hquine.htm">HYDROXYCHLOROQUINE SULFATE</a><br><b>Category: </b>ANTIMALARIAL AGENTS
<p>85<br><b>Brand Name: </b>HYDROXYPROG<br><b>Generic Name: </b>HYDROXYPROGESTERONE CAPRO<br><b>Category: </b>PROGESTINS
<p>86<br><b>Brand Name: </b>TEARGEN II<br><b>Generic Name: </b>HYDROXYPROPYLMETHYLCELLUL<br><b>Category: </b>MISCELLANEOUS EENT DRUGS
<p>87<br><b>Brand Name: </b>HYDREA<br><b>Generic Name: </b>HYDROXYUREA<br><b>Category: </b>ANTINEOPLASTIC AGENTS
<p>88<br><b>Brand Name: </b>ATARAX<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/hydrox.htm">HYDROXYZINE HCL</a><br><b>Category: </b>MISC. ANXIOLYTICS- SEDATIVES AND HYPNOTICS
<p>89<br><b>Brand Name: </b>VISTARIL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/hydrox.htm">HYDROXYZINE</a> PAMOATE<br><b>Category: </b>MISC. ANXIOLYTICS- SEDATIVES AND HYPNOTICS
<p>90<br><b>Brand Name: </b>HYDROCIL INST<br><b>Generic Name: </b>PSYLLIUM INSTANT SF<br><b>Category: </b>CATHARTICS AND LAXATIVES
<p>91<br><b>Brand Name: </b>HYDRISINOL<br><b>Generic Name: </b>VEGETABLE OIL/CASTOR OIL<br><b>Category: </b>MISCEL.SKIN AND MUCUS MEMBRANE AGENTS
<p></body></html>
<P><hr><a href="http://www.rxlist.com"><b>RxList Home Page</ul>
<hr>
</DOC>
<DOC>
<DOCNO>WT08-B13-35</DOCNO>
<DOCOLDNO>IA018-000200-B036-72</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/hum7030.htm 206.86.175.201 19970106225054 text/html 19397
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:44:39 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 19214
Last-modified: Sun, 11 Aug 1996 03:44:47 GMT
</DOCHDR>
<html>
<head>
   <title>Human Insulin 70/30 - RxList Generic Information</title>
   <meta name="Author" content="">
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Human Insulin 70/30</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [action]
[use] [contra] [<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>]
[<a href="#DRUG INTERACTIONS">drug-drug</a>] [side effects] [toxicity]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

 <a name="DESCRIPTION"></a><b>DESCRIPTION 
</b> <p>
70/30 HUMAN INSULIN 
 <p>
Human insulin is synthesized in a non-disease-producing special laboratory strain of
Escherichia Coli bacteria that has been genetically altered by the addition of
the gene for human insulin production. Human insulin 70/30 is a mixture of 70% Human
Insulin Isophane Suspension and 30% Human Insulin Injection. It is an
intermediate-acting insulin combined with the more rapid onset of action of
regular insulin. The duration of activity may last up to 24 hours following
injection. The time course of action of any insulin may vary considerably in
different individuals or at different times in the same individual. As with all 
insulin preparations, the duration of action of Human insulin 70/30 is dependent on
dose, site of injection, blood supply, temperature, and physical activity. 
Human insulin 70/30 is a sterile suspension and is for subcutaneous injection only.
It should not be used intravenously or intramuscularly. The concentration of
Human insulin 70/30 is 100 units/mL (U-100).  
 <p>
IDENTIFICATION 
 <p>
Your doctor has prescribed the type of insulin that he/she believes is best for you. 
DO NOT USE ANY OTHER INSULIN EXCEPT ON HIS/HER ADVICE AND DIRECTION.  
 <p>
Always check the carton and the bottle label for the name and letter
designation of the insulin you receive from your pharmacy to make sure it is
the same as that your doctor has prescribed
 <p>
Always examine the appearance of your bottle of insulin before withdrawing each 
dose. A bottle of Human insulin 70/30 must be carefully shaken or rotated before each 
injection so that the contents are uniformly mixed. Human insulin 70/30 should look
uniformly cloudy or milky after mixing. Do not use it if the insulin substance
(the white material) remains at the bottom of the bottle after mixing. Do not
use a bottle of Human insulin 70/30 if there are clumps in the insulin after mixing. 
Do not use a bottle of Human insulin 70/30 if solid white particles stick to the bottom or wall
of the bottle, giving it a frosted appearance. Always check the appearance of your bottle of
insulin before using, and if you note anything unusual in the appearance of your insulin or
notice your insulin requirements changing markedly, consult your doctor.  
 <p>
STORAGE 
 <p>
Insulin should be stored in a refrigerator but not in the freezer. If
refrigeration is not possible, the bottle of insulin that you are currently
using can be kept unrefrigerated as long as it is kept as cool as possible
(below 86 degF (30 degC)) and away from heat and light. Do not use insulin if
it has been frozen. Do not use a bottle of insulin after the expiration date
stamped on the label.  
 <p>
<a name="WARNINGS"></a><b>WARNINGS 
</b> <p>
INFORMATION FOR THE PATIENT 
 <p>
THIS HUMAN INSULIN PRODUCT DIFFERS FROM ANIMAL-SOURCE INSULINS, BECAUSE
IT IS STRUCTURALLY IDENTICAL TO THE INSULIN PRODUCED BY YOUR BODY'S PANCREAS
AND BECAUSE OF ITS UNIQUE MANUFACTURING PROCESS.  
 <p>
ANY CHANGE OF INSULIN SHOULD BE MADE CAUTIOUSLY AND ONLY UNDER MEDICAL
SUPERVISION. CHANGES IN PURITY, STRENGTH, BRAND (MANUFACTURER), TYPE (REGULAR,
NPH, LENTE, ETC), SPECIES (BEEF, PORK, BEEF-PORK, HUMAN), AND/OR METHOD OF
MANUFACTURE (RECOMBINANT DNA VERSUS ANIMAL-SOURCE INSULIN) MAY RESULT IN THE
NEED FOR A CHANGE IN DOSAGE.  
 <p>
SOME PATIENTS TAKING HUMAN INSULIN MAY REQUIRE A CHANGE IN DOSAGE FROM THAT USED WITH
ANIMAL-SOURCE INSULINS. IF AN ADJUSTMENT IS NEEDED, IT MAY OCCUR WITH THE FIRST DOSE OR DURING
THE FIRST SEVERAL WEEKS OR MONTHS.  
 <p>
DIABETES 
 <p>
Insulin is a hormone produced by the pancreas, a large gland that lies near the 
stomach. This hormone is necessary for the body's correct use of food,
especially sugar. Diabetes occurs when the pancreas does not make enough
insulin to meet your body's needs.  
 <p>
To control your diabetes, your doctor has prescribed injections of insulin to
keep your blood glucose at a nearly normal level. Proper control of your
diabetes requires close and constant cooperation with your doctor. In spite of
diabetes, you can lead an active, healthy, and useful life if you eat a
balanced diet daily, exercise regularly, and take your insulin injections as
prescribed.  
 <p>
You have been instructed to test your blood and/or your urine regularly for
glucose. If your blood tests consistently show above- or below-normal glucose
levels or your urine tests consistently show the presence of glucose, your
diabetes is not properly controlled and you must let your doctor know.  
 <p>
Always keep an extra supply of insulin as well as spare syringe and needle on
hand. Always wear diabetic identification so that appropriate treatment can be
given if complications occur away from home.  
 <p>
<a name="PRECAUTIONS"></a><b>PRECAUTIONS 
</b> <p>
Other things that may affect your insulin dose are:  
 <p>
ILLNESS 
 <p>
Illness, especially with nausea and vomiting, may cause your insulin
requirements to change. Even if you are not eating, you will still require
insulin. You and your doctor should establish a sick day plan for you to use in 
case of illness. When you are sick, test your blood/urine frequently and call
your doctor as instructed.  
 <p>
PREGNANCY 
 <p>
Good control of diabetes is especially important for you and your unborn baby.  
Pregnancy may make managing your diabetes more difficult. If you are planning
to have a baby, are pregnant, or are nursing a baby, consult your doctor.  
 <p>
MEDICATION 
 <p>
Insulin requirements may be increased if you are taking other drugs with
hyperglycemic activity, such as oral contraceptives, corticosteroids, or
thyroid replacement therapy. Insulin requirements may be reduced in the
presence of drugs with hypoglycemic activity, such as oral hypoglycemics,
salicylates (for example, aspirin), sulfa antibiotics, and certain
antidepressants. Always discuss any medications you are taking with your
doctor.  
 <p>
EXERCISE 
 <p>
Exercise may lower your body's need for insulin during and for some time after
the activity. Exercise may also speed up the effect of an insulin dose,
especially if the exercise involves the area of injection site (for example,
the leg should not be used for injection just prior to running). Discuss with
your doctor how you should adjust your regimen to accommodate exercise.  
 <p>
TRAVEL 
 <p>
Persons traveling across more than 2 time zones should consult their doctor
concerning adjustments in their insulin schedule.  
 <p>
COMMON PROBLEMS OF DIABETES 
 <p>
HYPOGLYCEMIA (INSULIN REACTION) 
 <p>
Hypoglycemia (too little glucose in the blood) is one of the most frequent
adverse events experienced by insulin users. It can be brought about by:  
 <p>
1. Taking too much insulin 
 <p>
2. Missing or delaying meals 
 <p>
3. Exercising or working more than usual 
 <p>
4. An infection or illness (especially with diarrhea or vomiting) 
                     <p>  
5. A change in the body's need for insulin 
 <p>
6. Diseases of the adrenal, pituitary, or thyroid gland, or progression of
kidney or liver disease 
 <p>
7. Interactions with other drugs that lower blood glucose, such as oral
hypoglycemics, salicylates (for example, aspirin), sulfa antibiotics, and
certain antidepressants 
 <p>
8. Consumption of alcoholic beverages 
 <p>
Symptoms of mild to moderate hypoglycemia may occur suddenly and can include: 
 <p>
-- sweating 
 <p>
-- dizziness 
 <p>
-- palpitation 
 <p>
-- tremor 
 <p>
-- hunger 
 <p>
-- restlessness 
 <p>
-- tingling in the hands, feet, lips, or tongue 
 <p>
-- lightheadedness 
 <p>
-- inability to concentrate 
 <p>
-- headache 
 <p>
-- drowsiness 
 <p>
-- sleep disturbances 
 <p>
-- anxiety 
 <p>
-- blurred vision 
 <p>
-- slurred speech 
 <p>
-- depressive mood 
 <p>
-- irritability 
 <p>
-- abnormal behavior 
 <p>
-- unsteady movement 
      <p>                 
-- personality changes 
 <p>
Signs of severe hypoglycemia can include:  
 <p>
-- disorientation 
 <p>
-- unconsciousness 
 <p>
-- seizures 
 <p>
-- death 
 <p>
Therefore, it is important that assistance be obtained immediately.  
 <p>
Early warning symptoms of hypoglycemia may be different or less pronounced
under certain conditions, such as long duration of diabetes, diabetic nerve
disease, medications such as beta-blockers, change in insulin preparations, or
intensified control (3 or more insulin injections per day) of diabetes.  
 <p>
A FEW PATIENTS WHO HAVE EXPERIENCED HYPOGLYCEMIC REACTIONS AFTER TRANSFER FROM
ANIMAL-SOURCE INSULIN TO HUMAN INSULIN HAVE REPORTED THAT THE EARLY WARNING
SYMPTOMS OF HYPOGLYCEMIA WERE LESS PRONOUNCED OR DIFFERENT FROM THOSE
EXPERIENCED WITH THEIR PREVIOUS INSULIN.  
 <p>
Without recognition of early warning symptoms, you may not be able to take
steps to avoid more serious hypoglycemia. Be alert for all of the various types 
of symptoms that may indicate hypoglycemia. Patients who experience
hypoglycemia without early warning symptoms should monitor their blood glucose
frequently, especially prior to activities such as driving. If the blood
glucose is below your normal fasting glucose, you should consider eating or
drinking sugar- containing foods to treat your hypoglycemia.  
 <p>
Mild to moderate hypoglycemia may be treated by eating foods or drinks that
contain sugar. Patients should always carry a quick source of sugar, such as
candy mints or glucose tablets. More severe hypoglycemia may require the
assistance of another person. Patients who are unable to take sugar orally or
who are unconscious require an injection of glucagon or should be treated with
intravenous administration of glucose at a medical facility.  
 <p>
You should learn to recognize your own symptoms of hypoglycemia. If you are
uncertain about these symptoms, you should monitor your blood glucose
frequently to help you learn to recognize the symptoms that you experience with 
hypoglycemia.  <p>
 
If you have frequent episodes of hypoglycemia or experience difficulty in
recognizing the symptoms, you should consult your doctor to discuss possible
changes in therapy, meal plans, and/or exercise programs to help you avoid
hypoglycemia.  
 <p>
HYPERGLYCEMIA AND DIABETIC ACIDOSIS 
                       <p>
Hyperglycemia (too much glucose in the blood) may develop if your body has too
little insulin. Hyperglycemia can be brought about by:  
 <p>
1. Omitting your insulin or taking less than the doctor has prescribed 
 <p>
2. Eating significantly more than your meal plan suggests 
 <p>
3. Developing a fever or infection 
 <p>
In patients with insulin-dependent diabetes, prolonged hyperglycemia can result 
in diabetic acidosis. The first symptoms of diabetic acidosis usually come on
gradually, over a period of hours or days, and include a drowsy feeling,
flushed face, thirst, loss of appetite, and fruity odor on the breath. With
acidosis, urine tests show large amounts of glucose and acetone. Heavy
breathing and a rapid pulse are more severe symptoms. If uncorrected, prolonged 
hyperglycemia or diabetic acidosis can result in loss of consciousness or
death. Therefore, it is important that you obtain medical assistance
immediately.  
 <p>
LIPODYSTROPHY 
 <p>
Rarely, administration of insulin subcutaneously can result in lipoatrophy
(depression in the skin) or lipohypertrophy (enlargement or thickening of
tissue). If you notice either of these conditions, consult your doctor. A
change in your injection technique may help alleviate the problem.  
 <p>
ALLERGY TO INSULIN 
 <p>
Local Allergy--Patients occasionally experience redness, swelling, and itching
at the site of injection of insulin. This condition, called local allergy,
usually clears up in a few days to a few weeks. In some instances, this
condition may be related to factors other than insulin, such as irritants in
the skin cleansing agent or poor injection technique. If you have local
reactions, contact your doctor.  
 <p>
Systemic Allergy--Less common, but potentially more serious, is generalized
allergy to insulin, which may cause rash over the whole body, shortness of
breath, wheezing, reduction in blood pressure, fast pulse, or sweating. Severe
cases of generalized allergy may be life threatening. If you think you are
having a generalized allergic reaction to insulin, notify a doctor immediately. 
 <p>
ADDITIONAL INFORMATION 
 <p>
Additional information about diabetes may be obtained from your diabetes
educator.  
 <p>
DIABETES FORECAST is a national magazine designed especially for patients with
diabetes and their families and is available by subscription from the American
Diabetes Association, National Service Center, 1660 Duke Street, Alexandria,
Virginia 22314.  
        <p>               
Another publication, DIABETES COUNTDOWN, is available from the Juvenile
Diabetes Foundation, 432 Park Avenue South, New York, New York 10016-8013.  
 <p>
<a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS 
</b> <p>
MEDICATION 
 <p>
Insulin requirements may be increased if you are taking other drugs with
hyperglycemic activity, such as oral contraceptives, corticosteroids, or
thyroid replacement therapy. Insulin requirements may be reduced in the
presence of drugs with hypoglycemic activity, such as oral hypoglycemics,
salicylates (for example, aspirin), sulfa antibiotics, and certain
antidepressants. Always discuss any medications you are taking with your
doctor.  
 
(See Also PRECAUTIONS).  <p>
 
<a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION 
</b> <p>
INJECTION PROCEDURES 
 <p>
CORRECT SYRINGE 
 <p>
Doses of insulin are measured in UNITS. U-100 insulin contains 100 units/mL (1
mL=1 cc). With Human insulin 70/30, it is important to use a syringe that is marked
for U-100 insulin preparations. Failure to use the proper syringe can lead to a 
mistake in dosage, causing serious problems for you, such as a blood glucose
level that is too low or too high.  
 <p>
SYRINGE USE 
 <p>
To help avoid contamination and possible infection, follow these instructions
exactly.  
 <p>
Disposable syringes and needles should be used only once and then discarded.  
 <p>
NEEDLES AND SYRINGES MUST NOT BE SHARED.  
 <p>
Reusable syringes and needles must be sterilized before each injection. FOLLOW
THE PACKAGE DIRECTIONS SUPPLIED WITH YOUR SYRINGE. Described below are 2
methods of sterilizing.  
 <p>
BOILING 
 <p>
1.  Put syringe, plunger, and needle in strainer, place in saucepan, and cover
with water. Boil for 5 minutes.  
 <p>
2.  Remove articles from water. When they have cooled, insert plunger into
barrel, and fasten needle to syringe with a slight twist.  
 <p>
3.  Push plunger in and out several times until water is completely removed.  
 <p>
ISOPROPYL ALCOHOL 
 <p>
If the syringe, plunger, and needle cannot be boiled, as when you are traveling 
they may be sterilized by immersion for at least 5 minutes in Isopropyl
Alcohol, 91%. Do not use bathing, rubbing, or medicated alcohol for this
sterilization.  If the syringe is sterilized with alcohol, it must be
absolutely dry before use.  
 <p>
PREPARING THE DOSE 
 <p>
1.  Wash your hands.  
 <p>
2.  Carefully shake or rotate the insulin bottle several times to completely
mix the insulin.  
 <p>
3.  Inspect the insulin. Human insulin 70/30 should look uniformly cloudy or milky.
Do not use it if you notice anything unusual in the appearance.  
 <p>
4.  If using a new bottle, flip off the plastic protective cap, but DO NOT
remove the stopper. When using a new bottle, wipe the top of the bottle with an 
alcohol swab.  
 <p>
5.  Draw air into the syringe equal to your insulin dose. Put the needle
through rubber top of the insulin bottle and inject the air into the bottle.  
 <p>
6.  Turn the bottle and syringe upside down. Hold the bottle and syringe firmly 
in 1 hand and shake gently.  
 <p>
7.  Making sure the tip of the needle is in the insulin, withdraw the correct
dose of insulin into the syringe.  
 <p>
8.  Before removing the needle from the bottle, check your syringe for air
bubbles which reduce the amount of insulin in it. If bubbles are present, hold
the syringe straight up and tap its side until the bubbles float to the top. 
Push them out with the plunger and withdraw the correct dose.  
 <p>
9.  Remove the needle from the bottle and lay the syringe down so that the
needle does not touch anything.  
 <p>
INJECTION 
 <p>
Cleanse the skin with alcohol where the injection is to be made. Stabilize the
skin by spreading it or pinching up a large area. Insert the needle as
instructed by your doctor. Push the plunger in as far as it will go. Pull the
needle out and apply gentle pressure over the injection site for several
seconds. DO NOT RUB THE AREA. To avoid tissue damage, give the next injection
at a site at least 1/2'' from the previous site.  
 <p>
DOSAGE 
 <p>
Your doctor has told you which insulin to use, how much, and when and how often 
to inject it. Because each patient's case of diabetes is different, this
schedule has been individualized for you.  
 <p>
Your usual insulin dose may be affected by changes in your food, activity, or
work schedule. Carefully follow your doctor's instructions to allow for these
changes.  
 <p>


<h2 align=center>
<hr width="100%" ></h2>

<h2 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-36</DOCNO>
<DOCOLDNO>IA018-000200-B037-208</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/huminsr.htm 206.86.175.201 19970106225656 text/html 4648
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 22:50:39 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 4466
Last-modified: Thu, 11 Jul 1996 07:39:26 GMT
</DOCHDR>
<html>
<head>
   <title>Human Insulin Regular (R) - RxList Generic Information</title>
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Human Insulin - Regular (R)</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [action]
[use] [contra] [<a href="#WARNINGS">warn!</a>] [caution] [drug-drug] [side
effects] [toxicity] [<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

<p><a name="DESCRIPTION"></a><b>DESCRIPTION </b></p>

<p>REGULAR HUMAN INSULIN </p>

<p>Human insulin is synthesized in a special non-disease-producing special
laboratory strain of Escherichia Coli bacteria that has been genetically
altered by the addition of the gene for human insulin production. Human
insulin R consists of zinc insulin crystals dissolved in a clear fluid.
Human insulin R has had nothing added to change the speed or length of
its action. It takes effect rapidly and has a relatively short duration
of activity (4 to 12 hours) as compared with other insulins. The time course
of action of any insulin may vary considerably in different individuals
or at different times in the same individual. As with all insulin preparations,
the duration of action of Human insulin R is dependent on dose, site of
injection, blood supply, temperature, and physical activity. Human insulin
R is a sterile solution and is for subcutaneous injection. It should not
be used intramuscularly. The concentration of Human insulin R is 100 units/mL
(U-100). </p>

<p>IDENTIFICATION </p>

<p>Your doctor has prescribed the type of insulin that he/she believes
is best for you. DO NOT USE ANY OTHER INSULIN EXCEPT ON HIS/HER ADVICE
AND DIRECTION. </p>

<p>Always check the carton and the bottle label for the name and letter
designation of the insulin you receive from your pharmacy to make sure
it is the same as that your doctor has prescribed.</p>

<p> Always examine the appearance of your bottle of insulin before withdrawing
each dose. Human insulin R is a clear and colorless liquid with a water-like
appearance and consistency. Do not use if it appears cloudy, thickened,
or slightly colored or if solid particles are visible. Always check the
appearance of your bottle of insulin before using, and if you note anything
unusual in the appearance of your insulin or notice your insulin requirements
changing markedly, consult your doctor. </p>

<p><a name="WARNINGS"></a><b>WARNINGS </b></p>

<p>INFORMATION FOR THE PATIENT </p>

<p>THIS HUMAN INSULIN PRODUCT DIFFERS FROM ANIMAL-SOURCE INSULINS BECAUSE
IT IS STRUCTURALLY IDENTICAL TO THE INSULIN PRODUCED BY YOUR BODY'S PANCREAS
AND BECAUSE OF ITS UNIQUE MANUFACTURING PROCESS. </p>

<p>ANY CHANGE OF INSULIN SHOULD BE MADE CAUTIOUSLY AND ONLY UNDER MEDICAL
SUPERVISION. CHANGES IN PURITY, STRENGTH, BRAND (MANUFACTURER), TYPE (REGULAR,
NPH, LENTE, ETC), SPECIES (BEEF, PORK, BEEF-PORK, HUMAN), AND/OR METHOD
OF MANUFACTURE (RECOMBINANT DNA VERSUS ANIMAL-SOURCE INSULIN) MAY RESULT
IN THE NEED FOR A CHANGE IN DOSAGE. </p>

<p>SOME PATIENTS TAKING Human insulin (HUMAN INSULIN, RECOMBINANT DNA ORIGIN)
MAY REQUIRE A CHANGE IN DOSAGE FROM THAT USED WITH ANIMAL-SOURCE INSULINS.
IF AN ADJUSTMENT IS NEEDED, IT MAY OCCUR WITH THE FIRST DOSE OR DURING
THE FIRST SEVERAL WEEKS OR MONTHS. </p>

<p><a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION
</b></p>

<p>INJECTION PROCEDURES </p>

<p>Do not rotate or shake the insulin bottle. </p>

<p>
<hr width="100%" ></p>

<h2 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;</a><a href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-37</DOCNO>
<DOCOLDNO>IA019-000201-B024-70</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/rxlist.cgi?drug=bell*?drug=*spas?drug=bellas*?drug=bella* 206.86.175.201 19970106234328 text/html 867
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:37:08 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE>www.rxlist.com - Neil Sandow, Pharm.D. 
copyright 1995</title></head> <body bgcolor="#ffffff">
<center><a href="http://www.rxlist.com"><img src="rx.gif" 
height=75 width=75 border=0><img src="count.gif" border=0></a></center> 
Searching for:</font> <b>BELL *?DRUG=*SPAS?DRUG=BELLAS*?DRUG=BELLA*</b><br>    
Scroll Down for Results</font>
<hr><hr>
<h1>Enter Brand or Generic Name or Category*</h1>
<h3> Narrow Your Search with <font size=5>*</font>(examples: 
ampi*, *mycin, antibiotic*)</h3>
<form method=get>
<action=>
<input size=30 maxlength=30 name=drug>
<input type=submit>
<input type=reset>
</form>
<HR>
<H3>Your RxList Search Results:</h3>
</body></html>
<P><hr><a href="http://www.rxlist.com"><b>RxList Home Page</ul>
<hr>
</DOC>
<DOC>
<DOCNO>WT08-B13-38</DOCNO>
<DOCOLDNO>IA019-000201-B024-84</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/rxlist.cgi?drug=sildenafil 206.86.175.201 19970106234337 text/html 1479
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:37:22 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE>www.rxlist.com - Neil Sandow, Pharm.D. 
copyright 1995</title></head> <body bgcolor="#ffffff">
<center><a href="http://www.rxlist.com"><img src="rx.gif" 
height=75 width=75 border=0><img src="count.gif" border=0></a></center> 
Searching for: <b>SILDENAFIL</b> <br>scroll down for results 
<hr><hr>
<h1>Enter Brand or Generic Name or Category*</h1>
<h3> Narrow Your Search with <font size=5>*</font>(examples: 
ampi*, *mycin, antibiotic*)</h3>
<form method=get>
<action=>
<input size=30 maxlength=30 name=drug>
<input type=submit>
<input type=reset>
</form>
<HR>
<H3>Your RxList Search Results:</h3>
1<br><b>Brand Name: </b>SOLATENE<br><b>Generic Name: </b>BETA CAROTENE<br><b>Category: </b>VITAMIN A
<p>2<br><b>Brand Name: </b>SALUTENSIN<br><b>Generic Name: </b>HYDROFLUMETHIAZIDE/RESERP<br><b>Category: </b><a href="http://www.rxlist.com/cardiova.htm">HYPOTENSIVE AGENTS</a> 
<p>3<br><b>Brand Name: </b>SELDANE<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/terfen.htm">TERFENADINE</A><br><b>Category: </b>ANTIHISTAMINE DRUGS
<p>4<br><b>Brand Name: </b>SELDANE D<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/tersud.htm">TERFENADINE/PSEUDOEPHED</a><br><b>Category: </b>ANTITUSSIVES-EXPECTS. &amp; MUCYOLYTIC AGENTS
<p></body></html>
<P><hr><a href="http://www.rxlist.com"><b>RxList Home Page</ul>
<hr>
</DOC>
<DOC>
<DOCNO>WT08-B13-39</DOCNO>
<DOCOLDNO>IA019-000201-B024-100</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/rxlist.cgi?drug=zocor?drug=simvastatin?drug= 206.86.175.201 19970106234350 text/html 836
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:37:32 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE>www.rxlist.com - Neil Sandow, Pharm.D. 
copyright 1995</title></head> <body bgcolor="#ffffff">
<center><a href="http://www.rxlist.com"><img src="rx.gif" 
height=75 width=75 border=0><img src="count.gif" border=0></a></center> 
Searching for: <b>ZOCOR?DRUG=SIMVASTATIN?DRUG=</b> <br>scroll down for results 
<hr><hr>
<h1>Enter Brand or Generic Name or Category*</h1>
<h3> Narrow Your Search with <font size=5>*</font>(examples: 
ampi*, *mycin, antibiotic*)</h3>
<form method=get>
<action=>
<input size=30 maxlength=30 name=drug>
<input type=submit>
<input type=reset>
</form>
<HR>
<H3>Your RxList Search Results:</h3>
</body></html>
<P><hr><a href="http://www.rxlist.com"><b>RxList Home Page</ul>
<hr>
</DOC>
<DOC>
<DOCNO>WT08-B13-40</DOCNO>
<DOCOLDNO>IA019-000201-B024-115</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/rxlist.cgi?drug=fosomax 206.86.175.201 19970106234400 text/html 1001
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:37:42 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE>www.rxlist.com - Neil Sandow, Pharm.D. 
copyright 1995</title></head> <body bgcolor="#ffffff">
<center><a href="http://www.rxlist.com"><img src="rx.gif" 
height=75 width=75 border=0><img src="count.gif" border=0></a></center> 
Searching for: <b>FOSOMAX</b> <br>scroll down for results 
<hr><hr>
<h1>Enter Brand or Generic Name or Category*</h1>
<h3> Narrow Your Search with <font size=5>*</font>(examples: 
ampi*, *mycin, antibiotic*)</h3>
<form method=get>
<action=>
<input size=30 maxlength=30 name=drug>
<input type=submit>
<input type=reset>
</form>
<HR>
<H3>Your RxList Search Results:</h3>
1<br><b>Brand Name: </b>FOSAMAX<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/alendron.htm">ALENDRONATE SODIUM</a><br><b>Category: </b>MISCELLANEOUS:OSTEOPOROSIS
<p></body></html>
<P><hr><a href="http://www.rxlist.com"><b>RxList Home Page</ul>
<hr>
</DOC>
<DOC>
<DOCNO>WT08-B13-41</DOCNO>
<DOCOLDNO>IA019-000201-B024-135</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/rxlist.cgi??drug=calan 206.86.175.201 19970106234418 text/html 35331
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:37:56 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE>www.rxlist.com - Neil Sandow, Pharm.D. 
copyright 1995</title></head> <body bgcolor="#ffffff">
<center><a href="http://www.rxlist.com"><img src="rx.gif" 
height=75 width=75 border=0><img src="count.gif" border=0></a></center> 
Searching for: <b></b> <br>scroll down for results 
<hr><hr>
<h1>Enter Brand or Generic Name or Category*</h1>
<h3> Narrow Your Search with <font size=5>*</font>(examples: 
ampi*, *mycin, antibiotic*)</h3>
<form method=get>
<action=>
<input size=30 maxlength=30 name=drug>
<input type=submit>
<input type=reset>
</form>
<HR>
<H3>Your RxList Search Results:</h3>
1<br><b>Brand Name: </b>DIASTAT<br><b>Generic Name: </b>DIAZEPAM RECTAL GEL<br><b>Category: </b>TREATMENT OF SEVERE EPILEPSY
<p>2<br><b>Brand Name: </b>EDEX<br><b>Generic Name: </b>ALPROSTADIL<br><b>Category: </b>TREATMENT OF ERECTILE DYSFUNCTION
<p>3<br><b>Brand Name: </b>GABITRIL<br><b>Generic Name: </b>TIAGABINE<br><b>Category: </b>ANTICONVULSANTS
<p>4<br><b>Brand Name: </b>URSO<br><b>Generic Name: </b>URSODEOXYCHOLIC ACID<br><b>Category: </b>TREATMENT OF PRIMARY BILIARY CIRRHOSIS
<p>5<br><b>Brand Name: </b>LIPITOR<br><b>Generic Name: </b>ATORVASTATIN<br><b>Category: </b>ANTILIPEMIC AGENTS
<p>6<br><b>Brand Name: </b>ZYFLO<br><b>Generic Name: </b>ZILEUTON<br><b>Category: </b>LEUKOTRIENE RECEPTOR ANTAGONIST (LTRA) FOR TREATMENT OF ASTHMA
<p>7<br><b>Brand Name: </b>FEMPATCH<br><b>Generic Name: </b>17-BETA ESTRADIOL (TRANSDERMAL)<br><b>Category: </b>ESTROGENS
<p>8<br><b>Brand Name: </b>DOSTINEX<br><b>Generic Name: </b>CABERGOLINE<br><b>Category: </b>TREATMENT OF HYPERPROLACTINEMIC DISORDERS
<p>9<br><b>Brand Name: </b>THERDERM EMTDS<br><b>Generic Name: </b>ESTRADIOL (TRANSDERMAL)<br><b>Category: </b>ESTROGENS
<p>10<br><b>Brand Name: </b>ELEQUIN<br><b>Generic Name: </b>LEVOFLOXACIN (INJ)<br><b>Category: </b>QUINOLINE ANTIBIOTICS
<p>11<br><b>Brand Name: </b>COPAXONE<br><b>Generic Name: </b>COPOLYMER-1 (INJ)<br><b>Category: </b>TREATMENT OF MULTIPLE SCLEROSIS
<p>12<br><b>Brand Name: </b>MONUROL<br><b>Generic Name: </b>FOSFOMYCIN TROMETHANE<br><b>Category: </b>TREATMENT OF UTI'S
<p>13<br><b>Brand Name: </b>OPATANOL<br><b>Generic Name: </b>OLOPATADINE HCL<br><b>Category: </b>TREATMENT OF ALLERGIC CONJUNCTIVITIS
<p>14<br><b>Brand Name: </b>GLYSET<br><b>Generic Name: </b>MIGLITOL<br><b>Category: </b>ANTIDIABETIC AGENTS
<p>15<br><b>Brand Name: </b>ZAGAM<br><b>Generic Name: </b>SPARFLOXACIN<br><b>Category: </b>QUINOLINE ANTIBIOTICS
<p>16<br><b>Brand Name: </b>ALORA<br><b>Generic Name: </b>ESTRADIOL TRANSDERMAL<br><b>Category: </b>ESTROGENS
<p>17<br><b>Brand Name: </b>LEVAQUIN<br><b>Generic Name: </b>LEVOFLOXACIN<br><b>Category: </b>QUINOLINE ANTIBIOTICS
<p>18<br><b>Brand Name: </b>APHTHASOL<br><b>Generic Name: </b>AMLEXANOX<br><b>Category: </b>TREATMENT OF APHTHOUS ULCERS
<p>19<br><b>Brand Name: </b>LOTREL<br><b>Generic Name: </b>AMLODIPINE/BENAZEPRIL HCL<br><b>Category: </b>SEE AMLODIPINE AND/OR BENAZEPRIL
<p>20<br><b>Brand Name: </b>ERGOMAR<br><b>Generic Name: </b>ERGOTAMINE TARTRATE<br><b>Category: </b>SYMPATHOLYTIC AGENTS
<p>21<br><b>Brand Name: </b>ERGOSTAT<br><b>Generic Name: </b>ERGOTAMINE TARTRATE<br><b>Category: </b>SYMPATHOLYTIC AGENTS
<p>22<br><b>Brand Name: </b>REZULIN<br><b>Generic Name: </b>TROGLITAZONE<br><b>Category: </b>ANTIDIABETIC AGENTS
<p>23<br><b>Brand Name: </b>MERIDIA<br><b>Generic Name: </b>SIBUTRAMINE HCL<br><b>Category: </b>ANTIDEPRESSANT/ANTIOBESITY
<p>24<br><b>Brand Name: </b>NORMIFLO<br><b>Generic Name: </b>ARDEPARIN SODIUM<br><b>Category: </b>ANTICOAGULANT
<p>25<br><b>Brand Name: </b>FERRISELTZ<br><b>Generic Name: </b>FERRIC AMMONIUM CITRATE<br><b>Category: </b>BOWEL CONTRAST AGENT FOR MRI
<p>26<br><b>Brand Name: </b>LEXXEL<br><b>Generic Name: </b>ENALAPRIL MALEATE/FELODIPINE<br><b>Category: </b>ANTIHYPERTENSIVES
<p>27<br><b>Brand Name: </b>ARICEPT<br><b>Generic Name: </b>DONEPEXIL HCL<br><b>Category: </b>TREATMENT OF ALZHEIMER'S DISEASE
<p>28<br><b>Brand Name: </b>E2020<br><b>Generic Name: </b>DONEPEXIL HCL<br><b>Category: </b>TREATMENT OF ALZHEIMER'S DISEASE
<p>29<br><b>Brand Name: </b>AMPHOTEC<br><b>Generic Name: </b>AMPHOTERICIN B CHOLESTERYL SULFATE COMPLEX<br><b>Category: </b>ANTIFUNGALS
<p>30<br><b>Brand Name: </b>MUSE<br><b>Generic Name: </b>ALPROSTADIL<br><b>Category: </b>TREATMENT OF IMPOTENCE
<p>31<br><b>Brand Name: </b>MECTIZAN<br><b>Generic Name: </b>IVERMECTIN<br><b>Category: </b>TREATMENT OF STRONGYLOIDES/ONCHOCERCIASIS
<p>32<br><b>Brand Name: </b>NASCOBAL<br><b>Generic Name: </b>CYANOCOBALAMIN<br><b>Category: </b>VITAMIN B COMPLEX
<p>33<br><b>Brand Name: </b>NIX<br><b>Generic Name: </b>PERMETHRIN<br><b>Category: </b>ERADICATION/PROPHYLAXIS OF HEAD LICE
<p>34<br><b>Brand Name: </b>SR-2599DC<br><b>Generic Name: </b>CLOPIDOGREL<br><b>Category: </b>ORAL ANTITHROMBIC AGENT (INVESTIGATIONAL)
<p>35<br><b>Brand Name: </b>GUAIFENESIN<br><b>Generic Name: </b>GUAIFENESIN<br><b>Category: </b>SEE <a href="http://www.rxlist.com/cgi/generic/guaicod.htm">GUAIFENESIN & CODEINE</a>
<p>36<br><b>Brand Name: </b>GUAIFENESIN<br><b>Generic Name: </b>GUAIFENESIN<br><b>Category: </b>SEE <a href="http://www.rxlist.com/cgi/generic/guaiphen.htm">GUAIFENESIN & PHENYLPROPANOLAMINE</a>
<p>37<br><b>Brand Name: </b>SYNERCID (RP 59500)<br><b>Generic Name: </b>QUINUPRISTIN/DALFOPRISTIN<br><b>Category: </b>ANTIBIOTICS (INVESTIGATIONAL)
<p>38<br><b>Brand Name: </b>DENAVIR<br><b>Generic Name: </b>PENCICLOVIR<br><b>Category: </b>ANTIVIRALS
<p>39<br><b>Brand Name: </b>FERTINEX<br><b>Generic Name: </b>FOLLICLE STIMULATING HORMONE (FSH)<br><b>Category: </b>HORMONES
<p>40<br><b>Brand Name: </b>FERTINEX<br><b>Generic Name: </b>FSH<br><b>Category: </b>HORMONES
<p>41<br><b>Brand Name: </b>COPAXONE<br><b>Generic Name: </b>COPOLYMER 1<br><b>Category: </b>TREATMENT OF M.S.
<p>42<br><b>Brand Name: </b>VIRACEPT<br><b>Generic Name: </b>NELFINAVIR<br><b>Category: </b>ANTIVIRALS
<p>43<br><b>Brand Name: </b>ERGOSET<br><b>Generic Name: </b>BROMOCRIPTINE<br><b>Category: </b>UNCLASSIFIED THERAPEUTIC AGENTS
<p>44<br><b>Brand Name: </b>SORIATANE<br><b>Generic Name: </b>ACITRETIN<br><b>Category: </b>TREATMENT OF PSORIASIS
<p>45<br><b>Brand Name: </b>ASTELIN<br><b>Generic Name: </b>AZELASTINE<br><b>Category: </b>ANTIHISTAMINES
<p>46<br><b>Brand Name: </b>RETAVASE<br><b>Generic Name: </b>RETEPLASE<br><b>Category: </b>THROMBOLYTICS
<p>47<br><b>Brand Name: </b>SAIZEN<br><b>Generic Name: </b>SOMATROPIN<br><b>Category: </b>PITUITARY
<p>48<br><b>Brand Name: </b>ESTROSTEP<br><b>Generic Name: </b>ETHINYL ESTRADIOL/NORETHINDRONE<br><b>Category: </b>CONTRACEPTIVES
<p>49<br><b>Brand Name: </b>LODINE XL<br><b>Generic Name: </b>ETODOLAC<br><b>Category: </b>NONSTEROIDAL ANTIINFLAMMATORY AGENTS
<p>50<br><b>Brand Name: </b>CYSTADANE<br><b>Generic Name: </b>BETAINE<br><b>Category: </b>TREATMENT OF HOMOCYSTINUREAL
<p>51<br><b>Brand Name: </b>COMBIVENT<br><b>Generic Name: </b>ALBUTEROL/IPRATROPIUM<br><b>Category: </b>BRONCHODILATORS
<p>52<br><b>Brand Name: </b>TARKA<br><b>Generic Name: </b>TRANDOLAPRIL/VERAPAMIL<br><b>Category: </b>ANTIHYPERTENSIVES
<p>53<br><b>Brand Name: </b>MENTAX<br><b>Generic Name: </b>BUTENAFINE HCL<br><b>Category: </b>ANTIFUNGALS
<p>54<br><b>Brand Name: </b>TIAMATE<br><b>Generic Name: </b>DILTIAZEM<br><b>Category: </b>ANTIHYPERTENSIVES
<p>55<br><b>Brand Name: </b>DURACLON<br><b>Generic Name: </b>CLONIDINE HCL<br><b>Category: </b>EPIDURAL ADJUNCT TO OPIATE THERAPY
<p>56<br><b>Brand Name: </b><a href="http://www.lec.org/DrugSearch/Documents/Rohypnol.html">ROHYPNOL</a><br><b>Generic Name: </b>FLUNITRAZEPAM<br><b>Category: </b>MISC. SEDATIVES/HYPNOTICS (NOTE: NOT MARKETED IN THE US)
<p>57<br><b>Brand Name: </b>KADIAN<br><b>Generic Name: </b>MORPHINE SULFATE SA<br><b>Category: </b>OPIATE AGONISTS
<p>58<br><b>Brand Name: </b>COCAINE<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/cocaine.htm">COCAINE HCL</a><br><b>Category: </b>ANTIPRURITICS AND LOCAL ANESTHETICS
<p>59<br><b>Brand Name: </b>TECZEM<br><b>Generic Name: </b>ENALAPRIL MALEATE & DILTIAZEM MALEATE<br><b>Category: </b>ANTIHYPERTENSIVES
<p>60<br><b>Brand Name: </b>TICLID<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/ticlop.htm">TICLOPIDINE HCL</a><br><b>Category: </b>PLATELET AGGREGATION INHIBITORS
<p>61<br><b>Brand Name: </b>PARACETAMOL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">SEE ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>62<br><b>Brand Name: </b>DHEA<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/dhea.htm">DEHYDROEPIANDROSTERONE</a><br><b>Category: </b>UNAPPROVED
<p>63<br><b>Brand Name: </b>ANTIBIOTIC<br><b>Generic Name: </b>TYPE ANTIBIOT*<br><b>Category: </b>USE * TO SORT ON CATEGORY
<p>64<br><b>Brand Name: </b>NILANDRON<br><b>Generic Name: </b>NILUTAMIDE<br><b>Category: </b>ANTIANDROGENS
<p>65<br><b>Brand Name: </b>PONDIMIN<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/fenflur.htm">FENFLURAMINE HCL</a><br><b>Category: </b>APPETITE SUPPRESSANT
<p>66<br><b>Brand Name: </b>ALPHAGAN<br><b>Generic Name: </b>BRIMONIDINE TARTRATE<br><b>Category: </b>MISCELLANEOUS EENT AGENTS (GLAUCOMA)
<p>67<br><b>Brand Name: </b>FERTINEX<br><b>Generic Name: </b>UROFOLLITROPIN<br><b>Category: </b>FOLLICLE STIMULATING HORMONE
<p>68<br><b>Brand Name: </b>IVY BLOCK<br><b>Generic Name: </b>URUSHIOL<br><b>Category: </b>MISCEL.SKIN AND MUCUS MEMBRANE AGENTS
<p>69<br><b>Brand Name: </b>ZENTATE<br><b>Generic Name: </b>VITAMINS PRENATAL<br><b>Category: </b>MULTIVITAMIN PREPARATIONS
<p>70<br><b>Brand Name: </b>ETOPOPHOS<br><b>Generic Name: </b>ETOPOSIDE PHOSPHATE<br><b>Category: </b>ANTINEOPLASTICS
<p>71<br><b>Brand Name: </b>SEROSTIM<br><b>Generic Name: </b>SOMATOTROPIN<br><b>Category: </b>PITUITARY
<p>72<br><b>Brand Name: </b>ZYPREXA<br><b>Generic Name: </b>OLANZAPINE<br><b>Category: </b>ANTIPSYCHOTICS
<p>73<br><b>Brand Name: </b>HURRICAINE<br><b>Generic Name: </b>BENZOCAINE<br><b>Category: </b>LOCAL ANESTHETICS
<p>74<br><b>Brand Name: </b>HURRICAINE<br><b>Generic Name: </b>BENZOCAINE<br><b>Category: </b>ANTIPRURITICS AND LOCAL ANESTHETICS
<p>75<br><b>Brand Name: </b>MERREM I.V.<br><b>Generic Name: </b>MEROPENEM<br><b>Category: </b>MISCELLANEOUS ANTIBIOTICS
<p>76<br><b>Brand Name: </b>PROAMATINE<br><b>Generic Name: </b>MIDODRINE<br><b>Category: </b>TREATMENT OF ORTHOSTATIC HYPERTENSION
<p>77<br><b>Brand Name: </b>RU-486<br><b>Generic Name: </b>MIFEPRISTONE<br><b>Category: </b>TERMINATION OF PREGNANCY
<p>78<br><b>Brand Name: </b>ALBENZA<br><b>Generic Name: </b>ALBENDAZOLE<br><b>Category: </b>ANTHELMINTICS
<p>79<br><b>Brand Name: </b>DIFFERIN<br><b>Generic Name: </b>ADAPALENE<br><b>Category: </b>MISCEL.SKIN AND MUCUS MEMBRANE AGENTS
<p>80<br><b>Brand Name: </b>CARBEX<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/seleg.htm">SELEGILINE HCL</a><br><b>Category: </b>FOR PARKINSON'S DISEASE
<p>81<br><b>Brand Name: </b>HELIDAC<br><b>Generic Name: </b>BISMUTH SUBSAL. METRONIDAZOLE & TETRACYCLINE<br><b>Category: </b>FOR PEPTIC ULCER DISEASE
<p>82<br><b>Brand Name: </b>TRITEC<br><b>Generic Name: </b>RANITIDINE BISMUTH CITRATE<br><b>Category: </b>MISCELLANEOUS GI DRUGS
<p>83<br><b>Brand Name: </b>CEREBYX<br><b>Generic Name: </b>FOSPHENYTOIN SODIUM<br><b>Category: </b>HYDANTOINS
<p>84<br><b>Brand Name: </b>ALLEGRA<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/fexofen.htm">FEXOFENADINE</a><br><b>Category: </b>ANTIHISTAMINES
<p>85<br><b>Brand Name: </b>CAMPTOSAR<br><b>Generic Name: </b>IRINOTECAN HCL<br><b>Category: </b>ANTINEOPLASTICS
<p>86<br><b>Brand Name: </b>XALATAN<br><b>Generic Name: </b>LATANOPROST<br><b>Category: </b>GLAUCOMA THERAPY
<p>87<br><b>Brand Name: </b>REMERON<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/mirtaz.htm">MIRTAZAPINE</a><br><b>Category: </b>ANTIDEPRESSANTS
<p>88<br><b>Brand Name: </b>VIRAMUNE<br><b>Generic Name: </b>NEVIRAPINE<br><b>Category: </b>ANIVIRALS
<p>89<br><b>Brand Name: </b>MYOTROPHIN<br><b>Generic Name: </b>SOMATOMEDIN C<br><b>Category: </b>FOR AMYOTROPHIC LATERAL SCLEROSIS
<p>90<br><b>Brand Name: </b>HUMULIN N<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/humnph.htm">HUMAN INSULIN NPH</a> <br><b>Category: </b>INSULINS
<p>91<br><b>Brand Name: </b>HUMULIN R<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/huminsr.htm">HUMAN INSULIN REGULAR</a><br><b>Category: </b>INSULINS
<p>92<br><b>Brand Name: </b>HUMULIN L<br><b>Generic Name: </b>HUMAN INSULIN LENTE<br><b>Category: </b>INSULINS
<p>93<br><b>Brand Name: </b>HUMULIN 70/30<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/hum7030.htm">HUMAN INSULIN NPH/REG 70/30</a><br><b>Category: </b>INULINS
<p>94<br><b>Brand Name: </b>ORTHO-NOVUM 7/7/7<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/norestoc.htm">NORETHINDRONE/ETHINYL ESTRADIOL</a> <br><b>Category: </b>CONTRACEPTIVES
<p>95<br><b>Brand Name: </b>ORTHO-CEPT<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/desest.htm">DESOGESTREL/ETHINYLESTRADIOL</A><br><b>Category: </b>CONTRACEPTIVES
<p>96<br><b>Brand Name: </b>ACCUPRIL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/quinap.htm">QUINAPRIL HCL</a><br><b>Category: </b>HYPOTENSIVE AGENTS
<p>97<br><b>Brand Name: </b>ACTHREL<br><b>Generic Name: </b>CORTICORELIN OVINE TRIFLUTATE<br><b>Category: </b>DIAGNOSTIC AGENTS
<p>98<br><b>Brand Name: </b>BUPHENYL<br><b>Generic Name: </b>SODIUM PHENYLBUTYRATE<br><b>Category: </b>FOR UREA CYCLE DISORDERS
<p>99<br><b>Brand Name: </b>VISIPAQUE<br><b>Generic Name: </b>IODIXANOL<br><b>Category: </b>ROENTGENOGRAPHY
<p>100<br><b>Brand Name: </b>NAPRELAN<br><b>Generic Name: </b>NAPROXEN SODIUM<br><b>Category: </b>NONSTEROIDAL ANTIINFLAMMATORY AGENTS
<p>101<br><b>Brand Name: </b>OXILAN<br><b>Generic Name: </b>IOXILAN<br><b>Category: </b>ROENTGENOGRAPHY
<p>102<br><b>Brand Name: </b>IONTOCAINE<br><b>Generic Name: </b>LIDOCAINE/EPINEPHRINE<br><b>Category: </b>LOCAL ANESTHETICS
<p>103<br><b>Brand Name: </b>PENTACEF<br><b>Generic Name: </b>CEFTAZIDINE<br><b>Category: </b>ANTIBIOTICS: CEPHALOSPORINS
<p>104<br><b>Brand Name: </b>METROCREAM<br><b>Generic Name: </b>METRONIDAZOLE<br><b>Category: </b>MISCELLANEOUS ANTI-INFECTIVES
<p>105<br><b>Brand Name: </b>GENOTROPIN<br><b>Generic Name: </b>SOMATROPIN<br><b>Category: </b>PITUITARY
<p>106<br><b>Brand Name: </b>SEVORANE<br><b>Generic Name: </b>SEVOFLURANE<br><b>Category: </b>GENERAL ANESTHETICS
<p>107<br><b>Brand Name: </b>BIOTROPIN<br><b>Generic Name: </b>SOMATROPIN<br><b>Category: </b>PITUITARY
<p>108<br><b>Brand Name: </b>ULTRAVIST<br><b>Generic Name: </b>IOPROMIDE<br><b>Category: </b>ROENTGENOGRAPHY
<p>109<br><b>Brand Name: </b>NORDITROPIN<br><b>Generic Name: </b>SOMATROPIN<br><b>Category: </b>PITUITARY
<p>110<br><b>Brand Name: </b>PROVEL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/ibup.htm">IBUPROFEN</A><br><b>Category: </b>NONSTEROIDAL ANTIINFLAMMATORY AGENTS
<p>111<br><b>Brand Name: </b>NISOCOR<br><b>Generic Name: </b>NISOLDIPINE<br><b>Category: </b>CARDIAC DRUGS
<p>112<br><b>Brand Name: </b>APTHASOL<br><b>Generic Name: </b>AMLEXANOX<br><b>Category: </b>TREATMENT OF CANKER SORES
<p>113<br><b>Brand Name: </b>ALPHANATE<br><b>Generic Name: </b>ANTIHEMOPHILIC FACTOR<br><b>Category: </b>HEMOSTATICS
<p>114<br><b>Brand Name: </b>OXYCONTIN<br><b>Generic Name: </b>OXYCODONE HCL<br><b>Category: </b>OPIATE AGONISTS
<p>115<br><b>Brand Name: </b>HYCAMTIN<br><b>Generic Name: </b>TOPOTECAN<br><b>Category: </b>ANTINEOPLASTICS
<p>116<br><b>Brand Name: </b>OXANDRIN<br><b>Generic Name: </b>OXANDROLONE<br><b>Category: </b>ANDROGENS
<p>117<br><b>Brand Name: </b>WINRHO SD<br><b>Generic Name: </b>RHO(D)IMMUNE GLOBULIN<br><b>Category: </b>SERUMS
<p>118<br><b>Brand Name: </b>AVONEX<br><b>Generic Name: </b>INTERFERON BETA-1A<br><b>Category: </b>TREATMENT OF MULTIPLE SCLEROSIS
<p>119<br><b>Brand Name: </b>GEMZAR<br><b>Generic Name: </b>GEMCITABINE HCL<br><b>Category: </b>ANTINEOPLASTICS
<p>120<br><b>Brand Name: </b>DEXFERRUM<br><b>Generic Name: </b>IRON DEXTRAN<br><b>Category: </b>IRON PRODUCTS
<p>121<br><b>Brand Name: </b>CORMAX<br><b>Generic Name: </b>CLOBETASOL PROPIONATE<br><b>Category: </b>ANTI-INFLAMMATORY AGENTS
<p>122<br><b>Brand Name: </b>VITRASERT<br><b>Generic Name: </b>GANCICLOVIR<br><b>Category: </b>ANTIVIRALS
<p>123<br><b>Brand Name: </b>CYTOVENE<br><b>Generic Name: </b>GANCICLOVIR<br><b>Category: </b>ANTIVIRALS
<p>124<br><b>Brand Name: </b>HUMALOG<br><b>Generic Name: </b>INSULIN LISPRO<br><b>Category: </b>INSULINS
<p>125<br><b>Brand Name: </b>DAUNOXOME<br><b>Generic Name: </b>DAUNORUBICIN CITRATE (LIPOSOME)<br><b>Category: </b>ANTINEOPLASTICS
<p>126<br><b>Brand Name: </b>ESTRING<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/estrad.htm">ESTRADIOL</A><br><b>Category: </b>ESTROGENS
<p>127<br><b>Brand Name: </b>ARIMEDEX<br><b>Generic Name: </b>ANASTROZOLE<br><b>Category: </b>ANTINEOPLASTICS
<p>128<br><b>Brand Name: </b>VISTIDE<br><b>Generic Name: </b>CIDOFOVIR<br><b>Category: </b>ANTIVIRALS
<p>129<br><b>Brand Name: </b>NICOTROL NS<br><b>Generic Name: </b>NICOTINE(NASAL)<br><b>Category: </b>MISCELLANEOUS AUTONOMIC DRUGS 
<p>130<br><b>Brand Name: </b>VIQUIN FORTE<br><b>Generic Name: </b>HYDROQUINONE<br><b>Category: </b>DEPIGMENTING AGENTS
<p>131<br><b>Brand Name: </b>REDUX<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/dexfen.htm">DEXFENFLURAMINE</a><br><b>Category: </b>ANTI-OBESITY AGENTS
<p>132<br><b>Brand Name: </b>ZANAFLEX<br><b>Generic Name: </b>TIZANIDINE HCL<br><b>Category: </b>SKELETAL MUSCLE RELAXANTS
<p>133<br><b>Brand Name: </b>PREVALITE<br><b>Generic Name: </b>CHOLESTYRAMINE<br><b>Category: </b>ANTILIPEMIC AGENTS
<p>134<br><b>Brand Name: </b>FERIDEX<br><b>Generic Name: </b>FERUMOXIDE<br><b>Category: </b>MAGNETIC RESONANCE IMAGING
<p>135<br><b>Brand Name: </b>MAVIK<br><b>Generic Name: </b>TRANDOLAPRIL<br><b>Category: </b><a href="http://www.rxlist.com/cardiova.htm">HYPOTENSIVE AGENTS</a> 
<p>136<br><b>Brand Name: </b>NAROPIN<br><b>Generic Name: </b>ROPIVACAINE<br><b>Category: </b>LOCAL ANESTHETICS
<p>137<br><b>Brand Name: </b>SCLEROSOL<br><b>Generic Name: </b>TALC<br><b>Category: </b>SCLEROSING AGENTS
<p>138<br><b>Brand Name: </b>TOPAMAX<br><b>Generic Name: </b>TOPIRAMATE<br><b>Category: </b>MISCELLANEOUS ANTICONVULSANTS
<p>139<br><b>Brand Name: </b>VAQTA<br><b>Generic Name: </b>HEPATITIS A VACCINE<br><b>Category: </b>VACCINES
<p>140<br><b>Brand Name: </b>MYOVIEW<br><b>Generic Name: </b>TETROPHOSMIN<br><b>Category: </b>RADIOPHARMACEUTICALS
<p>141<br><b>Brand Name: </b>OCUHIST<br><b>Generic Name: </b>PHENIRAMINE MALEATE<br><b>Category: </b>ANTIHISTAMINE DRUGS
<p>142<br><b>Brand Name: </b>COVERA-HS<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/verapsr.htm">VERAPAMIL</A> HCL<br><b>Category: </b><a href="http://www.rxlist.com/cardiova.htm">CARDIAC DRUGS</a> 
<p>143<br><b>Brand Name: </b>SYNOVIR<br><b>Generic Name: </b>THALIDOMIDE<br><b>Category: </b>AIDS-CACHEXIA
<p>144<br><b>Brand Name: </b>VESANOID<br><b>Generic Name: </b>TRETINOIN<br><b>Category: </b>ANTINEOPLASTIC AGENTS
<p>145<br><b>Brand Name: </b>TEICHOMYCIN<br><b>Generic Name: </b>TEICOPLANIN<br><b>Category: </b>MISCELLANEOUS ANTIBIOTICS
<p>146<br><b>Brand Name: </b>NORVIR<br><b>Generic Name: </b>RITONAVIR<br><b>Category: </b>ANTIVIRALS
<p>147<br><b>Brand Name: </b>NIMBEX<br><b>Generic Name: </b>CISATRACURIUM BESYLATE<br><b>Category: </b>SKELETAL MUSCLE RELAXANTS
<p>148<br><b>Brand Name: </b>MAXIPIME<br><b>Generic Name: </b>CEFEPIME<br><b>Category: </b>ANTIBIOTICS: CEPHALOSPORINS
<p>149<br><b>Brand Name: </b>PENNSAID<br><b>Generic Name: </b>DIMETHAID-D<br><b>Category: </b><a href="http://www.rxlist.com/nsaid.htm">NONSTEROIDAL ANTI-INFLAMMATORY AGENTS</a> 
<p>150<br><b>Brand Name: </b>ADDERALL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/amphet.htm">AMPHETAMINE MIXED SALTS</a><br><b>Category: </b>RESPIRATORY AND CEREBRAL STIMULANTS
<p>151<br><b>Brand Name: </b>CANDIN<br><b>Generic Name: </b>CANDIDA ALBICANS<br><b>Category: </b>FUNGI
<p>152<br><b>Brand Name: </b>ACTRON<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/ketoprof.htm">KETOPROFEN</a><br><b>Category: </b><a href="http://www.rxlist.com/nsaid.htm">NONSTEROIDAL ANTIINFLAMMATORY AGENTS</a> 
<p>153<br><b>Brand Name: </b>CEDAX<br><b>Generic Name: </b>CEFTIBUTEN<br><b>Category: </b>ANTIBIOTICS:CEPHALOSPORINS
<p>154<br><b>Brand Name: </b>RENOVA<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/tretinoin.htm">TRETINOIN</a><br><b>Category: </b>MISCEL.SKIN AND MUCUS MEMBRANE AGENTS
<p>155<br><b>Brand Name: </b>PHOTOFRIN<br><b>Generic Name: </b>PORFIMER SODIUM<br><b>Category: </b>ANTINEOPLASTIC AGENTS (PHOTODYNAMIC)
<p>156<br><b>Brand Name: </b>AMARYL<br><b>Generic Name: </b>GLIMEPIRIDE<br><b>Category: </b>ANTIDIABETIC AGENTS
<p>157<br><b>Brand Name: </b>FLOLAN<br><b>Generic Name: </b>EPOPROSTENOL SODIUM<br><b>Category: </b>VASODILATING AGENTS
<p>158<br><b>Brand Name: </b>RESPIGAM<br><b>Generic Name: </b>RSV-IGIV<br><b>Category: </b>SERUMS
<p>159<br><b>Brand Name: </b>CRIXIVAN<br><b>Generic Name: </b>INDINAVIR SULFATE<br><b>Category: </b>ANTIVIRALS
<p>160<br><b>Brand Name: </b>TRIPEDIA<br><b>Generic Name: </b>WHOOPING COUGH VACCINE<br><b>Category: </b>VACCINES
<p>161<br><b>Brand Name: </b>PROCANABID<br><b>Generic Name: </b>PROCAINAMIDE HCL<br><b>Category: </b>CARDIAC DRUGS
<p>162<br><b>Brand Name: </b>ZYRTEC<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/cetiriz.htm">CETIRIZINE HCL</a><br><b>Category: </b>ANTIHISTAMINE DRUGS
<p>163<br><b>Brand Name: </b>VIVELLE<br><b>Generic Name: </b>ESTRADIOL (TRANSDERMAL SYSTEM)<br><b>Category: </b>ESTROGEN
<p>164<br><b>Brand Name: </b>AZELEX<br><b>Generic Name: </b>ACELAIC ACID<br><b>Category: </b>SKIN AND MUCUS MEMBRANE AGENTS
<p>165<br><b>Brand Name: </b>ETHYOL<br><b>Generic Name: </b>AMIFOSTINE<br><b>Category: </b>UNCLASSIFIED THERAPEUTIC AGENTS
<p>166<br><b>Brand Name: </b>DOXIL<br><b>Generic Name: </b> DOXORUBICIN HCL (LIPOSOME INJECTION)<br><b>Category: </b>ANTIONEOPLASTIC AGENTS
<p>167<br><b>Brand Name: </b>ABELCET<br><b>Generic Name: </b>ABCL(AMPHOTERICIN B LIPID COMPLEX LIPOSOME INJ)<br><b>Category: </b>ANTIFUNGALS
<p>168<br><b>Brand Name: </b>PRECOSE<br><b>Generic Name: </b>ACARBOSE<br><b>Category: </b>ANTIDIABETIC AGENTS
<p>169<br><b>Brand Name: </b>RILUTEK<br><b>Generic Name: </b>RILUZOLE<br><b>Category: </b>FOR AMYOTROPHIC LATERAL SCLEROSIS
<p>170<br><b>Brand Name: </b>VALTREX<br><b>Generic Name: </b>VALACYCLOVIR<br><b>Category: </b>ANIVIRALS
<p>171<br><b>Brand Name: </b>FLOVENT<br><b>Generic Name: </b>FLUTICASONE PROPRIONATE<br><b>Category: </b>ANTIINFLAMMATORY AGENTS
<p>172<br><b>Brand Name: </b>DYNABAC<br><b>Generic Name: </b>DIRITHROMYCIN<br><b>Category: </b>ANTIBIOTICS:ERYTHROMYCINS
<p>173<br><b>Brand Name: </b>CORVERT<br><b>Generic Name: </b>IBUTILIDE<br><b>Category: </b>CARDIAC DRUGS
<p>174<br><b>Brand Name: </b>FARESTON<br><b>Generic Name: </b>TOREMIFENE CITRATE<br><b>Category: </b>ANTINEOPLASTIC AGENTS
<p>175<br><b>Brand Name: </b>COREG<br><b>Generic Name: </b>CARDEDILOL<br><b>Category: </b>CARDIAC DRUGS
<p>176<br><b>Brand Name: </b>TAXOTERE<br><b>Generic Name: </b>DOCETAXEL<br><b>Category: </b>ANTINEOPLASTIC AGENTS
<p>177<br><b>Brand Name: </b>BUTOX<br><b>Generic Name: </b>BOTULINUM TOXIN TYPE A<br><b>Category: </b>TOXOIDS
<p>178<br><b>Brand Name: </b>SULAR<br><b>Generic Name: </b>NISOLDIPINE<br><b>Category: </b>CARDIAC DRUGS
<p>179<br><b>Brand Name: </b>BLEO<br><b>Generic Name: </b>BLEOMYCIN<br><b>Category: </b>ANTINEOPLASTIC AGENTS
<p>180<br><b>Brand Name: </b>BLEOCIN<br><b>Generic Name: </b>BLEOMYCIN<br><b>Category: </b>ANTINEOPLASTIC AGENTS
<p>181<br><b>Brand Name: </b>BLENOXANE<br><b>Generic Name: </b>BLEOMYCIN<br><b>Category: </b>ANTINEOPLASTIC AGENTS
<p>182<br><b>Brand Name: </b>INVIRASE<br><b>Generic Name: </b>SAQUINAVIR<br><b>Category: </b>ANTIVIRALS
<p>183<br><b>Brand Name: </b>EPIVIR<br><b>Generic Name: </b>LAMIVUDINE<br><b>Category: </b>ANTIVIRALS
<p>184<br><b>Brand Name: </b>3TC<br><b>Generic Name: </b>LAMIVUDINE<br><b>Category: </b>ANTIVIRALS
<p>185<br><b>Brand Name: </b>AZT<br><b>Generic Name: </b>ZIDOVUDINE<br><b>Category: </b>ANTIVIRALS
<p>186<br><b>Brand Name: </b>NIZORAL<br><b>Generic Name: </b>KETOCONAZOLE<br><b>Category: </b>ANTIFUNGALS
<p>187<br><b>Brand Name: </b>NIZORAL TOPICAL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/ketocon.htm">KETOCONAZOLE TOPICAL</A><br><b>Category: </b>ANTIFUNGALS
<p>188<br><b>Brand Name: </b>METHERGINE<br><b>Generic Name: </b>METHYLERGONOVINE MALEATE<br><b>Category: </b>OXYTOCICS
<p>189<br><b>Brand Name: </b>LOTREL<br><b>Generic Name: </b>AMLODIPINE/BENAZEPRIL HCL<br><b>Category: </b><a href="http://www.rxlist.com/cardiova.htm">HYPOTENSIVE AGENTS</a> 
<p>190<br><b>Brand Name: </b>VEXOL<br><b>Generic Name: </b>RIMEXOLONE<br><b>Category: </b>OPTHALMIC CORTICOSTEROID
<p>191<br><b>Brand Name: </b>DR-3355<br><b>Generic Name: </b>LEVOFLOXACIN<br><b>Category: </b>INVESTIGATIONAL:ANTIBIOTICS:QUINOLINES
<p>192<br><b>Brand Name: </b>ORG-10172<br><b>Generic Name: </b>DANAPAROID<br><b>Category: </b>INVESTIGATIONAL:ANTICOAGULANTS
<p>193<br><b>Brand Name: </b>RU 44570<br><b>Generic Name: </b>TRANDOLAPRIL<br><b>Category: </b> <a href="http://www.rxlist.com/cardiova.htm">HYPOTENSIVE AGENTS</a> 
<p>194<br><b>Brand Name: </b>ACCOLATE<br><b>Generic Name: </b>ZAFIRLUKAST<br><b>Category: </b>RESPIRATORY:LEUKOTRIENE ANTAGONIST
<p>195<br><b>Brand Name: </b>TIAZAC<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/diltiaz.htm">DILTIAZEM HCL</a> <br><b>Category: </b><a href="http://www.rxlist.com/cardiova.htm">CARDIAC DRUGS</a> 
<p>196<br><b>Brand Name: </b>FOSAMAX<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/alendron.htm">ALENDRONATE SODIUM</a><br><b>Category: </b>MISCELLANEOUS:OSTEOPOROSIS
<p>197<br><b>Brand Name: </b>REOPRO<br><b>Generic Name: </b>ABCIXIMAB<br><b>Category: </b>UNCLASSIFIED THERAPEUTIC AGENTS
<p>198<br><b>Brand Name: </b>SECTRAL<br><b>Generic Name: </b>ACEBUTOLOL HCL<br><b>Category: </b><a href="http://www.rxlist.com/cardiova.htm">CARDIAC DRUGS</a> 
<p>199<br><b>Brand Name: </b>ACI-JEL W/APP<br><b>Generic Name: </b>ACET AC/RICINOLEIC/OXY<br><b>Category: </b>ANTI-INFECTIVES
<p>200<br><b>Brand Name: </b>ACEPHEN<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>201<br><b>Brand Name: </b>ACETAMIN<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>202<br><b>Brand Name: </b>ANACIN AF<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>203<br><b>Brand Name: </b>APAP<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>204<br><b>Brand Name: </b>BL INFANT N/A<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>205<br><b>Brand Name: </b>BL NON-ASPIRN<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>206<br><b>Brand Name: </b>FEVERALL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>207<br><b>Brand Name: </b>GENAPAP X/S<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>208<br><b>Brand Name: </b>GENEBS X/S<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>209<br><b>Brand Name: </b>GNP NON-ASPRN<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>210<br><b>Brand Name: </b>GNP NON-ASPRN<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>211<br><b>Brand Name: </b>GNP XS PAIN<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>212<br><b>Brand Name: </b>INFANTAIRE<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>213<br><b>Brand Name: </b>INFANTOL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>214<br><b>Brand Name: </b>MAPAP ACETAM<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>215<br><b>Brand Name: </b>PAIN &amp; FEVER<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>216<br><b>Brand Name: </b>PANADOL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>217<br><b>Brand Name: </b>PEDIAPAP<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>218<br><b>Brand Name: </b>TEMPRA 1<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>219<br><b>Brand Name: </b>TEMPRA 2<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>220<br><b>Brand Name: </b>TYLENOL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>221<br><b>Brand Name: </b>TYLENOL INFNT<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>222<br><b>Brand Name: </b>TYLENOL X/S<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>223<br><b>Brand Name: </b>BROMO SELTZER<br><b>Generic Name: </b>ACETAMINOPHEN BUFFERED<br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>224<br><b>Brand Name: </b>GENAPAP CHILD<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN CHEW</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>225<br><b>Brand Name: </b>ST JOS CHL/AF<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN CHEW</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>226<br><b>Brand Name: </b>TEMPRA 3 CHEW<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN CHEW</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>227<br><b>Brand Name: </b>TYLENOL CHILD<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN CHEW</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>228<br><b>Brand Name: </b>TYLENOL CHILD<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN CHEW</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>229<br><b>Brand Name: </b>TYLENOL X/RLF<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN SA</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>230<br><b>Brand Name: </b>PROMINOL<br><b>Generic Name: </b>ACETAMINOPHEN/BUTALBITAL<br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>231<br><b>Brand Name: </b>APAP/COD<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/acetcod.htm">ACETAMINOPHEN/CODEINE</a> <br><b>Category: </b><a href="opiate.htm">OPIATE AGONISTS</a> 
<p>232<br><b>Brand Name: </b>CAPITAL W/COD<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/acetcod.htm">ACETAMINOPHEN/CODEINE</a> <br><b>Category: </b><a href="opiate.htm">OPIATE AGONISTS</a> 
<p>233<br><b>Brand Name: </b>PHENAPHEN/COD<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/acetcod.htm">ACETAMINOPHEN/CODEINE</a> <br><b>Category: </b><a href="opiate.htm">OPIATE AGONISTS</a> 
<p>234<br><b>Brand Name: </b>TYLENOL/COD<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/acetcod.htm">ACETAMINOPHEN/CODEINE</a> <br><b>Category: </b><a href="opiate.htm">OPIATE AGONISTS</a> 
<p>235<br><b>Brand Name: </b>ACETAZOLAMIDE<br><b>Generic Name: </b>ACETAZOLAMIDE<br><b>Category: </b>CARBONIC ANHYDRASE INHIBITORS
<p>236<br><b>Brand Name: </b>DIAMOX<br><b>Generic Name: </b>ACETAZOLAMIDE<br><b>Category: </b>CARBONIC ANHYDRASE INHIBITORS
<p>237<br><b>Brand Name: </b>ACETASOL PLN<br><b>Generic Name: </b>ACETIC ACID OTIC<br><b>Category: </b>ANTI-INFECTIVES
<p>238<br><b>Brand Name: </b>DOMEBORO OTIC<br><b>Generic Name: </b>ACETIC ACID OTIC<br><b>Category: </b>ANTI-INFECTIVES
<p>239<br><b>Brand Name: </b>VOSOL OTIC<br><b>Generic Name: </b>ACETIC ACID OTIC<br><b>Category: </b>ANTI-INFECTIVES
<p>240<br><b>Brand Name: </b>ACETASOL HC<br><b>Generic Name: </b>ACETIC ACID/HYDROCORT OTI<br><b>Category: </b>ANTI-INFECTIVES
<p>241<br><b>Brand Name: </b>HYDRO/ACETIC<br><b>Generic Name: </b>ACETIC ACID/HYDROCORT OTI<br><b>Category: </b>ANTI-INFECTIVES
<p>242<br><b>Brand Name: </b>VASOTATE HC<br><b>Generic Name: </b>ACETIC ACID/HYDROCORT OTI<br><b>Category: </b>ANTI-INFECTIVES
<p>243<br><b>Brand Name: </b>VOSOL HC OTIC<br><b>Generic Name: </b>ACETIC ACID/HYDROCORT OTI<br><b>Category: </b>ANTI-INFECTIVES
<p>244<br><b>Brand Name: </b>DYMELOR<br><b>Generic Name: </b>ACETOHEXAMIDE<br><b>Category: </b>SULFONYLUREAS
<p>245<br><b>Brand Name: </b>LITHOSTAT<br><b>Generic Name: </b>ACETOHYDROXAMIC ACID<br><b>Category: </b>AMMONIA DETOXICANTS
<p>246<br><b>Brand Name: </b>SEBA-NIL<br><b>Generic Name: </b>ACETONE/ALCOHOL/POLYSORB<br><b>Category: </b>MISCEL.SKIN AND MUCUS MEMBRANE AGENTS
<p>247<br><b>Brand Name: </b>MIOCHOL E W/<br><b>Generic Name: </b>ACETYLCHOLINE CHL<br><b>Category: </b>MIOTICS
<p>248<br><b>Brand Name: </b>ACETYLCYSTEIN<br><b>Generic Name: </b>ACETYLCYSTEINE<br><b>Category: </b>MUCOLYTIC AGENTS
<p>249<br><b>Brand Name: </b>MUCOMYST<br><b>Generic Name: </b>ACETYLCYSTEINE<br><b>Category: </b>MUCOLYTIC AGENTS
<p>250<br><b>Brand Name: </b>MUCOSIL<br><b>Generic Name: </b>ACETYLCYSTEINE<br><b>Category: </b>MUCOLYTIC AGENTS
<p></body></html>
<P><hr><a href="http://www.rxlist.com"><b>RxList Home Page</ul>
<hr>
</DOC>
<DOC>
<DOCNO>WT08-B13-42</DOCNO>
<DOCOLDNO>IA018-000200-B044-51</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/temphtm.htm 206.86.175.201 19970106232124 text/html 114954
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:15:09 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 114770
Last-modified: Wed, 27 Nov 1996 18:33:54 GMT
</DOCHDR>
<html>
<body bgcolor="#ffffff">
<a href="http://www.rxlist.com">
<img src="rx.gif" height=50 width=50 border=0></a>
</body>
</html>
<HTML><HEAD>
<TITLE>World Wide Web Access Statistics for www.rxlist.com</TITLE>
</HEAD><BODY>
<H1>World Wide Web Access Statistics for www.rxlist.com</H1>
<EM>Last updated: Wed, 27 Nov 1996 10:09:40 (GMT -0800)</EM>
<UL>
<LI><A HREF="#Daily">Total Transfers by Request Date</A>
<LI><A HREF="#Hourly">Total Transfers by Request Hour</A>
<LI><A HREF="#Domain">Total Transfers by Client Domain</A>
<LI><A HREF="#Subdomain">Total Transfers by Reversed Subdomain</A>
<LI><A HREF="#Archive">Total Transfers by URL/Archive Section</A>
<LI><A HREF="stats-1996/Oct.monthstat.htm.gz">Previous Full Summary Period (.gz)</A>
</UL>
<H2>Totals:03:00-03:00(24 Hr) Period: Nov 26 1996 to Nov 27 1996</H2>
<PRE>
Requests Received During Summary Period           31142
Bytes Transmitted During Summary Period       181058029
Average Requests Received Daily                   15571
Average Bytes Transmitted Daily                90529014
</PRE>
<HR>
<H2><A NAME="Daily">Total Transfers by Request Date</A></H2>
<PRE>
%Reqs %Byte  Bytes Sent  Requests   Date
----- ----- ------------ -------- |------------
96.18 96.12    174036285    29953 | Nov 26 1996
 3.82  3.88      7021744     1189 | Nov 27 1996
</PRE>
<HR>
<H2><A NAME="Hourly">Total Transfers by Request Hour</A></H2>
<PRE>
%Reqs %Byte  Bytes Sent  Requests   Time
----- ----- ------------ -------- |-----
 1.01  1.08      1959471      314 |  00
 1.01  1.03      1858494      315 |  01
 1.23  1.21      2185011      383 |  02
 0.57  0.56      1018768      177 |  03
 0.87  0.92      1667575      271 |  04
 3.75  3.37      6103770     1167 |  05
 4.13  4.02      7278145     1286 |  06
 5.21  4.83      8743090     1622 |  07
 5.63  5.51      9974651     1754 |  08
 7.16  6.90     12491830     2231 |  09
 6.08  5.71     10347395     1892 |  10
 6.04  5.83     10557463     1880 |  11
 5.52  5.49      9935966     1719 |  12
 6.36  6.47     11718964     1982 |  13
 6.08  5.60     10147646     1892 |  14
 5.99  6.93     12552256     1865 |  15
 5.89  5.79     10476054     1833 |  16
 5.85  6.33     11466982     1823 |  17
 6.04  5.77     10453347     1881 |  18
 5.22  5.06      9168835     1626 |  19
 3.87  4.20      7601860     1204 |  20
 3.06  4.12      7458239      954 |  21
 2.12  2.04      3699768      661 |  22
 1.32  1.21      2192449      410 |  23
</PRE>
<HR>
<H2><A NAME="Domain">Total Transfers by Client Domain</A></H2>
<PRE>
%Reqs %Byte  Bytes Sent  Requests   Domain
----- ----- ------------ -------- |------------------------------------
 0.04  0.01        10872       12 | at    Austria
 0.52  0.74      1343016      162 | au    Australia
 0.05  0.05        92855       16 | be    Belgium
 0.48  0.65      1176489      149 | br    Brazil
 2.66  2.78      5031056      829 | ca    Canada
 0.02  0.01        14268        5 | ch    Switzerland
 0.02  0.03        56975        6 | cl    Chile
 0.01  0.02        41739        3 | cz    Czech Republic
 0.08  0.12       225893       25 | de    Germany
 0.09  0.10       188356       27 | dk    Denmark
 0.04  0.02        33430       14 | do    Dominican Republic
 0.04  0.02        37713       11 | eg    Egypt
 0.04  0.03        55797       13 | es    Spain
 0.15  0.13       232630       46 | fi    Finland
 0.18  0.13       236296       55 | fr    France
 0.05  0.03        55790       15 | gr    Greece
 0.04  0.02        27298       12 | hk    Hong Kong
 0.02  0.04        80903        6 | hr    Croatia (Hrvatska)
 0.01  0.02        28399        4 | hu    Hungary
 0.13  0.09       162572       39 | ie    Ireland
 0.12  0.10       177703       37 | il    Israel
 0.02  0.06       103379        5 | in    India
 0.18  0.19       344269       56 | it    Italy
 0.33  0.14       249223      104 | jp    Japan
 0.10  0.11       206068       32 | kr    Korea (South)
 0.03  0.01        19258        8 | lv    Latvia
 0.05  0.03        47208       15 | mx    Mexico
 0.00  0.00         3174        1 | my    Malaysia
 0.24  0.26       466273       74 | nl    Netherlands
 0.10  0.06       108334       30 | no    Norway
 0.14  0.16       288478       45 | nz    New Zealand (Aotearoa)
 0.07  0.05        94730       21 | pe    Peru
 0.00  0.00         3081        1 | ph    Philippines
 0.03  0.02        43885       10 | pk    Pakistan
 0.04  0.04        80023       11 | pt    Portugal
 0.01  0.02        37018        3 | ro    Romania
 0.12  0.15       269854       36 | se    Sweden
 0.09  0.18       326836       29 | sg    Singapore
 0.15  0.05        95794       48 | si    Slovenia
 0.04  0.02        35294       12 | th    Thailand
 0.02  0.01        25822        6 | tw    Taiwan
 0.87  0.78      1410313      272 | uk    United Kingdom
 1.10  1.24      2241400      342 | us    United States
 0.09  0.12       213259       28 | za    South Africa
32.41 31.55     57129796    10093 | com   Commercial
 8.05  7.96     14417541     2507 | edu   Educational
 1.22  1.74      3151931      380 | gov   Government
 0.48  0.57      1035965      149 | mil   US Military
25.69 25.75     46619584     7999 | net   Network
 1.09  1.20      2173155      338 | org   Non-Profit Organization
22.48 22.37     40507034     7001 | unresolved 
</PRE>
<HR>
<H2><A NAME="Subdomain">Total Transfers by Reversed Subdomain</A></H2>
<PRE>
%Reqs %Byte  Bytes Sent  Requests   Reversed Subdomain
----- ----- ------------ -------- |------------------------------------
22.48 22.37     40507034     7001 | Unresolved
 0.04  0.01         9677       11 | at.or.iaea
 0.00  0.00         1195        1 | at.via
 0.03  0.01        16846        8 | au.com.adam
 0.02  0.03        49299        6 | au.com.connect
 0.00  0.03        51164        1 | au.com.intercoast
 0.01  0.03        54599        3 | au.com.magna
 0.05  0.09       171764       15 | au.com.ozemail
 0.04  0.01        26698       11 | au.com.powerup
 0.01  0.00         4361        3 | au.com.southwest
 0.06  0.06       113602       18 | au.csiro.dap
 0.01  0.04        77667        3 | au.edu.csu.riv
 0.03  0.01        22493        9 | au.edu.curtin
 0.03  0.06       115714        9 | au.edu.newcastle
 0.04  0.02        28544       12 | au.edu.unsw.phys
 0.01  0.02        38784        3 | au.edu.unsw.servers
 0.05  0.09       165802       17 | au.gov.bom.qld
 0.01  0.04        63630        3 | au.gov.defence
 0.01  0.00         7419        3 | au.gov.nla
 0.06  0.08       139815       18 | au.gov.qld.citec
 0.02  0.04        75573        6 | au.net.camtech
 0.00  0.00         4349        1 | au.net.eis
 0.00  0.00         3263        1 | au.net.netspace.hobart
 0.02  0.05        82392        6 | au.net.questnet
 0.02  0.02        29238        6 | au.net.taunet
 0.04  0.03        47399       14 | be.ac.uia
 0.01  0.03        45456        2 | be.unicall
 0.01  0.02        31520        2 | br.com.brnet
 0.03  0.04        66481        9 | br.com.csf
 0.01  0.01        26888        3 | br.com.estaminas
 0.02  0.04        75333        6 | br.com.imagelink
 0.01  0.06       107613        4 | br.com.linkway
 0.05  0.02        42211       15 | br.com.macbbs
 0.13  0.10       181066       41 | br.com.mandic
 0.01  0.03        50621        3 | br.com.netium
 0.01  0.03        50621        3 | br.com.nutecnet.bsb
 0.01  0.03        50621        3 | br.com.nutecnet.cba
 0.01  0.03        50621        3 | br.com.nutecnet.rio
 0.06  0.05        89383       19 | br.com.sercomtel
 0.04  0.02        35442       11 | br.com.sti
 0.04  0.06       112116       12 | br.com.unisys
 0.03  0.05        98029        8 | br.gov.petrobras
 0.00  0.03        47221        1 | br.gov.senado
 0.01  0.03        50621        3 | br.net.embratel
 0.01  0.01        10081        3 | br.ufrgs
 0.02  0.01        19212        7 | ca.ab
 0.04  0.09       171842       13 | ca.ab.edmonton
 0.04  0.04        75402       13 | ca.ab.gov.enr
 0.02  0.01        14268        5 | ca.ab.spots
 0.01  0.02        29775        3 | ca.apotex
 0.00  0.03        47221        1 | ca.bc.gov
 0.01  0.03        54472        3 | ca.bc.gov.marh
 0.09  0.11       203584       28 | ca.bctel
 0.04  0.03        46669       14 | ca.bell
 0.01  0.03        55535        3 | ca.cbc
 0.08  0.12       218540       24 | ca.cgocable.hy
 0.01  0.02        36054        3 | ca.cgocable.tr
 0.02  0.00         8972        5 | ca.cyberus
 0.04  0.03        59165       12 | ca.cycor
 0.13  0.07       127403       40 | ca.direct
 0.04  0.03        48324       12 | ca.dnd.drea
 0.03  0.07       135775       10 | ca.gc.pwgsc
 0.01  0.01        23322        3 | ca.istar.hfx
 0.13  0.11       206869       42 | ca.istar.ott
 0.01  0.00         1463        4 | ca.istar.pem
 0.09  0.07       120030       28 | ca.istar.tor
 0.02  0.04        66554        6 | ca.magic
 0.00  0.00         3174        1 | ca.mb.cyberspc
 0.00  0.00         3141        1 | ca.mb.freenet
 0.02  0.01        15860        6 | ca.mb.mbnet
 0.04  0.03        46645       14 | ca.mis
 0.01  0.04        77667        3 | ca.mtt
 0.12  0.09       167156       38 | ca.nb.nbnet
 0.11  0.25       445803       35 | ca.netcom
 0.02  0.01        15860        6 | ca.nrc.hrb
 0.01  0.01        22606        3 | ca.ns.cbnet
 0.00  0.02        37064        1 | ca.ns.nstc
 0.03  0.01        19375        8 | ca.on.affinity
 0.01  0.01         9657        3 | ca.on.air
 0.05  0.05        95347       16 | ca.on.cmh
 0.03  0.06        99665       10 | ca.on.edu.wcbe
 0.01  0.01        24114        3 | ca.on.flemingc.knet
 0.01  0.02        33552        3 | ca.on.humberc
 0.05  0.06       107935       16 | ca.on.ibcinc
 0.05  0.08       142189       17 | ca.on.ices
 0.04  0.03        49916       14 | ca.on.netaccess
 0.04  0.07       128994       14 | ca.on.nornet
 0.01  0.01        19232        2 | ca.on.odyssey
 0.04  0.02        31899       14 | ca.on.sheridanc
 0.00  0.00          316        1 | ca.qc.hydro.ccr
 0.01  0.01        26406        3 | ca.queensu.n148
 0.04  0.03        58098       11 | ca.queensu.n90
 0.04  0.02        27509       11 | ca.queensu.tele
 0.00  0.00         3174        1 | ca.recorder
 0.01  0.02        27577        3 | ca.rogerswave
 0.01  0.01        19261        3 | ca.sk.saskatoon.city
 0.04  0.11       198199       13 | ca.stmarys
 0.01  0.01        21634        3 | ca.sympatico.nf
 0.07  0.07       132817       21 | ca.sympatico.ns
 0.15  0.13       233408       46 | ca.sympatico.on
 0.16  0.10       189673       50 | ca.sympatico.sk
 0.04  0.01        24220       11 | ca.teleglobe
 0.01  0.01        20071        3 | ca.ubc.net.annex2
 0.05  0.03        60604       17 | ca.ucalgary.lib
 0.00  0.03        47221        1 | ca.ucalgary.mgmt
 0.05  0.05        95629       15 | ca.ulaval.bibl
 0.06  0.04        67153       19 | ca.umanitoba.lib
 0.00  0.00         3174        1 | ca.umontreal.bib
 0.10  0.08       140979       30 | ca.utoronto.dialin
 0.00  0.01        24395        1 | ca.uvic.dialup
 0.14  0.10       189025       45 | ca.uwaterloo
 0.04  0.03        53211       13 | ca.uwo.slip
 0.02  0.01        14268        5 | ch.span
 0.01  0.01        22607        2 | cl.uach.uca
 0.01  0.02        34368        4 | cl.uchile.cec
 0.03  0.01        22014        9 | com.41mad
 0.01  0.02        30686        3 | com.abraxis
 0.11  0.05        86114       34 | com.accessnv
 0.09  0.16       282006       28 | com.accessone
 0.05  0.03        48063       15 | com.accutek
 0.01  0.03        50621        3 | com.acuson
 0.05  0.06       100770       17 | com.add-inc
 0.02  0.01        15860        6 | com.adi
 0.05  0.02        43840       17 | com.adnc
 0.04  0.05        82904       14 | com.airliquide
 0.01  0.00         6315        2 | com.allergan
 0.05  0.08       153598       15 | com.allied.tmp
 0.03  0.01        21351        9 | com.allina
 0.05  0.10       187052       17 | com.amgen
 0.04  0.02        31152       14 | com.amp
 0.05  0.04        66110       16 | com.ampersand
 0.01  0.01        10735        4 | com.amrex
 0.08  0.05        93418       24 | com.anasazi
 4.37  2.96      5358861     1360 | com.aol.proxy
 0.01  0.02        38784        3 | com.apple
 0.04  0.02        31540       13 | com.aracnet
 0.04  0.03        46385       12 | com.arts
 0.04  0.07       127279       12 | com.asizip
 0.23  0.23       419555       73 | com.astramerck
 0.04  0.02        28204       13 | com.atcon.syd
 0.03  0.14       250064        9 | com.atext
 0.11  0.12       212143       33 | com.att
 0.11  0.06       102488       33 | com.awinc.onramp2
 0.05  0.04        66619       16 | com.awod
 0.01  0.04        66087        3 | com.axionet
 0.01  0.02        36054        3 | com.axsnet
 0.03  0.02        41924       10 | com.ballroom
 0.09  0.06       111344       28 | com.bankerstrust
 0.15  0.10       187887       46 | com.basf-corp
 0.04  0.03        61095       14 | com.baxter.subnet159-198-227
 0.04  0.02        38161       12 | com.bbsx
 0.03  0.01        21483       10 | com.bdm
 0.04  0.01        23595       11 | com.bear
 0.04  0.02        29538       12 | com.belcan
 0.48  1.80      3256405      149 | com.best.vip
 0.03  0.02        30982       10 | com.biogen
 0.12  0.12       209462       38 | com.bls.bst
 0.04  0.01        19710       14 | com.bmnet
 0.04  0.03        59960       13 | com.bms
 0.02  0.01         9312        6 | com.boehringer-mannheim
 0.21  0.25       448254       64 | com.boeing
 0.03  0.03        46874        9 | com.bromcom
 0.01  0.01        18671        4 | com.btinternet
 0.01  0.00         5353        4 | com.buttenet
 0.05  0.02        34533       17 | com.bv
 0.03  0.01        24182       10 | com.cablesoft
 0.02  0.02        39494        5 | com.cadvision
 0.04  0.02        42506       14 | com.california
 0.03  0.03        48123        8 | com.callamer.dialup.snlo
 0.08  0.05        90709       26 | com.carlsbadnm
 0.01  0.01        20162        3 | com.carlson
 0.08  0.05        99259       26 | com.ccia
 0.02  0.02        37745        5 | com.ccnet
 0.01  0.02        27424        2 | com.ccri
 0.05  0.02        40156       15 | com.cde
 0.08  0.08       148709       25 | com.cdmgroup
 0.01  0.01        16527        3 | com.cftnet
 0.04  0.01        22520       11 | com.channel1
 0.01  0.02        36050        3 | com.chesco
 0.05  0.05        85343       17 | com.ciaccess
 0.03  0.01        17127        9 | com.ciba.ustc
 0.13  0.13       230861       42 | com.cinergy
 0.01  0.03        50621        3 | com.cirrus
 0.06  0.03        47152       18 | com.cisco
 0.05  0.04        78062       16 | com.clandjop
 0.01  0.01        20850        3 | com.cmp
 0.01  0.03        46389        4 | com.cmpco
 0.07  0.10       175753       22 | com.coastalnet
 0.04  0.04        65419       12 | com.colpal
 0.10  0.08       144143       30 | com.colybrand
 0.04  0.01        25696       11 | com.comco
 0.05  0.05        87904       16 | com.commnections
 0.12  0.08       153149       37 | com.compaq
 0.03  0.05        83498        9 | com.compass-da
 1.44  1.44      2600413      449 | com.compuserve
 0.04  0.02        44509       12 | com.computermethods
 0.01  0.01        19984        3 | com.copperhill
 0.03  0.03        49266        8 | com.coredcs
 0.07  0.08       148673       21 | com.corning
 0.06  0.03        50072       19 | com.cornish
 0.09  0.06       111100       27 | com.cove.cape
 0.04  0.02        43251       12 | com.cport
 0.01  0.02        29610        4 | com.cray
 0.02  0.06       102484        5 | com.crc
 0.00  0.01        18534        1 | com.cris
 0.03  0.01        19318        8 | com.crocker
 0.03  0.03        62380       10 | com.ctaz
 0.03  0.05        85778        9 | com.ctron
 0.09  0.12       224063       27 | com.cts
 0.03  0.03        52781       10 | com.curtech
 0.05  0.03        61157       17 | com.customersvc
 0.04  0.01        23850       11 | com.cwia
 0.01  0.03        51983        3 | com.cwo
 0.04  0.02        31720       12 | com.cyberlynk
 0.07  0.04        79086       21 | com.cyberport
 0.04  0.02        43372       12 | com.cybertron
 0.01  0.01        21934        3 | com.dacotah
 0.04  0.03        59305       13 | com.dallascowboys
 0.04  0.03        57050       11 | com.dash
 0.06  0.08       138828       19 | com.dec.das-x
 0.14  0.10       172734       45 | com.dec.pa-x
 0.03  0.01        18512        8 | com.depalma-group
 0.01  0.00         6778        3 | com.dgsys
 0.01  0.05        98354        4 | com.diamondmm.gw
 0.01  0.08       136233        2 | com.digital.altavista
 0.05  0.05        90544       15 | com.digital.research.crl
 0.05  0.04        64347       17 | com.digital.service
 0.05  0.08       140758       15 | com.digitalink
 0.03  0.01        20254        9 | com.dnai
 0.02  0.04        66699        5 | com.dnai.np
 0.03  0.03        49355        8 | com.drco
 0.02  0.03        51167        6 | com.dsc
 0.04  0.03        45625       14 | com.dsport
 0.04  0.01        15571       12 | com.dss
 0.06  0.08       142217       20 | com.dupont.lvs
 0.04  0.01        25158       11 | com.dupontmerck
 0.07  0.06       102600       22 | com.e-tex
 0.05  0.05        84635       15 | com.ecpi
 0.25  0.22       391300       79 | com.eds
 0.01  0.04        64524        4 | com.electriciti.cs9
 0.03  0.04        70206       10 | com.empnet
 0.01  0.02        33320        3 | com.ericsson
 0.56  0.66      1193585      175 | com.erols
 0.11  0.12       215521       35 | com.eskimo
 0.03  0.01        20168        9 | com.esslink
 0.01  0.02        31751        3 | com.etn
 0.28  0.26       475212       86 | com.execpc
 0.05  0.05        93727       17 | com.exit109
 0.04  0.04        78989       14 | com.explorers
 0.09  0.07       133720       29 | com.ey
 0.01  0.02        42863        3 | com.fail
 0.04  0.02        35742       11 | com.fh
 0.09  0.07       134091       27 | com.fmc
 0.12  0.14       246837       37 | com.ford
 0.04  0.02        27696       12 | com.frazmtn
 0.02  0.01        15860        6 | com.funtime
 0.03  0.01        20082        9 | com.garlic.loomis
 0.05  0.03        63034       15 | com.gatecom
 0.10  0.11       201121       31 | com.ge
 0.09  0.04        79235       27 | com.ge-harris
 0.03  0.03        56890       10 | com.gemcon
 0.04  0.02        34336       12 | com.gene
 0.02  0.01        15860        6 | com.ghbbs
 0.02  0.02        34750        7 | com.glaxowellcome
 0.09  0.07       132108       29 | com.gld
 0.07  0.15       269584       23 | com.gmeds
 0.04  0.01        26851       11 | com.gnn.client
 0.25  0.38       681837       77 | com.gnn.proxy
 0.05  0.03        57552       15 | com.gnt
 0.04  0.04        72402       12 | com.goodnet
 0.04  0.05        86772       14 | com.greenapple
 0.01  0.03        50621        3 | com.gs
 0.01  0.02        41036        3 | com.gtech
 0.03  0.04        66481        9 | com.gtetel
 0.08  0.04        68437       26 | com.gtrad
 0.05  0.04        65548       15 | com.hac.es
 0.02  0.03        51867        5 | com.hach
 0.14  0.18       325598       43 | com.halcyon
 0.11  0.12       212746       34 | com.halnet
 0.04  0.03        52996       11 | com.hcc
 0.03  0.01        17477        9 | com.healthall
 0.03  0.01        20610        9 | com.healthcom
 0.01  0.03        54127        3 | com.healtheon
 0.01  0.03        49249        3 | com.hidesert
 0.01  0.03        50621        3 | com.highend
 0.05  0.02        42112       17 | com.holli
 0.04  0.01        26288       12 | com.home.sfba.snvl1
 0.04  0.05        95912       13 | com.honeywell.dasd
 0.07  0.05        90036       23 | com.hp
 0.02  0.01        10358        5 | com.hp.access
 0.01  0.02        30456        4 | com.hp.atl
 0.09  0.06       104926       28 | com.hp.cns
 0.02  0.00         4928        6 | com.hp.cup
 0.10  0.09       166768       30 | com.hp.idacom
 0.05  0.01        13794       15 | com.hp.mayfield
 0.03  0.02        35896        9 | com.hp.sde
 0.05  0.02        36221       16 | com.hp.spk
 0.06  0.07       118821       19 | com.hp.vcd
 0.12  0.08       153072       36 | com.hsi
 0.01  0.03        46774        2 | com.humboldt1
 0.02  0.03        50544        5 | com.ibm.austin
 0.04  0.01        25700       12 | com.ibm.hursley
 0.03  0.06       114588       10 | com.ibm.us.ca
 0.04  0.11       197037       13 | com.ibm.us.ny
 0.01  0.02        36054        3 | com.icel
 0.01  0.03        50621        3 | com.iceonline
 0.01  0.01        13234        3 | com.icepr
 0.05  0.03        53535       17 | com.icongrp.crown
 0.09  0.10       173346       28 | com.icontech.mfld
 0.13  0.10       176298       40 | com.idirect
 0.02  0.05        93381        6 | com.idt
 0.01  0.03        51983        3 | com.iinet
 0.02  0.04        76290        6 | com.impsat1
 0.04  0.01        25342       12 | com.imsint
 0.01  0.01        22462        3 | com.inch.dialup
 0.05  0.03        58030       15 | com.inch.isdn
 0.04  0.05        89604       13 | com.inficad.phx.ts1
 0.05  0.02        31350       17 | com.infobahnos
 0.07  0.08       152836       22 | com.injersey
 0.05  0.02        34549       16 | com.inland
 0.02  0.00         4506        5 | com.innercite
 0.04  0.03        61832       13 | com.innovsoftd
 0.04  0.04        69996       11 | com.inreach
 0.01  0.02        35918        3 | com.instinet
 0.07  0.03        51736       21 | com.intel.sc
 0.06  0.05        98174       19 | com.interaccess.loop
 0.04  0.02        42075       12 | com.interaccess.nb
 0.03  0.07       134739        8 | com.interaccess.nwchi
 0.05  0.04        67430       15 | com.intercall
 0.06  0.03        48485       19 | com.intergate
 0.06  0.07       134924       19 | com.interlog.cc
 0.00  0.03        46478        1 | com.interlog.tor
 0.04  0.03        59010       12 | com.intermat
 0.01  0.02        31397        3 | com.interramp.al.mobile3
 0.04  0.03        48522       13 | com.interramp.az.phoenix
 0.00  0.01        17470        1 | com.interramp.ca.mountain-view
 0.02  0.05        90514        7 | com.interramp.ct.bridgeport2
 0.07  0.03        47697       22 | com.interramp.ct.hartford2
 0.01  0.02        42863        3 | com.interramp.dc.washington3
 0.04  0.04        81398       12 | com.interramp.la.shreveport
 0.01  0.01        10890        4 | com.interramp.mi.birmingham
 0.01  0.03        50621        3 | com.interramp.mi.midland
 0.09  0.03        45305       27 | com.interramp.nc.charlotte
 0.01  0.02        34524        3 | com.interramp.nc.fayetteville
 0.01  0.01        22671        3 | com.interramp.ny.garden-city
 0.03  0.02        40197        9 | com.interramp.ny.white-plains2
 0.13  0.17       299243       41 | com.interramp.ok.tulsa
 0.03  0.01        20166        9 | com.interramp.pa.reading
 0.06  0.02        43755       20 | com.interramp.tn.knoxville2
 0.04  0.02        43989       11 | com.interramp.va.leesburg
 0.20  0.12       215788       61 | com.intersurf.dialup
 0.00  0.00          300        1 | com.invsn
 0.03  0.17       303899       10 | com.io.austin
 0.04  0.01        24821       11 | com.iocc
 0.00  0.00          200        1 | com.iohk
 0.00  0.01        21247        1 | com.iserver
 0.01  0.04        66227        3 | com.ispace
 0.04  0.02        27377       12 | com.itsnet
 0.05  0.06       106692       16 | com.ivnet
 0.01  0.01        26888        3 | com.javanet
 0.04  0.02        34289       12 | com.jb.cs1
 0.01  0.04        65335        2 | com.jnj
 0.05  0.03        62794       15 | com.jpmorgan
 0.04  0.02        28757       13 | com.kci1
 0.01  0.01        15293        3 | com.kcstar
 0.04  0.03        48175       14 | com.kelco
 0.03  0.01        25626       10 | com.kellnet
 0.02  0.01        15949        6 | com.kentelec
 0.03  0.01        23937       10 | com.kivex
 0.08  0.04        63553       24 | com.kodak
 0.04  0.04        76098       14 | com.kspress.ppp
 0.03  0.01        20207        9 | com.kuntrynet
 0.04  0.03        51317       14 | com.lakes.madelia
 0.01  0.02        34635        3 | com.lakes.prairie
 0.05  0.02        43389       16 | com.lanline
 0.04  0.01        25794       11 | com.leadbelt
 0.04  0.02        42673       12 | com.lehman
 0.03  0.05        98800        9 | com.lexmark
 0.25  0.30       550690       79 | com.lilly.d48
 0.04  0.02        27358       11 | com.littondsd
 0.07  0.09       154092       22 | com.lmco.eds
 0.01  0.02        44387        3 | com.lnd
 0.08  0.06       108523       26 | com.localnet.syr
 0.07  0.04        76674       22 | com.loclnet
 0.03  0.01        22847        9 | com.lotus
 0.01  0.02        41320        3 | com.lrun.neo
 0.01  0.00         8506        3 | com.ls
 0.07  0.07       125080       23 | com.lucent
 0.12  0.10       180704       38 | com.lucent.proxy
 0.02  0.01        14273        5 | com.lundbeck
 0.09  0.12       215110       29 | com.map
 0.04  0.02        44648       13 | com.marriott
 0.05  0.05        94820       16 | com.masterpiece
 0.04  0.04        78865       14 | com.matnet
 0.02  0.05        84216        6 | com.mdc
 0.10  0.03        54118       30 | com.merck
 0.46  1.20      2164185      144 | com.metro1
 0.04  0.06       110971       11 | com.microcom
 0.09  0.12       213685       28 | com.microsoft
 0.06  0.07       129982       19 | com.microtronix
 0.49  0.39       703717      153 | com.mindspring.dialup
 0.04  0.02        29960       14 | com.mkg
 0.08  0.08       138452       24 | com.mmc.orl
 0.10  0.13       234396       32 | com.mmc.vf
 0.01  0.02        36054        3 | com.mmd
 0.02  0.01        15860        6 | com.mmt
 0.14  0.08       137579       44 | com.monmouth
 0.08  0.12       222096       24 | com.monsanto
 0.01  0.02        34277        3 | com.moore.research
 0.07  0.04        71306       22 | com.mosby
 0.04  0.03        62328       12 | com.mot
 0.01  0.01        24145        3 | com.mother.dav
 0.00  0.00         6366        1 | com.msen.aa
 0.05  0.07       129265       15 | com.mtnhome
 0.01  0.01        25188        3 | com.n-jcenter
 0.04  0.05        87342       14 | com.natinst
 0.04  0.03        47190       11 | com.naxs
 0.01  0.02        31397        3 | com.nbn
 0.04  0.02        30062       12 | com.ncfcomm
 0.05  0.03        58623       15 | com.ncia
 0.02  0.04        72379        6 | com.nec.ml.inoc
 0.04  0.04        74064       14 | com.neodata
 0.06  0.03        50115       20 | com.neosoft
 0.01  0.01        26888        3 | com.neosoft.ops
 0.03  0.04        75526        9 | com.netaxis
 0.01  0.01        22462        3 | com.netaxs.slip
 2.93  2.78      5032407      912 | com.netcom.ix
 0.01  0.00         4392        2 | com.netidea.nelson
 0.01  0.02        35302        2 | com.netmcr
 0.08  0.07       120041       24 | com.netrover
 0.01  0.00         5045        2 | com.netxn
 0.03  0.01        19029        8 | com.nicom
 0.03  0.01        22070        9 | com.njcc
 0.02  0.01        15860        6 | com.nmmc
 0.01  0.02        31064        3 | com.novell.sjf
 0.03  0.02        27243       10 | com.nsc
 0.04  0.04        64070       11 | com.nt
 0.06  0.03        58897       18 | com.ntplx.dialin.bristol1
 0.02  0.06       100499        6 | com.nwlink.annex2
 0.02  0.00         1998        6 | com.nwlink.mu3
 0.04  0.02        28142       12 | com.nytimes
 0.05  0.02        41016       15 | com.oanet
 0.01  0.03        50621        3 | com.ocs
 0.02  0.01        15860        6 | com.ocwd
 0.06  0.11       201879       19 | com.ogi
 0.04  0.01        23637       11 | com.omegabbs
 0.05  0.03        60224       16 | com.onetinc
 0.05  0.04        76093       16 | com.oracle.us
 0.19  0.09       171279       59 | com.owens-corning
 0.01  0.02        31543        3 | com.owt
 0.01  0.02        34524        3 | com.pacbell.esac
 0.01  0.02        38784        3 | com.pacesetter
 0.04  0.01        23551       12 | com.pacifier.van3
 0.06  0.04        79608       19 | com.para-net
 0.04  0.02        31418       14 | com.paramount
 0.04  0.03        58123       12 | com.pcix
 0.02  0.04        72108        6 | com.peganet
 0.05  0.03        58439       15 | com.penn
 0.10  0.05        89578       30 | com.pfizer
 0.03  0.01        22510        8 | com.philips.cp.us
 0.02  0.01        17564        6 | com.phoenixat
 0.01  0.02        34524        3 | com.phonet
 0.02  0.01        15941        5 | com.picker
 0.01  0.02        40762        3 | com.pioneer-net
 0.02  0.05        90791        7 | com.pios
 0.20  0.20       368244       63 | com.pipex.du
 0.04  0.04        68102       12 | com.pixi
 0.01  0.01        21473        3 | com.planeteer
 0.04  0.01        23628       11 | com.pld
 0.02  0.04        75024        6 | com.plumcreek
 0.01  0.02        38297        3 | com.po
 0.04  0.01        25556       11 | com.ppco
 0.02  0.04        66530        5 | com.preferred
 0.04  0.05        92123       13 | com.pressenter
 0.05  0.03        52437       16 | com.pressroom
 0.00  0.03        53416        1 | com.primenet
 0.22  0.22       398654       67 | com.primenet.phx
 0.08  0.05        96044       25 | com.proaxis
 0.63  0.80      1443521      197 | com.prodigy
 0.01  0.01        24369        3 | com.prodigy.dev
 0.01  0.01        22067        3 | com.pti-us
 0.02  0.03        51287        5 | com.pweh
 0.02  0.04        71990        6 | com.qconline
 0.05  0.04        64630       16 | com.qi3
 0.19  0.11       190235       59 | com.qnet.ca
 0.02  0.01        19034        7 | com.qns
 0.04  0.03        57802       13 | com.qntm
 0.01  0.03        50621        3 | com.qrc
 0.04  0.01        24747       13 | com.quancon
 0.04  0.01        20582       12 | com.quik.reno
 0.05  0.04        73058       16 | com.rapidramp
 0.00  0.00          382        1 | com.ray
 0.01  0.03        50621        3 | com.redshift
 0.04  0.04        66172       14 | com.reichhold
 0.01  0.02        35936        3 | com.richards
 0.10  0.04        76298       32 | com.rmc
 0.01  0.01        17992        3 | com.ro
 0.02  0.01        16078        7 | com.roche
 0.04  0.01        23072       11 | com.roche.bas
 0.01  0.01        16043        3 | com.rochesterdandc
 0.01  0.01        24501        3 | com.rockisland
 0.11  0.10       188550       35 | com.rohmhaas
 0.03  0.09       165550        8 | com.rose
 0.05  0.05        87921       17 | com.rt66
 0.01  0.03        50621        3 | com.rxlist
 0.05  0.01        21678       15 | com.samsung
 0.04  0.06       101593       11 | com.sas
 0.05  0.07       132274       17 | com.sbi
 0.02  0.00         7920        6 | com.scsnet
 0.01  0.01        24057        3 | com.seanet.dialup
 0.03  0.03        54970        9 | com.seidata
 0.00  0.00          316        1 | com.series2000
 0.04  0.06       100661       11 | com.servtech.ceh
 0.04  0.02        38807       14 | com.servtech.dan
 0.02  0.04        66893        5 | com.sgi
 0.04  0.03        49687       12 | com.shepards
 0.01  0.01        25136        3 | com.shumat
 0.07  0.03        54693       22 | com.siemenscom
 0.04  0.02        31862       14 | com.sierratel
 0.01  0.03        50621        3 | com.sincom
 0.01  0.01        13025        3 | com.sirius
 0.01  0.03        50621        3 | com.sisna
 0.04  0.01        14720       13 | com.smallmedia.sniff
 0.01  0.02        35215        3 | com.softdisk
 0.01  0.00         6137        3 | com.solgate
 0.04  0.03        46112       12 | com.sony.fw-bc
 0.03  0.02        40271        9 | com.sr66
 0.04  0.03        52416       12 | com.sri
 0.04  0.02        30731       12 | com.statefarm
 0.02  0.01        15949        6 | com.stelhq
 0.07  0.12       208690       22 | com.stlnet
 0.01  0.02        29934        2 | com.stratus.hqsl
 0.04  0.02        30634       12 | com.stream
 0.02  0.02        31455        7 | com.sun
 0.01  0.02        41036        3 | com.supra
 0.01  0.02        39912        3 | com.surf
 0.07  0.13       236632       22 | com.surfsouth
 0.02  0.01        15860        6 | com.sybase
 0.04  0.03        57060       14 | com.syix
 0.05  0.14       249535       15 | com.sylvania
 0.01  0.03        62390        4 | com.syntex
 0.06  0.03        46901       18 | com.systemcentral
 0.03  0.01        26381        8 | com.tab
 0.05  0.06       102759       15 | com.tandem.loc201
 0.04  0.04        71395       13 | com.taurus
 0.04  0.02        43333       12 | com.tci
 0.01  0.02        27383        3 | com.tdl
 0.01  0.00         9009        4 | com.tecinfo
 0.01  0.03        46732        3 | com.tek
 0.04  0.03        57950       12 | com.telcomplus
 0.00  0.00         3174        1 | com.telephonics
 0.22  0.24       430211       70 | com.teleport
 0.04  0.04        66988       12 | com.telia
 0.01  0.01         9766        3 | com.tezcat
 0.02  0.04        74396        7 | com.thecore
 0.01  0.02        34277        3 | com.theriver.ppp
 0.04  0.02        44608       12 | com.theriver.tc1
 0.16  0.10       187491       50 | com.ti
 0.00  0.00          383        1 | com.tiac.ma.ashbu.gw2
 0.06  0.11       191647       20 | com.tmai
 0.01  0.00          999        3 | com.toledotel
 0.01  0.00         4741        3 | com.tracor
 0.04  0.03        56946       11 | com.trader.pm2
 0.04  0.02        28118       12 | com.transarc
 0.02  0.01        14273        5 | com.tribune
 0.01  0.02        44387        3 | com.triticom
 0.04  0.09       158364       13 | com.trw.sp
 0.05  0.06       111336       16 | com.tsixroads
 0.01  0.01        20359        3 | com.tstonramp
 0.02  0.01        15860        6 | com.tuelectric
 0.01  0.02        35215        3 | com.turbonet
 0.04  0.03        55690       12 | com.twentieth-century
 0.03  0.01        20615        9 | com.u-net
 0.03  0.03        47806       10 | com.ubss
 0.02  0.02        35430        5 | com.ui
 0.06  0.01        18409       19 | com.ultranet
 0.06  0.02        42638       19 | com.unibase
 0.03  0.01        19375        8 | com.unisys
 0.03  0.02        41709       10 | com.upj
 0.04  0.01        25720       11 | com.usa1
 0.01  0.03        50621        3 | com.usaa
 0.01  0.02        36054        3 | com.uswest
 0.01  0.02        30456        4 | com.uswnvg
 0.02  0.01        14268        5 | com.utc.corphq
 0.00  0.03        49352        1 | com.utc.res
 0.06  0.02        29480       18 | com.vallnet.devinstar
 0.05  0.06       106648       15 | com.vallnet.pandora
 0.01  0.01        15169        3 | com.verti
 0.04  0.01        24732       12 | com.vir
 0.05  0.02        33889       15 | com.visuallink
 0.02  0.06       111379        5 | com.vivanet
 0.13  0.10       172916       41 | com.voicenet
 0.10  0.20       355495       30 | com.vpro
 0.04  0.04        67658       11 | com.walshdist
 0.01  0.01        26888        3 | com.wanet
 0.07  0.04        66074       21 | com.waveform
 0.01  0.00         1315        4 | com.wco
 0.04  0.03        57658       12 | com.well
 0.03  0.01        20270        9 | com.westell
 0.02  0.04        69606        6 | com.westol
 0.05  0.04        79364       16 | com.wl.aa.chemistry
 0.05  0.05        84767       15 | com.wl.aa.research
 0.04  0.04        66106       12 | com.wlc
 0.04  0.01        20699       12 | com.wln
 0.01  0.02        36534        3 | com.wolfenet
 0.06  0.05        85251       18 | com.wsii
 0.04  0.02        34193       12 | com.wwa
 0.05  0.03        52250       16 | com.wwdc
 0.01  0.03        50621        3 | com.wwilkins
 0.01  0.01        21934        3 | com.xerox
 0.02  0.01        15949        6 | com.xerox.parc
 0.01  0.00         4575        2 | com.xo.tong-mcknew
 0.01  0.02        35936        3 | com.xpressweb
 0.01  0.02        33168        2 | com.yankee
 0.03  0.01        20550        9 | com.yankeepub
 0.04  0.00         8785       12 | com.zelacom.me1
 0.01  0.02        41713        3 | com.zenox
 0.01  0.02        41739        3 | cz.zcu
 0.02  0.01        13215        5 | de.dtag.btx
 0.03  0.05        91009       10 | de.eunet.pf
 0.00  0.00         3174        1 | de.gmd.gex
 0.00  0.03        60606        1 | de.netsurf
 0.01  0.00         7788        3 | de.th-darmstadt.hrz
 0.01  0.01        25706        4 | de.tu-berlin.cs
 0.00  0.01        24395        1 | de.uni-bielefeld.hrz
 0.03  0.01        24233        9 | dk.ia
 0.01  0.02        27788        3 | dk.skivehs
 0.02  0.04        75650        5 | dk.tele.bal
 0.01  0.02        41473        3 | dk.tele.kbh
 0.02  0.01        19212        7 | dk.uni-c
 0.04  0.02        33430       14 | do.net.codetel
 0.00  0.00         3174        1 | edu.allegheny
 0.03  0.01        20672        9 | edu.arizona.duna
 0.03  0.04        75216       10 | edu.arizona.life
 0.21  0.22       395745       65 | edu.arizona.medlib
 0.01  0.03        50621        3 | edu.asu.inre
 0.04  0.04        64187       14 | edu.asu.la
 0.01  0.03        49878        3 | edu.asu.west
 0.02  0.00         4839        6 | edu.bc
 0.04  0.02        31720       12 | edu.berkeley.lib
 0.01  0.02        36054        3 | edu.bethel.pub
 0.01  0.02        42863        3 | edu.bgu.gsu
 0.04  0.10       174403       11 | edu.binghamton.lib
 0.03  0.01        11448       10 | edu.bradley
 0.11  0.08       153429       34 | edu.bu
 0.01  0.02        36209        3 | edu.buffalo.ppp-net
 0.02  0.04        76290        6 | edu.byu
 0.01  0.03        56889        2 | edu.calpoly.aix
 0.00  0.01        14992        1 | edu.caltech
 0.05  0.02        35619       17 | edu.cmh
 0.01  0.03        58790        3 | edu.cmu.andrew.slip
 0.03  0.09       162844        8 | edu.cmu.gsia
 0.05  0.03        58643       15 | edu.colorado
 0.04  0.03        46257       11 | edu.columbia.cc
 0.03  0.03        49607        9 | edu.columbia.cpmc
 0.01  0.01        21934        3 | edu.columbia.nevis
 0.04  0.05        87481       12 | edu.csbsju.pc
 0.03  0.12       224819       10 | edu.csuohio.async
 0.01  0.04        68408        4 | edu.dartmouth
 0.06  0.03        48111       18 | edu.deltast
 0.01  0.01        15136        2 | edu.depaul.sac235x
 0.01  0.00         4765        2 | edu.drew
 0.04  0.03        45433       13 | edu.duke.dorm
 0.04  0.01        24300       11 | edu.duke.mc
 0.10  0.11       200988       30 | edu.ecu.educ
 0.02  0.01        15860        6 | edu.eiu
 0.00  0.00          316        1 | edu.emory.mathcs
 0.01  0.02        41303        3 | edu.emory.resnet
 0.01  0.07       121694        3 | edu.epcc
 0.05  0.04        74766       17 | edu.evansville
 0.01  0.01        16043        3 | edu.fau
 0.04  0.03        53924       12 | edu.fccc
 0.01  0.00         4448        2 | edu.fingerlakes
 0.19  0.19       335761       59 | edu.firn
 0.01  0.01        20359        3 | edu.fsu.cmr
 0.04  0.03        49930       12 | edu.fsu.scri
 0.02  0.01         9310        6 | edu.gatech.gtri
 0.08  0.07       129879       25 | edu.gatech.res
 0.01  0.02        36054        3 | edu.gmi
 0.04  0.03        50671       13 | edu.goshen
 0.04  0.05        82881       11 | edu.hpu
 0.00  0.00         3263        1 | edu.iastate.ent
 0.02  0.01        15865        6 | edu.indiana.physics
 0.05  0.05        92804       17 | edu.indiana.ucs
 0.01  0.02        36054        3 | edu.isu
 0.07  0.03        55920       23 | edu.iupui.oitlc
 0.04  0.03        53313       12 | edu.jhu.his
 0.00  0.01        18234        1 | edu.jmu
 0.01  0.02        32957        3 | edu.ksu.slip
 0.01  0.01        15293        3 | edu.lafayette.skillman
 0.06  0.04        69733       19 | edu.latech.remote
 0.05  0.04        64359       17 | edu.louisville.kdp-baptist
 0.04  0.02        36665       12 | edu.louisville.remote
 0.01  0.02        36954        3 | edu.loyola
 0.04  0.01        20040       11 | edu.lsu.biochem
 0.04  0.01        26705       11 | edu.lsumc.mip
 0.01  0.02        30039        3 | edu.maine.ume
 0.05  0.08       138971       16 | edu.mass
 0.02  0.03        51287        5 | edu.mayo
 0.01  0.03        55082        3 | edu.mccc
 0.01  0.00         5034        2 | edu.mcneese.acc
 0.05  0.07       128325       15 | edu.mcp
 0.02  0.01        15860        6 | edu.mcw.intmed
 0.01  0.02        31520        2 | edu.mec.mtech
 0.04  0.02        29188       13 | edu.memphis
 0.07  0.04        68950       23 | edu.missouri.coin
 0.06  0.02        45067       19 | edu.missouri.rl
 0.04  0.03        46610       14 | edu.mit
 0.03  0.01        24136        9 | edu.mit.media
 0.01  0.02        38784        3 | edu.monroe
 0.00  0.01        11769        1 | edu.morehead-st
 0.01  0.00         4764        2 | edu.mssm
 0.03  0.03        51162        8 | edu.mssm.library
 0.02  0.04        80847        6 | edu.msus.moorhead
 0.02  0.04        69937        5 | edu.musc
 0.01  0.01        25492        3 | edu.ncsu.dialup
 0.01  0.02        29949        3 | edu.nd.development
 0.04  0.04        75463       12 | edu.nd.library
 0.01  0.03        51395        3 | edu.njit
 0.04  0.02        27652       13 | edu.nmsu
 0.01  0.00          666        2 | edu.nodak.ndsu.campus
 0.00  0.00         2648        1 | edu.nodak.ndsu.cc
 0.00  0.00          333        1 | edu.nodak.ndsu.pt07
 0.00  0.00          333        1 | edu.nodak.ndsu.pt16
 0.00  0.00         2648        1 | edu.nodak.ndsu.pt4
 0.03  0.11       192415       10 | edu.nodak.und.ctl
 0.03  0.03        59007       10 | edu.nova.acast
 0.23  0.19       338088       73 | edu.nova.microlab
 0.08  0.04        73269       24 | edu.nwu.ghsl
 0.01  0.03        52647        4 | edu.nwu.microbio
 0.11  0.10       177192       33 | edu.nwu.res-hall
 0.04  0.03        48923       12 | edu.nyu.med
 0.03  0.03        50193       10 | edu.odu.kdh
 0.03  0.00         6609        9 | edu.ohio-state.ce
 0.04  0.09       159639       14 | edu.ohio-state.homenet
 0.01  0.03        50821        4 | edu.ohio-state.rf
 0.04  0.04        65794       12 | edu.ohiou.dialnet
 0.04  0.03        51639       14 | edu.ohiou.plantbio
 0.00  0.00          316        1 | edu.ohsu
 0.13  0.10       175684       41 | edu.onu
 0.03  0.03        49266        8 | edu.orst.snell
 0.02  0.04        72439        6 | edu.orst.ucs
 0.07  0.06       114170       21 | edu.ou.modems
 0.10  0.03        59881       32 | edu.oxy.finaid
 0.03  0.04        78804        9 | edu.pitt.hsls
 0.13  0.09       166566       39 | edu.pitt.net.rmt
 0.03  0.01        20143        9 | edu.pitt.wpic
 0.05  0.02        35990       16 | edu.planet
 0.01  0.02        27788        3 | edu.plattsburgh.lab
 0.01  0.02        35968        4 | edu.princeton
 0.00  0.01        15402        1 | edu.psc
 0.04  0.06       114942       14 | edu.psu.cac
 0.01  0.01        18802        3 | edu.psu.hbg
 0.01  0.03        50621        3 | edu.psu.hhdev
 0.01  0.03        50621        3 | edu.purdue.mgmt
 0.03  0.01        25324        9 | edu.rpslmc.atr
 0.03  0.01        20985       10 | edu.rpslmc.campus
 0.04  0.02        36769       13 | edu.rpslmc.kid
 0.06  0.05        92144       20 | edu.rutgers
 0.01  0.01        11040        2 | edu.sfsu
 0.04  0.01        23823       11 | edu.sonoma
 0.02  0.01        15949        6 | edu.stanford
 0.14  0.06       105614       45 | edu.stlcop
 0.01  0.02        30456        4 | edu.suffolk.clas
 0.04  0.01        23619       11 | edu.syr
 0.03  0.07       120763        9 | edu.temple.ocis
 0.05  0.02        43568       15 | edu.tenet.isd.deer-park
 0.03  0.01        21615       10 | edu.tmc.mdacc
 0.02  0.01        15860        6 | edu.tmc.uth.hh
 0.04  0.02        31247       13 | edu.tmc.uth.med
 0.05  0.03        60426       16 | edu.tmc.uth.sph
 0.01  0.02        42431        4 | edu.toronto.math
 0.10  0.15       278877       30 | edu.ttuhsc.lubb
 0.04  0.07       133298       12 | edu.uark
 0.01  0.02        42863        3 | edu.uark.engr
 0.04  0.02        42667       14 | edu.uc.eng
 0.01  0.03        50621        3 | edu.uc.hpb
 0.10  0.18       332777       30 | edu.uc.med
 0.01  0.03        50621        3 | edu.uc.san
 0.04  0.02        41791       12 | edu.ucdavis
 0.03  0.01        20994        9 | edu.uchicago
 0.04  0.07       120645       14 | edu.uchicago.rh
 0.02  0.04        71627        5 | edu.uci.mc.lib
 0.01  0.04        68720        2 | edu.ucollege
 0.01  0.02        31397        3 | edu.ucop
 0.03  0.03        49266        8 | edu.ucr
 0.00  0.02        33004        1 | edu.ucsc
 0.07  0.07       128527       21 | edu.ucsd
 0.15  0.10       187865       46 | edu.ucsf
 0.05  0.06       113181       16 | edu.ucsf.library
 0.05  0.04        80699       17 | edu.udel.nss
 0.08  0.09       161646       26 | edu.ufl.health
 0.01  0.03        60281        3 | edu.ufl.nerdc
 0.03  0.01        20721       10 | edu.uga.rx
 0.03  0.01        20978       10 | edu.uic.lib
 0.01  0.03        63188        4 | edu.uiowa.biz
 0.02  0.06       101242        6 | edu.uiowa.radiology
 0.05  0.04        69412       16 | edu.uiuc.inhs
 0.01  0.01         9657        3 | edu.uiuc.mhc
 0.05  0.05        83673       15 | edu.uiuc.ocp
 0.08  0.12       218954       25 | edu.ukans.cc
 0.02  0.01        15519        7 | edu.uky.hosp
 0.04  0.01        23569       11 | edu.uky.mri
 0.02  0.04        70846        7 | edu.uky.pharm
 0.01  0.03        54564        3 | edu.umd
 0.08  0.03        54751       24 | edu.umd.ab
 0.03  0.01        26697        9 | edu.umd.dial
 0.01  0.01        19261        3 | edu.umd.dorm
 0.04  0.03        47190       11 | edu.umich.itd.ccs
 0.01  0.03        63332        2 | edu.uml.cs
 0.07  0.03        62857       22 | edu.umn.d
 0.08  0.07       127038       26 | edu.umn.dialup
 0.04  0.01        24245       11 | edu.umn.pharmacy
 0.02  0.00         4839        6 | edu.umsl
 0.03  0.01        22212        9 | edu.unc.hsl
 0.04  0.03        54465       11 | edu.uncc
 0.01  0.02        44197        3 | edu.uncwil.lslab
 0.02  0.03        49932        7 | edu.uni.dialup
 0.08  0.14       259005       24 | edu.unm
 0.07  0.07       130312       21 | edu.unomaha
 0.01  0.02        38787        4 | edu.uofs.chem
 0.04  0.03        48621       14 | edu.uofs.library
 0.01  0.01        19261        3 | edu.uop.cop
 0.06  0.05        98887       20 | edu.upenn
 0.04  0.03        60011       14 | edu.upenn.lib
 0.01  0.02        31064        3 | edu.upenn.nbc
 0.01  0.00         8226        2 | edu.ups
 0.03  0.01        20166        9 | edu.usc
 0.17  0.13       233368       52 | edu.usf.stpt
 0.00  0.02        43768        1 | edu.usfca
 0.01  0.02        28704        3 | edu.usl.ucs
 0.01  0.00          632        2 | edu.utah.cc
 0.01  0.01        11083        3 | edu.utah.unicomm
 0.08  0.05        90630       24 | edu.utexas.nur
 0.03  0.01        10151        8 | edu.utexas.ots
 0.04  0.03        45958       14 | edu.utexas.per
 0.01  0.01        15169        3 | edu.utk.ag
 0.04  0.03        48540       12 | edu.utk.hosp
 0.04  0.03        57020       14 | edu.utk.rmt
 0.01  0.02        34277        3 | edu.uwm.csd
 0.09  0.08       140524       28 | edu.uwsp
 0.03  0.06       111696        9 | edu.vill.law
 0.01  0.04        63630        3 | edu.virginia.acc
 0.03  0.02        33386        9 | edu.virginia.bootp
 0.01  0.03        50621        3 | edu.vt.ppws
 0.05  0.05        83863       17 | edu.wartburg.lib
 0.04  0.02        29901       12 | edu.washington.cac
 0.01  0.01        22246        3 | edu.washington.u
 0.05  0.07       125517       16 | edu.wesleyan.stu
 0.01  0.00         8470        4 | edu.widener
 0.03  0.06       109128       10 | edu.wilkes.rcrc
 0.01  0.03        54929        3 | edu.wilkes.weiss
 0.02  0.01        15860        6 | edu.wiu
 0.03  0.03        55984       10 | edu.wright.library
 0.01  0.03        47526        3 | edu.wsu.mme
 0.02  0.05        88201        7 | edu.wsu.vetmed
 0.00  0.01        15861        1 | edu.wvnet
 0.04  0.03        51037       12 | edu.wvnet.dialup
 0.01  0.02        33397        3 | edu.wvnet.fairmont
 0.06  0.05        82189       18 | edu.wvu.hsc
 0.03  0.02        43267        9 | edu.yale.cis
 0.01  0.01         9657        3 | edu.yale.physics
 0.04  0.02        37713       11 | eg.gov.idsc
 0.02  0.01        15949        6 | es.iponet
 0.01  0.02        35253        2 | es.redestb.116
 0.02  0.00         4595        5 | es.teleline
 0.03  0.02        40709       10 | fi.abo
 0.01  0.01        13234        3 | fi.eunet
 0.05  0.07       123677       15 | fi.funet
 0.02  0.01        15860        6 | fi.helsinki.pc
 0.02  0.01        15949        6 | fi.octel
 0.01  0.01        13234        3 | fi.tpu
 0.01  0.01         9967        3 | fi.vsonic
 0.03  0.03        57009       10 | fr.ap-hop-paris
 0.04  0.02        29310       13 | fr.chu-rouen
 0.06  0.06       105121       19 | fr.club-internet.neuilly
 0.04  0.02        44856       13 | fr.cyberstation
 0.01  0.03        50621        3 | gov.blm.ak
 0.01  0.04        79875        2 | gov.bnl.dir
 0.01  0.01        25526        3 | gov.ca.teale.lan
 0.05  0.04        69101       15 | gov.ca.water
 0.01  0.03        48346        4 | gov.cahwnet
 0.02  0.01        15949        6 | gov.cebaf
 0.02  0.06       104048        6 | gov.census
 0.02  0.01        15860        6 | gov.doe.dync
 0.03  0.01        21652        9 | gov.epa.dcrtr986
 0.03  0.01        23452       10 | gov.epa.r1air1
 0.01  0.01         9344        3 | gov.epa.rtp4501a
 0.04  0.01        24914       11 | gov.exim
 0.02  0.06       115058        7 | gov.fda.cder
 0.02  0.10       185636        5 | gov.fdic
 0.04  0.01        17277       14 | gov.frb
 0.01  0.03        50621        3 | gov.hud
 0.04  0.05        87515       11 | gov.inel
 0.02  0.07       128288        6 | gov.lanl
 0.07  0.03        58540       21 | gov.loc
 0.04  0.03        62615       13 | gov.nasa.gsfc
 0.01  0.01        15169        3 | gov.nasa.jpl
 0.04  0.05        82227       14 | gov.nasa.larc
 0.06  0.12       217073       18 | gov.nih.niams
 0.01  0.02        36054        3 | gov.nih.nlm
 0.01  0.03        54564        3 | gov.noaa.erl
 0.11  0.11       198559       33 | gov.pader
 0.01  0.03        47272        3 | gov.sandia
 0.01  0.03        50621        3 | gov.srp
 0.02  0.01        15949        6 | gov.ssa
 0.03  0.08       150185       10 | gov.texas.dhs
 0.03  0.11       202035       10 | gov.treas
 0.08  0.15       266990       26 | gov.usbr.do
 0.06  0.08       137564       18 | gov.usia
 0.23  0.27       483431       72 | gov.usps
 0.01  0.00         6902        3 | gr.auth.pharm
 0.04  0.03        48888       12 | gr.hol.ppp13
 0.04  0.01        24124       11 | hk.com.clp
 0.00  0.00         3174        1 | hk.cuhk.ie
 0.02  0.04        80903        6 | hr.tel
 0.01  0.01        25136        3 | hu.datanet.dialin
 0.00  0.00         3263        1 | hu.iif
 0.13  0.09       162572       39 | ie.indigo.cork
 0.01  0.01        13234        3 | il.ac
 0.03  0.01        19350        8 | il.co.trendline
 0.06  0.06       102861       20 | il.net.netmedia
 0.01  0.00         7734        3 | il.net.netvision.pop8a
 0.01  0.02        34524        3 | il.net.netvision.pop9a
 0.02  0.06       103379        5 | in.net.vsnl
 0.06  0.08       142848       19 | it.askesis
 0.04  0.04        70392       11 | it.dsnet
 0.01  0.01        18658        3 | it.nti
 0.07  0.06       112371       23 | it.vol
 0.00  0.00          300        1 | jp.ac.osaka-u.sci.phys
 0.13  0.03        59878       40 | jp.ac.tmd.dent
 0.00  0.00          300        1 | jp.ad.mesh.sp
 0.03  0.01        19152        9 | jp.go.riken
 0.00  0.00          300        1 | jp.or.aif
 0.00  0.00          300        1 | jp.or.biwako
 0.04  0.03        61246       14 | jp.or.cnet-ta
 0.00  0.00          300        1 | jp.or.fitweb.tym
 0.00  0.00          300        1 | jp.or.gadgetnet.akita
 0.00  0.00          300        1 | jp.or.highway
 0.05  0.02        31383       15 | jp.or.infoweb.ppp
 0.00  0.00          300        1 | jp.or.koganet
 0.03  0.03        54972        9 | jp.or.medbank.in
 0.01  0.01        18392        3 | jp.or.msn
 0.00  0.00          300        1 | jp.or.nsknet.toyama
 0.00  0.00          300        1 | jp.or.orange
 0.00  0.00          300        1 | jp.or.sakuranet
 0.00  0.00          300        1 | jp.or.sunfield
 0.00  0.00          300        1 | jp.or.wombat
 0.00  0.00          300        1 | jp.or.xaxon-net.osaka
 0.01  0.01        19261        3 | kr.ac.snu
 0.02  0.01        15860        6 | kr.co.kol
 0.07  0.09       170947       23 | kr.co.unitel
 0.03  0.01        19258        8 | lv.parks
 0.04  0.08       141865       14 | mil.af.afotec
 0.02  0.05        94844        6 | mil.af.hq
 0.04  0.01        26399       12 | mil.af.ramstein
 0.01  0.03        59740        3 | mil.army
 0.04  0.03        48615       12 | mil.army.gordon
 0.05  0.06       102632       16 | mil.army.gordon.termserv
 0.02  0.00         4839        6 | mil.army.tacom
 0.02  0.05        86675        6 | mil.army.usace.npp
 0.02  0.06       110418        7 | mil.army.usace.saj
 0.06  0.02        31545       19 | mil.dla.dscc
 0.01  0.02        45242        3 | mil.navy.chinalake
 0.01  0.03        47168        3 | mil.navy.nps.dmdc
 0.09  0.07       119348       27 | mil.nosc
 0.05  0.06       116635       15 | mil.ochampus.mp
 0.05  0.03        47208       15 | mx.com.spin
 0.00  0.00         3174        1 | my.jaring.ktk5
 0.05  0.02        37297       16 | net.2sprint
 0.02  0.01        15860        6 | net.3rivers
 0.04  0.03        51323       14 | net.abs
 0.01  0.01        20162        3 | net.acadiacom
 0.04  0.05        91156       13 | net.accent
 0.02  0.08       152773        6 | net.achilles
 0.09  0.06       104649       28 | net.acronet
 0.04  0.03        53280       14 | net.address
 0.05  0.04        73739       16 | net.agate.sdi
 0.01  0.05        97842        4 | net.agt
 0.05  0.08       137314       17 | net.alaska
 0.01  0.00         2367        2 | net.albany
 0.01  0.02        27795        3 | net.aloha.u
 0.09  0.08       140486       27 | net.ameritel.an2
 0.05  0.03        55072       17 | net.ao.tserver1
 0.03  0.01        20761        9 | net.apc
 0.06  0.02        41404       19 | net.apci
 0.01  0.01        15169        3 | net.apk.medina
 0.01  0.02        27635        3 | net.arinc
 0.04  0.02        30537       12 | net.aristotle
 0.04  0.01        23595       11 | net.athens
 0.01  0.01         9344        3 | net.atlantica
 0.03  0.00         8409       10 | net.att.dial-access.az.phoenix-001
 0.07  0.08       147027       22 | net.att.dial-access.ca.los-angeles-001
 0.04  0.02        45184       14 | net.att.dial-access.ca.los-angeles-002
 0.01  0.02        42776        3 | net.att.dial-access.ca.los-angeles-006
 0.00  0.01        16584        1 | net.att.dial-access.ca.los-angeles-007
 0.01  0.01        14114        3 | net.att.dial-access.ca.los-angeles-008
 0.00  0.00         3263        1 | net.att.dial-access.ca.san-diego-001
 0.03  0.02        38741        9 | net.att.dial-access.ca.san-francisco-001
 0.04  0.01        25577       11 | net.att.dial-access.ca.san-francisco-002
 0.02  0.01        14268        5 | net.att.dial-access.ca.san-francisco-003
 0.03  0.03        62491        8 | net.att.dial-access.ca.san-jose-001
 0.07  0.11       195746       23 | net.att.dial-access.co.denver-002
 0.15  0.10       177977       47 | net.att.dial-access.fl.miami-002
 0.05  0.03        61585       16 | net.att.dial-access.fl.orlando-001
 0.00  0.00         6366        1 | net.att.dial-access.fl.orlando-007
 0.04  0.09       168924       12 | net.att.dial-access.fl.orlando-02
 0.13  0.19       335076       42 | net.att.dial-access.fl.tampa-001
 0.10  0.09       156145       32 | net.att.dial-access.ga.atlanta-001
 0.06  0.12       214520       20 | net.att.dial-access.ga.atlanta-002
 0.15  0.10       175292       46 | net.att.dial-access.ga.atlanta-004
 0.01  0.02        36767        3 | net.att.dial-access.ga.atlanta-005
 0.05  0.03        61374       17 | net.att.dial-access.ga.atlanta-01
 0.02  0.03        46287        7 | net.att.dial-access.ga.atlanta-033
 0.15  0.08       139112       47 | net.att.dial-access.ga.atlanta-035
 0.03  0.01        20939        9 | net.att.dial-access.ga.atlanta-037
 0.04  0.03        58047       13 | net.att.dial-access.ga.atlanta-09
 0.07  0.08       147103       22 | net.att.dial-access.ga.atlanta-10
 0.05  0.03        47926       15 | net.att.dial-access.il.chicago-002
 0.07  0.08       143723       23 | net.att.dial-access.il.chicago-005
 0.04  0.02        43340       12 | net.att.dial-access.mn.minnesota-001
 0.05  0.02        35779       16 | net.att.dial-access.mn.minnesota-002
 0.10  0.10       178232       31 | net.att.dial-access.mo.bridgeton-002
 0.02  0.00         1665        5 | net.att.dial-access.mo.bridgeton-052
 0.07  0.07       132434       21 | net.att.dial-access.mo.bridgeton-053
 0.04  0.04        73911       13 | net.att.dial-access.mo.bridgeton-055
 0.04  0.05        91904       13 | net.att.dial-access.mo.bridgeton-058
 0.06  0.09       160533       20 | net.att.dial-access.mo.kansas-city-002
 0.08  0.13       233657       26 | net.att.dial-access.mo.st-louis-005
 0.06  0.05        92523       18 | net.att.dial-access.mo.st-louis-006
 0.04  0.01        24975       11 | net.att.dial-access.mo.st-louis-007
 0.05  0.05        84956       16 | net.att.dial-access.mo.st-louis-011
 0.01  0.00          999        3 | net.att.dial-access.nc.charlotte-001
 0.01  0.01        22462        3 | net.att.dial-access.ny.new-york-001
 0.09  0.04        79470       29 | net.att.dial-access.ny.new-york-003
 0.04  0.01        26950       12 | net.att.dial-access.ny.new-york-005
 0.04  0.03        55345       13 | net.att.dial-access.ny.new-york-007
 0.02  0.01        25553        5 | net.att.dial-access.ny.new-york-008
 0.01  0.01        18392        3 | net.att.dial-access.ny.new-york-009
 0.19  0.13       241472       58 | net.att.dial-access.ny.new-york-013
 0.00  0.03        62687        1 | net.att.dial-access.ny.new-york-016
 0.04  0.04        72110       14 | net.att.dial-access.oh.cleveland-002
 0.03  0.02        36022        9 | net.att.dial-access.tx.dallas-002
 0.01  0.02        31520        2 | net.att.dial-access.tx.dallas-006
 0.01  0.01        20359        3 | net.att.dial-access.tx.houston-004
 0.01  0.03        51694        3 | net.att.dial-access.va.middletown-01
 0.06  0.03        46637       19 | net.att.dial-access.va.middletown-02
 0.07  0.08       144218       22 | net.att.dial-access.va.middletown-03
 0.01  0.03        56064        2 | net.att.dial-access.va.middletown-51
 0.01  0.02        34635        3 | net.att.dial-access.va.middletown-58
 0.04  0.02        31720       12 | net.att.dial-access.wa.seattle-004
 0.04  0.02        39358       13 | net.barepower
 0.01  0.03        48386        2 | net.bayserve
 0.04  0.02        27980       13 | net.bconnex
 0.05  0.04        67129       15 | net.bctel
 0.03  0.01        20707        9 | net.beaches
 0.04  0.01        26956       11 | net.bellatlantic
 0.08  0.07       128438       25 | net.bellsouth.atl
 0.01  0.02        27795        3 | net.bellsouth.jax
 0.06  0.01        23060       18 | net.bellsouth.mia
 0.03  0.03        57115       10 | net.bellsouth.msy
 0.00  0.00          300        1 | net.best.noc
 0.00  0.00         1080        1 | net.bev
 0.09  0.05        82460       29 | net.binc
 0.01  0.02        31397        3 | net.bitstreet
 0.04  0.05        95378       14 | net.blue
 0.05  0.03        57599       15 | net.blueridge
 0.02  0.01        15949        6 | net.bridge
 0.11  0.09       167917       34 | net.bright.dial
 0.14  0.20       363177       44 | net.bright.win
 0.05  0.03        56617       16 | net.brightok
 0.02  0.05        94844        6 | net.buffnet
 0.32  0.27       481845       99 | net.c-zone.redding
 0.05  0.04        77275       16 | net.c2
 0.04  0.01        27148       12 | net.cancom
 0.03  0.01        23028       10 | net.cape
 0.02  0.04        66930        5 | net.capital.colnny1
 0.03  0.00         7445        9 | net.caribe
 0.10  0.06       110045       30 | net.cdepot
 0.11  0.14       245603       34 | net.cdsnet.dip
 0.02  0.01        15860        6 | net.centuryinter.av
 0.06  0.05        92756       18 | net.centuryinter.sm
 0.04  0.03        53208       12 | net.cg
 0.03  0.01        19375        8 | net.cibola.ep
 0.01  0.02        36054        3 | net.cinti
 0.02  0.04        75810        7 | net.citynet
 0.01  0.01        18392        3 | net.cloud9.dialup
 0.01  0.03        47168        3 | net.communique.msya
 0.03  0.02        42534        8 | net.computer
 0.56  0.60      1088688      175 | net.concentric
 0.03  0.01        23071       10 | net.connectmmic
 0.01  0.03        53779        3 | net.connix.pa.hfd
 0.18  0.09       163516       56 | net.coqui
 0.05  0.03        50146       15 | net.cot
 0.04  0.01        16273       14 | net.crosslink.us.va.culpeper.pm1
 0.01  0.02        38784        3 | net.crosslink.us.va.fredericksburg.pm1
 0.01  0.02        34524        3 | net.crosslink.us.va.northumberland.pm1
 0.04  0.00         5962       12 | net.crown
 0.01  0.01        10962        4 | net.csinet
 0.01  0.02        44125        3 | net.csra
 0.01  0.02        32167        4 | net.csrlink
 0.02  0.01        15860        6 | net.cybercomm.sl
 0.13  0.09       162840       39 | net.cyberenet.ppp
 0.07  0.12       226165       22 | net.cyberhighway.arc
 0.01  0.00         3982        3 | net.cyberhighway.sle
 0.05  0.01        24587       15 | net.datasys
 0.04  0.04        64619       14 | net.dayton
 0.08  0.13       232230       25 | net.dbtech
 0.04  0.01        25442       11 | net.deltech
 0.24  0.24       437162       76 | net.dialsprint
 0.03  0.01        22504       10 | net.digex.belt
 0.06  0.04        72879       18 | net.digital
 0.02  0.04        63430        7 | net.dmci
 0.02  0.01        15949        6 | net.durham
 0.47  0.33       603252      147 | net.earthlink
 0.01  0.03        59681        3 | net.earthlink.dynip.us.ca.agoura.maxa
 0.04  0.06       100495       14 | net.eazy
 0.04  0.02        28396       13 | net.ebicom
 0.01  0.01        10480        4 | net.en
 0.01  0.01        18802        3 | net.enter
 0.17  0.17       313669       52 | net.epix
 0.04  0.02        27474       12 | net.eri.dayton
 0.02  0.01        16455        5 | net.eskimo.ndip
 0.01  0.01        25136        3 | net.eu.at.wienerneustadt
 0.02  0.08       135807        7 | net.excel
 0.04  0.01        25928       12 | net.ez2
 0.05  0.06       114109       16 | net.eznet.roc-tc1
 0.05  0.05        95382       15 | net.fast
 0.06  0.03        52567       19 | net.fastlane
 0.04  0.03        62554       12 | net.fdt.gnv.ts2
 0.01  0.01        11083        3 | net.fgi
 0.05  0.07       127478       16 | net.fla
 0.31  0.30       546133       98 | net.flash
 0.06  0.09       162181       20 | net.fn
 0.01  0.03        50621        3 | net.foothill
 0.03  0.01        21299        9 | net.freespace.cardinal
 0.16  0.18       325568       51 | net.frontiernet.roc.dial
 0.14  0.50       910645       45 | net.ftn
 0.05  0.02        36781       16 | net.fullnet
 0.02  0.01        15860        6 | net.fuse
 0.05  0.03        52033       17 | net.fyi
 0.04  0.04        73736       13 | net.g-net
 0.07  0.06       101827       21 | net.gate
 0.06  0.05        91844       19 | net.gator
 0.12  0.10       175796       36 | net.generation
 0.05  0.02        37323       15 | net.gil
 0.04  0.05        93863       14 | net.gis
 0.04  0.06       109244       13 | net.globale
 0.04  0.01        27141       14 | net.globalserve
 0.20  0.12       222034       61 | net.gte
 0.01  0.00         4122        4 | net.gte.pac
 0.04  0.04        72861       11 | net.guam.kuentos
 0.03  0.00         2844        9 | net.gwi
 0.09  0.09       168588       28 | net.hawaiian
 0.02  0.01        19376        7 | net.hey
 0.02  0.01        15860        6 | net.hiline
 0.03  0.01        25096       10 | net.hit
 0.04  0.03        61667       12 | net.hiwaay
 0.04  0.06        99650       12 | net.hooked.ppp
 0.09  0.08       136413       28 | net.hookup.hfx
 0.04  0.03        46498       14 | net.hookup.lon
 0.06  0.04        68471       19 | net.hookup.tor
 0.04  0.06        99639       13 | net.hookup.wat
 0.04  0.01        26046       12 | net.hot1
 0.06  0.04        72822       19 | net.hurricane
 0.03  0.01        21109        9 | net.hutchtel
 0.03  0.04        68698        8 | net.i-2000.dh.access1
 0.03  0.01        18727        8 | net.i-2000.hackensack.access1
 0.04  0.01        18985       11 | net.i1
 0.01  0.01        21562        3 | net.i3
 0.07  0.11       191478       21 | net.iac
 0.47  0.45       815217      147 | net.iadfw.ppp
 0.00  0.01        16584        1 | net.iamerica
 0.06  0.08       150887       20 | net.ibm.au.sy
 0.01  0.02        36108        3 | net.ibm.ca.bc
 0.00  0.00         3174        1 | net.ibm.uk.pt
 0.01  0.02        30039        3 | net.ibm.us.ct
 0.05  0.03        62811       15 | net.ibm.us.ky
 0.01  0.00         3982        3 | net.ibm.us.nc
 0.07  0.08       135858       21 | net.ibm.us.pa
 0.03  0.02        34473        8 | net.ibm.us.va
 0.04  0.04        72029       14 | net.ibm.us.wi
 0.04  0.04        73767       11 | net.ibm.us.wv
 0.06  0.03        55095       20 | net.ica
 0.04  0.04        65730       14 | net.icanect.mia.ascend02.pool1
 0.01  0.01        21634        3 | net.icsi
 0.04  0.06       105560       13 | net.idir.idtskc2
 0.03  0.09       160566        9 | net.ids.egr-ri
 0.04  0.02        39691       14 | net.ids.pvd-ri
 0.04  0.04        63428       13 | net.idt.dc.ts-1
 0.10  0.06       112960       30 | net.idt.hck.ts-10
 0.06  0.08       142327       20 | net.idt.hck.ts-7
 0.00  0.00          539        1 | net.idt.hp.ts-1
 0.04  0.01        23030       11 | net.idt.hp.ts-2
 0.04  0.03        61927       13 | net.idt.mvl.ts-1
 0.06  0.04        65118       20 | net.idt.nyc.ts-13
 0.01  0.02        36054        3 | net.idt.nyc.ts-14
 0.03  0.01        24707        9 | net.idt.ptn.ts-1
 0.03  0.01        20358        9 | net.iglobal
 0.02  0.05        96023        6 | net.ih2000
 0.07  0.13       243145       21 | net.imag
 0.00  0.00         3263        1 | net.imine.ws
 0.03  0.01        21176        9 | net.imperium
 0.01  0.01        26804        3 | net.imt
 0.05  0.05        92684       16 | net.incom
 0.02  0.03        60111        6 | net.indy
 0.04  0.02        28944       13 | net.indy.ts
 0.06  0.12       222990       20 | net.inet
 0.04  0.03        57654       13 | net.inetworld
 0.01  0.02        34485        3 | net.infi.annap
 0.04  0.09       155491       12 | net.infi.clt
 0.12  0.06       102738       36 | net.infi.nr
 0.08  0.09       165092       24 | net.infi.orf
 0.01  0.02        39242        3 | net.infi.orh
 0.03  0.03        59355       10 | net.infi.phl
 0.04  0.01        26496       11 | net.infi.pit
 0.03  0.05        87638        9 | net.infi.richmond
 0.03  0.03        55422       10 | net.infi.roanoke
 0.02  0.03        55854        6 | net.infi.vegas
 0.04  0.03        51866       13 | net.infi.w54
 0.01  0.03        50621        3 | net.infi.x31
 0.02  0.01        14268        5 | net.infoave.nccrty.r2
 0.01  0.00         3982        3 | net.infoave.nclxtn.r02
 0.04  0.01        26643       12 | net.infoave.scsumt.r10
 0.06  0.06       115270       19 | net.infoave.tnpkvl.r1
 0.01  0.00         7760        4 | net.inland
 0.04  0.02        39505       12 | net.interconnect.cc
 0.04  0.03        58710       12 | net.internetland
 0.01  0.02        39712        2 | net.interpath
 0.03  0.12       216284        8 | net.interrural
 0.05  0.06       105147       15 | net.intex
 0.05  0.05        97432       17 | net.intrex.rtp
 0.04  0.05        93017       13 | net.ionet
 0.04  0.03        55086       13 | net.iquest
 0.05  0.04        78959       16 | net.iserv
 0.04  0.04        74248       14 | net.isl
 0.05  0.08       136943       16 | net.iu
 0.04  0.03        56750       13 | net.iw
 0.00  0.00          300        1 | net.lava
 0.03  0.01        23318        9 | net.lax
 0.04  0.01        15185       13 | net.leba
 0.05  0.08       149941       15 | net.li
 0.04  0.05        90801       14 | net.lightspeed
 0.08  0.05        82129       25 | net.linknet
 0.02  0.01        15860        6 | net.linkonline
 0.01  0.02        36108        3 | net.llano
 0.01  0.03        50621        3 | net.lr
 0.04  0.03        57496       14 | net.ltec
 0.01  0.01        26015        4 | net.luminet
 0.04  0.01        27023       11 | net.maas
 0.07  0.05        93534       21 | net.maui
 0.06  0.05        81861       18 | net.maz
 0.04  0.01        24578       11 | net.mc
 0.04  0.03        61822       13 | net.mci.atlanta.mix2
 0.04  0.02        27355       11 | net.mci.campus.appstate
 0.01  0.02        36054        3 | net.mci.campus.fau
 0.06  0.08       135927       18 | net.mci.campus.haz-uky
 0.00  0.00         3174        1 | net.mci.campus.nccu
 0.15  0.13       236309       46 | net.mci.campus.snaustel
 0.04  0.03        51010       13 | net.mci.campus.som-uky
 0.04  0.03        56682       12 | net.mci.campus.ucr
 0.05  0.04        76800       16 | net.mci.campus.ucsd
 0.01  0.02        33591        3 | net.mci.campus.uky
 0.08  0.03        56920       26 | net.mci.dallas
 0.03  0.01        22057        9 | net.mci.denver
 0.03  0.01        23328       10 | net.mcn
 0.03  0.06       102601        8 | net.mdc
 0.04  0.02        28975       11 | net.megsinet
 0.19  0.14       262344       59 | net.mich.dialip
 0.04  0.03        47752       12 | net.micron.boi
 0.02  0.04        79707        6 | net.micron.nam
 0.04  0.03        48413       12 | net.midplains.dial
 0.04  0.08       146804       12 | net.midusa.dodgecity
 0.04  0.02        32261       14 | net.midwest
 0.01  0.03        59159        4 | net.mindlink.nwm
 0.07  0.07       124748       22 | net.minn
 0.17  0.10       186275       53 | net.mis
 0.01  0.02        39242        3 | net.mistic
 0.02  0.05        94844        6 | net.miworld
 0.05  0.05        98231       16 | net.mnsi.win
 0.04  0.03        61038       11 | net.mountain
 0.04  0.02        30592       14 | net.mr.nas
 0.04  0.02        27987       12 | net.mtl
 0.04  0.03        58870       13 | net.mts
 0.05  0.02        35113       15 | net.mwci.dbq
 0.04  0.06       114094       12 | net.mwci.lan
 0.01  0.00         8152        3 | net.mylink
 0.13  0.06       110333       40 | net.nai
 0.06  0.04        75318       18 | net.nando
 0.02  0.04        76816        6 | net.naples.annex1
 0.03  0.01        22235        9 | net.nauticom.net2
 0.07  0.09       168707       22 | net.nbn
 0.05  0.05        94375       15 | net.net-link
 0.02  0.06        99684        6 | net.net-magic
 0.08  0.21       383089       25 | net.netdirect
 0.01  0.03        47168        3 | net.netexp
 0.06  0.03        54960       18 | net.netins.dialup
 0.02  0.09       160942        7 | net.netjava
 0.04  0.03        46761       12 | net.netonecom
 0.08  0.06       106722       24 | net.netreach
 0.02  0.00         8602        6 | net.netshop
 0.10  0.18       332856       31 | net.netusa1
 0.04  0.04        72216       12 | net.netwizards
 0.05  0.06       106474       15 | net.newcomm
 0.01  0.03        50621        3 | net.newnorth
 0.05  0.06       108137       15 | net.newreach.akron
 0.02  0.02        41740        6 | net.niagara
 0.01  0.02        29949        3 | net.niia
 0.01  0.00          999        3 | net.nl
 0.01  0.01        15169        3 | net.nortel
 0.05  0.03        50474       16 | net.norwich
 0.03  0.10       184780        9 | net.ns
 0.00  0.01        10714        1 | net.nyx
 0.10  0.08       140670       32 | net.olympus
 0.04  0.02        27574       13 | net.one.access
 0.02  0.04        68115        6 | net.onramp
 0.09  0.04        78241       28 | net.onslowonline
 0.04  0.02        31987       14 | net.orbonline.gil
 0.01  0.02        30427        4 | net.oxford
 0.04  0.03        52068       14 | net.oz
 0.01  0.02        33370        3 | net.p3
 0.01  0.03        47150        3 | net.pacbell.hywr01
 0.01  0.01        26888        3 | net.pacbell.irvn11
 0.06  0.02        41916       18 | net.pacbell.rdcy01
 0.03  0.01        16808        9 | net.pacbell.scrm01
 0.20  0.11       193847       63 | net.pacbell.sndg02
 0.11  0.16       284820       33 | net.pacbell.snfc21
 0.04  0.03        55734       12 | net.pacbell.sntc01
 0.05  0.04        64504       16 | net.pacbell.wnck11
 0.01  0.01         9789        3 | net.pacific
 0.01  0.00          600        2 | net.pce
 0.01  0.02        36054        3 | net.pe
 0.07  0.10       172728       23 | net.peakaccess.si1.dialup
 0.06  0.09       163051       19 | net.pernet
 0.01  0.02        33230        3 | net.phoenix
 0.04  0.01        26421       11 | net.phoenix.galv
 0.02  0.01        15860        6 | net.pi
 0.01  0.02        27635        3 | net.pi.uk
 0.06  0.04        64007       20 | net.pinn
 0.05  0.03        61496       15 | net.pla-net.ts
 0.00  0.00         3174        1 | net.port
 0.01  0.00         5149        2 | net.power
 0.07  0.12       211505       23 | net.premier.dialup
 0.01  0.01        15169        3 | net.primary
 0.04  0.04        67731       13 | net.primeline
 0.04  0.01        10937       12 | net.priority
 0.04  0.03        51020       11 | net.prodigy.la
 0.19  0.21       377959       60 | net.prodigy.nyc
 0.03  0.00         7679       10 | net.prodigy.ykt
 0.03  0.01        20104        9 | net.prysm
 0.01  0.01        10038        4 | net.ptd.pcn
 0.05  0.03        46858       16 | net.ptd.pot
 0.05  0.02        30861       16 | net.ptd.susquenet
 0.04  0.08       142616       14 | net.ptialaska.juneau
 0.05  0.04        68639       15 | net.ptialaska.kodiak
 0.04  0.01        23912       11 | net.pulsar
 0.02  0.03        52924        7 | net.qed
 0.04  0.08       146621       11 | net.qtm
 0.08  0.07       123980       25 | net.radix.annex4
 0.02  0.01        25916        6 | net.reach
 0.04  0.02        29893       14 | net.realtime
 0.07  0.09       157380       21 | net.redrose
 0.06  0.04        76644       19 | net.richnet
 0.01  0.02        42660        3 | net.rosenet
 0.02  0.06       110081        7 | net.sabre
 0.10  0.08       138815       32 | net.sat
 0.05  0.04        75134       17 | net.scsn
 0.01  0.02        33156        4 | net.sentex.gclabs
 0.10  0.13       230136       31 | net.shadow
 0.00  0.00          300        1 | net.shentel
 0.16  0.16       284350       49 | net.shore.lynnma
 0.13  0.18       320851       41 | net.sky
 0.01  0.01        18802        3 | net.skyenet
 0.08  0.09       160331       25 | net.skyinet
 0.01  0.03        47526        3 | net.skyinet.qzn.mb01
 0.01  0.01        25136        3 | net.skylink.nv.las_vegas.max2
 0.04  0.06       101797       13 | net.snet
 0.07  0.07       133900       21 | net.snider
 0.01  0.01        19800        3 | net.snip
 0.04  0.03        48550       12 | net.sonic.pm4
 0.08  0.11       207478       26 | net.sound
 0.03  0.04        69140        9 | net.southwind
 0.01  0.02        41724        3 | net.spacestar
 0.01  0.02        32439        3 | net.spec
 0.02  0.01        21527        5 | net.spidernet
 0.05  0.02        38642       16 | net.sprintans.ocal
 0.04  0.04        64830       12 | net.sundial
 0.05  0.03        55364       15 | net.sunline
 0.09  0.09       164907       28 | net.sunshine
 0.04  0.02        42165       11 | net.super.hk
 0.06  0.09       158606       20 | net.swweb
 0.03  0.05        95181        8 | net.sysnet
 0.04  0.02        44509       12 | net.tcccom
 0.04  0.01        25246       11 | net.tcnet
 0.02  0.01        15949        6 | net.tds.ccm
 0.03  0.00         7565        9 | net.techcom.ppp
 0.06  0.07       135268       19 | net.teclink
 0.01  0.01        16955        2 | net.terracom
 0.01  0.02        34764        3 | net.texas.sat
 0.04  0.03        60522       13 | net.texhoma
 0.03  0.01        21192        9 | net.tfs
 0.03  0.01        22890       10 | net.themall
 0.04  0.08       142975       11 | net.theshop
 0.03  0.01        21678       10 | net.thuntek
 0.03  0.01        19942        9 | net.tiac
 0.07  0.04        73231       22 | net.together.ramp
 0.01  0.00         5576        3 | net.total.mtl
 0.02  0.02        43801        5 | net.tricom
 0.08  0.04        75282       25 | net.trip
 0.06  0.04        76386       20 | net.tusco
 0.09  0.21       374311       28 | net.txdirect
 0.06  0.04        74890       18 | net.ultra.ma.wal
 0.08  0.08       152457       24 | net.usachoice
 0.09  0.24       436008       27 | net.usaor
 0.13  0.15       273709       42 | net.usit.dynamic
 0.07  0.05        96293       21 | net.uu.ms.ab.edmonton.max1
 0.03  0.01        24606       10 | net.uu.ms.az.phoenix.max2
 0.10  0.06       106999       31 | net.uu.ms.bc.vancouver.max1
 0.02  0.01        19212        7 | net.uu.ms.ca.los-angeles.max15
 0.06  0.13       228830       20 | net.uu.ms.ca.los-angeles.max22
 0.10  0.09       161345       32 | net.uu.ms.ca.los-angeles.max3
 0.08  0.08       148959       26 | net.uu.ms.ca.san-diego.max1
 0.04  0.03        57045       12 | net.uu.ms.ca.san-diego.max11
 0.01  0.01        26888        3 | net.uu.ms.ca.san-francisco.max1
 0.04  0.05        81602       14 | net.uu.ms.ca.san-francisco.max12
 0.01  0.02        31397        3 | net.uu.ms.ca.san-francisco.max13
 0.05  0.09       166308       16 | net.uu.ms.ca.san-francisco.max20
 0.01  0.01        18658        3 | net.uu.ms.ca.san-francisco.max3
 0.02  0.00         8013        7 | net.uu.ms.ca.san-francisco.max4
 0.05  0.04        81171       17 | net.uu.ms.ca.san-francisco.max9
 0.03  0.01        25980       10 | net.uu.ms.co.denver.max11
 0.02  0.02        31916        6 | net.uu.ms.co.denver.max4
 0.03  0.03        56116       10 | net.uu.ms.dc.washington.max1
 0.03  0.01        20159        9 | net.uu.ms.fl.miami.max11
 0.02  0.01        16060        7 | net.uu.ms.fl.miami.max3
 0.01  0.05        84300        3 | net.uu.ms.fl.miami.max7
 0.01  0.01        20162        3 | net.uu.ms.fl.orlando.max1
 0.03  0.01        22317       10 | net.uu.ms.fl.orlando.max10
 0.04  0.03        49125       14 | net.uu.ms.fl.orlando.max6
 0.05  0.02        28831       17 | net.uu.ms.ga.atlanta.max21
 0.04  0.05        84800       12 | net.uu.ms.ga.atlanta.max4
 0.04  0.04        65180       14 | net.uu.ms.ga.atlanta.max7
 0.04  0.03        60211       14 | net.uu.ms.il.chicago.max27
 0.03  0.01        21356        9 | net.uu.ms.il.chicago.max3
 0.04  0.03        53788       12 | net.uu.ms.il.chicago.max37
 0.01  0.03        55204        4 | net.uu.ms.il.chicago2.max2
 0.05  0.10       184725       17 | net.uu.ms.in.indianapolis.max4
 0.01  0.02        27795        3 | net.uu.ms.la.new-orleans.max3
 0.07  0.07       121213       21 | net.uu.ms.ma.boston.max10
 0.05  0.06       102713       16 | net.uu.ms.ma.boston.max11
 0.05  0.03        45705       16 | net.uu.ms.ma.boston.max20
 0.02  0.04        69606        6 | net.uu.ms.ma.boston.max28
 0.06  0.09       155912       18 | net.uu.ms.ma.boston.max4
 0.04  0.04        67506       14 | net.uu.ms.mi.detroit.max4
 0.04  0.02        39942       12 | net.uu.ms.mi.detroit.max5
 0.01  0.02        32290        2 | net.uu.ms.mi.detroit.max8
 0.01  0.02        35936        3 | net.uu.ms.mn.minneapolis.max4
 0.04  0.02        28815       12 | net.uu.ms.nc.raleigh.max3
 0.01  0.02        31064        3 | net.uu.ms.nc.raleigh.max7
 0.07  0.05        98442       21 | net.uu.ms.nj.newark.max1
 0.05  0.02        33488       17 | net.uu.ms.nj.newark.max13
 0.00  0.00          300        1 | net.uu.ms.nj.newark.max17
 0.01  0.02        36054        3 | net.uu.ms.nj.newark.max9
 0.06  0.03        61858       19 | net.uu.ms.nv.las-vegas.max2
 0.04  0.04        77274       13 | net.uu.ms.ny.new-york.max10
 0.01  0.02        36054        3 | net.uu.ms.ny.new-york.max13
 0.00  0.00          300        1 | net.uu.ms.ny.new-york.max14
 0.02  0.02        37736        7 | net.uu.ms.ny.new-york.max15
 0.03  0.03        47337        9 | net.uu.ms.ny.new-york.max17
 0.01  0.00          999        3 | net.uu.ms.ny.new-york.max18
 0.02  0.05        82110        7 | net.uu.ms.ny.new-york.max2
 0.01  0.02        38787        4 | net.uu.ms.ny.new-york.max42
 0.05  0.05        97261       17 | net.uu.ms.oh.cleveland.max1
 0.03  0.01        21859       10 | net.uu.ms.oh.cleveland.max10
 0.06  0.07       126973       20 | net.uu.ms.oh.cleveland.max2
 0.04  0.03        56744       12 | net.uu.ms.oh.cleveland.max30
 0.05  0.07       123660       16 | net.uu.ms.oh.cleveland.max8
 0.01  0.02        31397        3 | net.uu.ms.oh.cleveland.max9
 0.01  0.02        33552        3 | net.uu.ms.or.portland.max3
 0.01  0.02        36054        3 | net.uu.ms.or.portland.max6
 0.01  0.02        36404        3 | net.uu.ms.pa.philadelphia.max1
 0.01  0.02        41739        3 | net.uu.ms.pa.philadelphia.max18
 0.05  0.06       105872       17 | net.uu.ms.pa.philadelphia.max37
 0.00  0.00          300        1 | net.uu.ms.tx.dallas.max21
 0.02  0.01        15860        6 | net.uu.ms.tx.dallas.max7
 0.01  0.02        41739        3 | net.uu.ms.tx.dallas.max8
 0.20  0.92      1665866       62 | net.uu.ms.tx.houston.max10
 0.02  0.08       136147        6 | net.uu.ms.tx.houston.max11
 0.03  0.01        25843       10 | net.uu.ms.tx.houston2.max4
 0.01  0.02        38297        3 | net.uu.ms.tx.irving.max9
 0.02  0.05        89405        7 | net.uu.ms.wa.seattle.max1
 0.01  0.02        43759        4 | net.uu.ms.wa.seattle.max18
 0.04  0.01        25495       12 | net.uu.ms.wa.seattle.max20
 0.01  0.02        27635        3 | net.uu.ms.wa.seattle.max5
 0.01  0.01        24647        3 | net.uu.ms.wa.seattle.max6
 0.01  0.00          999        3 | net.vais
 0.06  0.07       117771       19 | net.valley-internet
 0.24  0.13       238362       76 | net.ven
 0.03  0.06       104639        8 | net.visi.nn
 0.05  0.05        99338       17 | net.vivid
 0.06  0.08       152468       18 | net.voyager.dial
 0.06  0.08       150107       18 | net.voyageronline.chatt
 0.29  0.27       481827       91 | net.warwick
 0.00  0.00          300        1 | net.webbernet
 0.31  0.51       920482       95 | net.webtv.alma.isp
 0.01  0.03        49275        4 | net.west.sb
 0.02  0.01        15860        6 | net.world-net
 0.04  0.04        70826       12 | net.worldlynx
 0.07  0.06       117408       23 | net.worldweb
 0.02  0.05        82540        6 | net.wt
 0.04  0.03        49669       14 | net.wtp
 0.03  0.04        74683       10 | net.zilker
 0.04  0.01        16218       12 | net.ziplink
 0.03  0.01        21056        9 | nl.cbs.vb
 0.01  0.02        42863        3 | nl.esa.estec
 0.00  0.00          341        1 | nl.ruu.cc
 0.01  0.02        39242        3 | nl.ruu.chem
 0.03  0.08       142382       10 | nl.surfnet.nic
 0.01  0.03        46993        4 | nl.vu.psy
 0.04  0.06       107532       11 | nl.wkap
 0.08  0.02        43433       24 | nl.worldaccess
 0.03  0.01        22431        9 | nl.worldonline
 0.04  0.04        79699       14 | no.eunet.kb-pm2-1
 0.03  0.01        20639        9 | no.sn.ppp
 0.01  0.00         1148        3 | no.telenor
 0.01  0.00         6848        4 | no.uio
 0.01  0.02        36404        3 | nz.ac.auckland.psy.hautus
 0.04  0.04        70036       14 | nz.co.iconz
 0.00  0.00          383        1 | nz.co.ihug
 0.01  0.01        20870        3 | nz.co.voyager.palmerstonnorth.net
 0.01  0.02        27951        4 | nz.co.xtra
 0.01  0.02        31397        3 | nz.gen.kcbbs
 0.05  0.06       101437       17 | nz.net.clear.wgtn
 0.05  0.08       148285       16 | org.afn
 0.03  0.01        22763        9 | org.ama-assn
 0.00  0.02        32165        1 | org.arbornet
 0.01  0.01        26888        3 | org.asm-intl
 0.05  0.07       132587       15 | org.cam.hip
 0.03  0.00         8560       10 | org.columbia-center
 0.01  0.03        58078        2 | org.cpcug
 0.05  0.02        40986       17 | org.crisny
 0.01  0.01         9522        3 | org.dmc
 0.02  0.04        72317        7 | org.fortnet
 0.01  0.05        92884        2 | org.freenet
 0.01  0.01        20540        3 | org.hal-pc
 0.09  0.07       134609       29 | org.hslc
 0.01  0.01        23971        3 | org.jeffnet
 0.01  0.03        50621        3 | org.kaiperm
 0.09  0.10       182855       28 | org.kern
 0.03  0.02        35851        9 | org.kpscal
 0.03  0.00         5551       10 | org.mcn
 0.04  0.04        71250       14 | org.mitretek
 0.05  0.02        30036       17 | org.mrtc
 0.01  0.01        19580        3 | org.nexusprime
 0.01  0.02        34764        3 | org.northnet.canton
 0.04  0.03        60087       13 | org.northnet.watertown
 0.02  0.03        58109        6 | org.orednet
 0.04  0.03        54257       12 | org.ori
 0.02  0.01        15860        6 | org.park
 0.05  0.06       100741       15 | org.path
 0.01  0.01        20262        3 | org.pmhs
 0.02  0.01        15860        6 | org.providence
 0.04  0.02        43068       12 | org.rain.sb.term2
 0.01  0.02        34764        3 | org.rain.sb.term3
 0.02  0.05        86675        6 | org.redondo
 0.00  0.01        23488        1 | org.sematech
 0.02  0.05        84974        5 | org.shf
 0.04  0.02        43202       12 | org.sunhealth
 0.01  0.02        36054        3 | org.uhhg
 0.01  0.02        36389        3 | org.usp
 0.06  0.08       149037       19 | org.wadsworth
 0.02  0.03        55665        6 | org.worldbank
 0.04  0.01        24075       11 | pe.edu.unitru
 0.03  0.04        70655       10 | pe.net.rcp
 0.00  0.00         3081        1 | ph.com.iconn
 0.03  0.02        43885       10 | pk.net.brain
 0.04  0.04        80023       11 | pt.ip
 0.01  0.01        16122        2 | ro.ici
 0.00  0.01        20896        1 | ro.sorostm
 0.05  0.05        93990       15 | se.artech
 0.01  0.03        51694        3 | se.communique
 0.01  0.04        63630        3 | se.gu.phil
 0.01  0.01        21934        3 | se.ivf
 0.03  0.01        20268        9 | se.katedral
 0.01  0.01        18338        3 | se.swipnet
 0.02  0.01        15860        6 | sg.com.cyberway
 0.06  0.13       243044       18 | sg.com.singnet
 0.02  0.04        67932        5 | sg.net.pacific
 0.03  0.01        13553        8 | si.eunet.slip
 0.04  0.01        24618       11 | si.kclj.trnovo
 0.09  0.03        57623       29 | si.lek
 0.04  0.02        35294       12 | th.co.inet
 0.02  0.00         6341        5 | tw.edu
 0.00  0.01        19481        1 | tw.net.ficnet
 0.01  0.03        52468        2 | uk.ac.aston
 0.04  0.01        26618       11 | uk.ac.bbsrc.cc
 0.10  0.08       150953       32 | uk.ac.bbsrc.irad
 0.00  0.00         3174        1 | uk.ac.dmu
 0.08  0.03        62200       25 | uk.ac.dundee.dentschool
 0.01  0.03        57049        2 | uk.ac.gla.cent
 0.02  0.03        56412        7 | uk.ac.hensa
 0.00  0.00         3089        1 | uk.ac.ic.cc
 0.01  0.02        44459        2 | uk.ac.leeds
 0.02  0.02        33314        5 | uk.ac.liv
 0.06  0.04        68338       19 | uk.ac.man.jb
 0.01  0.02        33230        3 | uk.ac.mrc.headoffice
 0.01  0.03        51983        3 | uk.ac.qub.oac
 0.02  0.01        15860        6 | uk.ac.unn
 0.01  0.03        51694        3 | uk.co.aspen-internet
 0.02  0.01        15860        6 | uk.co.britbio
 0.10  0.06       109527       30 | uk.co.capgemini
 0.14  0.11       203614       43 | uk.co.demon
 0.08  0.08       143120       25 | uk.co.easynet
 0.04  0.04        70737       12 | uk.co.guardian
 0.06  0.04        73366       19 | uk.co.i-way
 0.03  0.01        19375        8 | uk.co.internexus
 0.01  0.02        36108        3 | uk.co.merck
 0.00  0.00          382        1 | uk.co.vossnet
 0.01  0.02        27383        3 | uk.nhs
 0.04  0.01        21353       11 | us.al.fayette.onramp
 0.04  0.05        89791       14 | us.ca.cc.glendale
 0.01  0.02        31520        2 | us.ca.davis.dcn
 0.02  0.05        93381        6 | us.ca.k12.esd
 0.01  0.01        25877        4 | us.ca.k12.lausd
 0.01  0.03        47168        3 | us.ca.k12.lodiusd
 0.01  0.03        62934        3 | us.ca.oakland.ci
 0.02  0.06       116122        7 | us.co.k12.mesa
 0.01  0.02        33883        2 | us.de.state
 0.02  0.00         3485        6 | us.fl.hillsborough.co.epc
 0.05  0.06       111727       17 | us.fl.k12.leon.swiftcreek
 0.02  0.02        39978        6 | us.fl.state.dep
 0.03  0.01        20909       10 | us.fl.state.dms
 0.04  0.04        64828       14 | us.ga.state.house.research
 0.03  0.01        19941        9 | us.ia.cc.kirkwood
 0.03  0.01        22874       10 | us.il.cc.clc
 0.00  0.00          316        1 | us.il.lib.rsa
 0.05  0.05        97054       17 | us.in.plymouth
 0.01  0.04        77667        3 | us.la.lib.beau
 0.00  0.03        47221        1 | us.md.lib
 0.00  0.02        36836        1 | us.mn.lib.ramsey
 0.01  0.01        11994        3 | us.mn.owatonna.ic
 0.01  0.03        59013        4 | us.mn.willmar.rice
 0.00  0.01        10714        1 | us.nc.cc.wp.se
 0.14  0.06       102919       44 | us.ne.k12.esu10.gi
 0.05  0.05        86689       15 | us.ne.state.nde
 0.00  0.02        33562        1 | us.nh.lib.nhsl
 0.05  0.04        78932       17 | us.nj.lib.cherryhill
 0.01  0.03        50395        2 | us.ny.lib.suffolk
 0.01  0.02        38970        3 | us.oh.cc.owens
 0.13  0.10       174696       40 | us.ok.cc.neoam.generic
 0.10  0.07       132029       31 | us.or.cc.lbcc
 0.01  0.04        66227        3 | us.or.state.sos
 0.01  0.01        18392        3 | us.pa.k12.mciu.mountstjo
 0.01  0.05        90803        3 | us.tn.cc.jscc
 0.04  0.04        77926       12 | us.tx.state.cpa
 0.03  0.01        21360        9 | us.tx.state.tnrcc
 0.01  0.05        86530        3 | us.va.k12.nn.heritage
 0.00  0.02        35384        1 | us.wa.lib.pcl
 0.03  0.01        20401        9 | za.co.aztec
 0.01  0.05        89743        2 | za.co.global.net.ctya-anx1
 0.05  0.06       103115       17 | za.co.sabc
</PRE>
<HR>
<H2><A NAME="Archive">Total Transfers by URL/Archive Section</A></H2>
<PRE>
%Reqs %Byte  Bytes Sent  Requests   Archive Section
----- ----- ------------ -------- |------------------------------------
 6.68  3.57      6469707     2079 | <a href="/">/</a>
 6.19  3.69      6686519     1927 | <a href="/5per.gif">/5per.gif</a>
 0.13  0.09       162054       41 | <a href="/about.htm">/about.htm</a>
 0.13  0.06       113202       42 | <a href="/aceinh.htm">/aceinh.htm</a>
 0.21  0.20       365193       64 | <a href="/antidepr.htm">/antidepr.htm</a>
 0.86  0.47       859989      269 | <a href="/av.htm">/av.htm</a>
 0.61  0.33       603486      190 | <a href="/av2.htm">/av2.htm</a>
 1.57  0.86      1561183      489 | <a href="/av3.htm">/av3.htm</a>
 0.03  0.01        26293        8 | <a href="/av4.htm">/av4.htm</a>
 0.14  0.09       167500       44 | <a href="/bblock.htm">/bblock.htm</a>
 0.10  0.06       101718       30 | <a href="/calch.htm">/calch.htm</a>
 0.34  0.10       183300      105 | <a href="/cardiova.htm">/cardiova.htm</a>
 0.01  0.00          808        2 | <a href="/cgi/">/cgi/</a>
 0.02  0.04        76228        6 | <a href="/cgi/brand/image/ogen.gif">/cgi/brand/image/ogen.gif</a>
 0.09  0.11       198303       27 | <a href="/cgi/brand/image/provera.gif">/cgi/brand/image/provera.gif</a>
 0.02  0.12       225560        6 | <a href="/cgi/brand/ogen.htm">/cgi/brand/ogen.htm</a>
 0.09  0.27       490376       28 | <a href="/cgi/brand/provera.htm">/cgi/brand/provera.htm</a>
 0.09  0.01        20551       29 | <a href="/cgi/brand/redball.gif">/cgi/brand/redball.gif</a>
 0.11  0.04        80439       33 | <a href="/cgi/brand/rx.gif">/cgi/brand/rx.gif</a>
 0.02  0.00         2682        6 | <a href="/cgi/brand/tm.gif">/cgi/brand/tm.gif</a>
 5.67  0.57      1028808     1767 | <a href="/cgi/count.gif">/cgi/count.gif</a>
 0.04  0.00         4843       11 | <a href="/cgi/generic/">/cgi/generic/</a>
 0.06  0.15       279890       19 | <a href="/cgi/generic/acetcod.htm">/cgi/generic/acetcod.htm</a>
 0.07  0.55      1004202       22 | <a href="/cgi/generic/acyclo.htm">/cgi/generic/acyclo.htm</a>
 0.08  0.23       409209       25 | <a href="/cgi/generic/albut1.htm">/cgi/generic/albut1.htm</a>
 0.04  0.28       498740       14 | <a href="/cgi/generic/alendron.htm">/cgi/generic/alendron.htm</a>
 0.03  0.15       279509        9 | <a href="/cgi/generic/allopur.htm">/cgi/generic/allopur.htm</a>
 0.15  1.27      2299997       48 | <a href="/cgi/generic/alpraz.htm">/cgi/generic/alpraz.htm</a>
 0.08  0.31       566130       25 | <a href="/cgi/generic/amitrip.htm">/cgi/generic/amitrip.htm</a>
 0.05  0.20       359648       15 | <a href="/cgi/generic/amlod2.htm">/cgi/generic/amlod2.htm</a>
 0.18  0.42       765924       55 | <a href="/cgi/generic/amox.htm">/cgi/generic/amox.htm</a>
 0.09  0.39       704754       28 | <a href="/cgi/generic/amoxclav.htm">/cgi/generic/amoxclav.htm</a>
 0.04  0.15       268934       13 | <a href="/cgi/generic/amphet.htm">/cgi/generic/amphet.htm</a>
 0.04  0.07       123837       14 | <a href="/cgi/generic/apap.htm">/cgi/generic/apap.htm</a>
 0.05  0.15       279241       15 | <a href="/cgi/generic/asa.htm">/cgi/generic/asa.htm</a>
 0.01  0.05        93244        4 | <a href="/cgi/generic/astem.htm">/cgi/generic/astem.htm</a>
 0.12  0.81      1466023       37 | <a href="/cgi/generic/atenolol.htm">/cgi/generic/atenolol.htm</a>
 0.05  0.27       497800       17 | <a href="/cgi/generic/azith.htm">/cgi/generic/azith.htm</a>
 0.01  0.04        68613        3 | <a href="/cgi/generic/beclo.htm">/cgi/generic/beclo.htm</a>
 0.03  0.09       162157       10 | <a href="/cgi/generic/beclo1.htm">/cgi/generic/beclo1.htm</a>
 0.02  0.11       206988        6 | <a href="/cgi/generic/benaz.htm">/cgi/generic/benaz.htm</a>
 0.04  0.37       661001       11 | <a href="/cgi/generic/bishctz.htm">/cgi/generic/bishctz.htm</a>
 0.05  0.35       641712       15 | <a href="/cgi/generic/buprop.htm">/cgi/generic/buprop.htm</a>
 0.06  0.33       588744       18 | <a href="/cgi/generic/buspir.htm">/cgi/generic/buspir.htm</a>
 0.04  0.26       461937       14 | <a href="/cgi/generic/butalcod.htm">/cgi/generic/butalcod.htm</a>
 0.03  0.22       394174        8 | <a href="/cgi/generic/captop.htm">/cgi/generic/captop.htm</a>
 0.04  0.20       369281       12 | <a href="/cgi/generic/carbam.htm">/cgi/generic/carbam.htm</a>
 0.05  0.07       134183       16 | <a href="/cgi/generic/carisop.htm">/cgi/generic/carisop.htm</a>
 0.02  0.07       121523        7 | <a href="/cgi/generic/cefaclor.htm">/cgi/generic/cefaclor.htm</a>
 0.02  0.05        91741        7 | <a href="/cgi/generic/cefadrox.htm">/cgi/generic/cefadrox.htm</a>
 0.02  0.13       231938        7 | <a href="/cgi/generic/cefixime.htm">/cgi/generic/cefixime.htm</a>
 0.04  0.20       358031       12 | <a href="/cgi/generic/cefprozi.htm">/cgi/generic/cefprozi.htm</a>
 0.04  0.15       264146       12 | <a href="/cgi/generic/cefurox.htm">/cgi/generic/cefurox.htm</a>
 0.03  0.23       420860       10 | <a href="/cgi/generic/cemp.htm">/cgi/generic/cemp.htm</a>
 0.09  0.25       458820       28 | <a href="/cgi/generic/cephalex.htm">/cgi/generic/cephalex.htm</a>
 0.03  0.10       177008        8 | <a href="/cgi/generic/cetiriz.htm">/cgi/generic/cetiriz.htm</a>
 0.02  0.05        97080        6 | <a href="/cgi/generic/chlordia.htm">/cgi/generic/chlordia.htm</a>
 0.03  0.23       407970       10 | <a href="/cgi/generic/cimet.htm">/cgi/generic/cimet.htm</a>
 0.10  0.67      1209318       32 | <a href="/cgi/generic/cipro.htm">/cgi/generic/cipro.htm</a>
 0.03  0.09       165589        9 | <a href="/cgi/generic/cisap.htm">/cgi/generic/cisap.htm</a>
 0.08  0.40       722701       25 | <a href="/cgi/generic/clarith.htm">/cgi/generic/clarith.htm</a>
 0.01  0.04        71492        4 | <a href="/cgi/generic/clobet.htm">/cgi/generic/clobet.htm</a>
 0.07  0.38       685117       21 | <a href="/cgi/generic/clomiph.htm">/cgi/generic/clomiph.htm</a>
 0.03  0.23       419168        8 | <a href="/cgi/generic/clomipr.htm">/cgi/generic/clomipr.htm</a>
 0.05  0.13       229203       16 | <a href="/cgi/generic/clonaz.htm">/cgi/generic/clonaz.htm</a>
 0.05  0.13       237759       15 | <a href="/cgi/generic/clonidin.htm">/cgi/generic/clonidin.htm</a>
 0.03  0.03        54485        8 | <a href="/cgi/generic/cocaine.htm">/cgi/generic/cocaine.htm</a>
 0.11  0.56      1017288       33 | <a href="/cgi/generic/conest.htm">/cgi/generic/conest.htm</a>
 0.02  0.03        47676        5 | <a href="/cgi/generic/cromnas.htm">/cgi/generic/cromnas.htm</a>
 0.08  0.29       531508       26 | <a href="/cgi/generic/cyclobnz.htm">/cgi/generic/cyclobnz.htm</a>
 0.03  0.25       455048        8 | <a href="/cgi/generic/desest.htm">/cgi/generic/desest.htm</a>
 0.72  5.10      9239476      224 | <a href="/cgi/generic/dexfen.htm">/cgi/generic/dexfen.htm</a>
 0.03  0.00         8821        9 | <a href="/cgi/generic/dexfenx.htm">/cgi/generic/dexfenx.htm</a>
 0.06  0.01        26375       19 | <a href="/cgi/generic/dhea.htm">/cgi/generic/dhea.htm</a>
 0.05  0.12       224736       17 | <a href="/cgi/generic/diazepam.htm">/cgi/generic/diazepam.htm</a>
 0.03  0.16       292848        9 | <a href="/cgi/generic/diclofen.htm">/cgi/generic/diclofen.htm</a>
 0.04  0.12       214211       11 | <a href="/cgi/generic/dicyc.htm">/cgi/generic/dicyc.htm</a>
 0.05  0.44       802398       17 | <a href="/cgi/generic/dig.htm">/cgi/generic/dig.htm</a>
 0.02  0.03        57123        6 | <a href="/cgi/generic/dihydram.htm">/cgi/generic/dihydram.htm</a>
 0.04  0.23       421443       11 | <a href="/cgi/generic/diltiaz.htm">/cgi/generic/diltiaz.htm</a>
 0.02  0.13       239624        7 | <a href="/cgi/generic/dival.htm">/cgi/generic/dival.htm</a>
 0.03  0.15       267102        9 | <a href="/cgi/generic/doxazo.htm">/cgi/generic/doxazo.htm</a>
 0.06  0.17       314793       19 | <a href="/cgi/generic/doxepin.htm">/cgi/generic/doxepin.htm</a>
 0.08  0.43       774216       26 | <a href="/cgi/generic/doxycyc.htm">/cgi/generic/doxycyc.htm</a>
 0.02  0.07       125814        6 | <a href="/cgi/generic/ees.htm">/cgi/generic/ees.htm</a>
 0.04  0.40       729890       14 | <a href="/cgi/generic/enalap.htm">/cgi/generic/enalap.htm</a>
 0.01  0.04        63957        3 | <a href="/cgi/generic/eryst.htm">/cgi/generic/eryst.htm</a>
 0.05  0.17       303338       16 | <a href="/cgi/generic/erythro.htm">/cgi/generic/erythro.htm</a>
 0.04  0.26       462858       13 | <a href="/cgi/generic/estrad.htm">/cgi/generic/estrad.htm</a>
 0.00  0.02        43750        1 | <a href="/cgi/generic/estratd.htm">/cgi/generic/estratd.htm</a>
 0.02  0.14       251895        5 | <a href="/cgi/generic/ethynoc.htm">/cgi/generic/ethynoc.htm</a>
 0.03  0.19       351154        9 | <a href="/cgi/generic/etodolac.htm">/cgi/generic/etodolac.htm</a>
 0.02  0.08       143860        5 | <a href="/cgi/generic/famot.htm">/cgi/generic/famot.htm</a>
 0.14  0.40       729042       44 | <a href="/cgi/generic/fenflur.htm">/cgi/generic/fenflur.htm</a>
 0.01  0.05        83744        4 | <a href="/cgi/generic/fexofen.htm">/cgi/generic/fexofen.htm</a>
 0.04  0.24       433136       11 | <a href="/cgi/generic/finas.htm">/cgi/generic/finas.htm</a>
 0.02  0.11       196854        6 | <a href="/cgi/generic/flucon.htm">/cgi/generic/flucon.htm</a>
 0.02  0.08       138803        7 | <a href="/cgi/generic/fludro.htm">/cgi/generic/fludro.htm</a>
 0.17  1.29      2336745       54 | <a href="/cgi/generic/fluoxetine.htm">/cgi/generic/fluoxetine.htm</a>
 0.03  0.13       243900        9 | <a href="/cgi/generic/flutic.htm">/cgi/generic/flutic.htm</a>
 0.02  0.16       285422        7 | <a href="/cgi/generic/fluva.htm">/cgi/generic/fluva.htm</a>
 0.03  0.33       594806       10 | <a href="/cgi/generic/fluvox.htm">/cgi/generic/fluvox.htm</a>
 0.02  0.17       304520        7 | <a href="/cgi/generic/fosinop.htm">/cgi/generic/fosinop.htm</a>
 0.03  0.14       245340       10 | <a href="/cgi/generic/furos.htm">/cgi/generic/furos.htm</a>
 0.04  0.36       650692       14 | <a href="/cgi/generic/gabapent.htm">/cgi/generic/gabapent.htm</a>
 0.02  0.15       271938        6 | <a href="/cgi/generic/gemfib.htm">/cgi/generic/gemfib.htm</a>
 0.02  0.11       194082        7 | <a href="/cgi/generic/glip.htm">/cgi/generic/glip.htm</a>
 0.01  0.09       154096        4 | <a href="/cgi/generic/glipxl.htm">/cgi/generic/glipxl.htm</a>
 0.02  0.09       158583        7 | <a href="/cgi/generic/glybur.htm">/cgi/generic/glybur.htm</a>
 0.01  0.05        87878        3 | <a href="/cgi/generic/glymic.htm">/cgi/generic/glymic.htm</a>
 0.05  0.05        83882       16 | <a href="/cgi/generic/guaicod.htm">/cgi/generic/guaicod.htm</a>
 0.09  0.11       192741       27 | <a href="/cgi/generic/guaiphen.htm">/cgi/generic/guaiphen.htm</a>
 0.02  0.08       145215        7 | <a href="/cgi/generic/hctz.htm">/cgi/generic/hctz.htm</a>
 0.05  0.28       513315       17 | <a href="/cgi/generic/hctztri.htm">/cgi/generic/hctztri.htm</a>
 0.01  0.05        93616        4 | <a href="/cgi/generic/hquine.htm">/cgi/generic/hquine.htm</a>
 0.01  0.01        14544        3 | <a href="/cgi/generic/huminsr.htm">/cgi/generic/huminsr.htm</a>
 0.01  0.03        61983        3 | <a href="/cgi/generic/humnph.htm">/cgi/generic/humnph.htm</a>
 0.23  0.58      1042574       72 | <a href="/cgi/generic/hydrocod.htm">/cgi/generic/hydrocod.htm</a>
 0.03  0.05        86287       10 | <a href="/cgi/generic/hydrox.htm">/cgi/generic/hydrox.htm</a>
 0.04  0.12       219261       14 | <a href="/cgi/generic/hyoscy.htm">/cgi/generic/hyoscy.htm</a>
 0.07  0.38       692586       21 | <a href="/cgi/generic/ibup.htm">/cgi/generic/ibup.htm</a>
 0.04  0.20       364885       13 | <a href="/cgi/generic/imip.htm">/cgi/generic/imip.htm</a>
 0.02  0.10       172342        7 | <a href="/cgi/generic/indap.htm">/cgi/generic/indap.htm</a>
 0.05  0.38       694337       15 | <a href="/cgi/generic/indometh.htm">/cgi/generic/indometh.htm</a>
 0.02  0.04        70165        5 | <a href="/cgi/generic/ipratrop.htm">/cgi/generic/ipratrop.htm</a>
 0.02  0.09       164101        6 | <a href="/cgi/generic/isomono.htm">/cgi/generic/isomono.htm</a>
 0.01  0.03        62596        3 | <a href="/cgi/generic/isomono2.htm">/cgi/generic/isomono2.htm</a>
 0.04  0.23       412320       12 | <a href="/cgi/generic/isotret.htm">/cgi/generic/isotret.htm</a>
 0.04  0.11       203874       11 | <a href="/cgi/generic/kclsr.htm">/cgi/generic/kclsr.htm</a>
 0.02  0.03        51564        6 | <a href="/cgi/generic/ketocon.htm">/cgi/generic/ketocon.htm</a>
 0.03  0.25       451413       10 | <a href="/cgi/generic/ketoprof.htm">/cgi/generic/ketoprof.htm</a>
 0.04  0.33       594762       12 | <a href="/cgi/generic/ketor.htm">/cgi/generic/ketor.htm</a>
 0.07  0.47       844516       21 | <a href="/cgi/generic/lansop.htm">/cgi/generic/lansop.htm</a>
 0.06  0.27       490101       18 | <a href="/cgi/generic/levothy.htm">/cgi/generic/levothy.htm</a>
 0.09  0.77      1385749       28 | <a href="/cgi/generic/lisinop.htm">/cgi/generic/lisinop.htm</a>
 0.01  0.08       147187        4 | <a href="/cgi/generic/lngeed.htm">/cgi/generic/lngeed.htm</a>
 0.03  0.18       325127        8 | <a href="/cgi/generic/loracarb.htm">/cgi/generic/loracarb.htm</a>
 0.05  0.18       331177       17 | <a href="/cgi/generic/lorat.htm">/cgi/generic/lorat.htm</a>
 0.01  0.05        98994        3 | <a href="/cgi/generic/loratd.htm">/cgi/generic/loratd.htm</a>
 0.07  0.16       294921       22 | <a href="/cgi/generic/loraz.htm">/cgi/generic/loraz.htm</a>
 0.05  0.25       457599       15 | <a href="/cgi/generic/losar.htm">/cgi/generic/losar.htm</a>
 0.03  0.28       501063       10 | <a href="/cgi/generic/losarhct.htm">/cgi/generic/losarhct.htm</a>
 0.04  0.30       543123       14 | <a href="/cgi/generic/lovastat.htm">/cgi/generic/lovastat.htm</a>
 0.03  0.10       189220       10 | <a href="/cgi/generic/medrox.htm">/cgi/generic/medrox.htm</a>
 0.03  0.09       163044        9 | <a href="/cgi/generic/meper.htm">/cgi/generic/meper.htm</a>
 0.03  0.08       143289        8 | <a href="/cgi/generic/mesal.htm">/cgi/generic/mesal.htm</a>
 0.01  0.01        23616        4 | <a href="/cgi/generic/metax.htm">/cgi/generic/metax.htm</a>
 0.05  0.55       995853       16 | <a href="/cgi/generic/metformi.htm">/cgi/generic/metformi.htm</a>
 0.05  0.19       342196       16 | <a href="/cgi/generic/methdone.htm">/cgi/generic/methdone.htm</a>
 0.09  0.24       442800       27 | <a href="/cgi/generic/methphen.htm">/cgi/generic/methphen.htm</a>
 0.03  0.14       256374        9 | <a href="/cgi/generic/methprd.htm">/cgi/generic/methprd.htm</a>
 0.06  0.37       676163       20 | <a href="/cgi/generic/metopro.htm">/cgi/generic/metopro.htm</a>
 0.04  0.17       315337       11 | <a href="/cgi/generic/metopxl.htm">/cgi/generic/metopxl.htm</a>
 0.09  0.37       678662       27 | <a href="/cgi/generic/metronid.htm">/cgi/generic/metronid.htm</a>
 0.04  0.03        56499       12 | <a href="/cgi/generic/midrin.htm">/cgi/generic/midrin.htm</a>
 0.02  0.14       250894        7 | <a href="/cgi/generic/misopro.htm">/cgi/generic/misopro.htm</a>
 0.01  0.02        28646        2 | <a href="/cgi/generic/momet.htm">/cgi/generic/momet.htm</a>
 0.07  0.18       323775       22 | <a href="/cgi/generic/ms.htm">/cgi/generic/ms.htm</a>
 0.05  0.66      1188133       17 | <a href="/cgi/generic/mtx.htm">/cgi/generic/mtx.htm</a>
 0.01  0.01        13506        2 | <a href="/cgi/generic/mupi.htm">/cgi/generic/mupi.htm</a>
 0.06  0.25       461169       18 | <a href="/cgi/generic/nabume.htm">/cgi/generic/nabume.htm</a>
 0.11  0.55       993508       33 | <a href="/cgi/generic/naprox.htm">/cgi/generic/naprox.htm</a>
 0.07  0.66      1187013       22 | <a href="/cgi/generic/nefaz.htm">/cgi/generic/nefaz.htm</a>
 0.02  0.03        53725        5 | <a href="/cgi/generic/neopolhc.htm">/cgi/generic/neopolhc.htm</a>
 0.05  0.29       517039       16 | <a href="/cgi/generic/nifedxl.htm">/cgi/generic/nifedxl.htm</a>
 0.04  0.15       266723       11 | <a href="/cgi/generic/nitro25m.htm">/cgi/generic/nitro25m.htm</a>
 0.03  0.13       236456        8 | <a href="/cgi/generic/nizat.htm">/cgi/generic/nizat.htm</a>
 0.04  0.34       622917       14 | <a href="/cgi/generic/norestoc.htm">/cgi/generic/norestoc.htm</a>
 0.01  0.07       124131        3 | <a href="/cgi/generic/norgeth.htm">/cgi/generic/norgeth.htm</a>
 0.05  0.14       245960       17 | <a href="/cgi/generic/nortrip.htm">/cgi/generic/nortrip.htm</a>
 0.03  0.04        74547       10 | <a href="/cgi/generic/ntg.htm">/cgi/generic/ntg.htm</a>
 0.02  0.06       112686        6 | <a href="/cgi/generic/ntgtd.htm">/cgi/generic/ntgtd.htm</a>
 0.05  0.44       791835       15 | <a href="/cgi/generic/oflox.htm">/cgi/generic/oflox.htm</a>
 0.01  0.02        39572        2 | <a href="/cgi/generic/olsal.htm">/cgi/generic/olsal.htm</a>
 0.04  0.20       358092       12 | <a href="/cgi/generic/omepra.htm">/cgi/generic/omepra.htm</a>
 0.05  0.26       462456       16 | <a href="/cgi/generic/oxaproz.htm">/cgi/generic/oxaproz.htm</a>
 0.09  0.17       304431       27 | <a href="/cgi/generic/oxyapap.htm">/cgi/generic/oxyapap.htm</a>
 0.04  0.07       118008       12 | <a href="/cgi/generic/oxyasa.htm">/cgi/generic/oxyasa.htm</a>
 0.11  0.94      1693227       34 | <a href="/cgi/generic/parox.htm">/cgi/generic/parox.htm</a>
 0.02  0.04        74350        5 | <a href="/cgi/generic/pemoline.htm">/cgi/generic/pemoline.htm</a>
 0.01  0.02        36146        2 | <a href="/cgi/generic/pentox.htm">/cgi/generic/pentox.htm</a>
 0.02  0.04        71358        6 | <a href="/cgi/generic/penvk.htm">/cgi/generic/penvk.htm</a>
 0.22  0.35       629135       69 | <a href="/cgi/generic/phenterm.htm">/cgi/generic/phenterm.htm</a>
 0.04  0.18       328098       14 | <a href="/cgi/generic/phenyt.htm">/cgi/generic/phenyt.htm</a>
 0.03  0.16       288738        8 | <a href="/cgi/generic/pravast.htm">/cgi/generic/pravast.htm</a>
 0.16  0.66      1190410       49 | <a href="/cgi/generic/pred.htm">/cgi/generic/pred.htm</a>
 0.04  0.16       292372       12 | <a href="/cgi/generic/promcod.htm">/cgi/generic/promcod.htm</a>
 0.03  0.08       153729       10 | <a href="/cgi/generic/prometh.htm">/cgi/generic/prometh.htm</a>
 0.07  0.25       460029       21 | <a href="/cgi/generic/propox.htm">/cgi/generic/propox.htm</a>
 0.02  0.06       108940        5 | <a href="/cgi/generic/propox2.htm">/cgi/generic/propox2.htm</a>
 0.06  0.42       752720       20 | <a href="/cgi/generic/propran.htm">/cgi/generic/propran.htm</a>
 0.05  0.33       601630       15 | <a href="/cgi/generic/quinap.htm">/cgi/generic/quinap.htm</a>
 0.01  0.09       157040        4 | <a href="/cgi/generic/ramipril.htm">/cgi/generic/ramipril.htm</a>
 0.05  0.25       448119       16 | <a href="/cgi/generic/ranit.htm">/cgi/generic/ranit.htm</a>
 5.92  0.70      1267187     1845 | <a href="/cgi/generic/redball.gif">/cgi/generic/redball.gif</a>
 0.05  0.49       888345       16 | <a href="/cgi/generic/risperid.htm">/cgi/generic/risperid.htm</a>
 6.20  2.45      4430363     1931 | <a href="/cgi/generic/rx.gif">/cgi/generic/rx.gif</a>
 0.02  0.12       215225        5 | <a href="/cgi/generic/salmet.htm">/cgi/generic/salmet.htm</a>
 0.04  0.16       281781       11 | <a href="/cgi/generic/seleg.htm">/cgi/generic/seleg.htm</a>
 0.20  1.47      2660652       63 | <a href="/cgi/generic/sertral.htm">/cgi/generic/sertral.htm</a>
 0.05  0.42       765395       16 | <a href="/cgi/generic/simva.htm">/cgi/generic/simva.htm</a>
 0.02  0.04        79495        5 | <a href="/cgi/generic/sucral.htm">/cgi/generic/sucral.htm</a>
 0.02  0.06       103392        5 | <a href="/cgi/generic/sulfasal.htm">/cgi/generic/sulfasal.htm</a>
 0.03  0.18       333829        9 | <a href="/cgi/generic/sumitr.htm">/cgi/generic/sumitr.htm</a>
 0.06  0.38       683692       19 | <a href="/cgi/generic/tamox.htm">/cgi/generic/tamox.htm</a>
 0.03  0.06       115920        8 | <a href="/cgi/generic/temaz.htm">/cgi/generic/temaz.htm</a>
 0.03  0.20       360257        8 | <a href="/cgi/generic/teraz.htm">/cgi/generic/teraz.htm</a>
 0.03  0.09       169614        9 | <a href="/cgi/generic/terbin.htm">/cgi/generic/terbin.htm</a>
 0.01  0.02        31047        3 | <a href="/cgi/generic/tercon.htm">/cgi/generic/tercon.htm</a>
 0.08  0.44       797035       25 | <a href="/cgi/generic/terfen.htm">/cgi/generic/terfen.htm</a>
 0.05  0.30       551322       15 | <a href="/cgi/generic/tersud.htm">/cgi/generic/tersud.htm</a>
 0.09  0.48       876033       29 | <a href="/cgi/generic/testos.htm">/cgi/generic/testos.htm</a>
 0.06  0.16       285498       18 | <a href="/cgi/generic/tetcycl.htm">/cgi/generic/tetcycl.htm</a>
 0.02  0.07       134549        5 | <a href="/cgi/generic/theosr.htm">/cgi/generic/theosr.htm</a>
 0.02  0.11       191620        5 | <a href="/cgi/generic/ticlop.htm">/cgi/generic/ticlop.htm</a>
 0.00  0.02        31761        1 | <a href="/cgi/generic/timolol.htm">/cgi/generic/timolol.htm</a>
 0.08  0.38       684921       26 | <a href="/cgi/generic/tramadol.htm">/cgi/generic/tramadol.htm</a>
 0.11  0.43       787592       34 | <a href="/cgi/generic/traz.htm">/cgi/generic/traz.htm</a>
 0.04  0.08       139615       14 | <a href="/cgi/generic/tretinoin.htm">/cgi/generic/tretinoin.htm</a>
 0.01  0.03        46448        2 | <a href="/cgi/generic/triamaer.htm">/cgi/generic/triamaer.htm</a>
 0.02  0.06       105084        5 | <a href="/cgi/generic/triamnas.htm">/cgi/generic/triamnas.htm</a>
 0.08  0.39       697520       24 | <a href="/cgi/generic/trisulf.htm">/cgi/generic/trisulf.htm</a>
 0.05  0.54       979390       16 | <a href="/cgi/generic/venlafax.htm">/cgi/generic/venlafax.htm</a>
 0.03  0.18       325800        8 | <a href="/cgi/generic/verapsr.htm">/cgi/generic/verapsr.htm</a>
 0.08  0.50       897354       26 | <a href="/cgi/generic/warfarin.htm">/cgi/generic/warfarin.htm</a>
 0.06  0.06       107035       19 | <a href="/cgi/generic/yohimb.htm">/cgi/generic/yohimb.htm</a>
 0.04  0.34       609147       11 | <a href="/cgi/generic/zolpid.htm">/cgi/generic/zolpid.htm</a>
 0.00  0.00         1592        1 | <a href="/cgi/mbox.gif">/cgi/mbox.gif</a>
 5.63  2.15      3894066     1753 | <a href="/cgi/rx.gif">/cgi/rx.gif</a>
15.10  8.35     15126790     4702 | <a href="/cgi/rxlist.cgi">/cgi/rxlist.cgi</a>
 0.30  0.16       297699       93 | <a href="/disclaim.htm">/disclaim.htm</a>
 0.88  0.05        92629      274 | <a href="/formmail.cgi">/formmail.cgi</a>
 0.01  0.00         6526        2 | <a href="/hb.htm">/hb.htm</a>
 6.12  1.01      1825231     1905 | <a href="/hi_rec.gif">/hi_rec.gif</a>
 0.00  0.00         3174        1 | <a href="/index.shtml">/index.shtml</a>
 0.74  0.32       573257      230 | <a href="/interact.htm">/interact.htm</a>
 5.86  1.39      2525443     1824 | <a href="/mbox.gif">/mbox.gif</a>
 6.20  3.06      5544901     1930 | <a href="/med60.gif">/med60.gif</a>
 0.21  0.07       126999       66 | <a href="/mono.htm">/mono.htm</a>
 0.00  0.37       674201        1 | <a href="/monthstat.htm">/monthstat.htm</a>
 0.16  0.15       266950       51 | <a href="/nsaid.htm">/nsaid.htm</a>
 0.20  0.13       230748       62 | <a href="/opiate.htm">/opiate.htm</a>
 2.77  0.33       591068      864 | <a href="/redball.gif">/redball.gif</a>
 0.00  0.00         1004        1 | <a href="/restricted/">/restricted/</a>
 0.00  0.27       479809        1 | <a href="/restricted/httpd_2611.gz">/restricted/httpd_2611.gz</a>
 7.20  2.78      5026953     2243 | <a href="/rx.gif">/rx.gif</a>
 0.01  0.05        83380        4 | <a href="/rxlink2.htm">/rxlink2.htm</a>
 0.43  1.47      2655684      135 | <a href="/rxlinks.htm">/rxlinks.htm</a>
 0.11  0.03        56693       33 | <a href="/scoutsel.gif">/scoutsel.gif</a>
 0.00  0.37       674201        1 | <a href="/stats-1996/Oct.monthstat.htm">/stats-1996/Oct.monthstat.htm</a>
 0.01  0.11       193146        3 | <a href="/stats-1996/Oct.monthstat.htm.gz">/stats-1996/Oct.monthstat.htm.gz</a>
 0.09  0.04        66063       29 | <a href="/stats.htm">/stats.htm</a>
 0.20  2.74      4961366       62 | <a href="/tempstat.htm">/tempstat.htm</a>
 2.03  9.16     16585683      632 | <a href="/top200.htm">/top200.htm</a>
 0.21  0.95      1715650       65 | <a href="/top200a.htm">/top200a.htm</a>
 0.01  0.00         3096        4 | Code 302 Moved Temporarily
 0.01  0.00         1781        3 | Code 401 Unauthorized
 0.20  0.01        26746       62 | Code 404 Not Found
</PRE>
<HR>
<ADDRESS>This summary was generated by 
<A HREF="http://www.ics.uci.edu/pub/websoft/wwwstat/">wwwstat-2.0</A>
</ADDRESS>
<hr>
<ADDRESS>Return to 
<a href="http://www.rxlist.com/stats.htm">RxList Stats</a>
</BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-43</DOCNO>
<DOCOLDNO>IA019-000201-B024-144</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/rxlist.cgi?drug=bell*?drug=*spas?drug=bellas* 206.86.175.201 19970106234427 text/html 855
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:38:09 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE>www.rxlist.com - Neil Sandow, Pharm.D. 
copyright 1995</title></head> <body bgcolor="#ffffff">
<center><a href="http://www.rxlist.com"><img src="rx.gif" 
height=75 width=75 border=0><img src="count.gif" border=0></a></center> 
Searching for:</font> <b>BELL *?DRUG=*SPAS?DRUG=BELLAS*</b><br>    
Scroll Down for Results</font>
<hr><hr>
<h1>Enter Brand or Generic Name or Category*</h1>
<h3> Narrow Your Search with <font size=5>*</font>(examples: 
ampi*, *mycin, antibiotic*)</h3>
<form method=get>
<action=>
<input size=30 maxlength=30 name=drug>
<input type=submit>
<input type=reset>
</form>
<HR>
<H3>Your RxList Search Results:</h3>
</body></html>
<P><hr><a href="http://www.rxlist.com"><b>RxList Home Page</ul>
<hr>
</DOC>
<DOC>
<DOCNO>WT08-B13-44</DOCNO>
<DOCOLDNO>IA019-000201-B024-157</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/rxlist.cgi?drug=stemetil 206.86.175.201 19970106234441 text/html 1175
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:38:24 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE>www.rxlist.com - Neil Sandow, Pharm.D. 
copyright 1995</title></head> <body bgcolor="#ffffff">
<center><a href="http://www.rxlist.com"><img src="rx.gif" 
height=75 width=75 border=0><img src="count.gif" border=0></a></center> 
Searching for: <b>STEMETIL</b> <br>scroll down for results 
<hr><hr>
<h1>Enter Brand or Generic Name or Category*</h1>
<h3> Narrow Your Search with <font size=5>*</font>(examples: 
ampi*, *mycin, antibiotic*)</h3>
<form method=get>
<action=>
<input size=30 maxlength=30 name=drug>
<input type=submit>
<input type=reset>
</form>
<HR>
<H3>Your RxList Search Results:</h3>
1<br><b>Brand Name: </b>STIMATE NASAL<br><b>Generic Name: </b>DESMOPRESSIN ACETATE<br><b>Category: </b>PITUITARY
<p>2<br><b>Brand Name: </b>SALT PETRE<br><b>Generic Name: </b>SODIUM NITRATE<br><b>Category: </b>VASODILATING AGENTS
<p>3<br><b>Brand Name: </b>SOD THIOSUL<br><b>Generic Name: </b>SODIUM THIOSULFATE<br><b>Category: </b>HEAVY METAL ANTAGONISTS
<p></body></html>
<P><hr><a href="http://www.rxlist.com"><b>RxList Home Page</ul>
<hr>
</DOC>
<DOC>
<DOCNO>WT08-B13-45</DOCNO>
<DOCOLDNO>IA019-000201-B024-173</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/rxlist.cgi??drug=demerol 206.86.175.201 19970106234500 text/html 35331
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:38:38 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE>www.rxlist.com - Neil Sandow, Pharm.D. 
copyright 1995</title></head> <body bgcolor="#ffffff">
<center><a href="http://www.rxlist.com"><img src="rx.gif" 
height=75 width=75 border=0><img src="count.gif" border=0></a></center> 
Searching for: <b></b> <br>scroll down for results 
<hr><hr>
<h1>Enter Brand or Generic Name or Category*</h1>
<h3> Narrow Your Search with <font size=5>*</font>(examples: 
ampi*, *mycin, antibiotic*)</h3>
<form method=get>
<action=>
<input size=30 maxlength=30 name=drug>
<input type=submit>
<input type=reset>
</form>
<HR>
<H3>Your RxList Search Results:</h3>
1<br><b>Brand Name: </b>DIASTAT<br><b>Generic Name: </b>DIAZEPAM RECTAL GEL<br><b>Category: </b>TREATMENT OF SEVERE EPILEPSY
<p>2<br><b>Brand Name: </b>EDEX<br><b>Generic Name: </b>ALPROSTADIL<br><b>Category: </b>TREATMENT OF ERECTILE DYSFUNCTION
<p>3<br><b>Brand Name: </b>GABITRIL<br><b>Generic Name: </b>TIAGABINE<br><b>Category: </b>ANTICONVULSANTS
<p>4<br><b>Brand Name: </b>URSO<br><b>Generic Name: </b>URSODEOXYCHOLIC ACID<br><b>Category: </b>TREATMENT OF PRIMARY BILIARY CIRRHOSIS
<p>5<br><b>Brand Name: </b>LIPITOR<br><b>Generic Name: </b>ATORVASTATIN<br><b>Category: </b>ANTILIPEMIC AGENTS
<p>6<br><b>Brand Name: </b>ZYFLO<br><b>Generic Name: </b>ZILEUTON<br><b>Category: </b>LEUKOTRIENE RECEPTOR ANTAGONIST (LTRA) FOR TREATMENT OF ASTHMA
<p>7<br><b>Brand Name: </b>FEMPATCH<br><b>Generic Name: </b>17-BETA ESTRADIOL (TRANSDERMAL)<br><b>Category: </b>ESTROGENS
<p>8<br><b>Brand Name: </b>DOSTINEX<br><b>Generic Name: </b>CABERGOLINE<br><b>Category: </b>TREATMENT OF HYPERPROLACTINEMIC DISORDERS
<p>9<br><b>Brand Name: </b>THERDERM EMTDS<br><b>Generic Name: </b>ESTRADIOL (TRANSDERMAL)<br><b>Category: </b>ESTROGENS
<p>10<br><b>Brand Name: </b>ELEQUIN<br><b>Generic Name: </b>LEVOFLOXACIN (INJ)<br><b>Category: </b>QUINOLINE ANTIBIOTICS
<p>11<br><b>Brand Name: </b>COPAXONE<br><b>Generic Name: </b>COPOLYMER-1 (INJ)<br><b>Category: </b>TREATMENT OF MULTIPLE SCLEROSIS
<p>12<br><b>Brand Name: </b>MONUROL<br><b>Generic Name: </b>FOSFOMYCIN TROMETHANE<br><b>Category: </b>TREATMENT OF UTI'S
<p>13<br><b>Brand Name: </b>OPATANOL<br><b>Generic Name: </b>OLOPATADINE HCL<br><b>Category: </b>TREATMENT OF ALLERGIC CONJUNCTIVITIS
<p>14<br><b>Brand Name: </b>GLYSET<br><b>Generic Name: </b>MIGLITOL<br><b>Category: </b>ANTIDIABETIC AGENTS
<p>15<br><b>Brand Name: </b>ZAGAM<br><b>Generic Name: </b>SPARFLOXACIN<br><b>Category: </b>QUINOLINE ANTIBIOTICS
<p>16<br><b>Brand Name: </b>ALORA<br><b>Generic Name: </b>ESTRADIOL TRANSDERMAL<br><b>Category: </b>ESTROGENS
<p>17<br><b>Brand Name: </b>LEVAQUIN<br><b>Generic Name: </b>LEVOFLOXACIN<br><b>Category: </b>QUINOLINE ANTIBIOTICS
<p>18<br><b>Brand Name: </b>APHTHASOL<br><b>Generic Name: </b>AMLEXANOX<br><b>Category: </b>TREATMENT OF APHTHOUS ULCERS
<p>19<br><b>Brand Name: </b>LOTREL<br><b>Generic Name: </b>AMLODIPINE/BENAZEPRIL HCL<br><b>Category: </b>SEE AMLODIPINE AND/OR BENAZEPRIL
<p>20<br><b>Brand Name: </b>ERGOMAR<br><b>Generic Name: </b>ERGOTAMINE TARTRATE<br><b>Category: </b>SYMPATHOLYTIC AGENTS
<p>21<br><b>Brand Name: </b>ERGOSTAT<br><b>Generic Name: </b>ERGOTAMINE TARTRATE<br><b>Category: </b>SYMPATHOLYTIC AGENTS
<p>22<br><b>Brand Name: </b>REZULIN<br><b>Generic Name: </b>TROGLITAZONE<br><b>Category: </b>ANTIDIABETIC AGENTS
<p>23<br><b>Brand Name: </b>MERIDIA<br><b>Generic Name: </b>SIBUTRAMINE HCL<br><b>Category: </b>ANTIDEPRESSANT/ANTIOBESITY
<p>24<br><b>Brand Name: </b>NORMIFLO<br><b>Generic Name: </b>ARDEPARIN SODIUM<br><b>Category: </b>ANTICOAGULANT
<p>25<br><b>Brand Name: </b>FERRISELTZ<br><b>Generic Name: </b>FERRIC AMMONIUM CITRATE<br><b>Category: </b>BOWEL CONTRAST AGENT FOR MRI
<p>26<br><b>Brand Name: </b>LEXXEL<br><b>Generic Name: </b>ENALAPRIL MALEATE/FELODIPINE<br><b>Category: </b>ANTIHYPERTENSIVES
<p>27<br><b>Brand Name: </b>ARICEPT<br><b>Generic Name: </b>DONEPEXIL HCL<br><b>Category: </b>TREATMENT OF ALZHEIMER'S DISEASE
<p>28<br><b>Brand Name: </b>E2020<br><b>Generic Name: </b>DONEPEXIL HCL<br><b>Category: </b>TREATMENT OF ALZHEIMER'S DISEASE
<p>29<br><b>Brand Name: </b>AMPHOTEC<br><b>Generic Name: </b>AMPHOTERICIN B CHOLESTERYL SULFATE COMPLEX<br><b>Category: </b>ANTIFUNGALS
<p>30<br><b>Brand Name: </b>MUSE<br><b>Generic Name: </b>ALPROSTADIL<br><b>Category: </b>TREATMENT OF IMPOTENCE
<p>31<br><b>Brand Name: </b>MECTIZAN<br><b>Generic Name: </b>IVERMECTIN<br><b>Category: </b>TREATMENT OF STRONGYLOIDES/ONCHOCERCIASIS
<p>32<br><b>Brand Name: </b>NASCOBAL<br><b>Generic Name: </b>CYANOCOBALAMIN<br><b>Category: </b>VITAMIN B COMPLEX
<p>33<br><b>Brand Name: </b>NIX<br><b>Generic Name: </b>PERMETHRIN<br><b>Category: </b>ERADICATION/PROPHYLAXIS OF HEAD LICE
<p>34<br><b>Brand Name: </b>SR-2599DC<br><b>Generic Name: </b>CLOPIDOGREL<br><b>Category: </b>ORAL ANTITHROMBIC AGENT (INVESTIGATIONAL)
<p>35<br><b>Brand Name: </b>GUAIFENESIN<br><b>Generic Name: </b>GUAIFENESIN<br><b>Category: </b>SEE <a href="http://www.rxlist.com/cgi/generic/guaicod.htm">GUAIFENESIN & CODEINE</a>
<p>36<br><b>Brand Name: </b>GUAIFENESIN<br><b>Generic Name: </b>GUAIFENESIN<br><b>Category: </b>SEE <a href="http://www.rxlist.com/cgi/generic/guaiphen.htm">GUAIFENESIN & PHENYLPROPANOLAMINE</a>
<p>37<br><b>Brand Name: </b>SYNERCID (RP 59500)<br><b>Generic Name: </b>QUINUPRISTIN/DALFOPRISTIN<br><b>Category: </b>ANTIBIOTICS (INVESTIGATIONAL)
<p>38<br><b>Brand Name: </b>DENAVIR<br><b>Generic Name: </b>PENCICLOVIR<br><b>Category: </b>ANTIVIRALS
<p>39<br><b>Brand Name: </b>FERTINEX<br><b>Generic Name: </b>FOLLICLE STIMULATING HORMONE (FSH)<br><b>Category: </b>HORMONES
<p>40<br><b>Brand Name: </b>FERTINEX<br><b>Generic Name: </b>FSH<br><b>Category: </b>HORMONES
<p>41<br><b>Brand Name: </b>COPAXONE<br><b>Generic Name: </b>COPOLYMER 1<br><b>Category: </b>TREATMENT OF M.S.
<p>42<br><b>Brand Name: </b>VIRACEPT<br><b>Generic Name: </b>NELFINAVIR<br><b>Category: </b>ANTIVIRALS
<p>43<br><b>Brand Name: </b>ERGOSET<br><b>Generic Name: </b>BROMOCRIPTINE<br><b>Category: </b>UNCLASSIFIED THERAPEUTIC AGENTS
<p>44<br><b>Brand Name: </b>SORIATANE<br><b>Generic Name: </b>ACITRETIN<br><b>Category: </b>TREATMENT OF PSORIASIS
<p>45<br><b>Brand Name: </b>ASTELIN<br><b>Generic Name: </b>AZELASTINE<br><b>Category: </b>ANTIHISTAMINES
<p>46<br><b>Brand Name: </b>RETAVASE<br><b>Generic Name: </b>RETEPLASE<br><b>Category: </b>THROMBOLYTICS
<p>47<br><b>Brand Name: </b>SAIZEN<br><b>Generic Name: </b>SOMATROPIN<br><b>Category: </b>PITUITARY
<p>48<br><b>Brand Name: </b>ESTROSTEP<br><b>Generic Name: </b>ETHINYL ESTRADIOL/NORETHINDRONE<br><b>Category: </b>CONTRACEPTIVES
<p>49<br><b>Brand Name: </b>LODINE XL<br><b>Generic Name: </b>ETODOLAC<br><b>Category: </b>NONSTEROIDAL ANTIINFLAMMATORY AGENTS
<p>50<br><b>Brand Name: </b>CYSTADANE<br><b>Generic Name: </b>BETAINE<br><b>Category: </b>TREATMENT OF HOMOCYSTINUREAL
<p>51<br><b>Brand Name: </b>COMBIVENT<br><b>Generic Name: </b>ALBUTEROL/IPRATROPIUM<br><b>Category: </b>BRONCHODILATORS
<p>52<br><b>Brand Name: </b>TARKA<br><b>Generic Name: </b>TRANDOLAPRIL/VERAPAMIL<br><b>Category: </b>ANTIHYPERTENSIVES
<p>53<br><b>Brand Name: </b>MENTAX<br><b>Generic Name: </b>BUTENAFINE HCL<br><b>Category: </b>ANTIFUNGALS
<p>54<br><b>Brand Name: </b>TIAMATE<br><b>Generic Name: </b>DILTIAZEM<br><b>Category: </b>ANTIHYPERTENSIVES
<p>55<br><b>Brand Name: </b>DURACLON<br><b>Generic Name: </b>CLONIDINE HCL<br><b>Category: </b>EPIDURAL ADJUNCT TO OPIATE THERAPY
<p>56<br><b>Brand Name: </b><a href="http://www.lec.org/DrugSearch/Documents/Rohypnol.html">ROHYPNOL</a><br><b>Generic Name: </b>FLUNITRAZEPAM<br><b>Category: </b>MISC. SEDATIVES/HYPNOTICS (NOTE: NOT MARKETED IN THE US)
<p>57<br><b>Brand Name: </b>KADIAN<br><b>Generic Name: </b>MORPHINE SULFATE SA<br><b>Category: </b>OPIATE AGONISTS
<p>58<br><b>Brand Name: </b>COCAINE<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/cocaine.htm">COCAINE HCL</a><br><b>Category: </b>ANTIPRURITICS AND LOCAL ANESTHETICS
<p>59<br><b>Brand Name: </b>TECZEM<br><b>Generic Name: </b>ENALAPRIL MALEATE & DILTIAZEM MALEATE<br><b>Category: </b>ANTIHYPERTENSIVES
<p>60<br><b>Brand Name: </b>TICLID<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/ticlop.htm">TICLOPIDINE HCL</a><br><b>Category: </b>PLATELET AGGREGATION INHIBITORS
<p>61<br><b>Brand Name: </b>PARACETAMOL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">SEE ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>62<br><b>Brand Name: </b>DHEA<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/dhea.htm">DEHYDROEPIANDROSTERONE</a><br><b>Category: </b>UNAPPROVED
<p>63<br><b>Brand Name: </b>ANTIBIOTIC<br><b>Generic Name: </b>TYPE ANTIBIOT*<br><b>Category: </b>USE * TO SORT ON CATEGORY
<p>64<br><b>Brand Name: </b>NILANDRON<br><b>Generic Name: </b>NILUTAMIDE<br><b>Category: </b>ANTIANDROGENS
<p>65<br><b>Brand Name: </b>PONDIMIN<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/fenflur.htm">FENFLURAMINE HCL</a><br><b>Category: </b>APPETITE SUPPRESSANT
<p>66<br><b>Brand Name: </b>ALPHAGAN<br><b>Generic Name: </b>BRIMONIDINE TARTRATE<br><b>Category: </b>MISCELLANEOUS EENT AGENTS (GLAUCOMA)
<p>67<br><b>Brand Name: </b>FERTINEX<br><b>Generic Name: </b>UROFOLLITROPIN<br><b>Category: </b>FOLLICLE STIMULATING HORMONE
<p>68<br><b>Brand Name: </b>IVY BLOCK<br><b>Generic Name: </b>URUSHIOL<br><b>Category: </b>MISCEL.SKIN AND MUCUS MEMBRANE AGENTS
<p>69<br><b>Brand Name: </b>ZENTATE<br><b>Generic Name: </b>VITAMINS PRENATAL<br><b>Category: </b>MULTIVITAMIN PREPARATIONS
<p>70<br><b>Brand Name: </b>ETOPOPHOS<br><b>Generic Name: </b>ETOPOSIDE PHOSPHATE<br><b>Category: </b>ANTINEOPLASTICS
<p>71<br><b>Brand Name: </b>SEROSTIM<br><b>Generic Name: </b>SOMATOTROPIN<br><b>Category: </b>PITUITARY
<p>72<br><b>Brand Name: </b>ZYPREXA<br><b>Generic Name: </b>OLANZAPINE<br><b>Category: </b>ANTIPSYCHOTICS
<p>73<br><b>Brand Name: </b>HURRICAINE<br><b>Generic Name: </b>BENZOCAINE<br><b>Category: </b>LOCAL ANESTHETICS
<p>74<br><b>Brand Name: </b>HURRICAINE<br><b>Generic Name: </b>BENZOCAINE<br><b>Category: </b>ANTIPRURITICS AND LOCAL ANESTHETICS
<p>75<br><b>Brand Name: </b>MERREM I.V.<br><b>Generic Name: </b>MEROPENEM<br><b>Category: </b>MISCELLANEOUS ANTIBIOTICS
<p>76<br><b>Brand Name: </b>PROAMATINE<br><b>Generic Name: </b>MIDODRINE<br><b>Category: </b>TREATMENT OF ORTHOSTATIC HYPERTENSION
<p>77<br><b>Brand Name: </b>RU-486<br><b>Generic Name: </b>MIFEPRISTONE<br><b>Category: </b>TERMINATION OF PREGNANCY
<p>78<br><b>Brand Name: </b>ALBENZA<br><b>Generic Name: </b>ALBENDAZOLE<br><b>Category: </b>ANTHELMINTICS
<p>79<br><b>Brand Name: </b>DIFFERIN<br><b>Generic Name: </b>ADAPALENE<br><b>Category: </b>MISCEL.SKIN AND MUCUS MEMBRANE AGENTS
<p>80<br><b>Brand Name: </b>CARBEX<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/seleg.htm">SELEGILINE HCL</a><br><b>Category: </b>FOR PARKINSON'S DISEASE
<p>81<br><b>Brand Name: </b>HELIDAC<br><b>Generic Name: </b>BISMUTH SUBSAL. METRONIDAZOLE & TETRACYCLINE<br><b>Category: </b>FOR PEPTIC ULCER DISEASE
<p>82<br><b>Brand Name: </b>TRITEC<br><b>Generic Name: </b>RANITIDINE BISMUTH CITRATE<br><b>Category: </b>MISCELLANEOUS GI DRUGS
<p>83<br><b>Brand Name: </b>CEREBYX<br><b>Generic Name: </b>FOSPHENYTOIN SODIUM<br><b>Category: </b>HYDANTOINS
<p>84<br><b>Brand Name: </b>ALLEGRA<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/fexofen.htm">FEXOFENADINE</a><br><b>Category: </b>ANTIHISTAMINES
<p>85<br><b>Brand Name: </b>CAMPTOSAR<br><b>Generic Name: </b>IRINOTECAN HCL<br><b>Category: </b>ANTINEOPLASTICS
<p>86<br><b>Brand Name: </b>XALATAN<br><b>Generic Name: </b>LATANOPROST<br><b>Category: </b>GLAUCOMA THERAPY
<p>87<br><b>Brand Name: </b>REMERON<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/mirtaz.htm">MIRTAZAPINE</a><br><b>Category: </b>ANTIDEPRESSANTS
<p>88<br><b>Brand Name: </b>VIRAMUNE<br><b>Generic Name: </b>NEVIRAPINE<br><b>Category: </b>ANIVIRALS
<p>89<br><b>Brand Name: </b>MYOTROPHIN<br><b>Generic Name: </b>SOMATOMEDIN C<br><b>Category: </b>FOR AMYOTROPHIC LATERAL SCLEROSIS
<p>90<br><b>Brand Name: </b>HUMULIN N<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/humnph.htm">HUMAN INSULIN NPH</a> <br><b>Category: </b>INSULINS
<p>91<br><b>Brand Name: </b>HUMULIN R<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/huminsr.htm">HUMAN INSULIN REGULAR</a><br><b>Category: </b>INSULINS
<p>92<br><b>Brand Name: </b>HUMULIN L<br><b>Generic Name: </b>HUMAN INSULIN LENTE<br><b>Category: </b>INSULINS
<p>93<br><b>Brand Name: </b>HUMULIN 70/30<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/hum7030.htm">HUMAN INSULIN NPH/REG 70/30</a><br><b>Category: </b>INULINS
<p>94<br><b>Brand Name: </b>ORTHO-NOVUM 7/7/7<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/norestoc.htm">NORETHINDRONE/ETHINYL ESTRADIOL</a> <br><b>Category: </b>CONTRACEPTIVES
<p>95<br><b>Brand Name: </b>ORTHO-CEPT<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/desest.htm">DESOGESTREL/ETHINYLESTRADIOL</A><br><b>Category: </b>CONTRACEPTIVES
<p>96<br><b>Brand Name: </b>ACCUPRIL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/quinap.htm">QUINAPRIL HCL</a><br><b>Category: </b>HYPOTENSIVE AGENTS
<p>97<br><b>Brand Name: </b>ACTHREL<br><b>Generic Name: </b>CORTICORELIN OVINE TRIFLUTATE<br><b>Category: </b>DIAGNOSTIC AGENTS
<p>98<br><b>Brand Name: </b>BUPHENYL<br><b>Generic Name: </b>SODIUM PHENYLBUTYRATE<br><b>Category: </b>FOR UREA CYCLE DISORDERS
<p>99<br><b>Brand Name: </b>VISIPAQUE<br><b>Generic Name: </b>IODIXANOL<br><b>Category: </b>ROENTGENOGRAPHY
<p>100<br><b>Brand Name: </b>NAPRELAN<br><b>Generic Name: </b>NAPROXEN SODIUM<br><b>Category: </b>NONSTEROIDAL ANTIINFLAMMATORY AGENTS
<p>101<br><b>Brand Name: </b>OXILAN<br><b>Generic Name: </b>IOXILAN<br><b>Category: </b>ROENTGENOGRAPHY
<p>102<br><b>Brand Name: </b>IONTOCAINE<br><b>Generic Name: </b>LIDOCAINE/EPINEPHRINE<br><b>Category: </b>LOCAL ANESTHETICS
<p>103<br><b>Brand Name: </b>PENTACEF<br><b>Generic Name: </b>CEFTAZIDINE<br><b>Category: </b>ANTIBIOTICS: CEPHALOSPORINS
<p>104<br><b>Brand Name: </b>METROCREAM<br><b>Generic Name: </b>METRONIDAZOLE<br><b>Category: </b>MISCELLANEOUS ANTI-INFECTIVES
<p>105<br><b>Brand Name: </b>GENOTROPIN<br><b>Generic Name: </b>SOMATROPIN<br><b>Category: </b>PITUITARY
<p>106<br><b>Brand Name: </b>SEVORANE<br><b>Generic Name: </b>SEVOFLURANE<br><b>Category: </b>GENERAL ANESTHETICS
<p>107<br><b>Brand Name: </b>BIOTROPIN<br><b>Generic Name: </b>SOMATROPIN<br><b>Category: </b>PITUITARY
<p>108<br><b>Brand Name: </b>ULTRAVIST<br><b>Generic Name: </b>IOPROMIDE<br><b>Category: </b>ROENTGENOGRAPHY
<p>109<br><b>Brand Name: </b>NORDITROPIN<br><b>Generic Name: </b>SOMATROPIN<br><b>Category: </b>PITUITARY
<p>110<br><b>Brand Name: </b>PROVEL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/ibup.htm">IBUPROFEN</A><br><b>Category: </b>NONSTEROIDAL ANTIINFLAMMATORY AGENTS
<p>111<br><b>Brand Name: </b>NISOCOR<br><b>Generic Name: </b>NISOLDIPINE<br><b>Category: </b>CARDIAC DRUGS
<p>112<br><b>Brand Name: </b>APTHASOL<br><b>Generic Name: </b>AMLEXANOX<br><b>Category: </b>TREATMENT OF CANKER SORES
<p>113<br><b>Brand Name: </b>ALPHANATE<br><b>Generic Name: </b>ANTIHEMOPHILIC FACTOR<br><b>Category: </b>HEMOSTATICS
<p>114<br><b>Brand Name: </b>OXYCONTIN<br><b>Generic Name: </b>OXYCODONE HCL<br><b>Category: </b>OPIATE AGONISTS
<p>115<br><b>Brand Name: </b>HYCAMTIN<br><b>Generic Name: </b>TOPOTECAN<br><b>Category: </b>ANTINEOPLASTICS
<p>116<br><b>Brand Name: </b>OXANDRIN<br><b>Generic Name: </b>OXANDROLONE<br><b>Category: </b>ANDROGENS
<p>117<br><b>Brand Name: </b>WINRHO SD<br><b>Generic Name: </b>RHO(D)IMMUNE GLOBULIN<br><b>Category: </b>SERUMS
<p>118<br><b>Brand Name: </b>AVONEX<br><b>Generic Name: </b>INTERFERON BETA-1A<br><b>Category: </b>TREATMENT OF MULTIPLE SCLEROSIS
<p>119<br><b>Brand Name: </b>GEMZAR<br><b>Generic Name: </b>GEMCITABINE HCL<br><b>Category: </b>ANTINEOPLASTICS
<p>120<br><b>Brand Name: </b>DEXFERRUM<br><b>Generic Name: </b>IRON DEXTRAN<br><b>Category: </b>IRON PRODUCTS
<p>121<br><b>Brand Name: </b>CORMAX<br><b>Generic Name: </b>CLOBETASOL PROPIONATE<br><b>Category: </b>ANTI-INFLAMMATORY AGENTS
<p>122<br><b>Brand Name: </b>VITRASERT<br><b>Generic Name: </b>GANCICLOVIR<br><b>Category: </b>ANTIVIRALS
<p>123<br><b>Brand Name: </b>CYTOVENE<br><b>Generic Name: </b>GANCICLOVIR<br><b>Category: </b>ANTIVIRALS
<p>124<br><b>Brand Name: </b>HUMALOG<br><b>Generic Name: </b>INSULIN LISPRO<br><b>Category: </b>INSULINS
<p>125<br><b>Brand Name: </b>DAUNOXOME<br><b>Generic Name: </b>DAUNORUBICIN CITRATE (LIPOSOME)<br><b>Category: </b>ANTINEOPLASTICS
<p>126<br><b>Brand Name: </b>ESTRING<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/estrad.htm">ESTRADIOL</A><br><b>Category: </b>ESTROGENS
<p>127<br><b>Brand Name: </b>ARIMEDEX<br><b>Generic Name: </b>ANASTROZOLE<br><b>Category: </b>ANTINEOPLASTICS
<p>128<br><b>Brand Name: </b>VISTIDE<br><b>Generic Name: </b>CIDOFOVIR<br><b>Category: </b>ANTIVIRALS
<p>129<br><b>Brand Name: </b>NICOTROL NS<br><b>Generic Name: </b>NICOTINE(NASAL)<br><b>Category: </b>MISCELLANEOUS AUTONOMIC DRUGS 
<p>130<br><b>Brand Name: </b>VIQUIN FORTE<br><b>Generic Name: </b>HYDROQUINONE<br><b>Category: </b>DEPIGMENTING AGENTS
<p>131<br><b>Brand Name: </b>REDUX<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/dexfen.htm">DEXFENFLURAMINE</a><br><b>Category: </b>ANTI-OBESITY AGENTS
<p>132<br><b>Brand Name: </b>ZANAFLEX<br><b>Generic Name: </b>TIZANIDINE HCL<br><b>Category: </b>SKELETAL MUSCLE RELAXANTS
<p>133<br><b>Brand Name: </b>PREVALITE<br><b>Generic Name: </b>CHOLESTYRAMINE<br><b>Category: </b>ANTILIPEMIC AGENTS
<p>134<br><b>Brand Name: </b>FERIDEX<br><b>Generic Name: </b>FERUMOXIDE<br><b>Category: </b>MAGNETIC RESONANCE IMAGING
<p>135<br><b>Brand Name: </b>MAVIK<br><b>Generic Name: </b>TRANDOLAPRIL<br><b>Category: </b><a href="http://www.rxlist.com/cardiova.htm">HYPOTENSIVE AGENTS</a> 
<p>136<br><b>Brand Name: </b>NAROPIN<br><b>Generic Name: </b>ROPIVACAINE<br><b>Category: </b>LOCAL ANESTHETICS
<p>137<br><b>Brand Name: </b>SCLEROSOL<br><b>Generic Name: </b>TALC<br><b>Category: </b>SCLEROSING AGENTS
<p>138<br><b>Brand Name: </b>TOPAMAX<br><b>Generic Name: </b>TOPIRAMATE<br><b>Category: </b>MISCELLANEOUS ANTICONVULSANTS
<p>139<br><b>Brand Name: </b>VAQTA<br><b>Generic Name: </b>HEPATITIS A VACCINE<br><b>Category: </b>VACCINES
<p>140<br><b>Brand Name: </b>MYOVIEW<br><b>Generic Name: </b>TETROPHOSMIN<br><b>Category: </b>RADIOPHARMACEUTICALS
<p>141<br><b>Brand Name: </b>OCUHIST<br><b>Generic Name: </b>PHENIRAMINE MALEATE<br><b>Category: </b>ANTIHISTAMINE DRUGS
<p>142<br><b>Brand Name: </b>COVERA-HS<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/verapsr.htm">VERAPAMIL</A> HCL<br><b>Category: </b><a href="http://www.rxlist.com/cardiova.htm">CARDIAC DRUGS</a> 
<p>143<br><b>Brand Name: </b>SYNOVIR<br><b>Generic Name: </b>THALIDOMIDE<br><b>Category: </b>AIDS-CACHEXIA
<p>144<br><b>Brand Name: </b>VESANOID<br><b>Generic Name: </b>TRETINOIN<br><b>Category: </b>ANTINEOPLASTIC AGENTS
<p>145<br><b>Brand Name: </b>TEICHOMYCIN<br><b>Generic Name: </b>TEICOPLANIN<br><b>Category: </b>MISCELLANEOUS ANTIBIOTICS
<p>146<br><b>Brand Name: </b>NORVIR<br><b>Generic Name: </b>RITONAVIR<br><b>Category: </b>ANTIVIRALS
<p>147<br><b>Brand Name: </b>NIMBEX<br><b>Generic Name: </b>CISATRACURIUM BESYLATE<br><b>Category: </b>SKELETAL MUSCLE RELAXANTS
<p>148<br><b>Brand Name: </b>MAXIPIME<br><b>Generic Name: </b>CEFEPIME<br><b>Category: </b>ANTIBIOTICS: CEPHALOSPORINS
<p>149<br><b>Brand Name: </b>PENNSAID<br><b>Generic Name: </b>DIMETHAID-D<br><b>Category: </b><a href="http://www.rxlist.com/nsaid.htm">NONSTEROIDAL ANTI-INFLAMMATORY AGENTS</a> 
<p>150<br><b>Brand Name: </b>ADDERALL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/amphet.htm">AMPHETAMINE MIXED SALTS</a><br><b>Category: </b>RESPIRATORY AND CEREBRAL STIMULANTS
<p>151<br><b>Brand Name: </b>CANDIN<br><b>Generic Name: </b>CANDIDA ALBICANS<br><b>Category: </b>FUNGI
<p>152<br><b>Brand Name: </b>ACTRON<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/ketoprof.htm">KETOPROFEN</a><br><b>Category: </b><a href="http://www.rxlist.com/nsaid.htm">NONSTEROIDAL ANTIINFLAMMATORY AGENTS</a> 
<p>153<br><b>Brand Name: </b>CEDAX<br><b>Generic Name: </b>CEFTIBUTEN<br><b>Category: </b>ANTIBIOTICS:CEPHALOSPORINS
<p>154<br><b>Brand Name: </b>RENOVA<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/tretinoin.htm">TRETINOIN</a><br><b>Category: </b>MISCEL.SKIN AND MUCUS MEMBRANE AGENTS
<p>155<br><b>Brand Name: </b>PHOTOFRIN<br><b>Generic Name: </b>PORFIMER SODIUM<br><b>Category: </b>ANTINEOPLASTIC AGENTS (PHOTODYNAMIC)
<p>156<br><b>Brand Name: </b>AMARYL<br><b>Generic Name: </b>GLIMEPIRIDE<br><b>Category: </b>ANTIDIABETIC AGENTS
<p>157<br><b>Brand Name: </b>FLOLAN<br><b>Generic Name: </b>EPOPROSTENOL SODIUM<br><b>Category: </b>VASODILATING AGENTS
<p>158<br><b>Brand Name: </b>RESPIGAM<br><b>Generic Name: </b>RSV-IGIV<br><b>Category: </b>SERUMS
<p>159<br><b>Brand Name: </b>CRIXIVAN<br><b>Generic Name: </b>INDINAVIR SULFATE<br><b>Category: </b>ANTIVIRALS
<p>160<br><b>Brand Name: </b>TRIPEDIA<br><b>Generic Name: </b>WHOOPING COUGH VACCINE<br><b>Category: </b>VACCINES
<p>161<br><b>Brand Name: </b>PROCANABID<br><b>Generic Name: </b>PROCAINAMIDE HCL<br><b>Category: </b>CARDIAC DRUGS
<p>162<br><b>Brand Name: </b>ZYRTEC<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/cetiriz.htm">CETIRIZINE HCL</a><br><b>Category: </b>ANTIHISTAMINE DRUGS
<p>163<br><b>Brand Name: </b>VIVELLE<br><b>Generic Name: </b>ESTRADIOL (TRANSDERMAL SYSTEM)<br><b>Category: </b>ESTROGEN
<p>164<br><b>Brand Name: </b>AZELEX<br><b>Generic Name: </b>ACELAIC ACID<br><b>Category: </b>SKIN AND MUCUS MEMBRANE AGENTS
<p>165<br><b>Brand Name: </b>ETHYOL<br><b>Generic Name: </b>AMIFOSTINE<br><b>Category: </b>UNCLASSIFIED THERAPEUTIC AGENTS
<p>166<br><b>Brand Name: </b>DOXIL<br><b>Generic Name: </b> DOXORUBICIN HCL (LIPOSOME INJECTION)<br><b>Category: </b>ANTIONEOPLASTIC AGENTS
<p>167<br><b>Brand Name: </b>ABELCET<br><b>Generic Name: </b>ABCL(AMPHOTERICIN B LIPID COMPLEX LIPOSOME INJ)<br><b>Category: </b>ANTIFUNGALS
<p>168<br><b>Brand Name: </b>PRECOSE<br><b>Generic Name: </b>ACARBOSE<br><b>Category: </b>ANTIDIABETIC AGENTS
<p>169<br><b>Brand Name: </b>RILUTEK<br><b>Generic Name: </b>RILUZOLE<br><b>Category: </b>FOR AMYOTROPHIC LATERAL SCLEROSIS
<p>170<br><b>Brand Name: </b>VALTREX<br><b>Generic Name: </b>VALACYCLOVIR<br><b>Category: </b>ANIVIRALS
<p>171<br><b>Brand Name: </b>FLOVENT<br><b>Generic Name: </b>FLUTICASONE PROPRIONATE<br><b>Category: </b>ANTIINFLAMMATORY AGENTS
<p>172<br><b>Brand Name: </b>DYNABAC<br><b>Generic Name: </b>DIRITHROMYCIN<br><b>Category: </b>ANTIBIOTICS:ERYTHROMYCINS
<p>173<br><b>Brand Name: </b>CORVERT<br><b>Generic Name: </b>IBUTILIDE<br><b>Category: </b>CARDIAC DRUGS
<p>174<br><b>Brand Name: </b>FARESTON<br><b>Generic Name: </b>TOREMIFENE CITRATE<br><b>Category: </b>ANTINEOPLASTIC AGENTS
<p>175<br><b>Brand Name: </b>COREG<br><b>Generic Name: </b>CARDEDILOL<br><b>Category: </b>CARDIAC DRUGS
<p>176<br><b>Brand Name: </b>TAXOTERE<br><b>Generic Name: </b>DOCETAXEL<br><b>Category: </b>ANTINEOPLASTIC AGENTS
<p>177<br><b>Brand Name: </b>BUTOX<br><b>Generic Name: </b>BOTULINUM TOXIN TYPE A<br><b>Category: </b>TOXOIDS
<p>178<br><b>Brand Name: </b>SULAR<br><b>Generic Name: </b>NISOLDIPINE<br><b>Category: </b>CARDIAC DRUGS
<p>179<br><b>Brand Name: </b>BLEO<br><b>Generic Name: </b>BLEOMYCIN<br><b>Category: </b>ANTINEOPLASTIC AGENTS
<p>180<br><b>Brand Name: </b>BLEOCIN<br><b>Generic Name: </b>BLEOMYCIN<br><b>Category: </b>ANTINEOPLASTIC AGENTS
<p>181<br><b>Brand Name: </b>BLENOXANE<br><b>Generic Name: </b>BLEOMYCIN<br><b>Category: </b>ANTINEOPLASTIC AGENTS
<p>182<br><b>Brand Name: </b>INVIRASE<br><b>Generic Name: </b>SAQUINAVIR<br><b>Category: </b>ANTIVIRALS
<p>183<br><b>Brand Name: </b>EPIVIR<br><b>Generic Name: </b>LAMIVUDINE<br><b>Category: </b>ANTIVIRALS
<p>184<br><b>Brand Name: </b>3TC<br><b>Generic Name: </b>LAMIVUDINE<br><b>Category: </b>ANTIVIRALS
<p>185<br><b>Brand Name: </b>AZT<br><b>Generic Name: </b>ZIDOVUDINE<br><b>Category: </b>ANTIVIRALS
<p>186<br><b>Brand Name: </b>NIZORAL<br><b>Generic Name: </b>KETOCONAZOLE<br><b>Category: </b>ANTIFUNGALS
<p>187<br><b>Brand Name: </b>NIZORAL TOPICAL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/ketocon.htm">KETOCONAZOLE TOPICAL</A><br><b>Category: </b>ANTIFUNGALS
<p>188<br><b>Brand Name: </b>METHERGINE<br><b>Generic Name: </b>METHYLERGONOVINE MALEATE<br><b>Category: </b>OXYTOCICS
<p>189<br><b>Brand Name: </b>LOTREL<br><b>Generic Name: </b>AMLODIPINE/BENAZEPRIL HCL<br><b>Category: </b><a href="http://www.rxlist.com/cardiova.htm">HYPOTENSIVE AGENTS</a> 
<p>190<br><b>Brand Name: </b>VEXOL<br><b>Generic Name: </b>RIMEXOLONE<br><b>Category: </b>OPTHALMIC CORTICOSTEROID
<p>191<br><b>Brand Name: </b>DR-3355<br><b>Generic Name: </b>LEVOFLOXACIN<br><b>Category: </b>INVESTIGATIONAL:ANTIBIOTICS:QUINOLINES
<p>192<br><b>Brand Name: </b>ORG-10172<br><b>Generic Name: </b>DANAPAROID<br><b>Category: </b>INVESTIGATIONAL:ANTICOAGULANTS
<p>193<br><b>Brand Name: </b>RU 44570<br><b>Generic Name: </b>TRANDOLAPRIL<br><b>Category: </b> <a href="http://www.rxlist.com/cardiova.htm">HYPOTENSIVE AGENTS</a> 
<p>194<br><b>Brand Name: </b>ACCOLATE<br><b>Generic Name: </b>ZAFIRLUKAST<br><b>Category: </b>RESPIRATORY:LEUKOTRIENE ANTAGONIST
<p>195<br><b>Brand Name: </b>TIAZAC<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/diltiaz.htm">DILTIAZEM HCL</a> <br><b>Category: </b><a href="http://www.rxlist.com/cardiova.htm">CARDIAC DRUGS</a> 
<p>196<br><b>Brand Name: </b>FOSAMAX<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/alendron.htm">ALENDRONATE SODIUM</a><br><b>Category: </b>MISCELLANEOUS:OSTEOPOROSIS
<p>197<br><b>Brand Name: </b>REOPRO<br><b>Generic Name: </b>ABCIXIMAB<br><b>Category: </b>UNCLASSIFIED THERAPEUTIC AGENTS
<p>198<br><b>Brand Name: </b>SECTRAL<br><b>Generic Name: </b>ACEBUTOLOL HCL<br><b>Category: </b><a href="http://www.rxlist.com/cardiova.htm">CARDIAC DRUGS</a> 
<p>199<br><b>Brand Name: </b>ACI-JEL W/APP<br><b>Generic Name: </b>ACET AC/RICINOLEIC/OXY<br><b>Category: </b>ANTI-INFECTIVES
<p>200<br><b>Brand Name: </b>ACEPHEN<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>201<br><b>Brand Name: </b>ACETAMIN<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>202<br><b>Brand Name: </b>ANACIN AF<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>203<br><b>Brand Name: </b>APAP<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>204<br><b>Brand Name: </b>BL INFANT N/A<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>205<br><b>Brand Name: </b>BL NON-ASPIRN<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>206<br><b>Brand Name: </b>FEVERALL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>207<br><b>Brand Name: </b>GENAPAP X/S<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>208<br><b>Brand Name: </b>GENEBS X/S<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>209<br><b>Brand Name: </b>GNP NON-ASPRN<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>210<br><b>Brand Name: </b>GNP NON-ASPRN<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>211<br><b>Brand Name: </b>GNP XS PAIN<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>212<br><b>Brand Name: </b>INFANTAIRE<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>213<br><b>Brand Name: </b>INFANTOL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>214<br><b>Brand Name: </b>MAPAP ACETAM<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>215<br><b>Brand Name: </b>PAIN &amp; FEVER<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>216<br><b>Brand Name: </b>PANADOL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>217<br><b>Brand Name: </b>PEDIAPAP<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>218<br><b>Brand Name: </b>TEMPRA 1<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>219<br><b>Brand Name: </b>TEMPRA 2<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>220<br><b>Brand Name: </b>TYLENOL<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>221<br><b>Brand Name: </b>TYLENOL INFNT<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>222<br><b>Brand Name: </b>TYLENOL X/S<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>223<br><b>Brand Name: </b>BROMO SELTZER<br><b>Generic Name: </b>ACETAMINOPHEN BUFFERED<br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>224<br><b>Brand Name: </b>GENAPAP CHILD<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN CHEW</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>225<br><b>Brand Name: </b>ST JOS CHL/AF<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN CHEW</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>226<br><b>Brand Name: </b>TEMPRA 3 CHEW<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN CHEW</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>227<br><b>Brand Name: </b>TYLENOL CHILD<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN CHEW</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>228<br><b>Brand Name: </b>TYLENOL CHILD<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN CHEW</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>229<br><b>Brand Name: </b>TYLENOL X/RLF<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/apap.htm">ACETAMINOPHEN SA</a><br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>230<br><b>Brand Name: </b>PROMINOL<br><b>Generic Name: </b>ACETAMINOPHEN/BUTALBITAL<br><b>Category: </b>MISCELLANEOUS ANALGESICS AND ANTIPYRETICS
<p>231<br><b>Brand Name: </b>APAP/COD<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/acetcod.htm">ACETAMINOPHEN/CODEINE</a> <br><b>Category: </b><a href="opiate.htm">OPIATE AGONISTS</a> 
<p>232<br><b>Brand Name: </b>CAPITAL W/COD<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/acetcod.htm">ACETAMINOPHEN/CODEINE</a> <br><b>Category: </b><a href="opiate.htm">OPIATE AGONISTS</a> 
<p>233<br><b>Brand Name: </b>PHENAPHEN/COD<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/acetcod.htm">ACETAMINOPHEN/CODEINE</a> <br><b>Category: </b><a href="opiate.htm">OPIATE AGONISTS</a> 
<p>234<br><b>Brand Name: </b>TYLENOL/COD<br><b>Generic Name: </b><a href="http://www.rxlist.com/cgi/generic/acetcod.htm">ACETAMINOPHEN/CODEINE</a> <br><b>Category: </b><a href="opiate.htm">OPIATE AGONISTS</a> 
<p>235<br><b>Brand Name: </b>ACETAZOLAMIDE<br><b>Generic Name: </b>ACETAZOLAMIDE<br><b>Category: </b>CARBONIC ANHYDRASE INHIBITORS
<p>236<br><b>Brand Name: </b>DIAMOX<br><b>Generic Name: </b>ACETAZOLAMIDE<br><b>Category: </b>CARBONIC ANHYDRASE INHIBITORS
<p>237<br><b>Brand Name: </b>ACETASOL PLN<br><b>Generic Name: </b>ACETIC ACID OTIC<br><b>Category: </b>ANTI-INFECTIVES
<p>238<br><b>Brand Name: </b>DOMEBORO OTIC<br><b>Generic Name: </b>ACETIC ACID OTIC<br><b>Category: </b>ANTI-INFECTIVES
<p>239<br><b>Brand Name: </b>VOSOL OTIC<br><b>Generic Name: </b>ACETIC ACID OTIC<br><b>Category: </b>ANTI-INFECTIVES
<p>240<br><b>Brand Name: </b>ACETASOL HC<br><b>Generic Name: </b>ACETIC ACID/HYDROCORT OTI<br><b>Category: </b>ANTI-INFECTIVES
<p>241<br><b>Brand Name: </b>HYDRO/ACETIC<br><b>Generic Name: </b>ACETIC ACID/HYDROCORT OTI<br><b>Category: </b>ANTI-INFECTIVES
<p>242<br><b>Brand Name: </b>VASOTATE HC<br><b>Generic Name: </b>ACETIC ACID/HYDROCORT OTI<br><b>Category: </b>ANTI-INFECTIVES
<p>243<br><b>Brand Name: </b>VOSOL HC OTIC<br><b>Generic Name: </b>ACETIC ACID/HYDROCORT OTI<br><b>Category: </b>ANTI-INFECTIVES
<p>244<br><b>Brand Name: </b>DYMELOR<br><b>Generic Name: </b>ACETOHEXAMIDE<br><b>Category: </b>SULFONYLUREAS
<p>245<br><b>Brand Name: </b>LITHOSTAT<br><b>Generic Name: </b>ACETOHYDROXAMIC ACID<br><b>Category: </b>AMMONIA DETOXICANTS
<p>246<br><b>Brand Name: </b>SEBA-NIL<br><b>Generic Name: </b>ACETONE/ALCOHOL/POLYSORB<br><b>Category: </b>MISCEL.SKIN AND MUCUS MEMBRANE AGENTS
<p>247<br><b>Brand Name: </b>MIOCHOL E W/<br><b>Generic Name: </b>ACETYLCHOLINE CHL<br><b>Category: </b>MIOTICS
<p>248<br><b>Brand Name: </b>ACETYLCYSTEIN<br><b>Generic Name: </b>ACETYLCYSTEINE<br><b>Category: </b>MUCOLYTIC AGENTS
<p>249<br><b>Brand Name: </b>MUCOMYST<br><b>Generic Name: </b>ACETYLCYSTEINE<br><b>Category: </b>MUCOLYTIC AGENTS
<p>250<br><b>Brand Name: </b>MUCOSIL<br><b>Generic Name: </b>ACETYLCYSTEINE<br><b>Category: </b>MUCOLYTIC AGENTS
<p></body></html>
<P><hr><a href="http://www.rxlist.com"><b>RxList Home Page</ul>
<hr>
</DOC>
<DOC>
<DOCNO>WT08-B13-46</DOCNO>
<DOCOLDNO>IA019-000201-B022-544</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/wc.htm 206.86.175.201 19970106233717 text/html 3270
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:31:04 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 3088
Last-modified: Fri, 20 Dec 1996 18:08:56 GMT
</DOCHDR>
 <html>
<head>
<title>
RxList - The Internet Drug Index
</title>

</head>



<BODY Bgcolor="#ffffff">



<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi">
<img src="rx.gif" alt="click to search RxList" vspace=2 border=0
height=125 width=125 align=left>
</a><a href="http://www.reutershealth.com/ihw/reviews/rxint.html">                  
<img src="hi_rec.gif" height=38 width=25 align=right
border=0 alt="Reuter's review"></a>
</p></center>
<center>
<p><b><font SIZE=+3>RxList
<br>The Internet Drug Index </font></center></b></p>

<pre>
</pre><center>
<form method=post action="http://www.rxlist.com/cgi/rxlist.cgi">



<input name=drug size=25>

<input type=submit value="Search for Drug Name">

</dl></form><a href="http://www.pointcom.com">
<img src="5per.gif" alt="top 5%" vspace=1 border=0 height=65 width=65
align=left alt="Top5%">
</a>

<a href="http://www.arachnid.co.uk/award/health.html"><img src="med60.gif"        
align=right border=0 alt="Gold Medal"></a>
<h2><a href="http://www.rxlist.com/top200.htm">The Top 200
</a></h2>
<h5>[ <a href="http://www.rxlist.com/interact.htm"> Actions/Interactions ]</a>
| <a href="http://www.rxlist.com/rxlinks.htm">[ Links ]</a> | 
<a href="http://www.rxlist.com/about.htm">[ FAQ ]</a><br>[ <a href="http://www.rxlist.com/tempstat.htm">WWW Stats ]</a>  
[<a href="http://www.rxlist.com/stats.htm"> Stats ]</a> [<a href="#mini"> Mini-Survey ]</a><br>
<hr width=40%>
<a href="http://www.netmedicine.com"><img src="nm.gif"></a>
<hr></center>
<h2 align=center>
 
<a name="mini"></a><a href="http://www.rxlist.com/stats.htm#Results">RxList Wants to Know!</a></h2>
<form method="POST" action="formmail.cgi">
<input type=hidden name="recipient" value="survey@rxlist.com"><input type=hidden name="subject" value="Survey">
<input type=hidden name="redirect" value="http://www.rxlist.com">
<pre><ul><font size=4>
<b>Prescriber (i.e. MD, DDS,etc.)</b> <input name="pro" type="radio"
value="md"></pre>
</font><font size=4>

<pre><b>Pharmacist</b>                     <input name="pro" type="radio"
value="ph"></pre>
</font><font size=4>

<pre><b>Nurse</b>                          <input name="pro" type="radio"
value="rn"></pre>
</font><font size=4>

<pre><b>Other Health Professional</b>      <input name="pro" type="radio"
value="hp"></pre>
</font><font size=4>
<pre><b>Not a Health Professional</b>      <input name="pro" type="radio"
value="con"></pre></font>
</ul>
<center>
<p><b>Sex: <select NAME="Sex"><option>Male   <option>Female</select>   Age: <select NAME="Age"><option>Under 20<option>20-29<option>30-39<option>40-49<option>50-59<option>Over
60</select> </b><input type="submit" value="Submit Mini-Survey">
<hr><hr><a href="mailto:rx@rxlist.com">
<img src="mbox.gif" height=45 width=45 border=0 alt="e-mail"></a><br> <a 
href="mailto:rx@rxlist.com"><h4> E-mail Comments, 
Suggestions, & Corrections to </a><br>
 rx@rxlist.com </h4>
<h4>(707)746-8754 - Advertising, Press</h4>
<hr>
<hr>
<p>
<h5>
copyright 1996 - Neil Sandow, Pharm.D.
</h5></center>
<font COLOR="#FFFFFF">
<!--#counter file="rxcounter"--></font>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-47</DOCNO>
<DOCOLDNO>IA018-000200-B045-167</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/av5.htm 206.86.175.201 19970106232608 text/html 3270
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:19:54 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 3088
Last-modified: Fri, 20 Dec 1996 18:08:24 GMT
</DOCHDR>
 <html>
<head>
<title>
RxList - The Internet Drug Index
</title>

</head>



<BODY Bgcolor="#ffffff">



<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi">
<img src="rx.gif" alt="click to search RxList" vspace=2 border=0
height=125 width=125 align=left>
</a><a href="http://www.reutershealth.com/ihw/reviews/rxint.html">                  
<img src="hi_rec.gif" height=38 width=25 align=right
border=0 alt="Reuter's review"></a>
</p></center>
<center>
<p><b><font SIZE=+3>RxList
<br>The Internet Drug Index </font></center></b></p>

<pre>
</pre><center>
<form method=post action="http://www.rxlist.com/cgi/rxlist.cgi">



<input name=drug size=25>

<input type=submit value="Search for Drug Name">

</dl></form><a href="http://www.pointcom.com">
<img src="5per.gif" alt="top 5%" vspace=1 border=0 height=65 width=65
align=left alt="Top5%">
</a>

<a href="http://www.arachnid.co.uk/award/health.html"><img src="med60.gif"        
align=right border=0 alt="Gold Medal"></a>
<h2><a href="http://www.rxlist.com/top200.htm">The Top 200
</a></h2>
<h5>[ <a href="http://www.rxlist.com/interact.htm"> Actions/Interactions ]</a>
| <a href="http://www.rxlist.com/rxlinks.htm">[ Links ]</a> | 
<a href="http://www.rxlist.com/about.htm">[ FAQ ]</a><br>[ <a href="http://www.rxlist.com/tempstat.htm">WWW Stats ]</a>  
[<a href="http://www.rxlist.com/stats.htm"> Stats ]</a> [<a href="#mini"> Mini-Survey ]</a><br>
<hr width=40%>
<a href="http://www.netmedicine.com"><img src="nm.gif"></a>
<hr></center>
<h2 align=center>
 
<a name="mini"></a><a href="http://www.rxlist.com/stats.htm#Results">RxList Wants to Know!</a></h2>
<form method="POST" action="formmail.cgi">
<input type=hidden name="recipient" value="survey@rxlist.com"><input type=hidden name="subject" value="Survey">
<input type=hidden name="redirect" value="http://www.rxlist.com">
<pre><ul><font size=4>
<b>Prescriber (i.e. MD, DDS,etc.)</b> <input name="pro" type="radio"
value="md"></pre>
</font><font size=4>

<pre><b>Pharmacist</b>                     <input name="pro" type="radio"
value="ph"></pre>
</font><font size=4>

<pre><b>Nurse</b>                          <input name="pro" type="radio"
value="rn"></pre>
</font><font size=4>

<pre><b>Other Health Professional</b>      <input name="pro" type="radio"
value="hp"></pre>
</font><font size=4>
<pre><b>Not a Health Professional</b>      <input name="pro" type="radio"
value="con"></pre></font>
</ul>
<center>
<p><b>Sex: <select NAME="Sex"><option>Male   <option>Female</select>   Age: <select NAME="Age"><option>Under 20<option>20-29<option>30-39<option>40-49<option>50-59<option>Over
60</select> </b><input type="submit" value="Submit Mini-Survey">
<hr><hr><a href="mailto:rx@rxlist.com">
<img src="mbox.gif" height=45 width=45 border=0 alt="e-mail"></a><br> <a 
href="mailto:rx@rxlist.com"><h4> E-mail Comments, 
Suggestions, & Corrections to </a><br>
 rx@rxlist.com </h4>
<h4>(707)746-8754 - Advertising, Press</h4>
<hr>
<hr>
<p>
<h5>
copyright 1996 - Neil Sandow, Pharm.D.
</h5></center>
<font COLOR="#FFFFFF">
<!--#counter file="rxcounter"--></font>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-48</DOCNO>
<DOCOLDNO>IA018-000200-B045-140</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/av.htm/ 206.86.175.201 19970106232549 text/html 3270
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:19:35 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 3088
Last-modified: Fri, 20 Dec 1996 18:08:09 GMT
</DOCHDR>
 <html>
<head>
<title>
RxList - The Internet Drug Index
</title>

</head>



<BODY Bgcolor="#ffffff">



<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi">
<img src="rx.gif" alt="click to search RxList" vspace=2 border=0
height=125 width=125 align=left>
</a><a href="http://www.reutershealth.com/ihw/reviews/rxint.html">                  
<img src="hi_rec.gif" height=38 width=25 align=right
border=0 alt="Reuter's review"></a>
</p></center>
<center>
<p><b><font SIZE=+3>RxList
<br>The Internet Drug Index </font></center></b></p>

<pre>
</pre><center>
<form method=post action="http://www.rxlist.com/cgi/rxlist.cgi">



<input name=drug size=25>

<input type=submit value="Search for Drug Name">

</dl></form><a href="http://www.pointcom.com">
<img src="5per.gif" alt="top 5%" vspace=1 border=0 height=65 width=65
align=left alt="Top5%">
</a>

<a href="http://www.arachnid.co.uk/award/health.html"><img src="med60.gif"        
align=right border=0 alt="Gold Medal"></a>
<h2><a href="http://www.rxlist.com/top200.htm">The Top 200
</a></h2>
<h5>[ <a href="http://www.rxlist.com/interact.htm"> Actions/Interactions ]</a>
| <a href="http://www.rxlist.com/rxlinks.htm">[ Links ]</a> | 
<a href="http://www.rxlist.com/about.htm">[ FAQ ]</a><br>[ <a href="http://www.rxlist.com/tempstat.htm">WWW Stats ]</a>  
[<a href="http://www.rxlist.com/stats.htm"> Stats ]</a> [<a href="#mini"> Mini-Survey ]</a><br>
<hr width=40%>
<a href="http://www.netmedicine.com"><img src="nm.gif"></a>
<hr></center>
<h2 align=center>
 
<a name="mini"></a><a href="http://www.rxlist.com/stats.htm#Results">RxList Wants to Know!</a></h2>
<form method="POST" action="formmail.cgi">
<input type=hidden name="recipient" value="survey@rxlist.com"><input type=hidden name="subject" value="Survey">
<input type=hidden name="redirect" value="http://www.rxlist.com">
<pre><ul><font size=4>
<b>Prescriber (i.e. MD, DDS,etc.)</b> <input name="pro" type="radio"
value="md"></pre>
</font><font size=4>

<pre><b>Pharmacist</b>                     <input name="pro" type="radio"
value="ph"></pre>
</font><font size=4>

<pre><b>Nurse</b>                          <input name="pro" type="radio"
value="rn"></pre>
</font><font size=4>

<pre><b>Other Health Professional</b>      <input name="pro" type="radio"
value="hp"></pre>
</font><font size=4>
<pre><b>Not a Health Professional</b>      <input name="pro" type="radio"
value="con"></pre></font>
</ul>
<center>
<p><b>Sex: <select NAME="Sex"><option>Male   <option>Female</select>   Age: <select NAME="Age"><option>Under 20<option>20-29<option>30-39<option>40-49<option>50-59<option>Over
60</select> </b><input type="submit" value="Submit Mini-Survey">
<hr><hr><a href="mailto:rx@rxlist.com">
<img src="mbox.gif" height=45 width=45 border=0 alt="e-mail"></a><br> <a 
href="mailto:rx@rxlist.com"><h4> E-mail Comments, 
Suggestions, & Corrections to </a><br>
 rx@rxlist.com </h4>
<h4>(707)746-8754 - Advertising, Press</h4>
<hr>
<hr>
<p>
<h5>
copyright 1996 - Neil Sandow, Pharm.D.
</h5></center>
<font COLOR="#FFFFFF">
<!--#counter file="rxcounter"--></font>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-49</DOCNO>
<DOCOLDNO>IA018-000200-B047-50</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/test.htm 206.86.175.201 19970106233658 text/html 3270
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:30:44 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 3088
Last-modified: Sat, 21 Dec 1996 04:37:32 GMT
</DOCHDR>
 <html>
<head>
<title>
RxList - The Internet Drug Index
</title>

</head>



<BODY Bgcolor="#ffffff">



<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi">
<img src="rx.gif" alt="click to search RxList" vspace=2 border=0
height=125 width=125 align=left>
</a><a href="http://www.reutershealth.com/ihw/reviews/rxint.html">                  
<img src="hi_rec.gif" height=38 width=25 align=right
border=0 alt="Reuter's review"></a>
</p></center>
<center>
<p><b><font SIZE=+3>RxList
<br>The Internet Drug Index </font></center></b></p>

<pre>
</pre><center>
<form method=post action="http://www.rxlist.com/cgi/rxlist.cgi">



<input name=drug size=25>

<input type=submit value="Search for Drug Name">

</dl></form><a href="http://www.pointcom.com">
<img src="5per.gif" alt="top 5%" vspace=1 border=0 height=65 width=65
align=left alt="Top5%">
</a>

<a href="http://www.arachnid.co.uk/award/health.html"><img src="med60.gif"        
align=right border=0 alt="Gold Medal"></a>
<h2><a href="http://www.rxlist.com/top200.htm">The Top 200
</a></h2>
<h5>[ <a href="http://www.rxlist.com/interact.htm"> Actions/Interactions ]</a>
| <a href="http://www.rxlist.com/rxlinks.htm">[ Links ]</a> | 
<a href="http://www.rxlist.com/about.htm">[ FAQ ]</a><br>[ <a href="http://www.rxlist.com/tempstat.htm">WWW Stats ]</a>  
[<a href="http://www.rxlist.com/stats.htm"> Stats ]</a> [<a href="#mini"> Mini-Survey ]</a><br>
<hr width=40%>
<a href="http://www.netmedicine.com"><img src="nm.gif"></a>
<hr></center>
<h2 align=center>
 
<a name="mini"></a><a href="http://www.rxlist.com/stats.htm#Results">RxList Wants to Know!</a></h2>
<form method="POST" action="formmail.cgi">
<input type=hidden name="recipient" value="survey@rxlist.com"><input type=hidden name="subject" value="Survey">
<input type=hidden name="redirect" value="http://www.rxlist.com">
<pre><ul><font size=4>
<b>Prescriber (i.e. MD, DDS,etc.)</b> <input name="pro" type="radio"
value="md"></pre>
</font><font size=4>

<pre><b>Pharmacist</b>                     <input name="pro" type="radio"
value="ph"></pre>
</font><font size=4>

<pre><b>Nurse</b>                          <input name="pro" type="radio"
value="rn"></pre>
</font><font size=4>

<pre><b>Other Health Professional</b>      <input name="pro" type="radio"
value="hp"></pre>
</font><font size=4>
<pre><b>Not a Health Professional</b>      <input name="pro" type="radio"
value="con"></pre></font>
</ul>
<center>
<p><b>Sex: <select NAME="Sex"><option>Male   <option>Female</select>   Age: <select NAME="Age"><option>Under 20<option>20-29<option>30-39<option>40-49<option>50-59<option>Over
60</select> </b><input type="submit" value="Submit Mini-Survey">
<hr><hr><a href="mailto:rx@rxlist.com">
<img src="mbox.gif" height=45 width=45 border=0 alt="e-mail"></a><br> <a 
href="mailto:rx@rxlist.com"><h4> E-mail Comments, 
Suggestions, & Corrections to </a><br>
 rx@rxlist.com </h4>
<h4>(707)746-8754 - Advertising, Press</h4>
<hr>
<hr>
<p>
<h5>
copyright 1996 - Neil Sandow, Pharm.D.
</h5></center>
<font COLOR="#FFFFFF">
<!--#counter file="rxcounter"--></font>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-50</DOCNO>
<DOCOLDNO>IA018-000200-B045-152</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/av3.htm/ 206.86.175.201 19970106232556 text/html 3270
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:19:42 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 3088
Last-modified: Fri, 20 Dec 1996 18:08:16 GMT
</DOCHDR>
 <html>
<head>
<title>
RxList - The Internet Drug Index
</title>

</head>



<BODY Bgcolor="#ffffff">



<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi">
<img src="rx.gif" alt="click to search RxList" vspace=2 border=0
height=125 width=125 align=left>
</a><a href="http://www.reutershealth.com/ihw/reviews/rxint.html">                  
<img src="hi_rec.gif" height=38 width=25 align=right
border=0 alt="Reuter's review"></a>
</p></center>
<center>
<p><b><font SIZE=+3>RxList
<br>The Internet Drug Index </font></center></b></p>

<pre>
</pre><center>
<form method=post action="http://www.rxlist.com/cgi/rxlist.cgi">



<input name=drug size=25>

<input type=submit value="Search for Drug Name">

</dl></form><a href="http://www.pointcom.com">
<img src="5per.gif" alt="top 5%" vspace=1 border=0 height=65 width=65
align=left alt="Top5%">
</a>

<a href="http://www.arachnid.co.uk/award/health.html"><img src="med60.gif"        
align=right border=0 alt="Gold Medal"></a>
<h2><a href="http://www.rxlist.com/top200.htm">The Top 200
</a></h2>
<h5>[ <a href="http://www.rxlist.com/interact.htm"> Actions/Interactions ]</a>
| <a href="http://www.rxlist.com/rxlinks.htm">[ Links ]</a> | 
<a href="http://www.rxlist.com/about.htm">[ FAQ ]</a><br>[ <a href="http://www.rxlist.com/tempstat.htm">WWW Stats ]</a>  
[<a href="http://www.rxlist.com/stats.htm"> Stats ]</a> [<a href="#mini"> Mini-Survey ]</a><br>
<hr width=40%>
<a href="http://www.netmedicine.com"><img src="nm.gif"></a>
<hr></center>
<h2 align=center>
 
<a name="mini"></a><a href="http://www.rxlist.com/stats.htm#Results">RxList Wants to Know!</a></h2>
<form method="POST" action="formmail.cgi">
<input type=hidden name="recipient" value="survey@rxlist.com"><input type=hidden name="subject" value="Survey">
<input type=hidden name="redirect" value="http://www.rxlist.com">
<pre><ul><font size=4>
<b>Prescriber (i.e. MD, DDS,etc.)</b> <input name="pro" type="radio"
value="md"></pre>
</font><font size=4>

<pre><b>Pharmacist</b>                     <input name="pro" type="radio"
value="ph"></pre>
</font><font size=4>

<pre><b>Nurse</b>                          <input name="pro" type="radio"
value="rn"></pre>
</font><font size=4>

<pre><b>Other Health Professional</b>      <input name="pro" type="radio"
value="hp"></pre>
</font><font size=4>
<pre><b>Not a Health Professional</b>      <input name="pro" type="radio"
value="con"></pre></font>
</ul>
<center>
<p><b>Sex: <select NAME="Sex"><option>Male   <option>Female</select>   Age: <select NAME="Age"><option>Under 20<option>20-29<option>30-39<option>40-49<option>50-59<option>Over
60</select> </b><input type="submit" value="Submit Mini-Survey">
<hr><hr><a href="mailto:rx@rxlist.com">
<img src="mbox.gif" height=45 width=45 border=0 alt="e-mail"></a><br> <a 
href="mailto:rx@rxlist.com"><h4> E-mail Comments, 
Suggestions, & Corrections to </a><br>
 rx@rxlist.com </h4>
<h4>(707)746-8754 - Advertising, Press</h4>
<hr>
<hr>
<p>
<h5>
copyright 1996 - Neil Sandow, Pharm.D.
</h5></center>
<font COLOR="#FFFFFF">
<!--#counter file="rxcounter"--></font>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-51</DOCNO>
<DOCOLDNO>IA018-000200-B047-26</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/result.htm 206.86.175.201 19970106233645 text/html 85760
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:30:29 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 85577
Last-modified: Tue, 26 Nov 1996 07:04:30 GMT
</DOCHDR>
<HTML><HEAD>
<TITLE>World Wide Web Access Statistics for www.no_where.com</TITLE>
</HEAD><BODY>
<H1>World Wide Web Access Statistics for www.no_where.com</H1>
<EM>Last updated: Mon, 25 Nov 1996 23:03:32 (GMT -0800)</EM>
<UL>
<LI><A HREF="#Daily">Total Transfers by Request Date</A>
<LI><A HREF="#Hourly">Total Transfers by Request Hour</A>
<LI><A HREF="#Domain">Total Transfers by Client Domain</A>
<LI><A HREF="#Subdomain">Total Transfers by Reversed Subdomain</A>
<LI><A HREF="#Archive">Total Transfers by URL/Archive Section</A>
<LI><A HREF="stats-1996/Oct.wwwstats.html.gz">Previous Full Summary Period</A>
</UL>
<H2>Totals for Summary Period:  Nov 24 1996 to Nov 25 1996</H2>
<PRE>
Requests Received During Summary Period           23522
Bytes Transmitted During Summary Period       136433588
Average Requests Received Daily                   11761
Average Bytes Transmitted Daily                68216794
</PRE>
<HR>
<H2><A NAME="Daily">Total Transfers by Request Date</A></H2>
<PRE>
%Reqs %Byte  Bytes Sent  Requests   Date
----- ----- ------------ -------- |------------
94.08 94.41    128813206    22129 | Nov 24 1996
 5.92  5.59      7620382     1393 | Nov 25 1996
</PRE>
<HR>
<H2><A NAME="Hourly">Total Transfers by Request Hour</A></H2>
<PRE>
%Reqs %Byte  Bytes Sent  Requests   Time
----- ----- ------------ -------- |-----
 2.39  2.37      3230330      562 |  00
 1.70  1.53      2091502      400 |  01
 1.20  1.04      1421180      282 |  02
 1.87  1.83      2501010      440 |  03
 1.60  1.51      2060155      377 |  04
 2.21  2.01      2736933      519 |  05
 2.92  2.67      3646090      688 |  06
 3.96  3.92      5344317      931 |  07
 5.34  5.81      7925001     1255 |  08
 5.29  4.85      6617747     1244 |  09
 4.74  4.26      5813978     1114 |  10
 6.47  6.30      8589505     1522 |  11
 4.79  5.37      7333196     1126 |  12
 5.93  6.15      8385879     1395 |  13
 5.71  5.47      7467488     1344 |  14
 5.24  4.99      6805632     1233 |  15
 5.38  5.97      8150291     1265 |  16
 6.24  6.00      8182750     1467 |  17
 6.60  6.63      9043378     1552 |  18
 5.95  5.74      7835015     1400 |  19
 4.69  4.55      6205938     1104 |  20
 4.34  4.33      5906165     1021 |  21
 3.25  2.94      4017407      764 |  22
 2.20  3.75      5122701      517 |  23
</PRE>
<HR>
<H2><A NAME="Domain">Total Transfers by Client Domain</A></H2>
<PRE>
%Reqs %Byte  Bytes Sent  Requests   Domain
----- ----- ------------ -------- |------------------------------------
 0.02  0.05        61799        4 | ar    Argentina
 1.39  1.53      2084686      328 | au    Australia
 0.16  0.20       276668       37 | be    Belgium
 1.11  1.66      2261351      260 | br    Brazil
 3.40  3.16      4311474      800 | ca    Canada
 0.14  0.16       216448       34 | ch    Switzerland
 0.12  0.18       247331       28 | cl    Chile
 0.05  0.03        42684       12 | cz    Czech Republic
 0.23  0.24       329666       55 | de    Germany
 0.12  0.12       166943       28 | dk    Denmark
 0.02  0.03        46170        4 | ee    Estonia
 0.37  0.24       321339       87 | es    Spain
 0.13  0.28       375906       30 | fi    Finland
 0.08  0.12       158470       19 | fr    France
 0.11  0.05        63822       27 | gr    Greece
 0.08  0.04        54259       19 | gt    Guatemala
 0.19  0.19       258797       44 | hk    Hong Kong
 0.03  0.05        67715        7 | id    Indonesia
 0.06  0.05        62685       14 | ie    Ireland
 0.22  0.34       459566       51 | il    Israel
 0.09  0.09       116861       21 | in    India
 0.16  0.15       202841       37 | it    Italy
 0.31  0.65       884413       72 | jp    Japan
 0.01  0.00         5823        2 | lb    Lebanon
 0.17  0.29       389753       39 | lt    Lithuania
 0.02  0.06        75344        5 | mx    Mexico
 0.02  0.01        15069        5 | my    Malaysia
 0.18  0.19       260809       43 | nl    Netherlands
 0.11  0.10       136206       27 | no    Norway
 0.06  0.11       155739       13 | nz    New Zealand (Aotearoa)
 0.01  0.04        50621        3 | pe    Peru
 0.28  0.19       263427       65 | pl    Poland
 0.23  0.11       155399       54 | pt    Portugal
 0.10  0.07        92940       24 | ro    Romania
 0.01  0.01        15136        2 | ru    Russian Federation
 0.25  0.26       355270       58 | se    Sweden
 0.28  0.23       317582       66 | sg    Singapore
 0.13  0.17       228548       30 | si    Slovenia
 0.11  0.12       158765       26 | th    Thailand
 0.21  0.28       384486       50 | tr    Turkey
 0.04  0.01         8101        9 | tw    Taiwan
 1.24  0.98      1337419      292 | uk    United Kingdom
 0.59  0.81      1098671      138 | us    United States
 0.17  0.10       137958       41 | za    South Africa
31.92 31.70     43247231     7509 | com   Commercial
 6.06  6.71      9161418     1425 | edu   Educational
 0.37  0.37       501856       88 | gov   Government
 0.05  0.01        13834       12 | mil   US Military
32.90 31.45     42902978     7738 | net   Network
 0.92  0.85      1160423      217 | org   Non-Profit Organization
14.98 15.19     20730888     3523 | unresolved 
</PRE>
<HR>
<H2><A NAME="Subdomain">Total Transfers by Reversed Subdomain</A></H2>
<PRE>
%Reqs %Byte  Bytes Sent  Requests   Reversed Subdomain
----- ----- ------------ -------- |------------------------------------
14.98 15.19     20730888     3523 | Unresolved
 0.02  0.05        61799        4 | ar.com.pccp
 0.03  0.05        68087        7 | au.com.acay
 0.04  0.05        62981        9 | au.com.connect
 0.09  0.08       115680       20 | au.com.ozemail
 0.00  0.02        27997        1 | au.com.powerup
 0.06  0.05        72571       14 | au.com.telstra
 0.04  0.03        43564        9 | au.com.tpgi
 0.01  0.01        15169        3 | au.com.webnet.cis
 0.00  0.00         3090        1 | au.com.wr
 0.03  0.02        22426        8 | au.edu.unisa.underdale
 0.02  0.02        21428        4 | au.edu.usyd.mp
 0.03  0.08       115944        8 | au.edu.wa.eddept
 0.03  0.04        50090        8 | au.gov.nsw.cs.rpa
 0.10  0.08       103174       24 | au.gov.sa
 0.02  0.02        26709        5 | au.net.aone.melbourne
 0.02  0.06        81176        4 | au.net.campaspe
 0.09  0.06        88534       21 | au.net.camtech
 0.04  0.02        26265       10 | au.net.fl.syd
 0.11  0.11       151153       26 | au.net.iinet
 0.02  0.01        11376        5 | au.net.ip.syd
 0.00  0.00         1366        1 | au.net.ix
 0.01  0.04        51393        3 | au.net.mira
 0.01  0.03        36054        3 | au.net.netwise
 0.03  0.03        47570        7 | au.net.questnet
 0.07  0.03        39208       16 | au.net.starway.preston
 0.06  0.04        58391       13 | au.net.starway.wollongong
 0.05  0.08       108679       11 | au.net.terra
 0.03  0.07        90556        7 | au.net.tmns
 0.08  0.08       105006       19 | au.net.ultra
 0.00  0.03        38073        1 | au.net.werple
 0.02  0.02        30456        4 | au.org.nswcc
 0.21  0.26       354744       50 | au.oz.uq.cc.slip
 0.03  0.01        15776        6 | au.oz.uq.pharmacy
 0.07  0.08       113043       17 | be.ac.rug
 0.03  0.07        92151        6 | be.belbone.mons
 0.06  0.05        71474       14 | be.sky
 0.01  0.04        50621        3 | br.com.alanet
 0.01  0.01        15136        2 | br.com.bhnet
 0.01  0.04        50621        3 | br.com.brnet
 0.09  0.14       191777       21 | br.com.dglnet.sp
 0.03  0.04        56382        7 | br.com.elogica
 0.02  0.07        91562        5 | br.com.ez-poa
 0.03  0.06        81910        7 | br.com.homeshopping
 0.16  0.16       216345       37 | br.com.horizontes
 0.21  0.37       499656       49 | br.com.mandic
 0.06  0.01        10451       13 | br.com.nutecnet.cba
 0.06  0.03        35123       14 | br.com.openline
 0.01  0.04        49869        2 | br.com.opus
 0.01  0.06        84285        2 | br.com.originet
 0.03  0.07       101828        8 | br.com.procergs
 0.08  0.03        40314       19 | br.com.rionet
 0.01  0.04        50621        3 | br.com.riopreto
 0.02  0.06        83922        5 | br.com.starnet
 0.02  0.04        51373        4 | br.com.sul
 0.01  0.04        50621        3 | br.com.transnet
 0.01  0.04        50621        3 | br.com.trycomm
 0.06  0.12       160628       15 | br.com.unisys
 0.02  0.04        53711        4 | br.com.voyager
 0.01  0.04        50621        3 | br.org.ibase.du
 0.00  0.03        41687        1 | br.ufrgs
 0.11  0.07        91666       27 | br.unicamp.fee
 0.01  0.01        11083        3 | ca.ab.cuug
 0.00  0.04        53416        1 | ca.ab.edmonton.freenet
 0.02  0.01        16230        4 | ca.ab.sas
 0.03  0.01        15776        6 | ca.ab.supernet
 0.23  0.19       262029       54 | ca.bc.intergate
 0.01  0.03        42776        3 | ca.bc.lynx
 0.01  0.03        40762        3 | ca.bc.reelwest
 0.32  0.25       347427       75 | ca.bctel
 0.01  0.07        90201        2 | ca.bell
 0.01  0.05        67044        2 | ca.carleton
 0.03  0.08       115963        8 | ca.carleton.ccs
 0.01  0.02        23895        2 | ca.cbc
 0.00  0.00         3179        1 | ca.concordia
 0.04  0.02        22274       10 | ca.direct
 0.03  0.05        67776        6 | ca.escape
 0.04  0.00         5837        9 | ca.gc.ic.pitbull
 0.16  0.10       135965       37 | ca.intranet
 0.08  0.07        90418       19 | ca.istar.hfx
 0.05  0.02        26404       12 | ca.istar.tor
 0.00  0.03        42086        1 | ca.istar.vcr
 0.04  0.02        20979        9 | ca.isys
 0.23  0.24       324554       55 | ca.mb.magic
 0.07  0.02        26048       17 | ca.mb.mbnet
 0.04  0.09       125754        9 | ca.nb.nbnet
 0.03  0.01        19614        8 | ca.netcom
 0.04  0.02        23461        9 | ca.netcore
 0.09  0.04        49037       20 | ca.netinc
 0.00  0.01         8392        1 | ca.ns.halifax.region
 0.01  0.00          999        3 | ca.on.air
 0.14  0.14       189242       33 | ca.on.nornet
 0.01  0.05        64348        3 | ca.on.oncomdis
 0.10  0.09       123887       23 | ca.on.toronto.pmh.clinphys
 0.20  0.06        88573       47 | ca.on.wchat.brantford
 0.06  0.05        62974       15 | ca.pangea
 0.06  0.02        27731       13 | ca.qc
 0.12  0.14       191462       29 | ca.qc.collegeleboeuf
 0.06  0.05        63953       14 | ca.qc.gouv.sgo
 0.01  0.07        95257        3 | ca.qc.pandore
 0.04  0.02        20517        9 | ca.queensu.resnet.n212
 0.03  0.00         1998        6 | ca.queensu.tele
 0.01  0.02        23322        3 | ca.speedline
 0.08  0.10       136957       18 | ca.sympatico.adsl
 0.09  0.06        87112       22 | ca.sympatico.ns
 0.26  0.32       434967       61 | ca.sympatico.on
 0.09  0.08       115238       21 | ca.sympatico.sk
 0.14  0.14       196513       34 | ca.ubc.cstudies.labs
 0.01  0.03        35152        3 | ca.ubishops
 0.06  0.02        27822       13 | ca.ucalgary.acs
 0.05  0.01        15904       12 | ca.uleth.cc
 0.03  0.08       104289        6 | ca.utoronto.dialin
 0.03  0.03        38522        6 | ca.uvic.comp.ssg
 0.01  0.03        34764        3 | ca.uvic.csc
 0.05  0.02        24441       11 | ca.uvic.dialup
 0.01  0.02        27150        3 | ca.wbm
 0.03  0.01        15776        6 | ch.active
 0.03  0.07        97923        7 | ch.magnet
 0.09  0.08       102749       21 | ch.unil
 0.04  0.02        21248        9 | cl.interaccess
 0.08  0.17       226083       19 | cl.uchile.dic
 0.00  0.00          316        1 | com.1stinternet
 0.06  0.08       104364       15 | com.3-cities
 0.05  0.02        28069       11 | com.4ez
 0.06  0.04        57693       13 | com.abbott
 0.06  0.07        88926       13 | com.accsyst
 0.04  0.02        22327       10 | com.acmenet
 0.07  0.03        35969       16 | com.adnc
 0.05  0.02        20531       12 | com.allergan
 0.04  0.01         7026        9 | com.aloha
 0.03  0.01        15776        6 | com.alonline
 0.04  0.06        79026        9 | com.amdahl
 0.04  0.02        32803       10 | com.amoco
 5.51  3.98      5423772     1296 | com.aol.proxy
 0.00  0.00         3090        1 | com.aol2
 0.05  0.01        16329       12 | com.aonline
 0.01  0.01         7015        3 | com.asan
 0.08  0.07        97755       18 | com.atcon.ant
 0.01  0.01        14145        3 | com.atcon.mid
 0.03  0.17       235703        6 | com.atext
 0.07  0.11       145075       16 | com.atlanta
 0.13  0.10       132774       30 | com.att
 0.06  0.06        86982       14 | com.avicom
 0.05  0.05        68799       12 | com.awinc.microage-tb
 0.06  0.03        35799       14 | com.awod
 0.04  0.02        20755        9 | com.axess
 0.31  0.32       431330       74 | com.azstarnet
 0.08  0.03        45528       19 | com.banyan
 0.13  0.07        89670       30 | com.basinlink
 0.01  0.05        64348        3 | com.baynetworks
 0.05  0.01         8845       11 | com.bdt
 0.23  2.09      2853919       54 | com.best.vip
 0.07  0.06        86731       17 | com.bitmailer
 0.06  0.12       158767       15 | com.bix
 0.06  0.01        10466       15 | com.bls.pcs
 0.06  0.04        56171       15 | com.boeing
 0.03  0.02        28933        6 | com.brainlink.remote
 0.00  0.00         1080        1 | com.bytestogo
 0.25  0.26       348667       59 | com.cadvision
 0.03  0.10       143228        7 | com.carlsbadnm
 0.16  0.20       279572       37 | com.ccia
 0.01  0.02        27424        2 | com.ccsfx
 0.09  0.10       139626       20 | com.champint
 0.11  0.13       179006       25 | com.cinergy
 0.05  0.04        48427       12 | com.cisco
 0.14  0.12       163724       33 | com.cleaf
 0.00  0.00         4061        1 | com.cnct
 0.09  0.07        98219       22 | com.coastalnet
 0.05  0.04        56269       11 | com.comcat
 0.04  0.02        20949        9 | com.comland
 0.06  0.02        24924       13 | com.compassnet
 0.06  0.02        27614       14 | com.compucom
 0.03  0.11       147865        8 | com.compucon-mi
 0.08  0.03        41735       18 | com.compuex
 2.19  2.26      3082300      516 | com.compuserve
 0.01  0.04        50621        3 | com.conknet
 0.03  0.07        98444        7 | com.conterra
 0.11  0.12       160093       26 | com.copperhill
 0.03  0.05        70860        8 | com.craftech
 0.01  0.03        34524        3 | com.cris
 0.06  0.04        52089       13 | com.crl.as.sfo4
 0.07  0.04        48864       16 | com.crl.as.sts1
 0.16  0.10       131842       37 | com.cswnet
 0.06  0.04        55742       13 | com.cta.vv
 0.06  0.05        61914       13 | com.ctctel.dialup
 0.01  0.05        64006        3 | com.cts
 0.05  0.03        39166       12 | com.cwnet
 0.04  0.02        26161        9 | com.cwo
 0.10  0.09       127426       24 | com.cybergate
 0.09  0.04        55708       22 | com.datalytics
 0.04  0.02        24289       10 | com.datasync
 0.03  0.03        44874        6 | com.dcwi
 0.11  0.11       148043       26 | com.dec.pa-x
 0.04  0.02        25836        9 | com.deepcove
 0.10  0.08       106113       24 | com.digital.research.crl
 0.03  0.05        69132        6 | com.djb
 0.07  0.05        64667       17 | com.dmv.milford
 0.03  0.04        51659        6 | com.dnai
 0.01  0.01         9344        3 | com.doi
 0.07  0.05        71438       17 | com.draper.jsc
 0.01  0.04        50621        3 | com.dreamscape
 0.04  0.02        21640        9 | com.eaglenet
 0.08  0.10       134013       18 | com.ecis
 0.06  0.06        78455       14 | com.eden.austin
 0.07  0.04        51841       17 | com.electrotex.bmt
 0.08  0.12       170447       18 | com.eonet
 1.24  1.13      1536386      291 | com.erols
 0.14  0.23       307196       32 | com.execpc
 0.01  0.01        17428        3 | com.execulink.mercury
 0.03  0.01        15776        6 | com.ey
 0.04  0.05        74700       10 | com.flinet
 0.05  0.01        12170       11 | com.flnet
 0.12  0.07        98911       29 | com.ge
 0.01  0.05        66087        3 | com.giga
 0.04  0.02        21324        9 | com.gnn.client
 0.55  0.56       759431      130 | com.gnn.proxy
 0.08  0.06        77864       19 | com.gol
 0.02  0.06        80180        4 | com.goodnet
 0.06  0.04        56845       13 | com.gtii
 0.07  0.06        77359       17 | com.gulfnet
 0.06  0.02        24932       14 | com.gwis
 0.02  0.03        41947        4 | com.halcyon
 0.09  0.07        92757       20 | com.harborside.coos0
 0.02  0.07        99988        4 | com.harborside.gb0
 0.01  0.03        42752        3 | com.hargray
 0.14  0.17       237105       34 | com.hevanet
 0.15  0.23       311116       35 | com.hfs-inc
 0.06  0.05        62368       13 | com.hilconet
 0.11  0.04        53584       26 | com.hkstar
 0.06  0.10       137624       14 | com.holli
 0.11  0.14       193755       26 | com.hp.atl
 0.01  0.04        50621        3 | com.humboldt1
 0.02  0.06        88054        5 | com.iafrica
 0.08  0.05        68601       18 | com.ibm.austin
 0.10  0.05        71439       24 | com.ibm.us.ca
 0.04  0.05        67069       10 | com.icongrp.crown
 0.04  0.02        20834        9 | com.iddis
 0.06  0.03        38112       15 | com.idirect
 0.03  0.05        72162        6 | com.idsoftware
 0.05  0.03        44912       11 | com.iinet
 0.01  0.02        23328        2 | com.in-con
 0.05  0.04        60474       12 | com.inetp
 0.05  0.09       126802       12 | com.infinet
 0.01  0.02        26406        3 | com.informix
 0.01  0.05        63630        3 | com.infowest
 0.12  0.05        67385       28 | com.injersey
 0.08  0.11       151462       19 | com.inlink
 0.04  0.00         6434        9 | com.innercite
 0.06  0.05        68467       14 | com.inreach
 0.08  0.06        87219       18 | com.intel.isw
 0.01  0.01        17428        3 | com.interaccess.cloud
 0.09  0.07        92269       21 | com.interaccess.w
 0.12  0.09       122851       28 | com.intercall
 0.05  0.04        55377       12 | com.interlog
 0.10  0.15       198615       24 | com.internetwis
 0.03  0.01        15776        6 | com.interramp.ca.inglewood
 0.20  0.27       361570       47 | com.interramp.ct.new-haven
 0.06  0.02        32767       13 | com.interramp.nj.newark
 0.01  0.02        23328        2 | com.interramp.nj.vineland
 0.05  0.05        62546       12 | com.interramp.oh.akron
 0.08  0.03        35294       19 | com.interramp.pa.philadelphia
 0.05  0.06        84413       12 | com.intersurf.dialup
 0.00  0.00          911        1 | com.intralaw
 0.00  0.00          200        1 | com.iohk
 0.07  0.03        36025       17 | com.iop
 0.01  0.03        36209        3 | com.islandnet
 0.06  0.06        75233       15 | com.ispnet.ar.sea
 0.01  0.02        23745        3 | com.isx.east
 0.03  0.01        15776        6 | com.ittind.de.acdav
 0.07  0.05        68606       16 | com.jcave.cs2
 0.05  0.06        78859       11 | com.jcpenney
 0.03  0.03        45822        7 | com.jnj
 0.01  0.04        50621        3 | com.kcnet
 0.14  0.12       159996       32 | com.kspress.ppp
 0.01  0.03        36054        3 | com.lainet
 0.20  0.17       228676       48 | com.liberty
 0.09  0.05        71363       22 | com.lilly.d48
 0.05  0.03        38733       12 | com.lmco.fs
 0.03  0.10       130013        8 | com.lmtas
 0.08  0.03        39268       18 | com.lnd
 0.01  0.01        14758        3 | com.loop
 0.03  0.06        86675        6 | com.lotus
 0.01  0.01        11482        2 | com.macomb.dialup0
 0.03  0.07        99684        6 | com.madbbs
 0.05  0.04        50604       11 | com.masterpiece
 0.01  0.02        22462        3 | com.mea
 0.01  0.02        26888        3 | com.metronet
 0.01  0.00         6708        2 | com.microsoft
 0.01  0.03        34524        3 | com.mikesplace
 0.51  0.36       487420      121 | com.mindspring.dialup
 0.24  0.19       252631       57 | com.mnsinc
 0.01  0.01        11083        3 | com.montana
 0.07  0.08       106237       16 | com.mosaic-comp
 0.01  0.08       107223        3 | com.mot
 0.06  0.04        58994       15 | com.mv
 0.06  0.03        43172       14 | com.mwmc
 0.01  0.01         9657        3 | com.naxs
 0.06  0.06        87770       14 | com.net-gate
 0.01  0.02        31397        3 | com.netaxis
 4.04  4.11      5607448      950 | com.netcom.ix
 0.01  0.02        30645        2 | com.netheaven
 0.00  0.00         1118        1 | com.netidea.nelson
 0.01  0.03        45087        3 | com.netset.cmh.dialup
 0.07  0.04        53445       16 | com.netvigator
 0.02  0.04        48135        4 | com.netxn
 0.11  0.09       128090       27 | com.netxpress
 0.00  0.00         3179        1 | com.nicom
 0.06  0.06        80118       14 | com.nidlink
 0.01  0.02        27036        2 | com.nilenet
 0.02  0.01        10517        4 | com.nitco
 0.04  0.02        24528       10 | com.njcc
 0.05  0.05        67188       12 | com.nji
 0.06  0.03        38297       13 | com.northwest
 0.00  0.01        19312        1 | com.nwark
 0.03  0.01         8475        6 | com.nwinternet
 0.01  0.03        36054        3 | com.nwlink.annex4
 0.01  0.01        20071        3 | com.nwlink.annex5
 0.01  0.00         4310        2 | com.nwlink.annex6
 0.00  0.02        24395        1 | com.oleane.can
 0.09  0.13       172711       21 | com.onlinetoday
 0.08  0.04        57131       19 | com.onr
 0.06  0.05        67114       14 | com.oracle.us
 0.12  0.09       128406       28 | com.pacifier.van1
 0.11  0.05        71362       27 | com.paonline
 0.04  0.00         6087       10 | com.pcnet
 0.01  0.03        36054        3 | com.peganet
 0.03  0.05        65172        7 | com.pfizer
 0.06  0.06        87568       13 | com.phoenixat
 0.10  0.06        83437       23 | com.pipeline.uk
 0.10  0.09       123226       24 | com.pipex.du
 0.03  0.00         4844        6 | com.pipex.msn-uk.max1
 0.05  0.02        27176       11 | com.pipex.msn-uk.max12
 0.02  0.02        27137        4 | com.pipex.msn-uk.max13
 0.04  0.02        22624       10 | com.pipex.msn-uk.max15
 0.04  0.01        11038       10 | com.pipex.msn-uk.max25
 0.04  0.04        56884       10 | com.pipex.msn-uk.max29
 0.06  0.01        10684       15 | com.pixi
 0.01  0.00          698        2 | com.pld
 0.03  0.04        50168        6 | com.portup
 0.03  0.01        15865        6 | com.primenet.mci
 0.07  0.05        66121       17 | com.primenet.phx
 0.05  0.01        20199       12 | com.primenet.prc
 0.01  0.03        34764        3 | com.primenet.tus
 0.26  0.31       420917       61 | com.proaxis
 1.10  1.17      1595194      258 | com.prodigy
 0.04  0.00         6723        9 | com.psln
 0.06  0.06        84996       15 | com.pstbbs
 0.05  0.03        47358       11 | com.ptw
 0.13  0.15       203558       31 | com.q-com
 0.05  0.03        38489       12 | com.qnet.ca
 0.03  0.05        66003        6 | com.qni
 0.15  0.14       190679       35 | com.qualcomm
 0.06  0.02        31404       13 | com.quancon
 0.07  0.12       159438       17 | com.quik.reno
 0.05  0.06        76499       12 | com.rangenet
 0.04  0.02        20857        9 | com.reach
 0.01  0.04        51395        3 | com.rmii
 0.04  0.09       119544        9 | com.ro
 0.03  0.00         1998        6 | com.rrnet.dot
 0.01  0.02        23393        2 | com.rsabbs
 0.02  0.06        87112        5 | com.rsitex
 0.12  0.11       145868       29 | com.rt66
 0.07  0.12       161321       16 | com.sarnoff
 0.01  0.03        35215        3 | com.sco.london
 0.09  0.07        94726       21 | com.scruznet.sj
 0.17  0.20       271662       41 | com.scsnet
 0.03  0.01        15776        6 | com.seacoast
 0.10  0.08       105235       24 | com.seanet
 0.01  0.00          948        3 | com.series2000
 0.01  0.03        36108        3 | com.servtech.ceh
 0.14  0.13       174658       33 | com.sirius
 0.08  0.06        82778       18 | com.slb.sedco-forex.aberdeen
 0.00  0.02        32809        1 | com.slic
 0.05  0.10       133591       12 | com.snowhill.pmoz3
 0.00  0.00         3179        1 | com.softdisk
 0.04  0.02        22379       10 | com.sonnet
 0.01  0.01        11083        3 | com.spiritone
 0.14  0.16       212733       33 | com.starnetinc
 0.05  0.02        26736       12 | com.stlnet
 0.06  0.08       115483       15 | com.surfnetinc
 0.01  0.00          999        3 | com.syntex
 0.03  0.01        15776        6 | com.tcac
 0.05  0.06        82862       12 | com.tcity
 0.35  0.59       802013       82 | com.teleport
 0.09  0.02        32629       20 | com.televar
 0.06  0.06        76854       13 | com.telia
 0.05  0.03        40913       11 | com.texoma
 0.01  0.02        28531        3 | com.th
 0.00  0.00         3179        1 | com.the-spa
 0.03  0.04        59644        6 | com.theriver.pm2
 0.08  0.06        86190       19 | com.ti
 0.05  0.05        69874       12 | com.tiac.ma.ashbu.gw1
 0.00  0.00          383        1 | com.tiac.ma.ashbu.gw2
 0.03  0.01        15776        6 | com.tiac.ma.bedfo.ts19
 0.05  0.02        28182       11 | com.tiac.ma.bedfo.ts8
 0.03  0.04        57937        7 | com.tigerpaw
 0.01  0.03        45486        3 | com.timken
 0.11  0.09       120174       25 | com.tir
 0.01  0.01        18802        3 | com.tru
 0.03  0.01        15776        6 | com.trucom
 0.00  0.00          333        1 | com.u-net
 0.05  0.10       130282       12 | com.ucinet
 0.07  0.11       153810       17 | com.unocal
 0.03  0.07        94844        6 | com.usa1
 0.08  0.06        88563       18 | com.utw
 0.01  0.01        11994        3 | com.valmet
 0.03  0.11       155334        6 | com.van-net
 0.03  0.09       120169        8 | com.vicksburg
 0.01  0.03        42863        3 | com.visi.dynamic
 0.01  0.01        18658        3 | com.vivanet
 0.06  0.07        98008       15 | com.voicenet
 0.07  0.06        86883       16 | com.walrus.ts1
 0.05  0.02        23422       11 | com.wavenet
 0.05  0.04        49563       12 | com.wco
 0.02  0.04        51786        4 | com.wcoil
 0.01  0.03        41473        3 | com.webbnet
 0.04  0.02        22356       10 | com.well
 0.05  0.03        45958       12 | com.westol
 0.02  0.01         9283        4 | com.widomaker.wmbg
 0.06  0.05        72771       15 | com.winternet.dialup
 0.11  0.11       150513       27 | com.wolfenet
 0.05  0.02        27224       12 | com.wolsi
 0.11  0.06        77707       26 | com.worldaxes
 0.00  0.01         8594        1 | com.wvi
 0.06  0.06        81484       14 | com.wwa
 0.04  0.03        37517        9 | com.wwdc
 0.11  0.08       113555       25 | com.xmission.modem
 0.07  0.04        54786       16 | com.xnet
 0.03  0.01        13607        6 | com.ybb
 0.08  0.12       170279       19 | com.zianet
 0.04  0.01        19071        9 | com.zzz.pdx1
 0.05  0.03        42684       12 | cz.applet
 0.04  0.03        38766        9 | de.dhd
 0.06  0.08       108481       14 | de.dtag.btx
 0.08  0.09       123354       18 | de.eunet.msn.f-4
 0.01  0.02        33406        2 | de.inx
 0.05  0.02        25659       12 | de.metronet
 0.04  0.02        25081       10 | dk.cybernet
 0.02  0.07        90882        4 | dk.dknet.ppp
 0.03  0.01        19184        8 | dk.tele.bal
 0.03  0.02        31796        6 | dk.tele.sla
 0.06  0.05        66504       15 | edu.alaska
 0.01  0.04        50621        3 | edu.american.acc-lab
 0.05  0.02        31651       11 | edu.arizona.medlib
 0.08  0.07        95392       19 | edu.arizona.pharm
 0.01  0.03        37023        3 | edu.asu.inre
 0.01  0.03        40762        3 | edu.bc
 0.01  0.05        62800        2 | edu.bgsm.is
 0.03  0.02        22223        8 | edu.brandeis.cs
 0.02  0.04        52972        4 | edu.brown.cis
 0.01  0.02        21056        2 | edu.buffalo.acsu
 0.12  0.10       139745       28 | edu.buffalo.lib
 0.00  0.03        47221        1 | edu.byu.lib
 0.00  0.01         8392        1 | edu.calpoly.offcampus
 0.07  0.07        97773       16 | edu.calstatela
 0.01  0.01         9037        3 | edu.caltech.ugcs
 0.03  0.01        18866        7 | edu.catawba
 0.00  0.02        20969        1 | edu.clarku
 0.00  0.00          382        1 | edu.clu.upr
 0.03  0.04        50805        6 | edu.colorado
 0.04  0.02        25645       10 | edu.columbia.cc
 0.05  0.02        29589       12 | edu.cornell.med
 0.01  0.01        18392        3 | edu.cornell.resnet
 0.06  0.04        60375       15 | edu.csuohio.async
 0.01  0.04        50621        3 | edu.csupomona.dg1
 0.02  0.01        15227        5 | edu.csus.dialin
 0.01  0.04        48723        3 | edu.ctstateu.scsu
 0.01  0.04        54564        3 | edu.cwru.student
 0.01  0.03        44325        2 | edu.dartmouth
 0.08  0.04        48072       19 | edu.depaul.ac-sia
 0.03  0.01        15776        6 | edu.duke.async
 0.07  0.04        50276       17 | edu.emory.dialup
 0.00  0.00          316        1 | edu.emory.mathcs
 0.02  0.02        32208        4 | edu.emory.resnet
 0.01  0.06        80591        2 | edu.esu
 0.02  0.07       100888        5 | edu.firn
 0.02  0.05        71301        4 | edu.fsu.acns
 0.08  0.08       105380       19 | edu.fsu.housing
 0.17  0.20       270535       41 | edu.gmu
 0.01  0.04        50621        3 | edu.gmu.labs
 0.00  0.00         3179        1 | edu.harvard
 0.06  0.02        30312       14 | edu.hawaii.wcc
 0.03  0.01        15776        6 | edu.hutchcc
 0.01  0.04        54564        3 | edu.indiana.lib
 0.01  0.02        27424        2 | edu.indiana.ucs
 0.06  0.02        31677       13 | edu.jhuapl
 0.09  0.08       108570       22 | edu.jmu.lab
 0.01  0.05        66227        3 | edu.llu
 0.01  0.06        81231        3 | edu.marywood
 0.07  0.08       115741       16 | edu.mcp
 0.05  0.04        53748       12 | edu.mfldclin
 0.03  0.12       163525        8 | edu.mines
 0.06  0.09       123296       15 | edu.mit
 0.02  0.04        51532        4 | edu.mu.mccormick
 0.02  0.03        40573        5 | edu.neoucom.akron
 0.06  0.05        65466       13 | edu.neu.sp
 0.01  0.01         7461        3 | edu.nmu
 0.00  0.00         2648        1 | edu.nodak.ndsu.cc
 0.00  0.00          333        1 | edu.nodak.ndsu.pt11
 0.01  0.00          666        2 | edu.nodak.ndsu.pt15
 0.00  0.00          333        1 | edu.nodak.ndsu.pt3
 0.01  0.02        24947        3 | edu.nova.acast
 0.07  0.05        73926       16 | edu.nwu.nuts
 0.03  0.01        11370        6 | edu.nyu
 0.09  0.06        87977       21 | edu.ohio-state.homenet
 0.01  0.01         7056        3 | edu.okstate.biochem
 0.03  0.01        15776        6 | edu.okstate.educn
 0.02  0.02        27498        4 | edu.pace.dac
 0.01  0.04        50621        3 | edu.panam
 0.07  0.06        84188       16 | edu.pitt.cis.labs
 0.28  0.55       744571       67 | edu.pitt.net.rmt
 0.01  0.01        19261        3 | edu.pitt.wpic
 0.02  0.04        50954        4 | edu.plymouth
 0.08  0.06        78530       18 | edu.psu.cac
 0.06  0.05        66575       13 | edu.psu.hmc.biochem
 0.05  0.03        46462       12 | edu.purdue.cc
 0.02  0.02        30456        4 | edu.quincy
 0.11  0.03        44844       25 | edu.rice
 0.08  0.08       111270       19 | edu.rice.bioc
 0.04  0.02        21815        9 | edu.rit.isc
 0.25  0.10       130009       58 | edu.rutgers
 0.06  0.05        61930       14 | edu.siu.aixdialin
 0.15  0.20       274703       35 | edu.stanford
 0.03  0.01        15776        6 | edu.stlcop
 0.01  0.03        36054        3 | edu.swt.cc.modem1
 0.03  0.01        15776        6 | edu.tamu
 0.09  0.04        51453       20 | edu.tcnj
 0.03  0.04        56797        8 | edu.temple.ocis
 0.04  0.02        23753       10 | edu.tiua
 0.06  0.05        70084       15 | edu.tmc.uth.med
 0.01  0.03        38273        2 | edu.toronto.math
 0.08  0.08       103778       19 | edu.ua.dialup
 0.06  0.09       127783       14 | edu.uab.ppp.maze
 0.13  0.08       110262       31 | edu.ucdavis.ucdmc
 0.05  0.02        24773       11 | edu.uchicago
 0.04  0.12       159602       10 | edu.uchicago.rh
 0.01  0.01        19261        3 | edu.uci.slip
 0.11  0.25       340459       26 | edu.ucla.psych
 0.04  0.02        21029        9 | edu.ucla.resnet
 0.01  0.01        11136        3 | edu.ucla.ts.wla
 0.01  0.08       103080        3 | edu.ucollege
 0.06  0.03        35537       15 | edu.uconn.ppp
 0.01  0.01        14758        3 | edu.uconn.resnet
 0.00  0.02        32708        1 | edu.ucsb
 0.05  0.02        27657       12 | edu.ucsd.extern
 0.01  0.02        22671        3 | edu.ucsd.reshall
 0.03  0.01         8483        8 | edu.ucsf
 0.04  0.02        24823        9 | edu.ufl.chem
 0.09  0.04        59465       22 | edu.ufl.nerdc
 0.04  0.02        20967        9 | edu.uga.coe
 0.08  0.04        56602       19 | edu.uh.mr-building
 0.18  0.11       149677       42 | edu.uh.public-dialups
 0.02  0.02        26108        5 | edu.uiuc.ncsa
 0.06  0.03        37564       13 | edu.ukans.cc
 0.03  0.01        15776        6 | edu.umd
 0.01  0.03        37993        3 | edu.umd.umiacs
 0.01  0.03        40762        3 | edu.umich.dent
 0.04  0.04        53242        9 | edu.umich.med.subnet-139
 0.04  0.08       105333        9 | edu.umn.dialup
 0.01  0.02        27635        3 | edu.umr.student
 0.08  0.02        30852       19 | edu.umsl
 0.06  0.12       162189       15 | edu.unc.dialup
 0.04  0.02        23049       10 | edu.unc.hsl
 0.03  0.01        15776        6 | edu.unc.unch
 0.02  0.05        69406        4 | edu.upenn
 0.01  0.03        37993        3 | edu.upenn.biomed
 0.03  0.05        61980        8 | edu.upenn.humgen
 0.07  0.21       284065       16 | edu.utah.cc
 0.01  0.01         9537        3 | edu.utah.math
 0.02  0.07        92805        4 | edu.utexas.facsmf
 0.01  0.01         7461        3 | edu.utexas.ots
 0.06  0.06        83992       15 | edu.utpb.pol
 0.10  0.07        93993       23 | edu.uwrf.anetsrvcs
 0.01  0.04        59681        3 | edu.vanderbilt.vuse
 0.01  0.03        34764        3 | edu.vcu.uls
 0.01  0.06        77667        3 | edu.virginia.acc
 0.06  0.03        47073       14 | edu.virginia.bootp
 0.01  0.04        51830        3 | edu.virginia.itc
 0.07  0.15       199624       17 | edu.washington.u
 0.01  0.04        50621        3 | edu.westga.isil
 0.01  0.00         4340        2 | edu.williams.cc
 0.06  0.13       172660       13 | edu.wisc.net
 0.03  0.04        58990        8 | edu.wsc
 0.03  0.06        83222        6 | edu.wvnet.dialup
 0.04  0.05        64318       10 | edu.yale.cis
 0.02  0.03        46170        4 | ee.regio
 0.03  0.01        15865        6 | es.intercom
 0.05  0.02        25142       11 | es.jet
 0.10  0.08       115241       24 | es.recol
 0.10  0.05        67962       23 | es.redestb.bcn
 0.07  0.05        63893       16 | es.servicom.mad
 0.03  0.01        13731        6 | es.ub.far
 0.00  0.01        19505        1 | es.uc3m
 0.01  0.03        35215        3 | fi.clinet
 0.01  0.01        10500        3 | fi.eunet
 0.01  0.04        51395        3 | fi.helbp.atki
 0.01  0.01        13234        3 | fi.helsinki.in
 0.00  0.02        20936        1 | fi.orion
 0.01  0.00         4604        2 | fi.oulu
 0.00  0.00          333        1 | fi.sci.dyn
 0.06  0.18       239689       14 | fi.vsonic
 0.02  0.01        17958        4 | fr.ap-hop-paris
 0.01  0.05        65163        2 | fr.imaginet.paris
 0.06  0.06        75349       13 | fr.micronet
 0.04  0.03        39931       10 | gov.jccbi.mpb
 0.05  0.04        59174       12 | gov.nasa.gsfc
 0.07  0.09       117562       16 | gov.nasa.larc
 0.05  0.03        43872       12 | gov.nih
 0.03  0.03        43457        6 | gov.nps.dialup
 0.07  0.06        75128       17 | gov.pima.gis
 0.06  0.09       122732       15 | gov.usps
 0.11  0.05        63822       27 | gr.hol.ppp
 0.08  0.04        54259       19 | gt.com.infovia
 0.04  0.04        52613       10 | hk.com.clp
 0.03  0.01        17600        8 | hk.edu.cuhk.alumni
 0.00  0.00         1277        1 | hk.edu.cuhk.lib
 0.11  0.14       187307       25 | hk.org
 0.02  0.03        43658        4 | id.net.dnet
 0.01  0.02        24057        3 | id.net.indo.jakarta.gatsoe
 0.06  0.05        62685       14 | ie.indigo.cork
 0.14  0.18       240903       34 | il.ac
 0.01  0.07        98389        2 | il.co.orbotech
 0.01  0.05        63630        3 | il.co.trendline
 0.01  0.00          999        3 | il.net.netvision.pop4a
 0.04  0.04        55645        9 | il.net.netvision.pop8a
 0.09  0.09       116861       21 | in.net.vsnl
 0.01  0.00         3830        2 | it.cineca.sp2
 0.02  0.04        53711        4 | it.synapsis
 0.03  0.01        15776        6 | it.toscana.versilia
 0.01  0.03        34485        3 | it.uninetcom
 0.09  0.07        95039       22 | it.vol
 0.03  0.03        35088        7 | jp.ad.mesh.tm
 0.03  0.01        15776        6 | jp.co.impress
 0.00  0.00          316        1 | jp.or.bekkoame
 0.03  0.01        15776        6 | jp.or.iinet.tsukuba
 0.15  0.57       778593       35 | jp.or.interlink.max.tokyo4
 0.03  0.01        15865        6 | jp.or.kyoto-inet
 0.04  0.02        22683       10 | jp.or.linkclub
 0.00  0.00          316        1 | jp.or.win
 0.01  0.00         5823        2 | lb.com.inco
 0.17  0.29       389753       39 | lt.aiva
 0.05  0.01        13834       12 | mil.navy
 0.02  0.06        75344        5 | mx.com.spin
 0.01  0.01         9598        3 | my.jaring.ktk2
 0.01  0.00         5471        2 | my.jaring.ktk4
 0.06  0.02        30397       13 | net.acadia
 0.16  0.22       300016       37 | net.accent
 0.09  0.11       144326       20 | net.accessus
 0.03  0.02        32916        6 | net.accucomm
 0.07  0.09       120997       16 | net.achilles
 0.05  0.03        45272       11 | net.adams
 0.06  0.04        61077       13 | net.agate.sdi
 0.25  0.35       470990       59 | net.agt
 0.06  0.03        43077       13 | net.airnet
 0.06  0.04        56389       14 | net.ais.chi
 0.14  0.11       145945       32 | net.alaska
 0.01  0.02        33078        3 | net.albany
 0.06  0.02        32342       14 | net.alink.isdn
 0.04  0.05        67171        9 | net.aloha.u
 0.06  0.05        67071       13 | net.america
 0.06  0.04        50609       14 | net.ames
 0.01  0.02        31397        3 | net.anv
 0.02  0.01         9604        4 | net.apk.ravenna
 0.07  0.07        91017       17 | net.arc
 0.06  0.11       143773       14 | net.aristotle
 0.14  0.21       288956       33 | net.arn
 0.09  0.05        69059       20 | net.att.dial-access.az.phoenix-002
 0.08  0.05        67800       18 | net.att.dial-access.ca.los-angeles-001
 0.05  0.05        63272       12 | net.att.dial-access.ca.los-angeles-007
 0.09  0.07        99622       22 | net.att.dial-access.ca.san-francisco-003
 0.05  0.03        41947       11 | net.att.dial-access.ca.san-francisco-004
 0.09  0.11       146922       20 | net.att.dial-access.ca.santa-ana-002
 0.09  0.14       190160       22 | net.att.dial-access.ga.atlanta-001
 0.06  0.03        38738       14 | net.att.dial-access.ga.atlanta-005
 0.09  0.03        45745       20 | net.att.dial-access.ga.atlanta-035
 0.05  0.02        27098       11 | net.att.dial-access.ga.atlanta-09
 0.07  0.09       124530       16 | net.att.dial-access.ga.atlanta-10
 0.06  0.02        32918       13 | net.att.dial-access.il.chicago-002
 0.10  0.13       177139       24 | net.att.dial-access.il.chicago-004
 0.01  0.03        36054        3 | net.att.dial-access.il.chicago-006
 0.04  0.02        21319        9 | net.att.dial-access.il.chicago-007
 0.01  0.04        50621        3 | net.att.dial-access.mi.detroit-002
 0.03  0.01        15776        6 | net.att.dial-access.mn.minnesota-002
 0.07  0.11       152910       16 | net.att.dial-access.mo.bridgeton-057
 0.11  0.13       178623       25 | net.att.dial-access.mo.bridgeton-065
 0.09  0.11       151194       21 | net.att.dial-access.mo.st-louis-006
 0.03  0.04        54446        6 | net.att.dial-access.mo.st-louis-007
 0.03  0.03        45256        6 | net.att.dial-access.ny.new-york-002
 0.18  0.14       191897       42 | net.att.dial-access.ny.new-york-003
 0.01  0.04        50621        3 | net.att.dial-access.ny.new-york-009
 0.04  0.02        22618       10 | net.att.dial-access.ny.new-york-011
 0.00  0.00          316        1 | net.att.dial-access.ny.new-york-013
 0.07  0.08       112360       17 | net.att.dial-access.ny.new-york-014
 0.06  0.02        28805       13 | net.att.dial-access.oh.cleveland-001
 0.09  0.09       127702       22 | net.att.dial-access.or.portland-002
 0.03  0.08       106699        8 | net.att.dial-access.tx.dallas-010
 0.07  0.05        62001       17 | net.att.dial-access.tx.houston-001
 0.07  0.08       111964       17 | net.att.dial-access.tx.houston-002
 0.04  0.06        76681       10 | net.att.dial-access.tx.houston-004
 0.11  0.14       189425       27 | net.att.dial-access.va.arlington-001
 0.07  0.02        33441       16 | net.att.dial-access.va.arlington-004
 0.09  0.06        81686       22 | net.att.dial-access.va.middletown-03
 0.07  0.06        80495       17 | net.att.dial-access.va.middletown-51
 0.06  0.02        32521       14 | net.att.dial-access.va.middletown-52
 0.09  0.07        97632       21 | net.att.dial-access.va.middletown-56
 0.07  0.06        79077       16 | net.att.dial-access.wa.seattle-002
 0.01  0.00         5233        3 | net.att.ico
 0.03  0.01        15776        6 | net.beaches
 0.10  0.16       214820       23 | net.bee
 0.08  0.03        42812       18 | net.bellsouth.atl
 0.09  0.12       157315       21 | net.bellsouth.bna
 0.03  0.06        86736        6 | net.bellsouth.mia
 0.01  0.02        22462        3 | net.binc
 0.02  0.03        45511        4 | net.bitstream
 0.07  0.12       166026       17 | net.blue
 0.10  0.15       205650       23 | net.bright.dial
 0.03  0.03        42812        8 | net.bt
 0.17  0.09       123178       40 | net.buffnet
 0.01  0.03        36054        3 | net.caguas
 0.09  0.09       122569       20 | net.cancom
 0.19  0.13       182490       44 | net.capecod
 0.05  0.04        48063       12 | net.cardina
 0.07  0.02        32706       17 | net.caribe
 0.10  0.12       160495       23 | net.cdc.chattanooga
 0.05  0.02        22990       12 | net.cde
 0.09  0.07        95234       22 | net.cdsnet.dip
 0.06  0.03        45302       14 | net.cei.pb
 0.00  0.00         3090        1 | net.cei.rus
 0.03  0.01        15865        6 | net.centuryinter.jn
 0.05  0.04        58862       12 | net.chilepac
 0.04  0.02        22597       10 | net.cic.dial
 0.09  0.15       207387       22 | net.citynet
 0.06  0.03        36249       13 | net.cityscape
 0.04  0.02        24066       10 | net.compmore
 1.14  1.07      1458256      269 | net.concentric
 0.01  0.02        31397        3 | net.connect
 0.05  0.02        28126       11 | net.connectmmic
 0.06  0.02        32905       14 | net.coqui
 0.06  0.02        31735       13 | net.crosslink.us.va.king-george.pm1
 0.05  0.04        61114       12 | net.crown
 0.07  0.05        64667       16 | net.csra
 0.03  0.01        19207        8 | net.csrlink
 0.03  0.01        15776        6 | net.ctonline
 0.10  0.06        81761       24 | net.cyberatl
 0.03  0.01        15776        6 | net.cybercomm.sl
 0.05  0.01        10295       11 | net.cyberenet.ppp
 0.04  0.02        20737        9 | net.cyberhighway.rpt
 0.03  0.04        56153        6 | net.cyberramp
 0.06  0.06        76090       13 | net.cyberzone
 0.04  0.02        20842        9 | net.cynet
 0.06  0.03        35608       13 | net.datasys
 0.31  0.30       412152       73 | net.dialsprint
 0.01  0.06        83954        2 | net.digex
 0.00  0.00          383        1 | net.digisys
 0.05  0.02        26370       12 | net.dn.ppp
 0.07  0.03        43143       17 | net.dnet
 0.02  0.02        30456        4 | net.dwave
 0.03  0.04        57057        7 | net.earthcom
 0.76  0.57       774899      179 | net.earthlink
 0.06  0.06        87100       13 | net.earthlink.dynip.us.ca.los-angeles.maxc
 0.01  0.02        27215        3 | net.earthlink.dynip.us.ca.los_angeles.maxb
 0.03  0.01         8240        8 | net.eastlink
 0.07  0.05        62393       16 | net.easyway
 0.03  0.01        15776        6 | net.echo-on
 0.06  0.04        53146       14 | net.edge.nash
 0.20  0.27       367126       46 | net.edge.tull
 0.11  0.07        89682       26 | net.elite
 0.06  0.03        43044       13 | net.emi
 0.01  0.05        67314        3 | net.empire
 0.07  0.04        56029       16 | net.eon.planet.ascend.max01
 0.05  0.02        30345       12 | net.eon.planet.ascend.max03
 0.03  0.01        15776        6 | net.eon.planet.ascend.max05
 0.17  0.18       241216       41 | net.epix
 0.09  0.05        69678       21 | net.eri.dayton
 0.05  0.07        99027       12 | net.etsc
 0.13  0.12       170192       31 | net.evansville
 0.10  0.11       156025       23 | net.express-news
 0.08  0.18       241174       19 | net.eznet.roc-tc2
 0.05  0.04        48672       12 | net.fast
 0.06  0.04        48704       14 | net.fgi
 0.01  0.04        51694        3 | net.fia
 0.01  0.01        20359        3 | net.fishnet.vta
 0.26  0.36       492623       61 | net.flash
 0.04  0.05        69612       10 | net.frontiercomm.dialup
 0.01  0.02        31520        2 | net.frontiernet.roc.dial
 0.04  0.02        22310        9 | net.ftn
 0.09  0.07       101439       21 | net.fullnet
 0.05  0.03        36250       12 | net.fuse
 0.03  0.01        19809        8 | net.futurevision
 0.06  0.07        95221       14 | net.gamewood
 0.16  0.19       259848       37 | net.gcip
 0.07  0.06        77834       16 | net.gdi
 0.03  0.01        15776        6 | net.geneseo
 0.04  0.05        63316        9 | net.ghg
 0.06  0.04        53490       14 | net.globalserve
 0.08  0.05        71008       19 | net.gorge
 0.14  0.12       165194       32 | net.grid.atln
 0.07  0.05        62398       16 | net.grid.nwrk
 0.21  0.25       345967       50 | net.gte
 0.07  0.04        48583       17 | net.gte.pac
 0.05  0.05        67776       12 | net.gulf.pcola
 0.02  0.00         1580        5 | net.gwi
 0.06  0.04        54911       14 | net.hinet
 0.02  0.04        51272        4 | net.hit
 0.23  0.17       237438       53 | net.hiwaay
 0.03  0.07       101242        6 | net.homestar.ut801.gw03
 0.05  0.06        80014       12 | net.hooked.ppp
 0.01  0.00          999        3 | net.hookup.hfx
 0.05  0.05        68897       12 | net.hti
 0.00  0.00          333        1 | net.hula
 0.06  0.02        29767       15 | net.hurricane
 0.32  0.31       420213       75 | net.iadfw.ppp
 0.01  0.00          948        3 | net.iamerica
 0.04  0.10       137296        9 | net.ibm.br.ri
 0.03  0.06        84750        6 | net.ibm.ca.on
 0.15  0.16       214051       36 | net.ibm.ca.pq
 0.06  0.02        33752       15 | net.ibm.uk.pt
 0.06  0.10       135252       15 | net.ibm.us.ca
 0.01  0.03        38908        3 | net.ibm.us.ct
 0.05  0.06        85894       11 | net.ibm.us.fl
 0.04  0.00         6556        9 | net.ibm.us.nc
 0.09  0.08       112989       21 | net.ibm.us.tx
 0.06  0.05        71605       13 | net.ibm.ve
 0.06  0.06        81334       14 | net.ic.t.hubbard5
 0.09  0.08       106358       21 | net.icon
 0.06  0.03        34732       14 | net.icsi
 0.01  0.01        13025        3 | net.idir.idtswe1
 0.11  0.11       151181       26 | net.ids.pvd-ri
 0.05  0.02        24284       12 | net.idt.dfw.ts-1
 0.07  0.05        65627       16 | net.idt.hck.ts-14
 0.18  0.30       404363       43 | net.idt.hck.ts-9
 0.09  0.09       116985       22 | net.idt.la.ts-3
 0.05  0.04        60358       12 | net.idt.mvl.ts-1
 0.04  0.02        21839        9 | net.idt.nyc.ts-14
 0.01  0.03        38297        3 | net.idt.nyc.ts-6
 0.07  0.03        45735       16 | net.iglobal
 0.24  0.17       238546       56 | net.iglou
 0.07  0.03        38912       17 | net.igs.renc
 0.06  0.03        37446       15 | net.ih2000
 0.01  0.03        41036        3 | net.ils
 0.03  0.07       102141        6 | net.imperium
 0.05  0.05        69969       12 | net.impulse
 0.09  0.06        78920       21 | net.in
 0.02  0.03        44074        4 | net.indy.th
 0.03  0.01        19174        8 | net.inetdirect
 0.05  0.02        26081       12 | net.inetworld
 0.03  0.04        50182        7 | net.infi.clt
 0.03  0.05        75022        6 | net.infi.lex
 0.00  0.00          316        1 | net.infi.nr
 0.04  0.05        65230       10 | net.infi.sjc
 0.01  0.02        24145        3 | net.info2000
 0.01  0.04        59681        3 | net.infoave.ncbldw.r2
 0.03  0.05        72277        6 | net.infoave.ncelrb.r01
 0.03  0.01        15776        6 | net.infoave.nclxtn.r02
 0.05  0.04        59851       12 | net.infoave.scsumt.r10
 0.09  0.06        77468       22 | net.infoave.scsumt.r11
 0.09  0.04        48176       20 | net.infoave.tncphl.r02
 0.02  0.14       188884        4 | net.infoave.tnpkvl.r1
 0.00  0.00         3090        1 | net.inland
 0.01  0.01         7944        3 | net.interax.258
 0.07  0.03        35392       17 | net.intercom
 0.01  0.02        32903        3 | net.interhop.nmkt
 0.03  0.01        15776        6 | net.intermind
 0.01  0.04        48723        3 | net.internetland
 0.04  0.02        21904       10 | net.interpath
 0.03  0.04        49079        6 | net.intnet
 0.06  0.03        34337       14 | net.intrnet.ppp
 0.09  0.14       186663       22 | net.ionet
 0.30  0.26       351085       71 | net.iquest
 0.01  0.04        50621        3 | net.iserv
 0.03  0.06        81160        6 | net.itl.jsy
 0.09  0.02        24811       21 | net.iu
 0.04  0.03        42664        9 | net.jersey
 0.16  0.10       142983       37 | net.jetlink.dialup
 0.06  0.02        28159       14 | net.kdcol.io.cs00
 0.16  0.18       242694       37 | net.kingston
 0.06  0.04        58677       14 | net.kiva.newc
 0.00  0.02        21247        1 | net.knox
 0.07  0.03        39423       17 | net.lamere
 0.01  0.01        19232        2 | net.lcs
 0.08  0.03        38548       18 | net.leaco
 0.04  0.02        22529       10 | net.leba
 0.11  0.12       158866       25 | net.lightspeed
 0.15  0.08       102483       35 | net.livingston
 0.04  0.03        40957        9 | net.lkdllink
 0.00  0.00         2648        1 | net.ll
 0.01  0.02        21473        3 | net.ltec
 0.07  0.01         9815       16 | net.lvnexus
 0.01  0.02        32439        3 | net.ly.friend.country-school
 0.06  0.02        27962       13 | net.magg
 0.05  0.02        25991       12 | net.maui
 0.03  0.03        40746        6 | net.mc
 0.05  0.04        58625       12 | net.mci.bloomington.mix1
 0.10  0.03        38614       24 | net.mci.boston.mix2
 0.07  0.07       101335       16 | net.mci.campus.auburn
 0.03  0.07        90737        7 | net.mci.campus.austel
 0.03  0.01        15776        6 | net.mci.campus.fau-boca
 0.05  0.02        27117       12 | net.mci.campus.montana
 0.10  0.08       109173       24 | net.mci.campus.snaustel
 0.09  0.08       115189       21 | net.mci.campus.wku
 0.07  0.05        63374       16 | net.mci.dallas
 0.03  0.01        15776        6 | net.mci.houston
 0.06  0.04        59421       14 | net.mci.kansascity
 0.05  0.04        48531       12 | net.mci.washington
 0.06  0.01        19111       15 | net.mcs.pr
 0.01  0.03        42863        3 | net.mhv
 0.25  0.20       271357       58 | net.mich.dialip
 0.01  0.03        35918        3 | net.micron.boi
 0.06  0.03        37456       14 | net.midohio
 0.01  0.01        15169        3 | net.midusa.homecity
 0.11  0.19       256694       26 | net.midusa.salina
 0.12  0.09       119365       29 | net.midwest
 0.05  0.02        24085       12 | net.mindlink.nwm
 0.06  0.02        29679       14 | net.misslink
 0.00  0.00         3090        1 | net.mixi
 0.01  0.04        50621        3 | net.mlink.qbc.dynamic-ip
 0.08  0.10       132449       19 | net.mnsi.win
 0.03  0.03        45711        6 | net.monad.top
 0.01  0.00          999        3 | net.msys
 0.24  0.25       343310       57 | net.mts
 0.01  0.04        53520        3 | net.mwci.lan
 0.01  0.01         7482        3 | net.mylink
 0.09  0.08       106029       20 | net.myriad
 0.03  0.01        15776        6 | net.nando
 0.01  0.05        66087        3 | net.napanet
 0.04  0.04        51811       10 | net.nauticom.net1
 0.06  0.03        47498       15 | net.nauticom.net4
 0.08  0.07       101522       18 | net.ncn.royal
 0.03  0.06        82472        7 | net.ndak.dialup
 0.06  0.02        28720       13 | net.net-magic
 0.15  0.16       223288       36 | net.netins.dialup
 0.14  0.07       100095       33 | net.netlabs
 0.05  0.06        79759       12 | net.netpath
 0.06  0.06        82164       14 | net.netreach
 0.26  0.18       251788       60 | net.netshel
 0.01  0.02        30102        3 | net.nfx
 0.06  0.04        50585       15 | net.norlight.dul
 0.05  0.12       164158       11 | net.nortel
 0.06  0.02        30498       13 | net.novagate
 0.06  0.05        70637       14 | net.nrv.server1
 0.03  0.01        15776        6 | net.nt
 0.01  0.03        42660        3 | net.nut-n-but
 0.06  0.06        84339       15 | net.o2
 0.07  0.06        75910       17 | net.oklahoma.okc
 0.05  0.02        25260       11 | net.ole
 0.01  0.04        50621        3 | net.olympus
 0.02  0.03        36770        5 | net.p3
 0.06  0.02        25066       14 | net.pa.franklin.chmbg
 0.11  0.22       305627       25 | net.pacbell.anhm01
 0.06  0.03        44272       13 | net.pacbell.hywr01
 0.04  0.02        24416        9 | net.pacbell.irvn11
 0.01  0.02        22462        3 | net.pacbell.lsan03
 0.06  0.05        67851       14 | net.pacbell.okld03
 0.03  0.04        56216        6 | net.pacbell.psdn11
 0.02  0.02        30456        4 | net.pacbell.scrm01
 0.06  0.06        87872       15 | net.pacbell.sndg02
 0.05  0.01        13267       12 | net.pacbell.snrf01
 0.05  0.01        11311       12 | net.pacbell.sntc01
 0.06  0.02        29171       13 | net.pacbell.vntrcs
 0.01  0.01        11994        3 | net.pacbell.wnck11
 0.04  0.02        20838        9 | net.pacific
 0.01  0.02        24145        3 | net.pacificcoast
 0.03  0.01        15776        6 | net.pb
 0.06  0.09       128548       13 | net.pcisys
 0.09  0.09       121598       21 | net.pcrealm
 0.05  0.02        29304       12 | net.pe
 0.08  0.07        90548       18 | net.pi
 0.11  0.14       190189       25 | net.pipex
 0.04  0.02        24151       10 | net.planet
 0.01  0.02        33552        3 | net.port
 0.03  0.01        15776        6 | net.powernet
 0.03  0.03        42155        7 | net.premier1
 0.05  0.02        27368       11 | net.primecomm
 0.04  0.02        22468        9 | net.probe
 0.05  0.02        27927       12 | net.prodigy.bfld2
 0.02  0.09       122306        4 | net.promedia
 0.05  0.02        26047       11 | net.prtc
 0.05  0.06        79653       12 | net.prysm
 0.11  0.13       177292       27 | net.psci
 0.01  0.01        18802        3 | net.psi.ma.boston.isdn10
 0.03  0.06        83047        7 | net.psi.ny.new-york4.an5
 0.06  0.07        93649       13 | net.ptd.all
 0.01  0.04        50621        3 | net.ptd.mah
 0.09  0.07        90130       21 | net.ptd.pcn
 0.01  0.01        14948        2 | net.ptd.spa
 0.03  0.06        75960        6 | net.ptd.wil
 0.03  0.08       111806        7 | net.ptialaska.sitka
 0.00  0.00          316        1 | net.pubnix
 0.07  0.05        74029       16 | net.purplenet
 0.01  0.02        33615        3 | net.qis
 0.06  0.03        40155       14 | net.radix.annex4
 0.04  0.02        22999        9 | net.ramlink
 0.01  0.00         5164        3 | net.redrose
 0.06  0.02        33115       13 | net.rockies
 0.07  0.20       275272       17 | net.rose
 0.05  0.05        68317       12 | net.sat
 0.06  0.04        55011       14 | net.scsn
 0.07  0.08       107826       17 | net.sgi.mcm
 0.07  0.05        66981       17 | net.shadow
 0.02  0.08       102896        5 | net.shentel
 0.09  0.10       142242       20 | net.sierra
 0.04  0.02        24309       10 | net.skyinet.psg.mb01
 0.01  0.01        17992        3 | net.skypoint
 0.14  0.09       128548       33 | net.slip.dialup
 0.09  0.16       214498       22 | net.sloc.csu.northr1
 0.05  0.03        41452       12 | net.smart
 0.41  0.30       403279       97 | net.snet
 0.07  0.07        93329       16 | net.soltec.cu
 0.03  0.01        14398        6 | net.sound
 0.05  0.06        79846       12 | net.southeast
 0.01  0.04        50621        3 | net.southwind
 0.04  0.03        40848       10 | net.sowest
 0.05  0.10       141955       12 | net.spacestar
 0.00  0.00          300        1 | net.spec
 0.06  0.04        48802       14 | net.spectra
 0.01  0.06        77667        3 | net.speed
 0.11  0.06        86875       25 | net.startext
 0.08  0.06        83337       18 | net.stic
 0.01  0.02        20863        2 | net.sundial
 0.06  0.02        29463       13 | net.sunline
 0.09  0.19       262988       21 | net.sunlink
 0.03  0.01        15776        6 | net.swbell.rcsntx
 0.11  0.11       149491       25 | net.synapse
 0.07  0.05        65791       16 | net.tco
 0.26  0.30       410033       62 | net.teclink
 0.09  0.02        22663       21 | net.telenet
 0.03  0.01        15776        6 | net.themall
 0.00  0.01        18234        1 | net.thepoint.sellersburg
 0.04  0.08       106164       10 | net.theramp
 0.09  0.45       607211       22 | net.theshop
 0.09  0.05        70474       21 | net.thuntek
 0.16  0.10       133129       37 | net.tiac
 0.10  0.08       105901       24 | net.tis.hsv
 0.00  0.00          200        1 | net.tln
 0.01  0.02        22322        3 | net.together.ramp
 0.00  0.02        20680        1 | net.torfree
 0.06  0.06        84973       15 | net.total.mtl
 0.05  0.02        22665       11 | net.tvs
 0.46  0.27       375089      108 | net.twave
 0.01  0.00         6133        3 | net.txdirect
 0.10  0.13       175703       23 | net.tyler
 0.06  0.06        87869       14 | net.tyrell.tyrell
 0.05  0.02        24948       12 | net.u-net.is2.ascend3
 0.06  0.06        79930       14 | net.ultra.ma.blk
 0.03  0.05        70818        6 | net.ultra.ma.ltn
 0.01  0.03        36054        3 | net.up
 0.01  0.03        36385        3 | net.usacomputers
 0.24  0.21       282865       57 | net.usit.dynamic
 0.06  0.07        99283       14 | net.uu.ms.ab.edmonton.max1
 0.02  0.03        44706        4 | net.uu.ms.az.phoenix.max2
 0.05  0.02        33237       12 | net.uu.ms.bc.vancouver.max1
 0.03  0.02        25678        6 | net.uu.ms.ca.los-angeles.max10
 0.01  0.03        36054        3 | net.uu.ms.ca.los-angeles.max14
 0.01  0.01        20162        3 | net.uu.ms.ca.los-angeles.max15
 0.01  0.01         9657        3 | net.uu.ms.ca.los-angeles.max25
 0.04  0.02        22440        9 | net.uu.ms.ca.los-angeles.max35
 0.01  0.03        47526        3 | net.uu.ms.ca.los-angeles.max38
 0.03  0.03        41212        6 | net.uu.ms.ca.los-angeles.max7
 0.05  0.03        40184       12 | net.uu.ms.ca.los-angeles.max73
 0.00  0.00          383        1 | net.uu.ms.ca.los-angeles.max8
 0.05  0.02        24647       11 | net.uu.ms.ca.los-angeles.max9
 0.02  0.01        14184        5 | net.uu.ms.ca.san-francisco.max19
 0.01  0.03        36404        3 | net.uu.ms.ca.santa-clara.max3
 0.04  0.02        22700       10 | net.uu.ms.ca.santa-clara.max5
 0.06  0.03        41941       13 | net.uu.ms.ca.santa-clara.max7
 0.01  0.00          999        3 | net.uu.ms.co.denver.max10
 0.01  0.04        50621        3 | net.uu.ms.co.denver.max2
 0.02  0.03        44126        4 | net.uu.ms.co.denver.max9
 0.03  0.00         4755        6 | net.uu.ms.dc.washington.max13
 0.05  0.01        14779       12 | net.uu.ms.dc.washington.max17
 0.04  0.02        21319        9 | net.uu.ms.dc.washington.max19
 0.06  0.05        72564       13 | net.uu.ms.dc.washington.max4
 0.03  0.04        54629        6 | net.uu.ms.dc.washington.max5
 0.06  0.05        69807       13 | net.uu.ms.dc.washington.max9
 0.01  0.03        36404        3 | net.uu.ms.dc.washington2.max14
 0.01  0.03        38908        3 | net.uu.ms.fl.miami.max10
 0.01  0.03        44387        3 | net.uu.ms.fl.miami.max7
 0.14  0.10       134608       33 | net.uu.ms.fl.orlando.max10
 0.06  0.06        76648       14 | net.uu.ms.fl.orlando.max26
 0.02  0.05        74248        5 | net.uu.ms.fl.orlando.max5
 0.01  0.04        50621        3 | net.uu.ms.fl.orlando.max6
 0.06  0.03        36224       15 | net.uu.ms.fl.orlando.max9
 0.01  0.03        34277        3 | net.uu.ms.ga.atlanta.max13
 0.01  0.03        47526        3 | net.uu.ms.ga.atlanta.max29
 0.07  0.07        99944       16 | net.uu.ms.il.chicago.max17
 0.04  0.02        24256       10 | net.uu.ms.il.chicago.max2
 0.04  0.02        23615        9 | net.uu.ms.il.chicago.max25
 0.03  0.02        28745        7 | net.uu.ms.il.chicago.max3
 0.03  0.01        15776        6 | net.uu.ms.il.chicago.max30
 0.05  0.02        24705       11 | net.uu.ms.il.chicago.max4
 0.03  0.01        15776        6 | net.uu.ms.il.chicago2.max2
 0.01  0.03        36054        3 | net.uu.ms.in.indianapolis.max1
 0.06  0.02        24659       13 | net.uu.ms.in.indianapolis.max4
 0.12  0.08       111221       28 | net.uu.ms.la.new-orleans.max2
 0.01  0.00          999        3 | net.uu.ms.ma.boston.max10
 0.02  0.03        44446        4 | net.uu.ms.ma.boston.max12
 0.01  0.03        41739        3 | net.uu.ms.ma.boston.max8
 0.08  0.05        72317       18 | net.uu.ms.mi.detroit.max8
 0.09  0.08       111724       21 | net.uu.ms.mo.kansas-city.max5
 0.11  0.07        90601       27 | net.uu.ms.mo.st-louis.max1
 0.05  0.03        39298       12 | net.uu.ms.nc.raleigh.max15
 0.12  0.05        64882       28 | net.uu.ms.nc.raleigh.max4
 0.05  0.05        68897       12 | net.uu.ms.nj.newark.max1
 0.06  0.07        96050       15 | net.uu.ms.nj.newark.max11
 0.09  0.09       116143       20 | net.uu.ms.nj.newark.max3
 0.05  0.02        28396       12 | net.uu.ms.ny.new-york.max10
 0.03  0.07        94864        8 | net.uu.ms.ny.new-york.max12
 0.02  0.03        45509        4 | net.uu.ms.ny.new-york.max20
 0.06  0.04        50873       15 | net.uu.ms.ny.new-york.max43
 0.00  0.00         1080        1 | net.uu.ms.ny.new-york.max5
 0.19  0.42       570374       44 | net.uu.ms.oh.cleveland.max28
 0.01  0.02        26888        3 | net.uu.ms.oh.cleveland.max5
 0.08  0.05        68328       19 | net.uu.ms.oh.cleveland.max8
 0.06  0.02        33765       14 | net.uu.ms.on.toronto.max1
 0.02  0.03        35198        4 | net.uu.ms.or.portland.max1
 0.01  0.05        66227        3 | net.uu.ms.or.portland.max12
 0.01  0.01        20162        3 | net.uu.ms.or.portland.max9
 0.04  0.01         9409        9 | net.uu.ms.pa.philadelphia.max51
 0.11  0.21       285611       27 | net.uu.ms.pa.philadelphia.max7
 0.04  0.02        20832        9 | net.uu.ms.sc.columbia.max5
 0.04  0.05        71606       10 | net.uu.ms.tx.dallas.max12
 0.01  0.05        63630        3 | net.uu.ms.tx.dallas.max15
 0.01  0.04        50621        3 | net.uu.ms.tx.dallas.max4
 0.08  0.07        96873       18 | net.uu.ms.tx.dallas.max8
 0.08  0.03        38946       18 | net.uu.ms.tx.houston.max11
 0.10  0.18       244722       23 | net.uu.ms.tx.houston.max12
 0.01  0.03        38784        3 | net.uu.ms.tx.houston.max21
 0.06  0.09       116243       13 | net.uu.ms.tx.houston2.max5
 0.06  0.03        34291       13 | net.uu.ms.ut.salt-lake-city.max1
 0.01  0.03        41724        3 | net.uu.ms.ut.salt-lake-city.max5
 0.02  0.03        38787        4 | net.uu.ms.wa.seattle.max11
 0.06  0.09       124492       14 | net.uu.ms.wa.seattle.max14
 0.05  0.05        66537       12 | net.uu.ms.wa.seattle.max17
 0.01  0.01        17428        3 | net.uu.ms.wa.seattle.max28
 0.07  0.06        87503       17 | net.uu.ms.wa.seattle.max3
 0.06  0.03        47211       14 | net.uu.ms.wa.seattle.max41
 0.05  0.06        76184       12 | net.uu.ms.wa.seattle.max45
 0.11  0.09       121750       25 | net.uu.ms.wa.seattle.max7
 0.24  0.15       200847       57 | net.vcomm
 0.01  0.01        19800        3 | net.videotron.mmtl.223
 0.07  0.06        88635       17 | net.videotron.mque.209
 0.04  0.00         6707        9 | net.videotron.mque.229
 0.01  0.04        51694        3 | net.visi.nn
 0.00  0.00          732        1 | net.vni
 0.22  0.15       201314       52 | net.voyager
 0.04  0.02        21923        9 | net.voyager.dial
 0.01  0.05        64006        3 | net.voyageronline.chatt
 0.02  0.03        36387        4 | net.warwick
 0.13  0.08       110971       31 | net.wctc
 0.06  0.07        88817       14 | net.webstersite
 0.40  0.54       738363       94 | net.webtv.alma.isp
 0.06  0.03        44844       13 | net.weir
 0.05  0.09       123406       12 | net.west.vta
 0.04  0.02        23462       10 | net.why
 0.02  0.01        20402        4 | net.why.dal.max1
 0.12  0.17       237210       28 | net.worldweb
 0.03  0.01        19350        8 | net.wt
 0.04  0.15       210036       10 | net.xtn.greene
 0.17  0.23       312109       41 | net.zapcom
 0.02  0.05        70092        4 | net.ziplink
 0.07  0.13       171550       16 | net.zoomnet.jackson
 0.01  0.01        18338        3 | nl.caiw
 0.04  0.02        20708        9 | nl.eur.remote
 0.00  0.00          382        1 | nl.publishnet
 0.01  0.03        47168        3 | nl.tip.pop
 0.04  0.09       116706        9 | nl.worldaccess
 0.08  0.04        57507       18 | nl.worldonline
 0.02  0.05        65953        5 | no.sn.ppp
 0.09  0.05        70253       22 | no.telepost
 0.02  0.03        42905        4 | nz.ac.waikato
 0.01  0.02        24501        3 | nz.co.es
 0.01  0.02        22246        3 | nz.co.ramhb
 0.01  0.05        66087        3 | nz.co.xtra
 0.05  0.02        26789       11 | org.apc.chasque
 0.06  0.02        33159       13 | org.cam.hip
 0.03  0.08       105646        6 | org.carl
 0.04  0.04        57831       10 | org.childrenshc
 0.01  0.04        54127        3 | org.cpcug
 0.03  0.03        38035        6 | org.crisny
 0.00  0.00         3090        1 | org.freenet
 0.09  0.06        84859       21 | org.hal-pc
 0.01  0.02        31064        3 | org.hgea.annex4
 0.09  0.11       155860       21 | org.hslc
 0.04  0.02        24036       10 | org.io.net5a
 0.06  0.05        65686       14 | org.lafn
 0.06  0.06        82052       14 | org.madigan
 0.04  0.02        25438        9 | org.ncgr
 0.06  0.06        76928       15 | org.nexusprime
 0.03  0.01        15776        6 | org.nmaa
 0.04  0.02        26999       10 | org.northnet.gouverneur
 0.14  0.11       152175       32 | org.rain.sb.term2
 0.03  0.01        15776        6 | org.rcc
 0.01  0.04        48693        3 | org.telis
 0.01  0.03        36404        3 | org.whyy
 0.01  0.04        50621        3 | pe.net.unired
 0.00  0.01        16400        1 | pl.ternet.kaszub
 0.17  0.14       192538       41 | pl.tpnet.katowice
 0.10  0.04        54489       23 | pl.tpnet.warszawa
 0.23  0.11       155399       54 | pt.telepac
 0.05  0.04        59362       11 | ro.logicnet
 0.06  0.02        33578       13 | ro.mta
 0.01  0.01        15136        2 | ru.relcom.z194-58-230
 0.01  0.02        27788        3 | se.abc
 0.04  0.06        78114        9 | se.algonet
 0.03  0.04        55576        6 | se.algonet.ppp
 0.01  0.04        56816        3 | se.infovav
 0.01  0.04        56064        2 | se.liu.lysator.rydnet
 0.04  0.02        24070        9 | se.luth.cdt
 0.07  0.03        36130       17 | se.swipnet
 0.04  0.02        20712        9 | se.uu.bmc
 0.01  0.03        38784        3 | sg.ac.np
 0.11  0.11       145193       26 | sg.com.cyberway
 0.11  0.08       105385       26 | sg.com.singnet
 0.05  0.02        28220       11 | sg.net.pacific
 0.13  0.17       228548       30 | si.eunet.slip
 0.02  0.04        49610        5 | th.ac.ku.sci
 0.08  0.05        70371       18 | th.co.loxinfo
 0.01  0.03        38784        3 | th.go.moph
 0.16  0.26       350415       37 | tr.com.vol
 0.06  0.02        34071       13 | tr.edu.boun.cc
 0.03  0.01         7768        8 | tw.edu
 0.00  0.00          333        1 | tw.edu.ntu.ee
 0.03  0.01        16873        8 | uk.ac.cam.chu
 0.07  0.07       101848       16 | uk.ac.hensa
 0.21  0.11       156210       49 | uk.ac.rl.cis
 0.06  0.10       131988       14 | uk.ac.ucl.cs
 0.08  0.10       134287       19 | uk.co.compulink
 0.16  0.07       101801       37 | uk.co.demon
 0.05  0.02        33644       12 | uk.co.dircon.pool
 0.01  0.01        10976        3 | uk.co.easynet
 0.17  0.10       142192       41 | uk.co.elsevier
 0.00  0.02        33004        1 | uk.co.ggr
 0.01  0.04        47976        3 | uk.co.illumin
 0.09  0.11       147960       20 | uk.co.internet.planet.modem
 0.06  0.06        80194       14 | uk.co.netcomuk
 0.01  0.02        27424        2 | uk.co.pavilion
 0.01  0.03        47168        3 | uk.co.sol
 0.06  0.04        59738       15 | uk.co.tcp
 0.05  0.02        26177       11 | uk.co.ukonline
 0.02  0.00         1396        4 | uk.co.vossnet
 0.04  0.02        30143        9 | uk.net.netcom
 0.05  0.00         6420       11 | uk.nhs
 0.03  0.01        15865        6 | us.az.flagstaff
 0.01  0.04        50621        3 | us.ca.k12.shasta-co
 0.03  0.02        29881        6 | us.fl.greensboro
 0.02  0.01        10878        4 | us.ia.k12.aea10
 0.08  0.13       179793       18 | us.ia.lib.cedar-rapids
 0.08  0.05        70390       19 | us.il.state.isbe
 0.00  0.01        11769        1 | us.md.cc.pg
 0.03  0.09       117975        8 | us.md.lib
 0.08  0.11       150154       19 | us.md.lib.bcpl
 0.07  0.05        70535       17 | us.mi.cc.ncmc
 0.00  0.02        27664        1 | us.ny.lib.suffolk
 0.00  0.00         6366        1 | us.oh.columbus.freenet
 0.03  0.04        57388        7 | us.or.coos.cb
 0.03  0.11       151184        7 | us.tx.state.capnet
 0.06  0.02        30741       13 | us.ut.k12.sevier
 0.01  0.03        36054        3 | us.vt.k12
 0.00  0.01        15402        1 | us.vt.state.dol
 0.00  0.04        48583        1 | us.wa.lib.spl
 0.01  0.01        17428        3 | us.wi.tec.milwaukee
 0.04  0.05        65575       10 | za.co.hipsys
 0.13  0.05        72383       31 | za.co.icon
</PRE>
<HR>
<H2><A NAME="Archive">Total Transfers by URL/Archive Section</A></H2>
<PRE>
%Reqs %Byte  Bytes Sent  Requests   Archive Section
----- ----- ------------ -------- |------------------------------------
 6.79  3.55      4839890     1597 | /
 5.80  3.45      4710779     1365 | /5per.gif
 0.14  0.10       132062       33 | /about.htm
 0.11  0.05        74469       25 | /aceinh.htm
 0.19  0.19       262005       44 | /antidepr.htm
 0.79  0.42       571172      186 | /av.htm
 0.63  0.34       467979      149 | /av2.htm
 1.61  0.84      1148068      379 | /av3.htm
 0.02  0.01        16630        5 | /av4.htm
 0.19  0.13       174956       44 | /bblock.htm
 0.09  0.06        79398       22 | /calch.htm
 0.31  0.10       135959       73 | /cardiova.htm
 0.01  0.00          808        2 | /cgi/
 0.05  0.10       132260       12 | /cgi/brand/image/ogen.gif
 0.12  0.17       238409       29 | /cgi/brand/image/provera.gif
 0.06  0.41       557556       14 | /cgi/brand/ogen.htm
 0.14  0.44       604765       33 | /cgi/brand/provera.htm
 0.13  0.02        23312       31 | /cgi/brand/redball.gif
 0.17  0.08       103272       39 | /cgi/brand/rx.gif
 0.05  0.00         4917       11 | /cgi/brand/tm.gif
 5.40  0.93      1270212     1270 | /cgi/count.gif
 0.03  0.00         2706        6 | /cgi/generic/
 0.06  0.16       217352       15 | /cgi/generic/acetcod.htm
 0.09  0.67       917919       20 | /cgi/generic/acyclo.htm
 0.07  0.17       226983       16 | /cgi/generic/albut1.htm
 0.03  0.11       154022        6 | /cgi/generic/alendron.htm
 0.04  0.26       348970       10 | /cgi/generic/allopur.htm
 0.17  1.58      2154838       41 | /cgi/generic/alpraz.htm
 0.09  0.39       533170       22 | /cgi/generic/amitrip.htm
 0.08  0.36       497385       19 | /cgi/generic/amlod2.htm
 0.11  0.24       331489       27 | /cgi/generic/amox.htm
 0.04  0.16       221645        9 | /cgi/generic/amoxclav.htm
 0.06  0.23       317044       13 | /cgi/generic/amphet.htm
 0.04  0.06        86283       10 | /cgi/generic/apap.htm
 0.03  0.07        99943        6 | /cgi/generic/asa.htm
 0.01  0.03        46622        2 | /cgi/generic/astem.htm
 0.14  0.92      1253100       33 | /cgi/generic/atenolol.htm
 0.06  0.30       408177       14 | /cgi/generic/azith.htm
 0.01  0.03        45742        2 | /cgi/generic/beclo.htm
 0.03  0.10       131002        8 | /cgi/generic/beclo1.htm
 0.05  0.33       454641       11 | /cgi/generic/benaz.htm
 0.04  0.38       515245        9 | /cgi/generic/bishctz.htm
 0.05  0.33       447186       12 | /cgi/generic/buprop.htm
 0.07  0.36       490953       16 | /cgi/generic/buspir.htm
 0.05  0.29       390921       12 | /cgi/generic/butalcod.htm
 0.03  0.25       337578        6 | /cgi/generic/captop.htm
 0.08  0.38       520277       19 | /cgi/generic/carbam.htm
 0.05  0.08       115500       12 | /cgi/generic/carisop.htm
 0.05  0.15       202616       12 | /cgi/generic/cefaclor.htm
 0.02  0.05        72860        4 | /cgi/generic/cefadrox.htm
 0.02  0.10       132536        4 | /cgi/generic/cefixime.htm
 0.03  0.12       163256        7 | /cgi/generic/cefprozi.htm
 0.05  0.18       240163       11 | /cgi/generic/cefurox.htm
 0.05  0.37       505032       12 | /cgi/generic/cemp.htm
 0.09  0.26       352507       22 | /cgi/generic/cephalex.htm
 0.03  0.09       129440        8 | /cgi/generic/chlordia.htm
 0.05  0.30       408303       11 | /cgi/generic/cimet.htm
 0.07  0.50       687996       17 | /cgi/generic/cipro.htm
 0.04  0.12       165589        9 | /cgi/generic/cisap.htm
 0.07  0.32       439245       17 | /cgi/generic/clarith.htm
 0.04  0.12       161286       10 | /cgi/generic/clobet.htm
 0.09  0.44       597762       21 | /cgi/generic/clomiph.htm
 0.03  0.27       374245        8 | /cgi/generic/clomipr.htm
 0.08  0.19       253186       19 | /cgi/generic/clonaz.htm
 0.04  0.11       152631        9 | /cgi/generic/clonidin.htm
 0.03  0.05        61888        8 | /cgi/generic/cocaine.htm
 0.14  0.72       984696       33 | /cgi/generic/conest.htm
 0.00  0.01         9821        1 | /cgi/generic/cromnas.htm
 0.06  0.21       292795       14 | /cgi/generic/cyclobnz.htm
 0.02  0.21       280972        5 | /cgi/generic/desest.htm
 0.69  4.59      6267546      163 | /cgi/generic/dexfen.htm
 0.01  0.00         3495        3 | /cgi/generic/dexfenx.htm
 0.06  0.01        20004       13 | /cgi/generic/dhea.htm
 0.07  0.18       239341       17 | /cgi/generic/diazepam.htm
 0.06  0.32       439143       15 | /cgi/generic/diclofen.htm
 0.03  0.12       164568        8 | /cgi/generic/dicyc.htm
 0.05  0.44       605974       12 | /cgi/generic/dig.htm
 0.06  0.10       136629       13 | /cgi/generic/dihydram.htm
 0.06  0.25       346149       13 | /cgi/generic/diltiaz.htm
 0.05  0.28       376552       11 | /cgi/generic/dival.htm
 0.03  0.14       194852        8 | /cgi/generic/doxazo.htm
 0.03  0.08       104820        6 | /cgi/generic/doxepin.htm
 0.04  0.23       308770       10 | /cgi/generic/doxycyc.htm
 0.02  0.05        71299        4 | /cgi/generic/ees.htm
 0.07  0.54       730556       16 | /cgi/generic/enalap.htm
 0.00  0.02        21319        1 | /cgi/generic/eryst.htm
 0.01  0.04        58170        3 | /cgi/generic/erythro.htm
 0.06  0.38       520317       13 | /cgi/generic/estrad.htm
 0.02  0.18       251895        5 | /cgi/generic/ethynoc.htm
 0.05  0.38       517032       12 | /cgi/generic/etodolac.htm
 0.03  0.17       230176        8 | /cgi/generic/famot.htm
 0.14  0.35       476415       33 | /cgi/generic/fenflur.htm
 0.02  0.08       104680        5 | /cgi/generic/fexofen.htm
 0.02  0.12       157504        4 | /cgi/generic/finas.htm
 0.05  0.24       328423       11 | /cgi/generic/flucon.htm
 0.02  0.04        52479        4 | /cgi/generic/fludro.htm
 0.18  1.36      1852499       43 | /cgi/generic/fluoxetine.htm
 0.02  0.07        93788        4 | /cgi/generic/flutic.htm
 0.03  0.18       249024        8 | /cgi/generic/fluva.htm
 0.06  0.44       603731       13 | /cgi/generic/fluvox.htm
 0.03  0.23       312032        7 | /cgi/generic/fosinop.htm
 0.07  0.21       283694       16 | /cgi/generic/furos.htm
 0.03  0.18       249307        7 | /cgi/generic/gabapent.htm
 0.04  0.33       444971       10 | /cgi/generic/gemfib.htm
 0.01  0.04        55452        2 | /cgi/generic/glip.htm
 0.01  0.08       115572        3 | /cgi/generic/glipxl.htm
 0.02  0.08       105500        4 | /cgi/generic/glybur.htm
 0.01  0.06        88509        3 | /cgi/generic/glymic.htm
 0.03  0.03        41941        8 | /cgi/generic/guaicod.htm
 0.10  0.11       147309       23 | /cgi/generic/guaiphen.htm
 0.03  0.08       104058        6 | /cgi/generic/hctz.htm
 0.05  0.24       330822       11 | /cgi/generic/hctztri.htm
 0.03  0.07        94282        6 | /cgi/generic/hquine.htm
 0.01  0.03        39194        2 | /cgi/generic/hum7030.htm
 0.00  0.00         4848        1 | /cgi/generic/huminsr.htm
 0.02  0.08       103305        5 | /cgi/generic/humnph.htm
 0.21  0.51       702216       50 | /cgi/generic/hydrocod.htm
 0.04  0.06        77075       10 | /cgi/generic/hydrox.htm
 0.03  0.10       134896        8 | /cgi/generic/hyoscy.htm
 0.09  0.54       737148       21 | /cgi/generic/ibup.htm
 0.03  0.13       174234        6 | /cgi/generic/imip.htm
 0.01  0.04        55861        2 | /cgi/generic/indap.htm
 0.07  0.64       869788       17 | /cgi/generic/indometh.htm
 0.03  0.06        84531        7 | /cgi/generic/ipratrop.htm
 0.01  0.04        55730        2 | /cgi/generic/isomono.htm
 0.03  0.10       138036        6 | /cgi/generic/isomono2.htm
 0.06  0.33       446680       13 | /cgi/generic/isotret.htm
 0.03  0.10       129738        7 | /cgi/generic/kclsr.htm
 0.04  0.06        77346        9 | /cgi/generic/ketocon.htm
 0.05  0.40       551320       11 | /cgi/generic/ketoprof.htm
 0.01  0.12       169707        3 | /cgi/generic/ketor.htm
 0.04  0.27       368883        9 | /cgi/generic/lansop.htm
 0.05  0.26       357960       12 | /cgi/generic/levothy.htm
 0.09  0.69       942629       20 | /cgi/generic/lisinop.htm
 0.03  0.15       203519        8 | /cgi/generic/lngeed.htm
 0.01  0.06        83474        2 | /cgi/generic/loracarb.htm
 0.02  0.06        77924        4 | /cgi/generic/lorat.htm
 0.02  0.12       164990        5 | /cgi/generic/loratd.htm
 0.10  0.23       309282       24 | /cgi/generic/loraz.htm
 0.05  0.25       337282       11 | /cgi/generic/losar.htm
 0.03  0.33       447415        8 | /cgi/generic/losarhct.htm
 0.03  0.21       285152        6 | /cgi/generic/lovastat.htm
 0.03  0.08       113532        6 | /cgi/generic/medrox.htm
 0.02  0.05        72464        4 | /cgi/generic/meper.htm
 0.02  0.06        77417        5 | /cgi/generic/mesal.htm
 0.03  0.03        35424        6 | /cgi/generic/metax.htm
 0.03  0.37       502616        8 | /cgi/generic/metformi.htm
 0.04  0.13       171764       10 | /cgi/generic/methdone.htm
 0.06  0.14       197133       13 | /cgi/generic/methphen.htm
 0.03  0.19       260137        8 | /cgi/generic/methprd.htm
 0.04  0.25       344906       10 | /cgi/generic/metopro.htm
 0.02  0.08       114668        4 | /cgi/generic/metopxl.htm
 0.06  0.35       474544       15 | /cgi/generic/metronid.htm
 0.07  0.05        72150       16 | /cgi/generic/midrin.htm
 0.00  0.03        35842        1 | /cgi/generic/misopro.htm
 0.01  0.03        42969        3 | /cgi/generic/momet.htm
 0.06  0.15       200892       15 | /cgi/generic/ms.htm
 0.06  0.81      1105474       15 | /cgi/generic/mtx.htm
 0.04  0.18       240188       10 | /cgi/generic/nabume.htm
 0.11  0.50       686060       26 | /cgi/generic/naprox.htm
 0.04  0.38       525033       10 | /cgi/generic/nefaz.htm
 0.01  0.02        32235        3 | /cgi/generic/neopolhc.htm
 0.05  0.29       393286       12 | /cgi/generic/nifedxl.htm
 0.01  0.04        53278        2 | /cgi/generic/nitro25m.htm
 0.03  0.17       236456        8 | /cgi/generic/nizat.htm
 0.02  0.20       272080        5 | /cgi/generic/norestoc.htm
 0.00  0.02        20680        1 | /cgi/generic/norgeth.htm
 0.05  0.11       154312       11 | /cgi/generic/nortrip.htm
 0.02  0.03        41230        5 | /cgi/generic/ntg.htm
 0.00  0.01        18781        1 | /cgi/generic/ntgtd.htm
 0.05  0.40       542963       11 | /cgi/generic/oflox.htm
 0.01  0.03        39572        2 | /cgi/generic/olsal.htm
 0.08  0.40       548922       19 | /cgi/generic/omepra.htm
 0.03  0.10       132606        6 | /cgi/generic/oxaproz.htm
 0.09  0.19       253193       21 | /cgi/generic/oxyapap.htm
 0.04  0.06        85955       10 | /cgi/generic/oxyasa.htm
 0.13  1.02      1386972       30 | /cgi/generic/parox.htm
 0.02  0.04        59480        4 | /cgi/generic/pemoline.htm
 0.01  0.04        54219        3 | /cgi/generic/pentox.htm
 0.03  0.07        95144        8 | /cgi/generic/penvk.htm
 0.14  0.23       308658       34 | /cgi/generic/phenterm.htm
 0.05  0.19       264077       11 | /cgi/generic/phenyt.htm
 0.03  0.28       381340        8 | /cgi/generic/pravast.htm
 0.14  0.59       810357       34 | /cgi/generic/pred.htm
 0.03  0.11       153758        7 | /cgi/generic/promcod.htm
 0.03  0.07       102264        6 | /cgi/generic/prometh.htm
 0.05  0.16       218592       12 | /cgi/generic/propox.htm
 0.02  0.06        87485        5 | /cgi/generic/propox2.htm
 0.06  0.33       452298       14 | /cgi/generic/propran.htm
 0.04  0.26       354448        9 | /cgi/generic/quinap.htm
 0.02  0.12       157040        4 | /cgi/generic/ramipril.htm
 0.07  0.35       483773       17 | /cgi/generic/ranit.htm
 5.74  0.67       920925     1350 | /cgi/generic/redball.gif
 0.04  0.39       526605       10 | /cgi/generic/risperid.htm
 6.15  2.40      3268778     1446 | /cgi/generic/rx.gif
 0.04  0.24       326291        9 | /cgi/generic/salmet.htm
 0.02  0.11       145620        5 | /cgi/generic/seleg.htm
 0.19  1.33      1817255       45 | /cgi/generic/sertral.htm
 0.06  0.42       579434       14 | /cgi/generic/simva.htm
 0.02  0.05        63596        4 | /cgi/generic/sucral.htm
 0.05  0.16       220298       11 | /cgi/generic/sulfasal.htm
 0.03  0.21       292142        8 | /cgi/generic/sumitr.htm
 0.07  0.42       573495       16 | /cgi/generic/tamox.htm
 0.02  0.00         2268        5 | /cgi/generic/tar/
 0.00  1.36      1849129        1 | /cgi/generic/tar/gentar.gz
 0.03  0.08       114110        8 | /cgi/generic/temaz.htm
 0.02  0.20       270616        5 | /cgi/generic/teraz.htm
 0.02  0.07        94230        5 | /cgi/generic/terbin.htm
 0.02  0.04        51745        5 | /cgi/generic/tercon.htm
 0.03  0.17       226481        8 | /cgi/generic/terfen.htm
 0.03  0.17       227418        6 | /cgi/generic/tersud.htm
 0.11  0.60       813305       27 | /cgi/generic/testos.htm
 0.04  0.10       142749        9 | /cgi/generic/tetcycl.htm
 0.03  0.13       176162        6 | /cgi/generic/theosr.htm
 0.04  0.25       344916        9 | /cgi/generic/ticlop.htm
 0.03  0.12       159138        6 | /cgi/generic/timolol.htm
 0.13  0.57       782862       30 | /cgi/generic/tramadol.htm
 0.08  0.28       388629       18 | /cgi/generic/traz.htm
 0.03  0.06        85712        8 | /cgi/generic/tretinoin.htm
 0.06  0.24       325136       14 | /cgi/generic/triamaer.htm
 0.04  0.14       189488        9 | /cgi/generic/triamnas.htm
 0.07  0.37       509040       16 | /cgi/generic/trisulf.htm
 0.05  0.47       639473       11 | /cgi/generic/venlafax.htm
 0.05  0.33       447975       11 | /cgi/generic/verapsr.htm
 0.12  0.71       972078       28 | /cgi/generic/warfarin.htm
 0.06  0.06        75750       14 | /cgi/generic/yohimb.htm
 0.05  0.41       554103       11 | /cgi/generic/zolpid.htm
 0.00  0.00         1592        1 | /cgi/mbox.gif
 0.01  0.01        12057        3 | /cgi/opiate.htm
 0.01  0.00         2256        3 | /cgi/redball.gif
 5.39  1.97      2690944     1268 | /cgi/rx.gif
16.20  9.31     12699704     3811 | /cgi/rxlist.cgi
 0.32  0.18       247773       75 | /disclaim.htm
 0.95  0.06        76243      224 | /formmail.cgi
 0.03  0.01        19074        6 | /hb.htm
 5.86  0.95      1299996     1378 | /hi_rec.gif
 1.05  0.44       600700      247 | /interact.htm
 5.68  1.35      1841452     1337 | /mbox.gif
 5.89  2.90      3960426     1385 | /med60.gif
 0.27  0.09       119332       63 | /mono.htm
 0.21  0.20       266333       49 | /nsaid.htm
 0.21  0.14       186206       50 | /opiate.htm
 2.97  0.35       472102      698 | /redball.gif
 0.00  0.25       345232        1 | /restricted/httpd_2411.gz
 6.82  2.62      3576375     1605 | /rx.gif
 0.44  1.39      1890581      103 | /rxlinks.htm
 0.13  0.04        54451       31 | /scoutsel.gif
 0.16  0.07        93319       37 | /stats.htm
 0.04  1.31      1791754       10 | /tempstat.txt
 0.01  0.02        31584        3 | /ticker.txt
 1.99  8.44     11515489      468 | /top200.htm
 0.25  1.07      1457323       58 | /top200a.htm
 0.01  0.00         1560        2 | Code 302 Moved Temporarily
 0.00  0.00          584        1 | Code 401 Unauthorized
 0.00  0.00          556        1 | Code 403 Forbidden
 0.14  0.01        17813       33 | Code 404 Not Found
</PRE>
<HR>
<ADDRESS>This summary was generated by 
<A HREF="http://www.ics.uci.edu/pub/websoft/wwwstat/">wwwstat-2.0</A>
</ADDRESS>
</BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-52</DOCNO>
<DOCOLDNO>IA018-000200-B046-90</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/limit.html 206.86.175.201 19970106233200 text/html 1619
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:25:46 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 1437
Last-modified: Sun, 11 Aug 1996 03:52:57 GMT
</DOCHDR>
 <html>
<head>
<title>
RxList - The Internet Drug Index 
</title>

</head>



<BODY Bgcolor="#ffffff">



<a href="http://www.rxlist2.com/cgi/rxlist.cgi"><img 
src="rx.gif" height=125 width=125 border=0 alt = "click to search RxList" 
align = left vspace =2></a><a 
href="http://www.pointcom.com"><img src="5per.gif" height=72 
width = 72 border=0 alt="top 5%" align=right vspace=2></a><center><font 
size=6><b>RxList<br>The Internet Drug Index </b></font></center> <p><pre>

</pre><center>
<form method=post action="http://www.rxlist2.com/cgi/rxlist.cgi">



<input name=drug size=25>

<input type=submit value="Search for Drug Name">

</dl></form>


<a href="http://www.rxlist2.com/cgi/rxlist.cgi">
<h2><a href="http://www.rxlist2.com/top200.htm">The Top 200
</a></h2>
<h5><a href="http://www.rxlist2.com/mono.htm">[ Indications & Side Effects 
]</a> | <a href="http://www.rxlist2.com/rxlinks.htm">[ Known Links ]</a> | 
<a href="http://www.rxlist2.com/about.htm">[ About RxList ]</a>
<h5>
<hr>
RxList bandwidth limit of 200 megabytes/day and/or 50,000 hits/day has
been reached.  Switching to RxList mirror site!  
<hr>
<img src="mbox.gif" height=45 width=45><br> <a 
href="mailto:rx@rxlist2.com"><h4> E-mail Comments, 
Suggestions, & Corrections to </a><br>
 rx@rxlist2.com </h4>
<hr>
<hr>
<p>
<h5>
copyright 1995 - Neil Sandow, Pharm.D.
</h5></center>
<font COLOR="#FFFFFF">
<!--#counter file="rxcounter"--></font>
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT08-B13-53</DOCNO>
<DOCOLDNO>IA018-000200-B047-64</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/top200.htm/ 206.86.175.201 19970106233710 text/html 32455
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:30:52 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 32272
Last-modified: Sun, 29 Dec 1996 18:36:23 GMT
</DOCHDR>
<html>
<head>
   <title>The Top 200 Presciptions - RxList</title>
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<h2><a href="http://www.rxlist.com"><img src="rx.gif" border=0 height=75 width=75></a>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
<a name="TOP"></a>Top 200 Prescriptions*&nbsp;Ranked/<a href="http://www.rxlist.com/top200a.htm">Alpha</a></h2>

<h3 align=center><a href="#1995 US Prescriptions">By
Prescription Volume</a> | <a href="#*By RxList Search Frequency - Excluding Above">By
RxList Search Frequency*</a></h3>

<p>
<hr></p>

<h3 align=center><a name="1995 US Prescriptions"></a>1995 US Prescriptions
</h3>

<pre><b>Brand Name               Manufacturer              Generic Name</b>
<hr width="100%" ></pre>

<pre><b>Premarin                 Wyeth-Ayerst              <a href="http://www.rxlist.com/cgi/generic/conest.htm">Conjugated Estrogens
</a>Trimox                   Apothecon                 <a href="http://www.rxlist.com/cgi/generic/amox.htm">Amoxicillin
</a>Synthroid                Knoll                     <a href="http://www.rxlist.com/cgi/generic/levothy.htm">Levothyroxine
</a>Zantac                   Glaxo                     <a href="http://www.rxlist.com/cgi/generic/ranit.htm">Ranitidine
</a>Amoxil                   SmithKline Beecham        <a href="http://www.rxlist.com/cgi/generic/amox.htm">Amoxicillin
</a>Lanoxin                  Allen &amp; Hanburys          <a href="http://www.rxlist.com/cgi/generic/dig.htm">Digoxin
</a>Vasotec                  Merck                     <a href="http://www.rxlist.com/cgi/generic/enalap.htm">Enalapril
</a>Procardia XL             Pratt                     <a href="http://www.rxlist.com/cgi/generic/nifedxl.htm">Nifedipine</a> 
Prozac                   Dista                     <a href="http://www.rxlist.com/cgi/generic/fluoxetine.htm">Fluoxetine
</a>Proventil Aerosol        Schering                  <a href="http://www.rxlist.com/cgi/generic/albut1.htm">Albuterol
</a>Cardizem CD              Marion Merrell Dow        <a href="http://www.rxlist.com/cgi/generic/diltiaz.htm">Diltiazem</a> 
Coumadin                 Du Pont Pharm             <a href="http://www.rxlist.com/cgi/generic/warfarin.htm">Warfarin
</a>Zoloft                   Roerig                    <a href="http://www.rxlist.com/cgi/generic/sertral.htm">Sertraline</a>               
Biaxin                   Abbott                    <a href="http://www.rxlist.com/cgi/generic/clarith.htm">Clarithromycin
</a>Hydrocodone/APAP         Watson                    <a href="http://www.rxlist.com/cgi/generic/hydrocod.htm">Hydrocodone/APAP
</a>Augmentin                SmithKline Beecham        <a href="http://www.rxlist.com/cgi/generic/amoxclav.htm">Amoxicillin/Clavulanate
</a>Zestril                  Zeneca                    <a href="http://www.rxlist.com/cgi/generic/lisinop.htm">Lisinopril
</a>Triamterene/HCTZ         Geneva                    <a href="http://www.rxlist.com/cgi/generic/hctztri.htm">Triamterene/HCTZ</a>           
Cipro                    Bayer Pharm               <a href="http://www.rxlist.com/cgi/generic/cipro.htm">Ciprofloxacin
</a>Amoxicillin              Biocraft                  <a href="http://www.rxlist.com/cgi/generic/amox.htm">Amoxicillin</a> 
Prilosec                 Astra/Merck               <a href="http://www.rxlist.com/cgi/generic/omepra.htm">Omeprazole
</a>Ventolin Aerosol         Allen &amp; Hanburys          <a href="http://www.rxlist.com/cgi/generic/albut1.htm">Albuterol
</a>Norvasc                  Pfizer                    <a href="http://www.rxlist.com/cgi/generic/amlod2.htm">Amlodipine
</a>Acetaminophen/Codeine    Lemmon                    <a href="http://www.rxlist.com/cgi/generic/acetcod.htm">Acetaminophen/Codeine</a>     
Veetids                  Apothecon                 <a href="http://www.rxlist.com/cgi/generic/penvk.htm">Penicillin VK
</a>Furosemide                Mylan                     <a href="http://www.rxlist.com/cgi/generic/furos.htm">Furosemide
</a>Claritin                 Schering                  <a href="http://www.rxlist.com/cgi/generic/lorat.htm">Loratadine
</a>Mevacor                  Merck                     <a href="http://www.rxlist.com/cgi/generic/lovastat.htm">Lovastatin
</a>Propoxyphene N/APAP      Mylan                     <a href="http://www.rxlist.com/cgi/generic/propox.htm">Propoxyphene N/APAP</a>     
Dilantin                 Parke-Davis               <a href="http://www.rxlist.com/cgi/generic/phenyt.htm">Phenytoin
</a>Capoten                  Bristol-Myers Squibb      <a href="http://www.rxlist.com/cgi/generic/captop.htm">Captopril
</a>Humulin N                Lilly                     <a href="http://www.rxlist.com/cgi/generic/humnph.htm">Human Insulin-NPH
</a><a href="http://www.rxlist.com/cgi/brand/provera.htm">Provera</a>                  Upjohn                    <a href="http://www.rxlist.com/cgi/generic/medrox.htm">Medroxyprogesterone
</a>Paxil                    SmithKline Beecham        <a href="http://www.rxlist.com/cgi/generic/parox.htm">Paroxetine
</a>Hytrin                   Abbott                    <a href="http://www.rxlist.com/cgi/generic/teraz.htm">Terazosin
</a>Alprazolam               Geneva                    <a href="http://www.rxlist.com/cgi/generic/alpraz.htm">Alprazolam
</a>Ortho-Novum 7/7/7-28     Ortho Pharm               <a href="http://www.rxlist.com/cgi/generic/norestoc.htm">Norethindrone/Ethinyl Estradiol
</a>K-Dur                    Key                       <a href="http://www.rxlist.com/cgi/generic/kclsr.htm">Potassium Chloride</a> 
Pepcid                   Merck                     <a href="http://www.rxlist.com/cgi/generic/famot.htm">Famotidine
</a>Propacet 100             Lemmon                    <a href="http://www.rxlist.com/cgi/generic/propox.htm">Propoxyphene N/APAP
</a>Cephalexin               Biocraft                  <a href="http://www.rxlist.com/cgi/generic/cephalex.htm">Cephalexin
</a>lbuprofen                Knoll                     <a href="http://www.rxlist.com/cgi/generic/ibup.htm">Ibuprofen
</a>Acetaminophen/Codeine    Purepac                   <a href="http://www.rxlist.com/cgi/generic/acetcod.htm">Acetaminophen/Codeine
</a>Relafen                  SmithKline Beecham        <a href="http://www.rxlist.com/cgi/generic/nabume.htm">Nabumetone
</a>Zocor                    Merck                     <a href="http://www.rxlist.com/cgi/generic/simva.htm">Simvastatin</a>     
Seldane                  Marion Merrell Dow        <a href="http://www.rxlist.com/cgi/generic/terfen.htm">Terfenadine</a>     
Triphasil-28             Wyeth-Ayerst              <a href="http://www.rxlist.com/cgi/generic/lngeed.htm">L-Norgestrel/Ethinyl Estradiol</a>     
Klonopin                 Roche                     <a href="http://www.rxlist.com/cgi/generic/clonaz.htm">Clonazepam</a>     
Cefaclor                 Mylan                     <a href="http://www.rxlist.com/cgi/generic/cefaclor.htm">Cefaclor</a>     
Prinivil                 Merck                     <a href="http://www.rxlist.com/cgi/generic/lisinop.htm">Lisinopril</a>     
Atrovent                 Boehringer lngelheim      <a href="http://www.rxlist.com/cgi/generic/ipratrop.htm">Ipratropium</a>     
Estrace                  Bristol-Myers Squibb      <a href="http://www.rxlist.com/cgi/generic/estrad.htm">Estradiol</a>     
Vancenase AQ             Schering                  <a href="http://www.rxlist.com/cgi/generic/beclo1.htm">Beclomethasone
</a>Amitriptyline            Mylan                     <a href="http://www.rxlist.com/cgi/generic/amitrip.htm">Amitriptyline</a>               
Cephalexin               Apothecon                 <a href="http://www.rxlist.com/cgi/generic/cephalex.htm">Cephalexin
</a>Ceftin                   Burroughs Wellcome        <a href="http://www.rxlist.com/cgi/generic/cefurox.htm">Cefuroxime
</a>Pravachol                Bristol-Myers Squibb      <a href="http://www.rxlist.com/cgi/generic/pravast.htm">Pravastatin
</a>Ery-Tab                  Abbott                    <a href="http://www.rxlist.com/cgi/generic/erythro.htm">Erythromycin
</a>Ambien                   Searle                    <a href="http://www.rxlist.com/cgi/generic/zolpid.htm">Zolpidem
</a>Lodine                   Wyeth-Ayerst              <a href="http://www.rxlist.com/cgi/generic/etodolac.htm">Etodolac
</a>Axid                     Lilly                     <a href="http://www.rxlist.com/cgi/generic/nizat.htm">Nizatidine
</a>Estraderm                Ciba                      <a href="http://www.rxlist.com/cgi/generic/estratd.htm">Estradiol
</a>Hydrocodone w/APAP       Qualitest                 <a href="http://www.rxlist.com/cgi/generic/hydrocod.htm">Hydrocodone w/APAP
</a>Ortho-Cept 28            Ortho Pharm               <a href="http://www.rxlist.com/cgi/generic/desest.htm">Desogestrel/Ethinyl Estradiol
</a>Cefzil                   Bristol-Myers Squibb      <a href="http://www.rxlist.com/cgi/generic/cefprozi.htm">Cefprozil
</a>Nitrostat                Parke-Davis               <a href="http://www.rxlist.com/cgi/generic/ntg.htm">Nitroglycerin
</a>Calan SR                 Searle                    <a href="http://www.rxlist.com/cgi/generic/verapsr.htm">Verapamil</a> 
Levoxyl                  Daniels                   <a href="http://www.rxlist.com/cgi/generic/levothy.htm">Levothyroxine
</a>Dyazide                  SmithKline Beecham        <a href="http://www.rxlist.com/cgi/generic/hctztri.htm">Hydrochlorothiazide/Triamterine
</a>Xanax                    Upjohn                    <a href="http://www.rxlist.com/cgi/generic/alpraz.htm">Alprazolam
</a>Deltasone                Upjohn                    <a href="http://www.rxlist.com/cgi/generic/pred.htm">Prednisone
</a>Lotensin                 Ciba                      <a href="http://www.rxlist.com/cgi/generic/benaz.htm">Benazepril
</a>Daypro                   Searle                    <a href="http://www.rxlist.com/cgi/generic/oxaproz.htm">Oxaprozin
</a>Propulsid                Janssen                   <a href="http://www.rxlist.com/cgi/generic/cisap.htm">Cisapride
</a>Atenolol                 Mylan                     <a href="http://www.rxlist.com/cgi/generic/atenolol.htm">Atenolol
</a>Glyburide                Copley                    <a href="http://www.rxlist.com/cgi/generic/glybur.htm">Glyburide
</a>Roxicet                  Roxane                    <a href="http://www.rxlist.com/cgi/generic/oxyapap.htm">Oxycodone/APAP
</a>Lasix                    Hoechst-Roussel           <a href="http://www.rxlist.com/cgi/generic/furos.htm">Furosemide
</a>Duricef                  Bristol-Myers Squibb      <a href="http://www.rxlist.com/cgi/generic/cefadrox.htm">Cefadroxil
</a>Trimeth/Sulfameth        Blocraft                  <a href="http://www.rxlist.com/cgi/generic/trisulf.htm">Trimeth/Sulfameth
</a>Humulin 7O/30            Lilly                     <a href="http://www.rxlist.com/cgi/generic/hum7030.htm">Human Insulin 70/30
</a>Ultram                   McNeil                    <a href="http://www.rxlist.com/cgi/generic/tramadol.htm">Tramadol
</a>Claritin D               Schering                  <a href="http://www.rxlist.com/cgi/generic/loratd.htm">Loratidine/Pseudoephedrine</a>          
Voltaren                 Geigy                     <a href="http://www.rxlist.com/cgi/generic/diclofen.htm">Diclofenac
</a>Lotrisone                Key                       <a href="http://www.rxlist.com/cgi/generic/clobet.htm">Clotrimoxazole/Betamethasone
</a>Azmacort                 Rhone-Poulenc Rorer       <a href="http://www.rxlist.com/cgi/generic/triamaer.htm">Triamcinolone aerosol
</a>Desogen                  Organon                   <a href="http://www.rxlist.com/cgi/generic/desest.htm">Desogestrel/Ethinyl Estradiol
</a>Accupril                 Parke-Davis               <a href="http://www.rxlist.com/cgi/generic/quinap.htm">Quinapril
</a>Verapamil SR             Goldline                  <a href="http://www.rxlist.com/cgi/generic/verapsr.htm">Verapamil</a> 
Zithromax Z-Pak          Pfizer                    <a href="http://www.rxlist.com/cgi/generic/azith.htm">Azithromycin
</a>BuSpar                   Bristol-Myers Squibb      <a href="http://www.rxlist.com/cgi/generic/buspir.htm">Buspirone
</a>Methylphenidate          MD Pharm                  <a href="http://www.rxlist.com/cgi/generic/methphen.htm">Methylphenidate
</a>Lorazepam                Mylan                     <a href="http://www.rxlist.com/cgi/generic/loraz.htm">Lorazepam
</a>Cycrin                   ESI Pharm                 <a href="http://www.rxlist.com/cgi/generic/medrox.htm">Medroxyprogesterone
</a>Medroxyprogesterone      Greenstone Ltd.           <a href="http://www.rxlist.com/cgi/generic/medrox.htm">Medroxyprogesterone
</a>Prednisone               Schein                    <a href="http://www.rxlist.com/cgi/generic/pred.htm">Prednisone
</a>Adalat CC                Bayer                     <a href="http://www.rxlist.com/cgi/generic/nifedxl.htm">Nifedipine</a> 
Beconase AQ              Allen &amp; Hanburys          <a href="http://www.rxlist.com/cgi/generic/beclo1.htm">Beclomethasone
</a>Trental                  Hoechst-Roussel           <a href="http://www.rxlist.com/cgi/generic/pentox.htm">Pentoxifylline
</a>Timoptic                 Merck                     <a href="http://www.rxlist.com/cgi/generic/timolol.htm">Timolol
</a>Lorabid                  Lilly                     <a href="http://www.rxlist.com/cgi/generic/loracarb.htm">Loracarbef
</a>Darvocet-N 100           Lilly                     <a href="http://www.rxlist.com/cgi/generic/propox.htm">Propoxyphene-N/APAP
</a>Lorazepam                Purepac                   <a href="http://www.rxlist.com/cgi/generic/loraz.htm">Lorazepam
</a>Retin-A                  Ortho Derm                <a href="http://www.rxlist.com/cgi/generic/tretinoin.htm">Tretinoin
</a>Cimetidine               Mylan                     <a href="http://www.rxlist.com/cgi/generic/cimet.htm">Cimetidine
</a>Lo/Ovral-28              Wyeth-Ayerst              <a href="http://www.rxlist.com/cgi/generic/norgeth.htm">Norgestrel/Ethinyl Estradiol
</a>Seldane-D                Marion Merrell Dow        <a href="http://www.rxlist.com/cgi/generic/tersud.htm">Terfenadine/Pseudoephedrine
</a>Naproxen                 Mylan                     <a href="http://www.rxlist.com/cgi/generic/naprox.htm">Naproxen
</a>Glucotrol XL             Pratt                     <a href="http://www.rxlist.com/cgi/generic/glipxl.htm">Glipizide</a> 
Lescol                   Sandoz                    <a href="http://www.rxlist.com/cgi/generic/fluva.htm">Fluvastatin
</a>Diflucan                 Roerig                    <a href="http://www.rxlist.com/cgi/generic/flucon.htm">Fluconazole
</a>Hydrochlorothiazide      Zenith                    <a href="http://www.rxlist.com/cgi/generic/hctz.htm">Hydrochlorothiazide
</a>Potassium Chloride       Ethex                     <a href="http://www.rxlist.com/cgi/generic/kclsr.htm">Potassium Chloride
</a>Neomycin/Polymx/HC       Schein                    <a href="http://www.rxlist.com/cgi/generic/neopolhc.htm">Neomycin/Polymx/HC
</a>Cardura                  Roerig                    <a href="http://www.rxlist.com/cgi/generic/doxazo.htm">Doxazosin
</a>Atenolol                 Lederie SP                <a href="http://www.rxlist.com/cgi/generic/atenolol.htm">Atenolol
</a>Depakote                 Abbott                    <a href="http://www.rxlist.com/cgi/generic/dival.htm">Divalproex
</a>Glynase Prestab          Upjohn                    <a href="http://www.rxlist.com/cgi/generic/glymic.htm">Glyburide
</a>Tegretol                 Basel                     <a href="http://www.rxlist.com/cgi/generic/carbam.htm">Carbamazepine
</a>Alprazolam               Greenstone                <a href="http://www.rxlist.com/cgi/generic/alpraz.htm">Alprazolam
</a>Suprax                   Lederie Rx                <a href="http://www.rxlist.com/cgi/generic/cefixime.htm">Cefixime
</a>Gemfibrozil              Warner Chiloott           <a href="http://www.rxlist.com/cgi/generic/gemfib.htm">Gemfibrozil
</a>Trimeth/Sulfameth        Mutual                    <a href="http://www.rxlist.com/cgi/generic/trisulf.htm">Trimeth/Sulfameth
</a>Tri-Levlen 28            Berlex                    <a href="http://www.rxlist.com/cgi/generic/lngeed.htm">L-Norgestrel/Ethinyl Estradiol
</a>Lopressor                Geigy                     <a href="http://www.rxlist.com/cgi/generic/metopro.htm">Metoprolol
</a>Glipizide                Mylan                     <a href="http://www.rxlist.com/cgi/generic/glip.htm">Glipizide
</a>Motrin                   McNeil-CPC                <a href="http://www.rxlist.com/cgi/generic/ibup.htm">Ibuprofen
</a>Macrobid                 Procter &amp; Gamble          <a href="http://www.rxlist.com/cgi/generic/nitro25m.htm">Nitrofurantoin
</a>Amoxicillin Trihydrate   Warner Chilcott           <a href="http://www.rxlist.com/cgi/generic/amox.htm">Amoxicillin
</a>Metoprolol Tartrate      Geneva                    <a href="http://www.rxlist.com/cgi/generic/metopro.htm">Metoprolol
</a>Nitro-Dur                Key                       <a href="http://www.rxlist.com/cgi/generic/ntgtd.htm">Nitroglycerin
</a>Bactroban                SmithKline Beecham        <a href="http://www.rxlist.com/cgi/generic/mupi.htm">Mupirocin
</a>Amoxicillin Trihydrate   Novopharm                 <a href="http://www.rxlist.com/cgi/generic/amox.htm">Amoxicillin
</a>Humulin R                Lilly                     <a href="http://www.rxlist.com/cgi/generic/huminsr.htm">Human Insulin Regular
</a>Tenormin                 Zeneca                    <a href="http://www.rxlist.com/cgi/generic/atenolol.htm">Atenolol
</a>Zovirax Capsules         Burroughs Wellcome        <a href="http://www.rxlist.com/cgi/generic/acyclo.htm">Acyclovir
</a>DiaBeta                  Hoechst-Roussel           <a href="http://www.rxlist.com/cgi/generic/glybur.htm">Glyburide
</a>Phenergan                Wyeth-Ayerst              <a href="http://www.rxlist.com/cgi/generic/prometh.htm">Promethazine
</a>Lorcet 10/650            Forest                    <a href="http://www.rxlist.com/cgi/generic/hydrocod.htm">Hydrocodone/APAP</a>               
Cyclobenzaprine Hcl      Mylan                     <a href="http://www.rxlist.com/cgi/generic/cyclobnz.htm">Cyclobenzaprine
</a>Albuterol                Lemmon                    <a href="http://www.rxlist.com/cgi/generic/albut1.htm">Albuterol
</a>Atenolol                 Geneva                    <a href="http://www.rxlist.com/cgi/generic/atenolol.htm">Atenolol
</a>Lozol                    Rhone-Poulenc Rorer       <a href="http://www.rxlist.com/cgi/generic/indap.htm">Indapamide
</a>Altace                   Hoechst-Roussel           <a href="http://www.rxlist.com/cgi/generic/ramipril.htm">Ramipril
</a>Theo-Dur                 Key                       <a href="http://www.rxlist.com/cgi/generic/theosr.htm">Theophylline
</a>Verelan                  Lederie Rx                <a href="http://www.rxlist.com/cgi/generic/verapsr.htm">Verapamil
</a>Micronase                Upjohn                    <a href="http://www.rxlist.com/cgi/generic/glybur.htm">Glyburide
</a>Dilacor XR               Rhone-Poulenc Rorer       <a href="http://www.rxlist.com/cgi/generic/diltiaz.htm">Diltiazem
</a>Cephalexin               Zenith                    <a href="http://www.rxlist.com/cgi/generic/cephalex.htm">Cephalexin
</a>lmitrex                  Cerenex                   <a href="http://www.rxlist.com/cgi/generic/sumitr.htm">Sumatriptan
</a>Toradol                  Roche                     <a href="http://www.rxlist.com/cgi/generic/ketor.htm">Ketorolac
</a>Doxycycline Hyclate      Zenith                    <a href="http://www.rxlist.com/cgi/generic/doxycyc.htm">Doxycycline
</a>Terazol 7                Ortho Pharm               <a href="http://www.rxlist.com/cgi/generic/tercon.htm">Terconazole
</a>Klor-Con 10              Upsher-Smith              <a href="http://www.rxlist.com/cgi/generic/kclsr.htm">Potassium Chloride
</a>Tylenol/Codeine          McNeil Pharm              <a href="http://www.rxlist.com/cgi/generic/acetcod.htm">Acetaminophen/Codeine
</a>Nortriptyline HCI        Schein                    <a href="http://www.rxlist.com/cgi/generic/nortrip.htm">Nortriptyline
</a>Albuterol                Warrick                   <a href="http://www.rxlist.com/cgi/generic/albut1.htm">Albuterol
</a>Ortho-Novum 1/35-28      Ortho Pharm               <a href="http://www.rxlist.com/cgi/generic/norestoc.htm">Norethindrone/Ethinyl Estradiol
</a>Diazepam                 Mylan                     <a href="http://www.rxlist.com/cgi/generic/diazepam.htm">Diazepam
</a>Ceclor                   Lilly                     <a href="http://www.rxlist.com/cgi/generic/cefaclor.htm">Cefaclor
</a>Serevent                 Allen &amp; Hanburys          <a href="http://www.rxlist.com/cgi/generic/salmet.htm">Salmeterol
</a>Vanceril                 Key                       <a href="http://www.rxlist.com/cgi/generic/beclo.htm">Beclomethasone
</a>Floxin                   Ortho Pharm               <a href="http://www.rxlist.com/cgi/generic/oflox.htm">Ofloxacin
</a>Ritalin                  Ciba                      <a href="http://www.rxlist.com/cgi/generic/methphen.htm">Methylphenidate
</a>Methylprednisolone       Duramed                   <a href="http://www.rxlist.com/cgi/generic/methprd.htm">Methylprednisolone
</a>Erythrocin Stearate      Abbott                    <a href="http://www.rxlist.com/cgi/generic/eryst.htm">Erythromycin
</a>Metoprolol Tartrate      Mylan                     <a href="http://www.rxlist.com/cgi/generic/metopro.htm">Metoprolol
</a>Glucotrol                Pratt                     <a href="http://www.rxlist.com/cgi/generic/glip.htm">Glipizide
</a>Temazepam                Mylan                     <a href="http://www.rxlist.com/cgi/generic/temaz.htm">Temazepam
</a>Cyclobenzaprine HCI      Schein                    <a href="http://www.rxlist.com/cgi/generic/cyclobnz.htm">Cyclobenzaprine
</a>Carafate                 Marion Merrell Dow        <a href="http://www.rxlist.com/cgi/generic/sucral.htm">Sucralfate
</a>Dicyclomine HCI          Rugby                     <a href="http://www.rxlist.com/cgi/generic/dicyc.htm">Dicyclomine
</a>Hismanal                 Janssen                   <a href="http://www.rxlist.com/cgi/generic/astem.htm">Astemizole
</a>Effexor                  Wyeth-Ayerst              <a href="http://www.rxlist.com/cgi/generic/venlafax.htm">Venlafaxine</a>          
Loestrin-FE 1.5/30       Parke-Davis               <a href="http://www.rxlist.com/cgi/generic/norestoc.htm">Norethindrone/Ethinyl Estradiol
</a>Children's Advil         Wyeth-Ayerst              <a href="http://www.rxlist.com/cgi/generic/ibup.htm">Ibuprofen
</a>Sumycin                  Apothecon                 <a href="http://www.rxlist.com/cgi/generic/tetcycl.htm">Tetracycline
</a>Flonase                  Allen &amp; Hanburys          <a href="http://www.rxlist.com/cgi/generic/flutic.htm">Fluticasone
</a>Toprol-XL                Astra                     <a href="http://www.rxlist.com/cgi/generic/metopxl.htm">Metoprolol
</a>Vicodin                  Knoll                     <a href="http://www.rxlist.com/cgi/generic/hydrocod.htm">Hydrocodone/APAP
</a>Hydrocodone/APAP         Rugby                     <a href="http://www.rxlist.com/cgi/generic/hydrocod.htm">Hydrocodone/APAP
</a>Glyburide                Greenstone                <a href="http://www.rxlist.com/cgi/generic/glybur.htm">Glyburide
</a>Zovirax Tablets          Burroughs Wellcome        <a href="http://www.rxlist.com/cgi/generic/acyclo.htm">Acyclovir
</a>Elocon                   Schering                  <a href="http://www.rxlist.com/cgi/generic/momet.htm">Mometasone
</a>Cotrim DS                Lemmon                    <a href="http://www.rxlist.com/cgi/generic/trisulf.htm">Trimeth/Sulfameth
</a>Glyburide                Geneva                    <a href="http://www.rxlist.com/cgi/generic/glybur.htm">Glyburide
</a>E.E.S.                   Abbott                    <a href="http://www.rxlist.com/cgi/generic/ees.htm">Erythromycin
</a>Carisoprodol             Schein                    <a href="http://www.rxlist.com/cgi/generic/carisop.htm">Carisoprodol
</a>Oruvail                  Wyeth-Ayerst              <a href="http://www.rxlist.com/cgi/generic/ketoprof.htm">Ketoprofen
</a>Nasacort                 Rhone-Poulenc Rorer       <a href="http://www.rxlist.com/cgi/generic/triamnas.htm">Triamcinolone
</a>Valium                   Roche                     <a href="http://www.rxlist.com/cgi/generic/diazepam.htm">Diazepam
</a>Hydrocodone w/APAP       Warner Chilcott           <a href="http://www.rxlist.com/cgi/generic/hydrocod.htm">Hydrocodone/APAP
</a>Demulen 1/35-28          Searle                    <a href="http://www.rxlist.com/cgi/generic/ethynoc.htm">Ethynodiol/Ethinyl Estradiol</a>               
Monopril                 Bristol-Myers Squibb      <a href="http://www.rxlist.com/cgi/generic/fosinop.htm">Fosinopril
</a>Fiorinal/Codeine         Sandoz                    <a href="http://www.rxlist.com/cgi/generic/butalcod.htm">Butalbital/ASA/Caffeine/Codeine
</a>Promethazine/Codeine     Barre-National            <a href="http://www.rxlist.com/cgi/generic/promcod.htm">Promethazine/Codeine
</a>Penicillin VK            Mylan                     <a href="http://www.rxlist.com/cgi/generic/penvk.htm">Penicillin VK
</a>Guaifenesin/PPA          Duramed                   <a href="http://www.rxlist.com/cgi/generic/guaiphen.htm">Guaifenesin/Phenylpropanolamine
</a>Nizoral Cream    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;  Janssen                   <a href="http://www.rxlist.com/cgi/generic/ketocon.htm">Ketoconazole</a></b></pre>

<pre><i>*source: Pharmacy Times, April 1996</i>

<hr width="100%" ></pre>

<h3 align=center><a name="*By RxList Search Frequency - Excluding Above"></a>*By
RxList Search Frequency - Excluding Above Products</h3>

<pre><b>Brand Name               Manufacturer             Generic Name
<hr>
Redux                    Wyeth                     <a href="http://www.rxlist.com/cgi/generic/dexfen.htm">Dexfenfluramine
</a>Wellbutrin               Wellcome/Glaxo            <a href="http://www.rxlist.com/cgi/generic/buprop.htm">Bupropion
</a>Serzone                  Bristol Myers/Squibb      <a href="http://www.rxlist.com/cgi/generic/nefaz.htm">Nefazodone
</a>Pondimin                 A.H. Robins               <a href="http://www.rxlist.com/cgi/generic/fenflur.htm">Fen</a>fluramine
Fastin                   Smith Kline Beecham       <a href="http://www.rxlist.com/cgi/generic/phenterm.htm">Phen</a>termine
Zyrtec                   Pfizer                    <a href="http://www.rxlist.com/cgi/generic/cetiriz.htm">Cetirizine
</a>Accutane                 Roche                     <a href="http://www.rxlist.com/cgi/generic/isotret.htm">Isotretinoin
</a>Midrin                   Carnrick                  <a href="http://www.rxlist.com/cgi/generic/midrin.htm">Isometheptene/Dichloralphenazone/APAP
</a>Demerol                  Sanofi Winthrop           <a href="http://www.rxlist.com/cgi/generic/meper.htm">Meperidine
</a>Adderall                 Richwood                  <a href="http://www.rxlist.com/cgi/generic/amphet.htm">Mixed Amphetamine Salts 
</a>Aspirin                  Various                   <a href="http://www.rxlist.com/cgi/generic/asa.htm">Aspirin
</a>Fosamax                  Merck                     <a href="http://www.rxlist.com/cgi/generic/alendron.htm">Alendronate
</a>Neurontin                Parke-Davis               <a href="http://www.rxlist.com/cgi/generic/gabapent.htm">Gabapentin
</a>Glucophage               Bristol-Myers/Squibb      <a href="http://www.rxlist.com/cgi/generic/metformi.htm">Metformin
</a>Methotrexate             Various                   <a href="http://www.rxlist.com/cgi/generic/mtx.htm">Methotrexate
</a>Lamisil                  Sandoz                    <a href="http://www.rxlist.com/cgi/generic/terbin.htm">Terbinafine
</a>Ticlid                   Syntex                    <a href="http://www.rxlist.com/cgi/generic/ticlop.htm">Ticlopidine
</a>Tylenol                  Mc Neil                   <a href="http://www.rxlist.com/cgi/generic/apap.htm">Acetaminophen
</a>Proscar                  Merck                     <a href="http://www.rxlist.com/cgi/generic/finas.htm">Finasteride
</a>Risperdal                Janssen                   <a href="http://www.rxlist.com/cgi/generic/risperid.htm">Risperidone
</a>Desyrel                  Bristol-Myers/Squibb      <a href="http://www.rxlist.com/cgi/generic/traz.htm">Trazodone
</a>Inderal                  Wyeth-Ayerst              <a href="http://www.rxlist.com/cgi/generic/propran.htm">Propranolol
</a>Morphine                 Various                   <a href="http://www.rxlist.com/cgi/generic/ms.htm">Morphine
</a>Indocin                  Merck                     <a href="http://www.rxlist.com/cgi/generic/indometh.htm">Indomethacin
</a>Nasalcrom                Fisons                    <a href="http://www.rxlist.com/cgi/generic/cromnas.htm">Cromolyn
</a>Flagyl                   Searle                    <a href="http://www.rxlist.com/cgi/generic/metronid.htm">Metronidazole
</a>Cozaar                   Merck                     <a href="http://www.rxlist.com/cgi/generic/losar.htm">Losartan
</a>Cocaine                  Various                   <a href="http://www.rxlist.com/cgi/generic/cocaine.htm">Cocaine
</a>Benadryl                 Parke-Davis               <a href="http://www.rxlist.com/cgi/generic/dihydram.htm">Diphenhydramine
</a>Allegra                  Hoechst Marion Roussel    <a href="http://www.rxlist.com/cgi/generic/fexofen.htm">Fexofenadine
</a>Cylert                   Abbott                    <a href="http://www.rxlist.com/cgi/generic/pemoline.htm">Pemoline
</a>Yocon                    Palisades                 <a href="http://www.rxlist.com/cgi/generic/yohimb.htm">Yohimbine
</a>Skelaxin                 Carnrick                  <a href="http://www.rxlist.com/cgi/generic/metax.htm">Metaxalone
</a>Catapres                 Boehringer Ingelheim      <a href="http://www.rxlist.com/cgi/generic/clonidin.htm">Clonidine
</a>Sinequan                 Pfizer Roerig             <a href="http://www.rxlist.com/cgi/generic/doxepin.htm">Doxepin
</a>Luvox                    Solvay                    <a href="http://www.rxlist.com/cgi/generic/fluvox.htm">Fluvoxamine
</a>Clomid                   Marion Merrell Dow        <a href="http://www.rxlist.com/cgi/generic/clomiph.htm">Clomiphine
</a>Azulfidine               Pharmacia                 <a href="http://www.rxlist.com/cgi/generic/sulfasal.htm">Sulfasalazine
</a>Dipentum                 Pharmacia                 <a href="http://www.rxlist.com/cgi/generic/olsal.htm">Olsalazine
</a>Mesalamine               Various                   <a href="http://www.rxlist.com/cgi/generic/mesal.htm">Mesalamine
</a>Cytotec                  Searle                    <a href="http://www.rxlist.com/cgi/generic/misopro.htm">Misoprostol
</a>Eldepryl                 Somerset                  <a href="http://www.rxlist.com/cgi/generic/seleg.htm">Selegiline
</a>Darvon                   Lilly                     <a href="http://www.rxlist.com/cgi/generic/propox2.htm">Propoxyphene
</a>Atarax                   Pfizer Roerig             <a href="http://www.rxlist.com/cgi/generic/hydrox.htm">Hydroxyzine
</a>Florinef                 Bristol-Myers/Squibb      <a href="http://www.rxlist.com/cgi/generic/fludro.htm">Fludrocortisone
</a>Prevacid                 Tap                       <a href="http://www.rxlist.com/cgi/generic/lansop.htm">Lansoprazole 
</a></b></pre>

<p>
<hr width="100%" ><b><a href="http://www.rxlist.com/interact.htm">Search
for Interactions, Side Effects, Indications (etc.) with ALL Top 200 Drugs
!</a></b></p>

<h5 align=center><a href="#TOP">TOP</a></h5>

<h2 align=center><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;Search
RxList</a> <img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;Rxlist
Home Page</a> &nbsp; </h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-54</DOCNO>
<DOCOLDNO>IA018-000200-B046-68</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/interact.htm/ 206.86.175.201 19970106233144 text/html 2533
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:25:30 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 2351
Last-modified: Tue, 12 Nov 1996 10:22:26 GMT
</DOCHDR>


<html>
<head>
<title>RxList - Drug Interaction Check of Top 200 Drugs Using Alta Vista
Index</title>
</head>
<BODY Bgcolor="#ffffff">
<a href="http://www.rxlist.com"><img 
src="rx.gif" height=125 width=125 border=0 alt = "click to return
to RxList Home Page" 
align = left vspace =2></a><H2>RxList Interaction Check of <a
href="http://www.rxlist.com/top200.htm">Top 200 </a>
Drugs</h2>
<FORM method=GET
action="http://altavista.digital.com/cgi-bin/query" target="new"><P><INPUT
TYPE=hidden NAME=pg
VALUE=aq>
<a href="/cgi-bin/query?pg=ah&what=web"> </a>
<h3>Enter any <a href="http://www.rxlist.com/cgi/rxlist.cgi">generic
name</a> (use lower case for best results!) in the space below and click
the submit button  
to check for interactions with all <a
href="http://www.rxlist.com/top200.htm">Top 200 drugs</a> at once!
<input
type=hidden name=q value="(rxlist.com/cgi/generic or
rxlist.com/cgi/brand) AND (NOT av.htm) AND (NOT av2.htm) AND (NOT av3.htm)
AND (NOT 200 Prescriptions)"><p>

<input name=r size=20
max=50></textarea><P>
<INPUT TYPE=submit VALUE="Begin Cross-Check Using Alta
Vista - Page Down For Results"><p>
<b>
This search will open a new window on most advanced browsers.</b><br>
<h4>If you prefer you may enter a side effect, indication, or other keyword in
place of a generic name to locate matching Top 200 drugs.  <li>Remember to
use
lower case for best results! 
<OL>
<li>When Alta Vista appears, scroll down to view matching RxList generic 
information pages.
<li>Each matching page will contain the generic name you've entered
somewhere
within the
document, usually but not always in the drug-drug interaction section.
<li>Use your browser's search function to find the matching term.  
<li>If
there are no matching documents, Alta Vista will return the following
message: "No
documents match the query".  <p></h4>
</OL>
<p>
</FORM>
<hr width="100%" >
<h2 align=center><a
href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;</a><a
href="http://www.rxlist.com/top200.htm">Top
200&nbsp;&nbsp; <a href="http://www.rxlist.com/top200.htm"><img
src="redball.gif" border=0 height=17 width=17></a></a><a
href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17
width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;RxList
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-55</DOCNO>
<DOCOLDNO>IA018-000200-B045-359</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/action.cgi 206.86.175.201 19970106232858 text/html 711
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:22:43 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE>www.rxlist.com - Neil Sandow, Pharm.D. 
copyright 1995</title></head> <body bgcolor="#ffffff">
<center><a href="http://www.rxlist.com"><img src="rx.gif" 
height=75 width=75 border=0><img src="count.gif" border=0></a></center> 
<hr>
<h1>Enter Brand or Generic Name or Category*</h1>
<h3>Narrow Your Search With <font size=5>*</font> (examples: ampi*, 
*mycin, antibiotic*)</h3> 
<form method=get>
<action=>
<input size=30 maxlength=30 name=drug>
<input type=submit>
<input type=reset>
</form>
</body></html>
<P><hr><a href="http://www.rxlist.com"><b>RxList Home Page</ul>
<hr>
</DOC>
<DOC>
<DOCNO>WT08-B13-56</DOCNO>
<DOCOLDNO>IA018-000200-B045-425</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/rxlist.cgi/ 206.86.175.201 19970106232950 text/html 711
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:23:36 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE>www.rxlist.com - Neil Sandow, Pharm.D. 
copyright 1995</title></head> <body bgcolor="#ffffff">
<center><a href="http://www.rxlist.com"><img src="rx.gif" 
height=75 width=75 border=0><img src="count.gif" border=0></a></center> 
<hr>
<h1>Enter Brand or Generic Name or Category*</h1>
<h3>Narrow Your Search With <font size=5>*</font> (examples: ampi*, 
*mycin, antibiotic*)</h3> 
<form method=get>
<action=>
<input size=30 maxlength=30 name=drug>
<input type=submit>
<input type=reset>
</form>
</body></html>
<P><hr><a href="http://www.rxlist.com"><b>RxList Home Page</ul>
<hr>
</DOC>
<DOC>
<DOCNO>WT08-B13-57</DOCNO>
<DOCOLDNO>IA018-000200-B045-386</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/formmail.cgi 206.86.175.201 19970106232917 text/html 449
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:23:02 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
No recipient addresses found in header
/dev/null/dead.letter... cannot open: Permission denied
Content-type: text/html
</DOCHDR>
<html><head><title>Thanks You</title></head>
<body><h1>Thank You For Filling Out This Form</h1>
Thank you for taking the time to fill out our feedback form.Below is what you submitted to  on Mon Jan  6 15:22:59 PST 1997<hr>
</body></html>
</DOC>
<DOC>
<DOCNO>WT08-B13-58</DOCNO>
<DOCOLDNO>IA018-000200-B046-32</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/rxlist.cgi/rx.gif 206.86.175.201 19970106233114 text/html 711
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:25:00 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE>www.rxlist.com - Neil Sandow, Pharm.D. 
copyright 1995</title></head> <body bgcolor="#ffffff">
<center><a href="http://www.rxlist.com"><img src="rx.gif" 
height=75 width=75 border=0><img src="count.gif" border=0></a></center> 
<hr>
<h1>Enter Brand or Generic Name or Category*</h1>
<h3>Narrow Your Search With <font size=5>*</font> (examples: ampi*, 
*mycin, antibiotic*)</h3> 
<form method=get>
<action=>
<input size=30 maxlength=30 name=drug>
<input type=submit>
<input type=reset>
</form>
</body></html>
<P><hr><a href="http://www.rxlist.com"><b>RxList Home Page</ul>
<hr>
</DOC>
<DOC>
<DOCNO>WT08-B13-59</DOCNO>
<DOCOLDNO>IA018-000200-B045-452</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/rxlist.cgi/generic/ 206.86.175.201 19970106233006 text/html 711
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:23:52 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE>www.rxlist.com - Neil Sandow, Pharm.D. 
copyright 1995</title></head> <body bgcolor="#ffffff">
<center><a href="http://www.rxlist.com"><img src="rx.gif" 
height=75 width=75 border=0><img src="count.gif" border=0></a></center> 
<hr>
<h1>Enter Brand or Generic Name or Category*</h1>
<h3>Narrow Your Search With <font size=5>*</font> (examples: ampi*, 
*mycin, antibiotic*)</h3> 
<form method=get>
<action=>
<input size=30 maxlength=30 name=drug>
<input type=submit>
<input type=reset>
</form>
</body></html>
<P><hr><a href="http://www.rxlist.com"><b>RxList Home Page</ul>
<hr>
</DOC>
<DOC>
<DOCNO>WT08-B13-60</DOCNO>
<DOCOLDNO>IA018-000200-B045-439</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/rxlist.cgi/count.gif 206.86.175.201 19970106232959 text/html 711
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:23:44 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE>www.rxlist.com - Neil Sandow, Pharm.D. 
copyright 1995</title></head> <body bgcolor="#ffffff">
<center><a href="http://www.rxlist.com"><img src="rx.gif" 
height=75 width=75 border=0><img src="count.gif" border=0></a></center> 
<hr>
<h1>Enter Brand or Generic Name or Category*</h1>
<h3>Narrow Your Search With <font size=5>*</font> (examples: ampi*, 
*mycin, antibiotic*)</h3> 
<form method=get>
<action=>
<input size=30 maxlength=30 name=drug>
<input type=submit>
<input type=reset>
</form>
</body></html>
<P><hr><a href="http://www.rxlist.com"><b>RxList Home Page</ul>
<hr>
</DOC>
<DOC>
<DOCNO>WT08-B13-61</DOCNO>
<DOCOLDNO>IA018-000200-B045-399</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/generic/cefprozi.htm/ 206.86.175.201 19970106232926 text/html 32318
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:23:11 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
Content-length: 32135
Last-modified: Sun, 11 Aug 1996 03:43:09 GMT
</DOCHDR>
<html>
<head>
   <title>Cefprozil - RxList Generic Information</title>
   <meta name="GENERATOR" content="Mozilla/2.01Gold (Win32)">
</head>
<body text="#000000" bgcolor="#FFFFFF" link="#0000EE" vlink="#551A8B" alink="#FF0000">

<center><p><a href="http://www.rxlist.com/cgi/rxlist.cgi"><img src="rx.gif" border=0 height=125 width=125></a></p></center>

<h1 align=center>Cefprozil</h1>

<p>
<hr><font COLOR="#0000FF">[<a href="#DESCRIPTION">description</a>] [<a href="#ACTIONS/CLINICAL PHARMACOLOGY">action</a>]
[<a href="#INDICATIONS AND USAGE">use</a>] [<a href="#CONTRAINDICATIONS">contra</a>]
[<a href="#WARNINGS">warn!</a>] [<a href="#PRECAUTIONS">caution</a>] [<a href="#DRUG INTERACTIONS">drug-drug</a>]
[<a href="#ADVERSE REACTIONS">side effects</a>] [<a href="#OVERDOSAGE">toxicity</a>]
[<a href="#DOSAGE AND ADMINISTRATION">dosing</a>] </font></p>

<p><b>This is NOT the official FDA approved material for this drug. Therefore,
please consult the appropriate FDA approved package insert for additional
information!</b></p>

<p>
<hr width="100%" ></p>

 <a name="DESCRIPTION"></a><b>DESCRIPTION 
</b> <p>
Cefprozil is a semi-synthetic broad-spectrum cephalosporin antibiotic.  <p>
 
Cefprozil is a cis and trans isomeric mixture (&gt;/=90% cis). The chemical name
for the monohydrate is (6R,7R)-7-((R)-2- amino-2- (p-hydroxy-phenyl) acetamido) 
8-oxo-3-propenyl-5-thia-1-azabicyclo (4.2.0)oct-2-ene-2- carboxylic acid
monohydrate.  
 <p>
Cefprozil is a white to yellowish powder with a molecular formula for the
monohydrate of C18H19N3O5S.H2O and a molecular weight of 407.45.  
 <p>
<a name="ACTIONS/CLINICAL PHARMACOLOGY"></a><b>ACTIONS/CLINICAL PHARMACOLOGY 
</b> <p>
Following oral administration of cefprozil to fasting subjects, approximately
95% of the dose was absorbed. Using the investigational capsule formulation, no 
food effect was observed. The food effect on the tablet and on the suspension
formulations has not been studied.  
 <p>
The pharmacokinetic data were derived from the capsule dosing; however,
bioequivalence has been demonstrated for the oral solution, capsule, tablet and 
suspension formulations under fasting conditions.  
 <p>
Average peak plasma concentrations after administration of 250 mg, 500 mg, or 1 
g doses of cefprozil to fasting subjects were approximately 6.1, 10.5, and 18.3 
mcg/mL respectively, and were obtained within 1.5 hours after dosing. Urinary
recovery accounted for approximately 60% of the administered dose. (See Table.) 
 <p><pre>
----------------------------------------------------------------------------    
Dosage                       Mean Plasma Cefprozil*           8-hour Urinary    
(mg)                        Concentrations (mcg/mL)           Excretion (%)     
                   Peak               4 hr              8 hr                    
               appx. 1.5 hr                                                     
----------------------------------------------------------------------------    
 250 mg            6.1                1.7               0.2          60%        
 500 mg            10.5               3.2               0.4          62%        
1000 mg            18.3               8.4               1.0          54%        
----------------------------------------------------------------------------   </pre><p> 
*Data represent mean values of 12 healthy volunteers.                           
During the first 4-hour period after drug administration, the average urine
concentrations following the 250 mg, 500 mg, and 1g doses were approximately
700 mcg/mL, 1000 mcg/mL, and 2900 mcg/mL.  
 <p>
Plasma protein binding is approximately 36% and is independent of concentration 
in the range of 2 mcg/mL to 20 mcg/mL.  
 <p>
The average plasma half-life in normal subjects is 1.3 hours.  
 <p>
There was no evidence of accumulation of cefprozil in the plasma in individuals 
with normal renal function following multiple oral doses of up to 1000 mg every 
8 hours for 10 days.  
 <p>
In patients with reduced renal function, the plasma half-life may be prolonged
up to 5.2 hours depending on the degree of the renal dysfunction. In patients
with complete absence of renal function the plasma half-life of cefprozil has
been shown to be as long as 5.9 hours. The half-life is shortened during
hemodialysis. Excretion pathways in patients with markedly impaired renal
function have not been determined. (See PRECAUTIONS and DOSAGE AND
ADMINISTRATION.) 
 <p>
The average AUC observed in elderly subjects (&gt;/=65 years of age) is
approximately 35%-60% higher relative to young adults, and the average AUC in
females is approximately 15%-20% higher than in males. The magnitude of these
age and gender related changes in the pharmacokinetics of cefprozil are not
sufficient to necessitate dosage adjustments.  
 <p>
In patients with impaired hepatic function, the half-life increases to
approximately 2 hours. The magnitude of the changes does not warrant a dosage
adjustment for patients with impaired hepatic function.  
 <p>
Adequate data on CSF levels of cefprozil are not available.  
 <p>
MICROBIOLOGY 
 <p>
Cefprozil has In Vitro activity against a broad range of gram-positive and gram 
negative bacteria. The bactericidal action of cefprozil results from
inhibition of cell-wall synthesis. Cefprozil has been shown to be active
against most strains of the following organisms both In Vitro and in clinical
infections.  (See INDICATIONS AND USAGE.) 
 <p>
AEROBES, GRAM-POSITIVE:  
    <p>
Staphylococcus Aureus 
 <p>
(including penicillinase-producing strains) 
 <p>
NOTE: Cefprozil is inactive against methicillin-resistant staphylococci 
 <p>
Streptococcus Pneumoniae 
 <p>
Streptococcus Pyogenes 
 <p>
AEROBES, GRAM-NEGATIVE:  
 <p>
Moraxella (Branhamella) Catarrhalis 
 <p>
Haemophilus Influenzae 
 <p>
(including penicillinase-producing strains) 
 <p>
The following In Vitro data are available; however, their clinical significance 
is unknown.  
 <p>
Cefprozil exhibits In Vitro minimum inhibitory concentrations (MIC) of 8 mcg/mL 
or less against most strains of the following organisms. The safety and
efficacy of cefprozil in treating infections due to these organisms have not
been established in adequate and well-controlled trials.  
 <p>
AEROBES, GRAM-POSITIVE:  
 <p>
Enterococcus Durans 
 <p>
Enterococcus Faecalis 
 <p>
NOTE: Cefprozil is inactive against Enterococcus Faecium.  
 <p>
Listeria Monocytogenes 
 <p>
Staphylococcus Epidermidis 
 <p>
Staphylococcus Saprophyticus 
 <p>
Staphylococcus Warneri 
 <p>
Streptococci (Groups C, D, F, and G) 
 <p>
Viridans Group Streptococci 
 <p>
AEROBES, GRAM-NEGATIVE:  
 <p>
Citrobacter Diversus 
 <p>
Escherichia Coli 
<p>
 
Klebsiella Pneumoniae 
 <p>
Neisseria Gonorrhoeae 
 <p>
(including penicillinase-producing strains) 
 <p>
Proteus Mirabilis 
 <p>
Salmonella Spp.  
 <p>
Shigella Spp.  
 <p>
Vibrio Spp.  
 <p>
NOTE: Cefprozil is inactive against most strains of Acinetobacter, Enterobacter 
Morganella Morganii, Proteus Vulgaris, Providencia, Pseudomonas, and Serratia.
 <p>
ANAEROBES:  
 <p>
Bacteroides Melaninogenicus 
 <p>
NOTE: Most strains of the Bacteroides Fragilis group are resistant to
cefprozil.  
 <p>
Clostridium Perfringens 
 <p>
Clostridium Difficile 
 <p>
Fusobacterium spp.  
 <p>
Peptostreptococcus spp.  
 <p>
Propionibacterium Acnes 
 <p>
SUSCEPTIBILITY TESTS 
 <p>
DIFFUSION TECHNIQUES 
 <p>
Quantitative methods that require measurement of zone diameters give the most
precise estimate of the susceptibility of bacteria to antimicrobial agents. One 
such standardized procedure recommended for use with the 30-mcg cefprozil disk
is the National Committee for Clinical Laboratory Standards (NCCLS) approved
procedure. (REF.1) Interpretation involves correlation of the diameter obtained 
in the disk test with minimum inhibitory concentration (MIC) for cefprozil.  
 <p>
The class disk for cephalosporin susceptibility testing (the cephalothin disk)
is not appropriate because of spectrum differences with cefprozil. The 30-mcg
cefprozil disk should be used for all In Vitro testing of isolates.  
 <p>
Reports from the laboratory giving results of the standard single-disk
susceptibility test with a 30-mcg cefprozil disk should be interpreted
according to the following criteria:  <p><pre>
 
ZONE DIAMETER (MM)       INTERPRETATION                                         
      &gt;/=18           (S) Susceptible                                           
     15-17            (MS) Moderately Susceptible                               
     &lt; or =14            (R) Resistant       </pre><p>                                      
A report of &quot;Susceptible&quot; indicates that the pathogen is likely to be inhibited 
by generally achievable blood concentrations. A report of &quot;Moderately
Susceptible&quot; indicates that the organism would be susceptible if high dosage is 
used or if the infection is confined to tissues and fluids (eg, urine) in which 
high antibiotic levels are attained. A report of &quot;Resistant&quot; indicates that the 
achievable concentration of the antibiotic is unlikely to be inhibitory and
other therapy should be selected.  
 <p>
Standardized procedures require the use of laboratory control organisms. The 30 
mcg cefprozil disk should give the following zone diameters:  <p>
 <pre>
            ORGANISM                ZONE DIAMETER (MM)                          
Escherichia Coli ATCC 25922               21-27                                 
Staphylococcus Aureus ATCC 25923          27-33                                 
DILUTION TECHNIQUES 
 
Use a standardized dilution method (REF. 2) (broth, agar, microdilution) or
equivalent with cefprozil powder. The MIC values obtained should be interpreted 
according to the following criteria:  
 
MIC (MCG/ML)                 INTERPRETATION                                     
    &lt; or =8                   (S) Susceptible                                      
     16                    (MS) Moderately Susceptible                          
    &gt;/=32                  (R) Resistant                                        
As with standard diffusion techniques, dilution techniques require the use of
laboratory control organisms. Standard cefprozil powder should give the
following MIC values:  
 
            ORGANISM                  MIC (MCG/ML)                              
Enterococcus Faecalis ATCC 29212          4-16                                  
Escherichia Coli ATCC 25922               1-4                                   
Pseudomonas Aeruginosa ATCC 27853         &gt;32                                   
Staphylococcus Aureus ATCC 29213         0.25-1                                 
 </pre><p>

<a name="INDICATIONS AND USAGE"></a><b>INDICATIONS AND USAGE 
</b> <p>
Cefprozil(R)  is indicated for the treatment of patients with mild to
moderate infections caused by susceptible strains of the designated
microorganisms in the conditions listed below:  
 <p>
UPPER RESPIRATORY TRACT 
 <p>
PHARYNGITIS/TONSILLITIS caused by Streptococcus Pyogenes.  
 <p>
NOTE: The usual drug of choice in the treatment and prevention of streptococcal 
infections, including the prophylaxis of rheumatic fever, is penicillin given
by the intramuscular route. Cefprozil is generally effective in the eradication 
of Streptococcus Pyogenes from the nasopharynx; however, substantial data
establishing the efficacy of cefprozil in the subsequent prevention of
rheumatic fever are not available at present.  
 <p>
OTITIS MEDIA caused by Streptococcus Pneumoniae, Haemophilus Influenzae and
Moraxella (Branhamella) Catarrhalis. (See CLINICAL STUDIES section.) 
 <p>
NOTE: In the treatment of otitis media due to beta-lactamase producing
organisms, cefprozil had bacteriologic eradication rates somewhat lower than
those observed with a product containing a specific beta-lactamase inhibitor.
In considering the use of cefprozil, lower overall eradication rates should be
balanced against the susceptibility patterns of the common microbes in a given
geographic area and the increased potential for toxicity with products
containing beta-lactamase inhibitors.  
 <p>
LOWER RESPIRATORY TRACT 
 <p>
SECONDARY BACTERIAL INFECTION OF ACUTE BRONCHITIS AND ACUTE BACTERIAL
EXACERBATION OF CHRONIC BRONCHITIS caused by Streptococcus Pneumoniae,
Haemophilus Influenzae, (beta-lactamase positive and negative strains), and
Moraxella (Branhamella) Catarrhalis.  
 <p>
SKIN AND SKIN STRUCTURE 
 <p>
UNCOMPLICATED SKIN AND SKIN-STRUCTURE INFECTIONS caused by Staphylococcus
Aureus (including penicillinase-producing strains) and Streptococcus Pyogenes.  
Abscesses usually require surgical drainage.  
 <p>
Culture and susceptibility testing should be performed when appropriate to
determine susceptibility of the causative organism to cefprozil.  
 <p>
<a name="CONTRAINDICATIONS"></a><b>CONTRAINDICATIONS 
</b> <p>
Cefprozil is contraindicated in patients with known allergy to the cephalosporin
class of antibiotics.  
 <p>
<a name="WARNINGS"></a><b>WARNINGS 
</b> <p>
BEFORE THERAPY WITH Cefprozil IS INSTITUTED, CAREFUL INQUIRY SHOULD BE MADE TO
DETERMINE WHETHER THE PATIENT HAS HAD PREVIOUS HYPERSENSITIVITY REACTIONS TO
Cefprozil, CEPHALOSPORINS, PENICILLINS, OR OTHER DRUGS. IF THIS PRODUCT IS TO BE
GIVEN TO PENICILLIN-SENSITIVE PATIENTS, CAUTION SHOULD BE EXERCISED BECAUSE
CROSS-SENSITIVITY AMONG BETA-LACTAM ANTIBIOTICS HAS BEEN CLEARLY DOCUMENTED AND 
MAY OCCUR IN UP TO 10% OF PATIENTS WITH A HISTORY OF PENICILLIN ALLERGY. IF AN
ALLERGIC REACTION TO Cefprozil OCCURS, DISCONTINUE THE DRUG. SERIOUS ACUTE
HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER
EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS
ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS
CLINICALLY INDICATED.  <p>
 
PSEUDOMEMBRANOUS COLITIS HAS BEEN REPORTED WITH NEARLY ALL ANTIBACTERIAL AGENTS 
AND MAY RANGE FROM MILD TO LIFE-THREATENING. THEREFORE, IT IS IMPORTANT TO
CONSIDER THIS DIAGNOSIS IN PATIENTS WHO PRESENT WITH DIARRHEA SUBSEQUENT TO THE 
ADMINISTRATION OF ANTIBACTERIAL AGENTS.  
 <p>
Treatment with antibacterial agents alters the normal flora of the colon and
may permit overgrowth of clostridia. Studies indicate that a toxin produced by
Clostridium Difficile is a primary cause of &quot;antibiotic-associated colitis&quot;.  
 <p>
After the diagnosis of pseudomembranous colitis has been established,
therapeutic measures should be initiated. Mild cases of pseudomembranous
colitis usually respond to discontinuation of the drug alone. In moderate to
severe cases, consideration should be given to management with fluids and
electrolytes, protein supplementation and treatment with an antibacterial drug
effective against Clostridium Difficile.  <p>
 
<a name="PRECAUTIONS"></a><b>PRECAUTIONS 
</b> <p>
GENERAL 
 <p>
Evaluation of renal status before and during therapy is recommended, especially 
in seriously ill patients. In patients with known or suspected renal impairment 
(see DOSAGE AND ADMINISTRATION), careful clinical observation and appropriate
laboratory studies should be done prior to and during therapy. The total daily
dose of Cefprozil  should be reduced in these patients because high 
and/or prolonged plasma antibiotic concentrations can occur in such individuals 
from usual doses. Cephalosporins, including Cefprozil, should be given with
caution to patients receiving concurrent treatment with potent diuretics since
these agents are suspected of adversely affecting renal function.  
 <p>
Prolonged use of Cefprozil may result in the overgrowth of nonsusceptible
organisms. Careful observation of the patient is essential. If superinfection
occurs during therapy, appropriate measures should be taken.  
 <p>
Cefprozil should be prescribed with caution in individuals with a history of
gastrointestinal disease particularly colitis.  
 <p>
Positive direct Coombs' tests have been reported during treatment with
cephalosporin antibiotics.  
 <p>
INFORMATION FOR PATIENTS <p>
 
Phenylketonurics: Cefprozil for oral suspension contains phenylalanine 28 mg per 5 
mL (1 teaspoon) constituted suspension for both the 125 mg/5mL and 250 mg/5mL
dosage forms.  <p>
 
DRUG INTERACTIONS 
 <p>
Nephrotoxicity has been reported following concomitant administration of
aminoglycoside antibiotics and cephalosporin antibiotics. Concomitant
administration of probenecid doubled the AUC for cefprozil.  
 <p>
DRUG/LABORATORY TEST INTERACTIONS 
 <p>
Cephalosporin antibiotics may produce a false positive reaction for glucose in
the urine with copper reduction tests (Benedict's or Fehling's solution or with 
Clinitest(R) (REF. 3) tablets), but not with enzyme-based tests for glycosuria
(eg, Tes-Tape(R) (REF. 4)). A false negative reaction may occur in the
ferricyanide test for blood glucose. The presence of cefprozil in the blood
does not interfere with the assay of plasma or urine creatinine by the alkaline 
picrate method.  
 <p>
CARCINOGENESIS, MUTAGENESIS, AND IMPAIRMENT OF FERTILITY 
 <p>
No mutagenic potential of cefprozil was found in appropriate prokaryotic or
eukaryotic cells In Vitro or In Vivo. No In Vivo long-term studies have been
performed to evaluate carcinogenic potential.  
 <p>
Reproductive studies revealed no impairment of fertility in animals.  
 <p>
PREGNANCY: TERATOGENIC EFFECTS. PREGNANCY CATEGORY B 
 <p>
Reproduction studies have been performed in mice, rats, and rabbits at doses 14 
7, and 0.7 times the maximum daily human dose (1000 mg) based upon
mg/M(square), and have revealed no evidence of harm to the fetus due to
cefprozil. There are, however, no adequate and well-controlled studies in
pregnant women. Because animal reproduction studies are not always predictive
of human response, this drug should be used during pregnancy only if clearly
needed.  
 <p>
LABOR AND DELIVERY 
 <p>
Cefprozil has not been studied for use during labor and delivery. Treatment
should only be given if clearly needed.  
 <p>
NURSING MOTHERS 
 <p>
It is not known whether cefprozil is excreted in human milk. Because many drugs 
are excreted in human milk, caution should be exercised when Cefprozil
 is administered to a nursing mother.  
 <p>
PEDIATRIC USE 
 <p>
Safety and effectiveness in children below the age of 6 months have not been
established. However, accumulation of other cephalosporin antibiotics in
newborn infants (resulting from prolonged drug half-life in this age group) has 
been reported.  
 <p>
GERIATRIC USE 
 <p>
Healthy geriatric volunteers (&gt;/=65 years old) who received a single 1 g dose
of cefprozil had 35%-60% higher AUC and 40% lower renal clearance values when
compared to healthy adult volunteers 20-40 years of age. In clinical studies,
when geriatric patients received the usual recommended adult doses, clinical
efficacy and safety were acceptable and comparable to results in nongeriatric
adult patients.  
 <p>
<a name="DRUG INTERACTIONS"></a><b>DRUG INTERACTIONS 
</b> <p>
Nephrotoxicity has been reported following concomitant administration of
aminoglycoside antibiotics and cephalosporin antibiotics. Concomitant
administration of probenecid doubled the AUC for cefprozil.  
 <p>
(See Also PRECAUTIONS).  
 <p>
<a name="ADVERSE REACTIONS"></a><b>ADVERSE REACTIONS 
</b> <p>
The adverse reactions to cefprozil are similar to those observed with other
orally administered cephalosporins. Cefprozil was usually well tolerated in
controlled clinical trials. Approximately 2% of patients discontinued cefprozil 
therapy due to adverse events.  
 <p>
The most common adverse effects observed in patients treated with cefprozil
are:  
 <p>
GASTROINTESTINAL--Diarrhea (2.9%), nausea (3.5%), vomiting (1%) and abdominal
pain (1%).  <p>
 
HEPATOBILIARY--Elevation of AST (SGOT) (2%), ALT (SGPT) (2%), alkaline
phosphatase (0.2%), and bilirubin values (&lt;0.1%). As with some penicillins and
some other cephalosporin antibiotics, cholestatic jaundice has been reported
rarely.  
 <p>
HYPERSENSITIVITY--Rash (0.9%), urticaria (0.1%). Such reactions have been
reported more frequently in children than in adults. Signs and symptoms usually 
occur a few days after initiation of therapy and subside within a few days
after cessation of therapy.  <p>
 
CNS--Dizziness (1%), Hyperactivity, headache, nervousness, insomnia, confusion, 
and somnolence have been reported rarely (&lt;1%). All were reversible.  
 <p>
HEMATOPOIETIC--Decreased leukocyte count (0.2%), eosinophilia (2.3%).  
 <p>
RENAL--Elevated BUN (0.1%), serum creatinine (0.1%).  
 <p>
OTHER--Diaper rash and superinfection (1.5%), genital pruritus and vaginitis
(1.6%).  <p>
 
CEPHALOSPORIN CLASS PARAGRAPH 
 <p>
In addition to the adverse reactions listed above which have been observed in
patients treated with cefprozil, the following adverse reactions and altered
laboratory tests have been reported for cephalosporin-class antibiotics:  
 <p>
Anaphylaxis, Stevens-Johnson syndrome, erythema multiforme, toxic epidermal
necrolysis, serum-sickness like reaction, fever, renal dysfunction, toxic
nephropathy, aplastic anemia, hemolytic anemia, hemorrhage, prolonged
prothrombin time, positive Coombs' test, elevated LDH, pancytopenia,
neutropenia agranulocytosis, thrombocytopenia.  
 <p>
Several cephalosporins have been implicated in triggering seizures,
particularly in patients with renal impairment, when the dosage was not
reduced. (See DOSAGE AND ADMINISTRATION and OVERDOSAGE.) If seizures associated 
with drug therapy occur, the drug should be discontinued. Anticonvulsant
therapy can be given if clinically indicated.  <p>
 
<a name="OVERDOSAGE"></a><b>OVERDOSAGE 
</b> <p>
Cefprozil is eliminated primarily by the kidneys. In case of severe overdosage, 
especially in patients with comprised renal function, hemodialysis will aid in
the removal of cefprozil from the body.  
 <p>
<a name="DOSAGE AND ADMINISTRATION"></a><b>DOSAGE AND ADMINISTRATION 
</b> <p>
Cefprozil  is administered orally.  
 <p><pre>
POPULATION/INFECTION                               DOSAGE              DURATION 
                                                    (mg)                (days)  
-----------------------------------------------------------------------------   
ADULTS (13 years and older)                                                     
UPPER RESPIRATORY TRACT                                                         
   Pharyngitis/Tonsillitis                       500 q 24h               10*    
LOWER RESPIRATORY TRACT                                                         
   Secondary Bacterial Infection                 500 q 12h               10     
   of Acute Bronchitis and Acute Bacterial                                      
   Exacerbation of Chronic Bronchitis                                           
SKIN AND SKIN STRUCTURE                                                         
   Uncomplicated Skin and                        250 q 12h or            10     
   Skin Structure Infections                     500 q 24h or                   
                                                 500 q 12h                      
-----------------------------------------------------------------------------   
CHILDREN (2 years - 12 years)                                                   
  UPPER RESPIRATORY TRACT                                                       
  Pharyngitis/Tonsillitis                        7.5 mg/kg               10*    
                                                     q 12h                      
-----------------------------------------------------------------------------   
INFANTS &amp; CHILDREN (6 months-12 years)                                          
UPPER RESPIRATORY TRACT                                                         
   Otitis Media                                  15 mg/kg                10     
   (See INDICATIONS AND USAGE                      q 12h                        
   and CLINICAL STUDIES sections)                                               
-----------------------------------------------------------------------------   
*In the treatment of infections due to Streptococcus Pyogenes, Cefprozil should
 be administered for at least 10 days.                                         
RENAL IMPAIRMENT 
 
Cefprozil may be administered to patients with impaired renal function. The
following dosage schedule should be used 
 
CREATININE                                                                      
CLEARANCE        DOSAGE           DOSING INTERVAL                               
 (mL/min)         (mg)                                                          
------------------------------------------------------------------------------  
  30-120          standard        standard                                      
   0-30*       50% of standard    standard                                      
------------------------------------------------------------------------------  
*Cefprozil is in part removed by hemodialysis; therefore, cefprozil should      
 be administered after the completion of hemodialysis.        </pre><p>                  
HEPATIC IMPAIRMENT 
 <p>
No dosage adjustment is necessary for patients with impaired hepatic function.  
 <p>
 
CLINICAL STUDIES 
 <p>
STUDY ONE:  
 <p>
In a controlled clinical study of Acute Otitis Media performed in the United
States, where significant rates of beta-lactamase producing organisms were
found, cefprozil was compared to an oral antimicrobial agent that contained a
specific beta-lactamase inhibitor. In this study, using very strict
evaluability criteria and microbiologic and clinical response criteria at the
10-16 days post-therapy follow-up, the following presumptive bacterial
eradication/clinical cure outcomes (ie, clinical success) and safety results
were obtained:  <p><pre>
 
                          U.S. ACUTE OTITIS MEDIA STUDY                         
                           CEFPROZIL VS. BETA-LACTAMASE                         
                        INHIBITOR-CONTAINING CONTROL DRUG                       
EFFICACY                                                                        
                               % OF CASES                                       
PATHOGEN                     WITH PATHOGEN        OUTCOME                       
                                (N=155)                                         
S. Pneumoniae                     48.4%           cefprozil success             
                                                  rate 5% better                
                                                  than control                  
H. Influenzae                     35.5%           cefprozil success             
                                                  rate 17% less                 
                                                  than control                  
M. Catarrhalis                    13.5%           cefprozil success             
                                                  rate 12% less                 
                                                  than control                  
S. Pyogenes                        2.6%           cefprozil equivalent          
                                                  to control                    
Overall                          100.0%           cefprozil success rate        
                                                  5% less than                  
                                                  control                       
SAFETY 
 
The incidence of adverse events, primarily diarrhea and rash,* were clinically
and statistically significantly higher in the control arm versus the cefprozil
arm.  
 
AGE GROUP           CEFPROZIL                 CONTROL                           
6 months-2 years       21%                      41%                             
3-12 years             10%                      19%                             
*The majority of these involved the diaper area in young children.  
 
STUDY TWO:  
 
In a controlled clinical study of acute otitis media performed in Europe,
cefprozil was compared to an oral antimicrobial agent that contained a specific 
beta-lactamase inhibitor. As expected in a European population, this study had
a lower incidence of beta-lactamase-producing organisms than usually seen in
U.S.  trials. In this study, using very strict evaluability criteria and
microbiologic and clinical response criteria at the 10-16 days post-therapy
follow-up, the following presumptive bacterial eradication/clinical cure
outcomes (ie, clinical success) were obtained:  
 
                        EUROPEAN ACUTE OTITIS MEDIA STUDY                       
                           CEFPROZIL VS. BETA-LACTAMASE                         
                        INHIBITOR-CONTAINING CONTROL DRUG                       
EFFICACY                                                                        
                               % OF CASES                                       
PATHOGEN                     WITH PATHOGEN        OUTCOME                       
                                 (N=47)                                         
S. Pneumoniae                     51.0%           cefprozil equivalent          
                                                  to control                    
H. Influenzae                     29.8%           cefprozil equivalent          
                                                  to control                    
M. Catarrhalis                     6.4%           cefprozil equivalent          
                                                  to control                    
S. Pyogenes                       12.8%           cefprozil equivalent          
                                                  to control                    
Overall                          100.0%           cefprozil equivalent          
                                                  to control                    
SAFETY 
 
The incidence of adverse events in the cefprozil arm was comparable to the
incidence of adverse events in the control arm (agent that contained a specific 
beta-lactamase inhibitor).  </pre><p>
 
REFERENCES 
 <p>
1. National Committee for Clinical Laboratory Standards, Performance Standards
For Antimicrobial Disk Susceptibility Tests--Fourth Edition. Approved Standard
NCCLS Document M2-A4, Vol. 10, No. 7, NCCLS, Villanova, PA, April, 1990.  
 <p>
2. National Committee for Clinical Laboratory Standards, Methods For Dilution
Antimicrobial Susceptibility Tests For Bacteria That Grow Aerobically--Second
Edition. Approved Standard NCCLS Document M7-A2, Vol. 10, No. 8, NCCLS,
Villanova, PA, April, 1990.  
 <p>
3. Clinitest(R) is a registered trademark of Miles Laboratories, Inc.  
 <p>
4. Tes-Tape(R) is a registered trademark of Eli Lilly and Company.  

<p>
<h2 align=center>
<hr width="100%" ><a href="http://www.rxlist.com/top200.htm">Top 200&nbsp;&nbsp;
<a href="http://www.rxlist.com/top200.htm"><img src="redball.gif" border=0 height=17 width=17></a></a><a href="http://www.rxlist.com/cgi/rxlist.cgi">&nbsp;&nbsp;&nbsp;Search
RxList</a> &nbsp;&nbsp;<img src="redball.gif" border=0 height=17 width=17><a href="http://www.rxlist.com">&nbsp;&nbsp;Rxlist
Home Page</a></h2>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-62</DOCNO>
<DOCOLDNO>IA018-000200-B046-21</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/rxlist.cgi/generic/rx.gif 206.86.175.201 19970106233107 text/html 711
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:24:50 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE>www.rxlist.com - Neil Sandow, Pharm.D. 
copyright 1995</title></head> <body bgcolor="#ffffff">
<center><a href="http://www.rxlist.com"><img src="rx.gif" 
height=75 width=75 border=0><img src="count.gif" border=0></a></center> 
<hr>
<h1>Enter Brand or Generic Name or Category*</h1>
<h3>Narrow Your Search With <font size=5>*</font> (examples: ampi*, 
*mycin, antibiotic*)</h3> 
<form method=get>
<action=>
<input size=30 maxlength=30 name=drug>
<input type=submit>
<input type=reset>
</form>
</body></html>
<P><hr><a href="http://www.rxlist.com"><b>RxList Home Page</ul>
<hr>
</DOC>
<DOC>
<DOCNO>WT08-B13-63</DOCNO>
<DOCOLDNO>IA018-000200-B045-478</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/rxlist.cgi/generic/cycl.htm 206.86.175.201 19970106233023 text/html 711
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:24:08 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE>www.rxlist.com - Neil Sandow, Pharm.D. 
copyright 1995</title></head> <body bgcolor="#ffffff">
<center><a href="http://www.rxlist.com"><img src="rx.gif" 
height=75 width=75 border=0><img src="count.gif" border=0></a></center> 
<hr>
<h1>Enter Brand or Generic Name or Category*</h1>
<h3>Narrow Your Search With <font size=5>*</font> (examples: ampi*, 
*mycin, antibiotic*)</h3> 
<form method=get>
<action=>
<input size=30 maxlength=30 name=drug>
<input type=submit>
<input type=reset>
</form>
</body></html>
<P><hr><a href="http://www.rxlist.com"><b>RxList Home Page</ul>
<hr>
</DOC>
<DOC>
<DOCNO>WT08-B13-64</DOCNO>
<DOCOLDNO>IA018-000200-B046-9</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/rxlist.cgi/generic/pred.htm 206.86.175.201 19970106233057 text/html 711
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:24:41 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE>www.rxlist.com - Neil Sandow, Pharm.D. 
copyright 1995</title></head> <body bgcolor="#ffffff">
<center><a href="http://www.rxlist.com"><img src="rx.gif" 
height=75 width=75 border=0><img src="count.gif" border=0></a></center> 
<hr>
<h1>Enter Brand or Generic Name or Category*</h1>
<h3>Narrow Your Search With <font size=5>*</font> (examples: ampi*, 
*mycin, antibiotic*)</h3> 
<form method=get>
<action=>
<input size=30 maxlength=30 name=drug>
<input type=submit>
<input type=reset>
</form>
</body></html>
<P><hr><a href="http://www.rxlist.com"><b>RxList Home Page</ul>
<hr>
</DOC>
<DOC>
<DOCNO>WT08-B13-65</DOCNO>
<DOCOLDNO>IA018-000200-B045-466</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/rxlist.cgi/generic/count.gif 206.86.175.201 19970106233016 text/html 711
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:24:00 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE>www.rxlist.com - Neil Sandow, Pharm.D. 
copyright 1995</title></head> <body bgcolor="#ffffff">
<center><a href="http://www.rxlist.com"><img src="rx.gif" 
height=75 width=75 border=0><img src="count.gif" border=0></a></center> 
<hr>
<h1>Enter Brand or Generic Name or Category*</h1>
<h3>Narrow Your Search With <font size=5>*</font> (examples: ampi*, 
*mycin, antibiotic*)</h3> 
<form method=get>
<action=>
<input size=30 maxlength=30 name=drug>
<input type=submit>
<input type=reset>
</form>
</body></html>
<P><hr><a href="http://www.rxlist.com"><b>RxList Home Page</ul>
<hr>
</DOC>
<DOC>
<DOCNO>WT08-B13-66</DOCNO>
<DOCOLDNO>IA018-000200-B045-492</DOCOLDNO>
<DOCHDR>
http://www.rxlist.com:80/cgi/rxlist.cgi/generic/norgeth.htm 206.86.175.201 19970106233043 text/html 711
HTTP/1.0 200 OK
Date: Mon, 06 Jan 1997 23:24:17 GMT
Server: BESTWWWD/1.0
MIME-version: 1.0
Content-type: text/html
</DOCHDR>
<HTML><HEAD><TITLE>www.rxlist.com - Neil Sandow, Pharm.D. 
copyright 1995</title></head> <body bgcolor="#ffffff">
<center><a href="http://www.rxlist.com"><img src="rx.gif" 
height=75 width=75 border=0><img src="count.gif" border=0></a></center> 
<hr>
<h1>Enter Brand or Generic Name or Category*</h1>
<h3>Narrow Your Search With <font size=5>*</font> (examples: ampi*, 
*mycin, antibiotic*)</h3> 
<form method=get>
<action=>
<input size=30 maxlength=30 name=drug>
<input type=submit>
<input type=reset>
</form>
</body></html>
<P><hr><a href="http://www.rxlist.com"><b>RxList Home Page</ul>
<hr>
</DOC>
<DOC>
<DOCNO>WT08-B13-67</DOCNO>
<DOCOLDNO>IA058-000947-B026-57</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/index.html 206.97.63.16 19970109193251 text/html 3202
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:15:34 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 3031
Last-modified: Wed, 24 Jul 1996 17:27:36 GMT
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">

<HTML>
<HEAD>
<TITLE>Arizona Automobile Dealers Association</TITLE>
</HEAD>

<body background="gif/aadatile1x.gif" bgcolor="#E5E0E0" text="#000628" link="#55083C" vlink="#00120A" ALINK="#220652">

<center>
<img src="gif/aadaheader.gif">
</center>
<br>
<center>


<font size=4><b>
A partner in representing the business<br>
and legislative needs of <br>
franchised auto dealers . 
</b></font>

<br>
<table border=2>

<td><img align=left src="gif/spacecars2.gif">
<td><font size=5><b>NEWS<br> FLASH</b></font><p>
<font size=3><A HREF="newstalk.html">Ray Korte, Jr. dies</A><br>
</table>
<br>
<br>
<br>
<br>
<a href="about.html"><img src="gif/baboutusbutton.gif" border=0 alt="About Us"></a>
<a href="frontdoor.html"><img src="gif/bautomallbutton.gif" border=0 alt="Auto Mall"></a>
<a href="membership.html"><img src="gif/bmemberbutton.gif" border=0 alt="Membership"></a><br>
<a href="contact.html"><img src="gif/bcontactbutton.gif" border=0 alt="Contact Us"></a>
<a href="vendor.html"><img src="gif/bvendorbutton.gif" border=0 alt="Vendor Services"></a>
<a href="consumer.html"><img src="gif/bconsumerbutton.gif" border=0 alt="Consumer Info"></a><br>
<a href="newstalk.html"><img src="gif/bnewsflashbutton.gif" border=0 alt="News Flash"></a>
<a href="arizona.html"><img src="gif/bazautobutton.gif" border=0 alt="Auto Centennial"></a>
<a href="store.html"><img src="gif/bstorebutton.gif" border=0 alt="Store"></a><br>
<p>
[ <a href="about.html">About AADA</a>
| <a href="frontdoor.html">Auto Mall</a>
| <a href="membership.html">Membership</a>]<br>
[ <a href="contact.html">Contact AADA</a>
| <a href="vendor.html">Vendor Services</a>
| <a href="consumer.html">Consumer Information</a>]<br>
[ <a href="newstalk.html">News Flash</a>
| <a href="arizona.html">Arizona Auto Centennial</a>
| <a href="store.html">Store</a> ]<br>
</center>
<p>
<center><a href="frontdoor.html"><img src="gif/autobar.gif" border=0 alt="Auto Mall"></a></center>
<center><a href="frontdoor.html">[ Auto Mall ]</a></center>
<p>
<center>
For inquiries or comments, e-mail: <a href="mailto:aada@dasta.com">aada@dasta.com</a><p>
<p>
</center>

<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="http://www.dasta.com/gif/dastasig.gif"
			alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 25 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996
				<a href="http://www.dasta.com">DASTA VendorCat, LLC</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">This site was designed by 
		<a href="http://www.dasta.com">DASTA VendorCat</a><br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of
	<a href="http://www.dasta.com/anet.html">Association-Net</a>
	<sup>TM</sup></font></p>
</center>



</body>
</html>

</DOC>
<DOC>
<DOCNO>WT08-B13-68</DOCNO>
<DOCOLDNO>IA058-000947-B025-327</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/newstalk.html 206.97.63.16 19970109193127 text/html 2657
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:14:11 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 2486
Last-modified: Tue, 25 Jun 1996 23:06:23 GMT
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">

<HTML>
<HEAD>
<TITLE>Arizona Automobile Dealers Association - News Briefs</TITLE>
</HEAD>

<body background="gif/aadatile1x.gif" bgcolor="#E5E0E0" text="#000628" link="#55083C" vlink="#00120A" ALINK="#220652">


<center>
<table border=2>
<tr><td>
<img src="gif/headernewsflash.gif" alt="About AADA">
</td></tr>
</table>
</center>
<br>
<br>
<table width="100%">
<tr>
<td>
<center>
<hr size=4 width=175>
<font size=4><b>
Check out the latest<br>
topics in the automotive<br>
industry that are relevant<br>
to you and your business.</b></font>
<hr size=4 width=175></center>
</td></tr>
<p>
<tr><td align="center">
<a href="index.html"><img src="gif/mainpagebutton.gif" border=0 alt="Main Page"></a><br>
<a href="newsflash.html"><img src="gif/newsflashbutton.gif" border=0 alt="News Flash"></a>
<a href="bulletin.html"><img src="gif/bulletinbutton.gif" border=0 alt="bulletin"></a><br>
<a href="legalbriefs.html"><img src="gif/legalbutton.gif" border=0 alt="legal briefs"></a>
<a href="calendar.html"><img src="gif/calenbutton.gif" border=0 alt="calender"></a><br>
<a href="presidents_message.html"><img src="gif/presbutton.gif" border=0 alt="preszmessage"></a>
<a href="capitolwatch.html"><img src="gif/capitolbutton.gif" border=0 alt="capitol watch"></a><br>
</td>
</tr>
</table>
<br>
<p>
<center><a href="frontdoor.html"><img src="gif/autobar.gif" border=0 alt="Auto Mall"></a></center>
<center>[<a href="frontdoor.html">The Auto Mall</a>]</center>
<br>
<br>

<center>For inquiries or comments, e-mail: <a href="mailto:aada@dasta.com">aada@dasta.com</a></center><p>
<p>
<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="http://www.dasta.com/gif/dastasig.gif"
			alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 25 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996
				<a href="http://www.dasta.com">DASTA VendorCat, LLC</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">This site was designed by 
		<a href="http://www.dasta.com">DASTA VendorCat</a><br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of
	<a href="http://www.dasta.com/anet.html">Association-Net</a>
	<sup>TM</sup></font></p>
</center>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-69</DOCNO>
<DOCOLDNO>IA058-000947-B025-342</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/about.html 206.97.63.16 19970109193134 text/html 4715
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:14:17 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 4544
Last-modified: Tue, 25 Jun 1996 23:05:52 GMT
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">

<HTML>
<HEAD>
<TITLE>About Us</TITLE>
</HEAD>

<body background="gif/aadatilew.gif" bgcolor="#E5E0E0" text="#000628" link="#55083C" vlink="#00120A" ALINK="#220652">


<center>
<table border=2>
<tr><td>
<img src="gif/headerabout.gif" alt="About AADA">
</td></tr>
</table>
</center>
<p>
<center>
<font size=4>
A Message From AADA's President<br>
 - Stan Powell - 
</font>
</center>

<p>
<center>
<b><i>"Cyberspace is Where It's At! Better Catch Up With Your Competitors."</i></b><BR>
</center>
<P>
        A few years ago all the manufacturers were talking about
DCS - dealer communication systems. In a very short time span, every 
manufacturer developed electronic links to their dealer body, and have
continued to add features and simplify operation.
<P>
        But of course, all of this has not come without a price - simply
with a cost shifting from manufacturers to dealers. Although we gain 
information from DCS-type systems, the information we process and feed
manufacturers electronically - such as warranty claims - has reduced
their work load and the associated costs. To date, evolving in the 
information age has really been an expense to us - it hasn't offered 
ways to improve profitability.  
<P>
        The time has come. There's a buzz word out there called the
Internet, also referred to as the World Wide Web. The information on 
this critter is endless, and the marketing opportunities abundant. Some
U.S. dealers have grasped the Internet's vast opportunities early-on,
and have not only developed their own home pages, but are actively 
working cyberspace to snag sales from customers who place orders right 
on their computers! At least half a dozen Arizona dealers have their own
home pages on the Net or have them in the works. 
<P>   
     Most of the major manufacturers are online too, with exotic, 
power-packed home pages. The information available is extremely detailed
with digitized photos, audio tracks, vehicle specifications and much 
more. 
<P>  Please feel free to explore our own web site at your leisure, which provides its members with 
     instant access to AADA membership services and information plus a newsletter, legislative updates 
     and list of benefits. There's even a deluxe Auto Mall<font size="2"><sup>TM</sup></font>, which enables 
     the customer to have easy access to all AADA members' dealerships
      in an attractive, easy-to-understand format. As you can see, the opportunities 
     are endless.
<P>
        This is a medium that can make money for you. It can work. It IS 
working.  
<P>   
     Don't let the bus pass you by. The Internet is a serious way to 
market your business - not just in the year 2000, but NOW. If you 
haven't set up your dealership's own home page, there's no better time. See you in cyberspace.

</td></tr>

<tr>
<td></td>
<td>
<p>
<center><a href="frontdoor.html"><img src="gif/autobar.gif" border=0 alt="Auto Mall"></a></center>


<p>
<hr size=3>
<p>
<center>
<a href="index.html"><img src="gif/mainpagebutton.gif" border=0 alt="Main Page"></a>
<a href="bylaws.html"><img src="gif/bylawsbutton.gif" alt="Bylaws" border=0></a><br>
<a href="adstandards.html"><img src="gif/advertbutton.gif" alt="Ad Standards" border=0></a>
<a href="committees.html"><img src="gif/committeebutton.gif" alt="committees" border=0></a>
<p>
[ <a href="index.html">Main Page</a>
| <a href="bylaws.html">Bylaws</a>
| <a href="adstandards.html">Advertising Standards</a>
| <a href="committees.html">Committees</a> ]
</center>
<br>
<br>

<center>For inquiries or comments, e-mail: <a href="mailto:aada@dasta.com">aada@dasta.com</a></center>
<p>
<p>
<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="http://www.dasta.com/gif/dastasig.gif"
			alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 25 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996
				<a href="http://www.dasta.com">DASTA VendorCat, LLC</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">This site was designed by 
		<a href="http://www.dasta.com">DASTA VendorCat</a><br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of
	<a href="http://www.dasta.com/anet.html">Association-Net</a>
	<sup>TM</sup></font></p>
</center>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-70</DOCNO>
<DOCOLDNO>IA058-000947-B025-354</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/frontdoor.html 206.97.63.16 19970109193141 text/html 2660
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:14:24 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 2489
Last-modified: Wed, 16 Oct 1996 20:05:59 GMT
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">

<HTML>
<HEAD>
<TITLE>The Auto Mall</TITLE>
</HEAD>

<body bgcolor="#000000" text="#FFFCFF" link="#FFF601" vlink="#BABEBC" ALINK="#8EBCFF">

<center><a href="automall.html"><img src="gif/automall.gif" border=0></a></center><p>
<center><font size=4><b>
For faster load time and reduced graphics enter the Auto Mall <a href="automall2.html">HERE</a><br>
or you may experience a more graphically intense version of the Auto Mall <a href="automall.html">HERE</a>.</b></font></center>
<p>
<center>
<a href="automall.html"><img src="gif/aadaillo.gif" border=0></a>
</center>
<p>
<font size=4>
You've just driven up to <b>The AADA Auto Mall<font size=1><sup>TM</sup></font></b>.  This is THE place to be if you're looking 
for a new automobile or truck.  At The <b>Auto Mall<font size=1><sup>TM</sup></font></b> you can:
<p>
<font size=4>
<ul>
<li>Find the nearest participating 
dealer in your area, look for automotive dealerships by manufacturer
<li>find out who's got the 
best deals and special sales going on right now
<li>and contact the dealers of your choice directly 
on line.</font>
</ul>
<p>
<center><font size="+3"> -- all this from <b>The Auto Mall<sup>TM</sup></b>.</font>
 <p>
 
 <center>
 <hr size=4 width=250>
 <font size=6><b>
 This is THE way to shop<br>
  for your next automobile or truck.
</b></font>
<hr size=4 width=250>
<br><br><br><br>
<a href="automall.html"><img src="gif/cars.gif" border=0></a>
</center>
<br>
<br>

<br>
<br>

<center>For inquiries or comments, e-mail: <a href="mailto:aada@dasta.com">aada@dasta.com</a></center>
<p>
<p></center>

 <table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="http://www.dasta.com/gif/dastasig.gif"
			alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 25 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996
				<a href="http://www.dasta.com">DASTA VendorCat, LLC</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">This site was designed by 
		<a href="http://www.dasta.com">DASTA VendorCat</a><br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of
	<a href="http://www.dasta.com/anet.html">Association-Net</a>
	<sup>TM</sup></font></p>
</center>


</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-71</DOCNO>
<DOCOLDNO>IA058-000947-B025-374</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/membership.html 206.97.63.16 19970109193150 text/html 2672
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:14:32 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 2501
Last-modified: Tue, 25 Jun 1996 23:06:24 GMT
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">

<HTML>
<HEAD>
<TITLE>Arizona Automobile Dealers Association - Membership</TITLE>
</HEAD>

<body background="gif/newtile3.gif" text="#000F35" link="#012A22" vlink="#000F35" ALINK="#8A1053" BGCOLOR="#DDD9C6">

<center>
<table border=2>
<tr><td>
<img src="gif/memberbenhead.gif">
</td></tr>
</table>
</center>

<br>
<br>

<font size=5>

<BLOCKQUOTE> 
Members of the Arizona Automobile Dealers Association
benefit from an organization that focuses and caters to the
needs of its dealer members. The AADA provides many services
ranging from group health and workers compensation insurance
and useful legal advice to forms, training and supplies and
important news bulletins that provide information not available
from other sources.
</BLOCKQUOTE>

</font>

<br>
<br>
<center><a href="frontdoor.html"><img src="gif/autobar.gif" border=0 alt="Auto Mall"></a></center>
<center>[<a href="frontdoor.html">The Auto Mall</a>]</center>
<p>

<center>
<a href="index.html"><img src="gif/mainpagebutton.gif" border=0 alt="Main Page"></a>
<a href="executives.html"><img src="gif/execbutton.gif" border=0></a><br>
<a href="board.html"><img src="gif/boardbutton.gif" border=0></a>
<a href="benefits.html"><img src="gif/memberbutton.gif" border=0></a>
<p>
[ <a href="index.html">Main Page</a>
| <a href="executives.html">Executives</a>]<br>
[ <a href="board.html">Board of Directors</a>
| <a href="benefits.html">Membership Benefits</a> ]
</center>
<br>
<br>

<center>For inquiries or comments, e-mail: <a href="mailto:aada@dasta.com">aada@dasta.com</a></center>
<p>
<p>
<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="http://www.dasta.com/gif/dastasig.gif"
			alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 25 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996
				<a href="http://www.dasta.com">DASTA VendorCat, LLC</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">This site was designed by 
		<a href="http://www.dasta.com">DASTA VendorCat</a><br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of
	<a href="http://www.dasta.com/anet.html">Association-Net</a>
	<sup>TM</sup></font></p>
</center>

<!-- Last modified by Stacey-->
</body>
</html>

</DOC>
<DOC>
<DOCNO>WT08-B13-72</DOCNO>
<DOCOLDNO>IA058-000947-B025-389</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/contact.html 206.97.63.16 19970109193207 text/html 4133
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:14:40 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 3962
Last-modified: Tue, 25 Jun 1996 23:05:47 GMT
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">

<HTML>
<HEAD>
<TITLE>Contact Us</TITLE>
</HEAD>

<body background="gif/newtile4.gif" text=000040 link=600000 vlink=400040>

<center>
<table border=2>
<tr><td>
<img src="gif/headercontact.gif" alt="Contact AADA">
</td></tr>
</table>
</center>

<p>

<table>

<tr><td width="60%" align="top"></td><td><a href="mailto:aada@dasta.com"><img src="gif/contactbullet.gif" border=0></a></td>
<td><font size=4>Email address:<br><a href="mailto:aada@dasta.com">aada@dasta.com</a></font></td></tr>
<tr></tr>
<tr><td width="60%" align="top"></td><td><a href="#telephone"><img src="gif/contactbullet.gif" border=0></a></td>
<td><font size=4><a name="telephone">Phone:</a><br>(602) 468-0888<br>(800) 678-3875</font></td></tr>
<tr></tr>
<tr><td width="60%" align="top"></td><td><a href="#fax"><img src="gif/contactbullet.gif" border=0></a></td>
<td><font size=4><a name="fax">Fax:</a><br>(602) 468-9707</font></td></tr>
<tr></tr>
<tr><td width="60%" align="top"></td><td><a href="#mail"><img src="gif/contactbullet.gif" border=0></a></td>
<td><font size=4><a name="mail">Mailing address:</a><br>PO Box 32717<br>Phoenix, AZ<br>85064</font></td></tr>
<tr></tr>
<tr><td width="60%" align="top"></td><td><a href="#steet"><img src="gif/contactbullet.gif" border=0></a></td>
<td><font size=4><a name="steet">Street address:<br>4701 N. 24th St., Suite B-#<br>Phoenix, AZ<br>85016</font></td></tr>

</table>


<p>
<hr size=3>
<p>

</center>
<center><a href="frontdoor.html"><img src="gif/autobar.gif" border=0 alt="Auto Mall"></a></center>
<p>
<center><a href="index.html"><img src="gif/mainpagebutton.gif" border=0 alt="Main Page"></a>
<p>
[ <a href="index.html">Main Page</a> ] </center>
<br>
<br>
<br>
<center>
<a href="about.html"><img src="gif/baboutusbutton.gif" border=0 alt="About Us"></a>
<a href="frontdoor.html"><img src="gif/bautomallbutton.gif" border=0 alt="Auto Mall"></a>
<a href="membership.html"><img src="gif/bmemberbutton.gif" border=0 alt="Membership"></a><br>
<img src="gif/bcontactbutton.gif" border=0 alt="Contact Us">
<a href="vendor.html"><img src="gif/bvendorbutton.gif" border=0 alt="Vendor Services"></a>
<a href="consumer.html"><img src="gif/bconsumerbutton.gif" border=0 alt="Consumer Info"></a><br>
<a href="newstalk.html"><img src="gif/bnewsflashbutton.gif" border=0 alt="News Flash"></a>
<a href="arizona.html"><img src="gif/bazautobutton.gif" border=0 alt="Auto Centennial"></a>
<a href="store.html"><img src="gif/bstorebutton.gif" border=0 alt="Store"></a><br>
<p>
[ <a href="about.html">About AADA</a>
| <a href="frontdoor.html">Auto Mall</a>
| <a href="membership.html">Membership</a>]<br>
[ Contact AADA
| <a href="vendor.html">Vendor Services</a>
| <a href="consumer.html">Consumer Information</a>]<br>
[ <a href="newstalk.html">News Flash</a>
| <a href="arizona.html">Arizona Auto Centennial</a>
| <a href="store.html">Store</a> ]<br>
</center>


<br>
<br>
<br>
<center>For inquiries or comments, e-mail: <a href="mailto:aada@dasta.com">aada@dasta.com</a></center>
<p>
<p>

</td>
</tr>
</table>
<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="http://www.dasta.com/gif/dastasig.gif"
			alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 25 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996
				<a href="http://www.dasta.com">DASTA VendorCat, LLC</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">This site was designed by 
		<a href="http://www.dasta.com">DASTA VendorCat</a><br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of
	<a href="http://www.dasta.com/anet.html">Association-Net</a>
	<sup>TM</sup></font></p>
</center>


<!-- Last modified by Stacey -->
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-73</DOCNO>
<DOCOLDNO>IA058-000947-B025-404</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/vendor.html 206.97.63.16 19970109193216 text/html 11883
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:14:57 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 11711
Last-modified: Tue, 25 Jun 1996 23:06:17 GMT
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">

<HTML>
<HEAD>
<TITLE>Arizona Automobile Dealers Association - Vendor Services</TITLE>
</HEAD>

<body background="gif/aadatilep.gif" bgcolor="#E5E0E0" text="#000628" link="#55083C" vlink="#00120A" ALINK="#220652">

<center>
<table border=2>
<tr><td>
<img src="gif/headervendor.gif" alt="About AADA">
</td></tr>
</table>
</center>

<br>
<br>
<center>
<hr width=250 size=4>
<font size=4><b>
With the support and assistance of<br>
the Arizona Automobile Dealers Association,<br>
franchised automobile dealers<br>
are offered a wealth of vendor services and<br>
marketing opportunities.
</b></font>
<hr width=250 size=4>
</center>

<br>
<br>
<p>
<hr size=3>
<p>

AADA offers three avenues for marketing through the association: endorsement, recommendation, and advertising in the AADA newsletter.<p>

To inquire about endorsement or recommendation, please e-mail <a href="mailto:aada@dasta.com">aada@dasta.com</a>.<p>

<a href="adinfo.html">Advertising in the AADA newsletter</a>

<p>
<hr size=3>
<p>

<b>Legal Services</b><p>

<b>On-staff legal counsel</b>:  In addition to representing member dealers in legal matters that impact the retail auto industry, AADA's on-staff attorney is available to advise dealers and their employees on legal issues that arise in day-to-day business
 operations.<p>

The general counsel has represented a number of dealers on several tax issues, including the state of Arizona's sales tax assessments on dealer documentary fees. In addition, the general counsel recently served as co-counsel for several dealers in the suc
cessful lawsuit against the state of Arizona over mandatory insurance verification. This action brought a permanent injunction against the state requirement that dealers verify liability-insurance coverage on vehicles they sell, and payment of  AADA's att
orney fees.<p>

The general counsel also serves as legal advisor to AADA's executive vice president and board of directors, and to the AADA Insurance Trust and the stockholders of AADA Services, Inc., in legal matters that affect the association such as employment and ta
x law, antitrust law, insurance law and general association law.<p>

For more information on AADA's legal services program contact AADA General Counsel Michael Denea.<p>

<b>Employment-law services</b>: Complementing the services provided by on-staff legal counsel, specialized employment-law consultation and services are offered through the AADA-endorsed labor-law firm Steptoe & Johnson. The program includes:<p>
<li>Free phone consultation on most employment-law questions;
<li>Low, preset fees for special services such as compilation of an employee handbook or employee drug-testing policy.
<li>Periodic legal analyses on employment-law issues  in the AADA monthly  newsletter, Topics.
<p>

For more information on AADA employment-law services, contact David Selden or Julie Pace, Steptoe & Johnson, (602) 257-5211.

<p>
<hr size=3>
<p>


<b>Title & Registration Services</b><p>

The first privately operated vehicle title and registration program in the country, this revolutionary membership service offers a fast, hassle-free alternative to processing title work through the state. Plates, title and registration are mailed to the b
uyer within 48 hours, with a dramatically higher level of customer service for both you and your customer. AADA continues to offer duplicate titles and motor vehicle records, as well as Arizona and CARFAX (nationwide) title-history reports, as part of the
 new program. For more information contact AADA Title and Registration Program administrators Ted Boggs or Naomi Ramsey.

<p>
<hr size=3>
<p>

<b>Telephone services</b><p>


<b>Local-service cost auditing</b>: Local telephone-service cost auditing by Par-Tel, a US West agent, has saved AADA members an average of 35 percent off local billings. For more information contact John Stock, Par-Tel, (602) 278-7111.<p>

<p>
<hr size=3>
<p>

<b>Forms, Printing & Product Services</b><p>

AADA consistently offers the lowest prices available on business forms, printing services and specialty advertising products. Members also enjoy personalized service from in-house and field sales representatives, and the knowledge that their dollars are r
eturned to them through vital association services such as legislative representation. For more information contact AADA Forms and Products Director Mike Mastrangelo.

<p>
<hr size=3>
<p>

<b>Field Services</b><p>

AADA's Field Services Director travels statewide to member dealerships, making sure AADA stays in touch with the problems dealers face during day-to-day operations and providing a unique level of personal service to dealers and their staffs. A free servic
e to AADA members. For more information contact AADA Field Services Director Jeff Andresen.<p>

<p>
<hr size=3>
<p>

<b>Energy Savings</b><p>

The Energy Group has saved more than 100 Arizona companies from 20 to 40 percent on business energy expenses through installation of energy-efficient technologies. TEG delivers the savings it promises with no employee participation, no change in temperatu
re or light levels and no operational interruptions. Customized programs combine the right mix of proven technology. For more information contact Jack Smith, The Energy Group, (602) 814-0150.<p>

<p>
<hr size=3>
<p>

<b>Records Transfer/Storage</b><p>

Tempe-based DataLink transfers records to easily storable and retrievable media such as CD-ROM and microfiche, ending storage-room searches and overflowing file cabinets. AADA's endorsement of DataLink provides substantial member discounts off standard ra
tes. For more information contact Bob Dunn, DataLink, (602) 438-0601
Employee Drug-Testing  Accurate, 24-hour results on employee drug and alcohol tests are available to AADA members through nationally certified Southwest Laboratories. The professional technicians at Southwest's state-of-the-art Phoenix testing facility ut
ilize the latest screening and security technology. Southwest Labs' services are available to AADA members statewide at discounted group rates  negotiated by the association. For more information contact Scott Thompson, Southwest Labs, (602) 438-8507 or (
800) 279-0027.<p>

<p>
<hr size=3>
<p>


<b>Bonds</b><p>

Dealer, title, notary and other bonds are available through AADA's insurance department at affordable group rates. For more information contact Vickie Osborn in the AADA Insurance Trust office.<p>

<p>
<hr size=3>
<p>

<b>Check Guarantee and Credit Card Authorization Services</b><p>

The association's check-guarantee and credit-card-processing service, provided through industry leader National City Processing Company, offers a complete range of merchant payment-protection services. NPC is the official authorization provider for more t
han 50 automotive trade associations. For more information contact Kerry Morris, NPC, (800) 334-9897.

<p>
<hr size=3>
<p>

<b>Environmental Services</b><p>

The professional environmental consultants at Van's Environmental Services provide free advice to AADA members on environmental laws and regulations, and offer a wide range of affordable environmental services including compliance audits, underground stor
age tank removal/upgrades, drywell installation and spill cleanup. Van's also offers educational seminars and contributes articles on environmental issues to the monthly AADA newsletter, Topics. For more information contact Chris van Elk or Brian Vance, V
an's Environmental Services, (602) 944-8309.<p>

<p>
<hr size=3>
<p>

<b>News and Information Services</b><p>

<b>Monthly newsletter</b>:  The only newsletter published exclusively for Arizona's franchised auto dealers, AADA Topics reports on the latest legislative and legal developments, member news, industry events and much more. Topics includes articles contrib
uted by experts on employment law, environmental regulation and other fields, plus photos, good-news stories and a healthy dose of cartoons. Delivered free to all members each month. For more information contact the AADA communication and public relations
 office.<p>

<b>Membership Directory and Reference Guide</b>:  A tool you and your staff will use every day. Copies and summaries of state and federal laws and regulations that affect auto dealers, plus member directories organized by dealership name, location and fra
nchise, all in a convenient three-ring binder. One copy plus annual updates free to each member. For more information contact AADA Executive Secretary Patti Baca.

<b>Special Bulletins</b>:  AADA Special Bulletins, often sent by facsimile, quickly communicate urgent news, scam alerts, requests for dealer action on key legislation, and other important information. A free service to AADA-member dealerships. For more i
nformation contact AADA Executive Secretary Patti Baca.

<p>
<hr size=3>
<p>
<center><a href="frontdoor.html"><img src="gif/autobar.gif" border=0 alt="Auto Mall"></a></center>
<center>[<a href="frontdoor.html">The Auto Mall</a>]</center>
<br>
<br>
<br>
<center>
<a href="about.html"><img src="gif/baboutusbutton.gif" border=0 alt="About Us"></a>
<a href="frontdoor.html"><img src="gif/bautomallbutton.gif" border=0 alt="Auto Mall"></a>
<a href="membership.html"><img src="gif/bmemberbutton.gif" border=0 alt="Membership"></a><br>
<a href="contact.html"><img src="gif/bcontactbutton.gif" border=0 alt="Contact Us"></a>
<img src="gif/bvendorbutton.gif" border=0 alt="Vendor Services">
<a href="consumer.html"><img src="gif/bconsumerbutton.gif" border=0 alt="Consumer Info"></a><br>
<a href="newstalk.html"><img src="gif/bnewsflashbutton.gif" border=0 alt="News Flash"></a>
<a href="arizona.html"><img src="gif/bazautobutton.gif" border=0 alt="Auto Centennial"></a>
<a href="store.html"><img src="gif/bstorebutton.gif" border=0 alt="Store"></a><br>
<p>
[ <a href="about.html">About AADA</a>
| <a href="frontdoor.html">Auto Mall</a>
| <a href="membership.html">Membership</a>]<br>
[<a href="contact.html">Contact AADA</a>
|Vendor Services
| <a href="consumer.html">Consumer Information</a>]<br>
[<a href="newstalk.html">News Flash</a>
| <a href="arizona.html">Arizona Auto Centennial</a>
| <a href="store.html">Store</a> ]<br>
</center>
<center>
<a href="index.html"><img src="gif/mainpagebutton.gif" border=0 alt="Main Page"></a>
<a href="adinfo.html"><img src="gif/advertbutton.gif" border=0 alt="advertising"></a>
<a href="endorsed.html"><img src="gif/endorsebutton.gif" border=0 alt="Calendar"></a>
<p>
[ <a href="index.html">Main Page</a>
| <a href="adinfo.html">Advertising Information</a>
| <a href="endorsed.html">Endorsed and Recommended Vendors</a> ]
<br>
<br>
<br>
<center>For inquiries or comments, e-mail: <a href="mailto:aada@dasta.com">aada@dasta.com</a><p>
<p>
</center>

</td>
</tr>
</table>
<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="http://www.dasta.com/gif/dastasig.gif"
			alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 25 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996
				<a href="http://www.dasta.com">DASTA VendorCat, LLC</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">This site was designed by 
		<a href="http://www.dasta.com">DASTA VendorCat</a><br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of
	<a href="http://www.dasta.com/anet.html">Association-Net</a>
	<sup>TM</sup></font></p>
</center>


<!--last modified by Stacey-->
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-74</DOCNO>
<DOCOLDNO>IA058-000947-B026-11</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/consumer.html 206.97.63.16 19970109193224 text/html 3891
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:15:07 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 3720
Last-modified: Tue, 25 Jun 1996 23:05:47 GMT
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">

<HTML>
<HEAD>
<TITLE>Arizona Automobile Dealers Association - Consumer Information</TITLE>
</HEAD>

<body background="gif/aadatile1x.gif" text="#000628" link="#55083C" vlink="#00120A" ALINK="#220652" BGCOLOR="#E5E0E0">

<center>
<hr size=3>
<font size=4><b>
The American Automobile Dealers Association offers<br>
friendly and useful consumer-oriented services to the public. </b></font>
<hr size=3>
</center>
<br>
<br>
<center>
<img src="gif/highway.gif">
</center>

<br>
<br>
<center>
<hr size=3>
<font size=4><b>
AADA offers the following consumer services,<br> funded by the franchised new-car and truck-dealers of Arizona:
</b></font>
<hr size=3>
</center>
<p>
<table width=100%>
<tr><td valign="top"><img src="gif/purpleball.gif" hspace=5 align="middle"></td>
<td>Guidebooks on purchasing/leasing new vehicles and servicing vehicles at new-car dealerships,
published by the National Automobile Dealers Association.</td></tr>

<tr><td valign="top"><img src="gif/purpleball.gif" hspace=5 align="middle"></td>
<td>Telephone information and guidance related to franchised auto dealerships.</td></tr>

<tr><td valign="top"><img src="gif/purpleball.gif" hspace=5 align="middle"></td>
<td>Complaint-mediation through the nationwide <a href="autocap.html">Automotive Consumer Action Program</a>.</td></tr>
</table>
<br>
<center><a href="index.html"><img src="gif/mainpagebutton.gif" border=0 alt="Main Page"></a>
<p>
[ <a href="index.html">Main Page</a> ]</center>

<br>
<br>
<center>
<a href="about.html"><img src="gif/baboutusbutton.gif" border=0 alt="About Us"></a>
<a href="frontdoor.html"><img src="gif/bautomallbutton.gif" border=0 alt="Auto Mall"></a>
<a href="membership.html"><img src="gif/bmemberbutton.gif" border=0 alt="Membership"></a><br>
<a href="contact.html"><img src="gif/bcontactbutton.gif" border=0 alt="Contact Us"></a>
<a href="vendor.html"><img src="gif/bvendorbutton.gif" border=0 alt="Vendor Services"></a>
<img src="gif/bconsumerbutton.gif" border=0 alt="Consumer Info"><br>
<a href="newstalk.html"><img src="gif/bnewsflashbutton.gif" border=0 alt="News Flash"></a>
<a href="arizona.html"><img src="gif/bazautobutton.gif" border=0 alt="Auto Centennial"></a>
<a href="store.html"><img src="gif/bstorebutton.gif" border=0 alt="Store"></a><br>
<p>
[ <a href="about.html">About AADA</a>
| <a href="frontdoor.html">Auto Mall</a>
| <a href="membership.html">Membership</a>]<br>
[ <a href="contact.html">Contact AADA</a>
| <a href="vendor.html">Vendor Services</a>
| Consumer Information]<br>
[ <a href="newstalk.html">News Flash</a>
| <a href="arizona.html">Arizona Auto Centennial</a>
| <a href="store.html">Store</a> ]<br>
</center>
<br>
<br>
<center>For inquiries or comments, e-mail: <a href="mailto:aada@dasta.com">aada@dasta.com</a></center>
<p>

<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="http://www.dasta.com/gif/dastasig.gif"
			alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 25 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996
				<a href="http://www.dasta.com">DASTA VendorCat, LLC</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">This site was designed by 
		<a href="http://www.dasta.com">DASTA VendorCat</a><br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of
	<a href="http://www.dasta.com/anet.html">Association-Net</a>
	<sup>TM</sup></font></p>
</center>



<!--Last modified by Stacey-->
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-75</DOCNO>
<DOCOLDNO>IA058-000947-B026-27</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/arizona.html 206.97.63.16 19970109193232 text/html 3674
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:15:15 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 3503
Last-modified: Tue, 25 Jun 1996 23:05:51 GMT
</DOCHDR>

<html><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">

<head>
<title>Press Release: Arizona Auto Centennial</title>
</head>
<body background="gif/aadatile6x.gif" bgcolor="#E5E0E0" text="#000628" link="#55083C" vlink="#00120A" ALINK="#220652">
<hr>
<center>
<font size=6>
<b>CLASSIC/CONCEPT CARS TO <br>
GO ON DISPLAY ACROSS ARIZONA!</b>
</font>
</center>
<hr>
<p>
<center>
<img src="gif/oldcar2.gif">
</center>
<br>
<br>


<h2>
Arizona Auto Centennial Will Celebrate 100 Years of U.S. Auto Industry
And Arizona Automotive History
</h2>
<p>
<table width=100%>
<tr>
<td width=75%>
<b>PHOENIX-</b>From lovingly preserved turn-of-the-century antiques to 
classic 60's muscle cars and the high-tech vehicles of the next milennium, 
exhibits across Arizona this summer will showcase our favorite object of 
affection. Arizona is joining in the nationwide celebration of the 
automobile's 100th anniversary, and vehicle exhibits spanning the last
ten decades will highlight this spring's commemorative events. Exhibits
will feature not only rare automobiles but also fascinating photos of 
the automobile's unique history in Arizona.
<p>
</td>
<td width=25%><img src="gif/oldcar1.gif"></td>
</tr>
</table>
<p>
        The nationwide celebration marks the centennial of the first 
production-run automobile manufacured in America, assembled in 1896 by 
Charles and J. Frank Duryea. The Duryeas built 13 of their horseless 
wagons that year in Springfield, Mass., launching the development of the
mass-produced automobile - and the transformation of American life.
<p>
        In Arizona, classic car owners, manufacturers and business 
groups are joining the Arizona Automobile Dealers Association to bring
century-spanning auto shows to locations statewide. Chaired by Phoenix
auto dealer Don Luke, the Arizona Auto Centennial Committee is one of
more than 80 U.S. organizations scheduling commemorative events.
<p>
        Arizona Auto Centennial events will begin in April and run 
through mid-summer.

<p>
<center><a href="frontdoor.html"><img src="gif/autobar.gif" border=0 alt="Auto Mall"></a></center>
<center>[<a href="frontdoor.html">The Auto Mall</a>]</center>
<br>

<br>
<center>
<a href="index.html"><img src="gif/mainpagebutton.gif" border=0 alt="Main Page"></a>
<a href="azcommittee.html"><img src="gif/committeebutton2.gif" border=0 alt="Arizona Auto Committee"></a>
<p>
[ <a href="index.html">Main Page</a>
| Arizona Auto Centennial ]
</center>
<br>
<br>
<br>
<center>For inquiries or comments, e-mail: <a href="mailto:aada@dasta.com">aada@dasta.com</a></center>
<p>
<p>

</tr>
</td>
</table>

<!-- Last modified by Stacey-->
<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="http://www.dasta.com/gif/dastasig.gif"
			alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 25 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996
				<a href="http://www.dasta.com">DASTA VendorCat, LLC</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">This site was designed by 
		<a href="http://www.dasta.com">DASTA VendorCat</a><br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of
	<a href="http://www.dasta.com/anet.html">Association-Net</a>
	<sup>TM</sup></font></p>
</center>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-76</DOCNO>
<DOCOLDNO>IA058-000947-B026-43</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/store.html 206.97.63.16 19970109193239 text/html 4519
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:15:22 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 4348
Last-modified: Tue, 25 Jun 1996 23:06:20 GMT
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">

<HTML>
<HEAD>
<TITLE>Arizona Automobile Dealers Association Store</TITLE>
</HEAD>

<body background="gif/aadatileb.gif" bgcolor="#E5E0E0" text="#000628" link="#55083C" vlink="#00120A" ALINK="#220652">

<center>
<table border=2>
<tr><td>
<img src="gif/headerstore.gif" alt="AADA Store">
</td></tr>
</table>
</center>


<center>
<hr width=250 size=4>
<font size=4><b>
The AADA offers a diversity of<br>
stock specialty items and custom<br>
products and services.</b></font>
<hr width=250 size=4>
</center>
<p>

<p>
<center>
<font size=4><b>AADA's Forms and Products Warehouse offers:</b></font>
</center>
<p>
<table>
<tr><td><img src="gif/purpleball.gif" align="center"></td>
<td>A full range of dealership and general business forms, including odometer statements, purchase orders, powers of attorney, accounting forms, etc.</td></tr>
<tr><td><img src="gif/purpleball.gif"></td>
<td>Stock and customized advertising products such as fluorescent windshield numbers, license-plate frames/inserts, signs and banners, etc.</td></tr>
<tr><td><img src="gif/purpleball.gif"></td>
<td>Specialty dealership products such as seat covers, floor mats, key tags, addendum stickers, etc. and</td></tr>
<tr><td><img src="gif/purpleball.gif"></td>
<td>Customized printing services including business cards, business forms, letterhead/envelopes, checks, etc.</td></tr>
</table>

<p>
Many items are carried in stock at AADA and available for same-day pickup or next-day
delivery. Orders may be placed on your AADA account, paid for via cash or check at our order desk, or placed COD.
<p>

For a product catalog or more information on AADA forms and products, please e-mail 
<a href="mailto:aada@dasta.com">aada@dasta.com</a> or call us at (602) 468-0888 or (800) 678-3875.
<br>
<br>
<center><a href="frontdoor.html"><img src="gif/autobar.gif" border=0 alt="Auto Mall"></a></center>
<center>[<a href="frontdoor.html">The Auto Mall</a>]</center>
<br>

<center><a href="index.html"><img src="gif/mainpagebutton.gif" border=0 alt="Main Page"></a>
<p>
[ <a href="index.html">Main Page</a> ]</center>
<br>
<br>
<br>
<center>
<a href="about.html"><img src="gif/baboutusbutton.gif" border=0 alt="About Us"></a>
<a href="frontdoor.html"><img src="gif/bautomallbutton.gif" border=0 alt="Auto Mall"></a>
<a href="membership.html"><img src="gif/bmemberbutton.gif" border=0 alt="Membership"></a><br>
<a href="contact.html"><img src="gif/bcontactbutton.gif" border=0 alt="Contact Us"></a>
<a href="vendor.html"><img src="gif/bvendorbutton.gif" border=0 alt="Vendor Services"></a>
<a href="consumer.html"><img src="gif/bconsumerbutton.gif" border=0 alt="Consumer Info"></a><br>
<a href="newstalk.html"><img src="gif/bnewsflashbutton.gif" border=0 alt="News Flash"></a>
<a href="arizona.html"><img src="gif/bazautobutton.gif" border=0 alt="Auto Centennial"></a>
<img src="gif/bstorebutton.gif" border=0 alt="Store"><br>
<p>
[ <a href="about.html">About AADA</a>
| <a href="frontdoor.html">Auto Mall</a>
| <a href="membership.html">Membership</a>]<br>
[ <a href="contact.html">Contact AADA</a>
| <a href="vendor.html">Vendor Services</a>
| <a href="consumer.html">Consumer Information</a>]<br>
[ <a href="newstalk.html">News Flash</a>
| <a href="arizona.html">Arizona Auto Centennial</a>
| Store ]<br>
</center>
<br>
<br>
<br>
<center>For inquiries or comments, e-mail: <a href="mailto:aada@dasta.com">aada@dasta.com</a><center>
<p>


</tr>
</td>
</table>
</center>
<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="http://www.dasta.com/gif/dastasig.gif"
			alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 25 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996
				<a href="http://www.dasta.com">DASTA VendorCat, LLC</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">This site was designed by 
		<a href="http://www.dasta.com">DASTA VendorCat</a><br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of
	<a href="http://www.dasta.com/anet.html">Association-Net</a>
	<sup>TM</sup></font></p>
</center>


</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-77</DOCNO>
<DOCOLDNO>IA058-000947-B026-76</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/newsflash.html 206.97.63.16 19970109193258 text/html 3370
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:15:41 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 3199
Last-modified: Tue, 25 Jun 1996 23:06:24 GMT
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">

<HTML>
<HEAD>
<TITLE>Arizona Automobile Dealers Association - Member News Bulletins</TITLE>
</HEAD>

<body background="gif/aadatile1x.gif" bgcolor="#E5E0E0" text="#000628" link="#55083C" vlink="#00120A" ALINK="#220652">


<center>
<table border=2>
<tr><td>
<img src="gif/headernewsflash.gif">
</td></tr>
</table>
</center>

<p>
<hr size=3>
<p>


<b>
<font size=5><a name="korte">Ray Korte, Jr. dies</a><br>
February 26, 1996</b></font>
<p>
<font size=4>
SPECIAL NOTIFICATION<br>
</center>

Ray Korte, Jr., one of AADA's great long-time friends and supporters passed away Sunday, February 25th after a long illness.<p>

Ray had been in the car business since about 1940, first with his father and, beginning in 1970, with the Chevy store.<p>

Services will be held at Brophy Chapel, 4701 N. Central, Phoenix, at 10:00 a.m. Wednesday, Feb. 28.  In lieu of flowers, donations may be made to the Brophy College Prep Scholarship Fund, the Xavier College Prep Scholarship Fund or Hospice of the 
Valley.<p>

All of us at AADA, along with all of Ray's friends, extend our sympathy to his family.<p>
</font>
</td></tr>

<tr>
<td></td>
<td>
<p>
<center><a href="frontdoor.html"><img src="gif/autobar.gif" border=0 alt="Auto Mall"></a></center>
<center>[<a href="frontdoor.html">The Auto Mall</a>]</center>

<p>
<hr size=3>
<p>
<center>
<a href="index.html"><img src="gif/mainpagebutton.gif" border=0 alt="Main Page"></a>
<a href="bulletin.html"><img src="gif/bulletinbutton.gif" border=0 alt="bulletin"></a>
<a href="legalbriefs.html"><img src="gif/legalbutton.gif" border=0 alt="legal briefs"></a><br>
<a href="calendar.html"><img src="gif/calenbutton.gif" border=0 alt="calender"></a>
<a href="presidents_message.html"><img src="gif/presbutton.gif" border=0 alt="preszmessage"></a>
<a href="capitolwatch.html"><img src="gif/capitolbutton.gif" border=0 alt="capitol watch"></a>
<p>
[<a href="index.html">Main Page</a>
|<a href="bulletin.html">Bulletins</a>
|<a href="legalbriefs.html">Legal Briefs</a>]<br>
[<a href="calendar.html">Calendar</a>
|<a href="presidents_message.html">President's Message</a>
|<a href="capitolwatch.html">Capitol Watch</a>]
</center>
<br>
<br>
<br>

<center>For inquiries or comments, e-mail: <a href="mailto:aada@dasta.com">aada@dasta.com</a></center>
<p>
<p>

<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="http://www.dasta.com/gif/dastasig.gif"
			alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 25 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996
				<a href="http://www.dasta.com">DASTA VendorCat, LLC</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">This site was designed by 
		<a href="http://www.dasta.com">DASTA VendorCat</a><br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of
	<a href="http://www.dasta.com/anet.html">Association-Net</a>
	<sup>TM</sup></font></p>
</center>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-78</DOCNO>
<DOCOLDNO>IA058-000947-B026-92</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/bulletin.html 206.97.63.16 19970109193312 text/html 10587
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:15:48 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 10415
Last-modified: Tue, 25 Jun 1996 23:05:49 GMT
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">

<HTML>
<HEAD>
<TITLE>Arizona Automobile Dealers Association - Member News Bulletins</TITLE>
</HEAD>

<body background="gif/aadatilew.gif" bgcolor="#BABEBC" text="#000000" link="#570032" vlink="#0F388E" ALINK="#570032">

<center>
<table border=2>
<tr><td>
<img src="gif/headernewsflash.gif">
</td></tr>
</table>
</center>

<p>
<hr size=3>
<p>


<b>
<center>
<a name="korte">Ray Korte, Jr. dies</a><br>
February 26, 1996</b>
</center>
<p>
SPECIAL NOTIFICATION<br>
</center>

Ray Korte, Jr., one of AADA's great long-time friends and supporters passed away Sunday, February 25th after a long illness.<p>

Ray had been in the car business since about 1940, first with his father and, beginning in 1970, with the Chevy store.<p>

Services will be held at Brophy Chapel, 4701 N. Central, Phoenix, at 10:00 a.m. Wednesday, Feb. 28.  In lieu of flowers, donations may be made to the Brophy College Prep Scholarship Fund, the Xavier College Prep Scholarship Fund or Hospice of the 
Valley.<p>

All of us at AADA, along with all of Ray's friends, extend our sympathy to his family.<p>

<p>
<hr size=3>
<p>

<center><b>
Ford Contour/Mistique Fuel Tank Recall<br>
February 6, 1996<br>
</b></center>
<p>

Attn: Service Manager<p>

Coming soon is a bulletin from ATAE (Automotive Trade Association Executives) concerning the disposal of recalled fuel tanks.

<p>
<hr size=3>
<p>

<center><b>
Power of Attorney form changes<br>
January 31, 1996<br>
</b></center>

<p>

Deliver to General Manager<p>

        The Arizona law governing the form Powers of Attorney must take to be effective has been amended. Dealers should check their Power of Attorney forms to be sure they meet the following requirements:<p>

A)      In general, an adult, known as the principal, may designate another adult, known as the agent, to make financial or other decisions on that person's behalf by executing a written power of attorney.<p>

B)      That power of attorney must contain language that clearly indicates that the person intends to create the power of attorney and clearly identifies the agent.<p>

C)      The form must dated and signed by the principal, must be notarized; and<p>

D)      in a change from prior practice, the power of attorney must be witnessed by a person other than the agent, the agent's spouse or the agent's child.<p>

This change means that dealers and their agents may not witness powers of attorney. The forms must be witnessed by an independent third party to the transaction, or by an agent or spouse of the principal.<p>

AADA has produced new forms to comply with these changes. Samples of those forms are attached to this special bulletin and available through the AADA Forms and Products Division.  Please call AADA if you have any questions.<p>

<p>
<hr size=3>
<p>

<center><b>
Unions May Use New Supreme Court Decision to organize Non-Union Employers<br>
March 12, 1996<br>
</b></center>
<p>

DELIVER TO DEALER/PRINCIPAL<br>
Route to General Manager<p>

Thanks to  a new U.S. Supreme Court decision, unions now have a new weapon in their arsenal of methods to attempt to organize non-union employers. The Supreme Court recently ruled that union organizers who apply for a job are protected by law against 
discrimination. It has long been the law that employers may not discriminate against employees based on their union membership, support or sympathies. The new decision extends that protection to job applicants, even if the applicants are paid union organi

zers.<p>

This new court decision makes it important for automobile dealers to make sure that those who do their interviewing and hiring are aware that they must not allow their hiring decisions to be influenced by the fact that a job applicant may be a union membe

r or union organizer. All hiring decisions must be made for legitimate, non-discriminatory business reasons.<p>

The following example illustrates the predicament automobile dealers could face: A person who applies for a vacancy for a service technician might disclose during the job interview that he is a paid union organizer and that after he is hired, he intends t

o organize a union among the service technicians. If he is not hired, he will likely file a charge with the National Labor Relations Board ("NLRB") alleging that he was denied the job because he is a "salt" or "salter" -- common slang terms for paid union

 organizers.<p>

It is lawful for automobile dealers to decide not to hire union organizers for reasons other than the fact that they are union organizers. For example, other applicants may have more experience in the particular type of job. Union organizers may lack job 

stability and may have a history of working at a variety of places for relatively short periods of time. If an employer rejects a union organizer-applicant 
for those reasons, however, it will be necessary to be prepared to defend against an unfair labor practice charge before the NLRB by showing that other hiring decisions have been made based on an equivalent lack of relevant experience or similar lack of j

ob stability.<p>

The new Court decision will be particularly useful to unions as part of their indirect union organizing tactics being used more frequently. Rather than traditional organizational campaigns that are targeted at convincing employees to join a union, unions 

today are instigating government proceedings against employers to attempt to persuade employers to recognize unions. For example, unions and their members may initiate complaints regarding OSHA, wage and hour matters, EEOC charges, environmental regulatio

ns, and consumer issues in order to embroil non-union employers in governmental proceedings.<p>

If you have any questions about the foregoing, please contact Michael Denea, AADA General Counsel at 468-0888 or Julie Pace at AADA's endorsed labor law counsel, Steptoe and Johnson. Ms. Pace's telephone number is 257-5224.<p>

<p>
<hr size=3>
<p>

<center><b>
Vandalism Alert<br>
March 12, 1996<br>
</b></center>
<p>

A franchised dealer in Scottsdale was vandalized yesterday DURING BUSINESS HOURS; 25 vehicles were keyed, and a few vehicles' tops and upholstery were slashed. One other nearby franchised dealership may also have been hit by the same vandal.<p>

Possible suspect is described as a professional-looking male approximately 50 years old, 190 - 200 lbs., 5'9' with sandy grey hair.<p>

If you have any information that may relate to this incident please contact the Felony Division at the Scottsdale Police Department, 391-5000.<p>

<p>
<hr size=3>
<p>

<center><b>
March 12 is deadline to file for pre-1996 UST assistance<br>
March 12, 1996<br>
</b></center>
<p>

The Arizona Department of Environmental Quality announced this week that March 12, 1996 is the deadline to file claims for reimbursement from the State Underground Storage Tank Assistance Fund for pre-1996 UST cleanup costs. The deadline applies to 
tank closure reports filed with ADEQ before Jan. 1, 1996.<p>

If you have not yet arranged to file for reimbursement from the state assistance fund, or if you have questions concerning this issue, please contact Van's Environmental Services at (602) 944-8309. Van's can file the necessary paperwork for you. These ser

vices are provided as an AADA membership benefit.<p>

<p>
<hr size=3>
<p>

<center><b>
Luxury Tax threshold to increase Jan. 1<br>
Phaseout proposal still awaits outcome of budget-act negotiations<br>
Dec. 20, 1995<br>
</b></center>
<p>

The Internal Revenue Service recently confirmed that the federal luxury tax threshold, which in 1993 was indexed for inflation, will increase Jan. 1 to $34,000. This means auto dealers will apply the 10 percent luxury tax on that portion of a vehicle pric

e that exceeds $34,000. The current threshold is $32,000.<p>

The IRS has not yet announced the increase but has confirmed to the National Automobile Dealers Association that it will take effect as indicated above.<p>

Congress and President Clinton are still negotiating an agreement on some parts of the federal budget act, which includes a proposal to phase out the luxury tax over the next seven years. The phaseout proposal would gradually reduce the tax rate and accel

erate the annual increase in the price threshold.<p>

AADA will notify member dealers as soon as action is taken on the proposal, and provide details of the phaseout schedule.<p>


<hr size=3>
<p>
<center><a href="frontdoor.html"><img src="gif/autobar.gif" border=0 alt="Auto Mall"></a></center>
<center>[<a href="frontdoor.html">The Auto Mall</a>]</center>

<br>
<center>
<center>
<a href="index.html"><img src="gif/mainpagebutton.gif" border=0 alt="Main Page"></a>
<img src="gif/bulletinbutton.gif" border=0 alt="bulletin">
<a href="legalbriefs.html"><img src="gif/legalbutton.gif" border=0 alt="legal briefs"></a><br>
<a href="calendar.html"><img src="gif/calenbutton.gif" border=0 alt="calender"></a>
<a href="presidents_message.html"><img src="gif/presbutton.gif" border=0 alt="preszmessage"></a>
<a href="capitolwatch.html"><img src="gif/capitolbutton.gif" border=0 alt="capitol watch"></a>
<p>
[<a href="index.html">Main Page</a>
|Bulletins
|<a href="legalbriefs.html">Legal Briefs</a>]<br>
[<a href="calendar.html">Calendar</a>
|<a href="presidents_message.html">President's Message</a>
|<a href="capitolwatch.html">Capitol Watch</a>]
</center>
<br>
<br>
<br>

<center>For inquiries or comments, e-mail: <a href="mailto:aada@dasta.com">aada@dasta.com</a></center>
<p>
<p>
</center>.
<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="http://www.dasta.com/gif/dastasig.gif"
			alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 25 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996
				<a href="http://www.dasta.com">DASTA VendorCat, LLC</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">This site was designed by 
		<a href="http://www.dasta.com">DASTA VendorCat</a><br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of
	<a href="http://www.dasta.com/anet.html">Association-Net</a>
	<sup>TM</sup></font></p>
</center>


</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-79</DOCNO>
<DOCOLDNO>IA058-000947-B026-107</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/legalbriefs.html 206.97.63.16 19970109193321 text/html 7243
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:16:02 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 7072
Last-modified: Tue, 25 Jun 1996 23:06:11 GMT
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">

<HTML>
<HEAD>
<TITLE>Arizona Automobile Dealers Association - Legal Briefs</TITLE>
</HEAD>

<body background="gif/aadatilew.gif" bgcolor="#E5E0E0" text="#000628" link="#55083C" vlink="#00120A" ALINK="#220652">


<center>
<table border=2>
<tr><td>
<img src="gif/headernewstalk.gif" alt="About AADA">
</td></tr>
</table>
</center>

<br>
<br>
<center>
<hr size=4 width=250>
<font size=4><b>Legal Brief</b></font><br>
 - Bruce Myerson, Esq. Steptoe &amp; Johnson - 
</font>
<hr size=4 width=250>
<br>
<br>
<font size=5><b> "How Arbitration Can Be Good For Your Business"</b></font>
</center>
<br>
<br>
        As litigation costs continue to rise, more and more businesses
are examining alternative forms of dispute resolution such as mediation
and arbitration. A mediator acts as a facilitator to help the parties
reach a negotiated settlement of their dispute. An arbitrator listens to
the dispute and enters a binding award in favor of one party or the
other.<P>
        Using arbitration as a means of resolving disputes has
advantages and disadvantages.<P>
<P>
<font size=4><b>ARBITRATION VS. LITIGATION</b></font>
<P>
        Arbitration is like litigation in that the parties present their
positions in an "adversarial" setting, and the arbitrator, functioning
as both a judge and jury, adjucates in favor of one pary of the other.
Arbitration differs from litigation, however, in several important
respects:<P>
        Arbitration is faster. An arbitration hearing can be held within
a matter of months after the dispute arises. Litigation sometimes takes
years to conclude.<P>
        Arbitration is cheaper. The discovery phase of litigation, which
consists of taking depositions and exchanging documents, can be very
costly. In arbitration, usually there is only limited discovery on those
matters essential to resolution of the dispute.<P>
        Arbitration is almost never appealable. There are very few
limitations placed on a party's ability to appeal an adverse court
judgement. On the other hand, it is extremely difficult to appeal an
arbitration award. In fact, even if an arbitrator's decision is
incorrect, or is the arbitrator did not carefully follow the law, the
award still cannot be appealed.<P>
        Arbitrators can be selected for their expertise in the subject
of the dispute. In litigation, neither the judge not the jury will
necessarily have knowledge of the subject of the dispute. Arbitrators
typically are businesspeople, often from professional background. Many
believe it's preferable to have a business dispute decided by an
arbitrator rather than by a judge or jury.<P>
        Remedies can be limited in arbitration. In arbitration,
disputants can agree to limit the remedies available to the successful
party. For example, the parties could agree that the arbitrator would
not have authority to award punitive damages.<P>
<P>
<font size=4><b>ARBITRATION AGREEMENTS</b></font>
<P>
        An agreement to resolve a dispute through arbitration can be
included in a contract or entered into after a dispute arises. Most
disputants who arbitrate who do so because of pre-dispute arbitration
agreements: Once a dispute arises, it's often difficult to convince the
opposing party to agree to arbitration, particularly if that party wants
to present his/her case to a jury.<P>
        If you place an arbitration clause in a contract or agreement,
the clause should provide for an agency to administer the arbitration.
Most arbitration clauses provide that in the event of a dispute, the
arbitration will be conducted pursuant to the rules of the American
Arbitration Association, a nonprofit organization that administers
arbitrations for disputants.<P>
        The advantage to providing for an administering organization in
the agreement is that in the event of a dispute, a mechanism will be
in place to process the arbitration, which can prevent having to resort
to court action to force the opposing party to fulfill the agreement to
arbitrate. Also, by incorporating the arbitration rules of an
organization such as the AAA, both parties will be confident that the
arbitration will proceed according to rules that will be fair to both
sides.<P>
        An example of a typical arbitration clause is the following:

<BLOCKQUOTE>             Any controversy of claim arising out of or 
relating
             to this contract, or the breach thereof, shall be
             settled by arbitration administered by the American
             Arbitration Association under its Commercial
             Arbitration Rules, and judgment on the award rendered
             by the arbitrators may be entered in any court having
             jurisdiction thereof.</BLOCKQUOTE>

        Because of the binding nature of arbitration, parties should
draft arbitration clauses carefully and consult with legal counsel
before placing an arbitration clause in a contract or consenting to
arbitration.
<P>
        Look for information from AADA this month on an upcoming AADA
membership seminar on arbitration, co-sponsered by Steptoe & Johnson.
<p>
<hr size=3>
<p>
<center><a href="frontdoor.html"><img src="gif/autobar.gif" border=0 alt="Auto Mall"></a></center>
<center>[<a href="frontdoor.html">The Auto Mall</a>]</center>

<br>
<center>
<a href="index.html"><img src="gif/mainpagebutton.gif" border=0 alt="Main Page"></a>
<a href="bulletin.html"><img src="gif/bulletinbutton.gif" border=0 alt="bulletin"></a>
<img src="gif/legalbutton.gif" border=0 alt="legal briefs" ><br>
<a href="calendar.html"><img src="gif/calenbutton.gif" border=0 alt="calender"></a>
<a href="presidents_message.html"><img src="gif/presbutton.gif" border=0 alt="preszmessage"></a>
<a href="capitolwatch.html"><img src="gif/capitolbutton.gif" border=0 alt="capitol watch"></a>
<p>
[<a href="index.html">Main Page</a>
|<a href="bulletin.html">Bulletins</a>
|Legal Briefs]<br>
[<a href="calendar.html">Calendar</a>
|<a href="presidents_message.html">President's Message</a>
|<a href="capitolwatch.html">Capitol watch</a>]
</center>
<br>
<br>
<br>

<center>For inquiries or comments, e-mail: <a href="mailto:aada@dasta.com">aada@dasta.com</a></center>
<p>
<p>
<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="http://www.dasta.com/gif/dastasig.gif"
			alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 25 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996
				<a href="http://www.dasta.com">DASTA VendorCat, LLC</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">This site was designed by 
		<a href="http://www.dasta.com">DASTA VendorCat</a><br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of
	<a href="http://www.dasta.com/anet.html">Association-Net</a>
	<sup>TM</sup></font></p>
</center>


</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-80</DOCNO>
<DOCOLDNO>IA058-000947-B026-120</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/calendar.html 206.97.63.16 19970109193328 text/html 1956
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:16:11 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 1785
Last-modified: Tue, 25 Jun 1996 23:05:48 GMT
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">

<HTML>
<HEAD>
<TITLE>Arizona Automobile Dealers Association</TITLE>
</HEAD>

<body background="gif/aadatile1x.gif" bgcolor="#E5E0E0" text="#000628" link="#55083C" vlink="#00120A" ALINK="#220652">
<center><h1>The Calendar</h1>
</center>
<p>
<br>
<center>
<hr width="30%" size="5">
<strong>This page is currently under construction</strong>
<hr width="30%" size="4"></center>
<br>
<center>
<img src="gif/freeway.gif">
<br>
<br>
<br>
<hr width=250 size=5>
<font size=6><b>
This portion of this website<br>
is currently under development.
</b></font>
<hr width=250 size=5>

<br>
<br>
<a href="index.html"><img src="gif/mainpagebutton.gif" border=0 alt="Main Page"></a>

<center> <a href="index.html">Main Page</a> </center>
<br>
<br>
<br>
For inquiries or comments, e-mail: <a href="mailto:aada@dasta.com">aada@dasta.com</a><p>

</center>
<p>

 
<!--modified by Stacey-->
<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="http://www.dasta.com/gif/dastasig.gif"
			alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 25 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996
				<a href="http://www.dasta.com">DASTA VendorCat, LLC</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">This site was designed by 
		<a href="http://www.dasta.com">DASTA VendorCat</a><br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of
	<a href="http://www.dasta.com/anet.html">Association-Net</a>
	<sup>TM</sup></font></p>
</center>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-81</DOCNO>
<DOCOLDNO>IA058-000947-B026-131</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/presidents_message.html 206.97.63.16 19970109193345 text/html 5121
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:16:27 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 4950
Last-modified: Tue, 25 Jun 1996 23:06:23 GMT
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">

<HTML>
<HEAD>
<TITLE>Arizona Automobile Dealers Association - Member News Bulletins</TITLE>
</HEAD>

<body background="gif/aadatilew.gif" bgcolor="#BABEBC" text="#000000" link="#570032" vlink="#0F388E" ALINK="#570032">

<center>
<table border=2>
<tr><td>
<img src="gif/headernewstalk.gif" alt="About AADA">
</td></tr>
</table>
</center>

<center>
<hr size=4 width=250>
<font size=4>
A Message From AADA's President<br>
 - Stan Powell - 
</font>
<hr size=4 width=250>
</center>
<P>
<center>
<b><i>"Cyberspace is Where It's At! Better Catch Up With Your Competitors."</i></b><BR>
</center>
<P>
        A few years ago all the manufacturers were talking about
DCS - dealer communication systems. In a very short time span, every 
manufacturer developed electronic links to their dealer body, and have
continued to add features and simplify operation.
<P>
        But of course, all of this has not come without a price - simply
with a cost shifting from manufacturers to dealers. Although we gain 
information from DCS-type systems, the information we process and feed
manufacturers electronically - such as warranty claims - has reduced
their work load and the associated costs. To date, evolving in the 
information age has really been an expense to us - it hasn't offered 
ways to improve profitability.  
<P>
        The time has come. There's a buzz word out there called the
Internet, also referred to as the World Wide Web. The information on 
this critter is endless, and the marketing opportunities abundant. Some
U.S. dealers have grasped the Internet's vast opportunities early-on,
and have not only developed their own home pages, but are actively 
working cyberspace to snag sales from customers who place orders right 
on their computers! At least half a dozen Arizona dealers have their own
home pages on the Net or have them in the works. 
<P>   
     Most of the major manufacturers are online too, with exotic, 
power-packed home pages. The information available is extremely detailed
with digitized photos, audio tracks, vehicle specifications and much 
more. 
<P>   
     Please feel free to explore our own web site at your leisure, which provides its members with 
     instant access to AADA membership services and information plus a newsletter, legislative updates 
     and list of benefits. There's even a deluxe Auto Mall<font size="2"><sup>TM</sup></font>, which enables 
     the customer to have easy access to all AADA members' dealerships
      in an attractive, easy-to-understand format. As you can see, the opportunities 
     are endless.
<P>
        This is a medium that can make money for you. It can work. It IS 
working.  
<P>   
     Don't let the bus pass you by. The Internet is a serious way to 
market your business - not just in the year 2000, but NOW. If you 
haven't set up your dealership's own home page, there's no better time. See you in cyberspace.
</td></tr>

<tr>
<td></td>
<td>

<hr size=3>
<p>
<center><a href="frontdoor.html"><img src="gif/autobar.gif" border=0 alt="Auto Mall"></a></center>
<center>[<a href="frontdoor.html">The Auto Mall</a>]</center>
<br>
<center>
<a href="index.html"><img src="gif/mainpagebutton.gif" border=0 alt="Main Page"></a>
<a href="bulletin.html"><img src="gif/bulletinbutton.gif" border=0 alt="bulletin"></a>
<a href="legalbriefs.html"><img src="gif/legalbutton.gif" border=0 alt="legal briefs"></a><br>
<a href="calendar.html"><img src="gif/calenbutton.gif" border=0 alt="calender"></a>
<img src="gif/presbutton.gif" border=0 alt="preszmessage">
<a href="capitolwatch.html"><img src="gif/capitolbutton.gif" border=0 alt="capitol watch"></a>
<p>
[<a href="index.html">Main Page</a>
|<a href="bulletin.html">Bulletins</a>
|<a href="legalbriefs.html">Legal Briefs</a>]<br>
[<a href="calendar.html">Calendar</a>
|President's Message
|<a href="capitolwatch.html">Capitol Watch</a>]
</center>
<br>
<br>
<br>

<center>For inquiries or comments, e-mail: <a href="mailto:aada@dasta.com">aada@dasta.com</a></center>
<p>
<p>

<!-last modified by Stacey->
<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="http://www.dasta.com/gif/dastasig.gif"
			alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 25 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996
				<a href="http://www.dasta.com">DASTA VendorCat, LLC</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">This site was designed by 
		<a href="http://www.dasta.com">DASTA VendorCat</a><br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of
	<a href="http://www.dasta.com/anet.html">Association-Net</a>
	<sup>TM</sup></font></p>
</center>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-82</DOCNO>
<DOCOLDNO>IA058-000947-B026-146</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/capitolwatch.html 206.97.63.16 19970109193353 text/html 7826
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:16:35 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 7655
Last-modified: Tue, 25 Jun 1996 23:05:48 GMT
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">

<HTML>
<HEAD>
<TITLE>Arizona Automobile Dealers Association - Capitol Watch</TITLE>
</HEAD>

<body background="gif/aadatilew.gif" bgcolor="#BABEBC" text="#000000" link="#570032" vlink="#0F388E" ALINK="#570032">

<center>
<table border=2>
<tr><td>
<img src="gif/headernewsflash.gif">
</td></tr>
</table>
</center>
<p>
<hr>
<table width=100%>
<tr><td><img src="gif/purpleball.gif" hspace=5></td><td><b>House Subcommittee Passes Proposed Changes to State Franchise Law</b></td></tr>
<tr><td><img src="gif/purpleball.gif" hspace=5></td><td><b><a href="#proposals">Other AADA proposals moving through state legislature</a></b></td></tr>
<tr><td><img src="gif/purpleball.gif" hspace=5></td><td><b><a href="#auto">AADA Helps Nix Flawed Auto-Repair Proposal</a></b></td></tr>
<tr><td><img src="gif/purpleball.gif" hspace=5></td><td><b><a href="#bills">Other AADA bills</a></b></td></tr>

<tr><td><br><br><br><img src="gif/purpleball.gif" hspace=5></td>
<td><br><br><br><font size=4><a name="proposals"><font size=4><b>Other AADA proposals moving through state legislature</a><br></b></font></td></tr>

<tr><td></td><td>
<hr>
        AADA-proposed changes to state franchise laws recently passed
a House subcommittee with an amendment agreed upon by AADA and the 
manufacturers' association. 
<p>   
     With the amendment, the bill imposes a time limit on 
reimbursement of warranty claims, and prohibits factory restrictions
on franchise dualing (i.e. sharing dealership facilities with other
line makes) unless justified by reasonable business consideration. The
proposal is slated for a vote by the House Transportation Committee this
month.
<p> 
</td></tr>
<tr><td><img src="gif/purpleball.gif" hspace=5></td><td><font size=4><b><a name="bills">Other AADA bills are also moving:</a></b></font><br></td></tr>
<tr><td></td><td>
<hr>
        The House Ways and Means Committee passed AADA's tax-exemptions
bill, which will clarify that cities may not collect sales taxes on 
rebates, service contracts or sales to nonresidents delivered outside
of Arizona. The committee also approved two amendments that would 
prohibit state and city governments from collecting sales tax and 
interest on documentary fees. The bill will be up for final house vote
early this month, but is faced with fierce opposition by the League of
Cities and Towns; AADA may be calling on you this month to contact your
lawmakers in support of this important piece of legislation.
<p>
        The association's salvage vehicle disclosure bill is proceeding
without a hitch. The legislation would require any person (including a 
private seller) who knows that a vehicle has been salvaged or rebuilt
to disclose this fact to a buyer before completing the sale. The bill
would place Arizona ahead of the game an the salvage issue, as Congress
is hoping to pass a 50-state-title-branding mandate this year. 
<p>   
     Although the AADA Auto Dealer Omnibus bill failed in the House
Transportation Committee early this month, AADA is working on amendments
to other bills. The proposal would:<br>
<ul>    
<li>Eliminate the requirement that dealership owners to 
undergo criminal background investigations;
<li>Allow dealers to keep computerized records under Motor
Vehicle Division record-keeping requirements;
<li>Allow dealers throughout Arizona to use the Dealer 
Acquisition Contract, which makes it possible for dealers to sell a vehicle
without having its title in hand.
</ul>
<p>
	AADA's air quality proposal, which would allow Tucson dealers to 
utilize the three-day IM-240 disclosure form when selling to a Maricopa 
County resident, passed the Senate Transportation Committee this month.
<p>
	The association's auto brokers bill, which would require a written
contract between a buyer and broker, will be heard by the House Transportation
Committee this month. 
<p>
	Please contact Dolly Volini at AADA with questions concerning these
proposals or any legislative issue.
<p>
</td></tr>
<tr><td><img src="gif/purpleball.gif" hspace=5></td><td><font size=4><b><a name="auto">AADA Helps Nix Flawed Auto-Repair Proposal</a></b></font></td></tr>
<tr><td></td><td>
<hr>

<b><i>Legislation would have prevented service facilities from exercising 
mechanic's lien rights</i></b>

<p>
	A proposal that would have negated dealers' rights under the 
mechanic's lien law was killed before making it to the table last month after 
AADA's intervention.
<p> 
	Senator Randall Gnant (R-Scottsdale) had planned to introduce a bill
that would have allowed customers to purchase a bond to have their vehicle 
removed from a repair facility without paying for completed work. This 
essentially would have eliminated an Arizona law that allows the service 
facility to sell a vehicle to cover a repair bill for services performed.
<p>
	AADA met serval times with Gnant and the bill's supporters, which
included the Arizona Attorney General's Office and independant repair shops.
Grant agreed not to introduce legislation on the issue this session, 
noting concern about cumbersome new laws that, in attempting to catch the
bad guys, work against businesses that play by the rules. 
<p>
	AADA expects to work with Gnant next year to develop a revised 
proposal on the issue that would not have a detrimental effect on member 
dealerships. 
<p>
	Gnant is up for re-election this year; AADA hopes to support the
senator's campaign in recognition of his genuine interest in changing auto
-repair laws to address the problem without hindering dealers' rights to
 receive payment.
<p>
	Please call Dolly Volini at AADA with any questions on this issue. 
	</td></tr>
	</table>
<hr size=3>
<p>
<center><a href="frontdoor.html"><img src="gif/autobar.gif" border=0 alt="Auto Mall"></a></center>
<center><a href="frontdoor.html">[The Auto Mall]</a></center>
<br>
<center>
<a href="index.html"><img src="gif/mainpagebutton.gif" border=0 alt="Main Page"></a>
<a href="bulletin.html"><img src="gif/bulletinbutton.gif" border=0 alt="bulletin"></a>
<a href="legalbriefs.html"><img src="gif/legalbutton.gif" border=0 alt="legal briefs"></a><br>
<a href="calendar.html"><img src="gif/calenbutton.gif" border=0 alt="calender"></a>
<a href="presidents_message.html"><img src="gif/presbutton.gif" border=0 alt="preszmessage"></a>
<img src="gif/capitolbutton.gif" border=0 alt="capitol watch">
<p>
<a href="index.html">[Main Page</a>
|<a href="bulletin.html">Bulletins</a>
|<a href="legalbriefs.html">Legal Briefs</a>]<br>
[<a href="calendar.html">Calendar</a>
[<a href="presidents_message.html">President's Message</a>
|Capitol Watch]
</center>
<br>
<br>
<br>

<center>For inquiries or comments, e-mail: <a href="mailto:aada@dasta.com">aada@dasta.com</a></center>
<p>
<p>
<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="http://www.dasta.com/gif/dastasig.gif"
			alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 25 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996
				<a href="http://www.dasta.com">DASTA VendorCat, LLC</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">This site was designed by 
		<a href="http://www.dasta.com">DASTA VendorCat</a><br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of
	<a href="http://www.dasta.com/anet.html">Association-Net</a>
	<sup>TM</sup></font></p>
</center>


<!--Last modified by Stacey-->

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-83</DOCNO>
<DOCOLDNO>IA058-000947-B026-167</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/bylaws.html 206.97.63.16 19970109193403 text/html 42825
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:16:44 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 42653
Last-modified: Tue, 25 Jun 1996 23:05:48 GMT
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">

<HTML>
<HEAD>
<TITLE>Arizona Automobile Dealers Association Bylaws</TITLE>
</HEAD>

<body background="gif/aadabtile.gif" bgcolor="#E5E0E0" text="#000628" link="#55083C" vlink="#00120A" ALINK="#220652">

<center>
<table border=2>
<tr><td>
<img src="gif/headerabout.gif">
</td></tr>
</table>
</center>


<p>
<hr size=3>
<p>
<center>
Click here for <a href="adstan.html">Advertising Standards</a>

</center>

<p>
<hr size=3>
<p>

<center><b>
BYLAWS OF THE ARIZONA AUTOMOBILE DEALERS ASSOCIATION<br>
an ARIZONA NON-PROFIT CORPORATION<br>
amended through August 2, 1992<p>
</b></center>

<center><b>ARTICLE I</b></center><p>

<b>Section 1 - Name:</b><p>

The name of the Association shall be the Arizona Automobile Dealers Association.<p>

<center><b>ARTICLE II</b></center><p>

<b>Section 1 - Purpose:</b><p>

The purpose and objects for which the Association is formed are as follows:<p>

To afford such opportunities to members to associate and exchange views, to take such concerted action as may be desirable, 
looking to the betterment of trade conditions generally in the State of Arizona.<p>

To bring dignity and respect to the retail automobile industry in Arizona, build customer confidence and safeguard the interests of 
the public through adherence to the Association's adopted Code of Ethics governing member business practices.<p>

To make, enter into, carry out, and enforce any contract, agreement or transaction which it may believe to be for the benefit and 
best interest of it's members, and to do, perform, and engage in such other things as will promote and safeguard the interests of New Car and Truck Merchants in the State of Arizona.<p>

To foster constructive and progressive legislation, to discourage destructive, retrogressive legislation especially as it may affect the sale or operation of motor vehicles.<p>

To promote confidence, respect and good fellowship among all who are directly or indirectly engaged in the motor vehicle industry.<p>


<center><b>ARTICLE III<br>MEMBERSHIP</b></center><p>

<b>Section 1 - Membership:</b><p>

Membership in the Association shall consist of persons, partnerships, firms or corporations which: (1) are registered, licensed or enfranchised to sell new motor vehicles in the state of Arizona; (2) are enfranchised by a manufacturer of new motor vehicles and authorized to perform and make warranty repairs on behalf of the manufacturer, and; (3) operate and maintain adequate repair facilities and an adequate supply of replacement parts for the purpose of providing service and warranty repairs with respect to the line and make of vehicles which the member is enfranchised and authorized to sell in the state of Arizona.<p>

The term "new motor vehicle" includes new passenger automobiles and new automotive trucks, but does not include new motorcycles, motorscooters, freight or passenger trailers, or farm machinery.<p>

<b>Section 2 - Applications:</b><p>

Application for membership in the Association shall be submitted in writing to the Board of Directors at the office of the Association.  Such applications shall contain such information as may be required by the Board.,  Upon receipt of an application, the Board, within thirty (30) days, shall give written notice of the filing of the application to all members of the Association in the area in which the applicant has his place of business and from which a director is selected representing such area.  Within fifteen (15) days after the date of such notice any member or local dealers organization mat file with the Board written objections to the granting of the application.<p>

If no objections are received by the Board within such fifteen (15) day period, the President may direct a conditional acceptance of 
the application until such time as the Board of Directors may approve or reject the application at its next meeting.  If any objections are 
receive by the Board within such period, the application shall be considered by the Board at its next meeting at which time the applicant 
and the protestants shall have the right to appear and be heard.<p>

<b>Section 3 - Authorized Representative:</b><p>

Each member shall appoint and designate in its application for membership, an individual associated with such member in its new 
motor vehicle retailing business who shall  represent, vote, and act for the member in all affairs of the Association, including the holding 
of office therein; provided, however, that to be eligible to hold office in the Association, the designated individual must be an owner, a partner or stockholder and an office or executive actively engaged in the management of said member's business and must own at least fifteen percent (15%) of the dealership he represents.  Such individual shall be known as the "authorized representative."<p>

<b>Section 4 - Suspension or Expulsion:</b><p>

Any member who fails to pay his or its annual dues within thirty (30) days of the due date shall receive a notice of default in writing, and if dues are not paid within thirty (30) days of such notice, shall be suspended from the Association for a term fixed by the Board of Directors.  If all dues and charges are not current at the end of the period of suspension, the member shall be expelled.  Upon application for membership by a member expelled for nonpayment of dues and charges, the amount of such dues and charges owing before expulsion must be paid in full as a condition of readmission.  Any member who shall be guilty of improper conduct in or about the premises of the Association, or at any event held or sponsored by the Association, or any member who in the conduct of his business, or in his 
dealings with his fellow members or with the public, reflects discredit upon the Association or industry represented by it, or who fails to 
abide by these By-Laws, including the Association's Code of Ethics, may be disciplined in accordance with Article X of these By-Laws, and shall have the rights of appeal provided in said Article X.<p>

<center><b>ARTICLE IV<br>DUES and ASSESSMENTS</b></center><p>

<b>Section 1 - Dues:</b><p>

The annual dues for membership for dealers in the Association shall be as follows:<p>

All dealer members of the Association shall pay to the Association an amount equal to $1.00 per unit on all new unit sales, including fleet sales (dealer transfers excluded).  There shall be a minimum annual dues assessed to each dealer in the amount of $50.00 regardless of the fact that he sells fewer than fifty units annually, and no dealer member shall be assessed more tan $600.00 in any calendar year.  The new dues schedule is to become effective January 1, 1974.<p>

It shall be mandatory, where a dealer is operating in several towns, that there shall be a separate membership in each town for each establishment.<p>

<b>Section 2 - Payments:</b><p>

Statements for dues shall be mailed monthly to all members.  All dues shall be due and payable upon receipt of such monthly statement.  The Board of Directors in their discretion, may accept quarterly, semi-annual or annual payment of dues, if, in their opinion, the best interests of the Association are served.  The amount and/or manner of payment of dues may be changed from time to time by action of the Board of Directors.<p>

<center><b>ARTICLE V<br>MEETINGS</b></center><p>

<b>Section 1 - Members Annual Meetings:</b><p>

The annual membership meeting of the Association shall be held at the time of the annual State Convention, at such place as may be determined by the Board of Directors.  At least ten (10) days notice of such meeting shall be mailed to each member by letter addressed to his or its last known post office address.  The annual meeting of the Board of Directors may be held at such time and place as the Board determines and, if not held concurrently with the annual membership meeting, shall be held not more than thirty (30) days prior to the annual membership meeting.<p>

<b>Section 2 - Special Meetings (Membership):</b><p>

Special meetings of the Association may be called by the President at any time and must be called by him upon the written request of ten percent (10%) of the total membership.  Such latter meeting shall be held at such place as designated by the President.  Notice of all meetings shall be given to each member by letter addressed to his or its last known post office address ten (10) days prior to the date of such meeting and such notice shall state the purpose of the meeting and no other business other than 
that stated in such notice may be considered.<p>

<b>Section 3 - Special Meetings (Directors):</b><p>

Special meetings of the Board of Directors may be called at any time by the President and shall be called by him whenever a majority of the Board of Directors, in writing, requests him to do so, and notice of such meeting shall be given by the Manager to each member of the Board not less than 48 hours prior to the meetings so prescribed.<p>

<b>Section 4 - Quorum (Membership):</b><p>

At all membership meetings, twenty-five (25) members, if present in person or by proxy, shall constitute a quorum and any act of 
a majority of the quorum shall constitute an act of the membership.<p>

<b>Section 5 - Quorum (Directors):</b><p>

At all Board of Director's meetings, in order to constitute a quorum, it will be necessary to have present in person a majority of the total of the number of Board members and any act of the majority of the quorum shall constitute an act of the Board.<p>

<b>Section 6 - Adjourned meetings:</b><p>

If a quorum shall not be present at any annual or special meeting, such meeting may be adjourned to another day and hour of which adjournment notice need be given only to those directors absent at the earlier meeting.<p>

<b>Section 7 - Proxy:</b><p>

Any member may be represented at any meeting in the absence of the duly accredited representative of such member, by a proxy issued by such representative, to any other duly accredited representative or to any officer of department head of the Association.  The person holding such proxy pr proxies, if the same is properly issued, shall have the same rights at such meeting as the member or members could exercise if personally present.  At any annual Board meeting, in the absence of a duly elected new Board member who is not represented by proxy issued to another duly accredited representative, such absent member may be represented by the retiring board member from the same county if he be present.  Except as herein above provided, no member shall have the right to be represented at any meeting.<p>

<b>Section 8 - Order of Business:</b><p>

The order of business for any meeting may be determined by the rules prepared by the Board of Directors.  The usual parliamentary rules as laid down by Robert's Rules of Order shall govern all meetings, when not in conflict with these By-Laws.<p>

<center><b>ARTICLE VI<br>GOVERNMENT</b></center><p>

<b>Section 1 - Board of Directors:</b><p>

The government of the Association shall be vested in a Board of Directors consisting of members who shall be selected from the following categories:<p>

<ul>
                (a) one from each county (or area) in the state except Maricopa and Pima Counties;<p>
                (b) two from Pima County;<p>
                (c) one from the City of Phoenix, 1 from that portion of Maricopa County west of Central Avenue in Phoenix as extended 
north and south but excluding the City of Phoenix, 1 from the City of Scottsdale, and one from the balance of eastern Maricopa County;<p>
                (d) one Director-at-Large, who shall be the duly elected Arizona Director for the National Automobile Dealers Association;<p>
                (e) any elected officer of the Board or the immediate past president who does not qualify under (a), (b), (c) or (d);<p>
</ul>
<p>

The above names categories may be modified by the Board of Directors or the membership from time to time if deemed too small 
to merit a separate director.  Categories may be joined with another county to form an area.<p>

At the election of directors, to be held in the year 1971, 4 directors from category (a) and 1 from category (c) shall be elected for 
a term of 1 year, 4 directors from category (a) and 1 from category (b) and 1 from category (c) shall  be elected for a term of two years, 
and 4 directors from category (a), 1 from category (b) and 1 from category (c) shall be elected for a term of three years, with the 
directors to serve terms of 1, 2, 3 years to be designated in a manner selected by the Board of Directors.  Thereafter all directors 
shall be elected to serve a term of 3 years.<p>

<b>Section 2 - Officers:</b><p>

The Board, at its organization meeting, following the election of directors shall elect from the Association membership a president, a president-elect, a vice-president and a secretary-treasurer of the Association who shall serve for a term of (1) year or until such time as their respective successors are duly elected and qualified.  The president-elect shall automatically succeed to the president at the end of his term as president-elect provided he is then qualified as a member of the Association.  The Board may also select an Executive vice-president who shall be the manager of the Association and who shall not be a member of the Board or of the Association.<p>

The Executive Committee shall be composed of the President, the Immediate Past President, President-elect, Vice President, Secretary-Treasurer, and two members of the Board or of the Association.<p>

During the intervals between meetings of the Board of Directors, the Executive Committee shall possess and may exercise all the powers of the Board of Directors in the management and direction of the affairs of the Association.  The Executive Committee, however, shall not have the power or the authority to amend, alter, or rescind any basic policy adopted by the Board of Directors.<p>

All actions by the Executive Committee shall be reported to the Board of Directors at its meeting next succeeding such action, and shall be subject to revision and alteration by the Board, provided that no rights of third parties shall be adversely affected by any such revision or alteration.  Regular minutes of the proceedings of the Executive Committee shall be kept in a book provided for that purpose, and shall be reported to the members of the Board of Directors as soon as is practical after each meeting of the Executive Committee.<p>

A majority of the Committee shall constitute a quorum and the affirmative vote of a majority of its members shall be necessary 
to adopt or carry any motion or resolution.  The Executive Committee shall fix and declare its own rules and/or procedures, and shall meet as provided by such rules or by resolution of the Board of Directors, and it shall also meet at the call of the President or a majority of the Committee upon seven (7) days' notice by telegraph, telephone, or certified mail.<p>

<b>Section 3 - Absence:</b><p>

Any member of the Board of Directors absent from a meeting shall send a communication to the President or to the Manager stating his reason for his absence.  If any member fails to attend three (3) successive meetings of the Board without good cause, the Board, in its discretion, may declare his office vacant.<p>

<b>Section 4 - Vacancies:</b><p>

Any vacancies that may occur on the Board by reason of death, resignation or otherwise may be filled by the Board of Directors for the unexpired term.<p>

<b>Section 5 - Nominations-Elections:</b><p>

Nominations:<p>

Every member or accredited representative of every member in good standing and not in arrears in dues, shall be entitled to vote for a candidate for the office of Director for the County or area in which he resides.  Nominations for candidates for office of Director 
shall be conducted by mail.<p>

The Executive Vice President shall mail to every qualified member or accredited representative, a ballot bearing the names of all dealer members or their accredited representatives.  Every qualified member shall vote for not more than one nominee.  The two nominees receiving the highest number of votes shall be declared eligible for election as a Director of their representative county or area.  If more than two nominees are tied, the names of all receiving the highest two numbers of votes shall be placed on the final election ballot.<p>

Elections:<p>

Every member or accredited representative of every member in good standing, and not in arrears in dues, shall be entitled to cast one vote for candidate for office as a Director of the County or area in which he resides.  The election of candidates for office of Director shall be conducted by mail.<p>

The Executive Vice President of the association shall mail, to every qualified member or accredited representative, a ballot bearing the names of the two or more nominees in his county or area.<p>

The Executive Vice President shall be required to retain all such ballots as received and present the same to the Executive Committee, consisting of the President, President-elect, Vice President and Secretary-Treasurer, for the purpose of certification.  In the event of a tie ballot, the names of those nominees or candidates tied for candidacy for election shall be resubmitted to the membership within their county or area on another ballot taken, and the one receiving the highest number of votes shall be declared elected.<p>

The nomination and election of officers shall take place within not more than thirty (30) days nor less than ten (10) days preceding the date of the annual meeting.<p>

The Board of Directors shall make such rules and regulations as it may deem necessary to conduct elections.<p>

<b>Section 6 - Special Meetings:</b><p>

Each Director of the Association, in addition to performing all the duties heretofore prescribed, shall hold special meetings as directed by the President, and/or such regular meetings as directed by and for the members in the county or area he represents.<p>

<b>Section 7 - Duties:</b><p>

The President of the Association shall preside at all meetings of the Association and of its Board of Directors and shall perform such duties as the Board of Directors of the Association shall assign to  him.<p>

<b>Section 8 - Presiding Officer:</b><p>

The President-elect of the Association shall assist the President in the performance of his duties and in the absence of the President, the President-elect shall preside.  In the absence of the President and the President-elect, the Vice President shall preside, and in the absence of the three above named officers, the members of the Board of Directors may choose a chairman for the meeting.<p>

<b>Section 9 - Executive Vice President:</b><p>

There shall be appointed by the Board of Directors, an Executive Vice President to serve under the Board of Directors and whose salary shall be fixed by the Board of Directors.  His duties shall be to take charge of the management of the office or offices established or to be established by the Association, and to perform all duties incident to the management and operation thereof, including the hiring or firing of employees; except those employees designated a Vice President by the Board, as requiring board approval to terminate their employment.  Duties shall also be to print or cause to be printed a monthly bulletin and/or newsletter and whatever other special publication may be deemed necessary for distribution to all members of the Association.  In addition to the duties and powers heretofore prescribed, he shall act as corresponding secretary to the Association.  He shall keep all the books of the Association, and shall attend all meetings of the Board of Directors and the Association, and shall keep full and accurate minutes thereof.<p>

<b>Section 10 - Finances:</b><p>

The Executive Vice President shall deposit or cause to be deposited all funds of the Association in a depository as may be designated by the President and Secretary-Treasurer and all disbursements shall be by voucher or check cosigned by a member of the Board of Directors and the Executive Vice President. Both signers of such vouchers or checks shall give bond for such amount as may be determined by the Board of Directors from time to time.  A CPA audit shall be made of the Association books annually at the close of the fiscal year to determine the accuracy of the accounts.<p>

<b>Section 11 - Committees:</b><p>

The President, with the approval of the Board of Directors, may appoint committees and assign such duties and delegate such authority as may be determined by the needs of the Association from time to time.<p>

<center><b>ARTICLE VII</b></center><p>

<b>Section 1 - Antitrust Policy:</b><p>

Any action taken to eliminate, restrict, or govern competition among members or to affect prices of products sold is a violation of the antitrust laws and these By-Laws.  Association members pledge to abstain from such activities and such actions are specifically forbidden at Association meetings or otherwise.<p>

The Articles of Incorporation and these By-Laws should be interpreted in accordance with this policy.  The Code of Ethics is maintained by the Association pt protect the interest of the public.  Its enforcement is undertaken to benefit the consumer and not for the restraint of trade by or for the benefit of individual dealers or groups of dealers.<p>

<center><b>ARTICLE VIII<br>Miscellaneous</b></center><p>

<p>

<b>Section 1 - Fiscal Year:</b><p>

The fiscal year shall begin the first day in April in each year.<p>

<b>Section 2 - Waiver of Notice:</b><p>

Any notice required to be given under these By-Laws may be waived in writing, signed by the person or persons entitled to said 
notice, whether before or after the time stated therein.<p>

<center><b>ARTICLE IX</b></center><p>
(Reserved for future use)<p>

<center><b>ARTICLE X</b></center><p>

<b>Section 1 - Code of Ethics:</b><p>

PREAMBLE<p>

This code will set out standards under which all members of the Association will be expected to operate, the purpose of which will be to bring dignity and respect to our industry and protect the interest of the public.  These safeguards will enhance the value of your franchises and, at the same time, will build customer confidence in you as dealers.  Additionally, our dealer members will continue to support activities beneficial to motor vehicle owners, aid the promotion of good citizenship and development of the community through civic involvement, and maintain individual and associated contact with public officials at all governmental levels.<p>

Each dealer must abide by the Constitution and By-Laws as amended, under penalties, both pecuniary and possible expulsion, from 
this Association.<p>

The Code of Ethics was adopted unanimously by the Board of Directors of the Arizona Automobile Dealers Association on June 18, 1971.  It was signed by every member of the Association and became effective at the organizational meeting of the Ethics Judiciary Committee September 10, 1971.  Since that date, each new member has signed an agreement to abide by the Code of Ethics in its original or amended form.<p>

The Code follows:<p>

<ul>
        1.1     Maintain high standards and fair business practices in the sale and service of the products sold.<p>
        1.2     Each industry member should maintain dependable service facilities and fair customer labor rates.<p>
        1.3     Stock adequate replacement parts.<p>
        1.4     All agreements or guarantees pertaining to the sale or purchase of all vehicles shall be in writing.<p>
        1.5     Obey and uphold all State and Federal laws and regulations concerning advertising, financing, insurance, taxation, licensing and titling of all vehicles sold.<p>
        1.6     Recognize the interest of the public and benefits of employees within the industry by observing a schedule of regular working hours consistent with established local business practices.<p>
        1.7     Advertising shall be accurate and truthful in every respect and from any misuse of wording, illustrations, typographical arrangements or omission of vital information which might mislead or deceive any reader.<p>
        1.8     Each subscribing AADA member shall recognize and affirm the necessity for courteous, prompt and fair dealings with the customer.<p>        1.9     No member shall alter, or cause to be altered, the odometer reading of any motor vehicle.  In the case of damaged or inoperative odometers where replacement is required, the odometer replacement shall be conspicuously noted as per existing laws.<p>
        1.10    Members agree to support the policies and regulations of the Arizona Automobile Dealers Association.<p>
        1.11    Except as specified herein, on every new vehicle sale by a member dealer to any customer, the dealer shall immediately secure an Arizona Certificate of Title for such vehicle in the name of the customer. Sole exceptions are sales on transit tags, dealer trades between dealers selling the same makes of automobiles, used vehicles and vehicles not to be registered for use in Arizona.<p>
        1.12    Members agree to comply with the Standards for Advertising Motor Vehicles and as the same may hereafter be amended from time to time by action of the full Board of Directors.<p>
</ul>
<p>

<b>Section 2 - Ethics Judiciary Committee: Membership: Disqualification:</b>
<p>

2.1 Committee Organization and Duties:<p>

(a)     There is hereby created a permanent, standing committee to be  known as the "ETHICS JUDICIARY COMMITTEE," which shall be composed of six (6) members, three of whom shall be members of the Association in good standing, to be appointed by the President with the advice and approval of the Board of Directors.  The three dealer members shall serve staggered three-year terms. <p>

The three additional members of the Committee shall be members of the public at large, to be appointed by an impartial organization or 
governmental agency with which the Association has established a relationship for purposes of resolving consumer complaints.  The 
three public members shall serve a term to be determined by the appointing agency.<p>

(b)     The full Board of Directors shall have the authority to remove or replace any dealer-member or members of the 
Committee and shall have the right to recommend removal or replacement of any public member or members.<p>

(c)     The Chairman of the Committee shall be the dealer-member who is serving the last year of his term, and the Chairman's 
terms shall be for one year.<p>

(d)     The duties of the Committee shall be to supervise compliance with, and enforcement of, the Arizona Automobile Dealers 
Association Code of Ethics in this Article X.<p>

(e)     Meetings of the Ethics Judiciary Committee may be called at any time by the Chairman or, in his absence, by any two (2) of 
the other members thereof.  A quorum for the transaction of business shall be composed of four (4) members.<p>

(f)     The Committee may adopt general rules of procedure for carrying out its duties under this article and may, from time to 
time, alter, amend or repeal same.  Committee rules shall be available for inspection at any time by any member of the Association.<p>

(g)     Complaints brought to the Ethics Judiciary Committee are confidential.  No information on the progress or disposition of a complaint shall be released to any person or organization not a party to the complaint without the permission of the member against whom the complaint is lodged, and the complainant.  Agencies or individuals referring complaints to the Ethics Judiciary Committee may be apprised of the final disposition of the complaints they refer.<p>

2.2 Disqualification; Substitute Members:<p>

(a)     Dealer member or his dealership is the subject of the complaint.<p>
<ul>
                        (i)     the member or his dealership is the subject of the complaint<p>
                        (ii)    there exists any reason, in the mind of member, warranting disqualification, such as personal or business 
relationships with the dealer on the complaint or the complainant, or a recognized inability on the part of the member to fairly hear the 
complaint.<p>
        (b)     Consumer members shall disqualify themselves for the reason set forth in Sub-Section 2.2 (ii) above.<p>
        (c)     For cause shown on a particular complaint, any EJC member may request the chairman to (1) step down as chairman, or (2) 
disqualify himself, or may request any other member to disqualify himself.  Cause for such action, if the requested party does not agree 
to the request, shall be determined by a majority of the remaining committee, excluding the requesting and requested parties.<p>
        (d)     The Board of Directors shall utilize the services of former Dealer and Consumer members of the Ethics Judiciary Committee, said members to be utilized to serve on complaints upon which a regular committee member has disqualified himself or is, for any other reason, unable to attend a scheduled meeting.  An alternate member when so serving has the full powers and duties of a regular member.<p>
</ul>
<p>

<b>Section 3 - Complaint Procedure, Notice, Reply and Hearing:</b><p>

3.1     Complaints shall be received in writing from any interested party or any member dealer, or may be issued by the Ethics Judiciary Committee, any member thereof, or the Administrator of the Ethics Judiciary Committee.<p>

3.2     Immediately after a complaint has been received by any member of the Ethics Judiciary Committee, or the Arizona Automobile Dealers Association office,, the Executive Vice President of the Association, or his representative, shall contact the dealer against whom the complaint has been filed for purpose of giving notice of the charges in the complaint.<p>

3.3     Within seventy-two (72) hours after receipt of a written complaint, written notice of a complaint, including the facts set forth therein, shall be sent to the dealer against whom the complaint has been made.  This written notice to the dealer shall be sent by certified mail, return receipt.<p>

3.4     Within five (5) days after receipt of written notice of complaint, the dealer against whom the complaint has been made shall present, in person or by mail, a reply to the Chairman of the Ethics Judiciary Committee.  Said written reply shall be the dealer's answer to the complaint.  The dealer may appoint the "authorized representative" of the dealership (as described in Article III, Section 3) to respond to the complaint by so notifying the Committee.  In the event the response is generated by other than the above, an accompanying letter from the dealer is required, noting acknowledgment of the complaint and support of the response, on each individual case.  Failure of a dealer to present a reply within five (5) days, except for good cause shown, may be construed by the Ethics Judiciary Committee as a default or admission of charges.  One "default" notice will be phoned and/or faxed to the dealer allowing a twenty-four (24) hour response period. Failure to respond will allow Committee the option of finding automatically for consumer. <p>

3.5     A meeting of the Ethics Judiciary Committee shall be called no less that once per month for the purpose of reviewing the charges made and any response thereto.  The Committee has the option of inviting the dealer against whom the charges are made to attend the meeting.  The quorum requirement of Section 2.1 (e) shall be necessary to the conduct of the hearing.  Notice of the decision of the Committee shall be sent to all parties, including referring agency.  The Committee decision letter shall include a copy of the dealer response.<p>

<b>Section 4 - Sanctions:</b><p>

4.1     The following directives and sanctions are established and may be assessed or recommended, as appropriate, by the Ethics Judiciary Committee (EJC) after hearing or opportunity to be heard on any complaint:<p>

<ul>
                (a)     Private warning letter - requires a majority vote of the EJC; a copy will remain in the member's file for not less than two years, and may only be used in determining the level of sanction would another violation by that member be found by EJC in that two-year period.<p>
                (b)     Directive to Dealer - requires a majority vote of the EJC; this will be used when the EJC resolves a complaint where there were valid issues requiring resolution.  If the dealer complies with the directive in the time stated, the matter will be considered closed.  Failure of the member to comply with the directive in a timely manner shall be cause for the issuance of another complaint and possible sanctions.<p>
                (c)     A fine of up to one thousand dollars ($1,000) per violation - requires a majority vote of the EJC, who shall fix the time for payment.  Failure to timely pay the fine shall be cause for the issuance of another complaint and possible further sanctions.  A copy of the record of the fine shall remain in the file of the member for not less than two years, and may only be used in determining the level of sanction should another violation by that member be found by EJC in that two-year period.<p>
                (d)     Probation for a period of up to six (6) months - requires a majority vote of the EJC and the Executive Committee.  The Executive Committee shall review the proceedings of the EJC and shall indicate in writing its concurrence or non-concurrence with same.  The Executive Committee need not have a separate hearing unless such is called by the Executive Committee or such hearing is requested within ten (10) days of the action taken by EJC by the member whose probation is at issue.  Upon expiration of the term of probation, and there being no unresolved complaints then outstanding and all dues are paid currently, probation shall terminate upon concurrence by the EJC.  During probation, full membership privileges will continue upon proper payment of dues and charges.  A copy of the probation order shall remain in the member's file for three (3) years for use as set forth in (a) above.<p>
                (e)     Suspension from membership for a period of up to six (6) months - requires a majority vote of the EJC and shall indicate in writing its concurrence or non-concurrence with same.  The Executive Committee need not have a separate hearing unless such is called by the Executive Committee, or such hearing is requested within ten (10) days of the action taken by EJC by the member whose suspension is at issue.  Full membership privileges will be restored at the end of the suspension period in the same manner as at the end of a term of probation under (d) above.  A copy of the suspension order shall remain in the member's file for four (4) years for use as set forth in (a) above.  While suspended, a member shall lose all membership rights, privileges and benefits, except that the member may continue (but not join) any insurance program offered or administered by the Association or its affiliates so long as all 
related charges are paid.  During suspension, a member shall not pay dues, and shall be able to purchase supplies from the Association or 
its affiliate on a cash basis only.<p>
		(f)     Expulsion from membership - A recommendation for expulsion from membership may be made by a majority vote of the 
EJC.  In the event of such a recommendation, a joint meeting between the EJC and the Executive Committee, presided over by the Chairman of the EJC, shall be held for a hearing to allow the member whose expulsion is at issue to present such evidence as he desires.  A recommendation for expulsion shall require a majority vote of each committee, the EJC and the Executive Committee, taken separately.  The full Board of Directors shall consider the recommendation at a special meeting called for this purpose, which may be attended by the member whose expulsion is at issue, and the Board shall render a decision on the recommendation.  If a member is 
expelled, the member may request a re-hearing before the Board id a request for hearing is received in writing  by the president within 
ten (10) days of the vote of expulsion.<p>
<ul>                  
		(i)     after the effective date of expulsion, the Association or its affiliate shall cancel or not renew, at the earliest legally possibly time, all insurance or other programs in which the expelled member participates.  An expelled member shall thereafter be ineligible to participate in any program offered or administered by the Association or its affiliates.<p>
		(ii)    an expelled member may, after the expiration one (1) year from the effective date of expiration, reapply for membership in the Association.  Such application shall be processed in the same manner as a new member, except EJC shall make a recommendation of approval or disapproval on the application, after reasonable satisfying itself that the applicant will comply in the future with the policies of the Association, and the applicant has satisfactorily handled any known trade practice complaints arising prior to the meeting of EJC at which time the application is considered.<p>
</ul>
        (g)     Upon the effective date of suspension or expulsion or of a voluntary resignation, the Association shall so advise in writing 
those enforcement agencies in the relevant market area of the suspended, expelled, or resigned member, including, but not limited to:<p>

<ul>
                (i)     Financial Fraud Division, Office of the Attorney General of Arizona<p>
                (ii)    Appropriate County Attorney<p>
                (iii)   Better Business Bureau of appropriate area<p>
                (iv)    AUTOCAP Administrator, National Automobile Dealers Association<p>
                (v)     Other appropriate entities or agencies who have referred complaints against members to the Association.<p>
</ul>

This notification is necessary, since these agencies have cooperated and assisted throughout the years in the administration and 
enforcement of the Code of Ethics.  Only by this notification can these agencies be made aware of which franchised dealers remain in 
good standing as members of the Association.<p>
	(h)     All information pertaining to: 1) the existence of a complaint; 2) proceedings thereon; and 3) sanctions or recommendations 
of EJC, the Executive Committee or Board of Directors shall make public such information prior to the effective date of any action 
taken, except where the disclosure is specifically authorized, in writing, by the President to any law enforcement agency for official 
purposes only.<p>
	(i)     As soon as practicable after the effective date of sanctions under sections 4.1 (c) (d) (e) (f) (fine, probation, suspension or 
expulsion), the identity of the member, the action taken, and an abbreviated summary of the basis for the action shall be published in the 
Newsletter of the Association.<p>
</ul>

<b>Section 5 - Appeal:</b><p>

5.1     Any appeal of a directive or sanction imposed by EJC timely instituted and prosecuted by a member suspends the effect of the action until the conclusion of the appeal by the entry of an order by the highest appellate authority for that directive or sanction.<p>

5.2     Any member may appeal any directive or sanction imposed by EJC by a written communication directed to EJC and received at the offices of the Association within ten (10) business days after receipt of notice of the action of EJC from which the appeal is made.  Upon receipt of an appeal request, the appeal shall be referred to the President of the Association or his delegate, who within ten (10) business days shall set a meeting of the appropriate appellate body to hear the appeal.  The hearing on the appeal shall be held within forty-five (45) days.  All appeals shall be "de novo", and not limited solely to the record, except that the record may be considered by the appellate body in making its decision.<p>

5.3     Final orders disposing of appeals involving a private warning letter, a directive to a member, or the levy of a find shall be rendered by the Executive Committee of the Board of Directors.<p>

5.4     Final orders disposing of appeals involving the assessment of probation, suspension or expulsion shall be rendered by the full Board of Directors of the Association.<p>

<b>Section 6 - Procedure:</b><p>

6.1     Unless otherwise clear from the context, all time references in this Article X refer to business days, i.e., Monday through Friday excluding holidays recognized by the State of Arizona.<p>

6.2     All communications under this Article X directed to EJC, Executive Committee, Board of Directors, or the President of the Association shall be addressed to the appropriate addressee in care of the Association at the mailing address of the Association.<p>

<p>
<hr size=3>
<p>
<center>
<a href="index.html"><img src="gif/mainpagebutton.gif" border=0 alt="Main Page"></a>
<img src="gif/bylawsbutton.gif" alt="Bylaws" border=0><br>
<a href="adstandards.html"><img src="gif/advertbutton.gif" alt="Ad Standards" border=0></a>
<a href="committees.html"><img src="gif/committeebutton.gif" alt="committees" border=0></a>
<p>
[ <a href="index.html">Main Page</a>
| Bylaws
| <a href="adstandards.html">Advertising Standards</a>
| <a href="committees.html">Committees</a> ]
</center>
<br>
<br>

For inquiries or comments, e-mail: <a href="mailto:aada@dasta.com">aada@dasta.com</a><p>
<p>
<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="http://www.dasta.com/gif/dastasig.gif"
			alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 25 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996
				<a href="http://www.dasta.com">DASTA VendorCat, LLC</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">This site was designed by 
		<a href="http://www.dasta.com">DASTA VendorCat</a><br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of
	<a href="http://www.dasta.com/anet.html">Association-Net</a>
	<sup>TM</sup></font></p>
</center>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-84</DOCNO>
<DOCOLDNO>IA058-000947-B026-186</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/adstandards.html 206.97.63.16 19970109193412 text/html 17747
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:16:53 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 17575
Last-modified: Tue, 25 Jun 1996 23:05:51 GMT
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">

<HTML>
<HEAD>
<TITLE>Arizona Automobile Dealers Association - Advertising Standards</TITLE>
</HEAD>

<body background="gif/aadabtile.gif" bgcolor="#E5E0E0" text="#000628" link="#55083C" vlink="#00120A" ALINK="#220652">


<center>
<table border=2>
<tr><td>
<img src="gif/headerabout.gif">
</td></tr>
</table>
</center>


<p>
<hr size=3>
<p>


<b>STANDARDS FOR ADVERTISING MOTOR VEHICLES</b><br>
October, 1993<p>

</center>


<b>Statement of Intent and Purpose:</b><br>
The intent and purpose of these Advertising Standards are to promote free, open and fair competition among the member dealers by providing to potential customers true and accurate advertising.  These advertising Standards are intended to be enforced as a condition of membership in the Association, and as a supplement to governmental action by the state of Arizona through the office of the Attorney General or the Motor Vehicle Division of the Arizona Department of Transportation, and the Federal Trade Commission, and to private action through the various offices of the Better Business Bureau.<p>

As a result of an investigation by the Federal Trade Commission in mid-1993, the staff of the Federal Trade Commission took the position that prior Standards 4, 5, 6, and 11 were anti-competitive in that a literal reading of the Standards would allow the finding of a violation of the Standard even though the accused dealer did, in fact, undersell all other member dealers, or did, in fact, finance any customer or allow the customer to "name his own deal," or truthfully made disparaging statements about another member dealer.  The Association has elected, at the suggestion of the Federal Trade Commission staff, to cure the concerns of the Federal Trade Commission staff by deleting Standards 4, 5, 6 and 11, adding wording recommended by the staff of the Federal Trade Commission as new Standards 4, 5 and 6 (leaving Standard 11 blank), and making more clear the intent and purpose of its actions in the context of the 
regulation of dealer member advertising.<p>

As an interpretive guide, should the evidence offered by an accused dealer establish by a preponderance of the evidence that the contents of the ad which is the subject of the complaint are, in fact, true, the complaint against the dealer shall be dismissed.  Thus, for example, in a challenge to an advertisement stating that a dealer "finances everyone," or rejects no credit, if the evidence establishes that the dealer, in fact, does finance everyone or does not reject any credit application, the complaint against the dealer shall be dismissed.<p>

It is further the intent of the Association to fully cooperate with the governmental authorities and private entity named above in the enforcement of the respective advertising rules of each.<p>

The advertising practices described in this Section apply to all forms of advertising including, but not limited to:  newspaper, radio, television, billboards, road signs, window signs, circulars, handouts and direct mail.<p>

<b>It shall be improper:</b><p>

1.      To advertise and offer any year, make, engine, size, model, type, equipment, price, trade-in allowance, or terms, or make other claims or conditions pertaining to this sale, lease or rental of motor vehicles, which are not truthful and clear.<p>

2.      To advertise for sale, lease, or rental a specific motor vehicle which is not in the possession of the dealer, owner, or advertiser at the time the production of the advertisement was completed.  Unless otherwise specified, the motor vehicle advertised for sale shall be in operable condition.  Upon request by any person responding to an advertisement, the advertiser thereof shall present such 
records as will prove that the requirements of this Paragraph are satisfied.  Further, no advertisement should imply that a number of vehicles exist at a price, when only a limited number of vehicles is available.  In such case, the ad should clearly state the stock number(s).<p>

3.      To advertise a new motor vehicle at a price that does not include standard factory equipment with which it is fitted or is ordinarily fitted, without disclosing such facts, or to eliminate or remove any such equipment for the purpose of advertising a low price.<p>

4.      Advertisements shall not contain false or misleading statements.<p>

5.      Advertisements shall not make false or misleading statements that a product or service has certain desirable qualities which a competing product or service does not.<p>

6.      Advertisers have the duty to substantiate all statements made in an advertisement. In interpreting these provisions of the Standards, AADA shall be guided by the precedent established by judicial and/or administrative decisions interpreting the Arizona Consumer Fraud Act and Section 5(a) of the Federal Trade Commission, 15 U.S.C. & 45(a).<p>

7.      To advertise by making the layout, headlines, illustrations or type size of an advertisement such that it may convey or permit an erroneous impression as to which motor vehicle(s) are offered at featured prices.  No advertised offer, expression, or display of prices, terms, down payments, trade-in allowance, cash differences or savings, shall itself be misleading.  Any qualification to such offer, expression, or display shall be clearly and conspicuously set forth in comparative type size, type style, location, and layout, to prevent deception.<p>

8.      To Advertise:<br>
        (a)     the price of a motor vehicle without including all charges, such as freight and dealer additions, that are required as part of the price the customer must pay for the motor vehicle, excepting state and local tax, license, title and dealer documentary service fees;<br>
        (b)     a price described as "unpaid balance" unless it is the full cash selling price. <br>
        (c)     a price which is not the full selling price, even when qualified with expressions such as "with trade," or "with acceptable trade," or other similar words.<p>

9.      To advertise new vehicles referring to "cost" or "below cost" unless the advertised "cost" shall be the invoice price paid by the advertiser to the manufacturer from whom the advertised vehicle was purchased.<p>

10.     To advertise:<br>
        (a)     using the words "discount," "savings," or other words of similar import, unless they refer only to the manufacturer's suggested retain price for new motor vehicles, plus dealer installed options which are itemized and priced at the manufacturer's suggested list price; or to current retail prices for used motor vehicles as described in a recognized guide book used in the trade area, properly adjusted for mileage, equipment and condition;<br>
        (b)     using the word "rebate," unless it refers only to the manufacturer's suggested retail price for new motor vehicles, plus dealer installed options which are itemized and priced at the manufacturer's suggested list price; or to current retail prices for used motor vehicles as described in a recognized guide book used in the trade area, properly adjusted for mileage, equipment and condition, and 
any such advertising shall clearly disclose whether the rebate is by the dealer, by the manufacturer, or both.<br>
        (c)     transactions generally known as "buydowns," unless they refer only to the manufacturer's suggested retail price for new motor vehicles plus dealer installed options which are itemized and priced at the manufacturer's suggested list price; or to current retail prices for used motor vehicles as described in a recognized guide book used in the trade area, properly adjusted for mileage, equipment and condition.  Any such advertising shall clearly disclose whether the buydown is by the dealer, by the manufacturer, or both.<p>

11.     This section left blank intentionally.<p>

12.     To use advertisements allowing for a specific trade-in amount, or range of amounts, unless referring only to the manufacturer's suggested retail price for new motor vehicles, plus dealer installed options which are itemized and priced at the manufacturer's suggested retail price; or to current retail prices for used motor vehicles as described in a recognized guide book used in the trade area, 
properly adjusted for mileage, equipment and condition.<p>

13.     To advertise as having for sale new motor vehicles, unless the advertiser is enfranchised by the manufacturer of the motor vehicle offered for sale as new.  In the case of a modified vehicle, such as converted van, the dealer may advertise using the conversion firm's name, and referring to the chassis manufacturer.  In no instance should the dealer advertise such vehicles solely by a chassis manufacturer's name unless enfranchised to sell that make of vehicle.<p>

14.     To advertise used motor vehicles so as to create the impression they are new.  Used motor vehicles of the current and preceding model year must be clearly identified as "used," "executive driven," "demonstrator," "driver training," "lease," or "fleet" vehicles.<p>

Taxicabs and police motor vehicles must be specifically identified as such.  Descriptions such as "low mileage" and "slightly driven" may be applied only when correct.  The terms "demonstrator's," "executive's." and "official's" shall not be used except upon vehicles:<br>
        (a)     that have never been sold to a member of the public;<br>
        (b)     which were used by the dealer agency or their employees as demonstrator vehicles pursuant to law; and except when such vehicles are advertised for sale, as described, by a franchised dealer for the same make motor vehicle.  Phrases such as "last of the remaining," "close-out," "final clearance," and others of similar import shall not be used in advertising used motor vehicles, so as to convey the impression that the motor vehicles of the current and preceding model year are offered in the same advertisement, the offerings shall be clearly separated by description, layout or art treatment.<p>

15.     To advertise the following:<br>
        (a)     "Executive's" or "official's" motor vehicles, unless they have been used primarily by the personnel or executive(s) of the motor vehicle manufacturer or any authorized dealer of the same make thereof, and unless such motor vehicles have not been sold or titled to a member of the public prior to the appearance of the advertisement.<br>
        (b)     the "list price," "manufacturer's list price," "suggested retail price," or similar terms in comparison with the dealer's actual selling price for demonstrators or executive vehicles, unless such vehicles have never been sold.  Further, the price difference shall not be described as a "savings," "discount," or by any other words of similar meaning.<p>

16.     To advertise motor vehicles owned by or in the possession of dealers without using the name of the dealer or the word "dealer" in the impression they are being offered by private parties.<p>

17.     To advertise that a motor vehicle has a specific or supposed mileage or odometer reading, unless such mileage representation can be substantiated by the advertiser.<p>

18.     To advertise the terms "auction," "auction special," or other terms of similar import, unless said terms shall be used in connection with motor vehicles offered or sold at a bona fide auction, i.e., top the highest bidder at a certain time, date and place.<p>

19.     To advertise equipment, accessory, or other merchandise as "free" if its cost, or any part of its cost, is included in the price of the motor vehicle, or if the motor vehicle can be purchased for a lesser price without such equipment, accessory or merchandise.<p>

20.     To advertise a "free" driving trial, unless it means a trial without any obligation to the consumer.<p>

21.     To advertise in violation of federal Truth-In-Lending and consumer leasing statutes as they apply to advertising (please see following page).  The statutes and their regulations, promulgated and enforced by the Federal Trade Commission and the Federal Reserve Board, are incorporated into these Standards.<p>

<center><b>
CREDIT ADVERTISING<br>
TRUTH IN LENDING-REGULATION Z<br>
</b></center>
<p>

Covers--All types of advertising: television, radio, newspapers, magazines, leaflets, flyers, catalogs, public address announcements, direct mail, window displays, billboards.<p>

<center><b>
CLOSED END CREDIT<br>
</b></center>
<p>

IF YOU ADVERTISE ANY ONE OR MORE OF THE FOLLOWING:<br>
<ol>
<li>The amount or percentage of the down payment.<br>
<li>Amount of any payment.<br>
<li>Amount of any finance charge.<br>
<li>Number of payments of period of repayment.<br>
</ol>
        
THEN YOU MUST STATE ALL OF THE FOLLOWING:<br>
<ol>
<li>The amount or percentage of the down payment.<br>
<li>The terms of repayment.<br>
<li>The "annual percentage rate," using that term, and, if the rate may be increased after consummation, that fact must be disclosed.<br>
</ol>

<p>

The advertising of credit terms may be made by giving one or more examples of typical extensions of credit stating all of the terms applicable to each example.  The advertisement shall set forth one or more examples which are, in fact, typical of the type of credit and terms usually and customarily made available.  Each shall be clearly and conspicuously identified as examples of typical transactions.<p>


<center><b>
LEASING ADVERTISING<br>
TRUTH-IN-LENDING--REGULATION M<br>
</b></center>
<p>

Covers--All types of advertising: television, radio, newspapers, magazines, leaflets, flyers, catalogs, public address announcements, direct mail, window displays, billboards.<p>

According to the Truth-in-Leasing regulations which became effective April 1, 1981 [Regulation M, 12CFR-213.5(c)], no advertisement concerning any consumer lease shall state the amount of any payment, the number of required payments, or any information concerning a payment to be made at the consummation of the lease, unless the advertisement also states each of the following items of information 
as applicable.<p>

<ol>
<li>that the transaction advertised is a lease;<br>
<li>the total amount of any consummation payment, or that no consummation payment is necessary;<br>
<li>the number, amounts, due dates or periods of scheduled payments, and the total of such payments;<br>
<li>a statement of whether or not the lessee has an option to purchase, and at what price and times;<br>
<li>a statement of the amount or method of determining the amount of any liabilities the lease imposes upon the lessee at the end of the lease term, and a statement that the lessee shall be liable for any difference between estimated value and realized value of leased property at the end of the term, if the lessee has such liability.  A violation of this regulation can subject a dealer to criminal liability.<br>
</ol>
<p>


<center><b>
FAILURE TO DISCLOSE A "BUY-DOWN"<br>
MAY  BE AN UNFAIR OR DECEPTIVE PRACTICE<br>
</b></center>
<p>

Dealers should be aware that the failure to properly treat "buy downs" in credit disclosures and advertising may be considered an unfair or deceptive practice under Federal and state law.<p>

Though the FTC has neither published any definitive guidelines on "buy-downs" nor instituted any enforcement action against a dealer, there is some evidence that the FTC has the matter under investigation.<p>


<center><b>
WHAT SHOULD THE DEALER DO?<br>
</b></center>
<p>


NADA strongly urges dealers to discuss a "buy-down" with their respective attorneys and to thoroughly review the details of any and all "buy-down" programs with their attorneys, prior to participating in such programs.  If dealers participate, they should do so only with a complete understanding of their responsibilities and risks, under both Federal and state laws.  Dealers are encouraged to consult with 
AADA on "buy-down" disclosure.<p>

</td></tr>

<tr>
<td></td>
<td>
<p>
<center><a href="frontdoor.html"><img src="gif/autobar.gif" border=0 alt="Auto Mall"></a></center>
<br>
<center>
<a href="index.html"><img src="gif/mainpagebutton.gif" border=0 alt="Main Page"></a>
<a href="bylaws.html"><img src="gif/bylawsbutton.gif" alt="Bylaws" border=0></a><br>
<img src="gif/advertbutton.gif" alt="Ad Standards" border=0>
<a href="committees.html"><img src="gif/committeebutton.gif" alt="committees" border=0></a>
<p>
[ <a href="index.html">Main Page</a>
| <a href="bylaws.html">Bylaws</a>
| Advertising Standards
| <a href="committees.html">Committees</a> ]
</center>
<br>
<br>

For inquiries or comments, e-mail: <a href="mailto:aada@dasta.com">aada@dasta.com</a><p>
<p>

<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="http://www.dasta.com/gif/dastasig.gif"
			alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 25 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996
				<a href="http://www.dasta.com">DASTA VendorCat, LLC</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">This site was designed by 
		<a href="http://www.dasta.com">DASTA VendorCat</a><br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of
	<a href="http://www.dasta.com/anet.html">Association-Net</a>
	<sup>TM</sup></font></p>
</center>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-85</DOCNO>
<DOCOLDNO>IA058-000947-B026-203</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/committees.html 206.97.63.16 19970109193420 text/html 5648
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:17:03 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 5477
Last-modified: Tue, 25 Jun 1996 23:05:47 GMT
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">

<html>
<head>

<title>AADA Committees</title>
</head>
<body background="gif/aadatile1x.gif" bgcolor="#E5E0E0" text="#000000" link="#55083C" vlink="#00120A" ALINK="#220652">


<center>
<table border=2>
<tr><td>
<img src="gif/headerabout.gif" alt="About AADA">
</td></tr>
</table>
</center>

<table width=100%>
<tr><td></td><td colspan=4>
<img src="gif/purpleball.gif"><a href="#exec">Executive Committee</a><br>
<img src="gif/purpleball.gif"><a href="#board">Board of Directors</a><br>
<img src="gif/purpleball.gif"><a href="#staff">Staff</a><br>
</td></tr>



<tr><td></td><td colspan=3><font size=6><b><a name="exec">Executive Committee:</a></b></font></td></tr>
<tr><td></td><td>Stan Powell</td><td> President</td><td> (Powell Volvo-Mazda, Scottsdale)</td></tr>
<tr><td></td><td>Tom Quebedeaux</td><td> President-Elect</td><td>(Quebedeaux Pontiac, Tucson)</td></tr>
<tr><td></td><td>Keith Cowherd</td><td> Vice President</td><td>(Bell Dodge, Phoenix)</td></tr>
<tr><td></td><td>Karl Moedl</td><td> Secretary/Treasurer</td><td>(Karl Moedl Pontiac-Buick, Yuma)</td></tr>
<tr><td></td><td>LaVelle McCoy</td><td></td><td>(McCoy Motors, Flagstaff)</td></tr>
<tr><td></td><td>Fred York</td><td></td><td>(York Motors, Prescott)</td></tr>
<tr><td></td><td>Mark Phelps</td><td></td><td>(San-Man Ford, San Manuel)</td></tr>
<tr><td></td><td width=80% colspan=3></td></tr>
<tr><td></td><td width=80% colspan=3></td></tr>
<tr><td></td><td width=80% colspan=2></td></tr>
<tr><td></td><td colspan=3><font size=6><b><a name="board">Board of Directors:</a></b></font></td></tr>
<tr><td></td><td valign=top>Steve Christy</td><td>(Galloway Chrysler-Plymouth-<BR>Jeep Eagle, Tucson)</td></tr>
<tr><td></td><td>Gerald Hatch</td><td>(Hatch Motor Co., Snowflake)</td></tr>
<tr><td></td><td>David Kimmerle </td><td>(Sanderson Ford, Glendale)</td></tr>
<tr><td></td><td>Bill McGlocklin </td><td>(Bill McGlocklin Ford, Safford)</td></tr>
<tr><td></td><td valign=top>Mark Phelps </td><td>(San-Man Ford-Mercury,<BR> San Manuel)</td></tr>
<tr><td></td><td>Tom Ross </td><td>(Jack Ross Motors, Tempe)</td></tr>
<tr><td></td><td>Dan Rowe </td><td>(Precision Toyota, Tucson)</td></tr>
<tr><td></td><td>Peter Schminke </td><td>(Cobre Valley Motors, Globe)</td></tr>
<tr><td></td><td>Ron Slyter </td><td>(Sierra Toyota, Sierra Vista)</td></tr>
<tr ><td></td><td valign=top>Martin Swanty, NADA Director 
</td><td>(Martin Swanty <BR>Chrysler-Plymouth-Jeep Eagle, Kingman)</td></tr>
<tr><td></td><td valign=top>F. Kay Wilson</td><td>(The Corral Chrysler-Plymouth,<BR> Lake Havasu)</td></tr>
<tr><td></td><td width=80% colspan=3></td></tr>
<tr><td></td><td width=80% colspan=3></td></tr>
<tr><td></td><td width=80% colspan=2></td></tr>
<tr><td></td><td colspan=3><font size=6><b><a name="staff">Staff:</a></b></font></td></tr>
<tr><td></td><td>Executive Vice President</td><td>Marv Cronberg</td></tr>
<tr><td></td><td>General Counsel </td><td> Michael Denea</td></tr>
<tr><td></td><td>Public Affairs & Legislation</td><td>Dolly Volini</td></tr>
<tr><td></td><td>Administration & Operations</td><td>David Smith</td></tr>
<tr><td></td><td>Insurance Services</td><td> Lupe Sierra, Vickie Osborn</td></tr>
<tr><td></td><td>Field Services</td><td>Jeff Andresen</td></tr>
<tr><td></td><td>Forms & Products </td><td>Mike Mastrangelo, Greg Kroush</td></tr>
<tr><td></td><td>Communication & Public Relations</td><td>Mary Jo Heck</td></tr>
<tr><td></td><td>Information Management</td><td>Sharla Willard</td></tr>
<tr><td></td><td valign=top>Title & Registration</td><td>Ted Boggs, Naomi Ramsey,<BR> Laura Dierth, Sue Fulkerson,<BR> Karen Newingham, Voneree Littles,<BR> Olivia Medina, Christine Foxworth.</td></tr>
<tr><td></td><td>Executve Secretary/Meeting Planner</td><td valign=top>Patti Baca</td></tr>
<tr><td></td><td>Receptionist</td><td>Michele Deason</td></tr>
</table>
<p>
<center><a href="frontdoor.html"><img src="gif/autobar.gif" border=0 alt="Auto Mall"></a></center>
<br>

<center>
<a href="index.html"><img src="gif/mainpagebutton.gif" border=0 alt="Main Page"></a>
<a href="bylaws.html"><img src="gif/bylawsbutton.gif" alt="Bylaws" border=0></a><br>
<a href="adstandards.html"><img src="gif/advertbutton.gif" alt="Ad Standards" border=0></a>
<img src="gif/committeebutton.gif" alt="committees" border=0>
<p>
[ <a href="index.html">Main Page</a>
| <a href="bylaws.html">Bylaws</a>]<br>
[ <a href="adstandards.html">Advertising Standards</a>
| Committees> ]
</center>
<br>
<br>

<center>For inquiries or comments, e-mail: <a href="mailto:aada@dasta.com">aada@dasta.com</a></center><p>
<p>
<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="http://www.dasta.com/gif/dastasig.gif"
			alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 25 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996
				<a href="http://www.dasta.com">DASTA VendorCat, LLC</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">This site was designed by 
		<a href="http://www.dasta.com">DASTA VendorCat</a><br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of
	<a href="http://www.dasta.com/anet.html">Association-Net</a>
	<sup>TM</sup></font></p>
</center>


</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-86</DOCNO>
<DOCOLDNO>IA058-000947-B026-216</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/automall.html 206.97.63.16 19970109193428 text/html 5124
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:17:10 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 4953
Last-modified: Wed, 16 Oct 1996 20:05:31 GMT
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">

<HTML>
<HEAD>
<TITLE>AADA Auto Mall</TITLE>
</HEAD>

<body bgcolor="#000000" text="#FFFCFF" link="#FFF601" vlink="#BABEBC" ALINK="#8EBCFF">


<center><img src="gif/stars.gif"><img src="gif/automall.gif"><img src="gif/stars.gif"></center>

<center>
<hr width=250 size=5>

<font size=5><b>
This portion of this website<br>
is currently under development.
</b></font>

<hr width=250 size=5>

<p>
<font size=4><b>For faster load time and reduced graphics,<br>
go to List of Manufacturers <a href="automall2.html">HERE</a>.</b></font>
<p>
<font size=7><b>Click on Manufacturer for list of Dealerships</b></font>
</center>
<p>
<table width=100% border=0 cellpadding=0 cellspacing=0>
<tr>
<td align="center">
<img src="gif/newcars.gif"><br>
<img src="gif/stars.gif"><br>
<img src="gif/whatadeal.gif"><br>
<img src="gif/vans.gif"><br>
<img src="gif/stars.gif"><br>
<img src="gif/lease.gif"><br>
<img src="gif/stars.gif"><br>
<a href="mall/trucksfin.html"><img src="gif/trucks.gif" border=0 alt="Trucks!"></a><br>
<img src="gif/stars.gif"><br>
<img src="gif/unbeleiveable.gif"></td>


<td align="center"><A HREF="/cgi-bin/imagemap/manufacturers3.map" alt="List of manufacturers - use text links below">
<img src="gif/manufacturers3.gif" border=0 ismap></a>
<br>
[ <a href="mall/acurafin.html">Acura</a>
| <a href="mall/audifin.html">Audi</a>
| <a href="mall/bentleyfin.html">Bentley</a>
| <a href="mall/bmwfin.html">BMW</a>
| <a href="mall/buickfin.html">Buick</a>
| <a href="mall/cadillacfin.html">Cadillac</a>
| <a href="mall/chevroletfin.html">Chevrolet</a>
| <a href="mall/chryslerfin.html">Chrysler</a>
| <a href="mall/dodgefin.html">Dodge</a>
| <a href="mall/ferrarifin.html">Ferrari</a>
| <a href="mall/fordfin.html">Ford</a>
| <a href="mall/trucksfin.html">Freightliner</a>
| <a href="mall/geofin.html">Geo</a>
| <a href="mall/gmcfin.html">GMC</a>
| <a href="mall/trucksfin.html">Hino</a>
| <a href="mall/hondafin.html">Honda</a>
| <a href="mall/hummerfin.html">Hummer</a>
| <a href="mall/hyundaifin.html">Hyundai</a>
| <a href="mall/infinitifin.html">Infiniti</a>
| <a href="mall/isuzufin.html">Isuzu</a>
| <a href="mall/jaguarfin.html">Jaguar</a>
| <a href="mall/jeep_eaglefin.html">Jeep / Eagle</a>
| <a href="mall/trucksfin.html">Kenworth</a>
| <a href="mall/kiafin.html">Kia</a>
| <a href="mall/lamborghinifin.html">Lamborghini</a>
| <a href="mall/landroverfin.html">Land Rover</a>
| <a href="mall/lexusfin.html">Lexus</a>
| <a href="mall/lincolnfin.html">Lincoln</a>
| <a href="mall/trucksfin.html">Mack</a>
| <a href="mall/mazdafin.html">Mazda</a>
| <a href="mall/mercedes_benzfin.html">Mercedes Benz</a>
| <a href="mall/mercuryfin.html">Mercury</a>
| <a href="mall/mitsubishifin.html">Mitsubishi</a>
| <a href="mall/nissanfin.html">Nissan</a>
| <a href="mall/oldsmobilefin.html">Oldsmobile</a>
| <a href="mall/trucksfin.html">Peterbilt</a>
| <a href="mall/plymouthfin.html">Plymouth</a>
| <a href="mall/porschefin.html">Porsche</a>
| <a href="mall/rolls_roycefin.html">Rolls Royce</a>
| <a href="mall/saabfin.html">Saab</a>
| <a href="mall/saturnfin.html">Saturn</a>
| <a href="mall/suburufin.html">Suburu</a>
| <a href="mall/suzukifin.html">Suzuki</a>
| <a href="mall/toyotafin.html">Toyota</a>
| <a href="mall/trucksfin.html">Trucks</a>
| <a href="mall/volkswagenfin.html">Volkswagen</a>
| <a href="mall/volvofin.html">Volvo</a> ]
</td>
<td align="center">
<img src="gif/lease.gif"><br>
<img src="gif/stars.gif"><br>
<a href="mall/trucksfin.html"><img src="gif/trucks.gif" border=0 alt="Trucks!"></a><br>
<img src="gif/stars.gif"><br>
<img src="gif/unbeleiveable.gif"><br>
<img src="gif/newcars.gif"><br>
<img src="gif/stars.gif"><br>
<img src="gif/whatadeal.gif"><br>
<img src="gif/stars.gif"><br>
<img src="gif/vans.gif"></td>
</tr>
</table>


<br>
<br>
<center>
<a href="index.html"><img src="gif/mainpagebutton.gif" border=0 alt="Main Page"></a>
<p>
[ <a href="index.html">Main Page</a> ]
</center>

<br>
<br>

<center>For inquiries or comments, e-mail: <a href="mailto:aada@dasta.com">aada@dasta.com</a></center>
<p>
<p>
<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="http://www.dasta.com/gif/dastasig.gif"
			alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 25 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996
				<a href="http://www.dasta.com">DASTA VendorCat, LLC</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">This site was designed by 
		<a href="http://www.dasta.com">DASTA VendorCat</a><br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of
	<a href="http://www.dasta.com/anet.html">Association-Net</a>
	<sup>TM</sup></font></p>
</center>

</body></html>


</DOC>
<DOC>
<DOCNO>WT08-B13-87</DOCNO>
<DOCOLDNO>IA058-000947-B026-231</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/automall2.html 206.97.63.16 19970109193436 text/html 3947
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:17:18 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 3776
Last-modified: Wed, 16 Oct 1996 20:05:44 GMT
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">

<HTML>
	
	<HEAD>
		<TITLE>AADA Auto Mall</TITLE>
	</HEAD>

<body bgcolor="#000000" text="#FFFCFF" link="#FFF601" vlink="#BABEBC" ALINK="#8EBCFF">

<br><br><br><br>

<center><img src="gif/stars.gif"><img src="gif/automall.gif"><img src="gif/stars.gif"></center>

<br><br><br><br>

<center>

<table border="10">

<tr>
	<td width="50%" valign="top">
	
	<font size="+2">

	<ul>
		<li><a href="mall/acurafin.html">Acura</a>
		<li><a href="mall/audifin.html">Audi</a>
		<li><a href="mall/bentleyfin.html">Bentley</a>
		<li><a href="mall/bmwfin.html">BMW</a>
		<li><a href="mall/buickfin.html">Buick</a>
		<li><a href="mall/cadillacfin.html">Cadillac</a>
		<li><a href="mall/chevroletfin.html">Chevrolet</a>
		<li><a href="mall/chryslerfin.html">Chrysler</a>
		<li><a href="mall/dodgefin.html">Dodge</a>
		<li><a href="mall/ferrarifin.html">Ferrari</a>
		<li><a href="mall/fordfin.html">Ford</a>
		<li><a href="mall/trucksfin.html">Freightliner</a>
		<li><a href="mall/geofin.html">Geo</a>
		<li><a href="mall/gmcfin.html">GMC</a>
		<li><a href="mall/trucksfin.html">Hino</a>
		<li><a href="mall/hondafin.html">Honda</a>
		<li><a href="mall/hummerfin.html">Hummer</a>
		<li><a href="mall/hyundaifin.html">Hyundai</a>
		<li><a href="mall/infinitifin.html">Infiniti</a>
		<li><a href="mall/isuzufin.html">Isuzu</a>
		<li><a href="mall/jaguarfin.html">Jaguar</a>
		<li><a href="mall/jeep_eaglefin.html">Jeep / Eagle</a>
		<li><a href="mall/trucksfin.html">Kenworth</a>
		<li><a href="mall/kiafin.html">Kia</a>
	</ul>
	
	</font>

	</td>
	
	<td width="50%" valign="top">
	
	<font size="+2">
	
	<ul>
		
		
		<li><a href="mall/lamborghinifin.html">Lamborghini</a>
		<li><a href="mall/landroverfin.html">Land Rover</a>
		<li><a href="mall/lexusfin.html">Lexus</a>
		<li><a href="mall/lincolnfin.html">Lincoln</a>
		<li><a href="mall/trucksfin.html">Mack</a>
		<li><a href="mall/mazdafin.html">Mazda</a>
		<li><a href="mall/mercedes_benzfin.html">Mercedes Benz</a>
		<li><a href="mall/mercuryfin.html">Mercury</a>
		<li><a href="mall/mitsubishifin.html">Mitsubishi</a>
		<li><a href="mall/nissanfin.html">Nissan</a>
		<li><a href="mall/oldsmobilefin.html">Oldsmobile</a>
		<li><a href="mall/trucksfin.html">Peterbilt</a>
		<li><a href="mall/plymouthfin.html">Plymouth</a>
		<li><a href="mall/pontiacfin.html">Pontiac</a>
		<li><a href="mall/porschefin.html">Porsche</a>
		<li><a href="mall/rolls_roycefin.html">Rolls Royce</a>
		<li><a href="mall/saabfin.html">Saab</a>
		<li><a href="mall/saturnfin.html">Saturn</a>
		<li><a href="mall/suburufin.html">Suburu</a>
		<li><a href="mall/suzukifin.html">Suzuki</a>
		<li><a href="mall/toyotafin.html">Toyota</a>
		<li><a href="mall/trucksfin.html">Trucks</a>
		<li><a href="mall/volkswagenfin.html">Volkswagen</a>
		<li><a href="mall/volvofin.html">Volvo</a>

	</ul>

	</font>
	
	</td>
</tr>

</table>

</center>
<p>
<br>
<br>

<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="http://www.dasta.com/gif/dastasig.gif"
			alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 25 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996
				<a href="http://www.dasta.com">DASTA VendorCat, LLC</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">This site was designed by 
		<a href="http://www.dasta.com">DASTA VendorCat</a><br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of
	<a href="http://www.dasta.com/anet.html">Association-Net</a>
	<sup>TM</sup></font></p>
</center>


</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-88</DOCNO>
<DOCOLDNO>IA058-000947-B026-246</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/executives.html 206.97.63.16 19970109193445 text/html 4495
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:17:26 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 4324
Last-modified: Tue, 25 Jun 1996 23:05:46 GMT
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">

<html> 
<head> 
<title> </title> 
</head> 
<body background="gif/aadatile3a.gif" bgcolor="#000000" text="#000040" 
link="#600000" vlink="#400040">

<table width=100%>
<tr><td></td><td width=80% colspan=3></td></tr>
<tr><td></td><td colspan=3><font size=5>Executive Committee:</font></td></tr>
<tr><td></td><td>Stan Powell</td><td> President</td><td> (Powell Volvo-Mazda, Scottsdale)</td></tr>
<tr><td></td><td>Tom Quebedeaux</td><td>President-Elect</td><td>(Quebedeaux Pontiac, Tucson)</td></tr>
<tr><td></td><td>Keith Cowherd</td><td> Vice President</td><td>(Bell Dodge, Phoenix)</td></tr>
<tr><td></td><td>Karl Moedl</td><td> Secretary/Treasurer</td><td>(Karl Moedl Pontiac-Buick, Yuma)</td></tr>
<tr><td></td><td>LaVelle McCoy</td><td></td><td>(McCoy Motors, Flagstaff)</td></tr>
<tr><td></td><td>Fred York</td><td></td><td>(York Motors, Prescott)</td></tr>
<tr><td></td><td>Mark Phelps</td><td></td><td>(San-Man Ford, San Manuel)</td></tr>
<tr><td></td><td width=80% colspan=3></td></tr>
<tr><td></td><td width=80% colspan=3></td></tr>
<tr><td></td><td width=80% colspan=2></td></tr>
<tr><td></td><td colspan=3><font size=5>Board of Directors:</font></td></tr>
<tr><td></td><td valign=top>Steve Christy</td><td>(Galloway Chrysler-Plymouth-<BR>Jeep Eagle, Tucson)</td></tr>
<tr><td></td><td>Gerald Hatch</td><td>(Hatch Motor Co., Snowflake)</td></tr>
<tr><td></td><td>David Kimmerle </td><td>(Sanderson Ford, Glendale)</td></tr>
<tr><td></td><td>Bill McGlocklin </td><td>(Bill McGlocklin Ford, Safford)</td></tr>
<tr><td></td><td valign=top>Mark Phelps </td><td>(San-Man Ford-Mercury,<BR> San Manuel)</td></tr>
<tr><td></td><td>Tom Ross </td><td>(Jack Ross Motors, Tempe)</td></tr>
<tr><td></td><td>Dan Rowe </td><td>(Precision Toyota, Tucson)</td></tr>
<tr><td></td><td>Peter Schminke </td><td>(Cobre Valley Motors, Globe)</td></tr>
<tr><td></td><td>Ron Slyter </td><td>(Sierra Toyota, Sierra Vista)</td></tr>
<tr ><td></td><td valign=top>Martin Swanty, NADA Director
</td><td>(Martin Swanty <BR>Chrysler-Plymouth-Jeep Eagle, Kingman)</td></tr>
<tr><td></td><td valign=top>F. Kay Wilson</td><td>(The Corral Chrysler-Plymouth,<BR> Lake Havasu)</td></tr>
<tr><td></td><td width=80% colspan=3></td></tr>
<tr><td></td><td width=80% colspan=3></td></tr>
<tr><td></td><td width=80% colspan=2></td></tr>
<tr><td></td><td colspan=3><font size=5>Staff:</font></td></tr>
<tr><td></td><td>Executive Vice President</td><td>Marv Cronberg</td></tr>
<tr><td></td><td>General Counsel </td><td> Michael Denea</td></tr>
<tr><td></td><td>Public Affairs & Legislation</td><td>Dolly Volini</td></tr>
<tr><td></td><td>Administration & Operations</td><td>David Smith</td></tr>
<tr><td></td><td>Insurance Services</td><td> Lupe Sierra, Vickie Osborn</td></tr>
<tr><td></td><td>Field Services</td><td>Jeff Andresen</td></tr>
<tr><td></td><td>Forms & Products </td><td>Mike Mastrangelo, Greg Kroush</td></tr>
<tr><td></td><td>Communication & Public Relations</td><td>Mary Jo Heck</td></tr>
<tr><td></td><td>Information Management</td><td>Sharla Willard</td></tr>
<tr><td></td><td valign=top>Title & Registration</td><td>Ted Boggs, Naomi Ramsey,<BR> Laura Dierth, Sue Fulkerson,<BR> Karen Newingham, Voneree Littles,<BR> Olivia Medina, Christine Foxworth.</td></tr>
<tr><td></td><td>Executve Secretary/Meeting Planner</td><td valign=top>Patti Baca</td></tr>
<tr><td></td><td>Receptionist</td><td>Michele Deason</td></tr>
</table>
<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="http://www.dasta.com/gif/dastasig.gif"
			alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 25 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996
				<a href="http://www.dasta.com">DASTA VendorCat, LLC</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">This site was designed by 
		<a href="http://www.dasta.com">DASTA VendorCat</a><br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of
	<a href="http://www.dasta.com/anet.html">Association-Net</a>
	<sup>TM</sup></font></p>
</center>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-89</DOCNO>
<DOCOLDNO>IA058-000947-B026-263</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/board.html 206.97.63.16 19970109193504 text/html 4066
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:17:42 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 3895
Last-modified: Tue, 25 Jun 1996 23:05:49 GMT
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">

<HTML>
<HEAD>
<TITLE>Arizona Automobile Dealers Association - Membership</TITLE>
</HEAD>

<body background="gif/aadatile1x.gif" bgcolor="#E5E0E0" text="#000628" link="#55083C" vlink="#00120A" ALINK="#220652">

<center>
<table border=2>
<tr><td>
<img src="gif/memberbenhead.gif">
</td></tr>
</table>
</center>

<br>
<p>
<hr size=3>
<p>
<center>

<font size=5><b>OFFICERS AND BOARD MEMBERS</b></font><br>
1995-1996<p>

<p>

<b>EXECUTIVE COMMITTEE</b><p>

Stan Powell, Powell Volvo Mazda - President<br>
Tom Quebedeaux, Quebedeaux Pontiac - President-elect<br>
Keith Cowherd, Bell Dodge - Vice President<br>
Karl Moedl, Karl Moedl Pontiac - Secretary/Treasurer<br>
LaVelle McCoy, McCoy Motors - Past President<br>
Mark Phelps, San-Man Ford-Mercury - Appointee<br>
Fred York, York Motors - Appointee<br>
</center>
<p>
<center>
<table width=80%>
<tr>
<td colspan=2>
<center>
<b>BOARD OF DIRECTORS</b><p>
</td>
</tr>
<tr>
<td width=40% valign=top>
<center>
Stan Powell<br>
Powell Volvo Mazda <br>
Scottsdale District<br>

<p>

Tom Quebedeaux<br>
Quebedeaux Pontiac <br>
Keith Cowherd, Vice President<br>
Bell Dodge<br>
Phoenix District<br>

<p>

Karl Moedl<br>
Karl Moedl Pontiac-Buick-GMC<br>
Yuma/LaPaz Counties<br>

<p>

LaVelle McCoy<br>
McCoy Motors<br>
Coconino County<br>

<p>

Steve Christy<br>
Galloway Chrysler Plymouth J/E<br>
Pima/Santa Cruz Counties<br>

<p>

Gerald Hatch<br>
Hatch Motor Company<br>
Navajo/Apache Counties<br>

<p>

David Kimmerle<br>
Sanderson Ford<br>
West Maricopa County<br>

<p>

Bill McGlocklin<br>
Bill McGlocklin Ford<br>
Graham/Greenlee Counties<br>
</center>
</td>
<td width=40% valign=top>
<center>
<p>
Mark Phelps<br>
San-Man Ford-Mercury<br>
Pinal County<br>

<p>

Tom Ross<br>
Jack Ross Motors<br>
East Maricopa County<br>

<p>

Dan Rowe<br>
Precision Toyota<br>
Pima/Santa Cruz Counties<br>

<p>

Pete Schminke<br>
Cobre Valley Motors<br>
Gila County<br>

<p>

Ron Slyter<br>
Sierra Toyota<br>
Cochise County<br>

<p>

F. Kay Wilson<br>
The Corral Chrysler-Plymouth<br>
Mohave County<br>

<p>

Fred York<br>
York Motors<br>
Yavapai County<br>

<p>

Martin Swanty<br>
Martin Swanty Chrysler Plymouth Dodge<br>
NADA Director<br>
</center>
</td>
</tr>
</table>

</center>
<br>
<br>
<p>
<hr size=3>
<p>
<center><a href="frontdoor.html"><img src="gif/autobar.gif" border=0 alt="Auto Mall"></a></center>
<center>[<a href="frontdoor.html">The Auto Mall</a>]</center>
<p>

<center>
<a href="index.html"><img src="gif/mainpagebutton.gif" border=0 alt="Main Page"></a>
<a href="executives.html"><img src="gif/execbutton.gif" border=0></a><br>
<img src="gif/boardbutton.gif" border=0>
<a href="benefits.html"><img src="gif/memberbutton.gif" border=0></a>
<p>
[ <a href="index.html">Main Page</a>
| <a href="executives.html">Executives</a>]<br>
[ Board of Directors
| <a href="benefits.html">Membership Benefits</a> ]
</center>
<br>
<br>

<center>For inquiries or comments, e-mail: <a href="mailto:aada@dasta.com">aada@dasta.com</a></center>
<p>
<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="http://www.dasta.com/gif/dastasig.gif"
			alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 25 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996
				<a href="http://www.dasta.com">DASTA VendorCat, LLC</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">This site was designed by 
		<a href="http://www.dasta.com">DASTA VendorCat</a><br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of
	<a href="http://www.dasta.com/anet.html">Association-Net</a>
	<sup>TM</sup></font></p>
</center>



</body>
</html>


</DOC>
<DOC>
<DOCNO>WT08-B13-90</DOCNO>
<DOCOLDNO>IA058-000947-B026-285</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/benefits.html 206.97.63.16 19970109193518 text/html 7784
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:17:54 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 7613
Last-modified: Tue, 25 Jun 1996 23:05:49 GMT
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">

<HTML>
<HEAD>
<TITLE>Arizona Automobile Dealers Association - Membership Benefits</TITLE>
</HEAD>

<body background="gif/aadatiley.gif" bgcolor="#E5E0E0" text="#000628" link="#55083C" vlink="#00120A" ALINK="#220652">


<center>
<table border=2>
<tr><td>
<img src="gif/memberbenhead.gif">
</td></tr>
</table>
</center>


<center>
<hr>
<font size=4><b>Membership with AADA has some great benefits.</b></font>
<hr>
</center>
<br>

<b>Insurance Plans</b><p>

By doing business with the AADA Group Insurance Trust, you receive benefit a package written through a top-rated provider and developed with only your interests in mind. All commissions earned by the trust are returned to members through association services that meet dealers' operational needs and help them save money.<p>

<b>Workers Compensation</b>:  Through its long-standing partnership with Insurance Company of the West, AADA has built a workers compensation program that simply can't be matched. Dividends paid to participants with good loss ratios totaled nearly $2 million in 1994, having increased consistently for nearly a decade. Member participation in the plan is nearly 80 percent. While other companies try to clone the AADA plan and lure dealers with speculative dividends, the AADA plan's consistent, proven performance speaks for itself.<p>

<b>Group Health</b>:  A flexible range of plans at highly competitive premiums, serving dealers statewide through top providers including Humana Health Care. Members can choose from managed care, indemnity and combination plans, and select affordable benefits packages that best meet their individual dealership needs.<p>

<b>Disability/Section 125</b>:  An array of attractive benefits that can be offered to employees at no cost to the dealership is available through American Fidelity Assurance Co.<p>

<b>Dental</b>:  AADA now offers a prepaid provider-network plan through Employer's Dental Service, plus the new Pro Dental plan, which offers complete freedom of choice in selecting a dentist.<p>

<b>Vision</b>:  AADA members and employees receive 10 percent off regular prices for eye exams, glasses and contact lenses at Nationwide Vision Centers.<p>

For more information on any AADA insurance plan, contact AADA Insurance Trust Administrator Lupe Sierra.<p>

<p>
<hr size=3>
<p>


<b>Employment-law services</b>: Complementing the services provided by on-staff legal counsel, specialized employment-law consultation and services are offered through the AADA-endorsed labor-law firm Steptoe & Johnson. The program includes:<p>
<li>Free phone consultation on most employment-law questions;
<li>Low, preset fees for special services such as compilation of an employee handbook or employee drug-testing policy.
<li>Periodic legal analyses on employment-law issues  in the AADA monthly  newsletter, Topics.
<p>

For more information on AADA employment-law services, contact David Selden or Julie Pace, Steptoe & Johnson, (602) 257-5211.

<p>
<hr size=3>
<p>


<b>Title & Registration Services</b><p>

The first privately operated vehicle title and registration program in the country, this revolutionary membership service offers a fast, hassle-free alternative to processing title work through the state. Plates, title and registration are mailed to the buyer within 48 hours, with a dramatically higher level of customer service for both you and your customer. AADA continues to offer duplicate titles and motor vehicle records, as well as Arizona and CARFAX (nationwide) title-history reports, as part of the new program. For more information contact AADA Title and Registration Program administrators Ted Boggs or Naomi Ramsey.

<p>
<hr size=3>
<p>

<b>Telephone services</b><p>

<b>Long-distance</b>:  More than 125 AADA members participate in the AADA-endorsed long-distance service, provided by LDDS Metromedia Communications. The LDDS Savers Program has saved member dealers an average of 35 percent off their business long-distance charges. More than 60 percent of AADA members use LDDS for both intrastate and interstate long-distance service. For more information contact Jennifer Mund, LDDS, (602) 640-1080 or (800) 737-0773.<p>

<b>Cellular</b>:  AADA members enjoy group rates that are among the lowest available on cellular service through association-endorsed Cellular One, the nation's largest cellular provider. For more information contact Dennis Baker, Cellular         One, (602) 731-6100 or (602) 390-3792.<p>

<b>Local-service cost auditing</b>: Local telephone-service cost auditing by Par-Tel, a US West agent, has saved AADA members an average of 35 percent off local billings. For more information contact John Stock, Par-Tel, (602) 278-7111.<p>

<p>
<hr size=3>
<p>

<b>Field Services</b><p>

AADA's Field Services Director travels statewide to member dealerships, making sure AADA stays in touch with the problems dealers face during day-to-day operations and providing a unique level of personal service to dealers and their staffs. A free service to AADA members. For more information contact AADA Field Services Director Jeff Andresen.<p>


<p>
<hr size=3>
<p>


<b>Bonds</b><p>

Dealer, title, notary and other bonds are available through AADA's insurance department at affordable group rates. For more information contact Vickie Osborn in the AADA Insurance Trust office.<p>

<p>
<hr size=3>
<p>

<b>Environmental Services</b><p>

The professional environmental consultants at Van's Environmental Services provide free advice to AADA members on environmental laws and regulations, and offer a wide range of affordable environmental services including compliance audits, underground storage tank removal/upgrades, drywell installation and spill cleanup. Van's also offers educational seminars and contributes articles on environmental issues to the monthly AADA newsletter, Topics. For more information contact Chris van Elk or Brian Vance, Van's Environmental Services, (602) 944-8309.<p>
<p>
<hr size=3>
<p>
<center><a href="frontdoor.html"><img src="gif/autobar.gif" border=0 alt="Auto Mall"></a></center>
<p>

<center>
<a href="index.html"><img src="gif/mainpagebutton.gif" border=0 alt="Main Page"></a>
<a href="board.html"><img src="gif/execbutton.gif" border=0></a><br>
<a href="executives.html"><img src="gif/boardbutton.gif" border=0></a>
<a href="benefits.html"><img src="gif/memberbutton.gif" border=0></a>
<p>
[ <a href="index.html">Main Page</a>
| <a href="executives.html">Executives</a>]<br>
[ <a href="board.html">Board of Directors</a>
| <a href="benefits.html">Membership Benefits</a> ]
</center>
<br>
<br>

<center>For inquiries or comments, e-mail: <a href="mailto:aada@dasta.com">aada@dasta.com</a></center>
<p>
<p>
<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="http://www.dasta.com/gif/dastasig.gif"
			alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 25 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996
				<a href="http://www.dasta.com">DASTA VendorCat, LLC</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">This site was designed by 
		<a href="http://www.dasta.com">DASTA VendorCat</a><br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of
	<a href="http://www.dasta.com/anet.html">Association-Net</a>
	<sup>TM</sup></font></p>
</center>


</body>
</html>

</DOC>
<DOC>
<DOCNO>WT08-B13-91</DOCNO>
<DOCOLDNO>IA058-000947-B026-301</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/adinfo.html 206.97.63.16 19970109193528 text/html 5166
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:18:11 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 4995
Last-modified: Tue, 25 Jun 1996 23:05:52 GMT
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">

<HTML>
<HEAD>
<TITLE>Arizona Automobile Dealers Association - Vendor Advertising Services</TITLE>
</HEAD>

<body background="gif/aadatile6x.gif" bgcolor="#E5E0E0" text="#000628" link="#55083C" vlink="#00120A" ALINK="#220652">

<center>
<table border=2>
<tr><td>
<img src="gif/headervendor.gif" alt="About AADA">
</td></tr>
</table>
</center>




<p>
<hr size=3>
<p>

<font size=4><b>Publication Description</b><font size=3><p>

The official monthly membership publication of the Arizona Automobile Dealers Association.<p>

<b>Circulation</b>:  Approximately 98% of Arizonas franchised motor vehicle dealers (more than 210 dealerships). 1994 membership survey indicated estimated readership of 800 to 1000 principals, general managers, department managers and employees.<p>

<b>Specifications</b>:  12 pages, 8.5 x 11 trim size. Offset litho on matte-coated white stock. Three-color (PMS 288, PMS 201 and black) cover, two-color (PMS 288 and black) throughout. Saddle stitch.<p>

<b>Mechanical Requirements</b>:  Artwork must be camera-ready (color-separated if applicable). Computer files also may be acceptable with accompanying camera-ready hard copy. Please call before submitting non-camera-ready ads or computer files. Photos: black-and-white prints. No bleeds. Preprinted inserts: 250 single sheets. Proofs will be provided only for setup work we produce. <p>

<b>Closing Date</b>:  Artwork must be submitted by the 5th of the preceding month (preprinted inserts, 20th of preceding month).<p>

<b>Rate Schedule</b><p>

<table border>
<tr>
<td>Dimensions</td><td>Ad size/placement (w" x h")<td>1x<td>3x<td>6x<td>12x     
<tr>
<td>Quarter page<td>inside, vert. 2.3 x 8 - horiz. 7.3 x 2.5<td>$95<td>$75<td>$65<td>$60
<tr>
<td>Quarter page<td>page 3, 7.33 x 2.5<td>$140<td>$110<td>$100<td>$90
<tr>
<td>Half page<td>inside, 7.3 x 5<td>$175<td>$140<td>$120<td>$105
<tr>
<td>Full page<td>inside, 7.3 x 10.25<td>$300<td>$240<td>$210<td>$180
<tr>
<td>Full page<td>back cover, max. 8.25 x 10.75<td>$550<td>$440<td>$385<td>$300
<tr>
<td>Preprinted insert<td>max. 8.5 x 11<td>$95<td>$75<td>$65<td>$60

</table>
<p>

All rates per insertion plus applicable sales tax. Discount for '95 AADA Convention participation: $500-$999, 25%; $1000-$1999, 35%; $2000 or more, 50%. Each additional or alternate spot color $100 extra. Minimum one-time setup fee for non-camera-ready artwork: $40 quarter page; $60 half page; $75 full page; may vary based on complexity of artwork.

For more information please e-mail <a href="mailto:aada@dasta.com">aada@dasta.com</a> or call (602) 468-0888 or (800) 678-3875.<p>

<p>
<hr size=3>
<p>

<font size=4><b>Publication Description</b><font size=3><p>

<b>The official monthly membership publication of the Arizona Legislative Representation</b>:  AADA's legislative and regulatory staff proactively address problems dealers face in day-to-day operations, and cultivates constructive relationships with lawmakers and regulatory officials. Members depend on the association's long-respected voice at the state capitol, and on its vigilant watch over legislation and regulation that affect the retail auto industry. AADA also offers guidance in choosing candidates to support in state, local and congressional elections, and coordinates member contributions to the Arizona Committee of Automotive Retailers and the Dealers Election Action Committee. For more information contact Marv Cronberg or Dolly Volini in the AADA legislative affairs office.<p>
<p>
<center><a href="frontdoor.html"><img src="gif/autobar.gif" border=0 alt="Auto Mall"></a></center>

<br>

<center>
<a href="index.html"><img src="gif/mainpagebutton.gif" border=0 alt="Main Page"></a>
<img src="gif/advertbutton.gif" border=0 alt="advertising">
<a href="endorsed.html"><img src="gif/endorsebutton.gif" border=0 alt="Calendar"></a>
<p>
[ <a href="index.html">Main Page</a> 
| Advertising Information
| <a href="endorsed.html">Endorsed and Recommended Vendors</a> ]
<br>
<br>
<br>
For inquiries or comments, e-mail: <a href="mailto:aada@dasta.com">aada@dasta.com</a><p>
<p>
</center>

<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="http://www.dasta.com/gif/dastasig.gif"
			alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 25 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996
				<a href="http://www.dasta.com">DASTA VendorCat, LLC</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">This site was designed by 
		<a href="http://www.dasta.com">DASTA VendorCat</a><br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of
	<a href="http://www.dasta.com/anet.html">Association-Net</a>
	<sup>TM</sup></font></p>
</center>


</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-92</DOCNO>
<DOCOLDNO>IA058-000947-B026-317</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/endorsed.html 206.97.63.16 19970109193536 text/html 2692
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:18:19 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 2521
Last-modified: Tue, 25 Jun 1996 23:05:46 GMT
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">

<HTML>
<HEAD>
<TITLE>Arizona Automobile Dealers Association - Vendor Services</TITLE>
</HEAD>

<body background="gif/aadatile6x.gif" bgcolor="#E5E0E0" text="#000628" link="#55083C" vlink="#00120A" ALINK="#220652">


<center>
<table border=2>
<tr><td>
<img src="gif/headervendor.gif" alt="About AADA">
</td></tr>
</table>
<br>
<br>
<center>
<hr size=4 width=250>
<font size=6>
<center><b>AADA Endorsed and<br>
Recommended Vendors</b></font></center>

<hr size=4 width=250>                        
<table width=50%>
<tr><td>
<p>
<u>Endorsed:</u>
<ul>
<li>American Fidelity Assurance Co.
<li>CARFAX
<li>Cellular One
<li>Employers Dental Services
<li>Humana Health Care
<li>Insurance Company of the West
<li>LDDS Communications
<li>National City Processing Co. (NPC)
<li>Steptoe & Johnson
<li>The Energy Group
<li>Van's Environmental Services
</ul>
<p>
<u>Recommended:</u>
<ul>
<li>DataLink
<li>DTN Auto
<li>Safety Kleen
<li>Southwest Labs
</ul>
</td></tr>
</table>
</center>
<p>
<hr size=3>
<p>
<center><a href="frontdoor.html"><img src="gif/autobar.gif" border=0 alt="Auto Mall"></a></center>

<p>
<center>
<a href="index.html"><img src="gif/mainpagebutton.gif" border=0 alt="Main Page"></a>
<a href="adinfo.html"><img src="gif/advertbutton.gif" border=0 alt="advertising"></a>
<img src="gif/endorsebutton.gif" border=0 alt="Calendar">
<p>
[ <a href="index.html">Main Page</a>
| <a href="adinfo.html">Advertising Information</a>
| Endorsed and Recommended Vendors ]
<br>
<br>
<center>For inquiries or comments, e-mail: <a href="mailto:aada@dasta.com">aada@dasta.com</a></center>
<p>
<p>
</center></center>
<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="http://www.dasta.com/gif/dastasig.gif"
			alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 25 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996
				<a href="http://www.dasta.com">DASTA VendorCat, LLC</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">This site was designed by 
		<a href="http://www.dasta.com">DASTA VendorCat</a><br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of
	<a href="http://www.dasta.com/anet.html">Association-Net</a>
	<sup>TM</sup></font></p>
</center>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-93</DOCNO>
<DOCOLDNO>IA058-000947-B026-335</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/autocap.html 206.97.63.16 19970109193544 text/html 8043
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:18:26 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 7872
Last-modified: Tue, 25 Jun 1996 23:05:50 GMT
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">

<HTML>
<HEAD>
<TITLE>Arizona Automobile Dealers Association - Lemon Law</TITLE>
</HEAD>

<body background="gif/aadatile6x.gif" bgcolor="#E5E0E0" text="#000628" link="#55083C" vlink="#00120A" ALINK="#220652">

<center>
<table border=2>
<tr><td>
<img src="gif/highway.gif">
</tr></td>
</table>
</center>

<p>
<hr size=3>
<p>

<center><font size=4><b>AUTOCAP</b><font size=3></center>
<p>
<p>
<hr size=3>
<p>


<img src="gif/purpleball.gif" hspace=5 align="center"><b>Automotive Consumer Action Program</b><p>

A complaint resolution service sponsored by the Arizona Automobile Dealers Association in cooperation with the National Automobile Dealers Association, and endorsed by the Maricopa County and Pima County Attorneys' offices.<p>

<img src="gif/purpleball.gif" hspace=5 align="center"><b>A Consumer Service</b><p>

AUTOCAP (Automotive Consumer Action Program) is a free, easy-to-use public service sponsored by the Arizona Automobile Dealers Association in cooperation with the National Automobile Dealers Association, and endorsed by the Maricopa County Attorney's office.<p>

If you have a problem involving a participating new-car or truck dealer and are unable to reach an understanding with dealership representatives, AUTOCAP can informally mediate the dispute.<p>

The AUTOCAP panel is composed of three consumers appointed by the Maricopa County Attorney's office, and three new-car dealers appointed by the Arizona Automobile Dealers Association.<p>

AUTOCAP programs nationwide follow standards set by the National Automobile Dealers Association. These standards have been endorsed by the U.S. Office of Consumer Affairs as "a major step in addressing automotive complaints."<p>

<img src="gif/purpleball.gif" hspace=5 align="center"><b>If you have a problem:</b><p>

We hope you won't have any problems with your dealership, but if you do, follow these steps:<p>

Step 1.  Talk to someone in authority:<br>
The sales manager for a sales problem, the service manager for a service problem, etc. Explain your concerns and what you believe to be the best way to resolve the problem. If this is unsuccessful, speak with the general manager or owner of the dealership.<p>

Step 2. Contact AUTOCAP:<br>
If you cannot reach an understanding with dealership personnel, or have trouble reaching the appropriate person at the dealership, call AUTOCAP for assistance:
(602) 468-0888   (800) 678-3875 or you may e-mail <a href="mailto:aada@dasta.com">aada@dasta.com</a>.<p>

AUTOCAP staff may be able to help resolve the matter by phone, or may ask you to submit a written complaint, including:<br>
<ul>
<li>A brief explanation of your concerns;
<li>What resolution you consider fair;
<li>Your vehicle's year, make, model, identification number (VIN), mileage, date of purchase and selling dealer;
<li>Copies of any documents relevant to your complaint;
<li>Your address and phone number.
</ul>

<p>

<img src="gif/purpleball.gif" hspace=5 align="center"><b>What AUTOCAP will do:</b><p>

Upon receipt of your written complaint, AUTOCAP staff will:<br>
<ul>
<li>Forward a copy of your complaint to the dealership involved;
<li>Require a written response from the dealership's authorized representative;
<li>Urge the dealer to contact you and attempt to resolve your concerns.
</ul>
<p>

If staff intervention does not result in resolution of the dispute, the case will be referred to the AUTOCAP Committee for review and recommendation.
Participating dealers must honor AUTOCAP decisions; however, if you are not satisfied with the panel's decision, you are free to pursue other remedies.<p>

<img src="gif/purpleball.gif" hspace=5 align="center"><b>AUTOCAP cannot mediate if:</b><br>
<ul>
<li>Legal action has already begun or an attorney is acting on behalf of either party;
<li>You no longer own the vehicle in question.
</ul>
<p>

<center>
<b>
Arizona AUTOCAP<br>
PO Box 32717<br>
Phoenix, AZ  85064<br>
(602) 468-9719<br>
(800) 678-3875<br>
</b>
</center>
<p>

<font size=5><b>Be a knowledgeable consumer!</b></font><p>

<img src="gif/purpleball.gif" hspace=5 align="center"><b>Buying your vehicle:</b><br>
<ul>
<li>Before you sign any agreements, take the time to read them, front and back, and be sure you understand them. Don't let anyone rush you through the sale.
<li>Test drive the vehicle before you agree to purchase it, to make sure it meets your expectations.
<li>If you're buying a used car, get it inspected by an independent mechanic.
<li>Never rely on verbal statements or agreements! Get it in writing, and get it signed by the sales manager.
</ul>
<p>

<img src="gif/purpleball.gif" hspace=5 align="center"><b>Servicing your vehicle:</b><br>
<ul>
<li>Before you sign the repair order, make sure it accurately states the services you requested, any cost estimate made, and whether you want replaced parts returned to you. (You cannot keep parts replaced under warranty.)
<li>Get a copy of the repair order when you sign it.
<li>When you pick up your car, get a copy of the invoice, even if the work was performed at no charge to you.
<li>Keep all repair orders and invoices for the time you own the car.
</ul>
<p>

Call AUTOCAP for a free copy of the National Automobile Dealers Association brochure titled "Your Money, Your Car," which offers additional tips for buying and servicing your vehicle.<p>

<img src="gif/purpleball.gif" hspace=5 align="center"><b>What consumers are saying about AUTOCAP:</b><p>

<BLOCKQUOTE>
"Agreeing to participate in AUTOCAP and to be bound by its decisions is an excellent way for automobile dealers to demonstrate their commitment to quality and customer service."<br>
Virginia Knaur<br>
U.S. Office of Consumer Affairs<p>

"Again, my deepest thanks and respect for your fine work. I am glad to say your office is a fine credit to us citizens of Arizona."<br>
Willis Blair<br>
Sun City, Arizona<p>

"Once again, thank you for your help and assistance. Please relate to the dealership my sincere thanks for standing behind their product and making the deal satisfactory for both of us."<br>
Helen Lothrop<br>
Boston, Massachusetts<p>

"As an attorney with no small amount of experience in helping others with their consumer complaints, I must say that your results are most impressive."<br>
Patrick Corbin<br>
Duncanville, Texas<p>

"Because of your efforts I was able to get the results I wanted but had not been able to obtain on my own. Hopefully I will not have to call on your organization again, but if I do, I know I will be in good hands."<br>
Karen Ostiller<br>
Beverly Hills, California<p></BLOCKQUOTE>
<p>
<center><a href="frontdoor.html"><img src="gif/autobar.gif" border=0 alt="Auto Mall"></a></center>
<p>
<p>
<hr size=3>
<p>


<center>
<a href="index.html"><img src="gif/mainpagebutton.gif" border=0 alt="Main Page"></a>
<p>
[ <a href="index.html">Main Page</a> ]
</center>
<br>
<br>
<br>
For inquiries or comments, e-mail: <a href="mailto:aada@dasta.com">aada@dasta.com</a><p>
<p>

<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="http://www.dasta.com/gif/dastasig.gif"
			alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 25 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996
				<a href="http://www.dasta.com">DASTA VendorCat, LLC</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">This site was designed by 
		<a href="http://www.dasta.com">DASTA VendorCat</a><br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of
	<a href="http://www.dasta.com/anet.html">Association-Net</a>
	<sup>TM</sup></font></p>
</center>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-94</DOCNO>
<DOCOLDNO>IA058-000947-B026-352</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/azcommittee.html 206.97.63.16 19970109193552 text/html 3602
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:18:34 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 3431
Last-modified: Tue, 25 Jun 1996 23:05:50 GMT
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">

<html>
<head>
<title>Press Release: Arizona Auto Centennial Committee</title>
</head>
<body background="gif/aadatile6x.gif" bgcolor="#E5E0E0" text="#000628" link="#55083C" vlink="#00120A" ALINK="#220652">
<hr>
<center>
<font size=4>
<b>CLASSIC/CONCEPT CARS TO GO ON DISPLAY ACROSS ARIZONA!</b>
</font>
</center>
<hr>
<p>
<center>
<img src="gif/oldcar2.gif">
</center>
<br>
<br>

<table width=100%>
<tr><td></td><td colspan=4><font size=5><a name="arizona">AADA Arizona Auto Centennial Committee:</a></font></td></tr>
<tr><td width=25%></td><td width=25%>Chairman Don Luke</td><td width=25%> Bill Luke Chrysler-Plymouth</td></tr>
<tr><td></td><td>George Childress</td><td> Childress Buick-Kia</td></tr>
<tr><td></td><td>Tony M. Coury Jr</td><td> Tony M. Coury Buick-GMC</td></tr>
<tr><td></td><td>Tex Earnhardt</td><td> Earnhardt Auto Centers</td></tr>
<tr><td></td><td>Lou Grubb</td><td> Grubb Automotive, Inc.</td></tr>
<tr><td></td><td>David Kimmerle</td><td> Sanderson Ford</td></tr>
<tr><td></td><td>Ray Korte III</td><td> Ray Korte Chevrolet-Geo</td></tr>
<tr><td></td><td>Frank McClure</td><td>Holmes Tuttle Ford</td></tr>
<tr><td></td><td>LaVelle McCoy</td><td>McCoy Motors</td></tr>
<tr><td></td><td>Stan Powell</td><td>Powell Volvo-Mazda</td></tr>
<tr><td></td><td>Ron Bergamo</td><td>Bergamo Communications Inc.</td></tr>
<tr><td></td><td>Art Brooks</td><td>Arizona Broadcasters Association</td></tr>
<tr><td></td><td>Bill Buck</td><td>Arizona Hobbyist Council</td></tr>
<tr><td></td><td>Evelyn Cooper</td><td>PhD., Arizona Historical Foundation</td></tr>
<tr><td></td><td>Marv Cronberg</td><td>AADA</td></tr>
<tr><td></td><td>John Fearing</td><td>Arizona Newspaper Association</td></tr>
<tr><td></td><td>Nancy Fikes</td><td>Chris-Town Mall</td></tr>
<tr><td></td><td>Sue Martinez</td><td>Westcor Partners</td></tr>
<tr><td></td><td>Bill Moore</td><td>Chrysler Corporation</td></tr>
<tr><td></td><td>Gordon Murphy</td><td>Arizona Bankers Association</td></tr>
</table>
<center>
<p>
<center><a href="frontdoor.html"><img src="gif/autobar.gif" border=0 alt="Auto Mall"></a></center>
<br>
<a href="index.html"><img src="gif/mainpagebutton.gif" border=0 alt="Main Page"></a>
<a href="arizona.html"><img src="gif/azautobutton.gif" border=0 alt="Arizona Auto Centennial"></a>
<p>
[ <a href="index.html">Main Page</a>
| <a href="arizona.html">Arizona Auto Centennial</a> ]

</center>
<br>
<br>
<br>
<center>For inquiries or comments, e-mail: <a href="mailto:aada@dasta.com">aada@dasta.com</a></center>
<p>
<p>

<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="http://www.dasta.com/gif/dastasig.gif"
			alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 25 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996
				<a href="http://www.dasta.com">DASTA VendorCat, LLC</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">This site was designed by 
		<a href="http://www.dasta.com">DASTA VendorCat</a><br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of
	<a href="http://www.dasta.com/anet.html">Association-Net</a>
	<sup>TM</sup></font></p>
</center>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-95</DOCNO>
<DOCOLDNO>IA058-000947-B026-371</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/adstan.html 206.97.63.16 19970109193603 text/html 17743
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:18:42 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 17571
Last-modified: Tue, 25 Jun 1996 23:05:51 GMT
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">

<HTML>
<HEAD>
<TITLE>Arizona Automobile Dealers Association - Advertising Standards</TITLE>
</HEAD>

<body background="gif/aadatile1x.gif" bgcolor="#E5E0E0" text="#000628" link="#55083C" vlink="#00120A" ALINK="#220652">



<center>
<table border=2>
<tr><td>
<img src="gif/headerabout.gif">
</td></tr>
</table>
</center>


<p>
<hr size=3>
<p>


<b>STANDARDS FOR ADVERTISING MOTOR VEHICLES</b><br>
October, 1993<p>

</center>


<b>Statement of Intent and Purpose:</b><br>
The intent and purpose of these Advertising Standards are to promote free, open and fair competition among the member dealers by providing to potential customers true and accurate advertising.  These advertising Standards are intended to be enforced as a condition of membership in the Association, and as a supplement to governmental action by the state of Arizona through the office of the Attorney General or the Motor Vehicle Division of the Arizona Department of Transportation, and the Federal Trade Commission, and to private action through the various offices of the Better Business Bureau.<p>

As a result of an investigation by the Federal Trade Commission in mid-1993, the staff of the Federal Trade Commission took the position that prior Standards 4, 5, 6, and 11 were anti-competitive in that a literal reading of the Standards would allow the finding of a violation of the Standard even though the accused dealer did, in fact, undersell all other member dealers, or did, in fact, finance any customer or allow the customer to "name his own deal," or truthfully made disparaging statements about another member dealer.  The Association has elected, at the suggestion of the Federal Trade Commission staff, to cure the concerns of the Federal Trade Commission staff by deleting Standards 4, 5, 6 and 11, adding wording recommended by the staff of the Federal Trade Commission as new Standards 4, 5 and 6 (leaving Standard 11 blank), and making more clear the intent and purpose of its actions in the context of the 
regulation of dealer member advertising.<p>

As an interpretive guide, should the evidence offered by an accused dealer establish by a preponderance of the evidence that the contents of the ad which is the subject of the complaint are, in fact, true, the complaint against the dealer shall be dismissed.  Thus, for example, in a challenge to an advertisement stating that a dealer "finances everyone," or rejects no credit, if the evidence establishes that the dealer, in fact, does finance everyone or does not reject any credit application, the complaint against the dealer shall be dismissed.<p>

It is further the intent of the Association to fully cooperate with the governmental authorities and private entity named above in the enforcement of the respective advertising rules of each.<p>

The advertising practices described in this Section apply to all forms of advertising including, but not limited to:  newspaper, radio, television, billboards, road signs, window signs, circulars, handouts and direct mail.<p>

<b>It shall be improper:</b><p>

1.      To advertise and offer any year, make, engine, size, model, type, equipment, price, trade-in allowance, or terms, or make other claims or conditions pertaining to this sale, lease or rental of motor vehicles, which are not truthful and clear.<p>

2.      To advertise for sale, lease, or rental a specific motor vehicle which is not in the possession of the dealer, owner, or advertiser at the time the production of the advertisement was completed.  Unless otherwise specified, the motor vehicle advertised for sale shall be in operable condition.  Upon request by any person responding to an advertisement, the advertiser thereof shall present such 
records as will prove that the requirements of this Paragraph are satisfied.  Further, no advertisement should imply that a number of vehicles exist at a price, when only a limited number of vehicles is available.  In such case, the ad should clearly state the stock number(s).<p>

3.      To advertise a new motor vehicle at a price that does not include standard factory equipment with which it is fitted or is ordinarily fitted, without disclosing such facts, or to eliminate or remove any such equipment for the purpose of advertising a low price.<p>

4.      Advertisements shall not contain false or misleading statements.<p>

5.      Advertisements shall not make false or misleading statements that a product or service has certain desirable qualities which a competing product or service does not.<p>

6.      Advertisers have the duty to substantiate all statements made in an advertisement. In interpreting these provisions of the Standards, AADA shall be guided by the precedent established by judicial and/or administrative decisions interpreting the Arizona Consumer Fraud Act and Section 5(a) of the Federal Trade Commission, 15 U.S.C. & 45(a).<p>

7.      To advertise by making the layout, headlines, illustrations or type size of an advertisement such that it may convey or permit an erroneous impression as to which motor vehicle(s) are offered at featured prices.  No advertised offer, expression, or display of prices, terms, down payments, trade-in allowance, cash differences or savings, shall itself be misleading.  Any qualification to such offer, expression, or display shall be clearly and conspicuously set forth in comparative type size, type style, location, and layout, to prevent deception.<p>

8.      To Advertise:<br>
        (a)     the price of a motor vehicle without including all charges, such as freight and dealer additions, that are required as part of the price the customer must pay for the motor vehicle, excepting state and local tax, license, title and dealer documentary service fees;<br>
        (b)     a price described as "unpaid balance" unless it is the full cash selling price. <br>
        (c)     a price which is not the full selling price, even when qualified with expressions such as "with trade," or "with acceptable trade," or other similar words.<p>

9.      To advertise new vehicles referring to "cost" or "below cost" unless the advertised "cost" shall be the invoice price paid by the advertiser to the manufacturer from whom the advertised vehicle was purchased.<p>

10.     To advertise:<br>
        (a)     using the words "discount," "savings," or other words of similar import, unless they refer only to the manufacturer's suggested retain price for new motor vehicles, plus dealer installed options which are itemized and priced at the manufacturer's suggested list price; or to current retail prices for used motor vehicles as described in a recognized guide book used in the trade area, properly adjusted for mileage, equipment and condition;<br>
        (b)     using the word "rebate," unless it refers only to the manufacturer's suggested retail price for new motor vehicles, plus dealer installed options which are itemized and priced at the manufacturer's suggested list price; or to current retail prices for used motor vehicles as described in a recognized guide book used in the trade area, properly adjusted for mileage, equipment and condition, and 
any such advertising shall clearly disclose whether the rebate is by the dealer, by the manufacturer, or both.<br>
        (c)     transactions generally known as "buydowns," unless they refer only to the manufacturer's suggested retail price for new motor vehicles plus dealer installed options which are itemized and priced at the manufacturer's suggested list price; or to current retail prices for used motor vehicles as described in a recognized guide book used in the trade area, properly adjusted for mileage, equipment and condition.  Any such advertising shall clearly disclose whether the buydown is by the dealer, by the manufacturer, or both.<p>

11.     This section left blank intentionally.<p>

12.     To use advertisements allowing for a specific trade-in amount, or range of amounts, unless referring only to the manufacturer's suggested retail price for new motor vehicles, plus dealer installed options which are itemized and priced at the manufacturer's suggested retail price; or to current retail prices for used motor vehicles as described in a recognized guide book used in the trade area, 
properly adjusted for mileage, equipment and condition.<p>

13.     To advertise as having for sale new motor vehicles, unless the advertiser is enfranchised by the manufacturer of the motor vehicle offered for sale as new.  In the case of a modified vehicle, such as converted van, the dealer may advertise using the conversion firm's name, and referring to the chassis manufacturer.  In no instance should the dealer advertise such vehicles solely by a chassis manufacturer's name unless enfranchised to sell that make of vehicle.<p>

14.     To advertise used motor vehicles so as to create the impression they are new.  Used motor vehicles of the current and preceding model year must be clearly identified as "used," "executive driven," "demonstrator," "driver training," "lease," or "fleet" vehicles.<p>

Taxicabs and police motor vehicles must be specifically identified as such.  Descriptions such as "low mileage" and "slightly driven" may be applied only when correct.  The terms "demonstrator's," "executive's." and "official's" shall not be used except upon vehicles:<br>
        (a)     that have never been sold to a member of the public;<br>
        (b)     which were used by the dealer agency or their employees as demonstrator vehicles pursuant to law; and except when such vehicles are advertised for sale, as described, by a franchised dealer for the same make motor vehicle.  Phrases such as "last of the remaining," "close-out," "final clearance," and others of similar import shall not be used in advertising used motor vehicles, so as to convey the impression that the motor vehicles of the current and preceding model year are offered in the same advertisement, the offerings shall be clearly separated by description, layout or art treatment.<p>

15.     To advertise the following:<br>
        (a)     "Executive's" or "official's" motor vehicles, unless they have been used primarily by the personnel or executive(s) of the motor vehicle manufacturer or any authorized dealer of the same make thereof, and unless such motor vehicles have not been sold or titled to a member of the public prior to the appearance of the advertisement.<br>
        (b)     the "list price," "manufacturer's list price," "suggested retail price," or similar terms in comparison with the dealer's actual selling price for demonstrators or executive vehicles, unless such vehicles have never been sold.  Further, the price difference shall not be described as a "savings," "discount," or by any other words of similar meaning.<p>

16.     To advertise motor vehicles owned by or in the possession of dealers without using the name of the dealer or the word "dealer" in the impression they are being offered by private parties.<p>

17.     To advertise that a motor vehicle has a specific or supposed mileage or odometer reading, unless such mileage representation can be substantiated by the advertiser.<p>

18.     To advertise the terms "auction," "auction special," or other terms of similar import, unless said terms shall be used in connection with motor vehicles offered or sold at a bona fide auction, i.e., top the highest bidder at a certain time, date and place.<p>

19.     To advertise equipment, accessory, or other merchandise as "free" if its cost, or any part of its cost, is included in the price of the motor vehicle, or if the motor vehicle can be purchased for a lesser price without such equipment, accessory or merchandise.<p>

20.     To advertise a "free" driving trial, unless it means a trial without any obligation to the consumer.<p>

21.     To advertise in violation of federal Truth-In-Lending and consumer leasing statutes as they apply to advertising (please see following page).  The statutes and their regulations, promulgated and enforced by the Federal Trade Commission and the Federal Reserve Board, are incorporated into these Standards.<p>

<center><b>
CREDIT ADVERTISING<br>
TRUTH IN LENDING-REGULATION Z<br>
</b></center>
<p>

Covers--All types of advertising: television, radio, newspapers, magazines, leaflets, flyers, catalogs, public address announcements, direct mail, window displays, billboards.<p>

<center><b>
CLOSED END CREDIT<br>
</b></center>
<p>

IF YOU ADVERTISE ANY ONE OR MORE OF THE FOLLOWING:<br>
<ol>
<li>The amount or percentage of the down payment.<br>
<li>Amount of any payment.<br>
<li>Amount of any finance charge.<br>
<li>Number of payments of period of repayment.<br>
</ol>
        
THEN YOU MUST STATE ALL OF THE FOLLOWING:<br>
<ol>
<li>The amount or percentage of the down payment.<br>
<li>The terms of repayment.<br>
<li>The "annual percentage rate," using that term, and, if the rate may be increased after consummation, that fact must be disclosed.<br>
</ol>

<p>

The advertising of credit terms may be made by giving one or more examples of typical extensions of credit stating all of the terms applicable to each example.  The advertisement shall set forth one or more examples which are, in fact, typical of the type of credit and terms usually and customarily made available.  Each shall be clearly and conspicuously identified as examples of typical transactions.<p>


<center><b>
LEASING ADVERTISING<br>
TRUTH-IN-LENDING--REGULATION M<br>
</b></center>
<p>

Covers--All types of advertising: television, radio, newspapers, magazines, leaflets, flyers, catalogs, public address announcements, direct mail, window displays, billboards.<p>

According to the Truth-in-Leasing regulations which became effective April 1, 1981 [Regulation M, 12CFR-213.5(c)], no advertisement concerning any consumer lease shall state the amount of any payment, the number of required payments, or any information concerning a payment to be made at the consummation of the lease, unless the advertisement also states each of the following items of information 
as applicable.<p>

<ol>
<li>that the transaction advertised is a lease;<br>
<li>the total amount of any consummation payment, or that no consummation payment is necessary;<br>
<li>the number, amounts, due dates or periods of scheduled payments, and the total of such payments;<br>
<li>a statement of whether or not the lessee has an option to purchase, and at what price and times;<br>
<li>a statement of the amount or method of determining the amount of any liabilities the lease imposes upon the lessee at the end of the lease term, and a statement that the lessee shall be liable for any difference between estimated value and realized value of leased property at the end of the term, if the lessee has such liability.  A violation of this regulation can subject a dealer to criminal liability.<br>
</ol>
<p>


<center><b>
FAILURE TO DISCLOSE A "BUY-DOWN"<br>
MAY  BE AN UNFAIR OR DECEPTIVE PRACTICE<br>
</b></center>
<p>

Dealers should be aware that the failure to properly treat "buy downs" in credit disclosures and advertising may be considered an unfair or deceptive practice under Federal and state law.<p>

Though the FTC has neither published any definitive guidelines on "buy-downs" nor instituted any enforcement action against a dealer, there is some evidence that the FTC has the matter under investigation.<p>


<center><b>
WHAT SHOULD THE DEALER DO?<br>
</b></center>
<p>


NADA strongly urges dealers to discuss a "buy-down" with their respective attorneys and to thoroughly review the details of any and all "buy-down" programs with their attorneys, prior to participating in such programs.  If dealers participate, they should do so only with a complete understanding of their responsibilities and risks, under both Federal and state laws.  Dealers are encouraged to consult with 
AADA on "buy-down" disclosure.<p>

</td></tr>

<tr>
<td></td>
<td>
<p>
<center><a href="frontdoor.html"><img src="gif/autobar.gif" border=0 alt="Auto Mall"></a></center>

<center>
<a href="index.html"><img src="gif/mainpagebutton.gif" border=0 alt="Main Page"></a>
<a href="bylaws.html"><img src="gif/bylawsbutton.gif" alt="Bylaws" border=0></a><br>
<img src="gif/advertbutton.gif" alt="Ad Standards" border=0>
<a href="committees.html"><img src="gif/committeebutton.gif" alt="committees" border=0></a>
<p>
[ <a href="index.html">Main Page</a>
| <a href="bylaws.html">Bylaws</a>
|Advertising Standards
| <a href="committees.html">Committees</a> ]
</center>
<br>
<br>

For inquiries or comments, e-mail: <a href="mailto:aada@dasta.com">aada@dasta.com</a><p>
<p>
<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="http://www.dasta.com/gif/dastasig.gif"
			alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 25 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996
				<a href="http://www.dasta.com">DASTA VendorCat, LLC</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">This site was designed by 
		<a href="http://www.dasta.com">DASTA VendorCat</a><br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of
	<a href="http://www.dasta.com/anet.html">Association-Net</a>
	<sup>TM</sup></font></p>
</center>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-96</DOCNO>
<DOCOLDNO>IA058-000947-B026-390</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/mall/trucksfin.html 206.97.63.16 19970109193615 text/html 2811
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:18:58 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 2640
Last-modified: Tue, 16 Jul 1996 23:13:50 GMT
</DOCHDR>
<html>

	<head>
		<title>Truck Dealerships</title>
	</head>

<body TEXT="#FFFFFF" LINK="#95A401" VLINK="#F4C7B2" ALINK="#FF0000" BGCOLOR="#000000">

<br>

<table width="100%">
<tr>

<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>

<td align="center">

<hr width="50%">
<h1><a name="truck">Truck Dealerships</a></h1>
<hr width="50%">
</td>

<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>
</tr>
</table><br><br>
<p>


<table width="100%" border="10">
<tr>
<td valign="top" width="50%">
<ul>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Arizona Great Basin Trucks</a></font><br>
<font size="+1">
1139 N. 19th Ave.<br>
Phoenix, AZ 85009<br>
602/272-4077</font>
 <p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Arizona Truck Center</a></font><br>
<font size="+1">
1795 S. 19th Ave.<br>
Phoenix, AZ 85009<br>
602/258-4500</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">I-10 Int Trucks</a></font><br>
<font size="+1">
2202 S. Central Ave<br>
Phoenix, AZ  85004<br>
602/254-9241</font>
</ul>
</td>
<td valign="top" width="50%">
<ul>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Inland Kenworth</a></font><br>
<font size="+1">
1815 S. 39th Ave.<br>
602/258-7791</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Sundance Truck Center</a></font><br>
<font size="+1">
2702 W. Encanto Blvd<br>
Phoenix,AZ 85009<br>
602/269-2181</font>

</ul>
</td>
</tr>
</table>
<br><br><br><br>

<center>

<hr width="50%">

<font size="+1">

Return to the <a href="http://aada.dasta.com/automall.html">graphics oriented Auto Mall</a>.
<p>
Return to the <a href="http://aada.dasta.com/autmall2.html">text oriented Auto Mall</a>.

</font>

</center>

<br><br><br><br><br><br>
<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="gif/dastasig.gif" alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 21 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996 <a href="http://www.dasta.com">Dasta VendorCat</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">"This site was designed by DASTA VENDORCAT,<br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of <a href="http://www.dasta.com/anet.html">Association-Net</a><sup>TM</sup>."</font></p>
</center>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-97</DOCNO>
<DOCOLDNO>IA058-000947-B026-401</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/cgi-bin/imagemap/manufacturers3.map 206.97.63.16 19970109193622 text/html 259
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:19:06 GMT
Server: Apache/1.0.5
Content-type: text/html
</DOCHDR>
<title>Mapping Server Error</title><h1>Mapping Server Error</h1>This server encountered an error:<p>Wrong number of arguments, client may not support ISMAP.
</DOC>
<DOC>
<DOCNO>WT08-B13-98</DOCNO>
<DOCOLDNO>IA058-000947-B026-416</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/mall/acurafin.html 206.97.63.16 19970109193628 text/html 2464
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:19:12 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 2293
Last-modified: Tue, 16 Jul 1996 23:14:06 GMT
</DOCHDR>
<html>

	<head>
		<title>Acura Dealerships</title>
	</head>

<body TEXT="#FFFFFF" LINK="#95A401" VLINK="#F4C7B2" ALINK="#FF0000" BGCOLOR="#000000">

<br>

<table width="100%">
<tr>

<td width="50%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>

<td align="center">

<hr width="50%">
<h1><a name="acura">Acura Dealerships</a></h1>
<hr width="50%">

</td>

<td width="50%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>

</tr>

</table><br><br>

<p>



<table width="100%" border="10">
<tr>
<td valign="top" width="50%">

<ul>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Beaudry Motor Company</a></font><br>
<font size="+1">
4646 E. 22nd St.<br>
Tucson, AZ 85732<br>
520/748-1000</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Bell Acura</a></font><br>
<font size="+1">
1234 W. Bell Rd.<br>
Phoenix, AZ 85023<br>
602/375-3750</font>
</ul>
</td>
<td valign="top" width="50%">
<ul>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Scottsdale Acura</a></font><br>
<font size="+1">
6825 E. McDowell Rd.<br>
Scottsdale, AZ 85257<br>
602/990-3900</font>

</ul>

</td>
</tr>
</table>



<br><br><br><br>

<center>

<hr width="50%">

<font size="+1">

Return to the <a href="http://aada.dasta.com/automall.html">graphics oriented Auto Mall</a>.
<p>
Return to the <a href="http://aada.dasta.com/automall2.html">text oriented Auto Mall</a>.

</font>

</center>

<br><br><br><br><br><br>

<table>



	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="gif/dastasig.gif" alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 21 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996 <a href="http://www.dasta.com">Dasta VendorCat</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">"This site was designed by DASTA VENDORCAT,<br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of <a href="http://www.dasta.com/anet.html">Association-Net</a><sup>TM</sup>."</font></p>
</center>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-99</DOCNO>
<DOCOLDNO>IA058-000947-B026-439</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/mall/audifin.html 206.97.63.16 19970109193638 text/html 2285
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:19:21 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 2114
Last-modified: Tue, 16 Jul 1996 23:14:05 GMT
</DOCHDR>
<html>

	<head>
		<title>Audi Dealerships</title>
	</head>

<body TEXT="#FFFFFF" LINK="#95A401" VLINK="#F4C7B2" ALINK="#FF0000" BGCOLOR="#000000">

<br>
<table width="100%">

<tr>
<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>

<td align="center">

<hr width="50%">
<h1><a name="audi">Audi Dealerships</a></h1>
<hr width="50%">

</td>

<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>

</tr>

</table><br><br>
<p>



<table width="100%" border="10">

<tr>
<td valign="top" width="50%">
<ul>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Beaudry Motor Company</a></font><br>
<font size="+1">
4646 E. 22nd St.<br>
Tucson, AZ 85732<br>
520/748-1000</font>
</ul>
</td>
<td valign="top" width="50%">
<ul>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Joe Florek Volkswagen Audi</a></font><br>
<font size="+1">
1050 W. Hwy. 66<br>
Flagstaff, AZ 86001<br>
520/774-3393</font>

</ul>
</td>
</tr>
</table>


<br><br><br><br>

<center>

<hr width="50%">

<font size="+1">

Return to the <a href="http://aada.dasta.com/automall.html">graphics oriented Auto Mall</a>.
<p>
Return to the <a href="http://aada.dasta.com/autmall2.html">text oriented Auto Mall</a>.

</font>

</center>

<br><br><br><br><br><br>

<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="gif/dastasig.gif" alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 21 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996 <a href="http://www.dasta.com">Dasta VendorCat</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">"This site was designed by DASTA VENDORCAT,<br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of <a href="http://www.dasta.com/anet.html">Association-Net</a><sup>TM</sup>."</font></p>
</center>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-100</DOCNO>
<DOCOLDNO>IA058-000947-B026-452</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/mall/bentleyfin.html 206.97.63.16 19970109193648 text/html 2058
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:19:32 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 1887
Last-modified: Tue, 16 Jul 1996 23:14:05 GMT
</DOCHDR>
<html>

	<head>
		<title>Bentley Dealerships</title>
	</head>


<body TEXT="#FFFFFF" LINK="#95A401" VLINK="#F4C7B2" ALINK="#FF0000" BGCOLOR="#000000">

<br>
<table width="100%">

<tr>
<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>

<td align="center">
<hr width="50%">
<h1><a name="bentley">Bentley Dealerships</a></h1>
<hr width="50%">
</td>

<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>

</tr>

</table><br><br>
<p>


<table width="100%" border="10">
<tr>
<td valign="top">


<ul>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Auto Koenig Scottsdale</a></font><br>
<font size="+1">
9620 N. Scottsdale Rd.<br>
Scottsdale, AZ 85251<br>
602/945-4545</font>

</ul>

</td>
</tr>
</table>


<br><br><br><br>

<center>

<hr width="50%">

<font size="+1">
Return to the <a href="http://aada.dasta.com/automall.html">graphics oriented Auto Mall</a>.
<p>
Return to the <a href="http://aada.dasta.com/autmall2.html">text oriented Auto Mall</a>.
</font>

</center>

<br><br><br><br><br><br>

<table>



	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="gif/dastasig.gif" alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 21 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996 <a href="http://www.dasta.com">Dasta VendorCat</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">"This site was designed by DASTA VENDORCAT,<br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of <a href="http://www.dasta.com/anet.html">Association-Net</a><sup>TM</sup>."</font></p>
</center>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-101</DOCNO>
<DOCOLDNO>IA058-000947-B026-470</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/mall/bmwfin.html 206.97.63.16 19970109193656 text/html 2461
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:19:39 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 2290
Last-modified: Tue, 16 Jul 1996 23:14:04 GMT
</DOCHDR>
<html>

<head>
	<title>BMW Dealerships</title>
</head>

<body TEXT="#FFFFFF" LINK="#95A401" VLINK="#F4C7B2" ALINK="#FF0000" BGCOLOR="#000000">

<br>
<table width="100%">
<tr>

<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>

<td align="center">

<hr width="50%">
	<h1><a name="bmw">BMW Dealerships</a></h1>
<hr width="50%">

</td>

<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>

</tr>

</table><br><br>
<p>


<table width="100%" border="10">
<tr>
<td valign="top" width="50%">

<ul>
<li><a href="http://aada.dasta.com/notyet.html"><font size="+2">Camelback BMW</font><br></a>
<font size="+1">
1144 E. Camelback Rd.<br>
Phoenix, AZ 85014<br>
602/274-1000</font>
<p>
<li><a href="http://aada.dasta.com/notyet.html"><font size="+2">Chapman Scottsdale Autoplex</font><br></a>
<font size="+1">
6601 E. McDowell Rd.<br>
Scottsdale, AZ 85257<br>
602/949-7600</font>
</ul>
</td>
<td valign="top" width="50%">
<ul>
<li><a href="http://aada.dasta.com/notyet.html"><font size="+2">Don Mackey BMW/SAAB<br></font></a>
<font size="+1">
4635 E.22nd St.<br>
Tucson,AZ 85741<br>
520/748-1333</font>

</ul>

</td>
</tr>
</table>


<br><br><br><br>

<center>

<hr width="50%">

<font size="+1">
Return to the <a href="http://aada.dasta.com/automall.html">graphics oriented Auto Mall</a>.
<p>
Return to the <a href="http://aada.dasta.com/autmall2.html">text oriented Auto Mall</a>.
</font>

</center>

<br><br><br><br><br><br>


<table>
	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="gif/dastasig.gif" alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 21 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996 <a href="http://www.dasta.com">Dasta VendorCat</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">"This site was designed by DASTA VENDORCAT,<br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of <a href="http://www.dasta.com/anet.html">Association-Net</a><sup>TM</sup>."</font></p>
</center>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-102</DOCNO>
<DOCOLDNO>IA058-000947-B027-7</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/mall/buickfin.html 206.97.63.16 19970109193703 text/html 4773
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:19:46 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 4602
Last-modified: Wed, 17 Jul 1996 17:08:09 GMT
</DOCHDR>
<html>
	<head>
		<title>Buick Dealerships</title>
	</head>

<body TEXT="#FFFFFF" LINK="#95A401" VLINK="#F4C7B2" ALINK="#FF0000" BGCOLOR="#000000">

<br>

<table width="100%">

<tr>

<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>

<td align="center">
<hr width="50%">

<h1><a name="buick">Buick Dealerships</a></h1>

<hr width="50%">
</td>

<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>

</tr>

</table><br><br>

<p>


<table width="100%" border="10">
<tr>
<td valign="top" width="50%">

<ul>

<li><font size="+2"><a href="http://aada.dasta.com/~bromm">Bromm Chevrolet, Oldsmobile, Buick</a></font><br>
<font size="+1">
P.O. Drawer 1389<br>
Wickenburg, AZ 85358<br>
520/258-4120</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Childress Buick/Kia</a></font><br>
<font size="+1">
2223 W. Camelback Rd.<br>
Phoenix, AZ 85061<br>
602/249-1133</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Healy Auto Center</a></font><br>
<font size="+1">
Hwy 60<br>
Globe, AZ 85502<br>
520/425-3283</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Hendric Buick-Pontiac-GMC Truck</a></font><br>
<font size="+1">
777 S. Arizona Blvd.<br>
Coolidge, AZ 85228<br>
602/723-5444</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Karl Moedl Automotive Group</a></font><br>
<font size="+1">
1125 E. 32nd St.<br>
Yuma, AZ 85365<br>
520/726-6970</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Kempton Chevrolet Buick</a></font><br>
<font size="+1">
715 Fifth St.<br> 
Safford, AZ 85548<br>
520/428-0252</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Lawley Automotive Center</a></font><br>
<font size="+1">
2900 E. Fry Blvd.<br>
Sierra Vista, AZ 85635<br>
520/458-2141</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Liberty Buick</a></font><br>
<font size="+1">
8737 W. Bell Rd<br>
Peoria,AZ 85182 <br>
602/933-5000</font>
</ul>
</td>
<td valign="top" width="50%">
<ul>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Pitre Buick/Isuzu/Suzuki</a></font><br>
<font size="+1">
6640 E. McDowell Rd.<br>
Scottsdale, AZ 85257<br>
602/994-9451</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Royal Buick</a></font><br>
<font size="+1">
4333 E. Speedway<br>
Tucson, AZ 85712 <br>
520/795-0760</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Southern Arizona Auto Company</a></font><br>
<font size="+1">
1200 "G" Ave.<br>
Douglas, AZ 85607<br>
520/364-2424</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Steve Coury Buick Pontiac GMC Trucks</a></font><br>
<font size="+1">
18 N. Main<br>
Cottonwood, AZ 86326<br>
520/634-9576</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Tim's Buick Pontiac GMC Toyota</a></font><br> 
<font size="+1">
P.O. Box 10610<br>
1006 Commerce Drive<br>
Prescott,AZ 86304<br>
520/445-7350</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Tony M. Coury Buick &amp; GMC Trucks</a></font><br>
<font size="+1">
525 W. Main St.<br>
Mesa, AZ 85201<br>
602/834-0101</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Tyrrell Chevrolet Buick Mazda Geo</a></font><br>
<font size="+1">
P.O. Box 1909<br>
1118 W. Hwy 66<br>
520/774-2794</font>
<p>
</ul>

</td>
</tr>
</table>


<br><br><br><br>

<center>

<hr width="50%">

<font size="+1">

Return to the <a href="http://aada.dasta.com/automall.html">graphics oriented Auto Mall</a>.
<p>
Return to the <a href="http://aada.dasta.com/autmall2.html">text oriented Auto Mall</a>.

</font>

</center>

<br><br><br><br><br><br>

<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="gif/dastasig.gif" alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 21 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996 <a href="http://www.dasta.com">Dasta VendorCat</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">"This site was designed by DASTA VENDORCAT,<br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of <a href="http://www.dasta.com/anet.html">Association-Net</a><sup>TM</sup>."</font></p>
</center>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-103</DOCNO>
<DOCOLDNO>IA058-000947-B027-25</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/mall/cadillacfin.html 206.97.63.16 19970109193711 text/html 3970
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:19:53 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 3799
Last-modified: Tue, 16 Jul 1996 23:14:04 GMT
</DOCHDR>
<html>
	<head>
		<title>Cadillac Dealerships</title>
	</head>

<body TEXT="#FFFFFF" LINK="#95A401" VLINK="#F4C7B2" ALINK="#FF0000" BGCOLOR="#000000">

<br>

<table width="100%">

<tr>
<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>

<td align="center">
<hr width="50%">

<h1><a name="cadillac">Cadillac Dealerships</a></h1>

<hr width="50%">
</td>

<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>

</tr>

</table><br><br>

<p>


<table width="100%" border="10">
<tr>
<td width="50%" valign="top">

<ul>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Bill Alexander</a></font><br>
<font size="+1">
801 E. 32nd St.<br>
Yuma, AZ 85364 <br>
520/344-2200</font>

<p>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Cliff Findlay Auto</a></font><br>
<font size="+1">
3730 N. Stockton Hill Rd.<br>
Kingman, AZ 86101<br> 
800/574-4417</font>

<p>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Coulier Cadillac</a></font><br>
<font size="+1">
1188 E. Camelback Rd.<br>
Phoenix, AZ 85014<br>
602/264-1183</font>


<p>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Cobre Valley Motors</a></font><br>
<font size="+1">
1500 N. Broad<br>
Globe, AZ 85501<br>
520/425-4487</font>

<p>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Gary Cropper Auto</a></font><br> 
<font size="+1">
1990 N. Pinal Ave.<br>
Casa Grande, AZ 85222<br>
520/836-2147</font>

<p>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Horne Auto</a></font><br>
<font size="+1">
PO Box 2767 <br>
651 E. Deuce of Clubs<br>
520/537-5500</font>
</ul>
</td>
<td  width="50%" valign="top">
<ul>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">The Johnson Motors Corp.</a></font><br>
<font size="+1">
804 First Ave.<br>
Casa Grande, AZ 85548<br>
520/428-0140</font>

<p>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Kachina Cadillac</a></font><br>
<font size="+1">
1200 N. Scottsdale Rd.<br>
Scottsdale, AZ 85257<br>
602/945-1200</font>

<p>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Lawley Auto Center</a></font><br>
<font size="+1">
2900 E. Fry Blvd.<br>
Sierra Vista, AZ 85635<br>
520/458-2141</font>

<p>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Mackey Olds-Cadillac</a></font><br>
<font size="+1">
2121 E. Broadway<br>
Tucson, AZ 85719<br>
602/345-7700</font>

<p>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">McCoy Motors</a></font><br>
<font size="+1">
361 N. Switzer Canyon Dr.<br>
Flagstaff, AZ 86001<br>
520/774-1472</font>
 
</ul>
</td>
</tr>
</table>

<br><br><br><br>

<center>

<hr width="50%">

<font size="+1">

Return to the <a href="http://aada.dasta.com/automall.html">graphics oriented Auto Mall</a>.
<p>
Return to the <a href="http://aada.dasta.com/autmall2.html">text oriented Auto Mall</a>.

</font>

</center>

<br><br><br><br><br><br>

<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="gif/dastasig.gif" alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 21 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996 <a href="http://www.dasta.com">Dasta VendorCat</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">"This site was designed by DASTA VENDORCAT,<br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of <a href="http://www.dasta.com/anet.html">Association-Net</a><sup>TM</sup>."</font></p>
</center>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-104</DOCNO>
<DOCOLDNO>IA058-000947-B027-40</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/mall/chevroletfin.html 206.97.63.16 19970109193724 text/html 7238
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:20:01 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 7067
Last-modified: Mon, 23 Dec 1996 22:42:16 GMT
</DOCHDR>
<html>

	<head>
		<title>Chevrolet Dealerships</title>
	</head>

<body TEXT="#FFFFFF" LINK="#95A401" VLINK="#F4C7B2" ALINK="#FF0000" BGCOLOR="#000000">

<br>
	<table width="100%">
<tr>

<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>

<td align="center">	
<hr width="50%">

<h1><a name="chevrolet">Chevrolet Dealerships</a></h1>

<hr width="50%">
</td>

<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>

</tr>

</table><br><br>

<p>
<table width="100%" border="10">
<tr>
<td width="50%" valign="top">

<ul>

<li><font size="+2"><a href="http://aada.dasta.com/~bromm">Bromm Chevrolet, Oldsmobile, Buick</a></font><br>
<font size="+1">
P.O. Drawer 1389<br>
Wickenburg, AZ 85358 <br>
520/258-4120</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Brown &amp; Brown Chevrolet</a></font><br>
<font size="+1">
145 E. Main St.<br>
Mesa, AZ 85211<br>
602/833-3456</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Cake Chevrolet</a></font><br>
<font size="+1">
1200 E. 2nd St.<br>
Winslow, AZ 86047<br>
520/289-4681</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Chapman Chevrolet</a></font><br>
<font size="+1">
1717 E. Baseline Rd.<br> 
Tempe, AZ 85283<br>
602/838-1234</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Cliff Findlay Auto</a></font><br>
<font size="+1">
3730 N. Stockton Hill Rd.<br> 
Kingman, AZ 86101<br>
800/574-4417</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Cobre Valley Motors</a></font><BR>
<font size="+1">
1500 N. Broad<br>
Globe, AZ 85501<br>
520/425-4487</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Courtesy Chevrolet</a></font><br>
<font size="+1">
1233 E. Camelback Rd.<br>
Phoenix, AZ 85011<br>
602/279-3232</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Davis Chevrolet</a></font><br>
<font size="+1">
PO Box 1930<br>
Highway 160,<br>
Flagstaff, AZ 86045<br>
520/283-6244</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Garrett Motors</a></font><br>
<font size="+1">
197 N. Arizona Blvd.<br>
Coolidge, AZ 85228<br>
520/723-5401</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Gary Cropper Auto</a></font><br>
<font size="+1">
1990 N. Pinal Ave.<br>
Casa Grande, AZ 85222<br>
520/836-2147</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Horne Auto</a></font><br>
<font size="+1">
PO Box 2767<br>
651 E. Deuce of Clubs <br>
520/537-5500</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Lou Grubb Chev/Geo</a></font><br>
<font size="+1">
2645 W. Camelback Rd. <br>
Phoenix, AZ  85017<br>
602/242-5555</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Joe Gambino Chevrolet/Geo</a></font><br>
<font size="+1">
1000 Sandrello Dr.<br>
Prescott, AZ 86301<br>
602/932-4389</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Kempton Chevrolet Buick</a></font><br>
<font size="+1">
715 Fifth St.<br>
Safford, AZ 85546<br>
520/428-0252</font>
</ul>
</td>
<td valign="top" width="50%">
<ul>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Lamb Chevrolet</a></font><br>
<font size="+1">
828 Gail Gardner Way<br>
Prescott, AZ 86301<br>
520/778-5262</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Larry Green Chevrolet Oldsmobile Geo</a></font><br>
<font size="+1">
PO Box 1839<br>
737 S. Main<br>
Cottonwood, AZ  86326<br>
520/634-2229</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Midway Chevrolet</a></font><br>
<font size="+1">
2323 W. Bell Rd.<br> 
Phoenix, AZ 85023<br>
602/966-0102</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Munday Motors</a></font><br>
<font size="+1">
1201 S Hwy 80<br>
Benson, AZ 85602 <br>
520/586-2236</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/orielly/">O'Reilly Chevrolet Geo</a></font><br>
<font size="+1">
6100 E. Broadway<br>
Tucson, AZ 85732<br>
520/747-8000</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Patterson Motors</a></font><br>
<font size="+1">
70 E. Commercial St.<br>
St. Johns, AZ 85936<br>
520/337-2226</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Ray Korte Chevrolet</a></font><br>
<font size="+1">
7224 E. McDowell Rd.<br>
Scottsdale, AZ 85257<br>
602/947-3535</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Seabury Chevrolet-Geo</a></font><br>
<font size="+1">
3201 Chevy Lane<br>
Yuma, AZ 85365<br>
520/726-5500</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Southern Arizona Auto Company</a></font><br>
<font size="+1">
1200 "G" Ave.<br>
Douglas, AZ 85607<br>
520/364-2424</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Southwest Chevrolet</a></font><br>
<font size="+1">
2520 Industrial Park Place<br>
Parker, AZ  85344 <br>
520/569-2228</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/~star">Star Chevrolet</a></font><br>
<font size="+1">
3200 E. Fry Blvd. <br>
Sierra Vista, AZ 85635<br> 
520/458-6520</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Thoroughbred Chevrolet</a></font><br>
<font size="+1">
P.O Box 400<br>
2121 N.Arizona Avenue<br>
Chandler, AZ 85244<br>
602/899-0131</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Tyrrell Chevrolet Buick Mazda Geo</a></font><br> 
<font size="+1">
P.O. Box 1909<br>
1118 W. Hwy66<br>
Flagstaff, AZ 86001<br>
520/774-2794</font>
 
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Watson Chevrolet</a></font><br> 
<font size="+1">
P.O. Box 78180<br>
625 W.Automall<br>
Tucson, AZ 85703<br>
520/292-1500</font>
   

 
</ul>
</td>
</tr>
</table>
<br><br><br><br>

<center>

<hr width="50%">

<font size="+1">

Return to the <a href="http://aada.dasta.com/automall.html">graphics oriented Auto Mall</a>.
<p>
Return to the <a href="http://aada.dasta.com/automall2.html">text oriented Auto Mall</a>.

</font>

</center>

<br><br><br><br><br><br>


<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="gif/dastasig.gif" alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 21 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996 <a href="http://www.dasta.com">Dasta VendorCat</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">"This site was designed by DASTA VENDORCAT,<br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of <a href="http://www.dasta.com/anet.html">Association-Net</a><sup>TM</sup>."</font></p>
</center>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-105</DOCNO>
<DOCOLDNO>IA058-000947-B027-56</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/mall/chryslerfin.html 206.97.63.16 19970109193738 text/html 7287
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:20:21 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 7116
Last-modified: Wed, 28 Aug 1996 14:19:27 GMT
</DOCHDR>
<html>

        <head>
                <title>Chrysler Dealerships</title>
        </head>

<body TEXT="#FFFFFF" LINK="#95A401" VLINK="#F4C7B2" ALINK="#FF0000" BGCOLOR="#000000">

<br>

<table width="100%">
<tr>
<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>
<td align="center">

<hr width="50%">

<h1><a name="chrysler">Chrysler Dealerships</a></h1>

<hr width="50%">

</td>
<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>
</tr>

</table><br><br>

<p>

<table width="100%" border="10">
<tr>
<td valign="top" width="50%">
<ul>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Arnold Motor Sales</a></font></br>
<font size="+1">
735 Main St.<br>
Phoenix, AZ 85273<br>
520/689-2481</font>

<p>

<li><font size="+2"><a href="http://aada.dasta.com/~avondale">Avondale Motors</a></font><br>
<font size="+1">
803 East Van Buren<br>
Avondale, AZ  85323<br>
602/925-0011</font>

<p>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Biddulph Pontiac/ GMC/ Chrysler/ Plymouth/ Jeep Eagle</a></font></br>
<font size="+1">
4510 W. Glendale Ave.<br>
Glendale, AZ 85301<br>
602/931-9111</font>

<p>

<li><font size="+2"><a href="http://aada.dasta.com/~billluke">Bill Luke Chrysler Plymouth Jeep Eagle Dodge</a></font></br>
<font size="+1">
2425 W.Camelback Rd.<br>
Phoenix,AZ 85015<br>
602/249-1234</font>

<p>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Chapman Auto Center</a></font></br>
<font size="+1">
198 N. Beeline Hwy.<br>
Payson, AZ 85547<br>
520/474-5261</font>

<p>

<li><font size="+2"><a href="http://aada.dasta.com/~corral">The Corral Chrysler Plymouth Dodge Jeep Eagle</a></font></br>
<font size="+1">
669 N. Lake Havasu<br>
Lake Havasu City, AZ 86403<br>
520/855-5153</font>

<p>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Cropper's Nogales Auto Center</a></font></br>
<font size="+1">
1831 N. Grand Ave.<br>
Nogales, AZ 85521<br>
520/836-2147</font>

<p>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Darner Motor Sales</a></font></br>
<font size="+1">
837 W. Main St.<br>
Mesa, AZ 85201<br>
602/969-7311</font>

<p>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Diamond Dodge/Chrysler/Plymouth</a></font></br>
<font size="+1">
350 Switzer Canyon Dr.<br>
Flagstaff, AZ 86001<br>
602/779-3641</font>
<p>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Earnhardt Chrysler Plymouth</a></font></br>
<font size="+1">
577 E. Baseline Rd.<br>
Tempe, AZ  85283<br>
602/345-7700</font>

<p>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Ed Moses Chrysler Plymouth</a></font></br>
<font size="+1">
701 W. Auto Drive<br>
Tucson, AZ 85705<br>
520/888-8000</font>

<p>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Fisher Chrysler Plymouth Dodge Jeep Eagle</a></font></br>
<font size="+1">
349 E. 32nd St.<br>
Yuma, AZ 85364<br>
520/344-2650</font>

<p>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Galloway Chrysler Plymouth Jeep Eagle</a></font></br>
<font size="+1">
5200 E. Speedway Blvd.<br> 
Tucson, AZ 85712<br>
520/327-5561</font>
</ul>
</td>
<td valign="top" width="50%">
<ul>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Hatch Brothers</a></font></br>
<font size="+1">
1623 Thatcher Blvd.<br>
Safford, AZ  85545<br>
520/428-6000</font>
 
<p>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Hatch Motor</a></font></br>
<font size="+1">
PO Box 540<br>
117 S. Main<br>
Snowflake, AZ  85937<br>
520/536-4753</font>

<p>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Larry Miller Chrysler Plymouth Jeep-Eagle</a></font></br>
<font size="+1">
4600 W. Glendale Ave.<br>
Glendale, AZ 85301<br>
602/842-8500</font>

<p>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Martin Swanty Chrysler Plymouth Dodge Jeep Eagle</a></font></br> 
<font size="+1">
2640 E. Andy Devine Ave.<br>
Kingman,AZ 86401<br>
520/753-3131</font>

<p>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Moore Chrysler Plymouth</a></font></br>
<font size="+1">
8600 W. Bell Rd.<br>
Peoria, AZ 85382<br>
602/972-6004</font>

<p>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Munday Motors</a></font></br>
<font size="+1">
1201 S Hwy 80<br>
Benson, AZ 85602<br>
520/586-2236</font>

<p>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">O'Reilly Chrysler Plymouth Dodge Jeep Eagle</a></font></br>
<font size="+1">
1901 S. Highway 92<br>
Sierra Vista, AZ 85635<br>
520/458-8000</font>

<p>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Oxendale Chrysler Plymouth Dodge Jeep Eagle</a></font></br>
<font size="+1">
792 Hwy 89-A East<br>
Cottonwood, AZ 86326<br>
520/654-5450</font>

<p>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Pitre Automotive</a></font></br>
<font size="+1">
6460 E. McDowell Rd.<br>
Scottsdale, AZ 85257<br>
602/994-4999</font>

<p>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Pitre Chrysler-Plymouth-Jeep Eagle</a></font></br>
<font size="+1">
3121 E. Bell Rd.<br>
Phoenix, AZ 85022<br>
602/493-8000</font>

<p>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Swanty's Chrysler Plymouth Dodge Jeep Eagle</a></font></br>
<font size="+1">
2640 E. Andy Devine Ave.<br>
Kingman,AZ 86401 <br>
520/704-2222</font>
 
<p>

<li><font size="+2"><a href="http://companion.org/~york">York Motors</a></font></br>
<font size="+1">
209 North Montezuma Road<br>
Prescott, AZ  86301<br>
520/445-4970<br>
800/894-4970</font>

</ul>
</td>
</tr>
</table>
<br><br><br><br>


<center>

<hr width="50%">

<font size="+1">


Return to the <a href="http://aada.dasta.com/automall.html">graphics oriented Auto Mall</a>.
<p>
Return to the <a href="http://aada.dasta.com/automall2.html">text oriented Auto Mall</a>.

</font>

</center>

<br><br><br><br><br><br>

<table>

        <tr>
                        <th colspan="2"><hr></th>
        </tr>
        
        <tr>
                <td valign="middle"><a href="http://www.dasta.com">
                        <img src="gif/dastasig.gif" alt="DASTA VendorCat logo" border="0"></a></td>
                        
                <td>
                        <font size="-1">Last Updated: 21 Jun 96<br>
                        Comments/Questions: <a href="mailto:webmaster@dasta.com">webmaster@dasta.com</a></font></br>
                        
                        Copyright &#169; 1996 <a href="http://www.dasta.com">Dasta VendorCat</a>.
                                All rights reserved.</font>
                </td>
        </tr>
        
        <tr>
                <th colspan="2"><hr></th>
        </tr>
        
</table>

<center>
        <p><font size="-1">"This site was designed by DASTA VENDORCAT,<br>
        the Nation's Leading Internet Presence Provider for Associations<br>
        and the Sponsor of <a href="http://www.dasta.com/anet.html">Association-Net</a><sup>TM</sup>."</font></p>
</center>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-106</DOCNO>
<DOCOLDNO>IA058-000947-B027-66</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/mall/dodgefin.html 206.97.63.16 19970109193745 text/html 6145
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:20:28 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 5974
Last-modified: Wed, 28 Aug 1996 14:22:28 GMT
</DOCHDR>
<html>

<head>
        <title>Dodge Dealerships</title>
</head>

<body TEXT="#FFFFFF" LINK="#95A401" VLINK="#F4C7B2" ALINK="#FF0000" BGCOLOR="#000000">

<br>

<table width="100%">
<tr>
<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>
<td align="center">
<hr width="50%">

<h1><a name="dodge">Dodge Dealerships</a></h1>

<hr width="50%">

</td>
<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>
</tr>

</table>
<br><br>

<p>
<table width="100%" border="10">
<tr>
<td valign="top" width="50%">
<ul>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Ames Brothers Motors</a></font><br>
<font size="+1">
1001 E. Third St.,<br> 
Flagstaff, AZ 86047<br>
520/289-3354</font>

<p>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Arnold Motor Sales</a></font><br>
<font size="+1">
1201 S Hwy 80,<br> 
Benson, AZ 85602<br>
520/689-2481</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/~avondale">Avondale Dodge</a></font><br>
<font size="+1">
803 E. Van Buren,<br> 
Avondale, AZ 85323<br>
602/925-0011</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Bell Dodge</a></font><br>
<font size="+1">
1645 W. Bell Rd.,<br> 
Phoenix, AZ 85023<br>
602/942-9000</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Bill Breck Dodge</a></font><br>
<font size="+1">
4220 E. 22nd St.,<br> 
Tucson, AZ 85711<br>
520/745-1000</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/~billluke">Bill Luke Chrysler Plymouth Jeep Eagle Dodge</a></font><br>
<font size="+1">
2425 W. Camelback Rd.<br>
Phoenix, AZ  85015<br>
602/249-1234</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Chapman Auto Center</a></font><br>
<font size="+1">
198 N. Beeline Hwy.,<br> 
Payson, AZ 85547<br>
520/474-5261</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Chapman Scottsdale Autoplex</a></font><br>
<font size="+1">
6601 E. McDowell Rd.,<br> 
Scottsdale, AZ 85257<br>
602/949-7600</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/~corral">The Corral Chrysler Plymouth Dodge Jeep Eagle</a></font><br>
<font size="+1">
669 N. Lake Havasu,<br> 
Lake Havasu City, AZ 86403<br>
520/855-5153</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Diamond Dodge/Chrysler/Plymouth</a></font><br>
<font size="+1">
350 Switzer Canyon Dr.,<br> 
Flagstaff, AZ 86001<br>
602/779-3641</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Earnhardt Gilbert Dodge</a></font><br>
<font size="+1">
1301 N. Arizona Ave<br>
Gilbert, AZ  85233<br>
602/936-5000</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Ed Moses Dodge, Chrysler, Plymouth</a></font><br>
<font size="+1">
861 W. Mariposa Rd.,<br> 
Peoria, AZ 85382<br>
520/281-2111</font>
</ul>
</td>
<td width="50%" valign="top">
<ul>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Ferrell Motors</a></font><br>
<font size="+1">
1240 Iron Springs Rd<br>
Flagstaff, AZ  86301<br>
520/778-5500</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Fisher Chrysler Plymouth Dodge Jeep Eagle</a></font><br>
<font size="+1">
349 E. 32nd St.,<br> 
Yuma, AZ 85364<br>
520/344-2650

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Hatch Brothers</a></font><br>
<font size="+1">
1623 Thatcher Blvd<br>
Safford, AZ  85545<br>
520/428-6000</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Hatch Motor</a></font><br>
<font size="+1">
PO Box 540<br>
117 S. Main<br>
Snowflake, AZ  85937<br>
520/536-4753</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Healy Auto Center</a></font><br>
<font size="+1">
HW 60,<br> 
Globe, AZ 85502<br>
520/425-3283</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/~miller">Larry Miller Dodge</a></font><br>
<font size="+1">
8424 W. Bell Rd.,<br> 
Peoria, AZ 85382<br>
602/815-2200</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Munday Motors</a></font><br>
<font size="+1">
1201 S Hwy 80,<br> 
Benson, AZ 85602<br>
520/586-2236 </font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">O'Reilly Chrysler Plymouth Dodge Jeep Eagle</a></font><br>
<font size="+1">
1901 S. Highway 92,<br> 
Sierra Vista, AZ 85635<br>
520/458-8000</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Oxendale Chrysler Plymouth Dodge Jeep Eagle</a></font><br>
<font size="+1">
792 Hwy 89-A East,<br> 
Cottonwood, AZ 86326<br>
520/654-5450</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Performance Dodge</a></font><br>
<font size="+1">
4240 W. Glendale Ave.,<br> 
Phoenix, AZ 85051<br>
602/247-4444</font>


</ul>
</td>
</tr>
</table>
<br><br><br><br>

<center>

<hr width="50%">

<font size="+1">

Return to the <a href="http://aada.dasta.com/automall.html">graphics oriented Auto Mall</a>.
<p>
Return to the <a href="http://aada.dasta.com/autmall2.html">text oriented Auto Mall</a>.

</font>

</center>
<br><br><br><br><br><br>

<table>



	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="gif/dastasig.gif" alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 21 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996 <a href="http://www.dasta.com">Dasta VendorCat</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">"This site was designed by DASTA VENDORCAT,<br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of <a href="http://www.dasta.com/anet.html">Association-Net</a><sup>TM</sup>."</font></p>
</center>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-107</DOCNO>
<DOCOLDNO>IA058-000947-B027-80</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/mall/ferrarifin.html 206.97.63.16 19970109193752 text/html 1769
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:20:35 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 1598
Last-modified: Tue, 16 Jul 1996 23:14:02 GMT
</DOCHDR>
<html>

<head>
	<title>Ferrari Dealerships</title>
</head>

<body TEXT="#FFFFFF" LINK="#95A401" VLINK="#F4C7B2" ALINK="#FF0000" BGCOLOR="#000000">

<br>

<table width="100%">
<tr>
<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>
<td align="center">
<hr width="50%">

<h1><a name="ferrari">Ferrari Dealerships</a></h1>

<hr width="50%">
</td>
<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>
</tr>
</table>

<br><br><br><br><br><br><br><br>

<center>

<hr width="50%">

<font size="+1">

Return to the <a href="http://aada.dasta.com/automall.html">graphics oriented Auto Mall</a>.
<p>
Return to the <a href="http://aada.dasta.com/autmall2.html">text oriented Auto Mall</a>.

</font>

</center>

<br><br><br><br><br><br>

<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="gif/dastasig.gif" alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 21 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996 <a href="http://www.dasta.com">Dasta VendorCat</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">"This site was designed by DASTA VENDORCAT,<br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of <a href="http://www.dasta.com/anet.html">Association-Net</a><sup>TM</sup>."</font></p>
</center>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-108</DOCNO>
<DOCOLDNO>IA058-000947-B027-97</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/mall/fordfin.html 206.97.63.16 19970109193759 text/html 7002
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:20:42 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 6831
Last-modified: Fri, 26 Jul 1996 10:58:16 GMT
</DOCHDR>
<html>

<head>
	<title>Ford Dealerships</title>
</head>

<body TEXT="#FFFFFF" LINK="#95A401" VLINK="#F4C7B2" ALINK="#FF0000" BGCOLOR="#000000">

<br>

<table width="100%">
<tr>
<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>
<td align="center">
<hr width="50%">

<h1><a name="ford">Ford Dealerships</a></h1>

<hr width="50%">
</td>

<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>
</tr>

</table><br><br>

<p>

<table width="100%" border="10">
<tr>
<td valign="top" width="50%">
<ul>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Ames Brothers Motors</a></font><br>
<font size="+1">
1001 E. Third St.<br>
Flagstaff, AZ 86047<br>
520/289-3354</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Cholla Ford</a></font><br>
<font size="+1">
755 E. 4th St.<br>
Benson, AZ 85602 <br>
520/586-3661</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Bell Ford</a></font><br>
<font size="+1">
2401 W. Bell Rd.<br>
Phoenix, AZ 85080<br>
602/866-1776</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Berge Ford</a></font><br>
<font size="+1">
460 E. Auto Ctr.<br>
Mesa, AZ 85211<br>
602/497-1111</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Bill McGlocklin Ford, Lincoln, Mercury</a></font><br>
<font size="+1">
310 E. Highway 70<br>
Safford, AZ 85545<br>
520/428-1770</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Bradley Ford Lincoln Mercury</a></font><br>
<font size="+1">
1515 W. Broadway<br>
Mesa, AZ 85202<br>
520/855-1191</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Earnhardt Ford</a></font><br>
<font size="+1">
PO Box 26878<br>
777 E. Baseline Rd.<Br>
Tempe, AZ  85283 <br>
602/838-6000</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Five Star Ford</a></font><br>
<font size="+1">
7100 E. McDowell Rd.<br>
Scottsdale, AZ 85257<br>
602/946-3900</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Frank Cummings Ford Lincoln Mercury</a></font><br>
<font size="+1">
PO Box 428<br>
1777 N. Grand Avenue<br>
Tucson, AZ  85621<br>
520/281-1976</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/~fuller">Fuller's White Mountain Motors, Inc.</a></font><br>
<font size="+1">
1920 East Deuce of Clubs<br>
Show Low, AZ  85901<br>
520/537-5767</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Galpin Ford</a></font><br>
<font size="+1">
1000 Sandrello Dr.<br>
Prescott, AZ 86301<br>
520/445-3673</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Glenn Jones Ford Lincoln Mercury</a></font><br>
<font size="+1">
1648 N. Final Ave.<br>
Casa Grande, AZ 85222<br>
520/963-6111</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Holmes Tuttle Ford</a></font><br>
<font size="+1">
660 W. Automall Drive<br>
Tucson,AZ 85705<br>
520/292-3600</font>
</ul>
</td>
<td valign="top" width="50%">
<ul>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Jim Babbitt Ford</a></font><br>
<font size="+1">
11 N. Verde B6001<br>
Flagstaff, AZ 86002<br>
520/774-5063</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Jim Click Ford Lincoln Mercury</a></font><br>
<font size="+1">
6420 E. 22nd St.<br>
Tucson, AZ 85732<br>
520/747-2000</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Jones Ford Mercury</a></font><br>
<font size="+1">
781 W. Wickenburg Way<br>
Wickenburg, AZ 85358<br>
520/258-1611</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Lou Grubb Ford</a></font><br>
<font size="+1">
8555 Frank Lloyd Wright Blvd<br>
Scottsdale, AZ  85260<br>
602/991-3333</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">McSpadden Ford</a></font><br>
<font size="+1">
601 N. Broad St.<br>
Globe, AZ 85501<br>
520/425-4491</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Mel Clayton Ford</a></font><br>
<font size="+1">
1550 E. Camelback Rd.<br>
Phoenix, AZ 85014<br>
602/264-1611</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/~pageford">Page Ford</a></font><br> 
<font size="+1">
619 S. Lake Powell Blvd.<br>
Page, AZ 86040<br>
520/645-3656</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Phil White Ford</a></font><br>
<font size="+1">
P.O. Box 159<br>
256131 State Hwy 260<br>
Payson, AZ 85541<br>
520/474-8888</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Pioneer Ford</a></font><br>
<font size="+1">
2600 Grand Ave.<br>
Phoenix, AZ 86003<br>
602/257-1933</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">San-Man Ford Mercury</a></font><br>
<font size="+1">
130 N. Rodington<br>
San Manuel, AZ 85631<br>
520/385-2212</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Sanderson Ford</a></font><br>
<font size="+1">
6400 N. 51st Ave.<br>
Glendale, AZ 85301<br>
602/842-8600</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Sun Valley Ford Lincoln Mercury</a></font><br>
<font size="+1">
P.O. Drawer 3655<br>
Hwy. 80 West<br>
Douglas, AZ 85601<br>
520/364-2485</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Tom Jones Ford</a></font><br>
<font size="+1">
23454 W. Hwy 85<br>
Buckeye, AZ 853-26<br>
602/386-4429</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Verde Valley Ford Lincoln Mercury</a></font><br>
<font size="+1">
1516 E.Cottonwood<br>
Cottonwood,AZ 86326<br>
520/634-2291</font>

</ul>
</td>
</tr>
</table>
<br><br><br><br>

<center>

<hr width="50%">

<font size="+1">

Return to the <a href="http://aada.dasta.com/automall.html">graphics oriented Auto Mall</a>.
<p>
Return to the <a href="http://aada.dasta.com/autmall2.html">text oriented Auto Mall</a>.

</font>

</center>

<br><br><br><br><br><br>


<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="gif/dastasig.gif" alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 21 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996 <a href="http://www.dasta.com">Dasta VendorCat</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">"This site was designed by DASTA VENDORCAT,<br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of <a href="http://www.dasta.com/anet.html">Association-Net</a><sup>TM</sup>."</font></p>
</center>

</body>
</html>




</DOC>
<DOC>
<DOCNO>WT08-B13-109</DOCNO>
<DOCOLDNO>IA058-000947-B027-111</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/mall/geofin.html 206.97.63.16 19970109193808 text/html 4214
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:20:50 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 4043
Last-modified: Wed, 24 Jul 1996 06:37:14 GMT
</DOCHDR>
<html>

	<head>
		<title>Geo Dealerships</title>
	</head>

<body TEXT="#FFFFFF" LINK="#95A401" VLINK="#F4C7B2" ALINK="#FF0000" BGCOLOR="#000000">

<br>

<table width="100%">
<tr>
<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>
<td align="center">
<hr width="50%">

<h1><a name="geo">Geo Dealerships</a></h1>

<hr width="50%">
</td>

<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>
</tr>
</table><br><br>

<p>
<table width="100%" border="10">
<tr>
<td valign="top" width="50%">

<ul>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Chapman Auto Center</a></font><br>
<font size="+1">
198 N. Beeline Hwy.,<br> 
Payson, AZ 85547<br>
520/474-5261</font>

<p>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Cobre Valley Motors</a></font><br>
<font size="+1">
1500 N. Broad,<br> 
Globe, AZ 85501<br>
520/425-4487</font>

<p>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Cropper's Nogales Auto Center</a></font><br>
<font size="+1">
1831 N. Grand Ave.,<br> 
Nogales, AZ 85521<br>
520/836-2147</font>

<p>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Garrett Motors</a></font><br>
<font size="+1">
197 N. Arizona Blvd.,<br> 
Coolidge, AZ 85228<br>
520/723-5401</font>

<p>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Gary Cropper Auto</a></font><br>
<font size="+1">
1990 N. Pinal Ave.,<br> 
Casa Grande, AZ 85222<br>
520/836-2147</font>

<p>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Joe Gambino Chevrolet/Geo</a></font><br>
<font size="+1">
1000 Sandrello Dr.,<br> 
Prescott, AZ 86301<br>
520/932-4389</font>

</ul>
</td>

<td valign="top" width="50%">
<ul>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Larry Green Chevrolet Oldsmobile Geo</a></font><br>
<font size="+1">
PO Box 1839<br>
737 S. Main<br>
Cottonwood, AZ  86326<br>
520/634-2229</font>

<p>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Lou Grubb Chev/Geo</a></font><br>
<font size="+1">
2645 W. Camelback<br>
Phoenix, AZ  85017<br>
602/242-5555</font>

<p>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">O'Reilly Chevrolet Geo</a></font><br>
<font size="+1">
6100 E. Broadway,<br> 
Tucson, AZ 85732<br>
520/747-8000</font>

<p>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Seabury Chevrolet-Geo</a></font><br>
<font size="+1">
3201 Chevy Lane,<br> 
Yuma, AZ 85366<br>
520/726-5500</font>

<p>

<li><font size="+2"><a href="http://aada.dasta.com/~star">Star Chervrolet</a></font><br>
<font size="+1">
3200 Fry Blvd,<br>
Sierra Vista, AZ  85635<br>
520/458-6520</font>

<p>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Tyrrell Chevrolet Buick Mazda Geo</a></font><br>
<font size="+1">
P.O Box 1909<br>
1118 W.Hwy 66<br>
Flagstaff, Az 86001<br>
520/774-2794</font>
 
</ul>
</td>
</tr>
</table>
<br><br><br><br>

<center>

<hr width="50%">

<font size="+1">

Return to the <a href="http://aada.dasta.com/automall.html">graphics oriented Auto Mall</a>.
<p>
Return to the <a href="http://aada.dasta.com/autmall2.html">text oriented Auto Mall</a>.

</font>

</center>

<br><br><br><br><br><br>

<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="gif/dastasig.gif" alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 21 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996 <a href="http://www.dasta.com">Dasta VendorCat</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">"This site was designed by DASTA VENDORCAT,<br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of <a href="http://www.dasta.com/anet.html">Association-Net</a><sup>TM</sup>."</font></p>
</center>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-110</DOCNO>
<DOCOLDNO>IA058-000947-B027-131</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/mall/gmcfin.html 206.97.63.16 19970109193817 text/html 4939
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:21:00 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 4768
Last-modified: Fri, 26 Jul 1996 18:25:28 GMT
</DOCHDR>
<html>

        <head>
                <title>GMC Truck Dealerships</title>
        </head>

<body TEXT="#FFFFFF" LINK="#95A401" VLINK="#F4C7B2" ALINK="#FF0000" BGCOLOR="#000000">

<br>

<table width="100%">
<tr>
<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>
<td align="center">

<hr width="50%">

<h1><a name="gmc">GMC Truck Dealerships</a></h1>

<hr width="50%">
</td>
<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>
</tr>
</table><br><br>

<p>

<table width="100%" border="10">
<tr>
<td valign="top" width="50%">
<ul>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Biddulph Pontiac/ GMC/ Chrysler/ Plymouth/ Jeep Eagle</a></font><br>
<font size="+1">
4510 W. Glendale Ave.<br>
Glendale, AZ 85301<br>
602/931-9111</font>

<p>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Cliff Findlay Auto</a></font><br>
<font size="+1">
1001 Hwy. 95<br>
Bullhead City, AZ 86430<br>
800/852-6584</font>

<p>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Healy Auto Center</a></font><br>
<font size="+1">
Hwy 60<br>
Globe, AZ 85502<br>
520/425-3283</font>

<p>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Hendric Buick-Pontiac-GMC Truck</a></font><br>
<font size="+1">
777 S. Arizona Blvd.<br>
Coolidge, AZ 85228<br>
602/723-5444</font>

<p>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">The Johnson Motors Corp.</a></font><br>
<font size="+1">
804 First Ave.<br>
Casa Grande, AZ 85548<br>
520/428-0140</font>

<p>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Karl Moedl Automotive Group</a></font><br>
<font size="+1">
1125 E. 32nd St.<br>
Yuma, AZ 85365<br>
520/726-6970</font>

<p>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Lawley Auto Center</a></font><br>
<font size="+1">
2900 E. Fry Blvd.<br>
Sierra Vista, AZ 85635<br>
520/458-2141</font>

</ul>
</td>
<td valign="top" width="50%">
<ul>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">McCoy Motors</a></font><br>
<font size="+1">
361 N. Switzer Canyon Dr.<br>
Flagstaff, AZ 86001<br>
520/774-1472</font>

<p>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Showcase Pontiac-GMC-Mazda</a></font><br>
<font size="+1">
4635 N. 7th St.<br>
Phoenix, AZ 85014<br>
602/264-2481</font>

<p>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Southern Arizona Auto Company</a></font><br>
<font size="+1">
1200 "G" Ave.<br>
Douglas, AZ 85607<br>
520/364-2424</font>

<p>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Steve Coury Buick Pontiac GMC Trucks</a></font><br>
<font size="+1">
18 N. Main<br>
Cottonwood, AZ 86326<br>
520/634-9576</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Tim's Buick Pontiac GMC Toyota</a></font><br>  
<font size="+1">
P.O.Box 10610<br>
1006 Commerce Drive<br>
Prescott,AZ 86304<br>
520/445-7350</font>

<p>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Tony M. Coury Buick &amp; GMC Trucks</a></font><br>
<font size="+1">
525 W. Main St.<br>
Mesa, AZ 85201<br>
602/834-0101</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/~yates">Yates Pontiac GMC, Inc.</a></font><br>
<font size="+1">
104 N. Dysart Rd.<br> 
Avondale, AZ 85323<br>
602/932-1818</font>

</ul>
</td>
</tr>
</table>

<br><br><br><br>

<center>

<hr width="50%">

<font size="+1">

Return to the <a href="http://aada.dasta.com/automall.html">graphics oriented Auto Mall</a>.
<p>
Return to the <a href="http://aada.dasta.com/autmall2.html">text oriented Auto Mall</a>.

</font>

</center>

<br><br><br><br><br><br>

<table>

        <tr>
                <th colspan="2"><hr></th>
        </tr>

        <tr>
                <td valign="middle"><a href="http://www.dasta.com">
                        <img src="gif/dastasig.gif" alt="DASTA VendorCat logo" border="0"></a></td>
                <td>
                        <font size="-1">Last Updated: 21 Jun 96<br>
                        Comments/Questions: <a href="mailto:webmaster@dasta.com">
                                webmaster@dasta.com</a><br>
                        Copyright &#169; 1996 <a href="http://www.dasta.com">Dasta VendorCat</a>.
                                All rights reserved.</font>
                </td>
        </tr>

        <tr>
                <th colspan="2"><hr></th>
        </tr>

</table>

<center>
        <p><font size="-1">"This site was designed by DASTA VENDORCAT,<br> 
        the Nation's Leading Internet Presence Provider for Associations<br>
        and the Sponsor of <a href="http://www.dasta.com/anet.html">Association-Net</a><sup>TM</sup>."</font></p>
</center>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-111</DOCNO>
<DOCOLDNO>IA058-000947-B027-144</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/mall/hondafin.html 206.97.63.16 19970109193823 text/html 4343
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:21:07 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 4172
Last-modified: Wed, 16 Oct 1996 20:10:12 GMT
</DOCHDR>
<html>

<head>
	<title>Honda Dealerships</title>
</head>

<body TEXT="#FFFFFF" LINK="#95A401" VLINK="#F4C7B2" ALINK="#FF0000" BGCOLOR="#000000">

<br>

<table width="100%">
<tr>
<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>
<td align="center">

<hr width="50%">

<h1><a name="honda">Honda Dealerships</a></h1>

<hr width="50%">
</td>
<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>
</tr>
</table><br><br>

<p>

<table width="100%" border="10">
<tr>
<td valign="top" width="50%">
<ul>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Arrowhead Honda</a></font><br>
<font size="+1">
8380 W. Bell Rd.,<br> 
Peoria, AZ 85382<br>
602/974-9700</font>

<p>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Beaudry Motor Company</a></font><br>
<font size="+1">
4646 E. 22nd St.,<br> 
Tucson, AZ 85732<br>
520/748-1000</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Bell Honda</a></font><br>
<font size="+1">
701 W. Bell Rd.,<br> 
Phoenix, AZ 85080<br>
602/263-8180</font>

<p>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Cliff Findlay Auto</a></font><br>
<font size="+1">
1001 Hwy. 95,<br> 
Bullhead City, AZ 86430<br>
800/852-6584</font>

<p>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Country Club Honda</a></font><br>
<font size="+1">
1000 E. 32nd St.,<br> 
Yuma, AZ 85365<br>
520/344-1000</font>
 
<p>

<li><font size="+2"><a href="http://dobbs.dasta.com">Dobbs Motors of AZ</a></font><br>
<font size="+1">
810 W. Wetmore<br>
Tucson, AZ  85705-8550<br>
520/292-0790</font>

<p>


<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Ferrell Motors</a></font><br>
<font size="+1">
1240 Iron Springs Rd<br>
Flagstaff, AZ  86301<br>
520/778-5500</font>
 </ul>
</td>
<td valign="top" width="50%">
<ul>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Honda/Kia of Tempe</a></font><br>
<font size="+1">
411 E. Deuce of Clubs<br>
Flagstaff, AZ  85901 <br>
602/893-7900</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Honda Cars of Mesa/Mesa Mitsubishi</a></font><br>
<font size="+1">
1320 W. Broadway<br>
Mesa, AZ  85202<br>
602/833-5177</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Lawley Automotive Center</a></font><br>
<font size="+1">
2900 E. Fry Blvd.,<br> 
Sierra Vista, AZ 85635<br>
520/458-2141 </font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Mountain Honda Isuzu</a></font><br>
<font size="+1">
1160 W. Highway 66,<br> 
Flagstaff, AZ 86001<br>
520/774-5346</font>
 
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Scottsdale Honda</a></font><br>
<font size="+1">
6980 E. McDowell Rd.,<br> 
Scottsdale, AZ 85257<br>
602/949-1020</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Showcase Honda</a></font><br>
<font size="+1">
1400 E. Camelback Rd.,<br> 
Phoenix, AZ 85014<br>
602/274-3800</font>

</ul>
</td>
</tr>
</table>

<br><br><br><br>

<center>

<hr width="50%">

<font size="+1">

Return to the <a href="http://aada.dasta.com/automall.html">graphics oriented Auto Mall</a>.
<p>
Return to the <a href="http://aada.dasta.com/autmall2.html">text oriented Auto Mall</a>.

</font>

</center>

<br><br><br><br><br><br>

<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="gif/dastasig.gif" alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 21 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996 <a href="http://www.dasta.com">Dasta VendorCat</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">"This site was designed by DASTA VENDORCAT,<br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of <a href="http://www.dasta.com/anet.html">Association-Net</a><sup>TM</sup>."</font></p>
</center>

</body>
</html>





</DOC>
<DOC>
<DOCNO>WT08-B13-112</DOCNO>
<DOCOLDNO>IA058-000947-B027-158</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/mall/hummerfin.html 206.97.63.16 19970109193831 text/html 1773
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:21:14 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 1602
Last-modified: Tue, 16 Jul 1996 23:14:00 GMT
</DOCHDR>
<html>

	<head>
		<title>Hummer Dealerships</title>
	</head>

<body TEXT="#FFFFFF" LINK="#95A401" VLINK="#F4C7B2" ALINK="#FF0000" BGCOLOR="#000000">

<br>

<table width="100%">
<tr>
<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>
<td align="center">

<hr width="50%">

<h1><a name="hummer">Hummer Dealerships</a></h1>

<hr width="50%">
</td>

<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>

</tr>
</table>

<br><br><br><br><br>
<br><br><br><br><br>

<center>

<hr width="50%">

<font size="+1">

Return to the <a href="http://aada.dasta.com/automall.html">graphics oriented Auto Mall</a>.
<p>
Return to the <a href="http://aada.dasta.com/autmall2.html">text oriented Auto Mall</a>.

</font>

</center>

<br><br><br><br>

<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="gif/dastasig.gif" alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 21 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996 <a href="http://www.dasta.com">Dasta VendorCat</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">"This site was designed by DASTA VENDORCAT,<br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of <a href="http://www.dasta.com/anet.html">Association-Net</a><sup>TM</sup>."</font></p>
</center>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-113</DOCNO>
<DOCOLDNO>IA058-000947-B027-176</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/mall/hyundaifin.html 206.97.63.16 19970109193839 text/html 2868
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:21:21 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 2697
Last-modified: Tue, 16 Jul 1996 23:14:00 GMT
</DOCHDR>
<html>

<head>
	<title>Hyundai Dealerships</title>
</head>

<body TEXT="#FFFFFF" LINK="#95A401" VLINK="#F4C7B2" ALINK="#FF0000" BGCOLOR="#000000">

<br>

<table width="100%">
<tr>
<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>
<td align="center">
<hr width="50%">

<h1><a name="hyundai">Hyundai Dealerships</a></h1>

<hr width="50%">
</td>
<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>

</tr>
</table><br><br>

<p>

<table width="100%" border="10">
<tr>
<td valign="top" width="50%">
<ul>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Bell Road Mazda/Mitsubishi/Hyundai</a></font><br>
<font size="+1">
2121 W. Bell Rd.<br>
Phoenix, AZ 85023<br>
602/993-3322</font>
<p>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Desert Mazda/Hyundai</a></font><br>
<font size="+1">
4620 W. Camelback<br>
Glendale, AZ  85301<br>
520/721-8000</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Jim Click Mazda/Hyundai</a></font><br>
<font size="+1">
800 W. Auto Mall Drive<br>
Tucson, AZ 85705<br>
520/888-9760</font>

</ul>
</td>
<td valign="top" width="50%">
<ul>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Karl Moedl Automotive Group</a></font><br>
<font size="+1">
1125 E. 32nd St.<br>
Yuma, AZ 85365<br>
520/726-6970</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Lou Grubb Hyundai/Suzuki</a></font><br>
<font size="+1">
4620 W. Camelback<br>
Glendale, AZ  85301<br>
602/934-8555</font>

</ul>
</td>
</tr>
</table>
<br><br><br><br>

<center>

<hr width="50%">

<font size="+1">

Return to the <a href="http://aada.dasta.com/automall.html">graphics oriented Auto Mall</a>.
<p>
Return to the <a href="http://aada.dasta.com/autmall2.html">text oriented Auto Mall</a>.

</font>

</center>

<br><br><br><br><br><br>

<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="gif/dastasig.gif" alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 21 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996 <a href="http://www.dasta.com">Dasta VendorCat</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">"This site was designed by DASTA VENDORCAT,<br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of <a href="http://www.dasta.com/anet.html">Association-Net</a><sup>TM</sup>."</font></p>
</center>

</body>
</html>

</DOC>
<DOC>
<DOCNO>WT08-B13-114</DOCNO>
<DOCOLDNO>IA058-000947-B027-190</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/mall/infinitifin.html 206.97.63.16 19970109193847 text/html 2301
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:21:30 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 2130
Last-modified: Tue, 16 Jul 1996 23:13:59 GMT
</DOCHDR>
<html>

<head>
	<title>Infiniti Dealerships</title>
</head>


<body TEXT="#FFFFFF" LINK="#95A401" VLINK="#F4C7B2" ALINK="#FF0000" BGCOLOR="#000000">

<br>

<table width="100%">

<tr>
<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>

<td align="center">
<hr width="50%">

<h1><a name="infiniti">Infiniti Dealerships</a></h1>

<hr width="50%">
</td>
<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>

</tr>
</table><br><br>

<p>

<table width="100%" border="10">
<tr>
<td valign="top" width="50%">
<ul>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Culliver Infiniti</a></font><br>
<font size="+1">
2205 Bell Rd.<br>
Phoenix, AZ 85023<br>
602/856-6611</font>
</ul>
</td>
<td valign="top" width="50%">
<ul>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Infiniti of Scottsdale</a></font><br>
<font size="+1">
PO Box 9768<br>
5420 E. McDowell Rd<br>
Scottsdale, AZ  85257<br>
602/941-0711</font>

</ul>
</td>
</tr>
</table>
<br><br><br><br>

<center>

<hr width="50%">

<font size="+1">

Return to the <a href="http://aada.dasta.com/automall.html">graphics oriented Auto Mall</a>.
<p>
Return to the <a href="http://aada.dasta.com/autmall2.html">text oriented Auto Mall</a>.

</font>

</center>

<br><br><br><br><br><br>
<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="gif/dastasig.gif" alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 21 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996 <a href="http://www.dasta.com">Dasta VendorCat</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">"This site was designed by DASTA VENDORCAT,<br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of <a href="http://www.dasta.com/anet.html">Association-Net</a><sup>TM</sup>."</font></p>
</center>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-115</DOCNO>
<DOCOLDNO>IA058-000947-B027-201</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/mall/isuzufin.html 206.97.63.16 19970109193855 text/html 2476
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:21:39 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 2305
Last-modified: Wed, 24 Jul 1996 06:45:11 GMT
</DOCHDR>
<html>

	<head>
		<title>Isuzu Dealerships</title>
	</head>

<body TEXT="#FFFFFF" LINK="#95A401" VLINK="#F4C7B2" ALINK="#FF0000" BGCOLOR="#000000">

<br>

<table width="100%">

<tr>
<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>
<td align="center">

<hr width="50%">

<h1><a name="isuzu">Isuzu Dealerships</a></h1>

<hr width="50%">
</td>
<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>

</tr>
</table><br><br>
<p>

<table width="100%" border="10">

<tr>
	<td valign="top" width="50%">
	
<ul>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Mountain Honda Isuzu</a></font><br>
<font size="+1">
1160 W. Highway 66<br>
Flagstaff,  AZ 86001<br>
520/774-5346 </font>

<p>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Pitre Buick/Isuzu/Suzuki</a></font><br>
<font size="+1">
6640 E. McDowell Rd.<br>
Scottscale, AZ  85257<br>
602/994-9451</font>

</ul>
</td>

<td valign="top" width="50%">

<ul>
<li><font size="+2"><a href="http://aada.dasta.com/~star">Star Chevrolet</a></font><br>
<font size="+1">
3200 Fry Blvd<br>
Sierra Vista, AZ  85635<br>
520/458-6520</font>

</ul>
</td>
</tr>
</table>
<br><br><br><br>

<center>

<hr width="50%">

<font size="+1">

Return to the <a href="http://aada.dasta.com/automall.html">graphics oriented Auto Mall</a>.
<p>
Return to the <a href="http://aada.dasta.com/autmall2.html">text oriented Auto Mall</a>.

</font>

</center>

<br><br><br><br><br><br>

<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="gif/dastasig.gif" alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 21 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996 <a href="http://www.dasta.com">Dasta VendorCat</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">"This site was designed by DASTA VENDORCAT,<br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of <a href="http://www.dasta.com/anet.html">Association-Net</a><sup>TM</sup>."</font></p>
</center>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-116</DOCNO>
<DOCOLDNO>IA058-000947-B027-213</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/mall/jaguarfin.html 206.97.63.16 19970109193902 text/html 2265
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:21:45 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 2094
Last-modified: Tue, 16 Jul 1996 23:13:59 GMT
</DOCHDR>
<html>

	<head>
		<title>Jaguar Dealerships</title>
	</head>

<body TEXT="#FFFFFF" LINK="#95A401" VLINK="#F4C7B2" ALINK="#FF0000" BGCOLOR="#000000">

<br>

<table width="100%">
<tr>
<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>
<td align="center">

<h1><a name="jaguar">Jaguar Dealerships</a></h1>

<hr width="50%">
</td>
<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>

</tr>
</table><br><br>

<p>
<table width="100%" border="10">
<tr>
<td valign="top" width="50%">

<ul>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Beaudry Motor Company</a></font><br>
<font size="+1">
4646 E. 22nd St.<br>
Tucson, AZ 85732<br>
520/748-1000</font>

</ul>
</td>
<td valign="top" width="50%">
<ul>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Scottsdale Jaguar</a></font><br>
<font size="+1">
6725 E. McDowell Rd.<br>
Scottsdale, AZ 85257<br>
602/990-9000</font>

</ul>

</td>
</tr>
</table>
<br><br><br><br>

<center>

<hr width="50%">

<font size="+1">

Return to the <a href="http://aada.dasta.com/automall.html">graphics oriented Auto Mall</a>.
<p>
Return to the <a href="http://aada.dasta.com/autmall2.html">text oriented Auto Mall</a>.

</font>

</center>

<br><br><br><br><br><br>

<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="gif/dastasig.gif" alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 21 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996 <a href="http://www.dasta.com">Dasta VendorCat</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">"This site was designed by DASTA VENDORCAT,<br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of <a href="http://www.dasta.com/anet.html">Association-Net</a><sup>TM</sup>."</font></p>
</center>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-117</DOCNO>
<DOCOLDNO>IA058-000947-B027-230</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/mall/jeep_eaglefin.html 206.97.63.16 19970109193909 text/html 5920
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:21:52 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 5749
Last-modified: Wed, 28 Aug 1996 14:21:39 GMT
</DOCHDR>
<html>

<head>
        <title>Jeep-Eagle Dealerships</title>
</head>

<body TEXT="#FFFFFF" LINK="#95A401" VLINK="#F4C7B2" ALINK="#FF0000" BGCOLOR="#000000">

<br>

<table width="100%">

<tr>
<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>

<td align="center">
<hr width="50%">

<h1><a name="jeep_eagle">Jeep-Eagle Dealerships</a></h1>

<hr width="50%">
</td>
<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>

</tr>
</table><br><br>
<p>

<table width="100%" border="10">
<tr>
<td valign="top" width="50%">
<ul>

<li><font size="+2"><a href="http://aada.dasta.com/~avondale">Avondale Motors</a></font><br>
<font size="+1">
803 East Van Buren<br>
Avondale, AZ  85323<br>
602/925-0011</font>

<p>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Biddulph Pontiac/ GMC/ Chrysler/ Plymouth/ Jeep Eagle</a></font><br>
<font size="+1">
4510 W. Glendale Ave.<br>
Glendale, AZ 85301<br>
602/931-9111</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/~billluke">Bill Luke Chrysler Plymouth Jeep Eagle Dodge</a></font><br>
<font size="+1">
2425 W.Camelback Rd.<br>
Phoenix,AZ 85015<br>
602/249-1234</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Chapman Auto Center</a></font><br>
<font size="+1">
198 N. Beeline Hwy<br>
Payson, AZ 85547<br>
520/474-5261</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/~corral">The Corral Chrysler Plymouth Dodge Jeep Eagle</a></font><br>
<font size="+1">
669 N. Lake Havasu<br>
Lake Havasu City, AZ 86403<br>
520/855-5153</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Darner Motor Sales</a></font><br> 
<font size="+1">
837 W. Main St.<br>
Mesa, AZ 85201<br>
602/969-7311</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Deibel Jeep Eagle</a></font><br>
<font size="+1">
PO Box 22340 <br>
2608 N. West St. <br>
520/774-6681</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Fisher Chrysler Plymouth Dodge Jeep Eagle</a></font><br>
<font size="+1">
349 E. 32nd St.<br>
Yuma, AZ 85364<br>
602/520/344-2650</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/~fuller">Fuller's White Mountain Motors </a></font><br>
<font size="+1">
1920 E. Deuce of Clubs<br>
Show Low, AZ 85901<br>
520/333-4030</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Galloway Chrysler Plymouth Jeep Eagle</a></font><br>
<font size="+1">
5200 E. Speedway Blvd.<br>
Tucson, AZ 85712<br>
520/327-5561</font>
</ul>
</td>

<td valign="top" width="50%">
<ul>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Hatch Brothers</a></font><br>
<font size="+1">
1623 Thatcher Blvd <br>
Safford, AZ  85545 <br>
520/428-6000</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Healy Auto Center</a></font><br>
<font size="+1">
HW 60<br>
Globe, AZ 85502<br>
520/425-3283</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Larry Miller Chrysler Plymouth Jeep-Eagle</a></font><br> 
<font size="+1">
4600 W. Glendale Ave.<br>
Glendale, AZ 85301<br>
602/842-8500</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Munday Motors </a></font><br>
<font size="+1">
1201 S Hwy 80<br>
Benson, AZ 85602<br>
520/586-2236</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">O'Reilly Chrysler Plymouth Dodge Jeep Eagle</a></font><br>
<font size="+1">
1901 S. Highway 92<br>
Sierra Vista, AZ 85635<br>
520/458-8000</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Oxendale Chrysler Plymouth Dodge Jeep Eagle</a></font><br>792 Hwy 89-A East<br>
<font size="+1">
Cottonwood, AZ 86326<br>
520/654-5450</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Pitre Automotive</a></font><br>
<font size="+1">
6460 E. McDowell Rd.<br>
Scottsdale, AZ 85257<br>
602/994-4999</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Pitre Chrysler Plymouth Jeep Eagle</a></font><br>
<font size="+1">
3121 E. Bell Rd.<br>
Phoenix, AZ 85022<br>
602/493-8000</font>
<p>
<li><font size="+2"><a href="http://companion.org/~york">York Motors</a></font><br>
<font size="+1">
P.O. Box 2039<br>
209 N. Montezuma St.<br>
Prescott, AZ 86302 <br>
520/445-4970</font>

</ul>
</td>
</tr>
</table>
<br><br><br><br>

<center>

<hr width="50%">

<font size="+1"> 

Return to the <a href="http://aada.dasta.com/automall.html">graphics oriented Auto Mall</a>.
<p>
Return to the <a href="http://aada.dasta.com/autmall2.html">text oriented Auto Mall</a>.

</font>

</center>

<br><br><br><br><br><br>

<table>

        <tr>
                <th colspan="2"><hr></th>
        </tr>

        <tr>
                <td valign="middle"><a href="http://www.dasta.com">
                        <img src="gif/dastasig.gif" alt="DASTA VendorCat logo" border="0"></a></td>
                <td>
                        <font size="-1">Last Updated: 21 Jun 96<br>
                        Comments/Questions: <a href="mailto:webmaster@dasta.com">
                                webmaster@dasta.com</a><br>
                        Copyright &#169; 1996 <a href="http://www.dasta.com">Dasta VendorCat</a>.
                                All rights reserved.</font>
                </td>
        </tr>

        <tr>
                <th colspan="2"><hr></th>
        </tr>

</table>

<center>
        <p><font size="-1">"This site was designed by DASTA VENDORCAT,<br> 
        the Nation's Leading Internet Presence Provider for Associations<br>
        and the Sponsor of <a href="http://www.dasta.com/anet.html">Association-Net</a><sup>TM</sup>."</font></p>
</center>

</body>
</html>

</DOC>
<DOC>
<DOCNO>WT08-B13-118</DOCNO>
<DOCOLDNO>IA058-000947-B027-241</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/mall/kiafin.html 206.97.63.16 19970109193916 text/html 2276
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:21:59 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 2105
Last-modified: Tue, 16 Jul 1996 23:13:58 GMT
</DOCHDR>
<html>

	<head>
		<title>Kia Dealerships</title>
	</head>

<body TEXT="#FFFFFF" LINK="#95A401" VLINK="#F4C7B2" ALINK="#FF0000" BGCOLOR="#000000">

<br>

<table width="100%">
<tr>
<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>

<td align="center">

<hr width="50%">

<h1><a name="kia">Kia Dealerships</a></h1>

<hr width="50%">
</td>
<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>

</tr>

</table><br><br>

<p>

<table width="100%" border="10">
<tr>
<td valign="top" width="50%">
<ul>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Childress Buick/Kia</a></font><br>
<font size="+1">
2223 W. Camelback Rd.<br>
Phoenix, AZ 85061<br>
602/249-1133</font>
</ul>
</td>
<td valign="top" width="50%">
<ul>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Honda/Kia of Tempe</a></font><br>
<font size="+1">
7900 S. Autoplex Loop<br>
Tempe, AZ  85284<br>
502/893-7900</font>

</ul>
</td>
</tr>
</table>
<br><br><br><br>

<center>

<hr width="50%">

<font size="+1">

Return to the <a href="http://aada.dasta.com/automall.html">graphics oriented Auto Mall</a>.
<p>
Return to the <a href="http://aada.dasta.com/autmall2.html">text oriented Auto Mall</a>.

</font>

</center>

<br><br><br><br><br><br>

<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="gif/dastasig.gif" alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 21 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996 <a href="http://www.dasta.com">Dasta VendorCat</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">"This site was designed by DASTA VENDORCAT,<br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of <a href="http://www.dasta.com/anet.html">Association-Net</a><sup>TM</sup>."</font></p>
</center>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-119</DOCNO>
<DOCOLDNO>IA058-000947-B027-253</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/mall/lamborghinifin.html 206.97.63.16 19970109193922 text/html 1809
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:22:06 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 1638
Last-modified: Tue, 16 Jul 1996 23:13:57 GMT
</DOCHDR>
<html>

	<head>
		<title>Lamborghini Dealerships </title>
	</head>

<body TEXT="#FFFFFF" LINK="#95A401" VLINK="#F4C7B2" ALINK="#FF0000" BGCOLOR="#000000">

<br>

<table width="100%">

<tr>

<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>

<td align="center">
<hr width="50%">

<h1><a name="lamborghini">Lamborghini Dealerships</a></h1>

<hr width="50%">
</td>

<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>
</tr>

</table>


<br><br><br><br><br><br>

<br><br><br><br><br><br>

<center>

<hr width="50%">

<font size="+1">

Return to the <a href="http://aada.dasta.com/automall.html">graphics oriented Auto Mall</a>.
<p>
Return to the <a href="http://aada.dasta.com/autmall2.html">text oriented Auto Mall</a>.

</font>

</center>

<br><br><br><br><br><br>

<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="gif/dastasig.gif" alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 21 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996 <a href="http://www.dasta.com">Dasta VendorCat</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">"This site was designed by DASTA VENDORCAT,<br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of <a href="http://www.dasta.com/anet.html">Association-Net</a><sup>TM</sup>."</font></p>
</center>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-120</DOCNO>
<DOCOLDNO>IA058-000947-B027-267</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/mall/landroverfin.html 206.97.63.16 19970109193932 text/html 2061
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:22:15 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 1890
Last-modified: Tue, 16 Jul 1996 23:13:57 GMT
</DOCHDR>
<html>

	<head>
		<title>Land Rover Dealerships</title>
	</head>

<body TEXT="#FFFFFF" LINK="#95A401" VLINK="#F4C7B2" ALINK="#FF0000" BGCOLOR="#000000">

<br>

<table width="100%">
<tr>

<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>

<td align="center">

<hr width="50%">

<h1><a name="landrover">Land Rover Dealerships</a></h1>

<hr width="50%">

</td>

<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>

</tr>

</table>

<br><br>

<p>
<table width="100%" border="10">
<tr>
<td valign="top">

<ul>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Land Rover Scottsdale</a></font><br>
<font size="+1">
6905 E. McDowell Rd.<br>
Scottsdale, AZ 85257<br>
602/990-7000</font>
</ul>
</td>
</tr>
</table>
<br><br><br><br>

<center>

<hr width="50%">

<font size="+1">
Return to the <a href="http://aada.dasta.com/automall.html">graphics oriented Auto Mall</a>.
<p>
Return to the <a href="http://aada.dasta.com/autmall2.html">text oriented Auto Mall</a>.
</font>

</center>

<br><br><br><br><br><br>

<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="gif/dastasig.gif" alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 21 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996 <a href="http://www.dasta.com">Dasta VendorCat</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">"This site was designed by DASTA VENDORCAT,<br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of <a href="http://www.dasta.com/anet.html">Association-Net</a><sup>TM</sup>."</font></p>
</center>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-121</DOCNO>
<DOCOLDNO>IA058-000947-B027-281</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/mall/lexusfin.html 206.97.63.16 19970109193940 text/html 2451
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:22:23 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 2280
Last-modified: Tue, 16 Jul 1996 23:13:57 GMT
</DOCHDR>
<html>

	<head>
		<title>Lexus Dealerships</title>
	</head>

<body TEXT="#FFFFFF" LINK="#95A401" VLINK="#F4C7B2" ALINK="#FF0000" BGCOLOR="#000000">

<br>

<table width="100%">

<tr>

<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>

<td align="center">
<hr width="50%">

<h1><a name="lexus">Lexus Dealerships</a></h1>

<hr width="50%">
</td>

<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>

</tr>
</table><br><br>
<p>


<table width="100%" border="10">
<tr>
<td valign="top" width="50%">

<ul>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Bell Lexus</a></font><br>
<font size="+1">
2525 W. Bell Rd.<br>
Phoenix, AZ 85023<br>
602/866-3300</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Lexus of Tucson</a></font><br>
<font size="+1">
4373 E. Speedway,<br>
Tucson, AZ 85712<br>
520/745-3987</font>

</ul>
</td>
<td valign="top" width="50%">
<ul>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Scottsdale Lexus</a></font><br>
<font size="+1">
6905 E. McDowell Rd.<br>
Scottsdale, AZ 85257<br>
602/990-7000</font>

</ul>
</td>
</tr>
</table>
<br><br><br><br>

<center>

<hr width="50%">

<font size="+1">

Return to the <a href="http://aada.dasta.com/automall.html">graphics oriented Auto Mall</a>.
<p>
Return to the <a href="http://aada.dasta.com/autmall2.html">text oriented Auto Mall</a>.

</font>

</center>

<br><br><br><br><br><br>

<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="gif/dastasig.gif" alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 21 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996 <a href="http://www.dasta.com">Dasta VendorCat</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">"This site was designed by DASTA VENDORCAT,<br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of <a href="http://www.dasta.com/anet.html">Association-Net</a><sup>TM</sup>."</font></p>
</center>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-122</DOCNO>
<DOCOLDNO>IA058-000947-B027-297</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/mall/lincolnfin.html 206.97.63.16 19970109193951 text/html 6275
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:22:32 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 6104
Last-modified: Tue, 16 Jul 1996 23:13:56 GMT
</DOCHDR>
<html>

	<head>
		<title>Lincoln Dealerships</title>
	</head>

<body TEXT="#FFFFFF" LINK="#95A401" VLINK="#F4C7B2" ALINK="#FF0000" BGCOLOR="#000000">

<br>

<table width="100%">

<tr>

<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>

<td align="center">

<hr width="50%">

<h1><a name="lincoln">Lincoln Dealerships</a></h1>

<hr width="50%">

</td>

<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>

</tr>

</table><br><br>
<p>

<table width="100%" border="10">
<tr>
<td valign="top" width="50%">
<ul>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Ames Brothers Motors</a></font><br>
<font size="+1">
1001 E. Third St.<br>
Flagstaff, AZ 86047<br>
520/289-3354</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/automall.html">Bill Alexander</a></font><br>
<font size="+1">
801 E. 32nd St., <br>
Yuma, AZ 85364 <br>
520/344-2200</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Bill McGlocklin Ford, Lincoln, Mercury</a></font><br>
<font size="+1">
310 E. Highway 70<br>
Safford, AZ 85545<br>
520/428-1770</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Bradley Ford Lincoln Mercury</a></font><br>
<font size="+1">
1515 W. Broadway<br>
Mesa, AZ 85202<br>
520/855-1191</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Cholla Ford</a></font><br>
<font size="+1">
755 E. 4th St.<br>
Benson, AZ 85602<br>
520/586-3661 </font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Covey Lincoln Mercury</a></font><br>
<font size="+1">
1330 E. Camelback Rd.<br>
Phoenix, AZ 85014<br>
602/264-1851</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Frank Cummings Ford Lincoln Mercury</a></font><br>
<font size="+1">
PO Box 428 <br>
Tucson, AZ  85621 <br>
520/281-1976</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Holmes Tuttle Ford </a></font><br>
<font size="+1">
660 W.utomall Drive<br>
Tucson,AZ 85705<br> 
520/292-3600</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Hudgeons Ford Mercury</a></font><br>
<font size="+1">
PO Box 130<br>
296 N. Arizona Blvd<br>
Phoenix, AZ  85228<br>
520/723-5479</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Galpin Ford</a></font><br>
<font size="+1">
1000 Sandrello Dr.<br>
Prescott, AZ 86301<br>
520/445-3673</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Glenn Jones Ford Lincoln Mercury</a></font><br>
<font size="+1">
1648 N. Final Ave.<br>
Casa Grande, AZ 85222<br>
520/963-6111</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Jack Ross Lincoln Mercury</a></font><br>
<font size="+1">
2700 N. Scottsdale Rd.<br>
Tempe, AZ 85281<br>
602/994-4500</font>
</ul>
</td>
<td valign="top" width="50%">
<ul>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Jim Babbitt Ford</a></font><br>
<font size="+1">
11 N. Verde B6001<br>
Flagstaff, AZ 86002<br>
520/774-5063</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Jim Click Ford Lincoln Mercury</a></font><br>
<font size="+1">
6420 E. 22nd St.<br>
Tucson, AZ 85732<br>
520/747-2000</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">McSpadden Ford</a></font><br>
<font size="+1">
601 N. Broad St.<br>
Globe, AZ 85501<br>
520/425-4491</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Page Ford</a></font><br>
<font size="+1">
619 S. Lake Powell Blvd.<br>
Page, AZ 86040<br>
520/645-3656</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Parker Motor</a></font><br>
<font size="+1">
920 Arizona Ave.<br>
Parker, AZ 85344<br>
520/669-2291</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Phil White Ford</a></font><br>
<font size="+1">
P.O. Box 159<br>
256131 State Hwy260<br>
Payson,AZ 85541<br>
520/474-8888</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">San-Man Ford Mercury</a></font><br>
<font size="+1">
130 N. Rodington<br>
San Manuel, AZ 85631 <br>
520/385-2212</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Sanderson Lincoln Mercury</a></font><br>
<font size="+1">
2121 W. Bell Rd.<br>
Phoenix, AZ 85023<br>
602/375-7562</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Scott Nichols Motors </a></font><br>
<font size="+1">
6850 E. McDowell Rd.<br>
Scottsdale, AZ 85257<br>
520/458-8140</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Sunland Lincoln Mercury</a></font><br>
<font size="+1">
PO Box 336 <br>
4700 W. Glendale Ave. <br>
Glendale,Az 85301<br>
602/939-3301</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Verde Valley Ford Lincoln Mercury</a></font><br>
<font size="+1">
1516 E.Cottonwood<br>
Cottonwood,AZ 86326<br>
520/634-2291</font>

</ul>
</td>
</tr>
</table>
<br><br><br><br>

<center>

<hr width="50%">

<font size="+1">

Return to the <a href="http://aada.dasta.com/automall.html">graphics oriented Auto Mall</a>.
<p>
Return to the <a href="http://aada.dasta.com/autmall2.html">text oriented Auto Mall</a>.

</font>

</center>

<br><br><br><br><br><br>

<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="gif/dastasig.gif" alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 21 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996 <a href="http://www.dasta.com">Dasta VendorCat</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">"This site was designed by DASTA VENDORCAT,<br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of <a href="http://www.dasta.com/anet.html">Association-Net</a><sup>TM</sup>."</font></p>
</center>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-123</DOCNO>
<DOCOLDNO>IA058-000947-B027-311</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/mall/mazdafin.html 206.97.63.16 19970109193959 text/html 3433
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:22:41 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 3262
Last-modified: Wed, 17 Jul 1996 20:19:18 GMT
</DOCHDR>
<html>

<head>
	<title>Mazda Dealerships</title>
</head>

<body TEXT="#FFFFFF" LINK="#95A401" VLINK="#F4C7B2" ALINK="#FF0000" BGCOLOR="#000000">

<br>

<table width="100%">

<tr>

<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>

<td align="center">

<hr width="50%">

<h1><a name="mazda">Mazda Dealerships</a></h1>

<hr width="50%">

</td>

<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>

</tr>

</table><br><br>
<p>

<table width="100%" border="10">
<tr>
<td valign="top" width="50%">
<ul>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Bell Mazda/Mitsubishi/Hyundai</a></font><br>
<font size="+1">
2121 W. Bell Rd.<br>
Phoenix, AZ 85023<br>
602/993-3322</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/~berge">Berge Mazda/Volkswagen</a></font><br>
<font size="+1">
1515 W. Broadway<br>
Mesa, AZ 85202<br>
602/833-0001</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Bill Alexander</a></font><br>
<font size="+1">
801 E. 32nd St.<br> 
Yuma, AZ 85364 <br>
520/344-2200</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Desert Mazda/Hyundai</a></font><br>
<font size="+1">
7800 E. 22nd St.<br>
Tucson, AZ  85710<br>
520/721-8000</font>
</ul>
</td>
<td valign="top" width="50%">
<ul>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Jim Click Mazda/Hyundai</a></font><br>
<font size="+1">
800 W. Auto Mall Drive<br>
Tucson, AZ 85705<br>
520/888-9760</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Powell Volvo Mazda</a></font><br>
<font size="+1">
6500 E. McDowell Rd.<br>
Scottsdale, AZ 85257<br>
602/941-2400</font>
<p>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Showcase Pontiac-GMC-Mazda</a></font><br>
<font size="+1">
4635 N. 7th St.<br>
Phoenix, AZ 85014<br>
602/264-2481</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Tyrrell Chevrolet Buick Mazda Geo</a></font><br>
<font size="+1">
P.O.Box 1909<br>
1118 W. Hwy 66<br>
Flagstaff, AZ 86001<br>
520/774-2794</font>
<p>




</ul>
</td>
</tr>
</table>
<br><br><br><br>

<center>

<hr width="50%">

<font size="+1">

Return to the <a href="http://aada.dasta.com/automall.html">graphics oriented Auto Mall</a>.
<p>
Return to the <a href="http://aada.dasta.com/autmall2.html">text oriented Auto Mall</a>.

</font>

</center>

<br><br><br><br><br><br>

<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="gif/dastasig.gif" alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 21 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996 <a href="http://www.dasta.com">Dasta VendorCat</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">"This site was designed by DASTA VENDORCAT,<br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of <a href="http://www.dasta.com/anet.html">Association-Net</a><sup>TM</sup>."</font></p>
</center>

</body>
</html>


</DOC>
<DOC>
<DOCNO>WT08-B13-124</DOCNO>
<DOCOLDNO>IA058-000947-B027-327</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/mall/mercedes_benzfin.html 206.97.63.16 19970109194008 text/html 2465
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:22:50 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 2294
Last-modified: Tue, 16 Jul 1996 23:13:55 GMT
</DOCHDR>
<html>

	<head>
		<title>Mercedes-Benz Dealerships</title>
	</head>

<body TEXT="#FFFFFF" LINK="#95A401" VLINK="#F4C7B2" ALINK="#FF0000" BGCOLOR="#000000">

<br>

<table width="100%">

<tr>

<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>

<td align="center">

<h1><a name="mercedes-benz">Mercedes-Benz Dealerships</a></h1>

<hr width="50%">

</td>

<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>

</tr>

</table><br><br>
<p>

<table width="100%" border="10">
<tr>
<td valign="top" width="50%">

<ul>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Bill Alexander</a></font><br>
<font size="+1">
801 E. 32nd St. <br>
Yuma, AZ 85364 <br>
520/344-2200</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Phoenix Motor</a></font><br>
<font size="+1">
225 W. Indian School Rd. <br>
Phoenix, AZ 85013<br>
602/264-4791</font>
</ul>
</td>
<td valign="top" width="50%">
<ul>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Schumacher European</a></font><br>
<font size="+1">
15055 N. Hayden Rd. <br>
Scottsdale, AZ 85260<br>
602/991-1155</font>
</ul>
</td>
</tr>
</table>
<br><br><br><br>

<center>

<hr width="50%">

<font size="+1">
Return to the <a href="http://aada.dasta.com/automall.html">graphics oriented Auto Mall</a>.
<p>
Return to the <a href="http://aada.dasta.com/autmall2.html">text oriented Auto Mall</a>.
</font>

</center>

<br><br><br><br><br><br>
<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="gif/dastasig.gif" alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 21 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996 <a href="http://www.dasta.com">Dasta VendorCat</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">"This site was designed by DASTA VENDORCAT,<br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of <a href="http://www.dasta.com/anet.html">Association-Net</a><sup>TM</sup>."</font></p>
</center>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-125</DOCNO>
<DOCOLDNO>IA058-000947-B027-345</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/mall/mercuryfin.html 206.97.63.16 19970109194016 text/html 6283
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:22:58 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 6112
Last-modified: Tue, 16 Jul 1996 23:13:55 GMT
</DOCHDR>
<html>

	<head>
		<title>Mercury Dealerships</title>
	</head>

<body TEXT="#FFFFFF" LINK="#95A401" VLINK="#F4C7B2" ALINK="#FF0000" BGCOLOR="#000000">

<br>
<table width="100%">
<tr>

<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>

<td align="center">

<hr width="50%">

<h1><a name="mercury">Mercury Dealerships</a></h1>

<hr width="50%">
</td>

<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>

</tr>
</table><br><br>
<p>


<table width="100%" border="10">
<tr>
<td valign="top" width="50%">
<ul>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Ames Brothers Motors</a></font><br>
<font size="+1">
1001 E. Third St.<br>
Flagstaff, AZ 86047<br>
520/289-3354</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Bill Alexander</a></font><br>
<font size="+1">
801 E. 32nd St.<br> 
Yuma, AZ 85364 <br>
520/344-2200</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Bill McGlocklin Ford, Lincoln, Mercury</a></font><br>
<font size="+1">
310 E. Highway 70<br>
Safford, AZ 85545<br>
520/428-1770</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Bradley Ford Lincoln Mercury</a></font><br>
<font size="+1">
1515 W. Broadway<br>
Mesa, AZ 85202<br>
520/855-1191</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Cholla Ford </a></font><br>
<font size="+1">
755 E. 4th St.<br> 
Benson, AZ 85602 <br>
520/586-3661</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Covey Lincoln Mercury</a></font><br>
<font size="+1">
1330 E. Camelback Rd.<br>
Phoenix, AZ 85014<br>
602/264-1851</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Fiesta Lincoln Mercury</a></font><br>
<font size="+1">
1720 S. Mesa Dr.<br>
Mesa, AZ  85210<br>
602/813-4900</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Frank Cummings Ford Lincoln Mercury</a></font><br>
<font size="+1">
PO Box 428<br>
1777 N. Grand Ave <br>
Tucson, AZ  85621<br>
520/281-1976</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Galpin Ford</a></font><br>
<font size="+1">
1000 Sandrello Dr.<br>
Prescott, AZ 86301<br>
520/445-3673</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Glenn Jones Ford Lincoln Mercury</a></font><br>
<font size="+1">
1648 N. Final Ave.<br>
Casa Grande, AZ 85222<br>
520/963-6111</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Hudgeons Ford Mercury</a></font><br>
<font size="+1">
PO Box 130<br>
296 N. Arizona Blvd.<br>
Phoenix, AZ  85228<br>
520/723-5479</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Jack Ross Lincoln Mercury</a></font><br>
<font size="+1">
2700 N. Scottsdale Rd.<br> 
Tempe, AZ 85281<br>
602/994-4500</font>
</ul>
</td>
<td valign="top" width="50%">
<ul>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Jim Babbitt Ford</a></font><br>
<font size="+1">
11 N. Verde B6001<br>
Flagstaff, AZ 86002<br>
520/774-5063</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Jim Click Ford Lincoln Mercury</a></font><br>
<font size="+1">
6420 E. 22nd St.<br>
Tucson, AZ 85732<br>
520/747-2000</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">McSpadden Ford</a></font><br>
<font size="+1">
601 N. Broad St.<br>
Globe, AZ 85501<br>
520/425-4491</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Page Ford</a></font><br>
<font size="+1">
619 S. Lake Powell Blvd.<br>
Page, AZ 86040<br>
520/645-3656</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Parker Motor</a></font><br>
<font size="+1">
920 Arizona Ave.<br> 
Parker, AZ 85344<br>
520/669-2291</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Phil White Ford</a></font><br>
<font size="+1">
P.O. Box 159<br>
256131 State Hwy260<br>
Payson,AZ 85541<br>
520/474-8888</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">San-Man Ford Mercury</a></font><br>
<font size="+1">
130 N. Rodington<br>
San Manuel, AZ 85631<br>
520/385-2212</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Sanderson Lincoln Mercury</a></font><br>
<font size="+1">
2121 W. Bell Rd.<br> 
Phoenix, AZ 85023<br>
602/375-7562</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Scott Nichols Motors</a></font><br>
<font size="+1">
6850 E. McDowell Rd.<br> 
Scottsdale, AZ 85257<br>
520/458-8140</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Verde Valley Ford Lincoln Mercury</a></font><br>
<font size="+1">
1516 E.Cottonwood<br>
Cottonwood,AZ 86326<br>
520/634-2291</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html"> White Mountain Motors</a></font><br>
<font size="+1">
1920 E. Deuce of Clubs<br> 
Show Love, AZ 85901<br> 
520/537-5767</font>

</ul>
</td>
</tr>
</table>

<br><br><br><br>

<center>

<hr width="50%">

<font size="+1">

Return to the <a href="http://aada.dasta.com/automall.html">graphics oriented Auto Mall</a>.
<p>
Return to the <a href="http://aada.dasta.com/autmall2.html">text oriented Auto Mall</a>.

</font>

</center>

<br><br><br><br><br><br>


<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="gif/dastasig.gif" alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 21 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996 <a href="http://www.dasta.com">Dasta VendorCat</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">"This site was designed by DASTA VENDORCAT,<br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of <a href="http://www.dasta.com/anet.html">Association-Net</a><sup>TM</sup>."</font></p>
</center>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-126</DOCNO>
<DOCOLDNO>IA058-000947-B027-362</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/mall/mitsubishifin.html 206.97.63.16 19970109194024 text/html 3070
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:23:07 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 2899
Last-modified: Tue, 16 Jul 1996 23:13:55 GMT
</DOCHDR>
<html>

	<head>
		<title>Mitsubishi Dealerships</title>
	</head>

<body TEXT="#FFFFFF" LINK="#95A401" VLINK="#F4C7B2" ALINK="#FF0000" BGCOLOR="#000000">

<br>

<table width="100%">
<tr>

<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>

<td align="center">

<hr width="50%">

<h1><a name="mitsubishi">Mitsubishi Dealerships</a></h1>

<hr width="50%">
</td>

<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>
</tr>

</table><br><br>

<p>

<table width="100%" border="10">
<tr>

<td width="50%" valign="top">

<ul>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Beaudry Motor Company</a></font><br>
<font size="+1">
4646 E. 22nd St.<br>
Tucson, AZ 85732<br>
520/748-1000</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Bell Road Mazda/Mitsubishi/Hyundai</a></font><br>
<font size="+1">
2121 W. Bell Rd.<br>
Phoenix, AZ 85023<br>
602/993-3322</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Camelback Mitsubishi</a></font><br>
<font size="+1">
1303 E. Camelback Rd.<br>
Phoenix, AZ 85014<br>
602/265-3200</font>
</ul>
</td>
<td valign="top" width="50%">
<ul>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Glendale Mitsubishi</a></font><br>
<font size="+1">
4434 W. Glendale<br>
Glendale, AZ 85301<br>
602/934-1111</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Honda Cars of Mesa/Mesa Mitsubishi</a></font><br>
<font size="+1">
1320 W. Broadway<br>
Mesa, AZ  85202<br>
602/833-5177</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Scottsdale Auto Center</a></font><br>
<font size="+1">
6440 E. McDowell Rd.<br>
Scottsdale, AZ 85257<br>
602/945-4000</font>


</ul>
</td>
</tr>
</table>

<br><br><br><br>

<center>

<hr width="50%">

<font size="+1">
Return to the <a href="http://aada.dasta.com/automall.html">graphics oriented Auto Mall</a>.
<p>
Return to the <a href="http://aada.dasta.com/autmall2.html">text oriented Auto Mall</a>.
</font>

</center>

<br><br><br><br><br><br>

<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="gif/dastasig.gif" alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 21 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996 <a href="http://www.dasta.com">Dasta VendorCat</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">"This site was designed by DASTA VENDORCAT,<br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of <a href="http://www.dasta.com/anet.html">Association-Net</a><sup>TM</sup>."</font></p>
</center>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-127</DOCNO>
<DOCOLDNO>IA058-000947-B027-377</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/mall/nissanfin.html 206.97.63.16 19970109194031 text/html 4366
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:23:14 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 4195
Last-modified: Fri, 26 Jul 1996 10:04:14 GMT
</DOCHDR>
<html>

	<head>
		<title>Nissan Dealers</title>
	</head>

<body TEXT="#FFFFFF" LINK="#95A401" VLINK="#F4C7B2" ALINK="#FF0000" BGCOLOR="#000000">

<br>

<table width="100%">
<tr>

<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>

<td align="center">
<hr width="50%">

<h1><a name="nissan">Nissan Dealers</a></h1>

<hr width="50%">
</td>

<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>
</tr>
</table>

<br><br>
<p>

<table width="100%" border="10">
<tr>
<td valign="top" width="50%">
<ul>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">ABC Nissan</a></font><br>
<font size="+1">
1300 E. Camelback Rd.<br> 
Phoenix, AZ 85014<br>
602/264-2332</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Brown &amp; Brown Nissan</a></font><br>
<font size="+1">
7755 S. Autoplex Loop,<br> 
Tempe, AZ 85284<br>
602/698-6000</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Brown &amp; Brown Nissan - Mesa</a></font><br>
<font size="+1">
1701 W. Broadway Rd.,<br>
Mesa, AZ 85202<br>
602/834-0220</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Cerbat Hills Lincoln Mercury Nissan</a></font><br>
<font size="+1">
3505 N. Stockton Hill Rd.<br>
Kingman, AZ  86401<br>
520/757-3131 </font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Cropper's Nogales Auto Center</a></font><br>
<font size="+1">
1831 N. Grand Ave.<br>
Nogales, AZ 85521<br>
520/836-2147</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Flagstaff Nissan Subaru</a></font><br>
<font size="+1">
2020 E. Route 66<br> 
Flagstaff, AZ 86003<br>
520/774-9163</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Healy Auto Center</a></font><br> 
<font size="+1">
HW 60,<br> 
Globe, AZ 85502<br>
520/425-3283</font>
</ul>
</td>
<td valign="top" width="50%">
<ul>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Jim Click Nissan</a></font><br>
<font size="+1">
800 W. Auto Mall Drive<br> 
Tucson, AZ 85705<br>
520/884-4100</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">The Johnson Motors Corp.</a></font><br>
<font size="+1">
804 First Ave.<br> 
Casa Grande, AZ 85548<br>
520/428-0140</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Lawley Automotive Center</a></font><br>
<font size="+1">
2900 E. Fry Blvd.,<br> 
Sierra Vista, AZ 85635<br>
520/458-2141</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/~sonora">Sonora Nissan</a></font><br>
<font size="+1">
2000 E.32nd St.<br>
Yuma,AZ 85365<br>
520/726-0525</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Thoroughbred Cars</a></font><br>
<font size="+1">
5163 E.22nd Street<br>
Tucson,AZ 85711<br>
520/790-4941</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">West Valley Nissan</a></font><br>
<font size="+1">
P.O. Box 1497<br>
4850 W. Glendale Ave.<br> 
Glendale, AZ 85311<br>
602/934-3444</font>

</ul>
</td>
</tr>
</table>

<br><br><br><br>

<center>

<hr width="50%">

<font size="+1">
Return to the <a href="http://aada.dasta.com/automall.html">graphics oriented Auto Mall</a>.
<p>
Return to the <a href="http://aada.dasta.com/autmall2.html">text oriented Auto Mall</a>.
</font>

</center>

<br><br><br><br><br><br>

<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="gif/dastasig.gif" alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 21 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996 <a href="http://www.dasta.com">Dasta VendorCat</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">"This site was designed by DASTA VENDORCAT,<br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of <a href="http://www.dasta.com/anet.html">Association-Net</a><sup>TM</sup>."</font></p>
</center>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-128</DOCNO>
<DOCOLDNO>IA058-000947-B027-391</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/mall/oldsmobilefin.html 206.97.63.16 19970109194040 text/html 5150
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:23:21 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 4979
Last-modified: Wed, 17 Jul 1996 17:07:34 GMT
</DOCHDR>
<html>

	<head>
		<title>Oldsmobile Dealerships</title>
	</head>

<body TEXT="#FFFFFF" LINK="#95A401" VLINK="#F4C7B2" ALINK="#FF0000" BGCOLOR="#000000">

<br>

<table width="100%">

<tr>

<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>

<td align="center">
<hr width="50%">

<h1><a name="oldsmobile">Oldsmobile Dealerships</a></h1>

<hr width="50%">
</td>

<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>
</tr>

</table><br><br>

<p>

<table width="100%" border="10">
<tr>
<td valign="top" width="50%">
<ul>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Big Two Oldsmobile/Toyota</a></font><br>
<font size="+1">
1301 W. Broadway,<br>
Mesa, AZ 85211<br>
602/898-6000</font>

<p>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Biddulph Oldsmobile</a></font><br>
<font size="+1">
4611 W. Glendale Ave.<br>
Glendale, AZ 85338<br>
602/534-5211</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Bill Alexander</a></font><br>
<font size="+1">
801 E. 32nd St.<br>
Yuma, AZ  85364 <br>
520/344-2200</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/~bromm">Bromm Chevrolet, Oldsmobile, Buick</a></font><br>
<font size="+1">
P.O. Drawer 1389<br> 
Wickenburg, AZ 85358<br>
520/258-4120</font>
 
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Chapman Scottsdale Autoplex</a></font><br>
<font size="+1">
6601 E. McDowell Rd.<br> 
Scottsdale, AZ 85257<br>
602/949-7600</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Cliff Findlay Auto</a></font><br>
<font size="+1">
1001 Hwy.95<br> 
Bullhead City, AZ 86430<br>
800/852-6584</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Cliff Findlay Auto</a></font><br>
<font size="+1">
3730 N. Stockton Hill Rd.,<br> 
Kingman, AZ 86101<br>
800/574-4417</font>

<p> 
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Cobre Valley Motors</a></font><br>
<font size="+1">
1500 N. Broad<br> 
Globe, AZ 85501<br>
520/425-4487</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Garrett Motors</a></font><br>
<font size="+1">
197 N. Arizona Blvd.<br>
Coolidge, AZ 85228<br>
520/723-5401</font>

</ul>
</td>
<td valign="top" width="50%">
<ul>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Gary Cropper Auto</a></font><br>
<font size="+1">
1990 N. Pinal Ave.<br>
Casa Grande, AZ  85222<br>
520/836-2147</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Horne Auto</a></font><br>
<font size="+1">
PO Box 2767<br>
651 E. Deuce of Clubs<br>
Show Low, AZ  85901<br>
520/537-5500</font>
 
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">The Johnson Motors Corp.</a></font><br>
<font size="+1">
804 First Ave.<br>
Casa Grande, AZ 85548<br>
520/428-0140</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Konick Oldsmobile</a></font><br>
<font size="+1">
6350 E. Grant Rd.<br>
Tucson, AZ 85715<br>
520/721-2400</font>

<p>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Lawley Automotive Center</a></font><br>
<font size="+1">
2900 E. Fry Blvd.<br>
Sierra Vista, AZ 85635<br>
520/458-2141</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Mackey Oldsmobile-Cadillac</a></font><br>
<font size="+1">
2121 E. Broadway<br> 
Tucson, AZ 85719<br>
520/345-7700</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">McCoy Motors</a></font><br>
<font size="+1">
361 N. Switzer Canyon Dr.<br>
Flagstaff, AZ 86001<br>
520/774-1472</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Southern Arizona Auto Company</a></font><br>
<font size="+1">
1200 "G" Ave.<br> 
Douglas, AZ 85607<br>
520/364-2424</font>

</ul>
</td>
</tr>
</table>

<br><br><br><br>

<center>

<hr width="50%">

<font size="+1">

Return to the <a href="http://aada.dasta.com/automall.html">graphics oriented Auto Mall</a>.
<p>
Return to the <a href="http://aada.dasta.com/autmall2.html">text oriented Auto Mall</a>.

</font>

</center>

<br><br><br><br><br><br>
<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="gif/dastasig.gif" alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 21 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996 <a href="http://www.dasta.com">Dasta VendorCat</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">"This site was designed by DASTA VENDORCAT,<br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of <a href="http://www.dasta.com/anet.html">Association-Net</a><sup>TM</sup>."</font></p>
</center>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-129</DOCNO>
<DOCOLDNO>IA058-000947-B027-406</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/mall/plymouthfin.html 206.97.63.16 19970109194047 text/html 6392
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:23:30 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 6221
Last-modified: Wed, 28 Aug 1996 14:18:34 GMT
</DOCHDR>
<html>

        <head>
                <title>Plymouth Dealerships</title>
        </head>

<body TEXT="#FFFFFF" LINK="#95A401" VLINK="#F4C7B2" ALINK="#FF0000" BGCOLOR="#000000">

<br>

<table width="100%">
<tr>

<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>

<td align="center">

<hr width="50%">

<h1><a name="plymouth">Plymouth Dealerships</a></h1>

<hr width="50%">

</td>

<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>

</tr>
</table><br><br>

<p>
<table width="100%" border="10">
<tr>
<td valign="top" width="50%">
<ul>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Ames Brothers Motors</a></font><br>
<font size="+1">
1001 E. Third St.<br> 
Flagstaff, AZ 86047<br>
520/289-3354</font>

<p>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Arnold Motor Sales</a></font><br>
<font size="+1">
1201 S Hwy 80<br> 
Benson, AZ 85602<br>
520/689-2481</font>

<p>

<li><font size="+2"><a href="http://aada.dasta.com/~avondale">Avondale Motors</a></font><br>
<font size="+1">
803 East Van Buren<br>
Avondale, AZ  85323<br>
602/925-0011</font>

<p>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Biddulph Pontiac/ GMC/ Chrysler/ Plymouth/ Jeep Eagle</a></font><br>
<font size="+1">
4510 W. Glendale Ave.,<br> 
Glendale, AZ 85301<br>
602/931-9111</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/~billluke">Bill Luke Chrysler Plymouth Jeep Eagle Dodge</a></font><br>
<font size="+1">
2425 W.Camelback Rd.<br>
Phoenix,AZ 85015<br>
602/249-1234</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Chapman Auto Center</a></font><br>
<font size="+1">
198 N. Beeline Hwy.,<br> 
Payson, AZ 85547<br>
520/474-5261</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/~corral">The Corral Chrysler Plymouth Dodge Jeep Eagle</a></font><br>
<font size="+1">
669 N. Lake Havasu,<br> 
Lake Havasu City, AZ 86403<br>
520/855-5153</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Darner Motor Sales</a></font><br> 
<font size="+1">
837 W. Main St.<br>
Mesa, AZ 85201<br>
602/969-7311</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Diamond Dodge/Chrysler/Plymouth</a></font><br>
<font size="+1">
350 Switzer Canyon Dr.,<br> 
Flagstaff, AZ 86001<br>
602/779-3641</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Earnhardt Chrysler Plymouth</a></font><br>
<font size="+1">
577 E. Baseline Rd. <br>
Tempe, AZ  85283<br> 
602/345-7700</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Ed Moses Dodge, Chrysler, Plymouth</a></font><br>
<font size="+1">
861 W. Mariposa Rd.,<br> 
Peoria, AZ 85382<br>
520/281-2111</font>
 </ul>
 </td>
 <td valign="top" width="50%">
 <ul>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Fisher Chrysler Plymouth Dodge Jeep Eagle</a></font><br>
<font size="+1">
349 E. 32nd St.,<br> 
Yuma, AZ 85364<br>
520/344-2650</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Hatch Brothers</a></font><br>
<font size="+1">
1623 Thatcher Blvd.<br>
Safford, AZ  85545<br>
520/428-6000</font>
 
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Healy Auto Center</a></font><br>
<font size="+1">
Hwy. 60<br>
Globe, AZ 85502<br>
520/425-3283</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Larry Miller Chrysler Plymouth Jeep-Eagle</a></font><br>
<font size="+1">
4600 W. Glendale Ave.,<br> 
Glendale, AZ 85301<br>
602/842-8500</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Moore Chrysler Plymouth</a></font><br>
<font size="+1">
8600 W. Bell Rd.,<br> 
Peoria, AZ 85382<br>
602/972-6004</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Munday Motors</a></font><br>
<font size="+1">
1201 S Hwy 80,<br> 
Benson, AZ 85602<br>
520/586-2236</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">O'Reilly Chrysler Plymouth Dodge Jeep Eagle</a></font><br>
<font size="+1">
1901 S. Highway 92,<br> 
Sierra Vista, AZ 85635<br>
520/458-8000</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Oxendale Chrysler Plymouth Dodge Jeep Eagle</a></font><br>
<font size="+1">
792 Hwy 89-A East,<br> 
Cottonwood, AZ  86326<br>
520/654-5450</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Pitre Chrysler Plymouth Jeep Eagle</a></font><br>
<font size="+1">
3121 E. Bell Rd.,<br> 
Phoenix, AZ 85022<br>
602/493-8000</font>

<p>
<li><font size="+2"><a href="http://companion.org/~york">York Motors</a></font><br>
<font size="+1">
209 North Montezuma Street<br>
Prescott, AZ  86301<br>
520/445-4970<br>
800/894-4970</font>


</ul>
</td>
</tr>
</table>

<br><br><br><br>

<center>

<hr width="50%">

<font size="+1">

Return to the <a href="http://aada.dasta.com/automall.html">graphics oriented Auto Mall</a>.
<p>
Return to the <a href="http://aada.dasta.com/autmall2.html">text oriented Auto Mall</a>.

</font>

</center>

<br><br><br><br><br><br>

<table>

        <tr>
                <th colspan="2"><HR></th>
        </tr>
        
        <tr>
                <td valign="middle"><a href="http://www.dasta.com">
                        <img src="gif/dastasig.gif" alt="DASTA VendorCat logo" border="0"></a></td>
                <td>
                        <font size="-1">Last Updated: 21 Jun 96<br>
                        Comments/Questions: <a href="mailto:webmaster@dasta.com">
                                webmaster@dasta.com</a><br>
                        Copyright &#169; 1996 <a href="http://www.dasta.com">Dasta VendorCat</a>.
                                All rights reserved</font>.
                </td>
        </tr>
        
        <tr>
                <th colspan="2"><hr></th>
        </tr>

</table>

<center>
        <p><font size="-1">"This site was designed by DASTA VENDORCAT,<br>
        the Nation's Leading Internet Presence Provider for Associations<br>
        and the Sponsor of <a href="http://www.dasta.com/anet.html">Association-Net</a><sup>TM</sup>."</font></p>
</center>



</body>
</html>

</DOC>
<DOC>
<DOCNO>WT08-B13-130</DOCNO>
<DOCOLDNO>IA058-000947-B027-416</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/mall/porschefin.html 206.97.63.16 19970109194053 text/html 2045
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:23:37 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 1874
Last-modified: Tue, 16 Jul 1996 23:13:53 GMT
</DOCHDR>
<html>

	<head>
		<title>Porsche Dealerships</title>
	</head>

<body TEXT="#FFFFFF" LINK="#95A401" VLINK="#F4C7B2" ALINK="#FF0000" BGCOLOR="#000000">

<br>

<table width="100%">

<tr>

<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>

<td align="center">
<hr width="50%">

<h1><a name="porsche">Porsche Dealerships</a></h1>

<hr width="50%">
</td>

<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>

</tr>
</table><br><br>
<p>

<table width="100%" border="10">
<tr>
<td valign="top">
<ul>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Beaudry Motor Company</a></font><br>
<font size="+1">
4646 E. 22nd St.<br>
Tucson, AZ 85732<br>
520/748-1000</font>
</ul>

</td>
</tr>
</table>


<br><br><br><br>

<center>

<hr width="50%">

<font size="+1">

Return to the <a href="http://aada.dasta.com/automall.html">graphics oriented Auto Mall</a>.
<p>
Return to the <a href="http://aada.dasta.com/autmall2.html">text oriented Auto Mall</a>.

</font>

</center>

<br><br><br><br><br><br>

<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="gif/dastasig.gif" alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 21 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996 <a href="http://www.dasta.com">Dasta VendorCat</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">"This site was designed by DASTA VENDORCAT,<br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of <a href="http://www.dasta.com/anet.html">Association-Net</a><sup>TM</sup>."</font></p>
</center>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-131</DOCNO>
<DOCOLDNO>IA058-000947-B027-433</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/mall/rolls_roycefin.html 206.97.63.16 19970109194103 text/html 2303
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:23:46 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 2132
Last-modified: Tue, 16 Jul 1996 23:13:53 GMT
</DOCHDR>
<html>

	<head>
		<title>Rolls-Royce Dealerships</title>
	</head>

<body TEXT="#FFFFFF" LINK="#95A401" VLINK="#F4C7B2" ALINK="#FF0000" BGCOLOR="#000000">

<br>

<table width="100%">

<tr>
<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>

<td align="center">

<hr width="50%">

<h1><a name="rolls-royce">Rolls-Royce Dealerships</a></h1>

<hr width="50%">

</td>
<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>

</tr>
</table><br><br>
<p>

<table width="100%" border="10">
<tr>
<td valign="top" width="50%">

<ul>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Auto Koenig Scottsdale</a></font><br>
<font size="+1">
9620 N. Scottsdale Rd.<br>
Scottsdale, AZ 85251<br>
602/945-4545</font>
</ul>
</td>
<td valign="top" width="50%">
<ul>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Cavalliac Classics</a></font><br>
<font size="+1">
7652 E. Acoma<br>
Scottsdale, AZ 85260<br>
602/991-5322</font>

</ul>
</td>
</tr>
</table>
<br><br><br><br>

<center>

<hr width="50%">

<font size="+1">

Return to the <a href="http://aada.dasta.com/automall.html">graphics oriented Auto Mall</a>.
<p>
Return to the <a href="http://aada.dasta.com/autmall2.html">text oriented Auto Mall</a>.

</font>

</center>

<br><br><br><br><br><br>
<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="gif/dastasig.gif" alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 21 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996 <a href="http://www.dasta.com">Dasta VendorCat</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">"This site was designed by DASTA VENDORCAT,<br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of <a href="http://www.dasta.com/anet.html">Association-Net</a><sup>TM</sup>."</font></p>
</center>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-132</DOCNO>
<DOCOLDNO>IA058-000947-B027-440</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/mall/saabfin.html 206.97.63.16 19970109194110 text/html 2046
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:23:53 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 1875
Last-modified: Tue, 16 Jul 1996 23:13:52 GMT
</DOCHDR>
<html>

	<head>
		<title>Saab Dealerships</title>
	</head>

<body TEXT="#FFFFFF" LINK="#95A401" VLINK="#F4C7B2" ALINK="#FF0000" BGCOLOR="#000000">

<br>

<table width="100%">
<tr>

<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>

<td align="center">

<hr width="50%">

<h1><a name="saab">Saab Dealerships</a></h1>

<hr width="50%">

</td>

<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>

</tr>

</table><br><br>

<p>

<table width="100%" border="10">
<tr>
<td valign="top">

<ul>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Camelback VW/Saab/Subaru</a></font><br>
<font size="+1">
1499 E. Camelback Rd.<br>
Phoenix, AZ 85014<br>
602/265-6600</font>

</ul>
</td>
</tr>
</table>
<br><br><br><br>

<center>

<hr width="50%">

<font size="+1">

Return to the <a href="http://aada.dasta.com/automall.html">graphics oriented Auto Mall</a>.
<p>
Return to the <a href="http://aada.dasta.com/autmall2.html">text oriented Auto Mall</a>.

</font>

</center>

<br><br><br><br><br><br>
<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="gif/dastasig.gif" alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 21 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996 <a href="http://www.dasta.com">Dasta VendorCat</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">"This site was designed by DASTA VENDORCAT,<br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of <a href="http://www.dasta.com/anet.html">Association-Net</a><sup>TM</sup>."</font></p>
</center>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-133</DOCNO>
<DOCOLDNO>IA058-000947-B027-454</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/mall/saturnfin.html 206.97.63.16 19970109194118 text/html 2463
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:24:00 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 2292
Last-modified: Tue, 16 Jul 1996 23:13:52 GMT
</DOCHDR>
<html>

	<head>
		<title>Saturn Dealerships</title>
	</head>

<body TEXT="#FFFFFF" LINK="#95A401" VLINK="#F4C7B2" ALINK="#FF0000" BGCOLOR="#000000">

<br>

<table width="100%">

<tr>
<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>

<td align="center">
<hr width="50%">

<h1><a name="saturn">Saturn Dealerships</a></h1>

<hr width="50%">
</td>
<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>
</tr>
</table>
<br><br>
<p>

<table width="100%" border="10">
<tr>
<td valign="top" width="50%">

<ul>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Beaudry Motor Company</a></font><br>
<font size="+1">
4646 E. 22nd St.<br>
Tucson, AZ 85732<br>
520/748-1000</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Saturn of Glendale</a></font><br>
<font size="+1">
4610 W. Camelback Rd.<br>
Glendale, AZ 85301<br>
602/254-1111</font>
</ul>
</td>
<td valign="top" width="50%">
<ul>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Saturn of Tempe</a></font><br>
<font size="+1">
7799 S. Autoplex Loop<br>
Tempe, AZ 85284<br>
602/496-8888</font>

</ul>
</td>
</tr>
</table>
<br><br><br><br>

<center>

<hr width="50%">

<font size="+1">

Return to the <a href="http://aada.dasta.com/automall.html">graphics oriented Auto Mall</a>.
<p>
Return to the <a href="http://aada.dasta.com/autmall2.html">text oriented Auto Mall</a>.

</font>

</center>

<br><br><br><br><br><br>
<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="gif/dastasig.gif" alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 21 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996 <a href="http://www.dasta.com">Dasta VendorCat</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">"This site was designed by DASTA VENDORCAT,<br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of <a href="http://www.dasta.com/anet.html">Association-Net</a><sup>TM</sup>."</font></p>
</center>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-134</DOCNO>
<DOCOLDNO>IA058-000947-B027-471</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/mall/suburufin.html 206.97.63.16 19970109194127 text/html 2492
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:24:09 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 2321
Last-modified: Tue, 16 Jul 1996 23:13:51 GMT
</DOCHDR>
<html>
	
	<head>
		<title>Subaru Dealerships</title>
	</head>

<body TEXT="#FFFFFF" LINK="#95A401" VLINK="#F4C7B2" ALINK="#FF0000" BGCOLOR="#000000">

<br>

<table width="100%">
<tr>
<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>

<td align="center">

<hr width="50%">

<h1><a name="suburu">Subaru Dealerships</a></h1>

<hr width="50%">
</td>

<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>

</tr>
</table><br><br>
<p>

<table width="100%" border="10">
<tr>
<td valign="top" width="50%">
<ul>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Camelback VW/Saab/Subaru</a></font><br>
<font size="+1">
1499 E. Camelback Rd.<br>
Phoenix, AZ 85014<br>
602/265-6600</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Flagstaff Nissan Subaru</a></font><br>
<font size="+1">
2020 E. Route 66<br>
Flagstaff, AZ 86003<br>
520/774-9163</font>

</ul>
</td>
<td valign="top" width="50%">
<ul>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Horne Auto</a></font><br>
<font size="+1">
PO Box 2767 <br>
651 E. Deuce of Clubs <br>
Show Low, AZ  85901 <br>
520/537-5500</font>

</ul>
</td>
</tr>
</table>
<br><br><br><br>

<center>

<hr width="50%">

<font size="+1">
Return to the <a href="http://aada.dasta.com/automall.html">graphics oriented Auto Mall</a>.
<p>
Return to the <a href="http://aada.dasta.com/autmall2.html">text oriented Auto Mall</a>.
</font>

</center>

<br><br><br><br><br><br>
<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="gif/dastasig.gif" alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 21 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996 <a href="http://www.dasta.com">Dasta VendorCat</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">"This site was designed by DASTA VENDORCAT,<br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of <a href="http://www.dasta.com/anet.html">Association-Net</a><sup>TM</sup>."</font></p>
</center>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-135</DOCNO>
<DOCOLDNO>IA058-000947-B027-488</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/mall/suzukifin.html 206.97.63.16 19970109194138 text/html 2286
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:24:21 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 2115
Last-modified: Tue, 16 Jul 1996 23:13:51 GMT
</DOCHDR>
<html>

	<head>
		<title>Suzuki Dealerships</title>
	</head>

<body TEXT="#FFFFFF" LINK="#95A401" VLINK="#F4C7B2" ALINK="#FF0000" BGCOLOR="#000000">

<br>

<table width="100%">
<tr>
<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>
<td align="center">

<hr width="50%">

<h1><a name="suzuki">Suzuki Dealerships</a></h1>

<hr width="50%">
</td>

<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>
</tr>
</table><br><br>

<p>
<table width="100%" border="10">
<tr>
<td valign="top" width="50%">
<ul>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Lou Grubb Hyundai/Suzuki</a></font><br>
<font size="+1">
4620 W. Camelback Rd<br>
Phoenix, AZ  85301<br>
934-8555</font>
</ul>
</td>
<td valign="top" width="50%">
<ul>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Pitre Buick/Isuzu/Suzuki</a></font><br>
<font size="+1">
6640 E. McDowell Rd.<br>
Scottsdale, AZ 85257<br>
994-9451</font>

</ul>
</td>
</tr>
</table>
<br><br><br><br>

<center>

<hr width="50%">

<font size="+1">
Return to the <a href="http://aada.dasta.com/automall.html">graphics oriented Auto Mall</a>.
<p>
Return to the <a href="http://aada.dasta.com/autmall2.html">text oriented Auto Mall</a>.
</font>

</center>

<br><br><br><br><br><br>
<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="gif/dastasig.gif" alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 21 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996 <a href="http://www.dasta.com">Dasta VendorCat</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">"This site was designed by DASTA VENDORCAT,<br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of <a href="http://www.dasta.com/anet.html">Association-Net</a><sup>TM</sup>."</font></p>
</center>

 </body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-136</DOCNO>
<DOCOLDNO>IA058-000947-B027-506</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/mall/toyotafin.html 206.97.63.16 19970109194146 text/html 3551
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:24:30 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 3380
Last-modified: Tue, 16 Jul 1996 23:13:51 GMT
</DOCHDR>
<html>

	<head>
		<title>Toyota Dealerships</title>
	</head>

<body TEXT="#FFFFFF" LINK="#95A401" VLINK="#F4C7B2" ALINK="#FF0000" BGCOLOR="#000000">

<br>

<table width="100%">
<tr>
<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>

<td align="center">
<hr width="50%">
<h1><a name="toyota">Toyota Dealerships</a></h1>
<hr width="50%">
</td>

<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>
</tr>

</table><br><br>
<p>

<table width="100%" border="10">
<tr>
<td width="50%" valign="top">

<ul>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Bell Road Toyota</a></font><br>
<font size="+1">
2023 W. Bell Rd.<br>
Phoenix, AZ 85023<br> 
602/863-0600</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Big Two Oldsmobile/Toyota</a></font><br>
<font size="+1">
1301 W. Broadway<br>
Mesa, AZ 85211<br>
602/898-6000</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Bill Alexander</a></font><br>
<font size="+1">
801 E. 32nd St.<br>
Yuma, AZ 85364 <br>
520/344-2200</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Camelback Toyota</a></font><br>
<font size="+1">
1500 E. Camelback Rd.<br>
Phoenix, AZ 85014<br>
602/261-2841</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Desert Toyota</a></font><br>
<font size="+1">
7150 E. 22nd St. <br>
Tucson, AZ  85710 <br>
520/296-8535</font>
</ul>
</td>
<td valign="top" width="50%">
<ul>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Larry Miller Toyota</a></font><br>
<font size="+1">
4701 W. Glendale Ave.<br>
Glendale, AZ 85301<br>
602/272-3521</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">McCoy Motors</a></font><br>
<font size="+1">
361 N. Switzer Canyon Dr.<br>
Flagstaff, AZ 86001<br>
520/774-1472</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Precision Toyota</a></font><br>
<font size="+1">
3500 E. Speedway<br>
Tucson, AZ 85616<br>
520/795-5565</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Sierra Toyota</a></font><br>
<font size="+1">
2596 E. Fry Blvd.<br>
Sierra Vista, AZ 85635<br>
520/458-8880</font>

</ul>
</td>
</tr>
</table>
<br><br><br><br>

<center>

<hr width="50%">

<font size="+1">

Return to the <a href="http://aada.dasta.com/automall.html">graphics oriented Auto Mall</a>.
<p>
Return to the <a href="http://aada.dasta.com/autmall2.html">text oriented Auto Mall</a>.

</font>

</center>

<br><br><br><br><br><br>
<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="gif/dastasig.gif" alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 21 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996 <a href="http://www.dasta.com">Dasta VendorCat</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">"This site was designed by DASTA VENDORCAT,<br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of <a href="http://www.dasta.com/anet.html">Association-Net</a><sup>TM</sup>."</font></p>
</center>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-137</DOCNO>
<DOCOLDNO>IA058-000947-B027-520</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/mall/volkswagenfin.html 206.97.63.16 19970109194157 text/html 2855
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:24:41 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 2684
Last-modified: Wed, 17 Jul 1996 20:19:42 GMT
</DOCHDR>
<html>

	<head>
		<title>Volkswagen Dealerships</title>
	</head>

<body TEXT="#FFFFFF" LINK="#95A401" VLINK="#F4C7B2" ALINK="#FF0000" BGCOLOR="#000000">

<br>

<table width="100%">

<tr>

<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>

<td align="center">
<hr width="50%">

<h1><a name="volkswagen">Volkswagen Dealerships</a></h1>

<hr width="50%">
</td>

<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>

</tr>
</table><br><br>
<p>

<table width="100%" border="10">
<tr>

<td valign="top" width="50%">
<ul>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Beaudry Motor Company</a></font><br>
<font size="+1">
4646 E. 22nd St.<br>
Tucson, AZ 85732<br>
520/748-1000</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/~berge">Berge Mazda/Volkswagen</a></font><br>
<font size="+1">
1515 W. Broadway<br>
Mesa, AZ 85202<br>
602/833-0001</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Camelback VW</a></font><br>
<font size="+1">
1499 E. Camelback Rd.<br>
Phoenix, AZ 85014<br>
602/265-6600</font>
</ul>
</td>
<td valign="top" width="50%">
<ul>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Chapman Scottsdale Autoplex</a></font><br>
<font size="+1">
6601 E. McDowell Rd.<br>
Scottsdale, AZ 85257<br>
602/949-7600</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Joe Florek Volkswagen Audi</a></font><br>
<font size="+1">
1050 W. Hwy. 66<br>
Flagstaff, AZ 86001<br>
520/774-3393</font>

</ul>
</td>
</tr>
</table>
<br><br><br><br>

<center>

<hr width="50%">

<font size="+1">

Return to the <a href="http://aada.dasta.com/automall.html">graphics oriented Auto Mall</a>.
<p>
Return to the <a href="http://aada.dasta.com/autmall2.html">text oriented Auto Mall</a>.

</font>

</center>

<br><br><br><br><br><br>
<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="gif/dastasig.gif" alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 21 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996 <a href="http://www.dasta.com">Dasta VendorCat</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">"This site was designed by DASTA VENDORCAT,<br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of <a href="http://www.dasta.com/anet.html">Association-Net</a><sup>TM</sup>."</font></p>
</center>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-138</DOCNO>
<DOCOLDNO>IA058-000947-B027-536</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/mall/volvofin.html 206.97.63.16 19970109194204 text/html 2441
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:24:48 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 2270
Last-modified: Tue, 16 Jul 1996 23:13:50 GMT
</DOCHDR>
<html>

	<head>
		<title>Volvo Dealerships</title>
	</head>

<body TEXT="#FFFFFF" LINK="#95A401" VLINK="#F4C7B2" ALINK="#FF0000" BGCOLOR="#000000">

<br>

<table width="100%">

<tr>

<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>
<td align="center">

<hr width="50%">
<h1><a name="volvo">Volvo Dealerships</a></h1>
<hr width="50%">

</td>
<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>
</tr>
</table><br><br>
<p>

<table width="100%" border="10">
<tr>
<td valign="top" width="50%">

<ul>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Broadway Volvo</a></font><br>
<font size="+1">
930 E. Broadway<br>
Tucson, AZ 85719<br>
792-1070</font>
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Powell Volvo Mazda</a></font><br>
<font size="+1">
6500 E. McDowell Rd.<br>
Scottsdale, AZ 85257<br>
941-2400</font>
</ul>
</td>
<td valign="top" width="50%">
<ul>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Ray Tanner Volvo</a></font><br>
<font size="+1">
2134 W. Camelback Rd.<br>
Phoenix, AZ 85015<br>
246-7323</font>

</ul>
</td>
</tr>
</table>
<br><br><br><br>

<center>

<hr width="50%">

<font size="+1">
Return to the <a href="http://aada.dasta.com/automall.html">graphics oriented Auto Mall</a>.
<p>
Return to the <a href="http://aada.dasta.com/autmall2.html">text oriented Auto Mall</a>.
</font>

</center>

<br><br><br><br><br><br>
<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="gif/dastasig.gif" alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 21 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996 <a href="http://www.dasta.com">Dasta VendorCat</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">"This site was designed by DASTA VENDORCAT,<br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of <a href="http://www.dasta.com/anet.html">Association-Net</a><sup>TM</sup>."</font></p>
</center>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-139</DOCNO>
<DOCOLDNO>IA058-000947-B028-14</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/mall/pontiacfin.html 206.97.63.16 19970109194212 text/html 5263
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:24:55 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 5092
Last-modified: Wed, 31 Jul 1996 16:52:01 GMT
</DOCHDR>
<html>

<head>
        <title>Pontiac Dealerships</title>
</head>

<body TEXT="#FFFFFF" LINK="#95A401" VLINK="#F4C7B2" ALINK="#FF0000" BGCOLOR="#000000">

<br>

<table width="100%">

<tr>

<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>

<td align="center">
<hr width="50%">

<h1><a name="pontiac">Pontiac Dealerships</a></h1>

<hr width="50%">
</td>

<td width="25%" align="center"><img src="gif/amlogo.gif" alt="Auto Mall" border="0"></td>

</tr>
</table><br><br>

<p>

<table width="100%" border="10">
<tr>
<td valign="top" width="50%">
<ul>

<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Biddulph Pontiac/ GMC/ Chrysler/ Plymouth/ Jeep Eagle</a></font><br>
<font size="+1">
4510 W. Glendale Ave.<br> 
Glendale, AZ 85301<br>
602/931-9111</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Bud Beck Pontiac</a></font><br>
<font size="+1">
7000 E. McDowell,<br> 
Scottsdale, AZ 85271<br>
602/947-6311</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Cliff Findlay Auto</a></font><br>
<font size="+1">
3730 N. Stockton Hill Rd.<br> 
Kingman, AZ 86101<br>
800/574-4417</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Darner High Country</a></font><br>
<font size="+1">
411 E. Deuce of Clubs<br>
Flagstaff, AZ  85901<br>
520/537-4201</font>
 
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Healy Auto Center</a></font><br>
<font size="+1">
Hwy 60<br> 
Globe, AZ 85502<br>
520/425-3283</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Hendric Buick-Pontiac-GMC Truck</a></font><br>
<font size="+1">
777 S. Arizona Blvd.<br> 
Coolidge, AZ 85228<br>
602/723-5444</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">The Johnson Motors Corp.</a></font><br>
<font size="+1">
804 First Ave.,<br> 
Casa Grande, AZ 85548<br>
520/428-0140</font>
 
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Karl Moedl Automotive Group</a></font><br>
<font size="+1">
1125 E. 32nd St.<br> 
Yuma, AZ 85365<br>
520/726-6970</font>
 
</ul>
</td>
<td valign="top" width="50%">
<ul>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Lawley Automotive Center</a></font><br>
<font size="+1">
2900 E. Fry Blvd.<br> 
Sierra Vista, AZ 85635<br> 
520/458-2141</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">McCoy Motors</a></font><br>
<font size="+1">
361 N. Switzer Canyon Dr.<br> 
Flagstaff, AZ 86001<br>
520/774-1472</font>
 
<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Quebedeaux Pontiac</a></font><br>
<font size="+1">
3566 E. Speedway,<br> 
Tucson, AZ 85716<br>
520/795-5565</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Showcase Pontiac-GMC-Mazda</a></font><br>
<font size="+1">
4635 N. 7th St.<br> 
Phoenix, AZ 85014<br>
602/264-2481</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Southern Arizona Auto Company</a></font><br>
<font size="+1">
1200 "G" Ave.<br> 
Douglas, AZ 85607<br>
520/364-2424</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Steve Coury Buick Pontiac GMC Trucks</a></font><br>
<font size="+1">
18 N. Main,<br> 
Cottonwood, AZ 86326<br> 
520/634-9576</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/notyet.html">Sun Pontiac</a></font><br>
<font size="+1">
1600 W. Main Street<br> 
Mesa,AZ 85201<br>
602/835-0900</font>

<p>
<li><font size="+2"><a href="http://aada.dasta.com/~yates">Yates Pontiac GMC, Inc.</a></font><br>
<font size="+1">
104 N. Dysart Rd.<br> 
Avondale, AZ 85323<br>
602/932-1818</font>

</ul>
</td>
</tr>
</table>
<br><br><br><br>

<center>

<hr width="50%">

<font size="+1">

Return to the <a href="http://aada.dasta.com/automall.html">graphics oriented Auto Mall</a>.
<p>
Return to the <a href="http://aada.dasta.com/autmall2.html">text oriented Auto Mall</a>.

</font>

</center>

<br><br><br><br><br><br>

<table>

        <tr>
                <th colspan="2"><hr></th>
        </tr>

        <tr>
                <td valign="middle"><a href="http://www.dasta.com">
                        <img src="gif/dastasig.gif" alt="DASTA VendorCat logo" border="0"></a></td>
                <td>
                        <font size="-1">Last Updated: 21 Jun 96<br>
                        Comments/Questions: <a href="mailto:webmaster@dasta.com">
                                webmaster@dasta.com</a><br>
                        Copyright &#169; 1996 <a href="http://www.dasta.com">Dasta VendorCat</a>.
                                All rights reserved.</font>
                </td>
        </tr>

        <tr>
                <th colspan="2"><hr></th>
        </tr>

</table>

<center>
        <p><font size="-1">"This site was designed by DASTA VENDORCAT,<br> 
        the Nation's Leading Internet Presence Provider for Associations<br>
        and the Sponsor of <a href="http://www.dasta.com/anet.html">Association-Net</a><sup>TM</sup>."</font></p>
</center>

</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-140</DOCNO>
<DOCOLDNO>IA058-000947-B025-305</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/ 206.97.63.16 19970109193114 text/html 3202
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:13:57 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 3031
Last-modified: Wed, 24 Jul 1996 17:27:36 GMT
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">

<HTML>
<HEAD>
<TITLE>Arizona Automobile Dealers Association</TITLE>
</HEAD>

<body background="gif/aadatile1x.gif" bgcolor="#E5E0E0" text="#000628" link="#55083C" vlink="#00120A" ALINK="#220652">

<center>
<img src="gif/aadaheader.gif">
</center>
<br>
<center>


<font size=4><b>
A partner in representing the business<br>
and legislative needs of <br>
franchised auto dealers . 
</b></font>

<br>
<table border=2>

<td><img align=left src="gif/spacecars2.gif">
<td><font size=5><b>NEWS<br> FLASH</b></font><p>
<font size=3><A HREF="newstalk.html">Ray Korte, Jr. dies</A><br>
</table>
<br>
<br>
<br>
<br>
<a href="about.html"><img src="gif/baboutusbutton.gif" border=0 alt="About Us"></a>
<a href="frontdoor.html"><img src="gif/bautomallbutton.gif" border=0 alt="Auto Mall"></a>
<a href="membership.html"><img src="gif/bmemberbutton.gif" border=0 alt="Membership"></a><br>
<a href="contact.html"><img src="gif/bcontactbutton.gif" border=0 alt="Contact Us"></a>
<a href="vendor.html"><img src="gif/bvendorbutton.gif" border=0 alt="Vendor Services"></a>
<a href="consumer.html"><img src="gif/bconsumerbutton.gif" border=0 alt="Consumer Info"></a><br>
<a href="newstalk.html"><img src="gif/bnewsflashbutton.gif" border=0 alt="News Flash"></a>
<a href="arizona.html"><img src="gif/bazautobutton.gif" border=0 alt="Auto Centennial"></a>
<a href="store.html"><img src="gif/bstorebutton.gif" border=0 alt="Store"></a><br>
<p>
[ <a href="about.html">About AADA</a>
| <a href="frontdoor.html">Auto Mall</a>
| <a href="membership.html">Membership</a>]<br>
[ <a href="contact.html">Contact AADA</a>
| <a href="vendor.html">Vendor Services</a>
| <a href="consumer.html">Consumer Information</a>]<br>
[ <a href="newstalk.html">News Flash</a>
| <a href="arizona.html">Arizona Auto Centennial</a>
| <a href="store.html">Store</a> ]<br>
</center>
<p>
<center><a href="frontdoor.html"><img src="gif/autobar.gif" border=0 alt="Auto Mall"></a></center>
<center><a href="frontdoor.html">[ Auto Mall ]</a></center>
<p>
<center>
For inquiries or comments, e-mail: <a href="mailto:aada@dasta.com">aada@dasta.com</a><p>
<p>
</center>

<table>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

	<tr>
		<td valign="middle"><a href="http://www.dasta.com">
			<img src="http://www.dasta.com/gif/dastasig.gif"
			alt="DASTA VendorCat logo" border="0"></a></td>
		<td>
			<font size="-1">Last Updated: 25 Jun 96<br>
			Comments/Questions: <a href="mailto:webmaster@dasta.com">
				webmaster@dasta.com</a><br>
			Copyright &#169; 1996
				<a href="http://www.dasta.com">DASTA VendorCat, LLC</a>.
				All rights reserved.</font>
		</td>
	</tr>

	<tr>
		<th colspan="2"><hr></th>
	</tr>

</table>

<center>
	<p><font size="-1">This site was designed by 
		<a href="http://www.dasta.com">DASTA VendorCat</a><br> 
	the Nation's Leading Internet Presence Provider for Associations<br>
	and the Sponsor of
	<a href="http://www.dasta.com/anet.html">Association-Net</a>
	<sup>TM</sup></font></p>
</center>



</body>
</html>

</DOC>
<DOC>
<DOCNO>WT08-B13-141</DOCNO>
<DOCOLDNO>IA058-000947-B028-263</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/orielly/index.htm 206.97.63.16 19970109194442 text/html 880
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:27:26 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 710
Last-modified: Mon, 23 Dec 1996 22:38:52 GMT
</DOCHDR>

<HTML>
<HEAD>
<TITLE>O'Rielly Chevrolet Geo</TITLE></HEAD>
<BODY BACKGROUND="oriltile.gif">
<CENTER>

<MAP NAME="orielly">
<AREA SHAPE="rect" COORDS=71,114,139,137 HREF="history.htm">
<AREA SHAPE="rect" COORDS=182,14,248,40 HREF="lease.htm">
<AREA SHAPE="rect" COORDS=38,202,102,226 HREF="models.htm">
<AREA SHAPE="rect" COORDS=273,148,327,171 HREF="parts.htm">
<AREA SHAPE="rect" COORDS=225,222,291,246 HREF="service.htm">    
</MAP>
<IMG SRC="orielly2.gif" BORDER=0 USEMAP="#orielly">

</CENTER>
<P>
<CENTER>[ <A HREF="history.htm">History</A> | <A HREF="lease.htm">Leasing</A> | <A HREF="models.htm">Models</A> | <A HREF="parts.htm">Parts</A> | <A HREF="service.htm">Service</A> ]</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-142</DOCNO>
<DOCOLDNO>IA058-000947-B028-193</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/orielly/history.htm 206.97.63.16 19970109194406 text/html 4726
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:26:47 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 4555
Last-modified: Mon, 23 Dec 1996 22:38:51 GMT
</DOCHDR>

<HEAD>
<TITLE>O'Rielly Chevrolet Geo</TITLE></HEAD>
<BODY BACKGROUND="oriltile.gif">

<CENTER><H2>History of O'Rielly Chevrolet Geo</H2></CENTER>
A Dirt Road From Phoenix Leads to a Tucson Tradition Tucson of 1921 was a 
place where contracts were signed on the hood of a car, driving lessons were 
given by the salesman and Phoenix was a mere 5 hours and a couple of flat 
tires away.  Frank O'Rielly, fresh from military service during World War I, 
quit his Phoenix insurance job and braved the 120-mile, dirt-road trip to 
Tucson in search of a better life selling Buicks and Cadillacs for Tucson's 
Babbitt Brothers.  Within three years, O'Rielly had acquired enough 
experience and - thanks to local jewelers Fred Adams and Morris Greenwald - 
enough money to start his dream dealership: a Studebaker franchise.  When 
O'Rielly discovered the Studebaker franchise wasn't available in Tucson, he 
took the only one that was available - Chevrolet. O'Reilly Motor Company 
opened its doors on March 23, 1924, at 55 N. Sixth Avenue as Tucson's 
Chevrolet dealer. The first Chevrolet customers were able to find deals such 
as a Superior Model Chevrolet Roadster for only $630.  In 1927 Frank built a 
new dealership facility located at 415 North Sixth Avenue, way out on the 
north side of the Central business district. The <i>Tucson Daily Citizen</i> 
called it "one of the most modern plants in the southwest." "For its day, 
that facility was way ahead of its contemporaries," Buck O'Rielly, Frank's 
son and current owner.  Those early Chevrolets were not the smoothest rides 
- the closest thing to shock absorbers was the natural cushioning sat upon 
by the passengers themselves. "When Dad received his first delivery of new 
1924 Chevrolets at the rail siding, he drove the first car unloaded back to 
the dealership and thought, 'I don't mind selling these cars but I sure hate 
the thought of driving one for a demonstrator.'," Buck recalls. For 
Tucsonans, that changed in 1925 when O'Rielly began selling Chevy vehicles 
with "knee-action" suspension.  Even though O'Rielly had encountered nothing 
but success, he was not a man without a backup plan. In the event the new 
location failed, it was designed to be easily converted into a bowling alley.  
One reason O'Rielly Motor Company never had to start racking up the pins was 
O'Rielly's emphasis on maintaining strong service and parts departments. 
During World War II, there were no new cars to sell and no used inventory 
available, so he had to let his entire sales force go. O'Rielly survived 
solely on service, parts and a powerful reputation that continues to this 
day. 
 
<P>

Not only was Frank O'Rielly's business growing, but his family as well. In 
1955, Buck O'Rielly, who started out in junior high school as a parts runner 
for the mechanics, returned to Tucson and O'Rielly Motor Company after four 
years as a USAF fighter pilot during the Korean war conflict. In 1958 he 
became vice president and general manager of the business. He was selected 
as Time magazine's Arizona Quality Dealer for 1971.
<P>
Frank and Buck deliver a new '57 Chevrolet to Mr. Thomas, one of Frank's 
first customers.  Buck oversaw one of the boldest moves O'Rielly's made in 
its 72 years of Tucson business: moving the operation into the "boondocks" 
on Broadway, just west of Wilmot Road.  "Broadway east of Craycroft was only 
a two-lane road back then," Buck said. "People thought we were crazy to come 
this far out."  Once again, though, O'Rielly's business prospered, surviving 
the lean years of the energy crisis in the '70's. During this time, a 
shortage of gasoline saw an increase in the more energy-efficient import 
cars.  "The thing that changed imports was the energy crisis of '73," Buck 
said. "Americans were building cars bigger (that were more performance 
oriented.)  "Today, there's not a great difference in quality between U.S. 
and Japanese cars. We have very few problems with Chevrolet vehicles." Which 
means, just like the old days, service is often the deciding factor for a 
customer.  It is a credo the O'Rielly's have carried throughout their 72 
years of business in the Old Pueblo. "The way customers are treated has a 
lot to do with repeat business," Buck said. "Customers are very particular 
about what they will and won't accept."
<P>
<CENTER>
[ <A HREF="index.htm">Home Page</A> | <A HREF="lease.htm">Leasing</A> | <A HREF="models.htm">Models</A> | <A HREF="parts.htm">Parts</A> | <A HREF="service.htm">Service</A> ]
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-143</DOCNO>
<DOCOLDNO>IA058-000947-B028-209</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/orielly/lease.htm 206.97.63.16 19970109194414 text/html 2039
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:26:58 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 1868
Last-modified: Mon, 23 Dec 1996 22:38:56 GMT
</DOCHDR>


<HEAD>
<TITLE>O'Rielly Chevrolet Geo</TITLE></HEAD>
<BODY BACKGROUND="oriltile.gif">
<CENTER><H2>Why Should I Lease?</H2></CENTER><P>
Leasing is an alternative way of financing a vehicle, where you finance the 
depreciation of the vehicle - not the full price.  When you buy a vehicle, 
you have three options: Pay cash and pay all your depreciation up front, 
lose 25 to 50% of your money the first 12 to 24 months or use conventional 
financing (bank, credit union, etc.).  Unfortunately, with financing you pay 
most of your interest during the first half of your loan. The principal 
balance isn't affected for 12 to 24 months.<P>

Then there is leasing. With leasing you get a shorter term, smaller payment, 
minimum cash down and many more benefits. In other words, you only pay for 
what you use and you get more vehicle for your money.  Lease payments are 
less because you are financing less money. Popular terms for leasing are 24, 
36, 48 or 60 months - or we can create whatever works for you. Be aware that 
a 36-month lease will usually be the same as a 60 month finance contract. <P>

Why obligate yourself for five years?<P>

You can lease with almost no cash down. Leasing normally requires a first 
month's payment and license fees (sometimes a security deposit is also 
required). Because you are financing less money for a shorter term, you can 
get more equipment for your money.<P>
 
All makes and models - new and late - are available for leasing. Our 
organization has access to virtually any model vehicle you want. It can be 
built and ordered specifically to meet your needs. We can also locate that 
late model car or truck.<P>
<CENTER>
[ <A HREF="index.htm">Home Page</A> | <A HREF="history.htm">History</A> | <A HREF="models.htm">Models</A> | <A HREF="parts.htm">Parts</A> | <A HREF="service.htm">Service</A> ]
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-144</DOCNO>
<DOCOLDNO>IA058-000947-B028-221</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/orielly/models.htm 206.97.63.16 19970109194424 text/html 551
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:27:07 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 381
Last-modified: Mon, 23 Dec 1996 22:39:26 GMT
</DOCHDR>


<HEAD>
<TITLE>O'Rielly Chevrolet Geo</TITLE></HEAD>
<BODY BACKGROUND="oriltile.gif">
<CENTER><H2>WE OFFER ALL MAKES AND MODELS</H2><P><IMG SRC="models.gif"></CENTER>
<CENTER>
[ <A HREF="index.htm">Home Page</A> | <A HREF="lease.htm">Leasing</A> | <A HREF="history.htm">History</A> | <A HREF="parts.htm">Parts</A> | <A HREF="service.htm">Service</A> ]
</CENTER>
</BODY>
</HTML>


</DOC>
<DOC>
<DOCNO>WT08-B13-145</DOCNO>
<DOCOLDNO>IA058-000947-B028-235</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/orielly/parts.htm 206.97.63.16 19970109194430 text/html 564
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:27:14 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 394
Last-modified: Mon, 23 Dec 1996 22:41:41 GMT
</DOCHDR>
<HTML>
<HEAD>
<TITLE>O'Rielly Chevrolet Geo</TITLE></HEAD>
<BODY BACKGROUND="oriltile.gif">
<CENTER><H2>O'Rielly Chevrolet Geo, Parts Department</H2><P>

Coming soon...</CENTER><P>
<CENTER>
[ <A HREF="index.htm">Home Page</A> | <A HREF="history.htm">History</A> | <A HREF="lease.htm">Leasing</A> | <A HREF="models.htm">Models</A> | <A HREF="service.htm">Service</A> ]
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-146</DOCNO>
<DOCOLDNO>IA058-000947-B028-251</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/orielly/service.htm 206.97.63.16 19970109194436 text/html 1934
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:27:20 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 1763
Last-modified: Mon, 23 Dec 1996 22:41:49 GMT
</DOCHDR>


<HEAD>
<TITLE>O'Rielly Chevrolet Geo</TITLE></HEAD>
<BODY BACKGROUND="oriltile.gif">
<CENTER><H2>The O'Rielly Service Difference</H2></CENTER><P>

O'Rielly Chevrolet/Geo is committed to providing the best in customer 
service. This commitment extends beyond the sale of new and pre-owned 
vehicles and includes the body shop, parts department and our service 
department.  We've learned a great deal since our dealership opened here in 
Tucson more than 70 years ago. For example, in order to provide quality 
repair service, we need to start with top-level service advisors and 
technicians. Let us introduce you to Customer Service Manager Chuck McCoy, 
who's been employed at O'Rielly for more than a decade.  Chuck firmly 
believes that sucess in the service department is directly related to 
O'Rielly's understanding of the importance of listening to the customer 
throughout the service process.  "We start out by requesting that service 
customers fill out questionnaires related to their service needs or 
problems," Chuck said.  "By reading and using these fact finder sheets, 
O'Rielly is able to ensure that our service customers' problems are fixed 
right the first time."  Chuck sums up the O'Rielly service department 
philosopy: "Our reputation as a department and dealership- and ultimately 
our profitability- is directly related to <i>customer satisfaction</i>. 
Our strongest asset is that we listen to our customers and strive to respond 
to their needs in the best way possible."<P>

Call our Direct Service Line (520) 571-2222<P>
<CENTER>
[ <A HREF="index.htm">Home Page</A> | <A HREF="lease.htm">Leasing</A> | <A HREF="models.htm">Models</A> | <A HREF="parts.htm">Parts</A> | <A HREF="history.htm">History</A> ]
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-147</DOCNO>
<DOCOLDNO>IA058-000947-B028-65</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/orielly/ 206.97.63.16 19970109194241 text/html 880
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:25:25 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 710
Last-modified: Mon, 23 Dec 1996 22:38:52 GMT
</DOCHDR>

<HTML>
<HEAD>
<TITLE>O'Rielly Chevrolet Geo</TITLE></HEAD>
<BODY BACKGROUND="oriltile.gif">
<CENTER>

<MAP NAME="orielly">
<AREA SHAPE="rect" COORDS=71,114,139,137 HREF="history.htm">
<AREA SHAPE="rect" COORDS=182,14,248,40 HREF="lease.htm">
<AREA SHAPE="rect" COORDS=38,202,102,226 HREF="models.htm">
<AREA SHAPE="rect" COORDS=273,148,327,171 HREF="parts.htm">
<AREA SHAPE="rect" COORDS=225,222,291,246 HREF="service.htm">    
</MAP>
<IMG SRC="orielly2.gif" BORDER=0 USEMAP="#orielly">

</CENTER>
<P>
<CENTER>[ <A HREF="history.htm">History</A> | <A HREF="lease.htm">Leasing</A> | <A HREF="models.htm">Models</A> | <A HREF="parts.htm">Parts</A> | <A HREF="service.htm">Service</A> ]</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-148</DOCNO>
<DOCOLDNO>IA058-000947-B028-29</DOCOLDNO>
<DOCHDR>
http://aada.dasta.com:80/notyet.html 206.97.63.16 19970109194220 text/html 1690
HTTP/1.0 200 OK
Date: Thu, 09 Jan 1997 18:25:03 GMT
Server: Apache/1.0.5
Content-type: text/html
Content-length: 1519
Last-modified: Wed, 16 Oct 1996 20:06:49 GMT
</DOCHDR>
<html>

<head>
	<title>Under Construction</title>
</head>

<body background="gif/aadatile1x.gif">

<center><img src="gif/automall.gif"></center>

<hr>

<br><br>


<center>
<h1>This Portion of <b>The Auto Mall</b> is Currently Under Construction</h1>	

<br><br><br><br><br><br>

<font size="5">We do appreciate your patience as we continue to build the <b>Auto Mall</b> into <i>your</i> premiere one-stop automotive shopping resource on-line.</font>

<br><br><br><br>

<font size="4">**We look forward to seeing you upon the <b>Auto Mall's</b> completion**</font> 

<br><br><br><br><br><br>

<a href="index.html"><img src="gif/mainpagebutton.gif" border="0">
<br>
[ Main Page ]</a>

<br><br><br><br>
For inquiries or comments, e-mail: <a href="mailto:aada@dasta.com">aada@dasta.com</a><p>
<p>
<br>
</center>

<table>
<tr> <th colspan="2"><hr></th>
</tr>

<tr>
<td valign="middle"><a href="http://www.dasta.com">
 <img src="gif/dastasig.gif" alt="DASTA VendorCat logo" border="0"></a></td>
<td>
 <font size="-1">Last Updated: 25 Jun 96 <br>
 Comments/Questions: <a href="mailto:webmaster@dasta.com">
webmaster@dasta.com</a><br>
Copyright &#169; 1996 <a href="http://www.dasta.com">Dasta VendorCat</a>.
All rights reserved. </font>
</td>
</tr>
<tr>
<th colspan="2"><hr></th>
</tr>
</table>
<center>
<p><font size="-1">"This site was designed by DASTA VENDORCAT,<br>
the Nation's Leading Internet Presence Provider for Associations<br>
and the sponsor of Association-Net<sup>TM</sup>."</font></p>
</center>
</body>
</html>
</DOC>
<DOC>
<DOCNO>WT08-B13-149</DOCNO>
<DOCOLDNO>IA055-000919-B017-78</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/index.html 192.138.110.240 19970208022152 text/html 3750
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 02:22:02 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 3579
Last-modified: Thu, 06 Feb 1997 12:33:41 GMT
</DOCHDR>
<HTML>
<HEAD>
<TITLE>The Volvo Group Homepage</TITLE>
   
   <META NAME="KeyWords" CONTENT="volvo,trucks,cars,marine,safety,space,aero">

</HEAD>
<BODY BGCOLOR="FFFFFF">

<CENTER>
<IMG SRC="/images/header.gif" WIDTH=468 HEIGHT=94 ALIGN=MIDDLE BORDER=0>

<P ALIGN=CENTER>
<FONT SIZE=5><B>Welcome to the Volvo Group</B></FONT>

<P>
<A HREF="/images/vhkclg1.map">
<IMG SRC="/images/vhkclg1.gif" WIDTH=466 HEIGHT=105 ALIGN=CENTER BORDER=0 ISMAP></A>
<!--
<p>
<table><tr><td width=468>
<blockquote>
<div align=center><font color=red>
There are intermittent disturbances on our network connection. Our ISP is working on the problem. We apologize for the inconvenience and hope to be fully functional soon.<br>
<address><div align=right>Webmaster</div></address>
</font>
</div
</blockquote>
</td></tr></table> -->

<P>
<!--A HREF="/images/vhkmenu1.map"><IMG SRC="/images/vhkmenu1.gif" VSPACE=3 WIDTH=468 HEIGHT=72 ALIGN=CENTER BORDER=0 ISMAP usemap=#vhkmenu></A-->

<IMG SRC="/images/vhkmenu1.gif" VSPACE=3 WIDTH=468 HEIGHT=72 ALIGN=CENTER BORDER=0 usemap=#vhkmenu>

<map name="vhkmenu">
<area shape="rect" coords="236,53 468,72" href="/other/index.html">
<area shape="rect" coords="0,53 232,71" href="/cgi-bin/make_tot_press">
<area shape="rect" coords="0,23 73,49" href="/technical/index.html">
<area shape="rect" coords="78,23 153,49" href="/environment/index.html">
<area shape="rect" coords="157,23 232,49" href="/www.volvia.volvo.se/index.html">
<area shape="rect" coords="236,23 311,49" href="/corpinfo/museum/index.html">
<area shape="rect" coords="315,23 391,49" href="/sport/index.html">
<area shape="rect" coords="395,23 467,49" href="/opportunities/index.html">
<area shape="rect" coords="0,0 467,19" href="/corpinfo/index.html">
<area shape="default" nohref>
</map>

<p>
<IMG SRC="/images/vhkmap.gif" VSPACE=3 WIDTH=433 HEIGHT=179 ALIGN=CENTER BORDER=0 alt="Volvo Servers in the world (map)" usemap=#world>
<map name="world">
<area shape="rect" coords="217,61 230,74" href="http://www.volvo.se/">
<area shape="rect" coords="106,88 117,99" href="http://www.volvotrucks.volvo.com/">
<area shape="rect" coords="115,82 126,93" href="http://www.volvocars.com/">
<area shape="rect" coords="231,56 245,69" href="http://www.volvo.fi/">
<area shape="rect" coords="228,65 241,78" href="http://www.estnet.ee/ieg/volvo/">
<area shape="rect" coords="373,140 389,155" href="http://www.volvo.com.au/">
<area shape="default" nohref>
</map>


<P>
<HR WIDTH=468>
<font size="-1">
<P ALIGN="CENTER">[ <A HREF="/corpinfo/index.html">The Volvo Group - Facts and Figures</A> ]<BR>
[ <A HREF="/www.car.volvo.se/index.html">Volvo Cars</A> | 
<A HREF="/www.truck.volvo.se/index.html">Volvo Trucks</A> | 
<A HREF="/www.bus.volvo.se/index.html">Volvo Buses</A> | 
<A HREF="/www.vce.volvo.se/index.html">Volvo Construction Equipment</A> ]<BR>
[ <A HREF="/www.penta.volvo.se/index.html">Volvo Penta</A> | 
<A HREF="/www.aero.volvo.se/index.html">Volvo Aero</A> | 
<A HREF="/other/index.html">Support & Service units</A> ]
<BR>
[ <A HREF="/cgi-bin/make_tot_press">News & Press Releases for the Volvo Group</A> ]
<P>
	<CENTER>
	[ <A HREF="/technical/index.html">Research</A>
	| <A HREF="/environment/index.html">Environment</A> 
	| <A HREF="/www.volvia.volvo.se/index.html">Insurance</A> 
	| <A HREF="/corpinfo/museum/index.html">Museum</A>
	| <A HREF="/sport/index.html">Sports</A> 
	| <A HREF="/opportunities/index.html">Opportunities</A> ]

<P>
<HR WIDTH=468>
<P ALIGN="CENTER">
Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]
</font>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-150</DOCNO>
<DOCOLDNO>IA055-000919-B015-307</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/other/index.html 192.138.110.240 19970208021810 text/html 2255
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 02:18:15 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 2084
Last-modified: Mon, 17 Jun 1996 12:26:28 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Other Companies</TITLE></HEAD>
<body bgcolor=#ffffff>

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="/index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>
</TR>

<TR>
	<TD><HR></TD>
</TR>

<TR>
	<TD>

<BR>
<BR>

<BLOCKQUOTE>

<H1>Other Companies</H1>
<BR>
<BR>

<P>
<B>Volvo Group Finance</B><BR>
Volvo Group Finance (VGF) serves as an in-house bank for the Volvo Group and 
act as a support and service organization for Volvo companies in matters 
concerning financing, liquidity management, money and foreign exchange 
trading. VGF's income before taxes amounted to SEK 220 M (436).<BR>
<BR>

<A HREF="/www.volvia.volvo.se/index.html"><B>F&ouml;rs&auml;krings AB Volvia</B></A><BR>
Volvia provides direct-writing automobile insurance for Volvo and Renault cars 
in Sweden and administers Volvo's guarantee program. Volvia's income before 
taxes amounted to SEK 76 M (198).<BR>
<BR>

<A HREF="/www.data.volvo.se/index.html"><B>Volvo Data Corporation</B></A><BR>
Volvo Data is the Volvo Group's Center for IT competence.<BR>
<BR>

<B>Volvo Transport AB</B><BR>
Volvo Transport is responsible for the Volvo Group's external transports. 
The number of employees is approximately 400.<BR>
<BR>

<B>Fortos Group</B><BR>
Fortos is a wholly owned Volvo subsidiary which manages Volvo's ownership 
interest outside the transport equipment field. These holdings are intended 
to be divested prior to year-end 1996. 
The Fortos Group include a 28% holding of shares in the Pharmacia 
pharmaceutical company.<BR>
<BR>

<TABLE BORDER=0 WIDTH=450>

<TR>
	<TD><HR></TD>
</TR>

<TR>
	<TD>Source: Facts about Volvo</TD>
</TR>

</TABLE>

<P>

<BR>
</BLOCKQUOTE>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]

</TD>
</TR>
</TABLE>

</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-151</DOCNO>
<DOCOLDNO>IA055-000919-B016-20</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/cgi-bin/make_tot_press 192.138.110.240 19970208021840 text/html 15924
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 02:18:32 GMT
Server: Apache/1.1.3
Content-type: text/html
</DOCHDR>
<!doctype html public \"-//W30//DTD W3 HTML 2.0//EN\">
<HTML>
<HEAD>
<TITLE>Press Releases
</TITLE>
</HEAD>
<body bgcolor=#ffffff>
<center>
<a name="top_of_page"></a>
<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<br>
<br>
[ <a href="/">Volvo Group Homepage</a> | <a href="#end_of_page">End of page</a> ]
<br>
[ <a href="/cgi-bin/make_tot_press">News &amp; Press Releases</a> | <a href="/cgi-bin/make_tot_press_old">Old News &amp; Press Releases</a> ]
<br>
[ <a href="/cgi-bin/make_tot_press_se">Some Swedish News &amp; Press Releases</a> ]
<hr>
<H2>News &amp; Press Releases for the Volvo Group</H2>
<img src="/images/pressimages.gif" width="487" height="85" align="bottom" naturalsi
zeflag="3" border="2">
</center> 
<hr>
<ul>
<h4>
<li>
February  4, 1997<br><a href="/www.car.volvo.se/pr/970204e1.html">Volvo Car Corporation sales and production statistic 1996</a>
</h4>
<blockquote>
  The Volvo Car Corporation experienced a weak start to the year,  particularly in Europe. The situation improved towards the end of  the year, however, once the change-over to production of the  Volvo S40/V40 had been completed. Production of these models  reached 71,000 units, exceeding the planned figure of 65,000.  1996 was also characterised by strong sales trends for the 850  model (+ 5%...</blockquote>
</li>
<h4>
<li>
February  3, 1997<br><a href="/www.bus.volvo.se/pr/970203e1.html">Volvo Bus Corporation take an important step in India</a>
</h4>
<blockquote>
  At a ceremony in Bangalore, in the Indian state Karnataka, a  Memorandum of Understanding was today, February 3, signed  between Volvo Bus Corporation (VBC) and Karnataka State Road  Transport Corporation (KSRTC).    </blockquote>
</li>
<h4>
<li>
January 30, 1997<br><a href="/www.truck.volvo.se/pr/970130e1.html">Unveiling of the Truck Simulator at Stora Holm:Safe and environmentally optimised training for heavy-duty traffic</a>
</h4>
<blockquote>
  Icy roads can make it very difficult to handle a truck. This also  means it can be very risky to practice driving on such roads, and  there have hitherto been few opportunities to simulate such training  off the public roads.  Until now.  Thursday saw the unveiling at Stora Holm of the Truck Simulator - a  device which serves its purpose as well for those learning to drive as  it does for ex...</blockquote>
</li>
<h4>
<li>
January 30, 1997<br><a href="/www.truck.volvo.se/pr/970130e2.html">Truck Simulator at Stora Holm:Technology simulates reality</a>
</h4>
<blockquote>
  The creation of a reality which does not actually exist - that is the  task of the simulator. Leading-edge technology has to be harnessed in  order for the simulator to mirror reality as closely as possible.  Difficult or dangerous driving situations can be simulated and  repeated to offer the best learning environment.    </blockquote>
</li>
<h4>
<li>
January 30, 1997<br><a href="/www.truck.volvo.se/pr/970130e3.html">Volvo Trucks:the moving force behind the Truck Simulator at Stora Holm</a>
</h4>
<blockquote>
  Safety, environmental consideration and location are vital factors    </blockquote>
</li>
<h4>
<li>
January 27, 1997<br><a href="/www.volvo.se/pr/970127e1.html">Change of Presidents in Volvo</a>
</h4>
<blockquote>
 Leif Johansson to succeed S&ouml;ren Gyll at Annual General Meeting. </blockquote>
</li>
<h4>
<li>
January 17, 1997<br><a href="/www.truck.volvo.se/pr/970117e3.html">1996 in a nutshell: Volvo Trucks invests for continued success</a>
</h4>
<blockquote>
 1996 was an eventful year for Volvo Trucks. The total markets in North and South America were considerably smaller compared with 1995, prompting a reduction in truck sales. In Europe, Volvo Trucks consolidated its strong position as the second-largest manufacturer of heavy trucks. </blockquote>
</li>
<h4>
<li>
January 17, 1997<br><a href="/www.truck.volvo.se/pr/970117e1.html">Volvo Trucks at the 1997 Brussels show</a>
</h4>
<blockquote>
  7.5 tonne Volvo FLC - and a wider range of construction trucks    </blockquote>
</li>
<h4>
<li>
January 17, 1997<br><a href="/www.truck.volvo.se/pr/970117e2.html">Volvo Trucks extends its construction truck range</a>
</h4>
<blockquote>
  Powertronic transmission on the FL7 and all-wheel-drive on the  standard product range.    </blockquote>
</li>
<h4>
<li>
January  9, 1997<br><a href="/www.car.volvo.se/pr/970109e1.html">Volvo unveil stunning new BTCC challenger at autosport international</a>
</h4>
<blockquote>
Volvo Car Corporation are pleased to announce the first public showing of its stunning new BTCC challenger at the 1997 Autosport International Show at Birmingham's National Exhibition Centre on 9th January.  </blockquote>
</li>
<h4>
<li>
January  8, 1997<br><a href="/www.car.volvo.se/pr/c70c_eng8.html">Volvo C70 Convertible - The car for the five senses</a>
</h4>
<blockquote>
 Volvo C70 convertible is a car for the five senses; an exciting challenge for the human perceptability. Eyesight, hearing, the sense of smell and feeling, even the sense of taste are stimulated by the elegant open four-seater. Volvo C70 convertible is a concrete proof of Volvos ability to create specialized cars. The C70 convertible opens new roads for Volvo, in a dimension where the car is m...</blockquote>
</li>
<h4>
<li>
January  8, 1997<br><a href="/www.car.volvo.se/pr/c70c_eng7.html">Volvo C70 Convertible - Full freedom is a push-button away</a>
</h4>
<blockquote>
 Over the years, the methods for folding hoods and instead getting the sky for a headlining have been many. More or less fuss with complicated mechanisms, difficult latches or awkward storage of the folded hood. There have always been drawbacks. The Volvo C70 convertible has a really user-friendly hood of the highest quality, making the up and down operations an automatic bagatelle. Furthermor...</blockquote>
</li>
<h4>
<li>
January  8, 1997<br><a href="/www.car.volvo.se/pr/c70c_eng6.html">Volvo C70 Convertible - Enjoyable changes</a>
</h4>
<blockquote>
At the international motor show in Paris in the autumn of 1996, the Volvo C70 coupe was launched; a fourseater sports coupe with a shape and feelings that tops most. </blockquote>
</li>
<h4>
<li>
January  8, 1997<br><a href="/www.car.volvo.se/pr/c70c_eng5.html">Volvo C70 Convertible - New safety systems increase safety</a>
</h4>
<blockquote>
 "If Volvo is going to build an open car, it has to be the safe". This basic principle has guided Volvo for several decades and that is why there have not been any open Volvos since the 1950s. But now, in 1997, the open Volvo car exists. In the C70 convertible innovative and interesting technical solutions have been combined which provide a level of occupant safety that few real convertibles i...</blockquote>
</li>
<h4>
<li>
January  8, 1997<br><a href="/www.car.volvo.se/pr/c70c_eng4.html">Volvo C70 Convertible - A treat for the ear</a>
</h4>
<blockquote>
 That the eyesight gets a treat when looking at the beautiful shape of the Volvo C70 convertible is perhaps easier to understand than that also the senses of hearing and feeling get their kicks. Open the door, make yourself comfortable. The same sensational experience will reach you whether in front or in the rear seat. Now, let the very sophisticated audio system give the senses something to ...</blockquote>
</li>
<h4>
<li>
January  8, 1997<br><a href="/www.car.volvo.se/pr/c70c_eng3.html">Volvo C70 ConvertibleTechnical specifications:</a>
</h4>
<h4>
<li>
January  8, 1997<br><a href="/www.car.volvo.se/pr/c70c_eng2.html">The Volvo C70 Convertible - An open Mind for shapes</a>
</h4>
<blockquote>
 For the first time Volvo's own design department has been handed the task of creating an open car. It is 40 years since Volvo made an open car, and it was not styled at Volvo. The Volvo C70 convertible, on the other hand, has got its shape under the supervision of Peter Horbury. </blockquote>
</li>
<h4>
<li>
January  8, 1997<br><a href="/www.car.volvo.se/pr/c70c_eng1.html">Volvo C70 Convertible - The sky is the limit</a>
</h4>
<blockquote>
 An open car is not used and driven in the same way as a closed car. Volvo C70 convertible is sporty though no sports car. A comfortable tourer for four with impressive performance and with the blue sky within easy press-button reach. </blockquote>
</li>
<h4>
<li>
January  8, 1997<br><a href="/www.aero.volvo.se/pr/970108e1.html">Volvo Aero to move its operations in Arboga to Trollh&auml;ttan</a>
</h4>
<blockquote>
  The Board of Directors of Volvo Aero Corporation has adopted a structural resolution with the objective of moving Volvo Aero's operations in Arboga, Sweden, to the parent company in Trollh&auml;ttan. The decision to move operations means the closure of Volvo Aero Support and Volvo Aero Engine Services in Arboga.  </blockquote>
</li>
<h4>
<li>
January  7, 1997<br><a href="/www.truck.volvo.se/pr/970107e1.html">Tuve plant celebrates its 15th birthday by building its 100,000 truck</a>
</h4>
<blockquote>
  The Volvo Truck plant in Tuve outside G&ouml;teborg is currently  celebrating its 15th year in operation - a jubilee marked by the  building of the 100,000th truck to leave the plant.  </blockquote>
</li>
<h4>
<li>
January  7, 1997<br><a href="/www.car.volvo.se/pr/970107e1.html">The Volvo Car Channel -  A new communication tool</a>
</h4>
<blockquote>
  In connection with the launch of the Volvo C70 Convertible at the  Detroit Motor show, Volvo will start broadcasting on its Volvo Car  Channel on the Internet.  Using the communication tool Backweb,  Internet users around the world will be able to subscribe to news and  information of their choice.  </blockquote>
</li>
<h4>
<li>
December 16, 1996<br><a href="/www.aero.volvo.se/pr/961216e1.html">Mitsubishi buys rocket nozzles from Volvo Aero</a>
</h4>
<blockquote>
 Mitsubishi Heavy Industries is buying two rocket nozzles from Volvo Aero Corporation. The nozzles are intended for the LE-7A, the main engine of the Japanese H-2A launcher. </blockquote>
</li>
<h4>
<li>
December 12, 1996<br><a href="/www.vce.volvo.se/pr/961212e.html">European debut for Volvo Excavators</a>
</h4>
<blockquote>
 Volvo Construction Equipment introduces the Volvo EC280, EC340 and Volvo EC390; the first three models in a new generation of general purpose excavators 	designed, developed, manufactured, powered and marketed by Volvo. </blockquote>
</li>
<h4>
<li>
December 11, 1996<br><a href="/www.aero.volvo.se/pr/961211e1.html">MoU on collaboration between Volvo and MTU signed</a>
</h4>
<blockquote>
Volvo Aero Corporation, a subsidiary of Volvo, and MTU Mnchen, a  subsidiary of Daimler-Benz Aerospace (Dasa, Munich), today signed a  Memorandum of Understanding (MoU) on closer mutual cooperation.  </blockquote>
</li>
<h4>
<li>
December  6, 1996<br><a href="/www.truck.volvo.se/pr/961209e1.html">100 Volvo trucks to the Ukraine</a>
</h4>
<blockquote>
 Volvo Trucks has delivered 100 Volvo FH12 trucks to a customer in the Ukraine, Sovtransavto, the biggest transport company in that country with its headquarters in Lugansk in eastern Ukraine. </blockquote>
</li>
<h4>
<li>
December  2, 1996<br><a href="/www.car.volvo.se/pr/961202e1.html">Volvo Car Corporation and ABB to form joint engineering venture</a>
</h4>
<blockquote>
 Volvo Car Corporation and ABB have signed a Memorandum of Understanding concerning the formation of a joint venture in assembly line engineering and press automation. </blockquote>
</li>
<h4>
<li>
November 27, 1996<br><a href="/www.aero.volvo.se/pr/961127e1.html">Volvo Aero Corporation wins Swedish Quality Award of quality</a>
</h4>
<blockquote>
  Volvo Aero Corporation in Trollh&auml;ttan, Sweden, has been awarded  the &quot;Swedish Quality Award 1996&quot; in the class for large  organizations with 200 or more permanent employees. The distinction was  conferred by the Swedish Institute for Quality, SIQ, whose task is to promote  the development of quality in the whole of Swedish society. SIQs principals  are an association of 120  ...</blockquote>
</li>
<h4>
<li>
November 25, 1996<br><a href="/www.volvo.se/pr/961125e1.html">"Lex Asea" applicable to  Volvo's distribution of Swedish Match</a>
</h4>
<blockquote>
 Lex Asea is applicable to the distribution of Swedish Match to Volvo's shareholders. This was confirmed now that the Supreme Administrative Court in Sweden upheld the ruling by the Council for Advance Tax Rulings regarding the applicability of "Lex Asea." </blockquote>
</li>
<h4>
<li>
November 18, 1996<br><a href="/www.vce.volvo.se/pr/961118e1.html">$23 million investment</a>
</h4>
<blockquote>
 Volvo Construction Equipment continues to strengthen its position in North America - $23 million investment in the Asheville manufacturing plant. </blockquote>
</li>
<h4>
<li>
November 18, 1996<br><a href="/www.volvo.se/pr/961118e1.html">The Volvo Group's activities in Asia</a>
</h4>
<blockquote>
 The growth markets in Asia are of major strategic importance for Volvo. The company's objective is to further strengthen its presence in the region. </blockquote>
</li>
<h4>
<li>
November 14, 1996<br><a href="/www.car.volvo.se/pr/s90_v90.html">The Volvo S90 and V90  - synonyms for comfort</a>
</h4>
<blockquote>
 Along with the change of model name, Volvo's S90 and V90 flagships have undergone a far-reaching upgrade in terms of comfort, particularly in the interior. A number of new features have been introduced to elevate the already extremely high standards of comfort and offer customers an even wider range of individual choice. </blockquote>
</li>
<h4>
<li>
November  7, 1996<br><a href="/www.bus.volvo.se/pr/961107e1.html">Volvo signs Chinese agreement in the presence of the Swedish Prime Minister and the Mayor of Shanghai</a>
</h4>
<blockquote>
  The joint venture company will primarily produce and market modern  city buses and commuters. The vehicles produced by the company will set a   new standard in China regarding productivity, life-time, exhaust emission   levels and quality of buses.    </blockquote>
</li>
<h4>
<li>
November  5, 1996<br><a href="/www.car.volvo.se/pr/s70_v70.html">The Volvo S70 and V70 - upgrading world-class</a>
</h4>
<blockquote>
          The S70 and V70 - the new generation of the          1990s car with by far the most awards, the Volvo 850.          </blockquote>
</li>
<h4>
<li>
November  1, 1996<br><a href="/www.bus.volvo.se/pr/961101e1.html">Volvo Buses expands in Xian, China</a>
</h4>
<blockquote>
  The Volvo Bus Corporation has been operating in China since September 1994, when a joint-venture company, the Xian Silver Bus Corporation, was set up to produce tourist coaches of highest quality. The current plant has a capacity of 400 coaches, which capacity will be reached during 1997. Based upon the fast and prosperous development of the joint-ventures activities it has been decided to ...</blockquote>
</li>
</ul>
<p>
<hr>
<p><center>

<P ALIGN="CENTER">[ <A HREF="/corpinfo/index.html">The Volvo Group - Facts and Figures</A> ]<BR>
[ <A HREF="/www.car.volvo.se">Volvo Car</A> | 
<A HREF="/www.truck.volvo.se">Volvo Truck</A> | 
<A HREF="/www.bus.volvo.se/index.html">Volvo Bus</A> | 
<A HREF="/www.vce.volvo.se">Volvo Construction Equipment</A> ]<BR>
[ <A HREF="/www.penta.volvo.se">Volvo Penta</A> | 
<A HREF="/www.aero.volvo.se/index.html">Volvo Aero</A> | 
<A HREF="/other/index.html">Other Companies</A> ]
<BR>
[ <a href="/cgi-bin/make_tot_press">News &amp; Press Releases</a> | <a href="/cgi-bin/make_tot_press_old">Old News &amp; Press Releases</a> ]
<br>
[ <a href="/cgi-bin/make_tot_press_se">Some Swedish News &amp; Press Releases</a> ]
<br>
[ <a href="/">Volvo Group Homepage</a> |
<a href="#top_of_page">Top of page</a> ]
<p>
<hr>
<br>
<A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se] <br>
<a name="end_of_page"></a>
<br>
<hr>
</center>
</BODY>
</html>

</DOC>
<DOC>
<DOCNO>WT08-B13-152</DOCNO>
<DOCOLDNO>IA055-000919-B016-47</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/technical/index.html 192.138.110.240 19970208021848 text/html 3242
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 02:18:59 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 3071
Last-modified: Thu, 13 Jun 1996 14:47:49 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Technical research on Intelligent Transport Systems (ITS)</TITLE></HEAD>
<body bgcolor=#ffffff>

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="../index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>
</TR>

<TR>
	<TD><HR></TD>
</TR>

<TR>
	<TD>

<BR>
<BR>

<BLOCKQUOTE>

<H2>Technical research on Intelligent Transport Systems (ITS)</H2>
<BR>
<TABLE BORDER=0>

<TR>
	<TD><A HREF="dynaguide.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knbla.gif"></A></TD>
	<TD><FONT SIZE=4><A HREF="dynaguide.html">Dynaguide</A></FONT></td>
</TR>

<TR>
	<TD></TD>
	<TD>- Better traffic information on the road</TD>
</TR>

<TR>
	<TD><A HREF="mobiguide.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knbla.gif"></A></TD>
	<TD><FONT SIZE=4><A HREF="mobiguide.html">Mobiguide</A></FONT></td>
</TR>

<TR>
	<TD></TD>
	<TD>- More efficient transport</TD>
</TR>

<TR>
	<TD><A HREF="socrates.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knbla.gif"></A></TD>
	<TD><FONT SIZE=4><A HREF="socrates.html">Socrates</A></FONT></td>
</TR>

<TR>
	<TD></TD>
	<TD>- Dynamic navigation</TD>
</TR>

<TR>
	<TD><A HREF="promise.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knbla.gif"></A></TD>
	<TD><FONT SIZE=4><A HREF="promise.html">Promise</A></FONT></td>
</TR>

<TR>
	<TD></TD>
	<TD>- Portable information for travellers</TD>
</TR>

<TR>
	<TD><A HREF="uv-light.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knbla.gif"></A></TD>
	<TD><FONT SIZE=4><A HREF="uv-light.html">UV-Light</A></FONT></td>
</TR>

<TR>
	<TD></TD>
	<TD>- For better night vision</TD>
</TR>

<TR>
	<TD><A HREF="friction.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knbla.gif"></A></TD>
	<TD><FONT SIZE=4><A HREF="friction.html">Friction</A></FONT></td>
</TR>

<TR>
	<TD></TD>
	<TD>- Measuring roadholding</TD>
</TR>

<TR>
	<TD><A HREF="dynacruise_bus.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knbla.gif"></A></TD>
	<TD><FONT SIZE=4><A HREF="dynacruise_bus.html">Dynacruise-Bus</A></FONT></td>
</TR>

<TR>
	<TD></TD>
	<TD>- For comfort and safety on the road</TD>
</TR>

<TR>
	<TD><A HREF="dynacruise_car.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knbla.gif"></A></TD>
	<TD><FONT SIZE=4><A HREF="dynacruise_car.html">Dynacruise-Car</A></FONT></td>
</TR>

<TR>
	<TD></TD>
	<TD>- For comfort and safety on the road</TD>
</TR>

<TR>
	<TD><A HREF="dynafleet.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knbla.gif"></A></TD>
	<TD><FONT SIZE=4><A HREF="dynafleet.html">Dynafleet</A></FONT></td>
</TR>

<TR>
	<TD></TD>
	<TD>- More efficient transports for FH12/16 trucks</TD>
</TR>

</TABLE>

<BR>


<P>

<BR>
</BLOCKQUOTE>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]

</TD>
</TR>

</TABLE>

</CENTER>

</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-153</DOCNO>
<DOCOLDNO>IA055-000919-B016-76</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/environment/index.html 192.138.110.240 19970208021859 text/html 1666
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 02:19:09 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 1495
Last-modified: Thu, 13 Jun 1996 14:46:33 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Environment</TITLE></HEAD>
<body bgcolor=#ffffff>

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="/index.html"><IMG BORDER=0 
	SRC="../images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>
</TR>

<TR>
	<TD><HR></TD>
</TR>

<TR>
	<TD>

<BR>
<BR>

<BLOCKQUOTE>

<H1>Environment</H1>
<BR>
<FONT SIZE=4><A HREF="policy.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
src="/images/knbla.gif">Environmental Policy of the Volvo Group
</A></FONT><BR>
<BR>
<FONT SIZE=4><A HREF="prize.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
src="/images/knbla.gif">Volvo Environment Prize
</A></FONT><BR>
<BR>
<FONT SIZE=4><A HREF="report.95/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
src="/images/knbla.gif">Volvo Environmental Report 1995
</A></FONT><BR>
<BR>
<FONT SIZE=4><A HREF="/www.car.volvo.se/environment/index.html">
<img WIDTH=14 HEIGHT=14 BORDER=0 src="/images/knbla.gif">
Volvo Car Corporation</A></FONT><BR>
<BR>
<FONT SIZE=4><A HREF="/www.truck.volvo.se/envir/index.html">
<img WIDTH=14 HEIGHT=14 BORDER=0 src="/images/knbla.gif">
Volvo Truck Corporation</A></FONT><BR>
<BR>
<BR>


<P>

<BR>
</BLOCKQUOTE>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]

</TD>
</TR>

</TABLE>

</CENTER>

</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-154</DOCNO>
<DOCOLDNO>IA055-000919-B016-160</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/corpinfo/museum/index.html 192.138.110.240 19970208021930 text/html 2307
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 02:19:34 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 2136
Last-modified: Wed, 22 Jan 1997 08:51:05 GMT
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>
<HEAD>
   <TITLE>Volvo Museum</TITLE>
   <META NAME="Keywords" Content="Volvo, Museum, Cars, Trucks">
</HEAD>
<BODY BGCOLOR="#FFFFFF">

<CENTER><DT><A NAME="top"></A><IMG SRC="/images/placorp.gif">&nbsp;<BR>
<BR></DT></CENTER>

<CENTER><TABLE WIDTH="490" >
<TR VALIGN=TOP>
<TD ALIGN=RIGHT>
<DT><A HREF="/world.html"><IMG SRC="/images/kn_up.gif" ALT="UP" BORDER=0 HEIGHT=25 WIDTH=75></A>&nbsp;<A HREF="/index.html"><IMG SRC="/images/knapp_homep.gif" ALT="Home Page" BORDER=0 HEIGHT=25 WIDTH=75></A></DT>
</TD>
</TR>

<TR>
<TD>
<DT>
<HR></DT>
</TD>
</TR>
</TABLE></CENTER>

<DT>&nbsp;</DT>

<CENTER><TABLE WIDTH="490" >
<TR>
<TD>
<BLOCKQUOTE>
<DT><BR>
<FONT SIZE=+3>Welcome to the Volvo Museum</FONT><BR>
<BR></DT>
</BLOCKQUOTE>

<DT><IMG SRC="/images/museum1.gif" BORDER=1 HEIGHT=113 WIDTH=490 ALIGN=CENTER>&nbsp;</DT>

<BLOCKQUOTE>
<DT>
<FONT COLOR="#DD0000"><FONT SIZE=+2>Closed<BR>
</FONT>Please notice that the Volvo Museum is closed at the moment.<BR>
We will open again the 3 of March.<BR>
<BR>
<A HREF="/images/howto.html"><IMG SRC="/images/knbla.gif" BORDER=0 LEFT HEIGHT=14 WIDTH=14></A></FONT><FONT SIZE=+1><A HREF="howto.html">How
to get to the Volvo Museum&nbsp;<BR>
<BR>
<A HREF="history.html"><IMG SRC="/images/knbla.gif" BORDER=0 LEFT HEIGHT=14 WIDTH=14></A></A><A HREF="history.html">Knowledge
of the company's history&nbsp;<BR>
<BR>
<A HREF="pictures.html"><IMG SRC="/images/knbla.gif" BORDER=0 LEFT HEIGHT=14 WIDTH=14></A></A><A HREF="pictures.html">Volvo's
history in pictures&nbsp;</A></FONT><BR>
<BR>
<BR>
<BR>
<BR>
<BR>
<BR></DT>

<CENTER><P>[ <A HREF="/www.car.volvo.se/businessinfo/history/history.html">History
- Volvo Car Year by Year 1994-1927</A>&nbsp;<BR>
| <A HREF="/corpinfo/europe/focus.html">Volvo's focus on Europe, an historical
review</A> | <A HREF="/www.penta.volvo.se/corpinfo/company/vpchistory.html">History
- Volvo Penta 1994-1868</A> ]&nbsp;</P> 
</BLOCKQUOTE>

<DT>
<HR ALIGN=LEFT WIDTH=487>Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A>
[webmaster@www.volvo.se]&nbsp;</DT>
</TD>
</TR>
</TABLE></CENTER>

</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-155</DOCNO>
<DOCOLDNO>IA055-000919-B016-206</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/sport/index.html 192.138.110.240 19970208021943 text/html 5529
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 02:19:54 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 5358
Last-modified: Wed, 21 Aug 1996 08:57:07 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>VOLVO IN SPORTS</TITLE></HEAD>
<BODY>

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="../index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>
</TR>

<TR>
	<TD><HR></TD>
</TR>

<TR>
	<TD>

<BR>

<BLOCKQUOTE>


<FONT SIZE=6>Welcome to Volvo in Sports</FONT><BR>
<BR>

</BLOCKQUOTE>

<IMG BORDER=1 WIDTH=490 HEIGHT=120 SRC="/images/sport/sports.gif">

<BLOCKQUOTE>


<TABLE CELLPADDING=10 BORDER=0>


<TR>
	<TD COLSPAN=2><FONT SIZE=5>Volvo Event Management</FONT></TD>
</TR>

<TR>
	<TD VALIGN=TOP>

	The need to provide a consistent and co-ordinated approach to international 
	sponsorship programmes was first recognized in the late 80's.  The catalyst 
	was the need to consolidate budgets and develop long term sports marketing 
	strategies in the light of the rapid proliferation of television channels 
	created by satellite television.  Event Management Corporation, as the company 
	was then called, took on these responsibilities.  In addition, we also became 
	responsible for contractual negotiations and co-ordination, plus, where 
	required, the management of international sponsorships such as the Volvo Tour.

	<P ALIGN="LEFT">
	Today, as Volvo Event Management, in addition to the above our responsibilities 
	have expanded to include market research, media relations, event branding and 
	internal consultancy.  We take the primary role in developing, implementing 
	and managing international sponsorships, whilst at the same time, working with 
	all Volvo Product Companies on the presentation and utilisation of their own 
	domestic projects.

	<P ALIGN="LEFT">
	Volvo Event Management is owned equally by AB Volvo, Volvo Car Corporation and 
	Volvo Trucks, with representatives of all product companies making up the 
	Management Board.</TD>


	<TD VALIGN=TOP NOWRAP>
	<FONT SIZE=4><A HREF="golf.html">Golf</A></FONT><BR>
	<BR>
	<FONT SIZE=4><A HREF="biking.html">Mountain Biking</A></FONT><BR>
	<BR>
	<FONT SIZE=4><A HREF="equestrian.html">Equestrian</A></FONT><BR>
	<BR>
	<FONT SIZE=4><A HREF="motor.html">Motor Sport</A></FONT><BR>
	<BR>
	<FONT SIZE=4><A HREF="skiing.html">Alpine Skiing</A></FONT><BR>
	<BR>
	<FONT SIZE=4><A HREF="sailing.html">Sailing</A></FONT><BR>
	<BR>
	<FONT SIZE=4><A HREF="tennis.html">Tennis</A></FONT></TD><BR>
</TR>



<TR>
<TD COLSPAN=2>
<BR>
<BR>

<P>
<FONT SIZE=5>Background</FONT>

<P>
Sport has been an integral element of Volvo's international marketing and 
communications programme for over thirty years.  What started as a product 
development programme using the skills of Swedish International Rally Driver 
Gunnar Andersson was quickly recognised to be an effective communications tool.  
Sports sponsorship provides an added dimension to our communication, giving 
us an opportunity to reach out and touch people's lives in a way that 
traditional advertising cannot.  Our customers buy our products for a number 
of different reasons.  Some logical, technology or performance based, others 
less logical and based on image perceptions and emotional elements, and it is 
in this area where our sponsorship strategy begins to work.

<P>
Sponsorship gives us the capability to communicate the Volvo brand globally in 
association with visual images which transcend cultural and language barriers.  
It therefore provides a consistent and controlled image association, seen by 
millions of people throughout the world at a cost that could never be afforded 
in terms of traditional advertising.

<P>
Finally, our global sponsorship gives individual markets the opportunity to 
implement local marketing and sales initiatives against a major international 
image backdrop.

</TD>
</TR>

<TR>
<TD COLSPAN=2>

<BR>
<BR>

<P>
<FONT SIZE=5>Sponsorship Strategy</FONT>

<P>
<B>Objectives:</B>

<UL>
	<LI>To support the brand name Volvo through extensive media coverage of sponsored 
	events.<BR>
	<BR>

	<LI>To provide business hospitality at prestigious sporting events in a Volvo 
	dominated and controlled environment.<BR>
	<BR>

	<LI>To create customer contacts and marketing opportunities to sell Volvo products.<BR>
	<BR>
	
</UL>

<BR>
<P>
<B>Strategy:</B>

<UL>
	<LI>To concentrate any activity on the chosen sports of motor sport, equestrian, 
	golf, tennis, sailing, skiing and mountain biking.<BR>
	<BR>
	
	<LI>To become the dominant sponsor in the chosen sport.<BR>
	<BR>
	
	<LI>Volvo events will reflect the company's quality standards.<BR>
	<BR>
	
	<LI>Consider sports and sports events rather than individual endorsements as the 
	event will always be the winner.<BR>
	<BR>
	
	<LI>Maintain a long term involvement of at least three years, ideally five.  It 
	takes this period of time to establish a presence and maximise the marketing 
	opportunities and benefits.<BR>
	<BR>
	
	<LI>To integrate sponsorships into the marketing and communication mix both 
	internally and externally.<BR>
	<BR>
</UL>


<BR>
</TD>
</TR>
</TABLE>

<P>

<BR>
</BLOCKQUOTE>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]

</TD>
</TR>

</TABLE>

</CENTER>

</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-156</DOCNO>
<DOCOLDNO>IA055-000919-B016-236</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/opportunities/index.html 192.138.110.240 19970208021955 text/html 1248
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 02:20:06 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 1077
Last-modified: Tue, 27 Aug 1996 14:27:35 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Opportunities</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="/index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>
</TR>

<TR>
	<TD><HR></TD>
</TR>

</TABLE>



<TABLE WIDTH=490 BORDER=0>
<TR>
	<TD>

<BR>
<BR>
<BLOCKQUOTE>

<P>
<FONT SIZE=6>Opportunities</FONT>


<P ALIGN=LEFT>
<FONT SIZE=5>Students</FONT><BR>

<UL>
	<LI><A href="/www.car.volvo.se/students/index.html">Volvo Cars</A><BR>
	<BR>
	
	<LI><A href="/www.truck.volvo.se/student/index.html">Volvo Trucks</A><BR>
	<BR>
	
	<LI><A href="/www.data.volvo.se/student/index.html">Volvo Data</A><BR>
	<BR>
</UL>

<BR>

<CLEAR=ALL></BLOCKQUOTE><BR>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]
</TD>
</TR>
</TABLE>

</CENTER>

</BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-157</DOCNO>
<DOCOLDNO>IA055-000919-B016-266</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/corpinfo/index.html 192.138.110.240 19970208022004 text/html 1307
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 02:20:15 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 1136
Last-modified: Fri, 16 Aug 1996 13:03:55 GMT
</DOCHDR>
<HTML>
<HEAD>
<TITLE>The Volvo Group</TITLE>
</HEAD>
<BODY BGCOLOR="FFFFFF">

<CENTER>

<TABLE WIDTH=490 BORDER=0>

<TR>
	<TD><IMG SRC="/images/header1.gif" BORDER=0 WIDTH=490
HEIGHT=94></TD>
</TR>

<TR>
	<TD ALIGN=CENTER><FONT SIZE=5><B>Welcome to Volvo Facts and
Figures</B></FONT>
	</TD>
</TR>

<TR>
	<TD><IMG SRC="/images/factbild.gif" BORDER=0 WIDTH=490 HEIGHT=85>
	</TD>
</TR>

<TR>
	<TD><A HREF="/images/factmenu.map">
	<IMG SRC="/images/factmenu.gif" BORDER=0 WIDTH=490 HEIGHT=60 ISMAP></A></TD>
</TR>

<TR>
	<TD>
<BR>
<P>
<HR>
<P ALIGN="CENTER">
[ <A HREF="/index.html">The Volvo Group Homepage</A> ]<BR>
<BR>

[ <A HREF="fin.stat/index.html">Financial and Operating
Statistics</A> ]<BR>
[ <A HREF="annual.html">Annual Report</A> | 
<A HREF="int.rep/index.html">Interim Reports</A> | 
<A HREF="/opportunities/index.html">Students' Opportunities</A> ]<BR>
[ <A HREF="world.html">Volvo Around the World</A> | <A HREF="information.html">Information material</A> ]<BR>

<BR>
<CENTER>
Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]
</CENTER>

</TD>
</TR>
</TABLE>

</CENTER>

</BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-158</DOCNO>
<DOCOLDNO>IA055-000919-B015-264</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/ 192.138.110.240 19970208021756 text/html 3750
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 02:18:07 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 3579
Last-modified: Thu, 06 Feb 1997 12:33:41 GMT
</DOCHDR>
<HTML>
<HEAD>
<TITLE>The Volvo Group Homepage</TITLE>
   
   <META NAME="KeyWords" CONTENT="volvo,trucks,cars,marine,safety,space,aero">

</HEAD>
<BODY BGCOLOR="FFFFFF">

<CENTER>
<IMG SRC="/images/header.gif" WIDTH=468 HEIGHT=94 ALIGN=MIDDLE BORDER=0>

<P ALIGN=CENTER>
<FONT SIZE=5><B>Welcome to the Volvo Group</B></FONT>

<P>
<A HREF="/images/vhkclg1.map">
<IMG SRC="/images/vhkclg1.gif" WIDTH=466 HEIGHT=105 ALIGN=CENTER BORDER=0 ISMAP></A>
<!--
<p>
<table><tr><td width=468>
<blockquote>
<div align=center><font color=red>
There are intermittent disturbances on our network connection. Our ISP is working on the problem. We apologize for the inconvenience and hope to be fully functional soon.<br>
<address><div align=right>Webmaster</div></address>
</font>
</div
</blockquote>
</td></tr></table> -->

<P>
<!--A HREF="/images/vhkmenu1.map"><IMG SRC="/images/vhkmenu1.gif" VSPACE=3 WIDTH=468 HEIGHT=72 ALIGN=CENTER BORDER=0 ISMAP usemap=#vhkmenu></A-->

<IMG SRC="/images/vhkmenu1.gif" VSPACE=3 WIDTH=468 HEIGHT=72 ALIGN=CENTER BORDER=0 usemap=#vhkmenu>

<map name="vhkmenu">
<area shape="rect" coords="236,53 468,72" href="/other/index.html">
<area shape="rect" coords="0,53 232,71" href="/cgi-bin/make_tot_press">
<area shape="rect" coords="0,23 73,49" href="/technical/index.html">
<area shape="rect" coords="78,23 153,49" href="/environment/index.html">
<area shape="rect" coords="157,23 232,49" href="/www.volvia.volvo.se/index.html">
<area shape="rect" coords="236,23 311,49" href="/corpinfo/museum/index.html">
<area shape="rect" coords="315,23 391,49" href="/sport/index.html">
<area shape="rect" coords="395,23 467,49" href="/opportunities/index.html">
<area shape="rect" coords="0,0 467,19" href="/corpinfo/index.html">
<area shape="default" nohref>
</map>

<p>
<IMG SRC="/images/vhkmap.gif" VSPACE=3 WIDTH=433 HEIGHT=179 ALIGN=CENTER BORDER=0 alt="Volvo Servers in the world (map)" usemap=#world>
<map name="world">
<area shape="rect" coords="217,61 230,74" href="http://www.volvo.se/">
<area shape="rect" coords="106,88 117,99" href="http://www.volvotrucks.volvo.com/">
<area shape="rect" coords="115,82 126,93" href="http://www.volvocars.com/">
<area shape="rect" coords="231,56 245,69" href="http://www.volvo.fi/">
<area shape="rect" coords="228,65 241,78" href="http://www.estnet.ee/ieg/volvo/">
<area shape="rect" coords="373,140 389,155" href="http://www.volvo.com.au/">
<area shape="default" nohref>
</map>


<P>
<HR WIDTH=468>
<font size="-1">
<P ALIGN="CENTER">[ <A HREF="/corpinfo/index.html">The Volvo Group - Facts and Figures</A> ]<BR>
[ <A HREF="/www.car.volvo.se/index.html">Volvo Cars</A> | 
<A HREF="/www.truck.volvo.se/index.html">Volvo Trucks</A> | 
<A HREF="/www.bus.volvo.se/index.html">Volvo Buses</A> | 
<A HREF="/www.vce.volvo.se/index.html">Volvo Construction Equipment</A> ]<BR>
[ <A HREF="/www.penta.volvo.se/index.html">Volvo Penta</A> | 
<A HREF="/www.aero.volvo.se/index.html">Volvo Aero</A> | 
<A HREF="/other/index.html">Support & Service units</A> ]
<BR>
[ <A HREF="/cgi-bin/make_tot_press">News & Press Releases for the Volvo Group</A> ]
<P>
	<CENTER>
	[ <A HREF="/technical/index.html">Research</A>
	| <A HREF="/environment/index.html">Environment</A> 
	| <A HREF="/www.volvia.volvo.se/index.html">Insurance</A> 
	| <A HREF="/corpinfo/museum/index.html">Museum</A>
	| <A HREF="/sport/index.html">Sports</A> 
	| <A HREF="/opportunities/index.html">Opportunities</A> ]

<P>
<HR WIDTH=468>
<P ALIGN="CENTER">
Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]
</font>
</CENTER>
</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-159</DOCNO>
<DOCOLDNO>IA055-000919-B017-155</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/cgi-bin/make_tot_press_old 192.138.110.240 19970208022226 text/html 62776
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 02:22:30 GMT
Server: Apache/1.1.3
Content-type: text/html
</DOCHDR>
<!doctype html public \"-//W30//DTD W3 HTML 2.0//EN\">
<HTML>
<HEAD>
<TITLE>Press Releases
</TITLE>
</HEAD>
<body bgcolor=#ffffff>
<center>
<a name="top_of_page"></a>
<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<br>
<br>
[ <a href="/">Volvo Group Homepage</a> | <a href="#end_of_page">End of page</a> ]
<br>
[ <a href="/cgi-bin/make_tot_press">News &amp; Press Releases</a> | <a href="/cgi-bin/make_tot_press_old">Old News &amp; Press Releases</a> ]
<br>
[ <a href="/cgi-bin/make_tot_press_se">Some Swedish News &amp; Press Releases</a> ]
<hr>
<H2>News &amp; Press Releases for the Volvo Group</H2>
<img src="/images/pressimages.gif" width="487" height="85" align="bottom" naturalsi
zeflag="3" border="2">
</center> 
<hr>
<ul>
<h4>
<li>
October 29, 1996<br><a href="/www.truck.volvo.se/pr/961029e1.html">Globalisation of FH technology continues:  Volvo NH introduced in Australia</a>
</h4>
<blockquote>
 Volvo Truck Australia, Volvo Truck Corporation's subsidiary company in Australia, has introduced a new model  the Volvo NH. This a normal control version of the Volvo FH model, and has been developed specially for the Australian and New Zealand markets. </blockquote>
</li>
<h4>
<li>
October 28, 1996<br><a href="/www.vce.volvo.se/pr/961028e2.html">New Euclid mining hauler launched</a>
</h4>
<blockquote>
 The largest Euclid hauler, the Euclid R260, has been introduced to maximize productivity and better match the high capacity excavators used in today's largest mining applications. </blockquote>
</li>
<h4>
<li>
October 28, 1996<br><a href="/www.vce.volvo.se/pr/961028e3.html">French quarry success with new euclid hauler</a>
</h4>
<blockquote>
 Nine Euclid R40 rigid haulers have been delivered to France following its recent introduction by Volvo Construction Equipment. </blockquote>
</li>
<h4>
<li>
October 28, 1996<br><a href="/www.vce.volvo.se/pr/961028e1.html">New Euclid mining hauler launched</a>
</h4>
<blockquote>
 A new Euclid hauler, the Euclid R130B, has been introduced to maximize productivity and better match the high capacity excavators used in today's mining applications. </blockquote>
</li>
<h4>
<li>
October 23, 1996<br><a href="/www.volvo.se/pr/961023e1.html">Volvo interim report, nine months ended September 30, 1996</a>
</h4>
<blockquote>
 - short version - </blockquote>
</li>
<h4>
<li>
October 15, 1996<br><a href="/www.car.volvo.se/pr/961015e1.html">Volvo appointed the world's most beautiful estate - again</a>
</h4>
<blockquote>
 The Volvo V40 has by the jury of the Italian &quot;L'Automobile piu' bella del mondo&quot; (The world's most beautiful car) been voted the world's most beautiful estate among the recently introduced es- tates on the market. This is the second time a five door Volvo receives the honour. In 1993 it was bestowed upon the Volvo 850 estate. </blockquote>
</li>
<h4>
<li>
October  4, 1996<br><a href="/www.bus.volvo.se/pr/961004e6.html">Volvo and the environment &shy; a harmonious relationship</a>
</h4>
<blockquote>
  The decision to travel by bus is generally a conscious choice. There is a degree of environmental consideration behind that choice since it often represents a conscious effort to improve our environment. Therefore it is nothing less than logical that manufacturers of buses and bus chassis support this motivation and strengthen it by building buses which are as easy as possible on the environ...</blockquote>
</li>
<h4>
<li>
October  4, 1996<br><a href="/www.bus.volvo.se/pr/961004e5.html">Volvo Action Service Europe: the solution to every problem on your way</a>
</h4>
<blockquote>
  A bus or coach consists of rather more than just an engine and driveline. In a modern bus or coach there are a large number of components which can malfunction, thus turning the trip into an unpleasant experience for driver and passenger alike.    </blockquote>
</li>
<h4>
<li>
October  4, 1996<br><a href="/www.bus.volvo.se/pr/961004e4.html">Volvo B10L & B10LG &shy; for extremely efficient local public transport</a>
</h4>
<blockquote>
  Local public transport must be efficient if it wants to attract passengers and make a profit for its operator. This means the shortest possible waiting times at bus-stops, rapid and convenient boarding and exiting via wide doors with the lowest possible entry height, on-board convenience in buses with a very low floor. Volvo offers an extremely attractive solution with the B10L low-floor cha...</blockquote>
</li>
<h4>
<li>
October  4, 1996<br><a href="/www.bus.volvo.se/pr/961004e2.html">Volvo Bus: specialised in buses up to 15 metres</a>
</h4>
<blockquote>
  Volvo Bus can look back on its considerable success in the construction of chassis for buses with a length up to 15 metres. Vehicles of this length have been allowed in Sweden for many years. For buses and coaches with a length up to 15 metres, the B10M with a third axle is the perfect solution.    </blockquote>
</li>
<h4>
<li>
October  4, 1996<br><a href="/www.bus.volvo.se/pr/961004e1.html">Volvo bus chassis  for every application</a>
</h4>
<blockquote>
  Moving people is no longer a matter of doing as many transport jobs as possible with one single type of bus or chassis. Moving people has become a matter of customisation  being driven from one part of the city to the other requires one type of bus, while travelling hundreds of miles by coach imposes an entirely different set of requirements and standards. Volvo Bus responds to these varyin...</blockquote>
</li>
<h4>
<li>
October  4, 1996<br><a href="/www.bus.volvo.se/pr/961004e3.html">Volvo Bus: An extremely wide product range and worldwide production</a>
</h4>
<blockquote>
  Volvo Bus offers one of the widest bus chassis ranges on the market. European public transport and coach operators can now choose from the broadest selection of chassis Volvo Bus has offered ever during the company's history. This expansion of the range is still in progress: Volvo Bus is working hard on further refinement of the range and more dedicated products. From midibus to articulated ...</blockquote>
</li>
<h4>
<li>
September 30, 1996<br><a href="/www.car.volvo.se/pr/C70_eng7.html">High-tech and traditional craftsmanship in harmony</a>
</h4>
<blockquote>
 Working closely and efficiently together, Volvo and TWR have developed the Volvo C70 coupe, from preliminary study to finished car in just 30 months, combining both state-of-the-art hi-tech and many years of experience in the work.  </blockquote>
</li>
<h4>
<li>
September 30, 1996<br><a href="/www.car.volvo.se/pr/C70_eng6.html">Sporting safety</a>
</h4>
<blockquote>
The Volvo C70 coupe has an exciting new shape to go with its appeal as an inviting road machine. Volvo tradition dictates that all Volvo cars should be safe. Despite its svelte looks and prowling stance, the C70 coupe is no exception. The C70's  lines clothe one of the world's safest wheeled structures in terms of passive impact safety and dynamic driving safety. </blockquote>
</li>
<h4>
<li>
September 30, 1996<br><a href="/www.car.volvo.se/pr/C70_eng5.html">When individuality is important</a>
</h4>
<blockquote>
In an increasingly streamlined world, there is a greater than ever need to stand out from the crowd, to be seen, to emphasise one's presence. The Volvo C70 coupe is a car for individuals. </blockquote>
</li>
<h4>
<li>
September 30, 1996<br><a href="/www.car.volvo.se/pr/C70_eng4.html">Dynamics in a new dimension</a>
</h4>
<blockquote>
A sports coupe whose appearance is not matched by its driving characteristics and performance is not a real sports coupe. </blockquote>
</li>
<h4>
<li>
September 30, 1996<br><a href="/www.car.volvo.se/pr/C70_eng3.html">The designer's dream</a>
</h4>
<blockquote>
With the Volvo C70 coupe, Volvo's design chief Peter Horbury was given free hands to create the car of his dreams. The design brief for the C70 was simple and to the point: Don't design a car which customers need - design a car which they really desire. </blockquote>
</li>
<h4>
<li>
September 30, 1996<br><a href="/www.car.volvo.se/pr/C70_eng2.html">Emotion in motion</a>
</h4>
<blockquote>
The Volvo C70 coupe is a car which appeals directly to your emotions rather than to your mind, bowls you head over heels rather than seeks your approval. The Volvo C70 coupe is the product of freedom - the freedom given to designers and engineers. </blockquote>
</li>
<h4>
<li>
September 30, 1996<br><a href="/www.car.volvo.se/pr/C70_eng1.html">Ushering in a new volvo era</a>
</h4>
<blockquote>
The winds of change are blowing throughout Volvo. The new Volvo is becoming more evident. Especially in terms of the product range. </blockquote>
</li>
<h4>
<li>
September 26, 1996<br><a href="/www.car.volvo.se/pr/960926e1.html">10 million Volvo cars produced</a>
</h4>
<blockquote>
     At 3.05 pm local time on September 12, 1996, the 10 millionth      Volvo car came off the assembly line. This event took place      at the Swedish Motor's plant in Malaysia. </blockquote>
</li>
<h4>
<li>
September 25, 1996<br><a href="/www.car.volvo.se/pr/960925e1.html">New Volvo safety system increases protection against head injuries</a>
</h4>
<blockquote>
Volvo is developing a new safety concept which provides increased protection against head injuries in the event of side-collisions and multiple accidents, such as when the car is subjected to a succession of impacts during the same incident. </blockquote>
</li>
<h4>
<li>
September 23, 1996<br><a href="/www.car.volvo.se/pr/960923e3.html">Volvo 960 wins value rating</a>
</h4>
<blockquote>
To make a good buy is the prime object of every car customer. To have it objectively acknowledged that the car represents excellent value for money is even better. The Volvo 960 was ranked no 1 in the "Near Luxury Car" category when the US consumer research company Strategic Vision Inc issued its winner list the other day. </blockquote>
</li>
<h4>
<li>
September 23, 1996<br><a href="/www.car.volvo.se/pr/960923e1.html">Volvo cuts fuel consumption</a>
</h4>
<blockquote>
Volvo is continuing its long tradition of concern for the environment with an undertaking to reduce average fuel consumption by 25% by the year 2005. This applies to all Volvo cars sold in the EU in 2005 and is the company's contribution to Sweden's and the EU's commitments under the United Nations Conference on Environment and Development in Rio. </blockquote>
</li>
<h4>
<li>
September 23, 1996<br><a href="/www.car.volvo.se/pr/960923e2.html">Black on track - Volvo announces S40 and BTCC for 1997</a>
</h4>
<blockquote>
Swedish manufacturer Volvo will race its stylish new S40 model from 1997 onword, replacing the highly successful 850 in the international Class ll Super Touring Category. </blockquote>
</li>
<h4>
<li>
September 19, 1996<br><a href="/www.truck.volvo.se/pr/960919e4.html">Volvo Trucks at the IAA in Hanover 1996.  New 7.5-tonne truck the Volvo FLC, and uprated engines for the FH Range </a>
</h4>
<blockquote>
 Volvo Trucks is presenting its new FLC truck in the 7.5 tonne class at the IAA 1996 Show in Hanover. The FLC, C stands for City, has been developed in a short space of time in order to broaden the product range downwards with a medium duty, non-complex truck model for light distribution operations. The FLC is powered by a 4-litre engine, the Volvo D4A, which is also on show in Hanover.  </blockquote>
</li>
<h4>
<li>
September 19, 1996<br><a href="/www.truck.volvo.se/pr/960919e8.html">Tommy Rengman at the IAA in Hanover 1996  &quot;Volvo will continue to develop its product range&quot;</a>
</h4>
<blockquote>
 "We have worked intensively on further developing the FH Range, and we are also aiming to achieve a greater degree of modularisation a fact we are demonstrating with our new Volvo VN Range in North America. What's more, we are broadening our product range with the addition of a lighter truck model, the Volvo FLC." </blockquote>
</li>
<h4>
<li>
September 19, 1996<br><a href="/www.truck.volvo.se/pr/960919e2.html">Volvo FLC introduced. New, safe truck from Volvo in the 7.5-tonne class </a>
</h4>
<blockquote>
 Volvo Trucks is introducing a completely new truck for light duty distribution operations at this year's IAA Commercial Vehicles Show in Hanover - the Volvo FLC. C stands for City. </blockquote>
</li>
<h4>
<li>
September 19, 1996<br><a href="/www.truck.volvo.se/pr/960919e3.html">Volvo FLC introduced. Volvo Trucks broadens its product range with a new, lighter truck </a>
</h4>
<blockquote>
 Volvo Trucks has introduced a lighter type of truck - the FLC - that will be sold in one of Europe's biggest truck segments. The total market for the 7.5 tonne class amounts to between 40,000 and 60,000 trucks. The biggest individual markets in the segment are Great Britain and Germany, which together account for about two-thirds of the total market. </blockquote>
</li>
<h4>
<li>
September 19, 1996<br><a href="/www.truck.volvo.se/pr/960919e1.html">Volvo FLC introduced. Economic and reliable operation with the Volvo D4A </a>
</h4>
<blockquote>
 An in-line, four-cylinder, 4-litre developing 135 bhp at 2,500 r/min. Thats Volvo Trucks new engine for the FLC  Volvo D4A </blockquote>
</li>
<h4>
<li>
September 19, 1996<br><a href="/www.truck.volvo.se/pr/960919e7.html">Volvo FLC introduced.The FL Range - Volvo Trucks most versatile range of products</a>
</h4>
<blockquote>
With the introduction of the FLC, the Volvo Trucks FL Range now spansfrom the FLC, with 4-litre engine and power rating of 135 bhp, right upto the FL12, with a 12-litre engine and a power rating of 420 bhp.</blockquote>
</li>
<h4>
<li>
September 19, 1996<br><a href="/www.truck.volvo.se/pr/960919e6.html">Volvo Trucks introduces a new collision protection system - the Front Underrun Protection System (FUPS)</a>
</h4>
<blockquote>
 Volvo Trucks is introducing the Front Underrun Protection System (FUPS)  a new Volvo safety feature that can save many lives in traffic in Europe </blockquote>
</li>
<h4>
<li>
September 19, 1996<br><a href="/www.truck.volvo.se/pr/960919e5.html">Germany  Volvos second biggest FH market</a>
</h4>
<blockquote>
 Germany, the second biggest individual market in Europe, is also Volvos second biggest market for FH trucks. After the first seven months of 1996, Volvo has also succeeded for the first time in becoming the biggest import truck marque in Germany. </blockquote>
</li>
<h4>
<li>
September 18, 1996<br><a href="/www.car.volvo.se/pr/960918e2.html">Volvo's airbags top ratings in US report</a>
</h4>
<blockquote>
   The absolutely top-class performance of Volvo's airbags is confirmed   in a recent report from the independent US company Autofact International.   Autofact International ranks Volvo as number one in four of the six categories   included in the survey. Volvo's SIPS bag is, for example, regarded as the   best side airbag on the market. </blockquote>
</li>
<h4>
<li>
September 18, 1996<br><a href="/www.car.volvo.se/pr/960918e1.html">The Volvo Amazon - 40 years young</a>
</h4>
<blockquote>
   Autumn introductions of new car models were not unusual even back in   the 1950s. In September 1956 - exactly forty years ago - Swedish motoring   enthusiasts witnessed the unveiling of a new Volvo, the Amazon. Its international   debut, as the P121/122, followed in October of the same year at the London   Motor Show. </blockquote>
</li>
<h4>
<li>
September 18, 1996<br><a href="/www.car.volvo.se/pr/960918e3.html">The Volvo 140 series - a thirty-year old milestone in automotive history</a>
</h4>
<blockquote>
   &quot;This is a great day for us at Volvo. We will begin production   of a new car, a car that represents the greatest investment in Volvo's   history.&quot; These were the words of Gunnar Engellau, then President   of AB Volvo, as he opened the presentation of the new 140 Series in August   1966. </blockquote>
</li>
<h4>
<li>
September 13, 1996<br><a href="/www.bus.volvo.se/pr/960913e1.html">Volvo Buses reorganises for increased internationalisation</a>
</h4>
<blockquote>
  Volvo Buses reorganises for increased internationalisation    </blockquote>
</li>
<h4>
<li>
September 10, 1996<br><a href="/www.car.volvo.se/pr/960910e1.html">Volvo C70 Coupe debuts in Paris</a>
</h4>
<blockquote>
 Volvo C70 coupe makes its world premiere at the autoshow in Paris October 1. </blockquote>
</li>
<h4>
<li>
September  6, 1996<br><a href="/www.car.volvo.se/pr/960906e1.html">Volvo live on the Internet</a>
</h4>
<blockquote>
 Volvo is advancing on a number of fronts with the introduction of its new coup, the Volvo C70. Not just when it comes to cars either. The launch is taking place with the support of the very latest Internet technology. "The Volvo C70 symbolises the changes Volvo is undergoing. It is therefore only natural for us to test somewhat new channels and methods using the C70," says Henry Stnson, Sen...</blockquote>
</li>
<h4>
<li>
September  3, 1996<br><a href="/www.truck.volvo.se/pr/960903e1.html">New Volvo truck in North America.  Globalisation of the FH project continues with Volvo VN </a>
</h4>
<blockquote>
 Volvo Trucks' subsidiary in the USA, Volvo GM Heavy Truck Corporation, has introduced a new heavy truck series for the North-American market - the Volvo VN Series. </blockquote>
</li>
<h4>
<li>
September  3, 1996<br><a href="/www.volvo.se/pr/960903e1.html">1996 Volvo Environment Prize for Dr. James E. Lovelock</a>
</h4>
<blockquote>
 The 1996 Volvo Environment Prize has been awarded to Dr. James E. Lovelock, the British naturalist and scientist. Dr. Lovelock receives the SEK 1.5 million award for his invention of detectors for the chemical analysis of extremely low levels of environmentally hazardous substances. </blockquote>
</li>
<h4>
<li>
August 30, 1996<br><a href="/www.truck.volvo.se/pr/960828e1.html">Volvo supertruck hauls lego demonstration show into 2001</a>
</h4>
<blockquote>
  Volvo Trucks have recently constructed a hand built NL12 6x4 truck for  the Lego organisation. The Volvo long haul truck will tour Europe for the  next 5 years with a specially built exhibition trailer packed with imaginative  lego displays.  </blockquote>
</li>
<h4>
<li>
August 22, 1996<br><a href="/www.truck.volvo.se/pr/960822e1.html">Six-monthly interim report for Volvo Trucks</a>
</h4>
<blockquote>
 Volvo Trucks has reported an operating profit for the first six months of 1996 of Skr1,078 million (Skr2,942 million in the corresponding period 1995). The operating margin fell to 4.7% (11.4%). This fall is due above all to fewer deliveries to the North and South American markets. </blockquote>
</li>
<h4>
<li>
August 21, 1996<br><a href="/www.volvo.se/pr/960821e1.html">Volvo Interim Report, six months ended June 30, 1996 - short version -</a>
</h4>
<h4>
<li>
August  7, 1996<br><a href="/www.truck.volvo.se/pr/960807e1.html">Managing Director of Volvos new company in India appointed</a>
</h4>
<blockquote>
 Mr. Ravi Uppal will head Volvo's Indian operations and will be appointed Managing Director in the newly established Volvo India Pvt. Ltd. </blockquote>
</li>
<h4>
<li>
July  8, 1996<br><a href="/www.truck.volvo.se/pr/960708e1.html">110 Volvo trucks to South Africa</a>
</h4>
<blockquote>
  Volvo Truck Corporation has received an order for 110 FH trucks in South  Africa. The customer is Alex Carriers, one of South Africa's major transport  companies.  </blockquote>
</li>
<h4>
<li>
July  5, 1996<br><a href="/www.truck.volvo.se/pr/960705e1.html">Volvo updates its engines for the FH range of trucks.   Increased torque results in improved driveability.</a>
</h4>
<blockquote>
  Volvo Trucks is updating its engines for the FH range of trucks, the  D12A and D16A. The biggest changes are being made on the D12A, where among  other things the torque has been increased by 150 Nm. This means fewer  gearshifts and improved driveability.   </blockquote>
</li>
<h4>
<li>
July  3, 1996<br><a href="/www.car.volvo.se/pr/960703e1.html">Volvo ambulances to Thailand</a>
</h4>
<blockquote>
  Volvo will deliver 98 ambulances and 250 medical transport vehicles  to Thailand as part of a major investment projectin hospitals and clinics  in rural Thailand. Skanska, a Swedish construction and realestate company,  is responsible for the project on contract to the Thai government.  </blockquote>
</li>
<h4>
<li>
July  2, 1996<br><a href="/www.car.volvo.se/pr/960702e1.html">New head of Business Area 400</a>
</h4>
<h4>
<li>
June 25, 1996<br><a href="/www.volvo.se/pr/960625e1.html">Volvo proceeds with global offering of Pharmacia &amp; Upjohn shares</a>
</h4>
<blockquote>
 AB Volvo has decided to proceed with a global offering of a majority of its holding of shares in Pharmacia &amp; Upjohn, Inc. The offering, which comprises a total of 46,000,000 shares, will addressed to buyer in the U.S. and the Nordic countries, and in other international markets. In markets outside the United States, purchases will either be in the form of shares or Swedish depositar...</blockquote>
</li>
<h4>
<li>
June 25, 1996<br><a href="/www.car.volvo.se/pr/960625e1.html">Management changes at Nedcar</a>
</h4>
<blockquote>
  During the past five years, NedCar's operations have gradually changed  and today the company is mainly a production unit. As a consequence of  the transformation of the company, the Shareholders and the Board have  agreed to adopt a new management structure for NedCar.   </blockquote>
</li>
<h4>
<li>
June 22, 1996<br><a href="/www.truck.volvo.se/pr/960622e1.html">122 Volvo trucks sold to Pakistan</a>
</h4>
<blockquote>
  Volvo trucks has secured orders for 122 trucks to the Pakistani market.  </blockquote>
</li>
<h4>
<li>
June 12, 1996<br><a href="/www.volvo.se/pr/960612e1.html">Volvo divests Bure holding</a>
</h4>
<blockquote>
  Volvo today divested its entire holding, 9,652,033 shares corresponding  to 17.7% of the share capital and votes, in the Swedish investment  company Investment AB Bure.  </blockquote>
</li>
<h4>
<li>
June  5, 1996<br><a href="/www.car.volvo.se/pr/960605e1.html">Volvo Car safety engineer is awarded NHTSA safety prize</a>
</h4>
<blockquote>
 Bj&ouml;rn Lundell of Volvo Cars received the NHTSA (National Highway Traffic Safety Administration) Award for Safety Engineering Excellence. The award was handed over at the inauguration ceremony of the ESV (Enhanced Safety of Vehicles) conference in Melbourne, Australia, on 13 May.  </blockquote>
</li>
<h4>
<li>
May 22, 1996<br><a href="/www.car.volvo.se/pr/960522e2.html">New president of Volvo Deutschland</a>
</h4>
<blockquote>
  Wolff Huber has been appointed as the new president of the  Volvo Car Corporations's subsidiary in Germany, Volvo  Deutschland GmbH. He will take up his new appointment on  19 August, 1996.  </blockquote>
</li>
<h4>
<li>
May 22, 1996<br><a href="/www.volvo.se/pr/960522e1.html">Volvo Construction Equipment to sell Volvo Maskin Norger A/S to Catena</a>
</h4>
<blockquote>
  VCE and Catena AB have signed a Memorandum of Understanding   whereby VCE will sell its 100 % interest in Volvo Maskin Norge A/S   to Catena.    </blockquote>
</li>
<h4>
<li>
May 21, 1996<br><a href="/www.truck.volvo.se/pr/960521e1.html">Volvo Trucks serves redundancy notices on 555 employees</a>
</h4>
<blockquote>
  During this week, Volvo trucks will be submitting to the various County  Labour Boards concerned, notices of redundancy for 555 employees at Volvo  Trucks plants in Sweden.  </blockquote>
</li>
<h4>
<li>
May 21, 1996<br><a href="/www.volvo.se/pr/960521e1.html">Lars W Gustavsson appointed President of Volvo Cars in Norway</a>
</h4>
<blockquote>
  Lars W Gustavsson has been appointed President of Volvo Personbiler  Norge AS, which is a subsidiary of the Volvo Car Corporation.  </blockquote>
</li>
<h4>
<li>
May 15, 1996<br><a href="/www.car.volvo.se/pr/960515e1.html">Volvo 850 AWD - a perfect combination of versatility and driveability for an active lifestyle </a>
</h4>
<blockquote>
The Volvo 850 AWD combines the roadholding and power delivery of four wheel drive with the predictability and ride comfort of front wheel drive. An advanced drive system continuously monitors progress and allocates power to the wheels which can put it to best use. </blockquote>
</li>
<h4>
<li>
May 14, 1996<br><a href="/www.car.volvo.se/pr/960514e1.html">Volvo ranked third and best European in the U.S. From 26th to winners' stand in five years</a>
</h4>
<blockquote>
For the first time, Volvo has been ranked among the top three in the J.D. Power's customer survey in the U.S. The Initial Quality Study is a new car survey which measures the reliability of three-month-old cars. More than 30,000 new-car owners were surveyed, responding to some 80 questions about the product and the dealer's behavior. </blockquote>
</li>
<h4>
<li>
May 10, 1996<br><a href="/www.truck.volvo.se/pr/960510e1.html">International prizes awarded Volvo ECT</a>
</h4>
<blockquote>
 Volvo Trucks has been awarded three international prizes for the Volvo Environmental Concept Truck (ECT). </blockquote>
</li>
<h4>
<li>
April 29, 1996<br><a href="/www.volvo.se/pr/960429e1.html">Volvo Interim Report, three months ended March 31, 1996 - short version -</a>
</h4>
<h4>
<li>
April 24, 1996<br><a href="/www.volvo.se/pr/960424e1.html">Annual General Meeting of AB Volvo, April 24, 1996    </a>
</h4>
<blockquote>
  In his address to the shareholders at the Volvo Annual General  Meeting held on April 24, 1996, Volvo President and Chief Executive  Officer S&ouml;ren Gyll said: &quot;Volvo's intention is to carry  out product development under its own auspices with respect to  strategically important areas related to the product characteristics  upon which our trademark is based and where we can attain ec...</blockquote>
</li>
<h4>
<li>
April 17, 1996<br><a href="/www.truck.volvo.se/pr/960417e1.html">Volvo Trucks wins order from China</a>
</h4>
<blockquote>
 Volvo Trucks has received a major order from Cosco  International Intermodal Co. Ltd in China for 50 Volvo  FL10 tractor units. </blockquote>
</li>
<h4>
<li>
April  3, 1996<br><a href="/www.volvo.se/pr/960403e1.html">Volvo nomination committees proposal for election to the Board of Directors</a>
</h4>
<blockquote>
At Volvo's 1996 Annual General Meeting, the Meeting resolved to appoint a nomination committee which was assigned the task to present a proposal regarding election of the Board of Directors and fees to be paid to Board members. The nomination committee's tasks include review of the guidelines and rules set for the nomination committee and to present a proposal regarding any changes to them tha...</blockquote>
</li>
<h4>
<li>
April  2, 1996<br><a href="/www.penta.volvo.se/pr/960402p.html">New controls offer safety features</a>
</h4>
<blockquote>
  Volvo Penta has introduced a new range of top mounted and side mounted  single lever controls for power boats featuring comfortably formed handles  and durable, corrosion resistant housings.     </blockquote>
</li>
<h4>
<li>
April  1, 1996<br><a href="/www.penta.volvo.se/pr/960401p.html">Volvo Penta prepares for the mediterranean summer</a>
</h4>
<blockquote>
  Throughout the summer months, Volvo Penta will again be providing increased  support at a number of key centres in the Mediterranean to boat owners and  operators using the companys marine products  a special service which has  been operating each summer since 1987.  </blockquote>
</li>
<h4>
<li>
March 29, 1996<br><a href="/www.truck.volvo.se/pr/960329e1.html">Volvo Trucks is largest in Nordic region in 1995</a>
</h4>
<blockquote>
 Volvo Trucks secured its position during 1995 as the largest truck manufacturer in the Nordic region. In all Nordic countries, except Iceland, Volvo is the leading manufacturer of heavy and medium-heavy trucks. </blockquote>
</li>
<h4>
<li>
March 27, 1996<br><a href="/www.truck.volvo.se/pr/960327e1.html">1995: Major successes for Volvo Trucks in the Far East</a>
</h4>
<blockquote>
 During 1995, Volvo Trucks was the largest European manufacturer of heavy trucks in the Far East*. The company sold 2,500 trucks in the region in 1995, corresponding to a market share of 34 percent among the European brand names. </blockquote>
</li>
<h4>
<li>
March 22, 1996<br><a href="/www.truck.volvo.se/pr/960322e1.html">Volvo Trucks is forming a joint venture company in Pakistan</a>
</h4>
<blockquote>
 Volvo Trucks and Swedish Motor (Pvt) Ltd. are forming a joint venture company in Pakistan, to be called Volvo Pakistan Ltd. This company will produce, and be responsible for the distribution of Volvo trucks in Pakistan. </blockquote>
</li>
<h4>
<li>
March 21, 1996<br><a href="/www.vce.volvo.se/pr/l150c.html">New high-performance low-emission engine  improves both power and speed</a>
</h4>
<blockquote>
 Volvo has developed a new 10-litre high-performance low-emission engine for the Volvo BM L150C. More efficient fuel injection and turbocharging give the new engine, the TD 103 KCE, 37% higher peak torque at only 1100 r/min. The result is higher productivity and a more responsive performance.  The new engine improves the machine's penetration force, power and acceleration and makes the Volvo B...</blockquote>
</li>
<h4>
<li>
March 21, 1996<br><a href="/www.vce.volvo.se/pr/ecew130150.html">New excavators from Volvo Construction Equipment</a>
</h4>
<blockquote>
 New 13t and 15t kerman excavators introduced by Volvo Construction Equipment provide increased power and precision, and reduced noise and exhaust emissions. </blockquote>
</li>
<h4>
<li>
March  6, 1996<br><a href="/www.volvo.se/pr/960306e1.html">Ninety percent of Volvo's executives respond in support of options program</a>
</h4>
<blockquote>
 As announced previously, Skandia and Trygg-Hansa tendered an offer to senior executives in the Volvo Group to acquire call options pertaining to B shares in AB Volvo. </blockquote>
</li>
<h4>
<li>
March  5, 1996<br><a href="/www.bus.volvo.se/pr/960305e1.html">Extended co-operation to support internationalisation</a>
</h4>
<blockquote>
 Volvo Bus Corporation and the Finnish bus and body manufacturer Carrus Oy have agreed to extend their co-operation in the areas of product development and market projects outside the Nordic countries. </blockquote>
</li>
<h4>
<li>
February 29, 1996<br><a href="/www.aero.volvo.se/pr/960229e1.html">Sale of VOAC Hydraulics finalized</a>
</h4>
<blockquote>
 AVC Intressenter AB - a holding company jointly owned by Volvo Aero and Atlas Copco - has finalized the previously announced sale of VOAC Hydraulics. The buyer is the US-based company Parker Hanifinn Corporation. </blockquote>
</li>
<h4>
<li>
February 28, 1996<br><a href="/www.truck.volvo.se/pr/960228e.html">Volvo Truck Corporation introduces a new range of trucks in Brazil</a>
</h4>
<blockquote>
 Volvo Truck Corporations subsidiary company in Brazil - Volvo do Brasil - has introduced a new, updated range of trucks based on Volvos highly successful NL concept. </blockquote>
</li>
<h4>
<li>
February 22, 1996<br><a href="/www.truck.volvo.se/pr/960222e1.html">1995: Volvo Truck Corporation's most successful year ever</a>
</h4>
<blockquote>
Volvo Truck Corporation's operating profit rose in 1995 to Skr 5,073 million. This is 25 per cent up on 1994. The operating margin rose during the same period to 9.9 per cent. Volvo Truck Corporation achieved a total turnover amounting to Skr 51,027 million during 1995.  </blockquote>
</li>
<h4>
<li>
February 21, 1996<br><a href="/www.volvo.se/pr/960221e1.html">Volvo group report on 1995 operations  - short version -</a>
</h4>
<h4>
<li>
February  7, 1996<br><a href="/www.truck.volvo.se/pr/960207e3.html">Volvo D6A-250 Supercharger </a>
</h4>
<blockquote>
  The Volvo Truck Corporation is introducing the D6A-250 Supercharger, an engine which gives faster starting of the truck and fewer gearshifts. This is made possible by the engine being fitted with both a mechanically-operated compressor and a turbocharger. </blockquote>
</li>
<h4>
<li>
February  7, 1996<br><a href="/www.truck.volvo.se/pr/960207e2.html">Volvo Truck Corporation forms a joint-venture company with Terberg </a>
</h4>
<blockquote>
 Volvo Truck Corporation will form a joint venture company with the Dutch vehicle manufacturer Terberg Benschop B.V. The final decision will be taken by the Board of Volvo Truck Corporation. </blockquote>
</li>
<h4>
<li>
February  7, 1996<br><a href="/www.truck.volvo.se/pr/960207e0.html">Volvo Europa Truck wins environmental award</a>
</h4>
<blockquote>
 Volvo Truck Corporation's plant in Ghent, Belgium has won an environmental award issued by the Federation of Belgian Enterprises. </blockquote>
</li>
<h4>
<li>
February  7, 1996<br><a href="/www.truck.volvo.se/pr/960207e4.html">Volvo Truck Corporation at the 1996 RAI show: New, unique engine concept - the D6A-250 Supercharger, SRS Airbag, Globetrotter XL, and the Volvo ECT </a>
</h4>
<blockquote>
 Volvo Truck Corporation is presenting a new engine at the 1996 RAI Show - the D6A-250 Supercharger. This engine is fitted with both a turbocharger and a mechanically-operated compressor to give high performance across the entire engine speed range. </blockquote>
</li>
<h4>
<li>
February  1, 1996<br><a href="/www.penta.volvo.se/pr/960201p.html">Volvo Penta power for new B-28 speedster bat-boat</a>
</h4>
<blockquote>
  Swedish yacht and industrial designer, Ocke Mannerfelt, has launched a new  Speedster version of his B-28 Bat-boat, powered by a Volvo Penta 7.4GSi/DPX  V8 electronic fuel injected engine which delivers 405 hp at the crankshaft.  The B-28 Speedster reached a measured speed of 82 mph (72 knots) at launch.  </blockquote>
</li>
<h4>
<li>
January 29, 1996<br><a href="/www.car.volvo.se/pr/960129E1.html">Volvo's sales increased on important markets</a>
</h4>
<blockquote>
 Following a slight upswing in 1994, the total market for cars stagnated and 34.6 million cars were sold in 1995. The North American car market declined by just over 4%. The European market was virtually unchanged, but trends varied considerably from country to country. In Japan, demand rose by some 4%. </blockquote>
</li>
<h4>
<li>
January 11, 1996<br><a href="/www.bus.volvo.se/pr/960111e2.html">The B10L  an effective vehicle for fast, economic transport in city areas</a>
</h4>
<blockquote>
    The B10L has been built to achieve a flexible flow of passengers   with a minimum of variations in floor level. Special design   solutions for wheel suspension and engine location give a low   floor level throughout the inside of the bus. The boarding step   is very convenient, and there are no steps inside the bus.   Passenger and driver comfort are of the highest class.    The B10L is al...</blockquote>
</li>
<h4>
<li>
January 11, 1996<br><a href="/www.truck.volvo.se/pr/960111E1.html">50,000 Volvo FH units sold</a>
</h4>
<blockquote>
 Since the FH range was introduced on 1 September 1993, the Volvo Truck Corporation has received orders for 50,000 FH trucks. The biggest individual market is France, where a total of 8,000 FH trucks have been invoiced. </blockquote>
</li>
<h4>
<li>
January 11, 1996<br><a href="/www.bus.volvo.se/pr/960111e1.html">Volvo Bus Corporation continues its strategic expansion and is increasing its global sales and market shares in Western Europe</a>
</h4>
<blockquote>
  Strategically important new market establishments were made in Canada, Poland, and Israel. Global sales and market shares in Western Europe were increased, and the Volvo Bus Corporation's Swedish production facilities in Gothenburg and Bor&aring;s have been accredited with the ISO quality certificate.    </blockquote>
</li>
<h4>
<li>
January 10, 1996<br><a href="/www.aero.volvo.se/pr/960110E1.html">Plan of action at Volvo Aero Engine Services to reduce cost level by SEK 75 million</a>
</h4>
<blockquote>
 Volvo Aero Engine Services, VAES, in Bromma outside Stockholm has  decided to carry out a plan of action to ensure profitability. Despite  good order inflow during 1995 the company took a loss. The plan of  action includes a cost-level reduction of SEK 75 million which also  involves giving notice to 140 employees. VAES sales in 1995 amounted  to SEK 620 million and the company has 570 employ...</blockquote>
</li>
<h4>
<li>
January  8, 1996<br><a href="/www.bus.volvo.se/pr/960108E1.html">Volvo Bus Corporation has now closed the deal on Merkavim in a Swedish-Israeli joint venture</a>
</h4>
<blockquote>
 Volvo Bus Corporation has now finalized the deal with Koor Industries Ltd for the formation of a joint venture company in Israel. </blockquote>
</li>
<h4>
<li>
January  2, 1996<br><a href="/www.car.volvo.se/pr/S40andV40.html">New cars renamed Volvo S40 and V40</a>
</h4>
<blockquote>
 The new names for Volvo's compact segment cars will be Volvo S40 for the saloon model and Volvo V40 for the five-door version. </blockquote>
</li>
<h4>
<li>
January  1, 1996<br><a href="/www.penta.volvo.se/pr/960101p.html">New 225 hp V6 Aquamatic</a>
</h4>
<blockquote>
  Volvo Penta, Europes leading manufacturer and supplier of marine engines,  has extended its range of petrol Aquamatics with the introduction of the  4.3GS/DP engine/drive combination  a new pleasure duty, 225 hp (168 kW)  version of the popular six-cylinder 4.3GS petrol engine, matched with the  legendary Duoprop drive, which has been designed to give boat builders and  owners improved perfo...</blockquote>
</li>
<h4>
<li>
December 21, 1995<br><a href="/www.volvo.se/pr/royal.html">Royal Order conferred on Lennart Jeansson of AB Volvo</a>
</h4>
<blockquote>
 In conjunction with the official opening of NedCar's new plant, Her Royal Highness Queen Beatrix of the Netherlands conferred the rank of Knight Commander, Orange-Nassau Order, on AB Volvos's Executive Vice President Lennart Jeansson. The same rank was conferred on Dr. Hirokazu Nakamura, Chairman of Mitsubishi. </blockquote>
</li>
<h4>
<li>
December 20, 1995<br><a href="/www.volvo.se/pr/fortos.html">Volvo owned Fortos sells Partena</a>
</h4>
<blockquote>
 Jointly with Industrikapital 1989, Fortos, a wholly owned subsidiary of Volvo, has reached agreement regarding the sale of all of the shares in Partena AB, to the international service company Sodexho S.A. The total purchase price is SEK 1,500 million. </blockquote>
</li>
<h4>
<li>
December 15, 1995<br><a href="/www.truck.volvo.se/pr/india01.html">Volvo Truck Corporation plans to establish industrial operations in India</a>
</h4>
<blockquote>
 Volvo Truck Corporation  plans, as the first company in the Volvo Group, to establish industrial operations in India. An investment decision will be made in the spring of 1996 pending approval from the Indian authorities. </blockquote>
</li>
<h4>
<li>
December  6, 1995<br><a href="/www.volvo.se/pr/struk-e.html">Volvos strategy and capital requirement</a>
</h4>
<blockquote>
 During the next five years, the Volvo Group will invest heavily in product development. The average amount during the period is estimated in the range of SEK 8 billion annually. This information was disclosed at a meeting in Stockholm with investors and financial analysts at which Volvo management presented the main elements of the Volvo Groups future capital requirement.  </blockquote>
</li>
<h4>
<li>
December  6, 1995<br><a href="/www.volvo.se/pr/951206-e1.html">Volvo's strategy and capital requirement</a>
</h4>
<blockquote>
 During the next five years, the Volvo Group will invest heavily in product development. The average amount during the period is estimated to be in the range of SEK 8 billion annually. Volvos goal, over a business cycle, based on the current interest rate level, is to achieve a return on shareholders equity after tax of 12-15 percent. </blockquote>
</li>
<h4>
<li>
December  4, 1995<br><a href="/www.volvo.se/pr/951204-e2.html">Purchase price set for ABN AMRO Bank's acquisitions of Alfred Berg</a>
</h4>
<blockquote>
 On April 12, 1995, ABN AMRO Bank acquired from Volvo 100% of the shares in the subsidiary Alfred Berg Holding AB. The sale was carried out at a price of SEK 300 M, after Volvo received a dividend from Alfred Berg amounting to SEK 366 M. In addition, a sum of between SEK 300 M to SEK 900 M was to be paid depending upon Alfred Bergs earnings performance during the next four-year period. </blockquote>
</li>
<h4>
<li>
December  4, 1995<br><a href="/www.vce.volvo.se/pr/peljob.html">Important step in development of light equipment business. Volvo Construction Equipment to acquire French mini excavator manufacturer Pel-Job</a>
</h4>
<blockquote>
Volvo Construction Equipment has concluded an agreement for the acquisition of Groupe PEL-JOB (Pel-Job). </blockquote>
</li>
<h4>
<li>
November 30, 1995<br><a href="/www.penta.volvo.se/pr/intrvcarlsson.html">The moment of truth in Customer Relations</a>
</h4>
<blockquote>
Born in 1955, Stefan Carlsson has been Head of Business Area Parts &amp; Accessories since 1993. He started with the Volvo Group in 1974 and transferred to Volvo Penta in 1981. </blockquote>
</li>
<h4>
<li>
November 30, 1995<br><a href="/www.penta.volvo.se/pr/intrvhellman.html">The new man at the helm</a>
</h4>
<blockquote>
 40-year old Anders Hellman, a Master of Engineering from Chalmers University, joined Volvo Penta in 1985 and became President on the 21st September 1995. He is also a member of the Volvo Group Executive Committee. </blockquote>
</li>
<h4>
<li>
November 30, 1995<br><a href="/www.penta.volvo.se/pr/intrvlundberg.html">Developing the marine commercial market</a>
</h4>
<blockquote>
 Orvar Lundberg, born in 1943, has been running the Marine Commercial division for some four years. He joined the company's service division in 1966, becoming its head in 1981 and took over as head of Accesories and Parts in 1989. </blockquote>
</li>
<h4>
<li>
November 15, 1995<br><a href="/www.penta.volvo.se/pr/tamd122pnov.html">TAMD 122P enhances product range</a>
</h4>
<blockquote>
 The latest high performance engine to join Volvo Penta Marine Commercial&#180;s extensive range is the TAMD122P, the newest version of Volvo Penta&#180;s well known 12 litre in-line six cylinder unit and incorporates direct injection, turbocharging and aftercooling. </blockquote>
</li>
<h4>
<li>
November 15, 1995<br><a href="/www.penta.volvo.se/pr/elcontrol.html">Electronic control for Volvo Penta TAMD72P</a>
</h4>
<blockquote>
 With the launch of its new, 'intelligent' TAMD72P EDC, Volvo Penta Marine Commercial is again setting new standards for marine diesel engine performance, comfort, reduced emissions and simplified installation and maintenance. </blockquote>
</li>
<h4>
<li>
November 14, 1995<br><a href="/www.penta.volvo.se/pr/newtamd163.html">New version of Volvo Penta TAMD163 for workboats</a>
</h4>
<blockquote>
Following the successful introduction of the TAMD163P engine in 1994, Volvo Penta has announced another version, the TAMD163A. This is a propulsion engine designed for Heavy Duty (HD) operations in tough conditions such as in fishing vessels, ferries and inland waterway applications, and which is also suitable for auxiliary purposes including as a complete genset. It is the result of considera...</blockquote>
</li>
<h4>
<li>
November  9, 1995<br><a href="/www.truck.volvo.se/pr/3kvart.html">Third quarter:Continued success for the Volvo Truck Group</a>
</h4>
<blockquote>
 The Volvo Truck Group has reported an operating profit of Skr 4,025 million (Skr 2,591 million*) for the third quarter 1995. The operating margin rose to 10.6 per cent (7.8%*). This increase is based principally on a high sales volume and a high level of utilization of capacity at our production plants. </blockquote>
</li>
<h4>
<li>
November  9, 1995<br><a href="/www.bus.volvo.se/pr/busoftheyear.html">'Coach of the Year 1996':</a>
</h4>
<h4>
<li>
October 17, 1995<br><a href="/www.truck.volvo.se/pr/NewAwards.html">New international awards for Volvo&#180;s FH range of trucks</a>
</h4>
<blockquote>
 Volvo Truck Corporation&#180;s FH range has been voted 'Truck  of the Year' in Poland. This is the second year running the FH range has  won this award. The FH range has also won the 'Grand Prix de Transport Actualit&eacute;s'  award, the citation saying that they are &quot;the most transportefficient  heavy duty trucks in the industry&quot;.</blockquote>
</li>
<h4>
<li>
October 1995<br><a href="/www.penta.volvo.se/pr/trimaran.html">Unique 'Seatruck' trimaran in New Zealand</a>
</h4>
<blockquote>
The Q-West shipyard received an order to build a boat, the like of which no one had ever seen before - a large fishing boat offering good cargo-holding properties, plenty of speed, and which is extremely seaworthy. </blockquote>
</li>
<h4>
<li>
October 1995<br><a href="/www.penta.volvo.se/pr/bylock.html">Five Volvo Penta diesels keep the vessel going - when it's in port!</a>
</h4>
<blockquote>
 Deep in the bowels of the ship is a door with a sign bearing the legend 'Auxiliary engine room. From it comes the powerful throb of five large diesels - although the vessel is actually not at sea, but tied up in port. In the control room next door, the second engineer checks that each of the green-painted units is running smoothly at the same speed and delivering 100 kW. </blockquote>
</li>
<h4>
<li>
October 1995<br><a href="/www.penta.volvo.se/pr/bargetraffic.html">Large variety of boats on European waterways</a>
</h4>
<blockquote>
 As traffic on European roads suffers from growing congestion, it is becoming increasingly easier on the continent's canals and rivers. Every year, 11,000 barges carry at least 400 million tonnes of freight along the network of waterways connecting the North Sea, the Mediterranean, the Baltic and the Black Sea. However, boats of many other types also frequent these waters. </blockquote>
</li>
<h4>
<li>
October 1995<br><a href="/www.penta.volvo.se/pr/genset.html">Another major Chinese order for Volvo Penta</a>
</h4>
<blockquote>
Volvo Penta Marine Commercial has secured a major follow up order from Chinese Shipyards. The first order was worth about SEK 15 million and the new order SEK 13 million. </blockquote>
</li>
<h4>
<li>
September 26, 1995<br><a href="/www.truck.volvo.se/pr/LastF12.html">The last F12 produced at the Tuve plant - Volvo Truck Corporation's biggest-selling model so far</a>
</h4>
<blockquote>
 The last F12 truck has now been produced at Volvo Truck Corporation's assembly  plant in Tuve. More than 200,000 F trucks have been sold since they were  first introduced, and the F12 model is now being phased out after being  in production for 18 years. </blockquote>
</li>
<h4>
<li>
September 15, 1995<br><a href="/www.truck.volvo.se/pr/Offset.html">Volvo Truck Corporation unique with it's new &quot;OFFSET&quot; collision test</a>
</h4>
<blockquote>
 As part of development of the airbag for use in heavy duty trucks,  Volvo Truck Corporation has developed and implemented a new and unique collision  test for trucks &#173; the 'offset test'. Together with cab impact tests, crash barrier tests, and the work carried  out by the VTC's Accident Investigation Team, the offset test forms the  basis of the development of safe trucks.</blockquote>
</li>
<h4>
<li>
September 11, 1995<br><a href="/www.car.volvo.se/pr/my96.html">Volvo 850 with turbodiesel - one of many attractive new Volvo features for 1996</a>
</h4>
<blockquote>
 The Volvo Car Corporation's 1996 model programme will be crowned by the new Volvo 850 TDI, a high-performance diesel in every respect. In addition, the entire model programme features a whole host of exterior and interior news which will combine to make the Volvo programme for the 1996 model year even more comprehensive and attractive. </blockquote>
</li>
<h4>
<li>
September 11, 1995<br><a href="/www.car.volvo.se/pr/850r.html">Volvo 850 R - a car for the connoisseur</a>
</h4>
<blockquote>
 The Volvo 850 R is the latest addition to the 850 family. Comfortable, roomy and safe and, at the same time, the most powerful and fastest standard Volvo in the company's almost 70-year history. The perfect car choice for the intelligent connoisseur. </blockquote>
</li>
<h4>
<li>
September 11, 1995<br><a href="/www.car.volvo.se/pr/850tdi.html">Volvo 850 TDI - efficient high-performance diesel with comfort and driving pleasure</a>
</h4>
<blockquote>
 The Volvo 850 has become synonymous with the term &quot;dynamics&quot;. So it is only natural that the diesel version of the Volvo 850 offers both performance and comfort in the petrol engine class without sacrificing any of the fine driving dynamics or driving experience behind the wheel. An ultra-modern turbocharged, 5-cylinder, 2.5-litre diesel ensures that the Volvo 850 TDI is a genuine 8...</blockquote>
</li>
<h4>
<li>
September  5, 1995<br><a href="/www.truck.volvo.se/pr/GlobetrotterXL.html">A new range of cabs for FH trucks:A new and more spacious cab from Volvo Truck Corporation &#173; The Globetrotter XL</a>
</h4>
<blockquote>
 Volvo Truck Corporation is introducing the Globetrotter XL.  The cab has a full in-cab standing height of 193 cm. A new interior design  is also being introduced for all Volvo FH cabs. </blockquote>
</li>
<h4>
<li>
September  5, 1995<br><a href="/www.truck.volvo.se/pr/dynaflee.html">The Volvo Truck Corporation exhibits an international transport control system: Dynafleet helps to achieve more effective Transport and a cleaner Enviroment</a>
</h4>
<blockquote>
 Work on achieving more efficient forms of truck transport continues.  More than 1,000 design engineers at Volvo are engaged on developing not  only new and modern trucks, but also support services and systems to make  Volvo trucks even more efficient to use. </blockquote>
</li>
<h4>
<li>
September  5, 1995<br><a href="/www.truck.volvo.se/pr/Airbag.html">Volvo Truck Corporation is the first manufacturer in the world to offer  an airbag in heavy duty trucks</a>
</h4>
<blockquote>
 Volvo Truck Corporation is now the first manufacturer in the  world to introduce an airbag in truck production  An in-depth analysis of 94 accidents carried out by Volvo Truck Corporation's  Accident Investigation Team shows that an SRS Airbag (Supplementary Restraint  System Airbag) would have had an injury-preventive effect in about 20 per  cent of cases. But with the important rider &#173;...</blockquote>
</li>
<h4>
<li>
September 1995<br><a href="/www.penta.volvo.se/pr/partscatalogue.html">New 1995/96 Accessories and maintenance parts catalogue</a>
</h4>
<blockquote>
The latest edition of Volvo Penta's popular Accessories and Maintenance Parts Catalogue is now available, internationally, from authorised service dealers.</blockquote>
</li>
<h4>
<li>
August 30, 1995<br><a href="/www.truck.volvo.se/pr/1000ple.html">1.000 Volvo trucks produced in Poland</a>
</h4>
<blockquote>
 On 29 August 1995 the 1,000th Volvo truck built in Poland  left the Volvo Truck Corporation's assembly plant in Wroclaw. In less than  two years the VTC has established a production facility and a market company  in Poland. </blockquote>
</li>
<h4>
<li>
August 23, 1995<br><a href="/www.truck.volvo.se/pr/vlghalv.html">Continued success for the Volvo Truck Group</a>
</h4>
<blockquote>
 The Volvo Truck Group reported an operating profit of SKr 3,106  million for the first six months 1995 (compared with SKr 1,829 million the  first six months 1994). The operating margin rose to 10.6 per cent (7.5),  resulting chiefly from increased deliveries, the very high level of production  plant utilization, and a higher share of FH trucks sold.</blockquote>
</li>
<h4>
<li>
August  1, 1995<br><a href="/www.truck.volvo.se/pr/D6eng.html">All Volvo Truck Corporations engines now matched to the Euro 2 requirements</a>
</h4>
<blockquote>
 As from August, Volvo Truck Corporation's D6A and D10A engines  are adapted to match the Euro 2 requirements. This means that the entire  Volvo Truck Corporation range of engines is matched to the Euro 2 requirements. </blockquote>
</li>
<h4>
<li>
August 1995<br><a href="/www.truck.volvo.se/pr/1ordchin.html">Major order to China</a>
</h4>
<blockquote>
 One of Volvo Truck Corporation's distributors in China,  Taikoo Enterprises Ltd., has won its first major order in China. This is  for 20 Volvo FL10 4x2 Tractor units. </blockquote>
</li>
<h4>
<li>
August 1995<br><a href="/www.bus.volvo.se/pr/ECT.html">Driveline in bus roof enhances passenger comfort</a>
</h4>
<blockquote>
 The wheels in the corners, the driver in the middle, the boarding  height at kerb level, and the driveline in the roof- all these features  give passengers of the future a lot to look forward to. Moreover, the comfort features are combined with concern for the environment and a safety approach.  The ECB, Environmental Concept Bus, was being shown for the first time at  the UITP (Union Interna...</blockquote>
</li>
<h4>
<li>
July 1995<br><a href="/www.penta.volvo.se/pr/vpg2227.html">Grand Mistral official engine supplier</a>
</h4>
<blockquote>
 Volvo Penta marine diesel engines have been chosen to provide propulsion and auxiliary power for all of the one-design ocean racing yachts which will participate in the GRAND MISTRAL World Yacht Race in 1996-97. </blockquote>
</li>
<h4>
<li>
July 1995<br><a href="/www.penta.volvo.se/pr/vpg2217.html">Volvo Penta launches new TAMD122  - a new level of power</a>
</h4>
<blockquote>
Volvo Penta has introduced the new 441 kW (600 hp) direct-injected, turbocharged and aftercooled TAMD122P - the latest development of the company's renowned and well-proven 12-litre in-line six high performance diesel engines.</blockquote>
</li>
<h4>
<li>
July 1995<br><a href="/www.penta.volvo.se/pr/22sx.html">Volvo Penta 22/SX aquamatic diesels - a new dimension</a>
</h4>
<blockquote>
 Volvo Penta has launched the new turbocharged and aftercooled 79kW (105 hp) TAMD22/SX to further extend the recently introduced and highly acclaimed four-cylinder 22/SX Aquamatic diesel series. </blockquote>
</li>
<h4>
<li>
July 1995<br><a href="/www.penta.volvo.se/pr/vpg2201.html">Volvo Penta launches new TAMD72P EDC Diesel - First engine with electronic diesel control</a>
</h4>
<blockquote>
 Volvo Penta has again set new standards for marine diesel engine performance and comfort, reduced emissions, and simplified installation and maintenance, with the launch of the new 'intelligent' TAMD72P EDC (Electronic Diesel Control). </blockquote>
</li>
<h4>
<li>
July 1995<br><a href="/www.penta.volvo.se/pr/fuelinject.html">Fuel Injectors now part of exchange programme</a>
</h4>
<blockquote>
Volvo Penta&#180;s Exchange Parts programme, operated through the company&#180;s Europe-wide dealer network, has been extended to now include fuel injectors - one of the most important yet often neglected engine components.</blockquote>
</li>
<h4>
<li>
July 1995<br><a href="/www.penta.volvo.se/pr/vpg2223.html">Two-year worldwide warranty</a>
</h4>
<blockquote>
Volvo Penta, the world's leading manufacturer and supplier of marine engines, has introduced a unique free two-year worldwide warranty (effective from 1st September 1995) for all new propulsion diesel engines - in the power range 300 hp to 770 hp - for boats used for private leisure purposes.</blockquote>
</li>
<h4>
<li>
June 30, 1995<br><a href="/www.penta.volvo.se/pr/hellman.html">Anders Hellman named new President of Volvo Penta Corporation</a>
</h4>
<blockquote>
 Anders Hellman, currently head of Development and Diesel Engines Purchasing within Volvo Penta Corporation, has been named new President of the company, effective from the time of the company's board meeting in September. He will at the same time become co-opted member of AB Volvo's Group Executive Committee. </blockquote>
</li>
<h4>
<li>
June 20, 1995<br><a href="/www.penta.volvo.se/pr/ukroyal.html">UK Royal Navy order success</a>
</h4>
<blockquote>
Volvo Penta UK is supplying engines to power a new class of landing craft. These are being built for the UK Ministry of Defence and will be carried aboard one of Britain's largest warships. The prototype, designed and being built by Vosper Thornycroft, is constructed in aluminium and is 15m long with capacity for 35 personnel and nearly 2 tonnes of associated equipment. </blockquote>
</li>
<h4>
<li>
June 20, 1995<br><a href="/www.penta.volvo.se/pr/tamd122.html">TAMD 122P enhances product range</a>
</h4>
<blockquote>
The latest high performance engine to join Volvo Penta Marine Commercial's extensive range is the TAMD 122P, the newest version of Volvo Penta's well known 12 litre in-line six cylinder unit and which incorporates direct injection, turbocharging and aftercooling. </blockquote>
</li>
<h4>
<li>
June 19, 1995<br><a href="/www.penta.volvo.se/pr/lifeboats.html">Sweden donates lifeboats to Baltic states</a>
</h4>
<blockquote>
The lifeboats left Slite on Gotland in convoy on their maiden voyage across the Baltic Sea, where they will go into service for the different Baltic States. The five Swedish-built boats have been donated by Sweden and are powered by drivelines that combine Swedish and Finnish engineering. </blockquote>
</li>
<h4>
<li>
June 1995<br><a href="/www.penta.volvo.se/pr/iso9001.html">Volvo Penta ISO 9001 certified</a>
</h4>
<blockquote>
Lloyd's Register Quality Assurance Ltd. (LRQA) has carried out a third-party certification of Volvo Penta's operations in Sweden. The operations at the headquarters in G&ouml;teborg, the facilities at Arendal (G&ouml;teborg) and in Vara have now been granted certification. By this, Volvo Penta is the first of the Volvo product companies to also have certification of the management and the staf...</blockquote>
</li>
<h4>
<li>
June 1995<br><a href="/www.penta.volvo.se/pr/lcraft95.html">Leisure craft and the environment</a>
</h4>
<blockquote>
Volvo Penta is a leading player in the European marine diesel engine market. Although based in Sweden, the company exports 94% of its production, mainly to other EU countries. For this reason, Volvo Penta is working actively towards common European environmental protection standards offering scope for harmonisation with global standards in areas such as exhaust gas emissions and sound emission...</blockquote>
</li>
<h4>
<li>
June 1995<br><a href="/www.penta.volvo.se/pr/success.html">Major Success for Volvo Penta in 1994</a>
</h4>
<blockquote>
 Volvo Penta enjoyed further buoyant growth in 1994, continuing the trend set in 1993. Sales for the year showed an increase of 25%, while profits grew by no less than 83%. </blockquote>
</li>
<h4>
<li>
June 1995<br><a href="/www.penta.volvo.se/pr/lmjune95.html">Volvo Penta leads development with responsibility and innovative thinking</a>
</h4>
<blockquote>
 &quot;Our constant aim is to meet the needs of our customers - and their customers in turn - as well as taking an active part in the development of environment-friendly engines and establishing standards for the future.&quot; So says Tommy Boork, head of Leisure Marine, Europe and Overseas at Volvo Penta. </blockquote>
</li>
<h4>
<li>
May 19, 1995<br><a href="/www.penta.volvo.se/pr/emission.html">Volvo Penta's latest emission-controlled engines</a>
</h4>
<blockquote>
Volvo Penta Industry has now introduced two new units to its range of emission-controlled diesel engines that are suitable for off-highway applications. </blockquote>
</li>
<h4>
<li>
May 1995<br><a href="/www.penta.volvo.se/pr/lobster.html">Speed, performance and flexibility benefit Australian lobster fishers</a>
</h4>
<blockquote>
 Lobster fishing is a special sort of industry in western and southern Australia. Reminiscent of trucks, the high-powered boats used are built to carry high loads and are well-equipped for long trips. </blockquote>
</li>
<h4>
<li>
April 1995<br><a href="/www.vce.volvo.se/pr/ec450.html">Bauma debut for new &Aring;kerman EC450 excavator</a>
</h4>
<blockquote>
Volvo Construction Equipment unveiled a new 45 t excavator at Bauma in April. Designated the &Aring;kerman EC450, the excavator is the strongest and most powerful machine on the market in its class. It features a new low emission engine, increased lifting capacity and improved hydraulics. The capacity has improved by over 20% compared to its predecessors. </blockquote>
</li>
<h4>
<li>
April 1995<br><a href="/www.vce.volvo.se/pr/a40.html">US Debut for new heavyweight Volvo BM articulated hauler</a>
</h4>
<blockquote>
Volvo Construction Equipment is extending its range of Volvo BM articulated haulers with the addition of a new 40 sh tn machine, designed for high productivity, versatility and operator comfort.</blockquote>
</li>
<h4>
<li>
April 1995<br><a href="/www.vce.volvo.se/pr/cgeneration.html">The new wheel loader generation from Volvo Construction Equipment</a>
</h4>
<blockquote>
 The new Volvo BM &quot;C&quot; generation delivers high performance and low emissions. </blockquote>
</li>
<h4>
<li>
April 1995<br><a href="/www.vce.volvo.se/pr/r65.html">New generation of advanced rigid haulers</a>
</h4>
<blockquote>
A new Euclid hauler designated the Euclid R65, has been designed as a 60 t class unit featuring high performance, increased levels of comfort and safety, plus improved serviceability. </blockquote>
</li>
<h4>
<li>
March 16, 1995<br><a href="/www.penta.volvo.se/pr/chinese.html">Huge Chinese Order for Volvo Penta</a>
</h4>
<blockquote>
 Between 500 and 1,000 genset engines - every year for a decade! With this huge order worth at least SEK 450 million (some US$ 60 million), Volvo Penta Industry has now established a powerful base in China for the next 10 years. </blockquote>
</li>
<h4>
<li>
February 1995<br><a href="/www.penta.volvo.se/pr/indiabrazil.html">Breakthrough for Volvo Penta in India and Brazil</a>
</h4>
<blockquote>
Volvo Penta Industry has achieved a simultaneous breakthrough in two of the most important world markets of the future - India and Brazil.</blockquote>
</li>
</ul>
<p>
<hr>
<p><center>

<P ALIGN="CENTER">[ <A HREF="/corpinfo/index.html">The Volvo Group - Facts and Figures</A> ]<BR>
[ <A HREF="/www.car.volvo.se">Volvo Car</A> | 
<A HREF="/www.truck.volvo.se">Volvo Truck</A> | 
<A HREF="/www.bus.volvo.se/index.html">Volvo Bus</A> | 
<A HREF="/www.vce.volvo.se">Volvo Construction Equipment</A> ]<BR>
[ <A HREF="/www.penta.volvo.se">Volvo Penta</A> | 
<A HREF="/www.aero.volvo.se/index.html">Volvo Aero</A> | 
<A HREF="/other/index.html">Other Companies</A> ]
<BR>
[ <a href="/cgi-bin/make_tot_press">News &amp; Press Releases</a> | <a href="/cgi-bin/make_tot_press_old">Old News &amp; Press Releases</a> ]
<br>
[ <a href="/cgi-bin/make_tot_press_se">Some Swedish News &amp; Press Releases</a> ]
<br>
[ <a href="/">Volvo Group Homepage</a> |
<a href="#top_of_page">Top of page</a> ]
<p>
<hr>
<br>
<A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se] <br>
<a name="end_of_page"></a>
<br>
<hr>
</center>
</BODY>
</html>

</DOC>
<DOC>
<DOCNO>WT08-B13-160</DOCNO>
<DOCOLDNO>IA055-000919-B017-194</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/cgi-bin/make_tot_press_se 192.138.110.240 19970208022239 text/html 9018
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 02:22:49 GMT
Server: Apache/1.1.3
Content-type: text/html
</DOCHDR>
<!doctype html public \"-//W30//DTD W3 HTML 2.0//EN\">
<HTML>
<HEAD>
<TITLE>Press Releases
</TITLE>
</HEAD>
<body bgcolor=#ffffff>
<center>
<a name="top_of_page"></a>
<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<br>
<br>
[ <a href="/">Volvo Group Homepage</a> | <a href="#end_of_page">End of page</a> ]
<br>
[ <a href="/cgi-bin/make_tot_press">News &amp; Press Releases</a> | <a href="/cgi-bin/make_tot_press_old">Old News &amp; Press Releases</a> ]
<br>
[ <a href="/cgi-bin/make_tot_press_se">Some Swedish News &amp; Press Releases</a> | <a href="/cgi-bin/make_tot_press_se_old">Some Swedish Old News &amp; Press Releases</a> ]
<br>
<hr>
<H2>Nyheter &amp; Pressmeddelanden f&ouml;r Volvo Gruppen</H2>
<img src="/images/pressimages.gif" width="487" height="85" align="bottom" naturalsi
zeflag="3" border="2">
</center> 
<hr>
<ul>
<h4>
<li>
30 januari 1997<br><a href="/www.truck.volvo.se/prse/970130s1.html">Lastbilssimulator p Stora Holm presenterad:Sker och miljanpassad utbildning fr den tunga trafiken</a>
</h4>
<blockquote>
  Ishala vgar r en faktor som kan gra det mycket svrt att hantera en  lastbil. Det innebr stora risker att trna p det, och det har  funnits f mjligheter till att simulera trningen.  Fram till nu.  P torsdagen presenterades lastbilssimulatorn p Stora Holm, som  fungerar lika bra fr den som vill ta nytt krkort och fr den med  vana frn tung trafik som vill testa sina kunskaper.   ...</blockquote>
</li>
<h4>
<li>
30 januari 1997<br><a href="/www.truck.volvo.se/prse/970130s2.html">Lastbilssimulatorn p Stora Holm:Tekniken gr att det knns som p riktigt</a>
</h4>
<blockquote>
  Att skapa en verklighet som inte finns - det r simulatorns uppgift.  Fr att simulatorn skall ligga s nra verkligheten som mjligt mste  tekniken anpassas efter detta.  Svra eller farliga krsituationer kan simuleras och upprepas s att  bsta inlrning uppns.    </blockquote>
</li>
<h4>
<li>
30 januari 1997<br><a href="/www.truck.volvo.se/prse/970130s3.html">Volvo Lastvagnar initiativtagare till Lastbilssimulatorn p Stora Holm</a>
</h4>
<blockquote>
  Skerhet, miljhnsyn och placeringen viktiga faktorer    </blockquote>
</li>
<h4>
<li>
27 januari 1997<br><a href="/www.volvo.se/prse/970127s1.html">VD-skifte i Volvo</a>
</h4>
<blockquote>
 S&ouml;ren Gyll eftertr&auml;ds av Leif Johansson vid bolagsst&auml;mman. </blockquote>
</li>
<h4>
<li>
17 januari 1997<br><a href="/www.truck.volvo.se/prse/970117s2.html">Volvo Lastvagnar breddar sitt anlggningsprogram</a>
</h4>
<blockquote>
  Powertronic p FL7 och allhjulsdrift i ordinarie produktprogrammet  </blockquote>
</li>
<h4>
<li>
17 januari 1997<br><a href="/www.truck.volvo.se/prse/970117s3.html">&Aring;ret som g&aring;tt: Volvo Lastvagnar investerar f&ouml;r fortsatt framg&aring;ng</a>
</h4>
<blockquote>
  1996 var ett h&auml;ndelserikt &aring;r f&ouml;r Volvo Lastvagnar. Totalmarknaderna i  Nord- och Sydamerika blev betydligt l&auml;gre j&auml;mf&ouml;rt med 1995 och  resulterade i minskad lastbilsf&ouml;rs&auml;ljning. I Europa bef&auml;ste Volvo  Lastvagnar sin starka position som n&auml;st st&ouml;rsta tillverkare av tunga  lastbilar.    </blockquote>
</li>
<h4>
<li>
17 januari 1997<br><a href="/www.truck.volvo.se/prse/970117s1.html">Volvo Lastvagnar p&aring; Brysselm&auml;ssan 1997</a>
</h4>
<blockquote>
  7,5-tons lastbil - Volvo FLC, samt ett breddat anl&auml;ggningsprogram  </blockquote>
</li>
<h4>
<li>
10 januari 1997<br><a href="/www.truck.volvo.se/prse/970110s1.html">Volvo Lastvagnar och Ume&aring; universitet startar samarbete</a>
</h4>
<blockquote>
  Chauff&ouml;rernas arbetsmilj&ouml; skall f&ouml;rb&auml;ttras.    </blockquote>
</li>
<h4>
<li>
 8 januari 1997<br><a href="/www.aero.volvo.se/prse/970108s1.html">Volvo Aeros verksamheter i Arboga flyttas till Trollh&auml;ttan</a>
</h4>
<blockquote>
  Volvo Aero Corporations styrelse har tagit ett inriktningsbeslut som inneb&auml;r flyttning av Volvo Aeros verksamheter i Arboga till Trollh&auml;ttan. MBL-f&ouml;rhandlingar &auml;r inledda vid Volvo Aero Support AB och Volvo Aero Engine Services Arboga AB. Ett beslut om flyttning inneb&auml;r att Volvo Aero Support och Volvo Aero Engine Services Arboga l&auml;ggs ner. De 650 anst&auml;llda...</blockquote>
</li>
<h4>
<li>
 7 januari 1997<br><a href="/www.truck.volvo.se/prse/970107s1.html">Tuve-fabriken firar 15 &aring;r med att bygga 100.000:e lastbilen</a>
</h4>
<blockquote>
  Volvo Lastvagnars fabrik i Tuve utanf&ouml;r G&ouml;teborg fyller i dagarna 15  &aring;r. Samtidigt byggs den 100:000:e lastbilen i fabriken.  </blockquote>
</li>
<h4>
<li>
16 december 1996<br><a href="/www.truck.volvo.se/prse/961216s1.html">Factory 97, nytt produktionskoncept i Gent-fabriken</a>
</h4>
<blockquote>
 F&ouml;r tre &aring;r sedan fick Volvos lastvagnsfabrik i Gent, Belgien, klartecken att investera mer &auml;n en miljard belgiska franc i ett helt nytt produktionskoncept som skulle h&ouml;ja fabrikens produktionskapacitet till 26 000 enheter per &aring;r. Efter tv&aring; &aring;rs intensivt ombyggnadsarbete p&aring; fabriken, samtidigt som produktionen p&aring;gick i of&ouml;rminskad takt, k...</blockquote>
</li>
<h4>
<li>
16 december 1996<br><a href="/www.truck.volvo.se/prse/961216s2.html">Volvo Europa Truck levererar den 300 000:de lastvagnen</a>
</h4>
<blockquote>
 Den 3 december levererades den 300 000:e belgisktillverkade lastvagnen fr&aring;n Volvos lastvagnsfabrik i Gent, en FH12 Globetrotter, byggd f&ouml;r transportf&ouml;retaget Heyndrickx i Heist-op-den-Berg. </blockquote>
</li>
<h4>
<li>
11 december 1996<br><a href="/www.aero.volvo.se/prse/961211s1.html">Samarbete mellan volvo aero och MTU vrt fyra miljarder ger 200 nya jobb</a>
</h4>
<blockquote>
Volvo Aero har undertecknat ett samarbetsavtal, ett s k Memorandum of Understanding,  med den tyska flygmotortillverkaren MTU, ett fretag inom Daimler-Benz Aerospace. Avtalet r vrt totalt cirka fyra miljarder kronor under minst en 20-rsperiod och medfr en rlig omsttningskning fr Volvo Aero om 200 miljoner kronor. Avtalet innebr ett rekryteringsbehov p ver 200 medarbetare    till an...</blockquote>
</li>
<h4>
<li>
 6 december 1996<br><a href="/www.truck.volvo.se/prse/961209s1.html">100 Volvo-lastbilar till Ukraina</a>
</h4>
<blockquote>
 Volvo Lastvagnar har levererat 100 Volvo FH12 till Ukraina. Kunden &auml;r Sovransavto, landets st&ouml;rsta transportf&ouml;retag med s&auml;te i Lugansk i de &ouml;stra delarna av Ukraina. </blockquote>
</li>
<h4>
<li>
27 november 1996<br><a href="/www.aero.volvo.se/prse/961127s1.html">Utm&auml;rkelsen svensk kvalitet till Volvo Aero corporation</a>
</h4>
<blockquote>
 Volvo Aero Corporation i Trollh&auml;ttan har tilldelats &quot;Utm&auml;rkelsen Svenska Kvalitet 1996&quot; i klassen stora organisationer med 200 &aring;rsanst&auml;llda eller fler. Utm&auml;rkelsen utdelas av Institutet f&ouml;r Kvalitetsutveckling, SIQ, som har till uppgift att fr&auml;mja kvalitetsutvecklingen i hela det svenska samh&auml;llet. SIQ:s huvudm&auml;n &auml;r Intressentf&ouml...</blockquote>
</li>
<h4>
<li>
25 november 1996<br><a href="/www.volvo.se/prse/961125s1.html">"Lex Asea" till&auml;mplig p&aring; Volvos utdelning av Swedish Match</a>
</h4>
<blockquote>
 Lex Asea &auml;r till&auml;mplig p&aring; utdelningen av Swedish Match till Volvos aktie&auml;gare. Det st&aring;r klart sedan regeringsr&auml;tten nu har fastst&auml;llt skatter&auml;ttsn&auml;mndens f&ouml;rhandsbesked i &auml;rendet. </blockquote>
</li>
<h4>
<li>
22 november 1996<br><a href="/www.volvo.se/prse/961122s1.html">Volvo och Chalmers startar samarbete om fordonsteknisk forskning</a>
</h4>
<blockquote>
 AB Volvo och Chalmers Tekniska H&ouml;gskola har idag tecknat ett avtal om etablering av resurser f&ouml;r fordonsteknisk forskning vid Chalmers. </blockquote>
</li>
</ul>
<p>
<hr>
<p><center>

<P ALIGN="CENTER">[ <A HREF="/corpinfo/index.html">The Volvo Group - Facts and Figures</A> ]<BR>
[ <A HREF="/www.car.volvo.se">Volvo Car</A> | 
<A HREF="/www.truck.volvo.se">Volvo Truck</A> | 
<A HREF="/www.bus.volvo.se/index.html">Volvo Bus</A> | 
<A HREF="/www.vce.volvo.se">Volvo Construction Equipment</A> ]<BR>
[ <A HREF="/www.penta.volvo.se">Volvo Penta</A> | 
<A HREF="/www.aero.volvo.se/index.html">Volvo Aero</A> | 
<A HREF="/other/index.html">Other Companies</A> ]
<BR>
[ <a href="/cgi-bin/make_tot_press">News &amp; Press Releases</a> | <a href="/cgi-bin/make_tot_press_old">Old News &amp; Press Releases</a> ]
<br>
[ <a href="/cgi-bin/make_tot_press_se">Some Swedish News &amp; Press Releases</a> | <a href="/cgi-bin/make_tot_press_se_old">Some Swedish Old News &amp; Press Releases</a> ]
<br>
<br>
[ <a href="/">Volvo Group Homepage</a> |
<a href="#top_of_page">Top of page</a> ]
<p>
<hr>
<br>
<A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se] <br>
<a name="end_of_page"></a>
<br>
<hr>
</center>
</BODY>
</html>

</DOC>
<DOC>
<DOCNO>WT08-B13-161</DOCNO>
<DOCOLDNO>IA055-000919-B019-434</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/technical/dynaguide.html 192.138.110.240 19970208023104 text/html 2867
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 02:31:14 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 2696
Last-modified: Thu, 13 Jun 1996 14:47:47 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>DYNAGUIDE</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>
</TR>

<TR>
	<TD><HR></TD>
</TR>

</TABLE>

<TABLE WIDTH=490 BORDER=0>
<TR>
	<TD>
<BR>
<BR>
<P ALIGN="LEFT">
<FONT SIZE=7><B>DYNAGUIDE</B></FONT><BR>

<P ALIGN="LEFT">
<FONT SIZE=5><I>Better traffic information on the road</I></FONT>

<BLOCKQUOTE>
<BR>
<BR>

<P ALIGN="LEFT">
<IMG ALIGN=RIGHT BORDER=1 WIDTH=233 height=137 HSPACE=10 VSPACE=4 
SRC="/images/technical/dynaguide1.gif">

<FONT SIZE=5>DYNAGUIDE is a system for presenting traffic information, developed by 
Volvo for the new RDS/TMC European traffic information network.</FONT>

<P ALIGN="LEFT">
The driver receives information on an in-car screen about the current traffic 
situation. It is also possible with the aid of the satellite-based GPS - Global 
Positioning System - to locate the position of the car on the display.

<P ALIGN="LEFT">
DYNAGUIDE enables the driver to negotiate traffic more easily as details are 
presented on the screen about possible holdups ahead, allowing another route 
to be selected and avoiding queues, roadworks and traffic jams. The system 
uses coded messages which the vehicle receiver then processes into the 
desired language, wherever the vehicle happens to be in Europe. 

<P ALIGN="LEFT">
Smoother traffic flow and shorter queues reduce emission levels and 
contribute to a better environment, particularly in city centres. 

<P ALIGN="LEFT">

<IMG ALIGN=LEFT BORDER=1 WIDTH=173 height=137 HSPACE=10 VSPACE=4 
SRC="/images/technical/dynaguide2.gif">

DYNAGUIDE creates a safer driver who is well prepared for whatever may lie 
ahead. Frost warnings are issued in good time and the driver knows, for 
example, when the snowploughs have not managed to get through. When there 
is a risk of wild animals wandering onto the road or other hazards 
presenting themselves, warning signals are issued quickly. 

<P ALIGN="LEFT">
DYNAGUIDE uses the RDS/TMC communication system. Radio Data System is 
the channel used to transmit the message to the motorist. Traffic Message 
Channel is the means by which the message is coded. Communication takes 
place using the FM network




<BR>
<BR>

<P>
<BR>
</BLOCKQUOTE>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]
</TD>
</TR>
</TABLE>

</CENTER>

</BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-162</DOCNO>
<DOCOLDNO>IA055-000919-B020-31</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/technical/mobiguide.html 192.138.110.240 19970208023120 text/html 2842
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 02:31:28 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 2671
Last-modified: Thu, 13 Jun 1996 14:47:51 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE></TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>
</TR>

<TR>
	<TD><HR></TD>
</TR>

</TABLE>

<TABLE WIDTH=490 BORDER=0>
<TR>
	<TD>
<BR>
<BR>

<P ALIGN="LEFT">
<FONT SIZE=7><B>MOBIGUIDE</B></FONT><BR>

<FONT SIZE=5><I>More efficient transport</I></FONT>

<BLOCKQUOTE>
<BR>
<BR>

<P ALIGN="LEFT">
<IMG ALIGN=RIGHT BORDER=1 WIDTH=174 height=198 HSPACE=10 VSPACE=4 
SRC="/images/technical/mobiguide1.gif">


<FONT SIZE=5>MOBIGUIDE is a PC-based transport management system developed by 
Volvo, that uses the mobile telephone network to transmit text 
messages to and from different types of vehicle.</FONT>

<P ALIGN="LEFT">
Access to the system requires a PC with software that is easy to use. It 
then takes the transport supervisor just a few seconds, using a customer 
register of vehicles, customer addresses and standardised messages, to 
create the appropriate message and dispatch it via a modem.

<P ALIGN="LEFT">
The vehicle is equipped with a mobile telephone and built-in computer for 
speech and text communication although the driver does not need to be in 
the car or respond to the message. Messages can also be relayed from the 
car to the traffic control centre with the aid of standardised messages or 
using the buttons on a mobile telephone. 

<P ALIGN="LEFT">
<IMG ALIGN=LEFT BORDER=1 WIDTH=149 height=189 HSPACE=10 VSPACE=4 
SRC="/images/technical/mobiguide2.gif">

MOBIGUIDE uses a digital computer channel within the GSM and NMT mobile 
telephone systems. In doing so the existing infrastructure can be used 
and communication costs kept to a minimum.

<P ALIGN="LEFT">
The Global Positioning System (GPS) is a satellite-based positioning 
system where the recipient - the vehicle - can determine its position 
with the aid of 20 satellites. The level of accuracy is so high that 
the vehicle can be pinpointed to within 50 metres. 

<P ALIGN="LEFT">
With the MOBIGUIDE PC map module at the traffic control centre and a 
GPS receiver in the vehicle, it is possible to continually monitor 
the position of the car. The map also increases the level of safety 
thanks to the built-in alarm.
<BR>
<BR>

<P>
<BR>
</BLOCKQUOTE>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]
</TD>
</TR>
</TABLE>

</CENTER>

</BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-163</DOCNO>
<DOCOLDNO>IA055-000919-B020-53</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/technical/socrates.html 192.138.110.240 19970208023131 text/html 2740
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 02:31:41 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 2569
Last-modified: Thu, 13 Jun 1996 14:47:53 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>SOCRATES</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>
</TR>

<TR>
	<TD><HR></TD>
</TR>

</TABLE>

<TABLE WIDTH=490 BORDER=0>
<TR>
	<TD>
<BR>
<BR>


<P ALIGN="LEFT">
<FONT SIZE=7><B>SOCRATES</B></FONT><BR>

<P ALIGN="LEFT">
<FONT SIZE=5><I>Dynamic navigation</I></FONT>

<BLOCKQUOTE>
<BR>
<BR>

<P ALIGN="LEFT">
<IMG ALIGN=RIGHT BORDER=1 WIDTH=155 height=202 HSPACE=10 VSPACE=4 
SRC="/images/technical/socrates1.gif">

<FONT SIZE=5>In the smart car of the future, the driver will be accompanied by the 
perfect guide. A guide that knows exactly where the vehicle happens to be, 
recognises all the roads and indicates the quickest route to your 
destination - anywhere in Europe.</FONT>

<P ALIGN="LEFT">
SOCRATES (System of Cellular Radio for Traffic Efficiency and Safety) is a 
dynamic navigation system that takes into account the current traffic situation. 
There is two-way communication between the vehicle and a traffic control centre, 
which monitors the current traffic situation and in doing so facilitates 
more efficient use of the road network. 

<P ALIGN="LEFT">
A sophisticated system in the vehicle, working in collaboration with a 
satellite, maintains a continuous watch on the position of the vehicle. 
An onboard digital computer screen indicates on the map where the vehicle 
happens to be. The system is fitted with a CD unit that contains a map of 
the desired area, the destination is then decided and SOCRATES reports both 
vocally and visually how the driver can reach that destination.

<P ALIGN="LEFT">
<IMG ALIGN=LEFT BORDER=1 WIDTH=219 height=142 HSPACE=10 VSPACE=4 
SRC="/images/technical/socrates2.gif">

When full coverage has been achieved, SOCRATES will be able to maintain a 
dialogue with the traffic control centre in question. It will show the best 
way to the selected destination, avoiding traffic jams and other obstacles. 
Information is provided about the parking situation and alternative means 
of transport. Even hotel reservations can be made.


<BR>
<BR>
<BR>
<BR>

<P>
<BR>
</BLOCKQUOTE>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]
</TD>
</TR>
</TABLE>

</CENTER>

</BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-164</DOCNO>
<DOCOLDNO>IA055-000919-B020-79</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/technical/promise.html 192.138.110.240 19970208023148 text/html 2468
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 02:31:58 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 2297
Last-modified: Thu, 13 Jun 1996 14:47:52 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>PROMISE</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>
</TR>

<TR>
	<TD><HR></TD>
</TR>

</TABLE>

<TABLE WIDTH=490 BORDER=0>
<TR>
	<TD>
<BR>
<BR>



<P ALIGN="LEFT">
<FONT SIZE=7><B>PROMISE</B></FONT><BR>

<P ALIGN="LEFT">
<FONT SIZE=5><I>Portable information for travellers</I></FONT>

<BLOCKQUOTE>
<BR>
<BR>

<P ALIGN="LEFT">
<IMG ALIGN=LEFT BORDER=1 WIDTH=141 height=206 HSPACE=10 VSPACE=4 
SRC="/images/technical/promise1.gif">

<FONT SIZE=5>The aim of PROMISE is to develop a portable information system for the 
traveller. The focus in on solving traffic problems is cities and reducing 
the travelling time by increasing  accessibility of information. PROMISE 
produces proposals for different means of transport or a combination of 
car and bus.</FONT>

<P ALIGN="LEFT">
PROMISE can provide all types of valuable information prior to a journey. 
The concept includes, for example, details of different alternative means 
of transport, access to parking at the destination and other services for 
the tourist. All PROMISE terminals aim to have access to appropriate, 
reliable information.

<P ALIGN="LEFT">
<IMG ALIGN=RIGHT BORDER=1 WIDTH=143 height=132 HSPACE=10 VSPACE=4 
SRC="/images/technical/promise2.gif">

Several different terminals are being developed by manufacturers within the 
framework of the project. These are being produced by adapting existing 
terminals to the PROMISE concept.

<P ALIGN="LEFT">
PROMISE is an EU project, initiated and led by Volvo. The concept has been 
developed over a long period in Gothenburg and Birmingham, England, and 
PROMISE is one of a number of advanced transport technologies close to 
realisation. The goal is to develop PROMISE into a pan-European 
information system.




<BR>
<BR>

<P>
<BR>
</BLOCKQUOTE>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]
</TD>
</TR>
</TABLE>

</CENTER>

</BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-165</DOCNO>
<DOCOLDNO>IA055-000919-B020-118</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/technical/uv-light.html 192.138.110.240 19970208023201 text/html 2822
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 02:32:11 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 2651
Last-modified: Thu, 13 Jun 1996 14:47:54 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>UV-LIGHT</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>
</TR>

<TR>
	<TD><HR></TD>
</TR>

</TABLE>

<TABLE WIDTH=490 BORDER=0>
<TR>
	<TD>
<BR>
<BR>

<P ALIGN="LEFT">
<FONT SIZE=7><B>UV-LIGHT</B></FONT><BR>

<P ALIGN="LEFT">
<FONT SIZE=5><I>For better night vision</I></FONT>

<BLOCKQUOTE>
<BR>

<TABLE WIDTH=450 BORDER=0>
<TR>
	<TD VALIGN=BOTTOM>With dipped headlights vision is 65 metres.</TD>
	<TD><IMG ALIGN=RIGHT BORDER=1 WIDTH=316 height=135 HSPACE=10 VSPACE=4 
	SRC="/images/technical/uv1.gif"></td>
</TR>

<TR>
	<TD VALIGN=BOTTOM>With UV lights the vision is increased to 150 metres.</TD>
	<TD><IMG BORDER=1 WIDTH=316 height=135 HSPACE=10 VSPACE=4 
	SRC="/images/technical/uv2.gif"></TD>
</TR>

</TABLE>


<P ALIGN="LEFT">
<FONT SIZE=5>Darkness and poor vision are the cause of many accidents. The risk 
of being involved in a road accident is 2-3 times greater in the 
dark than in daylight.</FONT>

<P ALIGN="LEFT">
With dipped headlights vision is 65 metres, which means that the safety 
margin is minimal even at speeds that can be considered normal.

<P ALIGN="LEFT">
If a car is fitted with UV lights, the vision is increased to 150 metres, 
presupposing that pedestrians, road signs and other markings are wearing 
or are fitted with fluorescent material.

<P ALIGN="LEFT">
With UV light a full-beam effect is produced when meeting another vehicle 
without blinding the oncoming driver. 

<P ALIGN="LEFT">
<IMG ALIGN=LEFT BORDER=1 WIDTH=150 height=104 HSPACE=10 VSPACE=4 
SRC="/images/technical/uv3.gif">

UV light is a definite asset even in difficult weather conditions such as 
fog and snow. As the light reflected in the small water particles is 
invisible, the classic "curtain" effect does not occur when driving in fog.

<P ALIGN="LEFT">
During 1993-94, extensive and successful field tests were carried out and 
the Swedish Road Administration has adapted 100 km of roads in Sweden. 
There are also test roads in Germany and France. The Federal Highways 
Administration in USA will adapt a road south of Washington DC and carry 
out tests at the beginning of 1995.

<BR>
<BR>

<P>
<BR>
</BLOCKQUOTE>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]
</TD>
</TR>
</TABLE>

</CENTER>

</BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-166</DOCNO>
<DOCOLDNO>IA055-000919-B020-146</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/technical/friction.html 192.138.110.240 19970208023210 text/html 2782
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 02:32:21 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 2611
Last-modified: Thu, 13 Jun 1996 14:47:48 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>FRICTION</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>
</TR>

<TR>
	<TD><HR></TD>
</TR>

</TABLE>

<TABLE WIDTH=490 BORDER=0>
<TR>
	<TD>
<BR>
<BR>


<P ALIGN="LEFT">
<FONT SIZE=7><B>FRICTION</B></FONT><BR>

<P ALIGN="LEFT">
<FONT SIZE=5><I>Measuring roadholding</I></FONT>

<BLOCKQUOTE>
<BR>
<BR>

<P ALIGN="LEFT">
<IMG ALIGN=RIGHT BORDER=1 WIDTH=236 height=133 HSPACE=10 VSPACE=4 
SRC="/images/technical/friction1.gif">


<FONT SIZE=5>In collaboration with Link&ouml;ping University of Technology, Volvo 
has developed an advanced system for measuring and calculating the 
roadholding and grip between the tyres and the road surface.</FONT>

<P ALIGN="LEFT">
The system receives and measures signals from an ABS sensor and it then 
informs the driver about the roadholding, graded as GOOD - AVERAGE - POOR. 
Should the roadholding rapidly deteriorate, the driver is warned immediately. 
The system can also provide other systems in the car (ICC, for example) 
with friction information.

<P ALIGN="LEFT">
Constant measurement of the friction between the tyres and the road 
increases safety by furnishing appropriate information to the driver. 
The goal is to assess the roadholding under normal driving conditions 
and to find the most cost-effective solution that is simple to implement.

<P ALIGN="LEFT">
<IMG ALIGN=LEFT BORDER=1 WIDTH=108 height=104 HSPACE=10 VSPACE=4 
SRC="/images/technical/friction2.gif">


The calculation program for monitoring the roadholding has been developed 
and tested on a PC-based prototype in a Volvo 850 GLT. The existing 
sensors and signals are used (ABS sensor and torque).

<P ALIGN="LEFT">
The system's performance has been investigated with different combinations 
of tyres and road surfaces and additional evaluations are necessary 
before a decision regarding further development can be taken. If the 
system is verified in all combinations of tyres/surfaces, further 
development towards series production will be relatively simple thanks 
to the use of existing sensors and signals in the vehicle.


<BR>
<BR>

<P>
<BR>
</BLOCKQUOTE>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]
</TD>
</TR>
</TABLE>

</CENTER>

</BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-167</DOCNO>
<DOCOLDNO>IA055-000919-B020-171</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/technical/dynacruise_bus.html 192.138.110.240 19970208023220 text/html 2682
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 02:32:31 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 2511
Last-modified: Thu, 13 Jun 1996 14:47:45 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Dynacruise-Bus</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>
</TR>

<TR>
	<TD><HR></TD>
</TR>

</TABLE>

<TABLE WIDTH=490 BORDER=0>
<TR>
	<TD>
<BR>
<BR>


<P ALIGN="LEFT">
<FONT SIZE=7><B>DYNACRUISE</B></FONT><BR>

<P ALIGN="LEFT">
<FONT SIZE=5><I>For comfort and safety on the road</I></FONT>

<BLOCKQUOTE>
<BR>
<BR>

<P ALIGN="LEFT">
<IMG ALIGN=RIGHT BORDER=1 WIDTH=231 height=143 HSPACE=10 VSPACE=4 
SRC="/images/technical/icc-a1.gif">


<FONT SIZE=5>Dynacruise is a further development of the present-day cruise control. 
Dynacruise assists the driver in adapting the vehicle's performance to 
the prevailing traffic flow which in turn results in a higher level of 
safety on the road, reduced fuel consumption and lower emission levels. 
The system has been developed for several companies, including Volvo Bus 
Corporation.</FONT>

<P ALIGN="LEFT">
Dynacruise, as with a conventional cruise control, is a system that makes 
it easier for the driver to maintain the desired speed. Apart from the 
desired speed, the cruise control takes into consideration other traffic 
on the road,  as well as information from road signs through short-range 
communication.

<P ALIGN="LEFT">
<IMG ALIGN=LEFT BORDER=1 WIDTH=179 height=136 HSPACE=10 VSPACE=4 
SRC="/images/technical/icc-a2.gif">

The distance to the vehicle ahead is measured and the speed adapted to the 
current traffic flow. Information presented on road signs can be used by 
Dynacruise in a sophisticated manner; for example, when passing from a 
90 km/h speed limit zone into a 70 km/h zone, the speed will be 
automatically adjusted.

<P ALIGN="LEFT">
Measuring the distance to the vehicle in front is performed optically. 
The information from road signs is transferred to the vehicle using 
short-range communication via microwaves.

<P ALIGN="LEFT">
The cruise control uses the information to control the vehicle's speed 
by activating the engine starter and auxiliary brakes.




<BR>
<BR>

<P>
<BR>
</BLOCKQUOTE>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]
</TD>
</TR>
</TABLE>

</CENTER>

</BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-168</DOCNO>
<DOCOLDNO>IA055-000919-B020-199</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/technical/dynacruise_car.html 192.138.110.240 19970208023232 text/html 2600
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 02:32:39 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 2429
Last-modified: Thu, 13 Jun 1996 14:47:46 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Dynacruise-Car</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>
</TR>

<TR>
	<TD><HR></TD>
</TR>

</TABLE>

<TABLE WIDTH=490 BORDER=0>
<TR>
	<TD>
<BR>
<BR>


<P ALIGN="LEFT">
<FONT SIZE=7><B>DYNACRUISE</B></FONT><BR>

<P ALIGN="LEFT">
<FONT SIZE=5><I>For comfort and safety on the road</I></FONT>

<BLOCKQUOTE>
<BR>
<BR>

<P ALIGN="LEFT">
<IMG ALIGN=RIGHT BORDER=1 WIDTH=226 height=143 HSPACE=10 VSPACE=4 
SRC="/images/technical/icc-b1.gif">


<FONT SIZE=5>Dynacruise is a further development of the present-day cruise control system 
that will enable the driver to adapt to the prevailing traffic environment.</FONT>

<P ALIGN="LEFT">
The system takes into account the driver's desired speed, the speed of and 
distance to other vehicles, roadside information and roadholding to determine 
the car's speed. 

<P ALIGN="LEFT">
The speed of the car and distance to the vehicle in front is measured by 
means of a radar fitted to the front of the car that can calculate a safe 
distance to the vehicle ahead.

<P ALIGN="LEFT">
Information about the friction between the tyres and the road is used to 
adjust the speed and distance to other vehicles.

<P ALIGN="LEFT">
<IMG ALIGN=RIGHT BORDER=1 WIDTH=152 height=188 HSPACE=10 VSPACE=4 
SRC="/images/technical/icc-b2.gif">

The system uses short-range communication to collect information from the 
roadside and infrastructure about speed limitations, recommended speed and 
warnings. This information is then used to calculate the speed that will 
generate a good traffic flow and avoid hazardous situations.

<P ALIGN="LEFT">
Dynacruise uses the accelerator and brake to control the vehicle's speed 
although the driver can always override the system by pressing the brakes 
or accelerator.

<P ALIGN="LEFT">
A graphic display is used to indicate the distance to the car in front and 
to present roadside information.


<BR>
<BR>

<P>
<BR>
</BLOCKQUOTE>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]
</TD>
</TR>
</TABLE>

</CENTER>

</BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-169</DOCNO>
<DOCOLDNO>IA055-000919-B020-231</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/technical/dynafleet.html 192.138.110.240 19970208023248 text/html 4285
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 02:32:56 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 4114
Last-modified: Thu, 13 Jun 1996 14:47:46 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Dynafleet Info System</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>
</TR>

<TR>
	<TD><HR></TD>
</TR>

</TABLE>

<TABLE WIDTH=490 BORDER=0>
<TR>
	<TD>
<BR>
<BR>


<P ALIGN="LEFT">
<FONT SIZE=7><B>Dynafleet Info System</B></FONT><BR>

<P ALIGN="LEFT">
<FONT SIZE=5><I>More efficient transports for FH12/16 trucks</I></FONT>

<BLOCKQUOTE>
<BR>
<BR>

<P ALIGN="LEFT">
<IMG ALIGN=RIGHT BORDER=1 WIDTH=110 height=110 HSPACE=10 VSPACE=4 
SRC="/images/technical/dynafleet1.gif">


<FONT SIZE=5>Dynafleet Info System is a PC-based transport management system developed 
by Volvo, that uses the mobile phone network or a satellite network to 
transmit data (e.g. text messages, vehicle- and driver-information) to and 
from vehicles.
</FONT>

<P ALIGN="LEFT">
The mobile system is primarily aimed at FH12/16 trucks as it is integrated 
with the existing information systems in the truck. The system enables the 
driver to send and receive text messages (formatted or unformatted). Maps 
in various scales can be stored electronically so that by decoding traffic 
signals (based on the European RDS/TMC* standard) and using a GPS antenna** 
the vehicle position and the traffic situation in the surrounding area can 
be seen on the colour display mounted on the dashboard. This makes it 
easier for the driver to choose the best route. To ensure a safe and 
userfriendly driver environment, the driver is equipped with an easy 
to use remote control as well as an ordinary keyboard. In addition, 
GSM/SMS phone or satellite equipment is required. 

<P ALIGN="LEFT">
The PC-based office system is windows based and requires the same 
communication equipment as in the vehicle. In addition to the 
message/mail function, the system has an easy to use order/customer 
management function. The position of all the active trucks can be seen 
on maps available in different scales. Information concerning the 
vehicles and the driving conditions (Fuel consumption, RPM, speed, 
distance, load pressure on the different axles, driver time, etc) can 
automatically be transmitted to the office system for further analysis. 
The system is designed to be easily integrated with other existing office 
systems (e.g. invoicing, customer databases).

<P ALIGN="LEFT">
<IMG ALIGN=LEFT BORDER=1 WIDTH=237 height=126 HSPACE=10 VSPACE=4 
SRC="/images/technical/dynafleet2.gif">


By sending text rather than talking over the phone, Dynafleet Info System 
reduces the cost of communication and the risk of misunderstanding to a 
minimum. The increased speed in determining the current order status can 
speed up the invoicing process considerably. The positioning of the truck 
and the updated driver and vehicle status helps the traffic controller to 
improve vehicle utilisation.

<P ALIGN="LEFT">
The system is gradually being introduced on the European markets as the 
RDS/TMC standard and SMS*** service is introduced in the various countries.


<FONT SIZE=2>
<P ALIGN="LEFT">
* RDS/TMC is a new system for digital traffic information, under 
implementation in Europe. Traffic messages are compiled by road authorities 
and broadcast using existing FM transmitters.<BR>

** Global Positioning System (GPS) is a satellite based positioning system 
that every second gives an updated position with an accuracy +/- 50 metres.<BR>

*** SMS is a service available in most GSM cellular 
phone networks in Europe. SMS stands for Short Message Service and 
enables the user to transmit/receive short text messages.<BR>
</FONT>

<BR>
<BR>
<BR>

<HR WIDTH=447>
Source: Volvo Truck Corporation


<P>
<BR>
</BLOCKQUOTE>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]
</TD>
</TR>
</TABLE>

</CENTER>

</BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-170</DOCNO>
<DOCOLDNO>IA055-000919-B020-267</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/environment/policy.html 192.138.110.240 19970208023308 text/html 2388
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 02:33:08 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 2217
Last-modified: Wed, 25 Sep 1996 19:28:09 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>The Environmental Policy of the Volvo Group</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>
</TR>

<TR>
	<TD><HR></TD>
</TR>

<TR>
	<TD>

<BR>
<BR>

<BLOCKQUOTE>

<P ALIGN="CENTER">
<FONT SIZE=6>The Environmental Policy<BR>
	 of the Volvo Group</FONT>

<P ALIGN="LEFT">
Volvo pledges to minimize the environmental impact of its operations by

<UL>
	<LI TYPE=SQUARE>adopting a holistic approach to the
	environmental impact of its products
<BR>
<BR>
	<LI TYPE=SQUARE>developing and marketing products which
	possess the most favourable environmental properties and which meet	
	the highest possible efficiency standards
<BR>
<BR>
	<LI TYPE=SQUARE>adopting production processes which are as
	environmentally sound as possible
<BR>
<BR>
	<LI TYPE=SQUARE>specifying environmentally sound, recyclable
	materials in the development and manufacture of its products
<BR>
<BR>
	<LI TYPE=SQUARE>working to develop efficient transport systems
	having minimum environmental  impact
<BR>
<BR>

	<LI TYPE=SQUARE>seeking to ensure that its production processes
	and products comply with comparable environmental standards,
	wherever in the world the company operates
<BR>
<BR>
	<LI TYPE=SQUARE>seeking to ensure that a similar degree of
	environmental concern is exercised by its  working partners
<BR>
<BR>
	<LI TYPE=SQUARE>pursuing and participating in research and
	development activities in the environmental field
<BR>
<BR>
	<LI TYPE=SQUARE>providing information on the environmental
	impact of its operations in an open and factual manner
</UL>
<BR>

<TABLE BORDER=0 WIDTH=450>

<TR>
	<TD><HR></TD>
</TR>

<TR>
	<TD>Source: Volvo Environment Prize</TD>
</TR>

</TABLE>

<P>

<BR>
</BLOCKQUOTE>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]

</TD>
</TR>

</TABLE>

</CENTER>


</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-171</DOCNO>
<DOCOLDNO>IA055-000919-B020-300</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/environment/prize.html 192.138.110.240 19970208023322 text/html 18194
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 02:33:29 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 18022
Last-modified: Tue, 03 Sep 1996 15:22:51 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>The Volvo Environment Prize</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<A NAME="top"></A>


<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>
</TR>

<TR>
	<TD><HR></TD>
</TR>

<TR>
	<TD>

<BR>
<BR>


<BLOCKQUOTE>

<H1>The Volvo Environment Prize</H1>
<BR>
<FONT SIZE=4><A HREF="#foundation"><img WIDTH=14 HEIGHT=14 BORDER=0 
src="/images/knbla.gif" ALIGN=LEFT>The Foundation of The Volvo Environment Prize
</A></FONT><BR>
<BR>
<FONT SIZE=4><A HREF="#what"><img WIDTH=14 HEIGHT=14 BORDER=0 
src="/images/knbla.gif" ALIGN=LEFT>What price the environment?</A></FONT><BR>
<BR>
<FONT SIZE=4><A HREF="#prize"><img WIDTH=14 HEIGHT=14 BORDER=0 
src="/images/knbla.gif" ALIGN=LEFT>The Prize</A></FONT><BR>
	<UL>
		<LI>The <A HREF="1990.html">1990</A> Prize was awarded to
		<B>professors</B> <B>John V. Krutilla</B> and <B>Allen V. Kneese</B>.<BR>
		<BR>
		<LI>The <A HREF="1991.html">1991</A> Prize was awarded to
		<B>Professor</B> <B>Paul Crutzen</B>.<BR>
		<BR>
		<LI>The <A HREF="1992.html">1992</A> Prize was awarded to
		<B>Dr.</B> <B>Norman Myers</B> and <B>Professor Peter H. Raven</B>.<BR>
		<BR>
		<LI>The <A HREF="1993.html">1993</A> Prize was awarded to
		<B>Professor Paul R. Ehrlich</B> and <B>Professor John P. Holdren</B>.<BR>
		<BR>
		<LI>The <A HREF="1994.html">1994</A> Prize was awarded to
		<B>Dr. Gita Sen</B>.<BR>
		<BR>
		<LI>The <A HREF="1995.html">1995</A> Prize was awarded to
		<B>Professor Gilbert F. White</B>.<BR>
		<BR>
		<LI>The <A HREF="1996.html">1996</A> Prize was awarded to
		<B>Dr. James E. Lovelock</B>.<BR>
	</UL>
<BR>
<FONT SIZE=4><A HREF="#selection"><img WIDTH=14 HEIGHT=14 BORDER=0 
src="/images/knbla.gif" ALIGN=LEFT>The Selection Process</A></FONT><BR>
	<UL>
		<LI><A HREF="#criteria">Criteria</A>
		<LI><A HREF="#committee">The Prize Committee</A>
		<LI><A HREF="#scientific">The Scientific Committee</A>
		<LI><A HREF="#contact">Persons to contact</A>
		<LI><A HREF="#nominate">How to nominate</A>
		<LI><A HREF="nomination.html">Nomination form</A>
	</UL>
<FONT SIZE=4><img WIDTH=14 HEIGHT=14 src="/images/knbla.gif" ALIGN=LEFT>
The purpose of the Foundation</FONT><BR>

<UL>
	<LI><A HREF="#excerpt">Excerpt of The Articles of Association for 
"The Volvo Environment Prize Foundation" &#167; 2</A>

</UL>

<BR>

</BLOCKQUOTE>

<A NAME="foundation"></A>
<HR SIZE=1>
<BR>
<BR>	

<P ALIGN="CENTER">
<FONT SIZE=6>The Foundation of<BR>
The Volvo Environment Prize</FONT><BR>
<BR>
<BR>

<TABLE BORDER=0 CELPADDING=3 WIDTH=100%>

<TR>
	<TD WIDTH=50% VALIGN=MIDDLE><IMG WIDTH=120 HEIGHT=144 ALIGN=RIGHT SRC="/images/environment/env.gif"></TD>
	<TD WIDTH=50% VALIGN=MIDDLE>The Volvo Environment Prize was formally instituted 
	in May 1988 by the Volvo Annual Shareholders Meeting, with the objective of 
	promoting research and development across the environmental spectrum, by 
	acknowledging people who have made an outstanding contribution to understanding 
	or protecting the environment through scientific, socioeconomic or 
	technological innovation or discovery.</TD>
<TR>
</TABLE>	
<BR>
<BR>	
<BR>
<BR>	


<P ALIGN="CENTER">
<A NAME="what"><FONT SIZE=5>What price the environment?</FONT><BR></A>

<HR SIZE=1>	

<P ALIGN="LEFT">
The threats posed by pollution of the biosphere and 
the loss of its resources are today evident and all human activity has an 
impact on the environment. 
The landscape is changed, the quality of air and water 
deteriorates, and effluents and noise increase. Over the past few decades, 
a consensus is spreading across the social, industrial and political spectrum 
about the urgent need to show greater care for the Earth's 
ecosystems and their management.

<P ALIGN="LEFT">
The role of industrial manufacturers such as Volvo in this process, is to seek, 
develop and opt for 
manufacturing processes that have the least possible impact on the environment. 
Maximum environmental protection must be the guiding principle behind every 
manufacturing process.

<P ALIGN="LEFT">
Thus, in 1972, at the first United Nations Conference on the Environment, held 
in Stockholm, Volvo demonstrated its awareness of the issues at stake by 
initiating its own environmental programme concerning cars. Volvo fully 
believes it has a responsibility to ensure that its vehicles function 
efficiently from a 
proenvironment perspective (Volvo 1972, ''The Car in the Environment").

<P ALIGN="LEFT">
But the problem does not simply encompass the manufacturing process alone. 
The reality of environmental protection demands reflecting upon the entire 
lifecycle of a product from conception to design, 
production, use and, finally, its recycling or disposal.

<P ALIGN="LEFT">
It is only by taking such a global view of the 
problems that we will be able to solve them efficiently.

<P ALIGN="LEFT">
These are some of the reasons why Volvo came to the conclusion that it would 
support the efforts towards sustainable development and care for the environment, 
not only by the concept of using good technology for the long term benefit of 
the consumer and the society as a whole, but by the institution of a prize. 
The creation of the Volvo Environment Prize is an expression of Volvo's 
awareness of the interdependence of all actions, inventions and processes that 
sustain and protect the environmental base.
<BR>
<BR>	
<BR>
<BR>	

<P ALIGN="CENTER">
<A NAME="prize"><FONT SIZE=5>The Prize</FONT></A><BR>

<HR SIZE=1>	

<P ALIGN="LEFT">
With a foundation capital now totalling SEK 20 million, the Volvo 
Environment Prize is awarded annually to one or more individuals that the 
international Prize Committee deems to have made an outstanding innovation or 
discovery in the environmental field, e g in areas such as environmental control, 
pollution, hazardous waste, food, agriculture or nature and wildlife. Hitherto, 
the total annual prize sum has amounted to SEK 1.5 million.<BR>
<BR>
	<UL>
		<LI>The <A HREF="1990.html">1990</A> Prize was awarded to
		<B>professors</B> <B>John V. Krutilla</B> and <B>Allen V. Kneese</B>.<BR>
		<BR>
		<LI>The <A HREF="1991.html">1991</A> Prize was awarded to
		<B>Professor</B> <B>Paul Crutzen</B>.<BR>
		<BR>
		<LI>The <A HREF="1992.html">1992</A> Prize was awarded to
		<B>Dr.</B> <B>Norman Myers</B> and <B>Professor Peter H. Raven</B>.<BR>
		<BR>
		<LI>The <A HREF="1993.html">1993</A> Prize was awarded to
		<B>Professor Paul R. Ehrlich</B> and <B>Professor John P. Holdren</B>.<BR>
		<BR>
		<LI>The <A HREF="1994.html">1994</A> Prize was awarded to
		<B>Dr. Gita Sen</B>.<BR>
		<BR>
		<LI>The <A HREF="1995.html">1995</A> Prize was awarded to
		<B>Professor Gilbert F. White</B>.<BR>
		<BR>
		<LI>The <A HREF="1996.html">1996</A> Prize was awarded to
		<B>Dr. James E. Lovelock</B>.<BR>
	</UL>

<BR>
<BR>
<BR>
<BR>

<P ALIGN="CENTER">
<A NAME="selection"><FONT SIZE=6>The Selection Process</FONT></A>
<BR>
<BR>
<BR>
<BR>

<P ALIGN="CENTER">
<A NAME="criteria"><FONT SIZE=5>Criteria</FONT></A>
<HR SIZE=1>

<P ALIGN="LEFT">
A comprehensive selection procedure has been 
developed to ensure that those who are awarded the Volvo Environment Prize 
meet the requirement of having made outstanding innovations or discoveries - 
scientific, socioeconomic or technological - which have direct or indirect  
significance in the environmental field and are of global or regional importance. 
The Prize should reward achievement and priority should be given to an individual 
or group of named individuals rather than to an institution.
<BR>
<BR>
<BR>
<BR>

<P ALIGN="CENTER">
<A NAME="committee"><FONT SIZE=5>The Prize Committee</FONT></A>
<HR SIZE=1>

<P ALIGN="LEFT">
The responsibility for selecting the laureate or laureates of the annual 
Volvo Environment Prize lies with an international Prize Committee. The members 
of the Prize Committee are:<BR>
<BR>
<BR>

<IMG  ALIGN=LEFT BORDER=1 HSPACE=10 VSPACE=5 WIDTH=91 HEIGHT=101 SRC="/images/environment/brinkhorst.gif">

<B>Professor Laurens Jan Brinkhorst</B><BR>
<I>Member of the European Parliament, Brussels, Belgium.</I><BR>
Professor Brinkhorst took his 
law degree (LLM) at Leiden University in the Netherlands 
and also holds a Master's 
Degree in Public Law and Government from Columbia University, New York, USA. 

<P ALIGN="LEFT">
He has served as Director of the European Institute at Leiden University, 
and also as Professor of European Law at Groningen University.

<P ALIGN="LEFT">
Between 1973 and 1977 Professor Brinkhorst was State Secretary for Foreign 
Affairs in the Netherlands and became a member of second chamber of the Dutch 
Parliament, in 1977.

<P ALIGN="LEFT">
From 1977 to 1981 he was Vice Chairman of the parliamentary group 
"Democraten 66", and Parliamentary Leader of the party 1981-1982.

<P ALIGN="LEFT">
From 1982 to 1994 Professor Brinkhorst was with the European Commission, 
first as Head of Delegation of the Commission of the European Communities in 
Japan and from 1987 as the Director General of DG XI (Environment and Nuclear 
Safety).

<P ALIGN="LEFT">
Currently Professor Brinkhorst is a Member of the European Parliament. 
He also teaches International Environment Law at Leiden university. He has 
published several books and numerous articles on European 
integration and European Community Law.
<BR>
<BR>
<BR>


<IMG ALIGN=LEFT VALIGN=TOP BORDER=1 HSPACE=10 VSPACE=5 WIDTH=91 HEIGHT=101 SRC="/images/environment
/goodman.gif">
<B>Dr Gordon Goodman</B><BR>
<I>Former Chairman of the International Board and 
founding Director of the Stockholm Environment Institute (SEI)</I><BR>
 - has been 
active internationally in the field of environment and development since the 
early 1960s, as a scientific researcher and developer of environmental 
institutions. He founded the first international scientific group applying 
ecology to urban and industrial environments. As Professor of Applied Biology 
in the University of London, he led the 
writing of the first intergovernmental technical report setting out a 
"Global Environmental Monitoring System" for UNEP and was founding Director 
of its R&amp;D arm the "Monitoring and Assessment Research Centre". The Royal 
Swedish Academy of Sciences invited him to set up and direct their 
International Energy and Environment (Beijer) Institute. He also acted as 
adviser to the Brundtland Commission and the Rio conference (UNCED). He is 
author of numerous scientific publications and author or editor of eight 
books on various technical aspects of the environment.
<BR>
<BR>
<BR>

<IMG ALIGN=LEFT BORDER=1 HSPACE=10 VSPACE=5 WIDTH=91 HEIGHT=101 SRC="/images/environment/macneill.gif">
<B>Dr Jim MacNeill, O.C.</B><BR>
<I>As Secretary General and member of the World Commission on Environment 
and Development (the Brundtland Commission), headquartered in Geneva,</I> <BR>
Dr MacNeill was the principal architect and major author of its 
internationally acclaimed report, "Our Common Future", which sets out a 
new global agenda for sustainable development.

<P ALIGN="LEFT">
From 1978-84 Dr MacNeill was Director of Environment for the Organization 
for Economic Cooperation and Development (OECD). Earlier, he was Canada's 
Commissioner General and Ambassador Extraordinary and Plenipotentiary to 
the 1976 United Nations Conference on Human Settlements (Habitat), held 
in Vancouver.

<P ALIGN="LEFT">
Dr MacNeill is President of MacNeill and Associates in Ottawa, Chairman 
of the Board of the International Institute for Sustainable Development, 
Winnipeg, and a member of several boards, including the Woods Hole 
Research Center, Woods Hole, Mass.; Ontario Hydro, Toronto; and the 
Wuppertal Institute on Climate and Energy Policy in Germany. He is the 
recipient of numerous honours and honorary degrees, including the Order 
of Canada (O.C.), and the author of a number of books, publications and articles.
<BR>
<BR>
<BR>

<IMG  ALIGN=LEFT BORDER=1 HSPACE=10 VSPACE=5 WIDTH=91 HEIGHT=101 SRC="/images/environment/tolba.gif">
<B>Dr Mostafa Kamal Tolba</B><BR>
<I>Former Executive Director, United Nations Environment Programme, Nairobi, 
Kenya, and currently President of the International Centre for Environment and 
Development, and Member of the UN High Level Advisory Board on Sustainable 
Development.</I>

<P ALIGN="LEFT">
Dr Mostafa Kamal Tolba was appointed UNEP's deputy executive director in 
1973 and from 1976 to 1992 he was the organization's executive director. 
An experienced diplomat, Dr Tolba made the UNEP 
organization a catalyst which informs, assists and spurs governments and 
others to action. His negotiating skills and scientific knowledge contributed 
to UNEP's most widely acclaimed success - the historic 1987 agreement to 
protect the ozone layer - the Montreal Protocol. 

<P ALIGN="LEFT">
Dr Tolba has received his share of honours from the academic community for 
his outstanding services in preserving the global environment. He is the 
recipient of honorary degrees from several universities around the world.

<P ALIGN="LEFT">
Dr Tolba holds a special BSc degree in botany and PhD in plant pathology. 
Dr Tolba is the author of about 95 papers (1950-1973) on plant diseases, 
anti-fungal substances and the physiology of micro-organisms, 
and of more than 600 statements and numerous books and articles on the 
environment.
<BR>
<BR>
<BR>
<BR>

<P ALIGN="CENTER">
<A NAME="scientific"><FONT SIZE=5>The Scientific Committee</FONT></A>
<HR SIZE=1>

<P ALIGN="LEFT">
The Royal Society of Arts and Sciences, Gothenburg, 
Sweden has appointed a Scientific Committee headed by Professor Tor Kihlman, 
former Vice President of the Chalmers University of Technology. The 
Scientific Committee makes the evaluation necessary for the Prize Committee's 
selection of the Award Winner.

<P ALIGN="LEFT">
The Scientific Committee puts forward several <BR>
candidates for final consideration and selection by the Prize Committee. 
The proposed laureate is then <BR>
formally approved by the Board of the Volvo Environment Prize Foundation.

<P ALIGN="LEFT">
<B>The members of the Scientific Committee are:</B>

<P ALIGN="LEFT">
<B>Prof Tor Kihlman,</B> Building Acoustics, Chairman

<P ALIGN="LEFT">
<B>Prof Per Ahlberg,</B> Organic Chemistry

<P ALIGN="LEFT">
<B>Prof Gunnar Bergstr&ouml;m,</B> Ethological Chemistry

<P ALIGN="LEFT">
<B>Prof Kurt Gr&ouml;nfors,</B> Commercial Law

<P ALIGN="LEFT">
<B>Prof Lars &Aring;ke Hansson,</B> Clinical Immunology

<P ALIGN="LEFT">
<B>Prof Gunnar Weimarck,</B> Plant Taxonomy and Phytogeography

<P ALIGN="LEFT">
<B>Prof Karl-Erik Eriksson,</B> Physical Resource Theory
<BR>
<BR>
<BR>
<BR>

<P ALIGN="CENTER">
<A NAME="contact"><FONT SIZE=5>Persons to contact</FONT></A>
<HR SIZE=1>

<P ALIGN="CENTER">
Matters relating to the Volvo Environment Prize are handled by:

<P ALIGN="CENTER">
<B>Mr Claes Beyer</B><BR>
Acting Member of the Board of the Volvo Environment Prize Foundation

<P ALIGN="CENTER">
<B>Mr Anders K&auml;rrberg</B><BR>
Director of Environmental Affairs, AB Volvo

<P ALIGN="CENTER">
<B>Mrs Eeva-Liisa Book</B><BR>
Environmental Affairs, Volvo Environment Prize Secretariat, AB Volvo.
<BR>
<BR>
<BR>
<BR>

<P ALIGN="CENTER">
<A NAME="nominate"><FONT SIZE=5>How to nominate</FONT></A>
<HR SIZE=1>

<P ALIGN="LEFT">
Candidates for the Volvo Environment Prize are nominated by

<P ALIGN="LEFT">
<UL>
	<LI>universities, research institutes and their staffs

	<LI>scientists and engineers in the fields of environmental protection, 
       life sciences, earth sciences, and social sciences

	<LI>national academies of science and their staffs

	<LI>other persons or organizations by decision of the Prize Committee
</UL>

<P ALIGN="LEFT">
Nominations for the Prize should be submitted no later than 15 January of 
the prize year in question.

<P ALIGN="LEFT">
A special nomination form should be used. In addition, the nominee's name 
and curriculum vitae, a summary of accomplishments and a detailed description 
of contributions should be provided (in English).

<P ALIGN="LEFT">
Also the name, title, organization, and the telephone/telefax numbers of the 
nominator are required.

<P ALIGN="LEFT">
Further information on the nomination procedure, as well as nomination forms, 
can be obtained from:
<BR>
<BR>
<BR>
<BR>

<P ALIGN="CENTER">
The Volvo Environment Prize Foundation<BR>
Mrs Eeva-Liisa Book<BR>
Environmental Affairs <BR>
AB Volvo<BR>
S-405 08 G&ouml;teborg<BR>
Sweden<BR>

<P ALIGN="CENTER">
Telephone: +46 31 59 44 33<BR>
Telex: 27000 VOLVO S<BR>
Telefax: +46 31 59 10 44<BR>
<BR>
<BR>
<BR>
<BR>
<HR SIZE=1>
<BR>
<BR>


<A NAME="excerpt"></A>

<P ALIGN="CENTER">
<FONT SIZE=6>Excerpt of The Articles of <BR>
Association for <BR>
"The Volvo Environment Prize <BR>
Foundation"<BR>
<BR>
&#167; 2</FONT>

<P ALIGN="LEFT">
The purpose of the Foundation is to promote -- without profit motive by any 
individual or organization -- scientific research in the field of environmental 
protection through the annual award of a prize, designated the Volvo 
Environment Prize, to an institution, <BR>
organization, individual or other recipient that has demonstrated outstanding 
scientific innovativeness in the area of environmental protection.

<P ALIGN="LEFT">
Employees or companies within the Volvo Group shall not be eligible to receive 
the award. Nor shall the award be made to any party for research performed 
on behalf of the Volvo Group.
<BR>
<BR>
<BR>

<TABLE BORDER=0 WIDTH=490>

<TR>
	<TD><HR></TD>
</TR>

<TR>
	<TD>Source: Volvo Environment Prize</TD>
</TR>

</TABLE>

<BR>

<A HREF="#top"><IMG WIDTH=71 HEIGHT=14 BORDER=0
SRC="/images/knapp_top.gif" ALT="Top of page"></A>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]

</TD>
</TR>

</TABLE>

</CENTER>


</BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-172</DOCNO>
<DOCOLDNO>IA055-000919-B020-335</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/environment/report.95/index.html 192.138.110.240 19970208023341 text/html 2640
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 02:33:46 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 2469
Last-modified: Mon, 17 Jun 1996 13:28:15 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Volvo Environmental Report 1995</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="../index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>

<TR>
	<TD><HR></TD>
</TR>

<TR>
	<TD>

<BLOCKQUOTE>

<!-- ---- DIAGRAM 1 ---- -->
<BR>
<BR>
<FONT SIZE=6>Volvo Environmental Report 1995</FONT>
<BR>
<BR>


<IMG WIDTH=447 HEIGHT=111 BORDERR=0 SRC="/images/environment/report.95/header.gif">
<BR>
<BR>
<BR>


<FONT SIZE=5><B>Contents</B></FONT><BR>
	<BR>
	<A HREF="introduction.html">Introduction</A><BR>
	<BR>
	<A HREF="politik.html">Volvo's environmental policy</A><BR>
	<BR>
	<A HREF="framtid.html">Foreword: Towards the future</A><BR>
	<BR>
	<BR>

	<B>Organisation</B><BR>
	<BR>

<BLOCKQUOTE>
	<A HREF="internat.html">Volvo - an international group</A><BR>
	<BR>
	<A HREF="miljoarb.html">Volvo's environmental programmes</A><BR>
	<BR>
	<A HREF="verktyg.html">Tools</A><BR>
	<BR>
	<A HREF="utbild.html">Training and communication</A><BR>
	<BR>
	<BR>
	
</BLOCKQUOTE>
	<B>Production</B><BR>
	<BR>
	
<BLOCKQUOTE>
	<A HREF="produkt.html">Production processes and production plants</A><BR>
	<BR>
	<BR>

</BLOCKQUOTE>
	<B>Products in use</B><BR>
	<BR>

<BLOCKQUOTE>
	<A HREF="energi.html">Energy</A><BR>
	<BR>
	<A HREF="motor.html">Engine development</A><BR>
	<BR>
	<A HREF="koncept.html">Products and concepts</A><BR>
	<BR>
	<A HREF="transeff.html">Transport efficiency</A><BR>
	<BR>
	<BR>

</BLOCKQUOTE>
	<B>Waste management</B><BR>
	<BR>

<BLOCKQUOTE>
	<A HREF="atervinn.html">Recycling of vehicles</A><BR>
	<BR>
	<BR>

</BLOCKQUOTE>
	<A HREF="mal.html">Goals and action programmes</A><BR>
	<BR>
	<A HREF="mojligh.html">Opportunities and challenges</A><BR>
	<BR>
	<A HREF="pris.html">Volvo Environment Prize</A><BR>
	<BR>
	<A HREF="managers.html">Environmental managers</A><BR>
	<BR>
	<A HREF="knowmore.html">Want to know more?</A><BR>
	



<!-- -------- -->
<BR>
<BR>
<BR>
<BR>

<TABLE BORDER=0 WIDTH=450>

<TR>
	<TD>Source: Volvo Environmental Report 1995</TD>
</TR>

</TABLE>

<P>

</BLOCKQUOTE>

<HR ALIGN=LEFT WIDTH=487>


Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]

</TD>
</TR>
</TABLE>

</CENTER>


</BODY>
</HTML>






</DOC>
<DOC>
<DOCNO>WT08-B13-173</DOCNO>
<DOCOLDNO>IA055-000919-B021-33</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/corpinfo/museum/howto.html 192.138.110.240 19970208023436 text/html 1831
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 02:34:46 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 1660
Last-modified: Thu, 13 Jun 1996 14:45:49 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>How to get to the Volvo Museum</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<A NAME="top"></A>

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>
</TR>

<TR>
	<TD><HR></TD>
</TR>

</TABLE>


<TABLE WIDTH=490 BORDER=0>
<TR>
	<TD>
	<BR>
	
	<P ALIGN="CENTER">
	<FONT SIZE=5>How to get to the Volvo Museum</FONT><BR>
	<BR>
	<BR>
	
	<P>
	<TABLE WIDTH=490 BORDER=0>

	<TR VALIGN=TOP>
		<TD><B>Bus:</B> From Nils Erikssonsplatsen by the Central 
		Station, take bus no 28 to S&ouml;rred. Follow the signs to the 
		Volvo Museum.<BR>
		<BR>
		<B>Car:</B> From the E6, E20, rv 40 or rv 45, drive towards Hisingen
		and then Torslanda. Follow the signs to Volvo Arendal and
		Volvo Museum.<BR>
		<BR>
		<B>Opening hours:</B><BR>
		Tuesday - Friday, 10-17<BR>
		Saturday, 11-16<BR>
		<BR>
		<B>Price:</B><BR>
		Adults 30 SEK<BR>
		Children (6-12 years) 10 SEK<BR>
		Family 50 SEK<BR>
		Volvo employees with ID card, retired Volvo employees - free admittance.
		Groups (over fifteen people) must book in advance.<BR>
		Phone +46 31 66 48 14.</TD>
		
		<TD><IMG SRC="/images/museum/k1.gif" WIDTH=280 HEIGHT=228 
		ALIGN=MIDDLE BORDER=0></TD>
	</TR>

	</TABLE>
	
	</BLOCKQUOTE>
	<BR>
	<BR>

	<HR ALIGN=LEFT WIDTH=487>

	Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]

	</TD>
</TR>
</TABLE>

</CENTER>
</BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-174</DOCNO>
<DOCOLDNO>IA055-000919-B021-57</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/corpinfo/museum/history.html 192.138.110.240 19970208023447 text/html 5009
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 02:34:56 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 4838
Last-modified: Thu, 13 Jun 1996 14:45:48 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Volvo Museum</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<A NAME="top"></A>

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>
</TR>

<TR>
	<TD><HR></TD>
</TR>

</TABLE>

<TABLE WIDTH=490 BORDER=0>
<TR>
	<TD>

<BR>
<BR>


<P ALIGN="CENTER">
<FONT SIZE=5>...knowledge of the company's history<BR>
- the difficulties and successes -<BR>
is necessary to understand what we value and how we want Volvo to 
develop...</FONT><BR>
<BR>
<BR>

</BLOCKQUOTE>

<IMG SRC="/images/museum/museum2.gif" WIDTH=490 HEIGHT=113 ALIGN=MIDDLE BORDER=1>
<BR>
<BR>

<BLOCKQUOTE>

<P ALIGN="LEFT">
The Gay Twenties followed the dark days of the First World War. Louis 
Armstrong brought jazz from New Orleans and people danced the Charleston in 
the ballrooms and dance halls. Prime Minister Per Albin Hansson became the 
father figure of the Swedish Welfare State.

<P ALIGN="LEFT">
There was an air of optimism in the twenties and industrialization gathered 
momentum. The economist Assar Gabrielsson, and the engineer Gustaf Larson, 
joined forces in 1924 inspired with the same idea - to build a Swedish car 
for Swedish roads.

<P ALIGN="LEFT">
A trial series of 10 cars was built in 1926 and on the 14 April, 1927, the 
first Volvo - the &Ouml;V4 - rolled out of the factory in Lundby on Hising 
island in G&ouml;teborg.

<P ALIGN="LEFT">
<B>Building cars the Volvo way</B><BR>

Gabrielsson and Larson coined the expression "building cars the Volvo way". 
Contrary to the way things were done in the car industry of the time, Volvo 
designed the parts for its products itself and had suppliers manufacture 
these parts to Volvo's specifications. 

<P ALIGN="LEFT">
Many competitors bought ready-made components which they then assembled in 
their cars.

<P ALIGN="LEFT">
The Volvo model laid the foundations of Volvo's quality. Quality has always 
been the firm ground on  which Volvo has built and quality is also one of 
the guiding principles in the company's high-tech operations today.

<P ALIGN="LEFT">
<B>Unusual items and prototypes</B><BR>

This brochure will help you trace Volvo's development from the first &Ouml;V4 
to the cars, trucks, buses and others products being manufactured today. It 
will also tell you more about what you can see as you go round Volvo's museum.

<P ALIGN="LEFT">
There are lots of exciting items. The first vehicles - naturally - but there 
are also prototypes and many unusual items. There is also the desk shared 
by Gabrielsson and Larson in the early days of their partnership.

<P ALIGN="LEFT">
Then of special interest, there is a Volvo PV444, which has been placed 
on a patch of green representing a picnic area. This is the car which, 
more than any other, symbolizes Volvo's success and which became the real 
'people's car' in Sweden after the Second World War.

<P ALIGN="LEFT">
Among the prototypes there is Philip, a huge vehicle with a design influenced 
by the USA and with a V8-engine. There are also a number of experimental 
cars such as the VESC,  which preceded the 240 series, and the first electric 
car, the experimental taxi for New York and the fascinating LCP made of a 
new kind of material and designed to take new types of fuel.

<P ALIGN="LEFT">
<B>Lots to look at</B><BR>

A special section in the Volvo museum will remind you of the progress of Tom 
Trana and Gunnar Andersson racing their PV in rallies all over  the world. 
Compare a car like that with the current Volvo 850 for exclusive motor 
racing tracks.

<P ALIGN="LEFT">
There is also an exhibition, of course, of the products made by Volvo Aero 
and Volvo Penta. Pentaverken was making engines as many as 20 years before 
Volvo's first car saw the light of day. Penta then produced the Aquamatic 
and the Duoprop, both of them innovations on the world markets. In the 
Volvo Aero section, there is a radial engine from 1939 alongside the RM2B, 
the first jet engine with afterburner chamber.

<P ALIGN="LEFT">
We are very glad to be able to show you all these examples of Volvo's 
development under one and the same roof in the Arendal buildings, in premises 
which are also a part of the history of the G&ouml;teborg shipyards.

<P ALIGN="LEFT">
We are certain that a knowledge of the company's history - the difficulties 
and successes - is necessary to understand what we value and how we want 
Volvo to develop.

</BLOCKQUOTE>
<BR>
<BR>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]
</TD>
</TR>
</TABLE>

</CENTER>
</BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-175</DOCNO>
<DOCOLDNO>IA055-000919-B021-79</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/corpinfo/museum/pictures.html 192.138.110.240 19970208023455 text/html 1405
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 02:35:06 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 1234
Last-modified: Thu, 13 Jun 1996 14:45:50 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Volvo's history in pictures</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<A NAME="top"></A>

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>
	<TD ALIGN=RIGHT><A HREF="index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>
</TR>

<TR>
	<TD><HR></TD>
</TR>

</TABLE>

<TABLE WIDTH=490 BORDER=0>
<TR>
	<TD>

<BLOCKQUOTE>
<BR>

<BR>
<FONT SIZE=6>Volvo's history in pictures</FONT>
<BR>

<BR>
<FONT SIZE=4><A HREF="20-40.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
src="/images/knbla.gif"LEFT>The 1920s, 1930s and 1940s
</A></FONT><BR>
<BR>
<FONT SIZE=4><A HREF="50-70.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
src="/images/knbla.gif"LEFT>The 1950s, 1960s and 1970s
</A></FONT><BR>
<BR>
<FONT SIZE=4><A HREF="80-90.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
src="/images/knbla.gif"LEFT>The 1980s and 1990s
</A></FONT><BR>

<BR>
<BR>

</BLOCKQUOTE>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]
</TD>
</TR>
</TABLE>

</CENTER>
</BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-176</DOCNO>
<DOCOLDNO>IA055-000919-B021-161</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/corpinfo/europe/focus.html 192.138.110.240 19970208023533 text/html 9042
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 02:35:30 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 8871
Last-modified: Thu, 13 Jun 1996 14:40:55 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Volvo's focus on Europe</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<A NAME="top"></A>

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>
</TR>

<TR>
	<TD><HR></TD>
</TR>

</TABLE>



<TABLE WIDTH=490 BORDER=0>
<TR>
	<TD>

<BLOCKQUOTE>

<BR>
<P ALIGN="CENTER">
<FONT COLOR="000078" SIZE=7><B>Volvo's focus on Europe</FONT></B><BR>
<BR>
<BR>

<P ALIGN="LEFT">
<B><FONT COLOR="000078" SIZE=4>Exports begin at an early stage</FONT></B><BR>
<HR SIZE=1>

<P ALIGN="LEFT">
<FONT COLOR="000078"><B>1933</B></FONT> Volvo exports passenger cars to the Netherlands.<BR>
<BR>

<FONT COLOR="000078"><B>1937</B></FONT> Exports to Belgium get under way.<BR>
<BR>
<BR>

<P ALIGN="LEFT">
<B><FONT COLOR="000078" SIZE=4>European subsidiaries</FONT></B><BR>
<HR SIZE=1>

<FONT COLOR="000078"><B>1958</B></FONT> A subsidiary is established in 
Frankfurt-am-Main for sales to the German market.<BR>
<BR>

<FONT COLOR="000078"><B>1959</B></FONT> A subsidiary is based in Lausanne.<BR>
<BR>

<FONT COLOR="000078"><B>1960</B></FONT> Pressed Steel Co. Ltd. and Jensen Motors Ltd. agree to build the 
Volvo P1800.<BR>
<BR>
<BR>

<P ALIGN="LEFT">
<B><FONT COLOR="000078" SIZE=4>Investments in Ghent</FONT></B><BR>
<HR SIZE=1>
<FONT COLOR="000078"><B>1961</B></FONT> Facing the risk that Europe will be divided into 
two trading blocs, Volvo makes plans to become established in the European 
Economic Community (EEC) market.<BR>
<BR>

<FONT COLOR="000078"><B>1963</B></FONT> Construction of a passenger car plant in Belgium to supply EEC countries 
is approved.<BR>
<BR>

<FONT COLOR="000078"><B>1964</B></FONT> Volvo begins to assemble cars and trucks in a leased plant in Alsemberg, 
outside Brussels. The company's general agents in Portugal start up an 
assembly plant for cars and trucks. The assembly of passenger cars in Ghent, 
Belgium begins in February.<BR>
<BR>

<FONT COLOR="000078"><B>1965</B></FONT> The Ghent plant assembles 5,550 cars, compared with 2,650 in the 
start-up year.<BR>
<BR>

<FONT COLOR="000078"><B>1966</B></FONT> Volvo acquires a finance company, Volvonia SA, in Switzerland.<BR>
<BR>

Volvo begins to sell trucks to customers in Great Britain.<BR>
<BR>
<BR>

<P ALIGN="LEFT">
<B><FONT COLOR="000078" SIZE=4>The division into two trading blocs complicates Volvo's marketing</FONT></B><BR>
<HR SIZE=1>


<FONT COLOR="000078"><B>1968</B></FONT> "The association of 
individual countries in trading blocs that has occurred during the past 
decade has in certain cases created problems for exports through the 
establishment of outer tariff walls and other obstacles to imports. Many 
years of fruitless negotiations over a rapprochement between the EEC and 
EFTA (European Free Trade Association) have created uncertainty with respect 
to the long-range planning of export activities within Volvo."<BR>
<BR>

In the early 1960s Volvo faced the choice of either maintaining all of 
its production in Sweden and delivering finished cars to the EEC market 
or moving part of its manufacturing to the EEC. In the first case, high 
tariffs would have hampered sales, while production within the EEC 
would mean the loss of the benefits of long-series production in Sweden. 
Volvo elected to establish operations in Belgium with a passenger car 
plant in Ghent and a truck factory in Alsemberg.<BR>
<BR>

At the beginning of 1969 there were still no signs of an immediate solution 
of the EEC/EFTA issue. Accordingly, Volvo's plans for the 1970s included 
expanding production capacity in Belgium to 50,000 cars a year.<BR>
<BR>

<FONT COLOR="000078"><B>1971</B></FONT> Volvo reaches an agreement with Peugeot and Renault covering the 
development, design and production of passenger car engines in a new company, 
Soci&eacute;t&eacute; Franco Su&eacute;doise de Moteurs.<BR>
<BR>

An agreement is reached with Saviem (France), DAF (Holland) and 
Kl&ouml;cknerHumboldt-Deutz (Germany) to design and develop trucks in the 
6-to-13-ton total-weight class.<BR>
<BR>
<BR>


<P ALIGN="LEFT">
<B><FONT COLOR="000078" SIZE=4>Volvo stake in NedCar</FONT></B><BR>
<HR SIZE=1>

<FONT COLOR="000078"><B>1972</B></FONT> Volvo acquires a 33% interest in DAF 
BV and all of the shares of Dieseltechnik Nederland NV (now NedCar).<BR>
<BR>

Volvo acquires 75% of the shares of Ailsa Trucks Ltd. in Great Britain.<BR>
<BR>

Volvo's shares are listed on the London Stock Exchange.<BR>
<BR>
  
<FONT COLOR="000078"><B>1973</B></FONT> The purchase of Motoauto SpA in Bologna, Italy is completed in 
January.<BR>
<BR>

A new central warehouse is opened in Ghent.<BR>
<BR>

Seven new truck workshops are opened in Yugoslavia, Czechoslovakia 
and Poland. Volvo receives an order for 100 trucks from the Soviet Union.<BR>
<BR>

<FONT COLOR="000078"><B>1975</B></FONT> Construction of a new truck factory in Ghent. <BR>
<BR>

Volvo's shares are listed on the stock exchanges in D&uuml;sseldorf, 
Frankfurt-am-Main and Hamburg. <BR>
<BR>
<BR>


<P ALIGN="LEFT">
<B><FONT COLOR="000078" SIZE=4>European partnerships</FONT></B><BR>
<HR SIZE=1>

<P ALIGN="LEFT">
<FONT COLOR="000078"><B>1976</B></FONT> An agreement is reached with Volkswagen AG covering design and production 
of diesel engines for the Volvo 240 series.<BR>
<BR>

<P ALIGN="LEFT">
<FONT COLOR="000078"><B>1979</B></FONT> An agreement is reached with Renault to share Volvo's and Renault's 
expertise in the passenger car sector.<BR>
<BR>

<FONT COLOR="000078"><B>1980</B></FONT> Volvo Flygmotor becomes a part-owner of Arianespace.<BR>
<BR>
<BR>

<P ALIGN="LEFT">
<B><FONT COLOR="000078" SIZE=4>Volvo takes over import agencies and expands its bus operations 
in Europe</FONT></B><BR>
<HR SIZE=1>

<FONT COLOR="000078"><B>1985</B></FONT> Volvo acquires the Dutch importer, Nebim Bedrijfswagen BV. Volvo's shares 
are listed on the stock exchanges in Brussels and Antwerp.<BR>
<BR>

<FONT COLOR="000078"><B>1988</B></FONT> In March, Volvo acquires all of the shares in Leyland Bus Group Ltd. 
With delivery of the millionth passenger car, the factory in Ghent passes 
a milestone during the autumn.<BR>
<BR>

<FONT COLOR="000078"><B>1989</B></FONT> Volvo acquires all of the shares of Volvo Concesionarios, SA in 
Spain.<BR>
<BR>

Deliveries of heavy trucks in eastern Europe nearly double, to 720, 
compared with 340 a year earlier.<BR>
<BR>

Spare parts for Leyland and Volvo buses are delivered throughout the world 
from a new central warehouse in Great Britain.<BR>
<BR>

<FONT COLOR="000078"><B>1990</B></FONT> Volvo acquires 75% of the share capital and voting rights in Steyr Bus 
GesmbH (Austria).<BR>
<BR>

Operations in Alsemberg, Belgium are closed down and production is 
concentrated to the Ghent truck plant.<BR>
<BR>

All production of Leyland and Volvo buses is concentrated to the plant 
in Workington. <BR>
<BR>
<BR>


<P ALIGN="LEFT">
<B><FONT COLOR="000078" SIZE=4>Volvo 850 in Ghent</FONT></B><BR>
<HR SIZE=1>

<FONT COLOR="000078"><B>1991</B></FONT> A new body plant and a new unit for final assembly of the Volvo 
850 GLT are built in Ghent.<BR>
<BR>

Volvo Cars Marketing Europe, assumes responsibility for Volvo Cars' 
sales in Western Europe.<BR>
<BR>

Volvo Group Finance Europe BV becomes a subsidiary of Volvo Group Finance 
Sweden AB.<BR>
<BR>

The Dutch Government sells parts of its shareholding in Volvo Car BV to 
Mitsubishi Motors Corporation and Volvo Car Corporation.<BR>
<BR>

Volvo Construction Equipment acquires the German wheel loader 
manufacturer Zettelmeyer GmbH.<BR>
<BR>

In all, 1,210 Volvo trucks are delivered to customers in eastern 
European countries, compared with 580 a year earlier. <BR>
<BR>

<FONT COLOR="000078"><B>1992</B></FONT> Volvo acquires Volvo Concessionaires Ltd, the former importer in 
Great Britain.<BR>
<BR>

Volvo Penta enters into a joint venture with Perkins Engines Group Ltd. 
Great Britain to develop, produce and market small diesel engines 
for marine applications.<BR>
<BR>

<FONT COLOR="000078"><B>1993</B></FONT> Volvo Truck Corporation's handling of spare parts is concentrated 
to Ghent.<BR>
<BR>

The production of buses is transferred from the Workington plant to 
Volvo's truck factory in Irvine, Scotland.<BR>
<BR>

Both double-decker buses and trucks are produced at the plant in Irvine, 
Scotland.<BR>
<BR>
<BR>


<BR>
<BR>
<BR>

<TABLE BORDER=0 WIDTH=450>

<TR>
	<TD><HR></TD>
</TR>

<TR>
	<TD>Source: Volvo in Europe</TD>
</TR>

</TABLE>

</BLOCKQUOTE>

<BR>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]


</TD>
</TR>
</TABLE>

</CENTER>
</BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-177</DOCNO>
<DOCOLDNO>IA055-000919-B021-210</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/sport/golf.html 192.138.110.240 19970208023554 text/html 3089
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 02:36:04 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 2918
Last-modified: Wed, 21 Aug 1996 08:57:04 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Golf</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

        <TD ALIGN=RIGHT><A HREF="index.html"><IMG BORDER=0 
        SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
        <A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
        WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>
</TR>

<TR>
        <TD><HR></TD>
</TR>

</TABLE>

<TABLE WIDTH=490 BORDER=0>
<TR>
        <TD>

<BLOCKQUOTE>
<BR>
<BR>
If you are interested in the latest news from The PGA European Tour, take a look at <blink><A HREF="http://www.golfweb.com/ga96/epga/epgaindex.html">
The European Tour Homepage</blink></A>. <BR>

<P ALIGN="LEFT">
<FONT SIZE=6>Golf</FONT>

<P ALIGN="LEFT">
<IMG ALIGN=RIGHT BORDER=1 WIDTH=200 HEIGHT=132 HSPACE=10 VSPACE=4 
SRC="/images/sport/golf2.gif">
Golf has long been seen as the preserve of the businessman, the golf course, 
the place to talk business and strike deals.  At a professional level however 
the game had been dominated by the Americans for years, the rest of the world 
playing bit parts to the likes of Palmer and Nicklaus.  By the early 80's 
however things had begun to change, players such as Ballesteros, Faldo, Langer 
and Lyle began to dominate not only the European scene but in America as well.  
With their success and fuelled by massive media coverage European golf began a 
stage of rapid growth.  New courses began being constructed throughout Europe 
and amateurs flocked to the game.  Now, if ever, was the time for Volvo to 
become involved.

<P ALIGN="LEFT">
<IMG SRC="/images/sport/golf1.gif" BORDER=1 WIDTH=180 HEIGHT=242 ALIGN=LEFT
HSPACE=10 VSPACE=2>
The contract to become the first corporate sponsor of the PGA European Tour 
was signed in 1987, the Volvo Tour commencing on 1st January 1988.  In the 
subsequent 8 years Volvo have become synonymous with European Golf not only 
through the Volvo Tour but head sponsorship of tournaments in the UK, Germany, 
Sweden, Italy, Belgium and Spain.  Amateur tournaments, direct contact with 
customers are now a regular part of the implementation strategy in most 
countries and golf has led a host of marketing initiatives from special 
'action' cars to newspaper competitions.  Success in Europe has led to golf 
being used to help develop our presence in China and the Far East, with the 
Volvo China Tour and Volvo China Open commencing in 1995.  In February 1996, 
Volvo Cars International announced the Volvo Masters of Latin America, our 
first golfing initiative on that continent.

<BR>
<BR>
<BR>
</BLOCKQUOTE>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]
</TD>
</TR>
</TABLE>

</CENTER>

</BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-178</DOCNO>
<DOCOLDNO>IA055-000919-B021-241</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/sport/biking.html 192.138.110.240 19970208023609 text/html 1911
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 02:36:20 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 1740
Last-modified: Thu, 08 Aug 1996 16:06:00 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Mountain Biking</TITLE></HEAD>
<BODY BGCOLOR="#FFFFFF">

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>
</TR>

<TR>
	<TD><HR></TD>
</TR>

</TABLE>

<TABLE WIDTH=490 BORDER=0>
<TR>
	<TD>

<BLOCKQUOTE>
<BR>
<BR>

<P ALIGN="LEFT">
<FONT SIZE=6>Mountain Biking</FONT>

<P ALIGN="LEFT">
<IMG ALIGN=RIGHT BORDER=1 WIDTH=220 HEIGHT=143 HSPACE=10 VSPACE=4 
SRC="/images/sport/cyckel1.gif">
In 1994 Volvo Cars North America took a decision to become involved with the 
young and growing sport of mountain biking, with the objective of reaching a 
new, younger and more active audience.  This decision resulted in the creation 
of the Volvo Cannondale Mountain Bike Racing Team, Cannondale being a high 
quality, niche cycle manufacturer in North America.  Competing internationally 
as well as in North America, the team currently includes world champions in all 
three disciplines, downhill, cross country and trials.  It is by far the most 
high profile and successful team in the world.

<P ALIGN="LEFT">
European markets are now developing their own mountain biking programmes using 
the imagery of the team as the basis of their activity.

<BR>
<BR>
<BR>
<P ALIGN=CENTER>
[ See : <A HREF="http://www.cannondale.com/">Cannondale</A> ]
</P>


</BLOCKQUOTE>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]
</TD>
</TR>
</TABLE>

</CENTER>

</BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-179</DOCNO>
<DOCOLDNO>IA055-000919-B021-262</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/sport/equestrian.html 192.138.110.240 19970208023619 text/html 1744
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 02:36:30 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 1573
Last-modified: Wed, 04 Sep 1996 09:02:40 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Equestrian</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>
</TR>

<TR>
	<TD><HR></TD>
</TR>

</TABLE>

<TABLE WIDTH=490 BORDER=0>
<TR>
	<TD>

<BLOCKQUOTE>
<BR>
<BR>

<P ALIGN="LEFT">
<FONT SIZE=6>Equestrian</FONT>

<P ALIGN="LEFT">
<IMG ALIGN=RIGHT BORDER=1 WIDTH=180 HEIGHT=258 HSPACE=25 VSPACE=4 
SRC="/images/sport/horse.gif">
There are few relationships closer than between man and horse.  For centuries 
it provided the only alternative means of transport, only to be overtaken in 
the 20th Century by the arrival of the internal combustion engine and the motor 
car.  It was natural therefore for Volvo to take up the opportunity to sponsor 
the World Cup of Showjumping in 1978, for it not only consolidated an emotional 
link with the past but created major television and media coverage on a wide 
scale.

<P ALIGN="LEFT">
The sponsorship has now been running for 18 years and was joined in 1990 by 
the World Cup in Dressage, which together generate over 140 qualifying events 
on 5 continents.

<BR>
<BR>
<BR>

<P>
<BR>
</BLOCKQUOTE>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]
</TD>
</TR>
</TABLE>

</CENTER>

</BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-180</DOCNO>
<DOCOLDNO>IA055-000919-B021-297</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/sport/motor.html 192.138.110.240 19970208023633 text/html 2317
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 02:36:43 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 2146
Last-modified: Thu, 17 Oct 1996 11:16:30 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Motor Sport</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>
</TR>

<TR>
	<TD><HR></TD>
</TR>

</TABLE>

<TABLE WIDTH=490 BORDER=0>
<TR>
	<TD>

<BLOCKQUOTE>
<BR>
<BR>


<P ALIGN="LEFT">
<FONT SIZE=6>Motor Sport</FONT>

<P ALIGN="LEFT">
<IMG ALIGN=RIGHT BORDER=1 WIDTH=230 HEIGHT=153 HSPACE=10 VSPACE=4 
SRC="/images/sport/racing.gif">
Volvo's first involvement in international sport was in a car rally from 
Moscow to Leningrad and back in 1928.  Most of the big names in the motor 
industry were represented, but the Volvo was the only car to complete the 
rally without any mechanical problems.  However, it was not until 1958 that 
the company officially began its adventures in sports sponsorship with 
support for International Rally Champion, Gunnar Andersson.  Success was 
almost immediate with Gunnar winning the Midnight Sun Rally in Sweden, the 
day he was due to join the company.  The following year he became European 
Rally Champion and Volvo quickly recognised that this was a very effective 
communications tool.

<P ALIGN="LEFT">
Success in rallying helped build Volvo's reputation for strong reliable cars 
during the 60's.  Success on the race track following in the early 80's with 
the Volvo 240 winning the European Touring Car Championships.  After a break 
of almost ten years, Volvo are now back on the track with the dynamic 850 
saloon competing in the <A HREF="/www.car.volvo.se/850_racing_team/">British Touring Car Championships</A>, a promotion which 
is already changing people's attitudes to and perceptions of the latest range 
of Volvo cars.

<BR>
<BR>
<BR>

<P>
<BR>
</BLOCKQUOTE>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]
</TD>
</TR>
</TABLE>

</CENTER>

</BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-181</DOCNO>
<DOCOLDNO>IA055-000919-B021-336</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/sport/skiing.html 192.138.110.240 19970208023653 text/html 1573
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 02:36:57 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 1402
Last-modified: Mon, 01 Jul 1996 13:56:20 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Alpine Skiing</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>
</TR>

<TR>
	<TD><HR></TD>
</TR>

</TABLE>

<TABLE WIDTH=490 BORDER=0>
<TR>
	<TD>

<BLOCKQUOTE>
<BR>
<BR>

<P ALIGN="LEFT">
<FONT SIZE=6>Alpine Skiing</FONT>

<P ALIGN="LEFT">
<IMG ALIGN=RIGHT BORDER=1 WIDTH=220 HEIGHT=147 HSPACE=10 VSPACE=4 
SRC="/images/sport/skidor.gif">
Volvo ended a long association with skiing on a high note in 1994, as Official 
Partner responsible for transport at the Lillehammer Winter Olympics.  In the 
preceding years Volvo had been the main sponsor of the famous 'Club 5' group 
of World Cup downhill races which included Garmish, Val Gardena and the most 
famous race of all, the Hannenkammrennen at Kitzb&uuml;hel.  In addition the 
acrobatic Volvo ski show had thrilled thousands as it annually toured Europe, 
Japan and North America.

<BR>
<BR>
<BR>

<P>
<BR>
</BLOCKQUOTE>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]
</TD>
</TR>
</TABLE>

</CENTER>

</BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-182</DOCNO>
<DOCOLDNO>IA055-000919-B021-364</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/sport/sailing.html 192.138.110.240 19970208023706 text/html 1458
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 02:37:14 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 1287
Last-modified: Mon, 01 Jul 1996 13:56:12 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Sailing</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>
</TR>

<TR>
	<TD><HR></TD>
</TR>

</TABLE>

<TABLE WIDTH=490 BORDER=0>
<TR>
	<TD>

<BLOCKQUOTE>
<BR>
<BR>

<P ALIGN="LEFT">
<FONT SIZE=6>Sailing</FONT>

<P ALIGN="LEFT">
<IMG ALIGN=RIGHT BORDER=1 WIDTH=225 HEIGHT=151 HSPACE=10 VSPACE=4 
SRC="/images/sport/segling2.gif">
Sailing has featured strongly in the past, peaking with Volvo's sponsorship of 
the Swedish entry for the America's Cup in 1980.  Currently, involvement is 
restricted to a small number of national events such as the Tj&ouml;rn Runt 
in Sweden which has been supported by both Volvo and Volvo Penta since 1985.  
In addition, Volvo Penta are the Official Supplier to the Grande Mistral Race.

<BR>
<BR>
<BR>

<P>
<BR>
</BLOCKQUOTE>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]
</TD>
</TR>
</TABLE>

</CENTER>

</BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-183</DOCNO>
<DOCOLDNO>IA055-000919-B021-401</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/sport/tennis.html 192.138.110.240 19970208023721 text/html 1919
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 02:37:28 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 1748
Last-modified: Mon, 01 Jul 1996 13:56:33 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Tennis</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>
</TR>

<TR>
	<TD><HR></TD>
</TR>

</TABLE>

<TABLE WIDTH=490 BORDER=0>
<TR>
	<TD>

<BLOCKQUOTE>
<BR>
<BR>

<P ALIGN="LEFT">
<FONT SIZE=6>Tennis</FONT>

<P ALIGN="LEFT">
<IMG ALIGN=RIGHT BORDER=1 WIDTH=220 HEIGHT=153 HSPACE=10 VSPACE=4 
SRC="/images/sport/tennis2.gif">
In 1973 Volvo paid $12,500 to sponsor a professional tennis tournament in 
America.  This single event launched a tennis programme that grew steadily 
through the decade, fuelled by some of the greatest names in the game, 
Jimmy Connors, Chris Evert, John McEnroe, Martina Navratilova and Bj&ouml;rn 
Borg.  By 1980 Volvo were committed to a five year sponsorship of the world 
wide Grand Prix Tennis Tour - The Volvo Grand Prix.  This gave significant 
media exposure and marketing benefits to markets around the world in much the 
same way as the Equestrian World Cup and The Volvo Tour.  Tennis has played a 
major role in our overall sports marketing strategy for over twenty-two years 
but is now being scaled down, with the last two major tournaments, the Volvo 
Monte-Carlo Open and the Volvo International in Newhaven, Connecticut ending 
in 1995.

<BR>
<BR>
<BR>

<P>
<BR>
</BLOCKQUOTE>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]
</TD>
</TR>
</TABLE>

</CENTER>

</BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-184</DOCNO>
<DOCOLDNO>IA055-000921-B031-2</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/corpinfo/fin.stat/index.html 192.138.110.240 19970208023839 text/html 2237
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 02:38:49 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 2066
Last-modified: Thu, 13 Jun 1996 14:41:31 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Financial and Operating Statistics</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<A NAME="top"></A>

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="../index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>
</TR>

<TR>
	<TD><HR></TD>
</TR>

</TABLE>



<TABLE WIDTH=490 BORDER=0>
<TR>
	<TD>

<BLOCKQUOTE>

<BR>
<FONT SIZE=6>Financial and Operating Statistics</FONT><BR>
<BR>

<FONT SIZE=4><img WIDTH=14 HEIGHT=14 BORDER=0 
src="/images/knbla.gif"> Financial statistics, 
consolidated</FONT><BR>

<UL>

<LI><A HREF="tab1.html">Statements of income</A><BR>

<BR>
<LI><A HREF="tab2.html">Balance sheets</A><BR>

<BR>
<LI><A HREF="tab3.html">Statements of changes in financial position</A><BR>

<BR>
<LI><A HREF="tab4.html">Approximate net income in accordance with U.S. 
	GAAP</A><BR>

<BR>
<LI><A HREF="tab5.html">Key ratios</A><BR>

<BR>
<LI><A HREF="expl.html">Changes in accounting principles</A><BR>

</UL>

<BR>

<FONT SIZE=4><img WIDTH=14 HEIGHT=14 BORDER=0 
src="/images/knbla.gif"> Financial statistics by market area
</FONT><BR>

<UL>

<LI><A HREF="tab6.html">Number of employees at year-end</A><BR>

<BR>
<LI><A HREF="tab7.html">Salaries, wages and other remuneration
	(including social costs)</A><BR>

</UL>



<BR>

<FONT SIZE=4><img WIDTH=14 HEIGHT=14 BORDER=0 
src="/images/knbla.gif"> Operating statistics</FONT><BR>

<UL>

<LI><A HREF="tab8.html">Volvo vehicles sold</A><BR>

<BR>

<LI><A HREF="tab9.html">Volvo vehicles sold, quarterly figures</A><BR>

</UL>


<BR>

<BR>

<TABLE BORDER=0 WIDTH=450>

<TR>
	<TD><HR></TD>
</TR>

<TR>
	<TD>Source: Financial and Operating Statistics 1995</TD>
</TR>

</TABLE>

</BLOCKQUOTE>


<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]


</TD>
</TR>
</TABLE>

</CENTER>
</BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-185</DOCNO>
<DOCOLDNO>IA055-000921-B031-24</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/corpinfo/annual.html 192.138.110.240 19970208023850 text/html 1650
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 02:39:00 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 1479
Last-modified: Thu, 13 Jun 1996 14:40:06 GMT
</DOCHDR>
<HTML>
<HEAD>
<TITLE>Annual Report 1995</TITLE>
</HEAD>
<BODY BGCOLOR="FFFFFF">

<A NAME="top"></A>

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>
</TR>

<TR>
	<TD><HR></TD>
</TR>

<TR>
	<TD>
<BR>
<BR>

<BLOCKQUOTE>
<FONT SIZE=6>Annual Report 1995</FONT><BR>
<BR>
<BR>

<A HREF="descr/index.html"><img WIDTH=14 HEIGHT=14 hspace=5 BORDER=0 
src="/images/knbla.gif">The Volvo Group in Brief</A><br>
<P>
<A HREF="chief/index.html"><img WIDTH=14 HEIGHT=14 hspace=5 BORDER=0 
src="/images/knbla.gif">Comments by the Chief Executive Officer</A><br>
<P>
<A HREF="capital/index.html"><img WIDTH=14 HEIGHT=14 hspace=5 BORDER=0 
src="/images/knbla.gif">Capital structure and financial objectives</A><br>
<P>
<A HREF="share/index.html"><img WIDTH=14 HEIGHT=14 hspace=5 BORDER=0 
src="/images/knbla.gif">The Volvo Share</A><br>
<P>
<A HREF="board/index.html"><img WIDTH=14 HEIGHT=14 hspace=5 BORDER=0 
src="/images/knbla.gif">Group Management and AB Volvo's Board of
Directors</A><br>
</u>
</BLOCKQUOTE></FONT>
<br>
<br>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]
</TD>
</TR>
</TABLE>

</CENTER>

</BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-186</DOCNO>
<DOCOLDNO>IA055-000921-B031-45</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/corpinfo/int.rep/index.html 192.138.110.240 19970208023900 text/html 3529
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 02:39:11 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 3358
Last-modified: Wed, 23 Oct 1996 09:00:12 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Interim Reports</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="../index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>
</TR>

<TR>
	<TD><HR></TD>
</TR>

</TABLE>



<TABLE WIDTH=490 BORDER=0>
<TR>
	<TD>

<BR>
<BR>
<BLOCKQUOTE>

<P>
<BR>
<FONT SIZE=6>Interim Reports</FONT><BR>

<TABLE CELLSPACING=6 BORDER=0>

<TR ALIGN=LEFT VALIGN=TOP>
	<TD><A HREF="six.95/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0
	src="/images/knbla.gif"></A></TD>
	<TD><A HREF="six.95/index.html"><FONT SIZE=4> Six months ended 
	June 30, 1995</FONT></A></TD>
</TR>


<TR ALIGN=LEFT VALIGN=TOP>
	<TD><A HREF="nine.95/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knbla.gif"></A></TD>
	<TD><A HREF="nine.95/index.html"><FONT SIZE=4> Nine months ended September 30, 
	1995</FONT></A></TD>
</TR>

<TR ALIGN=LEFT VALIGN=MIDDLE>
	<TD><A HREF="report.95/index.html"><img WIDTH=14 HEIGHT=14 VALIGN=BOTTOM BORDER=0 
	src="/images/knbla.gif"></A></TD>
	<TD><A HREF="report.95/index.html"><FONT SIZE=4> Report on 1995 operations
	</FONT><A HREF="report.95/index.html"><IMG BORDER=0 WIDTH=31 HEIGHT=20 SRC="/images/eng4.gif"></A>
	<A HREF="report.95/index-sv.html"><IMG BORDER=0 WIDTH=31 HEIGHT=20 SRC="/images/sve4.gif"></A></TD>
</TR>

<TR ALIGN=LEFT VALIGN=TOP>
	<TD><A HREF="three.95/index.html"><img WIDTH=14 HEIGHT=14 VALIGN=BOTTOM BORDER=0 
	src="/images/knbla.gif"></A></TD>

	<TD><A HREF="three.96/index.html"><FONT SIZE=4> Three months ended March 31, 1996
	</FONT><A HREF="three.96/index.html"><IMG BORDER=0 WIDTH=31 HEIGHT=20 SRC="/images/eng4.gif"></A>
	<A HREF="three.96/index-sv.html"><IMG BORDER=0 WIDTH=31 HEIGHT=20 SRC="/images/sve4.gif"></A></TD>
</TR>

<TR ALIGN=LEFT VALIGN=TOP>
	<TD><A HREF="six.95/index.html"><img WIDTH=14 HEIGHT=14 VALIGN=BOTTOM BORDER=0 
	src="/images/knbla.gif"></A></TD>

	<TD><A HREF="six.96/index.html"><FONT SIZE=4>  Six months ended June 30, 1996
	</FONT><A HREF="six.96/index.html"><IMG BORDER=0 WIDTH=31 HEIGHT=20 SRC="/images/eng4.gif"></A>
	<A HREF="six.96/index-sv.html"><IMG BORDER=0 WIDTH=31 HEIGHT=20 SRC="/images/sve4.gif"></A></TD>
</TR>

<TR ALIGN=LEFT VALIGN=TOP>
	<TD><A HREF="nine.95/index.html"><img WIDTH=14 HEIGHT=14 VALIGN=BOTTOM BORDER=0 
	src="/images/knbla.gif"></A></TD>


	<TD><A HREF="nine.96/index.html"><FONT SIZE=4> Nine months ended September 30, 1996
	</FONT><A HREF="nine.96/index.html"><IMG BORDER=0 WIDTH=31 HEIGHT=20 SRC="/images/eng4.gif"></A>
	<A HREF="nine.96/index-sv.html"><IMG BORDER=0 WIDTH=31 HEIGHT=20 SRC="/images/sve4.gif"></A></TD>
</TR>

</TABLE>

<BR>
<BR>

<HR ALIGN=LEFT WIDTH=447>

<BR>
<BR>The reports can be obtained in Swedish and English, with the Annual 
Report also available in French.

<P ALIGN="LEFT">
All reports can be ordered from

<P ALIGN="LEFT">
Volvo, Publications<br>
Dept. 7940 ARUN<br>
S-405 08  G&ouml;teborg, Sweden<br>
Telefax: Int +46 31 66 20 20

<BR>

<CLEAR=ALL></BLOCKQUOTE><BR>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]
</TD>
</TR>
</TABLE>

</CENTER>

</BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-187</DOCNO>
<DOCOLDNO>IA055-000921-B031-71</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/corpinfo/world.html 192.138.110.240 19970208023910 text/html 1294
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 02:39:21 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 1123
Last-modified: Thu, 13 Jun 1996 14:45:52 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Volvo Around the World</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<A NAME="top"></A>

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>
</TR>

<TR>
	<TD><HR></TD>
</TR>

</TABLE>

<TABLE WIDTH=490 BORDER=0>
<TR>
	<TD>

<BLOCKQUOTE>

<BR>
<FONT SIZE=6>Volvo Around the World</FONT><BR>
<BR>

<BR>
<BR>

<BR>
<FONT SIZE=4><A HREF="europe/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
src="/images/knbla.gif"LEFT>Volvo in Europe
</A></FONT><BR>
<BR>
<FONT SIZE=4><A HREF="adress/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
src="/images/knbla.gif"LEFT>Volvo Around the World - Addresses
</A></FONT><BR>
<BR>
<BR>
<BR>

</BLOCKQUOTE>
<BR>
<BR>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]
</TD>
</TR>
</TABLE>

</CENTER>
</BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-188</DOCNO>
<DOCOLDNO>IA055-000921-B031-99</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/corpinfo/information.html 192.138.110.240 19970208023924 text/html 10772
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 02:39:33 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 10600
Last-modified: Mon, 30 Sep 1996 13:58:51 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Information</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>
<TD ALIGN=RIGHT><A HREF="index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>
</TR>

<TR>
	<TD><HR></TD>
</TR>

<TR>
	<TD>
<BLOCKQUOTE>
<BR>
<BR>

<P>
<FONT SIZE=5>Volvo Group Corporate Information 1996</FONT>

<P ALIGN=LEFT>

<BR>
<BR>
<P>
	<FONT SIZE=4><B>Annual Report 1995</B></FONT>
	<P>
	Volvo Annual Report is published in March and is aimed primarily at our shareholders.
	It contains information about what has happened during the year as well
	as the standard financial statements. <BR>
	Free of charge.</P>

	<P>
	The annual report can be ordered via the PUB Store on fax number: +46
	31 66 20 20 or E-Mail: <a href="mailto:vtab.volvoinf@memo.volvo.se">vtab.volvoinf@memo.volvo.se</a><BR>
	Please quote the product number.
	</P>

	<IMG SRC="/images/arsredo.gif" ALT="Annual Report 1995" HSPACE=3 VSPACE=3 
	HEIGHT=84 WIDTH=100 ALIGN=RIGHT>

<TABLE WIDTH=280 BORDER=0>

<TR>
	<TD COLSPAN=2><HR SIZE=1 WIDTH="100%"></TD>
</TR>

<TR VALIGN=TOP>
	<TD>Swedish</TD>
	<TD ALIGN=RIGHT>635-2102</TD>
</TR>

<TR VALIGN=TOP>
	<TD>English</TD>
	<TD ALIGN=RIGHT>635-2104</TD>
</TR>

<TR VALIGN=TOP>
	<TD>French</TD>
	<TD ALIGN=RIGHT>635-2113</TD>
</TR>

<TR>
	<TD COLSPAN=2><HR SIZE=1 WIDTH="100%"></TD>
</TR>

</table></blockquote></td></tr>
<tr><td><p></td></tr>

<TR>
	<TD><BLOCKQUOTE>
<P>
	<FONT SIZE=4><B>Quarterly Reports</B></FONT>
	<P>
	Three times annually, in April, August and October, Volvo publishes a 
	quarterly report on the Group's operations and income. At the end of 
	February a report on the preceding year's earnings is published. <BR>
	Free of charge.
	</P>

	<P>
	Quarterly reports can be ordered via the PUB Store on fax number: 
	+46 31 66 20 20 or E-Mail: <a href="mailto:vtab.volvoinf@memo.volvo.se">vtab.volvoinf@memo.volvo.se</a><BR>
	Please quote the product number.
	</P>

	<IMG SRC="/images/kvartal.gif" ALT="" HSPACE=3 VSPACE=3 
	HEIGHT=92 WIDTH=100 ALIGN=RIGHT>

<TABLE WIDTH=280 BORDER=0>

<TR>
	<TD COLSPAN=2><HR SIZE=1 WIDTH="100%"></TD>
</TR>

<TR VALIGN=TOP>
	<TD>Swedish</TD>
	<TD ALIGN=RIGHT>Q1:635-2106, Q2:635-2108<BR>
	Q3:635-2110, Year:635-2100</TD>
</TR>

<TR VALIGN=TOP>
	<TD>English</TD>
	<TD ALIGN=RIGHT>Q1:635-2107, Q2:635-2109<BR>
	Q3:635-2111, Year:635-2101</TD>
</TR>

<TR>
	<TD COLSPAN=2><HR SIZE=1 WIDTH="100%"></TD>
</TR>

</table></blockquote></td></tr>
<tr><td><p></td></tr>

<TR>
	<TD><BLOCKQUOTE>
<P>
	<FONT SIZE=4><B>Annual General Meeting Address 1996</B></FONT>
	<P>
	This document contains the speech by S&ouml;ren Gyll at the Annual General 
	Meeting in G&ouml;teborg on April 24, 1996. The document presents the outcome
	of operations during 1995, our current market position and future strategy.<BR>
	Free of charge
	</P>

	<P>
	The AGM speech can be ordered from the PUB Store by telefax: +46 31 66 20 20
	or E-Mail: <a href="mailto:vtab.volvoinf@memo.volvo.se">vtab.volvoinf@memo.volvo.se</a><BR>
	Please quote the product number.
	</P>

	<IMG SRC="/images/bolags.gif" ALT="" HSPACE=3 VSPACE=3 
	HEIGHT=89 WIDTH=100 ALIGN=RIGHT>

<TABLE WIDTH=280 BORDER=0>

<TR>
	<TD COLSPAN=2><HR SIZE=1 WIDTH="100%"></TD>
</TR>

<TR VALIGN=TOP>
	<TD>Swedish</TD>
	<TD ALIGN=RIGHT>635-2120</TD>
</TR>

<TR VALIGN=TOP>
	<TD>English</TD>
	<TD ALIGN=RIGHT>635-2121</TD>
</TR>

<TR>
	<TD COLSPAN=2><HR SIZE=1 WIDTH="100%"></TD>
</TR>

</table></blockquote></td></tr>
<tr><td><p></td></tr>

<TR>
	<TD><BLOCKQUOTE>
<P>
	<FONT SIZE=4><B>Environmental Report 1995</B></FONT>
	<P>
	This report describes how the Volvo environmental policy is translated 
	into actions. It gives examples of the environmental protection activities 
	throughout the Volvo Group. The brochure is intended for internal and external 
	readership. <BR>
	Free of charge.
	</P>
	
	<P>
	The Volvo Environmental Report can be ordered via the PUB Store on fax 
	number: +46 31 54 57 72 or E-Mail: <a href="mailto:vtab.volvoinf@memo.volvo.se">vtab.volvoinf@memo.volvo.se</a><BR>
	Please quote the product number.
	</P>

	<IMG SRC="/images/miljored.gif" ALT="" HSPACE=3 VSPACE=3 
	HEIGHT=95 WIDTH=100 ALIGN=RIGHT>

<TABLE WIDTH=280 BORDER=0>

<TR>
	<TD COLSPAN=2><HR SIZE=1 WIDTH="100%"></TD>
</TR>

<TR>
	<TD>Swedish</TD>
	<TD ALIGN=RIGHT>011-1355</TD>
</TR>

<TR>
	<TD>English</TD>
	<TD ALIGN=RIGHT>011-1356</TD>
</TR>

<TR>
	<TD>German</TD>
	<TD ALIGN=RIGHT>011-1357</TD>
</TR>

<TR>
	<TD>French</TD>
	<TD ALIGN=RIGHT>011-1358</TD>
</TR>

<TR>
	<TD COLSPAN=2><HR SIZE=1 WIDTH="100%"></TD>
</TR>

</table></blockquote></td></tr>
<tr><td><p></td></tr>

<TR>
	<TD><BLOCKQUOTE>
<P>
	<FONT SIZE=4><B>Volvo - A Corporate Presentation</B></FONT>
	<P>
	This corporate presentation provides the reader with a comprehensive 
	view of the Volvo Group. The 24 page brochure describes the operations 
	of the various operating sectors and the products.<BR>
	Free of charge.
	</P>

	<P>
	Volvo - A Corporate Presentation can be ordered from the PUB Store by 
	telefax: +46 31 54 57 72 or E-Mail: <a href="mailto:vtab.volvoinf@memo.volvo.se">vtab.volvoinf@memo.volvo.se</a><BR>
	Please quote the product number.
	</P>

	<IMG SRC="/images/presentation.gif" ALT="" HSPACE=3 VSPACE=3 
	HEIGHT=96 WIDTH=67 ALIGN=RIGHT BORDER=1>

<TABLE WIDTH=280 BORDER=0>

<TR>
	<TD COLSPAN=2><HR SIZE=1 WIDTH="100%"></TD>
</TR>

<TR>
	<TD>Swedish</TD>
	<TD ALIGN=RIGHT>620-6225</TD>
</TR>

<TR>
	<TD>English</TD>
	<TD ALIGN=RIGHT>620-6226</TD>
</TR>

<TR>
	<TD COLSPAN=2><HR SIZE=1 WIDTH="100%"></TD>
</TR>

</table></blockquote></td></tr>
<tr><td><p></td></tr>

<TR>
	<TD><BLOCKQUOTE>
<P>
	<FONT SIZE=4><B>Group Presentation OHs</B></FONT>
	<P>
	The 1996 version of Volvo's Group presentation is now complete. The package 
	comprises a total of 16 overheads and is available in Swedish and English. <BR>
	Free of charge.

	</P>

	<P>
	This overhead package can be ordered via the PUB Store on fax 
	number: +46 31 54 57 72 or E-Mail: <a href="mailto:vtab.volvoinf@memo.volvo.se">vtab.volvoinf@memo.volvo.se</a><BR>
	Please quote the product number.
	</P>

	<IMG SRC="/images/overhead.gif" ALT="" HSPACE=3 VSPACE=3 
	HEIGHT=75 WIDTH=110 ALIGN=RIGHT>

<TABLE WIDTH=280 BORDER=0>

<TR>
	<TD COLSPAN=2><HR SIZE=1 WIDTH="100%"></TD>
</TR>

<TR>
	<TD>Swedish</TD>
	<TD ALIGN=RIGHT>620-6223</TD>
</TR>

<TR>
	<TD>English</TD>
	<TD ALIGN=RIGHT>620-6224</TD>
</TR>

<TR>
	<TD COLSPAN=2><HR SIZE=1 WIDTH="100%"></TD>
</TR>

</table></blockquote></td></tr>
<tr><td><p></td></tr>

<TR>
	<TD><BLOCKQUOTE>
<P>
	<FONT SIZE=4><B>Facts about Volvo 1996</B></FONT>
	<P>
	Facts about Volvo 1996 is a four page A4 folder containing financial 
	information about the Group and the operating sectors. <BR>
	Free of charge.

	</P>

	<P>
	Facts about Volvo 1996 can be ordered via the PUB Store on fax number 
	+46 31 54 57 72 or E-Mail: <a href="mailto:vtab.volvoinf@memo.volvo.se">vtab.volvoinf@memo.volvo.se</a><BR>
	Please quote the product number.
	</P>

	<IMG SRC="/images/koncern.gif" ALT="" HSPACE=3 VSPACE=3 
	HEIGHT=93 WIDTH=95 ALIGN=RIGHT>

<TABLE WIDTH=280 BORDER=0>

<TR>
	<TD COLSPAN=2><HR SIZE=1 WIDTH="100%"></TD>
</TR>

<TR>
	<TD>Swedish</TD>
	<TD ALIGN=RIGHT>620-5000</TD>
</TR>

<TR>
	<TD>English</TD>
	<TD ALIGN=RIGHT>620-5001</TD>
</TR>

<TR>
	<TD COLSPAN=2><HR SIZE=1 WIDTH="100%"></TD>
</TR>

</table></blockquote></td></tr>
<tr><td><p></td></tr>

<TR>
	<TD><BLOCKQUOTE>
<P>
	<FONT SIZE=4><B>Facts about Volvo 1996, "pocket version"</B></FONT>
	
	<P>This version of Facts about Volvo 1996 is a 29 page, pocket-size brochure 
	which is easy to carry in your pocket or handbag. It contains brief key 
	data about the Volvo Group, both the Group as a whole and the operating 
	sectors. <BR>
	Free of charge.</P>

	<P>Pocket version of Facts about Volvo 1996 can be ordered via the PUB 
	Store on fax number: +46 31 54 57 72 or E-Mail: <a href="mailto:vtab.volvoinf@memo.volvo.se">vtab.volvoinf@memo.volvo.se</a><BR>
	Please quote the product number.
	</P>

	<IMG SRC="/images/pocket.gif" ALT="" HSPACE=3 VSPACE=3 
	HEIGHT=89 WIDTH=75 ALIGN=RIGHT>

<TABLE WIDTH=280 BORDER=0>

<TR>
	<TD COLSPAN=2><HR SIZE=1 WIDTH="100%"></TD>
</TR>

<TR>
	<TD>Swedish</TD>
	<TD ALIGN=RIGHT>620-98</TD>
</TR>

<TR>
	<TD>English</TD>
	<TD ALIGN=RIGHT>620-112</TD>
</TR>

<TR>
	<TD COLSPAN=2><HR SIZE=1 WIDTH="100%"></TD>
</TR>

</table></blockquote></td></tr>
<tr><td><p></td></tr>

<TR>
	<TD><BLOCKQUOTE>
<P>
	<FONT SIZE=4><B>Financial and Operating Statistics</B></FONT>
	<P>
	This is a statistical year-book in English and the contents are extremely 
	comprehensive. In addition to historical background, it also contains 
	information about the Group's operations in words, figures and tables. 
	Many of the tables cover the last eleven financial years. <BR>
	Free of charge.

	</P>

	<P>
	Financial and Operating Statistics can 
	be ordered via the PUB Store on fax number: + 46 31 66 20 20
	or E-Mail: <a href="mailto:vtab.volvoinf@memo.volvo.se">vtab.volvoinf@memo.volvo.se</a><BR>
	Please quote the product number.
	</P>

	<IMG SRC="/images/financial.gif" ALT="" HSPACE=3 VSPACE=3 
	HEIGHT=77 WIDTH=100 ALIGN=RIGHT BORDER=1>

<TABLE WIDTH=280 BORDER=0>

<TR>
	<TD COLSPAN=2><HR SIZE=1 WIDTH="100%"></TD>
</TR>

<TR>
	<TD>English</TD>
	<TD ALIGN=RIGHT>635-2112</TD>
</TR>

<TR>
	<TD COLSPAN=2><HR SIZE=1 WIDTH="100%"></TD>
</TR>

</table></blockquote></td></tr>
<tr><td><p></td></tr>

<TR>
	<TD><BLOCKQUOTE>
<P>
	<FONT SIZE=4><B>Volvo Today</B></FONT>
	<P>
	Volvo Today is an eight-minute video program presenting a comprehensive 
	description of the Group's history, products and core values. <BR>
	Free of charge..
	</P>

	<P>
	Volvo Today can be ordered via the PUB Store on fax number: +46 31 54 57 72
	or E-Mail: <a href="mailto:vtab.volvoinf@memo.volvo.se">vtab.volvoinf@memo.volvo.se</a><BR>
	Please quote the product number.
	</P>

	<IMG SRC="/images/video.gif" ALT="" HSPACE=3 VSPACE=3 
	HEIGHT=82 WIDTH=100 ALIGN=RIGHT>

<TABLE WIDTH=280 BORDER=0>

<TR>
	<TD COLSPAN=2><HR SIZE=1 WIDTH="100%"></TD>
</TR>

<TR>
	<TD>Swedish</TD>
	<TD ALIGN=RIGHT>620-6217</TD>
</TR>

<TR>
	<TD>English</TD>
	<TD ALIGN=RIGHT>620-6218</TD>
</TR>

<TR>
	<TD COLSPAN=2><HR SIZE=1 WIDTH="100%"></TD>
</TR>

</table>
</blockquote>

<BR>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]
</TD>
</TR>
</TABLE>

</CENTER>

</BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-189</DOCNO>
<DOCOLDNO>IA055-000921-B041-157</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/cgi-bin/make_tot_press_se_old 192.138.110.240 19970208030949 text/html 21289
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 03:09:56 GMT
Server: Apache/1.1.3
Content-type: text/html
</DOCHDR>
<!doctype html public \"-//W30//DTD W3 HTML 2.0//EN\">
<HTML>
<HEAD>
<TITLE>Press Releases
</TITLE>
</HEAD>
<body bgcolor=#ffffff>
<center>
<a name="top_of_page"></a>
<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<br>
<br>
[ <a href="/">Volvo Group Homepage</a> | <a href="#end_of_page">End of page</a> ]
<br>
[ <a href="/cgi-bin/make_tot_press">News &amp; Press Releases</a> | <a href="/cgi-bin/make_tot_press_old">Old News &amp; Press Releases</a> ]
<br>
[ <a href="/cgi-bin/make_tot_press_se">Some Swedish News &amp; Press Releases</a> | <a href="/cgi-bin/make_tot_press_se_old">Some Swedish Old News &amp; Press Releases</a> ]
<br>
<hr>
<H2>Nyheter &amp; Pressmeddelanden f&ouml;r Volvo Gruppen</H2>
<img src="/images/pressimages.gif" width="487" height="85" align="bottom" naturalsi
zeflag="3" border="2">
</center> 
<hr>
<ul>
<h4>
<li>
29 oktober 1996<br><a href="/www.truck.volvo.se/prse/961029s1.html">Globaliseringen av FH-teknologin g&aring;r vidare: Volvo NH introduceras i Australien</a>
</h4>
<blockquote>
 Volvo Truck Australia, Volvo Lastvagnars bolag i Australien har introducerat en ny modell, Volvo NH. Volvo NH &auml;r en normalbyggd variant av Volvo FH, speciellt utvecklad f&ouml;r marknaderna i Australien och Nya Zeeland. </blockquote>
</li>
<h4>
<li>
23 oktober 1996<br><a href="/www.volvo.se/prse/961023s1.html">Volvokoncernen de tre f&ouml;rsta kvartalen 1996</a>
</h4>
<blockquote>
  - sammanfattning - </blockquote>
</li>
<h4>
<li>
22 oktober 1996<br><a href="/www.aero.volvo.se/prse/961022s1.html">100 miljonersorder till Volvo Aero Engine Services</a>
</h4>
<blockquote>
 Volvo Aero Engine Services i Stockholm har ingtt ett avtal med det israeliska flygbolaget EL Al om underhll av motorer,Pratt & Whitney JT9D-7Q, till bolagets Boeing 747-flotta. Avtalet lper i tv r och kan frlngas ytterligare. Ordern r vrd 100 miljoner under tvrs-perioden. El Al flyger idag en flotta bestende av 13 Boeing 747, sju Boeing757 och fem Boeing 767. </blockquote>
</li>
<h4>
<li>
18 oktober 1996<br><a href="/www.truck.volvo.se/prse/961018s1.html">Omstrukturering av Volvo Lastvagnars verksamhet i Nordamerika</a>
</h4>
<blockquote>
 Styrelsen f&ouml;r Volvo GM Heavy Truck Corporation har idag beslutat att koncentrera lastbils-produktionen till f&ouml;retagets anl&auml;ggning i Dublin (New River Valley), Virginia. Beslutet inneb&auml;r att lastbilsproduktionen vid f&ouml;retagets anl&auml;ggning i Orrville, Ohio, flyttas till fabriken i Dublin. Flyttningen ska vara genomf&ouml;rd fullt ut under andra kvartalet 1997. </blockquote>
</li>
<h4>
<li>
25 september 1996<br><a href="/www.aero.volvo.se/prse/orlog.html">Marin gasturbinorder fr&aring;n Norge till Volvo Aero Support</a>
</h4>
<blockquote>
Volvo Aero Support, VAS, har f&aring;tt en order fr&aring;n norska Sj&ouml;f&ouml;rsvarets forsyningskommando om leverans av tv&aring; marina framdrivningssystem inneh&aring;llande gasturbiner, v&auml;xlar och kontrollutrustningar. </blockquote>
</li>
<h4>
<li>
19 september 1996<br><a href="/www.truck.volvo.se/prse/960919s8.html">Tommy Rengman p IAA-mssan i Hannover:  "Volvo Lastvagnars utveckling fortstter"</a>
</h4>
<blockquote>
 - Vi har arbetat intensivt med att vidareutveckla FH-serien. Vi arbetarocks fr en kad modularisering, vilket vi visar med Volvo VN- serien. Vi breddar ocks vrt produktprogram med en lttare lastbil, Volvo FLC.  - Allt detta visar att Volvo Lastvagnar r ett fretag som utvecklas. Och den utvecklingen kommer att fortstta. </blockquote>
</li>
<h4>
<li>
19 september 1996<br><a href="/www.truck.volvo.se/prse/960919s6.html">Volvo Lastvagnar p&aring; IAA i Hannover 1996. Ny 7,5-tons lastbil  Volvo FLC, och uppdaterade motorer f&ouml;r FH-serien </a>
</h4>
<blockquote>
 P&aring; IAA 1996 presenterar Volvo Lastvagnar FLC, en ny lastbil i 7,5-tonsklassen. FLC, C st&aring;r f&ouml;r City, &auml;r framtagen p&aring; kort tid f&ouml;r att bredda produktprogrammet ned&aring;t med en medeltung, okomplicerad lastbil f&ouml;r l&auml;ttare distributionsk&ouml;rning. FLC &auml;r utrustad med en 4-litersmotor, Volvo D4A, som ocks&aring; visas p&aring; m&auml;ssan. </blockquote>
</li>
<h4>
<li>
19 september 1996<br><a href="/www.truck.volvo.se/prse/960919s2.html">Volvo FLC introducerad. Ny, s&auml;ker lastbil fr&aring;n Volvo i 7,5-tonsklassen </a>
</h4>
<blockquote>
 Vid lastbilsm&auml;ssan IAA i Hannover introducerar Volvo Lastvagnar en ny lastbil f&ouml;r l&auml;tt distributionsk&ouml;rning  Volvo FLC. C st&aring;r f&ouml;r City.  I och med introduktionen av FLC breddar Volvo Lastvagnar sitt produktprogram ned&aring;t i viktklasserna. Volvo FLC har tagits fram p&aring; kort tid som ett led i Volvos arbete med att satsa p&aring; k&auml;rnverksamheten, d...</blockquote>
</li>
<h4>
<li>
19 september 1996<br><a href="/www.truck.volvo.se/prse/960919s3.html">Volvo FLC introducerad. Volvo Lastvagnar breddar sitt produktprogram med ny, l&auml;ttare lastbil </a>
</h4>
<blockquote>
 Volvo Lastvagnar har introducerat en l&auml;ttare lastbil, FLC, som kommer att s&auml;ljas i ett av Europas st&ouml;rsta lastbilssegment. Totalmarknaden f&ouml;r 7,5-tons-klassen uppg&aring;r varje &aring;r till 40 000 - 60 000 bilar. St&ouml;rsta enskilda marknader i segmentet &auml;r Storbritannien och Tyskland, som tillsammans svarar f&ouml;r ungef&auml;r tv&aring; tredjedelar av totalmark...</blockquote>
</li>
<h4>
<li>
19 september 1996<br><a href="/www.truck.volvo.se/prse/960919s1.html">Volvo FLC introducerad. Ekonomisk och drifts&auml;ker k&ouml;rning med Volvo D4A </a>
</h4>
<blockquote>
 En rak fyrcylindrig 4-litersmotor som ger 135 h&auml;stkrafter vid 2500 varv/min. Det &auml;r Volvo Lastvagnars nya motor f&ouml;r FLC, Volvo D4A. </blockquote>
</li>
<h4>
<li>
19 september 1996<br><a href="/www.truck.volvo.se/prse/960919s4.html">Volvo FLC introducerad.  FL-serien -Volvo Lastvagnars m&aring;ngsidigaste program </a>
</h4>
<blockquote>
 I och med introduktionen av FLC sp&auml;nner nu Volvo Lastvagnars FL-serie fr&aring;n FLC, med 4-litersmotor och 135 h&auml;stkrafter &auml;nda upp till FL12, med 12-litersmotor och 420 h&auml;stkrafter. </blockquote>
</li>
<h4>
<li>
19 september 1996<br><a href="/www.truck.volvo.se/prse/960919s5.html">Volvo Lastvagnar introducerar nytt krockskydd - Front Underrun Protection System (FUPS)</a>
</h4>
<blockquote>
 Volvo Lastvagnar introducerar Front Underrun Protection System (fr&auml;mre underk&ouml;rningsskydd), en Volvo-nyhet som kan r&auml;dda m&aring;nga liv i den europeiska trafiken. </blockquote>
</li>
<h4>
<li>
19 september 1996<br><a href="/www.truck.volvo.se/prse/960919s7.html">Tyskland  Volvos n&auml;st st&ouml;rsta FH-marknad</a>
</h4>
<blockquote>
 Tyskland, Europas st&ouml;rsta enskilda lastbilsmarknad, &auml;r ocks&aring; Volvos n&auml;st st&ouml;rsta FH-marknad. Efter de f&ouml;rsta sju m&aring;naderna 1996 &auml;r Volvo ocks&aring; f&ouml;r f&ouml;rsta g&aring;ngen st&ouml;rsta importerade m&auml;rke i Tyskland. </blockquote>
</li>
<h4>
<li>
 6 september 1996<br><a href="/www.aero.volvo.se/prse/civflyg.html">Flygmotororder f&ouml;r 300 Mkr till Volvo Aero</a>
</h4>
<blockquote>
 Volvo Aero har som riskdelande partner i olika flygmotorprogram tagit order till ett sammanlagt v&auml;rde av 300 Mkr. </blockquote>
</li>
<h4>
<li>
 3 september 1996<br><a href="/www.volvo.se/prse/960903s1.html">Volvos Miljpris 1996 till James E. Lovelock</a>
</h4>
<blockquote>
 Volvos Miljpris 1996 har tilldelats den brittiska naturforskaren och vetenskapsmannen Dr. James E. Lovelock.  Dr. James E. Lovelock fr Volvos Miljpris och 1,5 miljoner kronor fr uppfinnandet av detektorer som mjliggr kemiska analyser av mycket lga halter av miljfarliga mnen. </blockquote>
</li>
<h4>
<li>
 3 september 1996<br><a href="/www.truck.volvo.se/prse/960903s1.html">Ny Volvo-lastbil i Nordamerika.  Volvo VN fortstter globaliseringen av FH-projektet</a>
</h4>
<blockquote>
  Volvo Lastvagnars dotterbolag i USA, Volvo GM Heavy Truck Corporation, har introducerat en ny tung lastbilsserie fr den nordamerikanska marknaden - Volvo VN-serien. </blockquote>
</li>
<h4>
<li>
30 augusti 1996<br><a href="/www.truck.volvo.se/prse/960828s1.html">Volvos &quot;supertruck&quot; drar Legos demoshow fram till &aring;r 2001</a>
</h4>
<blockquote>
  Volvo Lastvagnar har nyligen konstruerat en handbyggd NL12 6x4 f&ouml;r  Lego. Volvo-lastbilen skall de n&auml;rmaste fem &aring;ren turnera i Europa  med en specialbyggd utst&auml;llningstrailer fullpackad med fantasifulla  Lego- utst&auml;llningar.  </blockquote>
</li>
<h4>
<li>
22 augusti 1996<br><a href="/www.aero.volvo.se/prse/sexman.html">&Ouml;kad f&ouml;rs&auml;ljning men minskat resultat</a>
</h4>
<blockquote>
Volvo Aero Corporation (Volvo Aerogruppens) sex&aring;nadersrapport visade p&aring; en f&ouml;rs&auml;ljnings&ouml;kning med 14 procent till 1.962 miljoner kronor. R&ouml;relseresultatet f&ouml;r perioden uppgick till 90 miljoner kronor att j&auml;mf&ouml;ra med 91 miljoner f&ouml;r samma period 1995. </blockquote>
</li>
<h4>
<li>
22 augusti 1996<br><a href="/www.truck.volvo.se/prse/960822s1.html">Frsta halvret fr Volvo Lastvagnar</a>
</h4>
<blockquote>
 Volvo Lastvagnar redovisar fr frsta halvret 1996 en rrelsevinst p 1 078 MSEK (2 942 MSEK). Rrelsemarginalen sjnk till 4,7 procent (11,4). Minskningen beror framfr allt p lgre leveranser till de nord- och sydamerikanska marknaderna.</blockquote>
</li>
<h4>
<li>
21 augusti 1996<br><a href="/www.volvo.se/prse/960821s1.html">Volvokoncernen det frsta halvret i sammandrag - sammanfattning -</a>
</h4>
<h4>
<li>
 7 augusti 1996<br><a href="/www.truck.volvo.se/prse/960807s1.html">VD tillsatt p Volvos nya bolag i Indien</a>
</h4>
<blockquote>
 Ravi Uppal kommer inom kort bli utsedd till VD fr det nyetablerade bolaget Volvo India Pvt Ltd. </blockquote>
</li>
<h4>
<li>
12 juli 1996<br><a href="/www.aero.volvo.se/prse/lm6000.html">Volvo Aero ing&aring;r avtal v&auml;rt 600 milj</a>
</h4>
<blockquote>
 Volvo Aero med huvudkontor i Trollh&auml;ttan sl&ouml;t i dag ett avtal med General Electric om del&auml;garskap i LM 6000 - en station&auml;r gasturbin f&ouml;r elgenerering. Uppg&ouml;relsen ber&auml;knas ge Volvo Aero int&auml;kter p&aring; 600 milj under de kommande 15 - 20 &aring;ren. Volvo skall ansvara f&ouml;r l&aring;gtrycksturbinhuset </blockquote>
</li>
<h4>
<li>
 8 juli 1996<br><a href="/www.truck.volvo.se/prse/960708s1.html">110 Volvo-lastbilar till Sydafrika</a>
</h4>
<blockquote>
  Volvo Lastvagnar har ftt en order p 110 FH-lastbilar i Sydafrika.  Kunden r Alex Carriers, en av Sydafrikas strsta transportfirmor.  </blockquote>
</li>
<h4>
<li>
 5 juli 1996<br><a href="/www.truck.volvo.se/prse/960705s1.html">Volvo uppdaterar motorerna fr FH-serien.  kat vridmoment ger frbttrad krbarhet.</a>
</h4>
<blockquote>
  Volvo Lastvagnar uppdaterar sina motorer fr FH-serien, D12A och D16A.  De strsta frndringarna sker p D12A, dr bl a vridmomentet har kats  med 150 Nm, vilket betyder frre vxlingar och en frbttrad krbarhet.  </blockquote>
</li>
<h4>
<li>
25 juni 1996<br><a href="/www.volvo.se/prse/960625s1.html">Volvo sljer huvuddelen av innehavet i Pharmacia &amp; Upjohn</a>
</h4>
<blockquote>
 AB Volvo har beslutat genomfra, frutsatt en fortsatt god marknadssituation, en internationell utfrsljning av merparten av sitt aktieinnehav i Pharmacia &amp; Upjohn, Inc. Erbjudandet, som omfattar totalt 46.000 000 aktier motsvarande tv tredjedelar av Volvos nuvarande innehav, kommer att ske till kpare p de amerikanska och nordiska marknaderna samt p vriga marknader. P marknad...</blockquote>
</li>
<h4>
<li>
22 juni 1996<br><a href="/www.truck.volvo.se/prse/960622s1.html">122 Volvo-lastbilar till Pakistan</a>
</h4>
<blockquote>
  Volvo Lastvagnar har skrat ytterligare order p 122 Volvo-lastbilar  till Pakistan.  </blockquote>
</li>
<h4>
<li>
12 juni 1996<br><a href="/www.volvo.se/prse/960612s1.html">Volvo avyttrar sitt innehav i Bure</a>
</h4>
<blockquote>
  Volvo har idag avyttrat hela sitt innehav, 9.652.033 aktier  motsvarande 17,7 procent av aktiekapital och rster, i det svenska  frvaltningsbolaget Investment AB Bure.  </blockquote>
</li>
<h4>
<li>
22 maj 1996<br><a href="/www.volvo.se/prse/960522s1.html">Catena kper Volvo Maskin Norge</a>
</h4>
<blockquote>
  Catena har tecknat en pricipverenskommelse om att frvrva Volvo Construction  Equipment Corporations (VCE) marknadsbolag i Norge, Volvo Maskin Norge  A/S. Catena har tecknat en pricipverenskommelse om att frvrva Volvo  Construction Equipment Corporations (VCE) marknadsbolag i Norge, Volvo  Maskin Norge A/S.   </blockquote>
</li>
<h4>
<li>
22 maj 1996<br><a href="/www.volvo.se/prse/960522s2.html">Ny chef fr Volvo Deutschland</a>
</h4>
<blockquote>
  Till ny verkstllande direktr fr Volvo Personvagnars dotterbolag i  Tyskland, Volvo Deutschland GmbH, har frn den 19 augusti utsetts Wolff  Huber Till ny verkstllande direktr fr Volvo Personvagnars dotterbolag  i Tyskland, Volvo Deutschland GmbH, har frn den 19 augusti utsetts Wolff  Huber   </blockquote>
</li>
<h4>
<li>
21 maj 1996<br><a href="/www.truck.volvo.se/prse/960521s1.html">Volvo Lastvagnar varslar 555 anst&auml;llda om upps&auml;gning  </a>
</h4>
<blockquote>
  Volvo Lastvagnar kommer under denna vecka till ber&ouml;rda L&auml;nsarbetsn&auml;mnder  att varsla om upps&auml;gning av 555 anst&auml;llda vid Volvo  Lastvagnars fabriker i Sverige.   </blockquote>
</li>
<h4>
<li>
21 maj 1996<br><a href="/www.volvo.se/prse/960521s1.html">Lars W Gustavsson ny vd fr Volvo Personbiler i Norge</a>
</h4>
<blockquote>
  Lars W Gustavsson har utsetts till ny verkstllande direktr fr Volvo  Personbiler Norge AS, som r ett dotterbolag till Volvo Personvagnar AB.  </blockquote>
</li>
<h4>
<li>
14 maj 1996<br><a href="/www.volvo.se/prse/960514s1.html">Volvo trea och bste europ i USA frn 26:e plats till prispallen p  fem r</a>
</h4>
<blockquote>
Powers kundunderskningar i USA. Underskningen, Initial Quality Study,  r en nybilsunderskning som mter korttidstillfrlitligheten p tre mnader  gamla bilar. Totalt deltog ver 30.000 nybilsgare i underskningen som  omfattar ett 80-tal frgor om svl produkten som terfrsljarens agerande.  Powers kundunderskningar i USA. Underskningen, Initial Quality Study,  r en nybilsunderskn...</blockquote>
</li>
<h4>
<li>
10 maj 1996<br><a href="/www.truck.volvo.se/prse/960510s1.html">Internationella priser till Volvo ECT</a>
</h4>
<blockquote>
 Volvo Lastvagnar har belnats med tre internationella priser fr miljkonceptfordonet Volvo Environmental Concept Truck (ECT). </blockquote>
</li>
<h4>
<li>
29 april 1996<br><a href="/www.volvo.se/prse/960429s1.html">Volvokoncernens tremnadersrapport i sammandrag - sammanfattning -</a>
</h4>
<h4>
<li>
24 april 1996<br><a href="/www.volvo.se/prse/960424s1.html">Bolagsst&auml;mma i AB Volvo den 24 april 1996   </a>
</h4>
<blockquote>
  - Volvos avsikt &auml;r att driva produktutveckling i egen regi  vad avser strategiskt viktiga omr&aring;den, som ber&ouml;r de  produktegenskaper som bygger v&aring;rt varum&auml;rke och d&auml;r  vi kan n&aring; skalekonomi. Men vi kommer ocks&aring; att s&ouml;ka  effektiva och f&ouml;rdjupade samarbeten med underleverant&ouml;rer,  andra biltillverkare och utvecklingsbolag.&quot;  </blockquote>
</li>
<h4>
<li>
17 april 1996<br><a href="/www.truck.volvo.se/prse/960417s1.html">Volvo Lastvagnar fr Kina-order</a>
</h4>
<blockquote>
 Volvo Lastvagnar har ftt en ny stor order i Kina p 50 Volvo FL10 dragvagn. </blockquote>
</li>
<h4>
<li>
29 mars 1996<br><a href="/www.truck.volvo.se/prse/960329s1.html">Volvo Lastvagnar st&ouml;rst i Norden under 1995</a>
</h4>
<blockquote>
Under 1995 bef&auml;ste Volvo Lastvagnar sin st&auml;llning som st&ouml;rsta lastbilstillverkare i Norden. P&aring; samtliga nordiska marknader f&ouml;rutom Island &auml;r Volvo ledande tillverkare, b&aring;de vad g&auml;ller tunga och medeltunga lastbilar.  </blockquote>
</li>
<h4>
<li>
27 mars 1996<br><a href="/www.truck.volvo.se/prse/960327s1.html">1995: Stora framg&aring;ngar f&ouml;r Volvo Lastvagnar i Fj&auml;rran &Ouml;stern</a>
</h4>
<blockquote>
 Volvo Lastvagnar var under 1995 st&ouml;rsta europeiska tillverkare av tunga lastbilar i Fj&auml;rran &Ouml;stern*. Under &aring;ret som gick s&aring;lde f&ouml;retaget 2.500 lastbilar i regionen vilket innebar en marknadsandel p&aring; 34 procent av de europeiska m&auml;rkena. </blockquote>
</li>
<h4>
<li>
22 mars 1996<br><a href="/www.truck.volvo.se/prse/960322s1.html">Volvo Lastvagnar bildar joint venture-bolag i Pakistan tillsammans med Swedish Motor (Pvt) Ltd</a>
</h4>
<blockquote>
 Volvo Lastvagnar AB och Swedish Motor (Pvt) Ltd bildar ett joint venture-bolag i Pakistan, Volvo Pakistan Ltd. Bolaget kommer att producera och ansvara f&ouml;r distributionen av Volvo-lastbilar i Pakistan. </blockquote>
</li>
<h4>
<li>
28 februari 1996<br><a href="/www.truck.volvo.se/prse/960228s.html">Volvo Lastvagnar introducerar ny lastbilsserie i Brasilien</a>
</h4>
<blockquote>
 Volvo Lastvagnars dotterbolag i Brasilien - Volvo do Brasil - har introducerat en ny uppdaterad lastbilsserie baserad p Volvos framgngsrika NL-koncept. </blockquote>
</li>
<h4>
<li>
22 februari 1996<br><a href="/www.truck.volvo.se/prse/960222s1.html">1995: Volvo Lastvagnars starkaste r ngonsin</a>
</h4>
<blockquote>
Volvo Lastvagnars rrelseresultat steg 1995 till 5 073 miljoner SEK. Det r en kning med 25 procent jmfrt med 1994. Under samma period steg rrelsemarginalen till 9,9 procent. Totalt omsatte Volvo Lastvagnar 51 027 miljoner SEK under 1995.  </blockquote>
</li>
<h4>
<li>
21 februari 1996<br><a href="/www.volvo.se/prse/960221s1.html">Volvokoncernens bokslutsrapport 1995 i sammandrag</a>
</h4>
<h4>
<li>
15 februari 1996<br><a href="/www.aero.volvo.se/prse/ages.html">Volvo Aero &ouml;kar &auml;gandet i AGES</a>
</h4>
<blockquote>
 Volvo Aero har &ouml;kat sin &auml;garandel i det amerikanska f&ouml;retaget AGES, Air Ground Equipment Sales, fr&aring;n fem till 25 procent. K&ouml;peskillingen &auml;r 22 miljoner dollar. AGES, som har sitt s&auml;te i Boca Raton, Florida, bedriver handel med flygplansmateriel huvudsakligen reservdelar till flygmotorer. Under 1995 omsatte f&ouml;retaget 187 miljoner dollar och hade ett    ...</blockquote>
</li>
<h4>
<li>
 7 februari 1996<br><a href="/www.truck.volvo.se/prse/960207s3.html">Volvo D6A-250 Supercharger</a>
</h4>
<blockquote>
   Volvo Lastvagnar introducerar D6A-250 Supercharger, en motor som ger hgt lgvarvsmoment och snabbare starter samt frre vxlingar Detta r mjligt genom att motorn r utrustad bde med en mekaniskt driven kompressor och en turboladdare. </blockquote>
</li>
<h4>
<li>
 7 februari 1996<br><a href="/www.truck.volvo.se/prse/960207s2.html">Volvo Lastvagnar bildar bolag tillsammans med Terberg</a>
</h4>
<blockquote>
 Volvo Lastvagnar kommer att bilda ett samgt produktionbolag tillsammans med den hollndska lastbilstillverkaren Terberg Benschop B.V.  Ett slutgiltigt beslut fattas av Volvo Lastvagnars styrelse inom kort. </blockquote>
</li>
<h4>
<li>
 7 februari 1996<br><a href="/www.truck.volvo.se/prse/960207s0.html">Miljpris till Volvo Europa Truck</a>
</h4>
<blockquote>
 Volvo Lastvagnars fabrik i Gent, Belgien, har tilldelats ett miljpris av The Federation of Belgian Enterprises fr sitt arbete med att n en god miljstyrning av verksamheten. </blockquote>
</li>
<h4>
<li>
 7 februari 1996<br><a href="/www.truck.volvo.se/prse/960207s4.html">Nytt unikt motorkoncept - D6A-250 Supercharger, SRS Airbag, Globetrotter XL och Volvo ECT</a>
</h4>
<blockquote>
 Volvo Lastvagnar presenterar en ny motor p RAI 1996 - D6A-250 Supercharger. Motorn r utrustad bde med turboladdare och mekanisk kompressor, vilket ger hga prestanda ver hela varvtalsomrdet.  </blockquote>
</li>
<h4>
<li>
 7 februari 1996<br><a href="/www.aero.volvo.se/prse/ariane.html">Ariane 4 raketens livsl&auml;ngd f&ouml;rl&auml;ngs</a>
</h4>
<blockquote>
 Br&auml;nnkammare fr&aring;n Volvo Aero f&ouml;r 100 milj </blockquote>
</li>
</ul>
<p>
<hr>
<p><center>

<P ALIGN="CENTER">[ <A HREF="/corpinfo/index.html">The Volvo Group - Facts and Figures</A> ]<BR>
[ <A HREF="/www.car.volvo.se">Volvo Car</A> | 
<A HREF="/www.truck.volvo.se">Volvo Truck</A> | 
<A HREF="/www.bus.volvo.se/index.html">Volvo Bus</A> | 
<A HREF="/www.vce.volvo.se">Volvo Construction Equipment</A> ]<BR>
[ <A HREF="/www.penta.volvo.se">Volvo Penta</A> | 
<A HREF="/www.aero.volvo.se/index.html">Volvo Aero</A> | 
<A HREF="/other/index.html">Other Companies</A> ]
<BR>
[ <a href="/cgi-bin/make_tot_press">News &amp; Press Releases</a> | <a href="/cgi-bin/make_tot_press_old">Old News &amp; Press Releases</a> ]
<br>
[ <a href="/cgi-bin/make_tot_press_se">Some Swedish News &amp; Press Releases</a> | <a href="/cgi-bin/make_tot_press_se_old">Some Swedish Old News &amp; Press Releases</a> ]
<br>
<br>
[ <a href="/">Volvo Group Homepage</a> |
<a href="#top_of_page">Top of page</a> ]
<p>
<hr>
<br>
<A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se] <br>
<a name="end_of_page"></a>
<br>
<hr>
</center>
</BODY>
</html>

</DOC>
<DOC>
<DOCNO>WT08-B13-190</DOCNO>
<DOCOLDNO>IA055-000921-B042-107</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/environment/1990.html 192.138.110.240 19970208031243 text/html 2418
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 03:12:54 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 2247
Last-modified: Thu, 13 Jun 1996 14:45:53 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Volvo Environment Prize 1990</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="prize.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>
</TR>

<TR>
	<TD><HR></TD>
</TR>

</TABLE>

<BR>
<BR>

<TABLE BORDER=0 CELLPADDING=10 WIDTH=490>


<TR>
	<TD COLSPAN=2 ALIGN=CENTER VALIGN=BOTTOM><IMG BORDER=1 HSPACE=10 WIDTH=80 
	HEIGHT=90 SRC="/images/environment/krutilla.gif">
	<B><FONT SIZE=7>1990</FONT></B>
	<IMG BORDER=1 HSPACE=10 WIDTH=80 HEIGHT=90 SRC="/images/environment/kneese.gif"></TD>
</TR>

<TR>
	<TD ALIGN=RIGHT><IMG BORDER=1 WIDTH=198 HEIGHT=138 
	SRC="/images/environment/prize.krutilla.gif"></TD>
	<TD ALIGN=LEFT><IMG BORDER=1 WIDTH=198 HEIGHT=138 
	SRC="/images/environment/prize.kneese.gif"></TD>
</TR>

<TR VALIGN=TOP>
	<TD>
	The first Volvo 
	Environment Prize was awarded to <B>professors</B> <B>John V. Krutilla
	</B> and <B>Allen V. Kneese</B>, both of the USA, who founded resource and 
	environmental economics as a research discipline. The two Laureates lead the 
	field in combining the sciences of economics and ecology, by systematically 
	analysing the various aspects of environmental impact within the current 
	economic system.
	</TD>
	<TD>
	<B>The Prize Committee's motivation:</B><BR>
	"Professor Krutilla and Professor Kneese were pioneers in developing the theory 
	of environmental economics and in demonstrating how the theory can be applied 
	to influence public policy decisions on various concrete issues. Their work laid 
	the foundation for a growing body of research on and knowledge about the complex 
	relationship between the environment and the economy."
	</TD>
</TR>

</TABLE>

<BR>
<BR>

<TABLE BORDER=0 WIDTH=490>

<TR>
	<TD><HR></TD>
</TR>

<TR>
	<TD>Source: Volvo Environment Prize</TD>
</TR>

<TR>
	<TD>

<P>

<BR>
</BLOCKQUOTE>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]

</TD>
</TR>

</TABLE>

</CENTER>

</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-191</DOCNO>
<DOCOLDNO>IA055-000921-B042-145</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/environment/1991.html 192.138.110.240 19970208031259 text/html 2158
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 03:13:08 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 1987
Last-modified: Thu, 13 Jun 1996 14:45:54 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Volvo Environment Prize 1991</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="prize.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>
</TR>

<TR>
	<TD><HR></TD>
</TR>

</TABLE>

<BR>
<BR>


<TABLE BORDER=0 CELLPADDING=10 WIDTH=490>

<TR>
	<TD ALIGN=LEFT VALIGN=BOTTOM><IMG BORDER=1 HSPACE=10 WIDTH=80 
	HEIGHT=90 SRC="/images/environment/crutzen.gif">
	<B><FONT SIZE=7>1991</FONT></B></TD>
	<TD ROWSPAN=2 VALIGN=BOTTOM>
	The 1991 Prize was awarded to <B>Professor</B> <B>Paul Crutzen</B> of 
	the Max Planck Institute of Chemistry in Mainz, Germany, one of the world's 
	leading research scientists in the field of atmospheric chemistry. Professor 
	Crutzen has achieved this eminence by undertaking a series of major research 
	projects over a period of more than 20 years, including studies of ozone layer 
	depletion and the greenhouse effect.<BR>
	<BR>
	
	<B>The Prize Committee's motivation:</B><BR>
	"Professor Crutzen was awarded the Prize for an outstanding ability to identify 
	and elucidate critical features governing the chemical behaviour of the 
	atmosphere. He has shown great ability to excel in a wide scope of interrelated 
	research activities in topics relevant to atmospheric science."
	</TD>
</TR>

<TR>
	<TD ALIGN=LEFT><IMG BORDER=1 WIDTH=198 HEIGHT=138 HSPACE=10 
	SRC="/images/environment/prize.crutzen.gif"></TD>
</TR>

</TABLE>

<BR>
<BR>

<TABLE BORDER=0 WIDTH=490>

<TR>
	<TD><HR></TD>
</TR>

<TR>
	<TD>Source: Volvo Environment Prize</TD>
</TR>

<TR>
	<TD>

<P>

<BR>
</BLOCKQUOTE>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]

</TD>
</TR>
</TABLE>

</CENTER>


</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-192</DOCNO>
<DOCOLDNO>IA055-000921-B042-171</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/environment/1992.html 192.138.110.240 19970208031318 text/html 2490
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 03:13:30 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 2319
Last-modified: Thu, 13 Jun 1996 14:45:55 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Volvo Environment Prize 1992</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="prize.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>
</TR>

<TR>
	<TD><HR></TD>
</TR>

</TABLE>

<BR>
<BR>

<TABLE BORDER=0 CELLPADDING=10 WIDTH=490>

<TR>
	<TD COLSPAN=2 ALIGN=CENTER VALIGN=BOTTOM><IMG BORDER=1 HSPACE=10 WIDTH=80 
	HEIGHT=90 SRC="/images/environment/myers.gif">
	<B><FONT SIZE=7>1992</FONT></B>
	<IMG BORDER=1 HSPACE=10 WIDTH=80 HEIGHT=90 SRC="/images/environment/raven.gif"></TD>
</TR>

<TR>
	<TD ALIGN=RIGHT><IMG BORDER=1 WIDTH=198 HEIGHT=138 
	SRC="/images/environment/prize.myers.gif"></TD>
	<TD ALIGN=LEFT><IMG BORDER=1 WIDTH=198 HEIGHT=138 
	SRC="/images/environment/prize.raven.gif"></TD>
</TR>

<TR VALIGN=TOP>
	<TD>
	The 1992 Laureates were <B>Dr.</B> <B>Norman Myers</B> and <B>Professor 
	Peter H. Raven</B>, for their efforts to promote international awareness of 
	the crucial importance of 
	biodiversity to the earth's environment. A British zoologist, Dr. Myers was 
	one of the first to understand and warn of the global threat posed by the 
	destruction of the tropical rain forests. Professor Raven is an American 
	botanist and 
	specialist in the evolution of plant species.
	</TD>
	<TD>
	<B>The Prize Committee's motivation:</B><BR>
	"The Prize was awarded to Dr. Norman Myers and Professor Peter H. Raven who 
	between them used comprehensive and penetrating scientific analysis of ecological 
	states and trends and made pioneering warnings and courageous expressions of concern 
	which have sensitized world opinion to the global consequences of the loss of 
	biodiversity and the process of deforestation, particularly in tropical regions."
	</TD>
</TR>

</TABLE>

<BR>
<BR>

<TABLE BORDER=0 WIDTH=490>

<TR>
	<TD><HR></TD>
</TR>

<TR>
	<TD>Source: Volvo Environment Prize</TD>
</TR>

<TR>
	<TD>

<P>

<BR>
</BLOCKQUOTE>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]

</TD>
</TR>
</TABLE>

</CENTER>

</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-193</DOCNO>
<DOCOLDNO>IA089-000951-B022-97</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/environment/1993.html 192.138.110.240 19970208031332 text/html 2393
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 03:13:42 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 2222
Last-modified: Thu, 13 Jun 1996 14:45:56 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Volvo Environment Prize 1993</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="prize.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>
</TR>

<TR>
	<TD><HR></TD>
</TR>

</TABLE>

<BR>
<BR>

<TABLE BORDER=0 CELLPADDING=10 WIDTH=490>

<TR>
	<TD COLSPAN=2 ALIGN=CENTER VALIGN=BOTTOM><IMG BORDER=1 HSPACE=10 WIDTH=80 
	HEIGHT=90 SRC="/images/environment/ehrlich.gif">
	<B><FONT SIZE=7>1993</FONT></B>
	<IMG BORDER=1 HSPACE=10 WIDTH=80 HEIGHT=90 SRC="/images/environment/holdren.gif"></TD>
</TR>

<TR>
	<TD COLSPAN=2 ALIGN=CENTER><IMG BORDER=1 WIDTH=198 HEIGHT=138 
	SRC="/images/environment/prize.ehrlich.gif"></TD>
</TR>

<TR>
	<TD VALIGN=TOP>
	In 1993, the Prize went to <B>Professor Paul R. Ehrlich</B> of Stanford 
	University and <B>Professor John P. Holdren</B> of the University of California 
	in Berkeley, whose work laid the foundations of our understanding of how the 
	dynamics of population growth, rising living standards and changing technology, 
	as well as the relationships between them, 
	interact in the context of environmental problems.
	</TD>
	<TD>
	<B>The Prize Committee's motivation:</B><BR>
	"This year's Prize is awarded to an evolutionary biologist, Professor Paul R. 
	Ehrlich, and an energy resources scientist, Professor John P. Holdren, for 
	their outstanding and pioneering contributions to our understanding of the 
	threats to human development and survival, particularly those arising from the 
	rapid growth of populations in developing countries and of the high level of 
	per capita resource consumption in industrialized countries."
	</TD>
</TR>

</TABLE>

<BR>
<BR>

<TABLE BORDER=0 WIDTH=490>

<TR>
	<TD><HR></TD>
</TR>

<TR>
	<TD>Source: Volvo Environment Prize</TD>
</TR>

<TR>
	<TD>
<P>

<BR>
</BLOCKQUOTE>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]

</TD>
</TR>
</TABLE>

</CENTER>

</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-194</DOCNO>
<DOCOLDNO>IA089-000951-B022-126</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/environment/1994.html 192.138.110.240 19970208031344 text/html 2135
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 03:13:53 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 1964
Last-modified: Thu, 13 Jun 1996 14:45:57 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Volvo Environment Prize 1994</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="prize.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>
</TR>

<TR>
	<TD><HR></TD>
</TR>

</TABLE>

<BR>
<BR>

<TABLE BORDER=0 CELLPADDING=5 WIDTH=490>

<TR>
	<TD ALIGN=CENTER VALIGN=BOTTOM COLSPAN=2><IMG BORDER=1 HSPACE=10 WIDTH=80 
	HEIGHT=90 SRC="/images/environment/sen.gif"><B><FONT SIZE=7>1994</FONT></B></TD>
</TR>

<TR>
	<TD ALIGN=CENTER COLSPAN=2><IMG BORDER=1 WIDTH=198 HEIGHT=138 
	SRC="/images/environment/prize.sen.gif"></TD>
</TR>

<TR VALIGN=TOP>
	<TD>
	The 1994 Laureate was <B>Dr. Gita Sen</B> of the Indian Institute of 
	Management in Bangalore. Dr. Sen's pioneering research has created a broader 
	understanding of the manner in which the relationship between environment 
	and development is conditioned by social structures and, in particular, 
	by the changing role of women within them.
	</TD>
	
	<TD>
	<B>The Prize Committee's motivation:</B><BR>
	"Dr. Sen's outstanding contribution takes the rich body of scholarship on how 
	patterns of resource exploitation are affected by household- and community-level 
	partitioning of rights and ownership, and successfully connects it to crucial 
	national and international policy debates on population growth, the status of 
	women, and sustainable development."
	</TD>
</TR>

</TABLE>

<BR>
<BR>

<TABLE BORDER=0 WIDTH=490>

<TR>
	<TD><HR></TD>
</TR>

<TR>
	<TD>Source: Volvo Environment Prize</TD>
</TR>

<TR>
	<TD>

<P>

<BR>
</BLOCKQUOTE>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]

</TD>
</TR>
</TABLE>

<CENTER>

</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-195</DOCNO>
<DOCOLDNO>IA089-000951-B022-154</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/environment/1995.html 192.138.110.240 19970208031359 text/html 2484
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 03:14:09 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 2313
Last-modified: Thu, 13 Jun 1996 14:45:58 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Volvo Environment Prize 1995</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="prize.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>
</TR>

<TR>
	<TD><HR></TD>
</TR>

</TABLE>

<BR>
<BR>

<TABLE BORDER=0 CELLPADDING=5 WIDTH=490>

<TR>
	<TD COLSPAN=2 ALIGN=CENTER VALIGN=BOTTOM><IMG BORDER=1 HSPACE=10 WIDTH=80 
	HEIGHT=90 SRC="/images/environment/white.gif"><B><FONT SIZE=7>1995</FONT></B></TD>
</TR>

<TR>
	<TD ALIGN=CENTER COLSPAN=2><IMG BORDER=1 WIDTH=198 HEIGHT=138 
	SRC="/images/environment/prize.white.gif"></TD>
</TR>

<TR VALIGN=TOP>
	<TD>
	The 1995 Volvo Environment Prize was awarded to <B>Professor Gilbert F. 
	White,</B> University of Colorado, USA, who has been studying major 
	environmental issues in a wide number of fields for over six decades. 
	Professor White is known especially for his work in the area of water 
	management which he has broadened to embrace issues of international 
	resource and hazard management. Over the years, he has been a source 
	of inspiration to generations of students, many of whom have since 
	achieved international recognition as leaders in environmental and 
	developmental affairs.
	</TD>
	
	<TD>
	<B>The Prize Committee's motivation:</B><BR>
	"From his pioneering work during the 1930s on natural resource planning, 
	with special attention to flood plain management, to his superlative 
	leadership in directing wide-ranging programs in natural hazards at the 
	University of Chicago in the 1960s, right through to his important work at 
	the University of Colorado on radioactive-waste management in the 1990s, 
	his career has been studded with accomplishments of extraordinary 
	significance."
	</TD>
</TR>

</TABLE>

<BR>
<BR>

<TABLE BORDER=0 WIDTH=490>

<TR>
	<TD><HR></TD>
</TR>

<TR>
	<TD>Source: Volvo Environment Prize</TD>
</TR>

<TR>
	<TD>
	
<P>

<BR>
</BLOCKQUOTE>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]

</TD>
</TR>
</TABLE>

</CENTER>

</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-196</DOCNO>
<DOCOLDNO>IA089-000951-B022-188</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/environment/1996.html 192.138.110.240 19970208031412 text/html 1917
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 03:14:21 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 1746
Last-modified: Tue, 03 Sep 1996 15:22:56 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Volvo Environment Prize 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="prize.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>
</TR>

<TR>
	<TD><HR></TD>
</TR>

</TABLE>

<BR>
<BR>

<TABLE BORDER=0 CELLPADDING=5 WIDTH=490>

<TR>
	<TD COLSPAN=2 ALIGN=CENTER VALIGN=BOTTOM><IMG BORDER=1 HSPACE=10 WIDTH=80 
	HEIGHT=90 SRC="/images/environment/lovelock.gif"><B><FONT SIZE=7>1996</FONT></B></TD>
</TR>


<TR VALIGN=TOP>
	<TD>
	The Volvo Environment Prize for 1996 is awarded to <B>Dr. James E. Lovelock,</B> 
	F.R.S., for his invention of the Electron Capture and Photo-ionisation 
	Detectors, nowadays indispensable tools in modern analytical chemistry 
	and essential for the recognition and measurement of minute traces of 
	pollutant substances and other chemical compounds in the environment.
	</TD>
	
	<TD>
	Using these detectors, Dr. Lovelock's initial discoveries of the regional 
	and global movements of contaminants in the atmosphere helped to lay the 
	foundation for subsequent international work on stratospheric ozone 
	depletion and long-range transboundary air pollution.
	</TD>
</TR>

</TABLE>

<BR>
<BR>

<TABLE BORDER=0 WIDTH=490>

<TR>
	<TD><HR></TD>
</TR>

<TR>
	<TD>Source: Volvo Environment Prize</TD>
</TR>

<TR>
	<TD>
	
<P>

<BR>
</BLOCKQUOTE>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]

</TD>
</TR>
</TABLE>

</CENTER>

</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-197</DOCNO>
<DOCOLDNO>IA089-000951-B022-210</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/environment/nomination.html 192.138.110.240 19970208031421 text/html 1813
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 03:14:32 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 1642
Last-modified: Thu, 13 Jun 1996 14:46:34 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Nomination Form</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF" vlink=000000>

<CENTER>

<FONT SIZE=3>NOMINATION FORM</FONT><BR>
<IMG BORDER=0 VSPACE=5 WIDTH=113 HIGHT=17 SRC="/images/logobl1.gif"><BR>
<FONT SIZE=5><I>Environment Prize</I></FONT><BR>
</CENTER>
<BR>
<BR>

The Volvo Environment Prize is awarded for outstanding innovations or
discoveries which have a direct or indirect sibnificance in the environmental 
field and are of global or regional importance.<BR>
<BR>
<BR>

We hereby nominate for the VOLVO ENVIRONMENT PRIZE:<BR>
<BR>
NOMINEE'S NAME:<BR>
<HR SIZE=1>
<BR>
OCCUPATIONAL TITLE AND INSTITUTION:<BR>
<HR SIZE=1>
<BR>
<HR SIZE=1>
<BR>
ADDRESS:<BR>
<HR SIZE=1>
<BR>
<HR SIZE=1>
<BR>
OFFICE AND PRIVATE TELEPHONE:<BR>
<HR SIZE=1>
<BR>
NATIONALITY:<BR>

<HR SIZE=1><BR>
<BR>
PLEASE PROVIDE (in English, please)<BR>
<BR>
<UL>
	<LI>nominee's name and curriculum vitae
	
	<LI>summary of accomplishment(s)
	
	<LI>if possible, detailed description of contribution(s)
</UL>
<BR>
<BR>
<BR>
<BR>
Nominations for the 1996 Volvo Enviroment Prize must be recived no later than  
<B>15 January 1996.</B><BR>
<BR>
Your, title, organizatin, address and telephone number:<BR>
<HR SIZE=1>
<BR>
<HR SIZE=1>
<BR>

Signature<BR>
<HR SIZE=1>
<BR>

<TABLE BORDER=0 WIDTH=100%>
<TR VALIGN=TOP>
	<TD>Mail to:</TD>
	<TD>The Volvo Enviroment Prize Foundation<BR>
	Ms. Eeva-Liisa Book<BR>
	Environmential Affairs<BR>
	AB Volvo<BR>
	351 VHK<BR>
	S-405 08 G&ouml;teborg<BR>
	Sweden</TD>
	<TD>Telephone: +46 31 59 44 33<BR>
	Telex: 27000 VOLVO S<BR>
	Fax: +46 31 59 10 44<BR>
	E-mail: vhk.elb@memo.volvo.se</TD>
</TR>
</TABLE>
</BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-198</DOCNO>
<DOCOLDNO>IA089-000951-B022-232</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/environment/report.95/introduction.html 192.138.110.240 19970208031429 text/html 4181
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 03:14:41 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 4010
Last-modified: Thu, 27 Jun 1996 16:07:39 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Introduction</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>

<TR>
	<TD><HR></TD>
</TR>

<TR>
	<TD>

<BLOCKQUOTE>

<!-- ---- DIAGRAM 1 ---- -->

<BR>
<BR>

<P ALIGN="LEFT">
<FONT SIZE=5>Introduction</FONT>


<P ALIGN="LEFT">
This report deals with the Volvo Group's automotive operations worldwide and 
has been published every year since 1991 as a complement to the annual report. 
Its main purposes are to supply our employees and customers with information 
about Volvo's environmental programmes, and to contribute to public debate 
in the area. The report also provides us with a valuable tool for evaluating 
environmental activities in our own production plants.

<P ALIGN="LEFT">
The report describes how environmental programmes are implemented at 
Volvo, including the environmental management and other systems which we use. 
For example, environmental management systems were implemented in three of 
our plants in 1995, and will be initiated in twenty other production plants 
and units in 1996.

<P ALIGN="LEFT">
Life-cycle assessment (LCA) is becoming increasingly important as a 
tool for evaluating the total environmental impact of our products. Volvo 
Car Corporation (VCC) is using LCA in its current car development projects.

<P ALIGN="LEFT">
The environmental impact of our production plants is described in 
much greater detail than in previous reports. The scope of reporting will 
be expanded and improved even further as better monitoring procedures are 
introduced.

<P ALIGN="LEFT">
&#009;Since about 80-90% of the life-cycle environmental impact of a 
conventional motor vehicle is generated during its useful life, we 
have devoted considerable space to the issues which are of main concern 
in this context. In the chapter entitled <I>Products in use,</I> these are dealt 
with under the headings of <I>Energy, Engine development, Products and 
concepts,</I> and <I>Transport efficiency.</I> Waste management is the subject of a 
separate chapter.

<P ALIGN="LEFT">
The report also describes Volvo's environmental goals and action 
programmes, highlighting some of the environment-related societal factors 
which may present us with opportunities as well as challenges in the future.

<P ALIGN="LEFT">
No internationally accepted 
standards of environmental reporting have yet been established, nor has the 
format of our own report yet been finalised. For example, although this year's 
report is the most comprehensive to date, it does not deal with the 
environment-related costs for which the Volvo Group is now, or may in future, 
be responsible.

<P ALIGN="LEFT">
The Volvo environmental report for 1995 has been published in Swedish, 
English, German, French and Chinese. If you would like to order any
of these language versions, please access <A HREF="knowmore.html">(Want to know more?)</A>


<P ALIGN="LEFT">
The environmental manager in the company concerned or at Volvo 
headquarters will be happy to answer any questions you may have on Volvo's 
environmental programmes.

<P ALIGN="LEFT">
The report does not deal with the operations of AB Fortos or its 
subsidiaries.


<!-- -------- -->
<BR>
<BR>
<BR>
<BR>
<P ALIGN=CENTER>
[ <A HREF="politik.html">Next chapter of the Environmental Report </A>| <BR>
 Previous chapter of the Environmental Report ]<BR> 
<BR>
<BR>
<P ALIGN=LEFT>
<HR ALIGN=LEFT WIDTH=447>
<BR>

<TABLE BORDER=0 WIDTH=450>

<TR>
	<TD>Source: Volvo Environmental Report 1995</TD>
</TR>

</TABLE>

<P>

</BLOCKQUOTE>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]

</TD>
</TR>
</TABLE>

</CENTER>


</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-199</DOCNO>
<DOCOLDNO>IA089-000951-B022-269</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/environment/report.95/politik.html 192.138.110.240 19970208031455 text/html 3848
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 03:15:05 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 3677
Last-modified: Mon, 17 Jun 1996 13:28:52 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Volvo's environmental policy</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>

<TR>
	<TD><HR></TD>
</TR>

<TR>
	<TD>

<BLOCKQUOTE>

<!-- ---- DIAGRAM 1 ---- -->
<BR>
<BR>

<P ALIGN="LEFT">
<FONT SIZE=5>Volvo's environmental policy</FONT>

<P ALIGN="LEFT">
Industrial activities and transportation not only 
require capital investment, raw materials and labour - they also
consume environmental resources.

<P ALIGN="LEFT">
All industrial operations have an 
impact on the environment. Landscapes are altered in appearance. Air and water 
quality is impaired. Noise and waste create problems. 

<P ALIGN="LEFT">
All types of land, sea and air 
transport have adverse environmental effects, mainly in the form of exhaust 
gas and noise emissions. 

<P ALIGN="LEFT">
Volvo's activities in the transport sector are such that its production 
processes, as well as its products, demand environmental resources.

<P ALIGN="LEFT">
High profitability creates scope for rational, environment-oriented 
investment in production and products. Effective environmental programmes, 
in turn, provide a basis for long-term profitability and satisfactory economic 
growth. These programmes, whether short or long-term, must be implemented at a 
high target level and must be designed - in terms of both time and scope - so 
that they contribute to Volvo's long-term competitiveness.
<BR>
<BR>

<P ALIGN="LEFT">
Volvo pledges to minimise the environmental impact of its operations by:

<UL>

	<LI>adopting an holistic approach to the environmental impact of its products;<BR>
	<BR>


	<LI>developing and marketing products which possess the most favourable 
	environmental properties and which meet the highest possible efficiency 
	standards;<BR>
	<BR>


	<LI>adopting production processes which are as environmentally sound as 
	possible;<BR>
	<BR>


	<LI>specifying environmentally sound, recyclable materials in the development 
	and manufacture of its products;<BR>
	<BR>

	<LI>working to develop efficient transport systems having minimum 
	environmental impact;<BR>
	<BR>


	<LI>seeking to ensure that its production processes and products comply with 
	comparable environmental standards, wherever in the world the company operates;<BR>
	<BR>

	<LI>seeking to ensure that a similar degree of environmental concern is 
	exercised by its working partners;<BR>
	<BR>


	<LI>pursuing and participating in research and development activities in the 
	environmental field;<BR>
	<BR>


	<LI>providing information on the environmental impact of its operations 
	in an open and factual manner.<BR>
	<BR>
</UL>

<P ALIGN="LEFT">
Each company head is responsible for implementing action programmes based 
on this policy.

<P ALIGN="LEFT">
Authorised as of 13 October 1994.


<!-- -------- -->
<BR>
<BR>
<BR>
<BR>
<P ALIGN=CENTER>
[ <A HREF="framtid.html">Next chapter of the Environmental Report</A> |<BR>
<A HREF="introduction.html">Previous chapter of the Environmental Report</A> ] 
<BR>
<BR>
<P ALIGN=LEFT>
<HR ALIGN=LEFT WIDTH=447>
<BR>

<TABLE BORDER=0 WIDTH=450>

<TR>
	<TD>Source: Volvo Environmental Report 1995</TD>
</TR>

</TABLE>

<P>

</BLOCKQUOTE>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]

</TD>
</TR>
</TABLE>

</CENTER>


</BODY>
</HTML>






</DOC>
<DOC>
<DOCNO>WT08-B13-200</DOCNO>
<DOCOLDNO>IA089-000951-B022-297</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/environment/report.95/framtid.html 192.138.110.240 19970208031516 text/html 3964
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 03:15:21 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 3793
Last-modified: Mon, 17 Jun 1996 13:28:15 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Towards the future</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>

<TR>
	<TD><HR></TD>
</TR>

<TR>
	<TD>

<BLOCKQUOTE>

<!-- ---- DIAGRAM 1 ---- -->
<BR>
<BR>


<P ALIGN="LEFT">
<FONT SIZE=5>Towards the future</FONT>

<P ALIGN="LEFT">
The United Nations Conference on 
Environment &amp; Development held in Rio de Janeiro in 1992 placed 
environmental issues high on the agenda of politicians, companies, organisations 
and nations once and for all.

<P ALIGN="LEFT">
Recognition of the consequences of global problems, such as the 
growing seriousness of the greenhouse effect, depletion of the ozone layer, 
and the acidification of soil and water, has had a powerful effect on the 
thinking of all concerned. A high degree of unanimity also exists regarding 
the need for cooperation across boundaries at all levels to solve the problems.

<P ALIGN="LEFT">
We in the automotive industry have a particular responsibility in 
this area.

<P ALIGN="LEFT">
Today, the car is an integral part of our western way of life, and 
has come to symbolise freedom and quality of life in a manner quite unlike 
any other product. Trucks and buses have created new conditions for 
efficient transport which, in turn, has had a decisive 
influence on economic growth and social development. At present, the 
transport sector as a whole accounts for approximately 40% of the world's 
oil consumption, and road traffic is one of the major sources of emissions 
of substances such as nitrogen oxides, hydrocarbons and anthropogenic 
carbon dioxide.

<P ALIGN="LEFT">
Environmental issues are accorded a very high priority by Volvo. 
<I>Quality, Safety</I> and <I>Environment</I> are the three core values on which 
our entire operation is founded. Among other 
factors, this is based on the conviction that those companies which 
best meet the environmental challenges of 
tomorrow will be uniquely placed to achieve long-term growth and 
profitability.

<P ALIGN="LEFT">
Our aim is to become, and to be considered as, one of the world's 
leading automotive manufacturers in the environmental field by the 
year 2000. The achievement of this goal calls for an holistic view of 
the environment - a view which not only permeates the entire work of our 
organisation, but extends to the 
environmental impact of every phase in the life cycle of our products. The 
Volvo action programme contains a series of concrete measures which will 
bring us - step by step - closer to our goal. Much remains to be done; 
however, I hope that this report will show that we have made significant 
progress along the road.

<BR>
<BR>

<IMG ALIGN=RIGHT BORDER=0 HEIGHT=155 WIDTH=155 SRC="/images/environment/report.95/gyll_rund.gif">
<IMG BORDER=0 HEIGHT=59 WIDTH=88 SRC="/images/environment/report.95/gyll.gif">

<BR>
<P ALIGN="LEFT">
S&ouml;ren Gyll

<P ALIGN="LEFT">
President, AB Volvo and CEO


<!-- -------- -->
<BR>

<BR>
<BR>
<BR>
<BR>
<P ALIGN=CENTER>
[ <A HREF="internat.html">Next chapter of the Environmental Report</A> |<BR>
<A HREF="politik.html">Previous chapter of the Environmental Report</A> ]
<BR>
<BR>
<P ALIGN=LEFT>
<HR ALIGN=LEFT WIDTH=447>
<BR>

<TABLE BORDER=0 WIDTH=450>

<TR>
	<TD>Source: Volvo Environmental Report 1995</TD>
</TR>

</TABLE>

<P>

</BLOCKQUOTE>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]

</TD>
</TR>
</TABLE>

</CENTER>


</BODY>
</HTML>






</DOC>
<DOC>
<DOCNO>WT08-B13-201</DOCNO>
<DOCOLDNO>IA089-000951-B023-6</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/environment/report.95/internat.html 192.138.110.240 19970208031531 text/html 2630
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 03:15:42 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 2459
Last-modified: Mon, 01 Jul 1996 13:26:43 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Volvo - an international group</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>

<TR>
	<TD><HR></TD>
</TR>

<TR>
	<TD>

<BLOCKQUOTE>

<!-- ---- DIAGRAM 1 ---- -->
<BR>
<BR>

<P ALIGN="LEFT">
<FONT SIZE=5>Volvo - an international group</FONT>

<P ALIGN="LEFT">
Volvo is one of the most international 
companies in the automotive industry and one of the biggest industrial 
groups in Scandinavia.

<P ALIGN="LEFT">
Founded in 1927, its main operations today are the manufacture of 
cars, trucks, buses, construction equipment, marine and industrial 
engines, and aircraft engines.

<P ALIGN="LEFT">
The Group has production facilities in 23 countries and is active 
in over 100 markets. Markets other than Sweden account for approximately 
90% of its sales of automotive products.

<P ALIGN="LEFT">
<IMG WIDTH=447 HEIGHT=300 SRC="/images/environment/report.95/karta.gif">
<IMG ALIGN=LEFT HSPACE=10 WIDTH=200 HEIGHT=398 SRC="/images/environment/report.95/karta_swe.gif">
<B>Key figures 1995</B><BR>


Automotive operations, total:<BR>


No. of employees at year end: 72,010<BR>


Sales: SEK154,496 million<BR>


Operating income: SEK7,493 million<BR>


Research and development costs: SEK7,151 million<BR>


Capital expenditure: SEK 8,171 million*<BR>

Invoiced sales, cars: 374,600<BR>

Invoiced sales, trucks: 76,500<BR>

Invoiced sales, buses: 6,830<BR>

<P ALIGN="LEFT">
<FONT SIZE=2>*Including capital expenditure on leasing and company vehicles 
totalling SEK2,585 million</FONT>


<!-- -------- -->
<BR>
<BR>
<BR>
<BR>
<!-- <TABLE BORDER=0 WIDTH=450> -->
</TD>
</TR>

<TR>
	<TD><BR>
<BR>
<BR>
<BR>
<P ALIGN=CENTER>
[ <A HREF="miljoarb.html">Next chapter of the Environmental Report</A> |<BR>
<A HREF="framtid.html">Previous chapter of the Environmental Report</A> ]
<BR>
<BR>
<P ALIGN=LEFT>

<BLOCKQUOTE>
<HR ALIGN=LEFT WIDTH=447>
<BR>

Source: Volvo Environmental Report 1995</TD>
</TR>

<TR>
	<TD>
<P>

</BLOCKQUOTE>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]

</TD>
</TR>
</TABLE>

</CENTER>


</BODY>
</HTML>






</DOC>
<DOC>
<DOCNO>WT08-B13-202</DOCNO>
<DOCOLDNO>IA089-000951-B023-35</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/environment/report.95/miljoarb.html 192.138.110.240 19970208031541 text/html 3801
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 03:15:52 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 3630
Last-modified: Mon, 17 Jun 1996 13:28:41 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Volvo's environmental programmes</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>

<TR>
	<TD><HR></TD>
</TR>

<TR>
	<TD>

<BLOCKQUOTE>

<!-- ---- DIAGRAM 1 ---- -->
<BR>
<BR>

<P ALIGN="LEFT">
<FONT SIZE=5>Volvo's environmental programmes</FONT>

<P ALIGN="LEFT">
Volvo's environmental organisation is 
a combination of line functions, networks, working groups and project 
groups. Since its aim is to further the integration of environmental 
activities in the line organisation, local responsibility for 
environmental affairs is vested in the appropriate line managers.
<BR>
<BR>
<BR>

<P ALIGN="CENTER">
<IMG WIDTH=447 HEIGHT=245 SRC="/images/environment/report.95/miljo_dia1.gif">
<BR>
<BR>
<BR>

<P ALIGN="LEFT">
An environmental council responsible for developing strategies 
and action programmes within the framework of Volvo's environmental 
policy has been established in each company and in most of the 
production plants. An environmental coordinator has also been appointed 
within each main unit to direct and evaluate environmental programmes 
at local level. In other respects, the organisation of environmental 
activities in the operating sectors is somewhat different. For example, 
VCC has established a dedicated central department - Environment - 
to develop goals and strategies, and to provide support for all of the 
company's activities. In addition, managers with environmental 
responsibility, as well as specialists, are integrated in the line 
organisation. The other operating sectors have opted for a more 
decentralised approach, in which managers with environmental 
responsibility and specialists are both integrated in the line 
organisation, and coordination is exercised by a small staff 
headed by an environmental manager. The Volvo Group Environmental 
Council is responsible for framing the Group's environmental 
policy, developing common guidelines and objectives, and for other 
Group-wide matters. The council also monitors the operating sectors' 
strategic environmental affairs, and ensures that the Group's 
environmental programmes are implemented in accordance with its own 
stated policy and with other relevant programmes. Several working groups 
and project groups common to the Group are associated with the Group 
council. These deal with issues relating to production, environmental 
policy and communications, environmental economics, climate change, 
and the introduction of environmental management and monitoring 
systems. Group-wide environmental issues of major strategic 
importance are processed by the Group council and submitted for 
decision to the Group Issue Board for Core Values, whose members 
are drawn from the Group Executive Committee.


<!-- -------- -->
<BR>
<BR>
<BR>
<P ALIGN=CENTER>
[ <A HREF="verktyg.html">Next chapter of the Environmental Report</A> |<BR>
<A HREF="internat.html">Previous chapter of the Environmental Report</A> ]
<BR>
<BR>
<P ALIGN=LEFT>

<HR ALIGN=LEFT WIDTH=447>
<BR>

<TABLE BORDER=0 WIDTH=450>

<TR>
	<TD>Source: Volvo Environmental Report 1995</TD>
</TR>

</TABLE>

<P>

</BLOCKQUOTE>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]

</TD>
</TR>
</TABLE>

</CENTER>


</BODY>
</HTML>






</DOC>
<DOC>
<DOCNO>WT08-B13-203</DOCNO>
<DOCOLDNO>IA089-000951-B023-64</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/environment/report.95/verktyg.html 192.138.110.240 19970208031553 text/html 9853
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 03:16:02 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 9682
Last-modified: Mon, 17 Jun 1996 13:29:23 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Tools</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>

<TR>
	<TD><HR></TD>
</TR>

<TR>
	<TD>

<BLOCKQUOTE>

<!-- ---- DIAGRAM 1 ---- -->
<BR>
<BR>

<P ALIGN="LEFT">
<FONT SIZE=5>Tools</FONT>

<P ALIGN="LEFT">
A global environmental management system is essential to the implementation 
of consistent and successful environmental programmes in an 
international company. Volvo has developed the Volvo Environmental 
Management System (VEMS) to meet this need. VEMS incorporates all current 
regulations, standards and recommendations, including EMAS, BS7750, 
ISO14001 and the ICC Business Charter for Sustainable Development.

<P ALIGN="LEFT">
Three Volvo plants - the VCC and VTC assembly plants in Ghent, 
Belgium and the VTC/VBC plant at Irvine in Scotland - received 
EMAS verification in 1995. The Irvine plant was also awarded EMAS 
registration by the end of the year, followed shortly after 
(in January 1996) by the Belgian plants, making Volvo one of the 
first companies in Europe to achieve this distinction.

<P ALIGN="LEFT">
A further 20 or so production plants and other Volvo units 
 will begin to implement VEMS in 1996.

<P ALIGN="LEFT">
<B>Environmental audits.</B> Activities at Volvo plants are monitored by the 
Group's own environmental auditor. Compliance with current legislation 
and with Volvo's own requirements is an integral part of the audit, as is 
evaluation of the likely effect of future legislation on the operation. 
Auditing also provides a basis for assessing how effectively Volvo's 
environmental policy is being implemented.

<P ALIGN="LEFT">
The auditing programme also includes the performance of 
environmental reviews preparatory to the introduction of VEMS. 
The activities of certain other companies associated with Volvo - 
such as suppliers, waste processing firms and companies in the 
process of acquisition or sale - are also subject to audit. 
Forty of our plants have undergone environmental auditing since 
1989, resulting in the implementation of a series of 
preventive environmental protection measures.

<P ALIGN="LEFT">
<B>Life-cycle assessment using EPS.</B> Volvo, in collaboration with the 
Federation of Swedish Industries and the Swedish Environmental 
Research Institute (IVL), has developed a life-cycle assessment 
system known as EPS (Environmental Priority Strategies in 
product design).

<P ALIGN="LEFT">
EPS enables the total life-cycle 
impact of a product, from raw materials extraction, through 
manufacture and use, to waste disposal, to be calculated.

<P ALIGN="LEFT">
A common unit known as an ELU (Environmental Load Unit) 
is used to compare and quantify different 
influencing factors. The EPS database includes environmental load 
indices for various materials and processes. These are calculated on 
the basis of their effects on biological diversity and human health, 
whether or not the production methods are sustainable in the long term, 
which natural resources are 
consumed and which aesthetic values are affected. The summated 
environmental load unit for the various 
alternative materials which may be used in production provides a basis 
for selecting the most environmentally favourable design. The EPS system 
is augmented, updated and improved 
continuously. Although used on a 
relatively small scale to date, it is 
gradually becoming more common. VCC uses life-cycle assessment 
based on EPS as part of its current car development projects, with 
the aim of identifying the environmental 
consequences of every major design phase and to make improvements 
on the basis of the findings. Another aim is to calculate the 
total environmental load produced by the car, to measure our overall 
improvement, and to provide customers and the general public with 
information on this aspect.

<P ALIGN="LEFT">
Together with other major Swedish companies, Volvo is a 
cooperative partner in a centre for environmental research at 
Chalmers University of Technology in Gothenburg, focusing on 
the further development of life-cycle assessment.

<P ALIGN="LEFT">
<B>MOTIV</B> (a Swedish acronym for Environment and Toxicology at Volvo) 
is a database containing detailed information on approximately 
5,000 chemical products. The database was established to 
minimise the use of environmentally hazardous substances and to 
simplify the specification of various chemicals. Since the 
information in MOTIV is available to the entire Volvo organisation, 
every unit throughout the world can exchange test findings and 
experience with others.

<P ALIGN="LEFT">
Since the introduction of MOTIV in 1991, the number of 
chemical products purchased by Volvo has been halved and several 
substances have been discontinued for health or environmental reasons.

<P ALIGN="LEFT">
<B>Industry-specific 'blacklists'</B> In 1995, Volvo compiled an 
inventory of the blacklists maintained by authorities 
responsible for monitoring hazardous chemicals in a number of 
countries, while MOTIV has enabled us to prepare a unique register of 
chemical substances of relevance to the automotive industry. From 1996 
on, the company will maintain a blacklist of chemicals 
which are either prohibited or due 
to be phased out, together with a 'grey list' of 
substances whose use is to be restricted. At present, each of these lists 
comprises about 35 substances or groups of substances.

<P ALIGN="LEFT">
<B>Cooperation with suppliers.</B> Since many of the materials, parts 
and components used in Volvo products are developed and manufactured 
outside the Group, it is important that our environmental philosophy 
should extend to the operations of our working partners.

<P ALIGN="LEFT">
Volvo suppliers and contractors must be familiar with the 
Group's environmental policy, and must be prepared to submit a report 
on their own environmental programmes, including information on 
the organisation, relevant statutory requirements, goals, action 
plans and results. Large and strategically important suppliers 
must either fulfil, or submit a timetable for fulfilment of the 
requirements of ISO14001, BS7750 or EMAS.

<P ALIGN="LEFT">
Suppliers must also monitor environmental developments in 
their respective industries, conduct an open dialogue with Volvo 
and report information which may be required, for example, as a 
basis for life-cycle assessment. Packaging and chemicals used 
by suppliers must comply with Volvo's environmental requirements. 
The environmental impact of packaging, waste and surplus 
materials must be minimised, while the feasibility of recovering 
and recycling materials must be considered in all cases before 
specifying designs and materials.

<BR>
<P ALIGN="LEFT">
NEW TOOLS UNDER DEVELOPMENT

<P ALIGN="LEFT">
<B>Monitoring.</B> Work on the development of a system of recording, 
monitoring and evaluating emissions, as well as energy and water 
consumptions, in Volvo production units was initiated in 1995. 
The system, which will also 
include the aspects of organisation and training, is expected to be 
ready for practical implementation in 1997.

<P ALIGN="LEFT">
<B>Environmental economics.</B> Volvo is examining a number of methods of 
reporting the economic results of the Group's environmental activities. 
At present, for example, there exists no clearcut definition of the 
concept of environment-specific investment, and a high proportion of the Group's 
product development costs may equally well be assigned to the 
environmental, economic or technical function if the end product is a 
vehicle offering lower fuel consumption, lower emissions, longer life etc.

<P ALIGN="LEFT">
<B>Environmental database for Volvo dealers.</B> VCC has established an 
environmental database which will enable Volvo dealer personnel to 
develop an environmental profile of each model of car in a simple manner. 
The database will undergo testing successively in a number of markets, 
starting with Sweden and Japan, in 1996.

<BR>
<P ALIGN="LEFT">
<B>Blacklist</B>

<P ALIGN="LEFT">
Chemical substances or groups of substances (numbers in brackets) 
which Volvo has phased out or decided to discontinue:

<UL>

	<LI>Certain aromatic amines (2)<BR>
	<BR>

	<LI>CFC compounds (5)<BR>
	<BR>

	<LI>Asbestos<BR>
	<BR>

	<LI>Brominated flame retardants (PBB, PBDE)<BR>
	<BR>

	<LI>Certain rubber chemicals (4)<BR>
	<BR>

	<LI>Halons (3)<BR>
	<BR>

	<LI>Chlorinated hydrocarbons (5)<BR>
	<BR>

	<LI>Lead chromate<BR>
	<BR>

	<LI>Cadmium<BR>
	<BR>

	<LI>Mercury<BR>
	<BR>

	<LI>Chlorinated paraffins<BR>
	<BR>

	<LI>Certain mineral oils (containing PAH)<BR>
	<BR>

	<LI>Nonylphenol<BR>
	<BR>

	<LI>Nonylphenolethoxilates<BR>
	<BR>

</UL>

<P ALIGN="LEFT">
A detailed list can be obtained by completing and posting the reply card 
at the rear of this report.


<!-- -------- -->
<BR>
<BR>
<BR>
<P ALIGN=CENTER>
[ <A HREF="utbild.html">Next chapter of the Environmental Report</A> |<BR>
<A HREF="miljoarb.html">Previous chapter of the Environmental Report</A> ]
<BR>
<BR>
<P ALIGN=LEFT>

<HR ALIGN=LEFT WIDTH=447>
<BR>

<TABLE BORDER=0 WIDTH=450>

<TR>
	<TD>Source: Volvo Environmental Report 1995</TD>
</TR>

</TABLE>

<P>

</BLOCKQUOTE>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]

</TD>
</TR>
</TABLE>

</CENTER>


</BODY>
</HTML>






</DOC>
<DOC>
<DOCNO>WT08-B13-204</DOCNO>
<DOCOLDNO>IA089-000951-B023-94</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/environment/report.95/utbild.html 192.138.110.240 19970208031603 text/html 8602
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 03:16:14 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 8431
Last-modified: Mon, 17 Jun 1996 13:29:22 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Training and communication</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>

<TR>
	<TD><HR></TD>
</TR>

<TR>
	<TD>

<BLOCKQUOTE>

<!-- ---- DIAGRAM 1 ---- -->
<BR>
<BR>

<P ALIGN="LEFT">

<P ALIGN="LEFT">
<FONT SIZE=5>Training and communication</FONT>

<P ALIGN="LEFT">
Everybody in the organisation must 
be involved if Volvo's environmental policy and objectives are to be 
translated into practice. Interest, knowhow and understanding are 
essential if the correct environmental decisions are to be taken.

<P ALIGN="LEFT">
<B>What do Volvo personnel think?</B> A survey of all Volvo employees was 
conducted over the last three years to determine what personnel think 
of activities such as the company's environmental programmes. The 
findings indicate that over half (52%) are pleased or very pleased 
with the manner in which Volvo exercises its responsibilities in this 
area.
<P ALIGN="LEFT">
<IMG WIDTH=380 HEIGHT=247 VSPACE=7 HSPACE=7 SRC="/images/environment/report.95/utbildning_dia2.gif">


<I>Are you happy with Volvo's approach to environmental protection? 
The percentage of Volvo employees who answered 'Yes' to this question 
varied around the world.</I>

<BR>
<P ALIGN="LEFT">
<B>Dialogue on the environment.</B> In 1995, VCC initiated an environmental 
training programme entitled <I>Dialogue on the environment</I> for all 
employees, suppliers and dealer personnel. The aims of the programme 
are to support the achievement of the company's overall environmental 
goals, stimulate personal involvement and help to develop an holistic 
view of environmental issues, all of which are in complete accordance 
with the underlying philosophy of Agenda 21 and the ICC Business 
Charter for Sustainable Development. The course is given in three 

<IMG ALIGN=RIGHT VSPACE=7 HSPACE=7 WIDTH=220 HEIGHT=165 SRC="/images/environment/report.95/utbildning_dia1.gif">

sessions under the headings of <I>The ecocycle and the environment; Energy, 
transportation and the environment</I> and <I>Volvo Car Corporation and the environment.</I>

<P ALIGN="LEFT">
About 29,000 employees had undergone the first stage of the 
programme by the end of 1995, while other Volvo companies and units 
will also implement the course in 1996. In addition to <I>Dialogue on 
the environment,</I> continuous training and information are also given on 
specific issues.

<P ALIGN="LEFT">
<B>Internal communication.</B> Information is distributed to various 
employee groups on an ongoing basis, for example in the form 
of newsletters from individual Group companies.

<P ALIGN="LEFT">
<B>External communication.</B> The environmental message is a vital 
part of Volvo's external communication 
activities. This includes the provision of regular information 
on the company's environmental programmes and its views on the 
issues involved, as well as active participation in the debate 
on the transport systems and energy sources of the future. As 
a member of several interest groups, Volvo seeks to maintain 
an open dialogue with customers, 
politicians, the mass media and the general public, while collaborating 
with various public agencies in projects designed to evaluate new 
technologies and fuels.

<P ALIGN="LEFT">
The fourth series of <I>Energy, engines and the environment</I> seminars 
organised by VCC for the media and public 
bodies was held in 1995. As part of the programme, topics including 
alternative fuels and propulsion systems, 
chemicals, life-cycle assessment and the environmental specification 
of Volvo cars were discussed with 
journalists from ten different countries.


<P ALIGN="LEFT">
<B>Sustainable transport for the future.</B> Volvo's concept vehicles, the 
Environmental Concept Truck (ECT) and Environmental Concept Bus (ECB), 
have been designed to demonstrate new 
technological approaches to the development of safe, efficient and 
environmentally compatible transport for the future. Volvo's aim in 
presenting the concepts at seminars and lectures on urban development, 
transport efficiency, engine development, fuels and safety, is to 
encourage dialogue with other interests and to promote debate on the 
issues. In 1995, the ECT and ECB were 
demonstrated to customers, politicians, journalists and other groups 
in Sweden, the Netherlands, Belgium, France and the USA.
<BR><BR>
<IMG WIDTH=447 HEIGHT=176 SRC="/images/environment/report.95/utbildning.gif">
<BR>
<BR>

<P ALIGN="LEFT">
<B>Environmental activities of marketing companies.</B> Environmental affairs 
are assuming steadily increasing importance among Volvo's marketing 
companies, both in their internal and external 
operations. For example, Volvo Cars of North America has established a 
working group for environmental affairs, in which independent dealers 
are also represented, and has participated in several national 
environmental 
conferences and media events. According to customer surveys, Volvo 
is the leading foreign automaker in the USA as regards environmental 
matters.

<P ALIGN="LEFT">
In Sweden, several dealers have won acclaim for the environmental 
information and environment-related services which they offer their 
customers. These include free exhaust system testing, the collection 
of scrap materials from DIY enthusiasts and the installation of 
parking heaters as standard equipment.

<P ALIGN="LEFT">
A successful information campaign focusing on anti-pollution 
measures and environmental knowhow was undertaken in Japan. This 
included exhibitions, seminars and prizewinning advertisements. 
Since 1993, the Volvo organisation in Japan - in conjunction with 
the World Wildlife Fund (WWF) - has held an annual essay-writing 
competition for 12 to 18-year-olds on the theme of <I>The environment 
and the future.</I> A total of 32,478 entries was 
received in 1995.

<P ALIGN="LEFT">
The Australian marketing company has produced an information 
brochure entitled <I>A guide to environmental awareness</I>.

<P ALIGN="LEFT">
<B>The working environment and 
industrial health.</B> Volvo has long attached considerable importance to 
the provision of a safe and attractive 
working environment for its employees. This area is the responsibility 
of special units within each operating sector, which will be glad to 
supply further information.<BR>
<BR>
<BR>

<P ALIGN="LEFT">
<B>Environmental training at Volvo</B>

<P ALIGN="LEFT">
<I>Major events, <BR>
1989-95</I>

<P ALIGN="LEFT">
<B><FONT SIZE=4>1989</FONT></B><BR>
Full-day session for Volvo's 400 top managers<BR>
<BR>

<B><FONT SIZE=4>1990 - 95</FONT></B><BR>
Training of management groups at all production plants<BR>
<BR>

<B><FONT SIZE=4>1993</FONT></B><BR>
Twelve hours of training 
for product engineers at VTC<BR>
<BR>

<B><FONT SIZE=4>1993 -</FONT></B><BR>
Annual conference for all environmental coordinators<BR>
<BR>

<B><FONT SIZE=4>1994 - 95</FONT></B><BR>
Training of all 6,000 employees of Volvo production 
plants in Belgium and Britain in conjunction with introduction of EMAS <BR>
<BR>

<B><FONT SIZE=4>1995</FONT></B><BR>
Training of environmental coordinators from all VBC marketing 
companies and VTC's Scandinavian marketing companies<BR>
<BR>

<B><FONT SIZE=4>1995 - 97</FONT></B><BR>
Courses for all VCC 
employees, together with the company's dealers and 
suppliers, totalling 70,000 people in all<BR>
<BR>

<P ALIGN="LEFT">
<B>....providing information on the environmental impact of its 
operations in an open and factual manner...</B>

<P ALIGN="LEFT">
- extract from Volvo's environmental policy

<!-- -------- -->
<BR>
<BR>
<BR>
<P ALIGN=CENTER>
[ <A HREF="produkt.html">Next chapter of the Environmental Report</A> |<BR>
<A HREF="verktyg.html">Previous chapter of the Environmental Report</A> ] 
<BR>
<BR>
<P ALIGN=LEFT>

<HR ALIGN=LEFT WIDTH=447>
<BR>

<TABLE BORDER=0 WIDTH=450>

<TR>
	<TD>Source: Volvo Environmental Report 1995</TD>
</TR>

</TABLE>

<P>

</BLOCKQUOTE>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]

</TD>
</TR>
</TABLE>

</CENTER>


</BODY>
</HTML>






</DOC>
<DOC>
<DOCNO>WT08-B13-205</DOCNO>
<DOCOLDNO>IA089-000951-B023-124</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/environment/report.95/produkt.html 192.138.110.240 19970208031623 text/html 9558
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 03:16:25 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 9387
Last-modified: Mon, 17 Jun 1996 13:29:17 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Production processes and production plants</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>

<TR>
	<TD><HR></TD>
</TR>

<TR>
	<TD>

<BLOCKQUOTE>

<!-- ---- DIAGRAM 1 ---- -->
<BR>
<BR>

<P ALIGN="LEFT">
<FONT SIZE=5>Production processes and production plants</FONT>

<P ALIGN="LEFT">
<A HREF="plant.html">Plants</A>

<P ALIGN="LEFT">
<IMG HEIGHT=161 WIDTH=160 ALIGN=RIGHT VSPACE=5 HSPACE=10 
SRC="/images/environment/report.95/lastbil.gif">

Open reporting of 
information on the environmental impact of its operations is an 
important element of Volvo's overall environmental policy. Under 
<A HREF="plant.html">plants</A>
, we present statistics on energy 
consumption, water consumption and 
emission levels in those plants in which monitoring systems have been 
established and permanent, common procedures implemented. This 
applies to Volvo's majority-owned plants in Sweden and to those 
plants in which our environmental management system has been 
implemented. Together, these account for approximately 80% of 
the Group's energy and water consumption. Information on other 
majority-owned plants is also given, although not in the same detail. 

<P ALIGN="LEFT">
The figures show that the consumption of energy and water, 
as well as atmospheric emission levels, can be related directly 
to production volume. In addition, reductions in these 
parameters are clearly discernible in those plants in which specific 
measures have been implemented. The work of improving the procedures 
for monitoring environment-specific production 
parameters is ongoing. Our intention is to report information on 
increasing numbers of plants in future editions of this report.

<P ALIGN="LEFT">
<B>Ongoing improvements.</B> The basic premise of our operations is that 
we shall, at all times, specify production processes which are as 
favourable as possible to the environment. In addition, we are 
working to ensure that our 
products, as well as our production processes, comply with comparable 
environmental standards wherever in the world we operate. We have not yet 
achieved the same progress in all of our plants; however, we have invested 
continuously in new improvement 
measures, taking due account of the environmental effects likely to 
ensue from every operational change. Compliance with national 
legislation is a fundamental assumption in every plant and the 
applicable provisions have been exceeded comfortably in many cases.

<P ALIGN="LEFT">
<B>Research and development.</B> Volvo is currently conducting a number of 
research projects aimed at cutting 
emissions from the Group's production plants. Examples include 
the development of methods to improve the 
efficiency of chemicals utilisation and to reduce the quantity 
of effluent from process baths. In cooperation with a supplier,VCC 
has developed a powder-based clear coat which is completely free 
of solvents, while the energy 
consumption of the painting process has been halved.

<P ALIGN="LEFT">
<B>Energy.</B> Most Volvo plants are heated mainly by natural gas or 
LPG, and are equipped with advanced energy 
management and energy/heat recovery systems. Over 80% of the 
heating needs of the company's plants at Torslanda are supplied 
by waste heat from the OK refinery in Gothenburg, the remainder 
being supplied by natural gas. At the VTC plant at Lundby in 
Gothenburg, the thermal energy 
generated by engine testing is not only sufficient to heat the plant 
itself, but provides a surplus which is sold to the local municipal 
district heating network for about SEK1 million per year. In addition, 
the engine test beds are equipped with generators producing electric 
power for sale to the local energy utility. Various other 
energy-saving measures have also been implemented at a number of 
other plants.

<P ALIGN="LEFT">
<IMG HEIGHT=255 HSPACE=7 VSPACE=5 WIDTH=200 ALIGN=LEFT 
SRC="/images/environment/report.95/evaporation.gif">
<B>Water.</B> Volvo has implemented a number of different programmes to cut 
water consumption and to reduce water-borne emissions. The company's 
first industrial effluent treatment plant was commissioned as long 
ago as the late 1960s and a global Volvo standard was 
developed, with the result that all majority-owned Volvo production 
facilities are now equipped with advanced treatment plants of this 
type (capital investment may be required in some newly acquired facilities.). At the company's plants in Sk&ouml;vde, K&ouml;ping and Arboga, 
used cutting and washing fluids are purified by ultrafiltration and 
reverse osmosis, techniques which offer high 
purification efficiency and minimum 
emissions. Evaporator technology and purification by means of 
activated carbon were introduced in Trollh&auml;ttan in September 
1995 to achieve the same results. 

<P ALIGN="LEFT">
During the year, a new method of recovering 
water from used cutting and washing fluids was tested at 
the Volvo Car Corporation plant in Floby. In this method, the waste 
fluid is collected in tanks and the water content is recovered 
by evaporation. The vapour is then 
condensed and returned to the fluid system, in which it is used 
to make up the evaporation losses which occur 
during machining. The plant's water consumption has been reduced 
by 95% by this means, with a corresponding reduction in the 
transport of waste fluids. Water consumption at the VCE wheel 
loader plant in Arvika has also been cut by 93% by the 
introduction of a closed cooling water system.

<P ALIGN="LEFT">
<B>CFCs.</B> The elimination of ozone-
depleting chlorofluorocarbons in 
stationary cooling equipment is ongoing, a reduction of 10% being 
achieved between 1994 and 1995. The proportion of CFC-free plants 
increased from 20% in 1993 to 60% in 1995.

<P ALIGN="LEFT">
<B>Solvents.</B> With the introduction of water-borne paints and 
advanced purification technology, the Volvo paint shops in 
Torslanda and Ume&aring; now boast the lowest solvent emission 
levels per unit of production in their respective sectors, 
complying comfortably with current and forthcoming EU limits. 
At Torslanda, solvent emissions were reduced to 2.2 kg per 
car in 1995. In Ume&aring;, the figure per truck cab was 
only 1 kg.

<P ALIGN="LEFT">
A new finishing paint shop, in which the primers used will be 
mainly water-based, is under construction in Ghent. At full production 
(in mid-1997), solvent emissions from the plant are expected to have 
been reduced by about 30% of current levels. Meanwhile, 
solvent emissions from most other Volvo plants have been cut in recent 
years by measures including new purification technology, more 
efficient painting processes and the replacement of solvent-based 
paints by types with low or zero solvent contents.

<P ALIGN="LEFT">
<B>NO<FONT SIZE=2>X</FONT> och SO<FONT SIZE=2>2</FONT>.</B> NO<FONT SIZE=2>X</FONT> 
and CO<FONT SIZE=2>2</FONT>. The introduction of cleaner forms of 
energy for heating purposes has reduced emissions of nitrogen oxides and 
sulphur dioxide from several plants.

<P ALIGN="LEFT">
At the Volvo engine plant in Sk&ouml;vde, the new engine 
technology which has been developed has cut nitrogen oxide emissions 
from engine testing from 63 g/kg of fuel in 1989 to 18 g/kg in 1995.

<P ALIGN="LEFT">
<B>Waste.</B> Presorting of waste at source is carried out at most 
production plants, although the degree varies. At some plants, 
such as Torslanda, corrugated board has been sorted for recovery 
since the early 1970s. The introduction of a packaging return 
system in the 1980s reduced the quantity of disposable packaging 
substantially. Nevertheless, packaging still accounts for the 
largest quantities of waste.

<P ALIGN="LEFT">
The handling of environmentally hazardous process waste, mainly 
residues of adhesives, paints and oils, is controlled by detailed 
regulations. These materials are collected and processed by approved 
specialist companies. The recovery of solvents has been initiated 
at the Ume&aring; and Torslanda paint shops. In the latter case, 
the energy content of the paint sludge is recovered by 
incineration of the material in a 
combined district heating/waste-to-energy plant.

<P ALIGN="LEFT">
<B>Breaches of legislation.</B> No breaches of legislation were 
recorded in any of Volvo's plants in 1995.

<BR>
<BR>
<BR>

<P ALIGN=LEFT>
<B>"...adopting production processes which are as environmentally sound as possible."</B>
<BR>
<BR>
- Extract from Volvo environmental policy

<!-- -------- -->
<BR>
<BR>
<BR>
<P ALIGN=CENTER>
[ <A HREF="energi.html">Next chapter of the Environmental Report</A> |<BR>
<A HREF="utbild.html">Previous chapter of the Environmental Report</A> ]
<BR>
<BR>
<P ALIGN=LEFT>

<HR ALIGN=LEFT WIDTH=447>
<BR>

<TABLE BORDER=0 WIDTH=450>

<TR>
	<TD>Source: Volvo Environmental Report 1995</TD>
</TR>

</TABLE>

<P>

</BLOCKQUOTE>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]

</TD>
</TR>
</TABLE>

</CENTER>


</BODY>
</HTML>






</DOC>
<DOC>
<DOCNO>WT08-B13-206</DOCNO>
<DOCOLDNO>IA089-000951-B023-156</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/environment/report.95/energi.html 192.138.110.240 19970208031645 text/html 8332
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 03:16:46 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 8161
Last-modified: Mon, 17 Jun 1996 13:28:14 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Energy</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>

<TR>
	<TD><HR></TD>
</TR>

<TR>
	<TD>

<BLOCKQUOTE>

<!-- ---- DIAGRAM 1 ---- -->

<TABLE WIDTH=450 BORDER=0>


<TR>
	<TD>
	
	
	
	
<P ALIGN="LEFT">
<FONT SIZE=5>Energy</FONT>

<P ALIGN="LEFT">
Since 80-90% of the total environmental impact of a 
conventional motor vehicle is generated during its useful life, this phase also offers 
the greatest 
potential for improvement. In the short term, this is mainly a 
matter of cutting fuel consumption, and further reducing emission 
and noise levels. In the longer term, the ultimate objective is 
to ensure that the impact of road traffic does not exceed what 
nature can tolerate.

<P ALIGN="LEFT">
Volvo can influence developments in the right direction 
by cooperation with fuel suppliers, customers, politicians, 
official agencies and other automakers. In addition, we can 
develop the expertise which we need to prepare ourselves 
for the future by continuously developing and testing 
different alternatives.

<P ALIGN="LEFT">
<B>Need for alternatives.</B> The future of our energy resources is of 
central concern to all mankind. Fossil fuels - our main source at 
present - must be replaced sooner or later since their adverse 
effects are undeniable and the available reserves are finite. A 
sustainable energy supply must be based on clean, renewable sources. 
Since no one of the alternatives available at present can replace oil, 
coal and natural gas, a variety of different fuels - all of which have 
a role to play - is emerging. Ultimately, however, we must learn to 
harness the only primary energy source which is available to us - 
the sun.

<P ALIGN="LEFT">
<B>Facts about fuels.</B> Volvo's fuel database is an information source 
which 
enables the overall environmental impact of different fuels to be 
evaluated over the life cycle of a product, from raw material 
extraction to production, 
distribution and the generation of exhaust emissions.

<P ALIGN="LEFT">
Since all of the alternative fuels have advantages and 
disadvantages, the choice must be determined by the 
environmental problems - local and 
global - which are accorded priority, in addition to the practical 
aspects of availability, cost, distribution, and 
storage and handling technology.

<P ALIGN="LEFT">
<B>Fossil fuels increase greenhouse effect.</B> Conventional fuels, 
such as diesel oil and petrol, as well as natural gas, are of 
fossil origin. As such, they are finite resources. Combustion 
of these fuels releases carbon in the form of carbon dioxide, 
increasing the 
reenhouse effect and promoting serious climate change, with 
consequences which are extremely difficult to predict.

<P ALIGN="LEFT">
<B>Petrol and diesel oil.</B> The advantages of conventional fuels 
include their high energy content, relatively satisfactory 
availability and low price, backed by a well-developed production 
and distribution system. In addition, 
emissions of hazardous exhaust gases have been cut dramatically in 
recent years by the development of new engine technologies and improved 
fuel grades. As a result, petrol and diesel are more than likely to 
dominate the fuel market for many years to come.

<P ALIGN="LEFT">
<B>CNG</B> (Compressed Natural Gas) 
consists mainly of methane. Natural gas is basically ready for combustion 
immediately following extraction and requires very little refining. 
Although the reserves are satisfactory, the fuel is more difficult 
to distribute, store and handle than liquid fuels. Emissions of 
hazardous substances from CNG are extremely low.

<P ALIGN="LEFT">
<B>LPG</B> (Liquid Petroleum Gas) is a by-product of petrol refining. Hazardous 
emissions from this fuel are lower than those from petrol and diesel.

<P ALIGN="LEFT">
<B>Renewable energy sources are part of the ecocycle.</B> Alcohol, vegetable 
oils, biogas, hydrogen, electricity etc. may be regarded as renewable 
energy sources provided they are produced from biomass, or from 
solar, wind or water power, since equilibrium will then exist between 
the greenhouse gases generated by combustion and the uptake by 
living plant life. In practice, however, fossil fuels are nearly 
always used to produce these fuels.

<P ALIGN="LEFT">
<B>Biogas,</B> like natural gas, consists largely of methane. The gas is a 
product of organic waste, for example from sewage treatment plants 
or from decayed agricultural crops. Burning methane rather than 
permitting it to leak from refuse tips and manure heaps can yield 
significant environmental benefits. Calculations show that 
sufficient biogas to fuel 500,000 cars could be obtained from 
this source alone in Sweden.

<P ALIGN="LEFT">
<B>Dimethyl ether (DME)</B> is a gaseous fuel which can be produced 
from biomass or natural gas. DME can be burned at the same 
efficiency in a diesel engine with a modified fuel system. The 
production process is considerably less energy-intensive than, for example, 
methanol production.

<P ALIGN="LEFT">
<B>Rapeseed oil,</B> for example in the form of rapeseed methyl ester (RME), 
can be burned in most modern diesel engines. However, rapeseed oil is 
expensive and energy-intensive to produce.

<P ALIGN="LEFT">
<B>Alcohols.</B> Methanol, ethanol and other fuels containing alcohol can be 
produced from forest raw materials or agricultural products (and also 
from natural gas and crude oil).

<P ALIGN="LEFT">
Although ethanol has a higher energy content than methanol, the 
production process is highly energy-intensive. If made from agricultural 
products, the amount of energy used in its production is at least as 
high as that of the end 
product. Since considerably more methanol than ethanol can be obtained 
from the same quantity of forest materials, it is less expensive to 
produce; however, methanol is toxic and more aggressive to engines 
and fuel systems.

<P ALIGN="LEFT">
<B>Hydrogen</B> can be produced from water by hydrolysis, using electricity. 
For this reason, the availability of the fuel is almost unlimited. 
The combustion of hydrogen produces no carbon dioxide or hydrocarbons,
 although small quantities of nitrogen oxides are formed. However, the fuel is 
difficult to store and necessitates the modification of existing 
engines, while its low energy content calls for complex and 
expensive on-board installations. Nevertheless, hydrogen may be the 
fuel of the future, provided that the electrical energy needed for 
its production can be generated in an environmentally 
favourable and economical manner from sources such as solar energy 
or nuclear fusion.

<P ALIGN="LEFT">
<B>Electricity</B> from water, solar power and wind-powered generators 
is perhaps the cleanest form of energy in existence. However, 
the generation of electricity in fossil fuel-fired thermal 
power stations or nuclear power plants also has 
undesirable environmental consequences.
	</TD>
</TR>


</TABLE>
</BLOCKQUOTE>
<BR>
<BR>

<P ALIGN="LEFT">
<IMG HEIGHT=301 WIDTH=487 SRC="/images/environment/report.95/energi_dia2.gif">

<P ALIGN="LEFT">
<IMG HEIGHT=310 WIDTH=487 SRC="/images/environment/report.95/energi_dia1x.gif">

<BLOCKQUOTE>
<!-- -------- -->
<BR>
<BR>
<P ALIGN="CENTER">
<A HREF="/environment/report.95/poll_facts.html">[Pollution Facts]</A>
<BR>
<BR>
<BR>
<P ALIGN=CENTER>
[ <A HREF="motor.html">Next chapter of the Environmental Report</A> |<BR>
<A HREF="produkt.html">Previous chapter of the Environmental Report</A> ]
<BR>
<BR>
<P ALIGN=LEFT>

<HR ALIGN=LEFT WIDTH=447>
<BR>
<TABLE BORDER=0 WIDTH=450>

<TR>
	<TD>Source: Volvo Environmental Report 1995</TD>
</TR>

</TABLE>

<P>

</BLOCKQUOTE>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]

</TD>
</TR>
</TABLE>

</CENTER>


</BODY>
</HTML>






</DOC>
<DOC>
<DOCNO>WT08-B13-207</DOCNO>
<DOCOLDNO>IA089-000951-B023-181</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/environment/report.95/motor.html 192.138.110.240 19970208031659 text/html 13198
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 03:17:06 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 13026
Last-modified: Mon, 17 Jun 1996 13:28:50 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Engine development</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>

<TR>
	<TD><HR></TD>
</TR>

<TR>
	<TD>

<BLOCKQUOTE>

<!-- ---- DIAGRAM 1 ---- -->

<TABLE WIDTH=450 BORDER=0>


<TR>
	<TD>
	
	
<BR>
<BR>	
	
<P ALIGN="LEFT">
<FONT SIZE=5>Engine development</FONT>

<P>
<TABLE WIDTH=450 BORDER=0>

<TR>
	<TD>

<IMG ALIGN=RIGHT HSPACE=7 WIDTH=200 HEIGHT=158 SRC="/images/environment/report.95/motor_dia3.gif">
Volvo is engaged in continuous research into 
alternative propulsion systems and fuels, in parallel with the 
development of conventional petrol and diesel engines. Gas and 
alcohol-burning engines are generally based on the same technology 
as diesel and petrol units, whereas different approaches are required in the case of electric vehicles 
and hybrids.

	</TD>
<TR>

</TABLE>
<BR>
<BR>



<P ALIGN="LEFT">
<IMG ALIGN=LEFT HSPACE=7 WIDTH=190 HEIGHT=336 SRC="/images/environment/report.95/motor_dia1.gif">
<B>The diesel engine</B> is - and is more than likely to remain - the most 
common type of engine used in heavy trucks, buses and construction 
equipment for many years to come. The main advantage of the type is 
its high efficiency (up to 45%), which delivers low fuel consumption 
in relation to the amount of transport work performed. This, in 
turn, means that the carbon dioxide emissions (which are directly 
proportional to the fuel consumption) are also comparatively low. 
Other factors in the diesel's favour are its high reliability, 
long life and wide versatility. A diesel engine can be modified 
to burn a range of fuels, including gases, vegetable oils and 
alcohols. However, conversion to the Otto process - which reduces 
the efficiency - is required to burn fuels such as 
natural gas or biogas. Over the last twenty years, the fuel 
consumption of Volvo heavy vehicle diesels has been reduced by 
17% - and potential for 
further improvement exists. With the development of cleaner 
engines, 
emissions of carbon monoxide, hydrocarbons and particulates 
from the typical heavy diesel are now about 85% less than 
twenty years ago, while nitrogen oxide emissions have been 
cut by 70% since 1975. Considerable technical potential 
still exists for reducing 
emissions from diesel engines burning diesel oil as well as alternative 
fuels.

<P ALIGN="LEFT">
<IMG ALIGN=RIGHT HSPACE=7 WIDTH=190 HEIGHT=355 SRC="/images/environment/report.95/motor_dia2.gif">
<B>The Otto engine</B> is the commonest type of engine used in cars. Although 
normally driven by petrol, the unit can be converted fairly simply to burn 
natural gas or alcohols. The most 
significant advance in reducing the emission of hazardous substances 
has been the introduction of the catalytic converter. Today, most 
Volvo cars (with the exception of those built for markets where 
unleaded petrol is unavailable) are equipped with three-way converters, 
which reduce emissions of hydrocarbons, nitrogen oxides and carbon 
monoxide by approximately 90%. The catalytic converter has no effect on 
carbon dioxide emissions; nevertheless, total emissions of greenhouse 
gases from Volvo cars have fallen by 40-50% since the early 1970s with the 
elimination of freons and the achievement of lower fuel consumption. 
In summary, therefore, the exhaust 
emissions from an Otto engine with a catalytic converter are much 
lower than from a diesel, although the efficiency is lower and the 
fuel consumption is higher.

<P ALIGN="LEFT">
<B>Although gas turbines</B> are used mainly in aircraft at the present 
time, they may, in the longer term, provide an attractive 
alternative for other forms of transport and for stationary 
power generation, partly because of their much lower emissions 
of hazardous exhaust gases. In this context, Volvo Aero 
Corporation (VAC) is currently involved in a 
number of joint projects to develop gas turbines with a high fuel 
efficiency and extremely low exhaust emissions. For example, the 
Eurodyn Eureka Team is working on the development of gas 
turbine engines for high-speed sea and rail freight applications. 
Eurodyn, like Volvo's own VT600 gas turbine, may also be used in 
land-based CHP 
applications.

<P ALIGN="LEFT">
Volvo Aero Corporation is also a partner in the EU AGATA 
(Advanced Gas Turbine for Automobiles) project to develop a gas 
turbine engine with a catalytic combustor for use in cars. 

<P ALIGN="LEFT">
In the longer term, the company is also involved in an EU project to 
develop combustion chambers for the aircraft jet engines of the future. 
The aim of the project is to design engines with extremely low emission 
levels, especially of nitrogen oxides.

<P ALIGN="LEFT">
EVGT, a national project in which VAC is collaborating with the 
Swedish technical universities and the Swedish power industry in the 
development of an evaporative gas turbine for electricity generation, 
was commenced in 1995. In this type of unit, water is injected into 
the gas turbine cycle, increasing its efficiency and lowering the 
nitrogen oxide emissions. Powered by biofuels, the unit has 
potential as a technology for electric power production.

<P ALIGN="LEFT">
The VAC VT100 gas turbine is the main power train component in the 
ECT and ECB concept vehicles. Apart from its extremely low emission 
levels, this application demonstrates another valuable attribute of 
the gas turbine - its fuel versatility.

<P ALIGN="LEFT">
<B>Electric vehicles and hybrids.</B> Electric vehicles have the major 
advantage of producing no exhaust emissions whatever. However, the 
endurance (range of operation) of the type is limited by the low 
energy storage capacity of the 
batteries. In this respect, not even the most efficient type of battery 
available today can offer anything approaching the endurance of a petrol 
or diesel-engined vehicle. As a result, the pure electric drive remains 
a viable option only in cars with a relatively limited range, such as 
city models, electric hybrid propulsion offering a better alternative 
for Volvo's family cars and commercial vehicles. In the electric hybrid, 
the batteries and electric motor are complemented by an additional power 
source, such as an Otto engine or gas turbine, giving it comparable 
endurance to today's conventional 
models while permitting exhaust-free operation over shorter distances. 
Volvo has built a complete series of concept vehicles (ECC, ECT and ECB)
 with electric hybrid drives and is currently working on the 
 application of the 
technology to conventional vehicles.<BR>
<BR>
<BR>


	<TABLE WIDTH=447 CELLPADDING=3 BORDER=0>
		
		<TR>
			<TD COLSPAN=5><B>Emissions from Volvo cars compared with statutory 
			limits</B></TD>
		</TR>
		
		<TR>
			<TD COLSPAN=5><HR></TD>
		</TR>
		
		<TR>
			<TD><B>1996 models, g/km</B></TD>
			<TD ALIGN=CENTER><B>CO</B></TD>
			<TD ALIGN=CENTER><B>NOx</B></TD>
			<TD ALIGN=CENTER><B>+ HC</B></TD>
			<TD ALIGN=CENTER><B>=</B></TD>
		</TR>
		
		<TR>
			<TD COLSPAN=5><HR></TD>
		</TR>
		
		<TR>
			<TD><B>S40, 2.0 litre</B></TD>
			<TD ALIGN=CENTER>0.42</TD>
			<TD ALIGN=CENTER></TD>
			<TD ALIGN=CENTER></TD>
			<TD ALIGN=CENTER>0.21</TD>
		</TR>
		
		<TR>
			<TD><B>940, 2.3 litre</B></TD>
			<TD ALIGN=CENTER>1.12</TD>
			<TD ALIGN=CENTER>0.09</TD>
			<TD ALIGN=CENTER>0.15</TD>
			<TD ALIGN=CENTER>0.24</TD>
		</TR>
		
		<TR>
			<TD><B>960, 2.5 litre</B></TD>
			<TD ALIGN=CENTER>0.63</TD>
			<TD ALIGN=CENTER>0.12</TD>
			<TD ALIGN=CENTER>0.17</TD>
			<TD ALIGN=CENTER>0.29</TD>
		</TR>

		<TR>
			<TD><B>850, 2.0 litre</B></TD>
			<TD ALIGN=CENTER>0.59</TD>
			<TD ALIGN=CENTER></TD>
			<TD ALIGN=CENTER></TD>
			<TD ALIGN=CENTER>0.27</TD>
		</TR>

		<TR>
			<TD><B>850, TLEV/ Environmental <BR>
			class1 (FTP)</B></TD>
			<TD ALIGN=CENTER>0.39</TD>
			<TD ALIGN=CENTER>0.07</TD>
			<TD ALIGN=CENTER>0.049</TD>
			<TD ALIGN=CENTER>0.119</TD>
		</TR>

		<TR>
			<TD><B>850 Bi-Fuel</B></TD>
			<TD ALIGN=CENTER>0.14</TD>
			<TD ALIGN=CENTER></TD>
			<TD ALIGN=CENTER></TD>
			<TD ALIGN=CENTER>0.19</TD>
		</TR>

		<TR>
			<TD><B>850 Bi-Fuel (FTP)</B></TD>
			<TD ALIGN=CENTER>0.30</TD>
			<TD ALIGN=CENTER>0.07</TD>
			<TD ALIGN=CENTER>0.020*</TD>
			<TD ALIGN=CENTER></TD>
		</TR>

		<TR>
			<TD><B>Statutory EU 96</B></TD>
			<TD ALIGN=CENTER>2.2</TD>
			<TD ALIGN=CENTER></TD>
			<TD ALIGN=CENTER></TD>
			<TD ALIGN=CENTER>0.5</TD>
		</TR>

		<TR>
			<TD><B>TLEV (FTP)</B></TD>
			<TD ALIGN=CENTER>2.1</TD>
			<TD ALIGN=CENTER>0.25</TD>
			<TD ALIGN=CENTER>0.078*</TD>
			<TD ALIGN=CENTER></TD>
		</TR>

		<TR>
			<TD><B>ULEV (FTP)</B></TD>
			<TD ALIGN=CENTER>1.06</TD>
			<TD ALIGN=CENTER>0.125</TD>
			<TD ALIGN=CENTER>0.025*</TD>
			<TD ALIGN=CENTER></TD>
		</TR>
		
		<TR>
			<TD COLSPAN=5><HR></TD>
		</TR>
		
	</TABLE>

<BLOCKQUOTE>

<P ALIGN="LEFT">
<FONT SIZE=2>All figures EU-certified unless otherwise stated.

<P ALIGN="LEFT">
* NMHC (Non-Methane Hydrocarbons) = hydrocarbons other than methane

<P ALIGN="LEFT">
FTP = Federal Test Procedure (USA)


<P ALIGN="LEFT">
ULEV = Ultra-Low Emission Vehicle (Californian emission control standard 
due for introduction in 2000)

<P ALIGN="LEFT">
TLEV = Traditional Low-Emission Vehicle (current Californian emission 
control standard)</FONT>

</BLOCKQUOTE>
<BR>
<BR>
<BR>

<TABLE WIDTH=447 CELLPADDING=3 BORDER=0>
		
		<TR>
			<TD COLSPAN=5><B>Emissions from Volvo trucks and buses compared with statutory 
			limits</B></TD>
		</TR>
		
		<TR>
			<TD COLSPAN=5><HR></TD>
		</TR>
		
		<TR>
			<TD><B>(g/kWh)</B></TD>
			<TD ALIGN=CENTER><B>CO</B></TD>
			<TD ALIGN=CENTER><B>NOx</B></TD>
			<TD ALIGN=CENTER><B>HC</B></TD>
			<TD ALIGN=CENTER><B>PM</B></TD>
		</TR>
		
		<TR>
			<TD COLSPAN=5><HR></TD>
		</TR>
		
		<TR>
			<TD><B>Modern diesel engine</B></TD>
			<TD ALIGN=CENTER>0.45</TD>
			<TD ALIGN=CENTER>6.5</TD>
			<TD ALIGN=CENTER>0.12</TD>
			<TD ALIGN=CENTER>0.08</TD>
		</TR>

		<TR>
			<TD><B>Natural gas engine<BR>
			with catalytic converter</B></TD>
			<TD ALIGN=CENTER>0.3</TD>
			<TD ALIGN=CENTER>2.0</TD>
			<TD ALIGN=CENTER>1.1</TD>
			<TD ALIGN=CENTER>0.05</TD>
		</TR>

		<TR>
			<TD><B>ECT</B></TD>
			<TD ALIGN=CENTER>0.5</TD>
			<TD ALIGN=CENTER>0.3</TD>
			<TD ALIGN=CENTER>0.1</TD>
			<TD ALIGN=CENTER>&lt;0.05</TD>
		</TR>

		<TR>
			<TD><B>Statutory limit as <BR>
			per EU 93 (Euro 1)</B></TD>
			<TD ALIGN=CENTER>4.5</TD>
			<TD ALIGN=CENTER>8.0</TD>
			<TD ALIGN=CENTER>1.1</TD>
			<TD ALIGN=CENTER>0.36</TD>
		</TR>

		<TR>
			<TD><B>Statutory limit as <BR>
			per EU 96 (Euro 2)</B></TD>
			<TD ALIGN=CENTER>4.0</TD>
			<TD ALIGN=CENTER>7.0</TD>
			<TD ALIGN=CENTER>1.1</TD>
			<TD ALIGN=CENTER>0.15</TD>
		</TR>


		<TR>
			<TD COLSPAN=5><HR></TD>
		</TR>
		
	</TABLE>
	<BR>
	<BR>
	<BR>


<TABLE WIDTH=447 CELLPADDING=3 BORDER=0>
		
		<TR>
			<TD COLSPAN=6><B>Statutory emission limits for construction 
			equipment g/kWh</B></TD>
		</TR>
		
		<TR>
			<TD COLSPAN=6><HR></TD>
		</TR>

		<TR>
			<TD ALIGN=CENTER><B>Output class, <BR>
			kW</B></TD>
			<TD ALIGN=CENTER><B>Applicable <BR>
			from:</B></TD>
			<TD ALIGN=CENTER><B>CO</B></TD>
			<TD ALIGN=CENTER><B>NOx</B></TD>
			<TD ALIGN=CENTER><B>HC</B></TD>
			<TD ALIGN=CENTER><B>PM</B></TD>
		</TR>

		<TR>
			<TD COLSPAN=6><HR></TD>
		</TR>


		<TR>
			<TD ALIGN=CENTER>130-560</TD>
			<TD ALIGN=CENTER>1 July 97</TD>
			<TD ALIGN=CENTER>5.0</TD>
			<TD ALIGN=CENTER>9.2</TD>
			<TD ALIGN=CENTER>1.3</TD>
			<TD ALIGN=CENTER>0.54</TD>
		</TR>

		<TR>
			<TD ALIGN=CENTER>75-130</TD>
			<TD ALIGN=CENTER>1 January 98</TD>
			<TD ALIGN=CENTER>5.0</TD>
			<TD ALIGN=CENTER>9.2</TD>
			<TD ALIGN=CENTER>1.3</TD>
			<TD ALIGN=CENTER>0.70</TD>
		</TR>

		<TR>
			<TD ALIGN=CENTER>37-75</TD>
			<TD ALIGN=CENTER>1 January 99</TD>
			<TD ALIGN=CENTER>6.5</TD>
			<TD ALIGN=CENTER>9.2</TD>
			<TD ALIGN=CENTER>1.3</TD>
			<TD ALIGN=CENTER>0.85</TD>
		</TR>

		<TR>
			<TD COLSPAN=6><HR></TD>
		</TR>
		
	</TABLE>
<BR>
<BR>
<BR>
<P ALIGN="LEFT">
<B>...developing and marketing products which possess the 
most favourable environmental properties and which meet the  
highest possible efficiency standards"</B>

<P ALIGN="LEFT">
- Extract from Volvo environmental policy



	</TD>
</TR>


</TABLE>


<!-- -------- -->
<BR>
<BR>
<BR>
<P ALIGN=CENTER>
[ <A HREF="koncept.html">Next chapter of the Environmental Report</A> |<BR> 
<A HREF="energi.html">Previous chapter of the Environmental Report</A> ]
<BR>
<BR>
<P ALIGN=LEFT>

<HR ALIGN=LEFT WIDTH=447>
<BR>


<TABLE BORDER=0 WIDTH=450>

<TR>
	<TD>Source: Volvo Environmental Report 1995</TD>
</TR>

</TABLE>

<P>

</BLOCKQUOTE>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]

</TD>
</TR>
</TABLE>

</CENTER>


</BODY>
</HTML>






</DOC>
<DOC>
<DOCNO>WT08-B13-208</DOCNO>
<DOCOLDNO>IA089-000951-B023-205</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/environment/report.95/koncept.html 192.138.110.240 19970208031708 text/html 8945
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 03:17:19 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 8774
Last-modified: Mon, 17 Jun 1996 13:28:20 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Products and concepts</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>

<TR>
	<TD><HR></TD>
</TR>

<TR>
	<TD>

<BLOCKQUOTE>

<!-- ---- DIAGRAM 1 ---- -->

<TABLE WIDTH=450 BORDER=0>


<TR>
	<TD>
	
<BR>
<BR>	
	
<P ALIGN="LEFT">	
<FONT SIZE=5>Products and concepts</FONT>

<P ALIGN="LEFT">
<B>Volvo 850 complies with environmental 
class 1.</B> Introduced in 1995, the Volvo 850 GLT complies with 
environmental class 1, the lowest exhaust emission level in the 
Swedish environmental classification system, which is equivalent 
to the Californian TLEV standard. This makes Volvo the first 
automaker to market a model to this standard in Sweden. Environmental 
class 1 means that emissions of hydrocarbons are only half of the 
permissible level.

<P ALIGN="LEFT">
<B>All heavy diesels ready for Euro 2.</B> 
By October 1995, all diesel engines used in VTC and VBC products 
achieved compliance with Euro 2, the new EU emission control standard 
which will be introduced in October 1996. Volvo bus engines can also 
be equipped with an oxidising catalytic converter to reduce emission 
levels even further.


<P ALIGN="LEFT">
<B>850 TDI returns 6 l/100 km.</B> In 1995, VCC introduced its new Volvo 850 
TDI, a direct-injection, turbocharged diesel with an intercooler. 
With a fuel consumption of only 6 l/100 km in mixed driving, the new 
model is one of the most fuel-efficient diesel cars in its segment. 
(Fuel consumption 
calculated using 'Drittelmix' formula, in which consumption figures 
at 90 km/h, 120 km/h and in ECE cycle each account for one-third of 
the total.)

<P ALIGN="LEFT">
<IMG HEIGHT=137 WIDTH=200 HSPACE=7 ALIGN=RIGHT SRC="/images/environment/report.95/dumper.gif">
<B>Low-emission engines for construction equipment.</B> VCE has introduced 
low-emission engines as standard 
equipment in all dumpers and wheel loaders marketed as Volvo BM 
models, and in the two biggest excavators 
marketed under the &Aring;kerman name. Emissions of nitrogen oxides 
from these units are approximately 50% lower compared with conventional 
engines. A VCE dumper, the Volvo BM A25C, became the first foreign 
model to be approved for underground service in Japan, an indication 
of the extremely strict emission standards with which it complies.

<P ALIGN="LEFT">
<B>Marine engines with electronic 
engine management.</B> Volvo Penta launched two new environmental marine 
engines in 1995. Of these, the TAMD 72 EDC is one of the first marine 
engines ever to be equipped with an electronic engine management 
system, reducing emissions of hazardous substances to very low levels. 
Equipped with a turbo and integrated boost 
pressure limiter, the TAMD 63 delivers high acceleration and 35% lower 
emissions than earlier units.

<P ALIGN="LEFT">
The Volvo Penta service of certifying complete on-board 
installations has acquired a stronger environmental thrust and is 
being used by growing numbers of customers.

<P ALIGN="LEFT">
<IMG HEIGHT=127 WIDTH=200 HSPACE=7 ALIGN=LEFT SRC="/images/environment/report.95/bi_fuel.gif">
<B>Bi-Fuel meets Californian standards.</B> 
Series production of the Volvo 850 
Bi-Fuel commenced at the start of 1996. The car is equipped with two 
fuel systems and can be run alternately on methane (natural gas or 
biogas) or petrol. In gas operation, the model 
already complies with the toughest 
exhaust emission standards applicable to cars with combustion 
engines - the ULEV standard due to come into force in California at 
the beginning of the next century.

<P ALIGN="LEFT">
<B>Growing interest in gas-powered buses.</B> Volvo delivered a further 55 
CNG-powered buses in 1995, bringing the total since 1993 to about 200. 
Eighteen LPG buses were also 
delivered and orders were received for 8 biogas-powered models.

<P ALIGN="LEFT">
Both VTC and VBC have also begun to study the feasibility of 
using dimethyl ether (DME) as an automotive fuel.

<P ALIGN="LEFT">
<B>Natural gas for trucks.</B> VTC has 
decided to concentrate on natural gas (CNG) as the main alternative 
to diesel oil as a truck fuel in urban traffic. The first two gas-powered 
FL10s were delivered during the year. Series production of natural gas 
engines for both trucks and buses commenced at the VTC engine plant in 
Sk&ouml;vde and will reach full output (approx. 200 units annually) in 
autumn 1996.

<P ALIGN="LEFT">
<B>Ethanol.</B> VBC delivered two ethanol-powered buses and VTC commenced 
field testing of four ethanol-burning FL7s in 1995.

<P ALIGN="LEFT">
Development of alcohol-powered cars continued at VCC during the 
year.

<P ALIGN="LEFT">
<IMG HEIGHT=305 WIDTH=200 HSPACE=7 ALIGN=RIGHT SRC="/images/environment/report.95/ecv.gif">
<B>ECT and ECB.</B> Volvo introduced its Environmental Concept Truck (ECT) and 
Environmental Concept Bus (ECB) in autumn 1995. Both vehicles incorporate 
a series of technical advances which have never before been tested in 
heavy vehicles. The ECT and ECB are intended to provide a platform 
for the future development of safe, environmentally compatible and 
efficient buses and trucks for urban service.

<P ALIGN="LEFT">
The driveline in the ECT and ECB is a refinement of the 
configuration 
introduced in the VCC Environmental Concept Car in 1992, consisting 
of a series hybrid based on a gas turbine with an integral high-speed 
generator, nickel/ metal hydride batteries and an electric motor. 
With a performance and endurance comparable to conventional vehicles, 
the ECT and ECB produce considerably lower emissions of 
harmful exhaust gases and permit pure electric operation over short 
distances, for example in environmentally sensitive urban areas. The 
vehicles are designed to burn basically any liquid or gaseous fuel. 
Emissions of hazardous exhaust constituents are particularly low; for 
example, the nitrogen oxide levels are 90-95% lower compared with the 
cleanest diesels in service today.

<P ALIGN="LEFT">
<B>Ongoing development.</B> As a direct continuation of the ECB project, 
Volvo is currently developing a further six electric hybrid buses, 
four with diesel engines as the main power source and two with gas 
turbines, all of which are expected to be in service in 1996-97. 

<IMG HEIGHT=75 WIDTH=120 HSPACE=7 ALIGN=LEFT SRC="/images/environment/report.95/bil.gif">

VTC is also continuing with its hybrid research and expects to have 
demonstration models available in 1997. In the area of cars, ongoing 
development work has resulted in the production of a test model based 
on the Volvo 850. Volvo is proceeding with research into nickel/metal 
hydride 
batteries as the type with the greatest development potential and a 
considerably lower environmental impact than the earlier nickel/ 
cadmium type.

<P ALIGN="LEFT">
<B>Hush House for Swedish Defence Forces.</B> VAC delivered a further Hush 
House during the year, this time to the Swedish Defence Forces, and 
has also concluded an agreement with a Korean company which may result 
in further sales. The Hush House is a facility which permits indoor 
testing of aero engines installed in aircraft, even in areas subject 
to strict external noise and pollution restrictions.


<P ALIGN="LEFT">
<IMG HEIGHT=173 WIDTH=220 HSPACE=7 ALIGN=RIGHT SRC="/images/environment/report.95/boat.gif">
<B>Leisure craft of the future.</B>
In autumn 1995, Volvo Penta 
announced an international 
competition for boat designers with the aim of stimulating 
development of the 'environmental' marine 
engine of the future. The challenge was to design a craft based on 
VPC's new 22/SX diesel, which was 
developed for boats designed for a power output of around 75 kW. 
In environmental terms, its high 
efficiency and low emissions make the unit an ideal alternative to 
large two-stroke engines. The competition was won by the 
London-based Wyndesign Group with its 'People's Boat'.


	</TD>
</TR>


</TABLE>


<!-- -------- -->
<BR>
<BR>
<BR>
<P ALIGN=CENTER>
[ <A HREF="transeff.html">Next chapter of the Environmental Report</A> |<BR>
<A HREF="motor.html">Previous chapter of the Environmental Report</A> ]
<BR>
<BR>
<P ALIGN=LEFT>

<HR ALIGN=LEFT WIDTH=447>
<BR>

<TABLE BORDER=0 WIDTH=450>

<TR>
	<TD>Source: Volvo Environmental Report 1995</TD>
</TR>

</TABLE>

<P>

</BLOCKQUOTE>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]

</TD>
</TR>
</TABLE>

</CENTER>


</BODY>
</HTML>






</DOC>
<DOC>
<DOCNO>WT08-B13-209</DOCNO>
<DOCOLDNO>IA089-000951-B023-231</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/environment/report.95/transeff.html 192.138.110.240 19970208031722 text/html 8935
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 03:17:33 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 8764
Last-modified: Mon, 17 Jun 1996 13:29:21 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Transport efficiency</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>

<TR>
	<TD><HR></TD>
</TR>

<TR>
	<TD>

<BLOCKQUOTE>

<!-- ---- DIAGRAM 1 ---- -->

<TABLE WIDTH=450 BORDER=0>


<TR>
	<TD>
	
<BR>
<BR>	
	
	
<P ALIGN="LEFT">
<FONT SIZE=5>Transport efficiency</FONT>

<P ALIGN="LEFT">
The environmental impact of road traffic is certain to be lessened as 
transport efficiency is improved. Shorter journeys, more uniform speeds 
and a smoother traffic flow will enable fuel consumption and exhaust 
emissions to be reduced. In the case of commercial vehicles, improved 
load factors will also contribute to a significant reduction in 
environmental loading and costs.

<P ALIGN="LEFT">
Volvo is participating actively in a number of joint projects 
with the aim of developing more efficient transport systems, and is 
also working to develop transport management and information technologies.

<P ALIGN="LEFT">
<IMG ALIGN=RIGHT HEIGHT=313 WIDTH=190 HSPACE=7 SRC="/images/environment/report.95/trans_dia.gif">
<B>Transport Development in the City project.</B> In 1995, Volvo broadened 
its cooperation with the City of Gothenburg within the framework of 
this project, which has been undertaken to develop new expertise in 
the area of transport in major conurbations. The project includes 
field trials of new environmental 
vehicles and the development of new, more efficient transport systems.

<P ALIGN="LEFT">
<B>Coordination of goods distribution.</B>
The first plans in a drive to coordinate the distribution of goods 
to a number of food stores in central Gothenburg were unveiled in 
1995. Estimates show that it may be possible to reduce the number 
of deliveries of this type by about 40%. Undertaken in collaboration 
with the Department of Urban Transport 
Planning at Chalmers University of Technology, Gothenburg, the 
project is financed by the Swedish Transport and Communications 
Research Board, VTC and the City of Gothenburg Traffic and Public 
Transport Authority. Preparatory work was initiated in spring 
1995 and practical trials will commence around mid-1996.

<P ALIGN="LEFT">
<B>Centre of excellence for transport and logistics.</B> The task of 
developing a centre of excellence for transport and logistics 
based in Gothenburg has been assigned to the VTS Transport 
Foundation by a number of interests including Volvo. About 40 
doctoral candidate posts will be established by 1999 with the 
expansion and coordination of 
research resources at Chalmers 
University of Technology and the University of Gothenburg.

<P ALIGN="LEFT">
<B>ITS.</B> Intensive international cooperation has been under way for several 
years in the area of Intelligent Transport Systems (ITS), a concept 
which uses information technology to make road traffic safer and more 
efficient, and to reduce its environmental impact.

<P ALIGN="LEFT">
A breakthrough in the work of 
establishing a European standard for transmitting digitally 
coded traffic information over ordinary FM 
transmitters was achieved in 1995, when the European Conference of 
Ministers of Transport (ECMT) passed a resolution that the RDS/TMC (Radio 
Data System/Traffic Message Channel) information system should be 
introduced without delay in all European countries. Volvo was a major 
motivating force behind this decision.

<P ALIGN="LEFT">
<B>Dynaguide, Dynafleet and Mobiguide.</B> 
Developed by Volvo, Dynaguide Info System, the first receiver for 
the new generation of traffic information 
systems underwent field testing in the USA in 1995, when the system 
was tested by Volvo in 135 commercial 
vehicles, in collaboration with agencies including the Minnesota 
Department of Transportation.

<P ALIGN="LEFT">
Dynafleet Info System, a further 
development of Dynaguide, was launched commercially in autumn 1995 
and received a very positive reception. Dynafleet is a truck fleet 
management system which has been custom-designed for Volvo FH series 
trucks. Apart from supplying traffic information by RDS/ TMC, the 
system boasts the following features:

<UL>
<LI>Data communications between truck and management centre for the 
transmission of information such as new job assignments<BR>
<BR>

<LI>Transmission of the actual position of the vehicle to the 
management centre<BR>
<BR>

<LI>Logging of vehicle data, such as fuel consumption, road 
speed and engine speed<BR>
<BR>

<LI>Driver monitoring to supply transport management with exact 
details of 
current working and rest times<BR>
<BR>

</UL>
<P ALIGN="LEFT">
The first orders for Mobiguide - a simpler version of 
Dynafleet - were also received in 1995.

<P ALIGN="LEFT">
<B>Portable information system.</B> Promise is an EU-financed ITS 
programme which was initiated by Volvo. The purpose of Promise 
is to develop a portable 
information system which will provide users with current information on 
various transport options, parking 
facilities, and so on. The technology was tested earlier in Gothenburg 
and Birmingham, and a second phase was commenced in autumn 1995.

<P ALIGN="LEFT">
Designed for both private and public transport, Promise employs a 
portable terminal with integrated minicomputer and mobile phone functions 
to provide direct access to on-board services.

<P ALIGN="LEFT">
<B>Intelligent cruise control.</B> Volvo has designed an intelligent cruise 
control system which, among other features, synchronises the vehicle 
speed with traffic signal changes to achieve a more uniform traffic 
flow in built-up areas. The equipment includes a radar installation 
in the car and transmitters on the traffic lights concerned. In 1995, 
the system underwent practical testing in collaboration with the City of 
Gothenburg and the Swedish National Road Administration, and the test 
results are now being analysed as part of the ongoing research and 
development 
programme.

<P ALIGN="LEFT">
<B>Navigation system shortens driving distances.</B> In a test programme 
carried out in Gothenburg, Volvo's traffic 
navigation system yielded a 10% reduction in driving distances and 
a 6% reduction in driving times. The 
reference group consisted of 159 
experienced, professional drivers with a high degree of local 
knowledge. The development of a commercial version of the product 
is proceeding.

<P ALIGN="LEFT">
<IMG HEIGHT=179 WIDTH=200 ALIGN=RIGHT HSPACE=10 VSPACE=5 SRC="/images/environment/report.95/buss.gif">
<B>New bus lane system in Colombia.</B> 
Volvo Bus Corporation, in collaboration with the Stagecoach bus 
company and local interests, is developing a new bus lane 
system in the Colombian capital of Bogot&aacute;. The system, 
which will have a capacity of at least 600,000 passengers per day 
when completed, is based on the creation of dedicated bus lanes 
in the existing street network. The buses and bus stops are 
designed for fast 
passenger throughput and high 
transport capacity. Scheduled for 
completion in 1997, the system is expected to yield considerable 
environmental benefits in the form of lower exhaust emission 
levels and reduced traffic congestion. The average bus speed 
is expected to be 25 km/h, compared with an average of 5 km/h 
for the city's traffic as a whole. The capital 
investment is a fraction of the cost of a rail-bound system.

<P ALIGN="LEFT">
Development of the Bogot&aacute; system is based largely on 
the experience gained from the similar system 
installed in the 1970s as a cooperative venture between Volvo and the 
City of Curitiba in Brazil.

<P ALIGN="LEFT">
<B>Volvo's own transport.</B> Volvo's success in reducing the environmental 
impact of its own transport activities clearly illustrates the 
potential available in the area of transport efficiency. Between 
1990 and 1995, emissions from this source on the island of Hisingen 
in Gothenburg were reduced by about 50%.





	</TD>
</TR>


</TABLE>


<!-- -------- -->
<BR>
<BR>
<BR>
<P ALIGN=CENTER>
[ <A HREF="atervinn.html">Next chapter of the Environmental Report</A> |<BR>
<A HREF="koncept.html">Previous chapter of the Environmental Report</A> ]
<BR>
<BR>
<P ALIGN=LEFT>

<HR ALIGN=LEFT WIDTH=447>
<BR>

<TABLE BORDER=0 WIDTH=450>

<TR>
	<TD>Source: Volvo Environmental Report 1995</TD>
</TR>

</TABLE>

<P>

</BLOCKQUOTE>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]

</TD>
</TR>
</TABLE>

</CENTER>


</BODY>
</HTML>






</DOC>
<DOC>
<DOCNO>WT08-B13-210</DOCNO>
<DOCOLDNO>IA089-000951-B023-261</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/environment/report.95/atervinn.html 192.138.110.240 19970208031747 text/html 9046
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 03:17:53 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 8875
Last-modified: Mon, 17 Jun 1996 13:28:14 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Recycling of vehicles</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>

<TR>
	<TD><HR></TD>
</TR>

<TR>
	<TD>

<BLOCKQUOTE>

<!-- ---- DIAGRAM 1 ---- -->

<TABLE WIDTH=450 BORDER=0>


<TR>
	<TD>
	<BR>
	<BR>
	
	
	
	<P ALIGN="LEFT">
	<FONT SIZE=5>Recycling of vehicles</FONT>
	
	<P ALIGN="LEFT">
	Re-use, recycling, 
	energy recovery or dumping? The final phase in the life of a 
	vehicle can take various forms. And the particular form which 
	is the best for the environment is not always clear.
	
	<P ALIGN="LEFT">
	<IMG HSPACE=15 WIDTH=220 HEIGHT=337 ALIGN=RIGHT SRC="/images/environment/report.95/atervinn_dia1.gif">
	As an example, the environmental benefit of reduced 
	raw material usage achieved by recycling at the end of a product's 
	useful life may well be sacrificed if the energy consumption of the 
	recycling process is excessive.
	
	<P ALIGN="LEFT">
	The many pitfalls on the road to an ecological society 
	make it essential for us to expand our knowhow, and to 
	develop a practically applicable holistic philosophy if the 
	action we take to achieve this aim are to be as effective as 
	possible.
	
	<P ALIGN="LEFT">
	The ECRIS facility commissioned in 1994 represents one 
	step in this direction. ECRIS, which stands for Environmental 
	Car Recycling in Scandinavia, is owned jointly by VCC, Stena 
	Bilfragmentering AB, AB Gotthard Nilsson and J&ouml;nk&ouml;pings 
	Bildemontering AB. Apart from scrap vehicles, the 
	system developed at ECRIS will be used to process waste materials 
	from suppliers and production operations, as well as workshop scrap 
	from dealers. Between 1994 and 1998, ECRIS will be used to:
	
	
	<UL>
		<LI>develop efficient methods of vehicle dismantling and sorting of 
		environmentally hazardous substances and recyclable materials;<BR>
		<BR>
		
		<LI>calculate the environmental loading of different recycling options 
		with the aid of life-cycle assessment (EPS);<BR>
		<BR>
		
		<LI>test various material recycling and energy recovery methods;<BR>
		<BR>

		<LI>evaluate the market for recycled materials.<BR>
		<BR>
	
	</UL>
	
	<P ALIGN="LEFT">
	The experience gained from ECRIS is intended as a basis for Volvo's 
	future recycling programmes.
	
	<P ALIGN="LEFT">
	<B>Designing for dismantling.</B> The conditions which facilitate re-use 
	and recycling are established substantially at the design stage, at 
	which specification of the appropriate materials is one key factor 
	and simplification of the waste management phase is another. ECRIS 
	is routinely used to train designers in car dismantling as a means 
	of ensuring that the operation is made as simple as possible. In 
	addition, Volvo has published dismantling manuals for all its cars from 
	1975 on and for its FH series trucks. On newer models, all plastic 
	components are marked to simplify definition and handling.
	
	<P ALIGN="LEFT">
	<B>Volvo V40 and S40.</B> The V40 and S40 are the cars with which Volvo 
	has achieved most progress in promoting environmentally 
	compatible waste management. The consistent application of life-cycle design to 
	the models has enabled the environmental impact of a series of 
	different components to be reduced dramatically. For example, 
	the use of plastics has been limited to a few different grades. 
	About 50% of the total weight of plastics consists of polypropylene, 
	while the quantity of PVC in the models has been reduced to 8 kg, 
	compared with 18 kg in the Volvo 400. The V40 and S40 also contain 
	recycled materials, amounting at present to 5 kg of plastics, and 
	7 kg of felt and wood- fibre materials.
	
	<P ALIGN="LEFT">
	Thanks to the design, the recycling factor, including re-use, is 
	over 90%.
	
	<P ALIGN="LEFT">
	<B>Recycling market.</B> An established market for used car parts and scrap 
	metal has existed for many years. However, apart from the need for suitable 
	processing technologies, expanding this market to include plastics, rubber 
	and other materials, which are often dumped at present, also calls 	for an 
	increased demand. In short, recycling must be made profitable. In this 
	context, the development of new, cost-effective dismantling and processing 
	methods is a key factor, as are legislation and other political initiatives.
	
	<P ALIGN="LEFT">
	Recycled materials must also be of a clearly specified quality 
	to enable them to be used for the appropriate purposes. In the case 
	of Volvo products, for example, all materials - whether new or recycled - 
	must meet the same high standards of strength, safety and finish.
	
	<P ALIGN="LEFT">
	The metals which comprise 85% by weight of the materials in the 
	modern truck are already recycled today. At present, the corresponding 
	figure for the car is 75%, and the aim is to increase this to 85% by the 
	year 2002.
	
	<P ALIGN="LEFT">
	<B>Return system for Volvo owners.</B> Volvo dealers have introduced a system for 
	returning worn car parts, engine oils, filters, gaskets, and other items, 
	to facilitate Volvo car owners who carry out their own service and repairs.

	<P ALIGN="LEFT">
	<B>100% recycling of aircraft engines.</B> All of the materials in an aircraft 
	engine are customarily recycled when the unit is scrapped. This is of 
	particular value since the materials in question are both special and 
	resource-intensive to produce.
	
	<P ALIGN="LEFT">
	<B>Low weight - low environmental impact.</B> Volvo has carried out its own life-cycle 
	assessment of three different car design concepts, using EPS, to determine 
	the environmental effects of reducing the vehicle weight. The cars were a 
	Volvo 850 built from sheet steel, a variant incorporating a high proportion 
	of aluminium and a model built mainly from composite materials.
	
	<P ALIGN="LEFT">
	Composites undoubtedly have the lowest environmental impact. 
	However, the strict recycling requirements envisaged in countries such as 
	Sweden - requiring 85% of the vehicle weight to be recyclable by the year 
	2002 - may actually prove an obstacle to the use of lighter materials. 
	Although feasible in the case of a conventional car, this is not possible 
	with a composite vehicle. Volvo is by no means opposed to recycling - 
	quite the reverse. However, the example clearly illustrates the importance 
	of an holistic view of the environment to ensure that an otherwise good 
	intention does not prove counter-productive.
	
	<P ALIGN="LEFT">
	<B>Lightweight vehicles.</B> In 1995, VCC carried out a study on the pros and 
	cons of a reduction in vehicle weight. A lightweight vehicle delivers a 
	lower fuel consumption and lower exhaust emissions. On the other hand, 
	new materials, new production processes and new design approaches, in which 
	the various functions of the vehicle are integrated in a different manner 
	than at present, are necessary to ensure that safety, comfort and quality 
	remain unimpaired.
	
	<BR>
	<BR>
	<BR>

	</TD>
</TR>


<TR>
	<TD>

<TABLE WIDTH=447 CELLPADDING=3 BORDER=0>
		<TR>
			<TD COLSPAN=4><B>Environmental loading of different car design concepts</B></TD>
		</TR>
		
		<TR>
			<TD COLSPAN=4><HR></TD>
		</TR>
		
		<TR>
			<TD> </TD>
			<TD ALIGN=CENTER>Weight,<BR>kg</TD>
			<TD ALIGN=CENTER>Fuel con-<BR>sumption,<BR>l/100 km</TD>
			<TD ALIGN=CENTER>Environmen-<BR>tal loading,<BR>ELU</TD>
		</TR>
		
		<TR>
			<TD COLSPAN=4><HR></TD>
		</TR>
		
		<TR>
			<TD>Steel</TD>
			<TD ALIGN=CENTER>1400</TD>
			<TD ALIGN=CENTER>9</TD>
			<TD ALIGN=CENTER>11000</TD>
		</TR>
		
		<TR>
			<TD>Aluminium</TD>
			<TD ALIGN=CENTER>1050</TD>
			<TD ALIGN=CENTER>7</TD>
			<TD ALIGN=CENTER>8500</TD>
		</TR>
		
		<TR>
			<TD>Composite</TD>
			<TD ALIGN=CENTER>840</TD>
			<TD ALIGN=CENTER>6</TD>
			<TD ALIGN=CENTER>7409</TD>
		</TR>
		
		<TR>
			<TD COLSPAN=4><HR></TD>
		</TR>
		
		<TR>
	<TD COLSPAN=4><FONT SIZE=2>
	Total environmental loading of different car design concepts over a
	driving distance of 200,000 km.</FONT>
</TD>

		
	</TABLE>
	</TD>
</TR>
	

</TABLE>


<!-- -------- -->
<BR>
<BR>
<BR>
<P ALIGN=CENTER>
[ <A HREF="mal.html">Next chapter of the Environmental Report</A> |<BR>
<A HREF="transeff.html">Previous chapter of the Environmental Report</A> ]
<BR>
<BR>
<P ALIGN=LEFT>

<HR ALIGN=LEFT WIDTH=447>
<BR>

<TABLE BORDER=0 WIDTH=450>

<TR>
	<TD>Source: Volvo Environmental Report 1995</TD>
</TR>

</TABLE>

<P>

</BLOCKQUOTE>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]

</TD>
</TR>
</TABLE>

</CENTER>


</BODY>
</HTML>






</DOC>
<DOC>
<DOCNO>WT08-B13-211</DOCNO>
<DOCOLDNO>IA089-000951-B023-284</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/environment/report.95/mal.html 192.138.110.240 19970208031758 text/html 13584
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 03:18:08 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 13412
Last-modified: Mon, 17 Jun 1996 13:28:36 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Goals and action programmes</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>

<TR>
	<TD><HR></TD>
</TR>

<TR>
	<TD>

<BLOCKQUOTE>

<!-- ---- DIAGRAM 1 ---- -->

	
	<BR>
	<BR>
	
	<P ALIGN="LEFT">
	<FONT SIZE=5>Goals and action programmes</FONT>
	
	<P ALIGN="LEFT">
	Volvo's aim is to be, and to be regarded 
	as, one of the world's leading automakers in terms of environmental 
	care by the year 2000. This means that we must adopt an holistic 
	approach to environmental issues, having regard to the total lifetime 
	environmental impact of our products, services and activities. We must 
	implement a common environmental management system in all major sections 
	of the organisation, and we must use the efficient tools at our disposal to 
	minimise the use of environmentally hazardous substances and materials. 
	Our plants must be resource-efficient as well as energy-efficient, and 
	must produce low environmental emissions. Our products must be among 
	the cleanest on the market and must comply with extremely strict 
	recycling conditions. The fuel consumption of our petrol and 
	diesel-powered vehicles must be reduced, and we must offer the market 
	vehicles designed to run on alternative fuels.
	
	<P ALIGN="LEFT">
	We must also participate in the development of new transport systems 
	and technical aids to more efficient transportation. We have already 
	made significant progress in many of these areas; however, clear and 
	measurable sub-objectives are necessary if complete success is to be 
	achieved.
	
	<P ALIGN="LEFT">
	In spring 1993, the Volvo Group Executive Committee decided to 
	implement the Environment 95 action programme, to run until 31 December 
	1995. The major goals of the programme, with a brief comment on each, are 
	described in the summary below.
	
	<P ALIGN="LEFT">
	A new programme of objectives, with the emphasis on the 
	environmental impact of our products, our environmental management 
	programmes, our production processes and communications relating to our 
	activities in the environmental field, will be implemented in 1996.
	
	<P ALING="LEFT">
	<IMG HEIGHT=16 WIDTH=447 SRC="/images/environment/report.95/goaltape.gif">



<TABLE CELLSPACE=7 WIDTH=450 BORDER=0>

<TR>
		<TD><IMG WIDTH=184 HEIGHT=0 SRC="/images/environment/report.95/test.gif"></TD>
		<TD><IMG WIDTH=60 HEIGHT=0 SRC="/images/environment/report.95/test.gif"></TD>
		<TD><IMG WIDTH=191 HEIGHT=0 SRC="/images/environment/report.95/test.gif"></TD>
</TR>

<TR>
		<TD VALIGN=TOP><B>1.</B> To establish a well-developed environmental organisation, with 
		clearly defined line and managerial responsibilities for environmental 
		affairs.</TD>
		
		<TD ALIGN=CENTER VALIGN=TOP><IMG HEIGHT=30 WIDTH=30 SRC="/images/environment/report.95/boll3.gif"></TD>
		
		<TD VALIGN=TOP>The delegation of responsibilities in the operating sectors is working 
		satisfactorily, although the impact of some reorganisation measures is 
		not yet clear. The task of appointing environmental coordinators in 
		addition to those in the production plants has also commenced.</TD>
</TR>

<TR><TD><BR></TD></TR>




<TR>
		<TD VALIGN=TOP><B>2.</B> To establish environmental councils in companies and plants.</TD>
		
		<TD ALIGN=CENTER VALIGN=TOP><IMG HEIGHT=30 WIDTH=30 SRC="/images/environment/report.95/boll2.gif"></TD>
		
		<TD VALIGN=TOP>Councils have been established at company level and in most plants, 
		although their function varies.</TD>
</TR>

<TR><TD><BR></TD></TR>




<TR>
		<TD VALIGN=TOP><B>3.</B> To implement regular training and information programmes in 
		environmental affairs for various personnel categories.</TD>
		
		<TD ALIGN=CENTER VALIGN=TOP><IMG HEIGHT=30 WIDTH=30 SRC="/images/environment/report.95/boll2.gif"></TD>
		
		<TD VALIGN=TOP>Information is being disseminated, although not always on a 
		well-structured basis. Training of all personnel was commenced at 
		VCC.</TD>
</TR>

<TR><TD><BR></TD></TR>




<TR>
		<TD VALIGN=TOP><B>4.</B> To implement the EPS system of life-cycle assessment as a design 
		aid, and also as a decisionmaking instrument at different levels.</TD>
		
		<TD ALIGN=CENTER VALIGN=TOP><IMG HEIGHT=30 WIDTH=30 SRC="/images/environment/report.95/boll5.gif"></TD>
		
		<TD VALIGN=TOP>EPS is used to a limited extent. To date, the system has been 
		implemented mostly by VCC.</TD>
</TR>

<TR><TD><BR></TD></TR>




<TR>
		<TD VALIGN=TOP><B>5.</B> To complete a first round of environmental audits in all production units.</TD>
		
		<TD ALIGN=CENTER VALIGN=TOP><IMG HEIGHT=30 WIDTH=30 SRC="/images/environment/report.95/boll2.gif"></TD>
		
		<TD VALIGN=TOP>The following plants 
		remain to be audited: Tuve, parts of Torslanda, Vienna and Orrville. 
		Complete audits of plants acquired in 1995 are also outstanding.</TD>
</TR>

<TR><TD><BR></TD></TR>




<TR>
		<TD VALIGN=TOP><B>6.</B> To establish an environmental communications strategy, with 
		the environmental message as a key element.</TD>
		
		<TD ALIGN=CENTER VALIGN=TOP><IMG HEIGHT=30 WIDTH=30 SRC="/images/environment/report.95/boll2.gif"></TD>
		
		<TD VALIGN=TOP>Several good examples of environmental communication exist, although 
		these are not part of a comprehensive plan. In addition, the emphasis 
		is overly Swedish.</TD>
</TR>

<TR><TD><BR></TD></TR>




<TR>
		<TD VALIGN=TOP><B>7.</B> To prioritise and seek to achieve environmental optimisation in 
		industrial processes in the following areas:</TD>
		
		<TD ALIGN=CENTER VALIGN=TOP><IMG HEIGHT=30 WIDTH=30 SRC="/images/environment/report.95/boll2.gif"></TD>
		
		<TD VALIGN=TOP></TD>
</TR>


<TR>
		<TD VALIGN=TOP>Energy (use and alternatives)</TD>
		
		<TD ALIGN=CENTER VALIGN=TOP></TD>
		
		<TD VALIGN=TOP>The work has proceeded furthest in the 
		Swedish plants. Potential for improvement exists.</TD>
</TR>

<TR>
		<TD VALIGN=TOP>Volatile organic solvents</TD>
		
		<TD ALIGN=CENTER VALIGN=TOP></TD>
		
		<TD VALIGN=TOP>In terms of these emissions, the paint shops at Torslanda and 
		Ume&aring; are the cleanest in their respective sectors.</TD>
</TR>

<TR>
		<TD VALIGN=TOP>Water pollution</TD>
		
		<TD ALIGN=CENTER VALIGN=TOP></TD>
		
		<TD VALIGN=TOP>Effluent treatment plants have been installed in all majority-owned 
		production plants, to BAT (Best Available Technology) level in Sk&ouml;vde, 
		K&ouml;ping and Trollh&auml;ttan.</TD>
</TR>

<TR>
		<TD VALIGN=TOP>Chemicals usage (specification and quantities)</TD>
		
		<TD ALIGN=CENTER VALIGN=TOP></TD>
		
		<TD VALIGN=TOP>MOTIV, the chemical 
		products database, is of high international standard and is used by 
		Volvo worldwide.</TD>
</TR>

<TR>
		<TD VALIGN=TOP>Waste (sorting, recycling, management)</TD>
		
		<TD ALIGN=CENTER VALIGN=TOP></TD>
		
		<TD VALIGN=TOP>Waste management 
		can be further improved, mainly in plants outside Sweden.</TD>
</TR>

<TR><TD><BR></TD></TR>




<TR>
		<TD VALIGN=TOP><B>8.</B> To monitor 
		the environmental performance of our suppliers, stipulating 
		environmental policy and auditing conditions in applicable cases.</TD>
		
		<TD ALIGN=CENTER VALIGN=TOP><IMG HEIGHT=30 WIDTH=30 SRC="/images/environment/report.95/boll5.gif"></TD>
		
		<TD VALIGN=TOP>Common environmental requirements for suppliers have been 
		established at Group level. Work has been commenced. VCC, Ghent leads in 
		terms of audits.</TD>
</TR>

<TR><TD><BR></TD></TR>




<TR>
		<TD VALIGN=TOP><B>9.</B> To implement a plan, where alternatives are 
		available, to phase out CFCs, halons and 1,1,1-trichloroethane in 
		order to protect the ozone layer.</TD>
		
		<TD ALIGN=CENTER VALIGN=TOP><IMG HEIGHT=120 WIDTH=60 SRC="/images/environment/report.95/special1.gif"></TD>
		
		<TD VALIGN=TOP>The use of halons has been discontinued almost entirely in 
		Sweden. Trichloroethane has been phased out. Phasing out of CFCs is in 
		progress.</TD>
</TR>

<TR><TD><BR></TD></TR>




<TR>
		<TD VALIGN=TOP><B>10.</B> To ensure that one unit in 
		each truck engine family complies with Euro 2.</TD>
		
		<TD ALIGN=CENTER VALIGN=TOP><IMG HEIGHT=30 WIDTH=30 SRC="/images/environment/report.95/boll1.gif"></TD>
		
		<TD VALIGN=TOP>All diesel engine 
		families have complied with Euro 2 since October 1995.</TD>
</TR>

<TR><TD><BR></TD></TR>




<TR>
		<TD VALIGN=TOP><B>11.</B> To develop a test series of distribution trucks 
		burning natural gas or alcohol.</TD>
		
		<TD ALIGN=CENTER VALIGN=TOP><IMG HEIGHT=30 WIDTH=30 SRC="/images/environment/report.95/boll1.gif"></TD>
		
		<TD VALIGN=TOP>A CNG/biogas truck was delivered for field testing in May 1995. 
		An ethanol truck was delivered for field testing in April 1995.</TD>
</TR>

<TR><TD><BR></TD></TR>




<TR>
		<TD VALIGN=TOP><B>12.</B> To introduce an environmental concept truck for 
		urban delivery applications.</TD>
		
		<TD ALIGN=CENTER VALIGN=TOP><IMG HEIGHT=30 WIDTH=30 SRC="/images/environment/report.95/boll1.gif"></TD>
		
		<TD VALIGN=TOP>The ECT and ECB were introduced in August 1995.</TD>
</TR>

<TR><TD><BR></TD></TR>




<TR>
		<TD VALIGN=TOP><B>13.</B> To ensure that at least one variant per model 
		family in the VCC range meets the requirements of the highest environmental 
		class in the relevant European incentive system.</TD>
		
		<TD ALIGN=CENTER VALIGN=TOP><IMG HEIGHT=30 WIDTH=30 SRC="/images/environment/report.95/boll4.gif"></TD>
		
		<TD VALIGN=TOP>The Volvo 850 GLT was the first model of car to comply 
		fully with the requirements of Swedish environmental class 1.</TD>
</TR>

<TR><TD><BR></TD></TR>




<TR>
		<TD VALIGN=TOP><B>14.</B> To ensure that VAC's small gas turbines have the 
		lowest emission levels on the market.</TD>
		
		<TD ALIGN=CENTER VALIGN=TOP><IMG HEIGHT=30 WIDTH=30 SRC="/images/environment/report.95/boll2.gif"></TD>
		
		<TD VALIGN=TOP>The emission performance of the units is 
		excellent. However, a complete competitor evaluation has not yet 
		been carried out.</TD>
</TR>

<TR><TD><BR></TD></TR>




<TR>
		<TD VALIGN=TOP><B>15.</B> To ensure that VPC is the first marine engine 
		manufacturer to have five diesels emission-approved for operation 
		on Lake Constance (Bodensee).</TD>
		
		<TD ALIGN=CENTER VALIGN=TOP><IMG HEIGHT=30 WIDTH=30 SRC="/images/environment/report.95/boll1.gif"></TD>
		
		<TD VALIGN=TOP>More than five VPC engines have been approved. The company 
		was also the first to gain such approval.</TD>
</TR>

<TR><TD><BR></TD></TR>




<TR>
		<TD VALIGN=TOP><B>16.</B> To develop and put in place a 
		system of recycling vehicle materials and parts in Sweden.</TD>
		
		<TD ALIGN=CENTER VALIGN=TOP><IMG HEIGHT=30 WIDTH=30 SRC="/images/environment/report.95/boll3.gif"></TD>
		
		<TD VALIGN=TOP>The system is under development and will be fully 
		operational in 1998.</TD>
</TR>

<TR><TD><BR></TD></TR>




<TR>
		<TD VALIGN=TOP><B>17.</B> To publish scrapping manuals for cars and trucks 
		from 1975 and 1978 respectively.</TD>
		
		<TD ALIGN=CENTER VALIGN=TOP><IMG HEIGHT=63 WIDTH=60 SRC="/images/environment/report.95/special2.gif"></TD>
		
		<TD VALIGN=TOP>VCC has achieved this goal. VTC has published manuals 
		for the FH series.</TD>
</TR>

<TR><TD><BR></TD></TR>




<TR>
		<TD VALIGN=TOP><B>18.</B> To participate in demonstration projects of 
		both cars and goods delivery trucks in built-up urban areas.</TD>
		
		<TD ALIGN=CENTER VALIGN=TOP><IMG HEIGHT=30 WIDTH=30 SRC="/images/environment/report.95/boll1.gif"></TD>
		
		<TD VALIGN=TOP>The agreement with the City 
		of Gothenburg, which was reported in detail on 13 November 1995, 
		covers electric vehicles, CNG vehicles and intelligent transport 
		systems.</TD>
</TR>

<TR><TD><BR></TD></TR>




<TR>
		<TD VALIGN=TOP><B>19.</B> To develop navigation, positioning and 
		communications systems for installation in demonstration vehicles and 
		for commercial sale. </TD>
		
		<TD ALIGN=CENTER VALIGN=TOP><IMG HEIGHT=30 WIDTH=30 SRC="/images/environment/report.95/boll1.gif"></TD>
		
		<TD VALIGN=TOP>Dynaguide, Mobiguide and Dynafleet are available 
		from Volvo.</TD>
</TR>

<TR><TD><BR></TD></TR>




<TR>
		<TD VALIGN=TOP><B>20.</B> To be, and to be considered as, one of the most 
		environmentally aware companies in the transport sector.</TD>
		
		<TD ALIGN=CENTER VALIGN=TOP><IMG HEIGHT=30 WIDTH=30 SRC="/images/environment/report.95/boll2.gif"></TD>
		
		<TD VALIGN=TOP>Competitor evaluations and attitude surveys indicate that 
		Volvo is well to the fore in this respect, particularly in trucks, 
		construction equipment, buses and marine engines.</TD>
</TR>

<TR><TD><BR></TD></TR>





</TABLE>


<!-- -------- -->
<BR>
<BR>
<BR>
<P ALIGN=CENTER>
[ <A HREF="mojligh.html">Next chapter of the Environmental Report</A> |<BR>
<A HREF="atervinn.html">Previous chapter of the Environmental Report</A> ]
<BR>
<BR>
<P ALIGN=LEFT>

<HR ALIGN=LEFT WIDTH=447>
<BR>


<TABLE BORDER=0 WIDTH=450>

<TR>
	<TD>Source: Volvo Environmental Report 1995</TD>
</TR>

</TABLE>

<P>

</BLOCKQUOTE>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]

</TD>
</TR>
</TABLE>

</CENTER>


</BODY>
</HTML>






</DOC>
<DOC>
<DOCNO>WT08-B13-212</DOCNO>
<DOCOLDNO>IA089-000951-B023-309</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/environment/report.95/mojligh.html 192.138.110.240 19970208031809 text/html 5546
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 03:18:19 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 5375
Last-modified: Mon, 17 Jun 1996 13:28:43 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Opportunities and challenges</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>

<TR>
	<TD><HR></TD>
</TR>

<TR>
	<TD>

<BLOCKQUOTE>

<!-- ---- DIAGRAM 1 ---- -->

<TABLE WIDTH=450 BORDER=0>


<TR>
	<TD>
	<BR>
	<BR>
	
	
	<P ALIGN="LEFT">
	<FONT SIZE=5>Opportunities and challenges</FONT>
	
	<P ALIGN="LEFT">
	The development of the vehicles and transport systems of the future 
	is influenced by a series of societal factors. New research findings 
	in the environmental field, political decisions relating to legislation 
	and taxation, changes in popular attitudes and behaviour, national 
	economic growth, and the availability and price of fuels are among the 
	many factors which will dictate the shape of tomorrow. This means that 
	we at Volvo must be constantly sensitive to change, while carefully 
	monitoring both the opportunities and challenges involved in every new 
	decision.
	
	<P ALIGN="LEFT">
	<B>Climate change.</B> Legislation controlling emissions of carbon dioxide 
	and other greenhouse gases is likely to be tightened in future as 
	efforts to arrest the greenhouse effect are intensified. In this 
	situation, politicians may feel disposed to influence developments 
	in favour of lighter and more fuel-efficient vehicles by modifying 
	the system of taxation of vehicles and fuels. Combining low weight 
	with vehicle safety will call for major development programmes.

	<P ALIGN="LEFT">
	<B>Congestion problems.</B> The problems of congestion and air pollution 
	caused by traffic, especially in major conurbations, may necessitate the 
	introduction of traffic restrictions and control measures, while 
	increasing the need for coordination between different forms of 
	transport.

	<P ALIGN="LEFT">
	<B>Tougher Californian standards.</B> The stricter emission control 
	standards due to be introduced in California may pave the way 
	for similar legislation in other countries.

	<P ALIGN="LEFT">
	<B>Fuel cost.</B> The price of oil products will have an influence on 
	the fuels which will be used in the future.

	<P ALIGN="LEFT">
	<B>Recycling.</B> Stricter recycling requirements will have an influence on 
	the materials which will be used in the vehicles of the future. Paradoxically, 
	this may have an adverse effect on the development of lighter and more 
	fuel-efficient vehicles. 

	<P ALIGN="LEFT">
	<B>Keener interest in environmental problems.</B> Public and politicians alike 
	are displaying a greater awareness of environmental issues, a 
	development which may expand the market for new, environmentally 
	superior products.

	<P ALIGN="LEFT">
	<B>Willingness to pay.</B> The willingness of the market to pay for new, more 
	environmentally acceptable products is of major importance. Products 
	manufactured in small volumes are more expensive, a factor which 
	can deter many customers.

	<P ALIGN="LEFT">
	<B>Harmonisation of legislation.</B> Adoption of the same legislation in a 
	large number of markets will reduce per-unit prices by permitting production 
	in large volumes. Differences in statutory requirements from market to market 
	result in smaller series, higher production costs and more expensive products.

	<P ALIGN="LEFT">
	<B>Growing transport volume.</B> If the volume of transport continues to grow 
	at the same rate as in recent decades, the resultant increase in atmospheric 
	pollution will outstrip the environmental gains achieved by developing 
	cleaner engines.

	<P ALIGN="LEFT">
	<B>Responsibility of producer.</B> The imposition of legal responsibility for 
	worn-out vehicles on producers is currently being discussed by the EU. 
	The automotive industry, together with the recycling industry, has 
	voluntarily undertaken to resolve the problem of recycling future models 
	at the end of their useful lives. Retrospective responsibility for the 
	existing vehicle population is also under discussion in some EU countries. 
	However, the financial implications of this proposal are such that 
	automakers would be unable to accept it without compensation.

	<P ALIGN="LEFT">
	<B>Tougher plant regulations.</B> Regulations governing the emission of 
	substances such as solvents from production plants may possibly be tightened, 
	necessitating capital investment in materials development and new purification 
	facilities.
	</TD>
</TR>


</TABLE>


<!-- -------- -->


<BR>
<BR>
<P ALIGN=CENTER>
<A HREF="/environment/report.95/milestone.html">[Milestones in Volvo's 
environmental programmes]</A>

<BR>
<BR>
<BR>
<BR>
<P ALIGN=CENTER>
[ <A HREF="pris.html">Next chapter of the Environmental Report</A> |<BR>
<A HREF="mal.html">Previous chapter of the Environmental Report</A> ]
<BR>
<BR>
<P ALIGN=LEFT>

<HR ALIGN=LEFT WIDTH=447>
<BR>



<TABLE BORDER=0 WIDTH=450>

<TR>
	<TD>Source: Volvo Environmental Report 1995</TD>
</TR>

</TABLE>

<P>

</BLOCKQUOTE>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]

</TD>
</TR>
</TABLE>

</CENTER>


</BODY>
</HTML>






</DOC>
<DOC>
<DOCNO>WT08-B13-213</DOCNO>
<DOCOLDNO>IA089-000951-B023-336</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/environment/report.95/pris.html 192.138.110.240 19970208031820 text/html 3548
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 03:18:32 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 3377
Last-modified: Mon, 17 Jun 1996 13:28:53 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Volvo Environment Prize</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>

<TR>
	<TD><HR></TD>
</TR>

<TR>
	<TD>

<BLOCKQUOTE>

<!-- ---- DIAGRAM 1 ---- -->

<TABLE WIDTH=450 BORDER=0>


<TR>
	<TD>
	
	<BR>
	<BR>
	
	<P ALIGN="LEFT">
	<FONT SIZE=5>Volvo Environment Prize</FONT>
	
<P ALIGN="LEFT">
<IMG HSPACE=7 VSPACE=5 WIDTH=200 HEIGHT=167 ALIGN=LEFT SRC="/images/environment/report.95/gyll_white.gif">
The 1995 Volvo Environment Prize was awarded to Professor Gilbert 
White of the University of Colorado in the USA for "his outstanding 
and sustained 
contribution to the understanding of and action on essentially regional 
and global environmental and natural resource issues."

<P ALIGN="LEFT">
Instituted in 1988, the Volvo Environment Prize was awarded for the 
first time in 1990. Volvo's aim is to promote environmental research 
across a broad spectrum by awarding an annual prize to one or more 
individuals adjudged to have made a unique contribution to the 
understanding or protection of the 
environment, through scientific, socio-economic or technological 
innovation or discovery. The prize is currently worth SEK1.5 million.

<P ALIGN="LEFT">
<B>Previous winners.</B> 1990: Professors John V. Krutilla and Allen V. Kneese, 
for the development of a theory of environmental economics.

<P ALIGN="LEFT">
1991: Professor Paul Crutzen, for his unique ability to identify and 
clarify critical factors governing the chemical behaviour of the atmosphere. 
Professor Crutzen shared the 1995 Nobel Prize for chemistry.

<P ALIGN="LEFT">
1992: Dr. Norman Myers and Professor Peter H. Raven, for their 
comprehensive scientific analysis of ecological states and trends, 
which alerted world opinion to the global consequences of the loss 
of biodiversity.

<P ALIGN="LEFT">
1993: Professors Paul R. Ehrlich and John P. Holdren, for their 
pioneering work in clarifying the relationships 
between population growth, the use of resources and the capacity of 
the earth to feed its population.

<P ALIGN="LEFT">
1994: Dr. Gita Sen, whose pioneering research has broadened our 
understanding of how the relationship between environment and 
development is 
conditioned by social structures, with particular emphasis on the 
changing role of women within them.	</TD>
</TR>


</TABLE>


<!-- -------- -->


<BR>
<BR>

<P ALIGN=CENTER>
[<A HREF="/environment/prize.html"> The Volvo Environment Prize</A> | 
<A HREF="/environment/report.95/wildlife.html">[Wildlife project</A> ]


<BR>
<BR>
<BR>
<P ALIGN=CENTER>
[ <A HREF="managers.html">Next chapter of the Environmental Report</A> |<BR>
<A HREF="mojligh.html">Previous chapter of the Environmental Report</A> ]
<BR>
<BR>
<P ALIGN=LEFT>

<HR ALIGN=LEFT WIDTH=447>
<BR>


<TABLE BORDER=0 WIDTH=450>

<TR>
	<TD>Source: Volvo Environmental Report 1995</TD>
</TR>

</TABLE>

<P>

</BLOCKQUOTE>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]

</TD>
</TR>
</TABLE>

</CENTER>


</BODY>
</HTML>






</DOC>
<DOC>
<DOCNO>WT08-B13-214</DOCNO>
<DOCOLDNO>IA089-000951-B024-15</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/environment/report.95/managers.html 192.138.110.240 19970208031830 text/html 2771
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 03:18:40 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 2600
Last-modified: Mon, 17 Jun 1996 13:28:38 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Environmental managers</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>

<TR>
	<TD><HR></TD>
</TR>

<TR>
	<TD>

<BLOCKQUOTE>

<!-- ---- DIAGRAM 1 ---- -->

<BR>
<BR>


<P ALIGN="LEFT">
<B>In charge of environmental affairs, <BR>
Group Executive Committee</B>

<P ALIGN="LEFT">
Per-Erik Mohlin<BR>
Executive Vice President<BR>
AB Volvo, <BR>
S-405 08 Gothenburg, Sweden.<BR>
Tel. +46-31-59 58 00<BR>
Fax  +46-31-59 12 08<BR>

<P ALIGN="LEFT">
<B>Environmental managers, <BR>
Volvo Group companies</B>

<P ALIGN="LEFT">
AB Volvo<BR>
Anders K&auml;rrberg<BR>
Dept. 370 VHK, <BR>
S-405 08 Gothenburg, Sweden<BR>
Tel. +46-31-59 12 00<BR>
Fax  +46-31-59 10 44<BR>

<P ALIGN="LEFT">
Volvo Car Corporation<BR>
Ulla-Britt Fr&auml;jdin Hellqvist<BR>
Dept. 56400 PVD 3:1, <BR>
S-405 08 Gothenburg, Sweden<BR>
Tel. +46-31-59 47 32<BR>
Fax  +46-31-59 40 89<BR>

<P ALIGN="LEFT">
Volvo Truck Corporation<BR>
Alf Rehnstr&ouml;m<BR>
Dept. 20150 VLH8, <BR>
S-405 08 Gothenburg, Sweden<BR>
Tel. +46-31-66 56 87<BR>
Fax  +46-31-22 96 59<BR>

<P ALIGN="LEFT">
Volvo Bus Corporation<BR>
Kerstin Sterner<BR>
Dept. 80900 VBA1, <BR>
S-405 08 Gothenburg, Sweden<BR>
Tel. +46-31-66 64 52<BR>
Fax  +46-31-66 72 88<BR>

<P ALIGN="LEFT">
Volvo Penta Corporation<BR>
Karl G&ouml;ran Andersson<BR>
Dept. 47100 Z21, <BR>
S-405 08 Gothenburg, Sweden<BR>
Tel. +46-31-66 81 68<BR>
Fax  +46-31-22 60 08<BR>

<P ALIGN="LEFT">
Volvo Construction Equipment Corporation<BR>
Jan Stighagen<BR>
S-631 85 Eskilstuna, Sweden<BR>
Tel. +46-16-15 26 13<BR>
Fax  +46-16-15 22 10<BR>

<P ALIGN="LEFT">
Volvo Aero Corporation<BR>
Leif Mowitz<BR>
S-461 81 Trollh&auml;ttan, Sweden<BR>
Tel. +46-520-939 30<BR>
Fax  +46-520-340 10<BR>


	
	

<!-- -------- -->
<BR>
<BR>
<BR>
<P ALIGN=CENTER>
[ <A HREF="knowmore.html">Next chapter of the Environmental Report</A> |<BR> 
<A HREF="pris.html">Previous chapter of the Environmental Report</A> ]
<BR>
<BR>
<P ALIGN=LEFT>

<HR ALIGN=LEFT WIDTH=447>
<BR>

<TABLE BORDER=0 WIDTH=450>

<TR>
	<TD>Source: Volvo Environmental Report 1995</TD>
</TR>

</TABLE>

<P>

</BLOCKQUOTE>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]

</TD>
</TR>
</TABLE>

</CENTER>


</BODY>
</HTML>






</DOC>
<DOC>
<DOCNO>WT08-B13-215</DOCNO>
<DOCOLDNO>IA089-000951-B024-49</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/environment/report.95/knowmore.html 192.138.110.240 19970208031850 text/html 5119
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 03:19:00 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 4948
Last-modified: Mon, 17 Jun 1996 13:28:17 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Want to know more?</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>

<TR>
	<TD><HR></TD>
</TR>

<TR>
	<TD>

<BLOCKQUOTE>

<!-- ---- DIAGRAM 1 ---- -->
<BR>
<BR>

<P ALIGN="LEFT">
<FONT SIZE=5>Want to know more?</FONT>

<P ALIGN="LEFT">
If you have any views on this year's environmental report or would like to 
receive a copy of any of the following publications, which contain further 
information on Volvo's environmental programmes, please contact: 

<P ALIGN="LEFT">
AB Volvo, Environmental Affairs, <BR>
S-405 08 Gothenburg, Sweden. <BR>
Tel. +46-31-59 44 33 <BR>
fax. +46-31-59 10 44.

<P ALIGN="LEFT">
<B>AB Volvo</B>

<UL>
	<LI TYPE=SQUARE>Volvo Environmental Report 1995 in Swedish, 
English, German, French and Chinese 
<BR>
<BR>
	<LI TYPE=SQUARE>Volvo Environmental Report 1994
<BR>
<BR>
	<LI TYPE=SQUARE>Volvo Environmental Report 1993
<BR>
<BR>
	<LI TYPE=SQUARE>On the road to a better environment
<BR>
<BR>
	<LI TYPE=SQUARE>Volvo's Environmental Management System, VEMS
<BR>
<BR>
	<LI TYPE=SQUARE>Volvo Environment Prize
<BR>
<BR>
	<LI TYPE=SQUARE>Volvo and recycling
<BR>
<BR>
	<LI TYPE=SQUARE>Environmental care - Requirements for suppliers and 
	contractors to the Volvo Group
<BR>
<BR>
	<LI TYPE=SQUARE>Volvo's black and grey lists for chemicals
</UL>
<BR>
<BR>


<BLOCKQUOTE>
<P ALIGN="LEFT">
<B>Volvo Car Corporation</B>
</BLOCKQUOTE>

<UL>
	<LI TYPE=SQUARE>Environmental measures - year by year
<BR>
<BR>
	<LI TYPE=SQUARE>Effective catalytic exhaust emission control
<BR>
<BR>
	<LI TYPE=SQUARE>Advanced combustion technology
<BR>
<BR>
	<LI TYPE=SQUARE>The rapid elimination of CFCs at the Volvo Car Corporation
<BR>
<BR>
	<LI TYPE=SQUARE>Effective water purification at the Volvo Torslanda Plant
<BR>
<BR>
	<LI TYPE=SQUARE>Environmentally-compatible heating at the Volvo Torslanda Plant
<BR>
<BR>
	<LI TYPE=SQUARE>Environmentally-compatible cleaning agents in car production
<BR>
<BR>
	<LI TYPE=SQUARE>Transport planning and the environment
<BR>
<BR>
	<LI TYPE=SQUARE>Reduced evaporation of hydrocarbon in refuelling and parking
<BR>
<BR>
	<LI TYPE=SQUARE>The elimination of asbestos, mercury and chromic acid
<BR>
<BR>
	<LI TYPE=SQUARE>New packaging policy saves money and the environment
<BR>
<BR>
	<LI TYPE=SQUARE>Environmental programme at market level
<BR>
<BR>
	<LI TYPE=SQUARE>Volvo's fuel data base
<BR>
<BR>
	<LI TYPE=SQUARE>Solvent-free underseal
<BR>
<BR>
	<LI TYPE=SQUARE>Environmentally-compatible surface treatment
<BR>
<BR>
	<LI TYPE=SQUARE>Volvo engines for alternative fuels
<BR>
<BR>
	<LI TYPE=SQUARE>Environmentally-compatible car scrapping
<BR>
<BR>
	<LI TYPE=SQUARE>Environmental audits at Volvo
<BR>
<BR>
	<LI TYPE=SQUARE>Life cycle assessment in product engineering
<BR>
<BR>
	<LI TYPE=SQUARE>Volvo ECC 1992
<BR>
<BR>
	<LI TYPE=SQUARE>Monitoring chemicals at Volvo
<BR>
<BR>
	<LI TYPE=SQUARE>Clear Facts - Newsletter from the environment department
</UL>
<BR>
<BR>


<BLOCKQUOTE>
<P ALIGN="LEFT">
<B>Volvo Truck Corporation</B>
</BLOCKQUOTE>

<UL>
	<LI TYPE=SQUARE>The truck in modern society
<BR>
<BR>
	<LI TYPE=SQUARE>ECT Environmental Concept Truck
<BR>
<BR>
	<LI TYPE=SQUARE>Ecomobility: The Volvo Truck Corporation removes substances 
	harmful to 
	the ozone layer
<BR>
<BR>
	<LI TYPE=SQUARE>Ecomobility: EPS helps design engineers to make the right 
	choice for the environment
<BR>
<BR>
	<LI TYPE=SQUARE>Ecomobility: 95% recycling of plastic components possible
<BR>
<BR>
	<LI TYPE=SQUARE>Ecomobility: Volvo makes it possible to replace freons in older 
	trucks
<BR>
<BR>
	<LI TYPE=SQUARE>Ecomobility: Vehicle noise - an underestimated problem
<BR>
<BR>
	<LI TYPE=SQUARE>Ecomobility: Volvo halved its emissions from transport 
	operations during a five-year period
<BR>
<BR>
	<LI TYPE=SQUARE>Ecomobility: Aerodynamics contribute essentially to fuel 
	reduction
<BR>
<BR>
	<LI TYPE=SQUARE>Ecomobility: What is VEMS?
</UL>
<BR>
<BR>

<BLOCKQUOTE>
<P ALIGN="LEFT">
<B>Volvo Bus Corporation</B>
</BLOCKQUOTE>
<UL>
	<LI TYPE=SQUARE>ECB Environmental Concept Bus
<BR>
<BR>
	<LI TYPE=SQUARE>Volvo Omnibus
</UL>	
	


<!-- -------- -->
<BR>
<BR>
<BR>
<P ALIGN=CENTER>
[ Next chapter of the Environmental Report |<BR>
<A HREF="managers.html">Previous chapter of the Environmental Report</A> ]
<BR>
<BR>
<P ALIGN=LEFT>

<HR ALIGN=LEFT WIDTH=447>
<BR>

<TABLE BORDER=0 WIDTH=450>

<TR>
	<TD>Source: Volvo Environmental Report 1995</TD>
</TR>

</TABLE>

<P>

</BLOCKQUOTE>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]

</TD>
</TR>
</TABLE>

</CENTER>


</BODY>
</HTML>






</DOC>
<DOC>
<DOCNO>WT08-B13-216</DOCNO>
<DOCOLDNO>IA089-000951-B024-70</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/corpinfo/museum/20-40.html 192.138.110.240 19970208031906 text/html 3753
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 03:19:17 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 3582
Last-modified: Mon, 25 Nov 1996 11:50:39 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>The 1920s, 1930s and 1940s</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="pictures.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>
</TR>

<TR>
	<TD><HR></TD>
</TR>

</TABLE>

<TABLE WIDTH=490 BORDER=0>
<TR>
	<TD>
<BR>
<BR>

<BLOCKQUOTE>

<FONT SIZE=6>The 1920s, 1930s and 1940s</FONT><BR>
<BR>
<BR>
<BR>


<TABLE WIDTH=450 BORDER=0>
<TR>
	<TD>
	<IMG BORDER=1 WIDTH=220 HIGHT=129 HSPACE=10 VSPACE=4 
	SRC="/images/museum/1927.gif"></TD>
	<TD ALIGN=LEFT VALIGN=TOP>
	<B>1927</B><BR>
	Volvo's first car, the &Ouml;V4. 
	Pictured here is a prototype from the first test-series built in 1926.
	</TD>
</TR>
</TABLE>
<BR>
<BR>


<TABLE WIDTH=450 BORDER=0>
<TR>
	<TD ALIGN=RIGHT VALIGN=TOP>
	<B>1928</B><BR>
	LV40. Trucks and buses dominated Volvo's product range during the early 
	decades.</TD>
	<TD>
	<IMG BORDER=1 WIDTH=170 HIGHT=105 HSPACE=10 VSPACE=4 
	SRC="/images/museum/1928.gif">
	</TD>
</TR>
</TABLE>
<BR>
<BR>


<TABLE WIDTH=450 BORDER=0>
<TR>
	<TD>
	<IMG BORDER=1 WIDTH=109 HIGHT=174 HSPACE=10 VSPACE=4 
	SRC="/images/museum/1930.gif"></TD>
	<TD ALIGN=LEFT VALIGN=TOP>
	<B>1930</B><BR>
	Volvo acquired the share majority in AB Pentaverken, 
	Sk&ouml;vde, and  in 1935 Volvo Penta was established in G&ouml;teborg 
	to convert engines for marine use.<BR>
	<BR>
	This Penta U-22  engine was manufactured between 1922- 1978.
	</TD>
</TR>
</TABLE>
<BR>
<BR>


<TABLE WIDTH=450 BORDER=0>
<TR>
	<TD ALIGN=RIGHT VALIGN=TOP>
	<B>1935</B><BR>
	PV36 - The Carioca. A provocative and streamlined car named after a 
	fashionable South American dance.</TD>
	<TD>
	<IMG BORDER=1 WIDTH=200 HIGHT=163 HSPACE=10 VSPACE=4 
	SRC="/images/museum/1935.gif"></TD>
</TR>
</TABLE>
<BR>
<BR>


<TABLE WIDTH=450 BORDER=0>
<TR>
	<TD>
	<IMG BORDER=1 WIDTH=108 HIGHT=97 HSPACE=10 VSPACE=4 
	SRC="/images/museum/1941.gif"></TD>
	<TD ALIGN=LEFT VALIGN=TOP>
	<B>1941</B><BR>
	Volvo became the majority shareholder in Svenska Flygmotor AB.
	(Volvo Aero Corp.)
	</TD>
</TR>
</TABLE>
<BR>
<BR>


<TABLE WIDTH=450 BORDER=0>
<TR>
	<TD ALIGN=RIGHT VALIGN=TOP>
	<B>1944</B><BR>
	PV60 "the Yankee car".</TD>
	<TD><IMG BORDER=1 WIDTH=200 HIGHT=97 HSPACE=10 VSPACE=4 
	SRC="/images/museum/1944-2.gif">
	</TD>
</TR>
</TABLE>
<BR>
<BR>


<TABLE WIDTH=450 BORDER=0>
<TR>
	<TD><IMG BORDER=1 WIDTH=231 HIGHT=137 HSPACE=10 VSPACE=4 
	SRC="/images/museum/1944-1.gif"></TD>
	<TD ALIGN=LEFT VALIGN=TOP>
	<B>1944</B><BR>
	The PV444/544 was an enormous success for Volvo - a total of 440,000 cars 
	were manufactured.
	</TD>
</TR>
</TABLE>
<BR>
<BR>


<TABLE WIDTH=490 BORDER=0>
<TR>
	<TD ALIGN=RIGHT VALIGN=TOP>
	<B> <A
HREF="http://194.2.74.64/cgi-bin/dbml.exe?template=/spantac/ok/ok.htm&pim=vm
ksarqxmdcjrihoduta&pam=upsertwivqafyuxicxbm&poum=xeumsaqhovldjrhyfndu&spanta
claus=plwicfjvqswjdgkdqteq">1946  </A></B><BR>
	The first diesel truck - the LV150 - was introduced.</TD>
	<TD><IMG BORDER=1 WIDTH=250 HIGHT=121 HSPACE=10 VSPACE=4 
	SRC="/images/museum/1946.gif"></TD>
</TR>
</TABLE>
<BR>
<BR>
<BR>


<P>
<BR>
</BLOCKQUOTE>
<P ALIGN="CENTER">[ <A HREF="50-70.html">The 1950s, 1960s and 1970s</A> | 
<A HREF="80-90.html">The 1980s and 1990s</A> ] 

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]
</TD>
</TR>
</TABLE>

</CENTER>

</BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-217</DOCNO>
<DOCOLDNO>IA089-000951-B024-97</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/corpinfo/museum/50-70.html 192.138.110.240 19970208031930 text/html 3475
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 03:19:36 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 3304
Last-modified: Thu, 13 Jun 1996 14:45:47 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>The 1950s, 1960s and 1970s</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="pictures.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>
</TR>

<TR>
	<TD><HR></TD>
</TR>

</TABLE>

<TABLE WIDTH=490 BORDER=0>
<TR>
	<TD>
<BR>
<BR>

<BLOCKQUOTE>

<FONT SIZE=6>The 1950s, 1960s and 1970s</FONT><BR>
<BR>
<BR>
<BR>



<TABLE WIDTH=450 BORDER=0>
<TR>
	<TD><IMG BORDER=1 WIDTH=200 HIGHT=125 HSPACE=10 VSPACE=4 
	SRC="/images/museum/1953.gif"></TD>
	<TD ALIGN=LEFT VALIGN=TOP>
	<B>1953</B><BR>
	Volvo Duett (PV445) - famous for its luggage capacity.
	</TD>
</TR>
</TABLE>
<BR>
<BR>


<TABLE WIDTH=460 BORDER=0>
<TR>
	<TD ALIGN=RIGHT VALIGN=TOP>
	<B>1956</B><BR>
	"The lines smack of the USA but they are flavoured with a pinch 
	of Italian " was one judgement about the Volvo Amazon (P120) when 
	it appeared on the scene.</TD>
	<TD><IMG BORDER=1 WIDTH=182 HIGHT=110 HSPACE=10 VSPACE=4 
	SRC="/images/museum/1956.gif">
</TD>
</TR>
</TABLE>
<BR>
<BR>


<TABLE WIDTH=450 BORDER=0>
<TR>
	<TD><IMG BORDER=1 WIDTH=258 HIGHT=92 HSPACE=10 VSPACE=4 
	SRC="/images/museum/1959-1.gif"></TD>
	<TD ALIGN=LEFT VALIGN=TOP>
	<B>1959</B><BR>
	P1800 - a sports car with room for Simon Templar "The Saint".</TD>
</TR>
</TABLE>
<BR>
<BR>


<TABLE WIDTH=450 BORDER=0>
<TR>
 	<TD ALIGN=RIGHT VALIGN=TOP>
	<B>1959</B><BR>
	The Aquamatic - a revolutionary combination of an inboard 
	engine and an outboard gear.</TD>
	<TD><IMG BORDER=1 WIDTH=168 HIGHT=97 HSPACE=10 VSPACE=4 
	SRC="/images/museum/1959-2.gif"></TD>
</TR>
</TABLE>
<BR>
<BR>


<TABLE WIDTH=450 BORDER=0>
<TR>
	<TD><IMG BORDER=1 WIDTH=182 HIGHT=119 HSPACE=10 VSPACE=4 
	SRC="/images/museum/1966.gif"></TD>
	<TD ALIGN=LEFT VALIGN=TOP>
	<B>1966 </B><BR>
	The Volvo 144 saw the introduction of the body lines which were 
	to remain for several decades.
	</TD>
</TR>
</TABLE>
<BR>
<BR>


<TABLE WIDTH=450 BORDER=0>
<TR>
	<TD ALIGN=RIGHT VALIGN=TOP>
	<B>1973</B><BR>
	N7 - the first modern standard-built truck. 12,000 of the N7's were 
	manufactured between 1973 and 1986.</TD>
	<TD><IMG BORDER=1 WIDTH=224 HIGHT=145 HSPACE=10 VSPACE=4 
	SRC="/images/museum/1973.gif">
</TD>
</TR>
</TABLE>
<BR>
<BR>


<TABLE WIDTH=450 BORDER=0>
<TR>
	<TD><IMG BORDER=1 WIDTH=221 HIGHT=93 HSPACE=10 VSPACE=4 
	SRC="/images/museum/1974.gif"></TD>
	<TD ALIGN=LEFT VALIGN=TOP>
	<B>1974</B><BR>
	The 240 series - a logical step towards ever safer cars.
	</TD>
</TR>
</TABLE>
<BR>
<BR>



<TABLE WIDTH=450 BORDER=0>
<TR>
	<TD ALIGN=RIGHT VALIGN=TOP>
	<B>1979</B><BR>
	Volvo Aero , earlier Volvo Flygmotor, manufactures the powerhouse in 
	a  JA37B Viggen.</TD>
	<TD><IMG BORDER=1 WIDTH=151 HIGHT=92 HSPACE=10 VSPACE=4 
	SRC="/images/museum/1979.gif">
</TD>
</TR>
</TABLE>
<BR>
<BR>
<P>
<BR>
</BLOCKQUOTE>
<P ALIGN="CENTER">[ <A HREF="20-40.html">The 1920s, 1930s and 1940s</A> | 
<A HREF="80-90.html">The 1980s and 1990s</A> ] 

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]
</TD>
</TR>
</TABLE>

</CENTER>

</BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-218</DOCNO>
<DOCOLDNO>IA089-000951-B024-127</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/corpinfo/museum/80-90.html 192.138.110.240 19970208031950 text/html 2436
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 03:19:59 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 2265
Last-modified: Thu, 13 Jun 1996 14:45:47 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>The 1980s and 1990s</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="pictures.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>
</TR>

<TR>
	<TD><HR></TD>
</TR>

</TABLE>

<TABLE WIDTH=490 BORDER=0>
<TR>
	<TD>
<BR>
<BR>

<BLOCKQUOTE>

<FONT SIZE=6>The 1980s and 1990s</FONT><BR>
<BR>
<BR>
<BR>


<TABLE WIDTH=450 BORDER=0>
<TR>
	<TD><IMG BORDER=1 WIDTH=168 HIGHT=107 HSPACE=10 VSPACE=4 
	SRC="/images/museum/1980.gif"></TD>
	<TD ALIGN=LEFT VALIGN=TOP>
	<B>1980s</B><BR>
	Volvo Buses volume-seller B10M, Mk III.
	</TD>
</TR>
</TABLE>
<BR>
<BR>


<TABLE WIDTH=450 BORDER=0>
<TR>
	<TD ALIGN=RIGHT VALIGN=TOP>
	<B>1982</B><BR>
	The Volvo 760 was launched at nine different places in Europe.</TD>
	<TD><IMG BORDER=1 WIDTH=221 HIGHT=114 HSPACE=10 VSPACE=4 
	SRC="/images/museum/1982-2.gif">
</TD>
</TR>
</TABLE>
<BR>
<BR>


<TABLE WIDTH=450 BORDER=0>
<TR>
	<TD><IMG BORDER=1 WIDTH=186 HIGHT=118 HSPACE=10 VSPACE=4 
	SRC="/images/museum/1982-1.gif"></TD>
	<TD ALIGN=LEFT VALIGN=TOP>
	<B>1982</B><BR>
	Volvo Penta aroused well-deserved attention with its Duoprop.
	</TD>
</TR>
</TABLE>
<BR>
<BR>


<TABLE WIDTH=450 BORDER=0>
<TR>
	<TD ALIGN=RIGHT VALIGN=TOP>
	<B>1991</B><BR>
	The Volvo 850- a completely new design with classic lines.</TD>
	<TD><IMG BORDER=1 WIDTH=239 HIGHT=139 HSPACE=10 VSPACE=4 
	SRC="/images/museum/1991.gif">
</TD>
</TR>
</TABLE>
<BR>
<BR>


<TABLE WIDTH=450 BORDER=0>
<TR>
	<TD><IMG BORDER=1 WIDTH=168 HIGHT=218 HSPACE=10 VSPACE=4 
	SRC="/images/museum/1994.gif"></TD>
	<TD ALIGN=LEFT VALIGN=TOP>
	<B>1994</B><BR>
	The FH-series chosen as "Truck of the Year 1994" by European 
	journalists.
	</TD>
</TR>
</TABLE>
<BR>
<BR>


<P>
<BR>
</BLOCKQUOTE>
<P ALIGN="CENTER">[ <A HREF="20-40.html">The 1920s, 1930s and 1940s</A> | 
<A HREF="50-70.html">The 1950s, 1960s and 1970s</A> ] 

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]
</TD>
</TR>
</TABLE>

</CENTER>

</BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-219</DOCNO>
<DOCOLDNO>IA089-000951-B024-155</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/corpinfo/europe/index.html 192.138.110.240 19970208032007 text/html 3324
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 03:20:16 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 3153
Last-modified: Thu, 13 Jun 1996 14:41:18 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Volvo in Europe</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<A NAME="top"></A>

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="../world.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>
</TR>

<TR>
	<TD><HR></TD>
</TR>

</TABLE>



<TABLE WIDTH=490 BORDER=0>
<TR>
	<TD>

<BLOCKQUOTE>

<BR>
<FONT COLOR="000078" SIZE=7><B>Volvo in Europe</FONT></B><BR>
<BR>
<BR>

<FONT SIZE=4><A HREF="chief.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
src="/images/knbla.gif"LEFT>The Chief Executive Officer
</A></FONT><BR>
<BR>

<FONT SIZE=4><A HREF="position.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
src="/images/knbla.gif"LEFT>Volvo's position worldwide and in 
Europe</A></FONT><BR>
<BR>

<FONT SIZE=4><A HREF="production.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
src="/images/knbla.gif"LEFT>Volvo production sites</A></FONT><BR>
<BR>

<FONT SIZE=4><A HREF="safety.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
src="/images/knbla.gif"LEFT>Safety</A></FONT><BR>
<BR>

<FONT SIZE=4><A HREF="environment.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
src="/images/knbla.gif"LEFT>Environment</A></FONT><BR>
<BR>

<FONT SIZE=4><A HREF="focus.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
src="/images/knbla.gif"LEFT>Volvos's focus on Europe, an 
historical review</A></FONT><BR>
<BR>

<FONT SIZE=4><A HREF="representation.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
src="/images/knbla.gif"LEFT>Volvo European representative 
office</A></FONT><BR>
<BR>
<BR>

<P ALIGN="LEFT">
Volvo's strategy is to develop the company's advanced position in the 
passenger car field and to further strengthen Volvo's standing as one 
of the world leaders in trucks and buses, construction equipment and 
power systems for marine and commercial use as well as aircraft engines.

<P ALIGN="LEFT">
Quality, safety and care for the environment are factors for success 
today and in the future.

<P ALIGN="LEFT">
Volvo is a global actor. Key components such as engines and transmissions  
are developed and manufactured in Sweden while assembly takes place in 
more than 30 wholly owned plants in Europe, North America, South 
America, Southeast Asia and Australia.

<P ALIGN="LEFT">
Approximately 90% of Volvo's sales is outside Sweden, mainly in Europe and 
North America. Aggressive efforts are being made in new markets in Asia 
and Latin America.

<P ALIGN="LEFT">
A comprehensive program of change is under way within the Group. The objective 
is a flexible organization with a high level of readiness to respond to 
rapid changes as well as growth-oriented leadership that involves Volvo's 
employees in a process of continuous improvement.
<BR>
<BR>


<TABLE BORDER=0 WIDTH=450>


<TR>
	<TD><HR></TD>
</TR>

<TR>
	<TD>Source: Volvo in Europe</TD>
</TR>

</TABLE>


</BLOCKQUOTE>

<BR>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]


</TD>
</TR>
</TABLE>

</CENTER>
</BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-220</DOCNO>
<DOCOLDNO>IA089-000951-B024-204</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/corpinfo/fin.stat/tab1.html 192.138.110.240 19970208032027 text/html 4828
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 03:20:39 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 4657
Last-modified: Thu, 13 Jun 1996 14:41:32 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Statements of income</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR>	
	<TD ALIGN=RIGHT VALIGN=TOP><A HREF="index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A></TD>
</TR>

<TR>
	<TD><HR></TD>
</TR>

<TR>
	<TD>

<BLOCKQUOTE>

<TABLE WIDTH=452 BORDER=0 CELLPADDING=3>

<TR VALIGN=TOP>
	<TD COLSPAN=6><FONT SIZE=5><NOBR>Statements of income</NOBR></FONT></td>
</TR>

<TR>
	<TD COLSPAN=6><HR></TD>
</TR>

<TR VALIGN=BOTTOM>
	<TD>SEK M</TD>
	<TD WIDTH=50 ALIGN=RIGHT>1991</TD>
	<TD WIDTH=50 ALIGN=RIGHT>1992</TD>
	<TD WIDTH=50 ALIGN=RIGHT>1993</TD>
	<TD WIDTH=50 ALIGN=RIGHT>1994</TD>
	<TD WIDTH=50 ALIGN=RIGHT>1995</td>
</TR>

<TR>
	<TD COLSPAN=6><HR></TD>
</TR>

<TR VALIGN=BOTTOM>
	<TD>Sales</TD>
	<TD ALIGN=RIGHT>77,223</TD>
	<TD ALIGN=RIGHT>83,002</TD>
	<TD ALIGN=RIGHT>111,155</TD>
	<TD ALIGN=RIGHT>155,866</td>
	<TD ALIGN=RIGHT>171,511</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>Costs and expenses</TD>
	<TD ALIGN=RIGHT>(74,930)</TD>
	<TD ALIGN=RIGHT>(81,785)</TD>
	<TD ALIGN=RIGHT>(105,465)</TD>
	<TD ALIGN=RIGHT>(141,388)</TD>
	<TD ALIGN=RIGHT>(156,831)</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>Depreciation and amortization</TD>
	<TD ALIGN=RIGHT>(3,129)</TD>
	<TD ALIGN=RIGHT>(3,119)</TD>
	<TD ALIGN=RIGHT>(3,777)</TD>
	<TD ALIGN=RIGHT>(5,107)</TD>
	<TD ALIGN=RIGHT>(5,656)</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD></TD>
	<TD COLSPAN=5 ALIGN=RIGHT><HR></TD>
</TR>

<TR VALIGN=BOTTOM>
	<TD><B>Operating income (loss) before nonrecurring items</TD>
	<TD ALIGN=RIGHT>(836)</TD>
	<TD ALIGN=RIGHT>(1,902)</TD>
	<TD ALIGN=RIGHT>1,913</TD>
	<TD ALIGN=RIGHT>9,371</TD>
	<TD ALIGN=RIGHT>9,024</B></td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>Nonrecurring items</TD>
	<TD ALIGN=RIGHT>-</TD>
	<TD ALIGN=RIGHT>(1,450)</TD>
	<TD ALIGN=RIGHT>(1,600)</TD>
	<TD ALIGN=RIGHT>-</TD>
	<TD ALIGN=RIGHT>1,215</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD></TD>
	<TD COLSPAN=5 ALIGN=RIGHT><HR></TD>
</TR>

<TR VALIGN=BOTTOM>
	<TD><B>Operating income (loss)</TD>
	<TD ALIGN=RIGHT>(836)</TD>
	<TD ALIGN=RIGHT>(3,352)</TD>
	<TD ALIGN=RIGHT>313</TD>
	<TD ALIGN=RIGHT>9,371</TD>
	<TD ALIGN=RIGHT>10,239</B></td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>Income from equity method investments</TD>
	<TD ALIGN=RIGHT>599</TD>
	<TD ALIGN=RIGHT>96</TD>
	<TD ALIGN=RIGHT>(1,788)</TD>
	<TD ALIGN=RIGHT>2,193</TD>
	<TD ALIGN=RIGHT>1,402</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD> Financial income and expenses</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>Dividends received</TD>
	<TD ALIGN=RIGHT>15</TD>
	<TD ALIGN=RIGHT>50</TD>
	<TD ALIGN=RIGHT>62</TD>
	<TD ALIGN=RIGHT>1,126</TD>
	<TD ALIGN=RIGHT>351</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>Gain (loss) on sale of securities, net</TD>
	<TD ALIGN=RIGHT>2,026</TD>
	<TD ALIGN=RIGHT>131</TD>
	<TD ALIGN=RIGHT>504</TD>
	<TD ALIGN=RIGHT>4,243</TD>
	<TD ALIGN=RIGHT>1,180</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>Interest income (expense)</TD>
	<TD ALIGN=RIGHT>(1,167)</TD>
	<TD ALIGN=RIGHT>(1,138)</TD>
	<TD ALIGN=RIGHT>(1,432)</TD>
	<TD ALIGN=RIGHT>(525)</TD>
	<TD ALIGN=RIGHT>197</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>Other financial income (expense)</TD>
	<TD ALIGN=RIGHT>166</TD>
	<TD ALIGN=RIGHT>(536)</TD>
	<TD ALIGN=RIGHT>(301)</TD>
	<TD ALIGN=RIGHT>(30)</TD>
	<TD ALIGN=RIGHT>(321)</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD></TD>
	<TD COLSPAN=5 ALIGN=RIGHT><HR></TD>
</TR>

<TR VALIGN=BOTTOM>
	<TD><B>Income (loss) before taxes and minority interests</TD>
	<TD ALIGN=RIGHT>803</TD>
	<TD ALIGN=RIGHT>(4,749)</TD>
	<TD ALIGN=RIGHT>(2,642)</TD>
	<TD ALIGN=RIGHT>16,378</TD>
	<TD ALIGN=RIGHT>13,048</B></td>
</TR>

<TR>
	<TD></TD>

</TR>

<TR>
	<TD></TD>

</TR>

<TR VALIGN=BOTTOM>
	<TD>Taxes</TD>
	<TD ALIGN=RIGHT>(560)</TD>
	<TD ALIGN=RIGHT>138</TD>
	<TD ALIGN=RIGHT>(468)</TD>
	<TD ALIGN=RIGHT>(2,783)</TD>
	<TD ALIGN=RIGHT>(3,741)</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD >Minority interests</TD>
	<TD ALIGN=RIGHT>439</TD>
	<TD ALIGN=RIGHT>1,291</TD>
	<TD ALIGN=RIGHT>(356)</TD>
	<TD ALIGN=RIGHT>(365)</TD>
	<TD ALIGN=RIGHT>(45)</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD></TD>
	<TD COLSPAN=5><HR></TD>
</TR>

<TR VALIGN=BOTTOM>
	<TD><B>Net income (loss)</TD>
	<TD ALIGN=RIGHT>682</TD>
	<TD ALIGN=RIGHT>(3,320)</TD>
	<TD ALIGN=RIGHT>(3,466)</TD>
	<TD ALIGN=RIGHT>13,230</TD>
	<TD ALIGN=RIGHT>9,262</B></td>
</TR>

<TR>
	<TD COLSPAN=6><HR></TD>
</TR>

</TABLE>
<BR>
<BR>
<TABLE BORDER=0 WIDTH=450>

<TR>
	<TD>Source: Financial and Operating Statistics 1995</TD>
</TR>

</TABLE>

<P>

</BLOCKQUOTE>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]

</TD>
</TR>
</TABLE>

</CENTER>


</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-221</DOCNO>
<DOCOLDNO>IA089-000951-B024-230</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/corpinfo/fin.stat/tab2.html 192.138.110.240 19970208032039 text/html 4775
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 03:20:49 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 4604
Last-modified: Thu, 13 Jun 1996 14:41:33 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Balance sheets</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR>	
	<TD ALIGN=RIGHT VALIGN=TOP><A HREF="index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A></TD>
</TR>

<TR>
	<TD><HR></TD>
</TR>

<TR>
	<TD>

<BLOCKQUOTE>

<TABLE WIDTH=452 BORDER=0 CELLPADDING=3>

<TR VALIGN=BOTTOM>
	<TD COLSPAN=6><FONT SIZE=5>Balance sheets</FONT></td>
</TR>

<TR>
	<TD COLSPAN=6><HR></TD>
</TR>

<TR VALIGN=BOTTOM>
	<TD>SEK M</TD>
	<TD ALIGN=RIGHT>1991</TD>
	<TD ALIGN=RIGHT>1992</TD>
	<TD ALIGN=RIGHT>1993</TD>
	<TD ALIGN=RIGHT>1994</TD>
	<TD ALIGN=RIGHT>1995</td>
</TR>

<TR>
	<TD COLSPAN=6><HR></TD>
</TR>

<TR VALIGN=BOTTOM>
	<TD COLSPAN=6><B>Assets</B></td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>Liquid funds</TD>
	<TD ALIGN=RIGHT>18,779</TD>
	<TD ALIGN=RIGHT>21,760</TD>
	<TD ALIGN=RIGHT>21,442</TD>
	<TD ALIGN=RIGHT>24,449</TD>
	<TD ALIGN=RIGHT>23,306</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>Receivables</TD>
	<TD ALIGN=RIGHT>17,065</TD>
	<TD ALIGN=RIGHT>19,519</TD>
	<TD ALIGN=RIGHT>27,424</TD>
	<TD ALIGN=RIGHT>30,545</TD>
	<TD ALIGN=RIGHT>28,906</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>Inventories</TD>
	<TD ALIGN=RIGHT>16,705</TD>
	<TD ALIGN=RIGHT>18,368</TD>
	<TD ALIGN=RIGHT>21,390</TD>
	<TD ALIGN=RIGHT>23,380</TD>
	<TD ALIGN=RIGHT>23,929</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD></TD>
	<TD COLSPAN=5><HR></TD>
</TR>

<TR VALIGN=BOTTOM>
	<TD>Current assets</FONT></TD>
	<TD ALIGN=RIGHT>52,549</TD>
	<TD ALIGN=RIGHT>59,647</TD>
	<TD ALIGN=RIGHT>70,256</TD>
	<TD ALIGN=RIGHT>78,374</TD>
	<TD ALIGN=RIGHT>76,141</td>
</TR>

<TR>
	<TD></td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>Investments in bonds</TD>
	<TD ALIGN=RIGHT>928</TD>
	<TD ALIGN=RIGHT>-</TD>
	<TD ALIGN=RIGHT>-</TD>
	<TD ALIGN=RIGHT>-</TD>
	<TD ALIGN=RIGHT>-</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>Restricted deposits in Bank of Sweden</TD>
	<TD ALIGN=RIGHT>41</TD>
	<TD ALIGN=RIGHT>2</TD>
	<TD ALIGN=RIGHT>-</TD>
	<TD ALIGN=RIGHT>-</TD>
	<TD ALIGN=RIGHT>-</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>Long-term assets</TD>
	<TD ALIGN=RIGHT>53,230</TD>
	<TD ALIGN=RIGHT>57,358</TD>
	<TD ALIGN=RIGHT>64,260</TD>
	<TD ALIGN=RIGHT>60,208</TD>
	<TD ALIGN=RIGHT>62,558</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD></TD>
	<TD COLSPAN=5><HR></TD>
</TR>

<TR VALIGN=BOTTOM>
	<TD>Total assets</TD>
	<TD ALIGN=RIGHT>106,748</TD>
	<TD ALIGN=RIGHT>117,007</TD>
	<TD ALIGN=RIGHT>134,516</TD>
	<TD ALIGN=RIGHT>138,582</TD>
	<TD ALIGN=RIGHT>138,699</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD></TD>
	<TD COLSPAN=5><HR></TD>
</TR>

<TR>
	<TD></td>
</TR>

<TR VALIGN=BOTTOM>
	<TD COLSPAN=6><B>Liabilities and shareholders' equity</B></TD>
</TR>

<TR VALIGN=BOTTOM>
	<TD>Current liabilities</TD>
	<TD ALIGN=RIGHT>47,778</TD>
	<TD ALIGN=RIGHT>59,386</TD>
	<TD ALIGN=RIGHT>74,958</TD>
	<TD ALIGN=RIGHT>72,212</TD>
	<TD ALIGN=RIGHT>59,769</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>Long-term liabilities</TD>
	<TD ALIGN=RIGHT>20,120</TD>
	<TD ALIGN=RIGHT>23,981</TD>
	<TD ALIGN=RIGHT>25,784</TD>
	<TD ALIGN=RIGHT>22,200</TD>
	<TD ALIGN=RIGHT>27,125</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>Minority interests</TD>
	<TD ALIGN=RIGHT>4,986</TD>
	<TD ALIGN=RIGHT>3,919</TD>
	<TD ALIGN=RIGHT>6,686</TD>
	<TD ALIGN=RIGHT>838</TD>
	<TD ALIGN=RIGHT>605</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>Shareholders' equity</TD>
	<TD ALIGN=RIGHT>33,864</TD>
	<TD ALIGN=RIGHT>29,721</TD>
	<TD ALIGN=RIGHT>27,088</TD>
	<TD ALIGN=RIGHT>43,332</TD>
	<TD ALIGN=RIGHT>51.200</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD></TD>
	<TD COLSPAN=5><HR></TD>
</TR>

<TR VALIGN=BOTTOM>
	<TD>Total liabilities and shareholders' equity</TD>
	<TD ALIGN=RIGHT>106,748</TD>
	<TD ALIGN=RIGHT>117,007</TD>
	<TD ALIGN=RIGHT>134,516</TD>
	<TD ALIGN=RIGHT>138,582</TD>
	<TD ALIGN=RIGHT>138,699</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD></TD>
	<TD COLSPAN=5><HR></TD>
</TR>

<TR>
	<TD></td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>Assets pledged</TD>
	<TD ALIGN=RIGHT>2,641</TD>
	<TD ALIGN=RIGHT>4,114</TD>
	<TD ALIGN=RIGHT>4,613</TD>
	<TD ALIGN=RIGHT>6,527</TD>
	<TD ALIGN=RIGHT>5,434</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>Contingent liabilities</TD>
	<TD ALIGN=RIGHT>4,691</TD>
	<TD ALIGN=RIGHT>6,808</TD>
	<TD ALIGN=RIGHT>8,656</TD>
	<TD ALIGN=RIGHT>7,581</TD>
	<TD ALIGN=RIGHT>7,450</td>
</TR>

<TR>
	<TD COLSPAN=6><HR></TD>
</TR>

</TABLE>



<BR>
<BR>
<TABLE BORDER=0 WIDTH=450>

<TR>
	<TD>Source: Financial and Operating Statistics 1995</TD>
</TR>

</TABLE>

<P>

</BLOCKQUOTE>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]

</TD>
</TR>
</TABLE>

</CENTER>


</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-222</DOCNO>
<DOCOLDNO>IA089-000951-B024-265</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/corpinfo/fin.stat/tab3.html 192.138.110.240 19970208032053 text/html 9034
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 03:21:00 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 8863
Last-modified: Thu, 13 Jun 1996 14:41:34 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Statements of changes in financial position</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR>	
	<TD ALIGN=RIGHT VALIGN=TOP><A HREF="index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A></TD>
</TR>

<TR>
	<TD><HR></TD>
</TR>

<TR>
	<TD>

<BLOCKQUOTE>

<TABLE WIDTH=452 BORDER=0 CELLPADDING=3>

<TR VALIGN=BOTTOM>
	<TD COLSPAN=7><FONT SIZE=5>Statements of changes in financial position
	<BR></FONT></TD>
</TR>

<TR>
	<TD COLSPAN=7><HR></TD>
</TR>

<TR VALIGN=BOTTOM>
	<TD COLSPAN=2>SEK M</TD>
	<TD ALIGN=RIGHT>1991</TD>
	<TD ALIGN=RIGHT>1992</TD>
	<TD ALIGN=RIGHT>1993</TD>
	<TD ALIGN=RIGHT>1994</TD>
	<TD ALIGN=RIGHT>1995</td>
</TR>

<TR>
	<TD COLSPAN=7><HR></TD>
</TR>

<TR VALIGN=BOTTOM>
	<TD COLSPAN=7><B>Year's operations</B></td>
</TR>

<TR VALIGN=BOTTOM>
	<TD COLSPAN=2>Net income (loss)<HR<SIZE=1></TD>
	<TD ALIGN=RIGHT>682</TD>
	<TD ALIGN=RIGHT>(3,320)</TD>
	<TD ALIGN=RIGHT>(3,466)</TD>
	<TD ALIGN=RIGHT>13,230</TD>
	<TD ALIGN=RIGHT>9,262</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD COLSPAN=2>Depreciation and amortization</TD>
	<TD ALIGN=RIGHT>3,129</TD>
	<TD ALIGN=RIGHT>3,119</TD>
	<TD ALIGN=RIGHT>3,777</TD>
	<TD ALIGN=RIGHT>5,107</TD>
	<TD ALIGN=RIGHT>5,656</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD COLSPAN=2>Write-down of fixed assets and shareholdings</TD>
	<TD ALIGN=RIGHT>725</TD>
	<TD ALIGN=RIGHT>315</TD>
	<TD ALIGN=RIGHT>-</TD>
	<TD ALIGN=RIGHT>574</TD>
	<TD ALIGN=RIGHT>1,817</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD COLSPAN=2>Income from equity method investments after taxes</TD>
	<TD ALIGN=RIGHT>(899)</TD>
	<TD ALIGN=RIGHT>417</TD>
	<TD ALIGN=RIGHT>2,815</TD>
	<TD ALIGN=RIGHT>(1,274)</TD>
	<TD ALIGN=RIGHT>(730)</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD COLSPAN=2>Dividends received from associated companies</TD>
	<TD ALIGN=RIGHT>675</TD>
	<TD ALIGN=RIGHT>700</TD>
	<TD ALIGN=RIGHT>717</TD>
	<TD ALIGN=RIGHT>160</TD>
	<TD ALIGN=RIGHT>404</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD COLSPAN=2>Gain on sales of securities</TD>
	<TD ALIGN=RIGHT>(2,026)</TD>
	<TD ALIGN=RIGHT>(131)</TD>
	<TD ALIGN=RIGHT>(504)</TD>
	<TD ALIGN=RIGHT>(4,243)</TD>
	<TD ALIGN=RIGHT>(1,180)</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD COLSPAN=2>Gain on sales of subsidiaries</TD>
	<TD ALIGN=RIGHT>-</TD>
	<TD ALIGN=RIGHT>-</TD>
	<TD ALIGN=RIGHT>-</TD>
	<TD ALIGN=RIGHT>-</TD>
	<TD ALIGN=RIGHT>(3,032)</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD COLSPAN=2>Minority interests after taxes</TD>
	<TD ALIGN=RIGHT>(439)</TD>
	<TD ALIGN=RIGHT>(1,286)</TD>
	<TD ALIGN=RIGHT>356</TD>
	<TD ALIGN=RIGHT>365</TD>
	<TD ALIGN=RIGHT>45</td>
</TR>

<TR VALIGN=CENTER>
	<TD ROWSPAN=2>Decrease (increase) in current operating assets</TD>
	<TD ALIGN=RIGHT>Receivables<BR>
	<HR SIZE=1></TD>
	<TD VALIGN=TOP ALIGN=RIGHT>(1,347)</TD>
	<TD VALIGN=TOP ALIGN=RIGHT>1,484</TD>
	<TD VALIGN=TOP ALIGN=RIGHT>(2,732)</TD>
	<TD VALIGN=TOP ALIGN=RIGHT>(3,538)</TD>
	<TD VALIGN=TOP ALIGN=RIGHT>(962)</td>
</TR>

<TR VALIGN=TOP>
	<TD ALIGN=RIGHT>Inventories</TD>
	<TD ALIGN=RIGHT>1,611</TD>
	<TD ALIGN=RIGHT>2,373</TD>
	<TD ALIGN=RIGHT>2,209</TD>
	<TD ALIGN=RIGHT>(2,687)</TD>
	<TD ALIGN=RIGHT>(516)</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD COLSPAN=2>Increase in current operating liabilities</TD>
	<TD ALIGN=RIGHT>608</TD>
	<TD ALIGN=RIGHT>1,859</TD>
	<TD ALIGN=RIGHT>6,312</TD>
	<TD ALIGN=RIGHT>5,915</TD>
	<TD ALIGN=RIGHT>570</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD COLSPAN=2>Increase (decrease) in deferred tax liabilities</TD>
	<TD ALIGN=RIGHT>(521)</TD>
	<TD ALIGN=RIGHT>(2,207)</TD>
	<TD ALIGN=RIGHT>(989)</TD>
	<TD ALIGN=RIGHT>(1,373)</TD>
	<TD ALIGN=RIGHT>(267)</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD COLSPAN=2></TD>
	<TD COLSPAN=5><HR></TD>
</TR>

<TR VALIGN=BOTTOM>
	<TD COLSPAN=2><B>Net financing from year's operations</TD>
	<TD ALIGN=RIGHT>2,198</TD>
	<TD ALIGN=RIGHT>3,323</TD>
	<TD ALIGN=RIGHT>8,495</TD>
	<TD ALIGN=RIGHT>12,253</td>
	<TD ALIGN=RIGHT>11,067</td>
</TR>

<TR>
	<TD></TD>

</TR>

<TR>
	<TD></TD>

</TR>


<TR VALIGN=BOTTOM>
	<TD COLSPAN=7><B>Investments (increase)</B></td>
</TR>

<TR VALIGN=CENTER>
	<TD ROWSPAN=2>Property, plant<BR>
	 and equipment, etc.</TD>
	<TD ALIGN=RIGHT>Capital expenditures<BR>
	<HR SIZE=1></TD></TD>
	<TD VALIGN=TOP ALIGN=RIGHT>(3,874)</TD>
	<TD VALIGN=TOP ALIGN=RIGHT>(4,267)</TD>
	<TD VALIGN=TOP ALIGN=RIGHT>(5,143)</TD>
	<TD VALIGN=TOP ALIGN=RIGHT>(6,769)</TD>
	<TD VALIGN=TOP ALIGN=RIGHT>(9,076)</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD ALIGN=RIGHT>Disposals</TD>
	<TD ALIGN=RIGHT>1,243</TD>
	<TD ALIGN=RIGHT>299</TD>
	<TD ALIGN=RIGHT>770</TD>
	<TD ALIGN=RIGHT>1,460</TD>
	<TD ALIGN=RIGHT>1,351</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD COLSPAN=2>Investments in shares, net</TD>
	<TD ALIGN=RIGHT>(7,238)</TD>
	<TD ALIGN=RIGHT>(224)</TD>
	<TD ALIGN=RIGHT>464</TD>
	<TD ALIGN=RIGHT>8,182</TD>
	<TD ALIGN=RIGHT>1,953</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD COLSPAN=2>Long-term receivables and loans, net</TD>
	<TD ALIGN=RIGHT>(102)</TD>
	<TD ALIGN=RIGHT>(1,620)</TD>
	<TD ALIGN=RIGHT>(280)</TD>
	<TD ALIGN=RIGHT>(1,563)</TD>
	<TD ALIGN=RIGHT>(1,953)</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD COLSPAN=2>Acquisitions and sales of companies</TD>
	<TD ALIGN=RIGHT>(210)</TD>
	<TD ALIGN=RIGHT>323</TD>
	<TD ALIGN=RIGHT>393</TD>
	<TD ALIGN=RIGHT>-</TD>
	<TD ALIGN=RIGHT>(4,420)</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD COLSPAN=2></TD>
	<TD COLSPAN=5><HR></TD>
</TR>

<TR VALIGN=BOTTOM>
	<TD COLSPAN=2><B>Remaining after net investments</B></TD>
	<TD ALIGN=RIGHT>(7,983)</TD>
	<TD ALIGN=RIGHT>(2,166)</TD>
	<TD ALIGN=RIGHT>4,699</TD>
	<TD ALIGN=RIGHT>13,546</TD>
	<TD ALIGN=RIGHT>(1,078)</td>
</TR>

<TR>
	<TD></TD>

</TR>

<TR>
	<TD></TD>

</TR>


<TR VALIGN=BOTTOM>
	<TD COLSPAN=7><B>Financing, dividends, etc.</B></td>
</TR>


<TR VALIGN=BOTTOM>
	<TD COLSPAN=2>Increase (decrease) in short-term loans</TD>
	<TD ALIGN=RIGHT>(1,542)</TD>
	<TD ALIGN=RIGHT>(298)</TD>
	<TD ALIGN=RIGHT>(5,104)</TD>
	<TD ALIGN=RIGHT>(6,233)</TD>
	<TD ALIGN=RIGHT>(3,993)</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD COLSPAN=2>Increase (decrease) in long-term loans</TD>
	<TD ALIGN=RIGHT>2,847</TD>
	<TD ALIGN=RIGHT>3,745</TD>
	<TD ALIGN=RIGHT>(753)</TD>
	<TD ALIGN=RIGHT>(2,011)</TD>
	<TD ALIGN=RIGHT>6,166</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD COLSPAN=2>(Increase) decrease in restricted deposits<BR>
	in Bank of Sweden</TD>
	<TD ALIGN=RIGHT>2,031</TD>
	<TD ALIGN=RIGHT>39</TD>
	<TD ALIGN=RIGHT>2</TD>
	<TD ALIGN=RIGHT>-</TD>
	<TD ALIGN=RIGHT>-</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD COLSPAN=2>Increase (decrease) in minority interests</TD>
	<TD ALIGN=RIGHT>5,282</TD>
	<TD ALIGN=RIGHT>122</TD>
	<TD ALIGN=RIGHT>15</TD>
	<TD ALIGN=RIGHT>145</TD>
	<TD ALIGN=RIGHT>(37)</td>
</TR>
<TR VALIGN=BOTTOM>
	<TD COLSPAN=2>Dividends paid to AB Volvo shareholders</TD>
	<TD ALIGN=RIGHT>(1,203)</TD>
	<TD ALIGN=RIGHT>(1,203)</TD>
	<TD ALIGN=RIGHT>(601)</TD>
	<TD ALIGN=RIGHT>(601)</TD>
	<TD ALIGN=RIGHT>(1,512)</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD COLSPAN=2>Dividends paid to minority shareholders</TD>
	<TD ALIGN=RIGHT>(157)</TD>
	<TD ALIGN=RIGHT>(81)</TD>
	<TD ALIGN=RIGHT>0</TD>
	<TD ALIGN=RIGHT>(132)</TD>
	<TD ALIGN=RIGHT>(3)</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD COLSPAN=2>Other</TD>
	<TD ALIGN=RIGHT>(7)</TD>
	<TD ALIGN=RIGHT>78</TD>
	<TD ALIGN=RIGHT>93</TD>
	<TD ALIGN=RIGHT><NOBR>(1,399)<FONT SIZE=1> 1)</FONT></NOBR></TD>
	<TD ALIGN=RIGHT>46</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD COLSPAN=2></TD>
	<TD COLSPAN=5><HR></TD>
</TR>

<TR VALIGN=BOTTOM>
	<TD COLSPAN=2><B>Increase (decrease) in liquid funds and<BR>
	investments in bonds,<BR>
	excl translation differences</B></TD>
	<TD ALIGN=RIGHT>(732)</TD>
	<TD ALIGN=RIGHT>236</TD>
	<TD ALIGN=RIGHT>(1,649)</TD>
	<TD ALIGN=RIGHT>3,315</TD>
	<TD ALIGN=RIGHT>(411)</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD COLSPAN=2>Translation differences in liquid funds</TD>
	<TD ALIGN=RIGHT>-</TD>
	<TD ALIGN=RIGHT>1,817</TD>
	<TD ALIGN=RIGHT>1,331</TD>
	<TD ALIGN=RIGHT>(308)</TD>
	<TD ALIGN=RIGHT>(732)</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD COLSPAN=2>Decrease (increase) in investments in bonds</TD>
	<TD ALIGN=RIGHT>1,926</TD>
	<TD ALIGN=RIGHT>928</TD>
	<TD ALIGN=RIGHT>-</TD>
	<TD ALIGN=RIGHT>-</TD>
	<TD ALIGN=RIGHT>-</td>
</TR>

<TR>
	<TD COLSPAN=2></TD>
	<TD COLSPAN=5><HR></TD>
</TR>

<TR VALIGN=BOTTOM>
	<TD COLSPAN=2><B>Increase (decrease) in liquid funds</B></TD>
	<TD ALIGN=RIGHT>1,194</TD>
	<TD ALIGN=RIGHT>2,981</TD>
	<TD ALIGN=RIGHT>(318)</TD>
	<TD ALIGN=RIGHT>3,007</TD>
	<TD ALIGN=RIGHT>(1,143)</td>
</TR>

<TR>
	<TD COLSPAN=7><HR></TD>
</TR>

</TABLE>


<OL>
<FONT SIZE=1)>
	<LI>Includes the payment of price adjustment to Renault, 1,422.<BR>
</FONT>
</OL>
<BR>
<BR>
<TABLE BORDER=0 WIDTH=450>

<TR>
	<TD>Source: Financial and Operating Statistics 1995</TD>
</TR>

</TABLE>

<P>

</BLOCKQUOTE>

<HR ALIGN=LEFT WIDTH=487>
</CENTER>
Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]

</TD>
</TR>
</TABLE>

</CENTER>


</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-223</DOCNO>
<DOCOLDNO>IA089-000951-B024-289</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/corpinfo/fin.stat/tab4.html 192.138.110.240 19970208032105 text/html 2849
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 03:21:17 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 2678
Last-modified: Thu, 13 Jun 1996 14:41:35 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Approximate net income in accordance with U.S. 
	generally
	accepted accounting principles (U.S. GAAP)</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR>	
	<TD ALIGN=RIGHT VALIGN=TOP><A HREF="index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A></TD>
</TR>

<TR>
	<TD><HR></TD>
</TR>

<TR>
	<TD>

<BLOCKQUOTE>


<TABLE WIDTH=452 BORDER=0 CELLPADDING=3>

<TR VALIGN=BOTTOM>
	<TD COLSPAN=7><FONT SIZE=5>Approximate net income in accordance with U.S. 
	generally<BR>
	accepted accounting principles (U.S. GAAP)</FONT></td>
</TR>

<TR>
	<TD COLSPAN=6><HR></TD>
</TR>

<TR VALIGN=BOTTOM>
	<TD></TD>
	<TD ALIGN=RIGHT>1991</TD>
	<TD ALIGN=RIGHT>1992</TD>
	<TD ALIGN=RIGHT>1993</TD>
	<TD ALIGN=RIGHT>1994</TD>
	<TD ALIGN=RIGHT>1995</td>
</TR>

<TR>
	<TD COLSPAN=6><HR></TD>
</TR>

<TR VALIGN=BOTTOM>
	<TD>Net income (loss) (SEK M)</TD>
	<TD ALIGN=RIGHT>816</TD>
	<TD ALIGN=RIGHT>(4,619)<FONT SIZE=1> 1)</FONT></TD>
	<TD ALIGN=RIGHT>2,938<FONT SIZE=1> 2)</FONT></TD>
	<TD ALIGN=RIGHT>14,122</TD>
	<TD ALIGN=RIGHT><NOBR>12,935<FONT SIZE=1> 3,4,5)</FONT></NOBR></td>
</TR>


<TR VALIGN=BOTTOM>
	<TD>Net income (loss) per share (SEK)</TD>
	<TD ALIGN=RIGHT>2.20</TD>
	<TD ALIGN=RIGHT>(12.40)<FONT SIZE=1> 1)</FONT></TD>
	<TD ALIGN=RIGHT>7.90<FONT SIZE=1> 2)</FONT></TD>
	<TD ALIGN=RIGHT>34.60</TD>
	<TD ALIGN=RIGHT>28.20<FONT SIZE=1> 3,4,5)</FONT></td>
</TR>

<TR>
	<TD COLSPAN=6><HR></TD>
</TR>

</TABLE>

<TABLE BORDER=0 WIDTH=450>
<TR>
<TD>
<OL>
  <FONT SIZE=1>
	<LI>Restructing costs increased loss before taxes by SEK 1.450 M and loss per
	share  by 2.20.<BR>

	<LI>Includes write-off of the remaining excess value of the shareholding in 
	Renault, SEK 3,603 M, and a provision for excess value pertaining to Volvo 
	Trucks, SEK 1,600 M, equal to SEK 13.40 per share.<BR>
	
	<LI>Includes write-off of Volvo Construction Equipment goodwill of SEK 1,817 M 
	and gain on sale of Alfred Berg SEK 280 M, equal to a loss of SEK 3.40 per 
	share.<BR>
	
	<LI>Includes gain on sale of Procordia Food and Abba Seafood SEK 2,300 M, equal 
	to SEK 5.00 per share.<BR>

	<LI>Includes gain on sale of Falcon Holding and additional payment for Alfred 
	Berg SEK 452 M, equal to SEK 1.00 per share.<BR>
	
	</FONT>
</OL>
</TD>
</TR>
</TABLE>

<BR>
<BR>
<TABLE BORDER=0 WIDTH=450>

<TR>
	<TD>Source: Financial and Operating Statistics 1995</TD>
</TR>

</TABLE>

<P>

</BLOCKQUOTE>

<HR ALIGN=LEFT WIDTH=487>


Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]

</TD>
</TR>
</TABLE>

</CENTER>


</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-224</DOCNO>
<DOCOLDNO>IA089-000951-B024-321</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/corpinfo/fin.stat/tab5.html 192.138.110.240 19970208032125 text/html 3021
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 03:21:35 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 2850
Last-modified: Thu, 13 Jun 1996 14:41:36 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Key ratios</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR>	
	<TD ALIGN=RIGHT VALIGN=TOP><A HREF="index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A></TD>
</TR>

<TR>
	<TD><HR></TD>
</TR>

<TR>
	<TD>

<BLOCKQUOTE>


<TABLE WIDTH=452 BORDER=0 CELLPADDING=3>

<TR VALIGN=BOTTOM>
	<TD COLSPAN=6><FONT SIZE=5>Key ratios</FONT></td>
</TR>

<TR>
	<TD COLSPAN=6><HR></TD>
</TR>

<TR VALIGN=BOTTOM>
	<TD></TD>
	<TD ALIGN=RIGHT>1991</TD>
	<TD ALIGN=RIGHT>1992</TD>
	<TD ALIGN=RIGHT>1993</TD>
	<TD ALIGN=RIGHT>1994</TD>
	<TD ALIGN=RIGHT>1995</td>
</TR>

<TR>
	<TD COLSPAN=6><HR></TD>
</TR>

<TR VALIGN=BOTTOM>
	<TD>Operating margin, %</TD>
	<TD ALIGN=RIGHT>(1.1)</TD>
	<TD ALIGN=RIGHT>(4.0)</TD>
	<TD ALIGN=RIGHT>0.3</TD>
	<TD ALIGN=RIGHT>6.0</TD>
	<TD ALIGN=RIGHT>6.0</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>Return on capital employed, %</TD>
	<TD ALIGN=RIGHT>6.4</TD>
	<TD ALIGN=RIGHT>1.1</TD>
	<TD ALIGN=RIGHT>3.7</TD>
	<TD ALIGN=RIGHT>23.4</TD>
	<TD ALIGN=RIGHT>18.0</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>Return on shareholders' equity, %</TD>
	<TD ALIGN=RIGHT>2.0</TD>
	<TD ALIGN=RIGHT>neg</TD>
	<TD ALIGN=RIGHT>neg</TD>
	<TD ALIGN=RIGHT>36.5</TD>
	<TD ALIGN=RIGHT>19.3</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>Interest coverage, times</TD>
	<TD ALIGN=RIGHT>1.1</TD>
	<TD ALIGN=RIGHT>0.2</TD>
	<TD ALIGN=RIGHT>0.6</TD>
	<TD ALIGN=RIGHT>5.5</TD>
	<TD ALIGN=RIGHT>4.6</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>Net financial assets (net debt), SEK M</TD>
	<TD ALIGN=RIGHT>(11,357)</TD>
	<TD ALIGN=RIGHT>(18,117)</TD>
	<TD ALIGN=RIGHT>(20,592)</TD>
	<TD ALIGN=RIGHT>(5,999)</TD>
	<TD ALIGN=RIGHT>1,245</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>Net financial assets (net debt)
	as percentage of shareholders'
	equity and minority interests</TD>
	<TD ALIGN=RIGHT>(29,2)</TD>
	<TD ALIGN=RIGHT>(53,9)</TD>
	<TD ALIGN=RIGHT>(61,0)</TD>
	<TD ALIGN=RIGHT>(13,6)</TD>
	<TD ALIGN=RIGHT>2,4</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>Shareholders' equity and minority interests
	as percentage of total assets</TD>
	<TD ALIGN=RIGHT>36.4</TD>
	<TD ALIGN=RIGHT>28.8</TD>
	<TD ALIGN=RIGHT>25.1</TD>
	<TD ALIGN=RIGHT>31.9</TD>
	<TD ALIGN=RIGHT>37,4</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>Shareholders' equity<BR>
	as percentage of total assets</TD>
	<TD ALIGN=RIGHT>31.7</TD>
	<TD ALIGN=RIGHT>25.4</TD>
	<TD ALIGN=RIGHT>20.1</TD>
	<TD ALIGN=RIGHT>31.3</TD>
	<TD ALIGN=RIGHT>36,9</td>
</TR>

<TR>
	<TD COLSPAN=6><HR></TD>
</TR>

</TABLE>

<BR>
<BR>
<BR>

<TABLE BORDER=0 WIDTH=450>

<TR>
	<TD>Source: Financial and Operating Statistics 1995</TD>
</TR>

</TABLE>

<P>

</BLOCKQUOTE>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]

</TD>
</TR>
</TABLE>

</CENTER>


</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-225</DOCNO>
<DOCOLDNO>IA089-000951-B024-349</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/corpinfo/fin.stat/expl.html 192.138.110.240 19970208032136 text/html 8560
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 03:21:46 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 8389
Last-modified: Thu, 13 Jun 1996 14:41:30 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Explanations</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR>	
	<TD ALIGN=RIGHT VALIGN=TOP><A HREF="index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A></TD>
</TR>

<TR>
	<TD><HR></TD>
</TR>

<TR>
	<TD>

<BLOCKQUOTE>

<TABLE BORDER=0 WIDTH=450>

<BR>
<FONT SIZE=5>Changes in accounting principles</FONT><BR>
<BR>

<BR>
<I>Nonrecurring costs</I><BR>
Effective in 1994, nonrecurring items are reported in operating income. The 
change reflects application of Recommendation RR4 of the Swedish Financial 
Accounting Standards Council which became effective January 1, 1994. 
Comparable figures for prior years have been restated.<BR>
<BR>
<P>

<I>Extraordinary income and expense</I><BR>
Effective in 1994, income and expenses are classified in accordance with 
Recommendation RR4 of the Swedish Financial Accounting Standards Council.  
The statements of income for prior years have been restated.<BR>
<BR>
<P>

<I>Type-specific tools</I><BR>
Effective in 1993, Volvo capitalizes type-specific tools. Capitalized 
tooling costs are being depreciated over the estimated economic life of 
the tools. The change in accounting method conforms with international
practice.<BR>
<BR>

<I>Reclassification of leasing vehicles and company vehicles</I><BR>
Up to and including 1992, leasing vehicles and company vehicles were included 
in Group inventories. Effective in 1993, these assets are reported among 
Property, plant and equipment. As a result of this reclassification, costs 
of leasing vehicles and company vehicles are included in capital expenditures. 
Depreciation of these vehicles is included in the item Depreciation on the 
income statement. The change does not affect operating income. Comparable figures 
for 1991-1992 have been restated.<BR>
<BR>

<I>Interest on pension liability and accruals for postretirement benefits</I><BR>
Effective in 1995, the Volvo Group's accounting has been adapted to conform with 
Recommendation 4 of the Swedish Institute of Authorized Public Accountants. 
Accordingly, the interest portion of pension expense is reported as an interest 
expense. Earlier, this item was included in operating income. Comparable figures 
for 1991-1994 have been restated.<BR>
<BR>
In addition, accruals for postretirement benefits are stated as an interest-bearing 
liability and are included in net financial assets/net debt. Comparable figures for 
prior years have been restated.<BR>
<BR>
 

<I>Foreign exchange gain (loss)</I><BR>
Effective in 1992, exchange gains (losses) on loans and other financial 
instruments in foreign currency, which hedge net assets in foreign subsidiaries 
and associated companies, are offset against translation differences on the 
shareholders' equity of the respective companies. The change in accounting 
principle is an adaptation to international practice. Application of this 
principle in 1991 would have reduced consolidated foreign exchange gains by
106.<BR>
<BR>
<P>

<I>Postretirement benefits other than pensions</I><BR>
Effective January 1, 1993, Volvo's subsidiaries in the United States are 
applying the new American accounting rules (SFAS 106: Employers' accounting
for 
postretirement benefits other than pensions) that became effective on that date. 
Earlier, income was charged only with current payments. The current value after 
taxes of benefits earned as of December 31, 1992 was estimated at 571. In the 
consolidated balance sheet, this amount reduced shareholders' equity by 301
and 
minority interests by 270. The greater part of the amount is attributable to 
companies within Volvo Trucks.<BR>
<BR>

Application of the above rules in the American associated companies, notably 
those in the Renault and VME groups, reduced shareholders' equity in these 
groups. The consolidated reported value of Volvo's holdings in the companies

affected was reduced by Volvo's share of the reduction in equity, 1,928.
This 
amount reduced consolidated shareholders' equity.<BR>
<BR>

The change in accounting principle thus reduced Volvo Group's
shareholders' 
equity in 1992 by 2,229, and minority interests by 270.<BR>
<BR>
<P>

<I>Associated companies</I><BR>
Effective in the 1989 accounts, associated companies are reported in accordance 
with the equity method. Accordingly, Volvo's share of reported income before

taxes in such companies, adjusted for minority interests, is included in the 
consolidated income statement, reduced in appropriate cases by amortization of 
excess values. The Group's share of reported taxes in associated companies
as 
well as estimated taxes in allocations are included in the Group's tax
expense. 
In the consolidated balance sheet, the reported value of shares and 
participations is affected by Volvo's share of the after-tax earnings of 
associated companies (reduced by amortization of excess values and dividends 
received).<BR>
<BR>

<P>
<I>Satements of changes in finacial position</I><BR>
In the statements of changes in financial position for 1992-95, the effects of 
major acquisitions and divestments of subsidiaries have been excluded from other 
changes in the balance sheet. Furthermore, the effects of changes in exchange 
rates at translation of foreign subsidiaries have been excluded, since these 
effects do not influence cash flow.<BR>
<BR>
<P>
The statements of changes in financial position for 1991-92 have also been 
adjusted as a consequence of the reclassification  of leasing vehicles and 
company vehicles in 1993.<BR>
<BR>

<P>
<I>Key ratios</I><BR>
<I>Operating margin</I><BR>
Operating income divided by sales.<BR>
<BR>

<I>Return on capital employed</I><BR>
Income divided by average total assets less average noninterest-bearing current 
liabilities. Income includes operating income, income from equity method 
investments, dividends received, gain (loss) on sales of securities and interest 
income.<BR>
<BR>

<I>Return on shareholders' equity</I><BR>
Net income divided by average shareholders' equity.<BR>
<BR>
 
<I>Interest coverage</I><BR>
Income divided by interest expense. Income includes operating income, income from 
equity method investments, dividends received, gain (loss) on sales of securities 
and interest income.<BR>
<BR>

<I>Net financial assets (net debt)</I><BR>
Current and long-term interest-bearing liabilities (including accrual for 
postretirement benefits) reduced by liquid funds, investments in bonds and 
long-term interest-bearing receivables. Effective in 1992, net debt in Volvo's 
sales finance companies is not included since interest expense in these companies 
is charged against operating income and does not affect net interest expense. 
Figures for 1991-1992 have been restated to reflect these changes.<BR>
<BR>


<I>Segment information</I><BR>
The Volvo Group is divided into six business segments, largely identical to the 
legal structure of the Group. The exception is Volvo Trucks and Volvo Buses, where 
the segments are calculated by subtracting the business segment Volvo Buses from 
the Volvo Truck group figures.<BR>
<BR>
<I>Volvo Construction Equipment</I><BR>
Volvo Construction Equipment is consolidated as from June 30, 1995. Thus figures 
for 1995 refer to six months.<BR>
<BR>

<I>Other companies and eliminations</I><BR>
Other companies are mainly Volvo's finance and insurance companies and certain 
internal service companies.<BR>
<BR>

<I>Fortos</I><BR>
Includes BCP and Alfred Berg Group, previously included in other companies.<BR>
<BR>


<I>Return on operating capital</I><BR>

<BR>
Return on operating capital is calculated as operating income divided by average 
operating capital. Operating capital is calculated as operating assets 
(inventories, receivables and long-term assets) less noninterest-bearing current 
liabilities. This key ratio is used only for business segments, not for the Volvo 
Group.<BR>
<BR>
<BR>
<BR>
<TR>
	<TD><HR></TD>
</TR>

<TR>
	<TD>Source: Financial and Operating Statistics 1995</TD>
</TR>

</TABLE>

</BLOCKQUOTE>

<A HREF="#top"><IMG WIDTH=71 HEIGHT=14 BORDER=0
SRC="/images/knapp_top.gif" ALT="Top of page"></A>

<HR ALIGN=LEFT WIDTH=487>

<A
Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]
</TD>
</TR>
</TABLE>

</CENTER>

</BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-226</DOCNO>
<DOCOLDNO>IA089-000951-B024-387</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/corpinfo/fin.stat/tab6.html 192.138.110.240 19970208032158 text/html 4155
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 03:22:02 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 3984
Last-modified: Thu, 13 Jun 1996 14:41:37 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Number of employees at year-end</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR>	
	<TD ALIGN=RIGHT VALIGN=TOP><A HREF="index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A></TD>
</TR>

<TR>
	<TD><HR></TD>
</TR>

<TR>
	<TD>

<BLOCKQUOTE>


<TABLE WIDTH=452 BORDER=0 CELLPADDING=3>

<TR VALIGN=BOTTOM>
	<TD COLSPAN=7><FONT SIZE=5>Number of employees at year-end</FONT></td>
</TR>

<TR>
	<TD COLSPAN=7><HR></TD>
</TR>

<TR VALIGN=BOTTOM>
	<TD COLSPAN=2></TD>
	<TD ALIGN=RIGHT>1991</TD>
	<TD ALIGN=RIGHT>1992</TD>
	<TD ALIGN=RIGHT>1993</TD>
	<TD ALIGN=RIGHT>1994</TD>
	<TD ALIGN=RIGHT>1995</td>
</TR>

<TR>
	<TD COLSPAN=7><HR></TD>
</TR>

<TR VALIGN=BOTTOM>
	<TD COLSPAN=2>Volvo Cars</TD>
	<TD ALIGN=RIGHT>29,570</TD>
	<TD ALIGN=RIGHT>28,450</TD>
	<TD ALIGN=RIGHT>26,800</TD>
	<TD ALIGN=RIGHT>29,080</TD>
	<TD ALIGN=RIGHT>31,050</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD COLSPAN=2>Volvo Trucks</TD>
	<TD ALIGN=RIGHT>20,290</TD>
	<TD ALIGN=RIGHT>19,480</TD>
	<TD ALIGN=RIGHT>17,780</TD>
	<TD ALIGN=RIGHT>19,790</TD>
	<TD ALIGN=RIGHT>21,670</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD COLSPAN=2>Volvo Buses</TD>
	<TD ALIGN=RIGHT>3,050</TD>
	<TD ALIGN=RIGHT>2,620</TD>
	<TD ALIGN=RIGHT>2,610</TD>
	<TD ALIGN=RIGHT>2,600</TD>
	<TD ALIGN=RIGHT>3,620</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD COLSPAN=2>Volvo Construction Equipment<FONT SIZE=1> 1)</FONT></TD>
	<TD ALIGN=RIGHT>-</TD>
	<TD ALIGN=RIGHT>-</TD>
	<TD ALIGN=RIGHT>-</TD>
	<TD ALIGN=RIGHT>-</TD>
	<TD ALIGN=RIGHT>7,610</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD COLSPAN=2>Volvo Penta</TD>
	<TD ALIGN=RIGHT>2,040</TD>
	<TD ALIGN=RIGHT>1,540</TD>
	<TD ALIGN=RIGHT>1,420</TD>
	<TD ALIGN=RIGHT>1,540</td>
	<TD ALIGN=RIGHT>1,570</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD COLSPAN=2>Volvo Aero</TD>
	<TD ALIGN=RIGHT>4,420</TD>
	<TD ALIGN=RIGHT>4,290</TD>
	<TD ALIGN=RIGHT>4,040</TD>
	<TD ALIGN=RIGHT>3,770</TD>
	<TD ALIGN=RIGHT>3,890</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD COLSPAN=2>Other companies</TD>
	<TD ALIGN=RIGHT>4,210</TD>
	<TD ALIGN=RIGHT>3,740</TD>
	<TD ALIGN=RIGHT>3,350</TD>
	<TD ALIGN=RIGHT>2,350</TD>
	<TD ALIGN=RIGHT>2,600</td>
</TR>

<TR>
	<TD COLSPAN=2></TD>
	<TD COLSPAN=5><HR></TD>
</TR>

<TR VALIGN=BOTTOM>
	<TD COLSPAN=2>Subtotal</TD>
	<TD ALIGN=RIGHT>63,580</TD>
	<TD ALIGN=RIGHT>60,120</TD>
	<TD ALIGN=RIGHT>56,000</TD>
	<TD ALIGN=RIGHT>59,130</TD>
	<TD ALIGN=RIGHT>72,010</td>
</TR>

<TR>
	<TD></td>
</TR>

<TR VALIGN=BOTTOM>
	<TD COLSPAN=2>Fortos Group</TD>
	<TD ALIGN=RIGHT>-</TD>
	<TD ALIGN=RIGHT>-</TD>
	<TD ALIGN=RIGHT>17,640</TD>
	<TD ALIGN=RIGHT>16,420</TD>
	<TD ALIGN=RIGHT>7,040</td>
</TR>

<TR>
	<TD COLSPAN=2></TD>
	<TD COLSPAN=5><HR></TD>
</TR>

<TR VALIGN=BOTTOM>
	<TD COLSPAN=2>Group total</TD>
	<TD ALIGN=RIGHT>63,580</TD>
	<TD ALIGN=RIGHT>60,120</TD>
	<TD ALIGN=RIGHT>73,640</TD>
	<TD ALIGN=RIGHT>75,550</TD>
	<TD ALIGN=RIGHT>79,050</td>
</TR>

<TR>
	<TD></td>
</TR>

<TR VALIGN=BOTTOM>
	<TD ROWSPAN=2 VALIGN=MIDDLE>of which,</TD>
	<TD>in Sweden<HR SIZE=1></TD>
	<TD VALIGN=TOP ALIGN=RIGHT>42,960</TD>
	<TD VALIGN=TOP ALIGN=RIGHT>39,130</TD>
	<TD VALIGN=TOP ALIGN=RIGHT>43,980</TD>
	<TD VALIGN=TOP ALIGN=RIGHT>44,880</TD>
	<TD VALIGN=TOP ALIGN=RIGHT>47,000</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>outside Sweden</TD>
	<TD ALIGN=RIGHT>20,620</TD>
	<TD ALIGN=RIGHT>20,990</TD>
	<TD ALIGN=RIGHT>29,660</TD>
	<TD ALIGN=RIGHT>30,670</TD>
	<TD ALIGN=RIGHT>32,050</td>
</TR>

<TR>
	<TD COLSPAN=7><HR></TD>
</TR>

</TABLE>


<OL>
<FONT SIZE=1>
	<LI>Number of employees at year-end for Volvo Construction Equipment for the 
	years 1991-1994: 8,540, 6,670, 6,350, 6,840.<BR>
</FONT>
</OL>
<BR>
<BR>
<TABLE BORDER=0 WIDTH=450>

<TR>
	<TD>Source: Financial and Operating Statistics 1995</TD>
</TR>

</TABLE>

<P>

</BLOCKQUOTE>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]

</TD>
</TR>
</TABLE>

</CENTER>


</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-227</DOCNO>
<DOCOLDNO>IA089-000951-B024-424</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/corpinfo/fin.stat/tab7.html 192.138.110.240 19970208032215 text/html 1566
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 03:22:19 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 1395
Last-modified: Thu, 13 Jun 1996 14:41:38 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Salaries, wages and other remuneration<BR> 
	(including social costs)</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR>	
	<TD ALIGN=RIGHT VALIGN=TOP><A HREF="index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A></TD>
</TR>

<TR>
	<TD><HR></TD>
</TR>

<TR>
	<TD>

<BLOCKQUOTE>


<TABLE WIDTH=452 BORDER=0 CELLPADDING=3>

<TR VALIGN=BOTTOM>
	<TD COLSPAN=6><FONT SIZE=5>Salaries, wages and other remuneration<BR> 
	(including social costs)</FONT></td>
</TR>

<TR>
	<TD COLSPAN=6><HR></TD>
</TR>

<TR VALIGN=BOTTOM>
	<TD>SEK M</TD>
	<TD ALIGN=RIGHT>1991</TD>
	<TD ALIGN=RIGHT>1992</TD>
	<TD ALIGN=RIGHT>1993</TD>
	<TD ALIGN=RIGHT>1994</TD>
	<TD ALIGN=RIGHT>1995</td>
</TR>

<TR>
	<TD COLSPAN=6><HR></TD>
</TR>

<TR VALIGN=BOTTOM>
	<TD></TD>
	<TD ALIGN=RIGHT>17,654</TD>
	<TD ALIGN=RIGHT>16,857</TD>
	<TD ALIGN=RIGHT>19,489</TD>
	<TD ALIGN=RIGHT>24,156</TD>
	<TD ALIGN=RIGHT>27,248</td>
</TR>

<TR>
	<TD COLSPAN=6><HR></TD>
</TR>

</TABLE>
<BR>
<BR>
<TABLE BORDER=0 WIDTH=450>

<TR>
	<TD>Source: Financial and Operating Statistics 1995</TD>
</TR>

</TABLE>

<P>

</BLOCKQUOTE>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]

</TD>
</TR>
</TABLE>

</CENTER>


</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-228</DOCNO>
<DOCOLDNO>IA089-000951-B024-443</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/corpinfo/fin.stat/tab8.html 192.138.110.240 19970208032222 text/html 3316
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 03:22:35 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 3145
Last-modified: Thu, 13 Jun 1996 14:41:39 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Volvo vehicles sold</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR>	
	<TD ALIGN=RIGHT VALIGN=TOP><A HREF="index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A></TD>
</TR>

<TR>
	<TD><HR></TD>
</TR>

<TR>
	<TD>

<BLOCKQUOTE>


<TABLE WIDTH=452 BORDER=0 CELLPADDING=3>

<TR VALIGN=BOTTOM>
	<TD COLSPAN=6><FONT SIZE=5>Volvo vehicles sold</FONT></td>
</TR>

<TR>
	<TD COLSPAN=6><HR></TD>
</TR>

<TR VALIGN=BOTTOM>
	<TD></TD>
	<TD ALIGN=RIGHT>1991</TD>
	<TD ALIGN=RIGHT>1992</TD>
	<TD ALIGN=RIGHT>1993</TD>
	<TD ALIGN=RIGHT>1994</TD>
	<TD ALIGN=RIGHT>1995</td>
</TR>

<TR>
	<TD COLSPAN=6><HR></TD>
</TR>

<TR VALIGN=BOTTOM>
	<TD>Large cars<FONT SIZE=1> 1)</FONT></TD>
	<TD ALIGN=RIGHT>212,200</TD>
	<TD ALIGN=RIGHT>214,100</TD>
	<TD ALIGN=RIGHT>216,700</TD>
	<TD ALIGN=RIGHT>256,100</TD>
	<TD ALIGN=RIGHT>293,500</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>Medium-size cars (NedCar)<FONT SIZE=1> 1)</FONT></TD>
	<TD ALIGN=RIGHT>97,100</TD>
	<TD ALIGN=RIGHT>93,200</TD>
	<TD ALIGN=RIGHT>85,400</TD>
	<TD ALIGN=RIGHT>95,200</TD>
	<TD ALIGN=RIGHT>81,100</td>
</TR>

<TR>
	<TD></TD>
	<TD COLSPAN=5><HR></TD>
</TR>

<TR VALIGN=BOTTOM>
	<TD>Total, cars<FONT SIZE=1> 1)</FONT></TD>
	<TD ALIGN=RIGHT>309,300</TD>
	<TD ALIGN=RIGHT>307,300</TD>
	<TD ALIGN=RIGHT>302,100</TD>
	<TD ALIGN=RIGHT>351,300</TD>
	<TD ALIGN=RIGHT>374,600</td>
</TR>

<TR>
	<TD></TD>

</TR>

<TR>
	<TD></TD>

</TR>

<TR VALIGN=BOTTOM>
	<TD>Heavy trucks</TD>
	<TD ALIGN=RIGHT>47,600</TD>
	<TD ALIGN=RIGHT>43,000</TD>
	<TD ALIGN=RIGHT>47,200</TD>
	<TD ALIGN=RIGHT>63,600</TD>
	<TD ALIGN=RIGHT>71,400</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD><NOBR>Medium-heavy trucks</NOBR></TD>
	<TD ALIGN=RIGHT>6,200</TD>
	<TD ALIGN=RIGHT>5,100</TD>
	<TD ALIGN=RIGHT>4,000</TD>
	<TD ALIGN=RIGHT>4,900</TD>
	<TD ALIGN=RIGHT>5,100</td>
</TR>

<TR>
	<TD></TD>
	<TD COLSPAN=5><HR></TD>
</TR>

<TR VALIGN=BOTTOM>
	<TD>Total trucks</TD>
	<TD ALIGN=RIGHT>53,800</TD>
	<TD ALIGN=RIGHT>48,100</TD>
	<TD ALIGN=RIGHT>51,200</TD>
	<TD ALIGN=RIGHT>68,500</TD>
	<TD ALIGN=RIGHT>76,500</td>
</TR>

<TR>
	<TD></TD>

</TR>

<TR>
	<TD></TD>

</TR>

<TR VALIGN=BOTTOM>
	<TD><NOBR>Buses and bus chassis<FONT SIZE=1> 2)</FONT></NOBR></TD>
	<TD ALIGN=RIGHT>4,650</TD>
	<TD ALIGN=RIGHT>5,580</TD>
	<TD ALIGN=RIGHT>5,450</TD>
	<TD ALIGN=RIGHT>5,770</TD>
	<TD ALIGN=RIGHT>6,830</td>
</TR>

<TR>
	<TD COLSPAN=6><HR></TD>
</TR>

</TABLE>

<TABLE BORDER=0 WIDTH=450>
<TR>
<TD>
<OL>
<FONT SIZE=1>
	<LI>Effective in 1995, units invoiced are reported. Earlier the term retail 
	sales was used. Figures for the years 1992-1994 have been adjusted to reflect 
	units invoiced.<BR>
<BR>
	<LI>As from July 1995 including Pr&eacute;vost Car Inc.<BR>
<BR>
</FONT>
</OL>
</TD>
</TR>
</TABLE>

<BR>
<BR>
<TABLE BORDER=0 WIDTH=450>

<TR>
	<TD>Source: Financial and Operating Statistics 1995</TD>
</TR>

</TABLE>

<P>

</BLOCKQUOTE>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]

</TD>
</TR>
</TABLE>

</CENTER>


</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-229</DOCNO>
<DOCOLDNO>IA089-000951-B025-26</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/corpinfo/fin.stat/tab9.html 192.138.110.240 19970208032243 text/html 14833
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 03:22:45 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 14661
Last-modified: Thu, 13 Jun 1996 14:41:40 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Volvo vehicles sold, quarterly figures</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR>	
	<TD ALIGN=RIGHT VALIGN=TOP><A HREF="index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A></TD>
</TR>

<TR>
	<TD><HR></TD>
</TR>

<TR>
	<TD>

<BLOCKQUOTE>

<BR>
<FONT SIZE=5>Volvo vehicles sold, quarterly figures</FONT><BR>
<BR>

<UL>

	<LI><A HREF="#1995">Quarterly figures 1995</A><BR>
	<BR>

	<LI><A HREF="#1994">Quarterly figures 1994</A><BR>
	<BR>

	<LI><A HREF="#1993">Quarterly figures 1993</A><BR>
	<BR>

	<LI><A HREF="#1992">Quarterly figures 1992</A><BR>
	<BR>


</UL>

<BR>
<BR>

<A NAME="1995"></A>

<TABLE WIDTH=452 BORDER=0 CELLPADDING=3>

<TR VALIGN=BOTTOM>
	<TD COLSPAN=6><FONT SIZE=5>Volvo vehicles sold, quarterly figures 1995</FONT></td>
</TR>

<TR>
	<TD COLSPAN=6><HR></TD>
</TR>

<TR VALIGN=BOTTOM>
	<TD></TD>
	<TD ALIGN=RIGHT>1st</TD>
	<TD ALIGN=RIGHT>2nd</TD>
	<TD ALIGN=RIGHT>3rd</TD>
	<TD ALIGN=RIGHT>4th</TD>
	<TD ALIGN=RIGHT>Total</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD><B>Volvo cars</B></TD>
	<TD ALIGN=RIGHT>104,580</TD>
	<TD ALIGN=RIGHT>94,220</TD>
	<TD ALIGN=RIGHT>87,330</TD>
	<TD ALIGN=RIGHT>88,480</TD>
	<TD ALIGN=RIGHT>374,600</td>
</TR>

<TR>
	<TD COLSPAN=6><HR></TD>
</TR>

<TR VALIGN=BOTTOM>
	<TD>200/700</TD>
	<TD ALIGN=RIGHT>-</TD>
	<TD ALIGN=RIGHT>-</TD>
	<TD ALIGN=RIGHT>-</TD>
	<TD ALIGN=RIGHT>-</TD>
	<TD ALIGN=RIGHT>-</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>400</TD>
	<TD ALIGN=RIGHT>22,000</TD>
	<TD ALIGN=RIGHT>22,100</TD>
	<TD ALIGN=RIGHT>20,850</TD>
	<TD ALIGN=RIGHT>16,150</TD>
	<TD ALIGN=RIGHT>81,100</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>800</TD>
	<TD ALIGN=RIGHT>51,570</TD>
	<TD ALIGN=RIGHT>43,780</TD>
	<TD ALIGN=RIGHT>42,060</TD>
	<TD ALIGN=RIGHT>49,490</TD>
	<TD ALIGN=RIGHT>186,900</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>940</TD>
	<TD ALIGN=RIGHT>18,810</TD>
	<TD ALIGN=RIGHT>18,350</TD>
	<TD ALIGN=RIGHT>14,090</TD>
	<TD ALIGN=RIGHT>13,250</TD>
	<TD ALIGN=RIGHT>64,500</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>960</TD>
	<TD ALIGN=RIGHT>12,200</TD>
	<TD ALIGN=RIGHT>9,990</TD>
	<TD ALIGN=RIGHT>10,330</TD>
	<TD ALIGN=RIGHT>9,590</TD>
	<TD ALIGN=RIGHT>42,100</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>Renault cars</TD>
	<TD ALIGN=RIGHT>4,720</TD>
	<TD ALIGN=RIGHT>4,580</TD>
	<TD ALIGN=RIGHT>4,850</TD>
	<TD ALIGN=RIGHT>4,900</TD>
	<TD ALIGN=RIGHT>19,050</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>Europe</TD>
	<TD ALIGN=RIGHT>58,920</TD>
	<TD ALIGN=RIGHT>56,060</TD>
	<TD ALIGN=RIGHT>53,000</TD>
	<TD ALIGN=RIGHT>51,530</TD>
	<TD ALIGN=RIGHT>219,800</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>North America</TD>
	<TD ALIGN=RIGHT>30,900</TD>
	<TD ALIGN=RIGHT>23,040</TD>
	<TD ALIGN=RIGHT>20,480</TD>
	<TD ALIGN=RIGHT>23,290</TD>
	<TD ALIGN=RIGHT>97,700</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>Other markets</TD>
	<TD ALIGN=RIGHT>14,760</TD>
	<TD ALIGN=RIGHT>15,120</TD>
	<TD ALIGN=RIGHT>13,840</TD>
	<TD ALIGN=RIGHT>13,290</TD>
	<TD ALIGN=RIGHT>57,100</td>
</TR>

<TR>
	<TD>
	</TD>
</TR>

<TR VALIGN=BOTTOM>
	<TD><B>Volvo trucks</B></TD>
	<TD ALIGN=RIGHT>19,510</TD>
	<TD ALIGN=RIGHT>18,830</TD>
	<TD ALIGN=RIGHT>18,380</TD>
	<TD ALIGN=RIGHT>19,780</TD>
	<TD ALIGN=RIGHT>76,500</td>
</TR>
<TR>
	<TD COLSPAN=6><HR></TD>
</TR>

<TR VALIGN=BOTTOM>
	<TD>Europe</TD>
	<TD ALIGN=RIGHT>8,550</TD>
	<TD ALIGN=RIGHT>8,030</TD>
	<TD ALIGN=RIGHT>8,060</TD>
	<TD ALIGN=RIGHT>10,570</TD>
	<TD ALIGN=RIGHT>35,210</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>North Amerika</TD>
	<TD ALIGN=RIGHT>6,890</TD>
	<TD ALIGN=RIGHT>6,290</TD>
	<TD ALIGN=RIGHT>8,440</TD>
	<TD ALIGN=RIGHT>5,870</TD>
	<TD ALIGN=RIGHT>27,110</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>Other markets</TD>
	<TD ALIGN=RIGHT>4,070</TD>
	<TD ALIGN=RIGHT>4,510</TD>
	<TD ALIGN=RIGHT>1,880</TD>
	<TD ALIGN=RIGHT>3,340</TD>
	<TD ALIGN=RIGHT>14,180</td>
</TR>

<TR>
	<TD>
	</TD>
</TR>

<TR VALIGN=BOTTOM>
	<TD><B>Volvo buses</B></TD>
	<TD ALIGN=RIGHT>1,140</TD>
	<TD ALIGN=RIGHT>1,710</TD>
	<TD ALIGN=RIGHT>1,680</TD>
	<TD ALIGN=RIGHT>2,290</TD>
	<TD ALIGN=RIGHT>6,830</td>
</TR>


<TR>
	<TD COLSPAN=6><HR></TD>
</TR>

</TABLE>

<BR>
<BR>
<BR>



<A NAME="1994"></A>

<TABLE WIDTH=452 BORDER=0 CELLPADDING=3>

<TR VALIGN=BOTTOM>
	<TD COLSPAN=6><FONT SIZE=5>Volvo vehicles sold, quarterly figures 1994</FONT></td>
</TR>

<TR>
	<TD COLSPAN=6><HR></TD>
</TR>

<TR VALIGN=BOTTOM>
	<TD></TD>
	<TD ALIGN=RIGHT>1st</TD>
	<TD ALIGN=RIGHT>2nd</TD>
	<TD ALIGN=RIGHT>3rd</TD>
	<TD ALIGN=RIGHT>4th</TD>
	<TD ALIGN=RIGHT>Total</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD><B>Volvo cars</B></TD>
	<TD ALIGN=RIGHT>91,400</TD>
	<TD ALIGN=RIGHT>90,650</TD>
	<TD ALIGN=RIGHT>75,420</TD>
	<TD ALIGN=RIGHT>93,800</TD>
	<TD ALIGN=RIGHT>351,270</td>
</TR>

<TR>
	<TD COLSPAN=6><HR></TD>
</TR>

<TR VALIGN=BOTTOM>
	<TD>200/700</TD>
	<TD ALIGN=RIGHT>-</TD>
	<TD ALIGN=RIGHT>-</TD>
	<TD ALIGN=RIGHT>-</TD>
	<TD ALIGN=RIGHT>-</TD>
	<TD ALIGN=RIGHT>-</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>400</TD>
	<TD ALIGN=RIGHT>25,340</TD>
	<TD ALIGN=RIGHT>23,910</TD>
	<TD ALIGN=RIGHT>25,360</TD>
	<TD ALIGN=RIGHT>20,590</TD>
	<TD ALIGN=RIGHT>95,200</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>800</TD>
	<TD ALIGN=RIGHT>39,110</TD>
	<TD ALIGN=RIGHT>39,210</TD>
	<TD ALIGN=RIGHT>36,040</TD>
	<TD ALIGN=RIGHT>49,580</TD>
	<TD ALIGN=RIGHT>163,940</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>940</TD>
	<TD ALIGN=RIGHT>22,420</TD>
	<TD ALIGN=RIGHT>23,550</TD>
	<TD ALIGN=RIGHT>10,620</TD>
	<TD ALIGN=RIGHT>15,950</TD>
	<TD ALIGN=RIGHT>72,540</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>960</TD>
	<TD ALIGN=RIGHT>4,530</TD>
	<TD ALIGN=RIGHT>3,980</TD>
	<TD ALIGN=RIGHT>3,400</TD>
	<TD ALIGN=RIGHT>7,680</TD>
	<TD ALIGN=RIGHT>19,590</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>Renault cars</TD>
	<TD ALIGN=RIGHT>3,030</TD>
	<TD ALIGN=RIGHT>4,260</TD>
	<TD ALIGN=RIGHT>3,770</TD>
	<TD ALIGN=RIGHT>3,840</TD>
	<TD ALIGN=RIGHT>14,900</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>Europe</TD>
	<TD ALIGN=RIGHT>52,230</TD>
	<TD ALIGN=RIGHT>54,750</TD>
	<TD ALIGN=RIGHT>49,710</TD>
	<TD ALIGN=RIGHT>51,880</TD>
	<TD ALIGN=RIGHT>208,570</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>North America</TD>
	<TD ALIGN=RIGHT>26,140</TD>
	<TD ALIGN=RIGHT>22,370</TD>
	<TD ALIGN=RIGHT>14,510</TD>
	<TD ALIGN=RIGHT>26,270</TD>
	<TD ALIGN=RIGHT>89,290</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>Other markets</TD>
	<TD ALIGN=RIGHT>13,030</TD>
	<TD ALIGN=RIGHT>13,530</TD>
	<TD ALIGN=RIGHT>11,210</TD>
	<TD ALIGN=RIGHT>15,650</TD>
	<TD ALIGN=RIGHT>53,420</td>
</TR>

<TR>
	<TD>
	</TD>
</TR>

<TR VALIGN=BOTTOM>
	<TD><B>Volvo trucks</B></TD>
	<TD ALIGN=RIGHT>16,150</TD>
	<TD ALIGN=RIGHT>16,290</TD>
	<TD ALIGN=RIGHT>16,990</TD>
	<TD ALIGN=RIGHT>19,060</TD>
	<TD ALIGN=RIGHT>68,490</td>
</TR>

<TR>
	<TD COLSPAN=6><HR></TD>
</TR>

<TR VALIGN=BOTTOM>
	<TD>Europe</TD>
	<TD ALIGN=RIGHT>6,900</TD>
	<TD ALIGN=RIGHT>6,070</TD>
	<TD ALIGN=RIGHT>6,570</TD>
	<TD ALIGN=RIGHT>8,540</TD>
	<TD ALIGN=RIGHT>28,080</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>North Amerika</TD>
	<TD ALIGN=RIGHT>6,370</TD>
	<TD ALIGN=RIGHT>6,780</TD>
	<TD ALIGN=RIGHT>6,620</TD>
	<TD ALIGN=RIGHT>67,000</TD>
	<TD ALIGN=RIGHT>26,470</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>Other markets</TD>
	<TD ALIGN=RIGHT>2,880</TD>
	<TD ALIGN=RIGHT>3,440</TD>
	<TD ALIGN=RIGHT>3,810</TD>
	<TD ALIGN=RIGHT>3,820</TD>
	<TD ALIGN=RIGHT>13,950</td>
</TR>

<TR>
	<TD>
	</TD>
</TR>

<TR VALIGN=BOTTOM>
	<TD><B>Volvo buses</B></TD>
	<TD ALIGN=RIGHT>1,010</TD>
	<TD ALIGN=RIGHT>1,320</TD>
	<TD ALIGN=RIGHT>1,490</TD>
	<TD ALIGN=RIGHT>1,950</TD>
	<TD ALIGN=RIGHT>5,770</td>
</TR>


<TR>
	<TD COLSPAN=6><HR></TD>
</TR>

</TABLE>

<BR>
<BR>
<BR>


<A NAME="1993"></A>

<TABLE WIDTH=452 BORDER=0 CELLPADDING=3>

<TR VALIGN=BOTTOM>
	<TD COLSPAN=6><FONT SIZE=5>Volvo vehicles sold, quarterly figures 1993</FONT></td>
</TR>

<TR>
	<TD COLSPAN=6><HR></TD>
</TR>

<TR VALIGN=BOTTOM>
	<TD></TD>
	<TD ALIGN=RIGHT>1st</TD>
	<TD ALIGN=RIGHT>2nd</TD>
	<TD ALIGN=RIGHT>3rd</TD>
	<TD ALIGN=RIGHT>4th</TD>
	<TD ALIGN=RIGHT>Total</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD><B>Volvo cars</B></TD>
	<TD ALIGN=RIGHT>69,470</TD>
	<TD ALIGN=RIGHT>78,890</TD>
	<TD ALIGN=RIGHT>61,920</TD>
	<TD ALIGN=RIGHT>91,840</TD>
	<TD ALIGN=RIGHT>302,120</td>
</TR>

<TR>
	<TD COLSPAN=6><HR></TD>
</TR>

<TR VALIGN=BOTTOM>
	<TD>200/700</TD>
	<TD ALIGN=RIGHT>7,850</TD>
	<TD ALIGN=RIGHT>9,280</TD>
	<TD ALIGN=RIGHT>1,680</TD>
	<TD ALIGN=RIGHT>330</TD>
	<TD ALIGN=RIGHT>19,140</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>400</TD>
	<TD ALIGN=RIGHT>19,480</TD>
	<TD ALIGN=RIGHT>22,380</TD>
	<TD ALIGN=RIGHT>20,620</TD>
	<TD ALIGN=RIGHT>22,950</TD>
	<TD ALIGN=RIGHT>85,430</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>800</TD>
	<TD ALIGN=RIGHT>20,720</TD>
	<TD ALIGN=RIGHT>22,990</TD>
	<TD ALIGN=RIGHT>20,130</TD>
	<TD ALIGN=RIGHT>37,810</TD>
	<TD ALIGN=RIGHT>101,650</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>940</TD>
	<TD ALIGN=RIGHT>19,050</TD>
	<TD ALIGN=RIGHT>21,490</TD>
	<TD ALIGN=RIGHT>16,490</TD>
	<TD ALIGN=RIGHT>27,000</TD>
	<TD ALIGN=RIGHT>84,030</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>960</TD>
	<TD ALIGN=RIGHT>2,370</TD>
	<TD ALIGN=RIGHT>2,750</TD>
	<TD ALIGN=RIGHT>3,000</TD>
	<TD ALIGN=RIGHT>3,750</TD>
	<TD ALIGN=RIGHT>11,870</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>Renault cars</TD>
	<TD ALIGN=RIGHT>1,540</TD>
	<TD ALIGN=RIGHT>2,080</TD>
	<TD ALIGN=RIGHT>2,330</TD>
	<TD ALIGN=RIGHT>2,310</TD>
	<TD ALIGN=RIGHT>8,260</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>Europe</TD>
	<TD ALIGN=RIGHT>40,830</TD>
	<TD ALIGN=RIGHT>43,940</TD>
	<TD ALIGN=RIGHT>38,520</TD>
	<TD ALIGN=RIGHT>50,540</TD>
	<TD ALIGN=RIGHT>173,830</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>North America</TD>
	<TD ALIGN=RIGHT>19,030</TD>
	<TD ALIGN=RIGHT>20,620</TD>
	<TD ALIGN=RIGHT>12,380</TD>
	<TD ALIGN=RIGHT>27,040</TD>
	<TD ALIGN=RIGHT>79,070</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>Other markets</TD>
	<TD ALIGN=RIGHT>9,610</TD>
	<TD ALIGN=RIGHT>14,340</TD>
	<TD ALIGN=RIGHT>11,020</TD>
	<TD ALIGN=RIGHT>14,260</TD>
	<TD ALIGN=RIGHT>49,230</td>
</TR>

<TR>
	<TD>
	</TD>
</TR>

<TR VALIGN=BOTTOM>
	<TD><B>Volvo trucks</B></TD>
	<TD ALIGN=RIGHT>10,880</TD>
	<TD ALIGN=RIGHT>12,690</TD>
	<TD ALIGN=RIGHT>12,310</TD>
	<TD ALIGN=RIGHT>15,370</TD>
	<TD ALIGN=RIGHT>51,250</td>
</TR>
<TR>
	<TD COLSPAN=6><HR></TD>
</TR>

<TR VALIGN=BOTTOM>
	<TD>Europe</TD>
	<TD ALIGN=RIGHT>3,610</TD>
	<TD ALIGN=RIGHT>4,640</TD>
	<TD ALIGN=RIGHT>4,420</TD>
	<TD ALIGN=RIGHT>5,830</TD>
	<TD ALIGN=RIGHT>18,500</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>North Amerika</TD>
	<TD ALIGN=RIGHT>4,920</TD>
	<TD ALIGN=RIGHT>5,440</TD>
	<TD ALIGN=RIGHT>5,220</TD>
	<TD ALIGN=RIGHT>6,230</TD>
	<TD ALIGN=RIGHT>21,810</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>Other markets</TD>
	<TD ALIGN=RIGHT>2,350</TD>
	<TD ALIGN=RIGHT>2,610</TD>
	<TD ALIGN=RIGHT>2,670</TD>
	<TD ALIGN=RIGHT>3,310</TD>
	<TD ALIGN=RIGHT>10,940</td>
</TR>

<TR>
	<TD>
	</TD>
</TR>

<TR VALIGN=BOTTOM>
	<TD><B>Volvo buses</B></TD>
	<TD ALIGN=RIGHT>1,130</TD>
	<TD ALIGN=RIGHT>1,330</TD>
	<TD ALIGN=RIGHT>1,050</TD>
	<TD ALIGN=RIGHT>1,940</TD>
	<TD ALIGN=RIGHT>5,450</td>
</TR>


<TR>
	<TD COLSPAN=6><HR></TD>
</TR>

</TABLE>

<BR>
<BR>
<BR>


<A NAME="1992"></A>
<TABLE WIDTH=452 BORDER=0 CELLPADDING=3>

<TR VALIGN=BOTTOM>
	<TD COLSPAN=6><FONT SIZE=5>Volvo vehicles sold, quarterly figures 1992</FONT></td>
</TR>

<TR>
	<TD COLSPAN=6><HR></TD>
</TR>

<TR VALIGN=BOTTOM>
	<TD></TD>
	<TD ALIGN=RIGHT>1st</TD>
	<TD ALIGN=RIGHT>2nd</TD>
	<TD ALIGN=RIGHT>3rd</TD>
	<TD ALIGN=RIGHT>4th</TD>
	<TD ALIGN=RIGHT>Total</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD><B>Volvo cars</B></TD>
	<TD ALIGN=RIGHT>80,350</TD>
	<TD ALIGN=RIGHT>86,300</TD>
	<TD ALIGN=RIGHT>57,800</TD>
	<TD ALIGN=RIGHT>82,880</TD>
	<TD ALIGN=RIGHT>307,330</td>
</TR>

<TR>
	<TD COLSPAN=6><HR></TD>
</TR>

<TR VALIGN=BOTTOM>
	<TD>200/700</TD>
	<TD ALIGN=RIGHT>20,450</TD>
	<TD ALIGN=RIGHT>21,220</TD>
	<TD ALIGN=RIGHT>10,180</TD>
	<TD ALIGN=RIGHT>11,930</TD>
	<TD ALIGN=RIGHT>63,780</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>400</TD>
	<TD ALIGN=RIGHT>23,730</TD>
	<TD ALIGN=RIGHT>24,800</TD>
	<TD ALIGN=RIGHT>20,680</TD>
	<TD ALIGN=RIGHT>23,990</TD>
	<TD ALIGN=RIGHT>93,200</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>800</TD>
	<TD ALIGN=RIGHT>7,140</TD>
	<TD ALIGN=RIGHT>9,090</TD>
	<TD ALIGN=RIGHT>7,630</TD>
	<TD ALIGN=RIGHT>18,810</TD>
	<TD ALIGN=RIGHT>42,670</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>940</TD>
	<TD ALIGN=RIGHT>24,370</TD>
	<TD ALIGN=RIGHT>26,850</TD>
	<TD ALIGN=RIGHT>15,270</TD>
	<TD ALIGN=RIGHT>24,590</TD>
	<TD ALIGN=RIGHT>91,080</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>960</TD>
	<TD ALIGN=RIGHT>4,660</TD>
	<TD ALIGN=RIGHT>4,340</TD>
	<TD ALIGN=RIGHT>4,040</TD>
	<TD ALIGN=RIGHT>3,560</TD>
	<TD ALIGN=RIGHT>16,600</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>Renault cars</TD>
	<TD ALIGN=RIGHT>2,170</TD>
	<TD ALIGN=RIGHT>3,340</TD>
	<TD ALIGN=RIGHT>2,340</TD>
	<TD ALIGN=RIGHT>2,230</TD>
	<TD ALIGN=RIGHT>10,080</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>Europe</TD>
	<TD ALIGN=RIGHT>54,410</TD>
	<TD ALIGN=RIGHT>56,780</TD>
	<TD ALIGN=RIGHT>40,420</TD>
	<TD ALIGN=RIGHT>46,710</TD>
	<TD ALIGN=RIGHT>198,320</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>North America</TD>
	<TD ALIGN=RIGHT>18,540</TD>
	<TD ALIGN=RIGHT>21,750</TD>
	<TD ALIGN=RIGHT>9,210</TD>
	<TD ALIGN=RIGHT>24,640</TD>
	<TD ALIGN=RIGHT>74,140</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>Other markets</TD>
	<TD ALIGN=RIGHT>7,380</TD>
	<TD ALIGN=RIGHT>7,760</TD>
	<TD ALIGN=RIGHT>8,160</TD>
	<TD ALIGN=RIGHT>11,540</TD>
	<TD ALIGN=RIGHT>34,840</td>
</TR>

<TR>
	<TD>
	</TD>
</TR>

<TR VALIGN=BOTTOM>
	<TD><B>Volvo trucks</B></TD>
	<TD ALIGN=RIGHT>11,720</TD>
	<TD ALIGN=RIGHT>12,650</TD>
	<TD ALIGN=RIGHT>11,110</TD>
	<TD ALIGN=RIGHT>12,650</TD>
	<TD ALIGN=RIGHT>48,130</td>
</TR>

<TR>
	<TD COLSPAN=6><HR></TD>
</TR>

<TR VALIGN=BOTTOM>
	<TD>Europe</TD>
	<TD ALIGN=RIGHT>5,900</TD>
	<TD ALIGN=RIGHT>5,950</TD>
	<TD ALIGN=RIGHT>5,440</TD>
	<TD ALIGN=RIGHT>5,950</TD>
	<TD ALIGN=RIGHT>23,240</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>North Amerika</TD>
	<TD ALIGN=RIGHT>3,930</TD>
	<TD ALIGN=RIGHT>4,580</TD>
	<TD ALIGN=RIGHT>3,890</TD>
	<TD ALIGN=RIGHT>4,320</TD>
	<TD ALIGN=RIGHT>16,720</td>
</TR>

<TR VALIGN=BOTTOM>
	<TD>Other markets</TD>
	<TD ALIGN=RIGHT>1,890</TD>
	<TD ALIGN=RIGHT>2,120</TD>
	<TD ALIGN=RIGHT>1,780</TD>
	<TD ALIGN=RIGHT>2,380</TD>
	<TD ALIGN=RIGHT>8,170</td>
</TR>

<TR>
	<TD>
	</TD>
</TR>

<TR VALIGN=BOTTOM>
	<TD><B>Volvo buses</B></TD>
	<TD ALIGN=RIGHT>1,480</TD>
	<TD ALIGN=RIGHT>1,330</TD>
	<TD ALIGN=RIGHT>1,040</TD>
	<TD ALIGN=RIGHT>1,730</TD>
	<TD ALIGN=RIGHT>5,580</td>
</TR>


<TR>
	<TD COLSPAN=6><HR></TD>
</TR>

</TABLE>


<BR>
<BR>
<TABLE BORDER=0 WIDTH=450>

<TR>
	<TD>Source: Financial and Operating Statistics 1995</TD>
</TR>

</TABLE>

<P>

</BLOCKQUOTE>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]

</TD>
</TR>
</TABLE>

</CENTER>


</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-230</DOCNO>
<DOCOLDNO>IA089-000951-B025-62</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/corpinfo/descr/index.html 192.138.110.240 19970208032259 text/html 6963
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 03:23:04 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 6792
Last-modified: Thu, 13 Jun 1996 14:40:22 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>The Volvo Group in Brief</TITLE></HEAD>

<BODY BGCOLOR="FFFFFF">

<A NAME="top"></A>

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="../annual.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>
</TR>

<TR>
	<TD><HR></TD>
</TR>

</TABLE>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>
	<TD><A HREF="../board/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knbla.gif"> Management and Board of
	Directors</A></TD>
	<TD><A HREF="../descr/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knrod.gif">	The Volvo Group in Brief</A></TD>
</TR>

<TR VALIGN=TOP>
	<TD><A HREF="../chief/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knbla.gif"> Comments by the Chief Executive Officer</A>
	<TD><A HREF="../share/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knbla.gif"> The Volvo Share</A></TD>
</TR>

<TR VALIGN=TOP>
	<TD><A HREF="../capital/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knbla.gif"> Capital structure and financial objectives</A>
	<TD></TD>
</TR>

</TABLE>


<TABLE WIDTH=490 BORDER=0>

<TR>
	<TD>

<HR ALIGN=LEFT WIDTH=487>

<BR>
<BR>

<BLOCKQUOTE>

<FONT SIZE=6>The Volvo Group in Brief</FONT><BR>
<BR>
<BR>

<IMG WIDTH=447 HEIGHT=173 SRC="/images/structure.gif" ALIGN=MIDDLE>
<BR>
<BR>
<BR>

<P ALIGN="LEFT">
Volvo is a concept far bigger than the brand name of a product. When people buy 
a Volvo they buy the Volvo concept as much as they buy the Volvo product. 
The Volvo concept is anchored in a set of values developed and nurtured over 
nearly seven decades. These basic values are quality, safety, and environmental 
care - all of them closely related to thoughtfulness and humanity.

<P ALIGN="LEFT">
Volvo's operations are concentrated on the automotive and transport 
vehicle industry. The objective is to further strengthen the Group's position 
in the passenger car sector and develop its position as one of the world's 
leading manufacturers of trucks, buses, construction equipment and drive systems 
for marine and industrial applications. In the aircraft engine field, Volvo has 
substantial resources for the overhaul of engines and the development of engine 
components.

<P ALIGN="LEFT">
Volvo's core values - quality, safety and environmental care - are in harmony 
with strong fundamental values in today's and tomorrow's societies. Volvo is a 
leader in the safety field, and its intensive development work has yielded a 
number of pioneering innovations. Volvo is intensifying its programs in the 
environmental area and preparing for a future shift in technology.

<P ALIGN="LEFT">
Volvo is a global company. Development and 
production of such strategic key components as engines and transmissions take 
place in Sweden, while assembly operations are carried out in wholly and partly 
owned plants in Europe, North America, Latin America, Southeast Asia and 
Australia. Approximately 90% of the sales of the automotive operations take 
place outside Sweden, mainly in Europe and North America. Forceful efforts are 
being made in new markets in Asia and Latin America.

<BR>
<BR>
<BR>
<BR>


<FONT SIZE=4>Volvo's operations in 1995</FONT><BR>

<UL>
	<LI>Operations in 1995 resulted in higher sales, but with a decline in order 
	bookings during the latter part of the year.<BR>
	<BR>

	<LI>Excluding nonrecurring items, operating income from automotive operations 
	amounted to SEK 7,493 M, the same high level as in 1994.<BR>
	<BR>
	
	<LI>Strong operating income in Volvo Trucks and the addition of Volvo Construction 
	Equipment compensated for lower operating income in Volvo Cars.<BR>
	<BR>
	
	<LI>Volvo's Board of Directors proposes that a cash dividend of SEK 4.00 per share 
	be paid on 1995 operations and that the entire holding of Swedish Match shares 
	be distributed to Volvo's shareholders.
</UL>
<BR>
<BR>
<BR>

<TABLE WIDTH=452 BORDER=0 CELLPADDING=3>

<TR>
	<TD COLSPAN=6><HR></TD>
</TR>

<TR>
	<TD ALIGN=LEFT VALIGN=BOTTOM><B></B></TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>1993</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>1994</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>1995</td>
</TR>

<TR>
	<TD COLSPAN=6><HR></TD>
</TR>

<TR>
	<TD VALIGN=BOTTOM>Sales</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>111,155</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>155,866</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>171,511</td>
</TR>

<TR>
	<TD VALIGN=BOTTOM>Operating income before nonrecurring items, automotive operations</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>1,913</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>7,486</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>7,493</td>
</TR>

<TR>
	<TD VALIGN=BOTTOM>of which Volvo Cars</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>626</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>2,771</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>1,089</td>
</TR>

<TR>
	<TD VALIGN=BOTTOM>Volvo Trucks</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>585</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>4,051</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>5,073</td>
</TR>

<TR>
	<TD VALIGN=BOTTOM>Net income (loss)</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>(3,466)</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>13,230</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>9,262</td>
</TR>

<TR>
	<TD VALIGN=BOTTOM>Income (loss) per share, SEK</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>(8.90)</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>31.80</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>20.20</td>
</TR>

<TR>
	<TD VALIGN=BOTTOM>Dividend per share, SEK</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>1.55</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>3.40</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>4.00</td>
</TR>

<TR>
	<TD VALIGN=BOTTOM>Capital expenditures for property, plant and equipment (incl leasing and company vehicles)</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>5,143</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>6,769</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>9,076</td>
</TR>

<TR>
	<TD VALIGN=BOTTOM>Research and development costs</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>4,386</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>4,604</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>7,289</td>
</TR>

<TR>
	<TD VALIGN=BOTTOM>Employees, year-end</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>73,640</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>75,550</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>79,050</td>
</TR>

<TR>
	<TD COLSPAN=6><HR></TD>
</TR>

</TABLE>
<BR>
<BR>
<BR>

<TABLE BORDER=0 WIDTH=450>

<TR>
	<TD><HR></TD>
</TR>

<TR>
	<TD>Source: Volvo Annual Report 1995</TD>
</TR>

</TABLE>

</BLOCKQUOTE>

<A HREF="#top"><IMG WIDTH=71 HEIGHT=14 BORDER=0
SRC="/images/knapp_top.gif" ALT="Top of page"></A>

<HR ALIGN=LEFT WIDTH=487>

<A
Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]
</TD>
</TR>
</TABLE>

</CENTER>

</BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-231</DOCNO>
<DOCOLDNO>IA089-000951-B025-95</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/corpinfo/chief/index.html 192.138.110.240 19970208032310 text/html 8926
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 03:23:19 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 8755
Last-modified: Thu, 13 Jun 1996 14:40:20 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Comments by the Chief Executive Officer</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<A NAME="top"></A>

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="../annual.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>
</TR>

<TR>
	<TD><HR></TD>
</TR>

</TABLE>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>
	<TD><A HREF="../board/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0
	 src="/images/knbla.gif"> Management and Board of
	Directors</A></TD>
	<TD><A HREF="../descr/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knbla.gif">	The Volvo Group in Brief</A></TD>
</TR>

<TR VALIGN=TOP>
	<TD><A HREF="../chief/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knrod.gif"> Comments by the Chief Executive Officer</A>
	<TD><A HREF="../share/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knbla.gif"> The Volvo Share</A></TD>
</TR>

<TR VALIGN=TOP>
	<TD><A HREF="../capital/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knbla.gif"> Capital structure and financial objectives</A>
	<TD></TD>
</TR>

</TABLE>


<TABLE WIDTH=490 BORDER=0>
<TR>
	<TD>

<HR ALIGN=LEFT WIDTH=487>

<BR>
<BR>

<BLOCKQUOTE>
<FONT SIZE=6>Comments<BR>
by the Chief Executive Officer</FONT><BR>


<BR>
<IMG WIDTH=210 HEIGHT=174 BORDER=1 ALIGN=LEFT HSPACE=10 SRC="/images/sgyll.gif">

The year 1995 was a successful year for the Volvo Group as a whole. Despite a 
weaker market at the end of the year, sales were higher in all segments of the 
automotive operations. Volvo Trucks recorded the highest income in its history. 
That the trend of Group earnings did not match the increase in sales was due 
mainly to weaker profitability in Volvo Cars, which was attributable to higher 
research and development and marketing costs and to an unfavorable trend of 
foreign exchange rates.

<P>
<FONT SIZE=6>V</FONT>
olvo Construction Equipment, which is now consolidated as a wholly owned 
subsidiary, has very good profitability. The company strengthened its 
positions in important segments of the market in Europe and North America.

<P>
Volvo Buses, which delivered a record number of buses in 1995, had a 
successful year. The acquisition of Pr&eacute;vost, a Canadian bus 
manufacturer, during the year represented a breakthrough in the North American 
market.

<P>
The value and volume of Volvo Penta's sales of both marine and industrial 
engines were higher. Important orders were obtained in India, Brazil and China.

<P>
Following four years of stagnation in the international market for civil 
aircraft, demand for Volvo Aero's civil aircraft engines increased. Volvo's 
participation in the joint European space program was strengthened through new 
orders for the Ariane project.

<P>
<FONT SIZE=6>W</FONT>
hile 1995 was a successful year, it must be viewed in a longer perspective. 
During the spring of 1994, following termination of the plan to merge with 
Renault, a new Group strategy was adopted that called for concentration on 
the automotive and transport equipment industry. The divestment of holdings 
that were not related to automotive operations was begun immediately and has 
to date brought in SEK 15.5 billion, including SEK 7.3 billion in 1995. During 
the year the core operations were strengthened through strategic acquisitions, 
notably Volvo Construction Equipment and Pr&eacute;vost, a bus manufacturer, 
at a total cost of SEK 6.3 billion.

<P>
Volvo Cars and Volvo Trucks entered a strong aggressive phase of development 
during 1995. The platforms for the two operations differ in many essential 
respects. While Volvo's commercial-vehicle units, Volvo Trucks, Volvo 
Construction Equipment, Volvo Buses and Volvo Penta, are substantial players 
on the world market, Volvo Cars' segment is limited. The basic objective is 
therefore to further enhance the strong positions of the commercial vehicles 
in their established markets and to increase their presence in developing 
markets. The task facing Volvo Cars is to take maximum advantage of the 
potentials for flexibility and speed that production of "niche" cars offers.

<P>
The common characteristics of the two operations are

<UL>
	<LI>that they are active in product segments that are growing<BR>
	<BR>
	<LI>that Volvo's technical expertise and the products' performance are world-class<BR>
	<BR>
	<LI>that our presence in established markets provides a stable base for further 
	growth, and<BR>
	<BR>
	<LI>that the Volvo name is one of the strongest in the transport-vehicle industry, 
	representing quality, safety and environmental care.<BR>
	<BR>
</UL>

<P>
With this as a starting point, the work of implementing the various business 
segments' product and marketing strategies was begun in 1995.

<P>
The main elements in the strategy for Volvo Cars is to broaden the range of 
products to include partly new customer groups, to present new models more 
frequently, and to introduce more cost-effective, modularized production 
methods. In line with this approach, product-development work has been 
accelerated and, calculated on an annual basis, has now reached the level and 
scope deemed necessary to ensure future competitiveness. The introduction of 
the medium-class Volvo S40 and Volvo V40, which were presented in 1995 and 
which will gradually replace the Volvo 400 series, involves a generational 
shift of great importance in moving toward the objective of broadening the 
customer base. The Volvo 850 and Volvo 960 increased their shares of the 
market in 1995. The development of the 850 diesel model and four-wheel drive, 
which were launched in 1995, and the development now under way of a cabriolet 
and coup&eacute;, are examples of the new variations that can be achieved 
based on a common technology and at lower development costs.

<P>
<FONT SIZE=6>V</FONT>
olvo Trucks, which recorded major successes in 1995, primarily with its FH 
series, is continuing to gain acceptance for its business concept in Europe 
and to solidify its global presence, industrially as well as commercially. 
This has resulted in additional market investments in North America and Asia, 
as well as advanced plans to establish operations in India and China. The 
Volvo FH 12 and FH 16 are the first models in a product family based on 
modular construction that will gradually replace all present heavy-truck 
models. When fully implemented, the changeover to a new components structure 
will mean increased value and greater flexibility for customers, as well as 
substantially lower costs due to the smaller number of different parts. The 
investments in increased capacity that were begun during the year are 
proceeding according to plan to ensure Volvo Trucks' long-term global growth. 

<P>
It is always difficult to forecast economic and market trends. The truck 
market in Europe is expected to level out in 1996, and the market in North 
America is now declining rapidly following two years of record-high growth. 
The market for cars is fragmented, but some slackening in demand is likely. 
Accordingly, steps are now being taken to adapt production and administrative 
resources to a weaker rate of growth than during the past two years. To reduce 
administrative and marketing costs, and as a consequence of the increasingly 
integrated development of products and processes, the number of Volvo Cars' 
employees will be cut back in 1996.

<P>
To sum up, Volvo has a strong line of products and an aggressive product plan 
that will ensure future competitiveness even in a harsher market climate. 
Long-term, the development program must be continued on a high and stable 
level to measure up to the high expectations that have been built up 
deliberately. This will also involve investments in information technology, 
thorough development of managers and employees, and a modern, decentralized 
and fast-moving organization in which the Group's collective experience and 
competence can be utilized in an environment of continuing renewal.

<P>
<IMG SRC="/images/gyll.gif" WIDTH=222 HEIGHT=72 ALIGN=middle>
<br>

S&ouml;ren Gyll<BR>
February 21, 1996

<BR>
<BR>

<TABLE BORDER=0 WIDTH=450>

<TR>
	<TD><HR></TD>
</TR>

<TR>
	<TD>Source: Volvo Annual Report 1995</TD>
</TR>

</TABLE>

<BR>

</BLOCKQUOTE>

<A HREF="#top"><IMG WIDTH=71 HEIGHT=14 BORDER=0
SRC="/images/knapp_top.gif" ALT="Top of page"></A>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]
</TD>
</TR>
</TABLE>

</CENTER>
</BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-232</DOCNO>
<DOCOLDNO>IA089-000951-B025-123</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/corpinfo/capital/index.html 192.138.110.240 19970208032325 text/html 3999
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 03:23:30 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 3828
Last-modified: Thu, 13 Jun 1996 14:40:19 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Capital structure and financial objectives</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<A NAME="top"></A>

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="../annual.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>
</TR>

<TR>
	<TD><HR></TD>
</TR>

</TABLE>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>
	<TD><A HREF="../board/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knbla.gif"> Management and Board of
	Directors</A></TD>
	<TD><A HREF="../descr/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knbla.gif">	The Volvo Group in Brief</A></TD>
</TR>

<TR VALIGN=TOP>
	<TD><A HREF="../chief/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knbla.gif"> Comments by the Chief Executive Officer</A>
	<TD><A HREF="../share/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knbla.gif"> The Volvo Share</A></TD>
</TR>

<TR VALIGN=TOP>
	<TD><A HREF="../capital/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knrod.gif"> Capital structure and financial objectives</A>
	<TD></TD>
</TR>

</TABLE>


<TABLE WIDTH=490 BORDER=0>

<TR>
	<TD>

<HR ALIGN=LEFT WIDTH=487>

<BR>
<BR>
<BLOCKQUOTE>

<FONT SIZE=6>Capital structure and financial objectives</FONT>


<P ALIGN="LEFT">
During 1994 the Board of Directors and Management designed a new strategic 
orientation for the Volvo Group: to concentrate on the automotive and transport 
equipment industry, with full control over core operations; strengthening of 
the balance sheet; and sharp improvement in the efficiency of core businesses, 
and in developing them.

<P ALIGN="LEFT">
Implementation of this strategy requires a stable trend of earnings with 
positive cash flows, as well as a balanced capital structure with an equity/ 
assets ratio that permits a high degree of financial freedom of action. Good 
credit ratings are essential to ensure financing for the Group at competitive 
costs even during recessions. The following objectives for return on 
shareholders' equity and the capital structure were established in 
December 1995:

<P ALIGN="LEFT">
to achieve a return of 12 to 15% on shareholders' equity, based on current 
levels of interest rates, over an economic cycle, which would exceed the 
current average for the industry.

<P ALIGN="LEFT">
to have an equity/assets ratio, excluding sales-financing operations, not 
lower than 40%. The equity/assets ratio in the finance operations should be not 
lower than 10%.

<P ALIGN="LEFT">
The Group will seek to maintain, but not to continuously exceed, net cash 
(financial assets less financial liabilities) amounting to 15% of shareholders' 
equity plus minority interests. The planning also stipulates that net debt in a 
more exposed or aggressive situation should not exceed 30% of shareholders' 
equity and minority interests.

<A NAME="tab">

<P ALIGN="LEFT">
see diagams:<BR>
<UL>
	<LI><A HREF="dia1.html">Return on shareholders' equity, %</A>
	<LI><A HREF="dia2.html">Shareholders' equity and minority interests as 
	percentage of total assets, %</A>
	<LI><A HREF="dia3.html">Net financial assets/debt as percentage 
	of shareholders' equity and minority interests</A>
</UL>
<BR>
<BR>
<BR>



<TABLE BORDER=0 WIDTH=450>

<TR>
	<TD><HR></TD>
</TR>

<TR>
	<TD>Source: Volvo Annual Report 1995</TD>
</TR>

</TABLE>

</BLOCKQUOTE>

<A HREF="#top"><IMG WIDTH=71 HEIGHT=14 BORDER=0
SRC="/images/knapp_top.gif" ALT="Top of page"></A>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]
</TD>
</TR>
</TABLE>

</CENTER>


</BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-233</DOCNO>
<DOCOLDNO>IA089-000951-B025-154</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/corpinfo/share/index.html 192.138.110.240 19970208032349 text/html 15012
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 03:23:54 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 14840
Last-modified: Thu, 13 Jun 1996 14:45:51 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>The Volvo share</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<A NAME="top"></A>

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="../annual.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>
</TR>

<TR>
	<TD><HR></TD>
</TR>

</TABLE>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>
	<TD><A HREF="../board/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knbla.gif"> Management and Board of
	Directors</A></TD>
	<TD><A HREF="../descr/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knbla.gif">	The Volvo Group in Brief</A></TD>
</TR>

<TR VALIGN=TOP>
	<TD><A HREF="../chief/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knbla.gif"> Comments by the Chief Executive Officer</A>
	<TD><A HREF="../share/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knrod.gif"> The Volvo Share</A></TD>
</TR>

<TR VALIGN=TOP>
	<TD><A HREF="../capital/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knbla.gif"> Capital structure and financial objectives</A>
	<TD></TD>
</TR>

</TABLE>


<TABLE WIDTH=490 BORDER=0>

<TR>
	<TD>

<HR ALIGN=LEFT WIDTH=487>

<BR>
<BR>
<BLOCKQUOTE>
<FONT SIZE=6>The Volvo Share</FONT>

<P ALIGN="LEFT">
Volvo is a public company. In September 1995 Volvo celebrated the 
sixtieth anniversary of the listing of the Volvo share on the Stockholm Stock 
Exchange. On the first day of trading, September 2, 1935, Volvo was valued at 
SEK 11 M. By the end of 1995 the value had increased to SEK 63 billion. This 
was equal to an average increase of 15.5% in value annually for 60 years, 
excluding new issues of shares and dividends.

<P ALIGN="LEFT">
In terms of the trading in Volvo shares, 1995 was a rather turbulent year, 
with major swings in share prices. Following a decline in the first half of 
the year during which a low of SEK 121 was recorded, the shares set a record 
of SEK 179 on September 20. Following this, the price of the Class B shares 
fell again, ending the year at SEK 136, just under the price at the beginning 
of 1995.

<P ALIGN="LEFT">
The total value of Volvo shares traded on the Stockholm Stock Exchange in 
1995 amounted to SEK 55 (72) billion, equal to 8% (11) of the total trading on the 
Exchange. At year-end, Volvo accounted for 5.3% (6.4) of the total market value,
SEK 1,179 billion (977), of shares listed on the Stockholm Exchange.

<P ALIGN="LEFT">
<B>Exchanges outside Sweden.</B><br>
To make Volvo's shares more readily available to 
investors outside Sweden, the shares are traded on a large number of foreign 
exchanges (see table below). The largest turnover takes place on the London 
Stock Exchange (SEAQ), 232.8 million Class B shares, and via the NASDAQ, 
electronic exchange in the U.S., 73.5 million American Depositary Receipts 
(ADRs), equal to the same number of Class B shares.

<P ALIGN="LEFT">
During 1995 investors outside Sweden continued to make net purchases of Volvo 
shares, with the result that foreign ownership of the share capital increased to 
37.5% (30.9). 

<P ALIGN="LEFT">
<B>Share capital.</B><br>
The outstanding 1987-1995 and 1990-1995 convertible 
debenture loans fell due for payment during the year, thereby increasing the share 
capital by SEK 97.6 M. At year-end 1995, AB Volvo's share capital amounted to 
SEK 2,318 M, represented by 463,558,252 shares, par value SEK 5 each.

<P ALIGN="LEFT">
Volvo has two classes of shares: Class A shares, which carry one vote, and 
Class B shares, which carry one tenth of a vote. The total number of votes is 
174,291,842.2.

<P ALIGN="LEFT">
<B>Change in share price relative to General Index.</B><br>
The price of the Volvo share 
declined by nearly 3% (1994: increase of 30%), while the Stockholm Stock Exchange 
General Index rose 18% (5). According to measurements made by the Exchange during 
the most recent four-year period (1992-1995), the beta value of the Volvo share is 
1.38 (1.24). Beta is a measurement of risk that indicates a share's price change 
compared with the stock market as a whole. Thus the price of the Volvo share 
changed, upward and downward, 38% more than the General Index.
<BR>
<BR>
<BR>
<BR>
<BR>


<P>
<IMG WIDTH=447 HEIGHT=305 SRC="/images/aktie95.gif" ALIGN=MIDDLE>

<BR>
<BR>
<BR>
<BR>
<BR>


<!-- TABLE 1 -->

<P>

<TABLE WIDTH=452 BORDER=0 CELLPADDING=3>

<TR>
	<TD COLSPAN=6><HR></TD>
</TR>

<TR>
	<TD ALIGN=LEFT VALIGN=BOTTOM><B>Per-share data</B></TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>1991</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>1992</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>1993</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>1994</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM><B>1995</B></td>
</TR>

<TR>
	<TD COLSPAN=6><HR></TD>
</TR>

<TR>
	<TD VALIGN=BOTTOM>Dividend, SEK</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>3.10</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>1.55</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>1.55</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>3.40</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>4.00<FONT SIZE=1> 1)</FONT></td>
</TR>

<TR>
	<TD VALIGN=BOTTOM>Share price at year-end, SEK (B share)</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>63</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>69</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>108</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>140</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>136</td>
</TR>

<TR>
	<TD VALIGN=BOTTOM>Shareholders' equity, SEK<FONT SIZE=1>2)</FONT></TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>87</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>77</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>70</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>98</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>110</td>
</TR>

<TR>
	<TD VALIGN=BOTTOM>Direct return,% (B share)<FONT SIZE=1>3)</FONT></TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>4.9</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>2.3</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>1.4</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>2.4</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>2.9</td>
</TR>

<TR>
	<TD VALIGN=BOTTOM>Effective return, % (B share)<FONT SIZE=1>4)</FONT></TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>61</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>13</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>60</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>32</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>0</td>
</TR>

<TR>
	<TD VALIGN=BOTTOM>Price/earnings ratio (B share)<FONT SIZE=1>5)</FONT></TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>36</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>-</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>-</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>4</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>7</td>
</TR>

<TR>
	<TD VALIGN=BOTTOM>Dividend payout, %<FONT SIZE=1>6)</FONT></TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>176</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>-</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>-</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>11</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>20</td>
</TR>

<TR>
	<TD VALIGN=BOTTOM>Income as percentage of average shareholders'
equity</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>2.0</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>neg</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>neg</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>36.5</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>19.3</td>
</TR>

<TR>
	<TD VALIGN=BOTTOM>Number of shareholders</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>170,500</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>163,800</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>147,300</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>182,700</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>206,700</td>
</TR>

<TR>
	<TD COLSPAN=6><HR></TD>
</TR>

</TABLE>



<BLOCKQUOTE>

<P>
<TABLE BORDER=0 WIDTH=410 CELLPADDING=3>

<TR VALIGN=TOP>
	<TD><FONT SIZE=1>1</FONT></TD>
	<TD><FONT SIZE=1>Proposed by the Board of Directors.</FONT></td>
</TR>

<TR VALIGN=TOP>
	<TD><FONT SIZE=1>2</FONT></TD>
	<TD><FONT SIZE=1>Shareholders' equity divided by the number of shares 
	outstanding at year-end.</FONT></td>
</TR>

<TR VALIGN=TOP>
	<TD><FONT SIZE=1>3</FONT></TD>
	<TD><FONT SIZE=1>Dividend divided by share price at
year-end.</FONT></td>
</TR>

<TR VALIGN=TOP>
	<TD><FONT SIZE=1>4</FONT></TD>
	<TD><FONT SIZE=1>Share price at year-end including dividend divided by 
	share price at beginning of the year.</FONT></td>
</TR>

<TR VALIGN=TOP>
	<TD><FONT SIZE=1>5</FONT></TD>
	<TD><FONT SIZE=1>Share price at year-end divided by income per
share.</FONT></td>
</TR>

<TR VALIGN=TOP>
	<TD><FONT SIZE=1>6</FONT></TD>
	<TD><FONT SIZE=1>Dividend divided by income per share.</FONT></td>
</TR>

</TABLE>

</BLOCKQUOTE>

<BR>
<BR>
<BR>


<!-- TABLE 2 -->


<P>

<TABLE WIDTH=270 BORDER=0 CELLPADDING=3>

<TR>
	<TD COLSPAN=2><HR></TD>
</TR>

<TR>
	<TH ALIGN=LEFT COLSPAN=2 VALIGN=BOTTOM>Listing of Volvo shares, location and
year<BR></TH>
</TR>

<TR>
	<TD COLSPAN=2><HR></TD>
</TR>

<TR>
	<TD VALIGN=BOTTOM>Stockholm</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>1935</td>
</TR>

<TR>
	<TD VALIGN=BOTTOM>London</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>1972</td>
</TR>

<TR>
	<TD VALIGN=BOTTOM>Frankfurt am Main, D&uuml;sseldorf, Hamburg</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>1974</td>
</TR>

<TR>
	<TD VALIGN=BOTTOM>Paris</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>1984</td>
</TR>

<TR>
	<TD VALIGN=BOTTOM>United States, (NASDAQ)</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>1985</td>
</TR>

<TR>
	<TD VALIGN=BOTTOM>Brussels, Antwerp</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>1985</td>
</TR>

<TR>
	<TD VALIGN=BOTTOM>Tokyo</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>1986</td>
</TR>

<TR>
	<TD VALIGN=BOTTOM>Z&uuml;rich, Basel, Geneva</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>1987</td>
</TR>

<TR>
	<TD COLSPAN=2><HR></TD>
</TR>

</TABLE>
<BR>
<BR>
<BR>


<!-- TABLE 3 -->


<P>
<TABLE WIDTH=452 BORDER=0 CELLPADDING=3>

<TR>
	<TD COLSPAN=4><HR></TD>
</TR>

<TR VALIGN=TOP>
	<TH ALIGN=LEFT COLSPAN=4 VALIGN=BOTTOM>The largest shareholders in AB Volvo,
December 31,
1995<BR></TH>
</TR>

<TR VALIGN=BOTTOM>
	<TD VALIGN=BOTTOM></TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>Number<BR> of shares</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>% of <BR>voting<BR> rights</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>% of <BR>share<BR> capital</td>
</TR>

<TR>
	<TD COLSPAN=4><HR></TD>
</TR>

<TR>
	<TD VALIGN=BOTTOM>The National Pension Insurance Fund,<BR>
		Fourth Fund managing board</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>21,958,990</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>7.9</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>4.7</td>
</TR>

<TR>
	<TD VALIGN=BOTTOM>R&eacute;gie Nationale des Usines Renault SA</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>13,360,190</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>7.7</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>2.9</td>
</TR>

<TR>
	<TD VALIGN=BOTTOM>Sparbanken savings funds</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>23,342,850</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>6.5</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>5.0</td>
</TR>

<TR>
	<TD VALIGN=BOTTOM>Svenska Handelsbanken	pension fund</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>8,700,000</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>5.0</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>1.9</td>
</TR>

<TR>
	<TD VALIGN=BOTTOM>S-E-Banken savings funds</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>8,511,991</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>4.8</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>1.8</td>
</TR>

<TR>
	<TD VALIGN=BOTTOM>F&ouml;rs&auml;kringsbolaget SPP &ouml;msesidigt<BR>
		(Pension funds)</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>15,675,117</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>4.6</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>3.4</td>
</TR>

<TR>
	<TD VALIGN=BOTTOM>Skandia-Gruppen (insurance group)</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>17,325,415</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>4.5</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>3.7</td>
</TR>

<TR>
	<TD VALIGN=BOTTOM>AMF Pensionsf&ouml;rs&auml;krings AB</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>12,785,000</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>3.3</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>2.8</td>
</TR>

<TR>
	<TD VALIGN=BOTTOM>Nordbanken savings funds</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>8,174,300</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>3.2</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>1.8</td>
</TR>

<TR>
	<TD VALIGN=BOTTOM>Parcitas Investments SA</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>4,975,000</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>2.9</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>1.1</td>
</TR>

<TR>
	<TD VALIGN=BOTTOM>Folksam incl, AMF (insurance group)</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>9,315,000</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>2.7</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>2.0</td>
</TR>

<TR>
	<TD VALIGN=BOTTOM>The National Pension Insurance Fund,<BR>
		Fifth Fund managing board</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>3,893,030</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>2.2</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>0.8</td>
</TR>

<TR>
	<TD VALIGN=BOTTOM>Trygg-Hansa F&ouml;rs&auml;kring (insurance)</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>9,761,896</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>1.9</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>2.1</td>
</TR>

<TR>
	<TD VALIGN=BOTTOM>SB Foundation</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>3,230,000</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>1.9</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>0.7</td>
</TR>

<TR>
	<TD VALIGN=BOTTOM>Svenska Handelsbanken savings funds</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>4,724,730</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>1.6</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>1.0</td>
</TR>

<TR>
	<TD COLSPAN=4><HR></TD>
</TR>

</TABLE>
<BR>
<BR>
<BR>



<P>
<TABLE WIDTH=452 BORDER=0 CELLPADDING=3>

<TR>
	<TD COLSPAN=6><HR></TD>
</TR>

<TR>
	<TD ALIGN=LEFT VALIGN=BOTTOM><B>Number of Volvo shares traded in Stockholm, 
	London and the United States</B></TD>
</TR>

<TR>
	<TD COLSPAN=6><HR></TD>
</TR>

</TD>
	<TD VALIGN=BOTTOM>Millions</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>1991</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>1992</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>1993</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>1994</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM><B>1995</B></td>
</TR>

<TR>
	<TD COLSPAN=6><HR></TD>
</TR>

<TR>
	<TD VALIGN=BOTTOM>Stockholm</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>99.2</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>186.3</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>262.8</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>519.6</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>386.5</td>
</TR>

<TR>
	<TD VALIGN=BOTTOM>London</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>89.1</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>178.9</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>150.7</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>287.5</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>232.8</td>
</TR>

<TR>
	<TD VALIGN=BOTTOM>USA NASDAQ (ADR)</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>9.9</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>9.4</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>11.5</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>19.0</TD>
	<TD ALIGN=RIGHT VALIGN=BOTTOM>73.5</td>
</TR>

<TR>
	<TD COLSPAN=6><HR></TD>
</TR>

</TABLE>
<BR>
<BR>

<TABLE BORDER=0 WIDTH=450>

<TR>
	<TD><HR></TD>
</TR>

<TR>
	<TD>Source: Volvo Annual Report 1995</TD>
</TR>

</TABLE>

</BLOCKQUOTE>

<A HREF="#top"><IMG WIDTH=71 HEIGHT=14 BORDER=0
SRC="/images/knapp_top.gif" ALT="Top of page"></A>

<HR ALIGN=LEFT WIDTH=487>

Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]
</TD>
</TR>
</TABLE>

</CENTER>


</BODY></HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-234</DOCNO>
<DOCOLDNO>IA089-000951-B025-182</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/corpinfo/board/index.html 192.138.110.240 19970208032404 text/html 8619
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 03:24:11 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 8448
Last-modified: Thu, 01 Aug 1996 15:26:02 GMT
</DOCHDR>
 
index.html*8'?
index.htmlzr 8t    XTEXTR*ch  E       r  *8'?                      7J  <HTML><HEAD><TITLE>AB Volvos Board</TITLE></HEAD><BODY BGCOLOR="FFFFFF"><A NAME="top"></A><CENTER><IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32><BR><BR><TABLE WIDTH=490 BORDER=0><TR VALIGN=TOP>	<TD ALIGN=RIGHT><A HREF="../annual.html"><IMG BORDER=0 	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD></TR><TR>	<TD><HR></TD></TR></TABLE><TABLE WIDTH=490 BORDER=0><TR VALIGN=TOP>	<TD><A HREF="../board/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0 	src="/images/knrod.gif"> Management and Board of	Directors</A></TD>	<TD><A HREF="../descr/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0 	src="/images/knbla.gif">	The Volvo Group in Brief</A></TD></TR><TR VALIGN=TOP>	<TD><A HREF="../chief/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0 	src="/images/knbla.gif"> Comments by the Chief Executive Officer</A>	<TD><A HREF="../share/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0 	src="/images/knbla.gif"> The Volvo Share</A></TD></TR><TR VALIGN=TOP>	<TD><A HREF="../capital/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0 	src="/images/knbla.gif"> Capital structure and financial objectives</A>	<TD></TD></TR></TABLE><TABLE WIDTH=490 BORDER=0><TR>	<TD><HR ALIGN=LEFT WIDTH=487><BR><BR><BLOCKQUOTE><FONT SIZE=6>Group Management<BR>and AB Volvo's Board of Directors</FONT><BR><CLEAR=ALL><BR><P><BR><A HREF="svanholm.html"><B>Bert-Olof Svanholm</B><br></A>Chairman. Born 1935, Master of Engineering. President of Asea Brown Boveri AB.Executive Vice President of ABB Asea Brown Boveri Ltd.<P><A HREF="eriksson.html"><B>Per-Olof Eriksson</B><br></A>  Born 1938, Master of Engineering, Honorary Doctor of Technology.<P><A HREF="frisinger.html"><B>H&aring;kan Frisinger</B><br></A>Born 1928, Master of Engineering, Honorary Doctor of Technology. <P><A HREF="hedelius.html"><B>Tom Hedelius</B><br></A>Born 1939, Master of Business Administration, Honorary Doctor of Economics.Chairman of the Boards of Svenska Handelsbanken and Bergman &amp; Beving AB.<P><A HREF="mannheimer.html"><B>S&ouml;ren Mannheimer</B><br></A>Born 1934, Bachelor of Laws. President of Stadshypotek AB, Region G&ouml;teborgsoch Bohus L&auml;n. Chairman of the National Pension Insurance Fund, Fourth FundManaging Board. <A NAME="ref3"></A><P><A HREF="svedberg.html"><B>Bj&ouml;rn Svedberg</B><br></A>Born 1937, Master of Engineering, Honorary Doctor of Technology. President andChief Executive Officer of Skandinaviska Enskilda Banken.<P><A HREF="gyll2.html"><B>S&ouml;ren Gyll</B><br></A>Born 1940. President of AB Volvo and Chief Executive Officer of the Volvo Groupsince 1992.<BR><BR><BR><BR><BR> <P><I>Designated by the employee organizations</I><P><A HREF="larsson.html"><B>Lars-G&ouml;ran Larsson</B><br></A>Born 1947. Representative for organizations of salaried employees (PTK).<P><A HREF="ludvigsson.html"><B>Olle Ludvigsson</B><br></A>Born 1948. Representative for plant trade union organizations.<P><A HREF="pedersen.html"><B>Verner Pedersen</B><br></A>Born 1952. Representative for plant trade union organizations.<BR><BR><BR><BR><BR><A NAME="ref4"></A><P><I>Deputy members of the Board</I><P><A HREF="berg.html"><B>Lars-Erik Berg</B><br></A>Born 1950, Master of Engineering. Representative for organizations of salariedemployees (PTK).<P><A HREF="nordgren.html"><B>Christer Nordgren</B><br></A>Born 1943. Representative for trade union organizations (LO/PTK) within BCPBranded Consumer Products AB.<BR><BR><BR><BR><BR><P><I>Secretary to the Board</I><P><A HREF="bodin2.html"><B>Fred Bodin</B><br></A>Born 1947, Bachelor of Laws. Senior Vice President of AB Volvo. Member of theGroup Executive Committee since 1993. Responsible for Legal.<BR><HR ALIGN=LEFT WIDTH=447><BR><BR><BR><BR><A NAME="ref1"></A><P><H2>Group management</H2><P><A HREF="gyll.html"><B>S&ouml;ren Gyll</B><br></A>Born 1940. President of AB Volvo and Chief Executive Officer of the Volvo Group.<P><A HREF="jeansson.html"><B>Lennart Jeansson</B><br></A>Born 1941, Master of Business Administration. Executive Vice President of ABVolvo since 1990. Member of the Group Executive Committee since 1986. With Volvosince 1966. <P><A HREF="langenius.html"><B>Sten Langenius</B><br></A>Born 1934. Executive Vice President of AB Volvo and member of the Group ExecutiveCommittee since 1990. With Volvo since 1976.<P><A HREF="mohlin.html"><B>Per-Erik Mohlin</B><br></A>Born 1946, Master of Engineering. Member ofthe Group Executive Committee since 1994. With Volvo since 1985.<P><A HREF="anell.html"><B>Lars Anell</B><br></A>Born 1941, Master of Business Administration. Senior Vice President of AB Volvo.Member of the Group Executive Committee since 1994. Responsible for CorporateCommunication. With Volvo since 1994.<P><A HREF="bodin.html"><B>Fred Bodin</B><br></A>Born 1947. Senior Vice President of AB Volvo. Secretary to the Volvo Board.<A NAME="ref2"></A><P><A HREF="engstrom.html"><B>Jan Engstr&ouml;m</B><br></A>Born 1950, Master of Business Administration. Senior Vice President of AB Volvo.Member of the Group Executive Committee since 1993. Chief Financial Officer of ABVolvo. With Volvo since 1973.<P><A HREF="hellman.html"><B>Anders Hellman</B><BR></A>Born 1955. Master of Engineering. President of AB Volvo Penta. Member of the Group Executive Committee since 1995. With Volvo since 1985. <P><A HREF="johannesson.html"><B>Tuve Johannesson</B><BR></A>President of Volvo Car Corporation. Member of the Group Executive Committee since 1995. <P><A HREF="b_larsson.html"><B>Bj&ouml;rn Larsson</B><BR></A>Born 1943. Bachelor of Business Administration. President of Volvo BusCorporation.Member of the Group Executive Committee since 1995. With Volvo since 1964.<P><A HREF="malmros.html"><B>Claes Malmros</B><BR></A>Born 1952. Senior Vice President of AB Volvo. Member of the Group ExecutiveCommitteesince 1995. Responsible for Group Stretegy & Business Development and Merger &Acquisitions.With Volvo since 1986.<P><A HREF="nilsson.html"><B>Leif &Aring;ke Nilsson</B><br></A>Born 1942, Senior Vice President of AB Volvo. Member of the Group ExecutiveCommittee since 1994. Responsible for Personnel. With Volvo since 1994.<P><A HREF="trogen.html"><B>Karl-Erling Trogen</B><br></A>Born 1946, Master of Engineering. President of Volvo Truck Corporation. Member ofthe Group Executive Committee since 1994. President of Volvo GM Heavy TruckCorporation 1991-94. With Volvo since 1971.<P><A HREF="wittlov.html"><B>Arne Wittl&ouml;v</B><BR></A>Born 1940. Honorary Doctor of Technology. President and Chief Executive Officer of Volvo Aero Corporation. Co-opted member of the Group Executive Committee since1993 andmember since 1995. With Volvo since 1984.<P><A HREF="ovlinger.html"><B>Bengt Ovlinger</B><BR></A>President of Volvo Construction Equipment Corporation. Member of the Group Executive Committee since 1995.<BR><BR><TABLE BORDER=0 WIDTH=450><TR>	<TD><HR></TD></TR><TR>	<TD>Source: Volvo Annual Report 1995</TD></TR></TABLE><BR></BLOCKQUOTE><A HREF="#top"><IMG WIDTH=71 HEIGHT=14 BORDER=0SRC="/images/knapp_top.gif" ALT="Top of page"></A><HR ALIGN=LEFT WIDTH=487>Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]</TD></TR></TABLE></CENTER></BODY></HTML>                   l  l   2                                
index.htmlx   TEXTR*ch T    TEXTR*ch T                  *8  r                                                                                                                Ingen            hR*chP= 0   )  )     	  Monaco                                                            P H H    ,7P {  P H H         d           '                 d      "q            p0/	  	  Monaco                                                                                                                            l  l   21"|,    2  BBSR   
P    1!                                                                                                  
</DOC>
<DOC>
<DOCNO>WT08-B13-235</DOCNO>
<DOCOLDNO>IA089-000951-B025-217</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/corpinfo/int.rep/six.95/index.html 192.138.110.240 19970208032418 text/html 31196
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 03:24:26 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 31024
Last-modified: Wed, 23 Oct 1996 09:00:50 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Six months ended June 30, 1995</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<A NAME="top"></A>

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="../index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>
</TR>

<TR>
	<TD><HR></TD>
</TR>

</TABLE>


<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>
	<TD><A HREF="index.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knrod.gif">
	<FONT SIZE=2> Six months ended June 30, 1995</FONT></A></TD>	
	<TD><A HREF="../three.96/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knbla.gif">
	<FONT SIZE=2> Three months ended March 31, 1996</FONT></A></TD>
</TR>

<TR VALIGN=TOP>
	<TD><A	HREF="../nine.95/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knbla.gif">
	<FONT SIZE=2> Nine months ended September 30, 1995</FONT></A></TD>
	<TD><A	HREF="../six.96/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0
	src="/images/knbla.gif">
	<FONT SIZE=2> Six months ended June 30,1996</FONT></A></TD>
</TR>

<TR VALIGN=TOP>
	<TD><A	HREF="../report.95/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knbla.gif">
	<FONT SIZE=2> Report on 1995 operations</FONT></A></TD>
	<TD><A	HREF="../nine.96/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knbla.gif">
	<FONT SIZE=2> Nine months ended September 30, 1996</FONT></TD>
</TR>

</TABLE>



<TABLE WIDTH=490 BORDER=0>

<TR>
	<TD>
	
<HR ALIGN=LEFT WIDTH=487>

<!-- -------- -->

<BLOCKQUOTE>
<BR>
<BR>


<FONT SIZE=6>Six months ended June 30, 1995</FONT>
<BR>
<BR>

<FONT SIZE=4><A HREF="#comments"><img WIDTH=14 HEIGHT=14 BORDER=0 
src="/images/knbla.gif"> Comments by the Chief Executive 
Officer</A></FONT><BR>
<BR>

<FONT SIZE=4><A HREF="#six"><img WIDTH=14 HEIGHT=14 BORDER=0 
src="/images/knbla.gif"> Six months ended June 30, 1995
</A></FONT><BR>
<BR>
<BLOCKQUOTE>
	
	<FONT SIZE=4><A	HREF="table.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knbla.gif"> Tables</A></FONT><BR>
	<BR>

	<FONT SIZE=4><A	HREF="diagram.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knbla.gif"> Diagrams</A></FONT><BR>
	<BR>

</BLOCKQUOTE>
<FONT SIZE=4><A HREF="#match"><img WIDTH=14 HEIGHT=14 BORDER=0 
src="/images/knbla.gif"> Swedish Match in brief</A></FONT><BR>
<BR>
<A NAME="ref0"></A>
<BR>

<HR ALIGN=LEFT WIDTH=447>
<BR>
<BR>

<FONT SIZE=4>
<B>Swedish Match to be distributed to Volvo's shareholders and introduced on the stock 
exchange.</B><BR>
<BR>

Continuing strong demand for Volvo's products.<BR>
<BR>

Operating income from automotive operations increased 
from SEK 3,677 M to SEK 4,913 M, excluding nonrecurring items.<BR>
<BR>

Operating income of Volvo Truck and Volvo Aero was substantially higher. Volvo 
Car's income was unchanged compared with the first six months 1994.<BR>

</FONT>
<BR>

(see table: <A HREF="tab0.html">First six months 1995</A>)<BR>
<BR>

<BR>
<BR>


<HR ALIGN=LEFT WIDTH=447>

<BR>
<P>

<FONT SIZE=5><A name="comments">Comments by the Chief Executive Officer<BR></FONT>
<BR>

<FONT SIZE=6>O</FONT>perations in the first half of 1995 were characterized 
by efforts to meet the 
continuing strong demand for Volvo products. Parallel with this, the 
implementation of Volvo Car's strategy to broaden its customer base and the 
program to expand Volvo Truck's capacity - whose full impact will be felt at 
the end of 1996 - were intensified.<BR>
<BR>

The trend of earnings for the Group as a whole is favorable. Excluding 
nonrecurring items, notably the write-down of the holding in Volvo Construction 
Equipment, operating income in the automotive operations amounted to SEK 
4,913 M, an increase of 34% compared with income in the year-earlier period.<BR>
<BR>

The growth in sales for Volvo Car demonstrates convincingly the strength of 
recent years' product introductions in the form of the Volvo 850 and the 
Volvo 960. Volvo's new car in the compact segment is ready for launching as 
the first in Volvo Car's integrated product and production strategy. Niche 
products for the prestige segment of the market are being developed in 
cooperation with TWR in the newly formed Autonova company.<BR>
<BR>

<A NAME="refdia1"></A>

<FONT SIZE=6>I</FONT>ncome from car operations has, however, been affected by unfavorable 
movements in exchange rates for the German mark and the Belgian franc and by 
rising marketing costs. In addition, the aggressive program undertaken by Volvo 
Car involves investments in product development and marketing that will 
restrain current earnings and those in the years immediately ahead. It is 
therefore of utmost importance to maintain a continuing program of 
efficiency-improvement measures.<BR>
<BR>

The very strong growth in earnings in Volvo Truck resulting from 
introduction of the competitive FH series is continuing. The change in name 
in the United States from WHITEGMC to Volvo has been well received in the 
market. The Environmental Concept Truck (ECT) unveiled recently shows Volvo's 
continuing innovative efforts to develop tomorrow's safe and environmentally 
compatible transports.<BR>
<BR>

The divestment of operations and interests outside the automotive field is 
continuing. After assessment of 
various alternatives, Volvo has decided to prepare an introduction of Swedish 
Match on the stock exchange and intends to propose that Volvo's Annual General 
Meeting in April 1996 vote to distribute the shares to Volvo's shareholders.<BR>
<BR>

Following the concentration on core operations, and strengthened by the 
acquisition of Volvo Construction Equipment, a Volvo Group is being created 
in which two sectors with equally large sales and distinct commercial missions 
and customer structures stand out: consumer goods, represented by the car 
operations, and producer goods, represented by trucks, construction equipment, 
buses, marine and aircraft engines. Volvo's  strong profile as a car 
manufacturer is thereby being balanced 
by very strong positions in the world market for commercial transport equipment.<BR>
<BR>

<FONT SIZE=6>O</FONT>ur task now is to take advantage of the potential synergies within the Group 
and to ensure that the prominent positions occupied by most of our operating 
sectors support and reinforce our common Volvo brand name and the values it 
represents: quality, safety and concern for the environment.<BR>
<BR>

(see diagram: <A HREF="dia1.html">Operating results, excluding 
nonrecurring items, rolling 12 months</A>)<BR
<BR>
<BR>

<HR ALIGN=LEFT WIDTH=447>
<BR>
<BR>
<BR>
<BR>

<!-- Six months ended June 30, 1995 -->

<FONT SIZE=5><A name="six">Six months ended June 30, 1995</FONT><BR>
<BR>
<BR>

<B>Acquisition of Volvo Construction Equipment and Pr&eacute;vost Car Inc., 
the bus manufacturer</B><BR>
<BR>

In the second quarter of 1995 AB Volvo acquired the outstanding 50% of the 
shares of Volvo Construction Equipment Corporation (formerly VME), held by 
Clark Equipment Company. The company is consolidated in the Group balance 
sheet as of June 30. In connection with the acquisition, the shareholding was 
written down by SEK 1.8 billion. This is the amount estimated to represent the 
portion of excess value in Volvo Construction Equipment that was attributable 
to the Volvo brand name at the date of acquisition. The remaining excess value, 
SEK 0.9 billion, is being amortized over 20 years.<BR>
<BR>

The purchase of Pr&eacute;vost Car Inc, the Canadian bus manufacturer, was completed 
in June 1995. Volvo Bus then sold 49% of the company's shares to Henlys Group 
plc in Great Britain, which owns Plaxton, a producer of bus bodies.<BR>
<BR>

Volvo Construction Equipment and Pr&eacute;vost Car Inc are included in Volvo's 
consolidated income statement as subsidiaries, effective in the third quarter 
1995.<BR>
<BR>
<BR>
<BR>
<BR>

<A NAME="ref1"></A>

<B>Consolidated income 
statements</B><BR>

(see table: <A HREF="tab1.html"> Cosolidated income statements</A>)<BR>
<BR>

<B>Volvo Group sales</B> in the first six months of 1995 amounted to SEK 85,134 M, 
compared with SEK 75,679 M in the first half of 1994. Sales in the automotive 
sector - the Volvo Group excluding the Fortos Group - rose 16%, excluding 
acquired units.<BR>
<BR>

<B>Operating income,</B> SEK 4,024 M, was charged with nonrecurring items in the 
amount of SEK 1,537 M consisting of a write-down of the acquired Volvo 
Construction Equipment shares of SEK 1,817 M and a capital gain on the sale 
of Alfred Berg Holding of SEK 280 M.<BR>
<BR>

Excluding nonrecurring items and the Fortos Group, operating income 
increased by SEK 1,236 M to SEK 4,913 M, compared with income in the first 
half last year.<BR>
<BR>

The increase in income was mainly the result of a larger volume of sales and 
high utilization of capacity; the increase was offset to some degree by 
gradually rising product development costs, by the unfavorable trend of 
exchange rates for the German mark and the Belgian franc, as well as by higher 
marketing costs in the Volvo Car Group.<BR>
<BR>

During the first half of 1995 the inflow in foreign currencies was hedged in 
part through forward contracts at exchange rates that were below the average 
spot rate. Operating income in the first six months includes losses of SEK 0.2 
billion (0.6) on such contracts.<BR>
<BR>
Of the restructuring reserve that was charged against income in 1992, 
SEK 66 M remained as of June 30, 1995.<BR>
<BR>

<B>Income from equity method investments</B> amounted to SEK 1,023 M (815), of which 
Pharmacia contributed SEK 600 M (533) and Volvo Construction Equipment 
SEK 478 M (335).<BR>
<BR>

<A NAME="ref2"></A>

<B>Gain on sale of securities</B><BR>
amounted to SEK 272 M (4,085) and was attributable primarily to Nordic Tel 
Holdings AB, SEK 176 M, and US Tobacco Inc, SEK 75 M. The figure in the 
preceding year included income from the sale of shares in Investment AB Cardo, 
AB Custos and Saga Petroleum a.s.<BR>
<BR>

<B>Net interest income</B> amounted to SEK 150 M as a result of the Volvo Group's 
stronger financial position, compared with net interest expense of SEK 479 M a 
year earlier.<BR>
<BR>

<B>Tax expense</B> amounted to SEK 2,366 M (1,097), including taxes of SEK 396 M 
(430) pertaining to associated companies. Tax expense in the year-earlier 
period had been reduced as a result of the lower deferred tax liability due 
to the loss carryforward that arose in connection with the exchange of shares 
with Renault.<BR>
<BR>
(see table:<A HREF="tab2.html">Key ratios</A>)<BR>
<BR>
<BR>
<BR>
<BR>
<A NAME="ref3,4"></A>

<B>Financial position 
of the Volvo Group</B><BR>
(see tables:<A HREF="tab3.html">Condensed consolidated balance sheets</A> and 
<A HREF="tab4.html">Change in group assets</A>)<BR>
<BR>

<B>Group assets</B> increased by SEK 9.2 billion during the first half of 1995. In 
the table below changes in the Group's asset items have been divided between 
changes attributable to acquisitions and sales of companies (acquisition of 
Volvo Construction Equipment and Pr&eacute;vost Car Inc and sale of Alfred Berg 
Holding) and other changes.<BR>
<BR>

Other current assets increased by SEK 3.9 billion, excluding acquisitions 
and sales of companies. The increase pertained mainly to accounts receivable 
and inventories in the Volvo Truck Group as a result of higher sales and to 
receivables in Volvo's sales financing operations.<BR>
<BR>

Investments in shares declined by SEK 1.2 billion due to the fact that Volvo 
Construction Equipment is no longer reported as an associated company and is 
now shown as a wholly owned subsidiary.<BR>
<BR>

Other noncurrent assets increased by SEK 4.3 billion. This figure includes 
an increase of SEK 2.1 billion in excess value attributable to the acquisition 
of the outstanding shares of Volvo Construction Equipment, SEK 1.7 billion 
(including acquired excess value of SEK 0.8 billion in the Volvo Construction 
Equipment Group), and Pr&eacute;vost Car Inc., SEK 0.4 billion. Financing of the V40 
project in NedCar, which involves development of Volvo's new medium-class car, 
increased other noncurrent assets by SEK 1.1 billion.<BR>
<BR>

The larger amount of capital tied up in receivables and inventory was 
financed partly through increased short-term liabilities. The percentage of 
long-term liabilities increased in line with Volvo's aim to extend the average 
maturity of Group loans.<BR>
<BR>

<A NAME="ref5"></A>

<B>Capital expenditures</B> for property, plant and equipment amounted to SEK 2.4 
billion (2.1) and investments in leasing and company vehicles totaled SEK 1.5 
billion (0.8).<BR>
<BR>

(see table: <A HREF="tab5.html">The increase in net dept</A>)<BR>
<BR>

<B>Net debt</B> increased from SEK 6.0 billion at December 31, 1994  to SEK 8.7 
billion (including accruals for postretirement benefits totaling SEK 6.1 
billion and SEK 7.2 billion, respectively).<BR>
<BR>

<A NAME="ref6"></A>
<A NAME="ref7"></A>

<B>Shareholders' equity</B> increased by SEK 3.2 billion and amounted to SEK 46.6 
billion at June 30, 1995. Shareholders' equity was equal to 31.5% of total 
assets, largely unchanged from the first of the year.<BR>
<BR>

(see tables: <A HREF="tab6.html">Statement of changes in consilidated 
financial position firs six months</A> and <A HREF="tab7.html">Number 
of shares</A>)<BR>
<BR>
<BR>
<BR>
<BR>

<A NAME="ref8"></A>
<A NAME="ref9"></A>

<B>Sales and operating results by company group</B><BR>

(see tables: <A HREF="tab8.html">Sales by company Group</A> and 
<A HREF="tab9.html">Operating income, excluding nonrecurring items
</A>)<BR>
<BR>

<A NAME="refdia2"></A>

<B>Volvo Car Group</B><BR>
The total market for passenger cars during the first half of 1995 was 
virtually unchanged from the year-earlier period. The North American market 
decreased by 6% while the market in Europe showed a mild upturn. The trend in 
Japan continued to be favorable and the market for passenger cars in that 
country increased by 14%.<BR>
<BR>

Volvo Car Group sales rose 14% during the first six months of 1995. 
The number of Volvo cars invoiced was 9% higher and a total of 198,800 
Volvo cars (182,000) were sold during the period.<BR>
<BR>

Volvo's sales and market shares were higher in the United States and Canada, 
as well as in most European countries. The number of Volvos registered in 
the Italian market was 15,900, an increase of 50% in a declining total market. 
The trend of Volvo's sales in Germany and The Netherlands was also highly 
favorable and market shares increased. Sales in Great Britain were largely 
unchanged, compared with the 1994 period. Volvo's sales and market shares 
declined in France and Spain. Sales increased in a number of Volvo's other 
markets, including Japan, up 17%, and Taiwan, up 25%.<BR>
<BR>

Operating income amounted to SEK 1,580 M (1,553). The larger volume combined 
with a more profitable product mix and higher utilization of capacity 
contributed to the favorable trend of income but higher costs of marketing and 
product development, as well as the negative impact of foreign exchange 
movements on purchases from Belgium and Germany had a restraining effect. 
The operating margin declined from 4.3% to 3.7%.<BR>
<BR>

(see diagram: <A HREF="dia2.html">Operating results, Volvo Car 
Group</A>)<BR>
<BR>

The 1996 model program, which includes a number of innovations, was 
presented in May. The Volvo 850 TDI, a diesel version of the Volvo 850, was 
among the models introduced. It has a straight-line five-cylinder engine with 
direct fuel injection and 140 hp at 4,000 rpm. Beginning in the 1996 model 
year the Volvo 960 will be equipped with side-impact airbags as standard 
equipment, as is the Volvo 850.<BR>
<BR>

<A NAME="refdia3"></A>

<B>Volvo Truck Group</B><BR>
The world market for heavy trucks continued to strengthen during the first 
half of 1995, relative to the market in the first six months of 1994. There 
was a distinct increase in the total markets in Europe and Brazil, while 
growth was smaller in the United States, where demand is gradually leveling 
off. The world market for heavy trucks is estimated to reach the highest level 
ever in 1995.<BR>
<BR>

Volvo Truck Group sales rose 18% during the first half of 1995, compared 
with the year-earlier period. During the first six months of the year Volvo 
delivered 38,340 medium-heavy and heavy trucks, 18% more than in the 
corresponding period of 1994. Demand for the FH series, which continued to be 
very strong, exceeded production capacity in all countries where the series is 
produced, resulting in longer delivery times. Orders for more than 40,000 FH 
series trucks have been received since the series was introduced in the autumn 
of 1993.<BR>
<BR>

During the first half of 1995 Volvo achieved a 16.4% (15.5) share of the 
market for heavy trucks in Europe. The comparable figure was 11.3% (12.3) in 
the U.S., and 31.0% (32.2) in Brazil.<BR>
<BR>

At June 30, 1995 the order backlog for heavy and medium-heavy trucks was 62% 
larger than on the same date a year earlier.<BR>
<BR>

Operating income amounted to SEK 3,106 M (1,829). The increase was due to 
larger volumes of deliveries, very high utilization of capacity and improved 
sales margins. The operating margin rose from 7.5% to 10.6%.<BR>
<BR>

On August 15, Volvo Truck presented the Environmental Concept Truck (ECT), 
which is designed for transports in densely populated areas. The ECT has two 
alternative power sources, a gas turbine engine and an electric motor - hybrid 
operation. The electric motor, which is designed to be used when the truck is 
being operated in urban centers, yields zero emissions. The ECT is also 
equipped with a large number of advanced technical systems designed to meet 
requirements in the next century - particularly in the safety field.<BR>
<BR>

<I>Volvo Bus.</I>Volvo delivered 2,860 buses and bus chassis (2,330) during the 
first six months of 1995. The market share in Europe rose and the order 
backlog at June 30 was 19% larger than a year earlier.<BR>
<BR>

Operating income  increased from SEK 141 M to SEK 164 M. The increase was 
due primarily to a larger volume of sales.<BR>
<BR>

Together with Carrus Oy, a Finnish manufacturer of bus bodies, Volvo Bus 
Corporation is forming a new company in Poland, Volvo Bus Poland. Volvo Bus 
will have a 55% interest in the new company, and Carrus 45%. The company will 
manufacture modern efficient low-emission buses for city and intercity traffic. 
As a consequence of the acquisition of Pr&eacute;vost, described on page 3, Volvo Bus 
gains significant presence in the American market for tourist buses.<BR>
<BR>

(see diagram: <A HREF="dia3.html">Operating results, Volvo 
Truck Group</A>)<BR>
<BR>

<B>Volvo Penta Group</B><BR>
Operating income increased to SEK 127 M (113), due primarily to increased 
demand for engines and spare parts from the marine market for recreational 
craft in Europe. The trend in the European market for commercial marine 
engines and industrial engines is also favorable. In contrast, growth in the 
American market for marine engines has subsided.<BR>
<BR>

<B>Volvo Aero Group</B><BR>
Operating income amounted to SEK 91 M, compared with a loss of SEK 17 M in the 
first half of 1994. The improvement was due in part to higher sales and in part 
to rationalization and restructuring measures. As a result of the growth in 
traffic in commercial aviation the number of surplus aircraft is now 
decreasing. Against this background, a long-term upward trend of production is 
anticipated. During the spring the Swedish Parliament approved SEK 500 M in 
credit guarantees to the Swedish aircraft engine industry during the next five 
years. This decision improves Volvo Aero's potential for expansion in 
commercial aircraft engine programs.<BR>
<BR>

Series deliveries of engines for the JAS 39 Gripen multi-role aircraft are 
continuing on schedule. Orders booked for commercial aircraft engine overhauls 
have increased sharply. Volvo Aero Engine Services has received a seven-year 
contract from Scandinavian Airlines System (SAS) covering maintenance of 
PW4000 engines used in Boeing 767 aircraft. The contract with SAS also 
includes maintenance of PW4000 engines in aircraft operated by Spanair 
(Spain) and Martinair (The Netherlands).<BR>
<BR>

<B>Fortos Group - continuing divestment of nonautomotive businesses</B><BR>
The program of divesting Volvo's involvement in the Fortos Group is proceeding 
in line with the objectives of satisfying the interests of the shareholders 
and assuming responsibility for creating appropriate industrial structures.<BR>
<BR>

Following evaluation of various alternatives, Volvo has decided to begin 
preparations for a stock exchange listing of Swedish Match. At Volvo's Annual 
General Meeting in April 1996 the Board of Directors intends to propose that 
Swedish Match's shares be distributed to Volvo's shareholders. The ambition 
is that the distribution will be effected in a manner that is as beneficial 
as possible to the shareholders.<BR>
<BR>

It is estimated that the public listing of Swedish Match shares can be 
effected in conjunction with the share distribution and be completed during 
1996. Between now and then work will be focused on creating an optimal 
financial and industrial structure for the company, thereby creating an 
investment opportunity that is attractive to the capital market, as well as 
a valuation of the company that is beneficial for Volvo's shareholders.<BR> 
<BR>

In a Swedish perspective, Swedish Match will be a relatively large 
exchange-listed company, with a broad ownership sphere and a major element 
of Swedish and international institutional investors. With its stable 
earnings capacity and strong cash flow, which facilitates a generous dividend 
policy, Swedish Match has the prerequisites for becoming an attractive 
addition to the Swedish stock market.<BR>
<BR>

A listing on the stock exchange provides Swedish Match the possibility as an 
independent company to continue to pursue its strategic efforts to expand 
internationally and develop the cooperation advantages which exist within the 
group. A brief description of Swedish Match's operations is provided on page 
16.<BR>
<BR>

The distribution of Swedish Match shares constitutes an important element in 
the divestment of nonautomotive operations that Volvo intends to complete 
before the end of 1996. The sale of Procordia's food business and the formation 
of Pripps Ringnes, owned jointly with Orkla (Norway) is expected to be completed 
in September 1995, following review by the anti-trust authorities.<BR>
<BR>

Volvo's entire holding of shares in Alfred Berg Holding was sold in April 
1995 to ABN AMRO Bank in Holland.<BR>
<BR>

Furthermore, AB Volvo's Board has concluded that the proposed merger between 
Pharmacia and Upjohn, the American pharmaceuticals company, is in the interest 
of Volvo's shareholders and subsequently supports the proposal. Accordingly, 
Volvo's shareholding in Pharmacia, corresponding to 27.3% of the share capital 
and 27.8% of the votes, will be exchanged for shares in the newly formed 
company (13.8% of the share capital and voting rights).<BR>
<BR>

Operating income of the Fortos Group, excluding gain on the sale of Alfred 
Berg, amounted to SEK 648 M (1,008). The decline is attributable primarily to 
divested operations, mainly Alfred Berg, and to lower income in Swedish Match. 
Increased competition in Brazil, as a result of lower import duties on matches, 
and a weaker dollar exchange rate affected income adversely.<BR>
<BR>

<B>Employees</B><BR>
The number of employees in the Volvo Group as of June 30, 1995 was 85,990, an 
increase of 10,440 since the first of the year. The increase was due in part 
to the acquisitions of Volvo Construction Equipment (7,100 persons) and Pr&eacute;vost 
Car (800), and in part to the hiring of new production employees in the Volvo 
Car Group and the Volvo Truck Group (2,600 persons).<BR>
<BR>

<B>Parent Company</B><BR>
AB Volvo had revenues of SEK 223 M (213) in the first half of 1995. The Company 
reported a loss of SEK 1,323 M before allocations and taxes, compared with 
income of SEK 4,599 M in the corresponding period a year earlier. This included 
nonrecurring items amounting to SEK 1,817 M pertaining to the write-down of the 
acquired shares of Volvo Construction Equipment. The 1995 results also included 
dividends of SEK 1,734 M (1,362) from subsidiaries, dividends of SEK 112 M 
(172) from non-Group companies, foreign exchange losses on loans of SEK 860 M 
(gains 53), and net interest expense of SEK 296 M (340). In the 1994 period, a 
gain on sale of securities was reported in the amount of SEK 3,707 M, 
pertaining primarily to the sale of Cardo, Custos and Hertz shares, as well as 
a write-down of SEK 209 M of the shares of N&auml;ringslivskredit NLK AB. Capital 
expenditures for property, plant and equipment amounted to SEK 6 M (3). Liquid 
funds at the close of the period totaled SEK 43 M, as against SEK 5,262 M at 
December 31, 1994. Net interest-bearing debt increased by SEK 10.1 billion, to 
SEK 14.1 billion, during the first six months of 1995. As of June 30, 1995, AB 
Volvo had 417 employees, compared with 393 at the first of the year.<BR>
<BR>

<B>Repurchase of properties</B><BR>
Volvo has concluded a contract with the other shareholders of Pleiad Real 
Estate AB covering the repurchase of the properties owned by Pleiad that are 
used in Volvo's operations in G&ouml;teborg. Volvo's involvement in Pleiad is 
thereby being terminated effective in the third quarter 1995. The other 
shareholders are retaining their holdings in Pleiad.<BR> 
<BR>

<B>New members of Volvo's Group Executive Committee</B><BR>
Claes Malmros has been named a member of Volvo's Group Executive Committee 
with responsibility for Group Strategy and Business Development. He will 
assume his new position on October 1, succeeding Mats G Ringesten. Bj&ouml;rn 
Larsson, President of Volvo Bus Corporation, was named a member of Volvo's 
Group Executive Committee, effective July 1, 1995.<BR>
<BR>

The report on operations during the first nine months of 1995 will be issued 
on November 8.<BR>
<BR>

G&ouml;teborg, August 22, 1995<BR>

<IMG SRC="/images/gyll.gif" WIDTH=222 HEIGHT=72 ALIGN=middle>
<BR>

S&ouml;ren Gyll<BR>

This report has not been reviewed by AB Volvo's auditors.<BR>
<HR ALIGN=LEFT WIDTH=447>
<BR>
<BR>
<BR>
<BR>


<!-- Swedish Match in brief -->

<FONT SIZE=5><A name="match">Swedish Match in brief</FONT><BR>
<BR>

The Board of Directors of AB Volvo intends to propose that Swedish Match's shares 
be distributed to Volvo's shareholders and listed on the stock exchange.<BR>
<BR>

<B>Swedish Match</B><BR>
Swedish Match develops, manufactures and markets primarily tobacco products, 
matches and disposable lighters as well as accessories to these products. 
Production is carried out in 27 plants. Swedish Match is represented by its 
own sales network in most western European markets and in the U.S. and Brazil. 
In the rest of the world, sales are through agents or export.<BR>
<BR>

Sales amounted to SEK 8,025 M in 1994 (8,673). Operating income rose during 
1994 by 22% to SEK 1,510 M (1,239), representing a significant improvement in 
margin. During the years 1991-1994 the company has had a relatively stable 
cash flow from operations of about SEK 1.5 billion annually. The number of 
employees during 1994 was slightly less than 8,000, of which 80% outside 
Sweden.<BR>
<BR>

<B>Division Tobacco Nordic</B><BR>
Division Tobacco Nordic, which manufactures and markets cigarettes, cigarillos, 
smoking tobacco and moist snuff, is the operational unit that consists 
primarily of Svenska Tobaks AB and its subsidiaries. The Nordic countries and 
Estonia represent the divisions domestic market. In the Swedish market for 
cigarettes, which is the most important, the market share in 1994 was 82%. The 
most well-known brand names include Blend as well as Prince, which is produced 
on license.<BR>
<BR>

The Division's sales in 1994 amounted to SEK 3,179 M (41% of total sales), 
an increase compared with 1993 of SEK 364 M. The number of employees during 
1994 was 1,456.<BR>
<BR>

<B>Division Tobacco EC</B><BR>
Division Tobacco EC comprises the Dutch company, EBAS Group B.V., which also 
has operational responsibility for the German cigar company, Arnold Andre & 
Co., in which the EBAS Group holds a 40% shareholding.<BR>
<BR>

The division holds a strong position as a producer of cigars and cigarillos 
in Europe, particularly in Germany, the Netherlands, Belgium and France. The 
most well-known brand name is La Paz.<BR>
<BR>

The Division's sales in 1994 amounted to SEK 678 M (9% of total sales), an 
increase compared with 1993 of SEK 23 M. The number of employees during 1994 
was 1,033. <BR>
<BR>

<B>Division Tobacco USA</B><BR>
Division Tobacco USA, which consists mainly of the Pinkerton Group, Inc. and 
its subsidiaries, is the market leader in North America in the loose leaf 
chewing tobacco category. The market share of these products is about 45%. 
Although moist snuff products as a whole hold a modest market share, viewed 
in terms of the entire North American market these are rapidly gaining ground.<BR> 
<BR>

The Division's sales in 1994 amounted to SEK 1.339 M (17% of total sales), 
an increase compared with 1993 of SEK 5 M. The number of employees in 1994 was 
759.<BR>
<BR>

<B>Division Lights</B><BR>
Division Lights is the world's largest producer of matches and the third 
largest producer of disposable lighters. The division is active in most parts 
of the world which offsets fluctuations in local markets.<BR>
<BR>

The Division's sales in 1994 amounted to SEK 2,550 M (33% of total sales), a 
decrease compared with 1993 of SEK 66 M. The number of employees in 1994 was 
4,393.<BR>
<BR>

<B>Development during 1995</B><BR>
Swedish Match reported sales in the first six months amounting to SEK 3,651 M 
(3,828) and operating income of SEK 545 M (662).<BR>
<BR>

The decline in sales and lower margin is mainly attributable to Division 
Lights, where a significant reduction in import duties in Brazil, resulting 
in an increased price competition, and a weaker dollar exchange rate affected 
earnings adversely.<BR>
<BR>
<BR>
<BR>
<BR>

<IMG WIDTH=447 HEIGHT=773 SRC="/images/six.95/dia11.gif">

<!-- -------- -->

<TABLE BORDER=0 WIDTH=450>

<TR>
	<TD><HR></TD>
</TR>

<TR>
	<TD>Source: Six months ended June 30, 1995</TD>
</TR>

</TABLE>

<P>

<BR>

</BLOCKQUOTE>

<A HREF="#top"><IMG WIDTH=71 HEIGHT=14 BORDER=0 
SRC="/images/knapp_top.gif" ALT="Top of page"></A>

<HR ALIGN=LEFT WIDTH=487>
Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]


</TD>
</TR>
</TABLE>

</CENTER>



</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-236</DOCNO>
<DOCOLDNO>IA089-000951-B025-252</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/corpinfo/int.rep/nine.95/index.html 192.138.110.240 19970208032437 text/html 23619
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 03:24:41 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 23447
Last-modified: Wed, 23 Oct 1996 09:00:13 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Nine months ended September 30, 1995</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<A NAME="top"></A>

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>

	<TD ALIGN=RIGHT><A HREF="../index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>
</TR>

<TR>
	<TD><HR></TD>
</TR>

</TABLE>


<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>
	<TD><A HREF="../six.95/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knbla.gif">
	<FONT SIZE=2> Six months ended June 30, 1995</FONT></A></TD>	
	<TD><A HREF="../three.96/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knbla.gif">
	<FONT SIZE=2> Three months ended March 31, 1996</FONT></A></TD>

<TR VALIGN=TOP>
	<TD><A	HREF="index.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knrod.gif">
	<FONT SIZE=2> Nine months ended September 30, 1995</FONT></A></TD>
	<TD><A	HREF="../six.96/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0
	src="/images/knbla.gif">
	<FONT SIZE=2> Six months ended June 30,1996</FONT></A></TD>
</TR>

<TR VALIGN=TOP>
	<TD><A	HREF="../report.95/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knbla.gif">
	<FONT SIZE=2> Report on 1995 operations</FONT></A></TD>
	<TD><A	HREF="../nine.96/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knbla.gif">
	<FONT SIZE=2> Nine months ended September 30, 1996</FONT></TD>
</TR>

</TABLE>

<TABLE WIDTH=490 BORDER=0>

<TR>
	<TD>


<HR ALIGN=LEFT WIDTH=487>

<!-- -------- -->

<BLOCKQUOTE>
<BR>
<BR>


<FONT SIZE=6>Nine months ended September 30, 1995</FONT>
<BR>
<BR>

<FONT SIZE=4><A HREF="#comments"><img WIDTH=14 HEIGHT=14 BORDER=0 
src="/images/knbla.gif"> Comments by the Chief Executive 
Officer</A></FONT><BR>
<BR>

<FONT SIZE=4><A HREF="#nine"><img WIDTH=14 HEIGHT=14 BORDER=0 
src="/images/knbla.gif"> Nine months ended September 30, 1995
</A></FONT><BR>
<BR>
<BLOCKQUOTE>
	
	<FONT SIZE=4><A	HREF="table.html"><img WIDTH=14 HEIGHT=14 BORDER=0
	 src="/images/knbla.gif"> Tables</A></FONT><BR>
	<BR>

	<FONT SIZE=4><A	HREF="diagram.html"><img WIDTH=14 HEIGHT=14 BORDER=0
	 src="/images/knbla.gif"> Diagrams</A></FONT><BR>
	<BR>

</BLOCKQUOTE>
<BR>
<BR>

<HR ALIGN=LEFT WIDTH=447>
<BR>
<A NAME="ref0"></A>
<BR>

<FONT SIZE=4>
Continuing favorable trend of sales in all sectors of the automotive operations.<BR>
<BR>

Lower operating income and unsatisfactory profitability trend in Volvo Car. 
Other operating sectors report higher profits compared with the first three 
quarters of 1994.<BR>
<BR>

Concentration on automotive operations continuing according to plan. 
Procordia Food and Abba Seafood divested in September.<BR>

</FONT>
<BR>

(see table: <A HREF="tab0.html">First nine months 1995</A>)<BR>

<BR>
<BR>


<HR ALIGN=LEFT WIDTH=447>
<BR>
<BR>
<BR>
<P>

<FONT SIZE=5><A name="comments">Comments by the Chief Executive Officer<BR></FONT>
<BR>

<FONT SIZE=6>D</FONT>emand for Volvo's products continues to be strong. 
Sales in all sectors of 
the automotive operations increased for the first three quarters of 1995. 
However, the growth in earnings during the year has not fully matched the 
increase in sales. The decline is attributable to Volvo Car which, despite 
increased sales and strong positions in most markets, reports lower operating 
income than in the corresponding period in 1994. This is attributable to 
an unfavorable development of foreign exchange 
rates in 1995 as well as rising product development and operating costs, among other 
factors. Part of these costs are planned and necessary  outlays to implement 
Volvo Car's product strategy. Strong restrictive measures are now being 
implemented for other, direct operating expenses. <BR>
<BR>

Despite the weakening in the car operations and the normal seasonal decline,  
operating income in the third-quarter of 1995 was the highest ever posted by 
Volvo in a third quarter. The strong earnings are attributable primarily to 
Volvo Truck, which is enjoying continued success with the FH series 
in Europe and whose earnings capacity is high. Volvo Construction Equipment, 
which is now a vital part of Volvo's commercial-vehicle sector, is developing 
well, though certain markets are now beginning to weaken, and has the highest 
operating margin of any Group unit.  Volvo Bus, Volvo Penta and Volvo Aero 
reported 
higher earnings, compared 
with the first three quarters in the preceding year.<BR>
<BR>

<A NAME="refdia1"></A>
Concentration on core operations is continuing according to plan. The contract 
with Orkla (Norway) covering the sale of Procordia's food business and the 
formation of Pripps Ringnes has been finalized. The proposal to distribute 
Swedish Match shares to Volvo shareholders in connection with a listing of 
the shares on the Stockholm Stock Exchange in 1996 is a major step in the 
concentration process and will enable the shareholders to participate in the 
growth in value that has occurred. Parallel with the release of financial 
resources Volvo Group's equity/assets ratio increases. This ratio was 34.6% at 
September 30. The objective is to achieve a streamlined 
and soundly capitalized Group structure that will facilitate implementation 
of the strategic direction and thereby enable us to give shareholders a 
favorable return on invested capital over the long term.<BR>
<BR>

Group operations as a whole developed satisfactorily in 1995. The phase of 
product and market development in which Volvo Car is now engaged 
will however continue to involve high investment costs on which a full return will
be realized within several years.<BR>
<BR>

S&ouml;ren Gyll<BR>
<BR>
<BR>

<HR ALIGN=LEFT WIDTH=447>
<BR>
<BR>
<BR>
<BR>


(see diagram: <A HREF="dia1.html">Operating income, excluding nonrecurring 
items</A>)<BR>
<BR>



<!-- Nine months ended September 30,1995 -->

<FONT SIZE=5><A name="nine">Nine months ended September 30, 1995</FONT><BR>
<BR>
<BR>

<B>Acquisitions and divestments of companies</B><BR>
<BR>

<A NAME="ref1"></A>
The transaction with Orkla A/S (Norway) was completed in September 1995 in 
accordance with the agreement announced in April. Volvo thereby sold the 
Procordia Food and Abba Seafood companies to Orkla. In addition, Volvo and 
Orkla formed a Nordic beverage company through a merger of Pripps - formerly 
part of  Procordia Food & Beverages - and Ringnes A/S of Norway. Volvo owns 50%
 of the capital in the new Pripps Ringnes company and a convertible debenture loan, 
which when converted increases Volvo's holding to 55%. The holding will be reported 
in accordance with the equity method. The contract with Orkla has resulted in a 
capital gain of SEK 2.3 
billion in the Volvo Group.<BR>
<BR>

The remaining 50% of the shares in Volvo Construction Equipment and 51% of 
Pr&eacute;vost Car Inc., a Canadian bus manufacturer, were acquired during the second 
quarter of 1995 and are included as subsidiaries in the Volvo Group income 
statement effective in  
the third quarter of the year. In this connection, the shareholding in 
Volvo Construction Equipment has been written down in the amount of SEK 1.8 
billion, attributable to excess value pertaining to the Volvo trademark. 
The remaining excess value, SEK 0.9 billion, is being amortized over 20 years.<BR>
<BR>
<BR>
<BR>
<BR>

(see table: <A HREF="tab1.html"> Cosolidated income statements</A>)<BR>
<BR>

<B>Volvo Group sales</B> in the first three quarters of 1995 amounted to SEK 
129,124 M, compared with SEK 112,173 M in the first three quarters of 1994. 
Excluding acquired units, sales attributable to automotive operations - the 
Volvo Group excluding Fortos - rose 15%. The increase was due to the 
continuing strong demand for Volvo products.<BR>
<BR>

<B>Operating income,</B> which amounted to SEK 8,844 M, included nonrecurring items 
of SEK 763 M pertaining to capital gains on the sales of 
Procordia Food and Abba Seafood SEK 2,300 M, and a gain of SEK 280 M on the 
sale of Alfred Berg Holding, as well as a write-down of SEK 1,817 M of the shares 
acquired in Volvo Construction Equipment. Excluding nonrecurring items and 
Fortos, operating income rose by SEK 1,676 M, to SEK 6,907 M. All operating 
sectors except Volvo Car reported higher profits in the first three 
quarters of 1995, compared with the corresponding period in 1994. The 
increase was most striking in Volvo Truck, where operating earnings 
rose from SEK 2,591 M to SEK 4,025 M. Operating income in Volvo Construction 
Equipment for the July-September period contributed SEK 313 M to Group 
earnings. Volvo's participation in the earnings of this company in earlier 
periods is included in income from equity method investments.<BR>
<BR>

Larger volumes of business and high utilization of capacity in all operating 
sectors - combined with improved profit margins, notably in Volvo Truck 
 - were the principal factors responsible for the improvement in income. 
This improvement was offset by higher costs for product development, marketing 
and administration. Foreign exchange movements in January-September 1995 had 
a negative impact of SEK 1.1 billion on operating income, compared with the 
corresponding period a year earlier. The effect was attributable primarily to 
Volvo Car and was due to higher effective exchange rates for the 
German mark and Belgian franc in which costs are incurred, and to lower rates 
for the U.S. dollar, in which Volvo Car has a high percentage of its sales.<BR>
<BR>

The inflow in foreign currencies was hedged in part through forward contracts 
during the first three quarters of 1995. The difference between the forward 
rate and the spot rate on such contracts was a deficit of SEK 0.2 billion (0.8).<BR>
<BR>

<B>Income from equity method investments</B> amounted to SEK 1,318 M (1,468), of which 
Pharmacia contributed SEK 934 M (868) and Volvo Construction Equipment SEK 478 M 
for the six-month period ended June 30 (548 for the nine-month period ended 
September 30, 1994). Volvo's share of the loss in NedCar in the first nine months 
of 1995 was SEK 385 M (214). The poor result in NedCar was due to lower volumes 
of business combined with the unfavorable trend of significant exchange rates.<BR>
<BR>

<B>Dividends received</B> included SEK 142 M from Renault.<BR>
<BR>

<B>Gain on sale of securities</B>
pertained mainly to the sale of holdings in 
NordicTel Holdings AB, SEK 176 M; Cultor Ab, SEK 166 M; and US Tobacco Inc., SEK 
75 M. Income in the 1994 period included gains in connection with the sale of 
shares in Investment AB Cardo, AB Custos and Saga Petroleum a.s.<BR>
<BR>

<B>Net interest</B> improved substantially compared with the first three quarters of 
1994, due to the Volvo Group's strong financial position. However, some weakening 
was noted in the third quarter due to the declining interest rates in Sweden.<BR>
<BR>

<A NAME="ref2"></A>
<B>Tax expense</B> amounted to SEK 3,192 M (2,069). Taxes attributable to associated 
companies amounted to SEK 563 M (673). Tax expense in the year-earlier period 
was reduced as a result of the lower deferred tax liability due to the loss 
carryforward that arose in connection with the exchange of shares with Renault.<BR>
<BR>
(see table:<A HREF="tab2.html"> Key ratios</A>)<BR>
<BR>

<A NAME="ref3"></A>

(see table: <A HREF="tab3.html">Condensed consolidated balance sheets</A>)<BR>
<BR>

<B>The Groups assets</B> increased by SEK 7.1 billion during the first nine months 
of the year. Excluding acquisitions and sales of companies, the increase was 
SEK 10.1 billion. Liquid funds rose by SEK 4.6 billion, due primarily to 
proceeds from the sales of Procordia Food and Abba Seafood at the end of the 
period and funds generated internally, while divestment of Alfred Berg Holding  
in April 1995, reduced liquid funds.<BR>
<BR>

Other noncurrent assets increased in the amount of SEK 2.9 billion. This 
includes an increase of SEK 1.7 billion in excess value attributable to the 
acquisition of the outstanding shares of Volvo Construction Equipment 
(including acquired excess values of SEK 0.8 billion in Volvo Construction 
Equipment) and those of Pr&eacute;vost Car Inc., SEK 0.4 billion. The excess value 
in Fortos was reduced by SEK 0.8 billion as a result of the sales of Procordia 
Food and Abba Seafood. Loan to NedCar for financing the development of 
Volvo's new medium-class car increased the value of other noncurrent  assets by 
SEK 1.4 billion.<BR>
<BR>

<B>Capital expenditures</B> for property, plant and equipment amounted to SEK 4.2 
billion (3.2) and investments in leasing and company vehicles totaled SEK 2.3 
billion (1.1).<BR>
<BR>

<A NAME="ref4,5"></A>

(see table: <A HREF="tab5.html">The decrease in net dept, first nine months 1995</A>)<BR>
<BR>

<B>Net debt</B> (including accruals for postretirement benefits) declined by SEK 6.0 
billion and amounted to 0 at the end of the third quarter.<BR>
<BR>

<B>Shareholders' equity</B> increased by SEK 7.1 billion and amounted to SEK 50.4 
billion at September 30, 1995. Shareholders' equity was equal to 34.6% (31.3%) 
of total assets.<BR>
<BR>

(see table: <A HREF="tab4.html">Statement of changes in consolidated 
financial position</A>)<BR>
<BR>
<BR>
<BR>
<BR>

<A NAME="car"></A>
<A NAME="refdia2"></A>
<A NAME="ref6,7"></A>
<B>Volvo Car</B><BR>

(see tables: <A HREF="tab6.html">Sales by company Group</A> and 
<A HREF="tab7.html">Operating income, excluding nonrecurring items</A>)<BR>
<BR>

The total market for passenger cars during the first three quarters of 1995 
was insignificantly smaller than in the corresponding period a year earlier. 
The North American market declined by 4% while the market in Europe showed a 
slight increase. The market for passenger cars in Japan rose 4%.<BR>
<BR>

A total of 286,490 (257,470) Volvo cars were sold during the first three 
quarters of 1995, 11% more than in the first nine months of  1994. The 
increase in sales was attributable to the Volvo 850 and Volvo 960 models, 
Volvo's cars in the upper segment of the market.<BR>
<BR>

Volvo's sales and market shares were higher in a number of countries in Europe, 
including Italy, Germany, the Netherlands and Sweden. Despite a declining 
total market, the number of Volvo cars registered in the United States and 
Canada  was also higher.<BR>
<BR>

Operating income amounted to SEK 1,930 M (2,071). The strong growth in 
volume, combined with a more favorable product mix and higher utilization 
of capacity, contributed to the positive trend of earnings. Offsetting this 
trend was the negative impact of foreign exchange rates in connection with 
purchases from Germany and Belgium and sales in the United States. In 
addition, sharply higher costs for product development and rising operating 
expenses in 1995 resulted in lower operating earnings than in the 1994 
period. The operating margin declined to 3.1% (3.9).<BR>
<BR>

(see diagram: <A HREF="dia2.html">Operating income, Volvo Car</A>)<BR>
<BR>

At the Frankfurt Auto Show in September, Volvo previewed its new medium-class 
car, based on a new platform developed in cooperation with Mitsubishi. The 
Volvo 850 R, a more powerful and faster version of the Volvo 850, was also 
unveiled during the autumn.<BR>
<BR>




<A NAME="truck"></A>
<A NAME="refdia3"></A>
<B>Volvo Truck</B><BR>
The world market for heavy trucks is expected to reach a record level in 1995. 
Growth in the market in Europe continues to be strong, except in Great Britain. 
Demand in the United States and Brazil has fallen off substantially during 
the second half of the year.<BR>
<BR>

During the first three quarters of the year Volvo delivered 56,700 medium-heavy 
and heavy trucks, 15% more than in the corresponding period a year earlier. 
Demand for the FH series remained strong and exceeded production capacity, 
resulting in continued long delivery times. Volvo's share of the market for 
heavy trucks in Europe was 16.1% (15.6), with market shares of 11.5% (12.3) 
in the United States and 28.1% (30.2) in Brazil.<BR>
<BR>

The backlog of orders at the end of September was 10% larger than on the 
same date a year earlier. The backlog has declined during the autumn as a 
result of the sharp drop in demand in the U.S.<BR>
<BR>

Operating income of Volvo Truck increased to SEK 4,025 M, compared 
with SEK 2,591 M in the 1994 period. The increase was based mainly on a high 
volume of sales and very high utilization of production facilities. The 
operating margin rose from 7.8% to 10.6%.<BR>
<BR>

(see diagram: <A HREF="dia3.html">Operating income, Volvo 
Truck</A>)<BR>
<BR>
<A NAME="bus"></A>

<B>Volvo Bus</B><BR>
Volvo delivered 4,540 buses and bus chassis during the first 
three quarters 
of 1995 (3,770). Volvo Bus's share of the market in western Europe has 
gradually increased and amounted to 18% (15), based on preliminary figures. 
The backlog of orders at the end of the third quarter was slightly more 
than 50% larger than a year earlier.<BR>
<BR>

Operating income amounted to SEK 282 M, as against SEK 196 M in the first 
three quarters of 1994. The improvement in earnings was attributable 
primarily to the higher volume of sales. Operating margin was 5.2% (4.7).<BR>
<BR>

In August the company displayed Volvo's Environmental Concept Bus for an 
international audience in Belgium. This concept bus constitutes a platform 
for continuing research and development of mass transportation vehicles of 
the future. The Volvo B12-600 bus was named "Coach of the Year, 1996" in 
October.<BR>
<BR>

<A NAME="vce"></A>

<B>Volvo Construction Equipment</B><BR>
The total market for construction equipment in the first three quarters of 
1995 was stronger than in the corresponding period a year earlier. Some 
softening in demand in several important markets has been noted in recent 
months, however, and order bookings show signs of stagnation or decline. This 
applies in particular to the German market, which is now beginning to weaken 
following its unusually high levels in recent years. A fall-off in demand 
has also been noted in North America.<BR>
<BR>

As a result of the larger total market and the company's ability to maintain 
or increase market shares in all product areas, Volvo Construction Equipment 
recorded higher volumes of sales, amounting to SEK 9,921 M (8,547), for the 
first three quarters of 1995. Higher volumes, improved prices and a more 
favorable product mix helped increase operating income to SEK 1,294 M 
(1,166) for the period. The operating margin was 13% (14).<BR>
<BR>

Effective in the third quarter of 1995, Volvo Construction Equipment is 
reported as a Volvo Group subsidiary.<BR>
<BR>

<A NAME="penta"></A>
<B>Volvo Penta</B><BR>
Volvo Penta's sales were 4% higher than in the year-earlier period. Order 
bookings declined in the third quarter. Demand for marine engines for 
recreational craft in the U.S. weakened in the third quarter and some 
sluggishness was also noted in Europe.<BR>
<BR>

There was continuing favorable demand for marine engines for commercial 
applications. Volvo Penta recorded a breakthrough in China where the 
company received a SEK 30 M order for generator sets from a shipyard. 
Demand for industrial engines also remained favorable.<BR>
<BR>

Operating income, SEK 197 M (196) was virtually unchanged from the preceding 
year. Operating margin was 6.6% (6.9).<BR>
<BR>

<A NAME="aero"></A>
<B>Volvo Aero</B><BR>
Commercial air traffic increased during the first three quarters of 1995. 
As a result, the surplus supply of aircraft is now decreasing. During 
the autumn Volvo Aero concluded agreements with IHI in Japan and General 
Electric in the U.S. covering deliveries of gas turbine and aircraft 
engine components. Under terms of the agreement with General Electric, 
Volvo Aero will be the sole supplier of low-pressure turbine housings 
for the CF6 engine used in Boeing 747s and 767s, among other aircraft.<BR>
<BR>

Series deliveries of engines for the JAS 39 Gripen multirole military 
aircraft continued on schedule. In order to adapt operations  to lower 
demand in the market for military overhaul services, 170 employees at 
Volvo Aero Support in Arboga received notices of termination of employment 
in September. In the field of commercial aircraft engine overhauls there 
is substantial excess capacity, resulting in continuing severe pressure 
on prices.<BR>
<BR>

During the autumn Volvo Aero received a contract from Societ&eacute; Europ&eacute;enne 
de Propulsion covering exhaust nozzles and drive turbines for hydrogen 
pumps used in the new European Ariane 5 rocket. The order comprises 
deliveries between now and 1998.<BR>
<BR>

As a result of higher volumes of sales and the effects of rationalization 
measures, Volvo Aero's operating income for the period increased to SEK 
97 M (16). Operating margin was 3.6% (0.1).<BR>
<BR>


<B>Fortos</B><BR>
Fortos' operating income, excluding the gain on the sale of subsidiaries, 
amounted to SEK 1,174 M (1,718). The decrease was attributable primarily 
to divestments, mainly the sale of Alfred Berg, and to lower income in 
Swedish Match.<BR>
<BR>



<B>Employees</B><BR>
The number of employees in the Volvo Group at the end of the first three 
quarters was 79,700, an increase of 4,200 since the first of the year. The 
increase was due in part to the acquisitions of Volvo Construction 
Equipment (7,100 persons) and Pr&eacute;vost Car (970), and in part to hiring 
in the Volvo Car Group (1,700) and Volvo Truck Group (2,000). The sales 
of Procordia Food and Abba Seafood reduced the number of Group employees 
by 8,000 persons.<BR>
<BR>




<B>Changes in Volvo Group management</B><BR>
In October, in line with Volvo's concentration on the transport vehicle 
field, changes were made in the organization of the Group Executive 
Committee.
Lennart Jeansson, Executive Vice President of AB Volvo, was named 
deputy to the Group Chief Executive Officer. Per-Erik Mohlin was named 
Executive Vice President of AB Volvo, with responsibility for the core 
values of quality control, safety and environmental matters within the 
Group.<BR>
<BR>

Tuve Johannesson, formerly president of Volvo Construction Equipment 
Corporation, was named President of Volvo Car Corporation, succeeding 
Per-Erik Mohlin. Bengt Ovlinger, the former Executive Vice President of 
Volvo Construction Equipment, was appointed President of the company. 
Tuve Johannesson and Bengt Ovlinger are new members of the Volvo Group 
Executive Committee.<BR>
<BR>

The report on operations for the full year 1995 will be 
issued on<BR>
<BR>

February 21, 1996.<BR>
<BR>


G&ouml;teborg, November 8, 1995<BR>

<IMG SRC="/images/gyll.gif" WIDTH=222 HEIGHT=72 ALIGN=middle>
<BR>

S&ouml;ren Gyll<BR>
President and Chief Executive Officer<BR>
<BR>

This report has not been reviewed by AB Volvo's auditors.<BR>
<BR>
<BR>


<!-- -------- -->

<TABLE BORDER=0 WIDTH=450>

<TR>
	<TD><HR></TD>
</TR>

<TR>
	<TD>Source: Nine months ended September 30, 1995</TD>
</TR>

</TABLE>

<P>

<BR>

</BLOCKQUOTE>

<A HREF="#top"><IMG WIDTH=71 HEIGHT=14 BORDER=0 
SRC="/images/knapp_top.gif" ALT="Top of page"></A>

<HR ALIGN=LEFT WIDTH=487>
Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]

</TD>
</TR>
</TABLE>

</CENTER>


</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-237</DOCNO>
<DOCOLDNO>IA089-000951-B025-280</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/corpinfo/int.rep/report.95/index.html 192.138.110.240 19970208032448 text/html 27811
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 03:24:57 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 27639
Last-modified: Wed, 23 Oct 1996 09:00:49 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Report on 1995 operations</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<A NAME="top"></A>

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>
	<TD COLSPAN=2 ALIGN=RIGHT><A HREF="../index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>
</TR>

<TR>
	<TD COLSPAN=2><HR></TD>
</TR>

</TABLE>


<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>
	<TD><A	HREF="../six.95/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knbla.gif">
	<FONT SIZE=2> Six months ended June 30, 1995</FONT></A></TD>	
	<TD><A HREF="../three.96/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knbla.gif">
	<FONT SIZE=2> Three months ended March 31, 1996</FONT></A></TD>
</TR>

<TR VALIGN=TOP>
	<TD><A	HREF="../nine.95/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knbla.gif">
	<FONT SIZE=2> Nine months ended September 30, 1995</FONT></A></TD>
	<TD><A	HREF="../six.96/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0
	src="/images/knbla.gif">
	<FONT SIZE=2> Six months ended June 30,1996</FONT></A></TD>
</TR>

<TR VALIGN=TOP>
	<TD><A HREF="index.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knrod.gif">
	<FONT SIZE=2> Report on 1995 operations</FONT></TD>
	<TD><A	HREF="../nine.96/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knbla.gif">
	<FONT SIZE=2> Nine months ended September 30, 1996</FONT></TD>
</TR>

</TABLE>



<TABLE WIDTH=490 BORDER=0>

<TR>
	<TD>
	
<HR ALIGN=LEFT WIDTH=487>

<!-- -------- -->

<BLOCKQUOTE>

<BR>
<BR>


<FONT SIZE=6>Report on 1995 operations</FONT>
<BR>
<BR>

<FONT SIZE=4><A HREF="#comments"><img WIDTH=14 HEIGHT=14 BORDER=0 
src="/images/knbla.gif"> Comments by the Chief Executive 
Officer</A></FONT><BR>
<BR>

<FONT SIZE=4><A HREF="#six"><img WIDTH=14 HEIGHT=14 BORDER=0 
src="/images/knbla.gif"> Report on 1995 operations
</A></FONT><BR>
<BR>

<FONT SIZE=4><A HREF="match.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
src="/images/knbla.gif"> Proposed distribution 
of the shares of Swedish Match</A></FONT><BR>
<BR>

<BLOCKQUOTE>
	
	<FONT SIZE=4><A	HREF="table.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knbla.gif"> Tables</A></FONT><BR>
	<BR>

	<FONT SIZE=4><A	HREF="diagram.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knbla.gif"> Diagrams</A></FONT><BR>
	<BR>

</BLOCKQUOTE>

<BR>
<A NAME="ref0"></A>
<BR>

<HR ALIGN=LEFT WIDTH=447>
<BR>
<BR>

<FONT SIZE=4>
<P ALIGN="LEFT">
Fiscal 1995 was characterized by higher sales but weakened order 
bookings toward-year end.


<P ALIGN="LEFT">
Excluding nonrecurring items, operating income of the automotive operations 
amounted to SEK 7,493 M, at the same high level as in 1994. 


<P ALIGN="LEFT">
Strong operating income reported by Volvo Truck and the contribution 
of Volvo Construction Equipment offset a lower operating income posted 
by Volvo Car.


<P ALIGN="LEFT">
The earnings decline within the car operations is attributable to the 
fourth quarter when sales volumes and margins did not offset higher 
costs within product development and marketing. In addition, the 
quarter was charged with SEK 303 M for planned personnel reductions.<BR>

</FONT>
<BR>

(see table: <A HREF="tab0.html">Report on 1995 operations</A>)<BR>
<BR>

<BR>
<BR>


<HR ALIGN=LEFT WIDTH=447>

<BR>
<P>

<FONT SIZE=5><A name="comments">Comments by the Chief Executive Officer<BR></FONT>
<BR>

<FONT SIZE=6>F</FONT>rom a sales viewpoint, 1995 was a successful year. All operations 
reported higher sales volumes than in 1994, despite a certain 
weakening in demand in important markets during the last few months 
of the year.

<P ALIGN="LEFT">
Volvo Truck reports its highest operating income ever, SEK 5,073 M. 
The market successes of the FH series continued and builds a 
platform for increased investment in product development to 
secure the FH's lead in technical and safety features. Production 
capacity in Europe was a limiting factor during the year and 
resulted in long delivery times. Despite this, Volvo Truck's 
share of the European market for heavy trucks increased again, 
to 16.3%. The ongoing expansion of capacity, which is part of an 
aggressive strategy for continued growth globally is proceeding 
as planned and long-term market investments were made during the 
year in North America and Asia.

<P ALIGN="LEFT">
The car business is becoming increasingly more competitive, with 
declining operating margins. This is also the case for Volvo Car, 
which reports unsatisfactory results, due mainly to the trend in 
the fourth quarter. The costs for product development rose significantly 
and reached a level at which they will level out. The Volvo 850 series 
and the Volvo 960 increased their shares on all of the 20 largest 
markets except France, due partly to increased marketing efforts 
and consequently costs. The decline in earnings is also attributable 
to the weak profitability of the Volvo 400 series, which is at the 
end of the product cycle, parallel with the costs for introduction 
in Europe of the Volvo S40/V40, sales of which will begin in the 
spring of 1996. 

<A NAME="refdia1"></A>

<P ALIGN="LEFT">
Implementation of Volvo Car's product strategy is continuing. At the 
same time, rationalization efforts are being intensified to achieve a 
competitively acceptable costs structure. This will affect production, 
administration and marketing.

<P ALIGN="LEFT">
Volvo Construction Equipment is, along with Volvo Truck the single most 
profitable operation in the Volvo Group. As with Volvo Truck, the company 
noted reduced order bookings in important markets towards year-end.

<P ALIGN="LEFT">
Volvo's concentration to core operations continues as planned.

<P ALIGN="LEFT">
Considering the assets released within Fortos in conjunction with 
divestments and to clarify the financial freedom of action which 
is required for future efforts in the core operations, Volvo 
disclosed its long-term financial goals and direction for the 
Group's capital structure in December.

<P ALIGN="LEFT">
Volvo's aim is that the Group's equity/assets ratio, excluding 
sales finance, should be at least 40 per cent. The Group shall 
strive to maintain, but not permanently exceed, a net cash balance 
of 15% of shareholders' equity and minority interests. Furthermore, 
planning is based on net debt in a more exposed or aggressive 
investment situation not exceeding 30% of shareholders' equity 
and minority interests.

<P ALIGN="LEFT">
 The Group is in an aggressive phase of development. At the same 
 time, a certain weakening in certain markets is occurring in the 
 world market for transport vehicles. Our capability of maintaining 
 stability in our development efforts while experiencing a weaker 
 market situation is our best guarantee for the future. Competition 
 will increase further in the immediate years ahead. Consequently, 
 our work must  be characterized by even greater precision and, among 
 other items, improved cost efficiency. However, with the current 
 product program, its competitiveness and our strong trademark, Volvo 
 has good possibilities to retain its position as a leading manufacturer 
 of transport vehicles, with high demand on quality, safety and concern 
 for the environment - Volvo's strongest competitive factors. 

<BR>
<BR>

(see diagram: <A HREF="dia1.html">Operating results, before 
nonrecurring items, rolling 12 months</A>)<BR
<BR>
<BR>

<HR ALIGN=LEFT WIDTH=447>
<BR>
<BR>
<BR>
<BR>

<!-- Six months ended June 30, 1995 -->

<FONT SIZE=5><A name="six">Report on 1995 operations</FONT><BR>
<BR>
<BR>

<P ALIGN="LEFT">
The concentration to the automotive and transport vehicle industry 
which the Volvo Board decided upon in the spring of 1994 continued 
during 1995. Volvo divested shares in non-automotive companies, 
which combined generated SEK 7.3 billion in proceeds and SEK 4.2 
billion in capital gains. Concurrently, the core operations were 
strengthened through the acquisition of companies with a total 
purchase amount of SEK 6.3 billion. 

<P ALIGN="LEFT">
An important addition in 1995 was the acquisition of the remaining 
50% of the shares in Volvo Construction Equipment, one of the largest 
manufacturers of construction equipment in the world, and a new complementary 
business area to the Volvo Group. In addition, 51% of the Canadian bus 
manufacturer Pr&eacute;vost Car Incorporated was acquired and at the end 
of the year all shares in Groupe Pel-Job, a French manufacturer of 
mini-excavators, were purchased. 

<P ALIGN="LEFT">
Divestments included Alfred Berg Holding AB, Procordia Food and Abba 
Seafood, Falcon Holding AB and the shareholdings in Partena AB, Cultor 
Ab, UST Inc (former US Tobacco Inc) and Nordic Tel Holdings AB. Through a merger of the 
Prippsgruppen, formerly wholly owned by Volvo, and Ringnes of Norway 
Volvo received 50% of the votes in the new company Pripps Ringnes AB. 
Volvo  also submitted its shareholdings in Pharmacia (27.3%) in exchange for 
shares in the newly formed company Pharmacia &amp; Upjohn, Inc. (13.8%).

<P ALIGN="LEFT">
Volvo Construction Equipment and Pr&eacute;vost are consolidated as 
subsidiaries of the Volvo Group as from July 1, 1995 and Procordia's food 
operations are excluded in the fourth quarter.

<BR>
<BR>
<BR>
<BR>


<B>Volvo's sales 1995</B> amounted to SEK 171,511 M, compared with SEK 
155,866 M a year earlier. Sales of the automotive operations, that is, Volvo 
excluding Fortos, rose 9%, excluding acquired units. Adjusted for 
foreign exchange movements sales increased 12%.

<P ALIGN="LEFT">
A total of  374,600 (351,000) Volvo cars were sold, up 7%. The increase 
in sales was attributable to the Volvo 850 and Volvo 960. 

<P ALIGN="LEFT">
Deliveries of Volvo trucks rose 12%, amounting to 76,500 vehicles 
(68,500), which is a record number. The success is due to the continued 
favorable demand for the FH series and the strong world market.

<P ALIGN="LEFT">
Volvo's deliveries of buses and bus chassis amounted to 6,830 (5,770) 
units. The other business activities also reported higher volumes and 
higher sales figures than in 1994.


<P ALIGN="LEFT">
<B>Operating income</B> of SEK 10,239 M (9.371) includes nonrecurring items 
totaling SEK 1,215 M,  which is a result of the extensive changes in the 
Group's composition. This includes gains on the sale of the subsidiaries 
Procordia Food and Abba Seafood, SEK 2,300 M,  Alfred Berg Holding, SEK 
515 M and Falcon Holding, SEK 217 M, and a write-down of the shares 
acquired in Volvo Construction Equipment, SEK 1,817 M.


<P ALIGN="LEFT">
Excluding nonrecurring items and Fortos, operating income amounted to 
SEK 7,493 M (7,486), that is, the same high level as in 1994. 

<A NAME="ref1"></A>

<P ALIGN="LEFT">
Increased sales volumes for all business areas 
contributed favorably to the Volvo Group's earnings trend in 1995. 
However, the sales successes in the car operations could not fully 
offset the increased costs in product development and marketing. 
Combined with negative currency effects and provision for planned 
personnel reductions, this resulted in Volvo Car reporting a loss in 
the fourth quarter.

<P ALIGN="LEFT">
 The currency trend in 1995 which contributed adversely to Volvo 
 Group earnings compared with 1994 has been estimated at SEK 1.4 billion, mainly attributable 
 to Volvo Car. The main reasons are the lower average spot rate for the inflow 
 currencies, the USD, GBP and the ITL and a higher average spot rate for 
 the outflow currencies, the DEM and BEF.

<P ALIGN="LEFT">
Operating income of Volvo Car declined SEK 1.7 billion compared to 1994. Volvo Truck's operating income rose SEK 1,0 billion and 
the acquisition of Volvo Construction Equipment added SEK 0.7 billion to 
operating income. Other operations in the automotive sector reported unchanged 
or slightly higher operating income.  <BR>
<BR>



(see table: <A HREF="tab1.html"> Consolidated income statements</A>)<BR>
<BR>


Operating income was charged with SEK 285 M (350) for profit-sharing bonus 
to Volvo Group employees in Sweden.
 
<BR>
<BR>
<BR>
<BR>
<BR>






<B>Income from equity method investments</B> amounted to SEK 1,402 M (2,193), of 
which Pharmacia accounted for SEK 1,155 M (1,286) and the former VME for 
SEK 478 M, for the January-June period  (788 for full-year 1994). Volvo's share 
of the loss in NedCar was SEK 635 M (226). The weak results in NedCar were 
due to lower volumes of the Volvo 400 series combined with unfavorable 
currency rate trends.<BR>

<P ALIGN="LEFT">
<B>Financial income and expenses.</B> Dividends received pertain mainly to Renault 
and Pharmacia &amp; Upjohn. The 1994 figure includes dividends from Protorp 
Intressenter AB, net SEK 933 M.

<A NAME="ref2"></A>
<A NAME="ref3"></A>


<P ALIGN="LEFT">
Gain on sales of securities pertains principally to: Partena AB, SEK 707 M; 
Nordic Tel Holdings AB, SEK 176 M; Cultor Ab, SEK 166 M and UST Inc, SEK 
75 M. The 1994 figure includes the gain on sales of shares in  Investment 
AB Cardo, AB Custos and Saga Petroleum a.s.

<P ALIGN="LEFT">
Net interest improved as a result of the Volvo Group's strong financial position.

<P ALIGN="LEFT">
<B>Tax expenses</B> pertain mainly to current taxes in foreign subsidiaries. 
Taxes attributable to associated companies in the amount of SEK 672 M 
(919) were included.


<BR>
<BR>
(see tables: <A HREF="tab3.html">Condensed consolidated balance sheets</A> and 
<A HREF="tab2.html"> Key ratios</A>)<BR>
<BR>



<P ALIGN="LEFT">
<B>Investments in shares</B> increased through the forming of Pripps Ringnes AB 
and declined through the sale of Partena AB, Cultor Ab, UST Inc and 
Nordic Tel Holdings AB and through the consolidation of Volvo 
Construction Equipment Corporation and restructuring of Pleiad Real Estate AB.

<P ALIGN="LEFT">
<B>Other noncurrent assets</B> rose by SEK 2.8 billion. This includes an increase 
in excess value attributable to acquisition of the shares outstanding in 
Volvo Construction Equipment, SEK 1.7 billion (including acquired excess 
values in Volvo Construction Equipment of SEK 0.8 billion) and Pr&eacute;vost 
Car, SEK 0.4 billion. The excess value in Fortos declined by SEK 0.8 billion 
through the sale of Procordia Food and Abba Seafood.

<P ALIGN="LEFT">
Loans to NedCar for financing of the development of the Volvo S40/V40 
increased other noncurrent assets by SEK 1.6 billion.
<BR>
<BR>


<P ALIGN="LEFT">
<B>Capital expenditures</B> for property, plant and equipment rose to SEK 6.5 
billion (4.3) and capital expenditures for leasing and company vehicles 
to SEK 2.6 billion  (2.5).

<A NAME="ref6"></A>
<A NAME="ref5"></A>


<P ALIGN="LEFT">
Capital expenditures in Volvo Car, excluding leasing and company vehicles, 
amounted to SEK 2.5 billion and pertained to expansion of capacity in the 
car assembly plants in Torslanda and Ghent and the engine plant in 
Sk&ouml;vde. Capital expenditures of SEK 2.1 billion were made in Volvo 
Truck, for capacity enhancement measures in the component supply channel 
and the assembly plants in Europe, rebuild of the spare parts warehouse in 
Ghent and efficiency enhancement measures at the plant in New River 
Valley, USA.



<P ALIGN="LEFT">
<B>Net debt,</B> which amounted to SEK 6.0 billion at the beginning of the 
year, was eliminated and net financial assets of SEK 1.2 billion were 
posted at year-end.<BR>
<BR>


<P ALIGN="LEFT">
<B>Shareholders' equity</B> increased by SEK 7.9 billion. Net income for the 
year and conversion of debentures generated SEK 9.3 billion and SEK 1.6 
billion, respectively. Dividends to Volvo shareholders reduced 
shareholders' equity by SEK 1.5 billion. The book value of Volvo's net 
assets outside Sweden declined by SEK 1.5 billion due to changes in 
currency rates.<BR>
<BR>

(see tables: <A HREF="tab6.html">Statement of changes in consilidated 
financial position</A> and <A HREF="tab5.html">Net financial assets/debt</A>)<BR>
<BR>
<BR>
<BR>
<BR>

<A NAME="ref8"></A>

(see table: <A HREF="tab8.html">Sales by company Group</A>)<BR>


<BR>
<BR>
</BLOCKQUOTE>
</TD>
</TR>
</TABLE>

<A NAME="refdia2"></A>
<A NAME="car"></A>

<TABLE WIDTH=490 BORDER=0>
<TR>
<TD>
<BLOCKQUOTE>

<B>Volvo Car</B><BR>
After a weak upturn in 1994, the total market for passenger cars 
stagnated and 34.6 million cars were sold during 1995. The North 
American car market declined by 4%. The European market was largely 
unchanged.

<P ALIGN="LEFT">
The total number of Volvo cars sold rose by 7% to  374,600 (351,000).Volvo's 
market share in the large car segment, which includes the Volvo 940/960 and 
Volvo 850, rose to 10% (8) in Europe and 9% (7) in North America.

<P ALIGN="LEFT">
Operating income declined from SEK 2,771 M to SEK 1,089 M. The positive 
volume trend and the high capacity utilization during most of the year 
was negated by successively rising costs for product development and 
marketing. In addition there are negative currency effects amounting 
to about SEK 1,240 M. The fourth quarter was charged with costs of SEK 
303 M for planned personnel reductions during the spring of 1996. In 
total this resulted in Volvo Car reporting  a loss in the fourth quarter 
of SEK 841 M. Operating margin declined to 1.3% (3.8) and return on 
operating capital was 8% (20).<BR>
<BR>

(see diagram: <A HREF="dia2.html">Operating results, Volvo Car 
Group</A>)<BR>
<BR>

<P ALIGN="LEFT">
During the autumn of 1995, Volvo's new mid-class cars Volvo S40 and 
Volvo V40 were previewed , both featuring an integrated safety concept 
which sets a new standard in the mid-class segment, including being 
the first in the segment with side-impact airbags. Sales of the Volvo 
S40 will begin in March, first in Germany and Italy and then it will 
be launched in several other European markets before summer 1996. 
<BR>
<BR>
</BLOCKQUOTE>
</TD>
</TR>
</TABLE>

<A NAME="refdia3"></A>
<A NAME="truck"></A>


<TABLE WIDTH=490 BORDER=0>
<TR>
<TD>
<BLOCKQUOTE>

<B>Volvo Truck</B><BR>
The world market  for heavy trucks rose during 1995 to a new high 
of 604,000 vehicles 
(530,000). Including India, China and the former Comecon countries, 
the figure is 700,000 trucks (660,000). Demand in Europe rose 27%, 
despite a weakening in Great Britain toward year-end. Demand in the 
U.S. declined during the second half of the year, from a record high 
level. Demand also softened in Brazil.

<P ALIGN="LEFT">
Deliveries of heavy and medium-heavy trucks from Volvo amounted to 
76,500 vehicles, up 12% compared with a year earlier. The upturn is 
based on the heavy demand for the FH series and the increased world 
market. Volvo's market share in Europe for heavy trucks increased to 
16.3% (15.8). In the corresponding weight class in the U.S., Volvo 
reached 11.6% (12.4). The softening demand in the U.S. during the 
second half of 1995 affected the total order backlog, which at 
year-end was 34% lower than in the preceding year.

<P ALIGN="LEFT">
Operating income rose to SEK 5,073 M (4,051). The increase is 
attributable mainly to the higher sales volume, strengthened sales 
margins as a result of the success of the FH series and favorable 
utilization of the production facilities in Europe. Earnings in 
South America weakened during the fourth quarter, due to reduced 
demand and depressed prices in Brazil. Operating margin rose to 9.9% 
(8.8) and, as in the preceding year,  return on operating capital 
exceeded 25%.<BR>
<BR>
<BR>

(see diagram: <A HREF="dia3.html">Operating results, Volvo 
Trucks</A>)<BR>
<BR>

<A NAME="bus"></A>

<B>Volvo Bus</B><BR>
Deliveries of buses and bus chassis from Volvo amounted to 6,830 
units  (5,770), an increase of 18% compared with a year earlier. 
This was a record delivery volume for Volvo Bus. The upturn is 
attributable to increased deliveries to most markets and the 
acquisition of Pr&eacute;vost Car Inc, which added 330 units.
At year-end 1995, the order backlog, excluding Pr&eacute;vost 
was about 55% higher than on the year-earlier date. Volvo Bus's 
market share in western Europe rose to preliminary 17.7% (15.2). 
Operating income increased to SEK 405 M (318), of which 
Pr&eacute;vost accounted for SEK 88 M. The operating margin was 
5.3% (5.2) and return on operating capital amounted to 18% (22).
<BR>

<A NAME="vce"></A>

<B>Volvo Construction Equipment</B><BR>
The market upturn for construction equipment, which has been under way since 
1992, was broken during the second half of 1995. A decline in demand was noted 
in Germany and stagnation in North America - two of the single most important 
markets for Volvo Construction Equipment.

<P ALIGN="LEFT">
Operating income for the full year 1995 amounted to SEK 1,679 M, of which SEK 
717 M is included in Volvo's consolidated income statement and pertains to the 
period July - December. Based on full-year values, operating margin was 12.3% 
and return on operating capital exceeded 25%.

<P ALIGN="LEFT">
Financial information from Volvo Construction Equipment for the years prior 
to 1995 is not ! reported. This information is reported in accordance with American accounting principles, 
U.S.GAAP and, consequently, is not fully comparable with 1995 reporting in 
accordance with Volvo's principles.

<P ALIGN="LEFT">
In December, Volvo Construction Equipment acquired the French company Groupe 
Pel-Job, a leading European manufacturer of mini-excavators and other light 
construction equipment.<BR>
<BR>

<A NAME="penta"></A>

<B>Volvo Penta</B><BR>
Operating income for Volvo Penta amounted to SEK 212 M which, adjusted for 
changes in the composition of Volvo Penta Group, represented an increase of 
SEK 51 M. Operating margin was 5.5% (6.0) and return on operating capital 17%. 
<BR>
<BR>

<A NAME="aero"></A>

<B>Volvo Aero</B><BR>
Higher sales of commercial aircraft engines and increased deliveries to the 
European Ariane Project, combined with continued rationalization and 
restructuring measures, contributed to the favorable earnings trend for 
Volvo Aero. Operating margin increased to 2.7% (1.7) and return on operating 
capital to 13% (5).
<BR>
<BR>

<A NAME="fortos"></A>

<B>Fortos</B><BR>
Divestment of companies and shareholdings outside the automotive 
operations continued during 1995 and generated a total of SEK 7.3 billion 
in proceeds, of which the sale of Procordia's food operations accounted 
for SEK 3.8 billion and Alfred Berg for SEK 0.9 billion.

<P ALIGN="LEFT">
AB Fortos' remaining holdings at December 31, 1995 were mainly Swedish 
Match and the shares in Pripps Ringnes AB. The publicly traded holdings - 
Pharmacia &amp; Upjohn, Inc., Investment AB Bure and Svensk 
Interkontinental Lufttrafik AB - have been transferred to a newly formed 
subsidiary in G&ouml;teborg, with a separate management.

<P ALIGN="LEFT">
The intention of divesting the current holdings in AB Fortos and the 
publicly traded holdings remains firm. As part of this divestment, the 
Board of AB Volvo is proposing that the Annual General Meeting on April 24, 
1996, in addition to a cash dividend, distribute all shares in Swedish 
Match to Volvo's shareholders. Conditional upon the approval of the proposal 
by the Annual General Meeting, the Swedish Match shares will subsequently 
be exchange listed on the Stockholm Stock Exchange and on NASDAQ in US.  

<P ALIGN="LEFT">
<B>Personnel</B><BR>

At year-end 1995, the Volvo Group had 79,050 employees, an increase of 3,500 
employees since the same date a year earlier. The increase is attributable 
to the acquisition of Volvo Construction Equipment (7,100 persons), Groupe 
Pel-Job (450) and Pr&eacute;vost Car (970), and new hiring by Volvo Car 
(1,600) and Volvo Truck (1,900). The sale of Procordia Food and Abba Seafood, 
Alfred Berg and Falcon and the formation of Pripps Ringnes resulted in 9,200 
persons leaving the Volvo Group. 

<P ALIGN="LEFT">
The total number of employees includes 47,000 (44,900) in Sweden and 
32,000 (30,700) abroad.

<A NAME="ref4"></A>

<P ALIGN="LEFT">
<B>Volvo Group excluding Swedish Match, pro forma</B><BR>

To provide a view of the Volvo Group, taking into account the distribution 
of Swedish Match, pro forma information, based on Volvos 1995 consolidated 
income statement and balance sheet, is provided below.

<P ALIGN="LEFT">
It is assumed in the pro forma income statement that the distribution of 
Swedish Match was implemented in the beginning of 1995, in order to show 
the effect on a full-year basis. In the pro forma balance sheet, the 
distribution is assumed to have been carried out on December 31, 1995. 

<P ALIGN="LEFT">
Income per share after full conversion declines by SEK 1.70 as a result 
of the Swedish Match Group not being consolidated as a part of Volvo. 
Total assets decline by SEK 7.5 billion and shareholders' equity by 
SEK 4.2 billion. Goodwill attributable to Volvo's acquisition of 
Swedish Match and goodwill within the Swedish Match Group in a total 
amount of SEK 3.2 billion have reduced both total assets and 
shareholders' equity.<BR>
<BR>



(see table:<A HREF="tab4.html"> Financial information pro forma</A>)

<A NAME="ref9"></A>

<BR>
<P ALIGN="LEFT">
<B>Parent Company</B><BR>
<BR>



(see table: <A HREF="tab9.html">Parent Company income statements
</A>)<BR>


<A NAME="ref7"></A>


<P ALIGN="LEFT">
Operating income includes a write-down of shares in Volvo 
Construction Equipment of SEK 1,817 M.

<P ALIGN="LEFT">
Dividends from subsidiaries amounted to SEK 1,734 M and from non-group 
companies to SEK 327 M. Allocations include group contributions of 
SEK 3,316 M, net.

<P ALIGN="LEFT">
<B>Dividend proposal</B><BR>

The Board of Directors and the President propose a dividend for 1995 of SEK 4.00 
per share (3.40) and one share in Swedish Match for each Volvo share held, 
regardless of series. The total cash dividend amounts to SEK 1,854 M (1,512), 
and the distribution of the holding in Swedish Match to SEK 8,000 M.<BR>
<BR>



(see table: <A HREF="tab7.html">Unrestricted equity in AB Volvo</A>)<BR>
<BR>


<P ALIGN="LEFT">
In addition to Volvos' Annual Report as a base for the Annual General 
Meeting's decision regarding distribution of dividend, a prospectus 
describing Swedish Match's earnings and financial position will be 
available in conjunction with the distribution of the annual report on 
March 22, 1996.

<P ALIGN="LEFT">
The Annual General Meeting will be held Wednesday April 24, 1996, at 
2:00 p.m. in Lisebergshallen, G&ouml;teborg, Sweden. April 29 has been 
proposed as the record date for payment of cash dividends, with 
estimated payment on May 7. May 13 is proposed as the record date 
for entitlement to distribution of shares in Swedish Match. Shares 
in Swedish Match are expected to be transferred to the shareholders' 
VP account on May 15, with first listing scheduled for the same day.


<P ALIGN="LEFT">
The report on first-quarter 1996 operations will be released on 
April 29.

<P ALIGN="LEFT">
G&ouml;teborg,  February 21, 1996

<P ALIGN="LEFT">
AB Volvo (publ)

<P ALIGN="LEFT">
Board of Directors



<BR>
<BR>
<BR>


<!-- -------- -->

<TABLE BORDER=0 WIDTH=450>

<TR>
	<TD><HR></TD>
</TR>

<TR>
	<TD>Source: Report on 1995 operations</TD>
</TR>

</TABLE>

<P>

<BR>

</BLOCKQUOTE>

<A HREF="#top"><IMG WIDTH=71 HEIGHT=14 BORDER=0 
SRC="/images/knapp_top.gif" ALT="Top of page"></A>

<HR ALIGN=LEFT WIDTH=487>
Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]


</TD>
</TR>
</TABLE>

</CENTER>



</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-238</DOCNO>
<DOCOLDNO>IA089-000951-B025-320</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/corpinfo/int.rep/report.95/index-sv.html 192.138.110.240 19970208032505 text/html 31475
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 03:25:10 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 31303
Last-modified: Wed, 23 Oct 1996 09:00:47 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Bokslutsrapport f&ouml;r 1995</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<A NAME="top"></A>

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>
	<TD COLSPAN=2 ALIGN=RIGHT><A HREF="../index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>
</TR>

<TR>
	<TD COLSPAN=2><HR></TD>
</TR>

</TABLE>


<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>
	<TD><A	HREF="../six.95/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knbla.gif" ALIGN=top>
	<FONT SIZE=2>Six months ended June 30, 1995</FONT></A></TD>	
	<TD><A HREF="../three.96/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knbla.gif">
	<FONT SIZE=2> Three months ended March 31, 1996</FONT></A></TD>
</TR>

<TR VALIGN=TOP>
	<TD><A	HREF="../nine.95/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knbla.gif" ALIGN=top>
	<FONT SIZE=2>Nine months ended September 30, 1995</FONT></A></TD>
	<TD><A	HREF="../six.96/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0
	src="/images/knbla.gif">
	<FONT SIZE=2> Six months ended June 30,1996</FONT></A></TD>
</TR>

<TR VALIGN=TOP>
	<TD><A HREF="index-sv.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knrod.gif" ALIGN=top>
	<FONT SIZE=2>Bokslutsrapport f&ouml;r 1995</FONT></TD>
	<TD><A	HREF="../nine.96/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knbla.gif">
	<FONT SIZE=2> Nine months ended September 30, 1996</FONT></TD>
</TR>

</TABLE>



<TABLE WIDTH=490 BORDER=0>

<TR>
	<TD>
	
<HR ALIGN=LEFT WIDTH=487>

<!-- -------- -->

<BLOCKQUOTE>
<BR>
<BR>


<FONT SIZE=6>Bokslutsrapport f&ouml;r 1995</FONT>
<BR>
<BR>

<FONT SIZE=4><A HREF="#comments"><img WIDTH=14 HEIGHT=14 BORDER=0 
src="/images/knbla.gif" ALIGN=LEFT>Koncernchefens kommentar</A></FONT><BR>
<BR>

<FONT SIZE=4><A HREF="#six"><img WIDTH=14 HEIGHT=14 BORDER=0 
src="/images/knbla.gif" ALIGN=LEFT>Bokslutsrapport f&ouml;r 1995
</A></FONT><BR>
<BR>

<FONT SIZE=4><A HREF="match-sv.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
src="/images/knbla.gif" ALIGN=LEFT>F&ouml;rslag till utdelning av 
aktierna i Swedish Match</A></FONT><BR>
<BR>

<BLOCKQUOTE>
	
	<FONT SIZE=4><A	HREF="table-sv.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knbla.gif" ALIGN=LEFT>Tabeller</A></FONT><BR>
	<BR>

	<FONT SIZE=4><A	HREF="diagram-sv.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knbla.gif" ALIGN=LEFT>Diagram</A></FONT><BR>
	<BR>



</BLOCKQUOTE>

<BR>
<A NAME="ref0"></A>
<BR>

<HR ALIGN=LEFT WIDTH=447>
<BR>
<BR>

<FONT SIZE=4>
Verksamhets&aring;ret 1995 innebar h&ouml;gre f&ouml;rs&auml;ljning  men d&auml;mpad ordering&aring;ng mot slutet 
av &aring;ret.<BR>
<BR>

Rensat f&ouml;r eng&aring;ngsposter uppgick r&ouml;relseresultatet i 
fordonsr&ouml;relsen till 7.493 Mkr, dvs samma h&ouml;ga niv&aring; 
som 1994. <BR>
<BR>

Ett starkt r&ouml;relseresultat f&ouml;r Volvo Lastvagnar och tillskottet 
av Volvo Construction Equipment kompenserade ett l&auml;gre 
r&ouml;relseresultat f&ouml;r Volvo Personvagnar.<BR>
<BR>

Resultatf&ouml;rs&auml;mringen inom personbilsr&ouml;relsen &auml;r 
h&auml;nf&ouml;rlig till det fj&auml;rde kvartalet d&aring;  
f&ouml;rs&auml;ljningsvolymer och marginaler inte kompenserade f&ouml;r  
&ouml;kande kostnader inom  produktutveckling och marknadsf&ouml;ring. 
D&auml;rut&ouml;ver belastades kvartalet med 303 Mkr f&ouml;r planerade 
personalreduktioner.<BR>

</FONT>
<BR>

(se tabell: <A HREF="tab0-sv.html">Bokslut</A>)<BR>


</BLOCKQUOTE>

	</TD>
</TR>
</TABLE>

<TABLE WIDTH=490 BORDER=0>

<TR>
	<TD>


<BLOCKQUOTE>

<HR ALIGN=LEFT WIDTH=447>
<BR>

<BR>
<BR>

<BR>
<P>

<FONT SIZE=5><A name="comments">Koncernchefens kommentar<BR></FONT>
<BR>

<FONT SIZE=6>U</FONT>r f&ouml;rs&auml;ljningssynpunkt var 1995 ett framg&aring;ngsrikt 
&aring;r. Samtliga verksamhetsgrenar redovisar h&ouml;gre 
f&ouml;rs&auml;ljningsvolymer &auml;n 1994 trots en viss avmattning i 
efterfr&aring;gan p&aring; viktiga marknader under &aring;rets sista 
m&aring;nader.  

<P ALIGN="LEFT">
Volvo Lastvagnar redovisar sitt h&ouml;gsta r&ouml;relseresultat 
n&aring;gonsin, 5.073 Mkr.  FH-seriens marknadsframg&aring;ngar fortsatte 
och bildar basen f&ouml;r &ouml;kade satsningar p&aring; produktutveckling 
f&ouml;r att bef&auml;sta FH:s tekniska och s&auml;kerhetsm&auml;ssiga 
f&ouml;rspr&aring;ng. Produktionskapaciteten i Europa var under &aring;ret 
en begr&auml;nsande faktor och medf&ouml;rde l&aring;nga leveranstider. 
Volvo Lastvagnars andel av den europeiska marknaden f&ouml;r tunga lastbilar 
&ouml;kade trots detta &aring;ter och uppgick till 16,3 %.  Den 
p&aring;g&aring;ende kapacitetsutbyggnaden, som &auml;r ett led i en offensiv 
strategi f&ouml;r en fortsatt global tillv&auml;xt, fullf&ouml;ljs planenligt 
och l&aring;ngsiktiga marknadsinvesteringar skedde under &aring;ret i 
Nordamerika och Asien. 

<P ALIGN="LEFT">
Personbilsbranschen pr&auml;glas av allt h&aring;rdare konkurrens och sjunkande 
r&ouml;relsemarginaler. Detta g&auml;ller ocks&aring; Volvo Personvagnar som 
redovisar ett otillfredsst&auml;llande resultat, framf&ouml;r allt 
h&auml;nf&ouml;rligt till utvecklingen under det fj&auml;rde kvartalet. 
Kostnaderna f&ouml;r produktutveckling steg markant och n&aring;dde en niv&aring; 
p&aring; vilken de kommer att plana ut. Volvo 850-serien och Volvo 960 
&ouml;kade sina andelar p&aring; de 20 st&ouml;rsta marknaderna utom Frankrike, 
delvis som ett resultat av &ouml;kade marknadsf&ouml;ringsinsatser och 
d&auml;rmed kostnader. Resultatf&ouml;rs&auml;mringen  beror ocks&aring; 
p&aring; den svaga l&ouml;nsamheten  f&ouml;r Volvo 400-serien, som befinner 
sig i slutskedet av produktcykeln, parallellt med kostnader f&ouml;r 
introduktionen i Europa av Volvo S40/V40, vars f&ouml;rs&auml;ljning inleds 
under v&aring;ren 1996.


<A NAME="refdia1"></A>

<P ALIGN="LEFT">
Implementeringen av Volvo Personvagnars produktstrategi forts&auml;tter. 
Samtidigt intensifieras rationaliseringsarbetet f&ouml;r att uppn&aring; en 
mer konkurrensduglig kostnadsstruktur. Det kommer att ber&ouml;ra 
s&aring;v&auml;l produktion, administration som marknadsf&ouml;ring.  
 
<P ALIGN="LEFT">
Volvo Construction Equipment &auml;r, j&auml;mte Volvo Lastvagnar, den enskilt 
mest l&ouml;nsamma verksamheten i Volvokoncernen. F&ouml;retaget noterade, 
liksom Volvo Lastvagnar, en minskad ordering&aring;ng p&aring; viktiga marknader.  

<P ALIGN="LEFT">
Volvos koncentration till k&auml;rnr&ouml;relsen forts&auml;tter planenligt. 

<P ALIGN="LEFT">
Mot bakgrund av de tillg&aring;ngar som frig&ouml;rs i samband med 
avvecklingar inom Fortos, och f&ouml;r att klarg&ouml;ra det finansiella 
handlingsutrymme som beh&ouml;vs f&ouml;r planerade framtidssatsningar i 
k&auml;rnr&ouml;relsen, presenterade Volvo i december koncernens l&aring;ngsiktiga 
finansiella m&aring;l och inriktningen f&ouml;r koncernens kapitalstruktur. 

<P ALIGN="LEFT">
Inriktningen &auml;r att koncernens soliditet, exklusive s&auml;ljfinansiering, 
skall vara l&auml;gst 40%. Koncernen skall str&auml;va efter att bibeh&aring;lla, 
men inte varaktigt &ouml;verskrida, en nettokassa p&aring; 15% av eget 
kapital och minoritetskapital. Planeringen utg&aring;r vidare ifr&aring;n 
att nettoskulden i en mer utsatt eller offensiv situation inte b&ouml;r 
&ouml;verskrida 30% av eget kapital och minoritetskapital.    

<P ALIGN="LEFT">
Koncernen &auml;r inne i ett offensivt skede. Samtidigt visar 
v&auml;rldsmarknaden f&ouml;r transportmedel avmattning p&aring; vissa 
marknader. V&aring;r f&ouml;rm&aring;ga att bibeh&aring;lla en stabilitet i 
v&aring;rt utvecklingsarbete ocks&aring; i en svagare marknadssituation 
&auml;r v&aring;r b&auml;sta garanti f&ouml;r framtiden. Konkurrensen 
kommer under de n&auml;rmaste &aring;ren att &ouml;ka ytterligare. 
V&aring;rt arbete m&aring;ste d&auml;rf&ouml;r pr&auml;glas av &auml;nnu 
st&ouml;rre precision och bl a b&auml;ttre kostnadseffektivitet. Med 
nuvarande produktprogram, dess konkurrenskraft  och v&aring;rt starka 
varum&auml;rke har Volvo dock goda m&ouml;jligheter att bibeh&aring;lla 
sin position som en ledande tillverkare av transportmedel med h&ouml;gsta 
krav p&aring; kvalitet, s&auml;kerhet och milj&ouml; - Volvos starkaste 
konkurrensfaktorer.<BR>
<BR>

(se diagram: <A HREF="dia1-sv.html">R&ouml;relseresultat f&ouml;re poster av 
eng&aring;ngskarakt&auml;r</A>)<BR
<BR>
<BR>

</BLOCKQUOTE>

	</TD>
</TR>
</TABLE>

<TABLE WIDTH=490 BORDER=0>

<TR>
	<TD>


<BLOCKQUOTE>


<HR ALIGN=LEFT WIDTH=447>
<BR>
<BR>
<BR>
<BR>

<!-- Bokslutsrapport f&ouml;r 1995 -->

<FONT SIZE=5><A name="six">Bokslutsrapport f&ouml;r 1995</FONT><BR>
<BR>
<BR>

<P ALIGN="LEFT">
Den koncentration till fordons- och transportmedelsindustrin som Volvos styrelse 
beslutade v&aring;ren 1994 fortsatte under 1995. Volvo avyttrade aktier i 
bolag utanf&ouml;r fordonsr&ouml;relsen, vilka tillsammans inbringade 7,3 
miljarder kronor i int&auml;kter och 4,2 miljarder i realisationsvinster. 
K&auml;rnr&ouml;relsen f&ouml;rst&auml;rktes samtidigt genom 
f&ouml;rv&auml;rv av bolag till en sammanlagd k&ouml;peskilling om 6,3 
miljarder kronor.

<P ALIGN="LEFT">
Ett viktigt tillskott 1995 var f&ouml;rv&auml;rvet av utest&aring;ende 
50% av aktierna i Volvo Construction Equipment, en av de st&ouml;rre 
tillverkarna i v&auml;rlden av anl&auml;ggningsmaskiner, och ett nytt 
kompletterande  aff&auml;rsomr&aring;de inom Volvokoncernen. Dessutom 
f&ouml;rv&auml;rvades 51% av den kanadensiska busstillverkaren 
Pr&eacute;vost Car Incorporated och vid slutet av &aring;ret samtliga 
aktier i Groupe Pel-Job, en fransk tillverkare av mini-gr&auml;vmaskiner. 

<P ALIGN="LEFT">
Avyttringarna avs&aring;g  Alfred Berg Holding AB, Procordia Food och Abba 
Seafood, Falcon Holding AB samt aktieinnehaven i Partena AB, Cultor Ab, UST 
Inc och Nordic Tel Holdings AB. Genom en sammanslagning av Prippsgruppen, 
tidigare hel&auml;gt av Volvo, och norska Ringnes erh&ouml;ll Volvo 50% av 
r&ouml;sterna i det nya bolaget Pripps Ringnes AB. Volvo l&auml;mnade sitt 
aktieinnehav i  Pharmacia (27,3%) i utbyte mot aktier i det nybildade bolaget 
Pharmacia &amp; Upjohn, Inc. (13,8%).

<P ALIGN="LEFT">
Volvo Construction Equipment och Pr&eacute;vost ing&aring;r som dotterbolag i 
Volvokoncernen fr o m halv&aring;rsskiftet och Procordias livsmedelsr&ouml;relse 
exkluderas fr o m det fj&auml;rde kvartalet.<BR>
<BR>
<BR>


<P ALIGN="LEFT">
<B>Volvokoncernens f&ouml;rs&auml;ljning</B> 1995 uppgick till 171.511 Mkr mot 
155.866 Mkr  f&ouml;reg&aring;ende &aring;r. F&ouml;r fordonsr&ouml;relsen, 
dvs Volvokoncernen exklusive Fortos, steg f&ouml;rs&auml;ljningen med 9% 
exklusive f&ouml;rv&auml;rvade enheter. Justerat &auml;ven f&ouml;r 
valutakursf&ouml;r&auml;ndringar &ouml;kade f&ouml;rs&auml;ljningen med 12%. 

<P ALIGN="LEFT">
Sammanlagt s&aring;ldes 374.600 (351.000) Volvo personbilar, en 
&ouml;kning med 7%. F&ouml;rs&auml;ljningsuppg&aring;ngen avs&aring;g 
Volvo 850 och Volvo 960. 

<P ALIGN="LEFT">
Leveranserna av Volvo lastbilar  &ouml;kade med 12% och uppgick till 
76.500 fordon (68.500), vilket &auml;r den h&ouml;gsta &aring;rssiffran 
n&aring;gonsin. Framg&aring;ngarna beror p&aring; den fortsatt goda 
efterfr&aring;gan p&aring; FH-serien samt den starka v&auml;rldsmarknaden. 

<P ALIGN="LEFT">
Volvos leveranser av bussar och busschassier steg till 6.830 (5.770) 
enheter. &Auml;ven &ouml;vriga verksamheter redovisade h&ouml;gre 
volymer och h&ouml;gre f&ouml;rs&auml;ljningsv&auml;rden &auml;n 
f&ouml;reg&aring;ende &aring;r.

<A NAME="ref1"></A>

<P ALIGN="LEFT">
<B>R&ouml;relseresultatet</B> om 10.239 Mkr (9.371) inkluderar poster av 
eng&aring;ngskarakt&auml;r om 1.215, vilka  &auml;r en f&ouml;ljd av 
omfattande f&ouml;r&auml;ndringar i koncernens sammans&auml;ttning. 
H&auml;ri ing&aring;r vinst vid f&ouml;rs&auml;ljning av dotterbolagen 
Procordia Food och Abba Seafood, 2.300 Mkr,  Alfred Berg Holding, 515 
Mkr och Falcon Holding, 217 Mkr, samt nedskrivning av f&ouml;rv&auml;rvade 
aktier i Volvo Construction Equipment, 1.817 Mkr.

<P ALIGN="LEFT">
Exklusive poster av eng&aring;ngskarakt&auml;r och Fortos uppgick 
r&ouml;relseresultatet  till 7.493 Mkr (7.486), dvs samma h&ouml;ga 
niv&aring; som 1994.


<P ALIGN="LEFT">
&Ouml;kade f&ouml;rs&auml;ljningsvolymer f&ouml;r samtliga aff&auml;rsomr&aring;den bidrog positivt 
till resultatutvecklingen. Inom personbilsr&ouml;relsen kunde emellertid 
inte f&ouml;rs&auml;ljningsframg&aring;ngarna fullt ut kompensera f&ouml;r 
&ouml;kade kostnader inom produktutveckling och marknadsf&ouml;ring. I 
kombination med negativa valutakurseffekter samt avs&auml;ttning f&ouml;r 
planerade personalreduktioner medf&ouml;rde detta att Volvo Personvagnar 
redovisade f&ouml;rlust fj&auml;rde kvartalet 1995.

<P ALIGN="LEFT">
Valutakursutvecklingen 1995 vilken bidrog negativt till Volvokoncernens 
r&ouml;relseresultat j&auml;mf&ouml;rt med f&ouml;reg&aring;ende  &aring;r har ber&auml;knats till 1,4 miljarder kronor,  
huvudsakligen h&auml;nf&ouml;rligt till  Volvo Personvagnar.  De 
fr&auml;msta orsakerna &auml;r en l&auml;gre genomsnittlig avistakurs 
f&ouml;r infl&ouml;desvalutorna US dollar, brittiska pund och 
italienska lire samt en h&ouml;gre genomsnittlig avistakurs f&ouml;r 
utfl&ouml;desvalutorna D-mark och belgiska franc. <BR>
<BR>




(se tabell: <A HREF="tab1-sv.html"> Koncernens resultatr&auml;kning</A>)<BR>
<BR>



<P ALIGN="LEFT">
Volvo Personvagnars r&ouml;relseresultat minskade med 1,7 miljarder 
kronor j&auml;mf&ouml;rt med motsvarande period 1994, Volvo Lastvagnars 
&ouml;kade med 1,0 miljard och f&ouml;rv&auml;rvet av Volvo Construction 
Equipment tillf&ouml;rde 0,7 miljarder kronor. &Ouml;vriga verksamheter 
inom fordonsr&ouml;relsen redovisade n&aring;got h&ouml;gre eller 
of&ouml;r&auml;ndrat r&ouml;relseresultat.

<P ALIGN="LEFT">
Resultatbonus till Volvokoncernens anst&auml;llda i Sverige, har belastat 
r&ouml;relseresultatet med 285 Mkr (350).



<P ALIGN="LEFT">
<B>Resultatandelar i intressebolag</B> uppgick till 1.402 Mkr (2.193), varav 
Pharmacia svarade f&ouml;r 1.155 Mkr (1.286) och fd VME f&ouml;r 478 Mkr, 
avseende perioden januari - juni (788 f&ouml;r hel&aring;ret 1994). 
Volvos andel av f&ouml;rlusten i NedCar uppgick till 635 Mkr (226). 
Det svaga resultatet i NedCar beror p&aring; l&auml;gre volymer av Volvo 
400-serien i kombination med of&ouml;rdelaktig valutakursutveckling. 

<P ALIGN="LEFT">
<B>Finansiella int&auml;kter och kostnader.</B> Utdelning p&aring; aktier avs&aring;g 
fr&auml;mst utdelning fr&aring;n  Renault och Pharmacia &amp; Upjohn. I 1994 
&aring;rs v&auml;rde ing&aring;r utdelning fr&aring;n Protorp Intressenter AB 
med netto 933 Mkr.
 
 
<A NAME="ref2"></A>
<A NAME="ref3"></A>
 
<P ALIGN="LEFT">
Resultat vid f&ouml;rs&auml;ljning av aktier avser huvudsakligen Partena AB, 
707 Mkr; Nordic Tel Holdings AB, 176 Mkr; Cultor Ab, 166 Mkr och UST Inc, 75 
Mkr. I 1994 &aring;rs v&auml;rde ing&aring;r resultat vid f&ouml;rs&auml;ljning 
av aktier i Investment AB Cardo, AB Custos och Saga Petroleum a.s.
 
<P ALIGN="LEFT">
R&auml;ntenettot f&ouml;rb&auml;ttrades till f&ouml;ljd av Volvokoncernens 
st&auml;rkta finansiella st&auml;llning.

<P ALIGN="LEFT">
<B>Skattekostnaden</B> avs&aring;g fr&auml;mst l&ouml;pande skatt i 
utl&auml;ndska dotterbolag. Skatt avseende intressebolag ingick med 672 
Mkr (919).<BR>
<BR> 
<BR>



(se tabeller: <A HREF="tab3-sv.html">Koncernens balansr&auml;kning i sammandrag</A> och 
<A HREF="tab2-sv.html">Nyckeltal</A></A>)<BR>
<BR>

<P ALIGN="LEFT">
<B>Aktier och andelar</B> &ouml;kade genom bildandet av Pripps Ringnes AB och 
minskade genom f&ouml;rs&auml;ljningen av Partena AB, Cultor Ab, UST Inc 
och Nordic Tel Holdings AB samt genom konsolideringen av Volvo 
Construction Equipment Corporation och omstrukturering av Pleiad Real 
Estate AB.

<P ALIGN="LEFT">
<B>&Ouml;vriga anl&auml;ggningstillg&aring;ngar</B> &ouml;kade med 2,8 miljarder 
kronor. H&auml;ri ing&aring;r en &ouml;kning av &ouml;verv&auml;rde 
h&auml;nf&ouml;rligt till f&ouml;rv&auml;rv av utest&aring;ende aktier 
i Volvo Construction Equipment, 1,7 miljarder kronor (inklusive 
f&ouml;rv&auml;rvade &ouml;verv&auml;rden inom Volvo Construction 
Equipment om 0,8 miljarder kronor) och Pr&eacute;vost Car, 0,4 miljarder 
kronor. &Ouml;verv&auml;rde i Fortos minskade med 0,8 miljarder kronor 
genom f&ouml;rs&auml;ljningen av Procordia Food och Abba Seafood.

<A NAME="ref6"></A>

<P ALIGN="LEFT">
L&aring;n till NedCar f&ouml;r finansiering av utvecklingen av Volvo S40/V40 
&ouml;kade &ouml;vriga anl&auml;ggningstillg&aring;ngar med 1,6 miljarder kronor.


<P ALIGN="LEFT">
<B>Investeringar i anl&auml;ggningar</B> &ouml;kade till 6,5 miljarder kronor (4,3) 
 och investeringar i leasing- och tj&auml;nstefordon till 2,6 miljarder 
 kronor (2,5).
 
<P ALIGN="LEFT">
Investeringar inom Volvo Personvagnar, exklusive investeringar i leasing- 
och tj&auml;nstefordon, uppgick till 2,5 miljarder kronor och avs&aring;g 
utbyggnad av kapaciteten i  personbilsfabrikerna i Torslanda och Gent samt 
motorfabriken i Sk&ouml;vde. Inom Volvo Lastvagnar genomf&ouml;rdes 
investeringar om 2,1 miljarder kronor f&ouml;r bl a kapacitetsh&ouml;jande 
&aring;tg&auml;rder  inom komponentledet och i monteringsanl&auml;ggningarna 
i Europa, en ombyggnad av reservdelslagret i Gent samt 
effektivitetsh&ouml;jande &aring;tg&auml;rder i monteringsfabriken i 
New River Valley, USA.
<BR>
<BR>

<A NAME="ref5"></A>

<P ALIGN="LEFT">
<B>Nettoskulden</B> som vid &aring;rets ing&aring;ng uppgick till 6,0 miljarder 
kronor &ouml;vergick  under &aring;ret till finansiella 
nettotillg&aring;ngar om 1,2 miljarder kronor. 


<P ALIGN="LEFT">
<B>Eget kapital</B> &ouml;kade med 7,9 miljarder kronor. &Aring;rets resultat 
samt konvertering av f&ouml;rlagsbevis tillf&ouml;rde 9,3 respektive 
1,6 miljarder kronor. Utdelning till AB Volvos aktie&auml;gare minskade 
det egna kapitalet med 1,5 miljarder kronor. Det bokf&ouml;rda v&auml;rdet 
p&aring; Volvos nettotillg&aring;ngar i utlandet minskade med 1,5 
miljarder kronor till f&ouml;ljd av &auml;ndrade valutakurser.<BR>
<BR>


(se tabeller: <A HREF="tab6-sv.html">Finansieringsanalys</A> och 
<A HREF="tab5-sv.html">Nettoskuldens f&ouml;r&auml;ndring</A>)<BR>
<BR>
<BR>
<BR>
<BR>

<A NAME="ref8"></A>

<B>F&ouml;rs&auml;ljning och r&ouml;relseresultat per aff&auml;rsomr&aring;de</B><BR>

(se tabell: <A HREF="tab8-sv.html">F&ouml;rs&auml;ljning och r&ouml;relseresultat 
per aff&auml;rsomr&aring;de</A>)<BR>
<BR>


<A NAME="refdia2"></A>
<A NAME="car"></A>

<P ALIGN="LEFT">
<B>Volvo Personvagnar</B><BR>
Efter en svag uppg&aring;ng 1994 stagnerade totalmarknaden f&ouml;r 
personbilar och 34,6 miljoner personbilar s&aring;ldes 1995. Den 
nordamerikanska personbilsmarknaden minskade med 4%. Europamarknaden 
var i stort sett of&ouml;r&auml;ndrad.

<P ALIGN="LEFT">
Antalet fakturerade Volvobilar &ouml;kade med 7% till 374.600 
(351.000). Volvos marknadsandel inom segmentet stora bilar, d&auml;r 
Volvo 940/960 och Volvo 850 ing&aring;r, &ouml;kade till 10% (8) i 
Europa och 9% (7) i Nordamerika.

<P ALIGN="LEFT">
R&ouml;relseresultatet minskade fr&aring;n 2.771 Mkr till 1.089 Mkr. Den 
positiva volymutvecklingen och det h&ouml;ga kapacitetsutnyttjandet under 
st&ouml;rre delen av &aring;ret motverkades av successivt stigande kostnader 
f&ouml;r produktutveckling och marknadsf&ouml;ring. D&auml;rtill kommer 
negativa valutakurseffekter om ca 1.240 Mkr. Det fj&auml;rde kvartalet 
belastades med kostnader om 303 Mkr f&ouml;r planerad personalreduktion 
under v&aring;ren 1996. Sammantaget medf&ouml;r detta att Volvo Personvagnar 
redovisar en f&ouml;rlust om 841 Mkr f&ouml;r &aring;rets sista kvartal. 
R&ouml;relsemarginalen minskade till 1,3% (3,8) och avkastningen p&aring; 
operativt kapital var 8% (20).<BR>
<BR>

(se diagram: <A HREF="dia2-sv.html">R&ouml;relseresultat Volvo Personvagnar</A>)<BR>
<BR>

<P ALIGN="LEFT">
Under h&ouml;sten 1995 f&ouml;rhandsvisades Volvos nya mellanklassbilar 
Volvo S40 och Volvo V40, b&aring;da med ett integrerat 
s&auml;kerhetst&auml;nkande som s&auml;tter en ny standard i 
mellanklassen genom att vara f&ouml;rst i segmentet med sidokrockkudde. 
F&ouml;rs&auml;ljningsstart av Volvo S40 sker  i mars med b&ouml;rjan i 
Tyskland och Italien f&ouml;r att sedan lanseras p&aring; flertalet 
&ouml;vriga marknader i Europa f&ouml;re sommaren 1996.<BR>
<BR>

<A NAME="refdia3"></A>
<A NAME="truck"></A>

<P ALIGN="LEFT">
<B>Volvo Lastvagnar</B><BR>
V&auml;rldsmarknaden f&ouml;r tunga 
lastbilar steg under 1995 till en ny  h&ouml;gsta niv&aring; p&aring; 
604.000 fordon (530.000). Inkluderas Indien, Kina och fd 
Comecon-l&auml;nderna uppg&aring;r siffran till 700.000 lastbilar 
(660.000). I Europa steg efterfr&aring;gan med 27% trots en avmattning 
i Storbritannien mot slutet av &aring;ret. I USA minskade 
efterfr&aring;gan under andra halv&aring;ret, fr&aring;n en rekordh&ouml;g 
niv&aring;. &Auml;ven i Brasilien mattades efterfr&aring;gan. 

<P ALIGN="LEFT">
Leveranserna av tunga och medeltunga lastbilar fr&aring;n Volvo uppgick till 
76.500  fordon, en &ouml;kning med 12% j&auml;mf&ouml;rt med &aring;ret 
innan. Uppg&aring;ngen baserar sig p&aring; den stora efterfr&aring;gan 
p&aring; FH-serien samt den &ouml;kade v&auml;rldsmarknaden. Volvos 
marknadsandel i Europa f&ouml;r tunga lastbilar steg till 16,3% (15,8). 
I USA n&aring;dde Volvo i motsvarande viktklass 11,6% (12,4). Den 
avtagande efterfr&aring;gan i USA under andra halv&aring;ret 
p&aring;verkade den totala orderboken, som vid utg&aring;ngen av &aring;ret 
var 34% l&auml;gre &auml;n f&ouml;reg&aring;ende &aring;r.

<P ALIGN="LEFT">
R&ouml;relseresultatet &ouml;kade till 5.073 Mkr (4.051). &Ouml;kningen grundar 
sig fr&auml;mst p&aring; h&ouml;gre f&ouml;rs&auml;ljningsvolymer, st&auml;rkta 
f&ouml;rs&auml;ljningsmarginaler till f&ouml;ljd av FH-seriens framg&aring;ng 
och v&auml;l  utnyttjade produktionsanl&auml;ggningar i Europa. Under det 
fj&auml;rde kvartalet f&ouml;rs&auml;mrades resultatet i Sydamerika, p&aring; 
grund av minskad efterfr&aring;gan och prispress i Brasilien. 
R&ouml;relsemarginalen steg till 9,9% (8,8) och avkastningen p&aring; 
operativt kapital &ouml;versteg liksom f&ouml;reg&aring;ende &aring;r  25%.<BR>
<BR>

(se diagram: <A HREF="dia3-sv.html">R&ouml;relseresultat Volvo Lastvagnar</A>)<BR>
<BR>

<A NAME="bus"></A>

<P ALIGN="LEFT">
<B>Volvo Bussar</B><BR>
Leveranserna av bussar och busschassier fr&aring;n Volvo uppgick till 
6.830 (5.770) enheter, dvs en &ouml;kning med 18% j&auml;mf&ouml;rt med 
f&ouml;reg&aring;ende &aring;r. Det var den h&ouml;gsta leveransvolymen 
n&aring;gonsin f&ouml;r Volvo Bussar. Uppg&aring;ngen beror p&aring; &ouml;kade 
leveranser till  flertalet marknader samt f&ouml;rv&auml;rvet av Pr&eacute;vost 
Car Inc, vilket gav ett tillskott om 330 enheter. Vid slutet av 1995 var 
orderstocken, exklusive Pr&eacute;vost ca 55% h&ouml;gre &auml;n vid motsvarande 
tid ett &aring;r tidigare. Volvo Bussars marknadsandel i V&auml;steuropa  
&ouml;kade till prelimin&auml;rt 17,7%  (15,2). R&ouml;relseresultatet steg 
till 405 Mkr (318). H&auml;rav svarade Pr&eacute;vost f&ouml;r 88 Mkr. 
R&ouml;relsemarginalen var 5,3% (5,2) och avkastningen p&aring; operativt 
kapital uppgick till 18% (22).

<A NAME="vce"></A>

<P ALIGN="LEFT">
<B>Volvo Construction Equipment</B><BR>
Marknadsuppg&aring;ngen f&ouml;r anl&auml;ggningsmaskiner, som 
p&aring;g&aring;tt sedan 1992, avbr&ouml;ts under andra halv&aring;ret 1
995. Bl a noterades en nedg&aring;ng i efterfr&aring;gan i Tyskland och  
en utplaning skedde i Nordamerika - tv&aring; av de viktigare enskilda 
marknaderna f&ouml;r Volvo Construction Equipment.

<P ALIGN="LEFT">
R&ouml;relseresultatet f&ouml;r hel&aring;ret 1995 uppgick till 1.679 Mkr, 
varav 717 Mkr ing&aring;r i Volvokoncernens resultatr&auml;kning och avser 
perioden juli - december. Baserat p&aring; hel&aring;rsv&auml;rden uppgick 
r&ouml;relsemarginalen till 12,3 % och avkastning p&aring; operativt kapital 
&ouml;versteg 25%. 

<P ALIGN="LEFT">
Ekonomisk information fr&aring;n Volvo Construction Equipment f&ouml;r &aring;ren 
f&ouml;re 1995 redovisas inte. Denna &auml;r baserad p&aring; amerikanska redovisningsprinciper, 
US GAAP, och  s&aring;ledes inte fullt j&auml;mf&ouml;rbar med 1995 &aring;rs 
redovisning enligt Volvos principer.

<P ALIGN="LEFT">
I december 1995 f&ouml;rv&auml;rvade Volvo Construction Equipment det franska 
f&ouml;retaget Groupe Pel-Job, en ledande europeisk tillverkare av 
mini-gr&auml;vmaskiner och andra l&auml;tta anl&auml;ggningsmaskiner.

<A NAME="penta"></A>

<P ALIGN="LEFT">
<B>Volvo Penta</B><BR>
R&ouml;relseresultatet f&ouml;r Volvo Penta uppgick till 212 Mkr vilket 
justerat f&ouml;r f&ouml;r&auml;ndringar i Volvo Pentagruppens 
sammans&auml;ttning innebar en &ouml;kning med 51 Mkr. R&ouml;relsemarginalen 
var 5,5% (6,0) och avkastning p&aring; operativt kapital 17%.

<A NAME="aero"></A>

<P ALIGN="LEFT">
<B>Volvo Aero</B><BR>
H&ouml;gre f&ouml;rs&auml;ljning av civila flygmotorer och &ouml;kade 
leveranser till det europeiska Arianeprojektet kombinerat med fortsatta 
rationaliserings- och omstrukturerings&aring;tg&auml;rder bidrog till d
en positiva resultatutvecklingen f&ouml;r Volvo Aero. R&ouml;relsemarginalen 
&ouml;kade till 2,7%  (1,7)  och avkastningen p&aring; operativt kapital till 
13% (5).

<A NAME="fortos"></A>

<P ALIGN="LEFT">
<B>Fortos</B><BR>
Avvecklingen av bolag och aktieinnehav utanf&ouml;r fordonsr&ouml;relsen 
fortsatte 1995 och inbringade sammanlagt 7,3 miljarder kronor i 
int&auml;kter varav f&ouml;rs&auml;ljningen av Procordias 
livsmedelsr&ouml;relse och Alfred Berg svarade f&ouml;r 3,8 miljarder 
respektive 0,9 miljarder kronor.

<P ALIGN="LEFT">
AB Fortos kvarvarande innehav den 31 december 1995 var huvudsakligen 
Swedish Match och aktierna i Pripps Ringnes AB. De b&ouml;rsnoterade 
innehaven i Pharmacia &amp; Upjohn, Inc., Investment AB Bure och Svensk 
Interkontinental Lufttrafik AB har  &ouml;verf&ouml;rts till ett nybildat 
dotterbolag i G&ouml;teborg under s&auml;rskild ledning.

<P ALIGN="LEFT">
Inriktningen att avveckla nuvarande innehav hos AB Fortos samt de 
b&ouml;rsnoterade innehaven ligger fast. Som ett  led i  avvecklingen 
f&ouml;resl&aring;r styrelsen  Volvos bolagsst&auml;mma den 24 april 
1996 att, f&ouml;rutom en kontant utdelning, dela ut samtliga aktier i 
Swedish Match till Volvos aktie&auml;gare. Under f&ouml;ruts&auml;ttning 
att bolagsst&auml;mman godk&auml;nner f&ouml;rslaget avses Swedish 
Match aktien sedan att marknadsnoteras p&aring; Stockholms Fondb&ouml;rs och
p&aring; NASDAQ i USA.

<P ALIGN="LEFT">
<B>Anst&auml;llda</B><BR>
Antalet anst&auml;llda i Volvokoncernen uppgick vid &aring;rsskiftet 1995 till 
79.050 personer, en &ouml;kning med 3.500 personer sedan f&ouml;reg&aring;ende 
&aring;rsskifte. &Ouml;kningen beror p&aring; f&ouml;rv&auml;rv av Volvo 
Construction Equipment (7.100 personer), Groupe Pel Job (450) och Pr&eacute;vost 
Car (970), samt p&aring; nyanst&auml;llningar i Volvo Personvagnar (1.600) och 
Volvo Lastvagnar (1.900). F&ouml;rs&auml;ljningen av Procordia Food och Abba 
Seafood, Alfred Berg och Falcon samt bildandet av Pripps Ringnes innebar att 
9.200 personer l&auml;mnade Volvokoncernen. 

<P ALIGN="LEFT">
Av totala antalet  var 47.000 (44.900) anst&auml;llda i Sverige och 32.000 
(30.700) utanf&ouml;r Sverige.


<A NAME="ref9"></A>

<A NAME="ref4"></A>

<P ALIGN="LEFT">
<B>Volvokoncernen exklusive Swedish Match, proforma</B><BR>


F&ouml;r att ge en bild av Volvokoncernen, beaktat utdelningen av Swedish 
Match, visas nedan proformainformation baserad p&aring; resultat- och 
balansr&auml;kning f&ouml;r Volvokoncernen 1995.

<P ALIGN="LEFT">
 I resultatr&auml;kningen proforma antas utdelningen av Swedish Match 
 vara genomf&ouml;rd i b&ouml;rjan av 1995, detta f&ouml;r att visa 
 effekten p&aring; hel&aring;rsbasis. I balansr&auml;kningen proforma 
 antas utdelningen vara genomf&ouml;rd den 31 december 1995. 

<P ALIGN="LEFT">
Resultat per aktie efter full konvertering minskar med kronor 1:70 till 
f&ouml;ljd av att Swedish Matchgruppen ej l&auml;ngre ing&aring;r i 
Volvokoncernen.<BR>
<BR>

(se tabell: <A HREF="tab9-sv.html">Moderbolagets resultatr&auml;kning</A>)<BR>
<BR>


<P ALIGN="LEFT">
Totala tillg&aring;ngar och eget kapital minskar med 7,5 miljarder kronor 
respektive 4,2 miljarder kronor. Goodwill h&auml;nf&ouml;rlig till Volvos 
f&ouml;rv&auml;rv av Swedish Match samt goodwill inom Swedish Matchgruppen 
om totalt 3,2 miljarder kronor har reducerat s&aring;v&auml;l totala 
tillg&aring;ngar som eget kapital.

<P ALIGN="LEFT">
I r&ouml;relseresultatet ing&aring;r en nedskrivning av aktieinnehavet i 
Volvo Construction Equipment om 1.817 Mkr. Utdelningar fr&aring;n dotterbolag 
uppg&aring;r till 1.734 Mkr och fr&aring;n utomst&aring;ende bolag till 327 Mkr. 
I bokslutsdispositioner ing&aring;r erh&aring;llna koncernbidrag om netto 3.316 Mkr.
<BR>
<BR>
 
(se tabell: <A HREF="tab4-sv.html">Volvokoncernen exklusive Swedish Match, proforma</A>)<BR>
<BR>
<BR>

<A NAME="ref7"></A>

<P ALIGN="LEFT">
<B>F&ouml;rslag till utdelning</B>
Styrelsen och verkst&auml;llande direkt&ouml;ren f&ouml;resl&aring;r en 
utdelning f&ouml;r 1995 om 4:00 kronor per aktie (3:40)  samt en aktie i 
Swedish Match f&ouml;r varje Volvoaktie, oavsett serie. Den kontanta utdelningen 
uppg&aring;r  sammanlagt till 1.854 Mkr (1.512) och utdelningen avseende Swedish Match till 
8.000 Mkr.<BR>
<BR>


(se tabell: <A HREF="tab7-sv.html">Fritt eget kapital i AB Volvo</A>)<BR>
<BR>


<P ALIGN="LEFT">
Som underlag f&ouml;r bolagsst&auml;mmans utdelningsbeslut kommer 
f&ouml;rutom Volvos &Aring;rsredovisning ett  prospekt som beskriver 
Swedish Matchs resultat och st&auml;llning att finnas tillg&auml;ngligt 
i samband med distributionen av  &aring;rsredovisningen den 22 mars 1996.

<P ALIGN="LEFT">
Volvos ordinarie bolagsst&auml;mma kommer att h&aring;llas onsdagen den 
24 april 1996, kl 14.00 i Lisebergshallen i G&ouml;teborg. Som 
avst&auml;mningsdag f&ouml;r r&auml;tt att erh&aring;lla kontant 
utdelning f&ouml;resl&aring;s den 29 april med ber&auml;knad utbetalning 
den 7 maj. Som avst&auml;mningsdag f&ouml;r r&auml;tt att erh&aring;lla 
utdelning av aktier i Swedish Match f&ouml;resl&aring;s den 13 maj. 
Aktierna i Swedish Match ber&auml;knas &ouml;verf&ouml;ras till 
aktie&auml;garnas VP-konton den 15 maj med ber&auml;knad f&ouml;rsta 
notering samma dag.


<P ALIGN="LEFT">
Rapport &ouml;ver f&ouml;rsta kvartalet 1996 kommer att l&auml;mnas 
den 29 april. 

<P ALIGN="LEFT">
G&ouml;teborg den 21 februari 1996

<P ALIGN="LEFT">
AB Volvo (publ)

<P ALIGN="LEFT">
Styrelsen
<P ALIGN="LEFT">

<BR>
<BR>
<BR>


<!-- -------- -->

<TABLE BORDER=0 WIDTH=450>

<TR>
	<TD><HR></TD>
</TR>

<TR>
	<TD>K&auml;lla: Bokslutsrapport f&ouml;r 1995</TD>
</TR>

</TABLE>

<P>

<BR>

</BLOCKQUOTE>

<A HREF="#top"><IMG WIDTH=71 HEIGHT=14 BORDER=0 
SRC="/images/knapp_top.gif" ALT="Top of page"></A>

<HR ALIGN=LEFT WIDTH=487>
Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]


</TD>
</TR>
</TABLE>

</CENTER>



</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-239</DOCNO>
<DOCOLDNO>IA089-000951-B025-386</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/corpinfo/int.rep/three.96/index.html 192.138.110.240 19970208032531 text/html 20967
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 03:25:34 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 20795
Last-modified: Wed, 23 Oct 1996 09:00:55 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Three months ended March 31, 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<A NAME="top"></A>

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>
	<TD COLSPAN=2 ALIGN=RIGHT><A HREF="../index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>
</TR>

<TR>
	<TD COLSPAN=2><HR></TD>
</TR>

</TABLE>


<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>
	<TD><A	HREF="../six.95/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knbla.gif">
	<FONT SIZE=2> Six months ended June 30, 1995</FONT></A></TD>	
	<TD><A HREF="../three.96/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knrod.gif">
	<FONT SIZE=2> Three months ended March 31, 1996</FONT></A></TD>
</TR>

<TR VALIGN=TOP>
	<TD><A	HREF="../nine.95/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knbla.gif">
	<FONT SIZE=2> Nine months ended September 30, 1995</FONT></A></TD>
	<TD><A	HREF="../six.96/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0
	src="/images/knbla.gif">
	<FONT SIZE=2> Six months ended June 30,1996</FONT></A></TD>
</TR>

<TR VALIGN=TOP>
	<TD><A HREF="../report.95/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knbla.gif">
	<FONT SIZE=2> Report on 1995 operations</FONT></TD>
	<TD><A	HREF="../nine.96/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knbla.gif">
	<FONT SIZE=2> Nine months ended September 30, 1996</FONT></TD>
</TR>

</TABLE>



<TABLE WIDTH=490 BORDER=0>

<TR>
	<TD>
	
<HR ALIGN=LEFT WIDTH=487>

<!-- -------- -->

<BLOCKQUOTE>

<BR>
<BR>


<FONT SIZE=6>Three months ended March 31, 1996</FONT>
<BR>
<BR>

<FONT SIZE=4><A HREF="#comments"><img WIDTH=14 HEIGHT=14 BORDER=0 
src="/images/knbla.gif"> Comments by the Chief Executive 
Officer</A></FONT><BR>
<BR>

<FONT SIZE=4><A HREF="#six"><img WIDTH=14 HEIGHT=14 BORDER=0 
src="/images/knbla.gif"> Three months ended March 31, 1996
</A></FONT><BR>
<BR>

<BR>

<BLOCKQUOTE>
	
	<FONT SIZE=4><A	HREF="table.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knbla.gif"> Tables</A></FONT><BR>
	<BR>

	<FONT SIZE=4><A	HREF="diagram.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knbla.gif"> Diagrams</A></FONT><BR>
	<BR>

</BLOCKQUOTE>

<BR>
<A NAME="ref0"></A>
<BR>

<HR ALIGN=LEFT WIDTH=447>
<BR>
<BR>

<FONT SIZE=4>
<P ALIGN="LEFT">
The Volvo Group income was affected adversely by lower sales of  passenger
cars, notably the Volvo 400 series in Europe, and weaker market for trucks
in North and South America.


<P ALIGN="LEFT">
Continuing high level of capital expenditures and research and development costs.


<P ALIGN="LEFT">
The Volvo S40/V40 models are being introduced 
in most European markets during the spring.


<P ALIGN="LEFT">
Swedish Match shares are distributed to Volvo shareholders.<BR>

</FONT>
<BR>

(see table: <A HREF="tab0.html">First three months 1996</A>)<BR>
<BR>

<BR>
<BR>


<HR ALIGN=LEFT WIDTH=447>

<BR>
<P>

<FONT SIZE=5><A name="comments">Comments by the Chief Executive Officer<BR></FONT>
<BR>

<FONT SIZE=6>V</FONT>olvo Group income for the first three months of 1996 was affected adversely by 
declining volumes of sales combined with continuing investments in product 
and market development. 

<P ALIGN="LEFT">
While the loss in Volvo Cars is unsatisfactory, it represented an improvement 
compared with operating results in the fourth quarter of 1995. The improvement 
was primarily due to internal rationalization measures, lower research and 
development costs and higher effective exchange rates. The decline in sales 
was attributable mainly to lower sales of the Volvo 400-series and to the fact 
that the Volvo 940 is no longer being offered in the American market. The Volvo 
S40/V40 models that were introduced in March have been very well received and 
order bookings are good. 


<A NAME="refdia1"></A>

<P ALIGN="LEFT">
Volvo Trucks is continuing to experience declining volumes of sales in North 
and South America. This, combined with increased costs of implementing the FH 
technology globally, as well as the increased costs of marketing programs 
had a negative effect on Volvo Trucks' income. 

<P ALIGN="LEFT">
Volvo's present aggressive phase involves investments to ensure future 
earnings capacity. Parallel with the implementation of the this long-term 
program, demands for high efficiency and control of operating costs are now 
being stepped up in all sectors of the Group.

<BR>
<BR>

(see diagram: <A HREF="dia1.html">Operating results, before 
nonrecurring items, rolling 12 months</A>)<BR
<BR>
<BR>

<HR ALIGN=LEFT WIDTH=447>
<BR>
<BR>
<BR>
<BR>

<!-- Six months ended June 30, 1995 -->

<FONT SIZE=5><A name="six">Three months ended March 31, 1996</FONT><BR>
<BR>
<BR>



<B>Volvo Group sales</B> in the first quarter of 1996 amounted to SEK 39,068 M, 
compared with sales of SEK 43,454 M in the first quarter of 1995. 
Automotive operations accounted for sales of SEK  37,301 M, which implied 
a decrease of  7%, adjusted for currency rate effects and divested and 
acquired units (primarily the acquisitions of Volvo Construction 
Equipment and the Pr&eacute;vost bus manufacturing company, which were 
not part of the Group during the first half of 1995). Sales were lower 
in all business segments except Volvo Buses and Volvo Aero.

<P ALIGN="LEFT">
Volvo's sales of passenger cars in Europe decreased, due mainly to the 
phasing out of the Volvo 400 series which is now being replaced by the 
new Volvo S40/V40 program in the medium-size class.

<P ALIGN="LEFT">
Volvo Trucks' sales decreased due to declining markets for trucks in 
the United States and in South America.


<P ALIGN="LEFT">
<B>Operating income</B> amounted to SEK 1,176 M (2,842)*, of which automotive 
operations accounted for SEK 970 M (2,669). The decrease relative to the 
corresponding period a year earlier was due mainly to smaller volumes of 
sales and continuing high research and development costs.

<P ALIGN="LEFT">
* Figures within parantheses pertain to first-quarter 1995 operations.<BR>
<BR>

<A NAME="ref1"></A>



(see table: <A HREF="tab1.html"> Consolidated income statements</A>)<BR>
<BR>

<P ALIGN="LEFT">
<B>Income from equity method investments</B> declined to SEK 222 M, compared with 
SEK 433 M in the first quarter of 1995. In the 1996 years' results the capital 
gain on the sale of VOAC Hydraulics of SEK 352 M is included. Volvo's share 
of the loss in NedCar was SEK 130 M (108). The weak results in NedCar were 
due to start-up costs for the Volvo S40/V40 series, to lower sales of the 
Volvo 400 series and to high research and development costs. Income from equity 
method investments in the 1995 period included Volvo Construction Equipment 
(SEK 216 M) and Pharmacia (SEK 247 M), which are no longer reported in 
accordance with the equity method.
<BR>

<P ALIGN="LEFT">
<B>Dividends received</B> pertained mainly to holdings in Pharmacia &amp; 
Upjohn, Inc. and Protorp F&ouml;rvaltnings AB.

<A NAME="ref2"></A>
<A NAME="ref3"></A>

<P ALIGN="LEFT">
<B>Net interest,</B> which showed a very favorable trend as a result of the Volvo
Group's strong financial position and a good result within Volvo Group 
Finance, amounted to SEK 343 M (146).

<P ALIGN="LEFT">
<B>Tax expenses</B> pertained mainly to current taxes in subsidiaries 
outside Sweden.

<BR>
<BR>
(see tables: <A HREF="tab3.html">Condensed consolidated balance sheets</A> and 
<A HREF="tab2.html"> Key ratios</A>)<BR>
<BR>



<P ALIGN="LEFT">
<B>Group assets</B> increased by SEK 7.9 billion during the first quarter of 1996. 
Of this amount, liquid funds accounted for SEK 4.6 billion. The increase is 
attributable mainly to the fact that Swedish Match, in connection with the 
pending stock exchange listing of its shares, replaced loans made within the 
Group with short-term external financing. This accounts for the increase in 
both liquid funds and short-term loans in the consolidated balance sheet.


<P ALIGN="LEFT">
<B>Capital expenditures</B> for property, plant and equipment amounted to SEK 1.8
billion (1.1) and investments in leasing vehicles totaled SEK 0.8 billion (0.7).


<A NAME="ref6"></A>
<A NAME="ref5"></A>


<P ALIGN="LEFT">
The Group's <B>net financial assets,</B> which amounted to SEK 1.2 billion at December 
31, 1995, increased to SEK 2.4 billion. 

<P ALIGN="LEFT">
<B>Shareholders' equity and minority interests</B> amounted to 36.2% of total assets, 
compared with 37.4% at December 31, 1995. 
<BR>
<BR>

(see tables: <A HREF="tab6.html">Statement of changes in consilidated 
financial position</A> and <A HREF="tab5.html">Operating income, excluding 
nonrecurring items</A>)<BR>
<BR>
<BR>
<BR>
<BR>

<A NAME="ref8"></A>

(see table: <A HREF="tab8.html">Sales by company Group</A>)<BR>


<BR>
<BR>
</BLOCKQUOTE>
</TD>
</TR>
</TABLE>

<A NAME="refdia2"></A>
<A NAME="car"></A>

<TABLE WIDTH=490 BORDER=0>
<TR>
<TD>
<BLOCKQUOTE>

<B>Volvo Cars</B><BR>
The total market for passenger cars increased slightly during the first three 
months of 1996, compared with the year-earlier period. The growth in Europe 
amounted to nearly 7%, while the trend of the market in North America was 
unchanged. The Japanese car market was smaller, following the upturn in 1995. 
The trend of the world market during the remainder of 1996 is expected to 
follow the present pattern.

<P ALIGN="LEFT">
The trend of Volvo Cars' sales in Europe was negative. This applied primarily 
to the Volvo 400 series which is now being phased out and replaced by the 
Volvo S40/V40. Sales of the Volvo 850 were stable and increased in a number 
of markets, including France and England. Volvo's sales in North America 
declined but its share of the market was unchanged, due to dealers' sales 
from inventory. The company's sales and market shares were higher in Japan 
and Thailand.<BR>
<BR>

(see diagram: <A HREF="dia2.html">Operating results, Volvo Car 
Group</A>)<BR>
<BR>

<P ALIGN="LEFT">
Volvo Cars' total sales were 12% lower than in the first three months of 
1995. The number of passenger cars invoiced fell by 19%, to 85,200 (104,600). 
Operating results improved by SEK 650 M, compared with the fourth quarter 
1995, but were still negative and amounted to a loss of SEK 191 M. Income 
was SEK 1,121 M lower than in the corresponding period of 1995. The decline 
was attributable primarily to the smaller volume of sales and higher research and 
development costs. The operating margin declined from plus 4.2% to minus 1.0%.
<BR>
<BR>
</BLOCKQUOTE>
</TD>
</TR>
</TABLE>

<A NAME="refdia3"></A>
<A NAME="truck"></A>


<TABLE WIDTH=490 BORDER=0>
<TR>
<TD>
<BLOCKQUOTE>

<B>Volvo Trucks</B><BR>
The total market for heavy trucks in Europe continued to be strong during 
the first quarter of 1996, but there was a slight downturn in Great Britain. 
The weakening of the total markets in North and South America that began 
during the second half of 1995 persisted during the first three months of 
the current year. The world market for heavy trucks in 1996 will be 
distinctly smaller than in 1995, which was a record year. The greatest 
decrease is expected to occur in North America, but weaker demand is 
also foreseen in Europe during the second half of the year.

<P ALIGN="LEFT">
Volvo Trucks' sales in the first quarter of 1996 decreased by 11%, to 
SEK 11,656 M. Shipments of heavy and medium-heavy trucks amounted to 16,700 
units, 14% fewer than in the first quarter of 1995. But deliveries within 
Europe rose by 13%, while Volvo's share of the market for heavy trucks 
declined slightly in Europe. Also in North America the market share declined. 
The backlog of orders at March 31, 1996 was 45% lower than on the 
year-earlier date, mainly due to the sharply declining demand in North 
and South America.
<P ALIGN="LEFT">
 
<P ALIGN="LEFT">
Volvo Trucks' operating income for the first quarter of 1996 amounted to 
SEK 731 M (1,515). The decrease was attributable to much smaller volumes 
of sales in North and South America and the resulting lower utilization of 
production capacity. Income was also affected by increased costs of product 
and market development. The operating margin was 6.3% (11.5).
<BR>
<BR>

(see diagram: <A HREF="dia3.html">Operating results, Volvo 
Trucks</A>)<BR>
<BR>

<A NAME="bus"></A>

<B>Volvo Buses</B><BR>
Volvo Buses delivered 1,490 (1,140) buses and bus chassis, with the Canadian 
bus manufacturer Pr&eacute;vost, which was aquired in 1995 accounting for 
138 buses. The company's share of the market in Europe was higher than in 
the preceding year. The backlog of orders at March 31, 1996 was approximately 
40% higher than on the same date a year earlier. Operating income rose to 
SEK 69 M (65), while the operating margin dropped to 3.7% (4.1).

<P ALIGN="LEFT">
In March 1996 Volvo Buses and Carrus Oy, the Finnish bus manufacturer, 
concluded an agreement covering closer cooperation in the areas of product 
development and marketing projects outside the Nordic region.<BR>

<BR>

<A NAME="vce"></A>

<B>Volvo Construction Equipment</B><BR>
Total demand for construction equipment declined in a number of important 
markets during the first quarter of 1996, relative to demand in the first 
quarter of 1995. This applied to in both North America and Germany, 
as well as other markets in Europe. The downturn in Germany, which was 
substantial, affected primarily the sale of light construction equipment.

<P ALIGN="LEFT">
Volvo Construction Equipment's sales decreased from SEK 3,243 M in the 
first quarter of 1995 to SEK 3,045 M in the first quarter of 1996. 
The decline in volume, combined with nonrecurring project costs and an 
unfavorable trend of foreign exchange rates, resulted in lower but 
sustained operating income of SEK 273 M (443). The operating margin 
was 9.0% (13.7). 
<BR>
<BR>

<A NAME="penta"></A>

<B>Volvo Penta</B><BR>
Volvo Penta's sales were 5% lower than in the first quarter of 1995. The 
lower sales figures were attributable primarily to movements in foreign 
exchange rates, but also to lower demand for engines and spare parts for 
leisure craft. In contrast, sales of marine engines for commercial 
applications were higher, as were sales of industrial engines. 

<P ALIGN="LEFT">
Volvo Penta's operating income amounted to SEK 17 M, a decrease of 
SEK 37 M from the year-earlier period. The weaker earnings were due mainly 
to lower margins as a consequence of the trend of exchange rates, as well 
as to higher production costs that could not be fully offset through price 
increases.<BR>
<BR>

<A NAME="aero"></A>

<B>Volvo Aero</B><BR>
Volvo Aero's sales rose 8%, to SEK 956 M. Operating income amounted to 
SEK 58 M (49) and the operating margin improved to 6.1% (5.5).
<P ALIGN="LEFT">
 
<P ALIGN="LEFT">
The market for large commercial aircraft continued to increase, 
resulting in higher order bookings in Volvo Aero's commercial engine 
operations. Deliveries to the Swedish Air Force of the RM12 engine used 
in the JAS 39 Gripen multirole aircraft proceeded according to plan. 
A bid for subseries 3 of the JAS 39 Gripen project was submitted to the 
Swedish Defense Materiel Administration by the JAS Industry Group. In 
its Commercial Overhauls business area, Volvo Aero increased its holding 
in Air Ground Equipment Sales (AGES) from 5% to 25%. AGES, which deals 
in aircraft engine materials, and which had sales of USD 187 M in1995, 
is of major strategic importance for the operations in Commercial 
Overhauls.

<P ALIGN="LEFT">
In March Volvo Aero and Atlas Copco completed the sale of VOAC Hydraulics -- in 
which each held a 50% interest -- to Parker Hannifin, an American company. 

<BR>
<BR>


<B>Operations being divested</B><BR>
Operating income of these operations consisted mainly of operating income 
in Swedish Match, which improved in all Swedish Match divisions as a result 
of larger volumes of business, cost reductions and the effects of 
rationalization of production. See also the interim report from Swedish Match.

<P ALIGN="LEFT">
As approved at Volvo's Annual General Meeting on April 24, Volvo's 
holding of Swedish Match shares will be distributed to Volvo's 
shareholders. The program to divest Volvo's remaining holdings in 
noncore businesses remains in effect. These holdings consist primarily 
of shares in Pripps Ringnes AB (49%) and the 14% holding in Pharmacia 
&amp; Upjohn, Inc.

<P ALIGN="LEFT">
In April 1996, Volvo sold its entire holding in Spira AB, equal to 
9.5% of the share capital and voting rights in the company. This sale, 
which is being reported in second quarter, will yield approximately SEK 
80 M in revenue and a small capital gain for Volvo.

<P ALIGN="LEFT">
<B>Employees</B><BR>

The number of employees in the Volvo Group at the end of the first 
quarter was 78,890, a decrease of 160 since January 1.

<A NAME="ref4"></A>

<P ALIGN="LEFT">
<B>Approvals at Volvo's Annual General Meeting</B><BR>

At the Annual General Meeting the proposal of the Board and the president 
for a cash dividend of SEK 4 per share and distribution of all shares in 
Swedish Match AB to the shareholders, with one Swedish Match share per 
Volvo share, was also approved.

<P ALIGN="LEFT">
 
<P ALIGN="LEFT">
The cash dividend totals SEK 1,854 M and distribution of shares in Swedish 
Match SEK 8,000 M, corresponding to the book value in AB Volvo.

<P ALIGN="LEFT">
The record date for entitlement to the cash dividend was set at April 29, 
1996. The record date for entitlement to receive dividends in the form of 
shares in Swedish Match AB was set at May 13, 1996.

<P ALIGN="LEFT">
Payment of the cash dividend is expected to be made through VPC (Swedish 
Securities Register Center) on May 7, 1996. The distributed shares in 
Swedish Match AB are expected to be transferred to the shareholders' VP 
(securities) accounts on May 15, 1996.

<P ALIGN="LEFT">
The Annual General Meeting voted a fee to the Board of Directors of SEK 
2,475,000, to be distributed among the members as decided by the Board.

<P ALIGN="LEFT">
The Annual General Meeting re-elected as members of Board of AB Volvo Bert-Olof 
Svanholm, Per-Olof Eriksson, H&aring;kan Frisinger, Tom Hedelius, Bj&ouml;rn 
Svedberg, S&ouml;ren Mannheimer and S&ouml;ren Gyll. Ragne Billing and Nils 
Brehmer were appointed auditors and Olle Gunnarsson and Anders Ivdal were 
appointed deputy auditors.<BR>
<BR>

<P ALIGN="LEFT">
<B>Options program for senior executives</B><BR>
In February 1996 the Skandia and Trygg-Hansa insurance companies offered 
approximately 100 senior executives in the Volvo Group an opportunity to 
acquire call options on AB Volvo's Series B shares. Approximately 90% of 
the executives had accepted the offer when the subscription period expired.

<P ALIGN="LEFT">
The call options, which may be exercised during the period beginning March 
4, 1996 through March 3, 2001, give the holder the right to acquire one AB 
Volvo Series B share for each option held. The option price, which is based 
on a market valuation, has been set at SEK 21.15 and the exercise price at 
SEK 200. Members of the Group Executive Committee were eligible to acquire 
6,000 or 10,000 options each. Other senior executives were eligible to acquire 
4,000 or 6,000 options each. Total number of options purchased in this program 
amounts to 514,000. 

<P ALIGN="LEFT">
<B>Pension funds</B><BR>

The Board of Directors of AB Volvo has decided to establish two pension 
funds for the Group to secure pension obligations within the framework 
of the industrial supplementary pension plan (ITP). Formation of the 
funds enables Volvo to conform more effectively with international 
conditions in connection with the management of its Swedish pension 
obligations. This does not affect Volvo's pension obligations to its 
employees.

<P ALIGN="LEFT">
Volvo's interim report covering operations during the first six 
months of 1996 will be released on August 21.

<P ALIGN="LEFT">
G&ouml;teborg, April 29, 1996

<P ALIGN="LEFT">
S&ouml;ren Gyll
<BR>
<IMG WIDTH=222 HEIGHT=72 BORDER=0 src="/images/gyll.gif">
<BR>
<P ALIGN="LEFT">
President and Chief Executive Officer

<P ALIGN="LEFT">
This report has not been reviewed by AB Volvo's auditors.




<BR>
<BR>
<BR>


<!-- -------- -->

<TABLE BORDER=0 WIDTH=450>

<TR>
	<TD><HR></TD>
</TR>

<TR>
	<TD>Source: Three months ended March 31, 1996</TD>
</TR>

</TABLE>

<P>

<BR>

</BLOCKQUOTE>

<A HREF="#top"><IMG WIDTH=71 HEIGHT=14 BORDER=0 
SRC="/images/knapp_top.gif" ALT="Top of page"></A>

<HR ALIGN=LEFT WIDTH=487>
Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]


</TD>
</TR>
</TABLE>

</CENTER>



</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-240</DOCNO>
<DOCOLDNO>IA089-000951-B025-422</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/corpinfo/int.rep/three.96/index-sv.html 192.138.110.240 19970208032553 text/html 21034
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 03:25:57 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 20862
Last-modified: Wed, 23 Oct 1996 09:00:54 GMT
</DOCHDR>
<HTML>
<HEAD><TITLE>Det f&ouml;rsta kvartalet 1996</TITLE></HEAD>
<BODY BGCOLOR="FFFFFF">

<A NAME="top"></A>

<CENTER>

<IMG SRC="/images/placorp.gif" BORDER=0 WIDTH=487 HEIGHT=32>
<BR>
<BR>

<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>
	<TD COLSPAN=2 ALIGN=RIGHT><A HREF="../index.html"><IMG BORDER=0 
	SRC="/images/kn_up.gif" WIDTH=75 HEIGHT=25 ALT="UP"></A>
	<A HREF="/index.html"><IMG BORDER=0 SRC="/images/knapp_homep.gif" 
	WIDTH=75 HEIGHT=25 ALT="Home Page"></A></TD>
</TR>

<TR>
	<TD COLSPAN=2><HR></TD>
</TR>

</TABLE>


<TABLE WIDTH=490 BORDER=0>

<TR VALIGN=TOP>
	<TD><A	HREF="../six.95/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knbla.gif">
	<FONT SIZE=2> Six months ended June 30, 1995</FONT></A></TD>	
	<TD><A HREF="../three.96/index-sv.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knrod.gif">
	<FONT SIZE=2> Det f&ouml;rsta kvartalet 1996</FONT></A></TD>
</TR>

<TR VALIGN=TOP>
	<TD><A	HREF="../nine.95/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knbla.gif">
	<FONT SIZE=2> Nine months ended September 30, 1995</FONT></A></TD>
	<TD><A	HREF="../six.96/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0
	src="/images/knbla.gif">
	<FONT SIZE=2> Six months ended June 30,1996</FONT></A></TD>
</TR>

<TR VALIGN=TOP>
	<TD><A HREF="../report.95/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knbla.gif">
	<FONT SIZE=2> Report on 1995 operations</FONT></TD>
	<TD><A	HREF="../nine.96/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knbla.gif">
	<FONT SIZE=2> Nine months ended September 30, 1996</FONT></TD>
</TR>

</TABLE>



<TABLE WIDTH=490 BORDER=0>

<TR>
	<TD>
	
<HR ALIGN=LEFT WIDTH=487>

<!-- -------- -->

<BLOCKQUOTE>
<BR>
<BR>


<FONT SIZE=6>Det f&ouml;rsta kvartalet 1996</FONT>
<BR>
<BR>

<FONT SIZE=4><A HREF="#comments"><img WIDTH=14 HEIGHT=14 BORDER=0 
src="/images/knbla.gif" ALIGN=LEFT>Koncernchefens kommentar</A></FONT><BR>
<BR>

<FONT SIZE=4><A HREF="#six"><img WIDTH=14 HEIGHT=14 BORDER=0 
src="/images/knbla.gif" ALIGN=LEFT>Det f&ouml;rsta kvartalet 1996
</A></FONT><BR>
<BR>

<BLOCKQUOTE>
	
	<FONT SIZE=4><A	HREF="table-sv.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knbla.gif" ALIGN=LEFT>Tabeller</A></FONT><BR>
	<BR>

	<FONT SIZE=4><A	HREF="diagram-sv.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knbla.gif" ALIGN=LEFT>Diagram</A></FONT><BR>
	<BR>



</BLOCKQUOTE>

<BR>
<A NAME="ref0"></A>
<BR>

<HR ALIGN=LEFT WIDTH=447>
<BR>
<BR>

<FONT SIZE=4>
Volvokoncernens r&ouml;relseresultat p&aring;verkades negativt av l&auml;gre personbilsf&ouml;rs&auml;ljning, 
fr&auml;mst Volvo 400-serien i Europa, samt vikande lastbilsmarknader i Nord- och Sydamerika.<BR>
<BR>

Investeringar och produktutvecklingskostnader p&aring; fortsatt h&ouml;g niv&aring;.<BR>
<BR>

Volvo S40/V40 lanseras p&aring; flertalet europeiska marknader under v&aring;ren.<BR>
<BR>

Swedish Match delas ut till Volvos aktie&auml;gare.<BR>
<BR>
</FONT>

(se tabell: <A HREF="tab0-sv.html">Det f&ouml;rsta kvartalet 1996</A>)<BR>



<BR>


</BLOCKQUOTE>

	</TD>
</TR>
</TABLE>

<TABLE WIDTH=490 BORDER=0>

<TR>
	<TD>


<BLOCKQUOTE>

<HR ALIGN=LEFT WIDTH=447>
<BR>

<BR>
<BR>

<BR>
<P>

<A NAME="refdia1"></A>

<FONT SIZE=5><A name="comments">Koncernchefens kommentar<BR></FONT>
<BR>




<FONT SIZE=6>V</FONT>olvokoncernens resultat f&ouml;r de f&ouml;rsta tre 
m&aring;naderna 1996 har p&aring;verkats negativt av vikande 
f&ouml;rs&auml;ljningsvolymer i kombination med fortsatta satsningar p&aring; 
produkt- och marknadsutveckling. F&ouml;rlusten i Volvo Personvagnar &auml;r 
otillfredsst&auml;llande, men inneb&auml;r trots l&auml;gre 
f&ouml;rs&auml;ljningsvolymer ett f&ouml;rb&auml;ttrat r&ouml;relseresultat 
j&auml;mf&ouml;rt med fj&auml;rde kvartalet 1995. Detta &auml;r fr&auml;mst 
resultatet av intern kostnadsrationalisering, l&auml;gre produktutvecklingskostnader 
och h&ouml;gre effektiva valutakurser. F&ouml;rs&auml;ljningsminskningen beror framf&ouml;r allt p&aring; l&auml;gre 
f&ouml;rs&auml;ljning av Volvo 400-serien och p&aring; att Volvo 940 inte l&auml;ngre 
s&auml;ljs p&aring; den amerikanska marknaden. De i mars introducerade 
S40/V40-modellerna har mottagits mycket v&auml;l och ordering&aring;ngen &auml;r god. 
Volvo Lastvagnar vidk&auml;nns fortsatt vikande f&ouml;rs&auml;ljningsvolymer i 
Nord- och Sydamerika. Detta i kombination med kostnader f&ouml;r att globalt implementera 
FH-teknologin samt &ouml;kade marknadssatsningar har belastat Volvo Lastvagnars resultat 
negativt. Den offensiva fas, som Volvo befinner sig i inneb&auml;r investeringar 
f&ouml;r framtida intj&auml;ningsf&ouml;rm&aring;ga. Parallellt med 
genomf&ouml;randet av detta l&aring;ngsiktiga arbete &ouml;kas nu kraven p&aring; 
h&ouml;g effektivitet och kontroll p&aring; r&ouml;relsens kostnader i samtliga 
koncernens delar.<BR>
  

<A NAME="refdia1"></A>


<BR>

</BLOCKQUOTE>

	</TD>
</TR>
</TABLE>

<TABLE WIDTH=490 BORDER=0>

<TR>
	<TD>


<BLOCKQUOTE>

<A NAME="ref1"></A>


<HR ALIGN=LEFT WIDTH=447>
<BR>
<BR>
<BR>
<BR>

<!-- Det f&ouml;rsta kvartalet 1996 -->

<FONT SIZE=5><A name="six">Det f&ouml;rsta kvartalet 1996</FONT><BR>
<BR>
<BR>
(se diagram: <A HREF="dia1-sv.html">R&ouml;relseresultat f&ouml;re poster av 
eng&aring;ngskarakt&auml;r</A>)<BR
<BR>





<P ALIGN="LEFT">
<B>Volvokoncernens f&ouml;rs&auml;ljning</B> under f&ouml;rsta kvartalet 1996 uppgick till 
39.068 Mkr (43.454). F&ouml;rs&auml;ljningen inom fordonsr&ouml;relsen svarade f&ouml;r 37.301 
Mkr, vilket inneb&auml;r en minskning med 7 % j&auml;mf&ouml;rt med motsvarande kvartal f&ouml;reg&aring;ende &aring;r 
justerat f&ouml;r valutakurseffekter samt avyttrade och f&ouml;rv&auml;rvade enheter 
(huvudsaklingen f&ouml;rv&auml;rvet av Volvo Construction Equipment och busstillverkaren 
Pr&eacute;vost, som ej ingick i Volvokoncernen under f&ouml;rsta halv&aring;ret 1995). 
F&ouml;rs&auml;ljningsutvecklingen var negativ f&ouml;r samtliga 
aff&auml;rsomr&aring;den utom Volvo Bussar och Volvo Aero.


<P ALIGN="LEFT">
I Europa minskade Volvos f&ouml;rs&auml;ljning av personbilar, fr&auml;mst p g a 
utfasning av Volvo 400-serien, som nu ers&auml;tts av Volvos nya satsning i 
mellanbilsklassen, Volvo S40/V40.

<P ALIGN="LEFT">
Volvo Lastvagnars f&ouml;rs&auml;ljning sj&ouml;nk p g a en fortsatt vikande 
lastbilsmarknad i USA och Sydamerika.

<A NAME="ref6"></A>


<P ALIGN="LEFT">
<B>R&ouml;relseresultatet</B> var 1.176 Mkr (2.842), varav fordonsr&ouml;relsen  svarade 
f&ouml;r 970 Mkr (2.669). Minskningen j&auml;mf&ouml;rt med motsvarande period f&ouml;reg&aring;ende 
&aring;r beror p&aring; l&auml;gre f&ouml;rs&auml;ljningsvolymer och fortsatt h&ouml;ga produktutvecklingskostnader.<BR>
<BR>



<A NAME="ref2"></A>
<A NAME="ref3"></A>



(se tabell: <A HREF="tab1-sv.html"> Koncernens resultatr&auml;kning</A>)<BR>

<P ALIGN="LEFT">
<B>Resultatandelar i intressebolag</B> minskade till 222 Mkr (433) j&auml;mf&ouml;rt 
med f&ouml;rsta kvartalet 1995. I 1996 &aring;rs resultat ing&aring;r vinst vid f&ouml;rs&auml;ljning av 
VOAC Hydraulics med 352 Mkr. Volvos andel av f&ouml;rlusten i NedCar uppgick 
till 130 Mkr (108). Det svaga resultatet i NedCar beror p&aring; 
ink&ouml;rningskostnader f&ouml;r Volvo S40/V40-serien och l&auml;gre volymer av 
Volvo 400-serien samt h&ouml;ga produktutvecklingskostnader. I 1995 &aring;rs 
resultatandel ingick Volvo Construction Equipment och Pharmacia, vilka inte 
l&auml;ngre redovisas enligt kapitalandelsmetoden, med 216 Mkr respektive 247 Mkr.

<P ALIGN="LEFT">
<B>Utdelning p&aring; aktier</B> avs&aring;g fr&auml;mst Pharmacia &amp; Upjohn, Inc och 
Protorp F&ouml;rvaltnings AB.

<A NAME="ref8"></A>

<P ALIGN="LEFT">
<B>R&auml;ntenettot,</B> som p&aring; grund av Volvokoncernens st&auml;rkta finansiella st&auml;llning 
och ett gott resultat inom Volvo Group Finance, visade en mycket positiv utveckling
och uppgick till 343 Mkr (146).

<P ALIGN="LEFT">
<B>Skattekostnaden</B> avs&aring;g fr&auml;mst l&ouml;pande skatt i utl&auml;ndska 
dotterbolag.

<P ALIGN="LEFT">
<B>Koncernens balansomslutning</B> &ouml;kade under det f&ouml;rsta kvartalet med 
7,9 miljarder kronor. H&auml;rav svarade likvida medel f&ouml;r 4,6 miljarder. Orsaken 
&auml;r bl a att Swedish Match, i samband med den f&ouml;rest&aring;ende b&ouml;rsintroduktionen, ersatt 
koncerninterna l&aring;n med extern kortfristig finansiering. Detta f&ouml;rklarar &ouml;kningen av 
b&aring;de likvida medel och kortfristiga l&aring;n i Volvokoncernens balansr&auml;kning.<BR>
<BR>

(se tabeller: <A HREF="tab3-sv.html">Koncernens balansr&auml;kning i sammandrag</A> och 
<A HREF="tab2-sv.html">Nyckeltal</A></A>)<BR>
<BR>

<P ALIGN="LEFT">
<B>Investeringar i anl&auml;ggningar</B> uppgick till 1,8 miljarder kronor (1,1) och 
investeringar i leasing- och tj&auml;nstefordon till 0,8 (0,7) miljarder kronor.


<P ALIGN="LEFT">
Koncernens <B>finansiella nettotillg&aring;ngar</B>  som vid &aring;rsslutet uppgick 
till 1,2 miljarder kronor &ouml;kade till 2,4 miljarder.

<P ALIGN="LEFT">
<B>Andelen eget kapital och minoritetskapital</B> utgjorde 36,2% av totala 
tillg&aring;ngar (37,4 den 31 december 1995).<BR>
<BR>


(se tabell: <A HREF="tab6-sv.html">Finansieringsanalys</A>)<BR>
<BR>
<BR>
<BR>
<BR>

<A NAME="ref8"></A>

<B>F&ouml;rs&auml;ljning och r&ouml;relseresultat per aff&auml;rsomr&aring;de</B><BR>
<BR>
(se tabell: <A HREF="tab8-sv.html">F&ouml;rs&auml;ljning</A>)<BR>
<BR>


<A NAME="refdia2"></A>
<A NAME="car"></A>

<P ALIGN="LEFT">
<B>Volvo Personvagnar</B><BR>
Totalmarknaden f&ouml;r personbilar &ouml;kade n&aring;got de tre f&ouml;rsta 
m&aring;naderna 1996 j&auml;mf&ouml;rt med motsvarande period f&ouml;reg&aring;ende 
&aring;r. Europa visade en uppg&aring;ng med n&auml;rmare 7%, medan 
marknadsutvecklingen i Nordamerika var of&ouml;r&auml;ndrad. Den japanska 
personbilsmarknaden minskade efter det sista &aring;rets uppg&aring;ng. Motsvarande 
trend f&ouml;r v&auml;rldsmarknadsutvecklingen f&ouml;rv&auml;ntas forts&auml;tta under 
&aring;terstoden av 1996.

<P ALIGN="LEFT">
Volvos Personvagnars f&ouml;rs&auml;ljningsutveckling i Europa var negativ. Det g&auml;llde fr&auml;mst Volvo 400-serien, som nu 
fasas ut och ers&auml;tts av Volvo S40/V40. F&ouml;rs&auml;ljningsutvecklingen 
f&ouml;r Volvo 850 var stabil och &ouml;kade p&aring; flera marknader, bl a Frankrike 
och England. Antalet fakturerade Volvo personbilar i Nordamerika minskade, medan 
marknadsandelen var of&ouml;r&auml;ndrad pga f&ouml;rs&auml;ljning fr&aring;n lager 
hos &aring;terf&ouml;rs&auml;ljare. I Japan och Thailand &ouml;kade 
f&ouml;rs&auml;ljning och marknadsandel.

<P ALIGN="LEFT">
F&ouml;rs&auml;ljningsv&auml;rdet f&ouml;r Volvo Personvagnar var 12% l&auml;gre 
&auml;n motsvarande period f&ouml;reg&aring;ende &aring;r. Antalet fakturerade 
personbilar sj&ouml;nk med 19% och sammanlagt s&aring;ldes 85.200 bilar (104.600). 
R&ouml;relseresultatet f&ouml;rb&auml;ttrades med 650 Mkr j&auml;mf&ouml;rt  med 
sista kvartalet 1995, men var fortfarande negativt och uppgick till minus 191 Mkr. 
J&auml;mf&ouml;rt med motsvarande period 1995 f&ouml;rs&auml;mrades resultatet med 
1.121 Mkr. Den fr&auml;msta orsaken &auml;r minskad f&ouml;rs&auml;ljningsvolym och 
d&auml;rmed l&auml;gre kapacitetsutnyttjande. D&auml;rtill kommer h&ouml;gre kostnader 
f&ouml;r produktutveckling. R&ouml;relsemarginalen minskade fr&aring;n 4,2% till minus 
1,0%.<BR> 
<BR>

(se diagram: <A HREF="dia2-sv.html">R&ouml;relseresultat Volvo Personvagnar</A>)<BR>
<BR>


<A NAME="refdia3"></A>
<A NAME="truck"></A>

<P ALIGN="LEFT">
<B>Volvo Lastvagnar</B><BR>
Totalmarknaden f&ouml;r tunga lastbilar i Europa l&aring;g p&aring; en fortsatt 
h&ouml;g niv&aring; under f&ouml;rsta kvartalet 1996. En viss nedg&aring;ng skedde 
dock i Storbritannien. F&ouml;rsvagningen av totalmarknaderna i Nord- och Sydamerika, 
som inleddes under andra halv&aring;ret 1995, bestod under de f&ouml;rsta tre 
m&aring;naderna i &aring;r. V&auml;rldsmarknaden f&ouml;r tunga lastbilar kommer 
1996 att klart understiga rekord&aring;ret 1995. Den st&ouml;rsta minskningen 
f&ouml;rv&auml;ntas ske i Nordamerika, men &auml;ven i Europa f&ouml;rutses en 
reducerad efterfr&aring;gan under andra halv&aring;ret.

<P ALIGN="LEFT">
Volvo Lastvagnars f&ouml;rs&auml;ljning under f&ouml;rsta kvartalet 1996 minskade 
med 11% till 11.656 Mkr. Leveranserna av tunga och medeltunga lastbilar uppgick till 
16.700 enheter en minskning med 14% j&auml;mf&ouml;rt med f&ouml;rsta kvartalet 1995. 
Leveranserna inom Europa steg dock med 13% medan marknadsandelen i klassen f&ouml;r 
tunga lastbilar minskade n&aring;got i Europa. &Auml;ven i Nordamerika sj&ouml;nk marknadsandelen 
under &aring;rets f&ouml;rsta kvartal. Orderboken var vid utg&aring;ngen av f&ouml;rsta kvartalet 
45% l&auml;gre &auml;n ett &aring;r tidigare, i f&ouml;rsta hand till f&ouml;ljd av 
kraftigt minskande efterfr&aring;gan i Nord- och Sydamerika.

<P ALIGN="LEFT">
Volvo Lastvagnars r&ouml;relseresultatet f&ouml;r f&ouml;rsta kvartalet 1996 uppgick 
till 731 kr (1.515). Orsaken till minskningen var prim&auml;rt betydligt l&auml;gre 
f&ouml;rs&auml;ljningsvolymer i Nord- och Sydamerika och d&auml;rmed minskat 
kapacitetsutnyttjande i produktionsanl&auml;ggningarna. Resultatet p&aring;verkades 
vidare av &ouml;kade satsningar p&aring; produkt- och marknadsutveckling. 
R&ouml;relsemarginalen uppgick till 6,3% (11,5).<BR>
<BR>

(se diagram: <A HREF="dia3-sv.html">R&ouml;relseresultat Volvo Lastvagnar</A>)<BR>
<BR>

<A NAME="bus"></A>

<P ALIGN="LEFT">
<B>Volvo Bussar</B><BR>
Volvo levererade 1.490 (1.140) bussar och busschassier under f&ouml;rsta kvartalet 1996. 
Pr&eacute;vost, som f&ouml;rv&auml;rvades i maj 1995, svarade
f&ouml;r 138 bussar. Marknadsandelen i Europa &ouml;versteg f&ouml;reg&aring;ende 
&aring;rs niv&aring;, orderboken var vid utg&aring;ngen av f&ouml;rsta kvartalet 
1996 cirka 40% h&ouml;gre &auml;n motsvarande tid 1995. Det operativa resultatet 
&ouml;kade till 69 Mkr (65) medan r&ouml;relsemarginalen sj&ouml;nk till 3,7% (4,1).

<P ALIGN="LEFT">
Volvo Bussar och den finske busstillverkaren Carrus Oy sl&ouml;t i mars 1996 ett avtal 
om f&ouml;rdjupat samarbete avseende produktutveckling och marknadsprojekt utanf&ouml;r 
Norden.

<A NAME="vce"></A>

<P ALIGN="LEFT">
<B>Volvo Construction Equipment</B><BR>
Totalmarknaden f&ouml;r anl&auml;ggningsmaskiner sj&ouml;nk p&aring; flera viktiga 
marknader under f&ouml;rsta kvartalet 1996 j&auml;mf&ouml;rt med motsvarande period 
f&ouml;reg&aring;ende &aring;r. Det g&auml;llde s&aring;v&auml;l Nordamerika och 
Tyskland som  andra marknader i Europa. Nedg&aring;ngen i Tyskland, 
som var betydande, ber&ouml;rde i f&ouml;rsta hand l&auml;ttare 
anl&auml;ggningsmaskiner. 

<P ALIGN="LEFT">
F&ouml;rs&auml;ljningsv&auml;rdet minskade till 3.045 Mkr (3.243). Volymminskningen, 
i kombination med projektkostnader av eng&aring;ngsnatur samt of&ouml;rm&aring;nlig 
utveckling av valutakurser ledde till ett minskat, men fortfarande h&auml;vdat, 
r&ouml;relseresultat om 273 Mkr (443). R&ouml;relsemarginalen var 9% (13,7). 


<A NAME="penta"></A>

<P ALIGN="LEFT">
<B>Volvo Penta</B><BR>
F&ouml;rs&auml;ljningsv&auml;rdet f&ouml;r Volvo Penta minskade med 5 %. Den 
l&auml;gre f&ouml;rs&auml;ljningen &auml;r framf&ouml;r allt en effekt av 
valutakursutvecklingen men &auml;ven av minskad efterfr&aring;gan p&aring; motorer 
och reservdelar f&ouml;r fritidsb&aring;tar. D&auml;remot har f&ouml;rs&auml;ljningen 
&ouml;kat f&ouml;r marinmotorer avsedda f&ouml;r den kommersiella marknaden och 
f&ouml;r industrimotorer. 

<P ALIGN="LEFT">
R&ouml;relseresultatet uppgick till 17 Mkr, 37 Mkr l&auml;gre &auml;n 
f&ouml;reg&aring;ende &aring;r. Resultatf&ouml;rs&auml;mringen beror fr&auml;mst 
p&aring; s&auml;nkta marginaler till f&ouml;ljd av valutakursutvecklingen och 
&ouml;kade produktkostnader vilka inte har kunnat kompenseras fullt ut genom 
prish&ouml;jningar.

<A NAME="aero"></A>

<P ALIGN="LEFT">
<B>Volvo Aero</B><BR>
F&ouml;rs&auml;ljningen &ouml;kade med  8% till 956 Mkr. R&ouml;relsresultatet 
uppgick till 58 Mkr (49) och r&ouml;relsemarginalen f&ouml;rb&auml;ttrades till 
6,1% (5,5).
<P ALIGN="LEFT">
Marknaden f&ouml;r stora trafikflygplan fortsatte att v&auml;xa, vilket ledde till 
en &ouml;kning av ordering&aring;ngen inom Volvo Aeros civila flygverksamhet. 
Leveranserna av JAS 39 Gripens motor RM12 till svenska flygvapnet l&ouml;pte planenligt.
 En offert p&aring; delserie 3 av JAS 39 Gripen &ouml;verl&auml;mnades av 
 Industrigruppen JAS  till F&ouml;rsvarets Materielverk. Inom aff&auml;rsomr&aring;de 
 Civila &ouml;versyner &ouml;kade Volvo Aero sin &auml;garandel i det amerikanska 
 f&ouml;retaget AGES, Air Ground Equipment Sales, fr&aring;n 5 till 25%. AGES, som 
 bedriver handel med flygmotormaterial och f&ouml;rra &aring;ret omsatte USD 187 M, 
 &auml;r av stor strategisk betydelse  f&ouml;r verksamheten inom Civila &ouml;versyner.

<P ALIGN="LEFT">
I mars 1996 slutf&ouml;rde Volvo Aero och Atlas Copco f&ouml;rs&auml;ljningen av det 
till lika delar &auml;gda VOAC Hydraulics till det amerikanska f&ouml;retaget Parker 
Hannifin. 
 

<A NAME="ref9"></A>


<A NAME="ref4"></A>



<BR>
<BR>
 

<A NAME="ref7"></A>




<P ALIGN="LEFT">
<B>Verksamheter under avveckling</B><BR>
R&ouml;relseresultatet f&ouml;r dessa verksamheter utgjordes huvudsakligen av r&ouml;relseresultatet 
i Swedish Match, vilket f&ouml;rb&auml;ttrades i samtliga divisioner till f&ouml;ljd av h&ouml;gre volymer, 
kostnadsbesparingar samt effekter av genomf&ouml;rda rationaliseringar i produktionen. Se vidare separat 
rapport &ouml;ver det f&ouml;rsta kvartalet 1996 fr&aring;n Swedish Match.

<P ALIGN="LEFT">
Enligt samma beslut p&aring; Volvos bolagsst&auml;mma den 24 april kommer Swedish Match att delas 
ut till Volvos aktie&auml;gare. Inriktningen att avveckla Volvos resterande innehav utanf&ouml;r 
fordonsr&ouml;relsen ligger fast. De utg&ouml;rs fr&auml;mst av aktierna i Pripps Ringnes AB (49%) och 
det b&ouml;rsnoterade innehavet i Pharmacia & Upjohn, Inc(14%)

<P ALIGN="LEFT">
I april 1996 avyttrade Volvo hela sitt aktieinnehav i Spira AB, motsvarande 9,5% av 
r&ouml;ster och kapital. F&ouml;rs&auml;ljningen som redovisas i andra kvartalet 1996 
inbringade ca 80 Mkr och medf&ouml;r en mindre bokf&ouml;ringsm&auml;ssig vinst 
f&ouml;r Volvo.

<P ALIGN="LEFT">
<B>Anst&auml;llda</B><BR>
Antalet anst&auml;llda i Volvokoncernen uppgick i slutet av f&ouml;rsta kvartalet 1996 till 
78.890 personer, en minskning med 160 personer sedan &aring;rsskiftet.

<P ALIGN="LEFT">
<B>Optionsprogram till ledande befattningshavare</B><BR>
Skandia och Trygg-Hansa l&auml;mnade i februari 1996 ett erbjudande till cirka 100 
ledande befattningshavare i Volvokoncernen om att f&ouml;rv&auml;rva k&ouml;poptioner 
avseende B-aktier i AB Volvo. Vid teckningstidens utg&aring;ng hade cirka 90% av dessa 
accepterat erbjudandet.

<P ALIGN="LEFT">
K&ouml;poptionerna l&ouml;per fr&aring;n och med 4 mars 1996 till och med den 3 mars 
2001 och ger innehavaren r&auml;tt till att f&ouml;r varje option f&ouml;rv&auml;rva 
en B-aktie i Volvo. Optionspriset, som grundar sig p&aring; en marknadsm&auml;ssig 
v&auml;rdering, har fastst&auml;llts till 21:15 kronor och  l&ouml;senpriset till 200 
kronor. Medlemmar av koncernledningen erbj&ouml;ds f&ouml;rv&auml;rva 6.000 alternativt 
10.000 optioner vardera. Andra ledande befattningshavare erbj&ouml;ds 
f&ouml;rv&auml;rva 4.000 alternativt 6.000 optioner vardera. Totalt tecknades 514,000 optioner.


<P ALIGN="LEFT">
<B>Koncerngemensamma pensionstiftelser</B><BR>
AB Volvos styrelse har beslutat bilda tv&aring; koncerngemensamma pensionsstiftelser 
f&ouml;r att trygga pensions&aring;taganden inom ramen f&ouml;r ITP-planen. Genom 
bildandet har Volvo b&auml;ttre m&ouml;jlighet att anpassa sig till internationella 
f&ouml;rh&aring;llanden vid hantering av de svenska pensions&aring;tagandena. 
Detta p&aring;verkar inte Volvos pensions&aring;taganden gentemot de anst&auml;llda.<BR>
<BR>

<P ALIGN="LEFT">
Rapport &ouml;ver f&ouml;rsta halv&aring;ret 1996 kommer att l&auml;mnas den 21 augusti.

<P ALIGN="LEFT">
G&ouml;teborg den 29 april 1996<BR>
<BR>

<IMG WIDTH=222 HEIGHT=72 BORDER=0 src="/images/gyll.gif">

<P ALIGN="LEFT">
S&ouml;ren Gyll

<P ALIGN="LEFT">
VD och koncernchef

<P ALIGN="LEFT">
Denna rapport har inte varit f&ouml;rem&aring;l f&ouml;r s&auml;rskild granskning av 
AB Volvos revisorer.

<BR>
<BR>
<BR>


<!-- -------- -->

<TABLE BORDER=0 WIDTH=450>

<TR>
	<TD><HR></TD>
</TR>

<TR>
	<TD>K&auml;lla: Det f&ouml;rsta kvartalet 1996</TD>
</TR>

</TABLE>

<P>

<BR>

</BLOCKQUOTE>

<A HREF="#top"><IMG WIDTH=71 HEIGHT=14 BORDER=0 
SRC="/images/knapp_top.gif" ALT="Top of page"></A>

<HR ALIGN=LEFT WIDTH=487>
Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A> [webmaster@www.volvo.se]


</TD>
</TR>
</TABLE>

</CENTER>



</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-241</DOCNO>
<DOCOLDNO>IA089-000951-B026-53</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/corpinfo/int.rep/six.96/index.html 192.138.110.240 19970208032628 text/html 22618
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 03:26:35 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 22446
Last-modified: Wed, 23 Oct 1996 09:00:53 GMT
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>
<HEAD>
   <TITLE>Six months ended June 30, 1996</TITLE>
   
</HEAD>
<BODY BGCOLOR="#FFFFFF">

<CENTER><P><A NAME="top"></A><IMG SRC="/images/placorp.gif" HEIGHT=32 WIDTH=487><BR>
<BR>
</P></CENTER>

<CENTER><TABLE WIDTH="490" BORDER=0>
<TR VALIGN=TOP>
<TD COLSPAN=2 ALIGN=RIGHT><A HREF="../index.html"><IMG SRC="/images/kn_up.gif" ALT="UP" BORDER=0 HEIGHT=25 WIDTH=75></A><A HREF="/index.html"><IMG SRC="/images/knapp_homep.gif" ALT="Home Page" HSPACE=1 BORDER=0 HEIGHT=25 WIDTH=75></A></TD>
</TR>

<TR>
<TD COLSPAN=2>
<HR></TD>
</TR>
</TABLE></CENTER>

<CENTER><TABLE WIDTH="490" >
<TR VALIGN=TOP>
<TD><A HREF="../six.95/index.html"><IMG SRC="/images/knbla.gif" BORDER=0 HEIGHT=14 WIDTH=14></A><FONT SIZE=-1><A HREF="../six.95/index.html">Six
months ended June 30, 1995</A></FONT></TD>

<TD><A HREF="../three.96/index.html"><IMG SRC="/images/knbla.gif" BORDER=0 HEIGHT=14 WIDTH=14></A><FONT SIZE=-1><A HREF="../three.96/index.html">Three
months ended March 31, 1996</A></FONT></TD>
</TR>

<TR VALIGN=TOP>
<TD><A HREF="../nine.95/index.html"><IMG SRC="/images/knbla.gif" BORDER=0 HEIGHT=14 WIDTH=14></A><FONT SIZE=-1><A HREF="../nine.95/index.html">Nine
months ended September 30, 1995</A></FONT></TD>

<TD><A HREF="../six.96/index.html"><IMG SRC="/images/knrod.gif" BORDER=0 HEIGHT=14 WIDTH=14></A><FONT SIZE=-1><A HREF="../six.96/index.html">Six
months ended June 30,1996</A></FONT></TD>
</TR>

<TR VALIGN=TOP>
<TD><A HREF="../report.95/index.html"><IMG SRC="/images/knbla.gif" BORDER=0 HEIGHT=14 WIDTH=14></A><FONT SIZE=-1><A HREF="../report.95/index.html">Report
on 1995 operations</A></FONT></TD>

	<TD><A	HREF="../nine.96/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knbla.gif">
	<FONT SIZE=2> Nine months ended September 30, 1996</FONT></TD>
</TR>
</TABLE></CENTER>

<CENTER><TABLE WIDTH="490" >
<TR>
<TD>
<HR ALIGN=LEFT WIDTH=487><!-- -------- -->
<BLOCKQUOTE>
<P><BR>
<BR>
<FONT SIZE=+3>Six months ended June 30,1996<BR>
<BR>
<A HREF="#comments"><IMG SRC="/images/knbla.gif" BORDER=0 HEIGHT=14 WIDTH=14></A></FONT><FONT SIZE=+1><A HREF="#comments">Comments
by the Chief Executive Officer<BR>
<BR>
<A HREF="#six"><IMG SRC="/images/knbla.gif" BORDER=0 HEIGHT=14 WIDTH=14></A></A><A HREF="#six">Six
months ended June 30, 1996</A></FONT><BR>
<BR>
<BR>
</P>

<BLOCKQUOTE>
<P><A HREF="table.html"><IMG SRC="/images/knbla.gif" BORDER=0 HEIGHT=14 WIDTH=14></A><FONT SIZE=+1><A HREF="table.html">Tables<BR>
<BR>
<A HREF="diagram.html"><IMG SRC="/images/knbla.gif" BORDER=0 HEIGHT=14 WIDTH=14></A></A><A HREF="diagram.html">Diagrams</A></FONT><BR>
<BR>
</P>
</BLOCKQUOTE>

<P><BR>
<A NAME="ref0"></A><BR>

<HR ALIGN=LEFT WIDTH=447><BR>
<BR>
</P>

<P><FONT SIZE=+1>Volvo Group sales were largely unchanged, adjusted for
divested and acquired units and the effect of foreign exchange rate movements.</FONT></P>

<P><FONT SIZE=+1>Income for the automotive operations was substantially
lower than in the comparable period in 1995, due to continued high product-
and market-development costs and the introduction of new products. Markets
and profitability for Volvo Trucks in North and South America also weakened.</FONT></P>

<P><FONT SIZE=+1>Car operations reported a profit following losses in the
two preceding quarters.</FONT></P>

<P><FONT SIZE=+1>Net interest income of SEK 633 M and gains of SEK 453
M on the sale of shares contributed to net earnings on a level with first-half
1995 results.</FONT></P>

<P><FONT SIZE=+1>Swedish Match shares were distributed to Volvo shareholders
in May. The greater part of Volvo's holding in Pharmacia &amp; Upjohn was
sold in July.<BR>
<BR>
</FONT>(see table: <A HREF="tab0.html">Six months ended June 30, 1996</A>)<BR>
<BR>
<BR>
<BR>

<HR ALIGN=LEFT WIDTH=447><BR>
</P>

<P><A NAME="comments"></A><FONT SIZE=+2>Comments by the Chief Executive
Officer<BR>
<BR>
</FONT><FONT SIZE=+3>T</FONT>he structural and industrial transformation
of the Volvo Group is continuing. Following the distribution of Swedish
Match shares to Volvo's shareholders and the sale of the greater part of
the holding in Pharmacia &amp; Upjohn, the concentration on automotive
operations has been virtually completed. At the same time, the Group's
two largest operating sectors, Volvo Cars and Volvo Trucks, are in a period
of aggressive change.</P>

<P>Income for the automotive operations was substantially lower than in
the comparable period in 1995, due to product- and market-development costs,
the introduction of new products, and declining markets and profitability
for Volvo Trucks in North and South America.</P>

<P>Volvo Trucks is maintaining its strong foothold in the growing European
market. A sharply negative and unacceptable trend of income in North America
is attributable to a declining market and excessively high operating costs
combined with the strategic investment in a new product program based on
the FH truck concept. A strong program of corrective measures has been
undertaken but the effects of this program are not expected to completely
compensate for the high level of costs in 1996.</P>

<P>The losses incurred in Volvo Cars in the two preceding quarters have
been turned into a profit, although a small one. The improvement is occurring
parallel with the impact of cost-reduction measures. Demand for the Volvo
S40/V40 models is strong. The problems with long delivery times during
the introduction period is gradually improving. The Volvo S40/V40 cars
are not expected to have an impact on earnings until the second half of
the current year.</P>

<P>Volvo Construction Equipment reported decreasing but still good earnings,
with an operating margin of 9.7 %, despite a weaker market trend and stiffening
competition.</P>

<P>Briefly stated, the results of operations in the first half of 1996
mean that the focus on cost trends in all Group units is being further
intensified. Parallel with this, through a rapid pace of product development,
we are continuing our efforts to further strengthen the Group's position
as a producer of transport equipment for the most demanding segment of
the market's customers.<BR>
<BR>
(see diagram: <A HREF="dia1.html">Operating income, before nonrecurring
items</A>)<BR 
<BR>
<BR>

<HR ALIGN=LEFT WIDTH=447><BR>
<BR>
<BR>
<BR>
<!-- Six months ended June 30, 1995 --><A NAME="six"></A><FONT SIZE=+2>Six
months ended June 30, 1996<BR>
<BR>
<BR>
</FONT><B>Volvo Group sales</B> in the first half of 1996 amounted to SEK
78,059 M, compared with SEK 85,134 M in the first six months of 1995. Sales
attributable to automotive operations decreased by 9%, excluding acquired
units. Adjusted also to reflect the effects of foreign exchange rate movements,
the decrease was one percent.</P>

<P>During the spring all the shares of Swedish Match were distributed to
Volvo's shareholders. Effective April 1, Swedish Match is no longer included
in Volvo's accounts and most of the wholly owned operations outside the
automotive operations have thus been divested.</P>

<P><B>Operating income</B> <B>before nonrecurring items</B> was SEK 3,280
M lower than in the year-earlier period. The decline was attributable mainly
to Volvo Trucks (decrease: SEK 1,864 M) and Volvo Cars (decrease: SEK 1,393
M) and was due to smaller volumes of sales, lower utilization of production
capacity, and increased sales- organization and product-development costs.
Despite a strengthening of the Swedish krona, positive currency effekts
were attained through hedging, contributing approximately SEK 200 M to
operating income.</P>

<P>Volvo Construction Equipment, which has been consolidated since June
30, 1995, contributed SEK 651 M to operating income. Group operating income
was reduced with SEK 433 M through divestment of operations, mainly Swedish
Match, Procordia and Abba Seafood.<BR>
<BR>
<A NAME="ref1"></A>(see table: <A HREF="tab1.html">Consolidated income
statements</A>)<BR>
<BR>
</P>

<P><B>Income from equity method investments</B> declined to SEK 200 M,
compared with SEK 1,023 M in the first half of 1995. Income in 1996 included
a capital gain of SEK 352 M on the sale of VOAC Hydraulics. Volvo's share
of the loss in NedCar was SEK 249 M (227)*. The weak results in NedCar
were attributable to start-up costs related to the Volvo S40/V40, smaller
volumes of the Volvo 400 model, and high product-development costs. Income
from equity method investments in 1995 included Volvo Construction Equipment
and Pharmacia, which are no longer reported in accordance with the equity
method, in the amounts of SEK 478 M and SEK 600 M, respectively.<BR>
</P>

<P><B>Dividends received</B> included SEK 256 M from Pharmacia &amp; Upjohn,
Inc., SEK 91 M from SAS Sverige AB, SEK 31 M from Investment AB Bure, and
SEK 33 M from Protorp F&ouml;rvaltnings AB.<A NAME="ref2"></A><A NAME="ref3"></A></P>

<P><B>Gains on sales of securities </B>pertained mainly to the sale of
all the shares of Investment AB Bure, which led to a profit of SEK 394
M.</P>

<P><B>Net interest income,</B> amounting to SEK 633 M (150), developed
very favorably due to the Volvo Group's strong financial position and good
results in Volvo Group Finance.</P>

<P><FONT SIZE=-1>* Figures within parentheses pertain to first-half 1995
operations.</FONT></P>

<P><B>Tax expenses</B> expense pertained largely to current taxes in foreign
subsidiaries and in operations being divested.<BR>
<BR>
(see tables: <A HREF="tab3.html">Condensed consolidated balance sheets</A>
and <A HREF="tab2.html">Key ratios</A>)<BR>
<BR>
</P>

<P><B>Group assets</B> assets declined by SEK 3.3 billion in the first
half of 1996. Excluding movements in foreign exchange rates, the decrease
was SEK 0.8 billion. As a result of changes in composition of the Group,
primarily the distribution of Swedish Match to Volvo's shareholders, total
assets decreased SEK 8.6 billion. Group assets were increased through investments
in property, plant and equipment, a larger volume of sales financing, and
increases in inventories, notably in Volvo Cars.</P>

<P><B>Capital expenditures</B> for property, plant and equipment amounted
to SEK 3.9 billion (2.4), including SEK 2.0 billion in Volvo Cars and SEK
1.4 billion in Volvo Trucks. Investments in leasing and company vehicles
totaled SEK 1.6 billion (1.5).<A NAME="ref6"></A><A NAME="ref5"></A></P>

<P><B>Net financial assets </B>assets rose from SEK 1.2 billion at December
31, 1995 to SEK 1.4 billion at June 30, 1996.</P>

<P><B>Shareholders' equity </B>adecreased by SEK 3.6 billion. The distribution
of the Swedish Match shares and payment of a cash dividend to AB Volvo
shareholders reduced shareholders' equity by SEK 4.2 billion and SEK 1.9
billion, respectively. Net income for the period increased shareholders'
equity by SEK 2.8 billion.<BR>
<BR>
(see tables: <A HREF="tab6.html">Statement of changes in consilidated financial
position</A> and <A HREF="tab5.html">Operating income, excluding nonrecurring
items</A>)<BR>
<BR>
<BR>
<BR>
<BR>
<A NAME="ref8"></A>(see table: <A HREF="tab8.html">Sales by company Group</A>)<BR>
<BR>
<BR>
</P>
</BLOCKQUOTE>
</TD>
</TR>
</TABLE></CENTER>

<CENTER><P><A NAME="refdia2"></A><A NAME="car"></A></P></CENTER>

<CENTER><TABLE WIDTH="490" >
<TR>
<TD>
<BLOCKQUOTE>
<P><B>Volvo Cars<BR>
</B>The total market for passenger cars increased by slightly more than
2% during the first six months of 1996, compared with the corresponding
period a year earlier. The market in Europe showed an increase of slightly
more than 5%, while the upturn in North America amounted to just over one
percent. The trend of the total market in Japan was negative and the passenger
car segment decreased by nearly one percent.</P>

<P>Volvo Cars' sales declined by 7%, to SEK 39,828 M. Adjusted for changes
in foreign exchange rates the sales increased with 2%, which is due to
a more favorable product- and market mix. The number of cars sold, 174,570
(198,790), declined by 12%. Sales of the Volvo 850 developed well, while
the volume of sales in the Volvo 940/960 series and the Volvo 400 series
decreased. The Volvo 900 series declined mainly in the US where sale of
the 940 modell was discontinued in conjunction with introduction of the
1996 models. The orderbookings in the medium-size class increased by 11%
though, as a result of the introduction of the Volvo S40/V40 models. Due
to delivery delays during the spring, deliveries of these cars could not
be made to the degree planned and fully compensate the sales reduction
of the Volvo 400 series.</P>

<P>In Europe,-- notably in Sweden, Great Britain and Italy,-- registrations
of Volvo cars and the company's market shares declined. Registrations of
Volvo cars in North America were virtually unchanged. Sales in Volvo's
other markets as a whole were higher. The favorable trend of sales in Japan
continued and 12,000 Volvo cars, an increase of 32%, were sold there.</P>

<P>Operating income for the first six months of 1996 amounted to SEK 187
M (1,580). The decrease was mainly due to smaller sales volumes of the
Volvo 900 series and Volvo 400 series and higher product development costs
offset in part by favorable effects of foreign exchange rates after taking
the forward contracts into account. Operating margin decreased to 0.5%
(3.7). But income improved by SEK 569 M, compared with the first quarter
of the year.</P>

<P>A new regional sales company, Volvo Car Asia Pacific, whose head office
is in Singapore, was formed to strengthen Volvo Cars' position in Southeast
Asia.<BR>
<BR>
(see diagram: <A HREF="dia2.html">Operating income, Volvo Car </A>)</P>
</BLOCKQUOTE>
</TD>
</TR>
</TABLE></CENTER>

<CENTER><P><A NAME="refdia3"></A><A NAME="truck"></A></P></CENTER>

<CENTER><TABLE WIDTH="490" >
<TR>
<TD>
<BLOCKQUOTE>
<P><B>Volvo Trucks<BR>
</B>The world market for heavy trucks declined during the first six months
of 1996, compared with the first half of 1995. The total market in North
and South America weakened perceptibly, while the market in Europe as a
whole was strengthened.</P>

<P>During the first two quarters of the year Volvo Trucks delivered 33,240
(38,340) medium-heavy and heavy trucks, 13% fewer units than in the first
half of 1995. The number of trucks delivered in Europe increased by 13%.
Volvo's share of the European market was slightly smaller but Volvo was
again the second-largest make in the market. Deliveries in North America
decreased by 31% and Volvo's share of the market for heavy trucks declined.</P>

<P>The order backlog at June 30, 1996 was 46% lower than on the same date
a year earlier, due primarily to the weaker order bookings in North and
South America.</P>

<P>Volvo Trucks' sales in the first half of 1996 amounted to SEK 23,112
M, a decrease of 10% compared with sales in the first six months of 1995.
Adjusted for foreign exchange rate movements, the decrease was 3%. Operating
income amounted to SEK 1,078 M (2,942). Earnings in Europe were satisfactory,
but lower than in the year-earlier period. Operations in North America
resulted in a substantial loss, due largely to a smaller volume of sales
and pressure on margins. A restructuring program is under way but a significant
loss is also anticipated in the second half of the year. Income in Latin
America was much lower than in the 1995 period. In addition, Volvo Trucks'
income was charged with higher product-development and marketing costs.
The operating margin was 4.7% (11.4).<BR>
<BR>
(see diagram: <A HREF="dia3.html">Operating income, Volvo Truck</A>)</P>

<P><BR>
<BR>
<A NAME="bus"></A><B>Volvo Buses<BR>
</B>Volvo Buses delivered 3,630 (2,860) buses and bus chassis during the
first half of 1996. The recently acquired company, Pr&eacute;vost Car Inc.,
in which Volvo Buses holds a 51% interest, accounted for 330 buses. According
to preliminary statistics, Volvo Buses' share of the European market increased
to 20% (19). The order backlog at June 30, 1996 was approximately 7% higher
than on the same date in 1995.</P>

<P>Excluding the acquisition of Pr&eacute;vost, in which Volvo Buses owns
51%, invoiced sales decreased by 2%. Operating income amounted to SEK 134
M (164). The operating margin declined to 3.2% (4.6). The decrease in income
was attributable to increased competition and lower gross profit margins.<BR>
<BR>
<A NAME="vce"></A><B>Volvo Construction Equipment<BR>
</B>Demand in a number of market areas -- of which North America and Germany
are the most important -- continued to be lower than in the comparable
period of 1995, resulting in a smaller total volume of sales. Invoiced
sales amounted to SEK 6,695 M (6,966).</P>

<P>Earnings continued to be strong, but on a lower level than a year earlier.
The effect of the smaller volume of sales was offset in part by a more
profitable product mix. But higher development costs, combined with less
favorable exchange rates than in 1995, had an impact on operating income,
which amounted to SEK 651 M (990). The operating margin was 9.7% (14.2).<BR>
<BR>
<A NAME="penta"></A><B>Volvo Penta<BR>
</B>Volvo Penta's sales declined by 3%. The trend of foreign exchange rates
was unfavorable, while the volume of sales was largely unchanged.</P>

<P>Operating income amounted to SEK 57 M, a decrease of SEK 70 M compared
with first-half 1995 income. Price increases could not compensate for unfavorable
exchange rates and higher costs.<BR>
<BR>
<A NAME="aero"></A><B>Volvo Aero<BR>
</B>The market for large commercial aircraft continued to be stable and
order bookings in Volvo Aero's commercial aviation operations were strong.
Demand for spare parts for commercial aircraft engines was also substantial.</P>

<P>Eight JAS 39 Gripen multirole military aircraft were delivered to the
Swedish Air Force during the first half of the year. In all, 21 aircraft
have been delivered since series deliveries were begun in 1993. The JAS
39 was introduced officially on June 9 in a ceremony at the Skaraborg F7
Wing headquarters. The bid covering equipment for Subseries 3 of the aircraft
was submitted to the Defense Materiel Administration by the JAS Industrial
Group.</P>

<P>The failure in connection with the first launch of the Ariane 5 space
rocket -- a project in which Volvo Aero is participating jointly with other
European companies -- was caused by a fault in the software of the control
system, which is outside Volvo Aero's area of responsibility. The Ariane
program is continuing and the next launch is scheduled for the spring of
1997.</P>

<P>Volvo Aero's operating income amounted to SEK 90 M (91). The operating
margin declined to 4.6% (5.3).</P>

<P>During the spring AVC Intressenter - a holding company jointly owned
by Volvo Aero and Atlas Copco - finalized the sale of VOAC Hydraulics.
The buyer was Parker Hannifin, an American firm.<BR>
<BR>
<B>Operations being divested - Distribution of Swedish Match<BR>
</B>As approved at Volvo's Annual General Meeting on April 24, the shares
of Swedish Match were distributed to Volvo's shareholders on May 13, 1996.
Swedish Match was listed on the &quot;O&quot; List of the Stockholm Stock
Exchange and on the NASDAQ exchange in the U.S. on May 15.</P>

<P>Volvo's shareholdings in Investment AB Bure and Spira AB were divested
during the second quarter. Proceeds of the sales amounted to SEK 525 M
and SEK 83 M, respectively.</P>

<P><B>Employees<BR>
</B>The Volvo Group had 71,250 employees at June 30, 1996, a decrease of
7,800 compared with the number at December 31, 1995. As a result of the
divestment of Volvo's shareholdings in Swedish Match, 7,000 persons left
the Group.<A NAME="ref4"></A></P>

<P><B>Parent Company<BR>
</B>The Parent Company, AB Volvo, had revenues amounting to SEK 227 M (223)
in the first half of 1996. Income before tax was SEK 853 M, as against
a loss of SEK 1,323 M in the year-earlier period. Income included dividends
of SEK 719 M (1,734) from subsidiaries, dividends of SEK 60 M (112) from
non-Group companies, exchange gains of SEK 640 M (loss: 860) on loans,
and net interest expense of SEK 344 M (296). Figures for the 1995 period
included nonrecurring items amounting to SEK 1,817 M pertaining to the
write-down of acquired shares in Volvo Construction Equipment Corporation.
Capital expenditures for property, plant and equipment amounted to SEK
17 M (6). Liquid funds at June 30, 1996 amounted to SEK 420 M, compared
with SEK 1,590 M at December 31, 1995. Net interest-bearing liabilities
increased by SEK 7.9 billion, to SEK 18.9 billion, during the first six
months of 1996. Following the acquisition of Swedish Match shares at a
cost of SEK 8.0 billion in connection to the distribution of the company
to the Volvo shareholders, AB Volvo has a corresponding liability to AB
Fortos.</P>

<P><B>Pharmacia &amp; Upjohn shares held by AB Volvo were divested in the
beginning of the third quarter<BR>
</B>The sale of 50,006,534 shares of Pharmacia &amp; Upjohn, Inc., which
included an overallotment of slightly more than four million shares, was
effected on July 23, 1996. The selling price was fixed at USD 40.00, equal
to SEK 262.82, per share. The buyers comprised a large number of institutional
investors, mainly in Europe and North America.</P>

<P>The Volvo Group's revenue from the sale, after deduction for sales commissions,
amounted to SEK 12.9 billion and the capital gain booked has been estimated
to SEK 7.8 billion. Following the sale, Volvo's holding in Pharmacia &amp;
Upjohn amounts to 3.9% of the share capital in the company.</P>

<P><B>Transfer to Groupwide pension funds<BR>
</B>In July 1996, pension liabilities totaling SEK 4.2 billion for 1995
and earlier years, were transferred from the Volvo Group to one of the
Groupwide pension funds that were established in May 1996.</P>

<P>The interim report covering operations during the first nine months
of 1996 will be released on October 23.</P>

<P>G&ouml;teborg, August 21, 1996<BR>
S&ouml;ren Gyll<BR>
<IMG SRC="/images/gyll.gif" HEIGHT=72 WIDTH=222><BR>
</P>

<P>This report has not been reviewed by AB Volvo's auditiors.<BR>
<BR>
<BR>
<!-- -------- --></P>

<TABLE WIDTH="450" >
<TR>
<TD>
<HR></TD>
</TR>

<TR>
<TD>Source: Six months ended June 30,1996</TD>
</TR>
</TABLE>

<P><BR>
</P>
</BLOCKQUOTE>

<P><A HREF="#top"><IMG SRC="/images/knapp_top.gif" ALT="Top of page" BORDER=0 HEIGHT=14 WIDTH=71></A>
<HR ALIGN=LEFT WIDTH=487>Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A>
[webmaster@www.volvo.se]</P>
</TD>
</TR>
</TABLE></CENTER>

</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-242</DOCNO>
<DOCOLDNO>IA089-000951-B026-92</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/corpinfo/int.rep/six.96/index-sv.html 192.138.110.240 19970208032650 text/html 24326
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 03:26:53 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 24154
Last-modified: Wed, 23 Oct 1996 09:00:52 GMT
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>
<HEAD>
   <TITLE>Det f&ouml;rsta halv&aring;ret 1996</TITLE>
</HEAD>
<BODY BGCOLOR="#FFFFFF">

<CENTER><P><A NAME="top"></A><IMG SRC="/images/placorp.gif" HEIGHT=32 WIDTH=487><BR>
<BR>
</P></CENTER>

<CENTER><TABLE WIDTH="490" >
<TR VALIGN=TOP>
<TD COLSPAN=2 ALIGN=RIGHT><A HREF="../index.html"><IMG SRC="/images/kn_up.gif" ALT="UP" BORDER=0 HEIGHT=25 WIDTH=75></A><A HREF="/index.html"><IMG SRC="/images/knapp_homep.gif" ALT="Home Page" HSPACE=1 BORDER=0 HEIGHT=25 WIDTH=75></A></TD>
</TR>

<TR>
<TD COLSPAN=2>
<HR></TD>
</TR>
</TABLE></CENTER>

<CENTER><TABLE WIDTH="490" >
<TR VALIGN=TOP>
<TD><A HREF="../six.95/index.html"><IMG SRC="/images/knbla.gif" BORDER=0 HEIGHT=14 WIDTH=14></A><FONT SIZE=-1><A HREF="../six.95/index.html">Six
months ended June 30, 1995</A></FONT></TD>

<TD><A HREF="../three.96/index.html"><IMG SRC="/images/knbla.gif" BORDER=0 HEIGHT=14 WIDTH=14></A><FONT SIZE=-1><A HREF="../three.96/index.html">Three
months ended March 31, 1996</A></FONT></TD>
</TR>

<TR VALIGN=TOP>
<TD><A HREF="../nine.95/index.html"><IMG SRC="/images/knbla.gif" BORDER=0 HEIGHT=14 WIDTH=14></A><FONT SIZE=-1><A HREF="../nine.95/index.html">Nine
months ended September 30, 1995</A></FONT></TD>

<TD><A HREF="../six.96/index-sv.html"><IMG SRC="/images/knrod.gif" BORDER=0 HEIGHT=14 WIDTH=14></A><FONT SIZE=-1><A HREF="../six.96/index-sv.html">Det
f&ouml;rsta halv&aring;ret 1996</A></FONT></TD>
</TR>

<TR VALIGN=TOP>
<TD><A HREF="../report.95/index.html"><IMG SRC="/images/knbla.gif" BORDER=0 HEIGHT=14 WIDTH=14></A><FONT SIZE=-1><A HREF="../report.95/index.html">Report
on 1995 operations</A></FONT></TD>

	<TD><A	HREF="../nine.96/index.html"><img WIDTH=14 HEIGHT=14 BORDER=0 
	src="/images/knbla.gif">
	<FONT SIZE=2> Nine months ended September 30, 1996</FONT></TD>
</TR>
</TABLE></CENTER>

<CENTER><TABLE WIDTH="490" >
<TR>
<TD>
<HR ALIGN=LEFT WIDTH=487><!-- -------- -->
<BLOCKQUOTE>
<P><BR>
<BR>
<FONT SIZE=+3>Det f&ouml;rsta halv&aring;ret 1996<BR>
<BR>
<A HREF="#comments"><IMG SRC="/images/knbla.gif" BORDER=0 HEIGHT=14 WIDTH=14 ALIGN=LEFT></A></FONT><FONT SIZE=+1><A HREF="#comments">Koncernchefens
kommentar<BR>
<BR>
<A HREF="#six"><IMG SRC="/images/knbla.gif" BORDER=0 HEIGHT=14 WIDTH=14 ALIGN=LEFT></A></A><A HREF="#six">Det
f&ouml;rsta halv&aring;ret 1996</A></FONT><BR>
<BR>
</P>

<BLOCKQUOTE>
<P><A HREF="table-sv.html"><IMG SRC="/images/knbla.gif" BORDER=0 HEIGHT=14 WIDTH=14 ALIGN=LEFT></A><FONT SIZE=+1><A HREF="table-sv.html">Tabeller<BR>
<BR>
<A HREF="diagram-sv.html"><IMG SRC="/images/knbla.gif" BORDER=0 HEIGHT=14 WIDTH=14 ALIGN=LEFT></A></A><A HREF="diagram-sv.html">Diagram</A></FONT><BR>
<BR>
</P>
</BLOCKQUOTE>

<P><BR>
<A NAME="ref0"></A><BR>

<HR ALIGN=LEFT WIDTH=447><BR>
<BR>
<FONT SIZE=+1>Volvokoncernens f&ouml;rs&auml;ljning var i stort sett of&ouml;r&auml;ndrad,
justerat f&ouml;r avyttringar och f&ouml;rv&auml;rv samt valutakurseffekter.<BR>
<BR>
Fortsatt h&ouml;ga kostnader f&ouml;r produkt- och marknadsutveckling,
samt introduktion av nya produkter medf&ouml;rde att resultatet f&ouml;r
fordonsr&ouml;relsen var avsev&auml;rt l&auml;gre &auml;n motsvarande period
1995. D&auml;rtill kommer vikande marknader och l&ouml;nsamhet f&ouml;r
Volvo Lastvagnar i Nord- och Sydamerika.<BR>
<BR>
Personbilsr&ouml;relsen redovisade vinst efter de tv&aring; senaste kvartalens
f&ouml;rluster.<BR>
<BR>
Ett positivt r&auml;ntenetto om 633 Mkr och vinst vid f&ouml;rs&auml;ljning
av aktier om 453 Mkr bidrog till ett nettoresultat i niv&aring; med f&ouml;reg&aring;ende
&aring;r.</FONT></P>

<P><FONT SIZE=+1>Swedish Match delades ut till Volvos aktie&auml;gare i
maj och merparten av Volvos aktieinnehav i Pharmacia &amp; Upjohn avyttrades
i juli.<BR>
<BR>
</FONT>(se tabell: <A HREF="tab0-sv.html">Det f&ouml;rsta halv&aring;ret
1996</A>)<BR>
<BR>
</P>
</BLOCKQUOTE>
</TD>
</TR>
</TABLE></CENTER>

<CENTER><TABLE WIDTH="490" >
<TR>
<TD>
<BLOCKQUOTE>
<P>
<HR ALIGN=LEFT WIDTH=447><BR>
<BR>
<BR>
<BR>
</P>

<P><A NAME="refdia1"></A><A NAME="comments"></A><FONT SIZE=+2>Koncernchefens
kommentar<BR>
<BR>
</FONT><FONT SIZE=+3>V</FONT>olvokoncernens strukturella och industriella
omdaning forts&auml;tter. Koncentrationen till fordonsr&ouml;relsen &auml;r,
efter utdelningen av Swedish Match och f&ouml;rs&auml;ljningen av merparten
av aktieinnehavet i Pharmacia &amp; Upjohn, i det n&auml;rmaste slutf&ouml;rd.
Samtidigt befinner sig koncernens tv&aring; st&ouml;rsta aff&auml;rsomr&aring;den,
Volvo Personvagnar och Volvo Lastvagnar, i en period av offensivt f&ouml;r&auml;ndringsarbete.</P>

<P>Produkt- och marknadsutveckling, introduktion av nya produkter i kombination
med vikande efterfr&aring;gan och l&ouml;nsamhet i Nord- och Sydamerika
f&ouml;r Volvo Lastvagnar har medf&ouml;rt att resultatet f&ouml;r fordonsr&ouml;relsen
&auml;r avsev&auml;rt l&auml;gre &auml;n motsvarande period 1995.</P>

<P>Volvo Lastvagnar beh&aring;ller sitt starka f&auml;ste p&aring; den
v&auml;xande europamarknaden. En starkt negativ och oacceptabel resultatutveckling
i Nordamerika f&ouml;rklaras av en vikande marknad och alltf&ouml;r h&ouml;ga
r&ouml;relsekostnader i kombination med kostnader f&ouml;r den strategiska
satsningen p&aring; ett nytt produktprogram utg&aring;ende fr&aring;n FH-konceptet.
Ett kraftfullt &aring;tg&auml;rdsprogram har inletts vars effekter dock
inte bed&ouml;ms att helt kompensera den h&ouml;ga kostnadsniv&aring;n
under 1996.</P>

<P>Inom Volvo Personvagnar har de tv&aring; senaste kvartalens f&ouml;rluster
f&ouml;rbytts i vinst, om &auml;n p&aring; en l&aring;g niv&aring;. F&ouml;rb&auml;ttringen
sker i takt med att de kostnadss&auml;nkande &aring;tg&auml;rderna f&aring;r
effekt. Efterfr&aring;gan p&aring; Volvo S40/V40 &auml;r god. Introduktionsproblemen
med l&aring;nga leveranstider f&ouml;rb&auml;ttras succesivt. Resultatm&auml;ssigt
f&ouml;rv&auml;ntas Volvo S40/V40 f&aring; genomslag f&ouml;rst under andra
halv&aring;ret 1996.</P>

<P>Volvo Construction Equipment redovisar ett vikande men fortsatt gott
resultat med en r&ouml;relsemarginal p&aring; 9,7%, trots en s&auml;mre
marknadsutveckling och h&aring;rdnande konkurrens.</P>

<P>Sammantaget inneb&auml;r resultatet f&ouml;r det f&ouml;rsta halv&aring;ret
1996 att uppm&auml;rksamheten p&aring; kostnadsutvecklingen i koncernens
alla enheter sk&auml;rps ytterligare. Parallellt forts&auml;tter arbetet
med att genom ett h&ouml;gt tempo i produktutveckling ytterligare st&auml;rka
koncernens st&auml;llning som producent av transportmedel f&ouml;r marknadens
mest kr&auml;vande kundsegment.<BR>
<A NAME="refdia1"></A><BR>
</P>
</BLOCKQUOTE>
</TD>
</TR>
</TABLE></CENTER>

<CENTER><TABLE WIDTH="490" >
<TR>
<TD>
<BLOCKQUOTE>
<P><A NAME="ref1"></A>
<HR ALIGN=LEFT WIDTH=447><BR>
<BR>
<BR>
<BR>
<!-- Det f&ouml;rsta kvartalet 1996 --><A NAME="six"></A><FONT SIZE=+2>Det
f&ouml;rsta halv&aring;ret 1996<BR>
<BR>
<BR>
</FONT>(se diagram: <A HREF="dia1-sv.html">R&ouml;relseresultat f&ouml;re
poster av eng&aring;ngskarakt&auml;r</A>)<BR 
<BR>
</P>

<P><B>Volvokoncernens f&ouml;rs&auml;ljning</B> det f&ouml;rsta halv&aring;ret
1996 uppgick till 78.059 Mkr mot 85.134 Mkr det f&ouml;rsta halv&aring;ret
1995. F&ouml;r fordonsr&ouml;relsen, dvs Volvokoncernen exklusive Fortos,
sj&ouml;nk f&ouml;rs&auml;ljningen med 9% exklusive f&ouml;rv&auml;rvade
enheter. Justerat &auml;ven f&ouml;r valutakurseffekter var minskningen
1%.</P>

<P>Under v&aring;ren utdelades samtliga aktier i Swedish Match till Volvos
aktie&auml;gare. Fr o m den 1 april ing&aring;r inte Swedish Match i Volvos
redovisning och huvuddelen av hel&auml;gda verksamheter inom Fortos har
d&auml;rmed avyttrats.<A NAME="ref6"></A></P>

<P><B>R&ouml;relseresultatet f&ouml;re poster av eng&aring;ngskarakt&auml;r</B>
15.561 Mkr, var 3.280 Mkr l&auml;gre &auml;n f&ouml;reg&aring;ende &aring;r.
Resultatnedg&aring;ngen h&auml;nf&ouml;r sig fr&auml;mst till Volvo Lastvagnar
(&shy;1.864 Mkr) och Volvo Personvagnar (&shy;1.393 Mkr) pga minskade f&ouml;rs&auml;ljningsvolymer,
l&auml;gre kapacitetsutnyttjande i produktionen samt &ouml;kade kostnader
inom f&ouml;rs&auml;ljningsorganisation och produktutveckling. Genom terminss&auml;kringar
erh&ouml;lls positiva valutaeffekter, trots en st&auml;rkt svensk krona
och r&ouml;relseresultatet p&aring;verkades positivt med ca 200 Mkr j&auml;mf&ouml;rt
med det f&ouml;rsta halv&aring;ret 1995.</P>

<P>Volvo Construction Equipment som ing&aring;r i Volvokoncernen sedan
30 juni 1995 tillf&ouml;rde 651 Mkr till r&ouml;relseresultatet. Koncernens
r&ouml;relseresultat reducerades med 433 Mkr genom avyttring av verksamheter,
fr&auml;ms Swedish Match, Procordia och Abba Seafood.<BR>
<BR>
<A NAME="ref2"></A><A NAME="ref3"></A>(se tabell: <A HREF="tab1-sv.html">Koncernens
resultatr&auml;kning</A>)<BR>
</P>

<P><B>Resultatandelar i intressebolag</B> minskade till 200 Mkr j&auml;mf&ouml;rt
med 1.023 Mkr det f&ouml;rsta halv&aring;ret 1995. I 1996 &aring;rs resultat
ing&aring;r vinst vid f&ouml;rs&auml;ljning av VOAC Hydraulics med 352
Mkr. Volvos andel av f&ouml;rlusten i NedCar uppgick till 249 Mkr (227).
Det svaga resultatet i NedCar beror p&aring; ink&ouml;rningskostnader f&ouml;r
Volvo S40/V40 och l&auml;gre volymer av Volvo 400 samt h&ouml;ga produktutvecklingskostnader.
I 1995 &aring;rs resultatandel ingick Volvo Construction Equipment och
Pharmacia, vilka inte l&auml;ngre redovisas enligt kapitalandelsmetoden,
med 478 Mkr respektive 600 Mkr.</P>

<P><B>Utdelning p&aring; aktier</B> nkluderar Pharmacia &amp; Upjohn, Inc.,
256 Mkr, SAS Sverige AB, 91 Mkr, Investment AB Bure, 31 Mkr samt Protorp
F&ouml;rvaltnings AB, 33 Mkr.</P>

<P><B>Resultat vid f&ouml;rs&auml;ljning av aktier</B> avser fr&auml;mst
utf&ouml;rs&auml;ljningen av samtliga aktier i Investment AB Bure, vilken
medf&ouml;rde en vinst om 394 Mkr.<A NAME="ref8"></A></P>

<P><B>R&auml;ntenettot,</B> 633 Mkr (150) visade en mycket positiv utveckling
p&aring; grund av Volvokoncernens st&auml;rkta finansiella st&auml;llning
och ett gott resultat inom Volvo Group Finance.</P>

<P><B>Skattekostnaden</B> avs&aring;g huvudsakligen l&ouml;pande skatt
i utl&auml;ndska dotterbolag samt verksamheter under avveckling</P>

<P><B>Koncernens tillg&aring;ngar</B> minskade under f&ouml;rsta halv&aring;ret
1996 med 3,3 miljarder kronor. Exklusive valutakursf&ouml;r&auml;ndringar
var minskningen 0,8 miljarder kronor. F&ouml;r&auml;ndringar i koncernens
sammans&auml;ttning, fr&auml;mst utdelningen av Swedish Match till AB Volvos
aktie&auml;gare, minskade balansomslutningen med 8,6 miljarder kronor.
Koncernens tillg&aring;ngar &ouml;kade genom investeringar i fastigheter,
maskiner och inventarier, &ouml;kad s&auml;ljfinansieringsverksamhet samt
&ouml;kat varulager fr&auml;mst inom Volvo Personvagnar.<BR>
<BR>
(se tabeller: <A HREF="tab3-sv.html">Koncernens balansr&auml;kning i sammandrag</A>
och <A HREF="tab2-sv.html">Nyckeltal</A>)<BR>
<BR>
</P>

<P><B>Investeringar i anl&auml;ggningar</B> uppgick till 3,9 miljarder
kronor (2,4) varav 2,0 miljarder inom Volvo Personvagnar och 1,4 inom Volvo
Lastvagnar. Investeringar i leasing- och tj&auml;nstefordon uppgick till
1,6 miljarder kronor (1,5).</P>

<P><B>Netto finansiella tillg&aring;ngar</B> &ouml;kade fr&aring;n 1,2
miljarder kronor vid utg&aring;ngen av 1995 till 1,4 miljarder kronor.</P>

<P><B>Eget kapital</B> minskade med 3,6 miljarder kronor. Utdelningen av
aktierna i Swedish Match och kontantutdelning till AB Volvos aktie&auml;gare
minskade eget kapital med 4,2 miljarder kronor respektive 1,9 miljarder
kronor. Periodens nettoresultat tillf&ouml;rde 2,8 miljarder kronor.<BR>
<BR>
(se tabell: <A HREF="tab6-sv.html">Finansieringsanalys</A>)<BR>
<BR>
<BR>
<BR>
<BR>
<A NAME="ref8"></A><B>F&ouml;rs&auml;ljning och r&ouml;relseresultat per
aff&auml;rsomr&aring;de<BR>
<BR>
</B>(se tabell: <A HREF="tab8-sv.html">F&ouml;rs&auml;ljning</A>)<BR>
<BR>
<A NAME="refdia2"></A><A NAME="car"></A></P>

<P><B>Volvo Personvagnar<BR>
</B>Totalmarknaden f&ouml;r personbilar &ouml;kade med drygt 2% under f&ouml;rsta
halv&aring;ret 1996 j&auml;mf&ouml;rt med motsvarande period f&ouml;reg&aring;ende
&aring;r. Europa visade en uppg&aring;ng med drygt 5% och Nordamerika med
drygt 1%. I Japan var utvecklingen av totalmarknaden negativ och personbilsmarknaden
minskade med n&auml;rmare 1%.</P>

<P>F&ouml;rs&auml;ljningsv&auml;rdet f&ouml;r Volvo Personvagnar sj&ouml;nk
med 7%, till 39.828 Mkr. Justerat f&ouml;r valutakursf&ouml;r&auml;ndringar
&ouml;kade f&ouml;rs&auml;ljningen med 2%, vilket beror p&aring; en mer
f&ouml;rdelaktig produkt- och marknadsmix. Antalet fakturerade personbilar
minskade med 12% och totalt s&aring;ldes 174.570 (198.790) bilar. Volvo
850 uppvisade en god f&ouml;rs&auml;ljningsutveckling, medan Volvo 940/960
och Volvo 400 serien tappade i volym. Volvo 900 serien tappar fr&auml;msti
USA d&auml;r f&ouml;rs&auml;ljningen av 940 upph&ouml;rde i och med 1996
&aring;rs modellbyte.</P>

<P>Ordering&aring;ngen i mellanbilsklassen &ouml;kade med totalt 11% genom
lansering av Volvo S40/V40. P&aring; grund av leveransf&ouml;rseningar
under v&aring;ren har inte Volvo S40/V40 kunnat levereras i planerad omfattning
och tillfullo kompensera f&ouml;rs&auml;ljningsbortfallet av Volvo 400
serien.</P>

<P>I Europa minskade Volvo Personvagnars registreringar och marknadsandelar
fr&auml;mst i Sverige, Storbritannien och Italien. I Nordamerika var Volvos
registreringar i det n&auml;rmaste of&ouml;r&auml;ndrade. P&aring; Volvos
&ouml;vriga marknader &ouml;kade f&ouml;rs&auml;ljningen sammantaget. Bl
a i Japan fortsatte den positiva f&ouml;rs&auml;ljningsutvecklingen och
antalet s&aring;lda bilar uppgick till 12.000, en uppg&aring;ng med 32%.</P>

<P>R&ouml;relseresultatet f&ouml;r det f&ouml;rsta halv&aring;ret 1996
var 187 Mkr (1.580). Resultatf&ouml;rs&auml;mringen f&ouml;rklaras fr&auml;mst
av minskade f&ouml;rs&auml;ljningsvolymer f&ouml;r Volvo 900serien och
400serien samt h&ouml;gre produktutvecklingskostnader, vilket till viss
del kompenserades av positiva valutaeffekter, efter beaktande av terminss&auml;kringar.
R&ouml;relsemarginalen sj&ouml;nk till 0,5% (3,7). Dock redovisas en resultatf&ouml;rb&auml;ttring
j&auml;mf&ouml;rt med f&ouml;rsta kvartalet 1996 med 569 Mkr.</P>

<P>F&ouml;r att f&ouml;rst&auml;rka Volvo Personvagnars aff&auml;r i Sydostasien
har ett nytt regionalt f&ouml;rs&auml;ljningsbolag bildats, Volvo Car Asia
Pacific, med huvudkontor i Singapore.<BR>
<BR>
(se diagram: <A HREF="dia2-sv.html">R&ouml;relseresultat Volvo Personvagnar</A>)<BR>
<BR>
<A NAME="refdia3"></A><A NAME="truck"></A></P>

<P><B>Volvo Lastvagnar<BR>
</B>V&auml;rldsmarknaden f&ouml;r tunga lastbilar sj&ouml;nk under f&ouml;rsta
halv&aring;ret 1996 j&auml;mf&ouml;rt med samma period f&ouml;reg&aring;ende
&aring;r. I Nord- och Sydamerika f&ouml;rsvagades totalmarknaden p&aring;tagligt
medan totalmarknaden i Europa f&ouml;rst&auml;rktes.</P>

<P>Volvo Lastvagnars leveranser av medeltunga och tunga lastbilar uppgick
under &aring;rets f&ouml;rsta tv&aring; kvartal till 33.240 enheter (38.340)
vilket &auml;r en minskning med 13% j&auml;mf&ouml;rt med f&ouml;rsta halv&aring;ret
1995. I Europa &ouml;kade leveranserna med 13%. Marknadsandelen i tunga
klassen var d&auml;r n&aring;got l&auml;gre men Volvo var &aring;ter n&auml;st
st&ouml;rsta m&auml;rke p&aring; marknaden. I Nordamerika minskade leveranserna
med 31% och marknadsandelen i tunga klassen sj&ouml;nk.</P>

<P>Orderboken var vid halv&aring;rsskiftet 46% l&auml;gre &auml;n vid samma
tidpunkt ett &aring;r tidigare, prim&auml;rt till f&ouml;ljd av den vikande
ordering&aring;ngen i Nord- och Sydamerika.</P>

<P>Volvo Lastvagnars f&ouml;rs&auml;ljning uppgick under f&ouml;rsta halv&aring;ret
1996 till 23.112 Mkr, en minskning med 10% j&auml;mf&ouml;rt med samma
tid 1995. Justerat f&ouml;r valutakursf&ouml;r&auml;ndringar var minskningen
3%. R&ouml;relseresultatet uppgick till 1.078 Mkr (2.942 Mkr). Vinsten
i Europa var tillfredsst&auml;llande men l&auml;gre &auml;n samma tid f&ouml;reg&aring;ende
&aring;r. Verksamheten i Nordamerika gav ett betydande underskott fr&auml;mst
till f&ouml;ljd av minskade f&ouml;rs&auml;ljningsvolymer och pressade
marginaler. Ett omstruktureringsprogram p&aring;g&aring;r, men &auml;ven
under andra halv&aring;ret f&ouml;rutses en v&auml;sentlig f&ouml;rlust.
I Latinamerika var resultatet avsev&auml;rt l&auml;gre &auml;n f&ouml;reg&aring;ende
&aring;r. Volvo Lastvagnars resultat har vidare belastats med &ouml;kade
kostnader f&ouml;r produkt- och marknadsutveckling.</P>

<P>R&ouml;relsemariginalen uppgick till 4,7% (11,4).<BR>
<BR>
(se diagram: <A HREF="dia3-sv.html">R&ouml;relseresultat Volvo Lastvagnar</A>)<BR>
<BR>
<A NAME="bus"></A></P>

<P><B>Volvo Bussar<BR>
</B>Volvo Bussar levererade 3.630 (2.860) bussar och busschassier under
f&ouml;rsta halv&aring;ret 1996, varav det nyf&ouml;rv&auml;rvade Pr&eacute;vost
Car Inc. i vilket Volvo Bussar &auml;ger 51%, svarade f&ouml;r 330 bussar.
Volvo Bussars marknadsandel i Europa &ouml;kade till 20% (19) enligt prelimin&auml;r
marknadsstatistik. Orderboken var vid utg&aring;ngen av andra halv&aring;ret
1996 ca 7% h&ouml;gre &auml;n motsvarande tid 1995.</P>

<P>F&ouml;rs&auml;ljningsv&auml;rdet minskade med 2%, exklusive f&ouml;rv&auml;rvet
av Pr&eacute;vost. Det operativa resultatet uppgick till 134 Mkr (164).
R&ouml;relsemarginalen sj&ouml;nk till 3,2% (4,6). Orsaken till det l&auml;gre
resultatet &auml;r &ouml;kad konkurrens och l&auml;gre bruttovinstmarginaler.<A NAME="vce"></A></P>

<P><B>Volvo Construction Equipment<BR>
</B>Efterfr&aring;gan inom flera marknadsomr&aring;den, med Nordamerika
och Tyskland som de mest v&auml;sentliga, var fortsatt l&auml;gre &auml;n
motsvarande period f&ouml;reg&aring;ende &aring;r vilket totalt sett medf&ouml;rde
en l&auml;gre f&ouml;rs&auml;ljningsvolym. F&ouml;rs&auml;ljningsv&auml;rdet
uppgick till 6.695 Mkr (6.966).</P>

<P>Resultatet var fortsatt starkt, men p&aring; en l&auml;gre niv&aring;
&auml;n motsvarande period f&ouml;reg&aring;ende &aring;r. Effekten av
l&auml;gre volymer motverkades delvis av f&ouml;rm&aring;nligare produktmix,
medan h&ouml;gre utvecklingskostnader i f&ouml;rening med of&ouml;rm&aring;nligare
valutakurser fick genomslag i r&ouml;relseresultatet vilket uppgick till
651 Mkr (990). R&ouml;relsemarginalen var 9,7% (14,2).<A NAME="penta"></A></P>

<P><B>Volvo Penta<BR>
</B>F&ouml;rs&auml;ljningsv&auml;rdet f&ouml;r Volvo Penta minskade med
3%. Valutakurs-utvecklingen var ogynnsam, medan f&ouml;rs&auml;ljningsvolymerna
i stort sett var of&ouml;r&auml;ndrade.</P>

<P>R&ouml;relseresultatet uppgick till 57 Mkr vilket var 70 Mkr l&auml;gre
&auml;n f&ouml;reg&aring;ende &aring;r. Valutakursutvecklingen och &ouml;kade
kostnader kunde inte kompenseras genom prish&ouml;jningar.<A NAME="aero"></A></P>

<P><B>Volvo Aero<BR>
</B>Marknaden f&ouml;r stora trafikflygplan var fortsatt stabil och ordering&aring;ngen
stark f&ouml;r Volvo Aeros civila flygverksamhet. Efterfr&aring;gan p&aring;
reservdelar till civila flygmotorer var ocks&aring; mycket stor.</P>

<P>Under f&ouml;rsta halv&aring;ret levererades &aring;tta JAS 39 Gripen
till det Svenska Flygvapnet. Sammanlagt har 21 flygplan levererats sedan
serieleveranserna p&aring;b&ouml;rjades 1993. Den 9 juni introducerades
JAS 39 officiellt vid en ceremoni p&aring; Skaraborgs flygflottilj F7.
En offert p&aring; delserie 3 &ouml;verl&auml;mnades av Industrigruppen
JAS till F&ouml;rsvarets Materielverk.</P>

<P>Haveriet i samband med premi&auml;ruppskjutningen av rymdraketen Ariane
5, d&auml;r Volvo Aero medverkar tillsammans med andra europeiska f&ouml;retag,
orsakades av ett fel i styrsystemets mjukvara, vilket ligger utanf&ouml;r
Volvo Aeros ansvar. Programmet forts&auml;tter med n&auml;sta uppskjutning
planerad till v&aring;ren 1997.</P>

<P>Volvo Aeros r&ouml;relseresultatet uppgick till 90 Mkr (91). R&ouml;relsemarginalen
sj&ouml;nk till 4,6% (5,3).</P>

<P>Under v&aring;ren slutf&ouml;rde AVC Intressenter AB - ett holdingbolag
till lika delar &auml;gt av - Volvo Aero och Atlas Copco f&ouml;rs&auml;ljningen
av VOAC Hydraulics. K&ouml;pare var det amerikanska f&ouml;retaget Parker
Hannifin.<A NAME="ref9"></A><A NAME="ref4"></A><BR>
<BR>
<A NAME="ref7"></A></P>

<P><B>Verksamheter under avveckling - utdelning av Swedish Match<BR>
</B>I enlighet med beslut p&aring; Volvos bolagsst&auml;mma den 24 april
delades Swedish Match ut till Volvos aktie&auml;gare den 13 maj 1996. F&ouml;retaget
b&ouml;rsnoterades p&aring; O-listan vid Stockholms Fondb&ouml;rs och p&aring;
NASDAQ i USA den 15 maj.</P>

<P>Under andra kvartalet 1996 avyttrades aktieinnehaven i Investment AB
Bure och Spira AB. F&ouml;rs&auml;ljningsint&auml;kterna uppgick till 525
Mkr respektive 83 Mkr.</P>

<P><B>Anst&auml;llda<BR>
</B>Antalet anst&auml;llda i slutet av f&ouml;rsta halv&aring;ret var 71.250
personer, en minskning med 7.800 personer sedan &aring;rsskiftet. Avvecklingen
av Volvos engagemang i Swedish Match innebar att 7.000 personer l&auml;mnade
Volvokoncernen.</P>

<P><B>Moderbolaget<BR>
</B>AB Volvos int&auml;kter under f&ouml;rsta halv&aring;ret 1996 var 227
Mkr (223). Vinst f&ouml;re skatter var 853 Mkr (f&ouml;rlust 1.323). I
resultatet ing&aring;r utdelningar fr&aring;n dotterbolag med 719 Mkr (1.734),
utdelningar fr&aring;n utomst&aring;ende med 60 Mkr (112), valutakursvinster
p&aring; l&aring;n med 640 Mkr (f&ouml;rlust 860) samt ett negativt r&auml;ntenetto
om 344 Mkr (296). I f&ouml;reg&aring;ende &aring;rs v&auml;rde ing&aring;r
poster av eng&aring;ngskarakt&auml;r, 1.817 Mkr, avseende nedskrivning
av f&ouml;rv&auml;rvade aktier i Volvo Construction Equipment Corporation.
Investeringar i anl&auml;ggningar uppgick till 17 Mkr (6). De likvida medlen
var vid utg&aring;ngen av perioden 420 Mkr mot 1.590 Mkr vid &aring;rsskiftet.
Under f&ouml;rsta halv&aring;ret &ouml;kade den r&auml;nteb&auml;rande
nettoskulden med 7,9 miljarder till 18,9 miljarder kronor. Efter f&ouml;rv&auml;rvet
av aktierna i Swedish Match f&ouml;r 8,0 miljarder, i samband med utdelningen
av bolaget till Volvos aktie&auml;gare, har AB Volvo motsvarande skuld
till AB Fortos.</P>

<P><B>AB Volvos aktieinnehav i Pharmacia &amp; Upjohn avyttrades i b&ouml;rjan
av tredje kvartalet 1996<BR>
</B>Den 23 juli 1996 genomf&ouml;rdes f&ouml;rs&auml;ljningen av 50.006.534
aktier i Pharmacia &amp; Upjohn, Inc., vilket inkluderar en &ouml;verteckningsoption
om drygt 4 miljoner aktier. F&ouml;rs&auml;ljningspriset fastst&auml;lldes
till USD 40:00 eller 262:82 kronor per aktie, och k&ouml;parna utgjordes
av ett stort antal institutionella placerare i fr&auml;mst Europa och Nordamerika.</P>

<P>Volvokoncernens f&ouml;rs&auml;ljningsint&auml;kter efter avdrag f&ouml;r
f&ouml;rs&auml;ljningsprovision uppgick till 12,9 miljarder kronor och
den bokf&ouml;ringsm&auml;ssiga realisationsvinsten har ber&auml;knats
till 7,8 miljarder kronor. Efter utf&ouml;rs&auml;ljningen uppg&aring;r
Volvos aktieinnehav i Pharmacia &amp; Upjohn till 3,9% av aktiekapitalet.</P>

<P><BR>
<B>&Ouml;verf&ouml;ring till koncerngemensamma pensionsstiftelser<BR>
</B>I juli 1996 &ouml;verf&ouml;rdes pensionsskulder, f&ouml;r &aring;r
1995 och tidigare, om sammanlagt 4,2 miljarder kronor fr&aring;n Volvokoncernen
till en av de koncerngemensamma pensionstiftelser som bildades i maj 1996.<BR>
</P>

<P>Rapport &ouml;ver de f&ouml;rsta nio m&aring;naderna 1996 kommer att
l&auml;mnas den 23 oktober.</P>

<P>G&ouml;teborg den 21 augusti 1996<BR>
<BR>
<IMG SRC="/images/gyll.gif" HEIGHT=72 WIDTH=222></P>

<P>S&ouml;ren Gyll</P>

<P>VD och koncernchef</P>

<P>Denna rapport har inte varit f&ouml;rem&aring;l f&ouml;r s&auml;rskild
granskning av AB Volvos revisorer.<BR>
<BR>
<BR>
<!-- -------- --></P>

<TABLE WIDTH="450" >
<TR>
<TD>
<HR></TD>
</TR>

<TR>
<TD>K&auml;lla: Det f&ouml;rsta halv&aring;ret 1996</TD>
</TR>
</TABLE>

<P><BR>
</P>
</BLOCKQUOTE>

<P><A HREF="#top"><IMG SRC="/images/knapp_top.gif" ALT="Top of page" BORDER=0 HEIGHT=14 WIDTH=71></A>
<HR ALIGN=LEFT WIDTH=487>Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A>
[webmaster@www.volvo.se]</P>
</TD>
</TR>
</TABLE></CENTER>

</BODY>
</HTML>
</DOC>
<DOC>
<DOCNO>WT08-B13-243</DOCNO>
<DOCOLDNO>IA089-000951-B026-137</DOCOLDNO>
<DOCHDR>
http://www.volvo.se:80/corpinfo/int.rep/nine.96/index.html 192.138.110.240 19970208032705 text/html 22189
HTTP/1.0 200 OK
Date: Sat, 08 Feb 1997 03:27:12 GMT
Server: Apache/1.1.3
Content-type: text/html
Content-length: 22017
Last-modified: Wed, 23 Oct 1996 09:15:37 GMT
</DOCHDR>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2//EN">
<HTML>
<HEAD>
   <TITLE>Nine months ended September 30, 1996</TITLE>
   <META NAME="GENERATOR" CONTENT="User-Agent: Mozilla/3.0Gold (Macintosh; I; PPC)">
</HEAD>
<BODY BGCOLOR="#FFFFFF">

<CENTER><P><A NAME="top"></A><IMG SRC="/images/placorp.gif" HEIGHT=32 WIDTH=487><BR>
<BR>
</P></CENTER>

<CENTER><TABLE WIDTH="490" >
<TR VALIGN=TOP>
<TD COLSPAN=2 ALIGN=RIGHT><A HREF="../index.html"><IMG SRC="/images/kn_up.gif" ALT="UP" BORDER=0 HEIGHT=25 WIDTH=75></A><A HREF="/index.html"><IMG SRC="/images/knapp_homep.gif" ALT="Home Page" HSPACE=1 BORDER=0 HEIGHT=25 WIDTH=75></A></TD>
</TR>

<TR>
<TD COLSPAN=2>
<HR></TD>
</TR>
</TABLE></CENTER>

<CENTER><TABLE WIDTH="490" >
<TR VALIGN=TOP>
<TD><A HREF="../six.95/index.html"><IMG SRC="/images/knbla.gif" BORDER=0 HEIGHT=14 WIDTH=14></A><FONT SIZE=-1><A HREF="../six.95/index.html">Six
months ended June 30, 1995</A></FONT></TD>

<TD><A HREF="../three.96/index.html"><IMG SRC="/images/knbla.gif" BORDER=0 HEIGHT=14 WIDTH=14></A><FONT SIZE=-1><A HREF="../three.96/index.html">Three
months ended March 31, 1996</A></FONT></TD>
</TR>

<TR VALIGN=TOP>
<TD><A HREF="../nine.95/index.html"><IMG SRC="/images/knbla.gif" BORDER=0 HEIGHT=14 WIDTH=14></A><FONT SIZE=-1><A HREF="../nine.95/index.html">Nine
months ended September 30, 1995</A></FONT></TD>

<TD><A HREF="../six.96/index.html"><IMG SRC="/images/knbla.gif" BORDER=0 HEIGHT=14 WIDTH=14></A><FONT SIZE=-1><A HREF="../six.96/index.html">Six
months ended June 30,1996</A></FONT></TD>
</TR>

<TR VALIGN=TOP>
<TD><A HREF="../report.95/index.html"><IMG SRC="/images/knbla.gif" BORDER=0 HEIGHT=14 WIDTH=14></A><FONT SIZE=-1><A HREF="../report.95/index.html">Report
on 1995 operations</A></FONT></TD>

<TD><A HREF="../nine.96/index.html"><IMG SRC="/images/knrod.gif" BORDER=0 HEIGHT=14 WIDTH=14></A><A HREF="../nine.96/index.html">
<FONT SIZE=-1>Nine months ended September 30, 1996</FONT></A></TD>
</TR>
</TABLE></CENTER>

<CENTER><TABLE WIDTH="490" >
<TR>
<TD>
<HR ALIGN=LEFT WIDTH=487><!-- -------- -->
<BLOCKQUOTE>
<P><BR>
<BR>
<FONT SIZE=+3>Nine months ended September 30, 1996<BR>
<BR>
<A HREF="#comments"><IMG SRC="/images/knbla.gif" BORDER=0 HEIGHT=14 WIDTH=14></A></FONT><FONT SIZE=+1><A HREF="#comments">Comment
by the Chief Executive Officer<BR>
<BR>
<A HREF="#six"><IMG SRC="/images/knbla.gif" BORDER=0 HEIGHT=14 WIDTH=14></A></A><A HREF="#six">Nine
months ended September 30, 1996</A></FONT><BR>
<BR>
<BR>
</P>

<BLOCKQUOTE>
<P><A HREF="table.html"><IMG SRC="/images/knbla.gif" BORDER=0 HEIGHT=14 WIDTH=14></A><FONT SIZE=+1><A HREF="table.html">Tables<BR>
<BR>
<A HREF="diagram.html"><IMG SRC="/images/knbla.gif" BORDER=0 HEIGHT=14 WIDTH=14></A></A><A HREF="diagram.html">Graphs</A></FONT><BR>
<BR>
</P>
</BLOCKQUOTE>

<P><BR>
<A NAME="ref0"></A><BR>

<HR ALIGN=LEFT WIDTH=447><BR>
<BR>
</P>

<P><FONT SIZE=+1>Operating income in the automotive operations declined
from SEK 6,907 M to SEK 2,160 M.</FONT></P>

<P><FONT SIZE=+1>Volvo Trucks reported a loss for the third quarter, which
is attributable to the operations in North America.</FONT></P>

<P><FONT SIZE=+1>Consolidated net income of SEK 10,668 M further strengthens
Volvo's financial position.</FONT></P>

<P><FONT SIZE=+1>The sale of shares in Pharmacia &amp; Upjohn resulted
in a capital gain of SEK 7.8 billion and an increase in net financial assets
of SEK 12.9 billion.</FONT></P>

<P><FONT SIZE=+1>Important product introductions including the Volvo C70
coup&eacute; and the Volvo VN for the American truck market<BR>
<BR>
</FONT>(see table: <A HREF="tab0.html">Nine months ended September 30,
1996</A>)<BR>
<BR>
<BR>
<BR>

<HR ALIGN=LEFT WIDTH=447><BR>
</P>

<P><A NAME="comments"></A><FONT SIZE=+2>Comment by the Chief Executive
Officer<BR>
<BR>
</FONT><FONT SIZE=+3>C</FONT>onsolidated net income for the period of SEK
10,7 billion represents a strong improvement in the Group's financial position.
The transformation into solely a transport vehicle group continued. The
sale of most of the shareholding in Pharmacia &amp; Upjohn yielded proceeds
of SEK 12.9 billion and a capital gain of SEK 7.8 billion. The concentration
process is thereby nearly completed.</P>

<P>Extensive efforts are under way in the Group within product development
and in the production, marketing and distribution channels, measures which
will create sustained profitability in line with Volvo's strategy.</P>

<P>Parallel with efforts to secure long-term competitive operations, efforts
are now focusing on rapidly restoring profitability to a satisfactory level.
The very weak operating income for the first nine months of the year was
caused by heavy price competition, an accelerating pace of product renewal
and unacceptably high operating costs in certain operating areas combined
with a significant loss in Volvo's North American truck operations. Cost-reduction
measures are being implemented in all units.</P>

<P>Development in the North American truck operations, illustrates a double
problem, which has not been solved in an acceptable manner: preparation
of the launch of a new product program - Volvo VN - while, concurrently,
in a weak market, maintaining cost efficiency and high activity in work
with the existing product program. The measures now being implemented,
including concentration of production to a single plant, are aimed at creating
an effective and profitable truck business in North America. The severity
of the profitability problem for Volvo Trucks in Brazil was significantly
lower at the end of the period. In Europe, Volvo Trucks maintains a strong
market position and favorable profitability.</P>

<P>Volvo Cars' income level is unsatisfactory, but is developing positively.
This is an effect of the cost rationalization measures implemented and
increased revenues from the Volvo S40 and V40. Exploitation of the initial
investment in the Volvo 850 is continuing with successive additions of
new and more exclusive versions to complement the basic model. The sales
of Volvo S40/V40 are favorable and meet expectations. The Volvo C70, a
coup&eacute; developed in cooperation with TWR was premiered in September
and was exceptionally well received. Sales will begin in spring 1997.</P>

<P>Despite the decline, operating income for Volvo Construction Equipment
was satisfactory considering the weakening in the entire market for construction
equipment in Europe.</P>

<P>Both Volvo Buses and Volvo Penta report unsatisfactory income, while
Volvo Aero develops favorably. </P>

<P>The weak operating income during the period does not reflect the Group's
strategic position. Volvo Cars and Volvo Trucks have very competitive product
programs today.</P>

<P>Based on the strength of high operating economy, safety and comfort,
Volvo Trucks FH series holds a strong market position despite heavy competition.
The product is now being launched globally. The American VN truck, which
was introduced in the autumn was very well received. Volvo FLC for the
European truck market represents a complement in the medium-heavy segment.</P>

<P>In addition to a strong product program, modularized production methods
in Volvo Trucks and Volvo Cars will result in higher efficiency and economies
of scale.</P>

<P>Establishment of a central warehouse in Europe to support after-sales
service and spare parts supply for the commercial vehicles will provide
significant synergy gains and quality improvements. Structural changes
in the car dealer network are being implemented in Europe and North America
as well as an upgrading in the sales channel for trucks and buses in South
America.</P>

<P>The Group's strategic focus of achieving sustained profitability remains
valid. The broadening of Volvo Cars' customer base into new segments and
the continued globalization of Volvo Trucks' operations are necessary for
the balanced growth which the Group seeks. Today, however, the overshadowing
task is to increase productivity and improve cost-efficiency internally.<BR>
<BR>
(see graph: <A HREF="dia1.html">Operating income, before nonrecurring items</A>)<BR 
<BR>
<BR>

<HR ALIGN=LEFT WIDTH=447><BR>
<BR>
<BR>
<BR>
<!-- Nine months ended September 30, 1996 --><A NAME="six"></A><FONT SIZE=+2>Nine
months ended September 30, 1996<BR>
<BR>
<BR>
</FONT><B>Volvo Group sales</B> in the first nine months of 1996 period
amounted to SEK 113,640 M, compared with SEK 129,124 M in the year-earlier
period. Sales attributable to automotive operations decreased by 9%, excluding
acquired units. Adjusted to reflect the effects of foreign exchange movements,
the decrease was 1%.</P>

<P><B>Operating income</B> <B>before nonrecurring items</B> was SEK 2,324
M, which was SEK 5,757 M lower than in the year-earlier period. Lower sales,
depressed prices and higher production and product development costs were
the main reasons for the decline. In addition, SEK 700 M pertaining to
the restructing of the American truck operations was charged against operating
income in the third quarter. Positive currency effects were achieved through
hedging, despite a strong Swedish krona, and operating income was positively
affected by about SEK 600 M compared with the first three quarters of 1995.</P>

<P>The income decline is attributable to Volvo Trucks (SEK 3,612 M), Volvo
Cars (SEK 1,357 M) and divestment of operations, mainly Swedish Match,
Procordia and Abba Seafood (SEK 1,010). Volvo Construction Equipment, which
is consolidated in the Volvo Group from June 30, 1995, contributed SEK
928 M to operating income in the first three quarters of 1996, compared
with SEK 313 M in the third quarter of 1995.<BR>
<BR>
<A NAME="ref1"></A>(see table: <A HREF="tab1.html">Consolidated income
statements</A>)<BR>
<BR>
</P>

<P><B>Income from equity method investments</B> amounted to SEK 184 M (SEK
1,318 M). This includes a capital gain of SEK 352 M on the sale of VOAC
Hydraulics and Volvo's share of the loss in NedCar of SEK 440 M (385).
Excluding write-down of fixed assets linked to the Volvo 400 series. Volvos
share of the loss in Ned Car was reduced through increased sales revenues
from the new Volvo S40/V40.</P>

<P>Income from equity-method investments in 1995 included Volvo Construction
Equipment and Pharmacia, which are no longer reported in accordance with
the equity method, in the amounts of SEK 478 M and SEK 934 M, respectively.<BR>
</P>

<P><B>Dividends received</B> included SEK 325 M from Pharmacia &amp; Upjohn,
Inc., SEK 124 M from Renault, SEK 91 M from SAS Sverige AB, SEK 31 M from
Investment AB Bure, and SEK 33 M from Protorp F&ouml;rvaltnings AB.<A NAME="ref2"></A><A NAME="ref3"></A></P>

<P><B>Gains on sales of securities </B>pertained mainly to the sale of
9.9% of the share capital in Pharmacia &amp; Upjohn, which yielded a gain
of SEK 7,766 M.</P>

<P><B>Net interest income,</B> amounting to SEK 880 M (149), developed
favorably due to the Volvo Group's strong financial position and good results
in Volvo Group Finance.</P>

<P><B>Tax expenses</B> pertained largely to current taxes in foreign subsidiaries
and Operations being divested. Sales of shares resulted in only lilited
tax change.<BR>
<BR>
(see tables: <A HREF="tab3.html">Condensed consolidated balance sheets</A>
and <A HREF="tab2.html">Key ratios</A>)<BR>
<BR>
</P>

<P><B>Group assets</B> declined by SEK 1.2 billion in the first three quarters
of 1996. Excluding movements in foreign currency rates, the increase was
SEK 1.3 billion. As a result of changes in composition of the Group, primarily
the distribution of Swedish Match to AB Volvo's shareholders, total assets
decreased with SEK 8.6 billion. The sale of Pharmacia &amp; Upjohn increased
liquid funds by SEK 12.9 billion and reduced shares and participations
by SEK 5.2 billion. Investments in property, plant and equipment, expanded
sales financing operations and higher inventories, mainly in Volvo Cars
resulted in an increase in Group assets.</P>

<P><B>Capital expenditures</B> for property, plant and equipment amounted
to SEK 5.9 billion (4.2), including SEK 3.1 billion in Volvo Cars and SEK
1.9 billion in Volvo Trucks. Investments in leasing and company vehicles
totaled SEK 2.5 billion (2.3).<A NAME="ref6"></A><A NAME="ref5"></A></P>

<P><B>Net financial assets</B> rose by SEK 14.2 billion since December
31, 1995 to SEK 15.4 billion, of which SEK 12.9 billion pertained to the
sale of shares in Pharmacia &amp; Upjohn.</P>

<P><B>Shareholders' equity </B>rose by SEK 4.4 billion. The distribution
of the Swedish Match shares and payment of a cash dividend to AB Volvo's
shareholders reduced shareholders' equity by SEK 4.2 billion and SEK 1.9
billion, respectively. Net income for the period contributed SEK 10,7 billion.<BR>
<BR>
(see tables: <A HREF="tab6.html">Statement of changes in consilidated financial
position</A> and <A HREF="tab5.html">Operating income, excluding nonrecurring
items</A>)<BR>
<BR>
<BR>
<BR>
<BR>
<A NAME="ref8"></A>(see table: <A HREF="tab8.html">Sales by company Group</A>)<BR>
<BR>
<BR>
</P>
</BLOCKQUOTE>
</TD>
</TR>
</TABLE></CENTER>

<CENTER><P><A NAME="refdia2"></A><A NAME="car"></A></P></CENTER>

<CENTER><TABLE WIDTH="490" >
<TR>
<TD>
<BLOCKQUOTE>
<P><B>Volvo Cars<BR>
</B>The total market for passenger cars increased by 3% during the first
nine months of 1996, compared with the corresponding period a year earlier.
The market in North America was largely unchanged, while Europe showed
an upturn of 7%. The car market in Japan was up slightly more than 1%.</P>

<P>A total of 264,270 Volvo cars (286,490) were invoiced, down 8%. The
decline is attributable to the Volvo 940/960, while the Volvo 850 reported
an increase of 8% compared with the first three quarters of 1995. Combined,
the Volvo 400 and the new Volvo S40/V40 posted a 1% decline. After some
delay, the rate of delivery of the Volvo S40/V40 stabilized at the end
of the period. </P>

<P>Volvo's market shares in Europe declined but were stable in North America
despite discontinuing the sale of the Volvo 940. Volvo strengthened its
positions in Japan.</P>

<P>Volvo Cars' sales declined by 5%, to SEK 59,832 M. When excluding foreign
exchange movements, sales rose by 3%. Operating income amounted to SEK
573 M (1,930). The decline is attributable mainly to the lower sales volume
for the Volvo 940/960 and high costs for product development, which to
some extent is offset by positive currency effects. Operating margin, which
improved somewhat during the third quarter, remained low, 1,0% (3.1).</P>

<P>The Volvo C70 coup&eacute;, an exclusive four-seat sport coup&eacute;
which strengthens Volvo's product range and broadens the customer base,
was presented in Paris in October.<BR>
<BR>
(see graph: <A HREF="dia2.html">Operating income, Volvo Car </A>)</P>
</BLOCKQUOTE>
</TD>
</TR>
</TABLE></CENTER>

<CENTER><P><A NAME="refdia3"></A><A NAME="truck"></A></P></CENTER>

<CENTER><TABLE WIDTH="490" >
<TR>
<TD>
<BLOCKQUOTE>
<P><B>Volvo Trucks<BR>
</B>The world market for heavy trucks declined during the first nine months
of 1996, compared with the corresponding period of 1995. The market in
Europe remained strong, while the total market in North and South America
continued to decline.</P>

<P>During the first three quarters of the year Volvo Trucks delivered 47,360
medium-heavy and heavy trucks, 16% fewer units than in the year-earlier
period. The number of trucks delivered in Europe increased by 6% and the
market share in the heavy segment rose through August to 16.5% (16.2).
Volvo is the second-largest make of heavy trucks in Europe. Deliveries
in North America decreased by 39%. Through August, market share in the
U.S. in Class 8 declined to 9.2% (11.4). The order backlog at September
30, 1996 was 40% lower than on the same date a year earlier, due primarily
to the lower demand in North and South America.</P>

<P>The new VN truck model, which was developed based on the successful
FH concept is being introduced successively in the US. Production resources
are being concentrated to the plant in New River Valley, Virginia, as a
result of which the plant in Orrville, Ohio, will be phased out during
the second quarter of 1997. In the commercial system a new sales financing
company was established and an upgrading of the dealer organization will
be carried out.</P>

<P>Volvo Trucks' sales in the first three quarters of 1996 amounted to
SEK 32,707 M, a decrease of 14% compared with the year-earlier period.
Adjusted for foreign exchange movements, the decrease was 7%. Operating
income amounted to SEK 413 M (4,025), of which a loss of SEK 665 M in the
third quarter (profit of SEK 1,083 M). </P>

<P>European operations continued to show favorable earnings, but the adjustment
to a tougher competitive climate resulted in depressed margins and reduced
profit. Operations in North America posted a significant loss in the first
nine months due to low volume of sales, pressure on product prices and
higher costs for production and product development and the costs for the
development and introduction of a new product program. SEK 700 M of the
total loss of about SEK 14,000 M in the North American operations is attributable
to costs for such measures as phasing out the plant in Orrville and write-down
of its asset value, a personnel reduction of about 940 persons from January
1, 1996 through June 30, 1997 and realignment costs for phasing out existing
products. The rationalization measures are expected to have a positive
effect during 1997. Volvo Trucks' operations in South America also showed
a loss in the first nine months of 1996. An income improvement was noted
in the third quarter.</P>

<P>Volvo Trucks' earnings were also charged with increased costs for product
and market development. Operating margin was 1.3% (10.6).<BR>
<BR>
(see graph: <A HREF="dia3.html">Operating income, Volvo Truck</A>)</P>

<P><BR>
<BR>
<A NAME="bus"></A><B>Volvo Buses<BR>
</B>Volvo Buses delivered 5,140 (4,540) buses and bus chassis during the
first nine months of 1996. The market share in Europe was 20% (19) according
to preliminary statistics. The order backlog at September 30, 1996 was
at the same level as on the same date in 1995.</P>

<P>As a result of increased competition and lower margins, operating income
declined to SEK 155 M (282). Operating margin was 2.6% (5.2).<BR>
<BR>
<A NAME="vce"></A><B>Volvo Construction Equipment<BR>
</B>The decline in the total market for construction equipment continued
during the third quarter, most particularly in Germany and the rest of
Europe, but was less notable in North America. Invoiced sales for Volvo
Construction Equipment amounted to SEK 9,631 M (9,921).</P>

<P>Operating income amounted to SEK 928 M (1,294). The decline compared
with the corresponding period in the preceding year was attributable mainly
to lower volumes, higher development costs for new products as well as
for the business as a whole and unfavorable exchange rates. Operating margin
was 9.6% (13.0).<BR>
<BR>
<A NAME="penta"></A><B>Volvo Penta<BR>
</B>Volvo Penta's invoiced sales declined by 3% compared with the year-earlier
period. Sales of marine engines and spare parts was lower in Europe, Japan,
Australia and Brazil. In contrast, sales increases were posted in the U.S.,
where market shares also improved. Sales of industrial engines rose due
to continued strong demand for gensets.</P>

<P>As a result of unfavorable exchange rates and cost increases, operating
income declined to SEK 63 M (197). In order to enhance efficiency and improve
long-term profitability, it has been decided to establish a new global
structure as of January 1, 1997.<BR>
<BR>
<A NAME="aero"></A><B>Volvo Aero<BR>
</B>Invoiced sales of Volvo Aero rose 6%, despite unfavorable exchange
rates. In the Commercial Engines segment, Volvo Aero entered into an agreement
with General Electric on part-ownership in LM 6000, a stationary gas turbine
for generating electrical power. The agreement is expected to generate
revenues of SEK 600 M during the next 15-20 years. During the international
air show at Farnborough, Volvo Aero secured orders as a partner in various
aircraft engine programs totaling SEK 300 M. Operating income amounted
to SEK 110 M (97). <BR>
<BR>
<B>Operations being divested<BR>
</B>During 1996, shareholdings in Swedish Match, Investment AB Bure and
Spira AB were sold as well as 50.006,534 shares in Pharmacia &amp; Upjohn,
Inc., corresponding to 9.9% of the share capital in the company.</P>

<P>The selling price for Pharmacia &amp; Upjohn was set at SEK 262.82 per
share and the buyers were a large number of institutional investors in
Europe and North America. The taxable initial value was SEK 258 per share,
which was calculated based on an advanced ruling from the Swedish Tax
Board. Following the sale, Volvo's holding in Pharmacia &amp; Upjohn, Inc.
amounts to 3.9% of share capital. Other remaining undertakings outside
the automotive operations include mainly the shareholding of 49% in Pripps
Ringnes AB.</P>

<P><B>Employees<BR>
</B>The Volvo Group had 70,220 employees as of September 30, 1996, a decrease
of 8,830 compared with the number at December 31, 1995. As a result of
the distribution of Swedish Match, 7,000 persons left the Group.<A NAME="ref4"></A></P>

<P>The preliminary report on operations for the full year 1996 will be
issued on February 19, 1997.</P>

<P>G&ouml;teborg, October 23, 1996<BR>
S&ouml;ren Gyll<BR>
President and Chief Executive Officer </P>

<P><IMG SRC="/images/gyll.gif" HEIGHT=72 WIDTH=222><BR>
</P>

<P>This report has not been reviewed by AB Volvo's auditiors.<BR>
<BR>
<BR>
<!-- -------- --></P>

<TABLE WIDTH="450" >
<TR>
<TD>
<HR></TD>
</TR>

<TR>
<TD>Source: Nine months ended September 30, 1996</TD>
</TR>
</TABLE>

<P><BR>
</P>
</BLOCKQUOTE>

<P><A HREF="#top"><IMG SRC="/images/knapp_top.gif" ALT="Top of page" BORDER=0 HEIGHT=14 WIDTH=71></A>

<HR ALIGN=LEFT WIDTH=487>Mail to: <A HREF="mailto:webmaster@www.volvo.se">Webmaster</A>
[webmaster@www.volvo.se]</P>
</TD>
</TR>
</TABLE></CENTER>

</BODY>
</HTML>
</DOC>
